PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Akagi, T; Ono, H; Shimotohno, K				Akagi, T; Ono, H; Shimotohno, K			Expression of cell-cycle regulatory genes in HTLV-I infected T-cell lines: Possible involvement of Tax1 in the altered expression of cyclin D2, p18(Ink4) and p21(Waf1/Cip1/Sdi1)	ONCOGENE			English	Article						HTLV-I; Tax1; cyclin; cdk; cdk-inhibitor; immortalization	PRIMARY HUMAN-LYMPHOCYTES; LEUKEMIA-VIRUS TYPE-1; DEPENDENT KINASES; TRANS-ACTIVATION; PROTEIN; LEUKOCYTES	To understand how the growth of T-cells transformed by Human T-cell leukemia virus type I(HTLV-I) is deregulated, we analysed the expression of cell-cycle regulatory genes in HTLV-I infected and non-infected T-cell lines, We investigated the gene for 6 cyclins, 4 cyclin-dependent kinases, and 5 cyclin-dependent kinase inhibitors, and found the following: (1) HTLV-I infected T-cell lines preferentially expressed cyclin D2, whereas cyclin D3 was the major D-type cyclin in HTLV-I negative T-cell lines; (2) HTLV-I infected T-cell lines expressed strikingly low levels of p18(Ink4) compared with those that were HTLV-I negative; (3) HTLV-I infected T-cell lines expressed high levels of p21(Waf1/Cip1/Sdi1), whereas p21(Waf1/Cip1/Sdi1) was undetectable in HTVL-I negative T-cell lines, These features were also found in T-cells immortalized by Tax1, which we established, Therefore, it is strongly suggested that Tax1 alters the expression of these cell-cycle regulatory genes.	NATL CANC CTR, RES INST, DIV VIROL, CHUO KU, TOKYO 104, JAPAN	National Cancer Center - Japan								AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; AKAGI T, 1991, GENE, V106, P255, DOI 10.1016/0378-1119(91)90207-R; AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; AKAGI T, 1995, BLOOD, V86, P4243, DOI 10.1182/blood.V86.11.4243.bloodjournal86114243; AKAGI T, 1995, FEBS LETT, V358, P34, DOI 10.1016/0014-5793(94)01390-M; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEUER G, 1992, BIOCHIM BIOPHYS ACTA, V1114, P223, DOI 10.1016/0304-419X(92)90017-S; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; GAZDAR AF, 1980, BLOOD, V55, P409; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HARPER JW, 1993, CELL, V75, P805; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; HIRAMA T, 1995, BLOOD, V86, P841; HOLLSBERG P, 1993, NEW ENGL J MED, V328, P1173, DOI 10.1056/NEJM199304223281608; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; JIANG HP, 1994, ONCOGENE, V9, P3397; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MICHIELI P, 1994, CANCER RES, V54, P3391; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OGAWA S, 1994, BLOOD, V84, P2431, DOI 10.1182/blood.V84.8.2431.bloodjournal8482431; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; SODROSKI JG, 1985, J VIROL, V55, P831, DOI 10.1128/JVI.55.3.831-835.1985; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467; Yoshida M, 1993, Trends Microbiol, V1, P131, DOI 10.1016/0966-842X(93)90127-D; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	48	118	120	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	1996	12	8					1645	1652						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622884				2022-12-28	WOS:A1996UG45800006
J	Tulchinsky, EM; Georgiev, GP; Lukanidin, EM				Tulchinsky, EM; Georgiev, GP; Lukanidin, EM			Novel AP-1 binding site created by DNA-methylation	ONCOGENE			English	Article						AP-1; DNA-methylation; gene expression; mts1 gene	GLOBIN GENE-EXPRESSION; MESSENGER-RNA; MTS1 GENE; PROTEIN; CELLS; FOS; JUN; IDENTIFICATION; SEQUENCES; PROMOTER	DNA-methylation is known to repress transcription either by inactivation of positive regulatory cis-elements containing CpG dinucleotides or via the sequence-nonspecific and methylation-specific binding of inhibiting methyl-CpG binding protein 1 (MeCP1). In the present work we describe the novel way DNA-methylation can influence gene expression: a binding site for transcription factors AP-1 might be created by DNA-methylation. Such a DNA-methylation-dependent AP-1 binding site was found in the first intron of the metastasis-associated mts1 gene, The expression level of this gene correlates with the hypomethylation of the mts1 first intron sequence in mouse adenocarcinoma cells. The DNA methylation-dependent AP-1 binding site was found to be functionally active in the nucleotide context of the mts1 gene. When methylated, this site reproducibly repressed transcription of CAT-containing DNA that had been transiently transfected into mouse adenocarcinoma CSML100 cells.	INST GENE BIOL, MOSCOW 117334, RUSSIA	Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences	Tulchinsky, EM (corresponding author), DANISH CANC SOC, DEPT MOL CANC BIOL, STRANDBLVD 49 43, DK-2100 COPENHAGEN, DENMARK.		Tulchinsky, Eugene/ABD-7070-2021					ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Antequera F., 1993, Experientia Supplementum (Basel), V64, P169; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BAHLER DW, 1985, J IMMUNOL, V134, P2790; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BARRACLOUGH R, 1984, NUCLEIC ACIDS RES, V12, P8097, DOI 10.1093/nar/12.21.8097; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BUSSLINGER M, 1983, CELL, V34, P197, DOI 10.1016/0092-8674(83)90150-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIES BR, 1993, ONCOGENE, V8, P999; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; Ehrlich M., 1993, Experientia Supplementum (Basel), V64, P145; FORD HL, 1995, ONCOGENE, V10, P1597; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GIBBS FEM, 1994, J BIOL CHEM, V269, P18992; GIZANGGINSBERG E, 1994, MOL ENDOCRINOL, V8, P249, DOI 10.1210/me.8.2.249; GOTO K, 1988, J BIOCHEM-TOKYO, V103, P48, DOI 10.1093/oxfordjournals.jbchem.a122237; GRIGORIAN M, 1994, ELECTROPHORESIS, V15, P463, DOI 10.1002/elps.1150150163; GRIGORIAN MS, 1993, GENE, V135, P229, DOI 10.1016/0378-1119(93)90070-J; HEIZMANN CW, 1991, NOVEL CALCIUM BINDIN; HOWCROFT TK, 1993, EMBO J, V12, P3163, DOI 10.1002/j.1460-2075.1993.tb05985.x; HU JM, 1994, MOL CELL BIOL, V14, P1531, DOI 10.1128/MCB.14.3.1531; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; JOEL P, 1993, NUCLEIC ACIDS RES, V21, P5786, DOI 10.1093/nar/21.24.5786; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; OSTAPCHUK P, 1989, MOL CELL BIOL, V9, P2787, DOI 10.1128/MCB.9.7.2787; PEDROCCHI M, 1994, INT J CANCER, V57, P684, DOI 10.1002/ijc.2910570513; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SINGERSAM J, 1993, DNA METHYLATION MOL, P359; SUETAKE I, 1993, NUCLEIC ACIDS RES, V21, P2125, DOI 10.1093/nar/21.9.2125; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; TULCHINSKY E, 1992, P NATL ACAD SCI USA, V89, P9146, DOI 10.1073/pnas.89.19.9146; TULCHINSKY E, 1993, ONCOGENE, V8, P79; YISRAELI J, 1988, P NATL ACAD SCI USA, V85, P4638, DOI 10.1073/pnas.85.13.4638; ZHANG XY, 1989, NUCLEIC ACIDS RES, V17, P1459, DOI 10.1093/nar/17.4.1459; ZHANG XY, 1990, NUCLEIC ACIDS RES, V18, P6253, DOI 10.1093/nar/18.21.6253	43	33	33	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	1996	12	8					1737	1745						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622894				2022-12-28	WOS:A1996UG45800016
J	YonedaKato, N; Look, AT; Kirstein, MN; Valentine, MB; Raimondi, SC; Cohen, KJ; Carroll, AJ; Morris, SW				YonedaKato, N; Look, AT; Kirstein, MN; Valentine, MB; Raimondi, SC; Cohen, KJ; Carroll, AJ; Morris, SW			The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1	ONCOGENE			English	Article						acute myeloid leukemia; fusion gene; myelodysplasia-myeloid leukemia factor 1 (MLF 1); nucleophosmin (NPM); t(3;5) chromosomal translocation	ACUTE NONLYMPHOCYTIC LEUKEMIA; MAJOR NUCLEOLAR PROTEINS; TRANSLOCATION T(3-5); NUCLEAR PROTEINS; NUMATRIN; DNA; B23; PHOSPHORYLATION; LEUKEMOGENESIS; IDENTIFICATION	A t(3;5)(q25.1;q34) chromosomal translocation associated with myelodysplastic syndrome and acute myeloid leukemia (AML) was found to rearrange part of the nucleophosmin (NPM) gene on chromosome 5 with sequences from a novel gene on chromosome 3. Chimeric transcripts expressed by these cells contain 5' NPM coding sequences fused in-frame to those of the new gene, which we named myelodysplasia/myeloid leukemia factor 1 (MLF1). RNA-based polymerase chain reaction analysis revealed identical NPM-MLF1 mRNA fusions in each of the three t(3;5)-positive cases of AML examined, The predicted MLF1 amino acid sequence lacked homology to previously characterized proteins and did not contain known functional motifs. Normal MLF1 transcripts were expressed in a variety of tissues, most abundantly in testis, ovary, skeletal muscle, heart, kidney and colon. Anti-MLF1 antibodies detected the wild-type 31 kDa protein in K562 and HEL erythroleukemia cell Lines, but not in HL-60, U937 or KG-1 myeloid leukemia lines. By contrast, t(3;5)-positive leukemia cells expressed a 54 kDa NPM-MLF1 protein, but not normal MLF1. Immunostaining experiments indicated that MLF1 is normally located in the cytoplasm, whereas NPM-MLF1 is targeted to the nucleus, with highest levels in the nucleolus. The nuclear/nucleolar localization of NPM-MLF1 mirrors that of NPM, indicating that NPM trafficking signals direct MLF1 to an inappropriate cellular compartment in myeloid leukemia cells.	ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL & ONCOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT PATHOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN USA; JOHNS HOPKINS UNIV HOSP, DEPT PEDIAT ONCOL, BALTIMORE, MD 21287 USA; UNIV ALABAMA, MED GENET LAB, BIRMINGHAM, AL USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Johns Hopkins University; Johns Hopkins Medicine; University of Alabama System; University of Alabama Birmingham			Raimondi, Susana C/N-8166-2018		NATIONAL CANCER INSTITUTE [P01CA020180, K08CA001702, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 20180, K08 CA 01702, CA 21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BERGER R, 1987, CANCER GENET CYTOGEN, V28, P261, DOI 10.1016/0165-4608(87)90212-3; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CHAN PK, 1986, J BIOL CHEM, V261, P14335; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; CHATTERJEE A, 1991, BIOCHEM BIOPH RES CO, V180, P805, DOI 10.1016/S0006-291X(05)81136-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; FEUERSTEIN N, 1991, EXP CELL RES, V194, P289, DOI 10.1016/0014-4827(91)90367-4; FEUERSTEIN N, 1990, BIOCHIM BIOPHYS ACTA, V1087, P127, DOI 10.1016/0167-4781(90)90196-9; FEUERSTEIN N, 1991, J BIOL CHEM, V266, P16200; FONAGY A, 1994, CANCER RES, V54, P1859; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; HERNANDEZVERDUN D, 1991, J CELL SCI, V99, P465; INOUYE CJ, 1994, J BIOL CHEM, V269, P6506; KEYES LN, 1992, CELL, V68, P933, DOI 10.1016/0092-8674(92)90036-C; KOEFFLER HP, 1986, SEMIN HEMATOL, V23, P223; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LIU QR, 1991, EUR J BIOCHEM, V200, P715, DOI 10.1111/j.1432-1033.1991.tb16236.x; LOOK AT, 1995, ADV CANCER RES; MORISHITA K, 1990, ONCOGENE RES, V5, P221; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; MORRIS SW, 1992, GENE CHROMOSOME CANC, V5, P385, DOI 10.1002/gcc.2870050414; OSHIMURA M, 1976, CANCER, V38, P748, DOI 10.1002/1097-0142(197608)38:2<748::AID-CNCR2820380218>3.0.CO;2-U; PERLAKY L, 1992, CANCER RES, V52, P428; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; PI D, 1986, CANCER GENET CYTOGEN, V20, P171, DOI 10.1016/0165-4608(86)90122-6; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAIMONDI SC, 1989, LEUKEMIA, V3, P42; REDNER RL, 1994, BLOOD, V84, pA375; ROWLEY JD, 1976, BLOOD, V47, P705; SCHMIDTZACHMANN MS, 1988, CHROMOSOMA, V96, P417, DOI 10.1007/BF00303035; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHARP RA, 1987, LEUKEMIA RES, V11, P629, DOI 10.1016/0145-2126(87)90035-X; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SMADJA N, 1986, CANCER GENET CYTOGEN, V20, P173, DOI 10.1016/0165-4608(86)90123-8; Steinmann-Zwicky M, 1990, Adv Genet, V27, P189; TAKEMURA M, 1994, BIOCHEM BIOPH RES CO, V199, P46, DOI 10.1006/bbrc.1994.1191; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; WERNERFAVRE C, 1985, CANCER GENET CYTOGEN, V16, P279, DOI 10.1016/0165-4608(85)90056-1; YUNG BYM, 1987, BIOCHIM BIOPHYS ACTA, V925, P74, DOI 10.1016/0304-4165(87)90149-8	47	253	263	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	1996	12	2					265	275						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570204				2022-12-28	WOS:A1996TR53800006
J	Kunath, T; OrdonezGarcia, C; Turbide, C; Beauchemin, N				Kunath, T; OrdonezGarcia, C; Turbide, C; Beauchemin, N			Inhibition of colonic tumor cell growth by biliary glycoprotein	ONCOGENE			English	Article						biliary glycoprotein; BGP; carcinoembryonic antigen; CEA; growth inhibitor; tumor; colon carcinoma	ANTIGEN GENE FAMILY; INTERCELLULAR-ADHESION MOLECULE; CARCINOEMBRYONIC ANTIGEN; ECTO-ATPASE; ENDOGENOUS SUBSTRATE; CYTOPLASMIC DOMAIN; TYROSINE KINASE; EXPRESSION; RECEPTOR; MEMBER	Biliary glycoproteins (BGPs) are members of the carcinoembryonic antigen (CEA) family. These glycoproteins function in vitro as intercellular adhesion molecules and, in the mouse, serve as receptors for the mouse hepatitis viruses. In previous studies, BGP expression has been reported to be generally downregulated in colon and liver carcinomas of human, rat and mouse origins. We now demonstrate that introduction of murine Bgp1 cDNA isoforms into a mouse colonic carcinoma cell line, negative for endogenous Bgpl expression, significantly alters the growth properties of these cells. Cells bearing two Bgpl isoforms were growth-retarded and exhibited a reduced ability to form colonies in an in vitro transformation assay, when compared to parental or control neo(r) cells. Furthermore, tumor formation was inhibited by 80% when cells bearing a full-length Bgpl isoform were injected into BALB/c syngeneic mice, while cells expressing a Bgpl isoform lacking most of the intracytoplasmic domain produced tumors as readily as the parental cells. These results indicate that a biliary glycoprotein isoform is involved in negative regulation of colonic tumor cell growth, by a process which requires its intracytoplasmic domain. The precise mechanisms causing Bgp-dependent tumor growth inhibition remain, however, to be defined.	MCGILL UNIV, CTR CANC, MONTREAL, PQ H3G 1Y6, CANADA; MCGILL UNIV, DEPT BIOCHEM, MONTREAL, PQ H3G 1Y6, CANADA; MCGILL UNIV, DEPT MED, MONTREAL, PQ H3G 1Y6, CANADA; MCGILL UNIV, DEPT ONCOL, MONTREAL, PQ H3G 1Y6, CANADA	McGill University; McGill University; McGill University; McGill University				Kunath, Tilo/0000-0002-8805-7356				AFAR DEH, 1992, BIOCHIM BIOPHYS ACTA, V1134, P46, DOI 10.1016/0167-4889(92)90026-8; BARNETT TR, 1993, MOL CELL BIOL, V13, P1273, DOI 10.1128/MCB.13.2.1273; BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BRATTAIN MG, 1980, CANCER RES, V40, P2142; CHEN W, 1991, J CELL BIOL, V114, P310; COUTELIER JP, 1994, EUR J IMMUNOL, V24, P1383, DOI 10.1002/eji.1830240622; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991; EDLUND M, 1993, FEBS LETT, V327, P90, DOI 10.1016/0014-5793(93)81046-3; GOLD P, 1965, J EXP MED, V122, P467, DOI 10.1084/jem.122.3.467; HIXSON DC, 1985, CANCER RES, V45, P3742; HSIEH JT, 1995, CANCER RES, V55, P190; KIMBALL PM, 1978, BRIT J CANCER, V37, P1015, DOI 10.1038/bjc.1978.147; KUPRINA NI, 1990, HISTOCHEMISTRY, V94, P179, DOI 10.1007/BF02440185; LIN SH, 1989, J BIOL CHEM, V264, P14408; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MCCUAIG K, 1993, GENE, V127, P173, DOI 10.1016/0378-1119(93)90716-G; MCCUAIG K, 1992, CELL GROWTH DIFFER, V3, P165; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NAJJAR SM, 1993, J BIOL CHEM, V268, P1201; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; NEDELLEC P, 1995, EUR J BIOCHEM, V231, P104, DOI 10.1111/j.1432-1033.1995.tb20676.x; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; OBRINK B, 1991, BIOESSAYS, V13, P227, DOI 10.1002/bies.950130505; OCKLIND C, 1982, J BIOL CHEM, V257, P6788; OIKAWA S, 1992, BIOCHEM BIOPH RES CO, V186, P881, DOI 10.1016/0006-291X(92)90828-9; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; REESJONES RW, 1985, J BIOL CHEM, V260, P4461; ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527; ROSENBERG M, 1993, CANCER RES, V53, P4938; SIPPEL CJ, 1993, J BIOL CHEM, V268, P2083; SPORNS O, 1995, P NATL ACAD SCI USA, V92, P542, DOI 10.1073/pnas.92.2.542; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; TURBIDE C, 1991, J BIOL CHEM, V266, P309; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089; VEGA MA, 1989, P NATL ACAD SCI USA, V86, P2688, DOI 10.1073/pnas.86.8.2688; VLERNINCKX K, 1991, CELL, V66, P107; YOKOMORI K, 1992, J VIROL, V66, P6194, DOI 10.1128/JVI.66.10.6194-6199.1992	40	154	157	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2375	2382						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570189				2022-12-28	WOS:A1995TK70200022
J	Nguyen, HQ; Selvakumaran, M; Liebermann, DA; Hoffman, B				Nguyen, HQ; Selvakumaran, M; Liebermann, DA; Hoffman, B			Blocking c-Myc and Max expression inhibits proliferation and induces differentiation of normal and leukemic myeloid cells	ONCOGENE			English	Note						c-myc; max; myeloid differentiation	IMMEDIATE EARLY RESPONSE; DNA-BINDING; TERMINAL DIFFERENTIATION; ONCOGENE EXPRESSION; GROWTH ARREST; PROTEIN; LINE; APOPTOSIS; HL-60; AMPLIFICATION	Given the central role c-Myc plays in growth control, differentiation and apoptosis, understanding how c-Myc functions will increase our understanding about normal cell development, and how alterations in these processes can lead to malignancy, C-Myc is a negative regulator of terminal myeloid differentiation; therefore, it was of interest to determine what effect blocking c-MSc expression would have on proliferation and differentiation, Tn this work we showed that blocking expression of either c-Myc or Max, its molecular partner, in myeloblastic leukemia M1 cells activated the differentiation program in the absence of an exogenous source of differentiation inducer; the cells assumed an intermediate stage myeloid morphology. Moreover, when both c-Myc and Max expression were concommitantly blocked, many of the cells underwent terminal differentiation, Finally, extending these studies to myeloblast enriched normal bone marrow (BM) cells has shown that blocking expression of either c-Myc or Max accelerated GM-CSF-induced differentiation along both the granulocytic and monocytic lineages, Thus, it can be concluded that blocking either c-Myc or Max expression in myeloid cells at specific stages of development activates and accelerates the terminal differentiation program.	TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NATIONAL CANCER INSTITUTE [R01CA051162, R01CA043618, P30CA012227] Funding Source: NIH RePORTER; NCI NIH HHS [1RO1CA51162, 5 P30 CA12227, 1RO1CA43618] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DALLAFAVERA R, 1982, NATURE, V299, P61; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GERWIRTZ AM, 1988, SCIENCE, V242, P180; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIEBERMANN D, 1981, INT J CANCER, V28, P285, DOI 10.1002/ijc.2910280306; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; SCHNEIDER MD, 1987, MOL CELL BIOL, V7, P1973, DOI 10.1128/MCB.7.5.1973; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028	29	31	31	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2439	2444						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570196				2022-12-28	WOS:A1995TK70200029
J	CUADRADO, A; CARNERO, A; DOLFI, F; JIMENEZ, B; LACAL, JC				CUADRADO, A; CARNERO, A; DOLFI, F; JIMENEZ, B; LACAL, JC			PHOSPHORYLCHOLINE - A NOVEL 2ND MESSENGER ESSENTIAL FOR MITOGENIC ACTIVITY OF GROWTH-FACTORS	ONCOGENE			English	Article							CHOLINE KINASE-ACTIVITY; PHOSPHATIDYLCHOLINE BREAKDOWN; PHOSPHOLIPASE-D; TYROSINE PHOSPHORYLATION; GUANINE-NUCLEOTIDE; PDGF RECEPTOR; RAS ONCOGENE; 3T3 CELLS; ACTIVATION; PROTEIN	Growth factor stimulation of quiescent cells induces a series of intracellular early and late events that ultimately lead to DNA synthesis and cell division. We describe here that production of phosphorylcholine is an essential component of the late events involved in the induction of DNA synthesis by platelet-derived growth factor (PDGF-BB), a prototype mitogen for fibroblasts. Moreover, phosphorylcholine itself is mitogenic when added exogenously to NIH3T3 cells, further indicating its role as a crucial intracellular messenger for DNA synthesis. Choline kinase, the first step in the route of phosphatidylcholine synthesis appears to be the critical regulatory enzyme in phosphorylcholine production, indicating that regulation of choline kinase represents a key step during mitogenic stimulation. We also describe that several growth factors (PDGF-AA, basic FGF, EGF and phorbol esters) rely on their ability to generate phosphorylcholine for their proliferating activity. In contrast, DNA synthesis induced by serum did not require phosphorylcholine. Moreover, the requirement for phosphorylcholine production in PDGF-stimulated cells can be over-ruled by addition of insulin. Thus, cell proliferation in NIH3T3 cells can be triggered off by alternative pathways and one of them involves generation of phosphorylcholine.	INST INVEST BIOMED,ARTURO DUPERIER 4,E-28029 MADRID,SPAIN; UNIV AUTONOMA MADRID,FAC MED,DEPT BIOQUIM,E-28029 MADRID,SPAIN	Autonomous University of Madrid			Cuenca, Benilde Jimenez/K-9959-2014; IBIS, CANCER/P-3323-2015; Lacal, Juan Carlos/AAL-2235-2020; Lacal, Juan Carlos/N-9064-2015	Lacal, Juan Carlos/0000-0002-1908-2777; Carnero, Amancio/0000-0003-4357-3979; Cuadrado, Antonio/0000-0002-4039-7140; Jimenez Cuenca, Benilde/0000-0002-1806-6636; Cuadrado, Antonio/0000-0002-3444-9012				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ANTHES JC, 1991, BIOCHEM BIOPH RES CO, V175, P236, DOI 10.1016/S0006-291X(05)81225-2; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; CANNON JG, 1988, PHARMACEUT RES, V5, P359, DOI 10.1023/A:1015955527100; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAO CK, 1988, BIOCHEM J, V254, P33, DOI 10.1042/bj2540033; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COOK SJ, 1992, BIOCHEM J, V285, P247, DOI 10.1042/bj2850247; CUADRADO A, 1993, UNPUB; DALY PF, 1987, J BIOL CHEM, V262, P14875; DOOPLER W, 1987, GENE, V54, P147; EXTON JH, 1990, J BIOL CHEM, V265, P1; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; GUYENET P, 1973, MOL PHARMACOL, V9, P630; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HELDIN CH, 1990, J CELL SCI, V96, P193; JIMENEZ B, 1992, INT J CANCER, V49, P417; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LACAL JC, 1988, ONCOGENE HDB, P255; LEACH KL, 1991, J BIOL CHEM, V266, P3215; MACARA IG, 1985, AM J PHYSIOL, V248, pC3, DOI 10.1152/ajpcell.1985.248.1.C3; MACARA IG, 1989, MOL CELL BIOL, V9, P325, DOI 10.1128/MCB.9.1.325; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MURRAY JJ, 1990, BIOCHEM J, V270, P63, DOI 10.1042/bj2700063; OHTSUKA T, 1990, BIOCHEM BIOPH RES CO, V170, P328, DOI 10.1016/0006-291X(90)91278-Z; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V779, P217, DOI 10.1016/0304-4157(84)90010-8; PLEDGER WJ, 1978, P NATL ACAD SCI USA, V75, P2839, DOI 10.1073/pnas.75.6.2839; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; PLEVIN R, 1991, BIOCHEM J, V279, P559, DOI 10.1042/bj2790559; PORTER TJ, 1990, J BIOL CHEM, V265, P414; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; TAMARU M, 1989, NEUROCHEM RES, V14, P607, DOI 10.1007/BF00964868; TAYLOR SJ, 1987, BIOCHEM J, V248, P791, DOI 10.1042/bj2480791; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; TSHOPP J, 1989, NATURE, V337, P272; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; WARDEN CH, 1985, J BIOL CHEM, V260, P6006	45	169	173	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2959	2968						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414498				2022-12-28	WOS:A1993MC09300009
J	BOHME, B; HOLTRICH, U; WOLF, G; LUZIUS, H; GRZESCHIK, KH; STREBHARDT, K; RUBSAMENWAIGMANN, H				BOHME, B; HOLTRICH, U; WOLF, G; LUZIUS, H; GRZESCHIK, KH; STREBHARDT, K; RUBSAMENWAIGMANN, H			PCR MEDIATED DETECTION OF A NEW HUMAN RECEPTOR-TYROSINE-KINASE, HEK-2	ONCOGENE			English	Note								We have previously amplified cDNA subfragments of protein-tyrosine-kinases (PTKs) by using the polymerase chain reaction (PCR) and specific sets of oligonucleotide primers derived from nucleotide sequences of their kinase domain. In this study we have used a more directed approach to identify new members of the EPH/elk-family by PCR of human embryonic cDNA: we utilized oligonucleotide primers specifically designed to a highly conserved N-terminal motif and the kinase region of EPH/elk-PTKs in RNA-PCRs. The 5' and 3' elongation of the primary PCR product was achieved by the RACE (rapid amplification of cDNA ends)-technique. Sequence analysis of 3.8 kb of overlapping PCR products allowed to identify a novel receptor-PTK, HEK 2 (human embryo kinase 2), as an additional member of this family, without the need to screen a cDNA library. This approach should be useful for the rapid isolation of other PTK-genes as well. Analysis of genomic DNA placed HEK 2 on chromosome 3. Northern blot analysis demonstrated the expression of a 4.6 kb HEK 2-mRNA in lung, brain, pancreas, liver, placenta, kidney, skeletal muscle, heart and several human cells. In a protein kinase assay with HEK 2-specific immunoprecipitates from the human epidermoid carcinoma cell line A431, a protein of 130 kDa was found phosphorylated.	CHEMOTHERAPEUT FORSCHUNGSINST, GEORG SPEYER HAUS, PAUL EHRLICH STR 42-44, W-6000 FRANKFURT 70, GERMANY	Octapharma			Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLTRICH U, 1991, P NATL ACAD SCI USA, V88, P10411, DOI 10.1073/pnas.88.23.10411; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SHERR CJ, 1990, BLOOD, V75, P1; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V161, P441, DOI 10.1111/j.1432-1033.1986.tb10464.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLECKE K, 1990, EUR J CELL BIOL, V53, P275	26	67	77	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2857	2862						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8397371				2022-12-28	WOS:A1993LX34300030
J	TENDIJKE, P; ICHIJO, H; FRANZEN, P; SCHULZ, P; SARAS, J; TOYOSHIMA, H; HELDIN, CH; MIYAZONO, K				TENDIJKE, P; ICHIJO, H; FRANZEN, P; SCHULZ, P; SARAS, J; TOYOSHIMA, H; HELDIN, CH; MIYAZONO, K			ACTIVIN RECEPTOR-LIKE KINASES - A NOVEL SUBCLASS OF CELL-SURFACE RECEPTORS WITH PREDICTED SERINE THREONINE KINASE-ACTIVITY	ONCOGENE			English	Note								Human cDNA clones encoding four novel putative transmembrane protein serine/threonine kinases, denoted activin receptor-like kinase (ALK) -1, -2, -3 and -4, were obtained using a polymerase chain reaction (PCR)-based strategy. The PCR primers were designed based upon the sequence similarity between the activin receptor type II and Daf-1. The cDNA clones for ALK-1, -2 and -3 encode complete proteins of 503, 509 and 532 amino acids respectively. The ALK-4 cDNA is incomplete and the predicted protein of 383 amino acids has a truncated extracellular domain. The ALKs share similar domain structures, comprising predicted signal sequences at the N-terminals, followed by hydrophilic cysteine-rich ligand-binding domains, single hydrophobic transmembrane regions and C-terminal intracellular portions that consist almost entirety of putative serine/threonine kinase domains. The ALKs have approximately 40% sequence identity to activin receptors type II and IIB, transforming growth factor-beta (TGF-beta) type II receptor and Daf-1 in the kinase domains. However, the sequence identities are higher (60-79%) between ALK-1, -2, -3 and -4, suggesting that they form a subfamily among the putative receptor serine/threonine kinases. The extracellular domains of ALKs show only tittle sequence identity to other putative receptor serine/threonine kinases, but the cysteine residues are conserved. Their structural properties suggest that ALK-1 to -4 are receptors that may bind ligands that are members of the TGF-beta super-family. The expression of mRNA in human tissues varied for the different ALKs; ALK-2 and ALK-4 showed ubiquitous tissue expression patterns, whereas the distribution of ALK-1 and ALK-3 varied strongly between different tissues with more restricted expression patterns. These results suggest that each ALK may have different in vivo functions.	UNIV TOKYO, DEPT INTERNAL MED 3, TOKYO 113, JAPAN	University of Tokyo	TENDIJKE, P (corresponding author), BIOMED CTR, LUDWIG INST CANC RES, BOX 595, S-75124 UPPSALA, SWEDEN.		Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; Ichijo, Hidenori/0000-0002-5005-6438				ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; CHEIFETZ S, 1986, J BIOL CHEM, V261, P9972; CHIEFETZ S, 1992, J BIOL CHEM, V267, P19027; CHIEFETZ S, 1988, J BIOL CHEM, V263, P17225; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; DONALDSON CJ, 1992, BIOCHEM BIOPH RES CO, V184, P310, DOI 10.1016/0006-291X(92)91194-U; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FORAGE RG, 1986, P NATL ACAD SCI USA, V83, P3091, DOI 10.1073/pnas.83.10.3091; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEIN J, 1990, METHOD ENZYMOL, V183, P626; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HINO M, 1989, J BIOL CHEM, V264, P10309; KAMB A, 1989, P NATL ACAD SCI USA, V86, P4372, DOI 10.1073/pnas.86.12.4372; KONDO M, 1991, BIOCHEM BIOPH RES CO, V181, P684, DOI 10.1016/0006-291X(91)91245-8; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LEGERSKI R, 1992, BIOCHEM BIOPH RES CO, V183, P672, DOI 10.1016/0006-291X(92)90535-S; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; MASON AJ, 1985, NATURE, V318, P659, DOI 10.1038/318659a0; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATZUK MM, 1992, BIOCHIM BIOPHYS ACTA, V1130, P105, DOI 10.1016/0167-4781(92)90472-C; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; NAKAMURA T, 1992, J BIOL CHEM, V267, P18924; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; OZKAYNAK E, 1992, J BIOL CHEM, V267, P25220; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; PARALKAR VM, 1991, P NATL ACAD SCI USA, V88, P3397, DOI 10.1073/pnas.88.8.3397; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PONCZ M, 1987, BLOOD, V69, P219; RAZ V, 1991, ONCOGENE, V6, P753; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; SING GK, 1988, BLOOD, V72, P1504; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4863; WANG EA, 1988, P NATL ACAD SCI USA, V85, P9484, DOI 10.1073/pnas.85.24.9484; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	60	314	347	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2879	2887						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8397373				2022-12-28	WOS:A1993LX34300034
J	ABRAHAM, SE; LOBO, S; YACIUK, P; WANG, HGH; MORAN, E				ABRAHAM, SE; LOBO, S; YACIUK, P; WANG, HGH; MORAN, E			P300, AND P300-ASSOCIATED PROTEINS, ARE COMPONENTS OF TATA-BINDING PROTEIN (TBP) COMPLEXES	ONCOGENE			English	Article							E2F TRANSCRIPTION FACTOR; HUMAN ADENOVIRUS TYPE-5; TFIID COMPLEX; DNA-SYNTHESIS; E1A GENE; PRODUCTS; DOMAINS; COACTIVATORS; ACTIVATION; ANTIBODIES	The transforming proteins encoded by the adenovirus E1A gene bind to a 300-kDa cellular product, p300, via the N-terminal E1A sequences. Residues important for p300 binding are required for the transformation function of E1A and for other E1A-mediated gene-regulating functions, including activation of cell cycle-regulated products and repression of tissue-specific enhancer activity. Recent evidence indicates that p300 is a DNA-binding protein with specific affinity for known enhancer motifs, suggesting that p300 may be a component of transcription factor complexes. The possibility that upstream element-binding factors might interact with basal transcription factors led us to investigate whether p300 interacts, directly or indirectly, with the TATA-binding protein (TBP). We report here that TBP-specific immunoprecipitations show a 300-kDa protein co-precipitating with TBP. This protein is lost from the precipitated material if the lysates are boiled in sodium dodecyl sulfate prior to immunoprecipitation, implying that its presence does not result from non-specific antibody cross-reactivity, but is dependent on specific association with TBP. The TBP-associated 300-kDa protein and p300 originally defined by EIA association show indistinguishable partial proteolytic digest patterns, indicating that these are identical or closely related species. Moreover, p300-specific complexes and TBP-specific complexes include at least two additional common polypeptide species, phosphoproteins of 64 and 59 kDa. These results suggest that p300 interacts with TBP, possibly through intermediate protein-protein associations. They thus provide additional biochemical evidence for postulated protein-protein interactions between upstream regulatory factors and the basal transcriptional machinery.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory					NATIONAL CANCER INSTITUTE [R01CA055330, R01CA053592] Funding Source: NIH RePORTER; NCI NIH HHS [CA-53592, CA-55330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; DYSON N, 1992, CANCER SURV, V12, P161; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LISCHWE MA, 1977, J BIOL CHEM, V252, P4976; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MORAN B, 1988, MOL CELL BIOL, V8, P1756, DOI 10.1128/MCB.8.4.1756; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X	41	132	134	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1639	1647						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502484				2022-12-28	WOS:A1993LE06400028
J	CARBONAROHALL, D; WILLIAMS, R; WU, LT; WARBURTON, D; ZEICHNERDAVID, M; MACDOUGALL, M; TOLO, V; HALL, F				CARBONAROHALL, D; WILLIAMS, R; WU, LT; WARBURTON, D; ZEICHNERDAVID, M; MACDOUGALL, M; TOLO, V; HALL, F			G1 EXPRESSION AND MULTISTAGE DYNAMICS OF CYCLIN-A IN HUMAN OSTEOSARCOMA CELLS	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; P34CDC2 PROTEIN-KINASE; MATURATION-PROMOTING FACTOR; DNA-BINDING PROTEIN; CDC2 PROTEIN; TRANSCRIPTION FACTOR; HISTONE-H1 KINASE; RB PROTEIN; M-PHASE; PHOSPHORYLATION	Cyclin A was initially characterized as a 'mitotic cyclin', believed to function exclusively at the G2-to-M phase transition; however, recent studies have provided compelling evidence that cyclin A additionally functions earlier in the mammalian somatic cell cycle as a putative 'S-phase-promoting factor'. Moreover, numerous inconsistencies have arisen concerning the temporal induction, subcellular localization, subunit configuration, covalent modification and proteolytic destruction of cyclin A, as well as the physiological function of the cyclin A-associated protein kinase complexes. Utilizing precisely synchronized human MG-63 osteosarcoma cells, the present study demonstrates that cyclin A mRNA and protein are clearly expressed in late G1 prior to S-phase entry, as is cyclin A-associated kinase activity and concomitant phosphorylation of the Rb protein. A series of monospecific cyclin A antibodies were generated and utilized to confirm that multiple covalent modifications of cyclin A occur during the course of the cell cycle, and to characterize the subcellular dynamics in additional detail. Pharmacological blockade with mimosine was utilized to further delineate cyclin A expression and to distinguish the temporal induction from the mechanisms of enzyme activation. Subcellular fractionation and immunocytochemical staining localized nascent cyclin A to the cytoplasm, and revealed a distinct translocation to the nucleus during the G1-to-S phase transition. The results of these studies support a multistage model of cyclin A metabolism and enzyme activation.	CHILDRENS HOSP, DIV ORTHOPAED SURG, 4650 SUNSET BLVD, LOS ANGELES, CA 90054 USA; UNIV SO CALIF, SCH MED, LOS ANGELES, CA 90033 USA; CHILDRENS HOSP, DIV NEONATAL & PEDIAT PULM, LOS ANGELES, CA 90054 USA; UNIV SO CALIF, SCH DENT, LOS ANGELES, CA 90089 USA; UNIV SO CALIF, CTR CRANIOFACIAL MOLEC BIOL, LOS ANGELES, CA 90089 USA; UNIV SO CALIF, SCH PHARM, LOS ANGELES, CA 90089 USA; UNIV SO CALIF, DEPT MOLEC PHARMACOL & TOXICOL, LOS ANGELES, CA 90089 USA	Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; University of Southern California; University of Southern California; University of Southern California; University of Southern California			Zeichner-David, Margarita/A-6567-2008					BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BLANQUET V, 1990, GENOMICS, V8, P595, DOI 10.1016/0888-7543(90)90052-V; BOUCHER P, 1988, J VIROL, V62, P534, DOI 10.1128/JVI.62.2.534-544.1988; Braun R K, 1989, Proc West Pharmacol Soc, V32, P15; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHAMBERS TC, 1990, J BIOL CHEM, V265, P16940; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; Cooper JA, 1990, CURR OPIN CELL BIOL, V2, P285, DOI 10.1016/0955-0674(90)90021-6; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; ERIKSON E, 1989, J BIOL CHEM, V264, P19577; FOX MH, 1987, CYTOMETRY, V8, P315, DOI 10.1002/cyto.990080312; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOSCIN LP, 1982, BIOCHEMISTRY-US, V21, P2513, DOI 10.1021/bi00539a034; HALL FL, 1990, J BIOL CHEM, V265, P6944; HALL FL, 1991, J BIOL CHEM, V266, P17430; Hall FL, 1991, CURR OPIN CELL BIOL, V3, P176, DOI 10.1016/0955-0674(91)90136-M; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; HUNT T, 1991, NATURE, V350, P462, DOI 10.1038/350462a0; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; Kulp K S, 1990, Proc West Pharmacol Soc, V33, P219; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LALANDE M, 1990, EXP CELL RES, V188, P117, DOI 10.1016/0014-4827(90)90285-I; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LU XP, 1992, J BIOL CHEM, V267, P2841; LUCA FC, 1989, J CELL BIOL, V109, P1895, DOI 10.1083/jcb.109.5.1895; Maniatis T., 1982, MOL CLONING; MARIA T, ONCOGENE, V43, P477; MARX J, 1991, SCIENCE, V252, P1490, DOI 10.1126/science.1828620; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MINSHULL J, 1989, J CELL SCI, P77; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MURRAY AW, 1991, NATURE, V349, P367, DOI 10.1038/349367a0; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NORBURY CJ, 1989, BIOCHIM BIOPHYS ACTA, V989, P85, DOI 10.1016/0304-419X(89)90036-X; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1990, New Biologist, V2, P389; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SAMIEI M, 1991, J BIOL CHEM, V266, P14889; SANGHERA JS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P335, DOI 10.1016/0167-4889(92)90240-C; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TAMURA T, 1990, ONCOGENE, V5, P1259; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; Vulliet P R, 1988, Proc West Pharmacol Soc, V31, P255; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WAGNER S, 1991, NATURE, V352, P189, DOI 10.1038/352189a0; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WHITE BA, 1982, J BIOL CHEM, V257, P8569; WILLIAMS RT, 1992, ONCOGENE, V7, P423; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	77	55	55	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1993	8	6					1649	1659						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502485				2022-12-28	WOS:A1993LE06400029
J	SCHWARTZ, D; GOLDFINGER, N; ROTTER, V				SCHWARTZ, D; GOLDFINGER, N; ROTTER, V			EXPRESSION OF P53 PROTEIN IN SPERMATOGENESIS IS CONFINED TO THE TETRAPLOID PACHYTENE PRIMARY SPERMATOCYTES	ONCOGENE			English	Article							WILD-TYPE P53; T-ANTIGEN; CELL-DEVELOPMENT; DNA-REPLICATION; SV40 ORIGIN; MUTANT; ONCOGENE; TRANSFORMATION; LOCALIZATION; INVITRO	The various steps of differentiation and maturation in spermatogenesis are well characterized and offer a convenient system to explore the possibility that p53 plays a role in cell differentiation in vivo. In situ hybridization experiments indicate that the p53 gene is expressed in tetraploid primary spermatocytes at the meiotic pachytene stage of the first round of spermatogenesis in young mice. An analysis of spermatogenic cells treated with anti-p53 antibodies reveals that the p53 protein is expressed in a discrete tetraploid cell population, with size and cellular structure parameters characteristic of mid-pachytene spermatocytes. The specific kinetics of p53 expression in the first round of spermatogenesis and its localization in adult testicular sections, coupled with the fact that the protein is expressed in the largest cells with lower DNA density, suggest that p53 expression is confined to the tetraploid primary spermatocytes of the meiotic pachytene phase. These observations identify p53 protein as a potential member of the meiosis control protein family.	WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ALCIVAR AA, 1992, BIOL REPROD, V46, P201, DOI 10.1095/biolreprod46.2.201; ALMON E, 1993, IN PRESS DEV BIOL; AUSTIN CR, 1982, GERM CELLS FERTILIZA; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHEN YM, 1991, ONCOGENE, V6, P1799; DILLER L, 1990, MOL CELL BIOL, V10, P5722; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOGEN B, 1986, MANIPULATING MOUSE E; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JANCA FC, 1986, BIOL REPROD, V34, P613, DOI 10.1095/biolreprod34.4.613; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7492; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MORA PT, 1980, NATURE, V288, P722, DOI 10.1038/288722a0; NEVEL BR, 1961, SCIENCE, V143, P832; PROPST F, 1988, ONCOGENE, V2, P227; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REISMAN D, 1993, IN PRESS CELL GROWTH; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; SAHW P, 1992, P NATL ACAD SCI USA, V89, P4495; SCHMID P, 1991, DEVELOPMENT, V113, P857; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1991, CANCER RES, V51, P5232; SHOHATFOORD O, 1991, NUCLEIC ACIDS RES, V19, P5191; STURZBECHER HW, 1988, ONCOGENE, V3, P405; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907; WOLGEMUTH DJ, 1991, MAMM GENOME, V1, P283, DOI 10.1007/BF00352340; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	49	140	146	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1487	1494						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502474				2022-12-28	WOS:A1993LE06400011
J	BACKER, JM; MENDOLA, CE; KOVESDI, I; FAIRHURST, JL; OHARA, B; EDDY, RL; SHOWS, TB; MATHEW, S; MURTY, VVVS; CHAGANTI, RSK				BACKER, JM; MENDOLA, CE; KOVESDI, I; FAIRHURST, JL; OHARA, B; EDDY, RL; SHOWS, TB; MATHEW, S; MURTY, VVVS; CHAGANTI, RSK			CHROMOSOMAL LOCALIZATION AND NUCLEOSIDE DIPHOSPHATE KINASE-ACTIVITY OF HUMAN METASTASIS-SUPPRESSOR GENES NM23-1 AND NM23-2	ONCOGENE			English	Note							HUMAN BREAST-CANCER; INSITU HYBRIDIZATION; BINDING-PROTEINS; TUMOR-METASTASIS; GOOD PROGNOSIS; HUMAN GENOME; EXPRESSION; ASSOCIATION; IDENTIFICATION; AMPLIFICATION	Human metastasis-suppressor genes nm23-1 (NME1) and nm23-2 (NME2) are implicated in control of the metastatic potential of malignant cells. Using somatic cell hybrid analysis and fluorescence in situ hybridization we co-localized both genes to 17q21.3. The 17q21 region carries the locus responsible for early-onset familial breast-ovarian cancer and several other genes that are involved in tumorigenesis and differentiation and undergo frequent rearrangements during neoplastic development. Thus, our mapping places the NME genes in a region that may be subjected to multiple selection pressures. NME1 and NME2 genes were expressed as soluble proteins in a T7 bacterial expression system. Both proteins are independently active nucleoside diphosphate kinases and readily form intra- and intermolecular disulfide bonds. The biochemical properties of these proteins may explain the diversity of mature eucaryotic nucleoside diphosphate kinases.	NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,DEPT HUMAN GENET,BUFFALO,NY 14263; MEM SLOAN KETTERING CANC CTR,CANC GENET LAB,NEW YORK,NY 10021	Roswell Park Cancer Institute; Memorial Sloan Kettering Cancer Center	BACKER, JM (corresponding author), AMER CYANAMID CO,LEDERLE LABS,MOLEC BIOL RES SECT,PEARL RIVER,NY 10965, USA.			Kovesdi, Imre/0000-0002-0322-3969				ABERDAM D, 1991, MOL CELL BIOL, V11, P554, DOI 10.1128/MCB.11.1.554; BACKER JM, 1991, AIDS RES HUM RETROV, V7, P1015, DOI 10.1089/aid.1991.7.1015; BARNES R, 1991, AM J PATHOL, V139, P245; BEVILACQUA G, 1990, PATHOL BIOL, V38, P774; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CLARK GM, 1991, CANCER RES, V51, P944; COHN KH, 1991, LANCET, V338, P722, DOI 10.1016/0140-6736(91)91444-Y; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; FAN YS, 1990, P NATL ACAD SCI USA, V87, P6223, DOI 10.1073/pnas.87.16.6223; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRANCIS B, 1989, MOL CARCINOGEN, V2, P168, DOI 10.1002/mc.2940020310; GILLES AM, 1991, J BIOL CHEM, V266, P8784; HAILAT N, 1991, J CLIN INVEST, V88, P341, DOI 10.1172/JCI115299; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HAUT M, 1991, J NATL CANCER I, V83, P712, DOI 10.1093/jnci/83.10.712; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; HENNESSY C, 1991, BRIT J CANCER, V63, P1024, DOI 10.1038/bjc.1991.223; HIRAYAMA R, 1991, J NATL CANCER I, V83, P1249, DOI 10.1093/jnci/83.17.1249; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KIKKAWA S, 1990, J BIOL CHEM, V265, P21536; LACOMBE ML, 1991, EUR J CANCER, V27, P1302, DOI 10.1016/0277-5379(91)90101-I; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1991, CANCER RES, V51, P2490; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1990, J NATL CANCER I, V82, P1170, DOI 10.1093/jnci/82.14.1170; MCALPINE PJ, 1991, CYTOGENET CELL GENET, V58, P5, DOI 10.1159/000133160; NAROD SA, 1991, LANCET, V338, P82; NEEL BG, 1982, P NATL ACAD SCI-BIOL, V79, P7842, DOI 10.1073/pnas.79.24.7842; OHTSUKI K, 1987, BIOCHEM BIOPH RES CO, V148, P300, DOI 10.1016/0006-291X(87)91110-7; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SASTREGARAU X, 1992, INT J CANCER, V50, P533, DOI 10.1002/ijc.2910500406; SHOWS T, 1984, SOMAT CELL MOLEC GEN, V10, P315, DOI 10.1007/BF01535253; SHOWS TB, 1983, ISOZYMES-CURR T BIOL, V10, P323; SHOWS TB, 1978, CYTOGENET CELL GENET, V21, P99, DOI 10.1159/000130882; SHOWS TB, 1982, ADV HUM GENET, V12, P341; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STEEG PS, 1989, CANCER METASTASIS, P48; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VARESCO L, 1992, GENE CHROMOSOME CANC, V4, P84, DOI 10.1002/gcc.2870040113; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WHITE JJ, 1991, GENOMICS, V11, P228, DOI 10.1016/0888-7543(91)90126-Y; ZABEL BU, 1983, P NATL ACAD SCI-BIOL, V80, P6932, DOI 10.1073/pnas.80.22.6932	47	139	144	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					497	502						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8381224				2022-12-28	WOS:A1993KN00600030
J	VASTRIK, I; KOSKINEN, PJ; ALITALO, R; MAKELA, TP				VASTRIK, I; KOSKINEN, PJ; ALITALO, R; MAKELA, TP			ITERNATIVE MESSENGER-RNA FORMS AND OPEN READING FRAMES OF THE MAX GENE	ONCOGENE			English	Note							DNA-BINDING; MYC	The max gene encodes a heterodimeric partner of Myc. We have recently identified an alternative max mRNA (DELTAmax) that contains an additional internal exon introducing an in-frame translational termination. Here we have studied the expression of human max mRNAs by Northern blotting analysis. In addition to the major 2.3-kb mRNA form, four bands were identified. Our results indicate that these bands represent differentially spliced mRNA forms, which contain altogether three open reading frames. In addition to the previously identified Max and DELTAMax proteins, sequence analysis of a 3.5-kb mRNA form predicted a protein that resembles DELTAMax in structure. Like DELTAMax, this protein enhanced the number of transformed foci in the ras-myc co-transformation assay. Although the 3.5-kb mRNA represents a minor form in actively proliferating cells, a shift from the major 2.3-kb mRNA to the 3.5-kb form was observed in response to high cell densitiy or acidification of the growth medium. Our results indicate the presence of several differentially spliced mRNA forms of the max gene, and suggest a possible mechanism for the production of functionally distinct Max proteins.	UNIV HELSINKI, DEPT PATHOL, CANC BIOL LAB, SF-00290 HELSINKI 29, FINLAND; UNIV HELSINKI, CENT HOSP, TRANSPLANTAT LAB, SF-00290 HELSINKI 29, FINLAND	University of Helsinki; University of Helsinki; Helsinki University Central Hospital	VASTRIK, I (corresponding author), UNIV HELSINKI, DEPT VIROL, CANC BIOL LAB, HAARTMANINKATU 3, SF-00290 HELSINKI 29, FINLAND.		Vastrik, Imre/C-2690-2009; makela, tomi/B-3734-2009; Koskinen, Päivi J/G-8939-2014	makela, tomi/0000-0002-4869-8044; 				BERBERICH S, 1992, ONCOGENE, V7, P775; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLACKWOOD EM, 1992, IN PRESS CURR OPIN G; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MAKELA TP, 1992, GENE, V118, P293, DOI 10.1016/0378-1119(92)90203-2; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SPENCER CA, 1991, ADV CANCER RES, V56, P1; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111	13	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					503	507						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426752				2022-12-28	WOS:A1993KN00600031
J	CHEN, JH; JEHA, S; OKA, T				CHEN, JH; JEHA, S; OKA, T			NEGATIVE REGULATORY ELEMENTS IN THE HUMAN ETS1 GENE PROMOTER	ONCOGENE			English	Article							LONG TERMINAL REPEAT; ONCOGENE C-ETS; DNA-BINDING; LOCALIZATION; EXPRESSION; PROTEIN; CELLS; IDENTIFICATION; THYMOCYTES; SEQUENCE	The human ETS1 gene promoter contains binding sites for transcription factors AP1, AP2 and ETS. These factors have been previously shown to be positive regulators for the expression of the ETS1 gene. In our previous report it was inferred that the ETS1 gene promoter also contains negative regulatory elements that might balance and prevent the overexpression of the ETS1 gene product. The studies reported here show that the ETS1 gene promoter also contains binding site motifs for transcription factors PEA3 and OCT. By subjecting deletion constructs of the ETS1 gene promoter to functional analysis, two negative regulatory elements (NREs) were located: NRE1 was mapped to 230 nt at the 5' end of the promoter, and NRE2 was mapped to 350 nt located between the second OCT motif and a 120-base sequence downstream from the SacI site. These NREs can also reduce the activity of a heterogeneous promoter. Gel mobility-shift assays showed that nuclear extracts from B-lymphoid (Daudi), T-lymphoid (HPB) and erthyromyeloid (K562) cells each form one major and several minor complexes with NRE1 and NRE2. The nuclear extract from promyelocytic (HL60) cells does not form complexes with either NRE1 or NRE2. The identification of NREs in the ETS1 gene promoter suggests that these elements play an important role in regulating the ETS1 gene expression in hematopoietic cells.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOLEC GENET,HOUSTON,TX 77030; ASAHIKAWA MED COLL,DEPT PEDIAT,ASAHIKAWA 07811,JAPAN	University of Texas System; UTMD Anderson Cancer Center; Asahikawa Medical College	CHEN, JH (corresponding author), UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT EXPTL PHYS,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.							BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; DETAISNE C, 1984, NATURE, V310, P581, DOI 10.1038/310581a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FISHER RJ, 1991, ONCOGENE, V6, P2249; FUJIWARA S, 1988, ONCOGENE, V2, P99; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; JORCYK CL, 1991, ONCOGENE, V6, P523; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OKA T, 1991, ONCOGENE, V6, P2077; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; SACCHI N, 1988, LEUKEMIA, V2, P12; STRONG RC, 1985, BLOOD, V65, P21; SVAREN J, 1987, NUCLEIC ACIDS RES, V21, P8739; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WOOD WM, 1989, J BIOL CHEM, V264, P14840; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	27	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					133	139						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423991				2022-12-28	WOS:A1993KN00500016
J	SLEEMAN, JP; LASKEY, RA				SLEEMAN, JP; LASKEY, RA			XENOPUS C-SKI CONTAINS A NOVEL COILED-COIL PROTEIN DOMAIN, AND IS MATERNALLY EXPRESSED DURING DEVELOPMENT	ONCOGENE			English	Article							MESSENGER-RNA; ONCOGENE PRODUCT; SKELETAL-MUSCLE; TGF-BETA; SEQUENCE; CLONING; CELLS; GENE; DIFFERENTIATION; IDENTIFICATION	v-ski is a virally transduced nuclear oncogene. The biology of its cellular progenitors is only poorly understood. The early development of Xenopus laevis provides an excellent model system for studying the role of genes in proliferation, differentiation and development. We have therefore characterized Xenopus c-ski. We report that Xenopus c-ski transcripts are maternally regulated during early development, and are widely expressed in adult tissues. Structural predictions indicate the presence of a previously unreported extensive C-terminal helical domain in Xenopus c-ski and ski-related proteins from other species. This domain shows homologies with proteins which contain heptad repeats characteristic of elongated coiled-coil formation, like myosin and the intermediate filament proteins, and itself has a heptad repeat structure. The ski C-terminal domain also contains two other previously unreported elements, a novel strictly alternating hydrophobic-basic motif that repeats along the helical domain, and an underlying 25-mer repeated sequence. The significance of these findings is discussed with reference to c-ski function and to the oncogenic activation of v-ski, which is a truncated version of c-ski and thus does not have the C-terminal helical domain.	WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND				Sleeman, Jonathan P/H-2515-2013	Sleeman, Jonathan P/0000-0003-1718-7687				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARKAS AE, 1986, VIROLOGY, V151, P131, DOI 10.1016/0042-6822(86)90111-X; Berger S.L., 1987, METHODS ENZYMOLOGY, V152; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BISBEE CA, 1977, SCIENCE, V195, P785, DOI 10.1126/science.65013; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CLAYCOMB WC, 1987, BIOCHEM J, V247, P701, DOI 10.1042/bj2470701; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; COLMENARES C, 1991, MOL CELL BIOL, V11, P1167, DOI 10.1128/MCB.11.2.1167; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DALE RMK, 1985, PLASMID, V13, P31, DOI 10.1016/0147-619X(85)90053-8; Davidson E. H., 1986, GENE ACTIVITY EARLY; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; ENOCH T, 1991, J CELL BIOL, V112, P797, DOI 10.1083/jcb.112.5.797; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUNAHASHI S, 1988, J GEN VIROL, V69, P35, DOI 10.1099/0022-1317-69-1-35; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GREEN KJ, 1990, J BIOL CHEM, V265, P2603; Gurdon J.B., 1977, Methods Cell Biol, V16, P125; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOYLE GW, 1988, J BIOL CHEM, V263, P7487; KAVINSKY CJ, 1984, J BIOL CHEM, V259, P2775; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KIRSCHNER M, 1985, TRENDS GENET, V1, P41, DOI 10.1016/0168-9525(85)90021-6; KLYMKOWSKY MW, 1989, DEV BIOL, V134, P479, DOI 10.1016/0012-1606(89)90121-8; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MANJULA BN, 1984, J BIOL CHEM, V259, P3686; McKeon F, 1991, CURR OPIN CELL BIOL, V3, P82, DOI 10.1016/0955-0674(91)90169-Y; NAGASE T, 1990, NUCLEIC ACIDS RES, V18, P337, DOI 10.1093/nar/18.2.337; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; PARRY DAD, 1981, J MOL BIOL, V153, P459, DOI 10.1016/0022-2836(81)90290-4; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; Robson RM, 1989, CURR OPIN CELL BIOL, V1, P36, DOI 10.1016/S0955-0674(89)80034-1; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P431; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; Stavnezer E., 1988, ONCOGENE HDB, P393; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; SUTRAVE P, 1989, MOL CELL BIOL, V9, P4046, DOI 10.1128/MCB.9.9.4046; SUTRAVE P, 1991, ONCOGENE, V6, P353; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; [No title captured]	50	36	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					67	77						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423997				2022-12-28	WOS:A1993KN00500008
J	Gleeson, CM; Sloan, JM; McGuigan, JA; Ritchie, AJ; Weber, JL; Russell, SEH				Gleeson, CM; Sloan, JM; McGuigan, JA; Ritchie, AJ; Weber, JL; Russell, SEH			Widespread microsatellite instability occurs infrequently in adenocarcinoma of the gastric cardia	ONCOGENE			English	Article						adenocarcinoma; gastric cardia; microsatellite instability; replication errors; DNA mismatch repair	NONPOLYPOSIS COLORECTAL-CANCER; LYNCH SYNDROME-II; GENETIC INSTABILITY; CARCINOMA; MUTATIONS; HOMOLOG; HISTORY; FAMILY; TUMORS; COLON	Hereditary non-polyposis colorectal cancer (HNPCC) is associated with an increased predisposition to colorectal cancer and extra-colonic cancers of the gastro-intestinal, urological and female reproductive tracts, These tumours are characterised by an underlying defect in DNA mismatch repair and exhibit numerous replication errors throughout the genome (RER(+) phenotype), HNPCC-associated gastric tumours, and a subset of sporadic, distally-located gastric tumours exhibit this RER(+) phenotype, It is recognised that proximal gastric tumours exhibit distinct epidemiological features, In this study we investigated the occurrence of microsatellite instability in a series of 38 primary gastric adenocarcinomas, arising in the proximal stomach, A total of 138 microsatellite markers, comprising mainly dinucleotide and tetranucleotide repeat units and covering all autosomal arms, excluding acrocentric arms, were analysed, One tumour demonstrated somatic microsatellite alterations at 62% (26 of 42) of loci tested, A further 32 tumours demonstrated levels of microsatellite instability ranging from 0.8% (1 of 128)-11.4% (15 of 132) of loci tested, Five tumours demonstrated no microsatellite alterations at any of the loci tested, These findings suggest that a high percentage of proximal gastric carcinomas exhibit a low level of microsatellite alterations at dinucleotide and tetranucleotide repeat loci, However, ubiquitous somatic alterations at these loci, characteristic of HNPCC-associated tumours, occur in a relatively small proportion of tumours.	QUEENS UNIV BELFAST,BELFAST CITY HOSP,DEPT MED GENET,BELFAST BT9 7AB,ANTRIM,NORTH IRELAND; ROYAL VICTORIA HOSP,DEPT PATHOL,BELFAST BT12 6BJ,ANTRIM,NORTH IRELAND; ROYAL VICTORIA HOSP,REG THORAC UNIT,BELFAST BT12 6BJ,ANTRIM,NORTH IRELAND; MARSHFIELD MED RES FDN,MARSHFIELD,WI 54449	Belfast City Hospital; Queens University Belfast					PHS HHS [NG00835] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CRISTOFARO G, 1987, CANCER, V60, P51, DOI 10.1002/1097-0142(19870701)60:1<51::AID-CNCR2820600110>3.0.CO;2-V; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FONG KM, 1995, CANCER RES, V55, P28; GAO XA, 1994, ONCOGENE, V9, P2999; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; HAN HJ, 1993, CANCER RES, V53, P5087; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KNUDSON AG, 1985, CANCER RES, V45, P1437; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAUREN P, 1965, ACTA PATHOL MIC SC, V5, P145; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LOTHE RA, 1993, CANCER RES, V53, P5849; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; LYNCH HT, 1988, AM J GASTROENTEROL, V83, P741; MELTZER SJ, 1994, CANCER RES, V54, P3379; MERLO A, 1994, CANCER RES, V54, P2098; MIRONOV NM, 1994, CANCER RES, V54, P41; NEW L, 1993, MOL GEN GENET, V239, P97, DOI 10.1007/BF00281607; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; OGASAWARA S, 1995, CANCER RES, V55, P891; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PEINADO MA, 1992, P NATL ACAD SCI USA, V89, P10065, DOI 10.1073/pnas.89.21.10065; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PELTOMAKI P, 1993, CANCER RES, V53, P5853; POWELL J, 1990, BRIT J CANCER, V62, P440, DOI 10.1038/bjc.1990.314; RHYU MG, 1994, ONCOGENE, V9, P29; RISINGER JI, 1993, CANCER RES, V53, P5100; SERUCA R, 1995, INT J CANCER, V64, P32, DOI 10.1002/ijc.2910640108; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SHRIDHAR V, 1994, CANCER RES, V54, P2084; SIDONI A, 1989, TUMORI, V75, P605, DOI 10.1177/030089168907500619; STRICKLER JG, 1994, CANCER RES, V54, P4750; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; YEE CJ, 1994, CANCER RES, V54, P1641	45	41	41	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1653	1662						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622885				2022-12-28	WOS:A1996UG45800007
J	DelSal, G; Murphy, M; Ruaro, EM; Lazarevic, D; Levine, AJ; Schneider, C				DelSal, G; Murphy, M; Ruaro, EM; Lazarevic, D; Levine, AJ; Schneider, C			Cyclin D1 and p21/waf1 are both involved in p53 growth suppression	ONCOGENE			English	Article						cyclin; D1; p53; p21/waf1; cell cycle G1 arrest	WILD-TYPE P53; CELL-CYCLE; DEPENDENT KINASES; PROTEIN; APOPTOSIS; GENE; DNA; TRANSFORMATION; FIBROBLASTS; INHIBITION	Overexpression of the wild type p53 gene in normal and transformed cells induces G1 arrest of cellular proliferation. In cell lines carrying the valine 135 temperature-sensitive p53 mutant gene, restoration of wild type p53 protein conformation at the permissive temperature causes an increase in the levels of cyclin D1, as well as the cyclin/cdk inhibitor p21/waf1, Accumulation of cyclin D1 is the result both of (post)transcriptional and post-translational regulatory mechanisms. Ablation of cyclin D1 induction by antisense cDNA microinjection significantly delays the onset of growth arrest, indicating that increased cyclin D1 levels Likely contribute to wild type p53 G1 arrest. Whereas antisense ablation of either cyclin D1 or p21/waf1 can delay the onset of p53-induced growth arrest, ablation of neither is able to overcome a pre-existing p53-induced G1 block. In summary, the accumulated evidence indicate that induction of both cyclin D1 and p21/waf1 are involved in establishing the p53-mediated growth arrest in murine cell lines expressing temperature sensitive p53 protein.	LAB NAZL CONSORZIO INTERUNIV BIOTECHNOL, I-34012 TRIESTE, ITALY; INT CTR GENET ENGN & BIOTECHNOL, I-34012 TRIESTE, ITALY; DIPARTIMENTO BIOCHIM BIOFIS & CHIM MACROMOLEC VL, I-34012 TRIESTE, ITALY; PRINCETON UNIV, LEWIS THOMAS LAB, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA	International Center for Genetic Engineering & Biotechnology (ICGEB); Princeton University			Lazarevic, Dejan/AAN-1861-2020	DEL SAL, GIANNINO/0000-0003-2185-6003; Murphy, Maureen/0000-0001-7644-7296; lazarevic, dejan/0000-0003-4527-290X				ATADJA P, 1995, EXP CELL RES, V217, P205, DOI 10.1006/excr.1995.1080; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P1633; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; EIZENBERG O, 1995, EMBO J, V14, P1136, DOI 10.1002/j.1460-2075.1995.tb07097.x; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TAM SW, 1994, ONCOGENE, V9, P2663; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	47	71	73	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	1996	12	1					177	185						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552389				2022-12-28	WOS:A1996TQ01400022
J	Vider, BZ; Zimber, A; Chastre, E; Prevot, S; Gespach, C; Estlein, D; Wolloch, Y; Tronick, SR; Gazit, A; Yaniv, A				Vider, BZ; Zimber, A; Chastre, E; Prevot, S; Gespach, C; Estlein, D; Wolloch, Y; Tronick, SR; Gazit, A; Yaniv, A			Evidence for the involvement of the Wnt 2 gene in human colorectal cancer	ONCOGENE			English	Article						Wnt genes; colorectal cancer	MAMMARY ONCOGENE INT-1; WINGLESS PROTEIN; DEVELOPMENTAL REGULATORS; PROVIRAL ACTIVATION; CELL-LINE; EXPRESSION; XENOPUS; EMBRYOS; TRANSFORMATION; FAMILY	Colorectal cancer (CRC) is onte of the most frequent cancers in humans. It develops via a multistage process involving alterations of both protooncogenes and tumor suppressor genes. In the present report we determined the level of expression of several Wnt genes in CRC by RT-PCR and direct sequencing. While Wnt-1 was not detectably expressed in any colonic tissues, Wnt-5a gene was efficiently expressed both in nontumorous as well as in colonic tumor tissues. In contrast, the Wnt-2 gene, which was expressed at low levels in normal colon, exhibited overexpression in all tumor tissue samples at the different Dukes' stages of CRC progression, including premalignant polyps and liver metastases. Overexpression of the Wnt-2 gene occurred also in other digestive neoplasms such as gastric and esophageal carcinomas, as well as in diverticulitis associated with stenosis or pseudo-tumor.	TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN MICROBIOL,IL-69978 TEL AVIV,ISRAEL; HEBREW UNIV JERUSALEM,DEPT ANIM SCI,IL-76100 REHOVOT,ISRAEL; HOSP ST ANTOINE,INSERM,U55,EQUIPE CANCEROGENESE & DIFFERENCIAT EPITHELIUM GA,F-75571 PARIS 12,FRANCE; HASHARON HOSP,DEPT SURG B,PETAH TIQWA,ISRAEL; SANTA CRUZ BIOTECHNOL,SANTA CRUZ,CA 95060	Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Rabin Medical Center			CHASTRE, Eric/L-8446-2018	CHASTRE, Eric/0000-0002-8993-1228				BLASBAND A, 1992, ONCOGENE, V7, P153; BOS JL, 1989, CANCER RES, V49, P4682; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; BUHLER TA, 1993, DEV BIOL, V155, P87, DOI 10.1006/dbio.1993.1009; BURKITT DP, 1978, AM J CLIN NUTR, V31, P118; CABALLERO OL, 1995, NUCLEIC ACIDS RES, V23, P192, DOI 10.1093/nar/23.1.192; CHAKRABARTI A, 1992, DEVELOPMENT, V115, P355; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK CC, 1993, GENOMICS, V18, P249, DOI 10.1006/geno.1993.1463; COHN KH, 1991, LANCET, V338, P722, DOI 10.1016/0140-6736(91)91444-Y; DEVITA G, 1993, EUR J CANCER, V29A, P887, DOI 10.1016/S0959-8049(05)80432-0; Dickinson ME, 1992, CURR OPIN GENET DEV, V2, P562, DOI 10.1016/S0959-437X(05)80172-8; DUKAS K, 1993, ANAL BIOCHEM, V215, P66, DOI 10.1006/abio.1993.1555; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY GJ, 1993, MUTAT RES, V290, P3, DOI 10.1016/0027-5107(93)90027-D; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HUGUET EL, 1994, CANCER RES, V54, P2615; HULSKEN J, 1994, CURR OPIN CELL BIOL, V6, P711, DOI 10.1016/0955-0674(94)90098-1; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; KITAJEWSKI J, 1992, MOL CELL BIOL, V12, P784, DOI 10.1128/MCB.12.2.784; LAWRENCE HJ, 1992, BLOOD, V80, P2445; LEJEUNE S, 1995, CLIN CANCER RES, V1, P215; LYNCH HT, 1992, CANCER, V70, P1300, DOI 10.1002/1097-0142(19920901)70:3+<1300::AID-CNCR2820701517>3.0.CO;2-O; MCCREA PD, 1993, J CELL BIOL, V123, P477, DOI 10.1083/jcb.123.2.477; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MOON RT, 1993, BIOESSAYS, V15, P91, DOI 10.1002/bies.950150204; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; OLSON DJ, 1994, CELL GROWTH DIFFER, V5, P197; PAINTER NS, 1971, BMJ-BRIT MED J, V2, P450, DOI 10.1136/bmj.2.5759.450; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PARKIN NT, 1993, GENE DEV, V7, P2181, DOI 10.1101/gad.7.11.2181; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; PORTE H, 1995, INT J CANCER, V64, P1; RAMAKRISHNA NR, 1993, DEVELOPMENT, P95; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; RODRIGUEZ E, 1994, CANCER RES, V54, P3398; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; ROELINK H, 1992, ONCOGENE, V7, P487; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; VANOOYEN A, 1985, EMBO J, V4, P2905, DOI 10.1002/j.1460-2075.1985.tb04021.x; WAINWRIGHT BJ, 1988, EMBO J, V7, P1743, DOI 10.1002/j.1460-2075.1988.tb03003.x; WANG LM, 1993, CANCER RES, V53, P717; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; ZAKANY J, 1993, NATURE, V362, P546, DOI 10.1038/362546a0	62	105	112	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					153	158						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552386				2022-12-28	WOS:A1996TQ01400019
J	Frank, R; Zhang, J; Uchida, H; Meyers, S; Hiebert, SW; Nimer, SD				Frank, R; Zhang, J; Uchida, H; Meyers, S; Hiebert, SW; Nimer, SD			The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B	ONCOGENE			English	Article						AML1/ETO; AML1B; GM-CSF promoter; transcriptional activation	COLONY-STIMULATING FACTOR; ACUTE MYELOID-LEUKEMIA; CELL RECEPTOR-DELTA; TRANSCRIPTIONAL ENHANCER; DNA-BINDING; TRANSLOCATION PROTEIN; REGULATORY ELEMENTS; ENDOTHELIAL-CELLS; GENE; RUNT	The t(8;21) translocation, commonly found myelogenous leukemia (AML), generates protein containing N-terminal AML1 and C-terminal ETO amino acids. The human AML1 gene encodes several related proteins that specifically bind to the sequence TGT/cGGT, located in the promoter regions of a variety of hematopoietic growth factor genes. To examine the abilities of the AML1B protein (which contains 479 amino acids), a shorter AML1A isoform (which contains amino acids 1-250), and the AML1/ETO fusion protein (which contains AML1A amino acids 1-177) to stimulate transcription from the GMCSF promoter, we performed co-transfection experiments in T cells using a human GM-CSF promoter-CAT reporter gene plasmid and expression vectors that contain the cDNAs for one of the above proteins, Our data demonstrate that AML1B, but not AML1A or AML1/ETO transactivates the GM-CSF promoter, requiring the TGTGGT sequence contained between base pairs -68 and -53. Furthermore, we show that AML1/ETO, but not AML1A, inhibits the ability of AML1B to stimulate CAT expression. Electrophoretic mobility shift assays demonstrated the specific binding of AML1 proteins to the GM-CSF promoter TGTGGT sequence, which does not require GM-CSF sequences immediately upstream of this binding site. Our data support a role for AML1B as a transcriptional activator and establish that the AML1/ETO fusion protein can act as a dominant negative protein on the human GMCSF promoter. Although AML1/ETO does not stimulate the transcription of GM-CSF, it may function by inhibiting the normal activity of AML1B in AML cells with the t(8;21) translocation.	MEM SLOAN KETTERING CANC CTR, SLOAN KETTERING INST, LAB MOLEC ASPECTS HEMATOPOIESIS, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, DEPT MED, DIV HEMATOL ONCOL, NEW YORK, NY 10021 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; St Jude Children's Research Hospital					NATIONAL CANCER INSTITUTE [R01CA064140, T32CA009512] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043025] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA64140, CA09512] Funding Source: Medline; NIDDK NIH HHS [R01 DK43025] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Ausubel FM, 1988, MOL REPROD DEV; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; BEGLEY CG, 1987, LEUKEMIA, V1, P1; BRADBURY D, 1990, LEUKEMIA, V4, P44; BROUDY VC, 1986, P NATL ACAD SCI USA, V83, P7467, DOI 10.1073/pnas.83.19.7467; CAMERON S, 1994, BLOOD, V83, P2851, DOI 10.1182/blood.V83.10.2851.2851; CHAN JY, 1986, P NATL ACAD SCI USA, V83, P8669, DOI 10.1073/pnas.83.22.8669; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERICKSON P, 1992, BLOOD, V80, P1825; FRASER JK, 1994, MOL CELL BIOL, V14, P2213, DOI 10.1128/MCB.14.3.2213; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GILL LL, 1991, EUR J IMMUNOL, V21, P807, DOI 10.1002/eji.1830210339; GOTTSCHALK LR, 1990, MOL CELL BIOL, V10, P5486, DOI 10.1128/MCB.10.10.5486; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; HAJRA A, 1995, P NATL ACAD SCI USA, V92, P1926, DOI 10.1073/pnas.92.6.1926; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAUSHANSKY K, 1989, J IMMUNOL, V143, P2525; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; NICHOLS J, 1992, BLOOD, V80, P2953; NIMER S, 1990, MOL CELL BIOL, V10, P6084, DOI 10.1128/MCB.10.11.6084; NIMER SD, 1989, J IMMUNOL, V143, P2374; NIMER SD, 1988, MOL CELL BIOL, V8, P1979, DOI 10.1128/MCB.8.5.1979; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; REDONDO JM, 1990, SCIENCE, V247, P1225, DOI 10.1126/science.2156339; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; SASSONECORSI P, 1986, TRENDS GENET, V2, P215, DOI 10.1016/0168-9525(86)90233-7; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SPECK NA, 1990, GENE DEV, V4, P233, DOI 10.1101/gad.4.2.233; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; YOUNG DR, 1986, BLOOD, V68, P1168; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	48	199	208	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2667	2674						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545124				2022-12-28	WOS:A1995TP18800023
J	King, AG; Ozanne, BW; Smythe, C; Ashworth, A				King, AG; Ozanne, BW; Smythe, C; Ashworth, A			Isolation and characterisation of a uniquely regulated threonine, tyrosine phosphatase (TYP 1) which inactivates ERK2 and p54(jnk)	ONCOGENE			English	Article						dual-specificity phosphatase; MAP kinase inhibitor	ACTIVATED PROTEIN-KINASE; IMMEDIATE-EARLY GENE; MAP KINASE; CELL-PROLIFERATION; MESSENGER-RNAS; GROWTH; DEPHOSPHORYLATION; TRANSFORMATION; PURIFICATION; SEQUENCE	The recent discovery of the vaccinia virus protein phosphatase VH1, and its mammalian counterparts has highlighted a novel subfamily of protein tyrosine phosphatases that exhibit dual specificity toward phosphotyrosine- and phosphoserine/threonine-residues. We have identified further members of this subfamily. The characterisation of one clone in particular, which we have named threonine-tyrosine phosphatase 1 (TYP 1), encodes a protein homologous to CL100, but differs dramatically in its regulation, TYP 1 is not expressed in human fibroblasts unlike other CL100-like genes, Furthermore, northern analysis has demonstrated that following mitogenic stimulation of squamous cells, induction of TYP 1 mRNA reaches its maximal levels after four hours, in contrast to the immediate early CL100-like genes, Both TYP 1 and CL100 mRNAs are induced upon TGF-beta treatment of squamous cell lines sensitive to the growth factors antiproliferative effects, When TYP 1 is transfected into COS-1 cells, the gene product inhibits both ERK2 and p54 MAP kinase subfamilies, In addition, we show that purified TYP 1 protein efficiently inactivates recombinant ERK2 in vitro by the concomitant dephosphorylation of both its phosphothreonine and -tyrosine residues, TYP 1 encodes a nuclear protein, which when expressed in COS cells is stabilised by EGF treatment.	BEATSON INST CANC RES,CANC RES CAMPAIGN LABS,GLASGOW G61 1BD,LANARK,SCOTLAND; UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Beatson Institute; University of Dundee; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK								ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ASHWORTH A, 1993, TRANSCRIPTION FACTOR, P125; BRAUTIGAN DL, 1992, BIOCHIM BIOPHYS ACTA, V1114, P63, DOI 10.1016/0304-419X(92)90007-L; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUFF JL, 1995, J BIOL CHEM, V270, P1; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; L'Allemain Gilles, 1994, Progress in Growth Factor Research, V5, P291, DOI 10.1016/0955-2235(94)90011-6; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LAU KHW, 1993, CRIT REV ONCOGENESIS, V4, P451; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; PALLEN CJ, 1991, P NATL ACAD SCI USA, V88, P6996, DOI 10.1073/pnas.88.16.6996; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RHEINWALD JG, 1981, CANCER RES, V41, P1657; ROBBINS DJ, 1994, ADV CANCER RES, V63, P93, DOI 10.1016/S0065-230X(08)60399-1; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SARCEVIC B, 1993, J BIOL CHEM, V268, P25075; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SETH A, 1992, J BIOL CHEM, V267, P24796; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STANTON P, 1994, BRIT J CANCER, V70, P427, DOI 10.1038/bjc.1994.322; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P25317; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WU J, 1994, FEBS LETT, V353, P9, DOI 10.1016/0014-5793(94)01000-5; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	65	57	58	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2553	2563						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545112				2022-12-28	WOS:A1995TP18800011
J	Abe, S; Yagi, T; Ishiyama, S; Hiroe, M; Marumo, F; Ikawa, Y				Abe, S; Yagi, T; Ishiyama, S; Hiroe, M; Marumo, F; Ikawa, Y			Molecular cloning of a novel serine/threonine kinase, MRK, possibly involved in cardiac development	ONCOGENE			English	Article						serine/threonine protein kinase; cardiac development	FIBROBLAST GROWTH-FACTOR; POLYMERASE CHAIN-REACTION; PROTEIN-KINASE; PHOSPHORYLATION SITES; REGULATORY PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE; ENDOTHELIAL-CELLS; PHORBOL ESTERS; P34CDC2 KINASE; MAP KINASE	We have isolated a novel member of putative serine/threonine kinase from a rat heart cDNA library using polymerase chain reaction methods, The novel kinase is transcribed as 2.6 kb mRNA encoding for a protein of 629 amino acids with the long C-terminal non-catalytic portion, Amino acids analysis revealed that the N-terminal catalytic domain is 87% identical to the male-germ cell associated kinase (MAK), a cdc2-related serine/threonine kinase found to promote meiosis during spermatogenesis, Therefore, we designated this novel kinase as the MAK-related kinase (MRK), MRK protein, with a molecular weight of 66 kD, was shown to phosphorylate itself and the exogenous substrates, histone H1 and myelin basic protein, In addition, phosphoamino acid analysis confirmed the serine/threonine-specific protein kinase activity of MRK, Although MRK was ubiquitous in adult rat tissues, the expression of MRK protein in embryos was restricted primarily to embryonic myocardium during early organogenesis, This finding suggests that MRK may be a participant in cardiac development.	RIKEN,INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,TSUKUBA,IBARAKI 305,JAPAN; TOKYO MED & DENT UNIV,SCH MED,DEPT INTERNAL MED 2,BUNKYO KU,TOKYO 113,JAPAN; TOKYO MED & DENT UNIV,SCH MED,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN	RIKEN; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)								AKHURST RJ, 1990, DEVELOPMENT, V108, P645; BARNETT JV, 1994, DEV DYNAM, V199, P12, DOI 10.1002/aja.1001990103; BERNARD O, 1991, P NATL ACAD SCI USA, V88, P7625, DOI 10.1073/pnas.88.17.7625; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BOGOYEVITCH MA, 1993, CIRC RES, V72, P757, DOI 10.1161/01.RES.72.4.757; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V64, P573; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONSIGLI SA, 1991, J CELL PHYSIOL, V146, P379, DOI 10.1002/jcp.1041460307; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEWEILENMANN CM, 1987, BASIC RES CARDIOL, V82, P507; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DUMONT DJ, 1992, ONCOGENE, V7, P1471; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ENGELMANN GL, 1994, CELL MOL BIOL RES, V40, P93; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8993; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; JIN Y, 1994, J MOL CELL CARDIOL, V26, P1449, DOI 10.1006/jmcc.1994.1164; JINNO A, 1993, MOL CELL BIOL, V13, P4146, DOI 10.1128/MCB.13.7.4146; JOUANNOT P, 1975, AM J PHYSIOL, V229, P355, DOI 10.1152/ajplegacy.1975.229.2.355; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KORHONEN J, 1994, ONCOGENE, V9, P395; KRANIAS EG, 1982, NATURE, V298, P182, DOI 10.1038/298182a0; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; Maniatis T, 1989, DECONTAMINATION DILU; MARCELLE C, 1992, ONCOGENE, V7, P2479; MATSUSHIME H, 1990, MOL CELL BIOL, V10, P2261, DOI 10.1128/MCB.10.5.2261; MUSLIN AJ, 1991, DEVELOPMENT, V112, P1095; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; OELRICHS RB, 1993, ONCOGENE, V8, P11; ORR UA, 1992, DEVELOPMENT, V115, P289; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RAZ V, 1991, ONCOGENE, V6, P753; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SHIGETA H, 1992, ENDOCR J, V40, P641; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; TORRES L, 1991, MOL MICROBIOL, V5, P2845, DOI 10.1111/j.1365-2958.1991.tb01993.x; WILKS AF, 1989, GENE, V85, P67, DOI 10.1016/0378-1119(89)90465-4; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WU Y, 1994, EMBO J, V8, P147; YAMAZAKI T, 1993, J BIOL CHEM, V268, P12069; YOSHIDA A, 1992, FEBS LETT, V309, P343, DOI 10.1016/0014-5793(92)80804-P	52	38	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2187	2195						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570168				2022-12-28	WOS:A1995TK70200001
J	HAUPT, Y; BATH, ML; HARRIS, AW; ADAMS, JM				HAUPT, Y; BATH, ML; HARRIS, AW; ADAMS, JM			BMI-1 TRANSGENE INDUCES LYMPHOMAS AND COLLABORATES WITH MYC IN TUMORIGENESIS	ONCOGENE			English	Note							V-ETS; MICE; ONCOGENE; COOPERATION; EXPRESSION; LEUKEMIA; MODELS; VIRUS	The bmi-1 gene was discovered as a frequent target of Moloney virus insertion in virally accelerated B-lymphoid tumors of Emu-myc transgenic mice and hence is thought to collaborate with the myc gene in lymphomagenesis, but its oncogenic potential has not previously been tested directly. To determine whether bmi-1 overexpression can contribute to hematopoietic neoplasia in vivo, strains of transgenic mice were generated in which bmi-1 expression was directed to the lymphoid compartment by a coupled immunoglobulin heavy chain enhancer (Emu). Although the Emu-bmi-1 transgene was expressed in both B and T cells, lymphoid development was not perturbed. Nevertheless, 14% of the mice in the strain with highest expression have developed lymphoma. Unexpectedly, most tumors were of the T-cell lineage, although one case of B lymphoma was observed. Furthermore, cross breeding Emu-bmi-1 and Emu-myc mice established that the bmi-1 transgene markedly accelerated the onset of pre-B and B lymphomas. These results demonstrate directly that bmi-1 can contribute to lymphomagenesis in the T and B cell lineages and collaborate with the myc gene in tumor development.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PO ROYAL MELBOURNE HOSP,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute			Adams, Jerry M/E-1199-2013	Adams, Jerry/0000-0002-4360-8628	NATIONAL CANCER INSTITUTE [R01CA043540] Funding Source: NIH RePORTER; NCI NIH HHS [CA43540] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1992, CANCER SURV, V15, P119; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; ALEXANDER WS, 1987, MOL CELL BIOL, V7, P1436, DOI 10.1128/MCB.7.4.1436; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HAUPT Y, 1992, THESIS U MELBOURNE; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LEVY LS, 1992, J VIROL, V66, P2885, DOI 10.1128/JVI.66.5.2885-2892.1992; LEVY LS, 1993, IN PRESS ONCOGENE; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1992, ONCOGENE, V7, P597; STRASSER A, 1990, CURR TOP MICROBIOL, V166, P175; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; WEINBERG RA, 1989, CANCER RES, V49, P3713	21	156	167	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3161	3164						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414519				2022-12-28	WOS:A1993MC09300034
J	CZIEPLUCH, C; WENZEL, A; SCHURMANN, J; SCHWAB, M				CZIEPLUCH, C; WENZEL, A; SCHURMANN, J; SCHWAB, M			ACTIVATION OF GENE-TRANSCRIPTION BY THE AMINO-TERMINUS OF THE N-MYC PROTEIN DOES NOT REQUIRE ASSOCIATION WITH THE PROTEIN ENCODED BY THE RETINOBLASTOMA SUPPRESSOR GENE RB1	ONCOGENE			English	Article							HUMAN NEUROBLASTOMA-CELLS; HELIX ZIPPER PROTEIN; DNA-BINDING PROTEINS; MAMMALIAN-CELLS; C-MYC; NEOPLASTIC TRANSFORMATION; ADENOVIRUS E1A; LEUCINE ZIPPER; EXPRESSION; YEAST	N-Myc encodes a nuclear phosphoprotein that contains a basic region (BR), a helix-loop-helix (HLH) and a leucine zipper (Zip). These motifs are hallmarks of certain transcription factors. In pursuit of the question if N-Myc can activate transcription, we have employed an experimental model involving the yeast transcription factor Gal4. We have first generated fusion proteins containing the Gal4 DNA-binding domain joined to portions of N-Myc. Subsequently we have analysed if chimeric proteins can transactivate the transcription of a reporter under the control of Gal4 binding sites. Here we show that the amino terminal portion of N-Myc activates transcription. Activation maps to a domain highly conserved among Myc-proteins and to other non-conserved sequences, suggesting functional redundancy. Previous studies had documented in vitro association of the RBI protein with N-Myc (Rustig et al., 1991). We here confirm this observation and identify the region encompassing the transactivation domain as responsible for RBI binding. Analyses of N-Myc transactivation in retinoblastoma cell line WERI lacking a function RBI protein gave results similar to those with cell lines having an intact RBI protein, showing that RBI protein is not required for transactivation by N-Myc. The present findings leave open the question if deregulated expression of N-Myc contributes to tumorigenesis by transcriptional activation of as yet unidentified target genes or by functionally inactivating the protein encoded by the tumor suppressor gene RB1, or by a combination of both.	GERMAN CANC RES CTR,DEPT CLASS & MOLEC CYTOGENET,NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)								ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BREIT S, 1989, J NEUROSCI RES, V24, P21, DOI 10.1002/jnr.490240105; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COUTURIER J, 1991, J VIROL, V65, P4534, DOI 10.1128/JVI.65.8.4534-4538.1991; DEUSCHLE U, 1989, P NATL ACAD SCI USA, V86, P5400, DOI 10.1073/pnas.86.14.5400; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HAMANN U, 1991, ONCOGENE, V6, P1745; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MAKELA TP, 1989, MOL CELL BIOL, V9, P1545; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ONDEK B, 1987, EMBO J, V6, P1017, DOI 10.1002/j.1460-2075.1987.tb04854.x; OROURKE RW, 1990, ONCOGENE, V5, P1829; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SCHWAB M, 1992, BIOCHIM BIOPHYS ACTA, V1114, P43, DOI 10.1016/0304-419X(92)90005-J; SCHWAB M, 1988, P NATL ACAD SCI USA, V85, P9589; SCHWAB M, 1988, ONCOGENE HDB, P381; SILVER PA, 1984, P NATL ACAD SCI-BIOL, V81, P5951, DOI 10.1073/pnas.81.19.5951; SMITH DB, 1990, CURRENT PROTOCOLS S, V10; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	47	11	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2833	2838						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378092				2022-12-28	WOS:A1993LX34300026
J	KUBOTA, S; FURUTA, R; MAKI, M; SIOMI, H; HATANAKA, M				KUBOTA, S; FURUTA, R; MAKI, M; SIOMI, H; HATANAKA, M			LONG CELLULAR REPEATS FLANKING A DEFECTIVE HTLV-I PROVIRUS - IMPLICATION FOR SITE-TARGETED INTEGRATION	ONCOGENE			English	Note							DNA; GENE; TRANSFORMATION; LEUKEMIA; INVITRO	Retroviruses generally integrate as proviruses which are flanked by long-terminal repeats (LTRs) on both 5' and 3' ends. Since these LTRs are required for the efficient integration mediated by the viral integrase, it is believed that defective proviruses with a single LTR are normally formed by deletion after integration. However, we found no deletion of cellular sequences around the integration site of such a defective HTLV-1. Rather, we identified 99 bp-long direct repeats adjacent to both ends of the defective provirus. The repeated cellular sequences contained a potential poly(A) signal followed by a retroviral primer-binding-site-like sequence. The presence of the direct repeats of cellular sequences can be explained by the integration of the defective virus through homologous recombination between cellular and viral read-through sequences.	KYOTO UNIV,INST VIRUS RES,SAKYO KU,KYOTO 60601,JAPAN	Kyoto University			Maki, Masatoshi/AAM-6839-2021; Siomi, Haruhiko/A-7020-2015	Maki, Masatoshi/0000-0001-9144-5491; Siomi, Haruhiko/0000-0001-8690-3822				CAMPBELL C R, 1989, New Biologist, V1, P223; Coffin J. M., 1990, VIROLOGY, P1437; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; Konishi H, 1984, Mol Biol Med, V2, P273; MAKI M, 1987, FEBS LETT, V223, P174, DOI 10.1016/0014-5793(87)80531-8; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MURATANI K, 1991, P NATL ACAD SCI USA, V88, P11315, DOI 10.1073/pnas.88.24.11315; OSAME M, 1986, LANCET, V1, P1031; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; SABE H, 1988, INT J CANCER, V41, P880, DOI 10.1002/ijc.2910410619; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; SHORTLE D, 1982, SCIENCE, V217, P371, DOI 10.1126/science.7046050; SINGH MK, 1982, VIROLOGY, V188, P451; SIOMI H, 1988, VIRUS GENES, V1, P373; SPIRNZL M, 1989, NUCLEIC ACIDS RES, V17, pR1; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; ZACK JA, 1992, J VIROL, V66, P1717, DOI 10.1128/JVI.66.3.1717-1725.1992	18	6	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2873	2877						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378096				2022-12-28	WOS:A1993LX34300033
J	MAYOL, X; GRANA, X; BALDI, A; SANG, NL; HU, QJ; GIORDANO, A				MAYOL, X; GRANA, X; BALDI, A; SANG, NL; HU, QJ; GIORDANO, A			CLONING OF A NEW MEMBER OF THE RETINOBLASTOMA GENE FAMILY (PRB2) WHICH BINDS TO THE E1A TRANSFORMING DOMAIN	ONCOGENE			English	Article							HUMAN ADENOVIRUS TYPE-5; TRANSCRIPTION FACTOR; RB GENE; HUMAN CANCER; HUMAN CDC2; PROTEIN; PRODUCT; CELLS; E2F; EXPRESSION	The product of the retinoblastoma tumor suppressor gene (pRb) and p107 share a high degree of structural homology in the pocket region, which is thought to play a primary role in the function of these proteins. It is conceivable that there exists a larger family of cellular proteins containing this pocket region. In this communication, we report cloning of a new human cDNA encoding a polypeptide that shows a high level of identity with pRb and p107 and possesses a pocket region. We have named it pRb2. From the deduced amino acid sequence, pRb2 has a predicted molecular weight of approximately 120 kD and its in vitro translated product binds to the adenovirus E1A protein. Due to its size, pRb2 may correspond to p130, which has previously been shown by us to interact with the transforming region of E1A in in vivo studies. Interestingly, pRb2 fails to bind an EIA mutant in the transforming domain 2 suggesting that pRb2 is involved in the transforming capacity of E1A.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,3307 N BROAD ST,PHILADELPHIA,PA 19140; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Giordano, Antonio/F-1927-2010; Mayol, Xavier/C-1391-2012; Baldi, Alfonso/ABG-2397-2021	Giordano, Antonio/0000-0002-5959-016X; Grana, Xavier/0000-0001-7134-0473; Baldi, Alfonso/0000-0002-8693-3842; Mayol, Xavier/0000-0001-7288-195X				BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HERMANN CH, 1991, J VIROL, V65, P5848; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, MOL CELL BIOL, V10, P3761; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; NEVINS JR, 1992, SCIENCE, V258, P424; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; WAGNER S, 1991, NATURE, V352, P189, DOI 10.1038/352189a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X	31	263	269	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2561	2566						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361765				2022-12-28	WOS:A1993LT36800029
J	SOWERBY, SJ; KENNEDY, MA; FITZGERALD, PH; MORRIS, CM				SOWERBY, SJ; KENNEDY, MA; FITZGERALD, PH; MORRIS, CM			DNA-SEQUENCE ANALYSIS OF THE MAJOR BREAKPOINT CLUSTER REGION OF THE BCR GENE REARRANGED IN PHILADELPHIA-POSITIVE HUMAN LEUKEMIAS	ONCOGENE			English	Note							ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; 1ST INTRON; ALU SEQUENCES; ABL GENES; TRANSLOCATION; CHROMOSOME; CONSENSUS; INSERTION; PATIENT	We sought sequence characteristics that might explain the apparent high recombination frequency of the 5-kb BgIII segment containing M-bcr exons 1, 2 and 3, and the intron to exon 4. An Alu sequence (subfamily Sx), in 5' --> 3' orientation, lay in the middle of a 3-kb region that contains the great majority of Philadelphia chromosome breakpoint sites. The breakpoint of only one out of five chronic myeloid leukemia patients, for whom the BCR breakpoint site had been sequenced, was located within this Alu. Other features of interest for recombination were a 51-bp AT-rich region close to the 3' end, six hypervariable minisatellite consensus octamers, GC[A/T]GG[A/T]GG, six lymphoid recombinase heptamer signal sequences, one nonamer and a 16-bp inverted repeat. Dot matrix comparisons of the 5-kb M-bcr sequence with a 3-kb m-bcr2 segment showed significant homology only in corresponding Alu sequences.	CHRISTCHURCH HOSP,CHRISTCHURCH SCH MED,DEPT PATHOL,CYTOGENET & MOLEC ONCOL UNIT,CHRISTCHURCH,NEW ZEALAND	Christchurch Hospital New Zealand; University of Otago			Morris, Christine/G-1690-2011; Sowerby, Stephen J/G-7601-2011; Kennedy, Martin A/A-4942-2008	Kennedy, Martin A/0000-0002-6445-8526				BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; BOEHM T, 1989, EUR J BIOCHEM, V185, P1, DOI 10.1111/j.1432-1033.1989.tb15074.x; CHEN SJ, 1989, NUCLEIC ACIDS RES, V17, P7631, DOI 10.1093/nar/17.19.7631; CHEN SJ, 1988, LEUKEMIA, V2, P634; CHEN SJ, 1989, ONCOGENE, V4, P195; CHEN SJ, 1989, BLOOD, V73, P1312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEKLEIN A, 1986, NUCLEIC ACIDS RES, V14, P7071, DOI 10.1093/nar/14.17.7071; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; FITZGERALD PH, 1991, CANCER GENET CYTOGEN, V55, P129, DOI 10.1016/0165-4608(91)90248-S; GALLI I, 1992, NUCLEIC ACIDS RES, V20, P3333, DOI 10.1093/nar/20.13.3333; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HEISTERKAMP N, 1988, NUCLEIC ACIDS RES, V16, P10069, DOI 10.1093/nar/16.21.10069; HEISTERKAMP N, 1985, NATURE, V317, P559, DOI 10.1038/317559b0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HOFMANN JFX, 1991, CELL, V64, P951, DOI 10.1016/0092-8674(91)90319-T; HOLZMAN D, 1991, SCIENCE, V254, P1728, DOI 10.1126/science.1662411; HUEBNER K, 1989, CANCER RES, V49, P4071; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KROWCZYNSKA AM, 1990, NUCLEIC ACIDS RES, V18, P1121, DOI 10.1093/nar/18.5.1121; LEFRANC MP, 1986, CELL, V45, P237, DOI 10.1016/0092-8674(86)90388-0; MATSUOKA M, 1991, SCIENCE, V254, P81, DOI 10.1126/science.1925563; MILLS KI, 1991, BLOOD, V78, P1155; MORRIS CM, 1991, BLOOD, V78, P1078; MURATANI K, 1991, P NATL ACAD SCI USA, V88, P11315, DOI 10.1073/pnas.88.24.11315; PAPADOPOULOS PC, 1990, GENE CHROMOSOME CANC, V1, P233, DOI 10.1002/gcc.2870010308; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; VANDERFELTZ MJM, 1989, NUCLEIC ACIDS RES, V17, P1, DOI 10.1093/nar/17.1.1; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0	32	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1679	1683						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502487				2022-12-28	WOS:A1993LE06400033
J	TOROK, I; HARTENSTEIN, K; KALMES, A; SCHMITT, R; STRAND, D; MECHLER, BM				TOROK, I; HARTENSTEIN, K; KALMES, A; SCHMITT, R; STRAND, D; MECHLER, BM			THE L(2)GL HOMOLOG OF DROSOPHILA-PSEUDOOBSCURA SUPPRESSES TUMORIGENICITY IN TRANSGENIC DROSOPHILA-MELANOGASTER	ONCOGENE			English	Article							NUCLEOTIDE-SEQUENCE; MOLECULAR EVOLUTION; GENE; REGION; ELEMENTS; PROTEIN; DNA; CLONING; PRODUCT; LOCUS	Mutations in the tumour-suppressor gene lethal(2)giant larvae (l(2)gl) of Drosophila cause malignant transformation of the optic centres of the larval brain and the imaginal discs. We report the cloning and sequencing of the l(2)gl gene from Drosophila pseudoobscura. comparison of this sequence with D. melanogaster reveals a significant sequence conservation within the l(2)gl protein-coding domain and a strong sequence divergence in the 5' promoter region and in the introns. The deduced amino acid sequence of the D. pseudoobscura l(2)gl protein shows 17.7% divergence from D. melanogaster. However, despite these evolutionary differences, the D. pseadoobscura l(2)gl gene can fully suppress tumorigenicity and restore a normal development in l(2)gl-deficient D. melanogaster flies, although the rescued animals display poor viability and fertility. Furthermore, in D. melanogaster transgenic flies, the D. pseudoobscura l(2)gl protein is produced at a similar level as the D. melanogaster l(2)gl protein and displays an identical spatial pattern of expression. This shows that the highly divergent cis-regulatory elements of the D. pseudoobscura transgene can be fully recognized in D. melanogaster and lead to the synthesis of a transgenic protein that has enough specificity conserved for replacing the tumour-suppressor function normally fulfilled by the D. melanogaster l(2)gl protein.			TOROK, I (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM, DEPT DEV GENET, NEUENHEIMER FELD 280, W-6900 HEIDELBERG, GERMANY.							AGGARWAL SK, 1969, J MORPHOL, V129, P171, DOI 10.1002/jmor.1051290204; AKAIH, 1975, CELL JAPAN, V4, P3841; BEVERLEY SM, 1984, J MOL EVOL, V21, P1, DOI 10.1007/BF02100622; BLACKMAN RK, 1986, J MOL BIOL, V188, P499, DOI 10.1016/S0022-2836(86)80001-8; BRADY JP, 1990, MOL BIOL EVOL, V7, P525; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; BURKE JF, 1984, GENE, V30, P63, DOI 10.1016/0378-1119(84)90105-7; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; COLOT HV, 1988, EMBO J, V7, P3929, DOI 10.1002/j.1460-2075.1988.tb03279.x; DALRYMPLE MA, 1989, CELL, V58, P811, DOI 10.1016/0092-8674(89)90930-6; FRIEDMAN TB, 1992, J MOL EVOL, V34, P62, DOI 10.1007/BF00163853; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GATEFF E, 1974, ROUX ARCH DEV BIOL, V176, P23, DOI 10.1007/BF00577830; GATEFF E, 1978, SCIENCE, V200, P1448, DOI 10.1126/science.96525; GATEFF E, 1969, NATL CANCER I MONOGR, P365; GATEFF E, 1989, Critical Reviews in Oncogenesis, V1, P221; GILLESPIE JH, 1986, ANNU REV ECOL SYST, V17, P637; Gloor H., 1943, Revue Suisse de Zoologie, V50, P339; GLOOR H, 1942, ARCH JUL KLAUS STIFT, V17, P438; GROB H, 1952, Z INDUKT ABSTAMM VER, V84, P320, DOI 10.1007/BF00309474; Hadorn E, 1937, P SOC EXP BIOL MED, V36, P632; HADORN E, 1961, DEV GENETICS LETHAL; HADORN E, 1942, REV SUISSE ZOOL, V49, P228; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HENIKOFF S, 1987, GENETICS, V117, P711; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; JACOB L, 1987, CELL, V50, P215, DOI 10.1016/0092-8674(87)90217-0; Kimura M., 1983, NEUTRAL THEORY MOL E; KLAMBT C, 1989, DEV BIOL, V133, P425, DOI 10.1016/0012-1606(89)90046-8; KRASNEY PA, 1990, MOL BIOL EVOL, V7, P155; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUTZELSCHWAB R, 1987, EMBO J, V6, P1791, DOI 10.1002/j.1460-2075.1987.tb02432.x; MECHLER B, 1989, ACCOMPLISHMENTS CANC, P226; MECHLER BM, 1991, ENVIRON HEALTH PERSP, V93, P63, DOI 10.2307/3431171; MECHLER BM, 1985, EMBO J, V4, P1551, DOI 10.1002/j.1460-2075.1985.tb03816.x; MECHLER BM, 1990, TUMOR SUPPRESSOR GEN, P123; MERZ R, 1990, ENVIRON HEALTH PERSP, V88, P163, DOI 10.2307/3431068; MORIYAMA EN, 1987, JPN J GENET, V62, P139, DOI 10.1266/jjg.62.139; OPPER M, 1987, ONCOGENE, V1, P91; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PIROTTA V, 1988, VECTORS SURVEY MOL C, P437; RILEY MA, 1989, MOL BIOL EVOL, V6, P33; Sambrook J, 1989, MOL CLONING LABORATO; SCHAEFFER SW, 1987, GENETICS, V117, P61; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STRAND D, 1991, ADV ENZYME REGUL, V31, P339, DOI 10.1016/0065-2571(91)90022-E; SZABAD J, 1991, GENETICS, V127, P525; Throckmorton L.H., 1975, P421; WILDE CD, 1987, EMBO J, V6, P1393, DOI 10.1002/j.1460-2075.1987.tb02380.x; WILSON AC, 1977, ANNU REV BIOCHEM, V46, P573, DOI 10.1146/annurev.bi.46.070177.003041; Zuckerkandl E, 1962, HORIZONS BIOCH	54	27	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1993	8	6					1537	1549						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8389031				2022-12-28	WOS:A1993LE06400017
J	SU, ZZ; AUSTIN, VN; ZIMMER, SG; FISHER, PB				SU, ZZ; AUSTIN, VN; ZIMMER, SG; FISHER, PB			DEFINING THE CRITICAL GENE-EXPRESSION CHANGES ASSOCIATED WITH EXPRESSION AND SUPPRESSION OF THE TUMORIGENIC AND METASTATIC PHENOTYPE IN HA-RAS-TRANSFORMED CLONED RAT EMBRYO FIBROBLAST CELLS	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; GTPASE ACTIVATING PROTEIN; HUMAN COLORECTAL TUMORS; ADENOVIRUS TYPE-5; MESSENGER-RNA; DROSOPHILA GENE; HUMAN CANCER; E1A GENE; NM23; PROGRESSION	Carcinogenesis requires a complex series of genetic changes often involving multiple oncogenes and the inactivation of multiple tumor-suppressor genes. We presently examined the effect of the Krev-1 tumor-suppressor gene on the tumorigenic and metastatic potential of Ha-ras-transformed cloned rat embryo fibroblast (CREF) cells. Ha-ras-transformed CREF cells are morphologically transformed and anchorage independent, produce reduced levels of nm23-H1 (a putative metastasis-suppressor gene product) and TIMP-1 (tissue inhibitor of metalloproteinase 1) transcripts and mRNA compared with CREF cells; produce increased levels of cripto, 94-kDa gelatinase/type IV collagenase (94-kDa GEL), osteopontin (OPN) and transin/stromelysin transcripts and mRNA compared with CREF cells; and are tumorigenic and metastatic in both nude mice and syngeneic rats. Ha-ras-transformed CREF cells coexpressing the Krev-1 gene display a reversion in cellular phenotype and gene expression to that of untransformed CREF cells. However, Ha-ras/Krev-1-coexpressing CREF cells retain, albeit with extended latency periods, both tumorigenic and metastatic potential that is not related directly to the final level of Ha-ras or Krev-1 mRNA or the Ha-ras p21 transforming protein. Development of metastatic potential is, however, directly correlated with a reduction in nm23-H1 and TIMP-1 transcription and mRNA levels and an enhanced expression of cripto, 94-kDa GEL, osteopontin and transin. In contrast, expression of additional tumor-suppressor genes, such as the RB gene and p53, or genes associated with tumorigenesis in other model systems, such as major excreted glycoprotein (MEP), 72-kDa gelatinase/type IV collagenase (72-kDa GEL), fibronectin (FIB), tenascin and intracellular adhesion molecule 1 (ICAM-1) is not altered in a consistent manner during in vitro transformation suppression or escape from tumorigenic and metastatic suppression. These results indicate that Krev-1 suppression of the Ha-ras-transformed/oncogenic phenotype is associated with a distinct program of gene expression changes manifested by altered rates of transcription and steady-state mRNA levels of specific oncogenic-suppressing and oncogenic-inducing genes. These data support a model of Ha-ras-induced metastasis in CREF cells that involves a direct modulation in the expression/suppression of specific combinations of oncogenic-suppressor genes and metastasis-promoting genes that are regulated coordinately in the process of tumor progression.	COLUMBIA UNIV COLL PHYS & SURG,DEPT UROL,INST CANC RES,CTR COMPREHENS CANC,650 W 168TH ST,NEW YORK,NY 10032; UNIV KENTUCKY,MED CTR,DEPT MED MICROBIOL & IMMUNOL,LEXINGTON,KY 40536; COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,INST CANC RES,CTR COMPREHENS CANC,NEW YORK,NY 10032	Columbia University; University of Kentucky; Columbia University					NCI NIH HHS [CA33434, CA43208, CA35675] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035675, R01CA043208, R01CA033434] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BABISS LE, 1985, SCIENCE, V228, P1099, DOI 10.1126/science.2581317; BABISS LE, 1984, J VIROL, V49, P731, DOI 10.1128/JVI.49.3.731-740.1984; BABISS LE, 1986, P NATL ACAD SCI USA, V83, P2167, DOI 10.1073/pnas.83.7.2167; Bar-Sagi D, 1992, Semin Cell Biol, V3, P93; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BERNHARD EJ, 1990, CANCER RES, V50, P3872; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOYLAN JF, 1990, ANTICANCER RES, V10, P717; BOYLAN JF, 1992, MOL CARCINOGEN, P118; CIARDIELLO F, 1991, CANCER RES, V51, P1051; CIARDIELLO F, 1991, P NATL ACAD SCI USA, V88, P7792, DOI 10.1073/pnas.88.17.7792; CRAIG AM, 1988, BIOCHEM BIOPH RES CO, V157, P166, DOI 10.1016/S0006-291X(88)80028-7; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; DORSCHHASLER K, 1980, J VIROL, V34, P305; DUIGOU GJ, 1990, MOL CELL BIOL, V10, P2027, DOI 10.1128/MCB.10.5.2027; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; FISHER PB, 1979, CANCER RES, V39, P3051; FISHER PB, 1984, MECHANISMS TUMOR PRO, V3, P57; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FRIEDMAN JM, 1986, MOL CELL BIOL, V6, P3791, DOI 10.1128/MCB.6.11.3791; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; Kerbel R S, 1990, Adv Cancer Res, V55, P87, DOI 10.1016/S0065-230X(08)60469-8; KERBEL RS, 1988, CANCER SURV, V7, P597; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KHOKKA R, 1991, J CANCER RES CLIN, V117, P333, DOI 10.1007/BF01630716; KITAYAMA H, 1990, JPN J CANCER RES, V81, P445, DOI 10.1111/j.1349-7006.1990.tb02589.x; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KUBOTA S, 1991, BIOCHEM BIOPH RES CO, V181, P1539, DOI 10.1016/0006-291X(91)92114-Y; KUNIYASU H, 1991, JPN J CANCER RES, V82, P969, DOI 10.1111/j.1349-7006.1991.tb01929.x; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1991, CANCER RES, V51, P2490; Liotta L A, 1990, Semin Cancer Biol, V1, P99; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; Matrisian L M, 1990, Semin Cancer Biol, V1, P107; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MCCORMICK F, 1992, PHILOS T ROY SOC B, V336, P43, DOI 10.1098/rstb.1992.0042; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; NICHOLSON GL, 1988, CANCER METAST REV, V7, P143; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STEEG PS, 1991, CANCER CELL-MON REV, V3, P257; SU ZZ, 1991, MOL CARCINOGEN, V4, P328, DOI 10.1002/mc.2940040412; SU ZZ, 1990, MOL CARCINOGEN, V3, P309, DOI 10.1002/mc.2940030512; SU ZZ, 1992, POLY ADP RIBOSYLATIO, P203; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210	63	77	84	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1211	1219						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479744				2022-12-28	WOS:A1993KY32800012
J	BROWN, PH; ALANI, R; PREIS, LH; SZABO, E; BIRRER, MJ				BROWN, PH; ALANI, R; PREIS, LH; SZABO, E; BIRRER, MJ			SUPPRESSION OF ONCOGENE-INDUCED TRANSFORMATION BY A DELETION MUTANT OF C-JUN	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; DNA-BINDING ACTIVITY; RAT EMBRYO CELLS; LEUCINE ZIPPER; HETERODIMER FORMATION; ENHANCER ELEMENTS; PROTO-ONCOGENE; V-JUN; FOS; ACTIVATION	Jun and Fos proteins are DNA-binding proteins that are involved in the control of gene expression through transcriptional regulation. We have made a deletion mutant of the c-jun gene that lacks amino acids 3-122 of c-jun, and thus is missing the major transactivation domain of c-jun, but retains the DNA-binding and leucine zipper domains. Unlike c-Jun, the mutant protein is unable to stimulate the transcription of an AP-1 responsive gene, and unlike c-jun this mutant gene is unable to transform rat embryo celts in cooperation with an activated ras gene. However, this mutant protein blocks in vitro DNA binding of Jun-Jun homodimers and Jun-Fos heterodimers, transcriptional activation induced by c-jun or c-fos and transformation of rat embryo cells induced by an activated ras gene and a deregulated c-jun or c-fos gene. In addition, transformation of rat embryo cells induced by an activated ras gene in the presence of the tumor promoter 12-0-tetradecanoyl phorbol 13-acetate (TPA) or by ras plus SV40 large T antigen is also inhibited by this dominant-negative mutant, suggesting that a member of the jun or fos family is involved in the pathways leading to transformation in these systems as well. The possible molecular mechanisms by which this dominant-negative mutant of c-jun blocks the functions of wild-type jun and fos family members are discussed.	NCI, DIV CANC PREVENT & CONTROL, BIOMARKERS & PREVENT RES BRANCH, 5516 NICHOLSON LANE,ROOM 100, KENSINGTON, MD 20895 USA; UNIV HLTH SCI, UNIFORMED SERV, BETHESDA, MD 20814 USA; HOWARD HUGHES MED INST, BETHESDA, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard Hughes Medical Institute				Alani, Rhoda/0000-0003-2741-2665; Szabo, Eva/0000-0003-3891-0942; Brown, Powel/0000-0002-3398-163X				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BENBROOK DM, 1990, ONCOGENE, V5, P295; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; DAVENPORT EA, 1988, ANTICANCER RES, V8, P959; DOSAKA AH, 1991, ONCOGENE, V6, P371; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HIRAI SI, 1990, ONCOGENE, V5, P39; HSIAO WLW, 1986, MOL CELL BIOL, V6, P1943, DOI 10.1128/MCB.6.6.1943; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MULLER R, 1987, ONCOGENE RES, V2, P19; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; OKUNO H, 1991, ONCOGENE, V6, P1491; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAMBROOK J, 1987, MOL CLONING LABORATO, P1666; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	54	250	254	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1993	8	4					877	886						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455942				2022-12-28	WOS:A1993KT22000008
J	HAMAGUCHI, M; XIAO, H; UEHARA, Y; OHNISHI, Y; NAGAI, Y				HAMAGUCHI, M; XIAO, H; UEHARA, Y; OHNISHI, Y; NAGAI, Y			HERBIMYCIN-A INHIBITS THE ASSOCIATION OF P60(V-SRC) WITH THE CYTOSKELETAL STRUCTURE AND WITH PHOSPHATIDYLINOSITOL-3' KINASE	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; CHICKEN-EMBRYO FIBROBLASTS; GTPASE-ACTIVATING PROTEIN; INSOLUBLE CELLULAR MATRIX; PLASMA-MEMBRANE MATRIX; SRC GENE-PRODUCT; TYROSINE KINASES; TRANSFORMING PROTEIN; CELLS; PHOSPHORYLATION	To search for the biochemical prerequisites for morphological transformation by p60v-src, we examined the effect of herbimycin A, a potent inhibitor of cell transformation. on chicken embryonic fibroblasts transformed by Rous sarcoma virus. A small dose of herbimycin (0.1-0.3 mug ml-1) was enough to convert the cell morphology to a normal phenotype with a concomitant reassembly of microfilament bundles. In the cells treated with the drug, the majority of the substrates for p60v-src remained phosphorylated and p60v-src was myristylated, membrane associated and fairly active as a protein kinase. Under the same conditions, however, the association of p60v-src with the cytoskeletal structure and with phosphatidylinositol 3' kinase was strongly inhibited, suggesting that the interactions of p60v-src with the cellular structure and the enzyme were indispensable for morphological transformation.	NATL INST HLTH,DEPT ANTIBIOT,TOKYO 141,JAPAN	National Institute of Health Sciences - Japan	HAMAGUCHI, M (corresponding author), NAGOYA UNIV,SCH MED,DIS MECH & CONTROL RES INST,TURUMAI CHO 65,SHOUWA KU,NAGOYA,AICHI 466,JAPAN.							BEUG H, 1978, CELL, V45, P105; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FUKAMI Y, 1986, P NATL ACAD SCI USA, V83, P4190, DOI 10.1073/pnas.83.12.4190; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GOULD KL, 1986, J CELL BIOL, V102, P660, DOI 10.1083/jcb.102.2.660; HAMAGUCHI M, 1985, VIROLOGY, V147, P295, DOI 10.1016/0042-6822(85)90132-1; HAMAGUCHI M, 1989, ONCOGENE RES, V4, P29; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAMAGUCHI M, 1990, MOL CELL BIOL, V10, P830, DOI 10.1128/MCB.10.2.830; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HANAFUSA H, 1969, P NATL ACAD SCI USA, V77, P1311; HANAFUSA H, 1977, COMPREHENSIVE VIROLO, V10, P401; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KRUEGER JG, 1983, CURR TOP MICROBIOL, V107, P51; LENK R, 1977, CELL, V10, P67, DOI 10.1016/0092-8674(77)90141-6; LEVINSON AD, 1978, CELL, V15, P561, DOI 10.1016/0092-8674(78)90024-7; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PASQUALE EB, 1986, P NATL ACAD SCI USA, V83, P5507, DOI 10.1073/pnas.83.15.5507; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STOCKER AW, 1986, J VIROL, V58, P876; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; WELHAM MJ, 1988, J VIROL, V62, P1898, DOI 10.1128/JVI.62.6.1898-1906.1988	40	51	51	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					559	564						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8382356				2022-12-28	WOS:A1993KN00800005
J	MOSIALOS, G; GILMORE, TD				MOSIALOS, G; GILMORE, TD			V-REL AND C-REL ARE DIFFERENTIALLY AFFECTED BY MUTATIONS AT A CONSENSUS PROTEIN-KINASE RECOGNITION SEQUENCE	ONCOGENE			English	Article							NF-KAPPA-B; VIRUS STRAIN-T; RETICULOENDOTHELIOSIS VIRUS; ONCOGENE; TRANSCRIPTION; TRANSFORMATION; DORSAL; EXPRESSION; CLONING; SUBUNIT	The avian retroviral oncoprotein v-Rel and its cellular homolog c-Rel are members of a family of related site-specific DNA-binding proteins. Towards the carboxy-terminal end of the highly conserved Rel homology (RH) domain in the majority of Rel proteins, there is a consensus recognition sequence for protein kinase A (PK-A). We have investigated the importance of this sequence (Arg-Arg-Pro-Ser) for several functional properties of v-Rel and c-Rel. Disruption of the PK-A sequence by a two amino acid insertion between the arginine and the proline residues completely abolished the ability of v-Rel and c-Rel to bind a kappaB site in vitro. When the phosphorylatable serine in this sequence (Ser-275 in v-Rel, Ser-266 in c-Rel) was replaced by an alanine, DNA binding by v-Rel was not affected, whereas the ability of c-Rel to bind DNA was reduced approximately fourfold by this mutation. Similarlv, a serine to tryptophan change greatly reduced the DNA-binding ability of c-Rel, whereas v-Rel was not appreciably affected by this change. When this serine was replaced by an acidic amino acid, DNA binding by v-Rel was reduced approximately twofold and the DNA-binding activity of c-Rel was nearly abolished. Glutaraldehyde cross-linking experiments indicated that mutations at the PK-A recognition site that reduced DNA binding also negatively affected protein oligomerization, which is likely to be responsible for the reduced ability of mutant v-Rel and c-Rel proteins to bind DNA. Domain-swapping experiments showed that structural differences between v-Rel and c-Rel in the central region of the proteins are primarily responsible for the higher sensitivity of c-Rel to a serine to alanine mutation in the PK-A site. One difference between v-Rel and c-Rel, a glutamine to alanine change in v-Rel located three amino acids carboxy-terminal to the PK-A phosphorylatable serine (Ala-278 in v-Rel; Glu-269 in c-Rel), is mainly responsible for the lack of an effect on DNA binding by v-Rel when Ser-275 is replaced by alanine. That is, a v-Rel double mutant (v-275A/278E) showed reduced DNA-binding and transforming abilities as compared with v-Rel and v-275A. Similarly, the mutations in c-Rel that affected DNA binding showed a corresponding effect on the ability of c-Rel proteins to activate transcription in yeast from a reporter gene containing upstream Rel binding sites. In summary, our results indicate that the structure of the PK-A recognition sequence is important for dimerization by Rel proteins, and that there is a good correlation between transformation by v-Rel and its ability to bind to kappaB target sites in vitro. In addition, our results show that c-Rel is more sensitive to mutations in the consensus PK-A recognition sequence than v-Rel, which has acquired mutations that may allow v-Rel to bind kappaB sites in a deregulated fashion.	BOSTON UNIV, DEPT CHEM, 5 CUMMINGTON ST, BOSTON, MA 02215 USA; BOSTON UNIV, DEPT BIOL, BOSTON, MA 02215 USA	Boston University; Boston University					NATIONAL CANCER INSTITUTE [R29CA047763, R01CA047763] Funding Source: NIH RePORTER; NCI NIH HHS [CA47763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BHAT GV, 1990, ONCOGENE, V5, P625; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BROWNELL E, 1989, ONCOGENE, V4, P935; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1992, CANCER SURV, V15, P69; GLASS DB, 1986, J BIOL CHEM, V261, P2987; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; ISODA K, 1992, GENE DEV, V6, P619, DOI 10.1101/gad.6.4.619; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KAMENS J, 1991, NEW BIOL, V3, P1005; KAO KR, 1991, P NATL ACAD SCI USA, V88, P2697, DOI 10.1073/pnas.88.7.2697; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MORIN PJ, 1992, NUCLEIC ACIDS RES, V20, P2453, DOI 10.1093/nar/20.10.2453; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Sambrook J, 1989, MOL CLONING LABORATO; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SIMEK S, 1988, ONCOGENE RES, V2, P103; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	42	44	45	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1993	8	3					721	730						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437855				2022-12-28	WOS:A1993KN00800024
J	OHMORI, Y; TANABE, J; TAKADA, S; LEE, WMF; OBINATA, M				OHMORI, Y; TANABE, J; TAKADA, S; LEE, WMF; OBINATA, M			FUNCTIONAL DOMAINS OF C-MYC INVOLVED IN THE COMMITMENT AND DIFFERENTIATION OF MURINE ERYTHROLEUKEMIA-CELLS	ONCOGENE			English	Article							DNA-BINDING; LEUCINE ZIPPER; ERYTHROID DIFFERENTIATION; NUCLEAR-LOCALIZATION; PROTEIN; GENE; SEQUENCE; TRANSLOCATION; EXPRESSION; TRANSFORMATION	In the early event of the induction of mouse erythroleukemia (MEL) cell differentiation, c-myc mRNA levels show a drastic change. The elevated expression of a transfected c-myc gene inhibits the commitment and differentiation of MEL cell transformants. In the present work, we have introduced human c-myc mutants into MEL cells under the inducible promoter to define the functional domains of c-Myc involved in erythroid differentiation. The c-Myc domains necessary for commitment and differentiation are not co-localized; almost entire regions are required for inhibition of commitment, whereas domains II and IV that are essential for co-tranforming activity with ras are required for inhibition of differentiation. Interestingly, mutants that delete domains for c-Myc dimerization motifs enhanced differentiation. These results suggest that c-Myc may regulate commitment and differentiation by interacting with proteins through different domains.	TOHOKU UNIV,TUBERCULOSIS & CANC RES INST,DEPT CELL BIOL,SEIRYOMACHI 4-1,SENDAI,MIYAGI 980,JAPAN; UNIV PENN,DEPT MED,ONCOL SECT,PHILADELPHIA,PA 19104; UNIV PENN,CTR CANC,PHILADELPHIA,PA 19104	Tohoku University; University of Pennsylvania; University of Pennsylvania				Takada, Shinji/0000-0003-4125-6056				ALONSO MC, 1988, EMBO J, V7, P2583; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BEIMLING P, 1985, BIOCHEMISTRY-US, V24, P6349, DOI 10.1021/bi00344a005; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; COPPOLA JA, 1986, NATURE, V320, P761; CROUCH DH, 1990, ONCOGENE, V5, P683; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DANG CV, 1989, MOL CELL BIOL, V9, P2477, DOI 10.1128/MCB.9.6.2477; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GUSELLA J, 1976, CELL, V9, P221, DOI 10.1016/0092-8674(76)90113-6; KLAEMBT C, 1989, EMBO J, V8, P203; KUME TU, 1988, J MOL BIOL, V202, P779, DOI 10.1016/0022-2836(88)90558-X; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; RUSTGI AK, 1991, NATURE, V352, P540; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAKADA S, 1992, JPN J CANCER RES, V83, P61, DOI 10.1111/j.1349-7006.1992.tb02352.x; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAMAMOTO T, 1989, CELL DIFFER DEV, V28, P129, DOI 10.1016/0922-3371(89)90049-X	34	16	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					379	386						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426744				2022-12-28	WOS:A1993KN00600017
J	ROSENBERG, CL; MOTOKURA, T; KRONENBERG, HM; ARNOLD, A				ROSENBERG, CL; MOTOKURA, T; KRONENBERG, HM; ARNOLD, A			CODING SEQUENCE OF THE OVEREXPRESSED TRANSCRIPT OF THE PUTATIVE ONCOGENE PRAD1/CYCLIN D1 IN 2 PRIMARY HUMAN TUMORS	ONCOGENE			English	Note							CANDIDATE ONCOGENE; CHROMOSOME 11Q13; SQUAMOUS-CELL; AMPLIFICATION; BCL-1; GENE; CARCINOMAS; EXPRESSION; CYCLINS; LOCUS	PRAD1 (cyclin Dl) is a recently identified member of the family of cyclin genes, believed to play roles in regulating transitions through the cell cycle. The PRAD1 gene, located at 11q13, has been implicated in the pathogenesis of a variety of tumors, including parathyroid adenomas, t(11;14) bearing B-lymphoid tumors (particularly centrocytic lymphomas) where it is highly likely to be the BCL1 oncogene, and possibly in breast carcinomas and squamous cell cancers of the head and neck as well. PRAD1's tumorigenic influence appears to be effected through overexpression of its normal-sized transcript, but it has not been established whether the transcript's coding sequence is normal or contains oncogenic mutations. We have sequenced the coding region of the overexpressed PRAD1 transcript from two primary tumors with clonal PRAD1 region rearrangements: a benign parathyroid adenoma and a malignant centrocytic lymphoma. Each sequence is identical to the normal PRAD1 cDNA sequence, and presumably encodes normal PRAD1 protein. Thus, PRAD1 likely functions as a direct-acting oncogene whose rearrangement in tumors leads to overexpression or deregulated expression of its normal protein product.	MASSACHUSETTS GEN HOSP, ENDOCRINE UNIT, WELLMAN 503, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, CTR CANC, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Motokura, Toru/X-3682-2019		NCI NIH HHS [CA55909] Funding Source: Medline; NIDDK NIH HHS [DK11794] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; BERENSON JR, 1990, ONCOGENE, V5, P1343; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LISCIA DS, 1989, ONCOGENE, V4, P1219; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; PROCTOR AJ, 1991, ONCOGENE, V6, P789; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; Sambrook J, 1989, MOL CLONING LABORATO; SCHUURING E, 1992, ONCOGENE, V7, P355; SETO M, 1992, ONCOGENE, V7, P1401; THEILLET C, 1989, ONCOGENE, V4, P915; WILLIAMS ME, 1992, IN PRESS LEUKEMIA; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; YANDELL DW, 1989, AM J HUM GENET, V45, P547; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	20	63	63	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					519	521						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426754				2022-12-28	WOS:A1993KN00600034
J	DIRENZO, MF; BERTOLOTTO, A; OLIVERO, M; PUTZOLU, P; CREPALDI, T; SCHIFFER, D; PAGNI, CA; COMOGLIO, PM				DIRENZO, MF; BERTOLOTTO, A; OLIVERO, M; PUTZOLU, P; CREPALDI, T; SCHIFFER, D; PAGNI, CA; COMOGLIO, PM			SELECTIVE EXPRESSION OF THE MET/HGF RECEPTOR IN HUMAN CENTRAL-NERVOUS-SYSTEM MICROGLIA	ONCOGENE			English	Note							HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; MET PROTO-ONCOGENE; C-MET; SCATTER FACTOR; MOLECULAR-CLONING; TRK PROTOONCOGENE; EPITHELIAL-CELLS; HEPATOPOIETIN-A; GENE	The c-MET proto-oncogene encodes the tyrosine kinase receptor for hepatocyte growth factor (HGF), also known as scatter factor, a powerful mitogen and motility factor for epithelial cells. We now show that the two previously described forms of the Met/HGF receptor, the intact p190MET and the truncated p14OMET, are expressed in physiological conditions in the human central nervous system (CNS). The receptors were identified by Western blot analysis with monoclonal antibodies directed against different epitopes. By immunohistochemical staining the Met/HGF receptor was found to be expressed in a homogeneous cell population, equally distributed between the grey and the white matter, showing morphological features and immunochemical markers specific for the resident microglial cells. These data suggest a possible role for the c-MET proto-oncogene and HGF in microglial reactions to CNS injuries.	UNIV TURIN,SCH MED,NEUROL CLIN 2,I-10126 TURIN,ITALY; UNIV TURIN,SCH MED,NEUROSURG CLIN,I-10126 TURIN,ITALY	University of Turin; University of Turin	DIRENZO, MF (corresponding author), UNIV TURIN,SCH MED,DEPT BIOMED SCI & ONCOL,I-10126 TURIN,ITALY.		DI RENZO, Maria Flavia/B-6091-2012; crepaldi, tiziana/AAY-7207-2020; Bertolotto, Antonio/K-8346-2015; olivero, martina/J-4811-2018	DI RENZO, Maria Flavia/0000-0002-5093-3373; crepaldi, tiziana/0000-0003-3410-947X; Bertolotto, Antonio/0000-0002-7052-1907; olivero, martina/0000-0002-6815-3498; Comoglio, Paolo/0000-0002-7056-5328				AKIYAMA H, 1990, J NEUROIMMUNOL, V30, P81, DOI 10.1016/0165-5728(90)90055-R; BARBACID M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P115, DOI 10.1016/0304-419X(91)90010-I; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO FD, 1992, IN PRESS J CELL BIOL; CHAN AML, 1988, ONCOGENE, V2, P593; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CUZNER ML, 1988, J NEUROIMMUNOL, V20, P203, DOI 10.1016/0165-5728(88)90161-0; Del Rio P., 1932, CYTOLOGY CELLULAR PA, P481; DICKSON DW, 1991, LAB INVEST, V64, P135; DIRENZO MF, 1991, ONCOGENE, V6, P1997; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRAEBER MB, 1988, J NEUROCYTOL, V17, P573, DOI 10.1007/BF01189811; GRAEBER MB, 1988, J NEUROSCI RES, V21, P18, DOI 10.1002/jnr.490210104; GRAEBER MB, 1990, J NEUROIMMUNOL, V27, P121, DOI 10.1016/0165-5728(90)90061-Q; HAASE VH, 1991, ONCOGENE, V6, P2319; HART IK, 1989, J CELL BIOL, V109, P3411, DOI 10.1083/jcb.109.6.3411; HART IK, 1989, DEVELOPMENT, V105, P595; HAYES GM, 1987, J NEUROL SCI, V80, P25, DOI 10.1016/0022-510X(87)90218-8; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PEUDENIER S, 1991, ANN NEUROL, V29, P152, DOI 10.1002/ana.410290207; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; PUTZOLU P, 1989, IMAGE ANAL NEUROHIST, P129; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SAWADA M, 1990, BRAIN RES, V509, P119, DOI 10.1016/0006-8993(90)90317-5; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209; TAHIRA T, 1991, ONCOGENE, V6, P2333; TILLOTSON ML, 1989, GLIA, V2, P412; WEGIEL J, 1990, ACTA NEUROPATHOL, V81, P116, DOI 10.1007/BF00334499; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WEIDNER KM, 1990, J CELL BIOL, V111, P2907; ZARNEGAR R, 1989, BIOCHEM BIOPH RES CO, V163, P1370, DOI 10.1016/0006-291X(89)91130-3; ZARNEGAR R, 1990, P NATL ACAD SCI USA, V87, P1252, DOI 10.1073/pnas.87.3.1252	52	64	77	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					219	222						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380919				2022-12-28	WOS:A1993KN00500028
J	Keegan, K; Cooper, JA				Keegan, K; Cooper, JA			Use of the two hybrid system to detect the association of the protein-tyrosine-phosphatase, SHPTP2, with another SH2-containing protein, Grb7	ONCOGENE			English	Article						SHPT2; Syp; Grb 2; Grb 7; 8H2 domain; two hybrid system	FACTOR RECEPTOR-BETA; PHOSPHOTYROSINE PHOSPHATASE; SACCHAROMYCES-CEREVISIAE; KINASE; PHOSPHORYLATION; ACTIVATION; CLONING; DOMAINS; SPECIFICITY; CORKSCREW	SHPTP2 is a ubiquitously-expressed SH2-containing tyrosine phosphatase that is tyrosine phosphorylated in response to activation of various receptor and nonreceptor tyrosine kinases. SHPTPZ associates with the platelet-derived growth factor (PDGF) receptor after ligand stimulation, and binding of SHPTPZ to this receptor promotes tyrosine phosphorylation of SHPTP2. The yeast two-hybrid system was modified to identify partners of tyrosine-phosphorylated proteins. Using SHPTP2 as bait and supplying an exogenous tyrosine kinase gene to the yeast cells, we have found that SHPTPZ interacts with another signaling protein, Grb7. We have localized the region of interaction to tyrosine 580 in the carboxyl end of SHPTP2 and to the SH2 domain in the carboxy-terminus of Grb7. We demonstrate that Grb7 binds to SHPTP2 in vitro under conditions where the latter is tyrosine-phosphorylated. These experiments show that this modified two hybrid technique may be useful for the identification of proteins involved in tyrosine kinase signal transduction cascades.	FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA	Fred Hutchinson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA054786] Funding Source: NIH RePORTER; NCI NIH HHS [CA 54786] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BLISKA JB, 1992, J EXP MED, V176, P1625, DOI 10.1084/jem.176.6.1625; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; CASE RD, 1994, J BIOL CHEM, V269, P10467; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FENG GS, 1994, ONCOGENE, V9, P1545; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FURUKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928, DOI 10.1073/pnas.91.23.10928; GERLACH MS, 1995, J BIOL CHEM, V270, P24635, DOI 10.1074/jbc.270.42.24635; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OOI J, 1995, ONCOGENE, V10, P1621; PERALDI P, 1994, P NATL ACAD SCI USA, V91, P5002, DOI 10.1073/pnas.91.11.5002; PERRIMON N, 1993, CELL, V74, P219, DOI 10.1016/0092-8674(93)90412-J; Rose M, 1990, LAB COURSE MANUAL ME; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YOUNG D, 1989, P NATL ACAD SCI USA, V86, P7989, DOI 10.1073/pnas.86.20.7989; ZAKIAN VA, 1982, MOL CELL BIOL, V2, P221, DOI 10.1128/MCB.2.3.221	47	89	91	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	1996	12	7					1537	1544						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622870				2022-12-28	WOS:A1996UF07600018
J	Smits, PHM; deWit, L; vanderEb, AJ; Zantema, A				Smits, PHM; deWit, L; vanderEb, AJ; Zantema, A			The adenovirus E1A-associated 300 kDa adaptor protein counteracts the inhibition of the collagenase promoter by E1A and represses transformation	ONCOGENE			English	Article						adenovirus E1A; CBP; cJun; collagenase promoter; p300	E2F TRANSCRIPTION FACTOR; CELL-CYCLE; 5 DNA; REGION; GENE; COMPLEXES; BINDING; PRODUCT; JUN; TRANSACTIVATION	Adenovirus E1A proteins modulate the expression of a large variety of genes in transformed cells by either stimulating or repressing their promoters. For example, the E1A proteins inhibit the collagenase promoter, whereas they activate the c-jun promoter. Both effects are mediated through AP-1/ATF-binding sites. Repression of transcription of the collagenase gene requires the amino-terminus and conserved region 1 (CR1) of Ad5 E1A, two regions that are also crucial for interaction of E1A with the recently isolated transcriptional adaptor protein p300. We show here that overexpressed p300 can counteract the repressive effect of E1A on the collagenase promoter. Using the CREB-binding protein (CBP), which is highly homologous to p300, the same results were obtained. The domains in E1A required for binding to p300 are also essential for E1A-mediated cell transformation. We therefore tested the effect of p300 and CBP on the transforming potential of Ad5 El in baby rat kidney (BRK) cells. It was found that E1A-induced focus formation was strongly inhibited by overexpression of p300 or CBP. Moreover the BRK cell colonies, obtained after cotransfection with Ad5E1 and p300, could not be established. These results indicate that one of the mechanisms by which E1A modulates transcription and transforms cells is via transcriptional adaptors like p300 and CBP.			Smits, PHM (corresponding author), LEIDEN STATE UNIV,SYLVIUS LAB,MOLEC CARCINOGENESIS LAB,WASSENAARSEWEG 72,2333 AL LEIDEN,NETHERLANDS.							ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BARBEAU D, 1994, ONCOGENE, V9, P359; BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DORMAN JC, 1995, J VIROL, V69, P2962; DYSON N, 1992, CANCER SURV, V12, P161; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HAGMEYER BM, 1995, BIOESSAYS, V17, P621, DOI 10.1002/bies.950170708; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Maniatis T, 1989, DECONTAMINATION DILU; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; NEVINS J, 1992, SCIENCE, V258, P242; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1989, ONCOGENE, V4, P1207; VANDENELSEN P, 1983, VIROLOGY, V128, P377; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988	40	45	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1529	1535						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622869				2022-12-28	WOS:A1996UF07600017
J	Takeda, S; Kondo, M; Kumada, T; Koshikawa, T; Ueda, R; Nishio, M; Osada, H; Suzuki, H; Nagatake, M; Washimi, O; Takagi, K; Takahashi, T; Nakao, A; Takahashi, T				Takeda, S; Kondo, M; Kumada, T; Koshikawa, T; Ueda, R; Nishio, M; Osada, H; Suzuki, H; Nagatake, M; Washimi, O; Takagi, K; Takahashi, T; Nakao, A; Takahashi, T			Allelic-expression imbalance of the insulin-like growth factor 2 gene in hepatocellular carcinomas and underlying disease	ONCOGENE			English	Article						genomic imprinting; IGF2; H19; hepatocellular carcinoma; hepatocarcinogenesis	II GENE; HEPATITIS-C; WILMS-TUMOR; P53 GENE; INTERFERON; TISSUES; RELAXATION; IGF2; RNA	It has been well documented that the liver is an exceptional organ in which the monoallelic expression of insulin-like growth factor 2 (IGF2) due to genomic imprinting is relaxed during the postnatal period, resulting in biallelic expression thereafter. In the present study, changes in the status of genomic imprinting were examined in 15 hepatocellular carcinomas (HCCs) as well as in 29 liver biopsies of chronic hepatitis or liver cirrhosis without clinical evidence of HCC, following screening for heterozygotes with an ApaI polymorphism in IGF2 in 34 HCCs and 80 such non-HCC cases. Extreme allelic-expression imbalance, leading to restoration of monoallelic IGF2 expression, was observed in 15 (100%) of 15 informative HCCs for the polymorphism with this monoallelic IGF2 expression appearing to be non-random from the paternal allele. Interestingly, the same allelic-expression imbalance was also present in a significant fraction of noncancerous liver specimens of patients with underlying disease known to be associated with HCC development. In contrast, the status of genomic imprinting of H19, another gene closely mapped at 11p15 under opposite imprinting, was strictly maintained in seven (100%) of seven cases informative for an RsaI polymorphism of H19. Together with the previous reports on altered genomic imprinting of IGF2 and H19 in embryonal lesions such as Wilms tumors as well as in lung cancers, the results suggest that perturbations of imprinting status occur as locus and tumor-type specific events in the development of human cancers.	AICHI CANC CTR,RES INST,LAB ULTRASTRUCT RES,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,RES INST,LAB CHEMOTHERAPY,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,RES INST,IMMUNOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR HOSP,DEPT PATHOL,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR HOSP,DEPT CLIN LABS,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR HOSP,DEPT INTERNAL MED,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; NAGOYA UNIV,SCH MED,DEPT SURG 2,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NAGOYA UNIV,SCH MED,DEPT INTERNAL MED 2,SHOWA KU,NAGOYA,AICHI 466,JAPAN; OGAKI MUNICIPAL HOSP,DEPT INTERNAL MED,OGAKI 503,JAPAN	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Nagoya University; Nagoya University; Ogaki Municipal Hospital			Takahashi, Takashi/I-7262-2014; Kondo, Masashi/I-7378-2014; Osada, Hiroyuki/AAY-6254-2020	Takahashi, Takashi/0000-0003-0615-7001; 				BARTOLOMEI MS, 1994, NAT GENET, V6, P220, DOI 10.1038/ng0394-220; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BROWN AL, 1986, J BIOL CHEM, V261, P3144; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; DAVIES SM, 1994, CANCER RES, V54, P2560; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DORR RT, 1993, DRUGS, V45, P177, DOI 10.2165/00003495-199345020-00003; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; HAGIWARA H, 1993, GASTROENTEROLOGY, V104, P877, DOI 10.1016/0016-5085(93)91025-D; HOLTHUIZEN P, 1990, BIOCHIM BIOPHYS ACTA, V1087, P341, DOI 10.1016/0167-4781(90)90010-Y; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; KANAI K, 1992, LANCET, V339, P1543, DOI 10.1016/0140-6736(92)91311-U; KAWAKITA N, 1992, AM J PATHOL, V140, P513; KONDO M, 1995, ONCOGENE, V10, P1193; KONDO M, 1994, ONCOGENE, V9, P3063; KUROKI T, 1995, BRIT J CANCER, V72, P383, DOI 10.1038/bjc.1995.342; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; NAKAJIMA T, 1994, J GASTROENTEROL, V29, P450, DOI 10.1007/BF02361242; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; NISHIDA N, 1993, CANCER RES, V53, P368; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SURANI MA, 1993, NATURE, V366, P302, DOI 10.1038/366302a0; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TANAKA K, 1991, CANCER RES, V51, P2842; TSAI JF, 1994, INT J CANCER, V56, P619, DOI 10.1002/ijc.2910560502; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; ZHANG X, 1994, CANCER RES, V54, P4177	33	51	55	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1589	1592						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622877				2022-12-28	WOS:A1996UF07600025
J	Kitada, S; Krajewski, S; Miyashita, T; Krajewska, M; Reed, JC				Kitada, S; Krajewski, S; Miyashita, T; Krajewska, M; Reed, JC			gamma-Radiation induces upregulation of Bax protein and apoptosis in radiosensitive cells in vivo	ONCOGENE			English	Article						Bax; Bcl-2; apoptosis; radiation	INDUCTION; P53; AGENTS; DEATH	Lymphoid cells and small intestinal epithelial (SIE) cells are among the most radiosensitive in the body. The factors that account for the differential sensitivity to gamma-radiation among different tissue-types remain poorly understood, but can only partly be explained by differences in rates of cell proliferation. Here we demonstrate that exposure of mice to 800 cGy of gamma-radiation results in rapid elevations in the levels of the Bax protein, a pro-apoptotic member of the Bcl-2 protein family, in lymphoid cells and SIEs. gamma-Radiation-induced increases in Bax protein were evident within 2 h and persisted for at least 24 h, as determined by immunoblotting and immunohistochemical assays. Increases in Bax were followed by massive apoptosis in lymphoid organs and in the small intestinal crypts, as determined by morphological criteria and in situ end-labeling of fragmented nuclear DNA by terminal deoxynucleotidyl transferase (TUNEL method). Radiation did not induce elevations in Bax or apoptosis in radioresistant tissues such as heart, skeletal muscle, brain, kidney, liver, lung, vascular smooth muscle and connective tissue. The findings suggest that Bax may be one of the mediators of radiation-induced apoptosis in vivo.	LA JOLLA CANC RES FDN,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					NCI NIH HHS [CA-60381] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRISTOW RG, 1994, ONCOGENE, V9, P1527; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; GORCZYCA W, 1992, INT J ONCOL, V1, P639; Hill R. P., 1992, BASIC SCI ONCOLOGY, P259; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HORNING SJ, 1993, SEMIN ONCOL, V20, P75; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MERRITT AJ, 1994, CANCER RES, V54, P614; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PEZZELLA F, 1990, AM J PATHOL, V137, P225; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; POTTEN CS, 1983, CYTOTOXIC INSULT TIS; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, ONCOGENE, V9, P3743	26	159	167	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					187	192						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552390				2022-12-28	WOS:A1996TQ01400023
J	Winston, JT; Coats, SR; Wang, YZ; Pledger, WJ				Winston, JT; Coats, SR; Wang, YZ; Pledger, WJ			Regulation of the cell cycle machinery by oncogenic ras	ONCOGENE			English	Article						ras; cell cycle; cyclins; cdk4; Kip1	EPIDERMAL GROWTH-FACTOR; FIBROBLASTS; INHIBITION; G(1); TRANSFORMATION; EXPRESSION; INDUCTION; KINASE; RAF-1; DNA	The ras proto-oncogene has been implicated during the formation of tumors in vivo as well as the transformation of cell lines in culture. Conditional expression of an activated ras mutant in Balb/c-3T3 fibroblasts failed to stimulate S phase entry in the absence of plasma-derived progression factors, but did shorten the G(1) interval from 12 to 6 h and abrogate the normal proliferative requirement for platelet-derived growth factor. Ras-dependent alteration of the 3T3 cell cycle was accompanied by a dramatic increase in the expression of the G(1) regulatory protein, cyclin D1, while expression of cyclin E and cyclin A proteins were only weakly induced. Cyclin/cdk complexes assembled in response to ectopic ras expression in the absence of growth factor stimulation bound the cdk inhibitory factor, Kip1, and were inactive. However, plasma-stimulated regulatory pathways functioned co-operatively with the oncogenic ras molecule to decrease Kip1 levels, induce the kinase activities associated with cyclins D, E and A, and trigger the initiation of DNA replication. Our results suggest that a ras-activated signal transduction pathway may link environmental mitogenic stimuli to the cell cycle machinery via modulation of G(1) cyclin expression.	UNIV S FLORIDA,H LEE MOFFITT CANC CTR & RES INST,TAMPA,FL 33612; UNIV S FLORIDA,DEPT INTERNAL MED,TAMPA,FL 33612; UNIV S FLORIDA,DEPT BIOCHEM & MOLEC BIOL,TAMPA,FL 33612; UNIV S FLORIDA,DEPT MED MICROBIOL,TAMPA,FL 33612; VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37232	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Vanderbilt University					NATIONAL CANCER INSTITUTE [P01CA043720, R01CA067360] Funding Source: NIH RePORTER; NCI NIH HHS [CA43720, CA67360] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONIADES HN, 1975, P NATL ACAD SCI USA, V74, P1973; ANZANO MA, 1985, MOL CELL BIOL, V5, P242, DOI 10.1128/MCB.5.1.242; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COATS SR, 1992, J CELL BIOCHEM, V48, P242, DOI 10.1002/jcb.240480304; COFFEY RJ, 1987, J CELL PHYSIOL, V132, P143, DOI 10.1002/jcp.1041320120; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; LEOF EB, 1989, CANCER RES, V49, P2356; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJITEK AB, 1993, CELL, V74, P206; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	39	197	200	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					127	134						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552383				2022-12-28	WOS:A1996TQ01400016
J	Ino, T; Yasui, H; Hirano, M; Kurosawa, Y				Ino, T; Yasui, H; Hirano, M; Kurosawa, Y			Identification of a member of the TIS11 early response gene family at the insertion point of a DNA fragment containing a gene for the T-cell receptor beta chain in an acute T-cell leukemia	ONCOGENE			English	Article						TIS11d gene; gene rearrangement; T-cell receptor gene; T-cell leukemia; leukemogenesis	SWISS 3T3 CELLS; CIRCULAR DNA; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; CONSTANT REGION; CYCLIC-AMP; PROTEIN; TRANSCRIPTION; RECOMBINATION; DELETION	In a previous paper (Proc. Natl. Acad. Sci. USA 84, 4264, 1987) we reported that a DNA fragment containing a gene for the T-cell receptor beta chain, which had been excised from chromosome 7q35 during D beta-J beta joining, was inserted into chromosome 6p21.3 in a patient with acute T-cell leukemia. We have since screened for genes in the vicinity of the insertion point and have identified a gene that is equivalent to the murine TIS11d gene, a member of TIS11 early response gene family, that contains unique Cysteine-Histidine motifs. The human TIS11d gene consists of two exons and encodes a polypeptide of 492 amino acids. The insertion of the DNA fragment observed in this patient is located at the carboxy-terminal portion of the TIS11d protein.	FUJITA HLTH UNIV,SCH MED,INST COMPREHENS MED SCI,TOYOAKE,AICHI 47011,JAPAN	Fujita Health University	Ino, T (corresponding author), FUJITA HLTH UNIV,SCH MED,DEPT INTERNAL MED,TOYOAKE,AICHI 47011,JAPAN.							BARNARD RC, 1993, NUCLEIC ACIDS RES, V21, P3580, DOI 10.1093/nar/21.15.3580; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; FOLGER KR, 1982, MOL CELL BIOL, V2, P1372, DOI 10.1128/MCB.2.11.1372; FUJIMOTO S, 1987, NATURE, V327, P242, DOI 10.1038/327242a0; GOMPERTS M, 1990, ONCOGENE, V5, P1081; INO T, 1987, P NATL ACAD SCI USA, V84, P4264, DOI 10.1073/pnas.84.12.4264; INO T, 1988, BIOCHEM BIOPH RES CO, V152, P257, DOI 10.1016/S0006-291X(88)80708-3; INO T, 1988, ACTA HEMATOL JPN, V51, P185; IWASATO T, 1990, CELL, V62, P143, DOI 10.1016/0092-8674(90)90248-D; KANEDA N, 1987, BIOCHEM BIOPH RES CO, V146, P971, DOI 10.1016/0006-291X(87)90742-X; LAI WS, 1990, J BIOL CHEM, V265, P16556; LIM RW, 1987, ONCOGENE, V1, P263; MATSUOKA M, 1990, CELL, V62, P135, DOI 10.1016/0092-8674(90)90247-C; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; OKAZAKI K, 1987, CELL, V49, P477, DOI 10.1016/0092-8674(87)90450-8; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TAYLOR GA, 1991, NUCLEIC ACIDS RES, V19, P3454, DOI 10.1093/nar/19.12.3454; TOYONAGA B, 1985, P NATL ACAD SCI USA, V82, P8624, DOI 10.1073/pnas.82.24.8624; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; VARNUM BC, 1989, ONCOGENE, V4, P119; VONSCHWEDLER U, 1990, NATURE, V345, P452, DOI 10.1038/345452a0	24	14	16	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2705	2710						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545129				2022-12-28	WOS:A1995TP18800028
J	Makela, TP; Hellsten, E; Vesa, J; Hirvonen, H; Palotie, A; Peltonen, L; Alitalo, K				Makela, TP; Hellsten, E; Vesa, J; Hirvonen, H; Palotie, A; Peltonen, L; Alitalo, K			The rearranged L-myc fusion gene (RLF) encodes a Zn-15 related zinc finger protein	ONCOGENE			English	Article						RLF-L-myc rearrangement; small-cell lung carcinoma; zinc finger; transcription factor	CELL LUNG-CANCER; EXPRESSION; AMPLIFICATION; DROSOPHILA; BINDING; COMMON; MAX	We have previously characterized intrachromosomal rearrangements at 1p32 fusing the first exon of the RLF gene with L-myc, Here we present the full-length cDNA sequence of the 6251 bp RLH mRNA, The predicted 1914 amino acid Rlf protein contains sixteen widely spaced zinc finger motifs, and is related to the Zn-15 transcription factor, RLF is widely expressed in fetal and adult tissues, suggesting that it has a general role in transcriptional regulation. The zinc fingers are not contained in the 79 amino acid N-terminal region of RLP involved in the RLF-L-myc fusions, and the transforming ability of the RLF-L-myc and the normal L-myc proteins is indistinguishable. These findings suggest that the role of the rearrangements fusing RLF and L-myc is to the tightly controlled deregulate expression of the L-myc gene.	HELSINKI UNIV, HAARTMAN INST, MOLEC CANC BIOL LAB, SF-00014 HELSINKI, FINLAND; WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; NATL PUBL HLTH INST, DEPT HUMAN MOLEC GENET, SF-00300 HELSINKI, FINLAND; UNIV TURKU, DEPT BIOCHEM MED, SF-20520 TURKU, FINLAND; HELSINKI UNIV, CENT HOSP, DEPT CLIN CHEM, SF-00290 HELSINKI, FINLAND	University of Helsinki; Massachusetts Institute of Technology (MIT); Whitehead Institute; Finland National Institute for Health & Welfare; University of Turku; University of Helsinki; Helsinki University Central Hospital			Alitalo, Kari K/J-5013-2014; makela, tomi/B-3734-2009	Alitalo, Kari K/0000-0002-7331-0902; makela, tomi/0000-0002-4869-8044; Palotie, Aarno/0000-0002-2527-5874				ALITALO K, 1992, GENE AMPLIFICATION M, P371; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; FASANO L, 1991, CELL, V64, P63, DOI 10.1016/0092-8674(91)90209-H; HELLSTEN E, 1995, GENOMICS, V25, P404, DOI 10.1016/0888-7543(95)80040-S; HIRVONEN H, 1991, BLOOD, V78, P3012; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIPKIN SM, 1993, GENE DEV, V7, P1674, DOI 10.1101/gad.7.9.1674; MACLEANHUNTER S, 1994, ONCOGENE, V9, P3509; MAKELA TP, 1992, ONCOGENE, V7, P405; MAKELA TP, 1991, MOL CELL BIOL, V11, P4015; MAKELA TP, 1992, GENE, V118, P293, DOI 10.1016/0378-1119(92)90203-2; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MAKELA TP, 1991, EMBO J, V10, P1331, DOI 10.1002/j.1460-2075.1991.tb07652.x; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; REUTER G, 1990, NATURE, V344, P219, DOI 10.1038/344219a0; RHODES D, 1993, SCI AM, V268, P56, DOI 10.1038/scientificamerican0293-56; SEKIDO Y, 1992, MOL CELL BIOL, V12, P1747, DOI 10.1128/MCB.12.4.1747	18	16	17	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2699	2704						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545128				2022-12-28	WOS:A1995TP18800027
J	MORI, M; BARNARD, GF; STANIUNAS, RJ; JESSUP, JM; STEELE, GD; CHEN, LB				MORI, M; BARNARD, GF; STANIUNAS, RJ; JESSUP, JM; STEELE, GD; CHEN, LB			PROTHYMOSIN-ALPHA MESSENGER-RNA EXPRESSION CORRELATES WITH THAT OF C-MYC IN HUMAN COLON-CANCER	ONCOGENE			English	Article							GENE-EXPRESSION; CELL-PROLIFERATION; LYMPHOCYTES-T; AMEX METHOD; ONCOGENE; PROTEIN; MUCOSA; FAMILY; TRANSCRIPTION; AMPLIFICATION	Prothymosin alpha (PT-alpha) is a nuclear protein involved in cell proliferation. Transcription of PT-alpha has been reported to be regulated by the c-myc gene in vitro. We identified PT-alpha as being overexpressed in a human colon cancer minus normal mucosa subtraction cDNA library. Northern blot (messenger RNA) analysis showed that both PT-alpha and c-myc genes were overexpressed in human colorectal cancers compared with adjacent normal tissues. Immunohistochemical studies for PT-alpha and c-myc supported these findings. There was no correlation between PT-alpha or c-myc messenger RNA expression and Dukes' stage of colorectal cancer; or between either of these two and actin messenger RNA expression. There was, however, a significant correlation between the PT-alpha expression and c-myc expression (P <0.001). These findings support the hypothesis that PT-alpha gene transcription may be associated with, and possibly under the control of, the c-myc gene in human colorectal cancers.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,44 BINNEY ST,BOSTON,MA 02115; NEW ENGLAND DEACONESS HOSP,DEPT SURG,BOSTON,MA 02215	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NCI NIH HHS [P01CA44704, 1F32CA9001] Funding Source: Medline; NIDDK NIH HHS [T32DK07533] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA044704, F32CA009001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNARD GF, 1992, CANCER RES, V52, P3067; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLEIBERG H, 1976, CANCER RES, V36, P325; CHENG GH, 1989, MOL CELL BIOL, V9, P2332, DOI 10.1128/MCB.9.6.2332; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONTEAS CN, 1990, P NATL ACAD SCI USA, V87, P3269, DOI 10.1073/pnas.87.9.3269; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P62; ERISMAN MD, 1989, P NATL ACAD SCI USA, V86, P4264, DOI 10.1073/pnas.86.11.4264; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; ESCHENFELDT WH, 1989, J BIOL CHEM, V264, P7546; ESCHENFELDT WH, 1986, P NATL ACAD SCI USA, V83, P9403, DOI 10.1073/pnas.83.24.9403; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FINLEY GG, 1989, ONCOGENE, V4, P963; FRANCO FJ, 1989, IMMUNOLOGY, V67, P263; GOMEZMARQUEZ J, 1989, J BIOL CHEM, V264, P8451; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANNAPPEL E, 1982, BIOCHEM BIOPH RES CO, V104, P266, DOI 10.1016/0006-291X(82)91969-6; HARITOS A, 1983, P NATL ACAD SCI USA, V80, P1008; JOHNSON BE, 1987, J CLIN INVEST, V79, P1629, DOI 10.1172/JCI112999; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAFUNE K, 1991, ARCH SURG-CHICAGO, V126, P462; MANROW RE, 1991, J BIOL CHEM, V266, P3916; PAVELIC K, 1990, Journal of Experimental Pathology (New York), V5, P143; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; RISIO M, 1991, CANCER RES, V51, P1917; ROTHBERG PG, 1984, MOL CELL BIOL, V4, P1096, DOI 10.1128/MCB.4.6.1096; ROYDS JA, 1992, J PATHOL, V166, P225, DOI 10.1002/path.1711660304; SATO Y, 1986, AM J PATHOL, V125, P431; SATO Y, 1992, AM J PATHOL, V140, P775; SBURLATI AR, 1991, P NATL ACAD SCI USA, V88, P253, DOI 10.1073/pnas.88.1.253; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; SZABO P, 1992, BIOCHEM BIOPH RES CO, V185, P953, DOI 10.1016/0006-291X(92)91719-7; TERPSTRA OT, 1987, GASTROENTEROLOGY, V92, P704, DOI 10.1016/0016-5085(87)90021-7; TULCHIN N, 1992, AM J PATHOL, V140, P917; VERSTEEG R, 1989, J EXP MED, V170, P621, DOI 10.1084/jem.170.3.621	41	113	114	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2821	2826						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378090				2022-12-28	WOS:A1993LX34300024
J	SHIIO, Y; YAMAMOTO, T; YAMAGUCHI, N				SHIIO, Y; YAMAMOTO, T; YAMAGUCHI, N			IDENTIFICATION OF A DNA ELEMENT THAT CAN ENHANCE P53-MEDIATED TRANSACTIVATION	ONCOGENE			English	Article							TUMOR SUPPRESSOR GENES; WILD-TYPE P53; BINDING-SITE; EXPRESSION; PROTEIN; PRODUCT	Recent studies have demonstrated that p53 binds to specific DNA sequences and the consensus sequence for the p53 binding site has been proposed. The p53 binding site has also been shown to act as positive p53-responsive element. Here we report the identification of a GC3 element that enhances p53-mediated transactivation when placed adjacent to the consensus p53 site. The GC3 element alone cannot act as a positive p53-responsive element. We also show that p53 activates transcription of the c-erbA-alpha gene through a DNA element that consists of the p53 quarter-sites and GC3 elements. Using gel mobility-shift assay, we identified a possible GC3 binding factor distinct from p53.	UNIV TOKYO,INST MED SCI,DEPT ONCOL,TOKYO 108,JAPAN	University of Tokyo	SHIIO, Y (corresponding author), UNIV TOKYO,INST MED SCI,DEPT VIROL,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN.							AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Mackett M., 1985, DNA CLONING PRACTICA, P191; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	18	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2059	2065						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8393159				2022-12-28	WOS:A1993LP17100005
J	MORELLO, D; LAVENU, A; POURNIN, S; BABINET, C				MORELLO, D; LAVENU, A; POURNIN, S; BABINET, C			THE 5' AND 3' NONCODING SEQUENCES OF THE C-MYC GENE, REQUIRED INVITRO FOR ITS POSTTRANSCRIPTIONAL REGULATION, ARE DISPENSABLE INVIVO	ONCOGENE			English	Article							MESSENGER-RNA DEGRADATION; MOUSE-LIVER REGENERATION; CELL-FREE SYSTEM; PROTEIN-SYNTHESIS; TRANSGENIC MICE; PREMATURE TERMINATION; STABILITY INVITRO; LYMPHOMA-CELLS; RAT-LIVER; EXPRESSION	We have previously shown that in vivo the steady-state level of c-myc mRNA in different quiescent organs and its induction in the early stages of hepatic regeneration and after inhibition of protein synthesis are mainly controlled by post-transcriptional mechanisms. In order to localize the target sequences for these mechanisms, transgenic lines expressing various versions of the human c-myc proto-oncogene have been constructed. To avoid all possible transcriptional controls due to the c-mye 5' regulatory region, the c-mye genomic sequences were fused to MHC H-2K(b) class I regulatory sequences, which have previously been shown to be able to drive reporter gene expression in most adult tissues. The transgenes contained either all human c-mye genomic sequences or were deleted for one of the sequences which have been shown in in vitro experiments to play a role in c-mye mRNA stabilization, in particular exon 1, intron 1 and the 3' non-coding region. Several independent transgenic lines were derived for each construct. Using S1 nuclease protection analysis, we have monitored H-2K, mouse c-myc and transgene mRNA expression in several quiescent adult organs, at the start of liver regeneration and after inhibition of protein synthesis in each transgenic line. Our results indicate that the 5' non-coding sequences, including exon 1 and intron 1, and the 3' untranslated region are all dispensable in the different aspects of c-myc post-transcriptional regulation.			MORELLO, D (corresponding author), INST PASTEUR, DEPT IMMUNOL, UNITE GENET MAMMIFERES, 25 RUE DR ROUX, F-75724 PARIS 15, FRANCE.							AGHIB DF, 1991, ONCOGENE, V6, P2371; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAUER SR, 1989, ONCOGENE, V4, P615; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BONNIEU A, 1990, ONCOGENE, V5, P1585; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; GOYETTE M, 1984, MOL CELL BIOL, V4, P1493, DOI 10.1128/MCB.4.8.1493; GRAVES RA, 1987, CELL, V48, P615, DOI 10.1016/0092-8674(87)90240-6; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KERPPOLA TK, 1988, MOL CELL BIOL, V8, P4389, DOI 10.1128/MCB.8.10.4389; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; LAIRDOFFRINGA IA, 1990, MOL CELL BIOL, V10, P6132, DOI 10.1128/MCB.10.12.6132; LAIRDOFFRINGA IA, 1991, NUCLEIC ACIDS RES, V19, P2387, DOI 10.1093/nar/19.9.2387; LATHE R, 1987, GENE, V57, P193, DOI 10.1016/0378-1119(87)90122-3; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LONDON L, 1991, MOL CELL BIOL, V11, P4599, DOI 10.1128/MCB.11.9.4599; MAKINO R, 1984, NATURE, V310, P697, DOI 10.1038/310697a0; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MARTIN P, 1986, EMBO J, V5, P1529, DOI 10.1002/j.1460-2075.1986.tb04393.x; MORELLO D, 1989, ONCOGENE, V4, P955; MORELLO D, 1989, ONCOGENE RES, V4, P111; MORELLO D, 1986, EMBO J, V5, P1877, DOI 10.1002/j.1460-2075.1986.tb04439.x; MORELLO D, 1990, MOL CELL BIOL, V10, P3185, DOI 10.1128/MCB.10.6.3185; MORELLO D, 1990, ONCOGENE, V5, P1511; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PEI R, 1988, MOL CELL BIOL, V8, P2860, DOI 10.1128/MCB.8.7.2860; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; PIECHACZYK M, 1987, TRENDS GENET, V3, P47, DOI 10.1016/0168-9525(87)90166-1; RABBITTS PH, 1985, EMBO J, V4, P3727, DOI 10.1002/j.1460-2075.1985.tb04141.x; RICHMAN A, 1989, MOL CELL BIOL, V9, P4962, DOI 10.1128/MCB.9.11.4962; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SOBCZAK J, 1989, ONCOGENE, V4, P1503; SWARTWOUT SG, 1989, MOL CELL BIOL, V9, P288, DOI 10.1128/MCB.9.1.288; THEODORAKIS NG, 1992, MOL CELL BIOL, V12, P791, DOI 10.1128/MCB.12.2.791; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WRIGHT S, 1989, P NATL ACAD SCI USA, V86, P505, DOI 10.1073/pnas.86.2.505	58	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1993	8	7					1921	1929						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510935				2022-12-28	WOS:A1993LG68200025
J	KLAGES, S; ADAM, D; EISEMAN, E; FARGNOLI, J; DYMECKI, SM; DESIDERIO, SV; BOLEN, JB				KLAGES, S; ADAM, D; EISEMAN, E; FARGNOLI, J; DYMECKI, SM; DESIDERIO, SV; BOLEN, JB			MOLECULAR-CLONING AND ANALYSIS OF CDNA-ENCODING THE MURINE C-YES-TYROSINE PROTEIN-KINASE	ONCOGENE			English	Article							SEQUENCE-ANALYSIS PROGRAMS; HEMATOPOIETIC-CELLS; COMPREHENSIVE SET; SRC FAMILY; GENE; CD4; EXPRESSION; P56LCK; VAX	The cellular yes (c-yes) gene is a member of the class of proto-oncogenes that encode non-receptor tyrosine protein kinases. In this report we describe the isolation of cDNAs that encode the murine c-yes gene product and analysis of the nucleotide sequence of the murine c-yes cDNA clones. The reading frame encodes a protein of 541 amino acids with a calculated molecular mass of 60.63 kDa that is reactive with anti-Yes antisera and possesses protein kinase activity.	BRISTOL MYERS SQUIBB CO,PHARMACEUT RES INST,DEPT MOLEC BIOL,POB 4000,PRINCETON,NJ 08543; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	Bristol-Myers Squibb; Howard Hughes Medical Institute; Johns Hopkins University			Adam, Dieter/E-9763-2010; Adam-Klages, Sabine/E-9761-2010	Adam, Dieter/0000-0002-5668-5032; 				BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COOKE M P, 1989, New Biologist, V1, P66; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; GHYSDAEL J, 1981, P NATL ACAD SCI-BIOL, V78, P2611, DOI 10.1073/pnas.78.4.2611; HOLTZMAN DA, 1987, P NATL ACAD SCI USA, V84, P8325, DOI 10.1073/pnas.84.23.8325; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KAWAI S, 1980, P NATL ACAD SCI-BIOL, V77, P6199, DOI 10.1073/pnas.77.10.6199; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KING FJ, 1990, ONCOGENE, V5, P337; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; PYPER JM, 1989, J NEUROSCI RES, V24, P89, DOI 10.1002/jnr.490240113; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; STEELE RE, 1989, ONCOGENE RES, V1, P223; SUDOL M, 1988, ONCOGENE RES, V2, P345; SUDOL M, 1988, NUCLEIC ACIDS RES, V16, P9876, DOI 10.1093/nar/16.20.9876; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391; ZHAO YH, 1991, ONCOGENE, V6, P1725; ZHAO YH, 1990, ONCOGENE, V5, P1629; ZHENG XF, 1989, ONCOGENE, V4, P99	32	8	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					713	719						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437854				2022-12-28	WOS:A1993KN00800023
J	DAVIS, LJ; HALAZONETIS, TD				DAVIS, LJ; HALAZONETIS, TD			BOTH THE HELIX-LOOP-HELIX AND THE LEUCINE ZIPPER MOTIFS OF C-MYC CONTRIBUTE TO ITS DIMERIZATION SPECIFICITY WITH MAX	ONCOGENE			English	Article							DNA-BINDING; PROTEIN; SEQUENCE; GENE; TRANSCRIPTION; ONCOGENE; DIMER; TRANSFORMATION; FIBROBLASTS; COMPLEXES	The oncoprotein c-Myc contains two dimerization motifs - the helix-loop-helix (HLH) and the leucine zipper (LZ) - through which c-Myc specifically dimerizes with Max. We substituted regions of the c-Myc HLH and LZ motifs with the corresponding regions of structurally related proteins that do not interact with Max. Specific association of c-Myc with Max was dictated by helices 1 and 2 of the HLH motif and by the LZ. Within helix 2, residues 6 and 7 were important determinants of dimerization specificity. c-Myc and Max proteins with three amino acids inserted between their HLH and LZ motifs interacted efficiently, suggesting that the spacing between the motifs can be varied. Furthermore, alignment of the motifs at the primary sequence level was not obligatory, since Max with the three amino acid insertion could interact with wild-type c-Myc. These findings are consistent with our recently proposed model for the architecture of HLH/LZ domains.	MERCK SHARP & DOHME LTD,DEPT CANC RES,WP 16-3,W POINT,PA 19486	Merck & Company			Halazonetis, Thanos/D-7923-2011					ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; CROUCH DH, 1990, ONCOGENE, V5, P683; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; ENRIETTO PJ, 1989, VIROLOGY, V168, P256, DOI 10.1016/0042-6822(89)90265-1; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HALAZONETIS TD, 1992, SCIENCE, V255, P464, DOI 10.1126/science.1734524; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SARID J, 1987, P NATL ACAD SCI USA, V84, P170, DOI 10.1073/pnas.84.1.170; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x	38	36	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					125	132						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423990				2022-12-28	WOS:A1993KN00500015
J	Byeon, MK; Westerman, MA; Maroulakou, IG; Henderson, KW; Suster, S; Zhang, XK; Papas, TS; Vesely, J; Willingham, MC; Green, JE; Schweinfest, CW				Byeon, MK; Westerman, MA; Maroulakou, IG; Henderson, KW; Suster, S; Zhang, XK; Papas, TS; Vesely, J; Willingham, MC; Green, JE; Schweinfest, CW			The down-regulated in adenoma (DRA) gene encodes an intestine-specific membrane glycoprotein	ONCOGENE			English	Article						colon; tumorigenesis; sulfate transporter; mucosa; differentiation	HUMAN COLORECTAL-CANCER; HUMAN-COLON CARCINOMA; HEPARAN-SULFATE; P-GLYCOPROTEIN; APC GENE; GASTRIC-CANCER; FREQUENT LOSS; EXPRESSION; MUTATIONS; IDENTIFICATION	The protein product of the DRA gene, a gene whose expression is down-regulated in colon adenomas and adenocarcinomas, is a membrane glycoprotein and a member of a family of sulfate transporters. It is expressed in the intestinal tract (duodenum, ileum, cecum, distal colon), but not in the esophagus or stomach, DRA mRNA expression is restricted to the mucosal epithelium, and DRA protein expression is further limited to the columnar epithelial cells, particularly to the brush border, Consistent with its expression in the differentiated columnar epithelium of the adult human colon, DRA is first expressed in the midgut of developing mouse embryos at day 16.5, corresponding with the time of differentiation of the epithelium of the small intestine, A model for the structure of the DRA protein is proposed and its possible role in colon tumorigenesis is discussed.	MED UNIV S CAROLINA,CTR MOLEC & STRUCT BIOL,HOLLINGS CANC CTR,CHARLESTON,SC 29425; NCI,MOLEC ONCOL LAB,FREDERICK,MD 21702; MT SINAI MED CTR,DEPT PATHOL & LAB MED,MIAMI BEACH,FL 33140; UNIV MIAMI,SCH MED,MIAMI,FL 33140; MED UNIV S CAROLINA,DEPT PATHOL & LAB MED,CHARLESTON,SC 29425	Medical University of South Carolina; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Mount Sinai Medical Center; University of Miami; Medical University of South Carolina								ABBASI AM, 1993, EUR J CANCER, V29A, P1995, DOI 10.1016/0959-8049(93)90461-N; AUGENLICHT LH, 1991, P NATL ACAD SCI USA, V88, P3286, DOI 10.1073/pnas.88.8.3286; BISSIG M, 1994, J BIOL CHEM, V269, P3017; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BURMER GC, 1989, P NATL ACAD SCI USA, V86, P2403, DOI 10.1073/pnas.86.7.2403; DAMICO D, 1992, CANCER RES, V52, P1996; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLEY GG, 1989, ONCOGENE, V4, P963; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FRANSSON LA, 1981, J BIOL CHEM, V256, P3044; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPER JW, 1993, CELL, V75, P805; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; HORII A, 1992, CANCER RES, V52, P3231; HORII A, 1992, CANCER RES, V52, P6696; JACOBY RF, 1994, GENOMICS, V22, P381, DOI 10.1006/geno.1994.1399; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KAWAKAMI H, 1981, BIOCHIM BIOPHYS ACTA, V646, P161, DOI 10.1016/0005-2736(81)90283-2; KOI M, 1994, CANCER RES, V54, P4308; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; MULDER JWR, 1994, LANCET, V344, P1470, DOI 10.1016/S0140-6736(94)90290-9; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PROLLA TA, 1994, SCIENCE, V265, P1092; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROBINSON J, 1984, J CELL BIOL, V98, P946, DOI 10.1083/jcb.98.3.946; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SCHWEINFEST CW, 1993, P NATL ACAD SCI USA, V90, P4166, DOI 10.1073/pnas.90.9.4166; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SIKORA K, 1987, CANCER-AM CANCER SOC, V59, P1289, DOI 10.1002/1097-0142(19870401)59:7<1289::AID-CNCR2820590710>3.0.CO;2-O; SILBERG DG, 1995, J BIOL CHEM, V270, P11897, DOI 10.1074/jbc.270.20.11897; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAGUCHI T, 1994, GENOMICS, V20, P147; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; THOMPSON AM, 1993, BRIT J CANCER, V68, P64, DOI 10.1038/bjc.1993.287; UCHINO S, 1992, CANCER RES, V52, P3099; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WIELENGA VJM, 1993, CANCER RES, V53, P4754; WINTERBOURNE DJ, 1981, J BIOL CHEM, V256, P4310; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; ZHANG JT, 1991, J BIOL CHEM, V266, P18224	50	80	80	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					387	396						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570216				2022-12-28	WOS:A1996TR53800018
J	Cowell, JK; Bia, B; Akoulitchev, A				Cowell, JK; Bia, B; Akoulitchev, A			A novel mutation in the promotor region in a family with a mild form of retinoblastoma indicates the location of a new regulatory domain for the RB1 gene	ONCOGENE			English	Article						RB1 gene; promoter; mutation	ONCOGENIC POINT MUTATIONS; HEREDITARY RETINOBLASTOMA; PENETRANCE; IDENTIFICATION; TRANSCRIPTION; CHROMOSOME-13; GERMLINE; LINKAGE	We describe a family segregating the retinoblastoma phenotype where the affected individuals have only unifocal tumours and where linkage analysis has identified unaffected mutant gene carriers. DNA from members of this 'low penetrance' pedigree was subjected to an exon-by-exon SSCP analysis of the RB1 gene, No mutations were found in the 27 exons of the coding region but an SSCP band shift was seen for PCR products covering the RB1 promotor region. Sequencing identified a G-->C change within a GGGCGG motif which is the core of the recognition sequence of the SP1 transcription factor. Electromobility shift assays demonstrated that SP1 does not bind to oligomers from this region of the RB1 promotor but bandshifts were seen for an, as yet, unidentified protein(s) which was not seen using an oligomer containing the G-->C mutation. Thus, identification of a naturally occurring mutation in a family with only 'mild' phenotypes has identified another regulatory sequence in the RB1 promotor which binds an endogenous cellular protein(s). Identification of this protein should allow a better understanding of the control of expression of the RB1 gene.	INST CHILD HLTH,IMPERIAL CANC RES FUND,ONCOL GRP,LONDON WC1N 1EH,ENGLAND; ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,RES LABS,HOWARD HUGHES MED INST,PISCATAWAY,NJ 08854	Cancer Research UK; University of London; University College London; Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center	Cowell, JK (corresponding author), CLEVELAND CLIN FDN,RES INST,DEPT NEUROSCI,9500 EUCLID AVE,NC30,CLEVELAND,OH 44195, USA.			Cowell, John/0000-0002-2079-5950				BLANQUET V, 1993, HUM MOL GENET, V2, P975, DOI 10.1093/hmg/2.7.975; CAVANEE WK, 1983, NATURE, V305, P779; COMINGS DE, 1973, P NATL ACAD SCI USA, V70, P3324, DOI 10.1073/pnas.70.12.3324; CONNOLLY MJ, 1983, HUM GENET, V65, P122, DOI 10.1007/BF00286647; Cowell John K., 1994, European Journal of Human Genetics, V2, P281; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRAPER GJ, 1992, BRIT J CANCER, V66, P211, DOI 10.1038/bjc.1992.244; DRYJA TP, 1993, AM J HUM GENET, V52, P1122; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; HOGG A, 1992, ONCOGENE, V7, P1445; HOGG A, 1993, P NATL ACAD SCI USA, V90, P7351, DOI 10.1073/pnas.90.15.7351; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KRATZKE RA, 1994, ONCOGENE, V9, P1321; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; OHTANIFUJITA N, 1994, ONCOGENE, V9, P1703; ONADIM Z, 1992, P NATL ACAD SCI USA, V89, P6177, DOI 10.1073/pnas.89.13.6177; ONADIM Z, 1991, BRIT J OPHTHALMOL, V75, P147, DOI 10.1136/bjo.75.3.147; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SAVOYSKY E, 1994, ONCOGENE, V9, P1839; SHIMIZU T, 1994, AM J HUM GENET, V54, P793; SPARKES RS, 1983, SCIENCE, V219, P971, DOI 10.1126/science.6823558; VOGEL F, 1979, HUM GENET, V52, P1; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; YUNIS JJ, 1978, AM J DIS CHILD, V132, P161, DOI 10.1001/archpedi.1978.02120270059012	27	43	43	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					431	436						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570221				2022-12-28	WOS:A1996TR53800023
J	Fujimura, Y; Ohno, T; Siddique, H; Lee, L; Rao, VN; Reddy, ESP				Fujimura, Y; Ohno, T; Siddique, H; Lee, L; Rao, VN; Reddy, ESP			The EWS-ATF-1 gene involved in malignant melanoma of soft parts with t(12;22) chromosome translocation, encodes a constitutive transcriptional activator	ONCOGENE			English	Article						malignant melanoma; EWS; transactivation; ATF-1; chromosome translocation	ETS-RELATED GENE; TISSUE-SPECIFIC EXTINGUISHER; PROTEIN-KINASE-A; EWINGS-SARCOMA; DNA-BINDING; REGULATORY SUBUNIT; TSE1 ENCODES; FACTOR CREB; CYCLIC-AMP; FLI-1 GENE	Molecular characterization of malignant melanoma of soft parts or soft tissue clear cell sarcoma which shares t(12;22) chromosome translocation revealed fusion of EWS with a transcriptional factor gene ATF-1. The EWS gene, which encodes an RNA binding protein, was also shown to be involved in Ewing sarcoma, related primitive neuroectodermal tumors and desmoplastic small round cell tumors. In order to understand the functional role of EWS-ATF-1 chimeric protein in human solid tumors, we have cloned the aberrant human ATF-1 (EWS-ATF-1) cDNA and studied its DNA binding, transcriptional activation properties and compared with normal ATF-1 protein. Our results demonstrate that EWS-ATF-1 binds weakly to DNA in vitro but functions as an efficient constitutive transcriptional activator unlike the normal ATF-1 which needs to be induced with cAMP. Deletion analysis revealed that EWS-fusion domain functions as a regulatory domain for the transcriptional activation properties of EWS-ATF-1 chimeric protein. Deletion of leucine zipper domain results in a loss of transcriptional activation of EWS-ATF-1 chimeric protein suggesting that protein-protein interaction play a role in the transcriptional activation properties of EWS-ATF-1. We demonstrate that EWS-fusion domain negatively regulates the DNA binding activity of EWS-ATF-1 chimeric protein. Therefore replacement of part of the amino-terminal kinase regulatory domain of ATF-1 protein with EWS regulatory domain results in an altered DNA binding, protein-protein interactions and transcriptional activation properties of EWS-ATF-1 causing deregulated gene expression which may be responsible for the genesis of t(12;22) chromosome translocation-bearing human solid tumors. Targeting the transcriptional cofactors (CBP, etc) by EWS-fusion proteins could be one of the mechanisms of activation of EWS-fusion proteins in human neoplasia.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; SAIC,FREDERICK,MD 21702	Jefferson University; Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [CA 51083, CA 58642, CA 57157] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051083, R01CA057157, R01CA058642] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; AURIAS A, 1983, NEW ENGL J MED, V309, P496; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BOSHART M, 1991, CELL, V66, P849, DOI 10.1016/0092-8674(91)90432-X; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; BROWN AD, 1995, ONCOGENE, V10, P1749; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUNN T, 1994, CANCER GENET CYTOGEN, V76, P19, DOI 10.1016/0165-4608(94)90063-9; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; HELM S, 1994, GENES CHROM CANC, V11, P256; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; ICHIKAWA H, 1994, CANCER RES, V54, P2865; JEON IS, 1995, ONCOGENE, V10, P1229; JONES KW, 1991, CELL, V66, P861, DOI 10.1016/0092-8674(91)90433-Y; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LADANYI M, 1994, CANCER RES, V54, P2837; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LIU F, 1993, J BIOL CHEM, V268, P6714; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MAO XH, 1994, J BIOL CHEM, V269, P18216; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MITELMAN F, 1991, CATALOG CHROMOSOME A; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; OUCHIDA M, 1995, ONCOGENE, V11, P1049; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; PRASAD DDK, 1994, ONCOGENE, V9, P669; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAO VN, 1992, ONCOGENE, V7, P2335; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1993, ONCOGENE, V8, P2167; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; VAIRO G, 1990, J BIOL CHEM, V265, P2692; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	55	103	104	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					159	167						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552387				2022-12-28	WOS:A1996TQ01400020
J	Schmidt, G; Lenzen, C; Simon, I; Deuter, R; Cool, RH; Goody, RS; Wittinghofer, A				Schmidt, G; Lenzen, C; Simon, I; Deuter, R; Cool, RH; Goody, RS; Wittinghofer, A			Biochemical and biological consequences of changing the specificity of p21(ras) from guanosine to xanthosine nucleotides	ONCOGENE			English	Article						Ras D119N mutant; interactions; change of specificity; xanthosine nucleotide	ELONGATION-FACTOR-TU; H-RAS P21; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; MOLECULAR-CLONING; BINDING-PROTEINS; PC12 CELLS; GTP; IDENTIFICATION; HYDROLYSIS	The D119N mutation of p21(ras) was prepared by site-directed mutagenesis. Its nucleotide binding properties were investigated using fluorescently labelled guanosine and xanthosine nucleotides. Its affinity for guanosine nucleotides is severely reduced, with a concomitant increase in the affinity for xanthosine nucleotides, which leads to an almost complete reversal of base specificity. The protein is a GTPase as well as a XTPase and the hydrolysis reaction can be efficiently stimulated by GAP. Dissociation of XDP from the mutant is stimulated by the guanine nucleotide exchange factor Cdc25(Mm) in a similar manner to that of GDP from wildtype. The interaction of the mutant with the effector domain of c-Raf kinase or Ral-GEF is normal. In microinjection experiments in PC12 and NIH3T3 cells the protein behaves as an oncogenic mutant due to its high dissociation rate for GDP. However, when the protein is loaded with XDP before microinjection the onset of the oncogenic signal can be efficiently retarded. Thus, the protein behaves initially as wildtype and later as an oncogenic protein.	MAX PLANCK INST MOLEK PHYSIOL,ABT STRUKT BIOL,D-44139 DORTMUND,GERMANY; MAX PLANCK INST MOLEK PHYSIOL,PHYS BIOCHEM ABT,D-44139 DORTMUND,GERMANY	Max Planck Society; Max Planck Society			Goody, Roger S/J-8845-2014	Goody, Roger S/0000-0002-0772-0444; Cool, Robbert/0000-0002-9845-2202				AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEVALLIERMULTON MC, 1993, J BIOL CHEM, V268, P11113; DER CJ, 1988, ONCOGENE, V3, P105; ECCLESTON JF, 1993, J BIOL CHEM, V268, P27012; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FEUERSTEIN J, 1987, J BIOL CHEM, V262, P8455; FRANKEN SM, 1993, BIOCHEMISTRY-US, V32, P8411, DOI 10.1021/bi00084a005; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GLAZEBROOK MA, 1990, J GEN MICROBIOL, V136, P581, DOI 10.1099/00221287-136-3-581; GOODY RS, 1991, TRENDS BIOCHEM SCI, V16, P327, DOI 10.1016/0968-0004(91)90134-H; GOODY RS, 1972, BIOCHIM BIOPHYS ACTA, V276, P155, DOI 10.1016/0005-2744(72)90016-2; GOODY RS, 1986, TETRAHEDRON LETT, V27, P3599, DOI 10.1016/S0040-4039(00)84859-5; HANEY SA, 1994, J BIOL CHEM, V269, P16541; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HERRMANN C, 1995, IN PRESS J BIOL CHEM; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HWANG YW, 1987, J BIOL CHEM, V262, P13081; JACQUET E, 1994, BIOCHEM BIOPH RES CO, V199, P497, DOI 10.1006/bbrc.1994.1256; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; JOHN J, 1993, J BIOL CHEM, V268, P923; JURNAK F, 1990, CELL, V60, P525, DOI 10.1016/0092-8674(90)90652-U; KANG C, 1994, J BIOL CHEM, V269, P24046; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NEAL SE, 1988, J BIOL CHEM, V263, P19718; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OKAMOTO K, 1995, J BIOL CHEM, V270, P7816, DOI 10.1074/jbc.270.14.7816; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; RENSLAND H, 1995, BIOCHEMISTRY-US, V34, P593, DOI 10.1021/bi00002a026; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; SCHWEINS T, 1994, CURR BIOL, V4, P547, DOI 10.1016/S0960-9822(00)00122-6; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3442; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; WEIJLAND A, 1994, BIOCHEMISTRY-US, V33, P10711, DOI 10.1021/bi00201a019; WEIJLAND A, 1994, TRENDS BIOCHEM SCI, V19, P188, DOI 10.1016/0968-0004(94)90018-3; WEIJLAND A, 1993, SCIENCE, V259, P1311, DOI 10.1126/science.8446899; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P383; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHONG JM, 1995, J BIOL CHEM, V270, P10002, DOI 10.1074/jbc.270.17.10002	67	61	62	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					87	96						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552403				2022-12-28	WOS:A1996TQ01400011
J	Chung, GTY; Sundaresan, V; Hasleton, P; Rudd, R; Taylor, R; Rabbitts, PH				Chung, GTY; Sundaresan, V; Hasleton, P; Rudd, R; Taylor, R; Rabbitts, PH			Sequential molecular genetic changes in lung cancer development	ONCOGENE			English	Article						chromosome 3; p53; LOH; pre-neoplasia; dysplasia; tumour progression	SMALL-CELL; SHORT ARM; P53 PROTEIN; DELETION; ABNORMALITIES; CHROMOSOME-3; EXPRESSION; CARCINOMA; HETEROZYGOSITY; ACCUMULATION	Epithelial tumours develop through a sequence of preinvasive lesions of increasing disarray driven by underlying somatic genetic changes, We have studied the occurrence of the two most common somatic genetic changes associated with lung cancer in a series of premalignant bronchial lesions representing different stages in lung tumorigenesis, We present evidence that allele loss on chromosome 3 precedes damage to the p53 gene, Damage to chromosome 3 itself appears to be sequential in that the pattern of allele loss seen in dysplasia is often much more discrete than in invasive tumours, This implies that preneoplastic lesions may be a useful source of material for deletion mapping studies aimed at localising the position of tumour suppressor genes, We illustrate this by the comparison of an interstitial deletion described in this study with a homozygous deletion we have described previously, which has resulted in a better definition of the localisation of a tumour suppressor gene believed to be involved in lung cancer development.	MRC, CLIN ONCOL & RADIOTHERAPEUT UNIT, MRC CTR, CAMBRIDGE CB2 2QH, ENGLAND; WYTHENSHAWE HOSP, REG CARDIOTHORAC CTR, DEPT PATHOL, MANCHESTER M23 9LT, LANCS, ENGLAND; LONDON CHEST HOSP, LONDON E2 9JX, ENGLAND	MRC Laboratory Molecular Biology; University of Cambridge; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of London; Queen Mary University London								BENNETT WP, 1993, CANCER RES, V53, P4817; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; DALY MC, 1991, GENOMICS, V9, P113, DOI 10.1016/0888-7543(91)90227-6; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DODSON MK, 1993, CANCER RES, V53, P4456; ELDER PA, 1994, ONCOGENE, V9, P3433; GANLY PS, 1992, GENOMICS, V12, P221, DOI 10.1016/0888-7543(92)90369-4; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HIBI K, 1992, ONCOGENE, V7, P445; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KLEIN N, 1993, LAB INVEST, V68, P26; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; LUBINSKI J, 1994, CANCER RES, V54, P3710; MARCHETTI A, 1993, CANCER RES, V53, P2846; MATHEW S, 1994, CANCER RES, V54, P6265; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NUORVA K, 1993, AM J PATHOL, V142, P725; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; RABBITTS PH, 1994, BRIT MED BULL, V50, P688, DOI 10.1093/oxfordjournals.bmb.a072917; RODENHUIS S, 1992, CANCER RES, V52, pS2665; RUBIO MP, 1993, CANCER RES, V53, P3465; SATO S, 1994, CANCER RES, V54, P5652; SATO T, 1991, CANCER RES, V51, P5794; SOZZI G, 1991, CANCER RES, V51, P400; SUGIO K, 1994, CANCER RES, V54, P5811; SUNDARESAN V, 1992, ONCOGENE, V7, P1989; SUNDARESAN V, 1995, IN PRESS ANNALS ONCO; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VIEL A, 1992, BRIT J CANCER, V66, P1030, DOI 10.1038/bjc.1992.405; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WALKER C, 1994, BRIT J CANCER, V70, P297, DOI 10.1038/bjc.1994.296; WHANGPENG J, 1991, GENE CHROMOSOME CANC, V3, P168, DOI 10.1002/gcc.2870030303; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; WU CL, 1994, CANCER RES, V54, P6484; YOKOYAMA S, 1992, CANCER RES, V52, P873	36	86	88	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2591	2598						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545116				2022-12-28	WOS:A1995TP18800015
J	OSHIMA, J; STEINMANN, KE; CAMPISI, J; SCHLEGEL, R				OSHIMA, J; STEINMANN, KE; CAMPISI, J; SCHLEGEL, R			MODULATION OF CELL-GROWTH, P34(CDC2) AND CYCLIN-A LEVELS BY SV40 LARGE T-ANTIGEN	ONCOGENE			English	Article							DNA-REPLICATION; PROTEIN-KINASE; FISSION YEAST; INDEPENDENT GROWTH; HUMAN-FIBROBLASTS; SENESCENT HUMAN; C-FOS; CDC2; GENE; TEMPERATURE	Immortalization of rat lung epithelial cells by either wild-type SV-40 T antigen, a mutant form of T antigen that cannot bind pRb, or a temperature-sensitive T antigen increased by five- to 20-fold the steady state levels of p34cdc2 and cyclin A, positive regulators of progression through the cell cycle. Increased abundance of p34cdc2 was not accompanied by equivalent increases in cdc2 mRNA, indicating that increased expression of p34cdc2 is due, at least partially, to post-transcriptional mechanisms. Levels of p34cdc2 and cyclin A protein in cells immortalized with a temperature-sensitive T antigen remained elevated at the restrictive temperature unless T antigen was reduced to levels significantly below those where proliferation ceased, indicating that these two functions can be dissociated. These results show that SV-40 T antigen can dramatically enhance the expression of certain cell cycle regulatory proteins by mechanisms that are independent of pRb binding and cell growth status.	HARVARD UNIV,SCH PUBL HLTH,DEPT MOLEC & CELLULAR TOXICOL,DIV BIOL SCI,665 HUNTINGTON AVE,BOSTON,MA 02115; LAWRENCE BERKELEY LAB,DIV CELL & MOLEC BIOL,BERKELEY,CA 94720	Harvard University; Harvard T.H. Chan School of Public Health; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory					NATIONAL CANCER INSTITUTE [R01CA049749, F32CA009235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG010004] Funding Source: NIH RePORTER; NCI NIH HHS [NCI CA09235, NCI CA49749] Funding Source: Medline; NIA NIH HHS [AG10004] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEMENT A, 1990, P NATL ACAD SCI USA, V87, P318, DOI 10.1073/pnas.87.1.318; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; DRAETTA G, 1988, ONCOGENE, V2, P553; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FLOROS J, 1981, EXP CELL RES, V132, P215, DOI 10.1016/0014-4827(81)90097-5; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; KIT S, 1964, VIROLOGY, V1, P69; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MCCAFFREY P, 1987, J BIOL CHEM, V262, P1442; MIGNOTTE B, 1990, ONCOGENE, V5, P1529; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OSHIMA J, 1992, THESIS BOSTON U MED; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RICHTER KH, 1991, CANCER RES, V51, P6010; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SESHADRI T, 1993, IN PRESS J BIOL CHEM; SOPRANO KJ, 1983, MOL CELL BIOL, V3, P214, DOI 10.1128/MCB.3.2.214; STEIN GH, 1991, P NATL ACAD SCI USA, V88, P11012, DOI 10.1073/pnas.88.24.11012; STUDIER FW, 1990, ANNU REV BIOCHEM, V185, P60; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253	41	39	39	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2987	2993						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414501				2022-12-28	WOS:A1993MC09300012
J	GARRIDO, C; PLAZA, S; GOSPODAROWICZ, D; SAULE, S				GARRIDO, C; PLAZA, S; GOSPODAROWICZ, D; SAULE, S			FOS EXPRESSION INDUCES GROWTH ARREST IN TUMORIGENIC NEURORETINA CELLS	ONCOGENE			English	Article							PROTO-ONCOGENE; C-MYC; V-FOS; GENE; JUN; TRANSFORMATION; PROTEINS; P135GAG-MYB-ETS; STIMULATION; INDUCTION	E26-infected chicken neuroretina (CNR) cells expressing P135gag-myb-ets are non-transformed and growth can be stimulated by basic fibroblast growth factor (bFGF). In contrast, MHE226-infected CNR cells, which express p61/63myc in addition to the P135gag-myb-ets of E26, are transformed, tumorigenic cells and are growth inhibited by bFGF. We looked for differences in both cells types which could help to understand the molecular basis of the bFGF response. We found marked differences in c-fos expression. In MHE226-CNR cells c-fos mRNA was induced by 12-0-tetradecanoyl phorbol 13-acetate (TPA) and bFGF, both inhibitors of MHE226-infected cell growth. In contrast, serum, a strong growth inducer, did not stimulate c-fos expression. In E26-infected cells all of these factors induced cell growth and c-fos expression. MHE226-CNR cells superinfected with v-fos(FBJ)-expressing retrovirus were inhibited in their growth and unresponsive to bFGF. Introduction of V-fos(FBJ) in E26 CNR cells transformed them but they remained sensitive to bFGF. These results suggest that fos is involved in the induced growth arrest of MHE226-CNR cells.	UNIV CALIF SAN FRANCISCO,MED CTR,CANC RES INST,M-1282,SAN FRANCISCO,CA 94143; INST PASTEUR,CNRS,EP 56,F-59019 LILLE,FRANCE	University of California System; University of California San Francisco; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			plaza, serge/F-5290-2015; Garrido, Carolina/GWM-5557-2022					AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AMOUYEL P, 1989, J VIROL, V63, P3382, DOI 10.1128/JVI.63.8.3382-3388.1989; BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; CRISANTICOMBES P, 1977, CELL TISSUE RES, V185, P159; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; ERBA HP, 1986, NUCLEIC ACIDS RES, V14, P5275, DOI 10.1093/nar/14.13.5275; FRICK KK, 1990, MOL CELL BIOL, V10, P184, DOI 10.1128/MCB.10.1.184; FUJIWARA KT, 1987, J VIROL, V61, P4012, DOI 10.1128/JVI.61.12.4012-4018.1987; GARRIDO C, 1992, J VIROL, V66, P160, DOI 10.1128/JVI.66.1.160-166.1992; GILLESPIE DAF, 1991, SEMINARS VIROLOGY, V2, P329; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GOSPODAROWICZ D, 1984, P NATL ACAD SCI-BIOL, V81, P6963, DOI 10.1073/pnas.81.22.6963; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IBA H, 1988, ONCOGENE RES, V2, P121; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; KAHN P, 1979, J CELL BIOL, V82, P1, DOI 10.1083/jcb.82.1.1; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NEUFELD G, 1987, J CELL PHYSIOL, V132, P287, DOI 10.1002/jcp.1041320213; OKUNO H, 1991, ONCOGENE, V6, P1491; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; ROBINSON CJ, 1991, TRENDS PHARMACOL SCI, V12, P123, DOI 10.1016/0165-6147(91)90525-W; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9	28	7	7	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2713	2719						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8397368				2022-12-28	WOS:A1993LX34300012
J	QUEVA, C; LEPRINCE, D; STEHELIN, D; VANDENBUNDER, B				QUEVA, C; LEPRINCE, D; STEHELIN, D; VANDENBUNDER, B			P54(C-ETS-1) AND P68(C-ETS-1), THE 2 TRANSCRIPTION FACTORS ENCODED BY THE C-ETS-1 LOCUS, ARE DIFFERENTIALLY EXPRESSED DURING THE DEVELOPMENT OF THE CHICK-EMBRYO	ONCOGENE			English	Article							AVIAN LEUKEMIA-VIRUS; ETS GENE FAMILY; V-ETS; C-ETS; DNA-BINDING; ERYTHROID-CELLS; PROTO-ONCOGENE; LYMPHOID-CELLS; E26 RETROVIRUS; MYB	The chicken c-ets-1 proto-oncogene encodes two transcription factors, p54c-ets-1 and p68c-ets-1, which contain the same DNA-binding domain but differ in their transactivating activities. We have investigated the spatial and temporal distribution of the transcripts encoding p54c-ets-1 and p68c-ets-1 throughout the development of the chick embryo. We report that p68c-ets-1 as well as p54c-ets-1 is expressed in a wide variety of cells of mesodermal origin, including endothelial cells and mesenchymal cells interacting with epithelium. However, whereas p54c-ets-1 transcripts are detected in most cells, p68c-ets-1 transcripts are restricted to a subset of these cells, randomly distributed. In contrast, p54c-ets-1 is expressed in the absence of p68c-ets-1 in T and B lymphocytes. We show that, during erythropoiesis, both p68c-ets-1 and p54c-ets-1 are expressed in immature erythroid cells in extraembryonic blood islands. The pattern of expression of p54c-ets-1 and p68c-ets-1 during embryonic development suggests the involvement of these transcription factors in the regulation of morphogenetic processes. In addition, we provide the first clue that p68c-ets-1, the cellular progenitor of the v-ets oncogene, is expressed in erythroid cells. This result is very important with respect to the properties of the v-ets oncogene, which confers on the retrovirus E26 the ability to transform erythroid cells.	INST PASTEUR,CNRS,URA1160,1 RUE CALMETTE,F-59019 LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille				Leprince, Dominique/0000-0002-1999-0775				BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BOUSSELUT R, 1990, EMBO J, V9, P3315; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DARDICK I, 1978, TISSUE CELL, V10, P355, DOI 10.1016/0040-8166(78)90029-0; DESBIENS X, 1991, DEVELOPMENT, V111, P699; Dieterlen-Lievre F., 1988, P257; DIETERLENLIEVRE F, 1981, DEV BIOL, V88, P180, DOI 10.1016/0012-1606(81)90228-1; DIETERLENLIEVRE F, 1984, DEV COMP IMMUNOL S, V3, P75; DOMENGET C, 1992, ONCOGENE, V7, P2231; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; FOULKES NS, 1992, NATURE, V355, P81; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; JORCYK CL, 1991, ONCOGENE, V6, P523; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1990, ONCOGENE RES, V5, P255; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MINIE ME, 1992, DEVELOPMENT, V115, P1149; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OKA T, 1991, ONCOGENE, V6, P2077; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; PARDANAUD L, 1989, DEVELOPMENT, V105, P473; QUEVA C, 1992, DEVELOPMENT, V114, P125; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; VANDENBUNDER B, 1989, DEVELOPMENT, V106, P265; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; YASSINE F, 1989, CELL DIFFER DEV, V27, P29, DOI 10.1016/0922-3371(89)90042-7	48	60	60	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2511	2520						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361762				2022-12-28	WOS:A1993LT36800023
J	AHMED, NN; FRANKE, TF; BELLACOSA, A; DATTA, K; GONZALEZPORTAL, ME; TAGUCHI, T; TESTA, JR; TSICHLIS, PN				AHMED, NN; FRANKE, TF; BELLACOSA, A; DATTA, K; GONZALEZPORTAL, ME; TAGUCHI, T; TESTA, JR; TSICHLIS, PN			THE PROTEINS ENCODED BY C-AKT AND V-AKT DIFFER IN POSTTRANSLATIONAL MODIFICATION, SUBCELLULAR-LOCALIZATION AND ONCOGENIC POTENTIAL	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; MURINE LEUKEMIA-VIRUS; MYRISTIC ACID; CELLS; GENE; TRANSFORMATION; MYRISTYLATION; EXPRESSION; BINDING; VECTORS	The acute retrovirus AKT8, isolated from an AKR mouse T-cell lymphoma, transforms mink lung cells in culture and is oncogenic when inoculated into newborn mice. The oncogene carried by this virus, v-akt, arose by recombination between Gag and the 5' untranslated region of the cellular gene c-akt. v-akt encodes a 105 kilodalton (kd) Gag-Akt fusion protein which is phosphorylated on serine and threonine residues. c-akt encodes a 55 kd serine-threonine protein-kinase, which is related to members of the protein kinase C (PKC) family and contains an SH2-like domain. The SH2-like and catalytic domains of Akt were expressed in E. coli as fusions to the carboxy-terminus of the Maltose binding protein (MBP). Antibodies against these proteins were raised in rabbits and they were used to determine the potential myristylation and subcellular localization of the v-akt and c-akt protein products. Immunoprecipitation of v-akt and c-akt from lysates of [S-35]methionine and [H-3]myristic acid labeled AKT8 transformed mink lung cells revealed that only v-akt was myristylated. Fractionation of Dounce-homogenized cellular extracts from uninfected and v-akt-transformed mink lung and PA317 cells and from uninfected PC12 cells by differential centrifugation showed that while the c-akt protein was localized primarily in the cytosol (90%), the v-akt protein was dispersed among the cellular compartments with approximately 40% on the plasma membranes, approximately 30% in the nucleus and approximately 30% in the cytosol. To determine whether the differences in post-translational modification and subcellular distribution between c-akt and v-akt translated into oncogenicity differences between the two proteins, we used retrovirus based constructs to express them both in the nontumorigenic rat T cell lymphoma line 5675. Intraperitoneal (IP) inoculation of the parental and c-akt expressing 5675 cells in nude Balb/c mice revealed that neither was oncogenic. In sharp contrast to these results, v-akt expressing 5675 cells inoculated in nude Balb/c mice were found to be highly oncogenic.	FOX CHASE CANC CTR,PHILADELPHIA,PA 19111	Fox Chase Cancer Center			Gonzalez, Maria Eugenia/B-5146-2008	Gonzalez, Maria Eugenia/0000-0003-0355-5469	NCI NIH HHS [CA-06927, CA-38047] Funding Source: Medline; NCRR NIH HHS [RR-05539] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, R01CA038047] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVRUCH J, 1971, BIOCHIM BIOPHYS ACTA, V233, P334, DOI 10.1016/0005-2736(71)90331-2; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BELLACOSA A, 1992, IN PRESS ONCOGENE; BIGBEE WL, 1983, MOL IMMUNOL, V20, P1353, DOI 10.1016/0161-5890(83)90166-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSS JE, 1985, J VIROL, V53, P7, DOI 10.1128/JVI.53.1.7-12.1985; BUSTOS JG, 1990, BIOCHIM BIOPHYS ACTA, V1071, P83; CHEN ZQ, 1985, J VIROL, V56, P607, DOI 10.1128/JVI.56.2.607-612.1985; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HARLOW E, 1988, ANTIBODIES LABORATOR; HAY AJ, 1974, VIROLOGY, V60, P398, DOI 10.1016/0042-6822(74)90335-3; HENDERSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P339, DOI 10.1073/pnas.80.2.339; HOMSEY VS, 1986, IMMUNOL METH, V93, P83; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KELJO DJ, 1978, BIOCHIM BIOPHYS ACTA, V508, P500, DOI 10.1016/0005-2736(78)90095-0; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; REIN A, 1986, P NATL ACAD SCI USA, V83, P7246, DOI 10.1073/pnas.83.19.7246; RHEE SS, 1987, J VIROL, V61, P1045, DOI 10.1128/JVI.61.4.1045-1053.1987; Sambrook J, 1989, MOL CLONING LABORATO; SCHULTZ AM, 1983, J VIROL, V46, P355, DOI 10.1128/JVI.46.2.355-361.1983; SCHULTZ AM, 1989, J VIROL, V63, P2370, DOI 10.1128/JVI.63.5.2370-2373.1989; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; WILLINGHAM MC, 1990, FOCUS, V12, P62; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; XIA YP, 1992, J VIROL, V66, P914, DOI 10.1128/JVI.66.2.914-921.1992	33	151	151	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1957	1963						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510938				2022-12-28	WOS:A1993LG68200028
J	TAMAGNONE, L; PARTANEN, J; ARMSTRONG, E; LASOTA, J; OHGAMI, K; TAZUNOKI, T; LAFORGIA, S; HUEBNER, K; ALITALO, K				TAMAGNONE, L; PARTANEN, J; ARMSTRONG, E; LASOTA, J; OHGAMI, K; TAZUNOKI, T; LAFORGIA, S; HUEBNER, K; ALITALO, K			THE HUMAN RYK CDNA SEQUENCE PREDICTS A PROTEIN CONTAINING 2 PUTATIVE TRANSMEMBRANE SEGMENTS AND A TYROSINE KINASE CATALYTIC DOMAIN	ONCOGENE			English	Note							GENE	The human ryk tyrosine kinase cDNA was originally identified as a PCR-amplified cDNA fragment (JTK5) from K562 leukemia cells and found to represent a ubiquitously expressed gene (Partanen et al., 1990). The open reading frame of human ryk, reported here, encodes a novel type of putative tyrosine kinase of 607 amino acid residues, having two potential transmembrane domains and homology to receptor tyrosine kinases, such as met (HGF/SF-R) and IGF-1R, in its catalytic domain. The gene maps to human chromosome 3q11-25. Expression of the 3.4 kb ryk mRNA was found in all human adult tissues examined.	UNIV HELSINKI,DEPT PATHOL,MOLEC CANC BIOL LAB,POB 21,SF-00014 HELSINKI,FINLAND; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107	University of Helsinki; Jefferson University			Alitalo, Kari K/J-5013-2014; Tamagnone, Luca/J-8948-2018	Alitalo, Kari K/0000-0002-7331-0902; Tamagnone, Luca/0000-0002-2884-7946; Partanen, Juha/0000-0001-8850-4825	NATIONAL CANCER INSTITUTE [P01CA021124] Funding Source: NIH RePORTER; NCI NIH HHS [CA-21124] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASLER K, 1988, CELL, V54, P299; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; Bishop JM, 1985, RNA TUMOR VIRUSES, P249; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; HUEBNER K, 1993, IN PRESS HUM GENETIC; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; MATSUSHIME H, 1990, J VIROL, V64, P2117, DOI 10.1128/JVI.64.5.2117-2125.1990; MORRIS SW, 1992, GENE CHROMOSOME CANC, V5, P385, DOI 10.1002/gcc.2870050414; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PAUL SR, 1992, INT J CELL CLONING, V10, P309, DOI 10.1002/stem.5530100509; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIEBURTH D, 1992, GENOMICS, V14, P59, DOI 10.1016/S0888-7543(05)80283-6; ULLRICH A, 1990, CELL, V61, P243; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	21	28	31	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					2009	2014						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8390040				2022-12-28	WOS:A1993LG68200034
J	ALT, M; GRASSMANN, R				ALT, M; GRASSMANN, R			RESISTANCE OF HUMAN FIBROBLASTS TO C-FOS MEDIATED TRANSFORMATION	ONCOGENE			English	Article							OSTEO-SARCOMA VIRUS; HERPESVIRUS-SAIMIRI; MAMMALIAN-CELLS; NUCLEOTIDE-SEQUENCE; DELETION MUTANTS; GENE-EXPRESSION; TRANSGENIC MICE; PROTEIN; TRANSCRIPTION; AP-1	Overexpression of the proto-oncogene c-fos induces transformation of primary avian and established rodent mesenchymal cells and tumor development in transgenic mice. As overexpression of Fos was also found in several human tumors of mesenchymal origin, we were interested whether c-fos is a transforming protein for human cells. Since fos genes transduced by infection competent vectors were most efficient in cellular transformation, expression cassettes of the human c-fos were introduced into a replication competent herpesvirus saimiri vector. Infection of human neonatal fibroblasts, cells of mesenchymal origin, resulted in episomal persistence of the recombinant viral genome and expression of c-fos in high excess. However careful examination for transformed phenotype failed to detect any changes in morphology, serum dependence, anchorage dependence, and life span, suggesting resistance of human mesechymal cells against c-fos mediated transformation.	UNIV ERLANGEN NURNBERG,INST KLIN & MOLEK VIROL,LOSCHGESTR 7,W-8520 ERLANGEN,GERMANY	University of Erlangen Nuremberg								ALT M, 1991, GENE, V102, P265, DOI 10.1016/0378-1119(91)90088-S; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; CELANDER D, 1984, NATURE, V312, P159, DOI 10.1038/312159a0; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; CURRAN T, 1984, CELL, V36, P259; Curran T, 1988, ONCOGENE HDB, P307; DESROSIERS RC, 1984, J VIROL, V49, P343, DOI 10.1128/JVI.49.2.343-348.1984; DESROSIERS RC, 1986, J VIROL, V57, P701, DOI 10.1128/JVI.57.2.701-705.1986; DESROSIERS RC, 1985, SCIENCE, V228, P184, DOI 10.1126/science.2983431; FAHRER C, 1989, INT J CANCER, V44, P652, DOI 10.1002/ijc.2910440416; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINKEL MP, 1966, SCIENCE, V151, P698, DOI 10.1126/science.151.3711.698; FINKEL MP, 1975, FRONTIERS RADIATION, V10, P28; FLECKENSTEIN B, 1975, J VIROL, V15, P398, DOI 10.1128/JVI.15.2.398-406.1975; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GARDELLA T, 1984, J VIROL, V50, P248, DOI 10.1128/JVI.50.1.248-254.1984; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRASSMANN R, 1989, J VIROL, V63, P1818, DOI 10.1128/JVI.63.4.1818-1821.1989; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; IBA H, 1988, ONCOGENE RES, V2, P121; LEE WMF, 1988, MOL CELL BIOL, V8, P5521, DOI 10.1128/MCB.8.12.5521; LUCIBELLO FC, 1988, ONCOGENE, V3, P43; MILLER AD, 1984, CELL, V36, P51; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SIMMER B, 1991, J GEN VIROL, V72, P1953, DOI 10.1099/0022-1317-72-8-1953; STAMMINGER T, 1990, J GEN VIROL, V71, P105, DOI 10.1099/0022-1317-71-1-105; TSAI LH, 1991, ONCOGENE, V6, P81; VANBEVEREN C, 1984, VIROLOGY, V135, P229, DOI 10.1016/0042-6822(84)90133-8; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VERMA I, 1968, TRENDS GENET, V2, P93; WARD JM, 1976, CANCER RES, V36, P3985; WISOM R, 1990, MOL CELL BIOL, V10, P5626; WU JX, 1990, ONCOGENE, V5, P989; YU SF, 1986, P NATL ACAD SCI USA, V83, P3194, DOI 10.1073/pnas.83.10.3194	42	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1421	1427						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8389028				2022-12-28	WOS:A1993LE06400004
J	KELLIHER, MA; WECKSTEIN, DJ; KNOTT, AG; WORTIS, HH; ROSENBERG, N				KELLIHER, MA; WECKSTEIN, DJ; KNOTT, AG; WORTIS, HH; ROSENBERG, N			ABL ONCOGENES DIRECTLY STIMULATE 2 DISTINCT TARGET-CELLS IN BONE-MARROW FROM 5-FLUOROURACIL-TREATED MICE	ONCOGENE			English	Article							HEMATOPOIETIC STEM-CELLS; CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE-ACTIVITY; PRE-B-CELL; BCR-ABL; V-ABL; PHILADELPHIA-CHROMOSOME; MONOCLONAL-ANTIBODIES; PROGENITOR CELLS; GROWTH-FACTORS	Mice reconstituted with BCR/ABL-infected 5-fluorouracil-treated bone marrow are considered a model system for human chronic myelogenous leukemia, a malignancy that arises in hematopoietic stem cells. These animals develop multiple types of hematopoietic tumors, which could arise either from undifferentiated cells that mature during tumor development or from progenitors committed to different lineages. To examine the BCR/ABL-sensitive target celts present in the marrow of mice treated with 5-fluorouracil, we used a single-step in vitro assay. These experiments revealed that both the P210 and P185 BCR/ABL proteins and the related v-abl protein induce lymphoid and myeloid colonies, colony types that mimic two of the prominent types of tumors found in the reconstitution model. The lymphoid colonies were similar to lymphoid colonies found following infection of normal bone marrow with respect to differentiation state and tumorigenicity. The cells in the myeloid colonies were differentiated and non-tumorigenic. Fluorescence-activated cell sorting revealed that most of the lymphoid and myeloid colonies arose from distinct precursors and that the lymphoid colonies arose from B-lineage-committed cells. These data suggest that most of the lymphomas observed in the reconstitution model arise from committed progenitors that are distinct from those involved in the myeloid disease.	TUFTS UNIV, SCH MED, DEPT PATHOL, SC-313, 136 HARRISON AVE, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, GRAD PROGRAM IMMUNOL, BOSTON, MA 02111 USA; NEW ENGLAND MED CTR, DEPT MED, DIV HEMATOL & ONCOL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT MOLEC BIOL & MICROBIOL, BOSTON, MA 02111 USA	Tufts University; Tufts University; Tufts Medical Center; Tufts University					NCI NIH HHS [CA 33771] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA033771, R01CA033771] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTERMAN LA, 1990, EUR J IMMUNOL, V20, P1597, DOI 10.1002/eji.1830200728; BOSWELL HS, 1984, J IMMUNOL, V133, P2940; BRUCE J, 1981, J IMMUNOL, V127, P2496; CHUNG SW, 1988, BLOOD, V71, P973; CLARK SS, 1989, ANNU REV MED, V40, P113; COFFMAN RL, 1981, J EXP MED, V153, P269, DOI 10.1084/jem.153.2.269; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1991, P NATL ACAD SCI USA, V88, P11335, DOI 10.1073/pnas.88.24.11335; ELEFANTY AG, 1992, MOL CELL BIOL, V12, P1755, DOI 10.1128/MCB.12.4.1755; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; ENGELMAN A, 1990, J VIROL, V64, P4242, DOI 10.1128/JVI.64.9.4242-4251.1990; ENGELMAN A, 1990, MOL CELL BIOL, V10, P4365, DOI 10.1128/MCB.10.8.4365; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIALKOW PJ, 1977, AM J MED, V63, P125, DOI 10.1016/0002-9343(77)90124-3; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GROSVELD G, 1986, MOL CELL BIOL, V6, P607, DOI 10.1128/MCB.6.2.607; HEIMFELD S, 1991, P NATL ACAD SCI USA, V88, P9902, DOI 10.1073/pnas.88.21.9902; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HO MK, 1982, J IMMUNOL, V128, P1221; HODGSON GS, 1979, NATURE, V281, P381, DOI 10.1038/281381a0; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KELLER G, 1986, COLD SPRING HARB SYM, V51, P1053, DOI 10.1101/SQB.1986.051.01.122; KELLIHER M, 1991, MOL CELL BIOL, V11, P4710, DOI 10.1128/MCB.11.9.4710; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KELLIHER MA, 1991, VIRUSES AFFECT IMMUN, P143; KINCADE PW, 1989, ANNU REV IMMUNOL, V7, P111, DOI 10.1146/annurev.iy.07.040189.000551; LEMISCHKA IR, 1986, CELL, V45, P917, DOI 10.1016/0092-8674(86)90566-0; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MARCU KB, 1980, CELL, V22, P187, DOI 10.1016/0092-8674(80)90167-1; MCKEARN JP, 1985, EUR J IMMUNOL, V15, P295, DOI 10.1002/eji.1830150316; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MULLERSIEBURG CE, 1986, CELL, V44, P653, DOI 10.1016/0092-8674(86)90274-6; MULLERSIEBURG CE, 1988, J EXP MED, V167, P1825, DOI 10.1084/jem.167.6.1825; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; RAMAKRISHNAN L, 1988, MOL CELL BIOL, V8, P5216, DOI 10.1128/MCB.8.12.5216; ROSENBERG N, 1976, J EXP MED, V143, P1453, DOI 10.1084/jem.143.6.1453; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SCOTT ML, 1991, P NATL ACAD SCI USA, V88, P6506, DOI 10.1073/pnas.88.15.6506; SHEVACH EM, 1989, IMMUNOL TODAY, V10, P195, DOI 10.1016/0167-5699(89)90324-1; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; TIDMARSH GF, 1989, MOL CELL BIOL, V9, P2665, DOI 10.1128/MCB.9.6.2665; VANZANT G, 1984, J EXP MED, V159, P679, DOI 10.1084/jem.159.3.679; Varmus H. E., 1982, RNA TUMOR VIRUSES, P369; WANECK GL, 1986, CELL, V44, P337, DOI 10.1016/0092-8674(86)90768-3; WILLIAMS DE, 1985, J IMMUNOL, V135, P1004; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0	52	22	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1249	1256						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479746				2022-12-28	WOS:A1993KY32800016
J	DAVIES, BR; DAVIES, MPA; GIBBS, FEM; BARRACLOUGH, R; RUDLAND, PS				DAVIES, BR; DAVIES, MPA; GIBBS, FEM; BARRACLOUGH, R; RUDLAND, PS			INDUCTION OF THE METASTATIC PHENOTYPE BY TRANSFECTION OF A BENIGN RAT MAMMARY EPITHELIAL-CELL LINE WITH THE GENE FOR P9KA, A RAT CALCIUM-BINDING PROTEIN, BUT NOT WITH THE ONCOGENE EJ-RAS-1	ONCOGENE			English	Article							FIBROBLAST-LIKE CELLS; MESSENGER-RNA; GEL ELECTROPHORESIS; ELONGATED CELLS; CARCINOMA-CELLS; DNA; CLONING; GROWTH; S-100; TUMOR	The rat mammary epithelial cell tine, Rama 37, yields benign, non-metastasizing adenomatous tumours in syngeneic Wistar-Furth rats. Transfection of this line with a drug resistance plasmid containing both the gene for resistance to Geneticin (neo) and the gene for p9Ka (pSV2neo-p9Ka), a rat calcium-binding protein, or with a similar plasmid containing neo and the oncogene EJ-ras-1 (pSV2neo-ras) yields drug-resistant transformants that express high levels of the p9Ka or EJ-ras-I mRNAs and proteins. These transfected cells all produce tumours when injected at subcutaneous sites with a shorter median latent period than the tumours produced by the parental untransfected Rama 37 cells in syngeneic hosts. Cells transfected with pSV2neo-p9Ka yield a higher incidence of tumours than untransfected Rama 37 cells, many of which metastasize to lungs and/or lymph nodes in syngeneic rats. However, cells transfected with pSV2neo-ras or pSV2neo plasmid alone yield tumours that fail to metastasize. Immunofluorescent studies suggest an association of p9Ka with the cytoskeleton, as depicted by F-actin staining with the reagent phalloidin. It is suggested that the transfection of copies of the gene for the rat calcium-binding protein p9Ka can enhance the tumorigenic potential and induce the metastatic phenotype in this rat mammary model, whereas transfection of control plasmid DNA or the oncogene EJ-ras-I fails to induce the metastatic phenotype, although EJ-ras-I transfectants, like those containing p9Ka, possess increased growth properties in vivo.	UNIV LIVERPOOL, DEPT BIOCHEM, CANCER & POLIO RES FUND LABS, LIVERPOOL L69 3BX, ENGLAND	University of Liverpool			Davies, Michael/GWV-2527-2022; Barraclough, Roger/AAH-6516-2020	Barraclough, Roger/0000-0002-7203-1194; Davies, Michael Peter Alan/0000-0002-7609-4977	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAILEY JM, 1976, ANAL BIOCHEM, V70, P75, DOI 10.1016/S0003-2697(76)80049-8; BARRACLOUGH R, 1984, NUCLEIC ACIDS RES, V12, P8097, DOI 10.1093/nar/12.21.8097; BARRACLOUGH R, 1987, J CELL PHYSIOL, V131, P393, DOI 10.1002/jcp.1041310311; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BARRACLOUGH R, 1982, EUR J BIOCHEM, V129, P335, DOI 10.1111/j.1432-1033.1982.tb07056.x; BARRACLOUGH R, 1990, BIOCHEM BIOPH RES CO, V169, P660, DOI 10.1016/0006-291X(90)90381-V; BARRACLOUGH R, 1984, BIOCHEM BIOPH RES CO, V120, P351, DOI 10.1016/0006-291X(84)91261-0; BARRACLOUGH R, 1991, NOVEL CALCIUM BINDIN, P105; BAUDIER J, 1988, J BIOL CHEM, V263, P5876; BENNETT DC, 1978, CELL, V15, P283, DOI 10.1016/0092-8674(78)90104-6; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEAR TN, 1990, MOL ASPECTS MED, V11, P243, DOI 10.1016/0098-2997(90)90005-M; DEVOUGE MW, 1992, ONCOGENE, V7, P109; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; DUNNINGTON DJ, 1984, CANCER RES, V44, P5338; DUNNINGTON DJ, 1984, THESIS U LONDON; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; Fidler I J, 1978, Adv Cancer Res, V28, P149, DOI 10.1016/S0065-230X(08)60648-X; GAO J, 1987, PATHOL RES PRACT, V182, P48, DOI 10.1016/S0344-0338(87)80141-3; GERKE V, 1985, EMBO J, V4, P2917, DOI 10.1002/j.1460-2075.1985.tb04023.x; GERKE V, 1991, NOVEL CALCIUM BINDIN, P140; GOTO K, 1988, J BIOCHEM-TOKYO, V103, P48, DOI 10.1093/oxfordjournals.jbchem.a122237; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HART IR, 1991, BRIT J CANCER, V63, P9, DOI 10.1038/bjc.1991.4; HART IR, 1989, BIOCHIM BIOPHYS ACTA, V989, P65, DOI 10.1016/0304-419X(89)90035-8; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; ISHHOROWICZ D, 1981, NUCLEIC ACIDS RES, V9, P2989, DOI 10.1093/nar/9.13.2989; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; JAMIESON S, 1990, INT J CANCER, V46, P1071, DOI 10.1002/ijc.2910460621; JAMIESON S, 1990, PATHOBIOLOGY, V58, P329, DOI 10.1159/000163605; JAMIESON S, 1987, THESIS U LONDON; KERBEL RS, 1987, P NATL ACAD SCI USA, V84, P1263, DOI 10.1073/pnas.84.5.1263; MAREEL MM, 1986, ANTICANCER RES, V6, P419; MCKAY IA, 1986, MOL CELL BIOL, V6, P3382, DOI 10.1128/MCB.6.10.3382; ORMEROD EJ, 1985, IN VITRO CELL DEV B, V21, P143, DOI 10.1007/BF02621351; RADLERPOHL A, 1988, INT J CANCER, V41, P840, DOI 10.1002/ijc.2910410611; RUDLAND PS, 1987, CANCER METAST REV, V6, P55, DOI 10.1007/BF00047609; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPANDIDOS DA, 1984, TRANSCRIPTION TRANSL, P1; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; TULCHINSKY E, 1992, IN PRESS ONCOGENE; VANROY FM, 1986, CANCER RES, V46, P4787; VERRELLE P, 1987, ANTICANCER RES, V7, P181; VOUSDEN KH, 1986, INT J CANCER, V37, P425, DOI 10.1002/ijc.2910370315; WAGHORNE C, 1987, ONCOGENE, V1, P149; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186	49	230	232	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1993	8	4					999	1008						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455951				2022-12-28	WOS:A1993KT22000023
J	FLEISCHMAN, LF; PILARO, AM; MURAKAMI, K; KONDOH, A; FISHER, RJ; PAPAS, TS				FLEISCHMAN, LF; PILARO, AM; MURAKAMI, K; KONDOH, A; FISHER, RJ; PAPAS, TS			C-ETS-1-PROTEIN IS HYPERPHOSPHORYLATED DURING MITOSIS	ONCOGENE			English	Article							LONG TERMINAL REPEAT; NUCLEAR-ENVELOPE BREAKDOWN; LEUKEMIA-VIRUS HTLV-1; PROTEIN KINASE-II; V-ETS ONCOGENE; DIFFERENTIAL PHOSPHORYLATION; TRANSCRIPTIONAL ACTIVATORS; C-ETS-1 PROTOONCOGENE; MAMMALIAN-CELLS; DNA-BINDING	The ets-1 and ets-2 proto-oncogene products can serve as transcription factors and become phosphorylated in response to Ca2+-mediated signals. We have examined expression of Ets proteins during the cell cycle in cells svnchronized by centrifugal elutriation or nocodazole-induced mitotic block. Both methods revealed the presence of a hyperphosphorylated isoform of Ets-1 during the mitotic phase. This isoform showed a characteristic mobility shift and was observed during mitosis in each of four cell lines (three human T-cell lines and a human astrocytoma) that express ets-1. In elutriated cells, only a small portion of the Ets-1 in cells from the G2/M fractions was hyperphosphorylated, while in nocodazole-arrested cells more of the Ets-1 was shifted. When cells were released from nocodazole arrest, this isoform disappeared within 1-2h as cells completed mitosis and entered G1. This suggests that hyperphosphorylated Ets-1 is present transiently during early mitosis, before or around the time of the metaphase-anaphase transition. Exposure of unsynchronized cells to okadaic acid resulted in a dramatic hyperphosphorylation of virtually all Ets-1, suggesting that changes in cellular phosphatase activity are important for cell cycle regulation of Ets-1. Hyperphosphorylated Ets-1 appears to arise from multiple phosphorylations on serine in the exon 7-encoded domain of the protein and did not appear to alter sequence-specific DNA-binding activity. Although enhanced phosphorylation of Ets-2 was detected in nocodazole-arrested cells, no Ets-2 hyperphosphorylation was seen.	NCI,EXPTL IMMUNOL LAB,FREDERICK,MD 21702; DYNCORP,PROGRAM RESOURCES INC,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	FLEISCHMAN, LF (corresponding author), NCI,MOLEC ONCOL LAB,FREDERICK,MD 21702, USA.		Fisher, Robert/B-1431-2009					AMOUYEL P, 1988, BRAIN RES, V447, P149, DOI 10.1016/0006-8993(88)90976-6; BAITINGER C, 1990, J CELL BIOL, V111, P1763, DOI 10.1083/jcb.111.5.1763; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1989, J IMMUNOL, V142, P672; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3163; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BOULUKOS KE, 1990, GENE DEV, V4, P401, DOI 10.1101/gad.4.3.401; BRAUTIGAN DL, 1990, NATURE, V344, P74, DOI 10.1038/344074a0; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CHEN ZQ, 1990, SCIENCE, V250, P1416, DOI 10.1126/science.2255913; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CYERT MS, 1989, CELL, V57, P891, DOI 10.1016/0092-8674(89)90325-5; FISHER RJ, 1991, ONCOGENE, V6, P2249; FISHER RJ, 1992, J BIOL CHEM, V267, P17957; FUJIWARA S, 1988, ONCOGENE, V2, P99; FUJIWARA S, 1990, MOL CELL BIOL, V10, P1249, DOI 10.1128/MCB.10.3.1249; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOIZUMI S, 1990, ONCOGENE, V5, P675; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; OHTA Y, 1990, P NATL ACAD SCI USA, V87, P5341, DOI 10.1073/pnas.87.14.5341; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; PRESCOTT DM, 1962, EXP CELL RES, V26, P260, DOI 10.1016/0014-4827(62)90176-3; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; SACCHI N, 1988, LEUKEMIA, V2, P12; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; STEINHARDT RA, 1988, NATURE, V332, P364, DOI 10.1038/332364a0; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; YUAN CC, 1989, J VIROL, V63, P205, DOI 10.1128/JVI.63.1.205-215.1989; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	49	31	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					771	780						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437861				2022-12-28	WOS:A1993KN00800030
J	SCHULZ, AS; SCHLEITHOFF, L; FAUST, M; BARTRAM, CR; JANSSEN, JWG				SCHULZ, AS; SCHLEITHOFF, L; FAUST, M; BARTRAM, CR; JANSSEN, JWG			THE GENOMIC STRUCTURE OF THE HUMAN UFO RECEPTOR	ONCOGENE			English	Note							PROMOTER REGION; LEUKEMIA-CELLS; SEQUENCE; GENE; PROTEINS; CLEAVAGE; KINASE	Using a DNA transfection-tumorigenicity assay we have recently identified the UFO oncogene. It encodes a tyrosine kinase receptor characterized by the juxtaposition of two immunoglobulin-like and two fibronectin type III repeats in its extracellular domain. Here we describe the genomic organization of the human UFO locus. The UFO receptor is encoded by 20 exons that are distributed over a region of 44 kb. Different isoforms of UFO mRNA am generated by alternative splicing of exon 10 and differential usage of two imperfect polyadenylation sites resulting in the presence or absence of 1.5-kb 3' untranslated sequences. Primer extension and Sl nuclease analyses revealed multiple transcriptional initiation sites including a major site 169 bp upstream of the translation start site. The promoter region is GC rich, lacks TATA and CAAT boxes, but contains potential recognition sites for a variety of trans-acting factors, including Sp1, AP-2 and the cyclic AMP response element-binding protein. Proto-UFO and its oncogenic counterpart exhibit identical cDNA and promoter regions sequences. Possible modes of UFO activation are discussed.	UNIV ULM,DEPT PEDIAT 2,MOLEC BIOL SECT,PRITTWITZSTR 43,W-7900 ULM,GERMANY	Ulm University								ARAKI E, 1987, J BIOL CHEM, V262, P16186; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLAKE CCF, 1985, INT REV CYTOL, V93, P149, DOI 10.1016/S0074-7696(08)61374-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FAUST M, 1992, ONCOGENE, V7, P1287; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; GHOSH D, 1990, NUCLEIC ACIDS RES, V18, P1749, DOI 10.1093/nar/18.7.1749; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JANSSEN WG, 1991, ONCOGENE, V6, P2113; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; RESCIGNO J, 1991, ONCOGENE, V6, P1909; SAMBROOK J, 1986, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WINGENDER E, 1988, NUCLEIC ACIDS RES, V16, P1879, DOI 10.1093/nar/16.5.1879; YOUSSOUFIAN H, 1990, MOL CELL BIOL, V10, P375	26	30	30	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					509	513						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8381225				2022-12-28	WOS:A1993KN00600032
J	Mujoo, K; Maneval, DC; Anderson, SC; Gutterman, JU				Mujoo, K; Maneval, DC; Anderson, SC; Gutterman, JU			Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma	ONCOGENE			English	Article						p53; adenoviral constructs; tumorigenicity; gene therapy	WILD-TYPE P53; CANCER CELLS; GROWTH; EXPRESSION; PROTEIN; MECHANISMS; MUTATIONS; APOPTOSIS	Mutations of p53 gene are reported in 50-60% of human cancers and reintroduction of wild-type p53 can suppress cell proliferation, In this study, replication deficient recombinant adenovirus encoding wild-type p53 (ACN53) under the control of the human cytomegalovirus (CMV) promoter was constructed. A specific incorporation of the p53 gene with ACN53 in SK-OV-3 (deleted p53 gene) cells was observed, ACN53 reduced the colony-forming ability of SK-OV-3 cells thereby supporting that 95-98% of cells are susceptible to infection by recombinant adenovirus. ACN53 inhibited the growth of 71-98% of SK-OV-3 cells 72-216 h after single infection, A highly aggressive ovarian xenograft model was established in which animals die between 25-45 days, A localization study with the adenovirus-containing beta galactosidase reporter gene showed effective gene transfer in the tumor tissues, Ex vivo treatment of SK-OV-3 cells with ACN53 followed by injection into nude mice, increased the survival of the p53 treated mice by more than 50% compared with control animals, Gene therapy with ACN53 in intraperitoneal model of SK-OV-3 cells in two independent experiments revealed that there were some long-term survivors in the group of mice [2/5 (66 and 120 days) and [2/8 (166 and 423 days)] treated with ACN53. These findings demonstrate the potential of the p53 tumor suppressor gene therapy in human ovarian carcinoma.	CANJI INC,SAN DIEGO,CA 92121		Mujoo, K (corresponding author), UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOLEC ONCOL,HOUSTON,TX 77030, USA.		Mujoo, Kalpana/S-9933-2019	Mujoo, Kalpana/0000-0002-4275-1051				BACCHETTI S, 1993, INT J ONCOL, V3, P781; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARTEK J, 1991, ONCOGENE, V6, P1699; BERCHUCK A, 1994, AM J OBSTET GYNECOL, V170, P246; Boente Matthew P., 1993, Current Opinion in Oncology, V5, P900, DOI 10.1097/00001622-199309000-00020; BOSARI S, 1993, HUM PATHOL, V24, P1175, DOI 10.1016/0046-8177(93)90212-Y; BRODY SL, 1994, ANN NY ACAD SCI, V716, P90, DOI 10.1111/j.1749-6632.1994.tb21705.x; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHEN YM, 1991, ONCOGENE, V6, P1799; CHENG J, 1992, CANCER RES, V52, P222; CLAYMAN GL, 1995, CANCER RES, V55, P1; GINSBERG HS, 1989, P NATL ACAD SCI USA, V86, P3823, DOI 10.1073/pnas.86.10.3823; GOODING LR, 1990, CRIT REV IMMUNOL, V10, P53; HOCK H, 1993, P NATL ACAD SCI USA, V90, P2774, DOI 10.1073/pnas.90.7.2774; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ISAACS WB, 1991, CANCER RES, V51, P4716; JACOBS IJ, 1992, J NATL CANCER I, V84, P1793, DOI 10.1093/jnci/84.23.1793; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KEURBITZ SJ, 1992, P NATL ACAD SCI USA, V9, P7491; KOHLER MF, 1993, OBSTET GYNECOL, V81, P643; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIU TJ, 1994, CANCER RES, V54, P3662; OKAMOTO A, 1991, CANCER RES, V51, P5171; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; ROEMER K, 1994, ANN NY ACAD SCI, V716, P265, DOI 10.1111/j.1749-6632.1994.tb21718.x; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SIEGFRIED W, 1993, EXP CLIN ENDOCRINOL, V101, P7, DOI 10.1055/s-0029-1211201; TAKAHASHI T, 1992, CANCER RES, V52, P2340; WANG NP, 1993, ONCOGENE, V8, P279; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WILLS KN, 1994, HUM GENE THER, V5, P1079, DOI 10.1089/hum.1994.5.9-1079; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; YAGINUMA Y, 1992, CANCER RES, V52, P4196; ZHANG WW, 1994, CANCER GENE THER, V1, P1	39	98	104	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1617	1623						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622881				2022-12-28	WOS:A1996UG45800003
J	Clark, J; Benjamin, H; Gill, S; Sidhar, S; Goodwin, G; Crew, J; Gusterson, BA; Shipley, J; Cooper, CS				Clark, J; Benjamin, H; Gill, S; Sidhar, S; Goodwin, G; Crew, J; Gusterson, BA; Shipley, J; Cooper, CS			Fusion of the EWS gene to CHN, a member of the steroid thyroid receptor gene superfamily, in a human myxoid chondrosarcoma	ONCOGENE			English	Article						CHN oncogene; chondrosarcoma; steroid thyroid receptor	ACUTE PROMYELOCYTIC LEUKEMIA; ALPHA LOCUS; DNA-BINDING; TRANSLOCATION; BREAKPOINT; REGION; TUMORS; FAMILY	The specific chromosomal translocation t(9;22)(q22-31;q11-12) has been observed in the myxoid variant of human chondrosarcoma. In agreement with this observation we report that the EWS gene located at chromosome band 22q12 becomes fused to CHN, a member of the steroid/thyroid receptor gene superfamily located at 9q22-31, in a skeletal myxoid chondrosarcoma. CHN appears to be the human homologue of the rat gene NOR1, which was recently identified as a sequence overexpressed in rat brain cells undergoing apoptosis. Our results also indicate that the chimaeric EWS-CHN gene encodes a EWS-CHN fusion protein in which the C-terminal RNA-binding domain of EWS is replaced by the entire CHN protein, comprising a long N-terminal domain, a central DNA binding domain and a C-terminal ligand-binding/dimerisation domain.	INST CANC RES,HADDOW LABS,SECT MOLEC CARCINOGENESIS,SUTTON SM2 5NG,SURREY,ENGLAND; INST CANC RES,HADDOW LABS,SECT CELL BIOL & EXPTL PATHOL,SUTTON SM2 5NG,SURREY,ENGLAND; CHESTER BEATTY LABS,SECT CELL & MOLEC BIOL,LONDON SW3 6JB,ENGLAND	University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK			gusterson, barry a/D-3752-2009	Shipley, Janet/0000-0001-6748-8678				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DEGOS L, 1992, Current Opinion in Oncology, V4, P45, DOI 10.1097/00001622-199202000-00007; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GILL S, 1995, CANCER, V12, P307; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HINRICHS SH, 1985, CANCER GENET CYTOGEN, V14, P219, DOI 10.1016/0165-4608(85)90187-6; JEON IS, 1995, ONCOGENE, V10, P1229; LADANYI M, 1994, CANCER RES, V54, P2837; MAGES HW, 1994, MOL ENDOCRINOL, V8, P1583, DOI 10.1210/me.8.11.1583; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MITELMAN F, 1991, CATALOG CHROMOSOME A; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V205, P1959, DOI 10.1006/bbrc.1994.2900; ORNDAL C, 1991, CYTOPATHOLOGY, V2, P261, DOI 10.1111/j.1365-2303.1991.tb00497.x; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SAINATI L, 1993, CANCER GENET CYTOGEN, V71, P144, DOI 10.1016/0165-4608(93)90020-M; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCEARCE LM, 1993, J BIOL CHEM, V268, P8855; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TARKKANEN M, 1994, GENE CHROMOSOME CANC, V9, P136, DOI 10.1002/gcc.2870090210; TSAI MJ, 1994, ANN REV BIOCH, V63, P431; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V30, P145, DOI 10.1016/0165-4608(88)90103-3; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WILSON TE, 1991, SCIENCE, V252, P1297; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	35	146	149	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					229	235						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570200				2022-12-28	WOS:A1996TR53800002
J	DAmbrosio, C; Hongo, A; Li, S; Baserga, R				DAmbrosio, C; Hongo, A; Li, S; Baserga, R			The role of Grb2 in the growth and transformation of mouse embryo cells	ONCOGENE			English	Article						Grb2; IGF-I receptor; transformation; T-antigen	INSULIN-RECEPTOR SUBSTRATE-1; MITOGENIC SIGNAL TRANSDUCTION; FACTOR-I; TYROSINE KINASES; SH3 DOMAIN; RAS; PROTEIN; EXPRESSION; IRS-1; GENE	An overexpressed insulin-like growth factor I receptor (IGF-IR) allows cells to grow in IGF-I only and to form colonies in soft agar. Conversely, cells with a targeted disruption of the IGF-IR genes, R(-) cells, are refractory to transformation by several oncoproteins and growth factor receptors, that readily transform their wild type counterparts, W cells. Grb2 is an SH2-SH3 domains protein that links tyrosine kinase receptors to ras signalling. In order to determine its role in mitogenesis and transformation, we have transfected a plasmid expressing Grb2 into R(-) and W cells, and their derivatives already expressing the SV40 large T antigen. In addition, we have used loss-of-function mutants of Grb2 to inquire whether they would act as dominant negatives. Our results show that: (1) an overexpressed Grb2 cannot replace the IGF-IR in IGF-I-mediated mitogenesis; (2) Grb2 also fails to transform either W or R(-) cells; (3) Grb2 and SV40 T antigen, singly transfected, cannot transform R(-) cells, but can do so when combined; and (4) SH3 domain mutants of Grb2 act as dominant negatives, causing reversion of the transformed phenotype. We conclude that Grb2 is necessary but not sufficient for transformation.	THOMAS JEFFERSON UNIV,JEFFERSON CANC CTR,PHILADELPHIA,PA 19107	Jefferson University					NIA NIH HHS [AG 00378] Funding Source: Medline; NIGMS NIH HHS [GM 33694] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033694] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG000378] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ARTEAGA CL, 1992, BREAST CANCER RES TR, V22, P101, DOI 10.1007/BF01833338; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BASERGA R, 1995, CANCER RES, V55, P249; BASERGA R, 1985, BIOL CELL REPRODUCTI; BASU T, 1994, ONCOGENE, V9, P3483; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COOK JR, 1993, LIFE SCI, V53, P803, DOI 10.1016/0024-3205(93)90502-T; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; DEANGELIS T, 1995, IN PRESS J CELL PHYS; DELALUNA S, 1988, GENE, V62, P121; FALCO JP, 1988, ONCOGENE, V2, P573; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; KALEBIC T, 1994, CANCER RES, V54, P5531; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; LI FZ, 1995, MOL CELL BIOL, V15, P4232; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI SW, 1994, J BIOL CHEM, V269, P32558; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LU KH, 1989, MOL CELL BIOL, V9, P3411, DOI 10.1128/MCB.9.8.3411; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MIURA M, 1995, CANCER RES, V55, P663; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; MORRIONE A, 1995, J VIROL, V69, P5300, DOI 10.1128/JVI.69.9.5300-5303.1995; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1994, CANCER RES, V54, P4848; RESNICOFF M, 1995, CANCER RES, V55, P2463; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SALCINI AE, 1994, ONCOGENE, V9, P2827; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; SELL C, 1995, CANCER RES, V55, P303; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; SURMACZ E, 1995, EXP CELL RES, V218, P370, DOI 10.1006/excr.1995.1168; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; TOBE K, 1993, J BIOL CHEM, V268, P11167; TORJAN J, 1993, SCIENCE, V256, P94; ULLRICH A, 1986, EMBO J, V5, P503; VALENTINIS B, 1994, ONCOGENE, V9, P825; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427	71	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					371	378						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570214				2022-12-28	WOS:A1996TR53800016
J	Huff, JL; Jelinek, MA; Jamieson, TA; Parsons, JT				Huff, JL; Jelinek, MA; Jamieson, TA; Parsons, JT			Expression and maturation of the cellular sea receptor, a member of the hepatocyte growth factor (HGF) receptor family of protein tyrosine kinases	ONCOGENE			English	Article						c-sea; receptor; protein tyrosine kinase; hepatocyte growth factor	MACROPHAGE STIMULATING PROTEIN; CHICKEN-EMBRYO FIBROBLASTS; SCATTER FACTOR-RECEPTOR; C-MET; AVIAN RETROVIRUS; EPITHELIAL-CELLS; SRC GENE; MYC GENE; PROTOONCOGENE; ONCOGENE	The c-sea proto-oncogene is a member of the Met/hepatocyte growth factor/scatter factor family of receptor protein tyrosine kinases. A distinguishing feature of this family, whose other member is the Ron/Stk receptor, is a novel heterodimeric structure. We have previously described cDNA clones encoding the avian Sea receptor. In this report we show that a fun length c-sea cDNA directed the synthesis of a single 155 kDa polypeptide chain in vitro, while irt vivo two polypeptides of 160 and 180 kDa were observed. We analysed the structure of the Sea receptor using a soluble chimeric protein consisting of the Sea extracellular domain linked to the hinge and constant regions of human IgG gamma 1. These studies indicated that the receptor undergoes proteolytic processing in the extracellular domain yielding an approximate 35 kDa alpha and a 160 kDa beta chain, and thus the Sea receptor appears to display a structure similar to that of the Met and Ron proteins. An examination of embryonic avian tissues using Sea extracellular domain-specific monoclonal antibodies revealed low levels of Sea receptor in a variety of tissues including kidney, intestine, liver, stomach, white blood cells and allantochorion. Elevated levels of expression were observed upon transformation of chicken embryo cells by the Src oncoprotein.	UNIV VIRGINIA, HLTH SCI CTR, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, CTR CANC, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia				Huff, Janice/0000-0003-4236-7698	NCI NIH HHS [CA 27578] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA027578] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BEUG H, 1985, VIROLOGY, V145, P141, DOI 10.1016/0042-6822(85)90209-0; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRYANT DL, 1984, MOL CELL BIOL, V4, P862, DOI 10.1128/MCB.4.5.862; CHAN AML, 1988, ONCOGENE, V2, P593; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; CREPALDI T, 1994, J BIOL CHEM, V269, P1750; CROWE AJ, 1991, J VIROL, V65, P2533, DOI 10.1128/JVI.65.5.2533-2538.1991; DIRENZO MF, 1991, ONCOGENE, V6, P1997; FARINA SF, 1992, J VIROL, V66, P2698, DOI 10.1128/JVI.66.5.2698-2708.1992; FRIEZNER DSJ, 1991, BIOCHEMISTRY-US, V30, P9781; FURLONG RA, 1991, J CELL SCI, V100, P173; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES; HAYMAN MJ, 1985, P NATL ACAD SCI USA, V82, P8237, DOI 10.1073/pnas.82.23.8237; HEANEY ML, 1986, J VIROL, V60, P167, DOI 10.1128/JVI.60.1.167-176.1986; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAEMMLI UK, 1994, NATURE, V269, P19457; LEE CC, 1994, J BIOL CHEM, V269, P19457; LINIAL M, 1982, VIROLOGY, V119, P382, DOI 10.1016/0042-6822(82)90097-6; MARK MR, 1992, J BIOL CHEM, V267, P26166; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RONSIN C, 1993, ONCOGENE, V8, P1195; SHIMAMOTO A, 1993, FEBS LETT, V333, P61, DOI 10.1016/0014-5793(93)80375-5; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; STOKER M, 1985, J CELL SCI, V77, P209; Stubbs EL, 1935, J EXP MED, V61, P593, DOI 10.1084/jem.61.5.593; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; WANG MH, 1994, SCIENCE, V266, P177; WEIDNER KM, 1993, AM J RESP CELL MOL, V8, P229, DOI 10.1165/ajrcmb/8.3.229; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097	58	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	1996	12	2					299	307						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570207				2022-12-28	WOS:A1996TR53800009
J	Jiang, HP; Lin, JJ; Su, ZZ; Goldstein, NI; Fisher, PB				Jiang, HP; Lin, JJ; Su, ZZ; Goldstein, NI; Fisher, PB			Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression	ONCOGENE			English	Article						terminal cell differentiation; cDNA cloning; peptide antibodies; in vitro translation	GLIOBLASTOMA-MULTIFORME CELLS; POLYMERASE CHAIN-REACTION; ANTIGENIC PHENOTYPE; TRANSFORMED PHENOTYPE; MAMMALIAN-CELLS; RESPONSE GENE; EXPRESSION; SUPPRESSION; PROTEIN; INTERFERON	Cultured human melanoma cells lose proliferative capacity and terminally differentiate after treatment with the combination of recombinant human fibroblast interferon (IFN-beta) and mezerein (MEZ). Subtraction hybridization of cDNA libraries prepared from actively proliferating human H0-1 melanoma cells from cDNA libraries produced from H0-1 cells treated with IFN-beta+MEZ identifies a novel melanoma differentiation-associated (mda) cDNA, mda-7, that displays elevated expression in differentiation inducer-treated H0-1 cells. mda-7 encodes a novel protein of 206 amino acids with a predicted size of 23.8 kDa. The level of mda-7 mRNA is elevated in actively proliferating normal human melanocytes versus primary and metastatic human melanomas. In the Matrigel-assisted melanoma progression model, mda-7 expression decreases in early vertical growth phase primary human melanoma cells selected for autonomous or enhanced tumor formation in nude mice. Treatment of human melanomas with IFN-beta+MEZ, and to a lesser extent with MEZ, results in growth suppression and induced or enhanced mda-7 expression, Immunoprecipitation analyses using peptide-derived rabbit polyclonal antibodies detect increases in mda-7 protein, and a higher molecular weight protein of similar to 90 to 100 kDa, in MEZ and IFN-beta+MEZ treated H0-1 cells. mda-7 is a highly conserved gene with an homologous sequence in the genome of yeast. Transfection of mda-7 expression constructs into H0-1 and C8161 human melanoma cells reduces growth and inhibits colony formation. These results confirm that mda-7 has antiproliferative properties in human melanoma cells and in this context may contribute to terminal cell differentiation, The mda-7 gene may also function as a negative regulator of melanoma progression.	COLUMBIA UNIV COLL PHYS & SURG, COLUMBIA PRESBYTERIAN MED CTR, DEPT PATHOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, COLUMBIA PRESBYTERIAN MED CTR, DEPT UROL, NEW YORK, NY 10032 USA; IMCLONE SYST INC, DEPT IMMUNOL MONOCLONAL ANTIBODIES, NEW YORK, NY 10014 USA	Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Eli Lilly					NCI NIH HHS [CA35675] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035675] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Chellappan Srikumar P., 1994, Molecular and Cellular Differentiation, V2, P201; CLARK WH, 1991, BRIT J CANCER, V64, P631, DOI 10.1038/bjc.1991.375; CLAUDIO PP, 1994, CANCER RES, V54, P5556; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DUIGOU GJ, 1991, ONCOGENE, V6, P1813; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FISHER PB, 1985, PHARMACOL THERAPEUT, V27, P143, DOI 10.1016/0163-7258(85)90067-1; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIOVANELLA BC, 1976, J NATL CANCER I, V56, P1131, DOI 10.1093/jnci/56.6.1131; GRAHAM GM, 1991, CANCER IMMUNOL IMMUN, V32, P382, DOI 10.1007/BF01741333; GUARINI L, 1992, PIGM CELL RES, P123; GUARINI L, 1989, CANCER IMMUNOL IMMUN, V30, P262, DOI 10.1007/BF01744892; GUSTINCICH S, 1993, CELL GROWTH DIFFER, V4, P753; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; Herlyn M, 1990, Adv Cancer Res, V54, P213, DOI 10.1016/S0065-230X(08)60812-X; HERLYN M, 1990, CANCER METAST REV, V9, P101, DOI 10.1007/BF00046337; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jiang Hongping, 1994, Molecular and Cellular Differentiation, V2, P221; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P41; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; JIANG HP, 1995, ONCOGENE, V11, P1179; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG HP, 1995, ONCOGENE, V10, P1855; JIANG HP, 1992, INT J ONCOL, V1, P227; JIMENEZ JJ, 1987, SCIENCE, V238, P1278, DOI 10.1126/science.3685979; Kerbel R S, 1990, Adv Cancer Res, V55, P87, DOI 10.1016/S0065-230X(08)60469-8; KOBAYASHI H, 1994, AM J PATHOL, V144, P776; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1988, J CELL BIOL, V107, P1, DOI 10.1083/jcb.107.1.1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIN J, 1994, INT J ONCOL, V5, P5; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MacDougall John R., 1993, Molecular and Cellular Differentiation, V1, P21; MANCIANTI ML, 1988, J INVEST DERMATOL, V90, P134, DOI 10.1111/1523-1747.ep12462099; MELBER K, 1989, CANCER RES, V49, P3650; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOOSLEHNER K, 1991, MOL CELL BIOL, V11, P886, DOI 10.1128/MCB.11.2.886; MURRAY A, 1994, CURR OPIN CELL BIOL, V6, P872, DOI 10.1016/0955-0674(94)90059-0; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5673, DOI 10.1073/pnas.86.15.5673; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; REDDY PG, 1991, J NATL CANCER I, V83, P1307, DOI 10.1093/jnci/83.18.1307; SACHS L, 1978, NATURE, V274, P535, DOI 10.1038/274535a0; Sang Nianli, 1995, Molecular and Cellular Differentiation, V3, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEN RQ, 1995, P NATL ACAD SCI USA, V92, P6778, DOI 10.1073/pnas.92.15.6778; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SU ZZ, 1991, MOL CARCINOGEN, V4, P231, DOI 10.1002/mc.2940040310; SU ZZ, 1993, CANCER RES, V53, P1929; TOKUNAGA K, 1987, CANCER RES, V47, P5616; VIEIRA P, 1991, P NATL ACAD SCI USA, V88, P1172, DOI 10.1073/pnas.88.4.1172; WAXMAN S, 1988, STATUS DIFFERENTIATI, V1; WAXMAN S, 1991, STATUS DIFFERENTIATI, V2; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	71	450	557	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2477	2486						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545104				2022-12-28	WOS:A1995TP18800003
J	Lengye, E; Singh, B; Gum, R; Nerlov, C; Sabichi, A; Birrer, M; Boyd, D				Lengye, E; Singh, B; Gum, R; Nerlov, C; Sabichi, A; Birrer, M; Boyd, D			Regulation of urokinase-type plasminogen activator expression by the v-mos oncogene	ONCOGENE			English	Article						urokinase; mos; MAPK; AP-1	PROTEIN-KINASE ACTIVITY; GENE-EXPRESSION; MAP KINASE; PHORBOL-ESTER; SARCOMA-VIRUS; C-JUN; TRANSFORMATION; PRODUCT; RAS; FOS	We undertook a study to determine if the serine-threonine kinase-encoding v-mos oncogene regulated the expression of the urokinase-type plasminogen activator. An expression vector encoding v-mos, but not a kinase-inactive mutant, stimulated urokinase promoter activity in CAT assays employing a squamous cell carcinoma cell line, The induction of urokinase promoter activity by v-mos was mediated, in part, via an increased AP-1 activity since (a) mutation of 2 AP-1 binding sites (at -1967 and -1885), or the co-expression of a transactivation domain-lacking c-jun mutant reduced the induction of the urokinase promoter by v-mos and (b) expression of v-mos increased the activity of a CAT reporter driven by three AP-1 tandem repeats, The stimulation of the urokinase promoter by v-mos was partially countered by co-expression of an ERK1/ERK2-inactivating phosphatase. Western blotting and zymographic analysis indicated that v-mos-transformed NM3T3 cells (MSV NIH-3T3) secreted more urokinase compared with NIH3T3 cells and this was associated with a higher level of activated ERK1 and ERK2, Expression of a catalytically-inactive MAPKK mutant reduced the activity of a urokinase promoter-driven CAT reporter in the MSV NIH-3T3 cells, In conclusion, the data herein indicate that urokinase expression is regulated by v-mos through a MAPKK-dependent signaling pathway.	MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; MD ANDERSON CANC CTR,DEPT HEAD & NECK SURG,HOUSTON,TX 77030; MD ANDERSON CANC CTR,DEPT MOLEC BIOL,HOUSTON,TX 77030; UNIV COPENHAGEN,INST MICROBIOL,COPENHAGEN,DENMARK; NIH,BIOMARKERS & PREVENT RES BRANCH,ROCKVILLE,MD	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Copenhagen; National Institutes of Health (NIH) - USA			Lengyel, Ernst/D-9220-2014	Lengyel, Ernst/0000-0001-8624-1507	NATIONAL CANCER INSTITUTE [R01CA058311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010845] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA58311] Funding Source: Medline; NIDCR NIH HHS [R01DE10845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALESSI DR, 1993, ONCOGENE, V8, P2015; ANDREASEN PA, 1990, ENDOCRINOLOGY, V126, P2567, DOI 10.1210/endo-126-5-2567; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BELL SM, 1990, J BIOL CHEM, V265, P1333; BELL SM, 1993, MOL CELL BIOL, V13, P5888, DOI 10.1128/MCB.13.9.5888; BROWN PH, 1993, ONCOGENE, V8, P877; CHAN JC, 1992, J BIOL CHEM, V267, P1099; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; JEHN B, 1992, MOL CELL BIOL, V12, P3890, DOI 10.1128/MCB.12.9.3890; KAMADA S, 1994, J BIOL CHEM, V269, P4565; KASAI S, 1985, J BIOL CHEM, V260, P2382; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; LIOTTA LA, 1981, CANCER RES, V41, P4629; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; NAKAGAWA J, 1988, J BIOL CHEM, V263, P2460; NANBU R, 1994, MOL CELL BIOL, V14, P4920, DOI 10.1128/MCB.14.7.4920; NERLOV C, 1991, ONCOGENE, V6, P1583; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; NIELSEN LS, 1982, BIOCHEMISTRY-US, V21, P6410, DOI 10.1021/bi00268a014; NOVAK U, 1991, NUCLEIC ACIDS RES, V19, P3389, DOI 10.1093/nar/19.12.3389; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANKOV R, 1994, P NATL ACAD SCI USA, V91, P873, DOI 10.1073/pnas.91.3.873; PHAM CD, 1995, ONCOGENE, V10, P1683; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; SALO T, 1982, INT J CANCER, V30, P669, DOI 10.1002/ijc.2910300520; SCHONTHAL A, 1990, New Biologist, V2, P143; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SINGH B, 1988, ONCOGENE, V3, P79; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SINGH B, 1992, MOL CARCINOGEN, V6, P182, DOI 10.1002/mc.2940060303; SINGH B, 1988, VIROLOGY, V164, P114, DOI 10.1016/0042-6822(88)90626-5; STACEY DW, 1991, ONCOGENE, V6, P2297; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; TESTA JE, 1989, INT J CANCER, V43, P816, DOI 10.1002/ijc.2910430513; TOURAY M, 1991, ONCOGENE, V6, P211; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0; VANBEVEREN C, 1981, NATURE, V289, P258, DOI 10.1038/289258a0; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; VERDE P, 1984, P NATL ACAD SCI-BIOL, V81, P4727, DOI 10.1073/pnas.81.15.4727; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x	53	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2639	2648						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545121				2022-12-28	WOS:A1995TP18800020
J	Welter, JF; Eckert, RL				Welter, JF; Eckert, RL			Differential expression of the fos and jun family members c-fos, fosB, Fra-1, Fra-2, c-jun, junB and junD during human epidermal keratinocyte differentiation	ONCOGENE			English	Article						activator protein 1; AP-1; Fra-1; Fra-2; jun; fos; keratinocyte differentiation; transcription factor; epidermis	HUMAN PAPILLOMAVIRUS TYPE-18; HUMAN INVOLUCRIN GENE; PROTEIN-KINASE-C; TRANSGENIC MICE; TRANSCRIPTION FACTOR; NONSPECIFIC-BINDING; EPITHELIAL-CELLS; AP-1; PROTOONCOGENE; INDUCTION	Activator protein 1 (AP1) family proteins have been implicated in the regulation of genes expressed in the epidermis. However, no comprehensive analysis of the expression patterns of the known AP1 family proteins in the human epidermis or any other terminally differentiating tissue has been performed. In the present study we describe the localization of c-fos, fosB, Fra-1, Fra-2, c-jun, junB and junD in the normal human epidermis. Each is expressed in specific epidermal layers, c-fos is localized in the nuclei of the upper spinous and granular layer cells. FosB is present in the nuclei in all layers. Fra-1 is absent from the basal layer, but is present in all other layers. Fra-2 is detected in all layers, but staining intensity is increased in the upper spinous layer. c-jun staining is limited to the granular layer, while junB and junD are present in all layers. The differentiation-dependent pattern of expression of the AP1 family members suggest an important role for these proteins in specifying the temporal and spatial pattern of gene expression during keratinoctye differentiation.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHYSIOL BIOPHYS, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT DERMATOL, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT REPROD BIOL, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT ONCOL, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT BIOCHEM, CLEVELAND, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University					NIAMS NIH HHS [AR41456, AR39750] Funding Source: Medline; NIDDK NIH HHS [DK07678] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041456, P30AR039750, R55AR041456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007678] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM WC, 1991, MOL NEUROBIOL, V5, P297, DOI 10.1007/BF02935553; AMSTAD P, 1990, B CANCER, V77, P501; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBER JR, 1987, ANN NY ACAD SCI, V511, P117, DOI 10.1111/j.1749-6632.1987.tb36242.x; BASSETSEGUIN N, 1990, J INVEST DERMATOL, V94, P418, DOI 10.1111/1523-1747.ep12874493; BERNERD F, 1992, J INVEST DERMATOL, V98, P902, DOI 10.1111/1523-1747.ep12460344; Bernerd Francoise, 1993, Gene Expression, V3, P187; BRIATA P, 1993, EXP CELL RES, V204, P136, DOI 10.1006/excr.1993.1018; CARRASCO D, 1995, ONCOGENE, V10, P1069; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CHAN WK, 1990, NUCLEIC ACIDS RES, V18, P763, DOI 10.1093/nar/18.4.763; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; Curran T, 1988, ONCOGENE HDB, P307; DLUGOSZ AA, 1994, J INVEST DERMATOL, V102, P409, DOI 10.1111/1523-1747.ep12372171; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; ECKERT RL, 1989, PHYSIOL REV, V69, P1316, DOI 10.1152/physrev.1989.69.4.1316; FISHER C, 1991, DEVELOPMENT, V111, P253; GANDARILLAS A, 1995, IN PRESS ONCOGENE; GILLARDON F, 1994, ONCOGENE, V9, P3219; GILOH H, 1982, SCIENCE, V217, P1252, DOI 10.1126/science.7112126; GRUBE D, 1980, HISTOCHEMISTRY, V66, P149, DOI 10.1007/BF00494642; GRUBE D, 1981, ACTA HISTOCHEM, P277; HUFF CA, 1993, J BIOL CHEM, V268, P377; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KHARBANDA S, 1993, BIOCHEM PHARMACOL, V45, P675, DOI 10.1016/0006-2952(93)90142-J; LU B, 1994, J BIOL CHEM, V269, P7443; MACK DH, 1991, P NATL ACAD SCI USA, V88, P9102, DOI 10.1073/pnas.88.20.9102; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MURTHY S, 1993, J STRUCT BIOL, V111, P68, DOI 10.1006/jsbi.1993.1037; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; RODDEY PK, 1994, J INVEST DERMATOL, V102, P296, DOI 10.1111/1523-1747.ep12371785; ROTHNAGEL JA, 1993, J INVEST DERMATOL, V101, P506, DOI 10.1111/1523-1747.ep12365886; RUCK P, 1990, J HISTOCHEM CYTOCHEM, V38, P859, DOI 10.1177/38.6.2335741; RYSECK RP, 1991, ONCOGENE, V6, P533; SAUNDERS NA, 1993, MOL ENDOCRINOL, V7, P387, DOI 10.1210/me.7.3.387; SHAH G, 1993, CANCER RES, V53, P38; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STERNBERGER LA, 1986, IMMUNOCYTOCHEMISTRY; STREEFKERK JG, 1972, J HISTOCHEM CYTOCHEM, V20, P829, DOI 10.1177/20.10.829; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; YAFFE MB, 1993, J INVEST DERMATOL, V100, P3, DOI 10.1111/1523-1747.ep12349857; YAMANISHI K, 1992, J BIOL CHEM, V267, P17858	54	117	120	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2681	2687						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545126				2022-12-28	WOS:A1995TP18800025
J	SHORE, SK; NABISSA, PM; REDDY, EP				SHORE, SK; NABISSA, PM; REDDY, EP			RIBOZYME-MEDIATED CLEAVAGE OF THE BCRABL ONCOGENE TRANSCRIPT - IN-VITRO CLEAVAGE OF RNA AND IN-VIVO LOSS OF P210 PROTEIN-KINASE ACTIVITY	ONCOGENE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; CELL-LINE; PHILADELPHIA-CHROMOSOME; ANTISENSE TRANSCRIPTS; EXPRESSION; POINT; GENE; K562	The t(9,22) chromosomal translocation generating the Philadelphia chromosome and the BCRABL oncogene has been shown both cytogenetically and molecularly to be the etiologic event in chronic myelogenous leukemia (CML). We have designed a ribozyme to cleave the BCRABL mRNA by targeting a GUU triplet adjacent to the junction of the c-BCR and c-ABL fused genes. This ribozyme efficiently cleaved BCRABL RNA transcripts as demonstrted by in vitro cleavage reactions. To determine the effect of constitutive expression of the ribozyme on the elimination of the BCRABL gene product, the ribozyme cDNA sequence was inserted into different retroviral expression vectors. Introduction of the recombinant retroviruses into the CML blast crisis cell-line K562, resulted in the elimination of the P210 protein-kinase activity in several single cell clones infected with the ribozyme expression cassette. Therefore BCR-ABL specific ribozymes may provide a potential genetic therapy for CML.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	SHORE, SK (corresponding author), TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST MOLEC BIOL & CANC RES,3307 N BROAD ST,PHILADELPHIA,PA 19140, USA.		Reddy, E. Premkumar/F-6233-2011		NCI NIH HHS [CA 47937-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047937] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARACCIOLO D, 1989, SCIENCE, V245, P1107, DOI 10.1126/science.2672339; COTTEN M, 1989, EMBO J, V8, P3861, DOI 10.1002/j.1460-2075.1989.tb08564.x; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; Kuzrock R, 1988, NEW ENGL J MED, V319, P990; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUBBERT M, 1988, J EXP MED, V167, P873, DOI 10.1084/jem.167.3.873; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; NOWELL PC, 1960, SCIENCE, V132, P1497; PERRIMAN R, 1992, GENE, V113, P157, DOI 10.1016/0378-1119(92)90391-2; ROWERY JD, 1973, NATURE, V243, P290; SCHTIVELMAN E, 1985, NATURE, V315, P550; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; SHORE SK, 1990, US PATENT TRADEMARK; SULLENGER BA, 1990, CELL, V63, P601, DOI 10.1016/0092-8674(90)90455-N; SULLENGER BA, 1990, MOL CELL BIOL, V10, P6512, DOI 10.1128/MCB.10.12.6512; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0	28	76	77	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3183	3188						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414522				2022-12-28	WOS:A1993MC09300037
J	TRAVERSE, S; COHEN, P; PATERSON, H; MARSHALL, C; RAPP, U; GRAND, RJA				TRAVERSE, S; COHEN, P; PATERSON, H; MARSHALL, C; RAPP, U; GRAND, RJA			SPECIFIC ASSOCIATION OF ACTIVATED MAP KINASE KINASE KINASE (RAF) WITH THE PLASMA-MEMBRANES OF RAS-TRANSFORMED RETINAL CELLS	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; MURINE SARCOMA-VIRUS; PROTEIN-KINASE; MONOCLONAL-ANTIBODIES; PHOSPHORYLATION; LOCALIZATION; ONCOGENE; CASCADE; P21RAS; GENE	Plasma membrane-enriched fractions were prepared from human embryonic retinal cells transformed with either adenovirus El A and oncogenic ras DNA, or E1A and E1B DNA. Ras comprised 5-10 % of the membrane protein from the E1A/ras transformed cells, whereas the membranes from EIA/E1B transformed cells did not overexpress Ras. The membranes from E1a/ras cells contained MAP kinase kinase kinase (MAPKKK) activity, even after washing in 0.5 M NaCl, whereas the membranes from E1A/EIB cells did not. Neither membrane fraction contained MAP kinase kinase or MAP kinase activity after washing with 0.5M NaCl. Immunoblotting experiments revealed about 10-fold more c-Raf in the membranes from EIA/ras cells than from E1A/E1B cells, and 50-60% of the MAPKKK activity in Triton X100-solubilised membranes from E1A/ras cells was immunoprecipitated with anti-Raf antibodies. A striking enrichment of c-Raf in the plasma membranes of E1A/ras cells was also demonstrated by immunocytochemistry, where it was co-localized with Ras. The MAPKKK activity in E1A/ras membranes was unaffected by incubation with protein phosphatases or by inclusion of protein phosphatase inhibitors during isolation, nor was it activated by GTP-Ras or inhibited by GDP-Ras. The results support the view that Ras and c-Raf interact with one another, but that neither c-Raf phosphorylation nor its interaction with GTP-Ras are alone sufficient for activation. The identification of MAPKKK activity in the membranes of ras-transformed cells may prove useful in elucidating the mechanism by which Raf is activated by Ras.	UNIV BIRMINGHAM,SCH MED,DEPT CANC STUDIES,CANC RES CAMPAIGN LABS,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND; NCI,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	University of Birmingham; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	TRAVERSE, S (corresponding author), UNIV DUNDEE,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND.							AELST LV, 1993, P NATL ACAD SCI USA, V90, P6213; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYRD P, 1982, NATURE, V298, P69, DOI 10.1038/298069a0; COHEN P, 1988, METHOD ENZYMOL, V159, P390; COHEN P, 1993, BIOCHEM SOC T, V214, P555; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FORCE T, 1993, IN PRESS P NATL ACAD; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GALLIMORE PH, 1986, ANTICANCER RES, V6, P499; GOMEZ N, 1992, FEBS LETT, V314, P461, DOI 10.1016/0014-5793(92)81527-S; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GRAND RJA, 1987, ONCOGENE, V1, P305; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JWOOD KW, 1992, CELL, V68, P1041; KAVACINA KS, 1990, J BIOL CHEM, V265, P12115; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1990, CANCER CELL-MON REV, V2, P377; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; ROZAKISADCOCK M, 1993, NATURE, V363, P831; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLINGHAM MC, 1983, EXP CELL RES, V149, P141, DOI 10.1016/0014-4827(83)90387-7; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	41	108	108	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3175	3181						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414521				2022-12-28	WOS:A1993MC09300036
J	SLACK, RS; HAMEL, PA; BLADON, TS; GILL, RM; MCBURNEY, MW				SLACK, RS; HAMEL, PA; BLADON, TS; GILL, RM; MCBURNEY, MW			REGULATED EXPRESSION OF THE RETINOBLASTOMA GENE IN DIFFERENTIATING EMBRYONAL CARCINOMA-CELLS	ONCOGENE			English	Article							E2F TRANSCRIPTION FACTOR; MOUSE PGK-1 GENE; RETINOIC ACID; NEUROECTODERMAL DIFFERENTIATION; NEURAL DIFFERENTIATION; SUSCEPTIBILITY GENE; MAMMALIAN-CELLS; STEM-CELLS; PROTEIN; PRODUCT	The expression of the retinoblastoma susceptibility (RB) gene was investigated in P19 embryonal carcinoma cells and in these cells induced to differentiate with retinoic acid (RA) or with dimethyl sulfoxide (DMSO). In undifferentiated cells very low levels of RB mRNA and protein were present. DMSO-treated P19 cell cultures develop into mesodermal and endodermal cells and RB expression increased only slightly in these differentiating celts. RA-treated P19 cells develop into neuroectoderm and this differentiation was accompanied by a marked increase in RB expression with mRNA levels increasing 15 fold by 4-6 days following initiation of RA treatment. No such increase occurred in mutant cells that fail to respond to RA. The RB promoter did not appear to be directly activated by RA. Nevertheless, the increase in RB expression in RA-treated cells appeared to be due to enhanced initiation of transcription because cells transfected with a reporter gene driven by the RB promoter expressed the reporter gene with kinetics similar to that of the RB gene. Thus the activation of the RB gene appears to be achieved indirectly by RA-induced factor(s) in differentiating neuroectodermal cells. The post-mitotic neurons that developed in RA-treated cultured contained only the hypophosphorylated form of the RB protein. Recent studies (Clarke et aL, 1992; Jacks et al., 1992; Lee et al., 1992) have shown that mice lacking the RB gene have abnormalities in early brain development suggesting that the rapid rise in RB expression and the hypophosphorylation of the protein are essential for neuronal cell differentiation.	UNIV OTTAWA,DEPT CHEM,OTTAWA K1N 6N5,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA	University of Ottawa; University of Toronto				Slack, Ruth/0000-0002-1552-2835				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; AIZAWA T, 1991, DEV BRAIN RES, V59, P89, DOI 10.1016/0165-3806(91)90033-F; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; DARLAND T, 1991, ONCOGENE, V6, P1367; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; EDWARDS SA, 1991, DEV BIOL, V148, P165, DOI 10.1016/0012-1606(91)90327-Y; Gill M., UNPUB; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMEL PA, 1992, TRENDS GENET, V8, P180, DOI 10.1016/0168-9525(92)90221-O; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCBURNEY MW, 1988, J NEUROSCI, V8, P1063; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MULLEN RJ, 1992, UNPUB; MURRAY EJ, 1991, MOL CELL BIOL, V1, P5534; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; PRATT MAC, 1992, UNPUB; ROSENSTRAUS MJ, 1982, DEV BIOL, V89, P516, DOI 10.1016/0012-1606(82)90340-2; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; RUSTGI AK, 1991, SYMPT QUANT BIOL, V56, P163; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SMITH SC, 1987, J CELL PHYSIOL, V131, P74, DOI 10.1002/jcp.1041310112; STAINES WA, 1992, UNPUB; STARNAUD R, 1989, ONCOGENE, V4, P1077; STARNAUD R, 1988, ONCOGENE, V3, P553; WEIGEL RJ, 1990, P NATL ACAD SCI USA, V87, P9878, DOI 10.1073/pnas.87.24.9878; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	54	94	94	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1585	1591						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502481				2022-12-28	WOS:A1993LE06400022
J	CUNNINGHAM, C; DUNLOP, MG; WYLLIE, AH; BIRD, CC				CUNNINGHAM, C; DUNLOP, MG; WYLLIE, AH; BIRD, CC			DELETION MAPPING IN COLORECTAL-CANCER OF A PUTATIVE TUMOR SUPPRESSOR GENE IN 8P22-P21.3	ONCOGENE			English	Note							POLYMERASE CHAIN-REACTION; POLYMORPHISM; CARCINOMAS; CHROMOSOME-17; LOCUS; PCR	Although previous studies of acquired loss of heterozygosity (LOH) in colorectal tumours have suggested that a tumour suppressor gene may lie within the short arm of chromosome 8, its precise localisation remains to be determined. To obtain a more accurate positional map 120 colorectal cancers were examined with eight chromosome 8 polymorphic markers comprising both restriction fragment length polymorphisms and microsatellite polymorphisms based on (CA)n repeats. 91 cases were informative and LOH was detected in 47 (51%). The markers most commonly sited within the lost region mapped to the lipoprotein lipase gene (LPL) at chromosome 8p22. From study of tumours showing break-points within 8p, a common region of deletion was established extending centromerically from LPL to the ankyrin 1 gene (ANK1) which is mapped to 8p21.1-11.2. This overlaps with common deleted regions observed in other studies of colorectal tumours (8p23.1-p21.3) and bladder tumours (8p21-q11.2). Taken together, the results in colorectal cancer delineate a region in 8p22-p21.3 where the putative tumour suppressor gene must lie. The chromosome 8p deletions appear to be independent of those involving 5q and 17p in the same tumours. No relationship was found between the presence of 8p deletion and site or stage of the tumour, or the sex or age of the patient at diagnosis.	MRC,HUMAN GENET UNIT,EDINBURGH,SCOTLAND	University of Edinburgh	CUNNINGHAM, C (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PATHOL,CANCER RES CAMPAIGN LABS,TEVIOT PL,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND.		Dunlop, Malcolm G/F-1973-2011	Dunlop, Malcolm G/0000-0002-3033-5851				ARMOUR JAL, 1991, NUCLEIC ACIDS RES, V19, P6344; ASHTONRICKARDT PG, 1989, ONCOGENE, V4, P1169; ASHTONRICKARDT PG, 1991, ONCOGENE, V6, P1881; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARKER D, 1987, SCIENCE, V236, P1100, DOI 10.1126/science.3107130; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BRUIN T, 1991, NUCLEIC ACIDS RES, V19, P6346, DOI 10.1093/nar/19.22.6346-a; EMI M, 1992, CANCER RES, V52, P5368; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P437; HEIGHWAY J, 1991, NUCLEIC ACIDS RES, V19, P6966, DOI 10.1093/nar/19.24.6966; HEIGHWAY J, 1992, NUCLEIC ACIDS RES, V20, P1160, DOI 10.1093/nar/20.5.1160; HEINZMANN C, 1987, NUCLEIC ACIDS RES, V15, P6763, DOI 10.1093/nar/15.16.6763; HORN GT, 1989, NUCLEIC ACIDS RES, V17, P2140, DOI 10.1093/nar/17.5.2140; KANEKO K, 1991, NUCLEIC ACIDS RES, V19, P6059, DOI 10.1093/nar/19.21.6059-a; KNOWLES MA, 1993, IN PRESS ONCOGENE; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MCDANIEL T, 1991, NUCLEIC ACIDS RES, V19, P4796, DOI 10.1093/nar/19.17.4796-a; MIKI Y, 1991, JPN J CANCER RES, V82, P1003, DOI 10.1111/j.1349-7006.1991.tb01935.x; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P969, DOI 10.1093/nar/19.4.969; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; SENGUPTA DN, 1986, BIOCHEM BIOPH RES CO, V136, P341, DOI 10.1016/0006-291X(86)90916-2; TOMFOHRDE J, 1992, GENOMICS, V14, P144, DOI 10.1016/S0888-7543(05)80297-6; VANDERBOSCH K, 1992, GENE CHROMOSOME CANC, V5, P91, DOI 10.1002/gcc.2870050114; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WAGNER MJ, 1991, GENOMICS, V10, P114, DOI 10.1016/0888-7543(91)90491-V; WANG LM, 1992, CANCER RES, V52, P4824; WEBER JL, 1989, AM J HUM GENET, V44, P388; 1991, CYTOGENET CELL GENET, V58, P1	32	90	93	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1391	1396						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479756				2022-12-28	WOS:A1993KY32800034
J	BELLACOSA, A; FRANKE, TF; GONZALEZPORTAL, ME; DATTA, K; TAGUCHI, T; GARDNER, J; CHENG, JQ; TESTA, JR; TSICHLIS, PN				BELLACOSA, A; FRANKE, TF; GONZALEZPORTAL, ME; DATTA, K; TAGUCHI, T; GARDNER, J; CHENG, JQ; TESTA, JR; TSICHLIS, PN			STRUCTURE, EXPRESSION AND CHROMOSOMAL MAPPING OF C-AKT - RELATIONSHIP TO V-AKT AND ITS IMPLICATIONS	ONCOGENE			English	Article							PROTEIN KINASE-C; SEQUENCE; HYBRIDIZATION; FAMILY	Sequence analysis of a nearly full-length murine c-akt cDNA clone and comparison with v-akt revealed the following: (a) The entire coding region of c-akt is identical to that of v-akt with the exception of five G to A transitions that do not alter the reading frame. The 3' untranslated regions of v-akt and c-akt are also identical with the exception of three single-base differences. (b) The recombination event that gave rise to v-akt occurred between the virus at nucleotide 785 from the Gag ATG codon and the 5' untranslated region of c-akt to 60 bp 5' from the c-akt ATG codon. (c) Three nucleotides absent from both Gag and c-akt were inserted at the junction between the two genes. The outcome of these events was to place, in frame, a 63-bp fragment between Gag and Akt. The resulting v-akt oncogene is predicted to encode a tripartite Gag (p12, p15, DELTAp30)-X-c-akt protein product. The c-akt protein contains, starting from its amino terminus, a src homology 2-like (SH2-like) domain, a domain rich in glutamic acid residues, part of which is predicted to form an amphipathic helix, and a kinase domain encoding a serine-threonine kinase with high degree of homology to members of the protein kinase C (PKC) family. The mouse c-akt is 90% homologous to human AKT1/RAC at the nucleic acid level and 98% homologous at the amino acid level. c-akt in the mouse is composed of 13 exons. The first exon contains a 5' untranslated GC-rich region. Since the recombination that gave rise to v-akt occurred with the 5' untranslated region, we hypothesize that the transduction of c-akt was preceded by provirus insertion upstream from or within the 5' untranslated region and in the same transcriptional orientation as the gene. c-akt was mapped by fluorescence in situ hybridization (FISH) to mouse chromosome 12 and rat chromosome 6 in close proximity to the Igh locus.	FOX CHASE CANC CTR,PHILADELPHIA,PA 19111	Fox Chase Cancer Center			Gonzalez, Maria Eugenia/B-5146-2008	Gonzalez, Maria Eugenia/0000-0003-0355-5469	NCI NIH HHS [CA-38047, CA-06927] Funding Source: Medline; NCRR NIH HHS [RR-05539] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, R01CA038047] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLACOSA A, 1991, MOL CELL BIOL, V11, P2864, DOI 10.1128/MCB.11.5.2864; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BISHOP JM, 1985, RNA TUMOR VIRUSES S, V2, P249; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FAN YS, 1990, P NATL ACAD SCI USA, V87, P6223, DOI 10.1073/pnas.87.16.6223; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOCH CA, 1991, SCIENCE, V252, P688; LIM HM, 1988, GENE ANAL TECH, V5, P32, DOI 10.1016/0735-0651(88)90024-6; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; ONO Y, 1988, J BIOL CHEM, V263, P6927; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; Schwartz RM, 1978, ATLAS PROTEIN SEQ S3, P353; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; Staal SP, 1988, GENOMICS, V2, P96, DOI 10.1016/0888-7543(88)90114-0; TESTA JR, 1993, IN PRESS CYTOGENET C; Tsichlis P N, 1991, Curr Top Microbiol Immunol, V171, P95; WEISS R, 1985, RNA TUMOR VIRUSES, V2, P139	33	159	165	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					745	754						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437858				2022-12-28	WOS:A1993KN00800027
J	MATHEW, S; MURTY, VVVS; DALLAFAVERA, R; CHAGANTI, RSK				MATHEW, S; MURTY, VVVS; DALLAFAVERA, R; CHAGANTI, RSK			CHROMOSOMAL LOCALIZATION OF GENES ENCODING THE TRANSCRIPTION FACTORS, C-REL, NF-KAPPA-BP50, NF-KAPPA-BP65, AND LYT-10 BY FLUORESCENCE INSITU HYBRIDIZATION	ONCOGENE			English	Note							NF-KAPPA-B; INT-2 GENES; CARCINOMAS; AMPLIFICATION; ONCOGENE; COAMPLIFICATION; LYMPHOMA; CLONING; SUBUNIT; CANCERS	We have used fluorescence in situ hybridization (FISH) to perform precise chromosomal mapping of the genes encoding the transcription factors c-rel, NF-kappaBp50, NF-kappaBp65, and lyt-10. The previously published assignments of c-rel and NF-kappaBp50 have been refined to specific bands. The map position of lyt-10, inferred from its isolation from a t(10;14)(q24;q32) translocation, has been confirmed. NF-kappaBp65 has now been mapped to 11q13, a site of frequent involvement in aberration in multiple tumor types.	MEM SLOAN KETTERING CANC CTR,CANC GENET LAB,1275 YORK AVE,NEW YORK,NY 10021; COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032	Memorial Sloan Kettering Cancer Center; Columbia University					NCI NIH HHS [CA-34775, CA-20194] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034775, P01CA020194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWNELL E, 1986, AM J HUM GENET, V39, P194; BROWNELL E, 1989, ONCOGENE, V4, P935; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LU D, 1991, ONCOGENE, V6, P1235; LUCIBELLO F C, 1991, Critical Reviews in Oncogenesis, V2, P259; MANIATIS T, 1982, MOL CLONING LABORATO, P109; MATHEW S, 1992, IN PRESS GENOMICS; NARAYANAN R, 1992, SCIENCE, V256, P357; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SOMERS KD, 1990, ONCOGENE, V5, P915; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; THEILLET C, 1989, ONCOGENE, V4, P915; TSUDA T, 1989, CANCER RES, V49, P5505; TSUTSUMI M, 1988, JPN J CANCER RES, V79, P428, DOI 10.1111/j.1349-7006.1988.tb01609.x; VANDENBERGHE H, 1979, CANCER, V44, P179; ZHOU DJ, 1988, ONCOGENE, V2, P279	23	64	65	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					191	193						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423996				2022-12-28	WOS:A1993KN00500023
J	OELRICHS, RB; REID, HH; BERNARD, O; ZIEMIECKI, A; WILKS, AF				OELRICHS, RB; REID, HH; BERNARD, O; ZIEMIECKI, A; WILKS, AF			NYK/FLK-1 - A PUTATIVE RECEPTOR PROTEIN TYROSINE KINASE ISOLATED FROM E10 EMBRYONIC NEUROEPITHELIUM IS EXPRESSED IN ENDOTHELIAL-CELLS OF THE DEVELOPING EMBRYO	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; DEVELOPING MOUSE-BRAIN; ONCOGENE C-KIT; W-LOCUS; CONSERVED FEATURES; CDNA; SEQUENCE; FAMILY; GENE; DNA	A protein tyrosine kinase (NYK/FLK-1), bearing all the hallmarks of a growth factor receptor, has been isolated from a cDNA library generated from enriched populations of mouse day 10 embryonic neuroepithelium and from day 18 embryonic colon. Sequence analysis of cDNAs covering the entire coding region of this 5.7 kb mRNA predicted the presence of seven immunoglobulin-like domains in the extracellular region of this molecule. This feature, coupled with the detection of an insert domain bisecting the kinase domain of the predicted protein sequence, places NYK/FLK-1 firmly in the Platelet-derived Growth Factor Receptor-related class of molecules. NYK/FLK-1 is expressed at high levels in adult heart, lung, kidney, brain and skeletal muscle, but is also expressed at lower levels in most other adult tissues. In situ hybridization of day 12.5 embryo sections demonstrated NYK/FLK-1 mRNA expression in endothelial cells lining the dorsal aorta and intervertebral veins. In addition, expression was found in cells lining the capillary plexus which surrounds the developing neuroepithelium, and in the endothelial cells which are found within the embryonic lung, spleen, liver and metanephros.	ROYAL MELBOURNE HOSP, LUDWIG INST CANC RES, PARKVILLE, VIC 3050, AUSTRALIA; ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA; UNIV BERN, INST CLIN & EXPTL CANC RES, CH-3004 BERN, SWITZERLAND	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Bern			Bernard, Olivier/J-1133-2014; Wilks, Andrew F/R-5542-2019	Bernard, Olivier/0000-0003-2539-9014; Wilks, Andrew F/0000-0002-8554-2399				BAER T, 1980, ADV ANAT EMBRYOL CEL, V264, P8222; BIRCHMEIER C, 1990, P NATL ACAD SCI USA, V87, P4799, DOI 10.1073/pnas.87.12.4799; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHOWCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DRAGO J, 1991, J NEUROSCI METH, V37, P251, DOI 10.1016/0165-0270(91)90031-T; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOVENS CM, 1992, IN PRESS P NATL ACAD; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; Maniatis T., 1982, MOL CLONING; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; REID HH, 1990, THESIS U MELBOURNE; ROSNET O, 1991, ONCOGENE, V6, P1641; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBUYA M, 1990, ONCOGENE, V5, P519; STEVENSON DA, 1991, P NATL ACAD SCI USA, V88, P6; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TERMAN BI, 1991, ONCOGENE, V6, P1677; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILKS AF, 1991, METHOD ENZYMOL, V200, P533; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	42	80	98	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1993	8	1					11	18						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423988				2022-12-28	WOS:A1993KN00500002
J	SIRINIAN, MI; MARCHETTI, A; DIROCCO, G; STARACE, G; JUCKER, R; NASI, S				SIRINIAN, MI; MARCHETTI, A; DIROCCO, G; STARACE, G; JUCKER, R; NASI, S			RAS ONCOGENE TRANSFORMATION OF HUMAN B-LYMPHOBLASTS IS ASSOCIATED WITH LYMPHOCYTE-ACTIVATION AND WITH A BLOCK OF DIFFERENTIATION	ONCOGENE			English	Article							MOLECULAR-CLONING; INTERLEUKIN-2 RECEPTOR; SIGNAL-TRANSDUCTION; BINDING-PROTEINS; CELL ACTIVATION; PC12 CELLS; H-RAS; TRANSCRIPTION; GENE; ADHESION	The p21ras small GTP binding proteins participate in signal transduction from cell surface receptors and affect neoplastic transformation and development in many different cell types. In the present study, we examined the relationship between ras transformation and differentiation of human B lymphocytes. We show that the constitutive expression of the T24 Ha-ras oncogene in EBV-immortalized B lymphoblasts was associated with the induction of the interleukin 2 receptor alpha subunit, with an impaired immunoglobulin gene expression, altered adhesion properties and increased survival in serum-free medium. Since induction of the IL-2 receptor alpha subunit is a hallmark of lymphocyte activation, we suggest that p21ras naturally triggers B cell activation. The ras-transformed lymphocytes displayed a fully functional IL-2r, as assessed by c-fos induction following treatment with IL-2; nevertheless, they were not growth stimulated by this lymphokine. The decreased expression of immunoglobulin genes indicates that the ras oncogene blocks terminal differentiation to plasma cells, possibly by inhibiting the activity of lymphocyte-specific transcription factors. Somewhat unexpectedly, the constitutive p21ras activity did not cause an increased DNA binding of transcription factors PEA1 (AP1), PEA3, Oct-2 or NF-kB.	UNIV ROME LA SAPIENZA,DIPARTIMENTO GENET & BIOL MOLEC,CNR,CTR ACIDI NUCL,I-00185 ROME,ITALY; CNR,IST MED SPERIMENTALE,ROME,ITALY	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR)			Di Rocco, Giuliana/G-5682-2012; Di Rocco, Giuliana/P-1413-2019; Di Rocco, Giuliana/J-4776-2018; Marchetti, Alessandra/AAD-5498-2019	Di Rocco, Giuliana/0000-0003-1210-6008; Di Rocco, Giuliana/0000-0003-1210-6008; MARCHETTI, ALESSANDRA/0000-0001-9706-848X				ARIMA N, 1987, J IMMUNOL, V138, P3069; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BICHTHUY LT, 1990, CELL IMMUNOL, V128, P22, DOI 10.1016/0008-8749(90)90003-A; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CARUSO M, 1990, EMBO J, V9, P947, DOI 10.1002/j.1460-2075.1990.tb08193.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK EA, 1991, ANNU REV IMMUNOL, V9, P97; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; DANG LH, 1991, J IMMUNOL, V146, P3273; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ENDO K, 1991, ONCOGENE, V6, P1391; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GILLIS S, 1978, J IMMUNOL, V120, P2027; GRAZIADEI L, 1990, NATURE, V347, P396, DOI 10.1038/347396a0; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; Karin M, 1991, CURR OPIN CELL BIOL, V3, P467, DOI 10.1016/0955-0674(91)90075-A; LANGDON WY, 1989, ONCOGENE RES, V4, P253; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MINGARI MC, 1984, NATURE, V312, P641, DOI 10.1038/312641a0; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; NASI S, 1990, ONCOGENE, V5, P117; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PULCIANI S, 1982, P NATL ACAD SCI-BIOL, V79, P2845, DOI 10.1073/pnas.79.9.2845; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEREMETIS S, 1989, SCIENCE, V243, P660, DOI 10.1126/science.2536954; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TIGGES MA, 1989, SCIENCE, V243, P781, DOI 10.1126/science.2492678; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; YAGURA H, 1990, BLUT, V60, P181, DOI 10.1007/BF01720273	45	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					157	163						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423993				2022-12-28	WOS:A1993KN00500019
J	Garrido, C; Leprince, D; Plaza, S; Aumercier, M; Stehelin, D; Saule, S				Garrido, C; Leprince, D; Plaza, S; Aumercier, M; Stehelin, D; Saule, S			Back-mutation of the v-Ets to the c-Ets carboxy-terminal amino acids in the P135(gag-myb-ets) results in chicken neuroretina cells transformation and loss of basic fibroblast growth factor responsiveness	ONCOGENE			English	Article						neuroretina; bFGF; ets; myb	AVIAN-MYELOBLASTOSIS VIRUS; LEUKEMIA-VIRUS; MYB ONCOGENE; DNA-BINDING; NUCLEOTIDE-SEQUENCE; ERYTHROID-CELLS; C-ETS-1 LOCUS; MYELOID CELLS; GENE FAMILY; E26 VIRUS	The v-Myb, v-Ets containing E26 retrovirus (called in this work E26ABC) induces the proliferation of chicken neuroretina (CNR) cells in minimal medium, strongly stimulated by basic Fibroblast Growth Factor (bFGF) which confers on them the ability to form colonies in soft agar. V-Ets differs from its cellular counterpart c-Ets-l by two point mutations and by the replacement of the 13 last C-terminal amino acids by 16 unrelated residues as a consequence of DNA segment inversion in the viral sequence. It has been documented that this different C-terminal sequence influences DNA binding activity and specificity. Replacement in E26ABC virus of the sequence encoding the 16 v-Ets last C-terminal amino acids by the sequence encoding the 13 c-Ets-l derived C-terminus (virus E26ABO), results in the production of a P135(gag-myb-ets) with modified biological properties on CNR cells. E26ABO infected CNR cells proliferate in minimal medium more efficiently than E26ABC, are unresponsive to bFGF and able to grow in soft agar. In contrast, CNR cells infected by viruses encoding Myb and Ets proteins either in the E26ABO or in the E26ABC configuration are bFGF responsive. Since Myb alone is sufficient to induce bFGF responsiveness on CNR cells, these results suggest that the c-Ets-l C-terminus interferes with the Myb activity of the E26ABO P135(gag-myb-ets) protein in CNR cells.	INST PASTEUR,CNRS EP56,F-59019 LILLE,FRANCE; INST PASTEUR,CNRS UA 1160,F-59019 LILLE,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			plaza, serge/F-5290-2015; Garrido, Carolina/GWM-5557-2022	Aumercier, Marc/0000-0002-0370-3452				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AMOUYEL P, 1989, J VIROL, V63, P3382, DOI 10.1128/JVI.63.8.3382-3388.1989; BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COMBES PC, 1977, CELL TISSUE RES, V185, P159; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERBA HP, 1986, NUCLEIC ACIDS RES, V14, P5275, DOI 10.1093/nar/14.13.5275; FRAMPTON J, 1993, EMBO J, V12, P1333, DOI 10.1002/j.1460-2075.1993.tb05778.x; Frykberg L, 1988, Oncogene Res, V3, P313; GARRIDO C, 1992, J VIROL, V66, P160, DOI 10.1128/JVI.66.1.160-166.1992; GARRIDO C, 1992, J VIROL, V66, P6773, DOI 10.1128/JVI.66.11.6773-6776.1992; GARRIDO C, 1992, ONCOGENE, V8, P2713; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GOSPODAROWICZ D, 1984, P NATL ACAD SCI-BIOL, V81, P6963, DOI 10.1073/pnas.81.22.6963; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HAHN SL, 1994, ONCOGENE, V9, P2499; KAHN P, 1979, J CELL BIOL, V82, P1, DOI 10.1083/jcb.82.1.1; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; LEPRINCE D, 1993, VIROLOGY, V194, P855, DOI 10.1006/viro.1993.1330; LEPRINCE D, 1992, ONCOGENE, V7, P9; LI RP, 1989, ONCOGENE RES, V5, P137; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NUNN M, 1984, VIROLOGY, V139, P330, DOI 10.1016/0042-6822(84)90378-7; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; QUEVA C, 1993, ONCOGENE, V8, P2511; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; ROBINSON CJ, 1991, TRENDS PHARMACOL SCI, V12, P123, DOI 10.1016/0165-6147(91)90525-W; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; WASYLYK C, 1993, NUCLEIC ACIDS RES, V21, P523, DOI 10.1093/nar/21.3.523; WASYLYK C, 1992, CELL GROWTH DIFFER, V3, P617; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	49	0	0	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1449	1456						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622861				2022-12-28	WOS:A1996UF07600009
J	Riese, DJ; Bermingham, Y; vanRaaij, TM; Buckley, S; Plowman, GD; Stern, DF				Riese, DJ; Bermingham, Y; vanRaaij, TM; Buckley, S; Plowman, GD; Stern, DF			Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta	ONCOGENE			English	Article						betacellulin; EGF; neuregulin; EGF receptor; ErbB receptors; signaling	TYROSINE PHOSPHORYLATION; EGF RECEPTOR; PROTEIN; CELLS; EXPRESSION; BINDING; KINASE; LINE; HETERODIMERIZATION; ANTIBODIES	Betacellulin is a member of the epidermal growth factor (EGF) family. These soluble proteins are ligands for one or more of the four receptor tyrosine kinases encoded by the erbB gene family (erbB-1/epidermal growth factor receptor (EGFR), neu/erbB-2/HER2, erbB-3/HER3 and erbB-4/HER4). While evidence suggests that betacellulin is a ligand for the EGFR, the ability of betacellulin to regulate other erbB family receptors has not been analysed. Previously we engineered derivatives of the mouse Ba/F3 hematopoietic cell line to ectopically express erbB family receptors, singly and in pairwise combinations. We have stimulated this panel of cell lines with betacellulin and two other EGF family members, EGF itself and neuregulin-beta (NRG-beta). In the cell lines expressing a single erbB family receptor, betacellulin not only stimulated EGFR tyrosine phosphorylation, but it activated erbB-4 as well. Furthermore, in the double recombinant Ba/F3 derivatives, betacellulin stimulated a complex pattern of receptor phosphorylation distinct from the patterns activated by NRG-beta and EGF. Moreover, betacellulin stimulated a complex pattern of interleukin-3 independence in the Ba/F3 derivatives distinct from those activated by NRG-beta and EGF. These data identify a novel receptor for betacellulin and establish that different EGF family ligands activate distinct patterns of receptor phosphorylation and coupling to cellular signaling pathways.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06520; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121; SUGEN INC,REDWOOD CITY,CA 94063	Yale University; Bristol-Myers Squibb			Riese, David/AAF-3581-2020; PLOWMAN, Greg D/E-2012-2011	Riese, David/0000-0002-8823-5802	NATIONAL CANCER INSTITUTE [R01CA045708] Funding Source: NIH RePORTER; NCI NIH HHS [CA-45708] Funding Source: Medline; NICHD NIH HHS [HD-07149] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; AVIEZER D, 1994, P NATL ACAD SCI USA, V91, P12173, DOI 10.1073/pnas.91.25.12173; BARBACCI EG, 1995, J BIOL CHEM, V270, P9585, DOI 10.1074/jbc.270.16.9585; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; COOK PW, 1995, J CELL PHYSIOL, V163, P407, DOI 10.1002/jcp.1041630221; COOK PW, 1995, J CELL PHYSIOL, V163, P418, DOI 10.1002/jcp.1041630222; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIGIOVANNA MP, 1995, CANCER RES, V55, P1946; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; ECKENSTEIN FP, 1994, J NEUROBIOL, V25, P1467; FAZIOLI F, 1992, J BIOL CHEM, V267, P5155; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; GILL GN, 1984, J BIOL CHEM, V259, P7755; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HARWERTH IM, 1992, J BIOL CHEM, V267, P15160; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; IBANEZ CF, 1994, J NEUROBIOL, V25, P1349, DOI 10.1002/neu.480251104; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON GR, 1994, J BIOL CHEM, V269, P27149; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; KARUNAGARAN D, 1995, J BIOL CHEM, V270, P9982, DOI 10.1074/jbc.270.17.9982; KIM HH, 1994, J BIOL CHEM, V269, P24747; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KITA YA, 1994, FEBS LETT, V349, P139, DOI 10.1016/0014-5793(94)00644-X; LANGTON BC, 1991, CANCER RES, V51, P2593; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; SASADA R, 1993, BIOCHEM BIOPH RES CO, V190, P1173, DOI 10.1006/bbrc.1993.1173; SEFTON B, 1979, J VIROL, V28, P957; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; THORNE BA, 1994, MOL CELL BIOL, V14, P1635, DOI 10.1128/MCB.14.3.1635; UENO H, 1992, J BIOL CHEM, V267, P1470; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WATANABE T, 1994, J BIOL CHEM, V269, P9966; Zar JH., 1999, BIOSTAT ANAL	54	225	231	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					345	353						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570211				2022-12-28	WOS:A1996TR53800013
J	Taylor, ICA; Roy, S; Varmus, HE				Taylor, ICA; Roy, S; Varmus, HE			Overexpression of the Sky receptor tyrosine kinase at the cell surface or in the cytoplasm results in ligand-independent activation	ONCOGENE			English	Article						Sky receptor tyrosine kinase; dimerization; isoforms	PROTEIN; ONCOGENE	Most receptor tyrosine kinases are activated by dimerization induced by their cognate ligands, Protein S, an abundant serum protein previously shown to be a potent anticoagulation factor, has been proposed to be a ligand for the Sky tyrosine kinase (Stitt et al., 1995), Here we show that Sky, when expressed to high levels, is tyrosine phosphorylated even in the absence of a ligand, Furthermore, a version of Sky (termed Sky Delta SS) engineered to be overexpressed in the cytoplasm and thus in a ligand-free environment, can function as a dimeric tyrosine kinase, Sky Delta SS can transform RatB1a fibroblasts and thus retains all the properties of the full-length Sky kinase, These data suggest that Sky, when overexpressed either at the cell surface or in the cytoplasm, is competent to form dimers even in the absence of its ligand. We also demonstrate that an isoform of Sky, originally reported as Brt and here termed Sky Isoform I, resides in the cytoplasm, Therefore, the activities of Sky Delta SS we describe may reflect those of the naturally occurring Isoform I.	NCI,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; BIESECKER LG, 1993, P NATL ACAD SCI USA, V90, P7044, DOI 10.1073/pnas.90.15.7044; BIESECKER LG, 1995, ONCOGENE, V10, P2239; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; CROSIER PS, 1994, GROWTH FACTORS, V11, P125, DOI 10.3109/08977199409001054; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAHLBACK B, 1994, MOL BASIS BLOOD DISE, P599; DAI W, 1994, ONCOGENE, V9, P975; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; FUJIMOTO J, 1994, ONCOGENE, V9, P693; GRECO A, 1992, ONCOGENE, V7, P237; LAI C, 1994, ONCOGENE, V9, P2567; MARK MR, 1994, J BIOL CHEM, V269, P10720; MARU Y, 1990, ONCOGENE, V5, P445; OHASHI K, 1994, ONCOGENE, V9, P699; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; TAYLOR ICA, 1995, J BIOL CHEM, V270, P6872, DOI 10.1074/jbc.270.12.6872; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x	21	40	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2619	2626						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545119				2022-12-28	WOS:A1995TP18800018
J	LIANG, XH; VOLKMANN, M; KLEIN, R; HERMAN, B; LOCKETT, SJ				LIANG, XH; VOLKMANN, M; KLEIN, R; HERMAN, B; LOCKETT, SJ			COLOCALIZATION OF THE TUMOR-SUPPRESSOR PROTEIN P53 AND HUMAN PAPILLOMAVIRUS-E6 PROTEIN IN HUMAN CERVICAL-CARCINOMA CELL-LINES	ONCOGENE			English	Article								The loss of the tumor-suppressor activity of p53, either by mutation or by interaction with the human papillomavirus (HPV) E6 protein, is considered to be an important mechanism in the carcinogenesis of cervical cancer. We have studied the cytological distribution of these proteins in human cervical carcinoma cell lines using polyclonal anti-p53 and monoclonal anti-E6 antibodies. The antibody specificity was confirmed by immunoblot and immunocompetition analyses. The intracellular localization of p53 and E6 was detected using the techniques of conventional and three-dimensional confocal microscopy. In the HPV-18 or -16 integrated cell lines, HeLa, CaSki and SiHa, viral oncoprotein E6 and endogenous tumor-suppressor protein, p53, were observed by immunofluorescence in the cytoplasm; p53 also had a weak punctate staining in the nuclei of HeLa and CaSki cells. In the HPV-negative cervical carcinoma cell lines, C-33A and HT-3, which have mutated p53, p53 was localized predominantly to the nucleus, with C-33A cells having elevated levels of p53 compared with the other cell lines. High spatial resolution imaging, using confocal microscopy, was performed on the cells after double fluorescence staining for p53 (fluorescein) and E6 (rhodamine). The images showed that both p53 and E6 had similar cytoplasmic distributions, which implied that these two proteins may exist as a cytoplasmic complex. To substantiate this implication, fluorescence resonance energy transfer microscopy was performed, which provided direct evidence of a close association between p53 and E6 within individual HeLa cells. The results from this study support the theory that p53 protein binds HPV-16/18 E6 protein in the cell cytoplasm, thus preventing p53 from exerting its tumor-suppressor function in the nucleus. Hence, inactivation of wild-type p53 by p53-E6 complex formation in cervical cancer may be a critical step in malignant transformation.	GERMAN CANC RES CTR, W-6900 HEIDELBERG, GERMANY; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC RES CTR, CHAPEL HILL, NC 27599 USA	Helmholtz Association; German Cancer Research Center (DKFZ); University of North Carolina; University of North Carolina Chapel Hill	LIANG, XH (corresponding author), UNIV N CAROLINA, DEPT CELL BIOL & ANAT, CELL BIOL LABS, 22 TAYLOR HALL, CB 7090, CHAPEL HILL, NC 27599 USA.				NATIONAL CANCER INSTITUTE [R37CA051323, R01CA051323] Funding Source: NIH RePORTER; NCI NIH HHS [CA51323] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; CHEN TM, 1992, ONCOGENE, V7, P1541; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1991, ONCOGENE, V6, P873; DEVILLIERS EM, 1992, GENITOURIN MED, V68, P50; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DOEBERITZ MV, 1991, P NATL ACAD SCI USA, V88, P1411, DOI 10.1073/pnas.88.4.1411; DURST M, 1985, J GEN VIROL, V66, P1515, DOI 10.1099/0022-1317-66-7-1515; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; GUIOT MCP, 1989, CANCER CEL, V7, P193; HAUSEN HZ, 1982, LANCET, V2, P1370; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HERMAN B, 1989, METHOD CELL BIOL, V30, P219; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOCKETT SJ, 1991, ANAL QUANT CYTOL, V13, P27; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MONTENARH M, 1987, J VIROL, V61, P940, DOI 10.1128/JVI.61.3.940-944.1987; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; REIHSAUS E, 1990, ONCOGENE, V5, P137; RIOU G, 1990, LANCET, V335, P1171; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHNEIDERGADICKE A, 1988, CANCER RES, V48, P2969; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SHAULSKY G, 1991, CELL GROWTH DIFFER, V2, P661; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SRIVASTAVA S, 1992, CARCINOGENESIS, V13, P1273, DOI 10.1093/carcin/13.7.1273; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302	41	73	77	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2645	2652						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8397367				2022-12-28	WOS:A1993LX34300005
J	CRESSMAN, DE; TAUB, R				CRESSMAN, DE; TAUB, R			I-KAPPA-B-ALPHA CAN LOCALIZE IN THE NUCLEUS BUT SHOWS NO DIRECT TRANSACTIVATION POTENTIAL	ONCOGENE			English	Note							DNA-BINDING ACTIVITY; REL-ASSOCIATED PP40; TRANSCRIPTION FACTOR; REGENERATING LIVER; G0-TO-G1 TRANSITION; MOUSE FIBROBLASTS; 65-KD SUBUNIT; ACTIVATION; INHIBITOR; PRECURSOR	Although IkappaB is a cytoplasmic inhibitor of NF-kappaB and c-Rel that prevents nuclear translocation of NF-kappaB, some forms of IkappaB have been found in the nucleus. Given that some other proteins with ankyrin-type repeats are transcription factors, we wondered if a nuclear form Of IkappaBalpha could itself be a transcriptional activator. We found that Gal4-IkappaBalpha fusion proteins strongly transactivate a Gal4 site-containing promoter in 3T3 fibroblasts. The IkappaBalpha domain responsible for this transactivation is not the acidic domain of IkappaBalpha, but the ankyrin repeat domain which is responsible for protein-protein interactions. To enhance our ability to detect cellular IkappaBalpha by immunofluorescence, we overexpressed the protein in transfected cells, and found that overexpressed IkappaBalpha is largely cytoplasmic in serum-deprived cells, but nuclear in serum-stimulated cells. However, in cell fractionation studies under all treatment conditions, IkappaBalpha appears mainly in cytoplasmic fractions, suggesting that it can rapidly move out of the nucleus through nuclear pores during extract preparation. Using double antibody immunoprecipitations, we found that IkappaBalpha in proliferating cells is strongly associated with RelA(p65). When IkappaBalpha is fused to the Gal4 DNA-binding domain, nuclear Gal4-IkappaBalpha is associated with RelA(p65). Thus, the activation domain of the associated RetA(p65) molecule could account for the ability of Gal4-IkappaBalpha to transactivate the Gal4 promoter. Unlike Bcl-3, an IkappaB which has been recently shown to directly transactivate through kappaB sites when associated with NFKB2 (p52), IkappaBalpha shows no ability to directly transactivate target promoters via its association with RelA(p65).	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania								Alberts B., 1989, MOL BIOL CELL; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; FAUSTO N, 1989, LAB INVEST, V60, P4; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1015; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LEMARCO K, 1991, SCIENCE, V253, P789; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MORIN PJ, 1992, NUCLEIC ACIDS RES, V20, P2453, DOI 10.1093/nar/20.10.2453; MORIN PJ, 1993, IN PRESS NUCLEIC ACI; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P649; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TEWARI M, 1992, NUCLEIC ACIDS RES, V20, P607, DOI 10.1093/nar/20.3.607; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	41	41	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2567	2573						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361766				2022-12-28	WOS:A1993LT36800030
J	DALY, MC; XIANG, RH; BUCHHAGEN, D; HENSEL, CH; GARCIA, DK; KILLARY, AM; MINNA, JD; NAYLOR, SL				DALY, MC; XIANG, RH; BUCHHAGEN, D; HENSEL, CH; GARCIA, DK; KILLARY, AM; MINNA, JD; NAYLOR, SL			A HOMOZYGOUS DELETION ON CHROMOSOME-3 IN A SMALL-CELL LUNG-CANCER CELL-LINE CORRELATES WITH A REGION OF TUMOR-SUPPRESSOR ACTIVITY	ONCOGENE			English	Article							SHORT ARM; DNA POLYMORPHISMS; CARCINOMA; GENE; RETINOBLASTOMA; SEQUENCE; 3P; IDENTIFICATION; HETEROZYGOSITY; PROTEIN	Small cell lung cancer (SCLC) tumors frequently display deletions on the short arm of chromosome 3 suggesting the existence of a 'tumor suppressor' gene within that region whose functional inactivation may be involved in tumorigenesis. Recently, a hybrid, HA(3)BB9F, was identified that contains a small fragment of human chromosome 3 of approximately 2 Mb on a mouse (A9) background (Killary et. al., 1992). This hybrid was utilized to define a functional tumor suppressor gene within 3p22-p21 which could suppress the tumorigenic properties of the mouse fibrosarcoma cell line. The existence of a tumor suppressor gene in the region 3p22-p21 is supported by the present report which describes the assessment of 89 SCLC and 32 non-SCLC lung cancer tumors and cell lines for the existence of a homozygous deletion(s) at 43 loci on the short arm of chromosome 3. One of the SCLC cell lines was found to harbor a homozygous deletion involving the loss of five markers on chromosome 3p. All five of the markers map to the region 3p21.3-p21.2 and four of the five markers are located within the chromosome 3 fragment exhibiting properties of tumor suppression in the HA(3)BB9F hybrid. The other tumors analysed all retained at least one copy of each of the markers assessed.	UNIV TEXAS,SW MED CTR,SIMMONS CANC INST,DALLAS,TX 75235; UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,HOUSTON,TX 77030; UNIFORMED SERV UNIV HLTH SCI,DEPT MED,MED ONCOL BRANCH,NCI NAVY MED ONCOL BRANCH,BETHESDA,MD 20814	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA	DALY, MC (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.				NATIONAL CANCER INSTITUTE [R29CA044764] Funding Source: NIH RePORTER; NCI NIH HHS [CA44764] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGERHEIM U, 1989, CANCER RES, V49, P1390; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; DALY MC, 1991, GENOMICS, V9, P113, DOI 10.1016/0888-7543(91)90227-6; DELEIJ L, 1985, CANCER RES, V45, P6024; DIDSBURY JR, 1987, FEBS LETT, V211, P160, DOI 10.1016/0014-5793(87)81428-X; DRABKINHA, 1992, GENE CHROMOSOME CANC, V5, P67; DRYJA TP, 1984, NEW ENGL J MED, V310, P550, DOI 10.1056/NEJM198403013100902; FALOR WH, 1985, CANCER GENET CYTOGEN, V16, P175, DOI 10.1016/0165-4608(85)90012-3; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUKUMOTO H, 1988, P NATL ACAD SCI USA, V85, P5434, DOI 10.1073/pnas.85.15.5434; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GARCIA DK, 1991, CYTOGENET CELL GENET, V58, P225; GEIHL D, 1989, CYTOGENET CELL GENET, V51, P1001; GORADIA TM, 1991, GENOMICS, V10, P748, DOI 10.1016/0888-7543(91)90459-R; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; HEPPELLPARTON AC, 1992, GENE CHROMOSOME CANC, V4, P228, DOI 10.1002/gcc.2870040307; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; JOHNSON BE, 1989, J NATL CANCER I, V81, P1223, DOI 10.1093/jnci/81.16.1223; JOHNSON BE, 1988, J CLIN INVEST, V82, P502, DOI 10.1172/JCI113624; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1989, CANCER RES, V49, P651; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEWIS W H, 1988, Genomics, V3, P25, DOI 10.1016/0888-7543(88)90154-1; MULERIS M, 1987, INT J CANCER, V39, P595, DOI 10.1002/ijc.2910390509; NAYLOR S, 1991, CYTOGENET CELL GENET, V58, P170, DOI 10.1159/000133163; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUTHERLAND GR, 1988, AM J HUM GENET, V43, P331; WATERS JJ, 1988, CANCER GENET CYTOGEN, V6, P119; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; YOKOTA J, 1989, CANCER RES, V49, P3598; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0; ZHANG R, 1989, CANCER RES, V49, P444	40	116	124	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1721	1729						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8390035				2022-12-28	WOS:A1993LG68200002
J	KATZAV, S				KATZAV, S			SINGLE-POINT MUTATIONS IN THE SH2 DOMAIN IMPAIR THE TRANSFORMING POTENTIAL OF VAV AND FAIL TO ACTIVATE PROTO-VAV	ONCOGENE			English	Article							CYTOPLASMIC SIGNALING PROTEINS; TYROSINE KINASE; V-FPS; GENE-PRODUCT; SRC GENE; PROTOONCOGENE; MUTAGENESIS; DELETIONS; P60C-SRC; CELLS	The importance of an intact Src Homology 2 (SH2) domain for transformation by members of the tyrosine kinase family, including v-src, c-src, c-abl, fps and fyn is well documented. To determine the role of the SH2 domain in transformation by a protein which is not a member of this family, we employed site directed mutagenesis to change four highly conserved residues in the SH2 domain of the vav oncogene and the vav proto-oncogene (proto-vav). Proto-vav encodes a protein that contains one SH2 domain and two Src Homology 3 (SH3) domains, in addition to a number of other motifs usually found in transcriptional factors and guanine nucleotide exchange factors. Substitution of arginine 629 to glycine (R629G) and arginine 647 to leucine (R647L) in vav did not impair its transforming potential in NIH3T3 fibroblasts. By contrast, substitutions of tryptophan 622 to arginine (W622R) and glycine 642 to valine (G642V) in the vav SH2, greatly reduced its transforming potential. Similar point mutations introduced in the SH2 domain of proto-vav did not activate the transforming potential of the normal gene. Interestingly, although all the vav SH2 mutant proteins were constitutively phosphorylated on tyrosine when expressed in NIH3T3 cells, they fail to bind to a phosphorylated epidermal growth factor receptor (EGFR), regardless of their transforming potential.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA	St Jude Children's Research Hospital					NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; BOGUSKI MS, 1992, NATURE, V358, P113, DOI 10.1038/358113a0; BOOKER GW, 1992, NATURE, V358, P685; BUESTLO XR, 1992, SCIENCE, V256, P1196; BUESTLO XR, 1992, NATURE, V356, P69; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DECLUE JE, 1987, P NATL ACAD SCI USA, V84, P9064, DOI 10.1073/pnas.84.24.9064; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; GALLAND F, 1992, ONCOGENE, V7, P585; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8952; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAMPS MP, 1988, ONCOGENE, V2, P305; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KATZAV S, 1992, BRIT J HAEMATOL, V81, P141, DOI 10.1111/j.1365-2141.1992.tb08198.x; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEVINSON AD, 1978, CELL, V15, P561, DOI 10.1016/0092-8674(78)90024-7; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PARSONS JT, 1989, CURR TOP MICROBIOL I, V147, P97; ROSENBERG NE, 1988, ADV VIRUS RES, V54, P39; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SEMBA K, 1990, MOL CELL BIOL, V10, P3095, DOI 10.1128/MCB.10.6.3095; ULRICH A, 1990, CELL, V61, P203; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989	40	48	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1757	1763						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510922				2022-12-28	WOS:A1993LG68200006
J	CARDER, P; WYLLIE, AH; PURDIE, CA; MORRIS, RG; WHITE, S; PIRIS, J; BIRD, CC				CARDER, P; WYLLIE, AH; PURDIE, CA; MORRIS, RG; WHITE, S; PIRIS, J; BIRD, CC			STABILIZED P53 FACILITATES ANEUPLOID CLONAL DIVERGENCE IN COLORECTAL-CANCER	ONCOGENE			English	Note							MUTATIONS; TUMORS; TUMORIGENESIS; EXPRESSION; ADENOMAS; MODEL	Mutations in the p53 tumour suppressor gene are amongst the most frequent genetic abnormalities acquired in tumours. Recent studies in vitro suggest that mutant p53 destabilises the genome and facilitates development of aneuploidy. Here, in a study of 83 colorectal carcinomas, we demonstrate that alterations in p53 (detected by immunocytochemical stabilisation) precede and apparently facilitate divergence of aneuploid sub-clones. Aneuploidy in these tumours (but not those with normal p53) is predominantly in the subtetraploid range, suggesting that endoreduplication is important in its origin. This association with a specific phase of carcinoma progression is not shared by other commonly acquired genetic abnormalities in these tumours. These observations highlight the critical role of p53 in the regulation of abnormal chromosome replication and afford an explanation for the association between p53 abnormalities, aneuploidy and biological aggression in cancer.	UNIV EDINBURGH,SCH MED,DEPT PATHOL,CANCER RES CAMPAIGN LABS,TEVIOT PL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; GEN INFIRM,DEPT HISTOPATHOL,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND	University of Edinburgh; Leeds General Infirmary				Purdie, Colin/0000-0002-1258-4010				AHSTONRICKARDT PG, 1991, ONCOGENE, V6, P1881; BAKER SJ, 1990, CANCER RES, V50, P7717; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BODNER SM, 1992, ONCOGENE, V7, P743; CUNNINGHAM J, 1992, CANCER RES, V52, P1974; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRIEDLANDER ML, 1984, J CLIN PATHOL, V37, P961, DOI 10.1136/jcp.37.9.961; FRITSCHE M, 1993, ONCOGENE, V8, P307; GIARETTI W, 1991, CANCER, V67, P1921, DOI 10.1002/1097-0142(19910401)67:7<1921::AID-CNCR2820670717>3.0.CO;2-X; HIDDEMANN W, 1986, CANCER, V58, P258, DOI 10.1002/1097-0142(19860715)58:2<258::AID-CNCR2820580210>3.0.CO;2-H; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JARVIS LR, 1987, J CLIN PATHOL, V40, P26, DOI 10.1136/jcp.40.1.26; JASS JR, 1989, J CLIN PATHOL, V42, P254, DOI 10.1136/jcp.42.3.254; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3965; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PURDIE CA, 1991, AM J PATHOL, V138, P807; QUIRKE P, 1986, BRIT J CANCER, V53, P477, DOI 10.1038/bjc.1986.75; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SHACKNEY SE, 1989, CANCER RES, V49, P3344; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; STARZYNSKA T, 1992, BRIT J CANCER, V66, P558, DOI 10.1038/bjc.1992.314; VANDENINGH HF, 1985, CANCER RES, V45, P3392; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WYNFORDTHOMAS D, 1992, J PATHOL, V166, P329, DOI 10.1002/path.1711660402; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	30	137	137	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1397	1401						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479757				2022-12-28	WOS:A1993KY32800035
J	GALLAND, F; KARAMYSHEVA, A; PEBUSQUE, MJ; BORG, JP; ROTTAPEL, R; DUBREUIL, P; ROSNET, O; BIRNBAUM, D				GALLAND, F; KARAMYSHEVA, A; PEBUSQUE, MJ; BORG, JP; ROTTAPEL, R; DUBREUIL, P; ROSNET, O; BIRNBAUM, D			THE FLT4 GENE ENCODES A TRANSMEMBRANE TYROSINE KINASE RELATED TO THE VASCULAR ENDOTHELIAL GROWTH-FACTOR RECEPTOR	ONCOGENE			English	Article							LARGE CELL LYMPHOMA; PERMEABILITY FACTOR; FMS; MITOGEN; PROTEIN; T(2-5)(P23-Q35); TRANSLOCATION; LOCALIZATION; TRANSDUCTION; DOMAINS	Three receptor tyrosine kinases, FLT1, FLK1 and FLT4, contain seven immunoglobin-like domains in their extracellular region and are strongly related by sequence similarities to each other and, to a lesser degree, to the class III receptors CSF1R/FMS, PDGFR, SLFR/KIT and FLT3/FLK2. They constitute a family of receptors putatively involved in the growth regulation of endothelial cells. We describe here the structure and pattern of expression of the human FLT4 gene. Two FLT4 transcripts of 5.8 and 4.5 kb are expressed in the human placenta and several hematopoietic celt lines. In mouse, a 5.8-kb transcript is expressed in a variety of tissues. A translational product 1298 amino acids in length is predicted to be encoded by the largest open reading frame. The FLT4 protein, when transiently expressed in Cos-7 cells and immunoprecipitated with a FLT4-specific rabbit immune serum, has an apparent molecular weight of 170 kDa.	INSERM, U119, ONCOL MOLEC LAB, 27 BD LEI ROURE, F-13009 MARSEILLE, FRANCE; CANC RES CTR, INST CARCINOGENESIS, MOSCOW 115478, RUSSIA; INSERM, U119, HEMATOL MOLEC LAB, F-13258 MARSEILLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)			Dubreuil, Patrice/V-4816-2019; Borg, Jean-Paul/AAX-8096-2020; Rosnet, Olivier/G-3536-2013; dubreuil, patrice/F-5346-2011	Dubreuil, Patrice/0000-0003-1155-1150; Borg, Jean-Paul/0000-0001-8418-3382; dubreuil, patrice/0000-0003-1155-1150; Rottapel, Robert/0000-0002-6024-5558; Birnbaum, Daniel/0000-0001-7920-9883; Rosnet, Olivier/0000-0002-3020-910X				ANDRE C, 1992, ONCOGENE, V7, P685; APRELIKOVA O, 1992, CANCER RES, V52, P746; BENZLEMOINE E, 1988, BLOOD, V72, P1045; BREIER G, 1992, DEVELOPMENT, V114, P521; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GALLAND F, 1992, GENOMICS, V13, P475, DOI 10.1016/0888-7543(92)90277-Y; GALLAND F, 1990, BIOCHIMIE, V72, P759, DOI 10.1016/0300-9084(90)90161-9; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEBEAU MM, 1989, LEUKEMIA, V3, P866; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAROC N, 1993, IN PRESS ONCOGENE; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; NOGUCHI T, 1991, Technique (Philadelphia), V3, P33; OELRICHS RB, 1993, ONCOGENE, V8, P11; PAJUSOLA K, 1992, CANCER RES, V52, P5738; RIMOKH R, 1989, BRIT J HAEMATOL, V71, P31, DOI 10.1111/j.1365-2141.1989.tb06270.x; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROSNET O, 1991, ONCOGENE, V6, P1641; ROSNET O, 1991, GENOMICS, V9, P380, DOI 10.1016/0888-7543(91)90270-O; ROSNET O, 1993, ONCOGENE, V8, P173; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; SARZANI R, 1992, BIOCHEM BIOPH RES CO, V186, P706, DOI 10.1016/0006-291X(92)90804-T; SATOH H, 1987, JPN J CANCER RES, V78, P772; SHIBUYA M, 1990, ONCOGENE, V5, P519; TERMAN BI, 1991, ONCOGENE, V6, P1677; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WARRINGTON JA, 1992, GENOMICS, V13, P803, DOI 10.1016/0888-7543(92)90156-M; WASMUTH JJ, 1991, CYTOGENET CELL GENET, V58, P261, DOI 10.1159/000133165; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	37	140	165	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1233	1240						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8386825				2022-12-28	WOS:A1993KY32800014
J	DEGROOT, RP; AUWERX, J; BOUROUIS, M; SASSONECORSI, P				DEGROOT, RP; AUWERX, J; BOUROUIS, M; SASSONECORSI, P			NEGATIVE REGULATION OF JUN/AP-1 - CONSERVED FUNCTION OF GLYCOGEN-SYNTHASE KINASE-3 AND THE DROSOPHILA KINASE SHAGGY	ONCOGENE			English	Article							DNA-BINDING ACTIVITY; JUN PROTO-ONCOGENE; TRANSCRIPTION FACTOR AP-1; CELLULAR FOS PROTEINS; C-JUN; MAMMALIAN-CELLS; GENE FAMILY; V-JUN; PHOSPHORYLATION; EXPRESSION	Transcription factor AP-1 is constituted by the products of the various fos and jun genes. AP-1 activity is modulated by second messengers and appears to involve post-translational modifications of Fos and Jun. It has been shown that phosphorylation mediated by glycogen synthase kinase 3 (GSK-3) is involved in negative regulation of c-Jun DNA-binding function in vitro. Here we show that two forms of GSK-3 function to decrease the DNA-binding activity as well as the transcriptional activation elicited by.c-Jun in vivo. Similarly, the other members of the jun family, JunB, JunD and v-Jun, are negatively regulated by GSK-3 in vivo, although to a slightly lesser extent than c-Jun. We have also tested the proteins encoded by the Drosophila shaggy gene (sgg) in our assays. The sgg proteins share homology with the mammalian GSK-3 and appear to be important for the normal segregation of bristle precursor cells in the imaginal epithelium in Drosophila. Here we show that the products of the sgg gene can also function as negative regulators of Jun/AP-1.	FAC MED STRASBOURG,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,UNITE 184,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE; CATHOLIC UNIV LEUVEN,DEPT DEV BIOL,EXPTL MED & ENDOCRINOL LAB,B-3000 LOUVAIN,BELGIUM	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; KU Leuven				Auwerx, Johan/0000-0002-5065-5393				ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUWERX J, 1990, NUCLEIC ACIDS RES, V18, P221, DOI 10.1093/nar/18.2.221; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOUROUIS M, 1989, NATURE, V341, P442, DOI 10.1038/341442a0; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BUSCH SJ, 1990, ONCOGENE, V5, P1549; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1984, CELL, V36, P259; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOEFFLER WK, 1992, IN PRESS EMBO J; HUGHES K, 1991, IN PRESS ADV PROT PH, V6; Ingham PW, 1991, CURR OPIN GENET DEV, V1, P261, DOI 10.1016/S0959-437X(05)80080-2; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAMPH WW, 1988, NATURE, V334, P592; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MELLSTROM B, 1991, ONCOGENE, V6, P1959; MULLER R, 1987, ONCOGENE RES, V2, P19; NARANJO JR, 1991, ONCOGENE, V6, P223; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; PERKINS KK, 1990, GENE DEV, V4, P822, DOI 10.1101/gad.4.5.822; PERRIMON N, 1989, DEV BIOL, V135, P287, DOI 10.1016/0012-1606(89)90180-2; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SIEGFRIED E, 1990, TRENDS GENET, V6, P357, DOI 10.1016/0168-9525(90)90277-D; SIMPSON P, 1989, DEVELOPMENT, V106, P57; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; Woodgett J R, 1990, Semin Cancer Biol, V1, P389; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZHANG K, 1990, P NATL ACAD SCI USA, V87, P6281, DOI 10.1073/pnas.87.16.6281	54	108	108	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					841	847						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8384355				2022-12-28	WOS:A1993KT22000004
J	BAE, SC; YAMAGUCHIIWAI, Y; OGAWA, E; MARUYAMA, M; INUZUKA, M; KAGOSHIMA, H; SHIGESADA, K; SATAKE, M; ITO, Y				BAE, SC; YAMAGUCHIIWAI, Y; OGAWA, E; MARUYAMA, M; INUZUKA, M; KAGOSHIMA, H; SHIGESADA, K; SATAKE, M; ITO, Y			ISOLATION OF PEBP2-ALPHA-B CDNA REPRESENTING THE MOUSE HOMOLOG OF HUMAN ACUTE MYELOID-LEUKEMIA GENE, AML1	ONCOGENE			English	Article							RECEPTOR ALPHA-GENE; HA-RAS ONCOGENE; POLYOMAVIRUS ENHANCER; TRANSCRIPTION FACTOR; PROTEIN; TRANSLOCATIONS; EXPRESSION; BINDING; DOMAIN; CELLS	Breakpoints of the t(8;21) chromosome translocation in acute myeloid leukemia are clustered within the human gene, AML1, located on chromosome 21 [Miyoshi, H., Shimizu, K., Maseki, N., Kaneko, Y. & Ohki, M. (1991). Proc. Natl. Acad. Sci. USA, 88, 10431-104341. The product of AML1 has a region about 130 amino acids long that is highly homologous to the Drosophila segmentation gene runt (runt homology region). The cDNA isolated from mouse fibroblasts encoding the alpha-subunit of polyomavirus enhancer binding protein 2 (PEBP2/PEA2) revealed that it also has a runt homology region (E. Ogawa et al., submitted). In this study, a different cDNA clone presumed to represent the mouse homolog of human AML1 (PEBP2alpha(B) was isolated from a cDNA library derived from B cells. The deduced amino acid sequence of PEBP2alphaB is 99% identical to that of AML1 for the first 241 residues, including the runt homology region, though their sequences diverge thereafter. On the other hand, PEBP2alphaB and PEBP2alpha share only 92% and 82% homologies at the amino acid and nucleotide levels respectively, even for the runt homology region, indicating that these proteins are encoded by distinct genes. While PEBP2alpha is highly expressed in T-cell lines but not in most of the B-cell lines and functions as an activator of T-cell-specific genes, PEBP2alphaB is expressed in both types of cells. A possible functional relationship between PEBP2alpha and PEBP2alphaB is discussed in relation to leukemogenic potential of AML1.	KYOTO UNIV,INST VIRUS RES,DEPT VIRAL ONCOL,SHOGOIN,SAKYO KU,KYOTO 606,JAPAN; KYOTO UNIV,INST VIRUS RES,DEPT GENET & MOLEC BIOL,KYOTO 606,JAPAN	Kyoto University; Kyoto University								CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; FURUKAWA K, 1990, CELL GROWTH DIFFER, V1, P135; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KIM KJ, 1979, J IMMUNOL, V122, P549; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; LEIDEN JM, 1992, IMMUNOL TODAY, V13, P22, DOI 10.1016/0167-5699(92)90200-Q; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MOORE GE, 1966, JNCI-J NATL CANCER I, V36, P405; OLD LJ, 1965, CANCER RES, V25, P813; PAIGE CJ, 1978, J IMMUNOL, V121, P641; PIETTE J, 1987, EMBO J, V6, P1331, DOI 10.1002/j.1460-2075.1987.tb02372.x; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RALPH P, 1973, J NATL CANCER I, V51, P883, DOI 10.1093/jnci/51.3.883; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V14, P4767; SATAKE M, 1992, JPN J CANCER RES, V83, P714, DOI 10.1111/j.1349-7006.1992.tb01971.x; SATAKE M, 1988, ONCOGENE, V3, P69; SATAKE M, 1989, J VIROL, V63, P3669, DOI 10.1128/JVI.63.9.3669-3677.1989; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656	26	268	274	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					809	814						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437866				2022-12-28	WOS:A1993KN00800036
J	DIBATTISTE, D; GOLUBIC, M; STACEY, D; WOLFMAN, A				DIBATTISTE, D; GOLUBIC, M; STACEY, D; WOLFMAN, A			DIFFERENCES IN THE INTERACTION OF P21(C-HA-RAS)-GMP-PNP WITH FULL-LENGTH NEUROFIBROMIN AND GTPASE-ACTIVATING PROTEIN	ONCOGENE			English	Article							RAS P21; TYPE-1 GENE; GROWTH-FACTOR; H-RAS; GAP; PRODUCT; STIMULATION; BINDING; IDENTIFICATION; PURIFICATION	Neurofibromin, the product of the neurofibromatosis type 1 gene, was found to form a stable complex with immobilized p21c-Ha-ras-GMP-PNP (a non-hydrolyzable GTP analog). This complex, detectable as early as 30 min after addition of crude brain extract, is extremely stable, with less than 50% dissociating after 5 h at 4-degrees-C. We interpret this to suggest that the dissociation of full-length neurofibromin from p21c-Ha-ras-GMP-PNP is tightly linked to the hydrolysis of GTP to GDP. Failure to remove a significant proportion of the bound neurofibromin in the presence of EDTA and GDP implies that the binding of neurofibromin to p21c-Ha-ras-GMP-PNP results in the ras protein becoming resistant to guanine nucleotide exchange. Under conditions in which neurofibromin quantitatively binds to p21c-Ha-ras-GMP-PNP, we were unable to detect a complex between p21c-Ha-ras and GAP (GTPase-activating protein). The failure to detect GAP binding to immobilized p21c-Ha-ras-GMP-PNP cannot be explained by the known differences in affinities of the GAP-related domain of neurofibromin and GAP for p21c-Ha-ras-GTP. GAP is, however, able to interact biochemically with immobilized p21c-Ha-ras suggesting a difference in the interaction between GAP and neurofibromin with p21c-Ha-ras-GMP-PNP.	CLEVELAND CLIN FDN,DEPT VASC CELL BIOL & ATHEROSCLEROSIS,9500 EUCLID AVE,CLEVELAND,OH 44195; CLEVELAND CLIN FDN,DEPT MOLEC BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation; Cleveland Clinic Foundation					NCI NIH HHS [CA53436, CA48662] Funding Source: Medline; NIGMS NIH HHS [GM41220] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GOLUBIC M, 1992, ONCOGENE, V7, P2151; HALL A, 1986, J BIOL CHEM, V261, P963; HATTORI S, 1991, BIOCHEM BIOPH RES CO, V177, P83, DOI 10.1016/0006-291X(91)91951-8; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; KAPLAN S, 1991, J BIOL CHEM, V266, P18934; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHLICHTING I, 1989, P NATL ACAD SCI USA, V86, P7687, DOI 10.1073/pnas.86.20.7687; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WOLFMAN A, 1989, J BIOL CHEM, V264, P10820; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	29	22	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					637	643						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437847				2022-12-28	WOS:A1993KN00800014
J	LARUE, L; DOUGHERTY, N; BRADL, M; MINTZ, B				LARUE, L; DOUGHERTY, N; BRADL, M; MINTZ, B			MELANOCYTE CULTURE LINES FROM TYR-SV40E TRANSGENIC MICE - MODELS FOR THE MOLECULAR GENETIC EVOLUTION OF MALIGNANT-MELANOMA	ONCOGENE			English	Article							MURINE MELANOCYTES; TUMOR PROGRESSION; PHORBOL ESTER; GROWTH; 12-O-TETRADECANOYLPHORBOL-13-ACETATE; TRANSFORMATION; REQUIREMENT; REPLICATION; MECHANISMS; EXPRESSION	Transgenic Tyr-SV40E mice previously produced on the C57BL/6 inbred-strain background, with SV40 oncogenic sequences specifically expressed in pigment cells, are predisposed to melanoma [Bradl, M., Klein-Szanto, A., Porter, S. & Mintz, B. (1991). Proc. Natl. Acad. Sci. USA, 88, 164-1681. Separate lines of these animals differ genetically only in the number of copies and chromosomal site of integration of the transgene. Skin melanocytes from young mice with no apparent skin lesions were established in continuous culture from hemizygous donors with low, medium and high numbers of transgene copies, and from a homozygous offspring of the low-copy mouse line. The standard culture conditions enable C57BL/6 wild-type melanocytes to become stably immortalized without transformation. The transgenic cell lines all changed over time in an orderly progression. However, with greater numbers of transgene copies, the cells more rapidly displayed shorter doubling times, increased anchorage independence, reduced serum and growth factor requirements, decreased tyrosinase expression and melanin content, increased oncogene expression, and capacity to form malignant melanomas when tested by grafting. Melanocytes with the lowest number of transgene copies were of special interest. They grew more rapidly than the wild-type cells from the outset, but did not become tumorigenic until an apparently small number of still-unknown genetic changes had spontaneously occurred, or until the number of transgene copies was increased slightly by homozygosity. In contrast to the hemizygous low-copy cells, the homozygous counter-parts underwent striking and rapid transformational changes and early conversion to malignancy. Thus such low-copy transgenic melanocyte lines afford an exceptional opportunity for molecular analysis of somatic genetic evolution toward malignant melanoma.	FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111	Fox Chase Cancer Center			Larue, Lionel/I-6532-2016; Larue, Lionel/F-7355-2013	Bradl, Monika/0000-0003-2239-1586	NCI NIH HHS [CA-06927, CA-42560] Funding Source: Medline; NCRR NIH HHS [RR-05539] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, R35CA042560] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ALBINO AP, 1988, ADV PIGMENT CELL RES, P361; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BENNETT DC, 1989, ENVIRON HEALTH PERSP, V80, P49, DOI 10.2307/3430731; Berenblum I, 1941, CANCER RES, V1, P807; BRADL M, 1991, P NATL ACAD SCI USA, V88, P164, DOI 10.1073/pnas.88.1.164; BRADL M, 1991, P NATL ACAD SCI USA, V88, P6447, DOI 10.1073/pnas.88.15.6447; CHENEVIXTRENCH G, 1990, ONCOGENE, V5, P1187; DOOLEY TP, 1988, ONCOGENE, V3, P531; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; GERARD RD, 1985, MOL CELL BIOL, V5, P3231, DOI 10.1128/MCB.5.11.3231; HALABAN R, 1986, J INVEST DERMATOL, V87, P95, DOI 10.1111/1523-1747.ep12523594; HERLYN M, 1987, LAB INVEST, V56, P461; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; JAMBROSIC J, 1989, INT J CANCER, V44, P1117, DOI 10.1002/ijc.2910440630; JIMBOW K, 1975, J CELL BIOL, V66, P663, DOI 10.1083/jcb.66.3.663; KATH R, 1989, ANTICANCER RES, V9, P865; KLEINSZANTO A, 1991, P NATL ACAD SCI USA, V88, P169, DOI 10.1073/pnas.88.1.169; LARUE L, 1992, P NATL ACAD SCI USA, V89, P9534, DOI 10.1073/pnas.89.20.9534; McKusick V. A., 1986, MENDELIAN INHERITANC; MELBER K, 1989, CANCER RES, V49, P3650; Mintz B, 1981, Adv Cancer Res, V34, P211, DOI 10.1016/S0065-230X(08)60243-2; MOORE M, 1992, J VIROL, V66, P641, DOI 10.1128/JVI.66.2.641-649.1992; MULLER G, 1988, EMBO J, V7, P2723, DOI 10.1002/j.1460-2075.1988.tb03126.x; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; Romerdahl C A, 1989, Cancer Commun, V1, P209; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; TAMURA A, 1987, IN VITRO CELL DEV B, V23, P519; TERAO M, 1989, BIOCHEM BIOPH RES CO, V159, P848, DOI 10.1016/0006-291X(89)90072-7; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WILSON RE, 1989, CANCER RES, V49, P711	35	22	23	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					523	531						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8382353				2022-12-28	WOS:A1993KN00800001
J	MODAK, SP; PRINCIPAUD, E; SPOHR, G				MODAK, SP; PRINCIPAUD, E; SPOHR, G			REGULATION OF XENOPUS C-MYC PROMOTER ACTIVITY IN OOCYTES AND EMBRYOS	ONCOGENE			English	Article							E2F TRANSCRIPTION FACTOR; TRANS-ACTIVATION; BINDING PROTEIN; CELL-DIVISION; MESSENGER-RNA; EXPRESSION; GENE; ELEMENT; ONCOGENE; LAEVIS	We have studied the regulation of transcription of the Xenopus c-myc I gene in oocytes and embryos. Various 5' and internal deletions of a 1310-bp-long c-myc I promoter fragment have been ligated upstream of the chloramphenicol acetyl transferase (CAT) reporter gene and microinjected into oocytes and fertilized eggs. Activity was determined by CAT assay and primer extension. The c-myc promoter drives transcription very efficiently, and a truncated promoter - 158/+ 46 essentially retains full activity. This region contains an overlapping E2F/SP1 site and two tandem Sp1 sites homologous to those found in the c-myc gene of mouse. Internal deletions show that both elements are equally active in oocytes in driving the expression of CAT. A germinal vesicle extract contains a DNA-binding activity specific for an Sp1 consensus sequence but not the E2F site. The data suggest that the high transcription level of the endogenous c-myc gene in Xenopus oocytes is mediated by Spl or a related transcription factor. In embryos a different mechanism emerges and the functional role of the Spl binding sites appears to be less important.	UNIV GENEVA,DEPT BIOL CELLULAIRE,30 QUAI ERNEST ANSERMET,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva								ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; BENHATTAR J, 1989, NUCLEIC ACIDS RES, V17, P10179, DOI 10.1093/nar/17.24.10179; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V337, P664; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; GODEAU F, 1986, EMBO J, V5, P3571, DOI 10.1002/j.1460-2075.1986.tb04684.x; Gurdon J. B., 1986, MICROINJECTION ORGAN, P269; GURDON JB, 1983, METHOD ENZYMOL, V101, P370; GUSSE M, 1989, MOL CELL BIOL, V9, P5395, DOI 10.1128/MCB.9.12.5395; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; KINNIBURGH AJ, 1989, NUCLEIC ACIDS RES, V17, P7771, DOI 10.1093/nar/17.19.7771; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MCKNIGHT SL, 1984, CELL, V37, P253, DOI 10.1016/0092-8674(84)90321-0; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NISHIKURA K, 1986, MOL CELL BIOL, V6, P4093, DOI 10.1128/MCB.6.11.4093; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; PRINCIPAUD E, 1991, NUCLEIC ACIDS RES, V19, P3081, DOI 10.1093/nar/19.11.3081; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; SAMBROOK I, 1989, MOL CLONING LABORATO; SCHNEIDER R, 1986, NUCLEIC ACIDS RES, V14, P1303, DOI 10.1093/nar/14.3.1303; SPENCER CA, 1990, ADV CANCER RES, V56, P1; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; VRIZ S, 1989, EMBO J, V8, P4091, DOI 10.1002/j.1460-2075.1989.tb08593.x; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	41	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					645	654						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437848				2022-12-28	WOS:A1993KN00800015
J	YAMAKAWA, K; TAKAHASHI, T; HORIO, Y; MURATA, Y; TAKAHASHI, E; HIBI, K; YOKOYAMA, S; UEDA, R; TAKAHASHI, T; NAKAMURA, Y				YAMAKAWA, K; TAKAHASHI, T; HORIO, Y; MURATA, Y; TAKAHASHI, E; HIBI, K; YOKOYAMA, S; UEDA, R; TAKAHASHI, T; NAKAMURA, Y			FREQUENT HOMOZYGOUS DELETIONS IN LUNG-CANCER CELL-LINES DETECTED BY A DNA MARKER LOCATED AT 3P21.3-P22	ONCOGENE			English	Article							FRAGMENT-LENGTH-POLYMORPHISM; K-RAS ONCOGENE; SHORT ARM; HUMAN CHROMOSOME-3; PATIENTS TUMORS; CARCINOMA; HETEROZYGOSITY; ADENOCARCINOMA; GENE; EXPRESSION	Frequent allelic losses of chromosome 3p in lung cancer have been reported in a number of studies, and we previously demonstrated that 3p21.3 is one of the common regions of deletion in lung cancers and renal cell carcinomas. To further define a region containing the putative tumor suppressor gene, we performed Southern-blot analysis of 26 small cell lung cancer (SCLC) cell lines and ten non-small cell lung cancer (NSCLC) cell lines with 40 cosmid markers located at 3p21.3-p22. One marker detected homozygous deletions of four SCLC cell fines and one NSCLC cell line. None of the other markers revealed homozygous deletions or chromosomal rearrangements in these cell lines. The region of homozygous deletion described here is estimated to consist of less than 1 megabase of DNA, and it is very likely to contain at least one of the tumor suppressor genes associated with carcinogenesis of lung cancer and, possibly, renal cell carcinoma.	JAPANESE FDN CANC RES,INST CANC,DIV BIOCHEM,1-37-1 KAMI IKEBUKURO,TOSHIMA KU,TOKYO 170,JAPAN; AICHI CANC CTR,CHEMOTHERAPY LABS,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,IMMUNOL LABS,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; NATL INST RADIOL SCI,DIV GENET,CHIBA 260,JAPAN	Japanese Foundation for Cancer Research; Aichi Cancer Center; Aichi Cancer Center; National Institutes for Quantum Science & Technology			Takahashi, Takashi/I-7262-2014; Yamakawa, Kazuhiro/N-5050-2015	Takahashi, Takashi/0000-0003-0615-7001; Yamakawa, Kazuhiro/0000-0002-1478-4390; Horio, Yoshitsugu/0000-0003-4661-6399				BERGERHEIM U, 1989, CANCER RES, V49, P1390; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; EHLEN T, 1990, ONCOGENE, V5, P219; GEMMA A, 1988, CANCER RES, V48, P6025; GERBER MJ, 1986, CYTOGENET CELL GENET, V42, P72, DOI 10.1159/000132254; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HIBI K, 1992, ONCOGENE, V7, P445; HIBI K, 1991, ONCOGENE, V6, P2291; JOHNSON BE, 1988, CANCER RES, V48, P5163; JOHNSON BE, 1988, J CLIN INVEST, V82, P502, DOI 10.1172/JCI113624; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KURZROCK R, 1986, CANCER RES, V46, P1530; LATIF F, 1992, CANCER RES, V52, P1451; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; MORI N, 1989, CANCER RES, V49, P5130; MORITA R, 1991, CANCER RES, V51, P820; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; RABBITTS P, 1989, GENE CHROMOSOME CANC, V1, P95, DOI 10.1002/gcc.2870010115; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; RODENHUIS S, 1988, CANCER RES, V48, P5738; SATO T, 1991, CANCER RES, V51, P5794; TAKAHASHI T, 1989, CANCER RES, V49, P2683; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; TAKASHI E, 1992, IN PRESS GENOMICS, V13; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; TRENT JM, 1985, CANCER GENET CYTOGEN, V14, P153, DOI 10.1016/0165-4608(85)90226-2; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WHANGPENG J, 1984, CANCER GENET CYTOGEN, V11, P91, DOI 10.1016/0165-4608(84)90102-X; YAMAKAWA K, 1991, GENOMICS, V9, P536, DOI 10.1016/0888-7543(91)90421-A; YAMAKAWA K, 1991, CANCER RES, V51, P4707; YAMAKAWA K, 1991, GENOMICS, V11, P565, DOI 10.1016/0888-7543(91)90063-K; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1989, CANCER RES, V49, P3598; YOKOYAMA S, 1992, CANCER RES, V52, P873; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	41	88	90	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					327	330						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8381220				2022-12-28	WOS:A1993KN00600011
J	Brockmann, D; Schafer, D; Kirch, HC; Esche, H				Brockmann, D; Schafer, D; Kirch, HC; Esche, H			Repression of c-Jun-induced mouse major histocompatibility class I promoter (H-2K(b)) activity by the Adenovirus type 12-unique 52R E1A protein	ONCOGENE			English	Article						adenovirus type 12; E1A; MHC class I; oncogenicity; transformation	NF-KAPPA-B; TRANSFORMED RAT-CELLS; EMBRYONAL CARCINOMA-CELLS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; GEL-ELECTROPHORESIS; NEGATIVE REGULATION; RESPONSE ELEMENT; FACTOR BINDING; AP-1 ACTIVITY	Down-regulation of major histocompatibility (MHC) class I gene expression by protein products of the early region 1A (E1A), which might allow transformed cells to escape the host immune system, is discussed as one cause for the oncogenicity of Adenovirus (Ad) subtype 12-transformed cells, The MHC class I promoter is activated through several cellular transcription factors among them AP-1, whose target sequences are located in the enhancers A and B, and NF kappa B, In this report we present evidence that the Ad12-unique 52R E1A protein inhibits c-Jun-induced activation of MHC class I gene expression, Repression occurs through both AP-1 recognition sequences with the AP-1 binding site of Enhancer A, which can be bound by c-Jun dimers irt vitro, being the main target for c-Jun activation as well as 52R-mediated down-regulation, Furthermore our data revealed that both promoter elements of Enhancer A, the AP-1 and NF kappa B binding sites, are necessary for full promoter activity, As NF kappa B is down-regulated by the 266R protein of Ad12 E1A our results suggest a model in which two Ad12 E1A proteins co-operate in the repression of MHC class I gene expression.			Brockmann, D (corresponding author), UNIV ESSEN GESAMTHSCH, SCH MED, INST MOL BIOL CANC RES, HUFELANDSTR 55, D-45122 ESSEN, GERMANY.							ACKRILL AM, 1988, ONCOGENE, V3, P483; ACKRILL AM, 1989, VIROLOGY, V172, P643, DOI 10.1016/0042-6822(89)90207-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKMANN D, 1994, VIROLOGY, V198, P717, DOI 10.1006/viro.1994.1085; BROCKMANN D, 1995, J BIOL CHEM, V270, P10754, DOI 10.1074/jbc.270.18.10754; BROCKMANN D, 1995, MOL REPERTOIRE ADENO, V3, P81; BYRD PJ, 1988, ONCOGENE, V2, P477; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FLANAGAN JR, 1991, P NATL ACAD SCI USA, V88, P3145, DOI 10.1073/pnas.88.8.3145; FLINT SJ, 1981, STRUCTURE GENOMIC OR, P383; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRIEDMAN DJ, 1988, VIROLOGY, V165, P303, DOI 10.1016/0042-6822(88)90689-7; GALLIMORE PH, 1974, J MOL BIOL, V89, P49, DOI 10.1016/0022-2836(74)90162-4; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GE RW, 1992, J VIROL, V66, P6969, DOI 10.1128/JVI.66.12.6969-6978.1992; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; ISRAEL A, 1989, NUCLEIC ACIDS RES, V17, P5245, DOI 10.1093/nar/17.13.5245; JELINEK T, 1994, J VIROL, V68, P888, DOI 10.1128/JVI.68.2.888-896.1994; JOCHEMSEN H, 1982, VIROLOGY, V122, P15, DOI 10.1016/0042-6822(82)90373-7; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KITABAYASHI I, 1991, NUCLEIC ACIDS RES, V19, P649, DOI 10.1093/nar/19.3.649; KORBER B, 1988, SCIENCE, V239, P1302, DOI 10.1126/science.3125612; KRALLI A, 1992, J VIROL, V66, P6979, DOI 10.1128/JVI.66.12.6979-6988.1992; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LIU XH, 1994, ONCOGENE, V9, P2183; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Maniatis T, 1989, MOL CLONING; MEIJER I, 1992, CELL IMMUNOL, V145, P56, DOI 10.1016/0008-8749(92)90312-D; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PROFFITT JL, 1994, NUCLEIC ACIDS RES, V22, P4779, DOI 10.1093/nar/22.22.4779; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHOUTEN GJ, 1995, EMBO J, V14, P1498, DOI 10.1002/j.1460-2075.1995.tb07136.x; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SEGARS JH, 1993, MOL CELL BIOL, V13, P6157, DOI 10.1128/MCB.13.10.6157; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHIROKI K, 1977, VIROLOGY, V82, P462, DOI 10.1016/0042-6822(77)90019-8; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; TANG XR, 1995, J BIOL CHEM, V270, P2327, DOI 10.1074/jbc.270.51.30428; TELLING GC, 1994, J VIROL, V68, P877, DOI 10.1128/JVI.68.2.877-887.1994; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; VANDEREB AJ, 1979, COLD SPRING HARB SYM, V44, P383, DOI 10.1101/SQB.1980.044.01.043; WHITE E, 1995, MOL REPERTOIRE ADENO, V3, P33; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WILLIAMS J, 1995, MOL REPERTOIRE ADENO, V3, P149; YAMITHEZI A, 1994, ONCOGENE, V9, P1065; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	66	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	1996	12	8					1715	1725						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622892				2022-12-28	WOS:A1996UG45800014
J	Hengstschlager, M; HengstschlagerOttnad, E; Pusch, O; Wawra, E				Hengstschlager, M; HengstschlagerOttnad, E; Pusch, O; Wawra, E			The role of p16 in the E2F-dependent thymidine kinase regulation	ONCOGENE			English	Article						p16; thymidine kinase; E2F; pRb; cell cycle	E2F TRANSCRIPTION FACTOR; CELL-CYCLE; RETINOBLASTOMA-PROTEIN; DEOXYCYTIDINE KINASE; BINDING-SITE; GENE; FAMILY; OVEREXPRESSION; IDENTIFICATION; INHIBITION	The role of alterations of the MTS1 tumor suppressor gene on chromosome 9p21, which encodes p16, the inhibitor of cyclin-dependent-kinase-4 and 6, in tumorigenesis is not yet clear, Phosphorylation of the retinoblastoma protein by cyclin-dependent-kinases 4 and 6 prevents its interaction with the transcription factor E2F, which subsequently promotes the expression of S phase regulated genes, such as thymidine kinase, Although a role of p16 in this regulation has been presumed, there is no proof so far that loss of this tumor suppressor gene really affects E2F-mediated regulations, We investigated the regulation of thymidine kinase in phytohemagglutinin-stimulated normal human lymphocytes and in the p16-negative human acute lymphoblastic leukemia cell lines, MOLT-4 and GEM. Compared to normal lymphocytes, MOLT-4 and CEM cells exhibited an altered cell cycle regulation of thymidine kinase, a much higher intracellular activity of this enzyme, and higher thymidine kinase mRNA expression, Transient expression of p16 in normal human lymphocytes caused arrest in G1, but was without effect on the cell growth of MOLT-4 and CEM cells, although all of them express functional retinoblastoma protein, Nevertheless, in the two leukemia cell lines transient overexpression of p16 reestablished the normal regulation of thymidine kinase, paralleled by an increase of the underphosphorylated form of retinoblastoma protein and a decrease of free E2F bound to its motif in the thymidine kinase promoter, We demonstrate that loss of p16 causes upregulation of this DNA precursor pathway enzyme via activation of E2F by a mechanism involving retinoblastoma protein.	UNIV VIENNA, VIENNA BIOCTR,INST MOLEC GENET, A-1030 VIENNA, AUSTRIA; UNIV VIENNA, VIENNA BIOCTR,INST MOLEC BIOL, A-1030 VIENNA, AUSTRIA	University of Vienna; Vienna Biocenter (VBC); University of Vienna; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)	Hengstschlager, M (corresponding author), UNIV VIENNA, DEPT PRENATAL DIAG & THERAPY, AKH-EBO-E6, WAHRINGER GURTEL 18-20, A-1090 VIENNA, AUSTRIA.			Pusch, Oliver/0000-0001-7166-2800				ADLER R, 1974, CELL, V2, P113, DOI 10.1016/0092-8674(74)90100-7; ARAP W, 1995, CANCER RES, V55, P1351; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BELLO LJ, 1974, EXP CELL RES, V89, P263, DOI 10.1016/0014-4827(74)90790-3; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN EH, 1995, J CLIN INVEST, V95, P1660, DOI 10.1172/JCI117841; DOU QP, 1994, J BIOL CHEM, V269, P1306; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; HENGSTSCHLAGER M, 1993, FEBS LETT, V321, P237, DOI 10.1016/0014-5793(93)80116-C; HENGSTSCHLAGER M, 1994, J BIOL CHEM, V269, P13836; HENGSTSCHLAGER M, 1994, CELL GROWTH DIFFER, V5, P1389; HENGSTSCHLAGER M, 1993, CYTOMETRY, V14, P39, DOI 10.1002/cyto.990140108; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KIM YK, 1992, J BIOL CHEM, V267, P2723; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Maniatis T, 1989, MOL CLONING; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NEVINS JR, 1992, SCIENCE, V258, P424; NEVINS JR, 1992, NATURE, V358, P375, DOI 10.1038/358375a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SCHULZE A, 1994, ONCOGENE, V9, P3475; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHOWS TB, 1979, CYTOGENET CELL GENET, V25, P96, DOI 10.1159/000131404; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; WALKER DG, 1995, CANCER RES, V55, P20; WAWRA E, 1981, J VIROL, V38, P973, DOI 10.1128/JVI.38.3.973-981.1981; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WINTERSBERGER E, 1992, ADV ENZYME REGUL, V32, P241; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572	46	37	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	1996	12	8					1635	1643						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622883				2022-12-28	WOS:A1996UG45800005
J	Luber, B; Arnold, N; Sturzl, M; Hohne, M; Schirmacher, P; Lauer, U; Wienberg, J; Hofschneider, PH; Kekule, AS				Luber, B; Arnold, N; Sturzl, M; Hohne, M; Schirmacher, P; Lauer, U; Wienberg, J; Hofschneider, PH; Kekule, AS			Hepatoma-derived integrated HBV DNA causes multi-stage transformation in vitro	ONCOGENE			English	Article						hepatitis B virus; X gene; liver carcinogenesis; incomplete oncogenes; transactivation	B VIRUS-DNA; HUMAN HEPATOCELLULAR-CARCINOMA; WOODCHUCK LIVER-TUMORS; X-GENE; INSITU HYBRIDIZATION; CELL-LINES; T-ANTIGEN; TRANSACTIVATOR; EXPRESSION; MECHANISMS	The hepatoma-derived hepatitis B virus (HBV) DNA insert HU-a has recently been shown to contain two viral transactivator genes, X and preS2/S-t, We report here that HU-a induces malignant transformation after stable transfection of the fetal mouse hepatocyte line FMH202, as indicated by soft agar growth and nude mouse tumorigenicity, Transfections with HU-a subclones, containing the X gene or the preS2/S-t gene alone or sequences without transactivator gene, respectively, suggested that the X gene is essential for transformation, Sequential stages of transformation and tumor progression were analysed by injection of the stably transfected FMH202 lines into nude mice, explantation of the resulting tumors and re-establishment of cell lines from the tumors, Comparison of two HU-a-transformed cell lines by HBV mRNA hybridization, Southern analysis and chromosomal in situ hybridization revealed that integrated HBV DNAs were involved in major chromosomal rearrangements in both cases, Interestingly, recombination of the HBV DNA insert during the nude mouse passage had completely abolished HBV-specific transcription in one case, indicating that expression of integrated HBV genes, while presumably involved in early transformation, is dispensable at later stages of tumor progression, The sequential transformation observed in this experimental system suggests that expression of the X gene by integrated viral DNA and subsequent hepatocyte genome mutations might both contribute to HBV-associated liver carcinogenesis.	MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY; INST ANTHROPOL & HUMAN GENET,D-80333 MUNICH,GERMANY; INST MED VIROL,D-35392 GIESSEN,GERMANY; INST PATHOL,D-55131 MAINZ,GERMANY	Max Planck Society			Arnold, Norbert/E-3012-2010; Stürzl, Michael/B-3019-2015	Arnold, Norbert/0000-0003-4523-8808; Stürzl, Michael/0000-0002-9276-2824				ARNOLD N, 1992, BIOTECH HISTOCHEM, V67, P59, DOI 10.3109/10520299209110009; BALSANO C, 1991, BIOCHEM BIOPH RES CO, V176, P985, DOI 10.1016/0006-291X(91)90379-L; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BRECHOT C, 1987, J HEPATOL, V4, P269, DOI 10.1016/S0168-8278(87)80090-9; BREIVIK J, 1994, BRIT J CANCER, V69, P367, DOI 10.1038/bjc.1994.67; BUENDIA MA, 1992, ADV CANCER RES, V59, P167, DOI 10.1016/S0065-230X(08)60306-1; CASELMANN WH, 1990, P NATL ACAD SCI USA, V87, P2970, DOI 10.1073/pnas.87.8.2970; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DIAMANTIS ID, 1992, J HEPATOL, V15, P400, DOI 10.1016/0168-8278(92)90077-3; FANNING E, 1992, MALIGNANT TRANSFORMA, P1; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; FUJIYAMA A, 1983, NUCLEIC ACIDS RES, V11, P4601, DOI 10.1093/nar/11.13.4601; GRAEF E, 1994, ONCOGENE, V9, P81; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HILGER C, 1991, J VIROL, V65, P4284, DOI 10.1128/JVI.65.8.4284-4291.1991; HINO O, 1991, P NATL ACAD SCI USA, V88, P9248, DOI 10.1073/pnas.88.20.9248; HINO O, 1989, J VIROL, V63, P2638, DOI 10.1128/JVI.63.6.2638-2643.1989; HOFFMANN B, 1989, J CELL PHYSIOL, V139, P654, DOI 10.1002/jcp.1041390328; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HUH N, 1981, GANN, V72, P178; KEKULE A, 1994, PRIMARY LIVER CANC E, P191; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; KOCH S, 1984, EMBO J, V3, P2185, DOI 10.1002/j.1460-2075.1984.tb02111.x; KOIKE K, 1994, J CLIN INVEST, V94, P44, DOI 10.1172/JCI117343; MARTIN RG, 1979, J VIROL, V31, P596, DOI 10.1128/JVI.31.3.596-607.1979; MATSUBARA K, 1991, MOL BIOL HEPATITIS B; MEYER M, 1992, HEPATOLOGY, V15, P665, DOI 10.1002/hep.1840150419; PAUL D, 1988, EXP CELL RES, V175, P354, DOI 10.1016/0014-4827(88)90199-1; PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3; RENNER M, 1995, J HEPATOL, V23, P53, DOI 10.1016/0168-8278(95)80311-4; RIED T, 1992, P NATL ACAD SCI USA, V89, P1388, DOI 10.1073/pnas.89.4.1388; RIED T, 1993, GENOMICS, V18, P381, DOI 10.1006/geno.1993.1479; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; Sambrook J., 1989, MOL CLONING; SCHLUTER V, 1994, ONCOGENE, V9, P3335; SEIFER M, 1991, J HEPATOL, V13, pS61, DOI 10.1016/0168-8278(91)90026-8; SETO E, 1991, J VIROL, V65, P2351, DOI 10.1128/JVI.65.5.2351-2356.1991; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; STURZL M, 1992, P NATL ACAD SCI USA, V89, P7046, DOI 10.1073/pnas.89.15.7046; TUCKER RW, 1977, CANCER RES, V37, P1571; UNGER T, 1990, EMBO J, V9, P1889, DOI 10.1002/j.1460-2075.1990.tb08315.x; WANG J, 1992, ONCOGENE, V7, P1653; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG WL, 1991, CANCER RES, V51, P4971; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WEI Y, 1992, J VIROL, V66, P5265, DOI 10.1128/JVI.66.9.5265-5276.1992; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	54	39	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1597	1608						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622879				2022-12-28	WOS:A1996UG45800001
J	Livneh, E; Shimon, T; Bechor, E; Doki, Y; Schieren, I; Weinstein, IB				Livneh, E; Shimon, T; Bechor, E; Doki, Y; Schieren, I; Weinstein, IB			Linking protein kinase C to the cell cycle: Ectopic expression of PKC eta in NIH3T3 cells alters the expression of cyclins and Cdk inhibitors and induces adipogenesis	ONCOGENE			English	Article						protein kinase C; cell cycle; cyclins; Cdk inhibitors; adipogenesis	RETINOBLASTOMA GENE-PRODUCT; DEPENDENT REGULATION; RAT FIBROBLASTS; PHORBOL ESTER; 3T3 CELLS; NPKC-ETA; DIFFERENTIATION; PHOSPHORYLATION; ACTIVATION; EPSILON	Protein kinase C encodes a family of enzymes implicated in cellular differentiation, growth control and tumor promotion. However, very little is known with respect to the molecular mechanisms that link protein kinase C to cell cycle control. Here we report that ectopic expression of PKC eta in NIH3T3 fibroblasts blocks the normal phosphorylation of the Rb protein in quiescent cultures restimulated to enter the cell cycle; PKC eta activates a cellular program that includes increased expression of cyclins E (but not cyclin D), as well as the induced expression of the cyclin-dependent kinase inhibitors p21(WAF1) and p27(KIP1). The increased expression of the latter inhibitors and their association with the cyclin E-Cdk2 complex results in decreased cyclin E associated kinase activity. Furthermore, in contrast to the control NIH3T3 cells, the cells that express PKC eta can be induced to undergo adipocyte differentiation in response to adipogenic hormones. Thus, PKC eta induces altered expression of several cell cycle related functions, which may contribute to its ability to promote cellular differentiation.	COLUMBIA UNIV COLL PHYS & SURG,COLUMBIA PRESBYTERIAN CANC CTR,NEW YORK,NY 10032	Columbia University	Livneh, E (corresponding author), WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL.				NCI NIH HHS [CA 02656] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BELL RM, 1991, J BIOL CHEM, V266, P4661; BORNER C, 1995, J BIOL CHEM, V270, P78, DOI 10.1074/jbc.270.1.78; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CACACE AM, 1993, ONCOGENE, V8, P2095; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COBRINIK D, 1992, TIBS, V17, P310; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DOI S, 1994, MOL CARCINOGEN, V11, P197, DOI 10.1002/mc.2940110405; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; ELDAR H, 1992, EXP CELL RES, V202, P259, DOI 10.1016/0014-4827(92)90073-H; ELDAR H, 1990, J BIOL CHEM, V265, P13290; FISHER GJ, 1993, J INVEST DERMATOL, V101, P553, DOI 10.1111/1523-1747.ep12365967; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREIF H, 1992, MOL CELL BIOL, V12, P1304, DOI 10.1128/MCB.12.3.1304; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IKUTA T, 1994, CELL GROWTH DIFFER, V5, P943; JIANG HP, 1994, ONCOGENE, V9, P3397; KATO J, 1993, GENE DEV, V7, P331; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LIVNEH E, 1994, SIGNAL ACTIVATED PHO, P165; LIYANAGE M, 1992, BIOCHEM J, V283, P781, DOI 10.1042/bj2830781; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; ONO Y, 1988, J BIOL CHEM, V263, P6927; OSADA S, 1993, CELL GROWTH DIFFER, V4, P167; OSADA S, 1990, J BIOL CHEM, V265, P22434; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TOKER A, 1994, J BIOL CHEM, V269, P32358; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WIMMEL A, 1994, ONCOGENE, V9, P995; ZANG R, 1994, BIOCHEM J, V304, P641, DOI 10.1042/bj3040641	63	75	76	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1545	1555						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622871				2022-12-28	WOS:A1996UF07600019
J	DubsPoterszman, MC; Tocque, B; Wasylyk, B				DubsPoterszman, MC; Tocque, B; Wasylyk, B			MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest	ONCOGENE			English	Article						E2F; transcription; Rb; inhibition; anchorage-independent growth	AUTOREGULATORY FEEDBACK LOOP; WILD-TYPE P53; GENE; EXPRESSION; PROTEIN; OVEREXPRESSION; AMPLIFICATION; SUPPRESSION; MUTATIONS; ONCOGENE	The p53 tumour-suppressor guards the genome in response to genotoxic stress by transcriptional regulation of genes involved in cell-cycle control, DNA replication, repair and apoptosis such as p21, GADD45, bar and mdm2 (Cox and Lane, 1995), Mdm2 is classically considered to be an inhibitor of p53, that forms an auto-regulatory loop (Momand et al., 1992; Oliner et al., 1993; Wu el al., 1993; Chen et al., 1994; Chen and Levine, 1995). It immortalises cells containing wild type p53 and transforms them together with Ras (Finlay, 1993). We show that, in the absence of p53, mdm2 confers a growth advantage to cells (ie ''transforms'' them) and can overcome a G1 cell-cycle arrest induced by p107, a member of the pRb tumour-suppressor family (Adams and Kaelin, 1995), The minimum ''transforming'' and p107 inhibiting region of Mdm2 corresponds to its p53 binding domain, p53 inhibits transformation by Mdm2, apparently without requiring transcription, p53 can be considered to be a suppressor of Mdm2, a positive effector of the cell cycle, Mdm2 over-expression in tumours is reminiscent of p53 mutations with gain of function, in that Mdm2 both transforms cells and inhibits p53 activity.	INST GENET & BIOL MOLEC & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE; RHONE POULENC RORER,CTR RECH VITRY ALFORTVILLE,F-94403 VITRY,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Sanofi-Aventis				WASYLYK, Bohdan/0000-0002-1718-1237				ADAMS PD, 1995, CANC BIOL, V6, P99; BATES S, 1995, CANCER BIOL, V6, P73; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CORDONCARDO C, 1994, CANCER RES, V54, P794; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; HAHN BC, 1995, NAT GENET, V9, P221; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEACH FS, 1993, CANCER RES, V53, P2231; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OTTO A, 1993, ONCOGENE, V8, P2591; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; QUESNEL B, 1994, BRIT J HAEMATOL, V88, P415, DOI 10.1111/j.1365-2141.1994.tb05044.x; REIFENBERGER G, 1993, CANCER RES, V53, P2736; SHAULSKY G, 1991, CANCER RES, V51, P5232; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; WATANABE T, 1994, BLOOD, V84, P3158; WHARTON W, 1989, CELL GROWTH DIVISION, P139; WHYTE P, 1995, CANCER BIOL, V6, P83; WOLF D, 1984, MOL CELL BIOL, V4, P552, DOI 10.1128/MCB.4.3.552; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	37	87	90	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2445	2449						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570197				2022-12-28	WOS:A1995TK70200030
J	BUCHOU, T; KRANENBURG, O; VANDAM, H; ROELEN, D; ZANTEMA, A; HALL, FL; VANDEREB, A				BUCHOU, T; KRANENBURG, O; VANDAM, H; ROELEN, D; ZANTEMA, A; HALL, FL; VANDEREB, A			INCREASED CYCLIN-A AND DECREASED CYCLIN-D LEVELS IN ADENOVIRUS-5 E1A-TRANSFORMED RODENT CELL-LINES	ONCOGENE			English	Article							LARGE T-ANTIGEN; E1A PROTEINS; TRANSFORMED-CELLS; MONOCLONAL-ANTIBODIES; GROWTH-FACTOR; FACTOR-I; FUNCTIONAL DOMAINS; CONSERVED REGION-1; NUCLEAR ANTIGEN; MESSENGER-RNAS	Adenovirus-(Ad)- E1A proteins carry two conserved domains (CR1 and CR2) required for transformation of primary rodent cells and essential for association with cellular proteins, including p105RB, p58cyclin A and p33cdk 2. We show that in normal rat kidney 49F (NRK) cell lines expressing various mutant Ad5-E1A genes, CR2-, but not CR-1-, deletion mutants induce a typical transformed phenotype as characterized by morphology, absence of density arrest and loss of serum requirement. This indicates that induction of these transformed properties is a function of CR1. The fact that E1A proteins with deletions in CR2 show a greatly reduced association with RB, cyclin A and p33cdk 2 suggests that these associations are dispensable for E1A-mediated transformation of NRK cells. Induction of the transformed properties is accompanied by a CR1-dependent increase in Proliferating Cell Nuclear Antigen and cyclin A gene expression. Elevated mRNA and protein levels of cyclin A were also found in Ad12-E1-transformed NRK cells but not in ras-transformed NRK cells. On the other hand, cyclin D expression is decreased in a CR1-dependent manner. Although Ad5-E1A proteins are sufficient to transform NRK cells, further deregulation of growth is obtained when Ad5-E1B proteins are co-expressed. One of the Ad5-E1B effects is the sequestration of the p53 protein into a cytoplasmic body containing the p53/Ad5-E1B-55 kD complex. Interestingly, in NRK cell lines expressing Ad5-E1B-55 kD, cyclin A could be detected not only in the nucleus but also in the cytoplasmic bodies. These results indicate that the deregulation of cell cycle control by the Adenovirus-E1 region may be due to a CR1-dependent alteration of the expression of cyclins A and D.	LEIDEN UNIV, SYLVIUS LAB, MOLEC CARCINOGENESIS LAB, POB 9503, 2300 RA LEIDEN, NETHERLANDS; CTR RECH PARIS ST ANTOINE, INSERM, U55, F-75571 PARIS 12, FRANCE; CHILDRENS HOSP LOS ANGELES, DIV ORTHOPAED SURG, LOS ANGELES, CA 90054 USA	Leiden University; Leiden University - Excl LUMC; Institut National de la Sante et de la Recherche Medicale (Inserm); Children's Hospital Los Angeles			BUCHOU, THIERRY/N-2553-2013; Kranenburg, Onno/K-4115-2015; BUCHOU, Thierry/F-3136-2019	Kranenburg, Onno/0000-0002-2112-4390; BUCHOU, Thierry/0000-0002-9206-2377; van Dam, Hans/0000-0002-8307-4325				ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; BERK AJ, 1978, CELL, V14, P695, DOI 10.1016/0092-8674(78)90252-0; BERNARDS R, 1986, VIROLOGY, V150, P126, DOI 10.1016/0042-6822(86)90272-2; BRANDS JHGM, 1986, EUR J BIOCHEM, V155, P167, DOI 10.1111/j.1432-1033.1986.tb09472.x; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FLINT SJ, 1990, MOL BIOL TUMOR VIRUS, V2, P547; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALL FL, 1991, J BIOL CHEM, V266, P17430; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; KIMELMAN D, 1986, MOL CELL BIOL, V6, P1487, DOI 10.1128/MCB.6.5.1487; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; KLEINBERGER T, 1991, P NATL ACAD SCI USA, V88, P11143, DOI 10.1073/pnas.88.24.11143; LAMMIE GA, 1991, ONCOGENE, V6, P439; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORAN B, 1988, MOL CELL BIOL, V8, P1756, DOI 10.1128/MCB.8.4.1756; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NIELSCH U, 1991, ONCOGENE, V6, P1031; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; OFFRINGA R, 1988, NUCLEIC ACIDS RES, V16, P10973, DOI 10.1093/nar/16.23.10973; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PERRICAUDET M, 1979, NATURE, V281, P694, DOI 10.1038/281694a0; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; RILEY TEW, 1990, MOL CELL BIOL, V10, P6664, DOI 10.1128/MCB.10.12.6664; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; SVENSSON C, 1991, VIROLOGY, V182, P553, DOI 10.1016/0042-6822(91)90596-4; TIMMERS HTM, 1988, J BIOL CHEM, V263, P1329; TIMMERS HTM, 1988, ONCOGENE RES, V3, P67; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VANDAM H, 1989, ONCOGENE, V4, P1207; VANDENELSEN P, 1983, VIROLOGY, V128, P377; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	70	64	64	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1993	8	7					1765	1773						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510923				2022-12-28	WOS:A1993LG68200007
J	BRYCE, DM; LIU, QR; KHOO, W; TSUI, LC; BREITMAN, ML				BRYCE, DM; LIU, QR; KHOO, W; TSUI, LC; BREITMAN, ML			PROGRESSIVE AND REGRESSIVE FATE OF LENS TUMORS CORRELATES WITH SUBTLE DIFFERENCES IN TRANSGENE EXPRESSION IN GAMMA-F-CRYSTALLIN-SV40 T-ANTIGEN TRANSGENIC MICE	ONCOGENE			English	Article							GAMMA-CRYSTALLIN GENES; MOUSE LENS; EYE LENS; REGULATORY ELEMENTS; CELL ELONGATION; RAT LENS; PROMOTER; DIFFERENTIATION; MORPHOGENESIS; ENHANCER	Regulatory elements of the mouse gammaF-crystallin gene were used to derive transgenic mice expressing SV40 large T antigen in terminally differentiating fiber cells of the ocular lens. The resulting gammaF-crystallin-T antigen mice developed either malignant or regressive lens tumors in a strain-dependent fashion. Developmental and RNA analyses revealed that in both 'tumor-progressing' and 'tumor-regressing' mouse strains expression of the transgene blocked morphological differentiation of lens fibers without appreciably affecting gamma-crystallin gene expression, a marker of terminal lens fiber cell differentiation. Strain-dependent differences in tumorigenic outcome could be correlated with both subtle differences in transgene expression and the ability of tumor cells to escape from the normal confines of the lens. The results implicate the importance of cellular environment to malignant tumor development and provide insight into those features of normal lens ontogeny that may render the lens refractory to the development of spontaneous tumors.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL 600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA; HOSP SICK CHILDREN,DEPT GENET,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto			Tsui, Lap-chee/A-1081-2010	Bryce, Dawn/0000-0002-7403-2940				BREITMAN ML, 1987, SCIENCE, V238, P1563, DOI 10.1126/science.3685993; BREITMAN ML, 1989, DEVELOPMENT, V106, P457; BREITMAN ML, 1984, P NATL ACAD SCI-BIOL, V81, P7762, DOI 10.1073/pnas.81.24.7762; CHEPELINSKY AB, 1987, MOL CELL BIOL, V7, P1807, DOI 10.1128/MCB.7.5.1807; COUNIS MF, 1989, INT J BIOCHEM, V21, P235, DOI 10.1016/0020-711X(89)90181-X; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; GORING DR, 1987, SCIENCE, V235, P456, DOI 10.1126/science.3099390; GORING DR, 1992, EXP EYE RES, V54, P785, DOI 10.1016/0014-4835(92)90034-P; GRIEP AE, 1989, GENE DEV, V3, P1075, DOI 10.1101/gad.3.7.1075; HAYASHI S, 1987, GENE DEV, V1, P818, DOI 10.1101/gad.1.8.818; LIU QR, 1991, MOL CELL BIOL, V11, P1531, DOI 10.1128/MCB.11.3.1531; LOK S, 1989, NUCLEIC ACIDS RES, V17, P3563, DOI 10.1093/nar/17.9.3563; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MATSUO I, 1991, DEVELOPMENT, V113, P539; MCAVOY JW, 1978, J EMBRYOL EXP MORPH, V44, P149; MCAVOY JW, 1978, J EMBRYOL EXP MORPH, V45, P271; MCAVOY JW, 1980, DIFFERENTIATION, V17, P137, DOI 10.1111/j.1432-0436.1980.tb01091.x; MEAKIN SO, 1989, EXP EYE RES, V48, P131, DOI 10.1016/0014-4835(89)90026-2; MURERORLANDO M, 1987, DEV BIOL, V119, P260, DOI 10.1016/0012-1606(87)90227-2; NAKAMURA T, 1989, New Biologist, V1, P193; OVERBEEK PA, 1985, P NATL ACAD SCI USA, V82, P7815, DOI 10.1073/pnas.82.23.7815; PEEK R, 1990, NUCLEIC ACIDS RES, V18, P1189, DOI 10.1093/nar/18.5.1189; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; SACHS E, 1948, AM J OPHTHALMOL, V31, P561, DOI 10.1016/0002-9394(48)90558-3; SIEZEN RJ, 1988, J MOL BIOL, V199, P475, DOI 10.1016/0022-2836(88)90619-5; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAKAHASHI Y, 1988, DEVELOPMENT, V102, P259; VANLEEN RW, 1987, DEV BIOL, V120, P457, DOI 10.1016/0012-1606(87)90249-1; YU CCK, 1990, DEVELOPMENT, V110, P131	30	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1611	1620						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8389033				2022-12-28	WOS:A1993LE06400025
J	URANO, T; FURUKAWA, K; SHIKU, H				URANO, T; FURUKAWA, K; SHIKU, H			EXPRESSION OF NM23 NDP KINASE PROTEINS ON THE CELL-SURFACE	ONCOGENE			English	Note							NUCLEOSIDE DIPHOSPHATE-KINASE; BINDING-PROTEINS; GENE; ASSOCIATION; DROSOPHILA; METASTASIS; CLONING	We determined whether proteins encoded by the nm23/nucleoside diphosphate (NDP) kinase gene, a potential metastasis-suppressor gene, are expressed on the cell surface. Monoclonal antibodies (mAb) specific for nm23-H1 or H2 proteins were prepared using the corresponding fusion proteins with glutathione S-transferase (GST) as immunogens. mAb H1-229 was specifically reactive with nm23-H1 protein, whereas mAb H2-439 was specific for nm23-H2 protein in immunoprecipitation and immunoblotting. mAb H1-229 was reactive with most human hematopoietic and some non-hematopoietic cell lines in flow cytometry. On the other hand, mAb H2-439 was reactive with only a limited number of cell lines. Based upon the surface expression of nm23/NDP kinase, cells were classified as nm23-H1+H2-, nm23-H1+H2+ or nm23-H1-H2-. No cell lines with nm23-H1-H2+ were found among those examined. The specificity of flow cytometry analysis was confirmed in the murine myeloma line NS-1 transfected with either the nm23-H1 or H2 genes. Both mAbs were reactive only to NS-1 transfected with the corresponding nm23 genes. Immunoprecipitation and SDS-PAGE analysis identified 20.5- and 18-kDa proteins with mAb H1-229 or H2-439, respectively, in cellular extracts of I-125-surface labeled NS-1 transfected with the corresponding genes. The presence of nm23/NDP kinase on the cell surface indicates an extracellular role for these proteins in addition to their reported intracellular functions.	NAGASAKI UNIV,SCH MED,DEPT ONCOL,1-12-4 SAKAMOTO,NAGASAKI 852,JAPAN	Nagasaki University				Urano, Takeshi/0000-0003-3383-3554				BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; Coligan JKA, 1991, CURRENT PROTOCOLS IM; GILLES AM, 1991, J BIOL CHEM, V266, P8784; HAMA H, 1991, GENE, V105, P31, DOI 10.1016/0378-1119(91)90510-I; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KIKKAWA S, 1990, J BIOL CHEM, V265, P21536; KIMURA N, 1990, J BIOL CHEM, V265, P15744; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2702; OHTSUKI K, 1987, BIOCHEM BIOPH RES CO, V148, P300, DOI 10.1016/0006-291X(87)91110-7; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; URANO T, 1992, FEBS LETT, V309, P358, DOI 10.1016/0014-5793(92)80807-S; URANO T, 1992, INT J ONCOL, V1, P425; WALSER A, 1989, J VIROL, V63, P3926, DOI 10.1128/JVI.63.9.3926-3933.1989	22	74	76	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1371	1376						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8386830				2022-12-28	WOS:A1993KY32800031
J	WADEWITZ, AG; WINER, MA; WOLGEMUTH, DJ				WADEWITZ, AG; WINER, MA; WOLGEMUTH, DJ			DEVELOPMENTAL AND CELL LINEAGE SPECIFICITY OF RAF FAMILY GENE-EXPRESSION IN MOUSE TESTIS	ONCOGENE			English	Article							COMPLETE CODING SEQUENCE; MALE GERM-CELLS; COMPLETE NUCLEOTIDE-SEQUENCE; RIBOSOMAL-RNA GENE; KINASE-ACTIVITY; PROTEIN-KINASE; INSITU HYBRIDIZATION; BIOLOGICAL-ACTIVITY; MESSENGER-RNAS; A-RAF	The proto-oncogene c-raf-1 and the related genes A-raf and B-raf encode serine/threonine protein kinases thought to be involved in regulating gene expression by transducing extracellular signals into the cell. All three raf family genes have been shown previously to be expressed in mouse testis. Northern and in situ hybridization analyses with probes specific for each gene demonstrated that c-raf-1 mRNA is ubiquitously expressed in both somatic and germ cells as a 3.1-kb transcript. Additionally, the levels of c-raf-1 expression are developmentally regulated in the germ cells, exhibiting highest expression in early pachytene spermatocytes and decreasing progressively through later stages. A-raf is expressed predominantly in the somatic compartment as two transcripts of 2.6 and 4.3 kb. A-raf expression in Leydig cells appears to be elevated in testes undergoing spermatogenesis. In contrast, B-raf is expressed as two major transcripts of 4.0 and 2.6 kb, with the 4.0-kb transcript first expressed at low levels in pachytene spermatocytes and the more abundant 2.6-kb transcript restricted to post-meiotic spermatids. These studies indicate that each raf gene exhibits a characteristic, limited pattern of expression and suggests that the different forms may play a unique regulatory role in androgen production and/or spermatogenesis.	COLUMBIA UNIV COLL PHYS & SURG,DEPT GENET & DEV,630 W 168TH ST,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,CTR REPROD SCI,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT OBSTET & GYNECOL,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University					NCRR NIH HHS [2-S07-RR05395] Funding Source: Medline; NICHD NIH HHS [P50 HD05077, F32 HD07414-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD005077, F32HD007414] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005395] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adashi EY, 1992, SPERMATOGENESIS FERT, P143; ALCIVAR AA, 1990, J BIOL CHEM, V265, P20160; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BECK TW, 1990, MOL CELL BIOL, V10, P3325, DOI 10.1128/MCB.10.7.3325; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHAPMAN DL, 1992, IN PRESS MOL REPROD; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; ERICKSON RP, 1990, TRENDS GENET, V6, P264, DOI 10.1016/0168-9525(90)90209-O; GIZANGGINSBERG E, 1987, P NATL ACAD SCI USA, V84, P1600, DOI 10.1073/pnas.84.6.1600; GIZANGGINSBERG E, 1985, DEV BIOL, V111, P293, DOI 10.1016/0012-1606(85)90484-1; HANDEL MA, 1979, BIOL REPROD, V20, P1031, DOI 10.1095/biolreprod20.5.1031; HASSOUNA N, 1984, NUCLEIC ACIDS RES, V12, P3563, DOI 10.1093/nar/12.8.3563; HECHT NB, 1990, J REPROD FERTIL, V88, P679, DOI 10.1530/jrf.0.0880679; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; HUMMEL KP, 1966, MOUSE NEWS LETT, V34, P31; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; JAFFE L, 1990, J IMMUNOL, V145, P3474; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KRUMLAUF R, 1987, DEVELOPMENT, V99, P603; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; MATHER JP, 1992, SPERMATOGENESIS FERT, P169; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NEBEL BR, 1961, SCIENCE, V134, P832, DOI 10.1126/science.134.3482.832; PARVINEN M, 1991, GROWTH FACTORS FERTI, P157; PONZETTO C, 1989, ONCOGENE, V4, P685; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAYNAL F, 1984, FEBS LETT, V167, P263, DOI 10.1016/0014-5793(84)80139-8; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; STEPHENS RM, 1992, UNPUB MOL CELL BIOL; STORM SM, 1990, ONCOGENE, V5, P345; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WILLISON K, 1987, TRENDS GENET, V3, P351, DOI 10.1016/0168-9525(87)90296-4; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907; WOLGEMUTH DJ, 1991, MAMM GENOME, V1, P283, DOI 10.1007/BF00352340; WOLGEMUTH DJ, 1985, GAMETE RES, V12, P1, DOI 10.1002/mrd.1120120102	48	34	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1055	1062						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455932				2022-12-28	WOS:A1993KT22000030
J	GOUTEBROZE, L; SAINTANDRE, CD; SCHERNECK, S; FEUNTEUN, J				GOUTEBROZE, L; SAINTANDRE, CD; SCHERNECK, S; FEUNTEUN, J			MUTATIONS WITHIN THE HAMSTER POLYOMAVIRUS LARGE T-ANTIGEN DOMAIN INVOLVED IN PRB-BINDING IMPAIR VIRUS PRODUCTIVE CYCLE AND IMMORTALIZATION CAPACITY	ONCOGENE			English	Article							TUMOR-ANTIGEN; RETINOBLASTOMA PROTEIN; KINASE-ACTIVITY; TRANSFORMATION; ASSOCIATION; GENE; IDENTIFICATION; PHOSPHATASE-2A; PAPOVAVIRUS; COMPLEXES	Hamster polyomavirus (HaPV) causes lymphoma and leukemia when injected into newborn Syrian hamsters and achieves full transformation of rodent fibroblasts in vitro. It offers a comprehensive model to study at a molecular level the contributions of the viral oncogenes to neoplastic transformation in vitro and in the animal. We have investigated the ability of HaPV large T antigen to form a complex with the product of the retinoblastoma gene (pRb) in vitro. In this report, we demonstrate that HaPV large T antigen can indeed complex the pRb polypeptide. In order to investigate to what extent this interaction might contribute to tumor induction by the virus, we have introduced two different point mutations within the putative pRb-binding sequence of large T antigen, and as a preliminary to in vivo experiments we have studied their effects in vitro on some biological activities relevant to tumor induction. We show that the substitution (Glu-134-->Lys) obliterates pRb binding, suggesting that Glu-134 participates in the interaction between pRb and large T antigen, whereas the substitution (Glu-135-->Lys) has no effect. The Lys-134 mutation is strongly deleterious to the immortalization capacity of the viral genome, whereas the Lys-135 mutation has no effect. Neither of the two mutations affects the capacity of the viral genome to induce foci formation in the rat established cell line F111. These results indicate that the interaction between large T and pRb is required in the immortalization process but irrelevant to transformation. Both mutants show at least partial impairment of replication and productive cycle.	INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,URA 1158,F-94805 VILLEJUIF,FRANCE; MAX DELBRUCK CENTRUM MOLEC MED TUMORIGENET,O-1115 BERLIN,GERMANY	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Helmholtz Association; Max Delbruck Center for Molecular Medicine			Goutebroze, Laurence/H-3543-2016; Feunteun, Jean/AAZ-1267-2020	Goutebroze, laurence/0000-0002-8712-000X; Feunteun, Jean/0000-0003-1212-9189				BASTIEN C, 1988, ONCOGENE, V2, P129; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COURTNEIDGE SA, 1991, J VIROL, V65, P3301, DOI 10.1128/JVI.65.6.3301-3308.1991; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DELMAS V, 1985, EMBO J, V4, P1279, DOI 10.1002/j.1460-2075.1985.tb03773.x; DELMAS V, 1992, ONCOGENE, V7, P295; DIAMANDOPOULOS GT, 1972, SCIENCE, V176, P173, DOI 10.1126/science.176.4031.173; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; GOUTEBROZE L, 1992, J VIROL, V66, P2495, DOI 10.1128/JVI.66.4.2495-2504.1992; GRAFFI A, 1969, P NATL ACAD SCI USA, V64, P1172, DOI 10.1073/pnas.64.4.1172; GRAFFI A, 1968, J NATL CANCER I, V40, P867; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LEWIS AM, 1979, J NATL CANCER I, V63, P695, DOI 10.1093/jnci/63.3.695; NORKIN LC, 1982, MICROBIOL REV, V46, P384, DOI 10.1128/MMBR.46.4.384-425.1982; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; SAINTANDRE CD, 1990, VIROLOGY, V177, P532; SALZMAN NP, 1986, VIRUSES PAPOVAVIRIDA, P1; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; ZHU J, 1991, J VIROL, V65, P6782	28	5	5	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					685	693						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8382359				2022-12-28	WOS:A1993KN00800020
J	NEBREDA, AR; PORRAS, A; SANTOS, E				NEBREDA, AR; PORRAS, A; SANTOS, E			P21RAS-INDUCED MEIOTIC MATURATION OF XENOPUS OOCYTES IN THE ABSENCE OF PROTEIN-SYNTHESIS - MPF ACTIVATION IS PRECEDED BY ACTIVATION OF MAP AND S6 KINASES	ONCOGENE			English	Article							ONCOGENIC RAS PROTEIN; LAEVIS OOCYTES; M-PHASE; CELL-CYCLE; TYROSINE PHOSPHORYLATION; OKADAIC ACID; P21; P34CDC2; INVIVO; SUBSTRATE	Microinjection of transforming p21ras into Xenopus oocytes caused a time-dependent increase in the level of total cell protein phosphorylation that culminated with germinal vesicle breakdown (GVBD). The same pattern of phosphorylation was observed in oocytes matured by either progesterone or insulin. Treatment with cycloheximide (CHX) completely blocked both GVBD and the associated de novo phosphorylations induced by the hormones, but did not abolish p21ras-induced maturation nor the occurrence of associated maturation promoting factor (MPF)-dependent and -independent phosphorylations. Thus, induction of GVBD by p21ras in the absence of protein synthesis correlated with the activation of cytosolic MPF-associated kinase activity similar in specificity on exogenous (histone H1) and endogenous (47 kDa and a 42 kDa proteins) substrates to the MPF activity of hormonally-matured oocytes. The injection of p21ras in the presence of CHX caused also activation of other kinase(s) preceding MPF activation which were responsible for the phosphorylation of endogenous substrates including a 41 kDa protein and a 92 kDa protein kinase that comigrated, respectively, with bands recognized specifically by antibodies to MAP2 kinase and S6 kinase. The phosphorylation of those bands correlated also with the activation of cytosolic kinases acting specifically on myelin basic protein (MBP) and a S6-derived peptide as substrates. These results indicate that, in the absence of protein synthesis, p21ras is able to activate phosphorylation events leading to GVBD and suggest that this oncoprotein can participate in at least two separate pathways of MPF activation. We propose that the activation of MAP/MBP kinases and S6 kinases is an early effect of p21ras oncoproteins.	NCI,CELLULAR & MOLEC BIOL LAB,BG 37,RM 1D28,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Nebreda, Angel Rodriguez/R-9594-2019; Porras, Almudena/N-2121-2015	Porras, Almudena/0000-0002-6495-3308				ALLENDE CC, 1988, FEBS LETT, V234, P426, DOI 10.1016/0014-5793(88)80130-3; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BELLE R, 1989, FEBS LETT, V255, P101, DOI 10.1016/0014-5793(89)81069-5; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CICIRELLI MF, 1988, J BIOL CHEM, V263, P2009; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DEHERREROS AG, 1991, J BIOL CHEM, V266, P6825; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; ERIKSON AK, 1990, J BIOL CHEM, V265, P19728; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; FERRELL JE, 1990, MOL CELL BIOL, V10, P3020, DOI 10.1128/MCB.10.6.3020; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GORIS J, 1989, FEBS LETT, V245, P91, DOI 10.1016/0014-5793(89)80198-X; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; JANSSEN GMC, 1991, J BIOL CHEM, V266, P14885; KAMATA T, 1990, MOL CELL BIOL, V10, P880, DOI 10.1128/MCB.10.3.880; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MALLER JL, 1985, DEV BIOL, V109, P150, DOI 10.1016/0012-1606(85)90355-0; MINSHULL J, 1991, J CELL BIOL, V114, P767, DOI 10.1083/jcb.114.4.767; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MULNERLORILLON O, 1989, FEBS LETT, V251, P219, DOI 10.1016/0014-5793(89)81458-9; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAN BT, 1990, MOL CELL BIOL, V10, P923, DOI 10.1128/MCB.10.3.923; PINES J, 1990, New Biologist, V2, P389; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; RIME H, 1990, CELL DIFFER DEV, V29, P47, DOI 10.1016/0922-3371(90)90023-P; SADLER SE, 1990, MOL CELL BIOL, V10, P1689, DOI 10.1128/MCB.10.4.1689; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SANTOS E, 1988, J BIOL CHEM, V263, P9853; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0	50	44	45	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					467	477						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8381222				2022-12-28	WOS:A1993KN00600026
J	WANG, NP; TO, H; LEE, WH; LEE, EYHP				WANG, NP; TO, H; LEE, WH; LEE, EYHP			TUMOR SUPPRESSOR ACTIVITY OF RB AND P53 GENES IN HUMAN BREAST-CARCINOMA CELLS	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; WILD-TYPE P53; HUMAN PROSTATE CARCINOMA; MEDIATED FOCUS FORMATION; RECESSIVE MUTATION; PROTO-ONCOGENE; OSTEO-SARCOMA; ALLELE LOSS; SHORT ARM; EXPRESSION	Breast cancer is the most common cancer of women in Western countries. Various genetic alterations have been implicated in its development. Two tumor suppressor genes, the retinsoblastoma susceptibility gene (RB) and the gene encoding the p53 protein, are frequently found to be deleted or mutated in breast cancer cell lines and primary tumor samples. Breast carcinoma cell lines MDA-MB468 and BT549 both harbor partial RB gene deletions as well as point mutations of their p53 genes, thus providing an excellent model system for testing the roles played by these two genes in the oncogenesis of breast cancer. Single copies of wild-type RB or p53 were delivered to these cells by retrovirus-mediated gene transfer. Restoration of RB expression in cells reduced their ability to grow in soft agar and their tumorigenicity in nude mice, although no significant alteration of growth rate in culture could be detected. Introduction of wild-type p53 into these cells exerted a similar effect on the neoplastic phenotypes. This effect occurred even in the presence of their endogenous mutated p53 alleles, which argues for the phenotypical dominance of the wild-type p53 over mutated p53 during human oncogenesis. The ability of RB and p53 genes to suppress the tumorigenicity of breast carcinoma cells provides functional evidence that deletion or mutational inactivation of tumor suppressor genes represents an important step in the genesis of breast cancer.	UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,CTR MOLEC MED,15355 LAMBDA DR,SAN ANTONIO,TX 78245	University of Texas System; University of Texas Health San Antonio								ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHEN YM, 1991, ONCOGENE, V6, P1799; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; Crawford L V, 1984, Mol Biol Med, V2, P261; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEVILEE P, 1990, CYTOGENET CELL GENET, V53, P52, DOI 10.1159/000132893; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GOODRICH DW, 1992, CANCER RES, V52, P1968; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HENSEL CH, 1990, CANCER RES, V50, P3067; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; LUNDBERG C, 1987, P NATL ACAD SCI USA, V84, P2372, DOI 10.1073/pnas.84.8.2372; MACKAY J, 1988, LANCET, V2, P1384; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Maniatis T., 1982, MOL CLONING; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MUNCASTER MM, 1992, CANCER RES, V52, P654; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PROSSER J, 1990, ONCOGENE, V5, P1573; Shew J.-Y., 1989, ONCOGENE RES, V1, P205; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; THOMPSON AM, 1990, BRIT J CANCER, V61, P74, DOI 10.1038/bjc.1990.17; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VARLEY JM, 1988, ONCOGENE, V3, P87; VARLEY JM, 1989, ONCOGENE, V4, P725; VARLEY JM, 1991, ONCOGENE, V6, P413; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; XU L, 1989, VIROLOGY, V171, P331, DOI 10.1016/0042-6822(89)90600-4	72	116	118	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					279	288						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426737				2022-12-28	WOS:A1993KN00600006
J	Okimoto, T; Kohno, K; Kuwano, M; Gopas, J; Kung, HF; Ono, M				Okimoto, T; Kohno, K; Kuwano, M; Gopas, J; Kung, HF; Ono, M			Regulation of epidermal growth factor receptor by activated H-ras and V-myc oncogenes in mouse Balb/3T3 cells: Possible roles of AP-1	ONCOGENE			English	Article						H-ras; EGF receptor; AP-1; dominant negative c-jun	DENSITY-LIPOPROTEIN RECEPTOR; TRANSCRIPTION FACTOR AP-1; TUMOR-NECROSIS-FACTOR; MIDDLE T-ANTIGEN; C-FOS GENE; PROTO-ONCOGENE; MALIGNANT TRANSFORMATION; CHEMICAL CARCINOGENS; MOLECULAR-CLONING; TYROSINE KINASE	We previously reported that introduction of H-ras oncogene decreases the epidermal growth factor (EGF) binding activity to cell surface EGF receptor in mouse Balb/3T3, In this study, we have further isolated four H-ras transfectants, four v-myc transfectants and three both H-ras and v-myc (H-ras/v-myc) transfectants of mouse Balb/3T3 cells. In comparison with introduction of v-myc alone or both H-ras and v-myc oncogenes, introduction of H-ras alone resulted in a loss of [I-125]EGF binding activity to the cell surface EGF receptor, RT-PCR analysis also showed much lower levels of EGF receptor gene expression in H-ras transfectants compared to that of parental untransformed cells (Balb-Neo1), v-myc and H-ras/v-myc transfectants, Our results demonstrated the activated binding of a transcription factor, Stat1 p84/p91, which directly interacts with EGF receptor, to c-sis-inducible element (SIE) in both v-myc and H-ras/v-myc transfectants, but not in H-ras transfectants, Among transcription factors which we have analysed, activator protein 1 (AP-1) but not SP-1 was modulated by H-ras. Gel shift assays demonstrated the mobility pattern of TPA-responsive element (TRE) binding complex with AP-1 derived from H-ras transfectants migrated faster than those from Balb-Neo1, v-myc and H-ras/v-myc. Expression of c-Jun and Fra-1 was increased more than threefold in H-ras transfectants compared with Balb-Neo1, v-myc and H-ras/v-myc transfectants, but that of c-Fos, Jun B and SP-1 was unchanged, Both transient and permanent expression of H-ras enhanced AP-1 activity in mouse cells, but further co-introduction of dominant negative c-jun mutant encoding a transcriptionally inactive product inhibited the H-ras dependent AP-1 induction, Transfection of the dominant negative c-jun mutant also restored down-regulation of EGF binding by activated H-ras oncogene, Down-regulation of EGF receptor by activated H-ras and the possible involvement of a transcription factor, AP-1, will be discussed.	KYUSHU UNIV,SCH MED,DEPT BIOCHEM,FUKUOKA 81282,JAPAN; SOROKA MED CTR,LAB ONCOL,IL-84101 BEER SHEVA,ISRAEL; BEN GURION UNIV NEGEV,FAC HLTH SCI,DEPT MICROBIOL & IMMUNOL,IL-84105 BEER SHEVA,ISRAEL; NCI,FREDERICK CANC RES & DEV CTR,LAB BIOCHEM PHYSIOL,FREDERICK,MD 21702	Kyushu University; Ben Gurion University; Soroka Medical Center; Ben Gurion University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick				Gopas, Jacob/0000-0001-9289-8898				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BROWN PH, 1993, ONCOGENE, V8, P877; CARBONE A, 1991, ONCOGENE, V6, P731; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; DELAGE SB, 1994, J BIOL CHEM, V269, P18686; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DONG ZG, 1994, CARCINOGENESIS, V15, P1001, DOI 10.1093/carcin/15.5.1001; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FRISCH SM, 1990, ONCOGENE, V5, P75; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GOPAS J, 1992, CELL MOL BIOL, V38, P605; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAMANAKA R, 1992, J BIOL CHEM, V267, P13160; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; IZUMI H, 1994, EXP CELL RES, V214, P654, DOI 10.1006/excr.1994.1303; JOHNSON AC, 1992, J BIOL CHEM, V267, P1689; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KAMADA S, 1994, J BIOL CHEM, V269, P4565; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KURATOMI Y, 1987, J CELL PHYSIOL, V130, P51, DOI 10.1002/jcp.1041300109; LAUTENBERGER JA, 1981, P NATL ACAD SCI-BIOL, V78, P1518, DOI 10.1073/pnas.78.3.1518; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; ONO M, 1988, MOL CELL BIOL, V8, P4190, DOI 10.1128/MCB.8.10.4190; ONO M, 1992, EXP CELL RES, V203, P456, DOI 10.1016/0014-4827(92)90021-Y; ONO M, 1991, CELL GROWTH DIFFER, V2, P317; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SHITE S, 1988, J BIOL CHEM, V263, P19286; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STEM DF, 1986, MOL CELL BIOL, V6, P870; TAINSKY MA, 1987, MOL CELL BIOL, V7, P1280, DOI 10.1128/MCB.7.3.1280; TANIGUCHI S, 1986, JPN J CANCER RES, V77, P1193; THOMSON TM, 1990, MOL CELL BIOL, V10, P1556, DOI 10.1128/MCB.10.4.1556; TOMITA K, 1987, J BIOL CHEM, V262, P1398; TSUCHIDA N, 1982, SCIENCE, V217, P937, DOI 10.1126/science.6287573; VALVERIUS EM, 1989, MOL ENDOCRINOL, V3, P203, DOI 10.1210/mend-3-1-203; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; YASUTAKE C, 1987, CANCER RES, V47, P4894	59	22	22	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1625	1633						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622882				2022-12-28	WOS:A1996UG45800004
J	Beretta, L; Gabbay, M; Berger, R; Hanash, SM; Sonenberg, N				Beretta, L; Gabbay, M; Berger, R; Hanash, SM; Sonenberg, N			Expression of the protein kinase PKR is modulated by IRF-1 and is reduced in 5q-associated leukemias	ONCOGENE			English	Article						tumor suppressor; translation	REGULATORY FACTOR-I; IFN-INDUCIBLE GENES; TRANSCRIPTION FACTOR; CELL-GROWTH; BETA GENES; INDUCTION; CHROMOSOME; ELEMENTS; DELETION; SYSTEM	The transcription factor IRF-1 (interferon regulatory factor 1) is an activator of type I interferon and interferon-inducible genes. IRF-1 manifests tumor suppresser activity. Its overexpression results in inhibition of cell growth, and gene were demonstrated in leukemias and myelodysplasias. Although the mechanism by which IRF-1 affects cell growth is unknown, it is believed that IRF-1 activates a Set of genes that negatively regulate cell growth. The double-stranded RNA-dependent protein kinase (PKR), which is an interferon-inducible gene, contains a promoter element for the binding of IRF-1 and exhibits antiproliferative properties. Consequently, we investigated the role of IRF-1 in PKR expression. Here, we show that in IRF-1-deficient embryonic fibroblasts, PKR expression is reduced relative to wildtype cells. This result predicts diminished expression of PKR as a potential consequence of deletion of the IRF-1 gene in human leukemias. We show that cells of the human leukemic U937 cell line contain a deletion of one IRF-1 gene and express low levels of PKR. We demonstrate that upregulation of IRF-1 expression in U937 cells by transfection is sufficient to induce PKR expression. We also found a marked reduction in the expression of PKR in blood samples from two patients with myelodysplasias, carrying a deletion of chromosome 5q, a locus to which IRF-1 was mapped. These results show that IRF-1 activates PKR expression and suggest that loss of one allele of the IRF-1 gene is sufficient to affect PKR expression. Therefore, PKR is a strong candidate for a mediator of the tumor suppressor activity of IRF-1.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA; HOP ST LOUIS,INST MOLEC GENET,INSERM U301,F-75010 PARIS,FRANCE; UNIV MICHIGAN,DEPT PEDIAT,ANN ARBOR,MI 48109	McGill University; McGill University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Michigan System; University of Michigan				Laura, Beretta/0000-0002-2054-684X				CHANG CH, 1992, IMMUNOGENETICS, V35, P378; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; ITOH S, 1991, GENOMICS, V10, P1097, DOI 10.1016/0888-7543(91)90208-V; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; KIRCHHOFF S, 1995, NUCLEIC ACIDS RES, V11, P439; KORBER B, 1988, SCIENCE, V239, P1302, DOI 10.1126/science.3125612; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LEBEAU MM, 1986, J CLIN ONCOL, V4, P325, DOI 10.1200/JCO.1986.4.3.325; LEBLANC JF, 1990, MOL CELL BIOL, V10, P3987, DOI 10.1128/MCB.10.8.3987; MACDONALD NJ, 1990, CELL, V60, P767, DOI 10.1016/0092-8674(90)90091-R; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MITELMAN F, 1994, HUMAN GENE MAPPING 1, P773; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; RUFFNER H, 1993, P NATL ACAD SCI USA, V90, P11503, DOI 10.1073/pnas.90.24.11503; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; VANDENBERGHE H, 1974, NATURE, V251, P437, DOI 10.1038/251437a0; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; YAMADA G, 1991, P NATL ACAD SCI USA, V88, P532, DOI 10.1073/pnas.88.2.532	28	65	70	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1593	1596						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622878				2022-12-28	WOS:A1996UF07600026
J	Eshleman, JR; Markowitz, SD; Donover, PS; Lang, EZ; Lutterbaugh, JD; Li, GM; Longley, M; Modrich, P; Veigl, ML; Sedwick, WD				Eshleman, JR; Markowitz, SD; Donover, PS; Lang, EZ; Lutterbaugh, JD; Li, GM; Longley, M; Modrich, P; Veigl, ML; Sedwick, WD			Diverse hypermutability of multiple expressed sequence motifs present in a cancer with microsatellite instability	ONCOGENE			English	Article						replication errors (RER); repetitive sequences; nucleic acid; genomic instability; colon cancer; HPRT	GUANINE PHOSPHORIBOSYLTRANSFERASE GENE; POLYMERASE CHAIN-REACTION; ESCHERICHIA-COLI; MISMATCH REPAIR; COLORECTAL-CANCER; HUMAN FIBROBLASTS; HPRT GENE; MUTATIONS; DNA; FRAMESHIFT	Colon cancer and an increasing number of other cancers have been found to exhibit instability of DNA microsatellite sequences. Such tumors have been designated as replication errors (RER) tumors. However, as microsatellites are only rarely found within coding regions of the genome, instability of these sequences cannot directly contribute to carcinogenesis. Recently, we have shown RER colon cancers also demonstrate a marked 100-fold increase in mutation rates measured within an expressed gene, hprt, suggesting the mutator phenotype in these tumors extends beyond microsatellite sequences. To determine whether the RER phenotype indeed destabilizes non-repetitive DNA sequences we have sequenced hprt gene mutations recovered from the RER colon cancer cell line RKO. Greater than 10% of hprt mutants proved to be a single 3 bp deletion located in a nonrepetitive ATTAT sequence motif. Additionally, 1-4 bp deletions or insertions were found to be randomly located throughout the hprt gene. Lastly, one third of hprt mutations proved to be transitions or transversions. The microsatellite instability demonstrated in RKO is thus a global mutator phenotype which destabilizes DNA sequences both inside and outside of repetitive sequence elements and which augments base substitutions as well as frameshifts. These findings extend the characteristics of mutations associated with RER tumors and suggest additional mechanisms by which mutator phenotypes may alter target oncogenes and tumor suppressor genes.	UNIV CLEVELAND HOSP,DEPT MED,CLEVELAND,OH 44106; UNIV CLEVELAND HOSP,DEPT PATHOL,CLEVELAND,OH 44106; UNIV CLEVELAND HOSP,IRELAND CANC CTR,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710	Case Western Reserve University; Duke University; Howard Hughes Medical Institute			Li, Guo-Min/I-5016-2014	Li, Guo-Min/0000-0002-9842-4578; Modrich, Paul/0000-0001-8708-9885	NATIONAL CANCER INSTITUTE [P01CA051183, P30CA043703] Funding Source: NIH RePORTER; NCI NIH HHS [P0 CA4370301, CA57208, P01 CA51183] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ANDERSSON B, 1992, ENVIRON MOL MUTAGEN, V20, P89, DOI 10.1002/em.2850200204; BAO CY, 1995, MUTAT RES-FUND MOL M, V326, P1, DOI 10.1016/0027-5107(94)00152-U; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; DOHET C, 1985, P NATL ACAD SCI USA, V82, P503, DOI 10.1073/pnas.82.2.503; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GIBBS RA, 1990, GENOMICS, V7, P235, DOI 10.1016/0888-7543(90)90545-6; GIVER CR, 1993, ENVIRON MOL MUTAGEN, V22, P138, DOI 10.1002/em.2850220305; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HANKE M, 1994, BIOTECHNIQUES, V17, P858; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LITT M, 1989, AM J HUM GENET, V44, P397; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MORRIS T, 1993, SOMAT CELL MOLEC GEN, V19, P9, DOI 10.1007/BF01233950; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; OLLER AR, 1994, GENETICS, V138, P263; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARK MS, 1995, RADIAT RES, V141, P11, DOI 10.2307/3579084; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PHEAR G, 1989, J MOL BIOL, V209, P577, DOI 10.1016/0022-2836(89)90595-0; ROBERTS JD, 1993, BIOCHEMISTRY-US, V32, P4083, DOI 10.1021/bi00066a033; SCHAAPER RM, 1987, P NATL ACAD SCI USA, V84, P6220, DOI 10.1073/pnas.84.17.6220; SLOANE DL, 1988, NUCLEIC ACIDS RES, V16, P6465, DOI 10.1093/nar/16.14.6465; STEINGRIMSDOTTIR H, 1992, NUCLEIC ACIDS RES, V20, P1201, DOI 10.1093/nar/20.6.1201; STREISINGER G, 1985, GENETICS, V109, P633; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; WEBER JL, 1989, AM J HUM GENET, V44, P388; YANG JL, 1991, CARCINOGENESIS, V12, P71, DOI 10.1093/carcin/12.1.71	42	51	52	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1425	1432						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622858				2022-12-28	WOS:A1996UF07600006
J	Bies, J; Hoffman, B; Amanullah, A; Giese, T; Wolff, L				Bies, J; Hoffman, B; Amanullah, A; Giese, T; Wolff, L			B-Myb prevents growth arrest associated with terminal differentiation of monocytic cells	ONCOGENE			English	Article						B-myb; differentiation; monocytic cells; growth arrest; apoptosis	MYELOID-LEUKEMIA CELLS; C-MYB; V-MYB; TRANSCRIPTIONAL ACTIVATION; REGULATED EXPRESSION; HEMATOPOIETIC-CELLS; MESSENGER-RNA; MIM-1 GENE; A-MYB; PROLIFERATION	B-Myb is a transcriptional regulator of gene expression and is highly homologous to c-Myb in its N-terminal DNA binding domain. However, unlike c-myb, whose expression is restricted largely to immature hematopoietic cells, B-myb mRNA has been found to be expressed in all proliferating mammalian cell lines and is clearly regulated in a cell cycle dependent manner. That c-Myb and B-Myb proteins perform different roles in proliferation and/or differentiation is suggested by the redundancy of their expression. It was previously shown that deregulated c-Myb expression can inhibit IL-6 induced terminal differentiation of the leukemia cell line M1. We found that, unlike the downregulation of c-Myb protein which is an early response of progenitor M1 cells to IL-6 treatment, the downregulation of B-Myb occurs late, just prior to terminal differentiation and growth arrest. It was, therefore, of interest to examine the role of the murine B-Myb protein in the proliferation and differentiation of the M1 cells and to compare these effects to those of c-Myb in the same system. Clones ectopically producing B-Myb, like those ectopically expressing c-Myb, proliferated in the presence of the differentiation-inducing agent and did not undergo the programmed cell death which normally follows terminal macrophage differentiation. In addition, the cell-cycle distribution of M1/B-Myb cells was comparable to untreated cells. Although M1/B-Myb and M1/c-Myb clones treated with IL-6 appeared quite immature, differentiation markers were demonstrated to be maintained at near normal levels (e.g. MyD88, Mac-2), or be partially reduced in expression (C3, Fc and Mac-1 receptors) suggesting that the cells had undergone commitment to maturation, but were unable to terminally differentiate.	NCI,GENET LAB,BETHESDA,MD 20892; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NCI NIH HHS [1RO1CA51162] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051162] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARSURA M, 1994, BLOOD, V83, P1778, DOI 10.1182/blood.V83.7.1778.bloodjournal8371778; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIES J, 1995, CANCER RES, V55, P501; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GOLAY J, 1992, J IMMUNOL, V149, P300; GOLAY J, 1991, BLOOD, V77, P149; GONDA TJ, 1991, SEMINARS VIROLOGY, V2, P351; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; KU DH, 1993, J BIOL CHEM, V268, P2255; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LORD KA, 1990, ONCOGENE, V5, P1095; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sambrook J, 1989, MOL CLONING LABORATO; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; TASHIRO S, 1995, ONCOGENE, V10, P1699; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267	48	55	55	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					355	363						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570212				2022-12-28	WOS:A1996TR53800014
J	Hodge, DR; Robinson, L; Watson, D; Lautenberger, J; Zhang, XK; Venanzoni, M; Seth, A				Hodge, DR; Robinson, L; Watson, D; Lautenberger, J; Zhang, XK; Venanzoni, M; Seth, A			Interaction of ETS-1 and ERGB/FLI-1 proteins with DNA is modulated by spacing between multiple binding sites as well as phosphorylation	ONCOGENE			English	Article						ETS-1,ERGB FL1-1; transcription factors; HIV-1 enhancer; transactivation; EBS palindrome; Cam-KII phosphorylation site	TRANSCRIPTION; COMPLEX; FAMILY; GENE; IDENTIFICATION; PROTOONCOGENE; ACTIVATION; MECHANISM; SEQUENCES; ONCOGENE	ETS is a family of transcription factors that contain a highly conserved ETS DNA binding domain. Various members of the ETS family are expressed in cells of hematopoietic lineage. ETS-1, ETS-2 and ERGB/FLI-1 are expressed at high levels in T-lymphocytes. HIV-1 infects T-cells and it has been shown that its LTR contains binding sites for various transcription factors. In this study we show that the HIV-1 core enhancer is directly regulated by ERGB/FLI-1 protein positively, as well as, negatively, depending upon the presence or absence of accessory factors in different cell types. In addition, we show that the ETS-1 transactivation activity is enhanced upon dephosphorylation of the Calmodulin-dependant Protein Kinase II phosphorylation site located in exon VII. Finally, we demonstrate that the spacing two EBS cores in palindromic or direct play a crucial role in binding of ETS proteins to DNA.	UNIV TORONTO, DEPT PATHOL, TORONTO, ON M5S 1B2, CANADA; UNIV TORONTO, MRC, PERIODONTAL PHYSIOL GRP, TORONTO, ON M5S 1B2, CANADA; WOMENS COLL HOSP, MOLEC PATHOL LAB, TORONTO, ON M5S 1B2, CANADA; NCI, MOLEC ONCOL LAB, FREDERICK, MD 21702 USA; PROGRAM RESOURCES INC DYNCORP, FREDERICK, MD 21702 USA; MED UNIV S CAROLINA, CTR MOLEC & STRUCT BIOL, CHARLESTON, SC 29425 USA	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Medical University of South Carolina								ASCIONE R, 1992, INT J ONCOL, V1, P631; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CULLEN BR, 1992, AIDS RES HUM RETROV, V8, P387, DOI 10.1089/aid.1992.8.387; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DALTON S, 1993, PHILOS T ROY SOC B, V340, P325, DOI 10.1098/rstb.1993.0074; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; FISHER RJ, 1994, PROTEIN SCI, V3, P257; FLEISCHMAN LF, 1993, ONCOGENE, V8, P771; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; HODGE DR, 1993, MIAMI SHORT REP, V3, P32; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANKNECHT R, 1994, ONCOGENE, V9, P1273; KOIZUMI S, 1990, ONCOGENE, V5, P675; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; PAPAS TS, 1991, SER SYMP AD, V4, P211; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RABAULT B, 1994, J BIOL CHEM, V269, P28143; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1989, ONCOGENE RES, V5, P61; SETH A, 1993, AIDS RES HUM RETROV, V9, P1017, DOI 10.1089/aid.1993.9.1017; SETH A, 1994, ONCOGENE, V9, P469; SETH A, 1990, ONCOGENE, V5, P1761; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; VENANZONI MC, 1996, IN PRESS ONCOGENE; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WATSON DK, 1986, P NATL ACAD SCI USA, V83, P1792, DOI 10.1073/pnas.83.6.1792	31	31	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					11	18						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552380				2022-12-28	WOS:A1996TQ01400002
J	Srinivasan, R; Maxwell, SA				Srinivasan, R; Maxwell, SA			A cellular protein activates the sequence-specific DNA-binding of p53 by interacting with the central conserved region	ONCOGENE			English	Article						p53; DNA-binding; regulation; non-small cell lung carcinoma; tumor suppressors	WILD-TYPE P53; LARGE T-ANTIGEN; TUMOR-SUPPRESSOR PROTEIN; CASEIN KINASE-II; SIMIAN VIRUS-40; MOUSE P53; TRANSCRIPTIONAL ACTIVATION; CONFORMATIONAL DOMAIN; GENE-PRODUCT; RAT-CELLS	Mutational inactivation of the p53 gene product is one of the most common genetic aberrations so far identified in human cancers. The p53 protein suppresses the transformed phenotype by transactivation or repression of genes involved in cell growth control. Missense mutations in the p53 protein coding sequence observed in human cancers are clustered within a central conserved (conformational) domain spanning amino acid residues 100-300 of a total of 393. Using the conformational domain of p53 fused with protein A, we have shown that the p53 conformational domain possesses Zn+2-dependent, sequence-specific DNA-binding activity. In addition to binding DNA, this domain interacts with at least five cellular proteins ranging in sizes from 30K to 90K M(r) and with the SV40 large T antigen viral oncoprotein. We investigated these cellular proteins for their modulatory effects on the sequence-specific DNA binding activity of full-length wild-type p53. A mixture of p53 conformational domain-binding proteins in bulk enhanced the DNA-binding activity of p53 greater than two-fold. Selective elution of the p53-binding proteins from the p53 hybrid protein by using a sequential step-wise NaCl gradient implicated one protein of 35K M(r) as contributing to a greater than four-fold activation of p53 DNA-binding activity. A p53 conformational domain protein containing a tumor-derived mutation at amino acid 175 failed to associate with the 35K M(r) protein. We propose that proteins interacting with the conformational domain of wild type p53 regulate the DNA-binding activity of p53, thus providing a biochemical basis for the alterations in its function induced by point mutations.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT THORAC & CARDIOVASC SURG,SECT THORAC MOLEC ONCOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA045187, P30CA016672, R37CA045187] Funding Source: NIH RePORTER; NCI NIH HHS [CA45187, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARTEK J, 1993, EUR J CANCER, V29A, P101, DOI 10.1016/0959-8049(93)90584-3; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; EFRAT S, 1987, EMBO J, V6, P2699, DOI 10.1002/j.1460-2075.1987.tb02562.x; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FUKASAWA K, 1991, MOL CELL BIOL, V11, P3472, DOI 10.1128/MCB.11.7.3472; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON J V, 1990, New Biologist, V2, P84; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HAINAUT P, 1993, CANCER RES, V53, P1739; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HARPER JW, 1993, CELL, V75, P805; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAMAL S, 1995, ONCOGENE, V10, P2095; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JIANG D, 1993, ONCOGENE, V8, P2805; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MAXWELL SA, 1993, ONCOGENE, V8, P3421; MAXWELL SA, 1995, ONCOL REP, V2, P81; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RIDGWAY PJ, 1993, ONCOGENE, V8, P1069; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHMIEG FI, 1993, ONCOGENE, V8, P2043; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, CANCER RES, V51, P5232; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SRINIVASAN R, 1993, CANCER RES, V53, P5361; STURZBECHER HW, 1988, ONCOGENE, V3, P405; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; TISHLER RB, 1993, CANCER RES, V53, P2212; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG WW, 1994, CANCER GENE THER, V1, P1; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992	81	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					193	200						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552392				2022-12-28	WOS:A1996TQ01400024
J	Gaudino, G; Avantaggiato, V; Follenzi, A; Acampora, D; Simeone, A; Comoglio, PM				Gaudino, G; Avantaggiato, V; Follenzi, A; Acampora, D; Simeone, A; Comoglio, PM			The proto-oncogene RON is involved in development of epithelial, bone and neuro-endocrine tissues	ONCOGENE			English	Article						bone; development; MSP; neuroendocrine tissues; RON	HEPATOCYTE GROWTH-FACTOR; MACROPHAGE STIMULATING PROTEIN; TYROSINE KINASE; SCATTER FACTOR; C-MET; FACTOR-RECEPTOR; PROTOONCOGENE; CELLS; IDENTIFICATION; EXPRESSION	We previously showed that the proto-oncogene RON encodes the tyrosine kinase receptor for Macrophage Stimulating Protein (MSP), originally isolated as a chemotactic factor for peritoneal macrophages. To elucidate the biological role of MSP we studied the expression of the Ron receptor in vivo, and the response to the factor in vitro, RON specific transcripts were detectable in mouse liver from early embryonal life (day 12.5 p.c.) through adult life, Adrenal gland, spinal ganglia, skin, lung and - unexpectedly - ossification centers of developing mandible, clavicle and ribs were also positive at later stages (day 13.5-16.5 p.c.). From day 17.5 RON was expressed in the gut epithelium and in a specific area of the central nervous system, corresponding to the nucleus of the hypoglossus, In adult mouse tissues RON transcripts were observed in brain, adrenal glands, gastro-intestinal tract, testis and kidney, Epithelial, osteoclast-like and neuroendocrine cells express the Ron receptor and respond to MSP in vitro. In the neuroendocrine PC12 cell line, while NGF induced growth arrest and morphological differentiation, MSP behaved as a strong mitogen. These findings show that the Ron receptor and its ligand are involved in the development of epithelial tissues, bones, and neuroendocrine derivatives driving cells towards the proliferation program.	UNIV TURIN,CANC RES INST,SCH MED,I-10126 TURIN,ITALY; INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY	University of Turin; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)			Simeone, Antonio/ABG-5269-2020; Acampora, Dario/C-2156-2013	Simeone, Antonio/0000-0003-2693-9836; Comoglio, Paolo/0000-0002-7056-5328; Follenzi, Antonia/0000-0001-9780-300X				BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHAN AML, 1988, ONCOGENE, V2, P593; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COMOGLIO PM, 1993, HEPATOCYTE GROWTH FA, P131; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DIRENZO MF, 1991, ONCOGENE, V6, P1997; FRIEZNERDEGEN SJ, 1991, BIOCHEMISTRY-US, V30, P9781; GALIMI F, 1994, J CELL BIOL, V127, P1743, DOI 10.1083/jcb.127.6.1743; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GRANO M, 1994, J BONE MINER RES, V9, P1013; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; Kuhlenbeck H., 1973, CENTRAL NERVOUS SYST; Larsen WJ, 1993, HUMAN EMBRYOLOGY; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PFEILSCHIFTER J, 1990, J BONE MINER RES, V5, P825; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RONSIN C, 1993, ONCOGENE, V8, P1195; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SACCONE S, 1992, GENOMICS, V13, P912, DOI 10.1016/0888-7543(92)90191-T; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS OFP, 1993, DEV BIOL, V160, P293, DOI 10.1006/dbio.1993.1308; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; THEILER K, 1989, HOUSE MOUSE; THOROGOOD P, 1988, DEVELOPMENT, V103, P141; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO; WOOLF AS, 1995, J CELL BIOL, V128, P171, DOI 10.1083/jcb.128.1.171; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461	43	102	107	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2627	2637						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545120				2022-12-28	WOS:A1995TP18800019
J	Klugbauer, S; Lengfelder, E; Demidchik, EP; Rabes, HM				Klugbauer, S; Lengfelder, E; Demidchik, EP; Rabes, HM			High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident	ONCOGENE			English	Article						RET oncogene; RT-PTC1; ret/PTC1; ret/PTC3; papillary thyroid carcinoma; RET/ELE transcript	TYROSINE KINASE ONCOGENES; PROTO-ONCOGENE; CARCINOMAS; ACTIVATION; CANCER; PTC; PROTOONCOGENE; EXPRESSION; GLAND; RAS	RET rearrangement was studied in papillary thyroid carcinomas (PTC) of children exposed to radioactive fallout in Belarus after the Chernobyl accident, To detect RET rearrangement in small tissue samples from thyroidectomy specimen (12 PTC of children; 2 PTC and 1 follicular carcinoma of adults; non-tumorous thyroid tissue of 4 children and 4 adults as controls), a RT-multiplex PCR was developed using primers suited to amplify fragments in different quantities depending on the presence or absence of RET rearrangements in the tissues, The type of rearrangement was determined by RT-PCR and direct sequencing using primers for ret/PTC1, 2 and 3, Two-thirds of the papillary thyroid carcinomas of the children revealed a RET rearrangement, with ret/PTC3 being more frequent by a factor of 3 than ret/PTC1. ret/PTC2 was not detected, All RET rearrangement-positive tumors had lymph node metastasis while half of the tumors with wild-type cRET had not, More than half of the cases with ret/PTC3 expressed not only the ELE/RET transcript as expected, but also the RET/ELE transcript, Intrachromosomal rearrangement involving RET and the adjacent H4 or ELE gene on chromosome no, 10 is a very frequent event in thyroid cancer of children of the Chernobyl-contaminated zone of Belarus.	UNIV MUNICH, INST PATHOL, D-80337 MUNICH, GERMANY; UNIV MUNICH, INST RADIAT BIOL, MUNICH, GERMANY; MED HIGH SCH MINSK, CHAIR ONCOL, MINSK, BELARUS	University of Munich; University of Munich								AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; BAVERSTOCK K, 1992, NATURE, V359, P21, DOI 10.1038/359021b0; BONGARZONE I, 1989, ONCOGENE, V4, P1457; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; BOS JL, 1989, CANCER RES, V49, P4682; CHOU Q, 1992, NUCLEIC ACIDS RES, V20, P1717, DOI 10.1093/nar/20.7.1717; DIRENZO MF, 1992, ONCOGENE, V7, P2549; EZAKI H, 1991, J RADIAT RES, V32, P193, DOI 10.1269/jrr.32.SUPPLEMENT_193; FABIEN N, 1992, BRIT J CANCER, V66, P1094, DOI 10.1038/bjc.1992.416; FURMANCHUK AW, 1992, HISTOPATHOLOGY, V21, P401, DOI 10.1111/j.1365-2559.1992.tb00423.x; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; ISHIZAKA Y, 1991, ONCOGENE, V6, P1667; ITO T, 1993, CANCER RES, V53, P2940; ITO T, 1992, CANCER RES, V52, P1369; ITO T, 1994, LANCET, V344, P259; JHIANG SM, 1992, ONCOGENE, V7, P1331; JHIANG SM, 1994, CANCER LETT, V78, P69, DOI 10.1016/0304-3835(94)90033-7; JHIANG SM, 1994, J LAB CLIN MED, V123, P331; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; KUMA K, 1993, MOL BIOL EVOL, V10, P539; KWOK JBJ, 1993, ONCOGENE, V8, P2575; MINOLETTI F, 1994, GENE CHROMOSOME CANC, V11, P51, DOI 10.1002/gcc.2870110108; NAGAO M, 1990, JPN J CANCER RES, V81, P309, DOI 10.1111/j.1349-7006.1990.tb02566.x; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO M, 1993, BRIT J CANCER, V68, P460, DOI 10.1038/bjc.1993.370; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1994, ONCOGENE, V9, P509; SHORE RE, 1993, AM J EPIDEMIOL, V137, P1068, DOI 10.1093/oxfordjournals.aje.a116610; SOZZI G, 1992, GENE CHROMOSOME CANC, V5, P212, DOI 10.1002/gcc.2870050307; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TSUZUKI T, 1995, ONCOGENE, V10, P191; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; WYNFORDTHOMAS D, 1993, CRIT REV ONCOGENESIS, V4, P1; ZOU MJ, 1994, CANCER, V73, P176, DOI 10.1002/1097-0142(19940101)73:1<176::AID-CNCR2820730130>3.0.CO;2-T	40	267	271	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2459	2467						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545102				2022-12-28	WOS:A1995TP18800001
J	HOWE, LR; MARSHALL, CJ				HOWE, LR; MARSHALL, CJ			IDENTIFICATION OF AMINO-ACIDS IN P21RAS INVOLVED IN EXCHANGE FACTOR INTERACTION	ONCOGENE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; ACTIVATING PROTEIN GAP; HA-RAS P21; SACCHAROMYCES-CEREVISIAE; GENE-PRODUCT; MONOCLONAL-ANTIBODIES; MOLECULAR MECHANISM; SIGNAL-TRANSDUCTION; TRANSFORMING GENE; VULVAR INDUCTION	Through the genetic analysis of vulva development in C elegans several different sites of mutation have been identified in the let-60 ras protein which have been postulated to affect the function of normal but not oncogenic p21ras (Beitel, G. J., S. G. Clark, and H. R. Horvitz. 1990. Nature 348: 503-509). We have introduced these mutations into mammalian Ha-ras and determined their effect on the function of cellular ras (c-ras), an oncogenically activated variant D12ras and the dominant negative N17ras. From these studies we conclude that two of the mutations S89 --> F89 and DELTA103-108 destabilise ras when it is in the GDP-bound form. However mutations at A66 and G75 lead to stable proteins on which a ras exchange factor SCD25 is unable to promote the formation of ras-GTP. The mutations at A66 show for the first time that helix alpha2 of p21ras is involved in the stimulation of guanine nucleotide exchange by exchange factors.	INST CANC RES,CHESTER BEATTY LABS,237 FULHAM RD,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK				Howe, Louise/0000-0002-1468-7136				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BOYMARCOTTE E, 1989, GENE, V77, P21, DOI 10.1016/0378-1119(89)90355-7; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FASANO O, 1988, EMBO J, V7, P3375, DOI 10.1002/j.1460-2075.1988.tb03210.x; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FUJIOKA H, 1992, J BIOL CHEM, V267, P926; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HALL A, 1986, J BIOL CHEM, V261; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HAN M, 1991, GENE DEV, V5, P2188, DOI 10.1101/gad.5.12a.2188; HANCOCK JF, 1988, ONCOGENE, V3, P187; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUGHES DA, 1990, NATURE, V344, P355, DOI 10.1038/344355a0; KAVOUNIS C, 1991, FEBS LETT, V281, P235, DOI 10.1016/0014-5793(91)80401-N; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; MARSHALL CJ, 1982, NATURE, V299, P171, DOI 10.1038/299171a0; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; REY I, 1991, ONCOGENE, V6, P347; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILLUMSEN BM, 1991, MOL CELL BIOL, V11, P6026, DOI 10.1128/MCB.11.12.6026; Wittinghofer F, 1992, Semin Cancer Biol, V3, P189; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9	57	35	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2583	2590						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361768				2022-12-28	WOS:A1993LT36800032
J	HELFTENBEIN, G; ALVAREZ, CV; TUOHIMAA, P; BEATO, M				HELFTENBEIN, G; ALVAREZ, CV; TUOHIMAA, P; BEATO, M			EXPRESSION OF EPITHELIAL PHENOTYPE IS ENHANCED BY V-HA-RAS IN RAT ENDOMETRIAL CELLS IMMORTALIZED BY SV40-T ANTIGEN	ONCOGENE			English	Article							GAP JUNCTION PROTEIN; HORMONAL-REGULATION; MOLECULAR-CLONING; PRIMARY CULTURES; GRANULOSA-CELLS; MESSENGER-RNA; DIFFERENTIATION; ONCOGENES; RECEPTOR; GROWTH	To study the interplay of steroid hormones and oncogenes in the control of endometrial cell proliferation and differentiation we have generated cell lines derived from rat endometrium by expressing the immortalizing oncogenes adeno EIA or SV40 large T antigen. These lines are positive for mesenchymal markers and contain very few characteristic epithelial proteins. Cell lines expressing a temperature-sensitive mutant of SV40 T antigen exhibit a temperature-dependent morphology and growth behavior, but do not manifest an epithelial phenotype at the non-permissive temperature. Cell lines additionally infected with retroviral vectors carrying the v-Ha-ras oncogene (p21ras(Arg-12)) no longer express collagen type III and recover part of their epithelial potential by expressing cytokeratins and/or cadherin E. Some of these cells also express characteristic decidual marker proteins such as desmin, whereas others express glandular epithelial markers such as uteroglobin. Uteroglobin mRNA levels in these cells are increased by glucocorticoids. The parental temperature-sensitive cells do not contain progesterone receptor but become positive for progesterone receptor at the permissive temperature after infection with the v-Ha-ras-expressing retrovirus. Our results indicate that there is a fluent transition and overlapping between mesenchymal, glandular epithelial and decidual phenotypes of endometrial cells, suggesting that these three cell types are derived from the same stem/precursor cells. The v-Ha-ras oncogene product appears to act on the differentiation pathway at an early step prior to the distinction between decidual and glandular epithelial lineage.	UNIV MARBURG,INST MOLEKULARBIOL & TUMORFORSCH,EMIL MANNKOPFF STR 2,W-3550 MARBURG,GERMANY; UNIV TAMPERE,DETP BIOMED SCI,SF-33101 TAMPERE,FINLAND	Philipps University Marburg; Tampere University			Beato, Miguel/B-5564-2015; Alvarez, Clara V/AAN-4173-2020	Beato, Miguel/0000-0002-2878-2222; Alvarez, Clara V/0000-0003-1500-4058				AMSTERDAM A, 1988, P NATL ACAD SCI USA, V85, P7582, DOI 10.1073/pnas.85.20.7582; ARCECI RJ, 1989, P NATL ACAD SCI USA, V86, P8818, DOI 10.1073/pnas.86.22.8818; AZUMA C, 1990, J MOL ENDOCRINOL, V5, P103, DOI 10.1677/jme.0.0050103; BEATO M, 1983, REGULATION GENE EXPR, P151; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BREITKREUTZ D, 1991, CANCER RES, V51, P4402; CONTI CJ, 1984, ENDOCRINOLOGY, V114, P345, DOI 10.1210/endo-114-2-345; DHAR R, 1982, SCIENCE, V217, P934, DOI 10.1126/science.6287572; EDELMAN GM, 1983, SCIENCE, V219, P450, DOI 10.1126/science.6823544; FRANKE WW, 1978, P NATL ACAD SCI USA, V75, P5034, DOI 10.1073/pnas.75.10.5034; GERSCHENSON LE, 1979, LIFE SCI, V24, P1337, DOI 10.1016/0024-3205(79)90002-X; GILULA NB, 1972, NATURE, V235, P262, DOI 10.1038/235262a0; GLASSER SR, 1988, J CELL BIOL, V107, P2409, DOI 10.1083/jcb.107.6.2409; GLASSER SR, 1986, BIOL REPROD, V35, P463, DOI 10.1095/biolreprod35.2.463; HACKENBERG R, 1992, J STEROID BIOCHEM, V43, P599, DOI 10.1016/0960-0760(92)90284-P; HAGEN G, 1990, NUCLEIC ACIDS RES, V18, P2939, DOI 10.1093/nar/18.10.2939; HANKINS WD, 1981, CELL, V26, P91, DOI 10.1016/0092-8674(81)90036-2; HELFTENBEIN G, 1991, EUR J CELL BIOL, V56, P49; HOWELLS RD, 1984, P NATL ACAD SCI-BIOL, V81, P7651, DOI 10.1073/pnas.81.23.7651; ISOM HC, 1992, CANCER RES, V52, P940; JIN DF, 1988, ENDOCRINOLOGY, V122, P1466, DOI 10.1210/endo-122-4-1466; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; LIAU G, 1985, J BIOL CHEM, V260, P531; LYNCH MP, 1986, P NATL ACAD SCI USA, V83, P4784, DOI 10.1073/pnas.83.13.4784; Maniatis T., 1982, MOL CLONING; MCCORMACK SA, 1980, ENDOCRINOLOGY, V106, P1634, DOI 10.1210/endo-106-5-1634; MISSEYANNI A, 1991, NUCLEIC ACIDS RES, V11, P2849; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; ODIN P, 1988, J HISTOCHEM CYTOCHEM, V36, P729, DOI 10.1177/36.7.3290331; PARK OK, 1991, MOL ENDOCRINOL, V5, P967, DOI 10.1210/mend-5-7-967; PARK OK, 1991, MOL ENDOCRINOL, V5, P1931; PAUL DL, 1986, J CELL BIOL, V103, P123, DOI 10.1083/jcb.103.1.123; PAYNE PA, 1987, P NATL ACAD SCI USA, V84, P8956, DOI 10.1073/pnas.84.24.8956; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; RISEK B, 1990, J CELL BIOL, V110, P269, DOI 10.1083/jcb.110.2.269; ROGENSTREIF LJ, 1989, DEV BIOL, V133, P284; ROSEN H, 1990, MOL ENDOCRINOL, V4, P146, DOI 10.1210/mend-4-1-146; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SCRATCHARD G, 1949, ANN NY ACAD SCI, V51, P660; STENBERG EA, 1989, MOL CELL BIOL, V9, P594; TABIBZADEH S, 1991, AM J REPROD IMMUNOL, V26, P5, DOI 10.1111/j.1600-0897.1991.tb00693.x; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; TUOHIMAA P, 1992, SERONO S PUBLICATION, V90, P245; VAIDYA TB, 1991, J CELL BIOL, V114, P809, DOI 10.1083/jcb.114.4.809; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WIEHLE RD, 1990, ONCOGENE, V5, P787; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG JT, 1989, J CELL BIOL, V109, P3391, DOI 10.1083/jcb.109.6.3391	53	19	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2075	2085						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8393160				2022-12-28	WOS:A1993LP17100007
J	FRIEDRICH, TD; LAFFIN, J; LEHMAN, JM				FRIEDRICH, TD; LAFFIN, J; LEHMAN, JM			HYPOPHOSPHORYLATED RETINOBLASTOMA GENE-PRODUCT ACCUMULATES IN SV40-INFECTED CV-1 CELLS ACQUIRING A TETRAPLOID DNA CONTENT	ONCOGENE			English	Note							CHINESE-HAMSTER CELLS; SV40 LARGE-T; SUSCEPTIBILITY GENE; SIMIAN VIRUS-40; TRANSCRIPTION FACTOR; CYCLE PROGRESSION; TUMOR SUPPRESSOR; CARCINOMA-CELLS; RB PROTEIN; G1 PHASE	Simian virus 40 (SV40) infection of monkey kidney cells induces successive rounds of cellular DNA synthesis without intervening mitosis. To gain an understanding of the mechanisms responsible for disruption of cell cycle control during lytic infection, pRB phosphorylation and cell cycle distribution were examined following SV40 infection of CV-1 cells. The hypophosphorylated pRB present in confluent CV-1 cells was phosphorylated within 14 h following SV40 infection. Phosphorylated pRB then remained the predominant form as cells progressed from late G1 through S phase. Hypophosphorylated pRB reappeared as cells moved through G2 and acquired a tetraploid (>G2) DNA content. The reappearance of hypophosphorylated pRB in a population with decreasing numbers of cells in G1 phase and increasing numbers of cells in >G2 suggests that accumulation of hypophosphorylated pRB may be involved in T antigen-induced tetraploidy.	ALBANY MED COLL, DEPT MICROBIOL IMMUNOL & MOLEC GENET, A-68, 47 NEW SCOTLAND AVE, ALBANY, NY 12208 USA	Albany Medical College			Lehman, John M./AAU-4849-2020	Lehman, John/0000-0002-4478-4885	NCI NIH HHS [CA 41608] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041608, R55CA041608] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BARTEK J, 1992, ONCOGENE, V7, P101; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; EVANS GA, 1992, BIOCHEM J, V282, P759, DOI 10.1042/bj2820759; FRIEDRICH TD, 1992, J VIROL, V66, P4576, DOI 10.1128/JVI.66.7.4576-4579.1992; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HOFFMAN BD, 1991, CYTOMETRY, V12, P26, DOI 10.1002/cyto.990120105; HORAN PK, 1974, INT J CANCER, V14, P514, DOI 10.1002/ijc.2910140411; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KHANDJIAN EW, 1992, ONCOGENE, V7, P909; KITAGAWA M, 1992, ONCOGENE, V7, P1067; Laffin J, 1990, Methods Cell Biol, V33, P271; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEHMAN JM, 1974, INT J CANCER, V14, P771, DOI 10.1002/ijc.2910140611; LEHMAN JM, 1988, CYTOMETRY, V9, P52, DOI 10.1002/cyto.990090109; LEHMAN JM, 1970, J VIROL, V6, P738, DOI 10.1128/JVI.6.6.738-749.1970; LEHMAN JM, 1992, IN VITRO CELL DEV-AN, V28A, P306; LEHMAN JM, 1974, INT J CANCER, V13, P164, DOI 10.1002/ijc.2910130203; LEHMAN JM, 1990, FLOW CYTOMETRY SORTI, P623; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUCAS JJ, 1992, J IMMUNOL, V148, P1804; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; PARSONS N, 1991, THESIS ALBANY MED CO; SHACKNEY SE, 1989, CANCER RES, V49, P3344; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TERADA N, 1991, J IMMUNOL, V147, P698; THOMAS NSB, 1991, ONCOGENE, V6, P317; TRIFILLIS P, 1990, J VIROL, V64, P1345, DOI 10.1128/JVI.64.3.1345-1347.1990; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WATSON PA, 1991, CYTOMETRY, V12, P242, DOI 10.1002/cyto.990120306; WILLIAMS RT, 1992, ONCOGENE, V7, P423; ZHANG HZ, 1992, BIOCHEM BIOPH RES CO, V189, P21, DOI 10.1016/0006-291X(92)91519-V	50	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1993	8	6					1673	1677						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8389034				2022-12-28	WOS:A1993LE06400032
J	VOUSDEN, KH; VOJTESEK, B; FISHER, C; LANE, D				VOUSDEN, KH; VOJTESEK, B; FISHER, C; LANE, D			HPV-16 E7 OR ADENOVIRUS E1A CAN OVERCOME THE GROWTH ARREST OF CELLS IMMORTALIZED WITH A TEMPERATURE-SENSITIVE P53	ONCOGENE			English	Note							HUMAN PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA GENE-PRODUCT; WILD-TYPE P53; SV40 LARGE T; CERVICAL-CARCINOMA; MUTANT P53; MUTATIONAL ANALYSIS; CYCLE REGULATION; SIMIAN VIRUS-40; PROTEIN-KINASE	Rat embryo fibroblasts immortalized with a temperature-sensitive p53 mutant and ras rapidly stop proliferating at 33-degrees-C. Expression of the viral oncoproteins human papillomavirus type 16 (HPV-16) E7 or adenovirus E1A efficiently overcame this growth arrest, although cells rescued by E7 or EIA displayed no detectable changes in p53 expression. Co-transfection of HPV-16 E6, which binds and directs the degradation of human p53, affected neither growth of the cells at 33-degrees-C nor the amount or conformation of the p53 protein, possibly reflecting an inability of E6 to interact with mouse p53 in rodent cells. Our results suggest either that the temperature-sensitive p53 failed to regain full wild-type suppressor activity at 33-degrees-C or that E7 and E1A can modulate wild-type p53 growth-suppressor activity without altering the conformation or stability of the protein.	UNIV DUNDEE,DEPT BIOCHEM,CANC RES CAMPAIGN LABS,CELL TRANSFORMAT RES GRP,DUNDEE DD1 4HN,SCOTLAND	University of Dundee	VOUSDEN, KH (corresponding author), ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,NORFOLK PL,LONDON W2 1PG,ENGLAND.		Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BARTEK J, 1990, ONCOGENE, V5, P893; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHEN TM, 1992, ONCOGENE, V7, P1541; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1991, ONCOGENE, V6, P873; CROOK T, 1991, ONCOGENE, V6, P1251; DAVIES R, 1993, IN PRESS J VIROL; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; GANNON JV, 1991, NATURE, V349, P802; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; HAMEL PA, 1992, TRENDS GENET, V8, P180, DOI 10.1016/0168-9525(92)90221-O; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; INOUE H, 1992, VIROLOGY, V187, P343, DOI 10.1016/0042-6822(92)90325-J; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KLEINBERGER T, 1991, P NATL ACAD SCI USA, V88, P11143, DOI 10.1073/pnas.88.24.11143; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHAELMICHALOVITZ D, 1991, J VIROL, V65, P4160, DOI 10.1128/JVI.65.8.4160-4168.1991; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; MORRIS JDH, 1993, ONCOGENE, V8, P893; MUNGER K, 1989, J VIROL, V63, P4417; PAGANO M, 1992, ONCOGENE, V7, P1681; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SANTHANAM J, 1992, P NATL ACAD SCI USA, V88, P7605; SCHEFFNER M, 1992, EMBO J, V11, P2425, DOI 10.1002/j.1460-2075.1992.tb05307.x; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULSKY G, 1991, CANCER RES, V51, P5232; SHEFFNER M, 1990, CELL, V63, P1129; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SIMON MC, 1987, MOL CELL BIOL, V7, P2884, DOI 10.1128/MCB.7.8.2884; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TOMMASINO M, 1993, ONCOGENE, V8, P195; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOUSDEN KH, 1989, ONCOGENE, V4, P153; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; VOUSDEN KH, 1989, CANCER CELL-MON REV, V1, P43; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	89	38	40	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1697	1702						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8389035				2022-12-28	WOS:A1993LE06400036
J	YAMAMOTO, M; MARUI, N; SAKAI, T; MORII, N; KOZAKI, S; IKAI, K; IMAMURA, S; NARUMIYA, S				YAMAMOTO, M; MARUI, N; SAKAI, T; MORII, N; KOZAKI, S; IKAI, K; IMAMURA, S; NARUMIYA, S			ADP-RIBOSYLATION OF THE RHOA GENE-PRODUCT BY BOTULINUM C3 EXOENZYME CAUSES SWISS 3T3 CELLS TO ACCUMULATE IN THE G(1) PHASE OF THE CELL-CYCLE	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; IMMOBILIZED PH GRADIENTS; CLOSTRIDIUM-BOTULINUM; RIBOSYLTRANSFERASE; GROWTH; SEQUENCE; IDENTIFICATION; PURIFICATION; FIBROBLASTS; EXPRESSION	Using botulinum C3 exoenzyme, which specifically ADP-ribosylates the rho gene products (rho proteins), we examined the role of these proteins in cell cycle progression in Swiss 3T3 cells. Incubation of cell lysates with C3 exoenzyme revealed a single [P-32]ADP-ribosylated protein with an M(r) of 23K. This protein was identified as rhoA protein by isoelectric focusing and peptide mapping. When C3 exoenzyme was added to the culture, it ADP-ribosylated the substrate protein in the celts and reduced their growth rate and saturation density. The reduction was dependent on the amount of C3 exoenzyme and on the extent of ADP-ribosylation of the rho protein in the cells. Flow cytometric analysis of logarithmically growing cells showed that the enzyme treatment concentration-dependently accumulated the cells in the G1 phase of the cell cycle. When G1-enriched cells were treated with C3 exoenzyme and cell cycle progression initiated by the addition of serum was monitored, inhibition of G1-S transition was clearly observed. These results suggest that the rhoA gene product plays a critical role in G1-S progression in cultured Swiss 3T3 cells and that the ADP-ribosylation abolishes this activity and causes the cells to accumulate in G1 phase.	KYOTO UNIV,FAC MED,DEPT PHARMACOL,FIS,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT DERMATOL,KYOTO 606,JAPAN; KYOTO PREFECTURAL UNIV MED,DEPT PREVENT MED,KAMIKYO KU,KYOTO 602,JAPAN; UNIV OSAKA PREFECTURE,COLL AGR,DEPT VET SCI,SAKAI,OSAKA 591,JAPAN	Kyoto University; Kyoto University; Kyoto Prefectural University of Medicine; Osaka Metropolitan University								AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; ALTLAND K, 1985, ELECTROPHORESIS, V6, P314, DOI 10.1002/elps.1150060704; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BENZEEV A, 1980, CELL, V21, P365, DOI 10.1016/0092-8674(80)90473-0; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DEAN PN, 1980, CELL TISSUE KINET, V13, P299, DOI 10.1111/j.1365-2184.1980.tb00468.x; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MATSUI Y, 1992, GENE, V114, P43, DOI 10.1016/0378-1119(92)90705-T; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; MORII N, 1991, J BIOL CHEM, V266, P7646; MORII N, 1992, J BIOL CHEM, V267, P20921; MORII N, 1990, J BIOCHEM-TOKYO, V107, P769, DOI 10.1093/oxfordjournals.jbchem.a123123; MORII N, 1988, J BIOL CHEM, V263, P12420; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; NEMOTO Y, 1992, J BIOL CHEM, V267, P20916; ONEILL C, 1990, J CELL SCI, V95, P577; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIMPILAINEN MA, 1985, ELECTROPHORESIS, V6, P419, DOI 10.1002/elps.1150060903; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; TOMINAGA T, 1993, IN PRESS J CELL BIOL; VINDELOV LL, 1977, VIRCHOWS ARCH B, V24, P227; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	40	173	175	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1449	1455						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502473				2022-12-28	WOS:A1993LE06400007
J	RAGIMOV, N; KRAUSKOPF, A; NAVOT, N; ROTTER, V; OREN, M; ALONI, Y				RAGIMOV, N; KRAUSKOPF, A; NAVOT, N; ROTTER, V; OREN, M; ALONI, Y			WILD-TYPE BUT NOT MUTANT-P53 CAN REPRESS TRANSCRIPTION INITIATION INVITRO BY INTERFERING WITH THE BINDING OF BASAL TRANSCRIPTION FACTORS TO THE TATA MOTIF	ONCOGENE			English	Article							RNA POLYMERASE-II; HIGH-LEVEL EXPRESSION; LARGE T-ANTIGEN; C-MYC-GENE; P53 PROTEIN; ACCURATE TRANSCRIPTION; NUCLEAR-LOCALIZATION; DNA-REPLICATION; TFIID COMPLEX; PROMOTER	It has previously been shown that excess wild type (wt) p53 can repress the transcriptional activity of a variety of promoters in intact cells. To determine whether this transcriptional repression represented a direct effect of p53, wt and mutant p53 were prepared from E. coli-produced p53 and from insect cells infected with a recombinant baculovirus. When added into an in vitro transcription system, wt p53, but not mutant p53 reduced markedly transcription from the c-myc promoter, as well as from an array of other promoters, with the exception of an MHC class I gene promoter. The presence of wt p53 seemed to affect specifically the formation of the transcription preinitiation complex because preformed initiation complexes were completely refractory to wt p53, as was also the process of transcript elongation. Wild-type but not mutant p53 interfered with the stable binding of TBP and TFIIA to the TATA motif, although both wt and mutant p53 could associate in vitro with purified TBP. We propose that upon binding to TBP, wt but not mutant p53 specifically blocks the ability of TBP to engage in interactions required for efficient transcriptional initiation. This may account, at least in part, for the ability of excess wt p53 to inhibit cell proliferation and to interfere with neoplastic processes.	WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science					NCI NIH HHS [R01 CA 40099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BENGAL E, 1991, J VIROL, V65, P4910, DOI 10.1128/JVI.65.9.4910-4918.1991; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CASEY G, 1991, ONCOGENE, V6, P1791; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAHMUS ME, 1983, J BIOL CHEM, V258, P2303; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EHRLICH R, 1988, MOL CELL BIOL, V8, P695, DOI 10.1128/MCB.8.2.695; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FIRE A, 1984, J BIOL CHEM, V259, P2509; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HAHN SR, 1985, NATURE, V314, P366; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HARLOW E, 1981, J VIROL, V34, P752; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; HOFER E, 1981, CELL, V23, P585, DOI 10.1016/0092-8674(81)90154-9; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1991, CANCER RES, V51, P6304; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; Maniatis T., 1982, MOL CLONING; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; OROURKE RW, 1990, ONCOGENE, V5, P1829; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REINBERG D, 1987, J BIOL CHEM, V262, P3310; REINBERG D, 1987, J BIOL CHEM, V262, P3322; REISMAN D, 1993, IN PRESS CELL GROWTH; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; Seiberg M, 1987, Virus Genes, V1, P97; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHOHATFOORD O, 1991, NUCLEIC ACIDS RES, V19, P5191; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STURZBECHER HW, 1988, ONCOGENE, V3, P405; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Summers MD, 1987, TEXAS AGR EXPT STATI; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TAUB R, 1984, CELL, V37, P511, DOI 10.1016/0092-8674(84)90381-7; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WATT R, 1983, P NATL ACAD SCI-BIOL, V80, P6307, DOI 10.1073/pnas.80.20.6307; Weinmann Roberto, 1992, Gene Expression, V2, P81; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WIMAN KG, 1991, ONCOGENE, V6, P1633; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAWEL L, 1992, IN PRESS PROG NUCLEI	87	193	195	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1183	1193						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479742				2022-12-28	WOS:A1993KY32800009
J	CHANG, KS; FAN, YH; STASS, SA; ESTEY, EH; WANG, G; TRUJILLO, JM; ERICKSON, P; DRABKIN, H				CHANG, KS; FAN, YH; STASS, SA; ESTEY, EH; WANG, G; TRUJILLO, JM; ERICKSON, P; DRABKIN, H			EXPRESSION OF AML1 ETO FUSION TRANSCRIPTS AND DETECTION OF MINIMAL RESIDUAL DISEASE IN T(8 21)-POSITIVE ACUTE MYELOID-LEUKEMIA	ONCOGENE			English	Article							BONE-MARROW TRANSPLANTATION; POLYMERASE CHAIN-REACTION; MESSENGER-RNA; TRANSLOCATION BREAKPOINT; T(15-17) TRANSLOCATION; RAR-ALPHA; GENE; AMPLIFICATION; CLASSIFICATION; T(14-18)	The t(8;21) translocation breakpoint, which is observed in acute myeloid leukemia (AML), has recently been cloned and a fusion transcript identified. We have now designed primer sets capable of amplifying the breakpoint junction of the fusion transcript by the reverse transcription-polymerase chain reaction (RT-PCR). Primer set 821U/821D1 amplified a 200-bp DNA fragment, and primer set 821U/821D2 amplified a 1.2-kb DNA fragment in all t(8;21)-positive AML tested. Sequence analysis of the amplified DNA fragments demonstrated that all fusion transcripts were fused at exactly the same site, indicating that this translocation breakpoint occurs within a single intron of the AML1 and ETO genes. Forty-five cycles of RT-PCR were used to detect residual t(8;21)-positive leukemia cells in three patients who had been in complete remission for 1, 3 and 5 years. Minimal residual disease was found in all three samples. Northern blot analysis demonstrated that two fusion transcripts of 7 and 10 kb were expressed in the t(8;21)-positive AML and that the ETO gene is not normally expressed in the hematopoietic system. Expression of a normal 5.5-kb ETO mRNA was found in the lung. From these results we concluded that expression of the ETO gene in t(8;21)-positive AML was activated as a result of the translocation.	UNIV COLORADO,CTR HLTH SCI & CANC,DIV MED ONCOL,DENVER,CO 80262	University of Colorado System; University of Colorado Denver	CHANG, KS (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DIV LAB MED,HEMATOPATHOL PROGRAM,HOUSTON,TX 77030, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD017449] Funding Source: NIH RePORTER; NICHD NIH HHS [P01HD017449] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CHANG KS, 1992, MOL CELL BIOL, V12, P800, DOI 10.1128/MCB.12.2.800; CHANG KS, 1992, BLOOD, V79, P554; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRESCENZI M, 1988, P NATL ACAD SCI USA, V85, P4869, DOI 10.1073/pnas.85.13.4869; DELFAU MH, 1990, LEUKEMIA, V4, P1; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DOBROVIC A, 1988, BLOOD, V72, P3063; ERICKSON P, 1992, BLOOD, V80, P1825; GAO JZ, 1991, P NATL ACAD SCI USA, V88, P4882, DOI 10.1073/pnas.88.11.4882; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; LANGE W, 1989, BLOOD, V73, P1735; LEE MS, 1987, SCIENCE, V237, P175, DOI 10.1126/science.3110950; MELLENTIN JD, 1989, SCIENCE, V246, P379, DOI 10.1126/science.2799390; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PIGNON JM, 1990, LEUKEMIA, V4, P83; SHIMIZU K, 1991, GENE CHROMOSOME CANC, V3, P163, DOI 10.1002/gcc.2870030302	24	94	98	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					983	988						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455949				2022-12-28	WOS:A1993KT22000021
J	LAUDET, V; VANACKER, JM; ADELMANT, G; BEGUE, A; STEHELIN, D				LAUDET, V; VANACKER, JM; ADELMANT, G; BEGUE, A; STEHELIN, D			CHARACTERIZATION OF A FUNCTIONAL PROMOTER FOR THE HUMAN THYROID-HORMONE RECEPTOR ALPHA (C-ERBA-1) GENE	ONCOGENE			English	Article							RETINOIC ACID RECEPTOR; TRANSCRIPTION FACTOR; REGULATED EXPRESSION; NUCLEAR RECEPTORS; RESPONSE ELEMENT; OPPOSITE STRAND; BINDING-SITE; MINUTE VIRUS; BETA-GENE; RAT-CELLS	The thyroid hormone receptor alpha (THRA or c-erbA-1) gene belongs to a family of genes that encode nuclear receptors for various hydrophobic ligands such as steroids, retinoic acid and thyroid hormones. We have previously described the genomic organization of the human THRA gene, which comprises 10 exons distributed along 27 kbp of genomic DNA. We describe here a promoter that initiates THRA transcription. This promoter contains no obvious TATA-like element but is very GC rich and harbors numerous Spl sites. It also contains several sites similar to previously described cis-acting sequences including hormone-responsive elements (HREs). When transfected into cultured HeLa cells, it drives the expression of a CAT reporter gene. The activity of this human THRA promoter is enhanced by the synthetic glucocorticoid dexamethasone but seems unaffected by thyroid hormones.			LAUDET, V (corresponding author), INST PASTEUR, CNRS, URA 1160, 1 RUE CALMETTE, F-59019 LILLE, FRANCE.							AMERO SA, 1992, MOL ENDOCRINOL, V6, P3, DOI 10.1210/me.6.1.3; BAKER BS, 1990, EMBO J, V9, P879, DOI 10.1002/j.1460-2075.1990.tb08185.x; BENBROOK D, 1987, SCIENCE, V238, P788, DOI 10.1126/science.3672126; BEUG H, 1991, NUCLEAR HORMONE RECE, P355; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRADLEY DJ, 1989, P NATL ACAD SCI USA, V86, P7250, DOI 10.1073/pnas.86.18.7250; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRAND NJ, 1990, NUCLEIC ACIDS RES, V18, P6799, DOI 10.1093/nar/18.23.6799; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; Chin W.W., 1991, NUCL HORMONE RECEPTO, P79; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CULOTTA VC, 1989, MOL CELL BIOL, V9, P1376, DOI 10.1128/MCB.9.3.1376; DEBUIRE B, 1984, SCIENCE, V224, P1456, DOI 10.1126/science.6328658; DENAYER P, 1987, EUR J CLIN INVEST, V17, P106, DOI 10.1111/j.1365-2362.1987.tb02388.x; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DOZIER C, 1991, ONCOGENE, V6, P1307; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; FUJITA T, 1985, CELL, V41, P489, DOI 10.1016/S0092-8674(85)80022-2; GALTON VA, 1990, ENDOCRINOLOGY, V127, P2997, DOI 10.1210/endo-127-6-2997; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GREEN S, 1991, NUCLEAR HORMONE RECE, P15; HABER DA, 1992, NEW BIOL, V4, P97; HODIN RA, 1990, J CLIN INVEST, V85, P101, DOI 10.1172/JCI114398; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; IZUMO S, 1990, MOL BIOL CARD SYST, V3, P111; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KANAMORI A, 1992, J BIOL CHEM, V267, P739; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LAUDET V, 1991, NUCLEIC ACIDS RES, V19, P1105, DOI 10.1093/nar/19.5.1105; LAZAR MA, 1990, J BIOL CHEM, V265, P12859; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P479, DOI 10.1210/mend-2-6-479; LAZAR MA, 1989, P NATL ACAD SCI USA, V86, P7771, DOI 10.1073/pnas.86.20.7771; LEE JT, 1991, PANCREAS, V6, P96, DOI 10.1097/00006676-199101000-00013; LUADET V, 1992, CURR BIOL, V2, P93; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MANITATIS T, 1989, MOL CLONING LABORATO; MARTINEZ E, 1991, NUCLEAR HORMONE RECE, P125; MELLSTROM B, 1991, MOL ENDOCRINOL, V5, P1339, DOI 10.1210/mend-5-9-1339; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; MITSUHASHI T, 1989, J BIOL CHEM, V264, P8900; MIYAJIMA N, 1989, CELL, V57, P31, DOI 10.1016/0092-8674(89)90169-4; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MOORE D D, 1990, New Biologist, V2, P100; MUCHARDT C, 1992, EMBO J, V11, P2573, DOI 10.1002/j.1460-2075.1992.tb05322.x; NIKI K, 1981, P JPN ACAD B-PHYS, V57, P271, DOI 10.2183/pjab.57.271; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PFAHL M, 1987, NUCLEIC ACIDS RES, V15, P9613, DOI 10.1093/nar/15.22.9613; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; SAMUELS HH, 1977, J BIOL CHEM, V252, P6052; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SPEGELAERE P, 1991, J VIROL, V65, P4919, DOI 10.1128/JVI.65.9.4919-4928.1991; THOMPSON CC, 1987, SCIENCE, V237, P1610, DOI 10.1126/science.3629259; VANHILLE B, 1989, VIROLOGY, V171, P89, DOI 10.1016/0042-6822(89)90514-X; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILLS KN, 1991, MOL ENDOCRINOL, V5, P1109, DOI 10.1210/mend-5-8-1109; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	70	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1993	8	4					975	982						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455948				2022-12-28	WOS:A1993KT22000020
J	Lee, JE; Beck, TW; Wojnowski, L; Rapp, UR				Lee, JE; Beck, TW; Wojnowski, L; Rapp, UR			Regulation of A-raf expression	ONCOGENE			English	Article						A-raf; steroid hormones; glucocorticoid receptor; transcription	MAMMARY-TUMOR VIRUS; DNA-BINDING DOMAIN; ESTROGEN-RESPONSIVE ELEMENT; STEROID-HORMONE RECEPTORS; GLUCOCORTICOID RECEPTOR; GENE-EXPRESSION; TRANSCRIPTION FACTORS; MMTV PROMOTER; GROWTH-FACTOR; AMINO-ACIDS	The Raf family proto-oncogenes encode cytoplasmic protein serine/threonine kinases which play a critical role in cell growth and development, A-raf shares several functional properties with Raf-1 including transforming activity, stimulation of the Raf/MAPK pathway and the ability of dominant negative versions to functionally block Ras signalling, A-raf transcripts are predominantly expressed in the mouse urogenital tissues, Interestingly, the human A-raf promoter region contains three potential glucocorticoid response elements GRE-1, GRE-2 and GRE-3, at positions -17, -34 and -168 respectively from the transcriptional start site, DNA sequence analysis of the mouse A-raf promoter region demonstrated that GRE-1 and -2 were conserved evolutionarily, To determine whether the human A-raf GREs represent functional motifs, an expression vector for the glucocorticoid receptor was cotransfected with A-raf promoter/reporter constructs into HeLa cells, A fivefold dexamethasone-dependent induction of A-raf promoter activity was observed using constructs containing all three GRE motifs whereas point mutations in the GREs either diminished or abolished dexamethasone induction, Electrophoretic mobility shift assays (EMSAs) using purified glucocorticoid receptor DNA binding domain (DBD) demonstrated that both GRE-2 and -3 motifs interact with DBD and oligonucleotide competition experiments established that these have different affinities for DBD, Using nuclear extracts from human and rodent cell lines in EMSAs, a specific protein-DNA complex was observed with GRE-1 which displayed binding properties unlike that of glucocorticoid receptor, These results demonstrate that the A-raf promoter is regulated in part by members of the glucocorticoid family of steroid hormone receptors and suggest a model for the regulation of A-raf expression in urogenital tissues.	NCI,FREDERICK CANC RES & DEV CTR,BIOL CARCINOGENESIS & DEV PROGRAM,DYN CORP,PROGRAM RESOURCES,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,VIRAL PATHOL SECT,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick								AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEATO M, 1991, Critical Reviews in Oncogenesis, V2, P195; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; BUETTI E, 1989, NUCLEIC ACIDS RES, V17, P3065, DOI 10.1093/nar/17.8.3065; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; GOWLAND PL, 1989, MOL CELL BIOL, V9, P3999, DOI 10.1128/MCB.9.9.3999; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; LANGER SJ, 1988, MOL CELL BIOL, V8, P3872, DOI 10.1128/MCB.8.9.3872; LEE JE, 1994, GENOMICS, V20, P43, DOI 10.1006/geno.1994.1125; LU XY, 1994, EMBO J, V13, P2592, DOI 10.1002/j.1460-2075.1994.tb06549.x; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MAGNUSON NS, 1994, SEMIN CANCER BIOL, V5, P247; MIKSICEK R, 1987, EMBO J, V6, P1355, DOI 10.1002/j.1460-2075.1987.tb02375.x; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; MORLEY KL, 1987, NUCLEIC ACIDS RES, V15, P6973, DOI 10.1093/nar/15.17.6973; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NOWOCK J, 1985, NUCLEIC ACIDS RES, V13, P2045, DOI 10.1093/nar/13.6.2045; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; RAPP UR, 1991, ONCOGENE, V6, P495; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SLATER EP, 1990, MOL ENDOCRINOL, V4, P604, DOI 10.1210/mend-4-4-604; STORM SM, 1990, ONCOGENE, V5, P345; TOOHEY MG, 1990, J VIROL, V64, P4477, DOI 10.1128/JVI.64.9.4477-4488.1990; TRUSS M, 1992, J STEROID BIOCHEM, V43, P365, DOI 10.1016/0960-0760(92)90071-P; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WADEWITZ AG, 1993, ONCOGENE, V8, P1055; WINER MA, 1993, MOL REPROD DEV, V35, P16, DOI 10.1002/mrd.1080350104	41	16	18	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1669	1677						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622887				2022-12-28	WOS:A1996UG45800009
J	Hansen, R; Reddel, R; Braithwaite, A				Hansen, R; Reddel, R; Braithwaite, A			The transforming oncoproteins determine the mechanism by which p53 suppresses cell transformation: pRb-mediated growth arrest or apoptosis	ONCOGENE			English	Article						p53; retinoblastoma protein; SV40 large T antigen; transformation; cell cycle; apoptosis	WILD-TYPE P53; LARGE T-ANTIGEN; RETINOBLASTOMA GENE-PRODUCT; SV40 LARGE-T; ADENOVIRUS E1A PROTEINS; LARGE TUMOR-ANTIGEN; HUMAN-DIPLOID FIBROBLASTS; TRANSCRIPTION FACTOR E2F; SIMIAN VIRUS-40; SUSCEPTIBILITY GENE	To investigate the mechanisms by which p53 suppresses cell transformation, we used the simian virus 40 (SV40) large T antigen (LTag), the adenovirus Ela proteins, and an activated ras protein (EJ-ras), to examine different pathways of transformation for their susceptibility to suppression by p53, While p53 can suppress transformation by various oncoproteins, we have shown that it is unable to suppress the transformation of rat embryo fibroblasts (REFs) by LTag, Interestingly, the function of LTag which enables it to overcome the proliferative effects of p53 is not the binding inactivation of p53, but the binding and inactivation of the pRb family of proteins, This observation indicates that pRb mediates a suppressive effect of p53 on cell transformation, We have also observed that in contrast to LTag, both Ela and EJ-ras cause transformation-related events which are susceptible to suppression by p53, Further studies have revealed that cells expressing Ela are susceptible to p53-mediated apoptosis, while cells expressing EJ-ras are susceptible to p53-induced growth inhibition, We therefore propose that p53 suppresses transformation either by arresting cell growth (mediated by pRb in late G1) or by inducing apoptosis, with the mechanism being determined by the transforming oncoprotein(s).	CHILDRENS MED RES INST,SYDNEY,NSW 2145,AUSTRALIA	Children's Medical Research Institute - Australia; University of Sydney	Hansen, R (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV CELL BIOL,CANBERRA,ACT 0200,AUSTRALIA.		Reddel, Roger R/A-6635-2014	Reddel, Roger R/0000-0002-6302-6107				BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BELLETT AJD, 1985, MOL CELL BIOL, V5, P1933, DOI 10.1128/MCB.5.8.1933; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DICKMANNS A, 1994, J VIROL, V68, P5496, DOI 10.1128/JVI.68.9.5496-5508.1994; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; DOBBELSTEIN M, 1992, ONCOGENE, V7, P837; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EGAN C, 1989, ONCOGENE, V4, P383; ELDIERY WS, 1993, CELL, V75, P817; ELDIERY WS, 1994, CANCER RES, V54, P1169; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GERSHEY EL, 1979, J VIROL, V30, P76, DOI 10.1128/JVI.30.1.76-83.1979; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, ONCOGENE, V10, P1563; HERMEKING H, 1994, P NATL ACAD SCI USA, V91, P10412, DOI 10.1073/pnas.91.22.10412; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hiscott J B, 1980, Cold Spring Harb Symp Quant Biol, V44 Pt 1,, P343; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; JACKSON P, 1993, ONCOGENE, V8, P589; JIANG D, 1993, ONCOGENE, V8, P2805; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KASTAN MB, 1991, CANCER RES, V51, P6304; KATO J, 1993, GENE DEV, V7, P331; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LIN JY, 1991, J VIROL, V65, P2066, DOI 10.1128/JVI.65.4.2066-2072.1991; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MACLEAN K, 1994, ONCOGENE, V9, P719; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MICHAELMICHALOVITZ D, 1991, J VIROL, V65, P4160, DOI 10.1128/JVI.65.8.4160-4168.1991; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MORGANBESSER AD, 1994, NATURE, V371, P72; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; NEVINS JR, 1992, SCIENCE, V258, P424; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RAY FA, 1990, J CELL BIOCHEM, V42, P13, DOI 10.1002/jcb.240420103; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; Reed Michael, 1993, Gene Expression, V3, P95; SAKAMOTO K, 1993, ONCOGENE, V8, P1887; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SEGAWA K, 1993, ONCOGENE, V8, P543; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SOMPAYRAC L, 1992, VIROLOGY, V191, P439, DOI 10.1016/0042-6822(92)90206-5; SOMPAYRAC L, 1991, VIROLOGY, V181, P412, DOI 10.1016/0042-6822(91)90516-E; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; VOUSDEN KH, 1993, ONCOGENE, V8, P1697; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992	97	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2535	2545						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545110				2022-12-28	WOS:A1995TP18800009
J	Zhan, SL; Shapiro, DN; Helman, LJ				Zhan, SL; Shapiro, DN; Helman, LJ			Loss of imprinting of IGF2 in Ewing's sarcoma	ONCOGENE			English	Article						IGF2; Ewing's sarcoma; genomic imprinting; pediatric sarcoma	FACTOR-II GENE; GROWTH-FACTOR; WILMS-TUMOR; METHYLATION; EXPRESSION; RELAXATION; TRANSLOCATION; FUSION	yInsulin-like Growth Factor 2 (IGF2) has recently been demonstrated to be maternally imprinted in both mice and humans, We previously reported loss of imprinting (LOI) of IGF2 in rhabdomyosarcoma (RMS) where IGF2 has been shown to act as an autocrine growth factor and play an important role in pathogenesis, Since IGF2 does not appear to play a role in the pathogenesis of Ewing's sarcoma, we sought to determine whether normal IGF2 imprinting was maintained in these tumors, Of 32 Ewing's tumors examined for imprinting of IGF2, 10 were informative heterozygotes and three of these expressed IGF2 biallelically. Furthermore, all three tumors with LOI and five of seven tumors with normal imprinting transcribed IGF2 mRNA at lower levels while relatively higher levels of IGFS expression was observed in the remaining two tumors with normal imprinting, These data demonstrate altered imprinting of IGF2 occurs some Ewing's sarcomas, However, LOI of IGF2 Ewing's sarcoma was not associated with increased expression of IGF2 mRNA, suggesting that LOI may not be involved in the regulation of IGF2 expression and may be related to genetic or epigenetic abnormalities in tumors independent of IGF2 expression.	NCI, PEDIAT BRANCH, MOLEC ONCOL SECT, BETHESDA, MD 20892 USA; ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, MEMPHIS, TN 38101 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); St Jude Children's Research Hospital					NATIONAL CANCER INSTITUTE [P01CA023099, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA-23099, CA-21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARLOW DP, 1993, SCIENCE, V260, P309, DOI 10.1126/science.8469984; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; EKSBERG R, 1993, NAT GENET, V5, P143; EVERSOLECIRE P, 1993, MOL CELL BIOL, V13, P4928, DOI 10.1128/MCB.13.8.4928; GLOUDEMANS T, 1992, CANCER RES, V52, P6516; HALL JG, 1990, AM J HUM GENET, V46, P857; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; KONDO M, 1995, ONCOGENE, V10, P1193; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; MURPHY LD, 1990, BIOCHEMISTRY-US, V29, P10351, DOI 10.1021/bi00497a009; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OGAWA O, 1993, NAT GENET, V5, P408, DOI 10.1038/ng1293-408; PEDONE PV, 1994, HUM MOL GENET, V3, P1117, DOI 10.1093/hmg/3.7.1117; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RAINIER S, 1995, CANCER RES, V55, P1836; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; REIK W, 1989, NATURE, V338, P112, DOI 10.1038/338112a0; SAKAI T, 1991, AM J HUM GENET, V48, P880; SAPIENZA C, 1989, DEVELOPMENT, V107, P165; SCHNEID H, 1993, J MED GENET, V30, P353, DOI 10.1136/jmg.30.5.353; STEENMAN MJC, 1994, NAT GENET, V7, P432; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; TURCCAREL C, 1983, NEW ENGL J MED, V309, P497; VU TH, 1995, J CLIN ENDOCR METAB, V80, P1670, DOI 10.1210/jc.80.5.1670; YEE D, 1990, J CLIN INVEST, V86, P1806, DOI 10.1172/JCI114910; YUNIS EJ, 1986, AM J SURG PATHOL, V10, P54; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344	31	62	64	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2503	2507						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545106				2022-12-28	WOS:A1995TP18800005
J	Koegl, M; Courtneidge, SA; SupertiFurga, G				Koegl, M; Courtneidge, SA; SupertiFurga, G			Structural requirements for the efficient regulation of the Src protein tyrosine kinase by Csk	ONCOGENE			English	Article						Src protein tyrosine kinase; Csk protein tyrosine kinase; SH2 domain; SH3 domain; autophosphorylation site; schizosaccharomyces pomte	C-SRC; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; AUTOPHOSPHORYLATION SITE; TRANSFORMING PROTEIN; CELL-TRANSFORMATION; FAMILY KINASES; SARCOMA-VIRUS; PP60C-SRC; PHOSPHORYLATION	Protein tyrosine kinases of the Src family are negatively regulated by phosphorylation in the C-terminal tail of the molecule, A different protein tyrosine kinase, Csk, is largely responsible for this regulation, The phosphorylated tail of c-Src engages with the SH2 domain in a conformation that is associated with low kinase activity and which involves stabilization by the SH3 domain, Inducible expression of c-Src in fission yeast is lethal unless Csk is coexpressed, Using this assay we present evidence that Src regulation by C-terminal phosphorylation does not require the myristylation signal or the unique domain at the N-terminus of the Src protein, Mutagenesis of the SH3 and SH2 domains of Csk show that neither are necessary in yeast or in vitro for efficient regulation of Src, Mutation of Tyr416 of Src, a site of autophosphorylation common to most protein tyrosine kinases, abolished the ability of Src to arrest growth of S. pombe and dramatically reduces the ability to phosphorylate endogenous proteins, Tyr416 had the same effect on a shorter form of Src consisting of the kinase domain only, indicating that the mutation affects a property intrinsic to the catalytic domain, The residual activity of full-length Src mutated at Tyr416 is efficiently repressed by Csk action, suggesting that regulation by C-terminal phosphorylation does not act by preventing phosphorylation at Tyr416.	EUROPEAN MOLEC BIOL LAB, DIFFERENTIAT PROGRAMME, D-69012 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)			Superti-Furga, Giulio/F-4755-2015; Superti-Furga, Giulio/AAE-5681-2019	Superti-Furga, Giulio/0000-0002-0570-1768; 				BAGRODIA S, 1993, MOL CELL BIOL, V13, P1464, DOI 10.1128/MCB.13.3.1464; BEACH D, 1985, CURR GENET, V10, P297, DOI 10.1007/BF00365626; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BERGMAN M, 1995, MOL CELL BIOL, V15, P711; BORCHERT TV, 1994, FEBS LETT, V341, P79, DOI 10.1016/0014-5793(94)80244-0; BRAUNINGER A, 1992, GENE, V110, P205, DOI 10.1016/0378-1119(92)90649-A; BRUGGE JS, 1987, MOL CELL BIOL, V7, P2180, DOI 10.1128/MCB.7.6.2180; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COURTNEIDGE SA, 1994, SEMIN CANCER BIOL, V5, P239; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FLORIO M, 1994, MOL BIOL CELL, V5, P283, DOI 10.1091/mbc.5.3.283; HARVEY R, 1989, MOL CELL BIOL, V9, P3647, DOI 10.1128/MCB.9.9.3647; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KNIGHTON DR, 1993, P NATL ACAD SCI USA, V90, P5001, DOI 10.1073/pnas.90.11.5001; KOEGL M, 1994, BIOCHEM J, V302, P737, DOI 10.1042/bj3020737; KOEGL M, 1992, SEMIN VIROL, V2, P375; KORNBLUTH S, 1987, P NATL ACAD SCI USA, V84, P4455, DOI 10.1073/pnas.84.13.4455; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIU XQ, 1993, ONCOGENE, V8, P1119; MARIN O, 1991, J BIOL CHEM, V266, P17798; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MCLEOD M, 1987, EMBO J, V6, P729, DOI 10.1002/j.1460-2075.1987.tb04814.x; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORGAN DO, 1994, CURR OPIN CELL BIOL, V6, P239, DOI 10.1016/0955-0674(94)90142-2; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1988, J BIOCHEM-TOKYO, V104, P297, DOI 10.1093/oxfordjournals.jbchem.a122461; OKADA M, 1993, J BIOL CHEM, V268, P18070; OKADA M, 1988, BIOCHEM BIOPH RES CO, V154, P796, DOI 10.1016/0006-291X(88)90210-0; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PARTANEN J, 1991, ONCOGENE, V6, P2013; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; RUDD CE, 1993, BIOCHIM BIOPHYS ACTA, V1155, P239, DOI 10.1016/0304-419X(93)90007-Y; RUZZENE M, 1994, J BIOL CHEM, V269, P15885; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SNYDER MA, 1983, CELL, V32, P891, DOI 10.1016/0092-8674(83)90074-0; SNYDER MA, 1984, VIROLOGY, V136, P375, DOI 10.1016/0042-6822(84)90174-0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STOVER DR, 1994, J BIOL CHEM, V269, P26885; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	72	38	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2317	2329						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570183				2022-12-28	WOS:A1995TK70200016
J	Lee, GH; Ogawa, K; Nishimori, H; Drinkwater, NR				Lee, GH; Ogawa, K; Nishimori, H; Drinkwater, NR			Most liver epithelial cell lines from C3B6F(1) mice exhibit parentally-biased loss of heterozygosity at the Lci (Liver cell immortalization) locus on chromosome 4	ONCOGENE			English	Article						hepatocyte; immortalization; tumor suppressor	TUMOR PROGRESSION; MOUSE-LIVER; SHORT ARM; HEPATOCELLULAR CARCINOMAS; GENETIC SUSCEPTIBILITY; B6C3F1 MOUSE; CANCER; NEOPLASIA; BREAST; EXPRESSION	Liver epithelial cell lines established from F-1 animals generated from hepatocarcinogen-sensitive C3H/HeJ and -resistant C57BL/6J mice were analysed for loss of heterozygosity at more than 60 simple sequence repeat marker loci distributed over all of the autosomal chromosomes, Nineteen of 20 clonal cell lines showed loss of heterozygosity at a chromosome 4 locus, designated Lci (Liver cell immortalization) and in most of the cases (18 of 19), alleles from the hepatocarcinogen-resistant parental strain, C57BL/6J, were lost, Detailed deletion mapping localized the putative suppressor gene for immortalization to within a 2 cM interval which includes a cluster of genes for gap junctional proteins. We also observed a loss of heterozygosity on chromosomes 7, 14, or 17 in more than 50% of the cell lines.	ASAHIKAWA MED COLL, DEPT PATHOL, ASAHIKAWA, HOKKAIDO 078, JAPAN; UNIV WISCONSIN, SCH MED, MCARDLE LAB CANC RES, MADISON, WI 53076 USA	Asahikawa Medical College; University of Wisconsin System; University of Wisconsin Madison					NATIONAL CANCER INSTITUTE [P30CA007175, P01CA022484] Funding Source: NIH RePORTER; NCI NIH HHS [CA07175, CA22484] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; BEER DG, 1988, CANCER RES, V48, P1610; Bennett L. M., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P144; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; CHO KR, 1992, J CELL BIOCHEM, P137; DAVIS LM, 1994, CARCINOGENESIS, V15, P1637; DEVILEE P, 1994, CANCER RES, V51, P1637; DIETRICH W, 1992, GENETICS, V131, P423; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DOULL J, 1987, ARCH TOXICOL, P3; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; DRAGANI TA, 1987, J CANCER RES CLIN, V113, P223, DOI 10.1007/BF00396377; DRAGANI TA, 1991, CANCER RES, V51, P6299; DRINKWATER NR, 1986, CARCINOGENESIS, V7, P1701, DOI 10.1093/carcin/7.10.1701; DRINKWATER NR, 1991, PROG EXP TUMOR RES, V33, P1; ELICEIRI B, 1991, P NATL ACAD SCI USA, V88, P2179, DOI 10.1073/pnas.88.6.2179; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FUJIMORI M, 1991, CANCER RES, V51, P89; GARIBOLDI M, 1993, CANCER RES, V53, P209; GENUARDI M, 1989, AM J HUM GENET, V45, P73; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GRASSO P, 1975, MOUSE HEPATIC NEOPLA, P111; HANIGAN MH, 1988, CARCINOGENESIS, V9, P885, DOI 10.1093/carcin/9.6.885; HEGI ME, 1994, CANCER RES, V54, P6257; Hillyard A. L., 1993, Mouse Genome, V91, P15; HOLDER JW, 1993, CANCER RES, V53, P3475; JANSSENTIMMEN U, 1986, CARCINOGENESIS, V7, P1475, DOI 10.1093/carcin/7.9.1475; JONES G, 1974, MOUSE HEPATIC NEOPLA, P21; KADOHAMA T, 1994, ONCOGENE, V9, P2845; KRESS S, 1992, MOL CARCINOGEN, V6, P148, DOI 10.1002/mc.2940060210; LEE GH, 1989, CANCER RES, V49, P403; LEE GH, 1990, CARCINOGENESIS, V11, P1145, DOI 10.1093/carcin/11.7.1145; LEE GH, 1995, GENETICS, V139, P387; LEE GH, 1991, INT J CANCER, V47, P60, DOI 10.1002/ijc.2910470112; LEISTER I, 1990, CANCER RES, V50, P7232; MANENTI G, 1994, GENOMICS, V23, P118, DOI 10.1006/geno.1994.1466; MANENTI G, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P119; MITAKA T, 1991, HEPATOLOGY, V13, P21, DOI 10.1016/0270-9139(91)90211-D; MOLEY JF, 1992, CANCER RES, V52, P770; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; NISHIMORI H, 1994, INT J CANCER, V59, P108, DOI 10.1002/ijc.2910590120; NORDENSKJOLD M, 1988, IMPORTANT ADV ONCOLO, V4, P83; OYAMADA M, 1990, MOL CARCINOGEN, V3, P273, DOI 10.1002/mc.2940030507; Poole T. M., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P255; POTTER M, 1994, CANCER RES, V54, P969; REYNOLDS SH, 1987, SCIENCE, V237, P1309, DOI 10.1126/science.3629242; SAPIENZA C, 1991, BIOCHIM BIOPHYS ACTA, V1072, P51, DOI 10.1016/0304-419X(91)90006-7; SATO T, 1990, CANCER RES, V50, P7184; SCRABLE HJ, 1987, NATURE, V329, P645, DOI 10.1038/329645a0; SIMON D, 1991, ONCOGENE, V6, P765; THEILLET C, 1986, CANCER RES, V46, P4776; VANDAMME B, 1992, CANCER RES, V52, P6646; WANG HP, 1988, CYTOGENET CELL GENET, V48, P72, DOI 10.1159/000132593; WISEMAN RW, 1994, P NATL ACAD SCI USA, V91, P3759, DOI 10.1073/pnas.91.9.3759; WISEMAN RW, 1986, P NATL ACAD SCI USA, V83, P5825, DOI 10.1073/pnas.83.16.5825; YEH SH, 1994, CANCER RES, V54, P4188; YOSHIE M, 1994, TR SOC PATHOL JPN, V88, P157; YOSHIMOTO K, 1989, CANCER RES, V49, P2716	60	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2281	2287						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570178				2022-12-28	WOS:A1995TK70200011
J	YonishRouach, E; Deguin, V; Zaitchouk, T; Breugnot, C; Mishal, Z; Jenkins, JR; May, E				YonishRouach, E; Deguin, V; Zaitchouk, T; Breugnot, C; Mishal, Z; Jenkins, JR; May, E			Transcriptional activation plays a role in the induction of apoptosis by transiently transfected wild-type p53	ONCOGENE			English	Article						p53, apoptosis; transcriptional-activation	CELL-CYCLE CONTROL; DNA-BINDING; MONOCLONAL-ANTIBODIES; T-ANTIGEN; PROTEIN; MUTANT; TRANSFORMATION; IDENTIFICATION; INHIBITION; MUTATIONS	The p53 tumor suppressor gene has been implicated in the induction of apoptosis in several cell systems, We have recently reported that transiently-transfected wt p53 is capable of inducing apoptosis in certain transformed cell lines, We demonstrated by quantitative analysis using flow cytometry that apoptosis was restricted to the population expressing wt, but not mutant, p53, In the present study we use this model system to analyse the functional domains of p53 in the induction of apoptosis, Several constructs expressing mutations or deletions in the C-terminal oligomerization domain, the N-terminal transactivation domain or the central DNA-binding domain were introduced into HeLa cells, and the ability of the expressed proteins to induce apoptosis was evaluated, All the functional domains were found to be necessary for the induction of apoptosis, In addition, cycloheximide and actinomycin D inhibited wt p53-induced apoptosis, We therefore conclude that p53 acts in this cell system, at least in part, as a transcriptional activator in the induction of apoptosis.	INST RECH SCI CANC, CNRS, CYTOMETRIE LAB, F-94801 VILLEJUIF, FRANCE; MARIE CURIE RES INST, SURREY RH8 0TL, ENGLAND	Centre National de la Recherche Scientifique (CNRS)	YonishRouach, E (corresponding author), INST RECH SCI CANC, CNRS, ONCOL MOLEC LAB, 7 RUE GUY MOQUET, F-94801 VILLEJUIF, FRANCE.							ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HADLAR S, 1994, CANCER RES, V54, P2095; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HEBEL M, 1986, Z NATURFORSCH C, V41, P94; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEGROS Y, 1994, ONCOGENE, V9, P2071; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MAY E, 1991, ONCOGENE, V6, P1363; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OMILLI F, 1986, MOL CELL BIOL, V6, P1875, DOI 10.1128/MCB.6.6.1875; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROMANO JW, 1989, ONCOGENE, V4, P1483; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TARUNINA M, 1993, ONCOGENE, V8, P3165; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WANG YS, 1993, ONCOGENE, V8, P3427; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yonish-Rouach E, 1994, Cell Death Differ, V1, P39; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZHANG W, 1994, ONCOGENE, V9, P2513	61	61	63	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2197	2205						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570169				2022-12-28	WOS:A1995TK70200002
J	IIDA, S; SETO, M; YAMAMOTO, K; KOMATSU, H; TOJO, A; ASANO, S; KAMADA, N; ARIYOSHI, Y; TAKAHASHI, T; UEDA, R				IIDA, S; SETO, M; YAMAMOTO, K; KOMATSU, H; TOJO, A; ASANO, S; KAMADA, N; ARIYOSHI, Y; TAKAHASHI, T; UEDA, R			MLLT3 GENE ON 9P22 INVOLVED IN T(9-11) LEUKEMIA ENCODES A SERINE PROLINE-RICH PROTEIN HOMOLOGOUS TO MLLT1 ON 19P13	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; RNA POLYMERASE-II; 11Q23 TRANSLOCATIONS; CHROMOSOMAL TRANSLOCATIONS; DROSOPHILA-TRITHORAX; LARGEST SUBUNIT; BREAKPOINT; CLONING; T(4-11); T(11-19)(Q23-P13)	Recently, the MLL gene at 11q23 was found to be involved in a subset of leukemias with an 11q23 abnormality. In the present study, we isolated chimeric cDNAs between the MLL and a gene designated MLLT3 at 9p22 from a cDNA library of an IMS-M1 cell line with a t(9;11)(p22;q23) translocation, a representative karyotypic abnormality seen in acute monocytic leukemia. We also isolated a normal MLLT3 cDNA and found an open reading frame encoding at least 318 amino acids with high serine/proline content (24.8%). The chimeric mRNAs were demonstrated to be fused to MLL in frame, as found in t(11;19) and t(4;11) leukemias. The predicted MLLT3 protein demonstrated a significant homology to that of the MLLT1 gene at 19p13 involved in t(11;19) leukemia. The highest homology, up to 74.1%, was found in 86 amino acids of the C-terminus, suggesting that this region is of particular importance for leukemogenesis in t(9;11) leukemia. Northern blot analysis with the MLLT3 cDNA probe against normal tissues revealed multiple transcripts in lymphoid organs. A survey of hematopoietic cell lines demonstrated relatively stronger signals in cells belonging to megakaryocytic and erythroid lineages. As previously found in t(11;19) leukemia, heterogeneous MLL-MLLT3 chimeric mRNAs could be detected by the reverse transcriptase-polymerase chain reaction (RT-PCR) in t(9;11) leukemia samples.	AICHI CANC CTR,RES INST,CHEMOTHERAPY LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR HOSP,DEPT HEMATOL & CHEMOTHERAPY,CHIKUSA KU,NAGOYA 464,JAPAN; AICHI CANC CTR,RES INST,IMMUNOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; UNIV TOKYO,INST MED SCI,DEPT MED,MINATO KU,TOKYO 108,JAPAN; HIROSHIMA UNIV,NUCL MED & BIOL RES INST,DEPT MED,MINAMI KU,HIROSHIMA 734,JAPAN	Aichi Cancer Center; Aichi Cancer Center; University of Tokyo; Hiroshima University								ABE R, 1984, CANCER GENET CYTOGEN, V13, P121, DOI 10.1016/0165-4608(84)90053-0; AHEARN JM, 1987, J BIOL CHEM, V262, P10695; AKAO Y, 1992, CANCER RES, V52, P6083; BERGER R, 1980, LEUKEMIA RES, V4, P119, DOI 10.1016/0145-2126(80)90051-X; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRODEUR GM, 1983, CANCER GENET CYTOGEN, V8, P93, DOI 10.1016/0165-4608(83)90041-9; CIMINO G, 1992, CANCER RES, V52, P3811; CIMINO G, 1991, CANCER RES, V51, P6712; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; DYER MJS, 1990, BLOOD, V75, P709; GIBBONS B, 1990, BRIT J HAEMATOL, V74, P264, DOI 10.1111/j.1365-2141.1990.tb02581.x; GOMEZMARQUEZ J, 1988, FEBS LETT, V226, P217, DOI 10.1016/0014-5793(88)81425-X; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GU Y, 1992, P NATL ACAD SCI USA, V89, P10464, DOI 10.1073/pnas.89.21.10464; HAGEMEIJER A, 1982, CANCER GENET CYTOGEN, V5, P95, DOI 10.1016/0165-4608(82)90001-2; IIDA S, 1992, LEUKEMIA RES, V16, P1155, DOI 10.1016/0145-2126(92)90113-L; IIDA S, 1993, JPN J CANCER RES, V84, P532, DOI 10.1111/j.1349-7006.1993.tb00172.x; KANEKO Y, 1986, BLOOD, V67, P484; KANEKO Y, 1982, BLOOD, V60, P389; KATZ F, 1988, BLOOD, V71, P1438; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MCCABE NR, 1992, P NATL ACAD SCI USA, V89, P11794, DOI 10.1073/pnas.89.24.11794; MORGAN GJ, 1992, BLOOD, V80, P2172; MORRISSEY J, 1993, BLOOD, V81, P1124; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PUI CH, 1991, BLOOD, V77, P440; PUI CH, 1987, BLOOD, V69, P1289; RAIMONDI SC, 1989, BLOOD, V73, P1627; ROWLEY JD, 1992, GENE CHROMOSOME CANC, V5, P264, DOI 10.1002/gcc.2870050316; SETO M, 1992, ONCOGENE, V7, P1401; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; YAMAMOTO K, 1993, ONCOGENE, V8, P479; YAMAMOTO K, 1993, IN PRESS ONCOGENE; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	36	99	99	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3085	3092						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414510				2022-12-28	WOS:A1993MC09300025
J	OOKAWA, K; SHISEKI, M; TAKAHASHI, R; YOSHIDA, Y; TERADA, M; YOKOTA, J				OOKAWA, K; SHISEKI, M; TAKAHASHI, R; YOSHIDA, Y; TERADA, M; YOKOTA, J			RECONSTITUTION OF THE RB GENE SUPPRESSES THE GROWTH OF SMALL-CELL LUNG-CARCINOMA CELLS CARRYING MULTIPLE GENETIC ALTERATIONS	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; HUMAN PROSTATE CARCINOMA; CANCER-CELLS; TUMOR SUPPRESSOR; OSTEO-SARCOMA; P53 GENE; C-MYC; EXPRESSION; TUMORIGENICITY; PROTEIN	Multiple genetic alterations, including inactivation of the RB gene, occur commonly in small-cell lung carcinoma (SCLC). To assess a functional role of RB inactivation in the development of SCLC, an RB expression plasmid was introduced by stable transfection into SCLC cell lines, Lu-135 and N417, in which the RB gene was inactivated. Lu-135 and N417 cells transfected with the wild-type RB gene formed G418-resistant colonies twofold less efficiently than those with a mutated RB gene or with the control vector. Intact exogenous wild-type RB genes were detected only in approximately 20% of G418-resistant clones; three of 14 in Lu-135 and three of 16 in N417, respectively. Transcripts from the transfected RB gene were also detected in two of these three clones from Lu-135 and two of three from N417 but the amount of RB mRNA and protein was less than one fifth of that in normal fibroblast celts WI-38. Furthermore, clones with exogenous wild-type RB expression showed either reduced growth rates in culture or suppressed tumorigenicity in nude mice. These findings suggest that functional correction of the RB gene is sufficient to suppress the growth of SCLC cells, even though several other genetic alterations in the cells remain uncorrected.	NATL CANC CTR,1-1 TSUKIJI 5 CHOME,CHUO KU,TOKYO 104,JAPAN; KYOTO UNIV,FAC MED,DEPT PATHOL 2,KYOTO 606,JAPAN; HIROSAKI UNIV,SCH MED,DEPT INTERNAL MED 1,HIROSAKI,AOMORI 036,JAPAN	National Cancer Center - Japan; Kyoto University; Hirosaki University								BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHEN PL, 1992, CELL GROWTH DIFFER, V3, P119; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GAZDAR AF, 1985, CANCER RES, V45, P2924; GOODRICH DW, 1992, CANCER RES, V52, P1968; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MORI N, 1989, CANCER RES, V49, P5130; MORI N, 1990, ONCOGENE, V5, P101; MUNCASTER MM, 1992, CANCER RES, V52, P654; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RABITTS P, 1990, GENE CHROMOSOME CANC, V2, P231; REISSMANN PT, 1989, ONCOGENE, V4, P839; Sambrook J, 1989, MOL CLONING LABORATO; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TERASAKI T, 1986, JPN J CLIN ONCOL, V16, P203; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; XU HJ, 1991, CANCER RES, V51, P2735; XU HJ, 1991, CANCER RES, V51, P4481; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1988, ONCOGENE, V3, P471; YOKOTA J, 1988, ONCOGENE, V2, P607	40	56	58	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2175	2181						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8393162				2022-12-28	WOS:A1993LP17100018
J	SIDDIQUE, HR; RAO, VN; LEE, L; REDDY, ESP				SIDDIQUE, HR; RAO, VN; LEE, L; REDDY, ESP			CHARACTERIZATION OF THE DNA-BINDING AND TRANSCRIPTIONAL ACTIVATION DOMAINS OF THE ERG PROTEIN	ONCOGENE			English	Article							PUTATIVE ONCOGENE SPI-1; MURINE LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; ETS ONCOGENE; C-ETS-1 PROTOONCOGENE; C-ETS; V-ETS; GENE; SEQUENCE; CHROMOSOME-21	erg, an ets related gene encodes a sequence specific DNA binding transcriptional activator protein. We have identified four functional domains of erg protein that are responsible for DNA binding, transcriptional activation and negative regulation of transcriptional activation. Deletion analysis revealed that the 3'-ets domain of the erg protein is sufficient for DNA binding activity. Analysis of these deletion mutants also revealed the presence of two autonomous transcriptional activation domains, one at the amino and the other at the carboxy-terminal region. This aminoterminal transcriptional activator domain (5'-ets domain) is conserved in six of the ets genes suggesting that it (ETA, ets Transcriptional Activation domain) may contribute to a common function among these genes. The transcriptional activation function of the carboxy terminal transcriptional activation domain (CTA) was inhibited by the presence of a Negative Regulatory Transcriptional activation domain (NRT), which is located at the amino terminal region of erg DNA binding domain. These results may help in understanding the structure/function relationship of other erg/ets related proteins.	JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; PROGRAM RESOURCES INC,FREDERICK,MD 21702	Jefferson University					NATIONAL CANCER INSTITUTE [P01CA051083, R01CA057157] Funding Source: NIH RePORTER; NCI NIH HHS [CA 57157, CA 51083] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTON IA, 1988, NATURE, V336, P719, DOI 10.1038/336719a0; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1988, ONCOGENE RES, V2, P371; COQUILLAND M, 1988, ONCOGENE RES, V2, P335; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; GARDINER K, 1990, EMBO J, V9, P25, DOI 10.1002/j.1460-2075.1990.tb08076.x; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; PRASAD DDK, 1992, CANCER RES, V52, P5833; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1988, ONCOGENE, V3, P497; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1993, CANCER RES, V53, P215; RAO VN, 1992, ONCOGENE, V11, P2335; RAO VN, 1993, IN PRESS ONCOGENE; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; REDDY ESP, 1993, IN PRESS ERG ELK 1 E; REDDY ESP, 1990, CANCER RES, V50, P5013; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SETH A, 1990, ONCOGENE, V5, P1761; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; [No title captured]	48	60	60	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1751	1755						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510921				2022-12-28	WOS:A1993LG68200005
J	WOLIN, M; KORNUC, M; HONG, C; SHIN, SK; LEE, F; LAU, R; NIMER, S				WOLIN, M; KORNUC, M; HONG, C; SHIN, SK; LEE, F; LAU, R; NIMER, S			DIFFERENTIAL EFFECT OF HTLV INFECTION AND HTLV TAX ON INTERLEUKIN-3 EXPRESSION	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; T-CELL LEUKEMIA; TRANS-ACTIVATOR PROTEIN; GENE-EXPRESSION; HUMAN-LYMPHOCYTES; MULTI-CSF; RECEPTOR; POLYMERASE; ELEMENT; DNA	To characterize the interactions between human T-cell leukemia virus (HTLV) infection and cellular gene expression, we examined the expression of the lymphokine interleukin 3 (IL-3) in the presence and absence of HTLV infection. IL-3, like granulocyte-macrophage colony-stimulating factor (GM-CSF), is produced by activated but not resting T cells, but although GM-CSF is constitutively expressed in HTLV-infected T cells IL-3 mRNA cannot be detected in either unstimulated or mitogen-stimulated HTLV-infected cells by polymerase chain reaction (PCR) analysis. In contrast, transient co-transfection studies with an IL-3 promoter-CAT reporter gene and an HTLV-II Tax expression construct demonstrate that Tax can transactivate the IL-3 promoter in HTLV-uninfected T cells. To determine whether differences in IL-3 promoter-binding proteins present in HTLV-infected and uninfected T cells account for this discrepancy, DNAase I footprinting of the IL-3 promoter was performed. Although crude nuclear extracts from both cell types protected the IL-3 sequences located between base pairs -168 and -125, the sequences between -125 and -103, which contain the lymphokine consensus sequences CK-1 and CK-2, were protected by extracts from HTLV-infected but not HTLV-uninfected T cells. Deletion of the region containing the CK-1 and CK-2 sequences from an IL-3 promoter CAT construct resulted in a sixfold rise in promoter activity in HTLV-infected but not uninfected T-cell lines, indicating that this region participates in the repression of IL-3 gene expression in HTLV-infected T cells.	UNIV CALIF LOS ANGELES,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	WOLIN, M (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90024, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043025] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43025] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDWIN GC, 1990, P NATL ACAD SCI USA, V87, P3933, DOI 10.1073/pnas.87.10.3933; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; CANN AJ, 1988, ONCOGENE, V3, P123; CHAN JY, 1986, P NATL ACAD SCI USA, V83, P8669, DOI 10.1073/pnas.83.22.8669; CHIRGWIN J, 1979, BIOCHEMISTRY-US, V118, P5294; CROSS SL, 1987, CELL, V49, P4756; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EMERSON SG, 1988, J CLIN INVEST, V82, P1282, DOI 10.1172/JCI113727; FRASER JD, 1992, MOL CELL BIOL, V12, P4357, DOI 10.1128/MCB.12.10.4357; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KAUSHANSKY K, 1989, J IMMUNOL, V143, P2525; LEARY AG, 1987, BLOOD, V70, P1343; MALEFYT RD, 1990, J IMMUNOL, V145, P2297; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NIEMEYER CM, 1989, BLOOD, V73, P945; NIMER SD, 1989, J IMMUNOL, V143, P2374; NIMER SD, 1989, ONCOGENE, V4, P671; NIMER SD, 1988, MOL CELL BIOL, V8, P1979, DOI 10.1128/MCB.8.5.1979; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SALAHUDDIN SZ, 1984, SCIENCE, V223, P703, DOI 10.1126/science.6320367; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHANNON MF, 1990, MOL CELL BIOL, V10, P2950, DOI 10.1128/MCB.10.6.2950; SHOEMAKER SG, 1990, P NATL ACAD SCI USA, V87, P9650, DOI 10.1073/pnas.87.24.9650; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; STANLEY E, 1985, EMBO J, V4, P2569, DOI 10.1002/j.1460-2075.1985.tb03972.x; SUGAMURA K, 1986, Cancer Reviews, V1, P96; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; UCHIYAMA T, 1985, J CLIN INVEST, V76, P446, DOI 10.1172/JCI111992; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0; YOSHIDA MI, 1982, P NATL ACAD SCI USA, V78, P2031	39	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1905	1911						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510934				2022-12-28	WOS:A1993LG68200023
J	CLEMENTS, DA; WANG, JK; DIONNE, CA; GOLDFARB, M				CLEMENTS, DA; WANG, JK; DIONNE, CA; GOLDFARB, M			ACTIVATION OF FIBROBLAST GROWTH-FACTOR (FGF) RECEPTORS BY RECOMBINANT HUMAN FGF-5	ONCOGENE			English	Article							EXPRESSION; BINDING; CELLS; PURIFICATION; CLONING; GENE; MUTANT; FAMILY	We have purified biologically active recombinant human fibroblast growth factor 5 (FGF-5) from Escherichia coli. In the presence of heparin, recombinant FGF-5 is as active as native growth factor, demonstrating that glycosylation does not significantly potentiate FGF-5 activity. FGF-5 can bind and induce autophosphorylation of human FGF receptors (FGFR) 1 and 2. Competition binding studies show that the K(D) for FGF-5-FGFR-1 and FGF-5-FGFR-2 interactions are both between 0.5 and 1.5 x 10(-9) M.	COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,INTEGRATED PROGRAM CELLULAR MOLEC & BIOPHYS STUDIES,NEW YORK,NY 10032; RHONE POULENC RORER CENT RES,COLLEGEVILLE,PA 19426	Columbia University; Columbia University					NCI NIH HHS [CA48054] Funding Source: Medline; NIGMS NIH HHS [GM07367] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BATES B, 1991, MOL CELL BIOL, V11, P1840, DOI 10.1128/MCB.11.4.1840; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; HAUB O, 1991, DEVELOPMENT, V112, P397; HAUB O, 1990, P NATL ACAD SCI USA, V87, P8022, DOI 10.1073/pnas.87.20.8022; HEBERT JM, 1991, DEVELOPMENT, V112, P407; HUGHES RA, 1993, IN PRESS NEURON; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LIPTON SA, 1988, P NATL ACAD SCI USA, V85, P2388, DOI 10.1073/pnas.85.7.2388; LOBB RR, 1986, ANAL BIOCHEM, V154, P1, DOI 10.1016/0003-2697(86)90487-2; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REPRESA J, 1991, NATURE, V353, P561, DOI 10.1038/353561a0; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHAN X, 1987, ONCOGENE, V1, P369; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	35	44	50	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1311	1316						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8386828				2022-12-28	WOS:A1993KY32800024
J	EELES, RA; WARREN, W; KNEE, G; BARTEK, J; AVERILL, D; STRATTON, MR; BLAKE, PR; TAIT, DM; LANE, DP; EASTON, DF; YARNOLD, JR; COOPER, CS; SLOANE, JP				EELES, RA; WARREN, W; KNEE, G; BARTEK, J; AVERILL, D; STRATTON, MR; BLAKE, PR; TAIT, DM; LANE, DP; EASTON, DF; YARNOLD, JR; COOPER, CS; SLOANE, JP			CONSTITUTIONAL MUTATION IN EXON-8 OF THE P53 GENE IN A PATIENT WITH MULTIPLE PRIMARY TUMORS - MOLECULAR AND IMMUNOHISTOCHEMICAL FINDINGS	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; CANCER FAMILY SYNDROME; LI-FRAUMENI SYNDROME; POINT MUTATIONS; DNA; SUPPRESSOR; CARCINOMAS; ONCOGENE; SARCOMAS; TUMORS	We report a constitutional mutation of codon 273 in exon 8 of the p53 gene. The affected individual has developed multiple independent benign and malignant tumours (tricholemmoma of the scalp, multiple trichoepitheliomata of the face, osteosarcoma of the ovary, bilateral breast cancer, maligant fibrous histiocytoma of the thigh and endometrial adenocarcinoma) and belongs to a family with some, but not all, features of the Li-Fraumeni syndrome. The mutation, found in both blood lymphocyte and tumour specimens, is a cytosine to thymine transition at codon 273, resulting in an amino acid change from arginine to cysteine. The mother and sister of the index case both died of tumours at an early age. We have demonstrated that formalin-preserved material from these tumours contains the same C-->T mutation at codon 273, indicating that this mutation has probably been transmitted through the germline. All tumours from the index case, both benign and malignant, showed immunohistochemical positivity with four antibodies to the p53 protein. Positive staining was also seen in scattered nuclei of morphologically normal epidermal keratinocytes and pilosebaceous cells, but not in lymphocytes or other morphologically normal cells from the index case. However, a similar staining pattern in apparently normal tissue was also observed in 13/48 sections from other individuals with various skin conditions (melanocytic naevi, psoriasis and normal skin adjacent to malignant melanoma and fibrous histiocytomas), suggesting that this pattern of p53 staining may not be unique to individuals with constitutional p53 mutations.	ROYAL MARSDEN HOSP, DEPT HISTOPATHOL, SUTTON SM2 5PT, SURREY, ENGLAND; INST HEMATOL & BLOOD TRANSFUS, DEPT TUMOUR BIOL, CS-10103 PRAGUE, CZECHOSLOVAKIA; UNIV DUNDEE, DEPT BIOCHEM, CANC RES CAMPAIGN LABS, DUNDEE DD1 4HN, SCOTLAND; INST CANC RES, MOLEC CARCINOGENESIS SECT, SUTTON SM2 5NG, SURREY, ENGLAND; INST CANC RES, EPIDEMIOL SECT, SUTTON SM2 5NG, SURREY, ENGLAND; ROYAL MARSDEN HOSP, DEPT GYNAECOL ONCOL, LONDON SW3 6JJ, ENGLAND	Royal Marsden NHS Foundation Trust; Institute of Hematology Prague; University of Dundee; University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust	EELES, RA (corresponding author), ROYAL MARSDEN HOSP, CRC, ACAD UNIT RADIOTHERAPY & ONCOL, DOWNS RD, SUTTON SM2 5PT, SURREY, ENGLAND.		Bartek, Jiri/G-5870-2014; Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545; Eeles, Rosalind/0000-0002-3698-6241				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARTEK J, 1991, ONCOGENE, V6, P1699; BARTKOVA J, 1991, INT J CANCER, V49, P196, DOI 10.1002/ijc.2910490209; CASEY G, 1991, ONCOGENE, V6, P1791; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; EHRLICH M, 1981, SCIENCE, V212, P1350, DOI 10.1126/science.6262918; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HARTLEY AL, 1989, CANCER GENET CYTOGEN, V42, P221, DOI 10.1016/0165-4608(89)90090-3; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LAW JC, 1991, CANCER RES, V51, P6385; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI FP, 1988, CANCER RES, V48, P5358; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; METZGER AK, 1991, P NATL ACAD SCI USA, V88, P7825, DOI 10.1073/pnas.88.17.7825; MIDGLEY CA, 1992, J CELL SCI, V101, P183; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PROSSER J, 1990, ONCOGENE, V5, P1573; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STRATTON MR, 1990, ONCOGENE, V5, P1297; STRATTON MR, 1989, CANCER RES, V49, P6324; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; VARLEY JM, 1991, ONCOGENE, V6, P413; VOJETSEK B, 1992, IN PRESS J IMMUNOL M	33	74	77	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1269	1276						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479749				2022-12-28	WOS:A1993KY32800019
J	FELIX, CA; STRAUSS, EA; DAMICO, D; TSOKOS, M; WINTER, S; MITSUDOMI, T; NAU, MM; BROWN, DL; LEAHEY, AM; HOROWITZ, ME; POPLACK, DG; COSTIN, D; MINNA, JD				FELIX, CA; STRAUSS, EA; DAMICO, D; TSOKOS, M; WINTER, S; MITSUDOMI, T; NAU, MM; BROWN, DL; LEAHEY, AM; HOROWITZ, ME; POPLACK, DG; COSTIN, D; MINNA, JD			A NOVEL GERMLINE P53 SPLICING MUTATION IN A PEDIATRIC-PATIENT WITH A 2ND MALIGNANT NEOPLASM	ONCOGENE			English	Article							CELLULAR PROTEIN P53; BREAST-CANCER; GENE; TUMOR; RETINOBLASTOMA; IDENTIFICATION; ANTIBODIES; EXPRESSION; COMPLEX	A novel germline p53 splicing mutation was identified in a pediatric patient with two metachronous primary cancers that are constituent tumors of the Li-Fraumeni syndrome. Genomic DNA from the second tumor showed the same mutation and loss of heterozygosity at the p53 locus. The mutant mRNA and protein were present in the tumor tissue. In contrast, in the normal tissues bearing the germline mutation in the heterozygous state, predominantly normal mRNA was expressed and the mutant p53 protein was not detectable. The functional silence and relative lack of mutant p53 mRNA expression in the normal tissues of this patient may be caused by decreased stability or decreased production. If this proves a more general pattern of expression of mutant p53 in individuals with germline mutations, these findings may explain the paucity of tumors in individuals affected with the Li-Fraumeni syndrome.	USN,MED ONCOL BRANCH,BETHESDA,MD 20892; UNIV TEXAS,SW MED CTR,SIMMONS COMPREHENS CANC RES CTR,DALLAS,TX 75235; NCI,PEDIAT BRANCH,BETHESDA,MD 20892; NCI,MED BRANCH,BETHESDA,MD 20892; NCI,PATHOL LAB,BETHESDA,MD 20892	United States Department of Defense; United States Navy; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	FELIX, CA (corresponding author), CHILDRENS HOSP,DEPT PEDIAT,DIV ONCOL,34TH ST & CIVIC CTR BLVD,ROOM 9093,PHILADELPHIA,PA 19104, USA.			Mitsudomi, Tetsuya/0000-0001-9860-8505				ADDISON C, 1990, ONCOGENE, V5, P423; BODNER SM, 1992, ONCOGENE, V7, P743; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CRAWFORD LV, 1982, INT J CANCER, V30, P403, DOI 10.1002/ijc.2910300404; DAMICO D, 1992, ONCOGENE, V7, P339; DEFROMENTEL CC, 1987, INT J CANCER, V39, P185, DOI 10.1002/ijc.2910390211; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FELIX CA, 1992, CANCER RES, V52, P2243; FELIX CA, 1992, J CLIN INVEST, V89, P649; FIDLER AE, 1992, LANCET, V339, P243, DOI 10.1016/0140-6736(92)90042-2; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IAVARONE A, 1992, P NATL ACAD SCI USA, V89, P4207, DOI 10.1073/pnas.89.9.4207; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LI FP, 1969, J NATL CANCER I, V43, P1365; LI FP, 1991, CANCER EPIDEM BIOMAR, V1, P91; LI FP, 1992, J NATL CANCER I, V84, P1156, DOI 10.1093/jnci/84.15.1156; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MEADOWS AT, 1988, B CANCER, V75, P125; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MULLEN MP, 1991, GENE DEV, V5, P642, DOI 10.1101/gad.5.4.642; NEGLIA JP, 1991, NEW ENGL J MED, V325, P1330, DOI 10.1056/NEJM199111073251902; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; WINTER SF, 1993, IN PRESS CANCER RES; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZHANG W, 1992, ONCOGENE, V7, P1645	44	48	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1203	1210						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479743				2022-12-28	WOS:A1993KY32800011
J	MORGAN, IM; ASANO, M; HAVARSTEIN, LS; ISHIKAWA, H; HIIRAGI, T; ITO, Y; VOGT, PK				MORGAN, IM; ASANO, M; HAVARSTEIN, LS; ISHIKAWA, H; HIIRAGI, T; ITO, Y; VOGT, PK			AMINO-ACID SUBSTITUTIONS MODULATE THE EFFECT OF JUN ON TRANSFORMATION, TRANSCRIPTIONAL ACTIVATION AND DNA-REPLICATION	ONCOGENE			English	Article							C-JUN; V-JUN; BINDING PROTEINS; MAMMALIAN-CELLS; LEUCINE ZIPPER; FOS; ONCOGENE; AP-1; INVITRO; ENCODES	The retroviral oncogene v-jun and its cellular counterpart code for proteins that function as major components of the transcription factor complex AP-1. Jun proteins bind to the AP-1 consensus sequence as homodimers or heterodimers with members of the Fos protein family. This report compares the ability of viral and cellular Jun proteins (v-Jun and c-Jun) to activate transcription and to stimulate DNA synthesis. The effect of amino acid substitutions on cellular transformation is also described. In F9 cells c-Jun is a more effective transactivator than v-Jun, which carries two amino acid substitutions in the carboxy-terminal region that together down-regulate transactivation. The delta deletion, present in the amino-terminal region of v-Jun, does not affect transactivation in F9 cells; however, it does modulate the stimulation of DNA synthesis. When delta is deleted, the amino acid substitutions are without consequence on DNA synthesis. In the presence of delta the amino acid substitutions down-regulate DNA synthesis. Deletion of the Jun transactivation domain, which is required for cellular transformation, abolishes both transactivation and stimulation of DNA synthesis. We conclude that transformation, transactivation and stimulation of DNA synthesis all depend on the presence of the transactivation domain. The three functions are, however, not tightly correlated, and further work is needed to define the role of the biochemical activities of Jun in oncogenesis.	USC,SCH MED,DEPT MICROBIOL,2011 ZONAL AVE,HMR 401,LOS ANGELES,CA 90033; KYOTO UNIV,INST VIRUS RES,SAKYO KU,KYOTO 606,JAPAN; NORRIS CANC CTR,LOS ANGELES,CA 90033	University of Southern California; Kyoto University			Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500; Havarstein, Leiv Sigve/0000-0001-8250-4322	NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42564] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL R, 1990, NEW BIOL, V1, P35; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BENBROOK DM, 1990, ONCOGENE, V5, P295; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; FRAME MC, 1991, ONCOGENE, V6, P205; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MORGAN IM, 1992, ONCOGENE, V7, P1119; MURAKAMI Y, 1991, P NATL ACAD SCI USA, V88, P3947, DOI 10.1073/pnas.88.9.3947; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; OLIVIERO S, 1992, IN PRESS GENES DEV; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SASSONECORSI P, 1990, ONCOGENE, V5, P427; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WASYLYK C, 1990, ONCOGENE, V5, P1055; WONG WY, 1992, IN PRESS ONCOGENE; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x	36	37	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1135	1140						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479738				2022-12-28	WOS:A1993KY32800004
J	RONSIN, C; MUSCATELLI, F; MATTEI, MG; BREATHNACH, R				RONSIN, C; MUSCATELLI, F; MATTEI, MG; BREATHNACH, R			A NOVEL PUTATIVE RECEPTOR PROTEIN TYROSINE KINASE OF THE MET FAMILY	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; RENAL-CELL CARCINOMA; SCATTER FACTOR; PROTOONCOGENE PRODUCT; SIGNAL TRANSDUCTION; HUMAN-CHROMOSOME; MESSENGER-RNAS; GENE-PRODUCT; DNA-SEQUENCE; REGION 3P21	By successive screenings of cDNA libraries prepared from human tumours and from human foreskin keratinocytes, we have isolated overlapping cDNAs coding for a novel protein which we call Ron, with sequence characteristics of a receptor protein tyrosine kinase. Ron is a 1400 amino acid protein structurally similar to the 1408 amino acid product of the C-MET proto-oncogene, the receptor for hepatocyte growth factor and scatter factor. The two proteins have 63% overall sequence identity in their intracellular regions. We have localised the RON gene to human chromosome region 3p21, a region frequently deleted in small cell carcinoma of the lung and in renal cell carcinoma, and which is believed to harbour unidentified tumour suppressor genes. Interestingly, normal lung tissue contains transcripts of the RON gene.	CHR NANTES,INST BIOL,INSERM,U211,9 QUAI MONCOUSU,F-44035 NANTES,FRANCE; GRP HOSP TIMONE,HOP ENFANTS,INSERM,U242,F-13385 MARSEILLE 5,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille			Muscatelli, Françoise/P-4650-2016; Breathnach, Richard/K-7599-2015	Muscatelli, Françoise/0000-0003-4001-6528; 				ANGLARD P, 1992, CANCER RES, V52, P348; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; COOPER CS, 1992, ONCOGENE, V7, P3; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510; GIORDANO S, 1989, ONCOGENE, V4, P1383; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HANKS SK, 1988, SCIENCE, V241, P45; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROSEN EM, 1991, CELL GROWTH DIFFER, V2, P603; Sambrook J, 1989, MOL CLONING LABORATO; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; TAYLORPAPADIMITRIOU J, 1982, CELL DIFFER DEV, V11, P169, DOI 10.1016/0045-6039(82)90008-2; TEMPEST PR, 1988, BRIT J CANCER, V58, P1; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; WITTE ON, 1989, MOL CELL BIOL, V9, P1263; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	49	325	345	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1195	1202						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8386824				2022-12-28	WOS:A1993KY32800010
J	CRENON, I; BERAUD, C; SIMARD, P; MONTAGNE, J; VESCHAMBRE, P; JALINOT, P				CRENON, I; BERAUD, C; SIMARD, P; MONTAGNE, J; VESCHAMBRE, P; JALINOT, P			THE TRANSCRIPTIONALLY ACTIVE FACTORS MEDIATING THE EFFECT OF THE HTLV-I TAX TRANSACTIVATOR ON THE IL-2R-ALPHA KAPPA-B ENHANCER INCLUDE THE PRODUCT OF THE C-REL PROTOONCOGENE	ONCOGENE			English	Article							RECEPTOR GENE-EXPRESSION; DNA-BINDING SUBUNIT; CELLULAR PROTEINS; 65-KD SUBUNIT; ALPHA-GENE; ACTIVATION; FAMILY; HIV; POLYPEPTIDE; INHIBITION	The transactivator HTLV-1 Tax activates the promoter of the gene coding for the interleukin 2 alpha-chain receptor (IL-2Ralpha) via a kappaB site that can bind several protein species of the rel family. Tax1 strongly activates the enhancer activity of this motif, in both epithelial HeLa and lymphoid Jurkat cells. This activation was not observed in undifferentiated embryocarcinoma F9 cells. Overexpression of the p50, p65 and Rel proteins in these cells showed that significant activation of the IL-2Ralpha kappaB site was observed only with Rel and Rel plus p65. Moreover, whereas both Tax and phorbol 12-myristate 13-acetate (PMA) are able to efficiently induce the binding of NF-kappaB to the IL-2Ralpha kappaB site, PMA is functionally inactive. Using the DNA affinity precipitation assay, we observed that Tax1 is able to efficiently induce the binding of Rel, whereas PMA is not. This established a clear difference between both stimuli, indicating that Rel is the functionally active factor. We conclude from these results that the functional activity of members of the rel family is regulated by their interaction with DNA and that Rel can be a potent transcriptional activator on specific kappaB sites.	ECOLE NORMALE SUPER LYON,BIOL MOLEC & CELLULAIRE LAB,46 ALLEE ITALIE,F-69364 LYON 7,FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON)				Philippe, Veschambre/0000-0001-6094-6795				ALEXANDRE C, 1991, J VIROL, V6, P543; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BERAUD C, 1991, EMBO J, V10, P3795, DOI 10.1002/j.1460-2075.1991.tb04949.x; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BROWNELL E, 1989, ONCOGENE, V4, P935; CHEVALLIERGRECO A, 1989, J VIROL, V63, P615, DOI 10.1128/JVI.63.2.615-623.1989; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; FRANZA BR, 1987, NATURE, V330, P391, DOI 10.1038/330391a0; FUJISAWA JI, 1991, J VIROL, V65, P4525, DOI 10.1128/JVI.65.8.4525-4528.1991; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HASKILL LK, 1991, CELL, V65, P1281; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LEE JH, 1991, ONCOGENE, V6, P665; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MONTAGNE J, 1990, EMBO J, V9, P957, DOI 10.1002/j.1460-2075.1990.tb08194.x; NAKAMURA M, 1989, NUCLEIC ACIDS RES, V17, P5207, DOI 10.1093/nar/17.13.5207; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PAN D, 1992, EMBO J, V11, P1837, DOI 10.1002/j.1460-2075.1992.tb05235.x; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, TRENDS CELL BIOL, V10, P3805; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6	45	54	55	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					867	875						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455941				2022-12-28	WOS:A1993KT22000007
J	DANIEL, J; SPIEGELMAN, GB; WEEKS, G				DANIEL, J; SPIEGELMAN, GB; WEEKS, G			CHARACTERIZATION OF A 3RD RAS GENE, RASB, THAT IS EXPRESSED THROUGHOUT THE GROWTH AND DEVELOPMENT OF DICTYOSTELIUM-DISCOIDEUM	ONCOGENE			English	Article							VULVAR INDUCTION; CELL-LINE; PROTEIN; BINDING; FAMILY; CDNAS; MICROINJECTION; TRANSFORMATION; IDENTIFICATION; SEQUENCES	Previous reports have indicated that the cellular slime mold Dictyostelium discoideum possesses two ras genes (rasG and rasD) and one rap gene (rap1). All three genes are developmentally regulated, with each showing a different pattern of transcription during the Dictyostelium life cycle. To establish whether there are additional ras or rap genes in Dictyostelium, we used -degenerate oligonucleotide primers to the highly conserved GTP-binding domains and both ras- and rap-unique sequences to amplify products from cDNA using the polymerase chain reaction (PCR). No additional rap genes were amplified, but a fragment whose nucleotide sequence predicted a novel ras gene was isolated. Using this PCR product as a probe, a full-length cDNA clone was isolated and sequenced. Its deduced amino acid sequence predicted a 197 amino acid protein that is 71% and 68% identical to RasG and RasD respectively. The new ras gene contains the conserved Ras-specific effector domain, the conserved binding site for the Ras-specific Y13-259 monoclonal antibody, and shows greater sequence similarity to the human H-Ras protein than to any other mammalian Ras protein. In view of this high level of identity to the ras gene subfamily, we have designated this gene rasB. Northern blot analysis has shown that rasB is developmentally regulated with maximum levels of a single 950-bp message detected during vegetative growth and the first 8 h of development.	UNIV BRITISH COLUMBIA,DEPT MICROBIOL,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER V6T 1Z3,BC,CANADA	University of British Columbia; University of British Columbia								BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BONNER JT, 1947, J EXP ZOOL, V106, P1, DOI 10.1002/jez.1401060102; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4380, DOI 10.1093/nar/17.11.4380; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCUCCI SM, 1970, J CELL BIOL, V45, P399, DOI 10.1083/jcb.45.2.399; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KRISTENSEN T, 1987, NUCLEIC ACIDS RES, V15, P5507, DOI 10.1093/nar/15.14.5507; LOOMIS WF, 1982, DEV DICTYOSTELIUM DI; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LUDERUS MEE, 1988, J CELL SCI, V90, P701; Maniatis T., 1982, MOL CLONING; MAUDAULE P, 1985, CELL, V41, P31; MIYAKE S, 1990, EMBO J, V9, P1417, DOI 10.1002/j.1460-2075.1990.tb08257.x; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PIZON V, 1988, ONCOGENE, V3, P201; REYMOND CD, 1986, NATURE, V323, P340, DOI 10.1038/323340a0; REYMOND CD, 1984, CELL, V39, P141, DOI 10.1016/0092-8674(84)90199-5; ROBBINS SM, 1990, NUCLEIC ACIDS RES, V18, P5265, DOI 10.1093/nar/18.17.5265; ROBBINS SM, 1989, P NATL ACAD SCI USA, V86, P938, DOI 10.1073/pnas.86.3.938; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SAXE SA, 1990, MOL CELL BIOL, V10, P2367, DOI 10.1128/MCB.10.5.2367; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; THIERY R, 1992, IN PRESS BIOCH CELL; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANHAASTERT PJM, 1987, P NATL ACAD SCI USA, V84, P4905	40	32	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1041	1047						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455930				2022-12-28	WOS:A1993KT22000028
J	STOREY, A; BANKS, L				STOREY, A; BANKS, L			HUMAN PAPILLOMAVIRUS TYPE-16 E6-GENE COOPERATES WITH EJ-RAS TO IMMORTALIZE PRIMARY MOUSE CELLS	ONCOGENE			English	Article							HUMAN FORESKIN KERATINOCYTES; HUMAN EPITHELIAL-CELLS; CERVICAL-CARCINOMA; ACTIVATED RAS; TUMOR-ANTIGEN; GENE-PRODUCT; E7 GENE; P53; TRANSFORMATION; EXPRESSION	Human papillomaviruses (HPVs) are small DNA tumor viruses, a subset of which is closely associated with the development of cervical cancer. The viral E6 and E7 open reading frames encode multifunctional proteins that bind respectively to the p53 protein and to the product of the retinoblastoma tumor-suppressor gene. In this study we demonstrate that the HPV-16 E6 gene cooperates with EJ-ras to immortalize primary cultures of mouse kidney epithelial cells. HPV-16-immortalized cell lines expressing E6 but not E7 contained low levels of wild-type p53 protein. In contrast, those cells immortalized by EJ-ras alone contained elevated p53 protein levels, and were shown to contain a mutation in the gene, These results suggest that activating mutations in the p53 gene can functionally substitute for HPV-16 E6 in transforming primary cells.			STOREY, A (corresponding author), INT CTR GENET ENGN & BIOTECHNOL,PADRICIANO 99,I-34012 TRIESTE,ITALY.			Storey, Alan/0000-0003-2001-9772				BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARTEK J, 1990, ONCOGENE, V5, P893; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1991, ONCOGENE, V6, P873; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1984, NUCLEIC ACIDS RES, V12, P5609, DOI 10.1093/nar/12.14.5609; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KAUR P, 1989, J GEN VIROL, V70, P1261, DOI 10.1099/0022-1317-70-5-1261; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MUNGER K, 1989, J VIROL, V63, P4417; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PECORARO G, 1989, P NATL ACAD SCI USA, V86, P563, DOI 10.1073/pnas.86.2.563; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SOUSSI T, 1990, ONCOGENE, V5, P945; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989	40	73	78	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					919	924						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8384359				2022-12-28	WOS:A1993KT22000013
J	SELF, AJ; PATERSON, HF; HALL, A				SELF, AJ; PATERSON, HF; HALL, A			DIFFERENT STRUCTURAL ORGANIZATION OF RAS-EFFECTOR AND RHO-EFFECTOR DOMAINS	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; GENE-PRODUCT; TRIPHOSPHATE CONFORMATION; BINDING DOMAIN; RAS-P21 GTPASE; GAP; P21; IDENTIFICATION; TRANSFORMATION; RESIDUES	Ras regulates proliferation and differentiation signals in cells, and activation of the protein can tead to malignant transformation. Activation of the related protein, Rho, affects cell morphology, and it has been suggested that it may also have some oncogenic potential. We show here that Rho does not induce a malignant phenotype in NIH3T3 cells but instead is a potent activator of actin stress fibre formation. The limited homology between Ras and Rho has enabled us to determine the amino acids specifying their different biological activities and GTPase-activating protein (GAP) protein sensitivities using chimeras. Rho substituted with amino acids 23-46 of Ras induces transformed foci in NIH3T3 monolayers, and we conclude that Ras has a single effector domain required for downstream signalling. Although mutational analysis of Rho has revealed that residues 32-42 are also essential for its biological activity, Ras substituted with amino acids 25-48 of Rho does not induce actin stress fibre formation. On the basis of these experiments, we propose that Rho may have two effector domains: one at amino acids 32-42 and corresponding to the effector region of Ras and the second located elsewhere in the carboxy-terminal two-thirds of the molecule.	INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK								ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; AVRAHAM H, 1990, BIOCHEM BIOPH RES CO, V168, P114, DOI 10.1016/0006-291X(90)91682-I; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GARRETT MD, 1991, BIOCHEM J, V276, P833, DOI 10.1042/bj2760833; GARRETT MD, 1989, J BIOL CHEM, V264, P10; HALL A, 1986, J BIOL CHEM, V261, P963; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HATA Y, 1990, J BIOL CHEM, V265, P7104; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; MARSHALL CJ, 1982, NATURE, V299, P171, DOI 10.1038/299171a0; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARUTA H, 1991, J BIOL CHEM, V266, P11661; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210	34	93	95	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					655	661						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437849				2022-12-28	WOS:A1993KN00800016
J	Athanasiou, M; Mavrothalassitis, GJ; Yuan, CC; Blair, DG				Athanasiou, M; Mavrothalassitis, GJ; Yuan, CC; Blair, DG			The Gag-Myb-Ets fusion oncogene alters the apoptotic response and growth factor dependence of interleukin-3 dependent murine cells	ONCOGENE			English	Article						v-ets; ETS oncogene; apoptosis; IT-3 dependent; erythropoietin; erythroid differentiation	TRANSCRIPTION FACTOR GATA-1; AVIAN LEUKEMIA-VIRUS; HEMATOPOIETIC-CELLS; ERYTHROPOIETIN RECEPTOR; NEURORETINA CELLS; GENE-EXPRESSION; LINE; E26; TRANSACTIVATION; DIFFERENTIATION	Expression of the avian E26-derived Gag-Myb-Ets fusion oncogene in interleukin-3(IL3)-dependent murine hematopoietic cell lines results in a pattern of cell line dependent changes in growth factor-induced proliferation and apoptosis. A drug-selectable retrovirus expressing p135(Gag-Myb-Ets) induced an erythropoietin(Epo)-responsive phenotype in the cell lines FDC-P2, BaF3 and 32Dc123. Gag-Myb-Ets expression alone did not increase expression of GATA-1 or the Epo receptor(EpoR) in the presence of IL3, and infected cell lines express increased GATA-1 and EpoR only when IL3 was replaced by Epo in the culture media. Indicative of Epo-induced erythroid differentiation, these cells also began to express beta-globin after 3-5 days growth in Epo. Unlike control cells, infected FDC-P2 cells failed to undergo programmed cell death (apoptosis) when transferred from IL3- to Epo-containing media, although a fraction of the cells failed to proliferate following the media shift. Three other IL3-dependent cell Lines showed no changes in growth behavior when induced to express the fusion oncogene. Our data shows that Gag-Myb-Ets can have different affects on growth factor pathways depending on the cell background, suggesting a model in which the p135(gag-myb-ets) fusion oncogene promotes these different responses through its affect on apoptosis.	SAIC,LAB CELLULAR BIOCHEM,FREDERICK,MD 21702; NCI,MOLEC ONCOL LAB,FREDERICK,MD	Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AMOUYEL P, 1989, J VIROL, V63, P3382, DOI 10.1128/JVI.63.8.3382-3388.1989; Ascione R., 1993, Genome research in molecular medicine and virology., P199; AURIGEMMA RE, 1992, J VIROL, V66, P3056, DOI 10.1128/JVI.66.5.3056-3061.1992; BERRIDGE MV, 1993, EXP HEMATOL, V21, P269; BISTER K, 1982, P NATL ACAD SCI-BIOL, V79, P3677, DOI 10.1073/pnas.79.12.3677; CALABRETTA B, 1991, Critical Reviews in Oncogenesis, V2, P187; CHIBA T, 1993, P NATL ACAD SCI USA, V90, P11593, DOI 10.1073/pnas.90.24.11593; CHIBA T, 1991, NUCLEIC ACIDS RES, V19, P3843, DOI 10.1093/nar/19.14.3843; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANDREA AD, 1994, CURR OPIN CELL BIOL, V6, P804, DOI 10.1016/0955-0674(94)90048-5; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DUBART A, 1994, MOL CELL BIOL, V14, P4834, DOI 10.1128/MCB.14.7.4834; EVANS T, 1991, MOL CELL BIOL, V11, P843, DOI 10.1128/MCB.11.2.843; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; GARRIDO C, 1992, J VIROL, V66, P160, DOI 10.1128/JVI.66.1.160-166.1992; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; ICHIKAWA H, 1994, CANCER RES, V54, P2865; ISFORT RJ, 1990, SOMAT CELL MOLEC GEN, V16, P109, DOI 10.1007/BF01233041; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; JURDIC P, 1987, J VIROL, V61, P3058, DOI 10.1128/JVI.61.10.3058-3065.1987; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KRAUT N, 1995, ONCOGENE, V10, P1027; LIBOI E, 1993, P NATL ACAD SCI USA, V90, P11351, DOI 10.1073/pnas.90.23.11351; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MCCUBREY JA, 1993, ONCOGENE, V8, P2905; MIGLIACCIO AR, 1991, P NATL ACAD SCI USA, V88, P11086, DOI 10.1073/pnas.88.24.11086; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NUNN M, 1984, VIROLOGY, V133, P330; ORKIN SH, 1992, BLOOD, V80, P575; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAVELCHAPUIS P, 1991, J VIROL, V65, P3928, DOI 10.1128/JVI.65.7.3928-3931.1991; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; RUSCETTI S, 1992, J VIROL, V66, P20, DOI 10.1128/JVI.66.1.20-26.1992; SETH A, 1993, ONCOGENE, V8, P1783; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VARIO G, 1990, J BIOL CHEM, V265, P2692; WANG LG, 1994, CELL GROWTH DIFFER, V5, P1243; WATSON DK, 1988, VIROLOGY, V164, P99, DOI 10.1016/0042-6822(88)90624-1; XU L, 1989, VIROLOGY, V171, P331, DOI 10.1016/0042-6822(89)90600-4; YUAN CC, 1989, J VIROL, V63, P205, DOI 10.1128/JVI.63.1.205-215.1989; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	51	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					337	344						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570210				2022-12-28	WOS:A1996TR53800012
J	Kataoka, K; Noda, M; Nishizawa, M				Kataoka, K; Noda, M; Nishizawa, M			Transactivation activity of Maf nuclear oncoprotein is modulated by Jun, Fos and small Maf proteins	ONCOGENE			English	Article						Maf; Jun; Fos; AP-1; NF-E2; transformation	AVIAN TRANSFORMING RETROVIRUS; DNA-BINDING SPECIFICITY; YA SUBUNIT GENE; LEUCINE ZIPPER; C-JUN; TRANSCRIPTIONAL ACTIVATION; V-MAF; EMBRYO FIBROBLASTS; RESPONSIVE ELEMENT; YEAST GCN4	The v-maf oncogene encodes a nuclear bZip protein which specifically recognizes relatively long palindromic sequences related to an AP-1 site. In this study, we investigated the relationship of transactivation and transformation activity of Maf. The amino-terminal two thirds of the molecule were dispensable for its DNA-binding activity but conferred its transactivation potential. Transactivation activities of a set of deletion mutants correlated well with their cell transforming abilities. However, a point mutant associated with enhanced oncogenic activity was not more effective in transactivation than the wild type, suggesting that some other function(s) of Maf is also important for its transforming ability. We also examined the effect of other bZip proteins on the transactivation activity of Maf. Three small Maf family proteins (MafK, MafF and MafG), which are missing the transactivation domain of v-Maf, competitively inhibited transactivation by Maf. Co-expression of Jun or Fos also affected the transactivation potential of Maf by forming Maf/Jun or Maf/Fos heterodimers of distinct DNA-binding specificities. In addition to these factors, we noticed the presence of a strong endogenous transactivating activity associated with a sequence related to an NF-E2 site rather than the typical AP-1 site in fibroblast cells. These results indicate that AP-1 site-like cis-regulatory elements of eukaryotic genes are regulated by multiple sets of bZip dimers with different DNA-binding and transactivation properties.	JAPANESE FDN CANC RES,INST CANC,DEPT VIRAL ONCOL,TOSHIMA KU,TOKYO 170,JAPAN	Japanese Foundation for Cancer Research								ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; BENBROOK DM, 1990, ONCOGENE, V5, P295; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; CHATTON B, 1994, ONCOGENE, V9, P375; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KAWAI S, 1992, VIROLOGY, V188, P778, DOI 10.1016/0042-6822(92)90532-T; KERPPOLA TK, 1994, ONCOGENE, V9, P3149; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATAOKA K, 1994, MOL CELL BIOL, V14, P700; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORGAN IM, 1993, ONCOGENE, V8, P1135; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; NISHIZAWA M, 1987, J VIROL, V61, P3733, DOI 10.1128/JVI.61.12.3733-3740.1987; OKUDA A, 1987, J BIOL CHEM, V262, P3858; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; SUCKOW M, 1994, NUCLEIC ACIDS RES, V22, P2198, DOI 10.1093/nar/22.12.2198; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; TZAMARIAS D, 1992, P NATL ACAD SCI USA, V89, P2007, DOI 10.1073/pnas.89.6.2007; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WANG B, 1994, BBA-GENE STRUCT EXPR, V1219, P645, DOI 10.1016/0167-4781(94)90223-2; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429; WONG WY, 1992, ONCOGENE, V7, P2077; XIE T, 1995, J BIOL CHEM, V270, P6894, DOI 10.1074/jbc.270.12.6894	45	51	56	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					53	62						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552399				2022-12-28	WOS:A1996TQ01400007
J	Kamano, H; Burk, B; NobenTrauth, K; Klempnauer, KH				Kamano, H; Burk, B; NobenTrauth, K; Klempnauer, KH			Differential splicing of the mouse B-myb gene	ONCOGENE			English	Article						B-myb; differential splicing; transactivation; heat shock promotor	C-MYB; V-MYB; A-MYB; MOLECULAR-CLONING; TRANS-ACTIVATION; MAMMALIAN-CELLS; HUMAN HSP70; EXPRESSION; ONCOGENE; PROLIFERATION	The myb gene family consists of three members, the c-myb proto-oncogene and two myb-related genes (A-myb and B-myb), all of which encode nuclear DNA-binding proteins. Unlike c-myb, which plays a critical role in hematopoietic cells, B-myb is expressed in a large spectrum of hematopoietic as well as non-homatopoietic cells and has been implicated in the control of cell proliferation. The isolation of B-myb cDNA clones from several species has shown that B-myb shares limited homology to the so-called exon 9A of the c-myb gene. This exon is involved in differential splicing as only a subfraction of c-myb mRNA contains exon 9A sequences. The presence in the B-myb cDNA of a sequence related to the exon 9A of c-myb has prompted us to investigate whether B-myb mRNA is also spliced differentially. We here show that B-myb mRNAs containing or lacking exon 9A related sequences are present in many cell types. In contrast to c-myb, where RNA containing the exon 9A constitutes only a minor mRNA fraction, B-myb RNA containing the exon 9A related sequences is the major mRNA form, The proteins encoded by the two B-myb mRNA species are unable to activate promoters to which they bind. Curiously, both B-myb proteins differ in their ability to activate the HSP70 promoter by a myb binding-site independent mechanism; B-myb protein containing exon 9A related aminoacid sequences activates the HSP70 promoter much more potently than the B-myb protein which lacks these sequences. Our results suggest that differential splicing may be a general feature of the members of the myb family and provide first evidence for functional differences of the splice variants.	MAX PLANCK INST IMMUNOBIOL,HANS SPEMANN LAB,D-79108 FREIBURG,GERMANY	Max Planck Society								ALESSANDRO A, 1987, P NATL ACAD SCI USA, V84, P1794; ARSURA M, 1992, BLOOD, V79, P2708; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; BURK O, 1991, EMBO J, V10, P3731; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DASGUPTA P, 1989, ONCOGENE, V4, P1419; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUDEK H, 1989, ONCOGENE, V4, P1061; FARRAR JJ, 1980, J IMMUNOL, V125, P2555; FOOS G, 1994, ONCOGENE, V9, P2481; FOOS G, 1993, ONCOGENE, V8, P1775; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLAY J, 1991, BLOOD, V77, P149; GOLAY J, 1994, ONCOGENE, V9, P2469; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; IGLESIAS A, 1991, EMBO J, V10, P2147, DOI 10.1002/j.1460-2075.1991.tb07749.x; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; KIM KJ, 1979, J IMMUNOL, V122, P549; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAM EWF, 1992, ONCOGENE, V7, P1185; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON J, 1988, ONCOGENE, V3, P717; METTUS RV, 1994, ONCOGENE, V9, P3077; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MIZGUCHI G, 1990, J BIOL CHEM, V265, P9280; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MUSCENSKI ML, 1991, CELL, V65, P677; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OI VT, 1983, P NATL ACAD SCI-BIOL, V80, P825, DOI 10.1073/pnas.80.3.825; PATULEIA MC, 1967, CANCER RES, V67, P726; RETH MG, 1985, NATURE, V317, P353, DOI 10.1038/317353a0; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; SCHUUR ER, 1993, ONCOGENE, V8, P1839; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHENONG GLC, 1989, MOL CELL BIOL, V9, P5456, DOI 10.1128/MCB.9.12.5456; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; Tavassoli M, 1983, BONE MARROW STRUCTUR; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WILLIAMS RL, 1988, CELL, V52, P121; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	58	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2575	2582						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545114				2022-12-28	WOS:A1995TP18800013
J	Kobayashi, T; Consoli, U; Andreeff, M; Shiku, H; Deisseroth, AB; Zhang, W				Kobayashi, T; Consoli, U; Andreeff, M; Shiku, H; Deisseroth, AB; Zhang, W			Activation of p21(WAF1/Cip1) expression by a temperature-sensitive mutant of human p53 does not lead to apoptosis	ONCOGENE			English	Article						p21; temperature-sensitive p53; K562 cells; apoptosis	WILD-TYPE P53; CELL-LINE; INHIBITION; GROWTH; TRANSFORMATION; SUPPRESSION; KINASES; P21	The cyclin-dependent kinase inhibitor p21(WAF1/Cip1) (p21) inhibits cellular proliferation and has been implicated in p53-dependent apoptosis. In this study, we examined the regulation of p21 in the K562 erythroleukemia cell line using a human temperature-sensitive mutant of p53, 143Ala. We showed that 143Ala at the permissive temperature (32 degrees C) activated the expression of p21. Stable cell lines expressing 143Ala or other p53 mutants were established. We then examined whether elevation of p21 promotes apoptosis and sensitizes cells to radiation-induced apoptosis. Our results showed that p21 elevation did not promote or sensitize K562 cells to apoptosis.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT NEUROONCOL, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT HEMATOL, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT TUMOR BIOL, HOUSTON, TX 77030 USA; MIE UNIV, SCH MED, DEPT INTERNAL MED 2, TSU, MIE 514, JAPAN	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Mie University			Consoli, Ugo/ADT-6954-2022		NATIONAL CANCER INSTITUTE [R01CA057639, P30CA016672, P01CA055164] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA55164, CA57639, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; GORCZYCA W, 1993, CANCER RES, V53, P1945; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; JUNG JM, 1995, CELL GROWTH DIFFER, V6, P909; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LINDENBOIM L, 1995, CANCER RES, V55, P1242; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PROSSER J, 1990, ONCOGENE, V5, P1573; RADINSKY R, 1994, ONCOGENE, V9, P1877; RAMQVIST T, 1993, ONCOGENE, V8, P1495; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x; ZHANG W, 1995, CANCER RES, V55, P668	43	53	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2311	2316						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570182				2022-12-28	WOS:A1995TK70200015
J	YAMAMOTO, K; SETO, M; KOMATSU, H; IIDA, S; AKAO, Y; KOJIMA, S; KODERA, Y; NAKAZAWA, S; ARIYOSHI, Y; TAKAHASHI, T; UEDA, R				YAMAMOTO, K; SETO, M; KOMATSU, H; IIDA, S; AKAO, Y; KOJIMA, S; KODERA, Y; NAKAZAWA, S; ARIYOSHI, Y; TAKAHASHI, T; UEDA, R			2 DISTINCT PORTIONS OF LTG19/ENL AT 19P13 ARE INVOLVED IN T(11 19) LEUKEMIA	ONCOGENE			English	Article								We previously isolated cDNA clones, MLL-a and MLL-b, derived from the 11q23 breakpoint region and detected gene rearrangements with MLL-b cDNA in infantile leukemia cell lines with 11q23 abnormalities. We also showed chimeric mRNAs between MLL and genes on partner chromosomes such as 4q21 and 19p13. In the present study, we isolated overlapping MLL cDNA clones of 11 kb and demonstrated that MLL-a and MLL-b were derived from the same gene, MLL/ALL-1/HRX. Northern analysis with an MLL cDNA probe detected different signals in t(11;19) cell lines, one being sized 10 kb in two cell lines, KOCL-33 and KOCL-44, and the other being 9.2 kb in the cell line, KOPN-1. To elucidate the molecular basis for the heterogeneity, we isolated cDNA clones of a translocation-associated gene on chromosome 19, LTG19, as well as chimeric cDNAs from KOPN-1. Northern analysis with LTG19 cDNA demonstrated the identical gene, encoding serine/proline rich 559 amino acid polypeptide, to be involved in all three cell lines. Sequence comparison revealed that the LTG19 portion of the predicted chimeric protein of KOPN-1 was fused in frame and contained the C-terminal 189 amino acids. This was shorter by 366 amino acids than those of KOCL-33 and KOCL-44, also fused in frame. Reverse transcriptase-PCR analysis demonstrated complex chimeric mRNAs in cell lines and leukemia samples. Although a chimeric mRNA of KOPN-1 type was rare, its presence suggested that the shared C-terminal portion of 189 amino acids of LTG19 contains important signal(s) for malignant transformation.	AICHI CANC CTR, RES INST,CHEMOTHERAPY LAB,1-1 KANOKODEN,CHIKUSA KU, NAGOYA, AICHI 464, JAPAN; AICHI CANC CTR, IMMUNOL LAB, CHIKUSA KU, NAGOYA, AICHI 464, JAPAN; AICHI CANC CTR HOSP, DEPT HEMATOL & CHEMOTHERAPY, CHIKUSA KU, NAGOYA 464, JAPAN; NAGOYA FIRST HOSP, JAPANESE RED CROSS, DEPT PEDIAT, NAKAMURA KU, NAGOYA 453, JAPAN; YAMANASHI MED COLL, DEPT PEDIAT, YAMANASHI 40938, JAPAN; NAGOYA FIRST HOSP, JAPANESE RED CROSS, DEPT INTERNAL MED, NAKAMURA KU, NAGOYA 453, JAPAN; OSAKA MED COLL, DEPT ANAT, TAKATSUKI, OSAKA 569, JAPAN	Aichi Cancer Center; Aichi Cancer Center; Japanese Red Cross Medical Center; Red Cross Nagoya Daiichi Hospital; University of Yamanashi; Japanese Red Cross Medical Center; Red Cross Nagoya Daiichi Hospital; Osaka Medical College								ABE R, 1984, CANCER GENET CYTOGEN, V13, P121, DOI 10.1016/0165-4608(84)90053-0; AKAO Y, 1991, CANCER RES, V51, P6708; AKAO Y, 1991, CANCER RES, V51, P1574; AKAO Y, 1992, CANCER RES, V52, P6083; CHEN CS, 1991, BLOOD, V78, P2498; CIMINO G, 1992, CANCER RES, V52, P3811; CIMINO G, 1991, CANCER RES, V51, P6712; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DAIBATA M, 1987, JPN J CANCER RES, V78, P1182; DAN L, 1992, NUCLEIC ACIDS RES, V20, P1967, DOI 10.1093/nar/20.8.1967; DAS S, 1992, GENE CHROMOSOME CANC, V5, P244, DOI 10.1002/gcc.2870050312; DAS S, 1991, GENE CHROMOSOME CANC, V3, P44, DOI 10.1002/gcc.2870030108; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; GIBBONS B, 1990, BRIT J HAEMATOL, V74, P264, DOI 10.1111/j.1365-2141.1990.tb02581.x; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GU Y, 1992, P NATL ACAD SCI USA, V89, P10464, DOI 10.1073/pnas.89.21.10464; HABER DA, 1992, NEW BIOL, V4, P97; IIDA S, 1992, LEUKEMIA RES, V16, P1155, DOI 10.1016/0145-2126(92)90113-L; IIDA S, 1993, JPN J CANCER RES, V84, P532, DOI 10.1111/j.1349-7006.1993.tb00172.x; KANEKO Y, 1986, BLOOD, V67, P484; KATZ F, 1988, BLOOD, V71, P1438; KEARNEY L, 1992, BLOOD, V80, P1659; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUBONISHI I, 1986, CANCER, V58, P1453, DOI 10.1002/1097-0142(19861001)58:7<1453::AID-CNCR2820580713>3.0.CO;2-B; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; MCCABE NR, 1992, P NATL ACAD SCI USA, V89, P11794, DOI 10.1073/pnas.89.24.11794; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITANI K, 1989, AM J HEMATOL, V31, P253, DOI 10.1002/ajh.2830310407; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORGAN GJ, 1992, BLOOD, V80, P2172; PRIETO F, 1990, CANCER GENET CYTOGEN, V45, P1, DOI 10.1016/0165-4608(90)90061-E; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; PUI CH, 1991, BLOOD, V77, P440; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RADICE P, 1992, GENE CHROMOSOME CANC, V5, P50, DOI 10.1002/gcc.2870050108; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; SETO M, 1992, ONCOGENE, V7, P1401; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WHITLOCK JA, 1991, CANCER, V68, P600, DOI 10.1002/1097-0142(19910801)68:3<600::AID-CNCR2820680326>3.0.CO;2-F; YAMAMOTO K, 1993, ONCOGENE, V8, P479; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	45	80	82	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2617	2625						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378076				2022-12-28	WOS:A1993LX34300002
J	KWOK, JBJ; GARDNER, E; WARNER, JP; PONDER, BAJ; MULLIGAN, LM				KWOK, JBJ; GARDNER, E; WARNER, JP; PONDER, BAJ; MULLIGAN, LM			STRUCTURAL-ANALYSIS OF THE HUMAN RET PROTOONCOGENE USING EXON TRAPPING	ONCOGENE			English	Article							THYROID PAPILLARY CARCINOMAS; MULTIPLE ENDOCRINE NEOPLASIA; RECEPTOR TYROSINE KINASE; NEUROBLASTOMA CELL-LINES; C-KIT; PROTOONCOGENE; CLONING; PTC; EXPRESSION; FRAGMENTS	A genomic contig of the human ret proto-oncogene was created with four overlapping cosmid clones isolated from two libraries. After southern analysis with portions of the ret cDNA, eight cosmid fragments were analysed in detail for the presence of ret exons using exon trapping. PCR products corresponding to spliced exons were isolated and subcloned. Exon boundaries were delineated by comparison of the PCR product sequence and the published ret cDNA sequence. The exons were initially positioned on a genomic map defined by BamHI, EcoRI and HindIII restriction sites. The positions of the exons were then refined by amplifying genomic DNA using primer pairs derived from one or more exons along the ret gene, the length of the PCR product indicating the approximate genomic distance between the exon sequences. The ret proto-oncogene is composed of at least 20 exons, ranging in size from 60 bp to 287 bp, distributed along 30 kb of genomic DNA. The extracellular domain is encoded by 10 exons and the cytoplasmic domain by 9 exons. The transmembrane domain is encoded by a single exon.	UNIV CAMBRIDGE,DEPT PATHOL,CRC,HUMAN CANC GENET RES GRP,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND; UNIV EDINBURGH,WESTERN GEN HOSP,HUMAN GENET UNIT,EDINBURGH EH4 2XU,SCOTLAND	University of Cambridge; University of Edinburgh				Kwok, John/0000-0001-9574-6195; warner, jonathan peter/0000-0001-5301-675X				ANDRE C, 1992, ONCOGENE, V7, P685; AUCH D, 1990, NUCLEIC ACIDS RES, V18, P6743, DOI 10.1093/nar/18.22.6743; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V34, P1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLOMEN RH, 1993, HUM MOL GENET, V2, P5, DOI 10.1093/hmg/2.1.5; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GARDNER E, 1993, HUM MOL GENET, V2, P241, DOI 10.1093/hmg/2.3.241; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HAMAGUCHI M, 1992, P NATL ACAD SCI USA, V89, P9779, DOI 10.1073/pnas.89.20.9779; IKEDA I, 1990, ONCOGENE, V5, P1291; ITOH F, 1992, ONCOGENE, V7, P1201; IWAMOTO T, 1993, ONCOGENE, V8, P1087; JHIANG SM, 1992, ONCOGENE, V7, P1331; LAIRMORE TC, 1991, GENOMICS, V9, P181, DOI 10.1016/0888-7543(91)90237-9; Lorens J B, 1991, PCR Methods Appl, V1, P140; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Miya A, 1992, Henry Ford Hosp Med J, V40, P215; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1993, GENE CHROMOSOME CANC, V6, P166, DOI 10.1002/gcc.2870060307; Sambrook J, 1989, MOL CLONING LABORATO; SANTORO M, 1990, ONCOGENE, V5, P1595; SCHIMKE RN, 1984, ANNU REV MED, V35, P25, DOI 10.1146/annurev.me.35.020184.000325; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SOZZI G, 1991, ONCOGENE, V6, P339; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TOKINO T, 1991, GENOMICS, V12, P401; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	38	91	96	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2575	2582						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361767				2022-12-28	WOS:A1993LT36800031
J	LEIBOVITCH, SA; GUILLIER, M; LENORMAND, JL; LEIBOVITCH, MP				LEIBOVITCH, SA; GUILLIER, M; LENORMAND, JL; LEIBOVITCH, MP			P34(CD2) PROTEIN IS COMPLEXED WITH THE C-MOS PROTEIN IN RAT SKELETAL-MUSCLE	ONCOGENE			English	Article							CELL-CYCLE; ONCOGENE PRODUCT; XENOPUS OOCYTES; KINASE-ACTIVITY; CDC2 KINASE; GERM-CELLS; MEIOSIS-II; EXPRESSION; PROTOONCOGENE; EGGS	We have used fractionation of subcellular components of the skeletal muscle followed by Western blot analyses to study the localization of the c-mos protein in adult rat muscle. We find that p43c-mos is predominantly located in the KCl supernatant fraction. We show that immunoprecipitates of p43c-mos phosphorylate in vitro two polypeptides of about 34 kDa and 80 kDa respectively. Muscle fractionation and immunodetection studies showed that the p34 protein associated with p43c-mos is the cdc2 protein. p43c-mos is coprecipitated with p34cdc2 when using either anti PSTAIR antibody, antibody directed against the conserved COOH terminal region of the p34cdc2 and by binding to beads that contain crosslinked p13suc1, a protein known to bind p34cdc2. Likewise p34cdc2 coprecipitated with p43c-mos when using anti mos antibody. However p43c-mos is not present in histone H1 kinase active p34cdc2 complex precipitated with anti p34cdc2 COOH-terminal peptide antibody. In adult muscle tissue tubulin is not complexed with p34cdc2 and p43c-mos as previously observed in c-mos and v-mos transformed cells. Gel filtration and crosslinking experiments show that a 170 kDa complex contains c-mos and p34cdc2 proteins. In addition during postnatal development of skeletal muscle we observe modifications in the migration pattern of p34cdc2 correlated with the accumulation of p43c-mos. Our findings raise the possibility of a p43c-mos-p34cdc2 complex could play a role in the differentiation process and maintenance of myotubes in Go.			LEIBOVITCH, SA (corresponding author), INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,URA126,UA 1158,39 RUE CAMILLE DESMOULINS,F-94805 VILLEJUIF,FRANCE.		Lenormand, Jean-Luc/ABF-3850-2021; Lenormand, Jean-Luc/M-6644-2014	Lenormand, Jean-Luc/0000-0002-2766-9180				BAI W, 1992, ONCOGENE, V7, P493; BAI WL, 1992, ONCOGENE, V7, P1757; DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; DOUCET JP, 1991, J BIOL CHEM, V266, P17613; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1988, ONCOGENE, V2, P533; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DUNN SMJ, 1989, J BIOL CHEM, V264, P11053; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HERZOG NK, 1989, ONCOGENE, V4, P1307; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; KREK W, 1989, EMBO J, V8, P3071, DOI 10.1002/j.1460-2075.1989.tb08458.x; KURUTA N, 1989, EMBO J, V8, P457; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEIBOVITCH SA, 1990, ONCOGENE, V5, P1149; LEIBOVITCH SA, 1991, ONCOGENE, V6, P1617; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LORCA T, 1992, EMBO J, V11, P2381, DOI 10.1002/j.1460-2075.1992.tb05302.x; LORCA T, 1991, EMBO J, V10, P2082; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PIERCE GN, 1985, J BIOL CHEM, V260, P6862; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINSET C, 1991, EMBO J, V10, P2411, DOI 10.1002/j.1460-2075.1991.tb07780.x; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TUANA BS, 1988, MOL CELL BIOCHEM, V80, P133; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604; ZHOU RP, 1992, MOL CELL BIOL, V12, P3583, DOI 10.1128/MCB.12.8.3583; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	38	12	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2361	2369						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8395677				2022-12-28	WOS:A1993LT36800006
J	SCHUUR, ER; DASGUPTA, P; REDDY, EP; RABINOVICH, JM; BALUDA, MA				SCHUUR, ER; DASGUPTA, P; REDDY, EP; RABINOVICH, JM; BALUDA, MA			ALTERNATIVE SPLICING OF THE CHICKEN C-MYB EXON-9A	ONCOGENE			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; GENE V-MYB; TRANSFORMING GENE; PROTO-ONCOGENE; MESSENGER-RNA; DIFFERENTIAL EXPRESSION; HEMATOPOIETIC-CELLS; NUCLEOTIDE-SEQUENCE; MYELOID-LEUKEMIA; DOWN-REGULATION	The c-myb gene products are thought to be regulators of cellular replication and of differentiation and heterogeneity may underlie their multiple functions. To investigate the possible existence of heterogeneity we have examined the chicken c-myb mRNAs by Northern blot analysis and polymerase chain reaction amplification of cDNAs (RT-PCR). Northern blot analysis with the c-myb cDNA clone pSG3, which contains the entire open reading frame (ORF) plus 500 base pairs of 3' untranslated sequences (Gerondakis & Bishop, 1986), and genomic probes revealed c-myb RNA species of 4.3 kb in addition to the major 4.0 kb species. The 4.3 kb c-myb RNA contained the alternatively spliced exon 9A which is highly conserved and has also been detected in a minor 4.3 kb alternatively spliced c-myb mRNA in murine and human cells. Sequencing of the avian exon 9A revealed 360 bp exon homologous to that found in murine and human mRNAs, which contains three highly conserved sequence regions shared by all three species. RT-PCR demonstrated usage of exon 9A in five hematopoietic tissues and revealed an additional splicing variant which used the 3' portion of exon 9A. Northern blot analysis using splice site-specific oligonucleotide probes spanning the two splice junctions between exon 9 and 9A revealed four additional c-myb RNAs of 4.4 kb, 2.2 kb, 2.0 kb and 1.4 kb.	UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90033; UNIV CALIF LOS ANGELES,SCH MED,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024; TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL & LAB MED,LOS ANGELES,CA 90024	University of Southern California; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [R01CA010197] Funding Source: NIH RePORTER; NCI NIH HHS [CA 10197] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BALUDA MA, 1990, ONCOGENESIS ONCOGENE, P131; BENDER TP, 1987, J IMMUNOL, V139, P3822; BERGER SL, 1987, METHOD ENZYMOL, V152, P227; BORTNER DM, 1991, NUCLEIC ACIDS RES, V19, P1533, DOI 10.1093/nar/19.7.1533; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; CHEN JH, 1980, J VIROL, V36, P162, DOI 10.1128/JVI.36.1.162-170.1980; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; DASGUPTA P, 1989, ONCOGENE, V4, P1419; DUDEK H, 1989, ONCOGENE, V4, P1061; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARCIA A, 1991, ONCOGENE, V6, P265; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GONDA TJ, 1983, J VIROL, V46, P212, DOI 10.1128/JVI.46.1.212-220.1983; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRASSER FA, 1992, ONCOGENE, V7, P1005; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; HAHN SL, 1989, MOL CELL BIOL, V9, P837, DOI 10.1128/MCB.9.2.837; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KIM WK, 1989, MOL CELL BIOL, V9, P3771, DOI 10.1128/MCB.9.9.3771; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; Lipsick J S, 1986, Gene Amplif Anal, V4, P73; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MANIATIS T, 1982, MOL CLONING LABORATO, P280; Moscovici C., 1973, Methods Cell Biol, V7, P313; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PERBAL B, 1983, J VIROL, V45, P925, DOI 10.1128/JVI.45.3.925-940.1983; PERBAL B, 1982, J VIROL, V44, P586, DOI 10.1128/JVI.44.2.586-594.1982; PERBAL B, 1982, J VIROL, V41, P250, DOI 10.1128/JVI.41.1.250-257.1982; PUNYAMMALEE B, 1991, ONCOGENE, V6, P11; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHUUR ER, 1991, ONCOGENE, V6, P1923; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHENONG GLC, 1989, MOL CELL BIOL, V9, P5456, DOI 10.1128/MCB.9.12.5456; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SORET J, 1990, FEBS LETT, V263, P254, DOI 10.1016/0014-5793(90)81387-4; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; VELLARD M, 1991, ONCOGENE, V6, P505; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WATSON RJ, 1987, EMBO J, V6, P1643, DOI 10.1002/j.1460-2075.1987.tb02413.x; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WESTIN EH, 1990, ONCOGENE, V5, P1117; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	57	16	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1839	1847						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510928				2022-12-28	WOS:A1993LG68200016
J	LEONE, A; SEEGER, RC; HONG, CM; HU, YY; ARBOLEDA, MJ; BRODEUR, GM; STRAM, D; SLAMON, DJ; STEEG, PS				LEONE, A; SEEGER, RC; HONG, CM; HU, YY; ARBOLEDA, MJ; BRODEUR, GM; STRAM, D; SLAMON, DJ; STEEG, PS			EVIDENCE FOR NM23 RNA OVEREXPRESSION, DNA AMPLIFICATION AND MUTATION IN AGGRESSIVE CHILDHOOD NEUROBLASTOMAS	ONCOGENE			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; DUCTAL BREAST CARCINOMAS; TUMOR-METASTASIS; N-MYC; DROSOPHILA DEVELOPMENT; PROTEIN-KINASE; GENE; EXPRESSION; ASSOCIATION; CANCER	Reduced expression of nm23 RNAs/proteins has been associated previously with high tumor metastatic potential. In contrast, we report that regional (state III) and metastatic (stage IV) childhood neuroblastomas exhibit elevated nm23 RNA levels as compared with localized tumors. Elevated neuroblastoma nm23 RNA levels were associated with significant reductions in patient survival in the overall (n = 75) and N-myc non-amplified (n = 61) portion of the cohort. Amplification of the chromosomal nm23-H1 gene was observed in 6/18 stage III and IV tumors; amplification of nm23-H2 was not demonstrated. Genomic amplification of nm23-H1 was associated with increased tumor nm23 RNA expression and reduced patient survival. Single-strand conformational polymorphism (SSCP) analysis was performed on seven neuroblastomas. Minor subpopulations of cDNAs exhibiting altered mobility were apparent in both nm23-H1 and nm23-H2 translated regions of stage III and IV tumors, suggestive.of mutations. Confirmation of the SSCP data was provided by direct sequencing of nm23-H2 in a stage IV tumor, revealing a leucine to valine mutation at position 48. The data indicate that molecular alterations to nm23 other than its reduced expression can be associated with tumor aggressiveness, and provide the first evidence for nm23 mutation in a human cancer.	NCI, PATHOL LAB, BLDG 10, ROOM 2A33, BETHESDA, MD 20892 USA; CHILDRENS HOSP LOS ANGELES, DEPT PEDIAT, DIV HEMATOL ONCOL, LOS ANGELES, CA 90027 USA; UNIV SO CALIF, SCH MED, LOS ANGELES, CA 90027 USA; CHILDRENS CANC GRP, ARCADIA, CA USA; UNIV CALIF LOS ANGELES, SCH MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90027 USA; WASHINGTON UNIV, SCH MED, DEPT PEDIAT, DIV HEMATOL ONCOL, ST LOUIS, MO 63110 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Children's Hospital Los Angeles; University of Southern California; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Washington University (WUSTL)			Leone, Alvaro/K-6410-2016; leone, alvaro/AAQ-7051-2020	Leone, Alvaro/0000-0003-3815-9052; 	NCI NIH HHS [CA 02649, CA49712, CA22794] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA022794, P01CA049712, U10CA002649] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMITAGE P, 1971, STATISTICAL METHODS; BARNES R, 1991, AM J PATHOL, V139, P245; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BUCKMAN VL, 1988, GENE, V70, P245; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COHN KH, 1991, LANCET, V338, P722, DOI 10.1016/0140-6736(91)91444-Y; COX DR, 1972, J R STAT SOC B, V34, P187; DEAROLF CR, 1988, DEV BIOL, V129, P159, DOI 10.1016/0012-1606(88)90170-4; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; GANSLER T, 1986, CANCER, V58, P2453, DOI 10.1002/1097-0142(19861201)58:11<2453::AID-CNCR2820581117>3.0.CO;2-I; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GOLDEN A, ONCOGENES TUMOR SUPP; HAILAT N, 1991, J CLIN INVEST, V88, P341, DOI 10.1172/JCI115299; HAMA H, 1991, GENE, V105, P31, DOI 10.1016/0378-1119(91)90510-I; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAUT M, 1991, J NATL CANCER I, V83, P712, DOI 10.1093/jnci/83.10.712; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; HIRAYAMA R, 1991, J NATL CANCER I, V83, P1259; HOSSAIN A, 1991, CLIN EXP METASTAS, V9, P500; KANEKO Y, 1987, CANCER RES, V47, P311; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; LANDSCHULTZ WH, 1988, SCIENCE, V240, P1750; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1991, CANCER RES, V51, P2490; MATSUNAGA T, 1991, CANCER RES, V51, P3148; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2702; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAYAMA T, 1992, J NATL CANCER I, V84, P1349, DOI 10.1093/jnci/84.17.1349; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SASTREGARAU X, 1992, INT J CANCER, V50, P533, DOI 10.1002/ijc.2910500406; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STAHL JA, 1991, CANCER RES, V48, P6550; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STEEG PS, 1989, CANCER METASTASIS, P48; SUZUKI T, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P210; TANAKA T, 1988, CANCER RES, V48, P1030; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199; YAGUE J, 1991, NUCLEIC ACIDS RES, V19, P6663, DOI 10.1093/nar/19.23.6663	43	220	223	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					855	865						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8384356				2022-12-28	WOS:A1993KT22000006
J	BAGNIS, C; COSSET, FL; SAMARUT, J; MOSCOVICI, G; MOSCOVICI, C				BAGNIS, C; COSSET, FL; SAMARUT, J; MOSCOVICI, G; MOSCOVICI, C			LEUKEMOGENICITY OF V-MYB-TRANSFORMED MONOBLASTS CELLS CAN BE MODULATED BY NORMAL BONE-MARROW ENVIRONMENT	ONCOGENE			English	Article							MEDIATED GENE-TRANSFER; CHICKEN OPTIC TECTUM; BETA-GALACTOSIDASE; RECOMBINANT RETROVIRUS; MYELOMONOCYTIC CELLS; LINEAGE ANALYSIS; C-MYB; EXPRESSION; ONCOGENE; DIFFERENTIATION	The avian myeloblastosis virus (AMV) causes monoblastic leukemia in the chick. Two non-producer clones of AMV-transformed monoblasts, BM2/C3A and BM2L/A2B5, have been described (see Bottazzi et al., this issue). They differ in their growth requirements and in their ability to induce leukemia when injected into the chick embryo. We first genetically tagged these clones by retroviral infection with a vector expressing the bacterial lacZ gene. Then, we injected the lacZ-positive cells via the chorioaltantoic vein into chick embryos. With BM2L/A2B5 cells, the bone marrow of the injected birds was rapidly invaded by lacZ-positive cells. In addition, these cells rapidly overgrew cultures of bone marrow cells derived from injected animals. Conversely, the growth of BM2/C3A was inhibited in the injected animals and only a few blue cells, with the morphology of macrophages, were detected in cultures of bone marrow cells. We developed an in vitro assay to mimic in vitro the differential growth of BM2/C3A and BM2L/A2B5 observed in vivo. These data strongly suggest that BM2/C3A cells retain their ability to differentiate into macrophages in the normal bone marrow environment and that BM2L/A2B5 cells differ from BMC/C3A in the loss of this capacity.	UNIV LYON 1,INST CHIM & BIOL MOLEC & CELLULAIRE,CNRS,UA 92,F-69622 VILLEURBANNE,FRANCE; VET ADM MED CTR,TUMOR VIROL LAB,GAINESVILLE,FL 32602	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; US Department of Veterans Affairs; Veterans Health Administration (VHA)	BAGNIS, C (corresponding author), ECOLE NORMALE SUPER LYON,BIOL MOLEC & CELLULAIRE LAB,CNRS,UMR 13,46 ALLEE ITALIE,F-69364 LYON 07,FRANCE.		Samarut, Jacques/AAD-2587-2019	Cosset, Francois-Loic/0000-0001-8842-3726				BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; BIGNAMI M, 1988, MOL CARCINOGEN, V1, P67, DOI 10.1002/mc.2940010113; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; COSSET FL, 1990, J VIROL, V64, P1070, DOI 10.1128/JVI.64.3.1070-1078.1990; COSSET FL, 1991, J VIROL, V65, P3388, DOI 10.1128/JVI.65.6.3388-3394.1991; CRAIG RW, 1984, CANCER RES, V44, P442; DURBAN EM, 1981, P NATL ACAD SCI-BIOL, V78, P3600, DOI 10.1073/pnas.78.6.3600; ELFOULY MH, 1989, MOL CARCINOGEN, V2, P131, DOI 10.1002/mc.2940020305; GALILEO DS, 1990, P NATL ACAD SCI USA, V87, P458, DOI 10.1073/pnas.87.1.458; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRAY GE, 1988, P NATL ACAD SCI USA, V85, P7356, DOI 10.1073/pnas.85.19.7356; KLARSFELD A, 1991, EMBO J, V10, P625, DOI 10.1002/j.1460-2075.1991.tb07990.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LIPSICK JS, 1986, J VIROL, V59, P267, DOI 10.1128/JVI.59.2.267-275.1986; MACGREEGOR JM, 1989, GENE EXPRESSION IN V; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; MANIATIS T, 1983, MOL CLONING; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; MOSCOVICI C, 1982, CONTINUOUS LINES AMV; MOSCOVICI C, 1982, ADV VIRAL ONCOLOGY T; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; SAMARUT J, 1980, J CELL PHYSIOL, V105, P553, DOI 10.1002/jcp.1041050320; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; STRAIR RK, 1990, NUCLEIC ACIDS RES, V18, P4759, DOI 10.1093/nar/18.16.4759; SYMONDS G, 1984, MOL CELL BIOL, V4, P2587, DOI 10.1128/MCB.4.12.2587; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WILSON JM, 1988, P NATL ACAD SCI USA, V85, P3014, DOI 10.1073/pnas.85.9.3014	32	13	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					737	743						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437857				2022-12-28	WOS:A1993KN00800026
J	George, RE; Kenyon, RM; McGuckin, AG; Malcolm, AJ; Pearson, ADJ; Lunec, J				George, RE; Kenyon, RM; McGuckin, AG; Malcolm, AJ; Pearson, ADJ; Lunec, J			Investigation of co-amplification of the candidate genes ornithine decarboxylase, ribonucleotide reductase, syndecan-1 and a DEAD box gene, DDX1, with N-myc in neuroblastoma	ONCOGENE			English	Article						N-myc; gene amplification; neuroblastoma; DDX1; pG21	HUMAN NEURO-BLASTOMA; DEPENDENT RNA HELICASE; CELL-LINES; DNA; EXPRESSION; ONCOGENE; FAMILY; TUMOR; COAMPLIFICATION; ASSOCIATION	Although N-myc amplification is strongly associated with a poor prognosis, not all patients with neuroblastomas having N-myc amplification fare badly. To investigate whether genes other than N-myc are responsible for contributing to the prognosis, we examined seven cell lines and 87 primary tumours for co-amplification of candidate genes known to be present near the normal N-myc locus: ornithine decarboxylase (ODC), ribonucleotide reductase (RRM2), syndecan-1 and a DEAD box protein gene, DDX1. Sequence analysis of the pG21 cDNA clone previously reported to represent an expressed gene frequently co-amplified with N-myc, showed this to be from the DDX1 gene. No coamplification with the first three genes was found in any of the cell lines or tumour samples. DDX1, however was found to be amplified along with N-myc in 4/6 (67%) cell lines and 6/16 (38%) of the N-myc amplified tumours. Co-amplification of DDX1 and N-myc was found more frequently in stage 4 or 4S tumours than lower stage (1-3) tumours. With the exclusion of a single 4S case, there was a highly significant reduction in the mean disease-free interval from 24.4 +/- 4.7 (SE, n = 10) months for cases with co-amplification of N-myc and DDX1 compared with 9.2 +/- 1.8 (SE, n = 5) months for those cases showing amplification of N-myc alone (P = 0.0056, Welch's unpaired t-test). No amplification of DDX1, ODC, RRM2, or syndecan-1 was found in the absence of N-myc amplification. These observations indicate that the N-myc amplicon is of varied size and/or position relative to the N-myc gene, with DDX1 representing at least one other gene frequently coamplified with N-myc. Further studies are required to confirm the biological and prognostic significance of DDX1 co-amplification and to elucidate the role that DDX1 plays in tumour genesis and progression.	UNIV NEWCASTLE UPON TYNE,SCH MED,CANC RES UNIT,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT CHILD HLTH,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT PATHOL,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK								AKIYAMA K, 1994, NUCLEIC ACIDS RES, V22, P187, DOI 10.1093/nar/22.2.187; AMLER LC, 1989, MOL CELL BIOL, V9, P4903, DOI 10.1128/MCB.9.11.4903; AMLER LC, 1995, IN PRESS GENES CHROM; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIEDLER JL, 1976, SCIENCE, V191, P185, DOI 10.1126/science.942798; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CARACHI R, 1987, BRIT J CANCER, V55, P407, DOI 10.1038/bjc.1987.80; DEBERNARDI B, 1995, J CLIN ONCOL, V13, P884, DOI 10.1200/JCO.1995.13.4.884; DEVALOIR T, 1991, P NATL ACAD SCI USA, V88, P2113, DOI 10.1073/pnas.88.6.2113; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GODBOUT R, 1993, P NATL ACAD SCI USA, V90, P7578, DOI 10.1073/pnas.90.16.7578; GRADYLEOPARDI EF, 1986, CANCER RES, V44, P5444; GURURAJAN R, 1991, NATURE, V349, P717, DOI 10.1038/349717a0; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; HIEMSTRA JL, 1994, ADV NEUROBLASTOMA RE, V4, P51; KHATIB ZA, 1993, CANCER RES, V53, P5535; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; LONGO L, 1988, J CANCER RES CLIN, V114, P636, DOI 10.1007/BF00398190; MALI M, 1990, J BIOL CHEM, V265, P6884; MOSHIER JA, 1990, J BIOL CHEM, V265, P4884; NISEN PD, 1988, J NATL CANCER I, V80, P1633, DOI 10.1093/jnci/80.20.1633; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESINGER HR, 1976, CANCER RES, V36, P3094; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SCHNEIDER SS, 1992, MOL CELL BIOL, V12, P5563, DOI 10.1128/MCB.12.12.5563; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; Seeger R C, 1988, Prog Clin Biol Res, V271, P41; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHILOH Y, 1986, CANCER RES, V46, P5297; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; SLAVC I, 1990, CANCER RES, V50, P1459; SMITH K, 1993, ONCOGENE, V8, P933; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SQUIRE JA, 1995, ONCOGENE, V10, P1417; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; WAHL GM, 1983, MOL CELL BIOL, V3, P2066, DOI 10.1128/MCB.3.11.2066; WHELDON TE, 1985, BRIT J RADIOL, V58, P661, DOI 10.1259/0007-1285-58-691-661	42	56	57	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1583	1587						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622876				2022-12-28	WOS:A1996UF07600024
J	Howard, JC; Berger, L; Bani, MR; Hawley, RG; BenDavid, Y				Howard, JC; Berger, L; Bani, MR; Hawley, RG; BenDavid, Y			Activation of the erythropoietin gene in the majority of F-MuLV-induced erythroleukemias results in growth factor independence and enhanced tumorigenicity	ONCOGENE			English	Article						friend erythroleukemia; Epo rearrangement; advanced tumorigenicity	MURINE LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; WILD-TYPE P53; TRANSGENIC MICE; INSERTIONAL ACTIVATION; RECEPTOR GENE; CELL-GROWTH; EXPRESSION; ONCOGENE; FLI-1	Retroviral insertional activation of I;li-l is the first detectable genetic alteration associated with F-MuLV-induced primary erythroleukemias, while mutations within p53 are only observed in Epo-dependent (ED) cell lines derived from syngeneic mice serially transplanted with F-MuLV-induced primary erythroleukemias. In this study we have determined the mechanism of growth factor independence in several Epo-independent (EI) cell lines established from adult mice previously injected with ED-erythroleukemia cell lines or serially transplanted primary tumor cells. Here we have shown constitutive expression of the Epa gene in 12 of 15 (80%) EI-erythroleukemia cell Lines. Among these 12 cell lines, eight were shown to possess clonal rearrangement of the Epo gene which could be detected in the tumors used to establish the majority of these EI-cell lines. Analysis of the pattern of proviral integration revealed that the activation of the Epo gene in these cell lines is independent of retroviral insertional mutagenesis, but apparently the result of genomic rearrangements. Furthermore, the acquisition of growth factor independence by these leukemic cells confers a selective growth advantage in vivo and is associated with enhanced tumorigenicity. Together these observations suggest that the activation of the Epo gene in the large majority of these F-MuLV-induced erythroleukemic cell lines establishes an autocrine loop resulting in the constitutive of the Epo receptor transduction pathway, thereby conferring advantage in vivo and in vitro.	SUNNYBROOK HLTH SCI CTR, DIV CANC BIOL RES, TORONTO, ON M4N 3M5, CANADA; UNIV TORONTO, DEPT MED BIOPHYS, TORONTO, ON M5S 1A1, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto			Bani, Maria Rosa/AAB-3397-2020	Bani, Maria Rosa/0000-0001-8178-1432; Hawley, Robert/0000-0003-3512-5818				BEN-DAVID Y, 1990, New Biologist, V2, P1015; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BENDAVID Y, 1992, MOL CELL BIOL, V12, P4449, DOI 10.1128/MCB.12.10.4449; BERGER LC, 1994, BIOCHEM BIOPH RES CO, V202, P596, DOI 10.1006/bbrc.1994.1970; BERU N, 1989, ANN NY ACAD SCI, V554, P29, DOI 10.1111/j.1749-6632.1989.tb22406.x; BONDURANT M, 1993, ERYTHROPOIETIN, P241; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HANKINS WD, 1989, ANN NY ACAD SCI, V554, P21, DOI 10.1111/j.1749-6632.1989.tb22405.x; HINO M, 1991, MOL CELL BIOL, V11, P5527, DOI 10.1128/MCB.11.11.5527; HOWARD JC, 1993, ONCOGENE, V8, P2721; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KRYSTAL G, 1983, EXP HEMATOL, V11, P649; LACOMBE C, 1991, J BIOL CHEM, V266, P6952; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANG RA, 1990, IMMUNOL TODAY, V11, P244, DOI 10.1016/0167-5699(90)90098-T; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; MCDONALD J, 1987, MOL CELL BIOL, V7, P365, DOI 10.1128/MCB.7.1.365; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1990, LEUKEMIA, V4, P20; OLIFF A, 1981, BLOOD, V58, P244; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RENCRICCA N J, 1970, Blood, V36, P764; SCHUSTER SJ, 1987, BLOOD, V70, P316; SEMENZA GL, 1990, MOL CELL BIOL, V10, P930, DOI 10.1128/MCB.10.3.930; SEMENZA GL, 1989, P NATL ACAD SCI USA, V86, P2301, DOI 10.1073/pnas.86.7.2301; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P8725, DOI 10.1073/pnas.88.19.8725; SHIBUYA T, 1983, P NATL ACAD SCI-BIOL, V80, P3721, DOI 10.1073/pnas.80.12.3721; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YANG XM, 1994, P NATL ACAD SCI USA, V91, P6924, DOI 10.1073/pnas.91.15.6924; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0	42	25	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	1996	12	7					1405	1415						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622856				2022-12-28	WOS:A1996UF07600004
J	Kaya, M; Yoshida, K; Higashino, F; Mitaka, T; Ishii, S; Fujinaga, K				Kaya, M; Yoshida, K; Higashino, F; Mitaka, T; Ishii, S; Fujinaga, K			A single ets-related transcription factor, E1AF, confers invasive phenotype on human cancer cells	ONCOGENE			English	Article						ets-related E1AF; MMPs; invasion; motility	TUMOR-CELLS; NEGATIVE REGULATION; BASEMENT-MEMBRANE; IV COLLAGEN; EXPRESSION; METASTASIS; ONCOGENE; GENE; PEA3; METALLOPROTEINASES	Invasion of cancer cells is the first step of metastasis. The invasive activity is thought to be dependent on the production of matrix metalloproteinases (MMPs), The transcription regulatory regions of MMP genes often contain binding sites for Ets and AP-1 transcription factors and they mediate oncogene- and growth factor-induced transcription of the genes, We recently isolated the cDNA encoding human E1AF, a new member of ets oncogene family, E1AF highly stimulated transcription from three different subclasses of MMP genes in transient expression assays, Here we show that transfection of the non-invasive human breast cancer cell line MCF-7 with the E1AF expression plasmid results in induction of invasive and motile activities, accompanied by an increase of 92 kD type IV collagenase (MMP-9) gene expression, Tumors derived from the E1AF transfectant were highly invasive and produced MMP-9, Expression of E1AF and MMP-9 genes was elevated in several invasive tumor cell lines. These results provide evidence for an important role of ets-related E1AF in tumor cell invasion.	SAPPORO MED UNIV, SCH MED, CANC RES INST, DEPT MOLEC BIOL, CHUO KU, SAPPORO, HOKKAIDO 060, JAPAN; SAPPORO MED UNIV, SCH MED, CANC RES INST, DEPT PATHOL, CHUO KU, SAPPORO, HOKKAIDO 060, JAPAN; SAPPORO MED UNIV, SCH MED, DEPT ORTHOPED SURG, CHUO KU, SAPPORO, HOKKAIDO 060, JAPAN	Sapporo Medical University; Sapporo Medical University; Sapporo Medical University			Higashino, Fumihiro/F-8510-2012; Mitaka, Toshihiro/K-9424-2013	Mitaka, Toshihiro/0000-0001-9467-4871				ALBINI A, 1987, CANCER RES, V47, P3239; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; GAIRE M, 1994, J BIOL CHEM, V269, P2032; GREVIN D, 1993, INT J DEV BIOL, V37, P519; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Liotta L A, 1990, Semin Cancer Biol, V1, P99; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; LIOTTA LA, 1991, CANCER RES, V51, pS5054; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; Matrisian L M, 1990, Semin Cancer Biol, V1, P107; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MOHLER JL, 1988, CANCER RES, V48, P4312; NAKAJIMA M, 1987, CANCER RES, V47, P4869; NAKAJIMA M, 1990, SEMIN CANCER BIOL, V1, P99; NERLOV C, 1991, ONCOGENE, V6, P1583; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PARTIN AW, 1989, P NATL ACAD SCI USA, V86, P1254, DOI 10.1073/pnas.86.4.1254; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; POWELL WC, 1993, CANCER RES, V53, P417; SATO H, 1992, ONCOGENE, V7, P77; SATO H, 1993, ONCOGENE, V8, P395; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SETH A, 1990, ADV AP BIOT, V6, P297; SHINDOH M, 1995, OBSTET GYNECOL, V85, P721, DOI 10.1016/0029-7844(95)00043-Q; TAKAHASHI K, 1990, IN VITRO CELL DEV B, V26, P265; TANIGUCHI S, 1989, CANCER RES, V49, P6738; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119; YOSHIDA K, 1995, CURR TOP MICROBIOL, V199, P113	41	118	119	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					221	227						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570199				2022-12-28	WOS:A1996TR53800001
J	Hadman, M; Gabos, L; Loo, M; Sehgal, A; Bos, TJ				Hadman, M; Gabos, L; Loo, M; Sehgal, A; Bos, TJ			Isolation and cloning of JTAP-1: A cathepsin like gene upregulated in response to V-Jun induced cell transformation	ONCOGENE			English	Article						Jun; targets; cysteine protease; transformation; cathepsin O	CHICKEN-EMBRYO FIBROBLASTS; C-JUN; GLUCOCORTICOID RECEPTOR; DNA-BINDING; FUNCTIONAL ANTAGONISM; COLLAGENASE GENE; FOS; EXPRESSION; AP-1; INHIBITION	The oncogenic potential of Jun in chicken embryo fibroblasts (CEF) varies depending on its structure. V-Jun, which has a number of structural differences from c-Jun is highly transforming and tumorigenic. C-Jun however, is only weakly transforming and is not tumorigenic. We have used this difference in oncogenic potential between v-Jun and c-Jun to screen for downstream target genes associated with the v-Jun induced transformed phenotype. We describe here the identification, cloning and characterization of one of these genes, JTAP-1. JTAP-1 is consistently overexpressed 7 to 10-fold in CEF transformed by v-Jun compared with c-Jun overexpressing or normal CEF. This pattern of expression suggests that JTAP-1 is associated with the transformed phenotype. DNA and amino acid homology search analysis revealed that JTAP-1 shares a high degree of similarity with over 100 cysteine proteases from a variety of species and is likely the chicken homolog of cathepsin O. Analysis of expression of JTAP-1 in CEF overexpressing other oncogenes including v-Ha-ras, v-Src, c-Fos, and Myc revealed that it's overexpression is unique to v-Jun transformed cells. Thus, JTAP-1 is likely a specific target of v-Jun overexpression and not simply a consequence of cell transformation.	EASTERN VIRGINIA MED SCH,DEPT MICROBIOL & IMMUNOL,NORFOLK,VA 23501	Eastern Virginia Medical School					NCI NIH HHS [R29 CA 51982] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA051982] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; ATKINS KB, 1995, CELL GROWTH DIFFER, V6, P713; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BLACK EJ, 1994, ONCOGENE, V9, P2363; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BOS TJ, 1989, ONCOGENE, V4, P123; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BRODT P, 1992, BIOCHIM BIOPHYS ACTA, V1139, P77, DOI 10.1016/0925-4439(92)90085-2; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; GINSBERG D, 1991, ONCOGENE, V6, P669; GIZANGGINSBERG E, 1990, GENE DEV, V4, P447; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HADMAN M, 1993, ONCOGENE, V8, P1895; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HARTL M, 1992, CELL GROWTH DIFFER, V3, P899; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HUGHES M, 1992, CELL GROWTH DIFFER, V3, P889; KASAI M, 1993, CELL IMMUNOL, V150, P124, DOI 10.1006/cimm.1993.1184; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; Kozyreva E. A., 1994, Voprosy Meditsinskoi Khimii, V40, P25; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; LETO G, 1994, IN VIVO, V2, P231; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; OBERHUBER H, 1995, MOL CARCINOGEN, V12, P198, DOI 10.1002/mc.2940120404; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; ROBINSON GLWG, 1995, MOL CELL BIOL, V15, P1398; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SHI GP, 1995, FEBS LETT, V357, P129, DOI 10.1016/0014-5793(94)01349-6; SLOANE BF, 1994, J CELL SCI, V107, P373; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SOLOVYEVA NI, 1995, INT J CANCER, V8; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; TOURAY M, 1991, ONCOGENE, V6, P1227; VALASCO G, 1994, J BIOL CHEM, V269, P27136; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; VOGT PK, 1990, CANCER BIOL, V1, P27; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	48	29	31	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					135	142						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552384				2022-12-28	WOS:A1996TQ01400017
J	GalchevaGargova, Z; Theroux, SJ; Davis, RJ				GalchevaGargova, Z; Theroux, SJ; Davis, RJ			The epidermal growth factor receptor is covalently linked to ubiquitin	ONCOGENE			English	Article						EGF; signal transduction; ubiquitin	TYROSINE KINASE-ACTIVITY; COATED PIT FORMATION; FACTOR BETA-RECEPTOR; MEDIATED ENDOCYTOSIS; PROTEIN-DEGRADATION; HUMAN-FIBROBLASTS; AFFINITY; PHOSPHORYLATION; BINDING; INTERNALIZATION	Incubation of cultured human fibroblasts with epidermal growth factor (EGF) causes a proliferative response that is mediated by the binding of the growth factor to specific cell surface receptors, One event that occurs rapidly following EGF binding is the covalent modification of the EGF receptor (EGF-R) by phosphorylation on Ser, Thr, and Tyr residues, Here we report the identification of ubiquitination as a second form of EGF-stimulated covalent modification of the receptor, The EGF receptor was not ubiquitinated in serum-starved cells, However, treatment with EGF caused a rapid increase in EGF-R ubiquitination, In contrast, no EGF-stimulated ubiquitination was found in experiments using cells that express a mutant tyrosine kinase-negative EGF-R. Similarly, ubiquitination of the EGF-R was not observed at 4 degrees C or if the cells are depleted of intracellular K+. Together, these data establish ubiquitination as a form of EGF-stimulated covalent modification of the EGF-R.	UNIV MASSACHUSETTS, SCH MED,HOWARD HUGHES MED INST,PROGRAM MOLEC MED, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01605 USA; ASSUMPTION COLL, WORCESTER, MA 01609 USA; HOWARD HUGHES MED INST, COCONUT GROVE, FL 33133 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Assumption College; Howard Hughes Medical Institute					NCI NIH HHS [R01-CA58396] Funding Source: Medline; NIGMS NIH HHS [R15-GM49465] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM049465] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEGUINOT L, 1985, P NATL ACAD SCI USA, V82, P2774, DOI 10.1073/pnas.82.9.2774; BENVENISTE M, 1989, J CELL BIOL, V109, P2105, DOI 10.1083/jcb.109.5.2105; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1994, FASEB J, V8, P182, DOI 10.1096/fasebj.8.2.8119489; COCHET C, 1984, J BIOL CHEM, V259, P2553; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; DAVIS RJ, 1993, ADV LIPID RES, V25, P131; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DAVIS RJ, 1984, J BIOL CHEM, V259, P8545; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; FAN Z, 1994, J BIOL CHEM, V269, P27595; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FRIEDMAN BA, 1984, P NATL ACAD SCI-BIOL, V81, P3034, DOI 10.1073/pnas.81.10.3034; GLENNEY JJ, 1993, J CELL BIOL, V121, P61; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HOU D, 1994, J BIOL CHEM, V269, P14244; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LARKIN JM, 1986, J CELL BIOL, V103, P2619, DOI 10.1083/jcb.103.6.2619; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LOETSCHER H, 1990, J BIOL CHEM, V265, P20131; MORI S, 1992, J BIOL CHEM, V267, P6429; MORI S, 1993, J BIOL CHEM, V268, P577; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; SELVA E, 1993, J BIOL CHEM, V268, P2250; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; SIEGELMAN M, 1986, SCIENCE, V231, P823, DOI 10.1126/science.3003913; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WILEY HS, 1982, J BIOL CHEM, V257, P4222; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	44	106	107	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2649	2655						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545122				2022-12-28	WOS:A1995TP18800021
J	Franklin, CC; Kraft, AS				Franklin, CC; Kraft, AS			Constitutively active MAP kinase kinase (MEK1) stimulates SAP kinase and c-Jun transcriptional activity in U937 human leukemic cells	ONCOGENE			English	Article						SAPK(JNK); MAPK(ERK); MEK; MPK-1; c-Jun	SERUM RESPONSE ELEMENT; PROTEIN-KINASE; ACTIVATION DOMAIN; SIGNAL-TRANSDUCTION; TERNARY COMPLEX; GENE-PRODUCT; FOS PROMOTER; PHOSPHORYLATION; DIFFERENTIATION; PROLIFERATION	Treatment of U937 human leukemic cells with the phorbol ester PMA, activates both mitogen-activated kinase (MAPK) and stress-activated protein kinase (SAPK), stimulates c-Jun phosphorylation and transcriptional activity, and induces a macrophage-like differentiation of U937 cells, The involvement of the MAPK pathway in mediating both the early phosphorylation and transcriptional activation events and the chronic differentiation of U937 cells was examined utilizing constitutively active MAPK kinase (MEK1) mutants, Transient expression of an activated MEK1 construct in U937 cells was found to stimulate MAPK and SAPK activity, as well as enhancing AP1-, SRE- and c-Jun-mediated transcriptional activity, Transient transfection of MAPK phosphatase-l (MKP-1), a protein phosphatase which preferentially dephosphorylates and inactivates MAPK, inhibited the functional effects of both PMA and the constitutively active MEK1 mutants, To determine whether specific activation of the MEK/MAPK pathway was sufficient to induce hematopoietic differentiation, U937 cell lines were established that conditionally expressed the activataed MEK1 mutant under the control of the human IIa metallothionein promoter, The induction of constitutively active MEK1 protein expression resulted in an increase in MEK1 activity, c-Jun and AP-1 transcriptional activity and an inhibition of U937 cell growth, However, this growth inhibition was not accompanied by U937 cell differentiation, These results suggest that a cross-talk mechanism exists between the MAPK and SAPK signal transduction pathways in U937 cells and that PMA-mediated SAPK activation may involve the MAPK pathway, Furthermore, selective activation of the MEK/MAPK pathway utilizing a constitutively active MEK1 mutant, while growth inhibitory, was not sufficient to induce the macrophage-like differentiation of U937 cells.	UNIV ALABAMA,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NATIONAL CANCER INSTITUTE [R01CA042533] Funding Source: NIH RePORTER; NCI NIH HHS [CA42533] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ADUNYAH SE, 1992, J CELL PHYSIOL, V151, P415, DOI 10.1002/jcp.1041510223; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRUNET A, 1994, ONCOGENE, V9, P3379; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAI TN, 1995, ONCOGENE, V10, P849; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FRANKLIN CC, 1993, CELL GROWTH DIFFER, V4, P377; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIU A, 1995, J BIOL CHEM, V270, P8377; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PERALDI P, 1994, P NATL ACAD SCI USA, V91, P5002, DOI 10.1073/pnas.91.11.5002; POLOTSKAYA A, 1994, J BIOL CHEM, V269, P14607; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHERMAN ML, 1990, J BIOL CHEM, V265, P3320; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; SZABO E, 1991, CELL GROWTH DIFFER, V2, P475; WAYS DK, 1994, CELL GROWTH DIFFER, V5, P1195; WILLIAM F, 1990, J BIOL CHEM, V265, P18166; YAN MH, 1994, NATURE, V372, P798; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	55	55	56	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2365	2374						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570188				2022-12-28	WOS:A1995TK70200021
J	Stoesz, SP; Gould, MN				Stoesz, SP; Gould, MN			Overexpression of neu-related lipocalin (NRL) in neu-initiated but not ras or chemically initiated rat mammary carcinomas	ONCOGENE			English	Article						lipocalin; neu; ras; mammary cancer	HUMAN-BREAST-CANCER; EPITHELIAL-CELLS; CLASS-I; GENE-EXPRESSION; PROTEIN FAMILY; ONCOGENE; SEQUENCE; GELATINASE; ANTIGENS; AMPLIFICATION	The activated neu (HER2/c-erbB-2) oncogene is extremely potent in inducing mammary cancer, For example, neu induces greater than 200 times as many tumors as the activated ras oncogene when directly introduced into in situ rat mammary epithelial cells using replication-defective retroviral vectors. In order to characterize mechanisms underlying this potency, we sought to identify uniquely overexpressed genes in neu-initiated tumors that were not overexpressed in tumors induced by weaker initiating agents, including activated ras and the chemical carcinogens dimethylbenz[a]anthracene and N-nitroso-N-methylurea. Several genes, including those encoding keratin K7 and the u haplotype of MHC class I RT1-A, were found to be overexpressed in neu-initiated carcinomas as well as in mammary carcinomas induced by other agents, when compared to their expression in normal mammary tissue, One gene, however, encoding a member of the lipocalin and calycin protein families, was 12-fold overexpressed in neu mammary tumors and was not overexpressed in ras or chemically induced carcinomas, This uniquely overexpressed gene was termed neu-related lipocalin (NRL). NRL protein was produced in a baculovirus system, purified and used to generate polyclonal antibodies, Western blot analysis indicated that neu-initiated mammary carcinomas express abundant NRL protein when compared to other mammary tumors.	UNIV WISCONSIN, DEPT HUMAN ONCOL, MADISON, WI 53792 USA; UNIV WISCONSIN, CELLULAR & MOLEC BIOL PROGRAM, MADISON, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison			Gould, Michael N/C-7414-2014		NCI NIH HHS [CA58328] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058328] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKERSTROM B, 1990, TRENDS BIOCHEM SCI, V15, P240, DOI 10.1016/0968-0004(90)90037-C; ANDERSSON LM, 1994, EXP CELL RES, V212, P389, DOI 10.1006/excr.1994.1159; BEDARD PA, 1989, MOL CELL BIOL, V9, P1371, DOI 10.1128/MCB.9.3.1371; BERGER MS, 1988, CANCER RES, V48, P1238; BERNHARD EJ, 1990, CANCER RES, V50, P3872; BIFLOFSKY HS, 1988, NUCLEIC ACIDS RES, V16, P1861; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BUNDGAARD JR, 1994, BIOCHEM BIOPH RES CO, V202, P1468, DOI 10.1006/bbrc.1994.2096; CANCEDDA FD, 1988, J CELL BIOL, V107, P2455, DOI 10.1083/jcb.107.6.2455; CHAN YL, 1988, NUCLEIC ACIDS RES, V16, P11368, DOI 10.1093/nar/16.23.11368; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DICKSON SR, 1992, J HISTOCHEM CYTOCHEM, V40, P697, DOI 10.1177/40.5.1315355; FLOWER DR, 1991, BIOCHEM BIOPH RES CO, V180, P69, DOI 10.1016/S0006-291X(05)81256-2; FLOWER DR, 1993, PROTEIN SCI, V2, P753, DOI 10.1002/pro.5560020507; GLASS C, 1985, J CELL BIOL, V101, P2366, DOI 10.1083/jcb.101.6.2366; GLASS C, 1988, J CELL BIOL, V107, P1337, DOI 10.1083/jcb.107.4.1337; GOULD MN, 1993, J CELL BIOCHEM, P66; GRAND RJA, 1987, INT J CANCER, V40, P213, DOI 10.1002/ijc.2910400215; HAAG JD, 1992, CANCER RES, V52, P4021; HRABARENEVEY S, 1989, ONCOGENE, V4, P601; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; MAUXION F, 1989, IMMUNOGENETICS, V29, P397, DOI 10.1007/BF00375868; MCCANN AH, 1991, CANCER RES, V51, P3296; MERUELO D, 1978, J EXP MED, V147, P470, DOI 10.1084/jem.147.2.470; MORRISON BW, 1994, ONCOGENE, V9, P3417; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P8889, DOI 10.1093/nar/17.21.8889; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SIVAPRASADARAO A, 1988, BIOCHEM J, V255, P561; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH GH, 1990, CELL GROWTH DIFFER, V1, P161; STRANGE R, 1992, DEVELOPMENT, V115, P49; SWEETSER MT, 1989, NATURE, V342, P180, DOI 10.1038/342180a0; TETU B, 1994, CANCER, V73, P2359, DOI 10.1002/1097-0142(19940501)73:9<2359::AID-CNCR2820730919>3.0.CO;2-9; TRASK DK, 1990, P NATL ACAD SCI USA, V87, P2319, DOI 10.1073/pnas.87.6.2319; WANG BC, 1991, CANCER RES, V51, P2642; WANG BC, 1991, CANCER RES, V51, P5649; YANG YM, 1994, J CELL BIOL, V127, P1097, DOI 10.1083/jcb.127.4.1097	43	55	76	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2233	2241						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570173				2022-12-28	WOS:A1995TK70200006
J	vanLeeuwen, FN; vanderKammen, RA; Habets, GGM; Collard, JG				vanLeeuwen, FN; vanderKammen, RA; Habets, GGM; Collard, JG			Oncogenic activity of Tiam1 and Rac1 in NIH3T3 cells	ONCOGENE			English	Article						Tiam1; oncogene; GDP dissociation stimulator	PROTEINS	We have recently identified the invasion-inducing Tiam1 gene by proviral insertional mutagenesis. The Tiam1 protein shares a Dbl homology (DH) domain with an increasing number of oncoproteins, some of which have been shown to function as GDP dissociation stimulators (GDS) for small GTPases of the Rho family. In vitro and in vivo analyses indicate that Tiam1 activates the Rho like GTPase Rad. Here we have analysed the consequences of overexpression of several mutant Tiam1 proteins in NIH3T3 fibroblasts. Similar to other proteins containing a DH domain, N-terminal truncation of the Tiam1 protein activates its oncogenic potential, establishing Tiam1 as a proto-oncogene. In addition, we show that sequences N-terminal of the catalytic DH domain are required for morphological transformation accompanied by the formation of membrane ruffling, but not for the induction of an oncogenic phenotype. Overexpression of constitutively active Rac1 (V12Rac1) in NIH3T3 cells produces a similar oncogenic phenotype, suggesting that the oncogenic effects of Tiam1 are a consequence of Rac activation.	NETHERLANDS CANC INST,DIV CELL BIOL,ANTONI VAN LEEUWENHOEKHUIS,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute			van Leeuwen, Frank/AAQ-6799-2020	van Leeuwen, Frank/0000-0003-1107-6513				CHAN AML, 1994, ONCOGENE, V9, P1057; COLLARD JG, 1985, INT J CANCER, V35, P207, DOI 10.1002/ijc.2910350211; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1994, J BIOL CHEM, V269, P62; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PERONA R, 1993, ONCOGENE, V8, P1285; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RON D, 1989, ONCOGENE, V4, P1067; SELF AJ, 1993, ONCOGENE, V8, P655; TOKSOZ D, 1994, ONCOGENE, V9, P621; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	29	110	112	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2215	2221						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570171				2022-12-28	WOS:A1995TK70200004
J	KUSSICK, SJ; BASLER, K; COOPER, JA				KUSSICK, SJ; BASLER, K; COOPER, JA			RAS1-DEPENDENT SIGNALING BY ECTOPICALLY-EXPRESSED DROSOPHILA-SRC GENE-PRODUCT IN THE EMBRYO AND DEVELOPING EYE	ONCOGENE			English	Article								The cellular functions of the Drosophila src 64B (Dsrc) gene product, Dsrc, and of most vertebrate Src-family kinases, are unknown. We have examined the effects of over-expression of wild type and mutated forms of Dsrc in transgenic Drosophila. Expression of both wild type Dsrc and a C-terminally truncated mutant at high levels during embryonic development induced extensive tyrosine phosphorylation of cellular proteins and caused considerable lethality, correlating with a block to germ-band retraction. Over-expression in the eye imaginal disc led to excess production of photoreceptor cells in the adult ommatidia. In contrast, expression of a kinase-inactive form of Dsrc caused distinct nervous system abnormalities in embryos and decreased the numbers of photoreceptor cells in the adult eye ommatidia. This suggests that active forms of Dsrc alter development by phosphorylation. Both the lethality and the eye roughening caused by activated Dsrc were partially suppressed by mutations in the Drosophila Ras1 gene. These results suggest that over-expressed Dsrc may function through Ras1 to stimulate differentiation in the embryonic nervous system and eye imaginal disc, and that kinase-active Dsrc interferes with these processes.	FRED HUTCHINSON CANC RES CTR, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA; COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA; UNIV WASHINGTON, SCH MED, DEPT PATHOL, SEATTLE, WA 98195 USA	Fred Hutchinson Cancer Center; Columbia University; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle				Basler, Konrad/0000-0003-3534-1529	NATIONAL CANCER INSTITUTE [R01CA041072, R37CA041072] Funding Source: NIH RePORTER; NCI NIH HHS [CA-41072] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BASLER K, 1990, GENE DEV, V4, P728, DOI 10.1101/gad.4.5.728; BASLER K, 1989, EMBO J, V8, P2381, DOI 10.1002/j.1460-2075.1989.tb08367.x; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BISHOP JG, 1988, GENE DEV, V2, P567, DOI 10.1101/gad.2.5.567; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHENG SH, 1991, J VIROL, V65, P170, DOI 10.1128/JVI.65.1.170-179.1991; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COUSSENS PM, 1985, MOL CELL BIOL, V5, P2753, DOI 10.1128/MCB.5.10.2753; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; HAFEN E, 1991, DEVELOPMENT, P123; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KUSSICK SJ, 1992, ONCOGENE, V7, P2461; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANO H, 1990, ONCOGENE, V5, P1781; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; Roberts D. B, 1986, DROSOPHILA PRACTICAL; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1983, NATURE, V302, P837, DOI 10.1038/302837a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SIMON MA, 1987, THESIS U CALIFORNIA; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRECKER TR, 1991, P NATL ACAD SCI USA, V88, P5824, DOI 10.1073/pnas.88.13.5824; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; ZIEGLER SF, 1989, MOL CELL BIOL, V9, P2724, DOI 10.1128/MCB.9.6.2724	74	24	25	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2791	2803						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378088				2022-12-28	WOS:A1993LX34300021
J	VIGON, I; FLORINDO, C; FICHELSON, S; GUENET, JL; MATTEI, MG; SOUYRI, M; COSMAN, D; GISSELBRECHT, S				VIGON, I; FLORINDO, C; FICHELSON, S; GUENET, JL; MATTEI, MG; SOUYRI, M; COSMAN, D; GISSELBRECHT, S			CHARACTERIZATION OF THE MURINE MPL PROTOONCOGENE, A MEMBER OF THE HEMATOPOIETIC CYTOKINE RECEPTOR FAMILY - MOLECULAR-CLONING, CHROMOSOMAL LOCATION AND EVIDENCE FOR A FUNCTION IN CELL-GROWTH	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; MYELOPROLIFERATIVE LEUKEMIA-VIRUS; AFFINITY INTERLEUKIN-5 RECEPTOR; IL-6 SIGNAL TRANSDUCER; GM-CSF RECEPTOR; EXPRESSION CLONING; INHIBITORY FACTOR; BINDING-PROTEIN; ERYTHROPOIETIN RECEPTOR; PROGENITOR CELLS	The v-mpl oncogene transduced in the myeloproliferative leukemia virus (MPLV) encodes a truncated form of a putative receptor protein that belongs to the cytokine receptor superfamily. We previously reported the cloning of complete human c-MPL cDNA. In the present report, we show that the murine Mpl proto-oncogene is located at the D-band of murine chromosome 4, in a region in synteny with human chromosome 1p34, where MPL was previously located. RNA blot analysis of murine hematopoietic tissues and cells lines indicated that Mpl is expressed in immature hematopoietic precursor cells. Molecular cloning of murine proto-oncogene c-Mpl cDNAs is also reported. Two cDNA species were isolated. One potentially encodes a transmembrane protein. The extracellular domain of this protein has two repeats of the cytokine receptor domain common to all members of this receptor family. The cytoplasmic domain has no protein kinase or phosphatase motifs, but does contain a sequence that has been shown to be essential for the transmission of a growth signal in several other members of the family. Comparison of murine and human putative proteins indicated that they shared 81% amino acid identity, the most conserved region being the cytoplasmic domain (91% identity). The other Mpl cDNA clones potentially encode a soluble form of this receptor chain. A chimeric receptor containing the extracellular domain of the granulocyte colony-stimulating factor (G-CSF) receptor fused to the transmembrane and cytoplasmic domains of Mpl was able to induce G-CSF responsiveness when transfected into the interleukin 3 (IL-3)-dependent cell line BAF/BO3. This demonstrated that the cytoplasmic Mpl domain is most probably implicated in proliferative signal transduction.	IMMUNEX RES & DEV CORP,SEATTLE,WA 98101; INST PASTEUR,GENET MAMMIFERES LAB,F-75724 PARIS 15,FRANCE; HOP ENFANTS,GRP HOSP TIMONE,INSERM,U242,F-13385 MARSEILLE 5,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	VIGON, I (corresponding author), HOP COCHIN,ICGM,INSERM,U363,27 RUE FAUBOURG ST JACQUES,F-75674 PARIS 14,FRANCE.		Souyri, Michele/L-5845-2017					BOUTIN JM, 1988, P NATL ACAD SCI USA, V88, P7744; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; EDERY M, 1989, P NATL ACAD SCI USA, V86, P2112, DOI 10.1073/pnas.86.6.2112; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; JONES SS, 1990, BLOOD, V76, P31; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LAYTON MJ, 1992, P NATL ACAD SCI USA, V89, P8616, DOI 10.1073/pnas.89.18.8616; LECONIAT M, 1989, HUM GENET, V83, P194; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NADEAU JH, 1986, GENETICS, V114, P1239; PALACIOS R, 1984, NATURE, V309, P126, DOI 10.1038/309126a0; RENAULD JC, 1992, P NATL ACAD SCI USA, V89, P5690, DOI 10.1073/pnas.89.12.5690; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; TAKAKI S, 1991, EMBO J, V10, P2833, DOI 10.1002/j.1460-2075.1991.tb07832.x; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WANG HM, 1992, J BIOL CHEM, V267, P979; WENDLING F, 1989, LEUKEMIA, V3, P475; WENDLING F, 1986, VIROLOGY, V149, P242, DOI 10.1016/0042-6822(86)90125-X; WENDLING F, 1989, BLOOD, V73, P1161; WEYDERT A, 1992, CR ACAD SCI III-VIE, V314, P429; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZIEGLER SF, 1991, NEW BIOL, V3, P1242	44	133	139	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2607	2615						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8397366				2022-12-28	WOS:A1993LX34300001
J	BARE, DJ; LAUDER, JM; WILKIE, MB; MANESS, PF				BARE, DJ; LAUDER, JM; WILKIE, MB; MANESS, PF			P59(FYN) IN RAT-BRAIN IS LOCALIZED IN DEVELOPING AXONAL TRACTS AND SUBPOPULATIONS OF ADULT NEURONS AND GLIA	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; NERVE GROWTH CONE; SRC GENE-PRODUCT; CEREBRAL-CORTEX; MOUSE; RECEPTOR; PROTOONCOGENE; PP60C-SRC; FAMILY	Expression of the c-fyn proto-oncogene was analysed in the developing and adult rat brain by subcellular fractionation and immunocytochemistry using polyclonal antibodies specific for its protein product (p59fyn). Immunoperoxidase staining revealed widespread localization of p59fyn in developing axonal tracts throughout the fetal (E18) rat brain. fyn immunoreactivity was not observed in most axon-rich regions of the adult brain, but continued to be expressed at elevated levels in the adult olfactory and vomeronasal systems. At other sites in the adult rat brain, fyn immunoreactivity was restricted to cell bodies of neuronal subpopulations, especially those in brain stem and hypothalamic nuclei, and to subpopulations of glial cells along axonal tracts in the medulla, optic nerve and white matter of the spinal cord. In the peripheral nervous system, fyn staining was also prominent in Schwann cells. Subcellular fractionation of fetal and adult rat brain confirmed the immunocytochemical localization, demonstrating an enrichment of p59fyn in membranes from a fetal brain fraction containing nerve growth cones, and lower levels in adult brain where there was only a small enrichment in synaptosomal membranes. The developmental regulation of p59fyn suggests that the fyn tyrosine kinase may serve separate cellular roles in axonal growth and specialized functions of mature neurons and glia.	UNIV N CAROLINA, SCH MED, DEPT CELL BIOL & ANAT, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NEI NIH HHS [EY06336] Funding Source: Medline; NINDS NIH HHS [NS26620] Funding Source: Medline; NATIONAL EYE INSTITUTE [F32EY006336] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026620] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BARBER PC, 1978, BRAIN RES, V147, P297, DOI 10.1016/0006-8993(78)90841-7; BISCARDI JS, 1993, IN PRESS EXP EYE RES; COHEN RS, 1977, J CELL BIOL, V74, P181, DOI 10.1083/jcb.74.1.181; COOKE M P, 1989, New Biologist, V1, P66; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; FENTRESS JC, 1981, ANAT EMBRYOL, V163, P275, DOI 10.1007/BF00315705; FULTS DW, 1985, MOL CELL BIOL, V5, P27, DOI 10.1128/MCB.5.1.27; GRAZIADEI PPC, 1978, NEURONAL PLASTICITY; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IGNELZI MA, 1992, J COMP NEUROL, V315, P171, DOI 10.1002/cne.903150205; IGNELZI MA, 1992, SOC NEUR ABSTR, V4614, P1095; INGRAHAM CA, 1992, ONCOGENE, V7, P95; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBEAU JM, 1991, J NEUROSCI RES, V28, P299, DOI 10.1002/jnr.490280217; LIUZZI FJ, 1987, BRAIN RES, V403, P385, DOI 10.1016/0006-8993(87)90081-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MEIRI KF, 1986, P NATL ACAD SCI USA, V83, P3537, DOI 10.1073/pnas.83.10.3537; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PFENNINGER KH, 1983, CELL, V35, P573, DOI 10.1016/0092-8674(83)90191-5; POMEROY SL, 1990, J NEUROSCI, V10, P1952; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SIMKOWITZ P, 1989, J NEUROSCI, V9, P1004; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWLE AC, 1984, J HISTOCHEM CYTOCHEM, V32, P766, DOI 10.1177/32.7.6145741; UNGER JW, 1991, NEUROSCIENCE, V42, P853, DOI 10.1016/0306-4522(91)90049-T; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WOODHAMS PL, 1981, ANAT EMBRYOL, V163, P331, DOI 10.1007/BF00315709; ZHAO YH, 1991, ONCOGENE, V6, P1725	38	84	85	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1993	8	6					1429	1436						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502471				2022-12-28	WOS:A1993LE06400005
J	BOTTAZZI, ME; GOODENOW, MM; MOSCOVICI, MG; MOSCOVICI, C				BOTTAZZI, ME; GOODENOW, MM; MOSCOVICI, MG; MOSCOVICI, C			BM2L IS A SPONTANEOUS LEUKEMOGENIC VARIANT OF A NON-LEUKEMOGENIC V-MYB-TRANSFORMED MYELOID CELL-LINE	ONCOGENE			English	Article							C-MYB; ONCOGENE; LEUKEMIA; VIRUSES; DIFFERENTIATION; SEQUENCES	Leukemogenesis is a complex process involving an accumulation of genetic lesions affecting both growth and differentiation in cells of the hematopoietic lineage. Our laboratory has established a non-producer v-myb-transformed cell line (BM2/C3A) which, when injected into the chicken embryo, does not produce leukemia. Recently, a spontaneous variant of this cell line, called BM2L, was obtained from in vivo experiments. BM2L produces an acute monoblastic leukemia when injected into the chicken embryo. BM2L cells do not differentiate in vivo or in vitro, but continue to proliferate under conditions in culture that allow for the differentiation of BM2/C3A cells into macrophages. In addition, BM2L cells have reduced requirements for exogenous growth factors. BM2L cells contain the v-myh allele and express v-Myb protein, but leukemogenicity does not involve point mutations in v-myb. The BM2 model, consisting of two non-producer cell lines differing in vivo in their leukemogenicity, provides a novel system for identifying genes that play a role in the induction or suppression of leukemogenesis.	UNIV FLORIDA,J HILLIS MILLER HLTH CTR,DEPT PATHOL,GAINESVILLE,FL 32610; VET ADM MED CTR,DEPT PEDIAT,DIV IMMUNOL,GAINESVILLE,FL 32602; VET ADM MED CTR,CTR MAMMALIAN GENET,GAINESVILLE,FL 32602; VET ADM MED CTR,TUMOR VIROL LAB,GAINESVILLE,FL 32602	State University System of Florida; University of Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA)				Bottazzi, Maria Elena/0000-0002-8429-0476	NATIONAL CANCER INSTITUTE [R01CA010697] Funding Source: NIH RePORTER; NCI NIH HHS [CA10697] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAER MR, 1991, ANNU REV MED, V42, P381, DOI 10.1146/annurev.me.42.020191.002121; CHEN JH, 1980, VIROLOGY, V103, P112, DOI 10.1016/0042-6822(80)90130-0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GAZZOLO L, 1979, CELL, V16, P627, DOI 10.1016/0092-8674(79)90036-9; GOODENOW MM, 1987, J VIROL, V61, P2489, DOI 10.1128/JVI.61.8.2489-2498.1987; GOUGH NM, 1989, CANCER CELL-MON REV, V1, P77; GRIMES HL, 1992, NUCLEIC ACIDS RES, V20, P1511, DOI 10.1093/nar/20.7.1511; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KIM WK, 1988, ONCOGENE RES, V3, P147; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOSCOVICI C, 1976, VIROLOGY, V73, P181, DOI 10.1016/0042-6822(76)90072-6; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; MOSCOVICI C, 1982, EXPRESSION DIFFERENT; MOSCOVICI C, 1982, ADV VIRAL ONCOLOGY, V1; MOSCOVICI MG, 1980, IN VIVO IN VITRO ERY, P503; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHUU RER, 1991, ONCOGENE, V6, P1409; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0	25	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					731	736						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437856				2022-12-28	WOS:A1993KN00800025
J	CORNELIS, RS; DEVILEE, P; VANVLIET, M; KUIPERSDIJKSHOORN, N; KERSENMAEKER, A; BARDOEL, A; KHAN, PM; CORNELISSE, CJ				CORNELIS, RS; DEVILEE, P; VANVLIET, M; KUIPERSDIJKSHOORN, N; KERSENMAEKER, A; BARDOEL, A; KHAN, PM; CORNELISSE, CJ			ALLELE LOSS PATTERNS ON CHROMOSOME-17Q IN 109 BREAST CARCINOMAS INDICATE AT LEAST 2 DISTINCT TARGET REGIONS	ONCOGENE			English	Article							TUMOR SUPPRESSOR GENES; P53 MUTATIONS; CANCER; CARCINOGENESIS; HETEROZYGOSITY; ASSOCIATION; PROGRESSION; MECHANISMS; DELETION; PROTEIN	Loss of heterozygosity (LOH) of markers for chromosome 17 is the most frequent genetic change observed in breast cancer to date. To assess whether the location of several candidate target genes is compatible with patterns of allele losses in the individual tumors, we examined the LOH status of chromosome 17 in 109 primary breast tumors with 15 polymorphic DNA markers (three for 17p and 12 for 17q). Allelic imbalance (AI) at 17q was observed in 44 of the 97 informative cases. A significant correlation was found between Al at the long arm and Al at the short arm of chromosome 17. The patterns of Al on 17q in the tumors differed and were highly complex in some cases. A number of tumors showed AI distal to the growth hormone locus, whereas others showed Al exclusively proximal of this marker. These results indicate that there are at least two different regions of allele loss on 17q.	LEIDEN UNIV,FAC MED,DEPT PATHOL,2333 AL LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC	CORNELIS, RS (corresponding author), LEIDEN UNIV,FAC MED,DEPT HUMAN GENET,WASSENAARSEWEG 72,2333 AL LEIDEN,NETHERLANDS.		DEVILEE, PETER/ABR-2140-2022					ANDERSEN TI, 1992, GENE CHROMOSOME CANC, V4, P113, DOI 10.1002/gcc.2870040203; BAKER SJ, 1990, CANCER RES, V50, P7717; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BORRESEN AL, 1991, AM J HUM GENET, V49, P44; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; CROPP CS, 1990, P NATL ACAD SCI USA, V87, P7737, DOI 10.1073/pnas.87.19.7737; DEVILEE P, 1990, CYTOGENET CELL GENET, V53, P52, DOI 10.1159/000132893; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DEVILEE P, 1991, ONCOGENE, V6, P1705; DEVILEE P, 1991, CANCER RES, V51, P1020; DEVILEE P, 1991, ONCOGENE, V6, P311; DEVILEE P, 1990, CANCER SURV, V9, P605; DEVILEE P, 1991, INT J CANCER, V47, P817, DOI 10.1002/ijc.2910470604; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; EASTON DF, 1993, IN PRESS AM J HUM GE; GELEICK D, 1990, CANCER GENET CYTOGEN, V46, P217, DOI 10.1016/0165-4608(90)90107-L; GERBAULTSEUREAU M, 1987, ANN GENET-PARIS, V30, P138; HALL JM, 1992, AM J HUM GENET, V50, P1235; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KNUDSON AG, 1989, BRIT J CANCER, V59, P661, DOI 10.1038/bjc.1989.137; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; LEONE A, 1991, CANCER RES, V51, P2490; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; NUELL MJ, 1991, MOL CELL BIOL, V11, P1372, DOI 10.1128/MCB.11.3.1372; OSBORNE RJ, 1991, CANCER RES, V51, P6194; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P689, DOI 10.1093/nar/19.3.689; PONDER B, 1989, NATURE, V340, P264, DOI 10.1038/340264a0; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; PROSSER J, 1990, ONCOGENE, V5, P1573; SASTREGARAU X, 1992, INT J CANCER, V50, P533, DOI 10.1002/ijc.2910500406; SATO T, 1991, CANCER RES, V51, P5794; SATO T, 1992, CANCER RES, V52, P1643; SATO T, 1990, CANCER RES, V50, P7184; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; SOLOMON E, 1991, CYTOGENET CELL GENET, V51; THOMPSON AM, 1992, INT J CANCER, V50, P528, DOI 10.1002/ijc.2910500405; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; VARLEY JM, 1991, ONCOGENE, V6, P413; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHITE JJ, 1991, GENOMICS, V11, P228, DOI 10.1016/0888-7543(91)90126-Y	44	77	79	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					781	785						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437862				2022-12-28	WOS:A1993KN00800031
J	REITH, AD; ELLIS, C; MAROC, N; PAWSON, T; BERNSTEIN, A; DUBREUIL, P				REITH, AD; ELLIS, C; MAROC, N; PAWSON, T; BERNSTEIN, A; DUBREUIL, P			W-MUTANT FORMS OF THE FMS RECEPTOR TYROSINE KINASE ACT IN A DOMINANT MANNER TO SUPPRESS CSF-1 DEPENDENT CELLULAR-TRANSFORMATION	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTOR; C-KIT RECEPTOR; POLYMERASE CHAIN-REACTION; PROTO-ONCOGENE; INSULIN-RECEPTOR; SIGNAL TRANSDUCTION; MOUSE DEVELOPMENT; PHOSPHATIDYLINOSITOL KINASE; PHOSPHOTYROSINE ANTIBODY	Point mutations in highly conserved amino acid residues in the catalytic domain of the Kit receptor tyrosine kinase (RTK) are responsible for the coat color, fertility and hematopoietic defects of mice bearing mutant alleles at the dominant white-spotting (W) locus. The dominant nature of structural Kit mutations suggests that expression of other kinase-defective RTKs might also specificity interfere with signal transduction by normal receptors. To test this possibility, we have investigated the functional consequences of introducing analogous mutations into the RTK encoded by the c-fms proto-oncogene. Both Fms37 (glu582-->lys) and Fms42 (asp776-->asn) mutant proteins, corresponding to the strongly dominant-negative W37 and W42 mutant c-kit alleles, had undetectable in vitro kinase activity and were unable to transform Rat-2 fibroblasts in the presence of exogenous CSF-1. Moreover, expression of Fms37 or Fms42 proteins in Rat-2 cells specifically inhibited anchorage-independent growth mediated by the normal Fms receptor in the presence of exogenous CSF-1 and conferred a dominant loss of Fms-associated P13-kinase activity on CSF-1 stimulation. Mutant RTKs, bearing point substitutions identical to those present in mild or severe W mutants, may provide a generally applicable strategy for inducing dominant loss of function defects in RTK-mediated signalling pathways.	UNIV TORONTO, DEPT MED BIOPHYS, TORONTO M5S 1A1, ONTARIO, CANADA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ONTARIO, CANADA; INST CANC RES, CHESTER BEATTY LABS, LONDON SW3 6JB, ENGLAND; INSERM, UNITE 119, F-13009 MARSEILLE, FRANCE	University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Institut National de la Sante et de la Recherche Medicale (Inserm)	REITH, AD (corresponding author), UCL, MIDDLESEX HOSP, LUDWIG INST CANC RES, 91 RIDING HOUSE ST, LONDON W1P 8BT, ENGLAND.		Pawson, Tony J/E-4578-2013; Dubreuil, Patrice/V-4816-2019; dubreuil, patrice/F-5346-2011	Dubreuil, Patrice/0000-0003-1155-1150; dubreuil, patrice/0000-0003-1155-1150; Maroc, Nicolas/0000-0001-7285-509X				ADAMSON ED, 1987, DEVELOPMENT, V99, P449; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ARCECI RJ, 1989, P NATL ACAD SCI USA, V86, P8818, DOI 10.1073/pnas.86.22.8818; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BOULTER CA, 1988, ONCOGENE, V2, P207; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DUBREUIL P, 1991, P NATL ACAD SCI USA, V88, P2341, DOI 10.1073/pnas.88.6.2341; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GEISSLER EN, 1981, GENETICS, V97, P337; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KACSER H, 1981, GENETICS, V97, P639; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLINKHAMER MP, 1989, EMBO J, V8, P2503, DOI 10.1002/j.1460-2075.1989.tb08387.x; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LETWIN K, 1988, ONCOGENE, V3, P621; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MARKS SC, 1976, J HERED, V67, P11, DOI 10.1093/oxfordjournals.jhered.a108657; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MERCOLA M, 1990, DEV BIOL, V138, P114, DOI 10.1016/0012-1606(90)90181-H; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MORAN MF, 1988, ONCOGENE, V3, P665; MOTRO B, 1991, DEVELOPMENT, V113, P1207; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; OHTSUKA M, 1990, MOL CELL BIOL, V10, P1664, DOI 10.1128/MCB.10.4.1664; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; POLLARD JW, 1991, DEV BIOL, V148, P273, DOI 10.1016/0012-1606(91)90336-2; RAY P, 1991, GENE DEV, V5, P2265, DOI 10.1101/gad.5.12a.2265; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; REGENSTREIF LJ, 1989, DEV BIOL, V133, P284, DOI 10.1016/0012-1606(89)90319-9; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, GENE DEV, V5, P1115, DOI 10.1101/gad.5.7.1115; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; REITH AD, 1991, GENOME ANAL, V3, P105; ROHRSCHNEIDER LR, 1989, ONCOGENE, V4, P1015; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SHERR CJ, 1990, BLOOD, V75, P1; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; TAIRA M, 1989, SCIENCE, V245, P63, DOI 10.1126/science.2544997; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	87	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1993	8	1					45	53						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380922				2022-12-28	WOS:A1993KN00500006
J	STEPHENS, EV; KALINEC, G; BRANN, MR; GUTKIND, JS				STEPHENS, EV; KALINEC, G; BRANN, MR; GUTKIND, JS			TRANSFORMING G-PROTEIN-COUPLED RECEPTORS TRANSDUCE POTENT MITOGENIC SIGNALS IN NIH 3T3 CELLS INDEPENDENT ON CAMP INHIBITION OR CONVENTIONAL PROTEIN-KINASE-C	ONCOGENE			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTORS; STIMULATES DNA-SYNTHESIS; GROWTH-FACTOR RECEPTOR; S PHASE PROGRESSION; A9 L-CELLS; PERSISTENT ACTIVATION; HAMSTER FIBROBLASTS; CARBACHOL ACTION; PHORBOL ESTERS; EXPRESSION	We have used the expression of human acetylcholine muscarinic receptor (mAChR) genes in NIH 3T3 cells as a model for dissecting the molecular basis of cellular transformation induced by G protein-coupled receptors. Those mAChR subtypes efficiently coupled to PIP, hydrolysis (m1, m3 and m5) induced agonist-dependent celt transformation whereas those inhibiting adenylyl cyclase (m2, m4) lack transforming activity. In the present study, we demonstrate that in cells expressing ml but not m2 mAChRs the cholinergic agonist (carbachol) is alone as potent a stimulant for DNA synthesis as platelet-derived growth factor (PDGF) or serum. Furthermore, induction of DNA synthesis is shown to correlate with activation of PIP, hydrolysis but not with inhibition of adenylyl cyclase. We also examined the rote of protein kinase C (PKC) in mitogenic signalling through ml mAChRs, and found that NIH 3T3 cells express PKC-alpha and PCK-zeta as the only conventional or Ca2+-independent PKC isozyme, respectively. Prolonged treatment with TPA depleted cells of PKC-alpha but not of PKC-zeta. In TPA-treated NIH 3T3 celts, the mitogenic response to a subsequent stimulation with TPA was absolutely abolished, but the response to PDGF or serum was not. Moreover, PKC depletion did not decrease DNA synthesis induced by carbachol. We conclude that carbachol potently induces reinitiation of DNA synthesis through the activation of transforming mAChR subtypes, independently of inhibition of adenylyl cyclase and conventional PKCs.	NIDR,MOLEC SIGNALING GRP,CELLULAR REV & ONCOL LAB,9000 ROCKVILLE PIKE,BETHESDA,MD 20892; UNIV VERMONT,COLL MED,DEPT PSYCHIAT,NEUROSCI RES UNIT,BURLINGTON,VT 05405	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Vermont			Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; 				AKITA Y, 1990, J BIOL CHEM, V265, P354; ASHKENAZI A, 1989, NATURE, V340, P146, DOI 10.1038/340146a0; BERNARDS R, 1991, EMBO J, V10, P1119, DOI 10.1002/j.1460-2075.1991.tb08052.x; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BOWENPOPE DF, 1985, METHOD ENZYMOL, V109, P69; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CONKLIN BR, 1988, P NATL ACAD SCI USA, V85, P8698, DOI 10.1073/pnas.85.22.8698; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FINZI E, 1987, P NATL ACAD SCI USA, V84, P3733, DOI 10.1073/pnas.84.11.3733; GUSOVSKY F, 1991, MOL PHARMACOL, V39, P124; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JONES SVP, 1988, MOL PHARMACOL, V34, P421; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; LEAL F, 1985, SCIENCE, V230, P327, DOI 10.1126/science.2996133; MOOLENAAR WH, 1991, CELL GROWTH DIFFER, V2, P359; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PASTI G, 1986, NATURE, V324, P375, DOI 10.1038/324375a0; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SEUWEN K, 1988, NATURE, V335, P254, DOI 10.1038/335254a0; SEUWEN K, 1990, BIOCHEM PHARMACOL, V39, P985, DOI 10.1016/0006-2952(90)90276-Q; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; STRULOVICI B, 1991, J BIOL CHEM, V266, P168; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	46	37	37	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					19	26						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380916				2022-12-28	WOS:A1993KN00500003
J	TOMMASINO, M; ADAMCZEWSKI, JP; CARLOTTI, F; BARTH, CF; MANETTI, R; CONTORNI, M; CAVALIERI, F; HUNT, T; CRAWFORD, L				TOMMASINO, M; ADAMCZEWSKI, JP; CARLOTTI, F; BARTH, CF; MANETTI, R; CONTORNI, M; CAVALIERI, F; HUNT, T; CRAWFORD, L			HPV16 E7 PROTEIN ASSOCIATES WITH THE PROTEIN-KINASE P33CDK2 AND CYCLIN-A	ONCOGENE			English	Note							HUMAN PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA GENE-PRODUCT; E2F TRANSCRIPTION FACTOR; ADENOVIRUS E1A PROTEINS; RB PROTEIN; TRANSACTIVATION; MECHANISM; PHOSPHORYLATION; TRANSFORMATION; THIAMINE	E7 is the major transforming protein of human papillomavirus type 16 (HPV16). It has been found to associate with the retinoblastoma protein Rb1. We investigated whether HPV16 E7 protein was associated with other cellular proteins, in particular with those involved in cell cycle control. Immunoprecipitates from CaSki cell extracts with an anti E7 monoclonal antibody contained a histone H1 kinase. Recombinant E7, synthesized in yeast, when mixed with protein extracts from epithelial cells bound histone H1 kinase activity in vitro. The in vivo and the in vitro-formed E7-kinase complex had the same periodicity of activity during the cell cycle, being most active in S and G2/M. Immunoblotting of E7 immunoprecipitates with an antibody raised against the p33CDK2, revealed a 33 kDa protein band not detected by an anti-p34cdc2 antibody, suggesting that the E7-associated kinase activity is due to the p33CDK2. The interaction appears to be via cyclin A, since probing of similar immunoblots showed a 50 kDa band corresponding to cyclin A. The association of E7 with cyclin A appeared to be direct, not involving Rb1 or other proteins.	UNIV CAMBRIDGE,DEPT PATHOL,IMPERIAL CANC RES FUND,VIRUS GRP,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND; IRIS,I-53100 SIENA,ITALY; IMPERIAL CANC FUND,GROWTH CONTROL & DEV LAB,LONDON WC2A 3PX,ENGLAND; IMPERIAL CANC RES FUND,POTTERS BAR EN6 3LD,HERTS,ENGLAND	University of Cambridge; Novartis								BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BANKS L, 1990, ONCOGENE, V5, P1383; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHESTERS PM, 1989, J GEN VIROL, V70, P353, DOI 10.1099/0022-1317-70-2-353; CRAWFORD LV, 1979, J VIROL, V29, P587, DOI 10.1128/JVI.29.2.587-596.1979; CROOK T, 1988, P NATL ACAD SCI USA, V85, P353; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GREENFIELD I, 1991, P NATL ACAD SCI USA, V88, P11217, DOI 10.1073/pnas.88.24.11217; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; KLEINBERGER T, 1991, P NATL ACAD SCI USA, V88, P11143, DOI 10.1073/pnas.88.24.11143; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1992, ONCOGENE, V7, P1681; PAGANO M, 1991, Progress in Growth Factor Research, V3, P267, DOI 10.1016/0955-2235(91)90004-N; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SMOTKIN D, 1987, J VIROL, V61, P1686, DOI 10.1128/JVI.61.5.1686-1689.1987; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TINDLE RW, 1990, J GEN VIROL, V71, P1347, DOI 10.1099/0022-1317-71-6-1347; TOMMASINO M, 1990, GENE, V93, P265, DOI 10.1016/0378-1119(90)90234-I; TOMMASINO M, 1991, CURR GENET, V20, P63, DOI 10.1007/BF00312766; TOMMASINO M, 1992, GENE, V111, P93, DOI 10.1016/0378-1119(92)90607-Q; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VOUSDEN KH, 1989, ONCOGENE, V4, P153; YAMASHITA M, 1991, DEV GROWTH DIFFER, V33, P617	39	141	155	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					195	202						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380917				2022-12-28	WOS:A1993KN00500024
J	Martinerie, C; Chevalier, G; Rauscher, FJ; Perbal, B				Martinerie, C; Chevalier, G; Rauscher, FJ; Perbal, B			Regulation of nov by WT1: A potential role for nov in nephrogenesis	ONCOGENE			English	Article						novH; nephrogenesis; Wilms' tumor; WT1; IGF-binding-protein	WILMS-TUMOR GENE; GROWTH FACTOR-II; IMMEDIATE-EARLY GENE; ZINC FINGER PROTEIN; FACTOR-A-CHAIN; PROMOTER ACTIVITY; BINDING-PROTEIN; RECEPTOR GENE; KIDNEY DEVELOPMENT; SUPPRESSOR WT1	The nov gene encodes a putative Insulin-like-Growth Factor-Binding Protein (IGFBP) of a novel type which is structurally related to a family of growth-factors likely to play a role in the control of cell proliferation. In the kidney, nov is expressed essentially at the embryonic stage and alterations of nov expression, relative to the normal kidney, have been detected in both avian nephroblastomas and human Wilms' tumors. The levels of human nov (novH) and WT1 mRNA in individual Wilms' tumors have been shown to be inversely correlated, suggesting that the expression of novH could be under the negative control of WT1. We have now established the nucleotide sequence of the 5' flanking region,and identified two transcription start sites by RNase protection assays and primer extension. We report that in transient cotransfection experiments the transcription activity of novH promoter constructs was repressed by two isoforms of WT1 proteins (WT1 and WT1 + KTS). Repression of the novH promoter required both intact zinc finger regions and the NH, transcription repression domain of WT1. Inasmuch as the minimal region of novH promoter required to mediate WT1 repression irt vivo failed to bind recombinant WT1 protein in in vitro footprinting assays this repression may be mediated by either (i) low affinity sites cooperative interactions or (ii) indirectly via protein-protein interactions with another factor(s). Furthermore, constitutive expression of wild type WT1 into 293 cells resulted in a decrease of endogenous NOVH protein levels, suggesting that novH may be a physiological target for WT1. The downregulation of novH expression by WT1 might represent a key element in normal and tumoral nephrogenesis.	INST CURIE,LAB ONCOL VIRALE & MOL,F-91405 ORSAY,FRANCE; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; UNIV PARIS 07,UFR BIOCHIM,F-75221 PARIS,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; The Wistar Institute; UDICE-French Research Universities; Universite Paris Cite								ARAKI E, 1987, J BIOL CHEM, V262, P16186; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DESSEN P, 1990, FRENCH SERVICE ACCES; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GANSLER T, 1989, AM J PATHOL, V135, P961; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GERALD WL, 1992, AM J PATHOL, V140, P1031; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HASELBACHER GK, 1987, P NATL ACAD SCI USA, V84, P1104, DOI 10.1073/pnas.84.4.1104; HEINE U, 1962, JNCI-J NATL CANCER I, V29, P41; HUFF V, 1993, BIOCHIM BIOPHYS ACTA, V1155, P295, DOI 10.1016/0304-419X(93)90011-Z; ISHIGURO H, 1962, J NATL CANCER I, V29, P1; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; KIEFER MC, 1991, BIOCHEM BIOPH RES CO, V176, P219, DOI 10.1016/0006-291X(91)90912-Q; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; LIU XW, 1993, NUCLEIC ACIDS RES, V21, P4954, DOI 10.1093/nar/21.21.4954; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MADDEN SL, 1993, ONCOGENE, V8, P405; MAHASWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100; MALOISEL V, 1990, Methods in Molecular and Cellular Biology, V1, P245; MARTINERIE C, 1994, ONCOGENE, V9, P2729; MARTINERIE C, 1991, CR ACAD SCI III-VIE, V313, P345; MARTINERIE C, 1992, ONCOGENE, V7, P2529; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MIWA H, 1992, J NATL CANCER I, V84, P181, DOI 10.1093/jnci/84.3.181; MORRIS JF, 1991, ONCOGENE, V6, P2339; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; PATCHNIS V, 1993, DEVELOPMENT, V119, P1005; PATWARDHAN S, 1991, ONCOGENE, V6, P917; Perbal B, 1995, INFECT AGENT DIS, V4, P212; PERBAL B, 1994, CRIT REV ONCOGENESIS, V5, P589; PERBAL B, 1994, B CANCER, V81, P957; Perbal B., 1988, PRACTICAL GUIDE MOL; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; ROTHENPIELER UW, 1993, DEVELOPMENT, V119, P711; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; RYAN G, 1995, DEVELOPMENT, V121, P867; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Saxen L., 1987, DEV CELL BIOL SERIES, V19; Scholz G, 1996, MOL CELL BIOL, V16, P481; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; THOMAS MJ, 1990, MOL CELL BIOL, V10, P5378, DOI 10.1128/MCB.10.10.5378; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1995, ONCOGENE, V10, P1243; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WERNER H, 1994, J BIOL CHEM, V269, P12577; WERNER H, 1995, MOL CELL BIOL, V15, P3516; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; WYANG ZY, 1995, ONCOGENE, V10, P415; YEGER H, 1992, CELL GROWTH DIFFER, V3, P855	75	56	61	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1479	1492						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622864				2022-12-28	WOS:A1996UF07600012
J	Fromm, L; Overbeek, PA				Fromm, L; Overbeek, PA			Regulation of cyclin and cyclin-dependent kinase gene expression during lens differentiation requires the retinoblastoma protein	ONCOGENE			English	Article						retinoblastoma; cell cycle; cyclins; cyclin-dependent kinases; lens; crystallins	CELL-CYCLE; PRODUCT; PHOSPHORYLATION; MOUSE; IDENTIFICATION; ACTIVATION	The retinoblastoma protein (pRb) functions as a negative regulator of the cell cycle and is essential to maintain certain cell types in a post-mitotic state during terminal differentiation. In the ocular lens, inactivation of this protein is sufficient to cause lens fiber cells, which are normally post-mitotic, to enter the cell cycle. The current studies address whether regulation of the cell cycle during lens fiber differentiation in normal lenses or in lenses in which pRB has been inactivated is accompanied by changes in expression of cyclin and cyclin-dependent kinase genes. In the normal lens, our experiments using in-situ hybridization reveal that the expression of cyclin A, cyclin B1, cdc2 and cdk2 is restricted to the proliferative epithelial cells, with no expression in the differentiating fiber cells. Cyclins D1 and D2 and cdk4 show a less restrictive pattern and are expressed in some of the post-mitotic cells. Lenses from RB-deficient embryos, in contrast, show inappropriate expression in the fiber cells of cyclins A, B1 and E, as well as cdc2 and cdk2. The lens fiber cells in these embryos express protein markers for differentiation, such as beta- and gamma-crystallins, even though the cells do not withdraw from the cell cycle. These results indicate that the regulated expression of multiple cell cycle regulatory genes during lens fiber cell differentiation requires the presence of pRb.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT OPHTHALMOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine				Overbeek, Paul/0000-0001-9784-2084				CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P263, DOI 10.1002/cne.901880205; CHAPMAN DL, 1992, MOL REPROD DEV, V33, P259, DOI 10.1002/mrd.1080330305; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DAMJANOV I, 1994, BIOCHEM BIOPH RES CO, V201, P994, DOI 10.1006/bbrc.1994.1800; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FROMM L, 1994, MOL CELL BIOL, V14, P6743, DOI 10.1128/MCB.14.10.6743; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; ISHII T, 1993, EXP CELL RES, V208, P407, DOI 10.1006/excr.1993.1262; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KATO J, 1993, GENE DEV, V7, P331; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCAVOY JW, 1978, J EMBRYOL EXP MORPH, V44, P149; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NEVINS JR, 1992, SCIENCE, V258, P424; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; ROBINSON ML, 1995, DEVELOPMENT, V121, P505; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SPITKOVSKY D, 1994, J VIROL, V68, P2206, DOI 10.1128/JVI.68.4.2206-2214.1994; SPURR NK, 1990, J DNA SEQUENCING MAP, V1, P49; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	40	44	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					69	75						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552401				2022-12-28	WOS:A1996TQ01400009
J	CROMME, FV; SNIJDERS, PJF; VANDENBRULE, AJC; KENEMANS, P; MEIJER, CJLM; WALBOOMERS, JMM				CROMME, FV; SNIJDERS, PJF; VANDENBRULE, AJC; KENEMANS, P; MEIJER, CJLM; WALBOOMERS, JMM			MHC CLASS-I EXPRESSION IN HPV-16 POSITIVE CERVICAL CARCINOMAS IS POSTTRANSCRIPTIONALLY CONTROLLED AND INDEPENDENT FROM C-MYC OVEREXPRESSION	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS GENOTYPES; POLYMERASE CHAIN-REACTION; INTRAEPITHELIAL NEOPLASIA; ONCOGENE EXPRESSION; UTERINE CERVIX; HISTOCOMPATIBILITY ANTIGENS; SILVER INTENSIFICATION; INSITU HYBRIDIZATION; COLORECTAL-CANCER; HEAVY-CHAINS	Squamous cell carcinomas of the uterine cervix (n = 23) were selected for the presence of human papillomavirus type 16 (HPV 16) using the polymerase chain reaction (PCR). Localization of transcripts coding for the E7 protein was demonstrated in neoplastic cells with RNA in situ hybridization. Consecutive tissue sections were investigated for expression of the major histocompatibility complex class I (MHC-I) and c-myc using immunohistochemical double staining procedures, since a role has been suggested for the c-myc protein in MHC-I down-regulation and c-myc overexpression has been described in cervical carcinomas. Reduced expression of class I heavy chains was observed in neoplastic cells from 18 out of 23 carcinomas (78%). Varying levels of c-myc overexpression were observed in 12 carcinomas (52%), from which four showed positive MHC-I expression in c-myc overexpressing cells. In the remaining eight c-myc overexpressing carcinomas MHC-I down-regulation was observed. Additional RNA in situ hybridization with class I heavy chain locus-specific RNA-probes revealed presence of class I mRNAs in those neoplastic cells that show negative staining for MHC-I protein. These data strongly indicate that MHC-I down-regulation in cervical carcinomas involves post-transcriptional mechanisms, not directly related to E7 transcription and overexpression of c-myc.	FREE UNIV AMSTERDAM HOSP, INST PATHOL,DEPT PATHOL,MOLEC PATHOL SECT, DE BOELELAAN 1117, 1081 HV AMSTERDAM, NETHERLANDS; FREE UNIV AMSTERDAM HOSP, DEPT GYNAECOL & OBSTET, 1081 HV AMSTERDAM, NETHERLANDS	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER								BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BERGERON C, 1992, AM J SURG PATHOL, V16, P641, DOI 10.1097/00000478-199207000-00002; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BROKER TR, 1989, CANCER CEL, V7, P197; CONNOR ME, 1990, INT J CANCER, V46, P1029, DOI 10.1002/ijc.2910460614; COUTURIER J, 1991, J VIROL, V65, P4534, DOI 10.1128/JVI.65.8.4534-4538.1991; CROMME FV, 1993, BRIT J CANCER, V67, P1372, DOI 10.1038/bjc.1993.254; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; DURST M, 1987, ONCOGENE, V1, P251; FELTNER DE, 1989, J IMMUNOL, V143, P4292; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAUSEN HZ, 1989, CANCER RES, V49, P4677; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; IWASAKA T, 1992, GYNECOL ONCOL, V46, P298, DOI 10.1016/0090-8258(92)90220-D; KLAR D, 1989, EMBO J, V8, P475, DOI 10.1002/j.1460-2075.1989.tb03400.x; KOLLER BH, 1984, P NATL ACAD SCI-BIOL, V81, P5175, DOI 10.1073/pnas.81.16.5175; LENARDO M, 1989, EMBO J, V8, P3351, DOI 10.1002/j.1460-2075.1989.tb08497.x; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LORINCZ AT, 1992, OBSTET GYNECOL, V79, P328, DOI 10.1097/00006250-199203000-00002; LUNGU O, 1992, JAMA-J AM MED ASSOC, V267, P2493, DOI 10.1001/jama.267.18.2493; MAUDSLEY DJ, 1991, IMMUNOL TODAY, V12, P429, DOI 10.1016/0167-5699(91)90013-J; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MERCHENTHALER I, 1989, J HISTOCHEM CYTOCHEM, V37, P1563, DOI 10.1177/37.10.2674275; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; MORRIS A, 1990, ANTICANCER RES, V10, P1161; MULLINK H, 1992, J HISTOCHEM CYTOCHEM, V40, P495, DOI 10.1177/40.4.1532404; MULLINK H, 1987, APPLICATION MONOCLON, P37; MUNGER K, 1989, J VIROL, V64, P519; NEEFJES JJ, 1988, EUR J IMMUNOL, V18, P801, DOI 10.1002/eji.1830180522; OCADIZ R, 1987, CANCER RES, V47, P4173; OUDEJANS CBM, 1989, J EXP MED, V169, P447, DOI 10.1084/jem.169.2.447; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PILLAI R, 1991, CANCER LETT, V59, P171, DOI 10.1016/0304-3835(91)90183-I; PINION SB, 1991, LANCET, V337, P819, DOI 10.1016/0140-6736(91)92518-7; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; REDONDO M, 1991, CANCER RES, V51, P2463; RIOU G, 1987, LANCET, V1, P761; RIOU GF, 1988, CANCER SURV, V7, P441; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SCHRIER PI, 1993, ADV CANCER RES, V60, P181; SIKORA K, 1987, CANCER-AM CANCER SOC, V59, P1289, DOI 10.1002/1097-0142(19870401)59:7<1289::AID-CNCR2820590710>3.0.CO;2-O; SNIJDERS PJF, 1990, J GEN VIROL, V71, P173, DOI 10.1099/0022-1317-71-1-173; SOONG TW, 1991, CANCER DETECT PREV, V15, P231; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; STAM NJ, 1986, J IMMUNOL, V137, P2299; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANDENBRULE AJC, 1991, INT J CANCER, V48, P404, DOI 10.1002/ijc.2910480317; VANDENBRULE AJC, 1990, J CLIN MICROBIOL, V28, P2739, DOI 10.1128/JCM.28.12.2739-2743.1990; VANDENBRULE AJC, 1991, AM J PATHOL, V139, P1037; VERSTEEG R, 1988, EMBO J, V7, P1023, DOI 10.1002/j.1460-2075.1988.tb02909.x; VERSTEEG R, 1989, J EXP MED, V170, P621, DOI 10.1084/jem.170.3.621; WOODWORTH CD, 1990, CANCER RES, V50, P3709	56	42	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1993	8	11					2969	2975						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414499				2022-12-28	WOS:A1993MC09300010
J	YAMASHITA, T; SEGAWA, K; FUJINAGA, Y; NISHIKAWA, T; FUJINAGA, K				YAMASHITA, T; SEGAWA, K; FUJINAGA, Y; NISHIKAWA, T; FUJINAGA, K			BIOLOGICAL AND BIOCHEMICAL-ACTIVITY OF E7 GENES OF THE CUTANEOUS HUMAN PAPILLOMAVIRUS TYPE-5 AND TYPE-8	ONCOGENE			English	Article							LARGE T-ANTIGEN; CARCINOMA CELL-LINES; EPIDERMODYSPLASIA VERRUCIFORMIS; ADENOVIRUS E1A; TRANSFORMING ACTIVITY; EPITHELIAL-CELLS; PROTEIN-BINDING; RAT-CELLS; DNA; TRANSCRIPTION	In contrast to the observed activity of the E7 genes of the genital high-risk human papillomavirus (HPV)16 and HPV18, E7s of the cutaneous high-risk HPV5 and HPV8 show no in vitro transforming activity in established rodent cells. We recently reported that the HPV8 E7 driven by the SV40 enhancer/promoter oncogenically transforms primary rat embryo fibroblast (REF) cells collaboratively with the EJras oncogene (Jpn. J. Cancer Res., 82, 1340-1343, 1991). To study the functional differences between cutaneous HPV5 and HPV8 E7s and genital HPV16 E7, we cloned each of the E7 open reading frames and tested their immortalizing and transforming activities, the binding ability of their products with retinoblastoma protein (RB) and their complementation activity of a RB-nonbinding adenovirus E1A mutant. In contrast to results with HPV16 E7, transfection of HPV5 and HPV8 E7s did not produce any G418-resistant colonies in primary baby rat kidney (BRK) cells. However, they induced morphological transformation of primary BRK cells as well as of primary REF cells when cotransfected with the EJras oncogene. The ras-cooperating activity of HPV8 E7 appears to be extremely low, since, unlike the case of HPV5 and HPV16 E7s, transformed BRK colonies induced by HPV8 E7 plus ras have had a very low survival rate. The in vitro RB binding experiment showed that HPV5 and 8 E7s are able to form complexes with RB protein with reduced affinities of about one fourth and one nineteenth that of HPV16 E7, respectively. Moreover, not only HPV16 E7 but also HPV5 and 8 E7s complemented a nontransforming adenovirus 5 E1A mutant (dl922/947) incapable of binding to RB in inducing E1A-specific transformed foci on primary BRK cells. Since both the activities, the ras-collaborative transformation and complementation of the inert EIA mutant by E7s, all correlate with in vitro RB binding affinity (HPV16 E7 > HPV5 E7 > HPV8 E7), it is likely that RB binding of HPV5 and HPV8 E7s is an integral part of the biological activities of these proteins.	KEIO UNIV,SCH MED,DEPT MICROBIOL,SHINJUKU KU,TOKYO 160,JAPAN	Keio University	FUJINAGA, K (corresponding author), SAPPORO MED UNIV,SCH MED,CANC RES INST,DEPT MOLEC BIOL,S 1,W 17,CHUO KU,SAPPORO 060,JAPAN.							BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BANKS L, 1988, VIROLOGY, V165, P326, DOI 10.1016/0042-6822(88)90695-2; BANKS L, 1990, ONCOGENE, V5, P1383; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; BUNNEY MH, 1987, LANCET, V2, P151; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DYSON N, 1989, CANCER CEL, V7, P235; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; FIRZLAFF J M, 1989, New Biologist, V1, P44; FUCHS PG, 1986, J VIROL, V58, P626, DOI 10.1128/JVI.58.2.626-634.1986; GAGE JR, 1990, J VIROL, V64, P723, DOI 10.1128/JVI.64.2.723-730.1990; GIORDANO A, 1991, ONCOGENE, V6, P481; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HOWLEYNELSON P, 1989, EMBO J, V8, P3905; IFTNER T, 1990, VIROLOGY, V179, P428, DOI 10.1016/0042-6822(90)90311-E; IFTNER T, 1988, J VIROL, V62, P3655, DOI 10.1128/JVI.62.10.3655-3661.1988; KANDA T, 1988, VIROLOGY, V165, P321, DOI 10.1016/0042-6822(88)90694-0; KIYONO T, 1992, VIROLOGY, V186, P628, DOI 10.1016/0042-6822(92)90029-O; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; NISHIKAWA T, 1991, JPN J CANCER RES, V82, P1340, DOI 10.1111/j.1349-7006.1991.tb01802.x; ORTH G, 1987, PAPOVAVIRIDAE PAPILL, P199; OSTROW RS, 1982, P NATL ACAD SCI-BIOL, V79, P1634, DOI 10.1073/pnas.79.5.1634; PFISTER H, 1981, INT J CANCER, V27, P645, DOI 10.1002/ijc.2910270511; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; SAMBROOK J, 1989, MOL CLONING LAB MANU, P931; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SEGAWA K, 1987, MOL CELL BIOL, V7, P556, DOI 10.1128/MCB.7.1.556; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STOREY A, 1990, J GEN VIROL, V71, P165, DOI 10.1099/0022-1317-71-1-165; TRAUGH JA, 1974, J BIOL CHEM, V249, P1207; van der Eb A J, 1980, Methods Enzymol, V65, P826; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; Yatsudo M, 1988, VIROLOGY, V166, P594; ZACHOW KR, 1987, VIROLOGY, V158, P251, DOI 10.1016/0042-6822(87)90263-7	45	44	46	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2433	2441						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8395681				2022-12-28	WOS:A1993LT36800014
J	DEBUIRE, B; PATERLINI, P; PONTISSO, P; BASSO, G; MAY, E				DEBUIRE, B; PATERLINI, P; PONTISSO, P; BASSO, G; MAY, E			ANALYSIS OF THE P53 GENE IN EUROPEAN HEPATOCELLULAR CARCINOMAS AND HEPATOBLASTOMAS	ONCOGENE			English	Note							TUMOR-SUPPRESSOR GENE; BREAST-CANCER; CELL-LINES; MUTATIONS; POLYMORPHISM; LYMPHOMA; SARCOMAS; TP53	Human hepatocellular carcinomas (HCC) and hepatoblastomas (HB) from patients in France and Italy, respectively, which are both areas with a low incidence of HCC and a low dietary exposure to aflatoxin B1 (AFB1), were analysed for alterations of the p53 tumour suppressor gene. An abnormality in the p53 gene was detected in only one of the seven HCCs examined. Sequencing of the cDNA of this HCC revealed a G to T transversion at the first nucleotide of codon 245 that was not found in normal tissue, excluding the possibility of germinal transmission of this alteration. All tumours had the wild-type sequence at codon 249, which has been reported to be a mutational hot spot in the p53 gene in HCCs from high incidence areas, such as China and Southern Africa. Seven samples of HB, the most common hepatic tumour of children, were also tested for loss of heterozygosity (LOH) and mutations in the p53 gene. In contrast to what is observed in HCC of adulthood, for which environmental conditions are important etiological risk factors, HB probably stems uniquely from genetic disorders. PCR-direct sequencing of exons 4 to 8 and PCR-single strand conformation polymorphism (PCR-SSCP) of exons 2, 3 and 9 revealed no mutations in the coding sequences examined. LOH was observed in one of the five informative cases when codon 72 and intron 6 were subjected to polymorphism analysis.	UNIV PADUA,PEDIAT CLIN,I-35123 PADUA,ITALY; CHU NECKER,INSERM,U75,F-75073 PARIS 15,FRANCE; UNIV PADUA,MED CLIN,I-35123 PADUA,ITALY	University of Padua; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Padua	DEBUIRE, B (corresponding author), CNRS,UPR 275,F-94801 VILLEJUIF,FRANCE.		PONTISSO, PATRIZIA/K-3574-2018	PONTISSO, PATRIZIA/0000-0003-2077-9202; BASSO, GIUSEPPE/0000-0002-2634-9302				BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUETOW KH, 1992, P NATL ACAD SCI USA, V89, P9622, DOI 10.1073/pnas.89.20.9622; CHALLEN C, 1992, HEPATOLOGY, V16, P1362, DOI 10.1002/hep.1840160610; CHUMAKOV PM, 1991, NUCLEIC ACIDS RES, V19, P6969, DOI 10.1093/nar/19.24.6969-a; DEAN M, 1991, BIOTECHNIQUES, V10, P332; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DUTHU A, 1992, ONCOGENE, V7, P2161; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HARRIS AL, 1991, NATURE, V350, P377, DOI 10.1038/350377a0; HAYWARD NK, 1991, NATURE, V352, P764, DOI 10.1038/352764a0; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; KRESS S, 1992, CANCER RES, V52, P3220; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MURAKAMI Y, 1991, CANCER RES, V51, P5520; ODA T, 1992, CANCER RES, V52, P6358; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; ROMANO JW, 1989, ONCOGENE, V4, P1483; SCORSONE KA, 1992, CANCER RES, V52, P1635; SHEU JC, 1992, CANCER RES, V52, P6098; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494	27	46	46	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2303	2306						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8393166				2022-12-28	WOS:A1993LP17100034
J	LEUNG, S; MCCRACKEN, S; GHYSDAEL, J; MIYAMOTO, NG				LEUNG, S; MCCRACKEN, S; GHYSDAEL, J; MIYAMOTO, NG			REQUIREMENT OF AN ETS-BINDING ELEMENT FOR TRANSCRIPTION OF THE HUMAN LCK TYPE-I PROMOTER	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASES; RECEPTOR ALPHA-GENE; HUMAN LYMPHOCYTES-T; LYMPHOMA CELL-LINE; NUCLEAR FACTOR-I; C-FOS; EXPRESSION; ACTIVATION; SEQUENCE; ENHANCER	The requirement for cis-acting DNA sequences for transcriptional activity of the human lck type I promoter was investigated in two human cell lines that express type I transcripts, the leukemic T-cell line, Jurkat, and the colon carcinoma line, SW620. Transient transfection assays in Jurkat and SW620 cells revealed negative and positive cis-acting regulatory elements in the lck type I promoter between -570 and -480 and between -128 and -63 respectively. For the latter, a triple point mutation of a sequence, GCAGGAAGT, from -99 and -91, resulted in complete loss of lck type I promoter activity in both Jurkat and SW620 cells. In vitro binding assays indicated that this sequence, denoted the ETS-binding element or EBE, can interact with the lymphoid-specific transcription factor ETS-1. Thus, a protein(s) in the ETS family appears to be required for transcription of the lck type I promoter in T cells and may be important for the activation of the lck gene in human colon carcinoma.	PRINCESS MARGARET HOSP,ONTARIO CANC INST,DIV CELLULAR & MOLEC BIOL,500 SHERBOURNE ST,TORONTO M4X 1K9,ONTARIO,CANADA; INST CURIE,BIOL SECT,CNRS,UNITE 1443,F-91405 ORSAY,FRANCE; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M4X 1K9,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Toronto			GHYSDAEL, Jacques/F-3377-2013					ADLER HT, 1988, J VIROL, V62, P4113, DOI 10.1128/JVI.62.11.4113-4122.1988; ALLEN JM, 1992, MOL CELL BIOL, V12, P2758, DOI 10.1128/MCB.12.6.2758; BHAT NK, 1989, J IMMUNOL, V142, P672; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; CASNELLIE JE, 1983, J BIOL CHEM, V258, P738; DAILEY L, 1986, P NATL ACAD SCI USA, V83, P7241, DOI 10.1073/pnas.83.19.7241; DANILITION SL, 1991, NUCLEIC ACIDS RES, V19, P6913, DOI 10.1093/nar/19.24.6913; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FREDERICKSON RM, 1989, NUCLEIC ACIDS RES, V17, P253, DOI 10.1093/nar/17.1.253; FUJIWARA S, 1990, MOL CELL BIOL, V10, P1249, DOI 10.1128/MCB.10.3.1249; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GORMAN C, 1985, DNA CLONING, V2, P152; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; GRONOSTAJSKI RM, 1986, NUCLEIC ACIDS RES, V14, P9117, DOI 10.1093/nar/14.22.9117; GUNTHER CV, 1990, GENE DEV, V4, P67; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KOGA Y, 1989, J IMMUNOL, V142, P4493; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; LEIDEN JM, 1992, IMMUNOL TODAY, V13, P22, DOI 10.1016/0167-5699(92)90200-Q; LEUNG S, 1991, J CELL PHYSIOL, V148, P344, DOI 10.1002/jcp.1041480304; LEUNG S, 1989, NUCLEIC ACIDS RES, V17, P1177, DOI 10.1093/nar/17.3.1177; LEUNG S, 1992, THESIS U TORONTO; LO K, 1991, MOL CELL BIOL, V11, P5229, DOI 10.1128/MCB.11.10.5229; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MARTH JD, 1987, EMBO J, V6, P2727, DOI 10.1002/j.1460-2075.1987.tb02566.x; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MILLS GB, 1992, INT IMMUNOL, V4, P1233, DOI 10.1093/intimm/4.11.1233; OOSTERWEGEL M, 1991, J EXP MED, V173, P1133, DOI 10.1084/jem.173.5.1133; PERLMUTTER R M, 1988, Biochimica et Biophysica Acta, V948, P245; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; ROUER E, 1989, GENE, V84, P105, DOI 10.1016/0378-1119(89)90144-3; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SACCHI N, 1988, LEUKEMIA, V2, P12; SARTOR O, 1989, MOL CELL BIOL, V9, P2983, DOI 10.1128/MCB.9.7.2983; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; TREVILLYAN JM, 1986, BIOCHIM BIOPHYS ACTA, V888, P286, DOI 10.1016/0167-4889(86)90228-4; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; VORONOVA AF, 1987, MOL CELL BIOL, V7, P4407, DOI 10.1128/MCB.7.12.4407; VORONOVA AF, 1984, MOL CELL BIOL, V4, P2705, DOI 10.1128/MCB.4.12.2705; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383	56	39	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					989	997						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455950				2022-12-28	WOS:A1993KT22000022
J	MA, A; MOROY, T; COLLUM, R; WEINTRAUB, H; ALT, FW; BLACKWELL, TK				MA, A; MOROY, T; COLLUM, R; WEINTRAUB, H; ALT, FW; BLACKWELL, TK			DNA-BINDING BY N-MYC AND L-MYC PROTEINS	ONCOGENE			English	Note							LOOP-HELIX PROTEIN; LEUCINE-ZIPPER REGION; C-MYC; TRANSCRIPTION FACTOR; ACTIVATES TRANSCRIPTION; TRANSGENIC MICE; ENHANCER; MYOD; OLIGOMERIZATION; EXPRESSION	N- and L-Myc, like c-Myc, contain adjacent basic region (BR), helix-loop-helix (HLH) and leucine zipper (LZ) motifs, which characterize a family of DNA-binding proteins. We have used a polymerase chain reaction (PCR)-based binding site selection technique to demonstrate that the most highly preferred binding site for both N- and L-Myc fusion proteins contains a CACGTG motif, the core binding sequence previously identified for c-Myc. Further analysis identified other N-Myc binding sequences, including asymmetric sequences such as CATGTG. N-Myc, like c-Myc, preferentially forms heterodimeric DNA-binding complexes with Max protein. Mutational analyses of N-Myc basic region (BR), helix-loop-helix (HLH) and leucine zipper (LZ) regions revealed that all three regions are necessary for DNA binding by N-Myc-Max complexes, and that dimerization requires both HLH and LZ motifs, while BR sequences are needed only for DNA binding. Our findings support the notion that the LZ motif is a critical element in dimer formation by bHLH-LZ proteins.	CHILDRENS HOSP MED CTR,HOWARD HUGHES MED INST,BOSTON,MA 02115; FRED HUTCHINSON CANC RES CTR,HOWARD HUGHES MED INST,SEATTLE,WA 98104; FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,SEATTLE,WA 98104	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; Fred Hutchinson Cancer Center			Moroy, Tarik/D-9923-2011		NCI NIH HHS [CA23767] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023767] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALEX R, 1992, NUCLEIC ACIDS RES, V20, P2257, DOI 10.1093/nar/20.9.2257; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALOZENETIS T, 1992, SCIENCE, V255, P464; HALOZENETIS T, 1991, P NATL ACAD SCI USA, V88, P6162; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAKAJIMA H, 1989, ONCOGENE, V4, P999; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; ROSENBAUM H, 1989, EMBO J, V8, P749, DOI 10.1002/j.1460-2075.1989.tb03435.x; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	39	41	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1093	1098						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455937				2022-12-28	WOS:A1993KT22000036
J	GUILHOT, C; BENCHAIBI, M; FLECHON, JE; SAMARUT, J				GUILHOT, C; BENCHAIBI, M; FLECHON, JE; SAMARUT, J			THE 12S-ADENOVIRAL E1A-PROTEIN IMMORTALIZES AVIAN CELLS AND INTERACTS WITH THE AVIAN RB-PRODUCT	ONCOGENE			English	Article							ADENOVIRUS E1A PROTEINS; LARGE TUMOR-ANTIGEN; REGION 1A PROTEINS; EPITHELIAL-CELLS; GENE-PRODUCT; GROWTH; LINE; ESTABLISHMENT; ASSOCIATION; ONCOGENE	Quail cells were immortalized for the first time by using retroviruses expressing the 12S adenoviral E1A gene. In these cells, interaction between the 12S E1A product and the quail RB protein was shown, suggesting that the 12S adenoviral E1A product works in avian cells through similar biochemical pathways as in mammalian cells by interacting and inactivating host cellular proteins, including the RB product. These results confirm that the RB product exhibits a universal function among higher vertebrates in controlling cellular growth and tumor progression.	ECOLE NORMALE SUPER LYON,INRA,BIOL MOLEC & CELLULAIRE LAB,CNRS,UMR 49,46 ALLEE ITALIE,F-69364 LYON 07,FRANCE; INRA,UNITE BIOL CELLULAIRE & MICROSCOPIE ELECTR,F-78350 JOUY EN JOSAS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); INRAE; INRAE; UDICE-French Research Universities; Universite Paris Saclay			Samarut, Jacques/AAD-2587-2019					BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BEUG H, 1982, J CELL PHYSL S, V1, P195; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CONE RD, 1988, MOL CELL BIOL, V8, P1036, DOI 10.1128/MCB.8.3.1036; COSSET FL, 1990, J VIROL, V64, P1070, DOI 10.1128/JVI.64.3.1070-1078.1990; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; EMAMI S, 1989, P NATL ACAD SCI USA, V86, P3194, DOI 10.1073/pnas.86.9.3194; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GILARDI P, 1984, NUCLEIC ACIDS RES, V12, P7877, DOI 10.1093/nar/12.20.7877; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; KAWAGUCHI T, 1987, CANCER RES, V47, P4460; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINDER S, 1990, EXP CELL RES, V191, P1, DOI 10.1016/0014-4827(90)90027-8; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; ULRICH E, 1992, GENE DEV, V6, P876, DOI 10.1101/gad.6.5.876; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WIEHLE RD, 1990, ONCOGENE, V5, P787	29	13	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					619	624						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437845				2022-12-28	WOS:A1993KN00800012
J	YAMAMOTO, K; SETO, M; AKAO, Y; IIDA, S; NAKAZAWA, S; OSHIMURA, M; TAKAHASHI, T; UEDA, R				YAMAMOTO, K; SETO, M; AKAO, Y; IIDA, S; NAKAZAWA, S; OSHIMURA, M; TAKAHASHI, T; UEDA, R			GENE REARRANGEMENT AND TRUNCATED MESSENGER-RNA IN CELL-LINES WITH 11Q23 TRANSLOCATION	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CHROMOSOME; BREAKPOINT; LYMPHOMA; FUSION; T(4-11)(Q21-Q23); AMPLIFICATION; HETEROGENEITY; NEOPLASIA; T(11-14)	We have previously demonstrated that the breakpoints of t(11;19)(q23;p13) leukemias are within 360 kb of the CD3 gene. One of the phage clones, 6n, which was isolated from the yeast artificial chromosome clone yB22B2 containing CD3, was found to be within 60 kb of t(11;19) breakpoints. In this study, gene walking was conducted and two phage clones (lambdaHp8-3 and lambdaHp23-13) were isolated from a human placenta genomic library. Southern blot analysis with a genomic probe from lambdaHp8-3 detected gene rearrangements in t(4;11) and t(11;19) cell lines with BamHI digestion. Subsequently, using reiterated sequence-free probes from both ends of 6n that detected transcriptional units in various hematopoietic cells, we isolated cDNA clones. These cDNA clones were classified into two groups (designated MLL-a and MLL-b), which do not hybridize to each other. Northern blot analysis with MLL-a cDNA detected 15-, 14- and 12-kb mRNAs, while MLL-b detected the additional 9.7- and 5-kb mRNAs in peripheral blood lymphocytes. MLL-b cDNA detected a truncated form of 12.5-kb mRNA in t(4;11) cell lines and a truncated form of 10-kb or 9.2-kb mRNA in t(11;19) cell lines. MLL-a did not demonstrate a truncated form of mRNA, but the stronger 14-kb signal was noted in t(4;11) cells, while this signal was very weak in t(11;19) cells. By Southern blot analysis, MLL-b cDNA detected gene rearrangement in cell lines with t(4;11) and t(11;19), whereas MLL-a did not. Furthermore, chimeric cDNA clones were isolated from cDNA libraries of t(4;11) and t(11;19) cell lines with a MLL-b cDNA probe. These results indicate that the MLL-b cDNA is derived from the common target gene involved in 11q23 translocation with 4q21 or 19p13.	AICHI CANC CTR,CHEMOTHERAPY LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; YAMANASHI MED COLL,DEPT PEDIAT,YAMANASHI 40938,JAPAN; TOTTORI UNIV,SCH LIFE SCI,DEPT MOLEC & CELL GENET,YONAGO,TOTTORI 684,JAPAN; AICHI CANC CTR,IMMUNOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Aichi Cancer Center; University of Yamanashi; Tottori University; Aichi Cancer Center								ABE R, 1984, CANCER GENET CYTOGEN, V13, P121, DOI 10.1016/0165-4608(84)90053-0; ABE T, 1990, JPN J CLIN HEMATOL, V31, P1304; AKAO Y, 1991, CANCER RES, V51, P6708; AKAO Y, 1991, CANCER RES, V51, P1574; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CHEN CS, 1991, BLOOD, V78, P2498; CIMINO G, 1991, CANCER RES, V51, P6712; COTTER FE, 1991, GENE CHROMOSOME CANC, V3, P8, DOI 10.1002/gcc.2870030103; DAIBATA M, 1987, JPN J CANCER RES, V78, P1182; DAS S, 1991, GENE CHROMOSOME CANC, V3, P44, DOI 10.1002/gcc.2870030108; GIBBONS B, 1990, BRIT J HAEMATOL, V74, P264, DOI 10.1111/j.1365-2141.1990.tb02581.x; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; KUBONISHI I, 1986, CANCER, V58, P1453, DOI 10.1002/1097-0142(19861001)58:7<1453::AID-CNCR2820580713>3.0.CO;2-B; MITANI K, 1989, AM J HEMATOL, V31, P253, DOI 10.1002/ajh.2830310407; MITELMAN F, 1984, NATURE, V310, P325, DOI 10.1038/310325a0; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; PUI CH, 1991, BLOOD, V77, P440; ROWLEY JD, 1990, CANCER RES, V50, P3816; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; SAVAGE PD, 1988, CYTOGENET CELL GENET, V49, P289, DOI 10.1159/000132680; SETO M, 1992, ONCOGENE, V7, P1401; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; VANDERPOEL SZ, 1991, P NATL ACAD SCI USA, V88, P10735; YUNIS JJ, 1989, GENOMICS, V5, P84, DOI 10.1016/0888-7543(89)90090-6; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310	27	47	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					479	485						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426751				2022-12-28	WOS:A1993KN00600027
J	LIU, JX; CAMPBELL, M; GUO, JQ; LU, D; XIAN, YM; ANDERSSON, BS; ARLINGHAUS, RB				LIU, JX; CAMPBELL, M; GUO, JQ; LU, D; XIAN, YM; ANDERSSON, BS; ARLINGHAUS, RB			BCR-ABL TYROSINE KINASE IS AUTOPHOSPHORYLATED OR TRANSPHOSPHORYLATES P160 BCR ON TYROSINE PREDOMINANTLY WITHIN THE 1ST BCR EXON	ONCOGENE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; PHILADELPHIA-CHROMOSOME; CELL-LINE; C-ABL; ONCOGENE PRODUCT; GENE-PRODUCTS; PROTEIN; MICE	The role of BCR gene sequences in Philadelphia (Ph) chromosome-positive leukemia is not well understood. Our previous studies demonstrated that P210 BCR-ABL co-precipitates with P160 BCR following immunoprecipitation with antibodies to the C-terminal domain of P160 BCR, sequences lacking in P210 BCR-ABL. We now report that tryptic peptides shared by both P160 BCR and P210 BCR-ABL are phosphorylated on tyrosine in vitro either when using immune complexes containing P160 BCR complexed to BCR-ABL or when P160 BCR is phosphorylated in trans by P210 BCR-ABL immune complexes from cells lacking functional P160 BCR. P185 BCR-ABL produced in a cell line derived from a Ph chromosome-positive acute lymphocytic leukemia patient also co-immunoprecipitated with P160 BCR. As with P210 BCR-ABL, P160 BCR tyrosine phosphopeptides were shared with P185 BCR-ABL, indicating that the major sites of tyrosine phosphorylation in vitro are contained within the first exon of P160 BCR. Similarly, BCR-ABL autophosphorylation was found to occur predominantly at tyrosines within BCR exon 1 sequences. These results raise the possibility that the activated ABL protein kinase of BCR-ABL proteins modulates the putative signal transduction activities of P160 BCR by tyrosine phosphorylation of exon 1 sequences.	UNIV TEXAS, MD ANDERSON HOSP & TUMOR INST, DEPT MOLEC PATHOL, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON HOSP & TUMOR INST, DEPT HEMATOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON BS, 1987, CANCER GENET CYTOGEN, V24, P335, DOI 10.1016/0165-4608(87)90116-6; ARLINGHAUS RB, 1992, MOL CARCINOGEN, V5, P171, DOI 10.1002/mc.2940050302; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; CAMPBELL ML, 1991, ADV CANCER RES, V57, P227; CAMPBELL ML, 1990, ONCOGENE, V5, P773; CHAMPLIN RE, 1985, BLOOD, V65, P1039; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; GUO JQ, 1991, CANCER RES, V51, P3048; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; LI WJ, 1989, ONCOGENE, V4, P127; LI WJ, 1988, ONCOGENE, V2, P559; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MAXWELL SA, 1987, CANCER RES, V47, P1731; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; NAUMOVSKI L, 1988, CANCER RES, V48, P2876; NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85; PENDERGAST AM, 1989, ONCOGENE, V4, P759; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PRIEST JR, 1980, BLOOD, V56, P15; RON D, 1991, NEW BIOL, V3, P372; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SMITH RG, 1981, J IMMUNOL, V126, P596; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; TIMMONS MS, 1989, ONCOGENE, V4, P559	34	57	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1993	8	1					101	109						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423987				2022-12-28	WOS:A1993KN00500012
J	ROSNET, O; STEPHENSON, D; MATTEI, MG; MARCHETTO, S; SHIBUYA, M; CHAPMAN, VM; BIRNBAUM, D				ROSNET, O; STEPHENSON, D; MATTEI, MG; MARCHETTO, S; SHIBUYA, M; CHAPMAN, VM; BIRNBAUM, D			CLOSE PHYSICAL LINKAGE OF THE FLT1 AND FLT3 GENES ON CHROMOSOME-13 IN MAN AND CHROMOSOME-5 IN MOUSE	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASE; ENDOTHELIAL-CELL MITOGEN; ONCOGENE C-KIT; GROWTH-FACTOR; W-LOCUS; LOCALIZATION; FMS; EXPRESSION; REGION; MICE	Receptor-type tyrosine kinases (RTK) with five or seven immunoglobulin-like domains in their extracellular region are encoded by genes grouped in clusters. In human, two such clusters have been individualized, in chromosomal regions 4q11-q12 and 5q33-qter respectively. We define here a third cluster located on chromosome 13q and containing two contiguous RTK genes, FLT1 and FLT3. The former has recently been shown to encode a RTK of a new class while the latter codes for a hematopoietic receptor closely related to the products of the FMS and KIT genes. The physical linkage is also evidenced in mouse, where the two genes appear to lie within a 350 kb Mlu I fragment, on mouse chromosome 5.	ROSWELL PK CANC INST,DEPT MOLEC & CELLULAR BIOL,BUFFALO,NY 14263; UNIV TOKYO,INST MED SCI,DEPT GENET,MINATO KU,TOKYO 108,JAPAN; HOP LA TIMONE,INSERM,U242,F-13385 MARSEILLE 4,FRANCE	Roswell Park Cancer Institute; University of Tokyo; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	ROSNET, O (corresponding author), INSERM,U119,MOLEC ONCOL LAB,27 BLVD LEI ROURE,F-13009 MARSEILLE,FRANCE.		Rosnet, Olivier/G-3536-2013	Rosnet, Olivier/0000-0002-3020-910X	NHGRI NIH HHS [HG00170] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; ANDRE C, 1992, ONCOGENE, V7, P685; ANDRE C, 1992, THESIS U PARIS 7; APRELIKOVA O, 1992, CANCER RES, V52, P746; ARMSTRONG E, 1992, GENE CHROMOSOME CANC, V4, P94, DOI 10.1002/gcc.2870040116; BIRG F, 1992, IN PRESS BLOOD; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHAPMAN VM, 1986, CURR TOP MICROBIOL, V127, P114; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; DAURIOL L, 1988, HUM GENET, V78, P374, DOI 10.1007/BF00291740; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; GALLAND F, 1992, GENOMICS, V13, P475, DOI 10.1016/0888-7543(92)90277-Y; GEISSLER E, 1988, CELL, V5, P185; GEISSLER EN, 1981, GENETICS, V97, P337; GOKKEL E, 1992, ONCOGENE, V7, P1423; GRUNEBERG H, 1960, GENET RES, V1, P69, DOI 10.1017/S0016672300000094; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; HAMPE A, 1989, ONCOGENE RES, V7, P9; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HSIEH CL, 1991, CYTOGENET CELL GENET, V56, P160, DOI 10.1159/000133076; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KOZAK C, 1992, IN PRESS MAMMALIAN G, V3; KOZAK C, 1991, MAMM GENOME, V1, P579; LACOMBE C, 1988, BLOOD, V72, P1440; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LI WH, 1991, FUNDAMENTALS MOL EVO, P136; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MCDONALD JD, 1986, MOL CELL BIOL, V6, P842, DOI 10.1128/MCB.6.3.842; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; NGUYEN C, 1987, EMBO J, V6, P3285, DOI 10.1002/j.1460-2075.1987.tb02647.x; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OELRICHS RB, 1993, ONCOGENE, V8, P15; PANTAZIS P, 1991, P NATL ACAD SCI USA, V88, P2481, DOI 10.1073/pnas.88.6.2481; PFISTER K, 1982, BIOCHEM GENET, V20, P519, DOI 10.1007/BF00484702; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROSNET O, 1991, ONCOGENE, V6, P1641; ROSNET O, 1991, GENOMICS, V9, P380, DOI 10.1016/0888-7543(91)90270-O; Sambrook J., 1989, MOL CLONING; SARZANI R, 1992, BIOCHEM BIOPH RES CO, V186, P706, DOI 10.1016/0006-291X(92)90804-T; SATOH H, 1987, JPN J CANCER RES, V78, P772; SHIBUYA M, 1990, ONCOGENE, V5, P519; SINGH G, 1991, P NATL ACAD SCI USA, V88, P10706, DOI 10.1073/pnas.88.23.10706; SMITH EA, 1991, P NATL ACAD SCI USA, V88, P4811, DOI 10.1073/pnas.88.11.4811; STENMAN G, 1989, GENE CHROMOSOME CANC, V1, P155, DOI 10.1002/gcc.2870010208; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; TERMAN BI, 1991, ONCOGENE, V6, P1677; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDENBARK GR, 1992, ONCOGENE, V7, P1259; VISVADER J, 1989, MOL CELL BIOL, V9, P1336, DOI 10.1128/MCB.9.3.1336; WARRINGTON JA, 1992, GENOMICS, V13, P803, DOI 10.1016/0888-7543(92)90156-M; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x	56	70	74	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					173	179						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380915				2022-12-28	WOS:A1993KN00500021
J	Muraoka, M; Konishi, M; KikuchiYanoshita, R; Tanaka, K; Shitara, N; Chong, JM; Iwama, T; Miyaki, M				Muraoka, M; Konishi, M; KikuchiYanoshita, R; Tanaka, K; Shitara, N; Chong, JM; Iwama, T; Miyaki, M			p300 gene alterations in colorectal and gastric carcinomas	ONCOGENE			English	Article						p300 gene; NF2 gene; colorectal carcinoma; gastric carcinoma; somatic mutation	FAMILIAL ADENOMATOUS POLYPOSIS; CHROMOSOME-22	Colorectal tumors frequently have loss of heterozygosity on chromosome 22q, suggesting that inactivation of tumor suppressor gene(s) on 22q participates in the tumor development. Neurofibromatosis 2 (NF2) gene and E1A binding protein p300 gene, recently identified on 22q, are thought to be candidates for tumor suppressor genes. In this study, mutation of the NF2 gene in 59 colorectal carcinomas, and mutation of the p300 gene in 27 colorectal and two gastric carcinomas, were analysed using PCR-SSCP, RT-PCR-SSCP and direct sequencing methods. Missense mutations of p300 gene were detected in a colorectal carcinoma, and in a gastric carcinoma, though no mutation of NF2 gene was detected. Both p300 mutations were somatic and coupled to deletion of the second allele of the gene, which suggests inactivation of the p300 gene in these carcinomas. The mutations are located within the Cys/His-rich regions, which are assumed to play important roles in the function of p300. These are the first cases in which p300 gene has been found to be altered in both alleles, suggesting that inactivation of the p300 gene may be involved in the development of carcinomas, and that this gene may be the target of loss of 22q in carcinomas of the digestive tract.	TOKYO METROPOLITAN INST MED SCI,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN KOMAGOME HOSP,DEPT PATHOL,TOKYO,JAPAN; TOKYO METROPOLITAN KOMAGOME HOSP,DEPT NEUROSURG,TOKYO,JAPAN; TOKYO MED & DENT UNIV,DEPT SURG 2,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Tokyo Medical & Dental University (TMDU)								ARAKAWA H, 1994, HUM MOL GENET, V3, P565, DOI 10.1093/hmg/3.4.565; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; GREENBLATT MS, 1994, CANCER RES, V54, P4855; IINO H, 1994, CANCER, V73, P1324, DOI 10.1002/1097-0142(19940301)73:5<1324::AID-CNCR2820730503>3.0.CO;2-W; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3965; KONISHI M, 1993, JPN J CANCER RES, V84, P893, DOI 10.1111/j.1349-7006.1993.tb02063.x; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MIYAKI M, 1990, CANCER RES, V50, P7166; MIYAKI M, 1995, CRIT REV ONCOL HEMAT, V19, P1, DOI 10.1016/1040-8428(94)00129-H; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUBIO MP, 1994, CANCER RES, V54, P45; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; SEIZINGER BR, 1986, NATURE, V322, P644, DOI 10.1038/322644a0; SEIZINGER BR, 1987, P NATL ACAD SCI USA, V84, P5419, DOI 10.1073/pnas.84.15.5419; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; SEKIDO Y, 1995, CANCER RES, V55, P1227; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TWIST EC, 1994, HUM MOL GENET, V3, P147, DOI 10.1093/hmg/3.1.147; YANA I, 1995, INT J CANCER, V60, P174, DOI 10.1002/ijc.2910600207	26	264	276	1	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1565	1569						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622873				2022-12-28	WOS:A1996UF07600021
J	Zhu, JG; Guo, SZ; Beggs, AH; Maruyama, T; Santarius, T; Dashner, K; Olsen, N; Wu, JK; Black, P				Zhu, JG; Guo, SZ; Beggs, AH; Maruyama, T; Santarius, T; Dashner, K; Olsen, N; Wu, JK; Black, P			Microsatellite instability analysis of primary human brain tumors	ONCOGENE			English	Article						brain neoplasms; polymerase chain reaction; microsatellite markers; loss of heterozygosity; replication errors; microsatellite instability	COLORECTAL-CANCER; GENETIC INSTABILITY; MUTATIONS; CARCINOMA; HOMOLOG; REPEAT; COLON; LOCUS; DNA	Microsatellite instability, as shown by the presence of additional alleles or shifts of electrophoretic mobility at simple sequence tandem repeat loci, has been demonstrated in hereditary and sporadic colorectal tumors and many other tumor types. To study microsatellite instability in human brain tumors, we examined a total of 144 sporadic neoplasms. These included 33 astrocytic tumors, 23 oligodendrogliomas, six gangliogliomas, 41 meningiomas, 10 vestibular schwannomas and 31 pituitary adenomas. Di-, tri- and tetranucleotide repeat microsatellite markers localized on chromosome 4 and 9, X, 13 and 22, respectively, were used to assess whether instability was a significant aspect of their abnormal chromosomal pattern. Instability of microsatellite markers was detected in four oligodendrogliomas (17.4%), one pituitary adenoma (3.2%), one meningioma (2.4%), one astrocytic tumor (3.0%) and not at all in gangliogliomas and schwannomas. Therefore, our results suggest that the microsatellite instability which occurs in colorectal cancers with defective mismatch repair is infrequent in many types of human brain tumors and that the lower level of instability observed in brain tumors may be reflective of other mechanisms of genetic instability.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CHILDRENS HOSP,DANA FARBER CANC INST,NEUROSURG LABS,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CHILDRENS HOSP,DANA FARBER CANC INST,BRAIN TUMOR CTR,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CHILDRENS HOSP,DIV GENET,BOSTON,MA 02115; TUFTS UNIV,NEW ENGLAND MED CTR,DEPT NEUROSURG,BOSTON,MA 02111	Harvard University; Boston Children's Hospital; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Tufts Medical Center; Tufts University				Beggs, Alan/0000-0001-8818-0568				AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALLEN RC, 1992, AM J HUM GENET, V51, P1229; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLACK PM, 1991, NEW ENGL J MED, V324, P1555, DOI 10.1056/NEJM199105303242205; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BUETOW KH, 1993, GENOMICS, V18, P329, DOI 10.1006/geno.1993.1473; BURKS RT, 1994, ONCOGENE, V9, P1163; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; HAN HJ, 1993, CANCER RES, V53, P5087; HENSON JW, 1994, ANN NEUROL, V36, P714, DOI 10.1002/ana.410360505; ICHIMURA K, 1994, CANCER RES, V54, P3127; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LOTHE RA, 1993, CANCER RES, V53, P5849; MERIO A, 1994, CANCER RES, V54, P2098; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PELTOMAKI P, 1993, CANCER RES, V53, P5853; Petrukhin Konstantin E., 1992, Human Molecular Genetics, V1, P349, DOI 10.1093/hmg/1.5.349; RHYU MG, 1994, ONCOGENE, V9, P29; RISINGER JI, 1993, CANCER RES, V53, P5100; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; SEIZINGER BR, 1986, NATURE, V322, P644, DOI 10.1038/322644a0; SHAPIRO S, 1989, J NEUROSURG, V71, P77, DOI 10.3171/jns.1989.71.1.0077; SHRIDHAR V, 1994, CANCER RES, V54, P2084; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; SUN Y, 1992, BIOTECHNIQUES, V12, P639; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VENTER DJ, 1991, ONCOGENE, V6, P445; VONDEIMLING A, 1994, INT J CANCER, V57, P676, DOI 10.1002/ijc.2910570511; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; Wu J K, 1992, Neurol Res, V14, P39; YANDELL DW, 1989, AM J HUM GENET, V45, P547; YEE CJ, 1994, CANCER RES, V54, P1641; ZHU JG, 1994, J CLIN ENDOCR METAB, V78, P922, DOI 10.1210/jc.78.4.922	43	54	54	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1417	1423						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622857				2022-12-28	WOS:A1996UF07600005
J	Liu, Q; Ji, X; Breitman, ML; Hitchcock, PF; Swaroop, A				Liu, Q; Ji, X; Breitman, ML; Hitchcock, PF; Swaroop, A			Expression of the bZIP transcription factor gene Nrl in the developing nervous system	ONCOGENE			English	Article						neuronal development; gene expression; transcription factor	LEUCINE-ZIPPER; MAF ONCOGENE; V-MAF; RETINA; DOMAIN; FOS; MECHANISMS; DIVERSITY; PROTEINS; ENCODES	Proteins of the Maf/Nrl subfamily of bZIP transcription factors are involved in the regulation of tissue-specific gene expression. The Nrl gene, initially identified from a subtracted retinal library, is expressed in all cell layers of the adult retina, including photoreceptors. The Nrl protein has high sequence homology with Maf proteins, binds to an AP-1 like sequence element, and in photoreceptors appears to be involved in regulating the expression of rhodopsin. In the present study, we investigated the expression of Nrl in the developing and adult mouse using in situ hybridization and RT-PCR. We demonstrate that beginning at embryonic day 12.5 Nrl is expressed throughout the developing central and peripheral nervous system, with the exception of the nasal epithelium. The spatial pattern of hybridization suggests that Nrl is transcribed in post-mitotic, differentiating neurons, the developing cephalic mesenchyme and lens. Nrl expression is downregulated postnatally in the brain, and becomes restricted to neocortex and brainstem in the adult. High levels of Nrl transcripts, however, persist in the mature photoreceptors and other retinal neurons. Our studies suggest a role for the Nrl protein in neuronal differentiation and in mature neurons of the adult retina.	UNIV MICHIGAN, WK KELLOGG EYE CTR, DEPT OPHTHALMOL, ANN ARBOR, MI 48105 USA; UNIV MICHIGAN, WK KELLOGG EYE CTR, DEPT ANAT & CELL BIOL, ANN ARBOR, MI 48105 USA; UNIV MICHIGAN, WK KELLOGG EYE CTR, DEPT HUMAN GENET, ANN ARBOR, MI 48105 USA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO, ON M5G 1X5, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO, ON M5S 1X5, CANADA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Hitchcock, Peter/AAY-9559-2020	Hitchcock, Peter/0000-0001-9454-2684; Swaroop, Anand/0000-0002-1975-1141	NEI NIH HHS [EY07003, EY07060] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; BLAY HM, 1992, ANNU REV BIOCHEM, V6, P1213; BOK D, 1989, RETINA, P69; CAUBET JF, 1989, MOL CELL BIOL, V9, P2269, DOI 10.1128/MCB.9.5.2269; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; FARJO Q, 1993, GENOMICS, V18, P216, DOI 10.1006/geno.1993.1458; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KERPPOLA TK, 1994, ONCOGENE, V9, P675; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAVAIL MM, 1991, J COMP NEUROL, V309, P86, DOI 10.1002/cne.903090107; LIU ISC, 1994, NEURON, V13, P377, DOI 10.1016/0896-6273(94)90354-9; MANDEL G, 1993, ANNU REV NEUROSCI, V16, P323, DOI 10.1146/annurev.ne.16.030193.001543; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; REHEMTULLA A, IN PRESS P NATL ACAD; Sidman RL, 1961, STRUCTURE EYE, P487; STRUHL K, 1991, NEURON, V7, P177, DOI 10.1016/0896-6273(91)90256-Y; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215	28	58	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	1996	12	1					207	211						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552394				2022-12-28	WOS:A1996TQ01400026
J	Marhin, WW; Hei, YJ; Chen, SJ; Jiang, Z; Gallie, BL; Phillips, RA; Penn, LZ				Marhin, WW; Hei, YJ; Chen, SJ; Jiang, Z; Gallie, BL; Phillips, RA; Penn, LZ			Loss of Rb and Myc activation co-operate to suppress cyclin D1 and contribute to transformation	ONCOGENE			English	Article						Myc; Rb; cyclin D1; MEF; transformation	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; CELL-CYCLE; SUSCEPTIBILITY GENE; NEGATIVE AUTOREGULATION; BINDING PROTEIN; G1 PHASE; LARGE-T; EXPRESSION; PHOSPHORYLATION	Cyclin D1 can bind and phosphorylate the product (pRb) of the retinoblastoma gene (RB-1) and recent evidence suggests pRb, in turn, may regulate cyclin D1 protein expression. In transformed cell lines, loss of pRb activity strongly correlates with a decrease in cyclin D1 protein expression, and conversely, introduction of pRb can induce cyclin D1 promoter activity. We show here that pRb does not regulate cyclin D1 directly as basal and serum-stimulated levels of cyclin D1 protein and kinase activity are similar in wildtype and pRb-deficient primary mouse embryonic fibroblasts (MEFs). These observations suggest that the suppression of cyclin D1 in pRb-minus tumour cell lines requires both loss of pRb and at least one additional genetic event. We have determined that constitutive, ectopic Myc expression in pRb-deficient, but not wildtype, MEFs suppresses cyclin D1 protein expression and kinase activity. Regulation is evident at either the level of RNA or protein expression. Phenotypically, pRb-deficient MEFs consistently exhibited a delayed growth response in comparison to wildtype MEFs. This growth delay is abrogated in pRb-deficient MEFs which are expressing ectopic Myc protein, coincident with the loss of cyclin D1 protein expression. Moreover, these cells exhibit an increased proliferative capacity, and they no longer show contact inhibition. Our results support a cross-regulatory mechanism between Myc, pRb and cyclin D1 and suggest a novel role for cyclin D1 in tumorigenesis.	HOSP SICK CHILDREN, RES INST, DEPT MICROBIOL, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, RES INST, DEPT IMMUNOL & CANC, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, RES INST, DEPT MED & MOLEC GENET, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, TORONTO, ON M5G 1X8, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto				Penn, Linda/0000-0001-8133-5459; Gallie, Brenda/0000-0002-9697-9211				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P1633; BATES S, 1994, ONCOGENE, V9, P71; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUCHOU T, 1993, ONCOGENE, V8, P1765; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Cleveland J L, 1988, Oncogene Res, V3, P357; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V1072, P103, DOI 10.1016/0304-419X(91)90009-A; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FACCHINI LM, 1994, CELL GROWTH DIFFER, V5, P637; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; FUNG YKT, 1993, ONCOGENE, V8, P2659; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAMEL PA, 1990, MOL CELL BIOL, V10, P6586, DOI 10.1128/MCB.10.12.6586; HAUPT Y, 1995, ONCOGENE, V10, P1563; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HORTON LE, 1995, CELL GROWTH DIFFER, V6, P395; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, ONCOGENE, V9, P707; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NEVINS JR, 1992, SCIENCE, V258, P424; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Penn L J, 1990, Semin Cancer Biol, V1, P69; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SPENCER CA, 1991, ADV CANCER RES, V56, P1; SQUIRE J, 1986, NATURE, V322, P555, DOI 10.1038/322555a0; TAM SW, 1994, ONCOGENE, V9, P2663; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4	82	34	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	1996	12	1					43	52						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552398				2022-12-28	WOS:A1996TQ01400006
J	Chattopadhyay, P; Banerjee, M; Sarkar, C; Mathur, M; Mohapatra, AK; Sinha, S				Chattopadhyay, P; Banerjee, M; Sarkar, C; Mathur, M; Mohapatra, AK; Sinha, S			Infrequent alteration of the c-myc gene in human glial tumours associated with increased numbers of c-myc positive cells	ONCOGENE			English	Article						gliomas; c-myc rearrangement; c-myc immunohistochemistry	HUMAN GLIOBLASTOMA; AMPLIFICATION; EXPRESSION; LEUKEMIA; LINE; OVEREXPRESSION; REARRANGEMENT; CARCINOMA; ONCOGENES; PROTEIN	Twenty five human glial rumours of different grades of malignancy were examined by Southern blotting and polymerase chain reaction (PCR) for alterations (rearrangements, amplification and deletions) in the c-myc gene, Number of c-myc positive cells per thousand cells were also counted in all the rumours after immunohistochemical staining for c-myc protein was done on fixed sections of the tumours, No rumours exhibited any amplification of the gene, as found by Southern blotting, One astrocytoma and one mixed glioma showed some rearrangements in the 3' end of the gene, as detected by Southern blotting and hydridization, These two tumours had higher number of c-myc positive cells than in other rumours of the same histopathological groups, Deletion in the first promoter region, as determined by PCR, was seen in only one astrocytoma. However, the number of c-myc positive cells in that tumour did not show any deviation from that found in other astrocytomas. In light of present literature, it is speculated that the 3' rearrangements may be the cause of increased number of c-myc immunopositive cells in those tumours by disrupting the 3' end of the gene leading to increased c-myc mRNA stability, Such a mechanism may play a part in small subset of glial and possibly other tumours.	ALL INDIA INST MED SCI,DEPT BIOCHEM,NEW DELHI 110029,INDIA; ALL INDIA INST MED SCI,DEPT PATHOL,NEW DELHI 110029,INDIA; ALL INDIA INST MED SCI,DEPT NEUROSURG,NEW DELHI 110029,INDIA	All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi			Banerjee, Moinak/X-4471-2018	Banerjee, Moinak/0000-0002-0842-0398				AGHIB DF, 1991, ONCOGENE, V6, P2371; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Dixon WJ, 1983, INTRO STAT ANAL, P92; ENGELHARD HH, 1989, J NEUROSURG, V71, P224, DOI 10.3171/jns.1989.71.2.0224; FLEMING WH, 1986, CANCER RES, V46, P1535; HOLM R, 1993, J PATHOL, V169, P21, DOI 10.1002/path.1711690105; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; ORIAN JM, 1992, BRIT J CANCER, V66, P106, DOI 10.1038/bjc.1992.225; PETRONI D, 1992, CARCINOGENESIS, V13, P883, DOI 10.1093/carcin/13.5.883; RAMAEL M, 1993, J PATHOL, V169, P421, DOI 10.1002/path.1711690406; SAGLIO G, 1986, CANCER RES, V46, P1413; Sambrook J, 1987, MOL CLONING LAB MANU; SHINDO H, 1993, ACTA NEUROPATHOL, V86, P345, DOI 10.1007/BF00369446; TRENT J, 1986, P NATL ACAD SCI USA, V83, P470, DOI 10.1073/pnas.83.2.470; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	18	11	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2711	2714						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545130				2022-12-28	WOS:A1995TP18800029
J	Conzen, SD; Cole, CN				Conzen, SD; Cole, CN			The three transforming regions of SV40 T antigen are required for immortalization of primary mouse embryo fibroblasts	ONCOGENE			English	Article						SV40 large T antigen; immortalization; senescence; apoptosis	LARGE TUMOR-ANTIGEN; P53 BINDING; GENE; MUTANTS; CELLS; DNA; VIRUS; E1A; IDENTIFICATION; ADENOVIRUS-E1A	Simian virus 40 (SV40) is a small DNA tumor virus whose early region gene product, large T antigen, is sufficient to immortalize primary rodent cells and transform established rodent cell lines, Three functional domains of large T antigen are required for transformation of the rat embryo fibroblast REF 52 cell line: the extreme amino-terminal region, a domain which binds p105(Rb) family members, and the bipartite p53-binding region, Many studies have attempted to define the activities and regions of SV40 large T antigen required for immortalization of mouse embryo fibroblasts (MEFs), In most of these studies, investigators have used survival of T antigen-expressing primary MEF colonies at the time when control MEFs undergo senescence as a measurement of 'immortalization' and concluded that immortalization of MEFs is correlated with large T antigen's ability to sequester the human tumor suppressor gene product p53 and separable from its p105(Rb)-binding or N terminal functions, In order to more rigorously define the regions of SV40 large T antigen required for escape from senescence, individual T antigen-expressing primary MEF colonies were systematically subcultured for >60 population doublings beyond the time of control MEF senescence under conditions known to limit the number of spontaneously immortalized cells, We found that although interaction of T antigen with p53 was sufficient to substantially extend the lifespan of MEFs, all three SV40 large T antigen domains required for REF 52 transformation were necessary to immortalize primary MEFs, These results indicate that p53 inactivation alone is insufficient to immortalize primary MEFs; rather, immortalization requires multiple activities of T antigen which are also required for efficient transformation.	DARTMOUTH COLL SCH MED,DEPT BIOCHEM,HANOVER,NH 03755	Dartmouth College			Cole, Charles/GRR-1551-2022		NCI NIH HHS [CA39259, CA16038] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039259, P01CA016038] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASSELIN C, 1985, J VIROL, V56, P958, DOI 10.1128/JVI.56.3.958-968.1985; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; COLBY WW, 1982, P NATL ACAD SCI-BIOL, V79, P5189, DOI 10.1073/pnas.79.17.5189; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DOBBELSTEIN M, 1992, ONCOGENE, V7, P837; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOGAN J, 1981, VIROLOGY, V115, P419, DOI 10.1016/0042-6822(81)90126-4; LOWE S, 1994, P NATL ACAD SCI USA, V91, P1026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MAULBECKER C, 1992, J VIROL, V4, P2195; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SCHAEFER DI, 1993, CANCER RES, V53, P4946; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SOMPAYRAC L, 1991, VIROLOGY, V181, P412, DOI 10.1016/0042-6822(91)90516-E; SOUTHERN PJ, 1982, J MOL APPL GENET, V1, P324; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TEVETHIA MJ, 1984, VIROLOGY, V137, P414, DOI 10.1016/0042-6822(84)90234-4; TEVETHIA MJ, 1988, VIROLOGY, V162, P76, DOI 10.1016/0042-6822(88)90396-0; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHITE AE, 1994, GENE DEV, V15, P667; WHITE E, 1993, P SOC EXP BIOL MED, V204, P30; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WOODS C, 1994, ONCOGENE, V9, P2943; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116; ZHU J, 1992, J VIROL, V65, P6872; ZHU JY, 1989, J VIROL, V63, P4777, DOI 10.1128/JVI.63.11.4777-4786.1989; ZHU JY, 1991, J VIROL, V65, P2778, DOI 10.1128/JVI.65.6.2778-2790.1991; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992	40	51	52	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2295	2302						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570180				2022-12-28	WOS:A1995TK70200013
J	Sakamuro, D; Eviner, V; Elliott, KJ; Showe, L; White, E; Prendergast, GC				Sakamuro, D; Eviner, V; Elliott, KJ; Showe, L; White, E; Prendergast, GC			c-Myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms	ONCOGENE			English	Article						Myc; p53; apoptosis; epithelial cells	ORNITHINE DECARBOXYLASE; ADENOVIRUS E1A; P53; BCL-2; GENE; EXPRESSION; PROLIFERATION; MUTATIONS; LYMPHOMA; DEATH	We tested the hypothesis that wild-type p53 activity is required for c-Myc-dependent apoptosis in epithelial cells, Primary baby rat kidney epithelial cell lines were generated by immortalization through the concerted action of c-Myc and a temperature-sensitive (ts) dominant inhibitory mutant allele of p53 (BRK myc/p53ts cells), When shifted to the permissive temperature for wild-type p53 activity, the BRK myc/p53ts cells underwent growth arrest and apoptosis, However, apoptosis also could be induced by serum deprivation at the nonpermissive temperature, when p53 was in the mutant state, Bcl-2 suppressed both modes of cell death, Apoptosis induced by wild-type p53 but not by serum deprivation was accompanied by G1 cell cycle arrest and increased expression of the Bcl-2 antagonist Bar. We concluded that c-Myc could induce apoptosis in epithelial cells by at least two mechanisms that could be distinguished by their p53 requirement, Our results support the possibility that c-Myc-dependent cell death might be exploited for therapeutic ends during carcinoma development, without regard to p53 status of the target cell.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,MOLEC BIOL GRAD GRP,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104; CTR ADV BIOCHEM & MED,PISCATAWAY,NJ 08854; RUTGERS STATE UNIV,DEPT BIOMED SCI,PISCATAWAY,NJ 08854	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; Rutgers State University New Brunswick			White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065; Eviner, Valerie/0000-0001-5530-9417	NCI NIH HHS [CA-10815-28, CA-53370] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053370, P30CA010815, R01CA053370] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERT T, 1994, ONCOGENE, V9, P759; ASKEW DS, 1993, BLOOD, V82, P2079; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN G, 1994, PHILOS T R SOC B, V345, P269, DOI 10.1098/rstb.1994.0105; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FRYKBERG L, 1987, ONCOGENE, V1, P415; GIBSON AW, 1995, EXP CELL RES, V218, P351, DOI 10.1006/excr.1995.1166; HARPER JW, 1993, CELL, V75, P805; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HERMEKING H, 1994, P NATL ACAD SCI USA, V91, P10412, DOI 10.1073/pnas.91.22.10412; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; RAJCHEL A, 1987, NUCLEIC ACIDS RES, V16, P2347; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; TEODORO JG, 1995, ONCOGENE, V11, P467; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WANG YS, 1993, ONCOGENE, V8, P3427; YANO T, 1993, ONCOGENE, V8, P2741	53	157	160	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2411	2418						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570193				2022-12-28	WOS:A1995TK70200026
J	FATTAEY, AR; HELIN, K; DEMBSKI, MS; DYSON, N; HARLOW, E; VUOCOLO, GA; HANOBIK, MG; HASKELL, KM; OLIFF, A; DEFEOJONES, D; JONES, RE				FATTAEY, AR; HELIN, K; DEMBSKI, MS; DYSON, N; HARLOW, E; VUOCOLO, GA; HANOBIK, MG; HASKELL, KM; OLIFF, A; DEFEOJONES, D; JONES, RE			CHARACTERIZATION OF THE RETINOBLASTOMA BINDING-PROTEINS RBP1 AND RBP2	ONCOGENE			English	Note							CELLULAR TRANSCRIPTION FACTOR; ADENOVIRUS E1A PROTEINS; LARGE T-ANTIGEN; GENE-PRODUCT; TUMOR SUPPRESSOR; CARCINOMA-CELLS; DNA-BINDING; 2 DISTINCT; FACTOR E2F; IDENTIFICATION	The retinoblastoma gene product, pRB, regulates cell proliferation by binding to and inhibiting the activity of key growth promoting proteins. Several cellular proteins have been shown to bind directly to pRB and the genes encoding a number of them have been isolated. The protein product of one of these genes is the transcription factor E2F. We have now isolated cDNA clones that contain the full-length coding sequence of two other proteins, RBP1 and RBP2, cloned originally by their interaction with pRB. The products of the RBP1 and RBP2 genes are ubiquotosly expressed, large (200 kDa for RBP1 and 195 kDa for RBP2) nuclear phosphoproteins with structural motifs that suggest a role in transcriptional regulation. In addition we have been able to identify complexes of pRB and RBP1 in vivo that are dissociated in the presence of purified human papillomavirus E7 protein.	MERCK & CO INC,RES LABS,DEPT CANC RES,W POINT,PA 19486	Merck & Company	FATTAEY, AR (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,BLDG 149,13TH ST,BOSTON,MA 02129, USA.		Helin, Kristian/K-2526-2019; Helin, Kristian/HDM-8306-2022	Helin, Kristian/0000-0003-1975-6097				Ausubel FM, 1988, CURRENT PROTOCOLS MO, V1; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, IN PRESS MOL CELL BI; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; PETERSON MG, 1991, NATURE, V354, P369; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; STIRDIVANT SM, 1992, MOL CELL BIOL, V12, P1905, DOI 10.1128/MCB.12.5.1905; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; WANG PN, 1993, ONCOGENE, V8, P279; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	48	158	167	1	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3149	3156						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414517				2022-12-28	WOS:A1993MC09300032
J	VANTVEER, LJ; VANDERFELTZ, MJM; VANDENBERGBAKKER, CAM; CHENG, NC; HERMENS, RPMG; VANOORSCHOT, DAJ; KIEVITS, T; SCHRIER, PI				VANTVEER, LJ; VANDERFELTZ, MJM; VANDENBERGBAKKER, CAM; CHENG, NC; HERMENS, RPMG; VANOORSCHOT, DAJ; KIEVITS, T; SCHRIER, PI			ACTIVATION OF THE MAS ONCOGENE INVOLVES COUPLING TO HUMAN ALPHOID SEQUENCES	ONCOGENE			English	Article								We have shown previously that mouse NIH3T3 cells transfected with DNA from a human ovarian carcinoma were rendered tumourigenic by an activated mas oncogene in four independent transfection experiments. In all cases the 5'-noncoding region was rearranged in comparison to the original ovarian tumour DNA. We now report that in all four transfectants the newly acquired sequences consist of human centromeric alpha satellite repeat DNA. In at least three transfectants the alphoid DNA originates from the centromere of chromosome three. Analysis of the sequences of the recombination site in one transfectant revealed that a homologous sequence of five base pairs (CAGCA) is present in both parental strands, and might thus have contributed to the recombinational event. To establish a conclusive role for alphoid DNA in the activation of mas, we performed a co-transfection experiment in NIH3T3 cells with cloned alphoid DNA and the mas coding sequence. We show that the transfectants expressing a transformed phenotype contain amplified mas linked to alphoid DNA. NIH3T3 cells transfected with plasmids that contained alphoid sequences cloned directly upstream of the mas coding sequence, and injected into nude mice, gave rise to tumours with amplified mas sequences (7/7). In six of these tumours the alphoid sequences were amplified as well. Our data suggest a novel mechanism of oncogene activation: recombination with normal alphoid repeat DNA resulting in amplification of the oncogene.	UNIV HOSP LEIDEN, DEPT CLIN ONCOL, BLDG 1, K-1-P, POB 9600, 2300 RC LEIDEN, NETHERLANDS; LEIDEN UNIV, DEPT HUMAN GENET, SYLVIUS LABS, 2300 RA LEIDEN, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University - Excl LUMC			Hermens, Rosella P.M.G./N-3581-2014	Hermens, Rosella P.M.G./0000-0001-7624-7120				AMBROZ C, 1991, BIOCHIM BIOPHYS ACTA, V1133, P107, DOI 10.1016/0167-4889(91)90248-V; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; DELATTRE O, 1988, HUM HERED, V38, P156, DOI 10.1159/000153777; DEVILEE P, 1988, CANCER RES, V48, P5825; DOVER G, 1982, NATURE, V299, P111, DOI 10.1038/299111a0; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; HEARTLEIN MW, 1988, MOL CELL BIOL, V8, P3611, DOI 10.1128/MCB.8.9.3611; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; JANSSEN JWG, 1988, LEUKEMIA, V2, P318; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KIYAMA R, 1987, J MOL BIOL, V198, P589, DOI 10.1016/0022-2836(87)90202-6; KONOPKA AK, 1988, NUCLEIC ACIDS RES, V16, P1739, DOI 10.1093/nar/16.5.1739; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; MANUELIDIS L, 1978, CHROMOSOMA, V66, P23, DOI 10.1007/BF00285813; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; VANTVEER LJ, 1988, ONCOGENE RES, V3, P247; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; WAYE JS, 1987, NUCLEIC ACIDS RES, V15, P7549, DOI 10.1093/nar/15.18.7549; WILLARD HF, 1987, TRENDS GENET, V3, P192, DOI 10.1016/0168-9525(87)90232-0; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3; YUNIS JJ, 1987, ONCOGENE, V1, P59; ZANCA DM, 1986, NATURE, V319, P743	34	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2673	2681						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378079				2022-12-28	WOS:A1993LX34300008
J	COGLIATI, T; DUNN, BK; BARNER, M; CULTRARO, CM; SEGAL, S				COGLIATI, T; DUNN, BK; BARNER, M; CULTRARO, CM; SEGAL, S			TRANSFECTED WILD-TYPE AND MUTANT MAX REGULATE CELL-GROWTH AND DIFFERENTIATION OF MURINE ERYTHROLEUKEMIA-CELLS	ONCOGENE			English	Article							C-MYC; DNA-BINDING; ERYTHROID-DIFFERENTIATION; EXPRESSION; COMMITMENT; GENE; PROTEIN; G0/G1	Max protein forms specific DNA-binding dimeric complexes with itself and with proteins of the c-myc gene family. A large volume of data has accumulated on the role of the c-myc proto-oncogene in cell proliferation, differentiation and tumorigenesis. To elucidate the role of max in regulating c-myc functions and the effect of both proteins on cell proliferation and differentiation, we transfected murine erythroleukemia (MEL) cells with a full-length wild-type (wt) human max gene and a mutant containing a double point mutation in the basic region (bm), which abolishes specific DNA binding. All clones expressing wt-max grow slowly, and the process of inducer-mediated differentiation is delayed. Furthermore, cells transfected with the mutated max exhibit growth retardation, accumulation in the G0/G1 phase of the cell cycle and spontaneous differentiation. Our findings are consistent with a model in which a large excess of wt-Max in the cells enhances the formation of Max-Max growth-suppressor complexes, while elevated bm-Max deprives the cell of growth-promoting Myc-Max heterodimers in a dominant-negative manner, presumably by inactivating endogenous Myc and Max.	UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20814; NCI,MED ONCOL BRANCH,BETHESDA,MD 20889	Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BARNER M, 1992, CELL GROWTH DIFFER, V3, P183; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BIRRER MJ, 1989, MOL CELL BIOL, V9, P2734, DOI 10.1128/MCB.9.6.2734; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; COLE MD, 1991, CELL, V65, P715, DOI 10.1016/0092-8674(91)90377-B; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CUTTITTA F, 1988, J CLIN ENDOCR METAB, V67, P576, DOI 10.1210/jcem-67-3-576; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; DAVIS LG, 1986, METHODS MOL BIOL; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DUBE SK, 1974, DIFFERENTIATION CONT, P99; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; FRIED J, 1978, J HISTOCHEM CYTOCHEM, V26, P921, DOI 10.1177/26.11.82573; GELLER R, 1978, J CELL PHYSIOL, V95, P213, DOI 10.1002/jcp.1040950211; GUSELLA J, 1976, CELL, V9, P221, DOI 10.1016/0092-8674(76)90113-6; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KAHN S M, 1990, Technique (Philadelphia), V2, P27; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; Sambrook J, 1989, MOL CLONING LABORATO; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TERADA M, 1977, P NATL ACAD SCI USA, V74, P248, DOI 10.1073/pnas.74.1.248; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x	37	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1263	1268						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479748				2022-12-28	WOS:A1993KY32800018
J	FAZIOLI, F; WONG, WT; ULLRICH, SJ; SAKAGUCHI, K; APPELLA, E; DIFIORE, PP				FAZIOLI, F; WONG, WT; ULLRICH, SJ; SAKAGUCHI, K; APPELLA, E; DIFIORE, PP			THE EZRIN-LIKE FAMILY OF TYROSINE KINASE SUBSTRATES - RECEPTOR-SPECIFIC PATTERN OF TYROSINE PHOSPHORYLATION AND RELATIONSHIP TO MALIGNANT TRANSFORMATION	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; PHOSPHOLIPASE-C-GAMMA; PDGF BETA-RECEPTOR; ROUS-SARCOMA VIRUS; GTPASE-ACTIVATING PROTEIN; SIGNAL TRANSDUCTION; CDNA CLONING; MONOCLONAL-ANTIBODIES; MEMBRANE SKELETON; CELLULAR PROTEINS	A method for the isolation of tyrosine kinases substrates was developed. The method takes advantage of immunoaffinity purification of an entire set of proteins phosphorylated by tyrosine kinases, followed by generation of antisera against the purified protein pool and immunological screening of bacterial expression libraries with these antisera. By applying this methodology to the study of the phosphorylation events triggered by activation of the epidermal growth factor receptors, we have isolated several cDNAs encoding novel putative tyrosine kinase substrates. One of these cDNAs encodes radixin, a protein belonging to the band 4.1 family of proteins and highly related to ezrin and moesin. We demonstrated that, despite a high degree of relatedness, these three proteins exhibit a distinct receptor-specific pattern of phosphorylation, raising the possibility that they might mediate receptor-specific cellular changes. In addition the generation of antibodies specific for either radixin, ezrin or moesin allowed us to show that a previously described tumor transplantation antigen is indeed ezrin, thus implicating this protein in the determination of the biological phenotype of certain tumors.	NCI, MOLEC & CELLULAR BIOL LAB, BLDG 37, ROOM 1D23, BETHESDA, MD 20892 USA; NCI, CELL BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950; Sakaguchi, Kazuyasu/0000-0002-8434-4171				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; BASSIRI RM, 1972, ENDOCRINOLOGY, V90, P722, DOI 10.1210/endo-90-3-722; BENNETT V, 1989, BIOCHIM BIOPHYS ACTA, V988, P107, DOI 10.1016/0304-4157(89)90006-3; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; BRETSCHER A, 1986, METHOD ENZYMOL, V134, P24; BURRIDGE K, 1983, J CELL BIOL, V97, P359, DOI 10.1083/jcb.97.2.359; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P9512, DOI 10.1073/pnas.83.24.9512; COOPER JA, 1983, J VIROL, V48, P752, DOI 10.1128/JVI.48.3.752-764.1983; COOPER JA, 1982, CELL, V31, P263, DOI 10.1016/0092-8674(82)90426-3; CORREAS I, 1986, J BIOL CHEM, V261, P3362; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DUBOIS GC, 1982, P NATL ACAD SCI-BIOL, V79, P7669, DOI 10.1073/pnas.79.24.7669; DUBOIS GC, 1980, CANCER RES, V40, P4204; EGERTON M, 1992, J IMMUNOL, V149, P1847; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FAZIOLI F, 1992, J BIOL CHEM, V267, P5155; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GARRELS JI, 1979, J BIOL CHEM, V254, P7961; GLENNEY JR, 1991, METHOD ENZYMOL, V201, P92; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GOULD KL, 1986, J CELL BIOL, V102, P660, DOI 10.1083/jcb.102.2.660; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; HUNTER T, 1981, CELL, V24, P741, DOI 10.1016/0092-8674(81)90100-8; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KELLIE S, 1988, BIOESSAYS, V8, P25, DOI 10.1002/bies.950080107; KRIEG J, 1992, J BIOL CHEM, V267, P19258; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LANKES W, 1988, BIOCHEM J, V251, P831, DOI 10.1042/bj2510831; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; LETO TL, 1986, MEMBRANE SKELETONS C, P201; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Luna EJ, 1991, CURR OPIN CELL BIOL, V3, P120, DOI 10.1016/0955-0674(91)90174-W; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PASQUALE EB, 1986, P NATL ACAD SCI USA, V83, P5507, DOI 10.1073/pnas.83.15.5507; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SAMBROOK J, 1989, MOL BIOL LABORATORY; SATO N, 1991, J CELL BIOL, V113, P321, DOI 10.1083/jcb.113.2.321; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; TSUKITA S, 1989, J CELL BIOL, V108, P2369, DOI 10.1083/jcb.108.6.2369; TURUNEN O, 1989, J BIOL CHEM, V264, P16727; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH SJ, 1986, MOL IMMUNOL, V23, P545, DOI 10.1016/0161-5890(86)90118-5; ULLRICH SJ, 1986, P NATL ACAD SCI USA, V83, P3121, DOI 10.1073/pnas.83.10.3121; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949	67	96	103	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1335	1345						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479753				2022-12-28	WOS:A1993KY32800027
J	PERONA, R; ESTEVE, P; JIMENEZ, B; BALLESTERO, RP; CAJAL, SR; LACAL, JC				PERONA, R; ESTEVE, P; JIMENEZ, B; BALLESTERO, RP; CAJAL, SR; LACAL, JC			TUMORIGENIC ACTIVITY OF RHO GENES FROM APLYSIA-CALIFORNICA	ONCOGENE			English	Article							GTP-BINDING PROTEINS; BOTULINUM ADP-RIBOSYLTRANSFERASE; PARTIAL-PURIFICATION; ESCHERICHIA-COLI; BRAIN CYTOSOL; RAS; PRODUCT; SUBSTRATE; FAMILY; SEQUENCE	rho genes have been found in both lower and higher eucaryotes. They code for proteins of 21 kDa, highly conserved in evolution, which belong to the superfamily of ras GTPases. Among the members of this superfamily there are proteins with a regulatory function, such as ras, and proteins involved in vesicular trafficking, such as the family of rab proteins. We have investigated the putative role of rho proteins from Aplysia californica as transforming GTPases utilizing the wild-type and a Val-14 mutant, equivalent to the oncogenic Val-12 mutation of ras genes found in animal and human tumors. Overexpression of either rho gene was sufficient to confer anchorage- and serum-independent growth. Moreover, when introduced into nude mice, selected clones generated from either gene were able to induce tumors, although those carrying the mutated version were more efficient. Pathological analysis indicated that generated tumors corresponded to well-differentiated fibrosarcomas with distinct and intersecting bundles and spindle cells. By contrast, ras-induced tumors were poorly differentiated fibrosarcomas. Thus, our results indicate that under appropriate conditions rho genes function as oncogenes and may have a role in the regulation of proliferation in fibroblast cells.	CSIC,INST INVEST BIOMED,ARTURO DUPERIER 4,MADRID 6,SPAIN; CLIN PUERTA HIERRO,DEPT PATOL,MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda			Lacal, Juan Carlos/AAL-2235-2020; Cuenca, Benilde Jimenez/K-9959-2014; Espinosas, Maribel/H-8083-2012; Ramon y Cajal, Santiago/H-4955-2016; Lacal, Juan Carlos/N-9064-2015	Ramon y Cajal, Santiago/0000-0002-3867-1390; Lacal, Juan Carlos/0000-0002-1908-2777; Jimenez Cuenca, Benilde/0000-0002-1806-6636; Perez-Ballestero, Rafael/0000-0001-8251-2875				AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; ANDERSON PS, 1987, MOL CELL BIOL, V7, P3620, DOI 10.1128/MCB.7.10.3620; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; AVRAHAM H, 1990, BIOCHEM BIOPH RES CO, V168, P114, DOI 10.1016/0006-291X(90)91682-I; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIECKMANN D, 1991, NATURE, V351, P400; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; ISOMURA M, 1990, BIOCHEM BIOPH RES CO, V169, P652, DOI 10.1016/0006-291X(90)90380-6; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; LACAL JC, 1986, EMBO J, V5, P679, DOI 10.1002/j.1460-2075.1986.tb04267.x; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MOHR C, 1990, FEBS LETT, V275, P168, DOI 10.1016/0014-5793(90)81464-Y; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NGSEE JK, 1991, J BIOL CHEM, V266, P2675; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; QUILLIAM LA, 1989, FEBS LETT, V247, P221, DOI 10.1016/0014-5793(89)81339-0; REIBEL L, 1991, BIOCHEM BIOPH RES CO, V175, P451, DOI 10.1016/0006-291X(91)91585-Z; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sambrook J, 1989, MOL CLONING LABORATO; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SHIGESKUNI K, 1989, MOL BRAIN RES, V6, P167; SHIMIZU K, 1991, BIOCHEM BIOPH RES CO, V175, P199, DOI 10.1016/S0006-291X(05)81220-3; TOKI C, 1989, BIOCHEM BIOPH RES CO, V164, P333, DOI 10.1016/0006-291X(89)91722-1; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; WIELAND T, 1990, FEBS LETT, V274, P111, DOI 10.1016/0014-5793(90)81342-L; YAMAMOTO J, 1990, MOL BRAIN RES, V8, P105, DOI 10.1016/0169-328X(90)90054-H; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869	37	126	127	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1285	1292						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479750				2022-12-28	WOS:A1993KY32800021
J	DEED, RW; BIANCHI, SM; ATHERTON, GT; JOHNSTON, D; SANTIBANEZKOREF, M; MURPHY, JJ; NORTON, JD				DEED, RW; BIANCHI, SM; ATHERTON, GT; JOHNSTON, D; SANTIBANEZKOREF, M; MURPHY, JJ; NORTON, JD			AN IMMEDIATE EARLY HUMAN GENE ENCODES AN ID-LIKE HELIX LOOP HELIX PROTEIN AND IS REGULATED BY PROTEIN-KINASE-C ACTIVATION IN DIVERSE CELL-TYPES	ONCOGENE			English	Article							DNA-BINDING; NEGATIVE REGULATOR; MURINE HOMOLOG; SARCOMA-VIRUS; 3T3 CELLS; MYC; EXPRESSION; FIBROBLASTS; SEQUENCE; MUSCLE	Transcription factors characterized by the presence of a helix-loop-helix (HLH) domain play a central role in the regulation of cell growth/differentiation and tumorigenesis. We report here the cDNA sequence of a human early-response gene, designated HLH 1R21, encoding a 15-kDa HLH protein that lacks a basic, DNA-binding domain and which by a number of criteria appears to be the human homologue of mouse HLH 462. Like its murine counterpart, HLH 1R21 protein functions as an Id (inhibitor of DNA binding) transcription factor by inhibiting the binding of E2A-containing protein complexes to muscle creatine kinase E-box enhancer oligonucleotide in vitro. However HLH 1R21 does not inhibit the binding of HLH Max protein to a Max-binding oligonucleotide in vitro, indicating that it has limited promiscuity in its ability to antagonize the function of other HLH transcription factors. In addition, HLH 1R21 mRNA transcripts are regulated by phorbol ester treatment of a diverse range of human cell lines and, when overexpressed in mouse NIH3T3 cells, HLH 1R21 induces a morphologically transformed phenotype.	CHRISTIE HOSP NHS TRUST,PATERSON INST CANC RES,CRC DEPT GENE REGULAT,WILMSLOW RD,MANCHESTER M20 9BX,ENGLAND; CHRISTIE HOSP NHS TRUST,PATERSON INST CANC RES,CRC DEPT CANC GENET,MANCHESTER M20 9BX,ENGLAND; KINGS COLL,IMMUNOL SECT,LONDON W8 7AH,ENGLAND	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of London; King's College London			Atherton, Graham/GZK-4237-2022	Atherton, Graham/0000-0002-7425-3153				BECKENGESER G, 1991, HUM GENE THER, V2, P61, DOI 10.1089/hum.1991.2.1-61; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIGGS J, 1992, P NATL ACAD SCI USA, V89, P1512, DOI 10.1073/pnas.89.4.1512; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; GOLDFARB M, 1991, ONCOGENE, V6, P65; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HARVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSAIO WL, 1989, MOL CELL BIOL, V9, P2641; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; MILLER AD, 1984, CELL, V36, P51; MURPHY JJ, 1990, BIOCHIM BIOPHYS ACTA, V1049, P261; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NORTON JD, 1984, J VIROL, V50, P439, DOI 10.1128/JVI.50.2.439-444.1984; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; VISVADER J, 1991, TRENDS BIOCHEM SCI, V16, P330, DOI 10.1016/0968-0004(91)90137-K; VLODAVSKY GM, 1980, CELL, V19, P606; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAMADA KM, 1976, P NATL ACAD SCI USA, V73, P1217, DOI 10.1073/pnas.73.4.1217	36	105	107	2	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					599	607						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437843				2022-12-28	WOS:A1993KN00800010
J	MAHER, DW; STRAWN, LM; DONOGHUE, DJ				MAHER, DW; STRAWN, LM; DONOGHUE, DJ			ALANINE MUTAGENESIS OF CONSERVED RESIDUES IN THE PLATELET-DERIVED GROWTH-FACTOR FAMILY - IDENTIFICATION OF RESIDUES NECESSARY FOR DIMERIZATION AND TRANSFORMATION	ONCOGENE			English	Article							V-SIS GENE; ENDOTHELIAL-CELL MITOGEN; TERMINAL CODING REGION; PDGF-B-CHAIN; BOVINE PAPILLOMAVIRUS; AMINO-ACIDS; RECEPTOR; PROTEIN; BINDING; AUTOPHOSPHORYLATION	Platelet-derived growth factor (PDGF) and vascular endothelial growth factor define a family of dimeric proteins characterized by eight conserved cysteine residues involved in disulfide bonds. Thirteen non-cysteine residues conserved among the platelet-derived/vascular endothelial growth factors were individually mutated to alanine in v-sis/PDGF-B. In addition, five other residues flanking F148 were also mutated to alanine. The resulting mutants were assayed for transformation of NIH3T3 cells, and the mutant proteins were assayed for their ability to dimerize. Four residues were found to be crucial for disulfide-linked dimer formation: P152 and (;162 were mandatory, while R159 and H205 also contributed to efficient dimerization. Four of the mutant proteins (at residues N147, F148, L149 and K185) dimerized efficiently yet exhibited less than 50% transforming activity compared with wild-type v-sis. Two mutants (at residues D142 and F148) were located in a region important for PDGF receptor interaction and were further studied with regard to secretion and PDGF receptor autophosphorylation. A series of substitutions at residue F148 revealed a strong preference for aromatic amino acids. One mutant from this series (F148G) dimerized but was completely inactive for transformation. This study thus identifies four residues in v-sis/PDGF-B important for dimerization and also identifies additional residues critical for full activation of PDGF receptors. The E5 oncoprotein encoded by bovine papillomavirus type I exhibits two short regions of amino acid similarity when compared with the minimal transforming region of v-sis/PDGF-B. Several of the v-sis mutants discussed in this work affect residues that are also present in the E5 oncoprotein, including F148, L149 and H205.	UNIV CALIF SAN DIEGO,DEPT CHEM,DIV BIOCHEM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [R01CA040573] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40573] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLEMENTS JM, 1991, EMBO J, V10, P4113, DOI 10.1002/j.1460-2075.1991.tb04988.x; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEUEL TF, 1981, J BIOL CHEM, V256, P8896; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; GIESE N, 1990, MOL CELL BIOL, V10, P5496, DOI 10.1128/MCB.10.10.5496; GIESE NA, 1987, SCIENCE, V236, P1315, DOI 10.1126/science.3035718; HANNINK M, 1986, MOL CELL BIOL, V6, P1304, DOI 10.1128/MCB.6.4.1304; HANNINK M, 1984, SCIENCE, V226, P1197, DOI 10.1126/science.6095451; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HEIN J, 1990, METHOD ENZYMOL, V183, P626; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HORWITZ BH, 1988, MOL CELL BIOL, V8, P4071, DOI 10.1128/MCB.8.10.4071; HUANG JS, 1984, P NATL ACAD SCI-BIOL, V81, P342, DOI 10.1073/pnas.81.2.342; HUANG JS, 1983, J CELL BIOL, V97, P383, DOI 10.1083/jcb.97.2.383; IBANEZ CF, 1990, EMBO J, V9, P1477, DOI 10.1002/j.1460-2075.1990.tb08265.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAROCHELLE WJ, 1990, SCIENCE, V248, P1541, DOI 10.1126/science.2163109; LAROCHELLE WJ, 1989, MOL CELL BIOL, V9, P3538, DOI 10.1128/MCB.9.8.3538; LEE BA, 1991, J CELL BIOL, V113, P361, DOI 10.1083/jcb.113.2.361; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; OSTMAN A, 1991, J BIOL CHEM, V266, P10073; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; RAINES EW, 1984, P NATL ACAD SCI USA, V81, P3423; RAMACHANDRAN GN, 1966, BIOPHYS J, V6, P849, DOI 10.1016/S0006-3495(66)86699-7; ROSS R, 1974, P NATL ACAD SCI USA, V71, P1207, DOI 10.1073/pnas.71.4.1207; SAUER MK, 1986, J VIROL, V59, P292, DOI 10.1128/JVI.59.2.292-300.1986; SAUER MK, 1988, MOL CELL BIOL, V8, P1011, DOI 10.1128/MCB.8.3.1011	36	10	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					533	541						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437840				2022-12-28	WOS:A1993KN00800002
J	Tanaka, K; KikuchiYanoshita, R; Muraoka, M; Konishi, M; Oshimura, M; Miyaki, M				Tanaka, K; KikuchiYanoshita, R; Muraoka, M; Konishi, M; Oshimura, M; Miyaki, M			Suppression of tumorigenicity and invasiveness of colon carcinoma cells by introduction of normal chromosome 8p12-pter	ONCOGENE			English	Article						tumor suppressor gene; colon carcinoma; chromosome 8	FAMILIAL ADENOMATOUS POLYPOSIS; COLORECTAL CARCINOMAS; WILMS-TUMOR; SHORT ARM; GENE; IDENTIFICATION; EXPRESSION; CANCER; LINES; DELETIONS	The development of human colon carcinomas is associated with a number of genetic alterations, A high frequency of deletion of the short arm of chromosome 8 at a late stage of colon carcinogenesis was detected by DNA analysis of colon carcinomas, which suggests the presence of a tumor suppressor gene, We therefore, introduced normal human chromosome 8 into colon carcinoma cells that showed allele loss on 8p21, through microcell hybridization, Five clones of hybrid cells were obtained from independent experiments. Three hybrids exhibited morphological alteration and suppressed tumorigenicity in the subcutis of nude mice, but the other two did not, The difference between the two types of hybrids was the region of the introduced normal chromosome 8: Three hybrids exhibiting morphological alteration and suppressed tumorigenicity had the entire region of the introduced chromosome 8, whereas the other two, exhibiting no change, lacked 8p12-pter from the introduced chromosome, Furthermore, the invasiveness of the hybrids with suppressed tumorigenicity was reduced to one-fifth of that of the parental cells, These results indicate that 8p12-pter carries a gene that contributes to suppression of both tumorigenicity and invasiveness of colon carcinomas.	TOKYO METROPOLITAN INST MED SCI,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; TOTTORI UNIV,FAC MED,DEPT MOLEC & CELL GENET,YONAGO,TOTTORI 683,JAPAN	Tokyo Metropolitan Institute of Medical Science; Tottori University								ALBINI A, 1987, CANCER RES, V47, P3239; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BROWN PD, 1990, CANCER RES, V50, P6184; CHEN JM, 1991, J BIOL CHEM, V266, P5113; CUNNINGHAM C, 1993, ONCOGENE, V8, P1391; DOWDY SF, 1991, SCIENCE, V254, P293, DOI 10.1126/science.1656527; EMI M, 1992, CANCER RES, V52, P5368; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUJIWARA Y, 1993, CANCER RES, V53, P1172; FUJIWARA Y, 1995, ONCOGENE, V10, P891; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAMAGUCHI M, 1995, ONCOGENE, V10, P1037; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; ICHIKAWA T, 1994, CANCER RES, V54, P2299; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; KIKUCHIYANOSHIT.R, 1992, CANCER RES, V53, P3965; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3801; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNOWLES MA, 1993, ONCOGENE, V8, P1357; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; Liotta L A, 1982, Cancer Metastasis Rev, V1, P277, DOI 10.1007/BF00124213; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; MCGOWAN JI, 1994, CANCER RES, V54, P2568; MIYAKI M, 1990, CANCER RES, V50, P7166; MIYAKI M, 1995, CRIT REV ONCOL HEMAT, V19, P1, DOI 10.1016/1040-8428(94)00129-H; MULERIS M, 1990, CANCER GENET CYTOGEN, V46, P143, DOI 10.1016/0165-4608(90)90100-O; OHATA H, 1993, GENE CHROMOSOME CANC, V7, P85, DOI 10.1002/gcc.2870070204; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SHIMIZU M, 1990, ONCOGENE, V5, P185; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; TANAKA K, 1993, ONCOGENE, V8, P2253; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; VANDERBOSCH K, 1992, GENE CHROMOSOME CANC, V5, P91, DOI 10.1002/gcc.2870050114; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WELCH DR, 1994, ONCOGENE, V9, P255; YAMADA H, 1990, ONCOGENE, V5, P1141; YAREMKO ML, 1994, GENE CHROMOSOME CANC, V10, P1, DOI 10.1002/gcc.2870100102; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817	41	27	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					405	410						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570218				2022-12-28	WOS:A1996TR53800020
J	Clark, GJ; Kinch, MS; Gilmer, TM; Burridge, K; Der, CJ				Clark, GJ; Kinch, MS; Gilmer, TM; Burridge, K; Der, CJ			Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancers	ONCOGENE			English	Article						transformation; adherens junctions; motility	MAMMARY EPITHELIAL-CELLS; HA-RAS; AMINO-ACIDS; ONCOGENE; TRANSFORMATION; EXPRESSION; ACTIVATION; CARCINOMAS; LINE; INVIVO	Although experimental studies suggest that aberrant Ras function can promote the malignant progression of human breast epithelial cells, the occurrence of mutated pas genes in breast tumors is infrequent. One possible explanation for this apparent paradox is that aberrant function of the Ras-related protein TC21/R-Ras2, which causes malignant transformation of NIH 3T3 cells via upregulation of the Ras signal transduction pathway, may contribute to breast tumor development in the absence of Ras mutations. To address this possibility, we utilized two complementary approaches. First, we determined that aberrant TC21 function caused transformation of the MCF-10A human breast epithelial cell line. TC21-transformed MCF-10A cells exhibited altered cellular morphology associated with a disruption of cell-cell adherens junctions, formed colonies in soft agar, and showed enhanced motility in vitro. These alterations were similar to, but more dramatic than, those observed with oncogenic Ras-transformed MCF-10A cells. Furthermore, overexpression of normal TC21, but not Ras, also caused transformation of these cells. Second, we observed that TC21 protein expression was greatly elevated in 7 of 9 breast tumor lines when compared to untransformed MCF-10A cells. Taken together, these results support the possibility that overexpression of TC21 may contribute to aberrant growth properties of breast carcinoma cells.	UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT CELLULAR BIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; GLAXO INC,RES INST,DEPT CELL BIOL,RES TRIANGLE PK,NC 27709	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; GlaxoSmithKline				Kinch, Michael/0000-0003-3939-3756; Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA055008, R01CA052072, R01CA042978] Funding Source: NIH RePORTER; NCI NIH HHS [CA55008, CA52072, CA42978] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BASOLO F, 1991, MOL CARCINOGEN, V4, P25, DOI 10.1002/mc.2940040106; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUSS JE, 1988, MOL CELL BIOL, V8, P3960, DOI 10.1128/MCB.8.9.3960; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; CLAIR T, 1987, CANCER RES, V47, P5290; CLARDIELLO F, 1992, MOL CARCINOGEN, V6, P43; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; CLARK GJ, 1993, GTPASES BIOL, V108, P259; CLARK R, 1988, CANCER RES, V48, P4689; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; COX AD, 1994, ONCOGENE, V9, P3281; DANDEKAR S, 1986, MOL CELL BIOL, V6, P4104, DOI 10.1128/MCB.6.11.4104; DEBORTOLI ME, 1985, BIOCHEM BIOPH RES CO, V127, P699, DOI 10.1016/S0006-291X(85)80218-7; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; GUNZBURG WH, 1988, CARCINOGENESIS, V9, P1849, DOI 10.1093/carcin/9.10.1849; HAND PH, 1987, J NATL CANCER I, V79, P59; HYNES NE, 1985, MOL CELL BIOL, V5, P268, DOI 10.1128/MCB.5.1.268; HYNES NE, 1994, CANCER BIOL, V4, P19; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; OCHIENG J, 1991, INVAS METAST, V11, P38; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; PRESS MF, 1994, CANCER RES, V54, P2771; QUI RG, 1995, NATURE, V374, P457; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; REDMOND SMS, 1988, ONCOGENE, V2, P259; SAEZ R, 1994, ONCOGENE, V9, P2977; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOULE HD, 1990, CANCER RES, V50, P6075; SPANDIDOS DA, 1987, ANTICANCER RES, V7, P991; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; THOR A, 1986, LAB INVEST, V6, P603; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001	47	81	85	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					169	176						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552388				2022-12-28	WOS:A1996TQ01400021
J	Fueyo, J; GomezManzano, C; Yung, WKA; Clayman, GL; Liu, TJ; Bruner, J; Levin, VA; Kyritsis, AP				Fueyo, J; GomezManzano, C; Yung, WKA; Clayman, GL; Liu, TJ; Bruner, J; Levin, VA; Kyritsis, AP			Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells	ONCOGENE			English	Article						brain tumors; tumor suppressor genes; p16/CDKN2; adenovirus		The p16 (MTS1/CDKN2) gene localized at the 9p21 chromosomal region encodes for a cell cycle inhibitor protein and is altered in many human cancers. The frequency of p16 alterations in gliomas exceeds 50%. To restore the missing wild-type p16 gene efficiently in glioma cells an adenovirus vector carrying the full length coding sequence of the wild-type p16 cDNA, Ad5RSV-p16, was constructed. Three human glioma cell lines, U-251 MG, U-87 MG and D54 MG, that did not express endogenous p16/CDKN2 gene and were easily infected with adenovirus vectors were selected for these experiments. Introduction of the Ad5RSV-p16 in these malignant glioma cell lines directed the biosynthesis of functional p16 protein in the majority of the exposed cells, significantly inhibited cell growth, influenced cell morphology and modified the transformed phenotype of cells including the ability to form colonies in soft agar. Flow cytometric studies revealed that the majority of the Ad5RSV-p16 infected glioma cells were arrested in the G0-G1 phases of the cell cycle. These results suggest that p16/CDKN2 inactivation is a significant factor in the genesis and progression of gliomas and that the restoration of the wild-type p16 protein could have clinical and therapeutic utility.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEAD & NECK SURG,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fueyo, J (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT NEUROONCOL,HOUSTON,TX 77030, USA.			Gomez-Manzano, Candelaria/0000-0002-1259-2133; Fueyo, Juan/0000-0001-6941-2335	NATIONAL CANCER INSTITUTE [P01CA055261] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA55261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKLI S, 1993, NAT GENET, V3, P224, DOI 10.1038/ng0393-224; ARAP W, 1995, CANCER RES, V55, P1351; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHEN SH, 1994, P NATL ACAD SCI USA, V91, P3054, DOI 10.1073/pnas.91.8.3054; CLAYMAN GL, 1995, CANCER RES, V55, P1; GIANI C, 1994, CANCER RES, V54, P6338; Graham FL, 1991, METHOD MOL BIOL, P109; GRUNHAUS A, 1992, SEMIN VIROL, V3, P237; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JEN J, 1994, CANCER RES, V54, P6353; JIN XM, 1995, CANCER RES, V55, P3250; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LI Y, 1994, CANCER RES, V54, P6078; LIU TJ, 1994, CANCER RES, V54, P3662; LIU TJ, 1995, CANCER RES, V55, P3117; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; PERSHOUSE MA, 1993, CANCER RES, V53, P5043; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; TGAKI H, 1994, BIOCHEM BIOPH RES CO, V203, P1090; WANG JX, 1995, CANCER GENE THER, V2, P9; WASHIMI O, 1995, CANCER RES, V55, P514; ZHANG WW, 1993, BIOTECHNIQUES, V15, P868; ZHANG WW, 1994, CANCER GENE THER, V1, P5	27	92	99	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					103	110						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552379				2022-12-28	WOS:A1996TQ01400013
J	Holland, EA; Beaton, SC; Becker, TM; Grulet, OMC; Peters, BA; Rizos, H; Kefford, RF; Mann, GJ				Holland, EA; Beaton, SC; Becker, TM; Grulet, OMC; Peters, BA; Rizos, H; Kefford, RF; Mann, GJ			Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds	ONCOGENE			English	Article						p16; CDKN2; familial melanoma; mutation linkage; cyclin dependent kinase inhibitor	FAMILIAL MELANOMA; LINKAGE ANALYSIS; LOCUS	CDKN2 has been implicated as a melanoma susceptibility gene in some kindreds with a family history of this disease, Mutation analysis of CDKN2 in 17 familial melanoma Australian kindreds revealed a paucity of exon mutations and none of the previously described disease-related mutations, One novel germline mutation was found in exon one, Arg24Pro, which segregates with melanoma in 1/17 kindreds, Two previously described polymorphisms, A1a148Thr and a base change at nucleotide 540 were detected and one novel polymorphism in the untranslated region of exon 3 (nucleotide 580) was also found, Together with other recent reports, these findings provide support for CDKN2 as a susceptibility locus for familial melanoma but suggest that other loci are involved in some hereditary melanoma kindreds.			Holland, EA (corresponding author), UNIV SYDNEY,WESTMEAD HOSP,DEPT MED ONCOL,WESTMEAD,NSW 2145,AUSTRALIA.		; Mann, Graham/G-4758-2014	Kefford, Richard/0000-0001-9251-9229; Becker, Therese/0000-0002-5636-9902; Rizos, Helen/0000-0002-2094-9198; Mann, Graham/0000-0003-1301-405X				CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CANNONALBRIGHT LA, 1994, GENOMICS, V23, P265, DOI 10.1006/geno.1994.1491; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GOLDSTEIN AM, 1993, AM J HUM GENET, V52, P537; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; GRUIS NA, 1995, AM J PATHOL, V146, P1199; GRUIS NA, 1993, MELANOMA RES, V3, P271; HOLLAND EA, 1994, ONCOGENE, V9, P1361; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KEFFORD RF, 1991, CANCER GENET CYTOGEN, V51, P45, DOI 10.1016/0165-4608(91)90007-H; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; MACGEOCH C, 1994, HUM MOL GENET, V3, P2195, DOI 10.1093/hmg/3.12.2195; MAMELKA PM, 1993, PEDIGREE DRAW VERSIO; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NANCARROW DJ, 1993, AM J HUM GENET, V53, P936; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OHTA M, 1994, CANCER RES, V54, P5269; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Ott J., 1991, ANAL HUMAN GENETIC L; PETTY EM, 1993, AM J HUM GENET, V53, P96; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; Sambrook J, 1989, MOL CLONING LABORATO; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; WALKER GJ, 1994, ONCOGENE, V9, P819; WALKER GJ, 1995, 7TH LORN CANC C LORN; WEAVERFELDHAUS J, 1994, P NATL ACAD SCI USA, V91, P7563, DOI 10.1073/pnas.91.16.7563; XU L, 1994, CANCER RES, V54, P5262	34	96	97	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2289	2294						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570179				2022-12-28	WOS:A1995TK70200012
J	Ishino, M; Ohba, T; Sasaki, H; Sasaki, T				Ishino, M; Ohba, T; Sasaki, H; Sasaki, T			Molecular cloning of a cDNA encoding a phosphoprotein, Efs, which contains a Src homology 3 domain and associates with Fyn	ONCOGENE			English	Article						Src homology; fyn; yes; tyrosine phosphorylation; embryo	IDENTIFICATION; PROTEIN; CONSTRUCTION; SUBSTRATE; PAXILLIN; SEQUENCE; SYSTEM; CELLS	Src homology 2 and 3 (SH2 and SH3) domains mediate protein-protein interactions in intracellular signaling by protein-tyrosine kinases (PTKs), We have isolated cDNA clones from mouse embryo cDNA expression library that encode a new signaling protein which we call Efs (Embryonal Fyn-associated Substrate), The deduced amino acid sequence of 560 residues in length revealed one SH3 domain at its amino-terminal region, two proline-rich motifs with the consensus sequences of binding to Src-family SH3s, and a cluster of YXXP motifs that are possibly tyrosine-phosphorylated to serve as ligands binding to SH2 domains, Structure and alignment of these characteristic sequences are homologous to those of p130(Cas), but Efs and p130(Cas) are different proteins, Expression of the Efs gene was higher in placenta, embryo and brain than in other adult tissues, Transfection of COS-7 cells with a plasmid encoding an epitope-tagged Efs resulted in the expression of a 83 kDa protein, The epitope-tagged Efs was hyperphosphorylated when cotransfected with a vector expressing Fyn, In an in vitro kinase assay with the PCC4 cell lysate, Efs became phosphorylated on tyrosine residues and coprecipitated with p59(fyn) and p62(yes); the result suggests that Efs is a physiological substrate of these PTKs.	SAPPORO MED UNIV, SCH MED, CANC RES INST, DEPT BIOCHEM, CHUO KU, SAPPORO, HOKKAIDO 060, JAPAN	Sapporo Medical University								ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAUMANN G, 1994, EUR J IMMUNOL, V24, P1799, DOI 10.1002/eji.1830240812; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FLYNN DC, 1995, J BIOL CHEM, V270, P3894, DOI 10.1074/jbc.270.8.3894; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; SUDOL M, 1994, ONCOGENE, V9, P2145; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TSYGANKOV AY, 1994, J BIOL CHEM, V269, P7792; WENG ZG, 1993, J BIOL CHEM, V268, P14956; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; YAMSHITA Y, 1992, TUMOR RES, V27, P59; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHAN X, 1994, J BIOL CHEM, V269, P20221; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	36	106	107	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2331	2338						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570184				2022-12-28	WOS:A1995TK70200017
J	Sitzmann, J; NobenTrauth, K; Klempnauer, KH				Sitzmann, J; NobenTrauth, K; Klempnauer, KH			Expression of mouse c-myb during embryonic development	ONCOGENE			English	Article						transcription factors; c-myb; A-myb; mouse development	B-MYB; A-MYB; CHICK-EMBRYO; MIM-1 GENE; DIFFERENTIATION; CDNA; PROLIFERATION; TRANSCRIPTION; HEMATOPOIESIS; REQUIRES	Three members of the myb gene family, designated as A-myb, B-myb and c-myb, have been described in many vertebrates, A large body of evidence indicates that the c-myb gene is essential for the development of most hematopoietic lineages, By contrast, the functions of A-myb and B-myb are less well understood. To further explore the relationship between the different myb family members we have compared the expression of A-myb and c-myb during mouse embryogenesis by Northern blotting and by in situ hybridization, In accordance with the important role of c-myb in the hematopoietic system, we detect high levels of c-myb expression in hematopoietic organs such as the fetal liver and the thymus, Surprisingly, we find that high levels of c-myb expression are not restricted to hematopoietic cells, We show that c-myb is strongly expressed in the neural retina and in epithelia of the respiratory tract, The side-by-side analysis of c-myb and A-myb expression clearly shows that both genes are expressed in different, but overlapping sets of tissues, Our results suggest that the function of c-myb may not be restricted to hematopoietic cells.	MAX PLANCK INST IMMUNOBIOL,HANS SPEMANN LAB,D-79108 FREIBURG,GERMANY	Max Planck Society								BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; BROWN KE, 1992, J BIOL CHEM, V267, P4625; BURK O, 1991, EMBO J, V10, P3731; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DESBIENS X, 1991, DEVELOPMENT, V111, P699; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLAY J, 1991, BLOOD, V77, P149; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KLEMPNAUER KH, 1983, J VIROL, V48, P565, DOI 10.1128/JVI.48.3.565-572.1983; LAM EWF, 1992, ONCOGENE, V7, P1185; LEON Y, 1992, DEV BIOL, V153, P407, DOI 10.1016/0012-1606(92)90126-2; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MCMAHON J, 1988, ONCOGENE, V3, P717; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; PLAZA S, 1995, ONCOGENE, V10, P329; QUEVA C, 1992, DEVELOPMENT, V114, P125; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; THIELE CJ, 1987, J CLIN INVEST, V80, P801; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x	29	68	70	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2273	2279						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570177				2022-12-28	WOS:A1995TK70200010
J	MCCUBREY, JA; SMITH, SR; ALGATE, PA; DEVENTE, JE; WHITE, MK; STEELMAN, LS				MCCUBREY, JA; SMITH, SR; ALGATE, PA; DEVENTE, JE; WHITE, MK; STEELMAN, LS			RETROVIRAL INFECTION CAN ABROGATE THE FACTOR-DEPENDENCY OF HEMATOPOIETIC-CELLS BY AUTOCRINE AND NONAUTOCRINE MECHANISMS DEPENDING ON THE PRESENCE OF A FUNCTIONAL VIRAL ONCOGENE	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; V-SRC; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; AUTONOMOUS GROWTH; GENE-EXPRESSION; ABELSON VIRUS; INTERLEUKIN-3; LINE; TRANSFORMATION	The mechanisms responsible for abrogation of the growth factor-dependency of a hematopoietic cell line were investigated. FDC-P1 cells were infected with retroviral constructs containing the neo gene and either a wild-type or a temperature-sensitive v-src oncogene. v-src(wt) abrogated the factor-dependency of these cells since each G418r colony gave rise to factor-independent cells and no autocrine growth factor activity was detected. Moreover, the vast majority (<99%) of cells infected with the v-src(ts) mutant gave rise to conditional factor-independent cells. Therefore a functional v-src gene product was required for growth factor-independence which occurred by a non-autocrine mechanism. A minority of factor-independent cells which arose after v-src(ts) infection, grew at the non-permissive temperature and one-half secreted granulocyte/macrophage-colony stimulating factor (GM-CSF) which supports the growth of the parental cells. Since the v-src(ts) viral stock contained a helper virus, Murine Leukemia Virus (MuLV), the ability of this virus to relieve factor-dependency was examined. A low frequency of factor-independent transformants was recovered after MuLV infection and one-half secreted GM-CSF. Therefore, retroviruses such as MuLV which lack an oncogene, can transform cells by stimulating autocrine growth factor secretion. Subsequent experiments performed with helper-free v-src preparations indicated that they could abrogate factor-dependency directly by a non-autocrine mechanism. These results demonstrate that a hematopoietic cell line can be transformed by two different mechanisms after retroviral infection and may be relevant for understanding hematopoietic cell transformation after persistent viral infection.			MCCUBREY, JA (corresponding author), E CAROLINA UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,GREENVILLE,NC 27858, USA.			McCubrey, James/0000-0001-6027-3156	NCI NIH HHS [NCI RO1CA51025] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051025] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALGATE PA, 1993, ONCOGENE, V8, P1221; ANDERSON SM, 1990, ONCOGENE, V5, P317; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BARLOW DP, 1987, EMBO J, V6, P617, DOI 10.1002/j.1460-2075.1987.tb04799.x; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1802; BRONSTEIN I, 1992, BIOTECHNIQUES, V12, P748; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DUHRSEN U, 1990, EMBO J, V9, P1087, DOI 10.1002/j.1460-2075.1990.tb08214.x; FUNG MC, 1984, NATURE, V307, P233, DOI 10.1038/307233a0; GOUGH NM, 1985, EMBO J, V4, P645, DOI 10.1002/j.1460-2075.1985.tb03678.x; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HARBERS K, 1981, P NATL ACAD SCI-BIOL, V78, P7609, DOI 10.1073/pnas.78.12.7609; IHLE JN, 1987, J IMMUNOL, V138, P3051; IHLE JN, 1983, J IMMUNOL, V131, P282; JHAPPAN C, 1986, J VIROL, V60, P750, DOI 10.1128/JVI.60.2.750-753.1986; KIPREOS ET, 1988, ONCOGENE RES, V2, P277; KITAMURA T, 1991, CELL, V66, P165; KUFF EL, 1990, CANCER CELL-MON REV, V2, P398; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MCCUBREY J, 1989, ONCOGENE RES, V4, P97; MCCUBREY JA, 1991, ONCOGENE RES, V6, P1; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; NICOLA NA, 1986, J BIOL CHEM, V261, P2384; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; NORI M, 1990, MOL CELL BIOL, V10, P4155, DOI 10.1128/MCB.10.8.4155; OVERELL RW, 1987, MOL CELL BIOL, V7, P3394, DOI 10.1128/MCB.7.10.3394; PALASZYNSKI EW, 1984, J IMMUNOL, V132, P1872; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; ROWE WP, 1970, VIROLOGY, V42, P1136, DOI 10.1016/0042-6822(70)90362-4; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; WHEELER EF, 1987, MOL CELL BIOL, V7, P1673, DOI 10.1128/MCB.7.5.1673; WHITE MK, 1988, MOL CELL BIOL, V8, P138, DOI 10.1128/MCB.8.1.138; WYKE JA, 1973, VIROLOGY, V53, P152, DOI 10.1016/0042-6822(73)90474-1	44	51	51	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2905	2915						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414494				2022-12-28	WOS:A1993MC09300003
J	MULLER, E; BOLDYREFF, B; SCHEIDTMANN, KH				MULLER, E; BOLDYREFF, B; SCHEIDTMANN, KH			CHARACTERIZATION OF PROTEIN-KINASE ACTIVITIES ASSOCIATED WITH P53-LARGE-T IMMUNE-COMPLEXES FROM SV40-TRANSFORMED RAT-CELLS	ONCOGENE			English	Article							LARGE T-ANTIGEN; SV40 LARGE-T; TUMOR-SUPPRESSOR PROTEIN; DNA-BINDING DOMAIN; WILD-TYPE; CYCLE CONTROL; P53 PROTEIN; 3T3 CELLS; MONOCLONAL-ANTIBODIES; PHOSPHORYLATION SITES	Interaction of viral oncoproteins, such as SV40 large T, with cellular growth suppressor proteins Rb and p53 is presumed to inactive or modulate their growth suppression functions, thereby leading to transformation. An additional transformation-related activity of LT leads to hyperphosphorylation of p53. To search for kinases that might be responsible for this effect, p53-LT complexes were immunopurified from different SV40-transformed rat cell lines and assayed for associated kinase activities, in vitro. Protein kinase activity was readily observed in p53-LT immunecomplexes from wild-type transformed cells but was low or undetectable in p53 from mutant-transformed or normal cells. Optimal activity required the presence of Mn++. p53 was phosphorylated at all sites found in vivo. In contrast, LT was phosphorylated only at a subset of formerly identified sites and at additional sites not seen in vivo. The p53-LT-kinase complex was assayed for the presence of casein kinases, cdk like kinases, or DNA-activated kinase, using specific effectors, antibodies, or purified enzymes as tools. DNA-activated kinase or cdc2/cdk2 were not detectable, although the purified enzymes phosphorylated p53 in vitro. Casein kinase 2 represented the major activity, which on p53 phosphorylated not only the C-terminal Ser390 but also several sites in the N-terminal region. One additional activity, not identified so far, may represent an LT-induced or activated kinase. This kinase seems to enhance overall phosphorylation of p53 and, perhaps other substrates, and may thereby contribute to transformation.	UNIV BONN,INST GENET,ABT MOLEK GENET,ROMERSTR 164,W-5300 BONN 1,GERMANY; UNIV SAARLAND,INST HUMAN GENET,W-6600 SAARBRUCKEN,GERMANY	University of Bonn; Saarland University								BALL RK, 1984, EMBO J, V3, P1488; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BAUER M, 1987, J VIROL, V61, P1821, DOI 10.1128/JVI.61.6.1821-1827.1987; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CHEN JD, 1992, ONCOGENE, V7, P1167; DEPPERT W, 1990, ONCOGENE, V5, P1701; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1988, ONCOGENE, V3, P313; ELLEDGE SJ, 1991, EMBO J, V10, P1653; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; GADBOIS DM, 1992, BIOCHEM BIOPH RES CO, V184, P80, DOI 10.1016/0006-291X(92)91160-R; GRASSER FA, 1988, VIROLOGY, V165, P13, DOI 10.1016/0042-6822(88)90653-8; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HEBEL M, 1986, Z NATURFORSCH C, V41, P94; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAY G, 1981, P NATL ACAD SCI-BIOL, V78, P2932, DOI 10.1073/pnas.78.5.2932; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25; KERN SE, 1991, ONCOGENE, V6, P131; KRAISS S, 1990, ONCOGENE, V5, P845; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1991, CANCER CELL-MON REV, V3, P341; LEESMILLER SP, 1989, J BIOL CHEM, V264, P17275; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1989, COMMON MECHANISMS TR; LUO K, 1990, ONCOGENE, V5, P921; MANFREDI JJ, 1990, J VIROL, V64, P5250, DOI 10.1128/JVI.64.11.5250-5259.1990; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MEEK DW, 1990, J VIROL, V64, P1734, DOI 10.1128/JVI.64.4.1734-1744.1990; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1990, ONCOGENE, V5, P973; MEYERSON M, 1991, COLD SPRING HARB SYM, V56, P177; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PATSCHINSKY T, 1992, J VIROL, V66, P3846, DOI 10.1128/JVI.66.6.3846-3859.1992; PERICH JW, 1992, BIOCHEMISTRY-US, V31, P5893, DOI 10.1021/bi00140a027; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SCHEIDTMANN KH, 1991, J VIROL, V65, P1479, DOI 10.1128/JVI.65.3.1479-1490.1991; SCHEIDTMANN KH, 1989, CURR TOP MICROBIOL, V144, P85; SCHNEIDER HR, 1986, EUR J BIOCHEM, V161, P733, DOI 10.1111/j.1432-1033.1986.tb10501.x; SCHNEIDER HR, 1989, BIOTEC EUROPE, V6, P82; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHOHAT O, 1987, ONCOGENE, V1, P277; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOUSSI T, 1990, ONCOGENE, V5, P949; STEINMEYER K, 1988, ONCOGENE, V3, P501; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TUZAON PT, 1991, 2ND MESSENGER PHOSPH, V23, P123; VANROY F, 1984, MOL CELL BIOL, V4, P232, DOI 10.1128/MCB.4.2.232; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WALTER G, 1980, P NATL ACAD SCI-BIOL, V77, P5197, DOI 10.1073/pnas.77.9.5197; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WEISSKER SN, 1992, ONCOGENE, V7, P1921; ZHU J, 1992, J VIROL, V66, P6872	89	25	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2193	2205						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8393163				2022-12-28	WOS:A1993LP17100020
J	HASSAPOGLIDOU, S; DIAMANDIS, EP; SUTHERLAND, DJA				HASSAPOGLIDOU, S; DIAMANDIS, EP; SUTHERLAND, DJA			QUANTIFICATION OF P53 PROTEIN IN TUMOR-CELL LINES, BREAST-TISSUE EXTRACTS AND SERUM WITH TIME-RESOLVED IMMUNOFLUOROMETRY	ONCOGENE			English	Article							CONFORMATION POLYMORPHISM ANALYSIS; PROGNOSTIC FACTORS; SUPPRESSOR GENE; CANCER; MUTATIONS; FREQUENT; EXPRESSION; ANTIBODIES	We have developed a highly sensitive time-resolved immunofluorometric procedure for quantifying mutant or wild-type, human or murine, p53 protein. The method uses monoclonal PAb240 or PAb421 antibodies for capture and a polyclonal rabbit antibody for detection. The final immunocomplex is quantified with an alkaline phosphatase substrate which, when hydrolyzed by the enzyme, forms highly fluorescent long-lived complexes with Tb3+-EDTA. The detection limit is approximately 1 pg of protein per assay. The assay was applied for the quantification of p53 protein in lysates from 23 cell lines and overproducers of mutant protein were identified. Eight hundred cancer patients sera tested negative for the presence of p53. We have also applied the quantitative immunofluorometric procedure for measuring mutant p53 protein in breast tumor extracts specifically prepared for steroid hormone receptor analysis. Sixty-four out of the 264 extracts (24%) were positive for p53. Significant negative correlations between levels of p53 and steroid hormone receptors were found. The proposed analytical methodology simplifies the assessment of p53 status in tumor extracts, has many advantages over immunohistochemical techniques and is proposed as a method of choice for routine clinical use and other investigations involving p53.	TORONTO HOSP,TORONTO WESTERN DIV,DIV CLIN BIOCHEM,399 BATHURST ST,TORONTO M5T 258,ON,CANADA; UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO M5G 1L5,ONTARIO,CANADA; UNIV TORONTO,SUNNYBROOK MED CTR,TORONTO BAYVIEW REG CANC CTR,TORONTO M4N 3M5,ON,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center				Diamandis, Eleftherios/0000-0002-1589-820X				BARTEK J, 1991, ONCOGENE, V6, P1699; BARTEK J, 1990, ONCOGENE, V5, P893; BARTON CM, 1991, BRIT J CANCER, V64, P1076, DOI 10.1038/bjc.1991.467; BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALLAHAN R, 1992, J NATL CANCER I, V84, P826, DOI 10.1093/jnci/84.11.826; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CHANG K, 1991, J HISTOCHEM CYTOCHEM, V39, P1281, DOI 10.1177/39.9.1680897; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHIBA I, 1990, ONCOGENE, V5, P1603; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; CHRISTOPOULOS TK, 1992, ANAL CHEM, V64, P342, DOI 10.1021/ac00028a004; CRAWFORD LV, 1982, INT J CANCER, V30, P403, DOI 10.1002/ijc.2910300404; DAVIDOFF AM, 1991, SURGERY, V110, P259; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; DIAMANDIS EP, 1988, CLIN BIOCHEM, V21, P139, DOI 10.1016/S0009-9120(88)80104-8; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GRAVES RF, 1988, THESIS U LONDON; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HENDERSON IC, 1991, BREAST DISEASES, P332; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KOENDERS PG, 1991, CANCER RES, V51, P4544; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MALKIN D, 1990, SCIENCE, V250, P233; MIDGLEY CA, 1992, IN PRESS J CELL SCI; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MURAKAMI Y, 1991, CANCER RES, V51, P3356; OSTROWSKI JL, 1991, J PATHOL, V164, P75, DOI 10.1002/path.1711640113; PROSSER J, 1992, BRIT J CANCER, V65, P527, DOI 10.1038/bjc.1992.109; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROMANO JW, 1989, ONCOGENE, V4, P1483; SINGERLAND J M, 1991, Blood, V77, P1500; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TAMURA G, 1991, CANCER RES, V51, P3056; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; VISAKORPI T, 1992, J NATL CANCER I, V84, P883, DOI 10.1093/jnci/84.11.883; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WINFORDTHOMAS D, 1992, J PATHOL, V166, P329; WINTER SF, 1992, CANCER RES, V52, P4168	49	70	71	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1501	1509						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502476				2022-12-28	WOS:A1993LE06400013
J	BOEHM, T				BOEHM, T			ANALYSIS OF MULTIGENE FAMILIES BY DNA FINGERPRINTING OF CONSERVED DOMAINS - DIRECTED CLONING OF TISSUE-SPECIFIC PROTEIN TYROSINE PHOSPHATASES	ONCOGENE			English	Note							POLYMERASE CHAIN-REACTION; NERVOUS-SYSTEM AXONS; KINASES; IDENTIFICATION; EXPRESSION; RHOMBOTIN; HOMOLOGY; GENES	Little is known about the number of mouse protein tyrosine phosphatases (PTPs) and their developmental and tissue-specific expression patterns. A new procedure based on fingerprinting of amplified catalytic domains detects expression of at least 20 different mouse PTPs during development. The majority of these PTPs show developmentally regulated expression patterns; some display a unique tissue specificity. Diagnostic fragments detected in the fingerprint analysis are used here as specific probes to directly clone two previously unknown ubiquitously expressed PTPs and PTP1C, a protein tyrosine phosphatase highly expressed in thymus RNA. The fingerprinting procedure is also applicable to the analysis of protein tyrosine kinases and may also be used to study the expression pattern of other multigene families.			BOEHM, T (corresponding author), UNIV FREIBURG,DEPT MED 1,MOLEC MED GRP,HUGSTETTER STR 55,W-7800 FREIBURG,GERMANY.							BOEHM T, 1991, ONCOGENE, V6, P695; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARIHARAN IK, 1991, P NATL ACAD SCI USA, V88, P11266, DOI 10.1073/pnas.88.24.11266; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KREUGER NX, 1992, EMBO J, V89, P7417; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LOMBROSO PJ, 1991, P NATL ACAD SCI USA, V88, P7242, DOI 10.1073/pnas.88.16.7242; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; NISHI M, 1990, FEBS LETT, V271, P178, DOI 10.1016/0014-5793(90)80400-D; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; YI TL, 1991, BLOOD, V78, P2222	26	13	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1385	1390						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479755				2022-12-28	WOS:A1993KY32800033
J	CHOWDHURY, M; KUNDU, M; KHALILI, K				CHOWDHURY, M; KUNDU, M; KHALILI, K			GA GC-RICH SEQUENCE CONFERS TAT RESPONSIVENESS TO HUMAN NEUROTROPIC VIRUS PROMOTER, JCVL, IN CELLS DERIVED FROM CENTRAL-NERVOUS-SYSTEM	ONCOGENE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; HUMAN-BRAIN CELLS; TRANS-ACTIVATION; HIV-1 TAT; GENE-EXPRESSION; LOOP SEQUENCE; PROTEIN; RNA; TYPE-1	The human immunodeficiency virus type I (HIV-1) nuclear protein, Tat, is a potent transactivating factor that stimulates the rate of transcription of responsive promoters. Evidently, to exert its activity, Tat requires to be localized in close proximity of the transcription initiation site. Previous studies in our laboratory have demonstrated that Tat has the capacity to increase transcriptional activity of the late gene of a human neurotropic virus JC (JCV) in glial cells. In the present study, using deletion mutation analysis, we have identified a region upstream of the JCV late RNA start sites, termed upstream target (upTAR), that positively responds to Tat activation in glial cells. Using synthetic oligonucleotides spanning the upTAR sequence linked to a heterologous promoter, we have identified a GA/GC-rich region (GGAGGCGGAGGC) that confers TAT responsiveness preferentially on glial cell lines. Using gel mobility-shift and UV cross-linking assays, we have demonstrated that four major complexes (a-d) from glial and HeLa (non-glial) cells interact with the upTAR sequence. Whereas the molecular weights of the participant proteins in these complexes are similar in both glial and non-glial extracts, glial cells are enriched in proteins that form a major c complex. Interestingly, the participant proteins in complex c are developmentally regulated during brain development. The possible role of these proteins in increasing local concentrations of Tat in the vicinity of the JCV late RNA start sites is discussed.	THOMAS JEFFERSON UNIV,JEFFERSON INST MOLEC MED,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107	Jefferson University			Kundu, Mondira/N-8139-2018	Kundu, Mondira/0000-0001-9946-2472	NCI NIH HHS [CA 47996] Funding Source: Medline; NIAID NIH HHS [AI 28272] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA047996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028272] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKSAMIT AJ, 1988, ANN NEUROL, V24, P471; BERGER JR, 1987, ANN INTERN MED, V107, P78, DOI 10.7326/0003-4819-107-1-78; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BERKHOUT B, 1989, J VIROL, V63, P5501, DOI 10.1128/JVI.63.12.5501-5504.1989; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CHOWDHURY M, 1992, J VIROL, V66, P7355, DOI 10.1128/JVI.66.12.7355-7361.1992; CHOWDHURY M, 1990, ONCOGENE, V5, P1737; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; KAMINE J, 1992, J VIROL, V66, P3932, DOI 10.1128/JVI.66.6.3932-3936.1992; KENNEY S, 1984, SCIENCE, V226, P1337, DOI 10.1126/science.6095453; KENNEY S, 1986, J VIROL, V58, P210; KHALILI K, 1988, EMBO J, V7, P1205, DOI 10.1002/j.1460-2075.1988.tb02932.x; KRUPP LB, 1985, ANN NEUROL, V17, P344, DOI 10.1002/ana.410170407; LEVY RM, 1985, J NEUROSURG, V62, P475, DOI 10.3171/jns.1985.62.4.0475; LIU JS, 1992, J VIROL, V66, P3883, DOI 10.1128/JVI.66.6.3883-3887.1992; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAJOR EO, 1992, CLIN MICROBIOL REV, V5, P49, DOI 10.1128/CMR.5.1.49-73.1992; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MULLER WEG, 1990, J BIOL CHEM, V265, P3803; PADGETT BL, 1973, J INFECT DIS, V127, P467, DOI 10.1093/infdis/127.4.467; ROSEN CA, 1991, GENE EXPRESSION, V1, P85; ROY S, 1990, J VIROL, V64, P1402, DOI 10.1128/JVI.64.3.1402-1406.1990; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SMALL JA, 1986, CELL, V46, P13, DOI 10.1016/0092-8674(86)90855-X; SOUTHGATE C, 1990, NATURE, V345, P640, DOI 10.1038/345640a0; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; STONER GL, 1991, J NEUROPATH EXP NEUR, V50, P342; TADA H, 1989, J VIROL, V63, P463, DOI 10.1128/JVI.63.1.463-466.1989; TADA H, 1990, P NATL ACAD SCI USA, V87, P3479, DOI 10.1073/pnas.87.9.3479; TADA H, 1991, VIROLOGY, V52, P456; TAYLOR JP, 1992, EMBO J, V11, P3395, DOI 10.1002/j.1460-2075.1992.tb05418.x; WALKER DL, 1978, HDB CLIN NEUROLOGY, V34, P307; WALKER DL, 1985, HDB CLIN NEUROLOGY, V47, P503; WROBLEWSKA Z, 1980, ARCH VIROL, V65, P141, DOI 10.1007/BF01317325; ZURHEIN GM, 1969, PROG MED VIROL, V11, P185	40	63	65	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					887	892						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8384357				2022-12-28	WOS:A1993KT22000009
J	ESCOT, C; SIMONYLAFONTAINE, J; MAUDELONDE, T; PUECH, C; PUJOL, H; ROCHEFORT, H				ESCOT, C; SIMONYLAFONTAINE, J; MAUDELONDE, T; PUECH, C; PUJOL, H; ROCHEFORT, H			POTENTIAL VALUE OF INCREASED MYC BUT NOT ERBB2 RNA LEVELS AS A MARKER OF HIGH-RISK MASTOPATHIES	ONCOGENE			English	Article							HUMAN-BREAST-CANCER; C-MYC; ONCOGENE EXPRESSION; ESTROGEN-RECEPTOR; DIFFERENTIAL EXPRESSION; CARCINOMA INSITU; BENIGN; CELLS; LESIONS; TISSUE	MYC and ERBB2 levels were measured in 38 benign breast diseases using a semiquantitative in situ hybridization technique. Mean levels of MYC and ERBB2 gene expression in benign tissues were similar to those measured in 15 breast cancers with no amplification at the loci concerned. Interestingly, MYC but not ERBB2 RNA levels were increased (t-test, P = 0.03) in benign mastopathies of patients with a first-degree (mother/sister) family history (FH) of breast cancer. Among patients without a first-degree FH, MYC RNA levels were significantly higher (t-test, P = 0.02) during the follicular (preovulatory) than the luteal (post-ovulatory) phase and also significantly higher than levels observed in patients with no menstrual cycle (peri- or postmenopausal) (P = 0.004), indicating an in vivo hormonal regulation of MYC. After exclusion of the first-degree FH patients a higher MYC expression was detected in atypia than in other histological types at the follicular but not at the luteal phase, suggesting an increased sensitivity of these high-risk lesions to estrogens. We propose that in addition to a family history and proliferative atypia, elevated MYC RNA levels during the post-ovulatory phase could potentially be used as a marker of the risk of developing breast cancer. The increase in MYC RNA in high-risk breast diseases also suggests that MYC deregulation might be involved in the early stages of mammary carcinogenesis.	INSERM,U148,UNITE HORMONE & CANC,F-34090 MONTPELLIER,FRANCE; CTR VAL AURELLE,F-34094 MONTPELLIER 5,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM)								ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; BARNES DM, 1992, EUR J CANCER, V28A, P644, DOI 10.1016/S0959-8049(05)80117-0; BENZ CC, 1989, JNCI-J NATL CANCER I, V81, P1704, DOI 10.1093/jnci/81.22.1704; BURCK KB, 1988, ONCOGENES INTRO CONC; CALLAHAN R, 1989, JNCI-J NATL CANCER I, V81, P1780, DOI 10.1093/jnci/81.23.1780; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHALBOS D, 1990, JNCI-J NATL CANCER I, V82, P602, DOI 10.1093/jnci/82.7.602; DATI C, 1990, ONCOGENE, V5, P1001; DUBIK D, 1987, CANCER RES, V47, P6517; ESCOT C, 1991, ANAL CELL PATHOL, V3, P215; GARCIA M, 1986, CANCER RES, V46, P3734; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HAAGENSEN CD, 1978, CANCER, V42, P737, DOI 10.1002/1097-0142(197808)42:2<737::AID-CNCR2820420247>3.0.CO;2-T; HUTCHINSON WB, 1980, J NATL CANCER I, V65, P13; JACQUEMIER JD, 1990, BREAST CANCER RES TR, V15, P109, DOI 10.1007/BF01810783; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; LEROY X, 1991, ONCOGENE, V6, P431; LIU E, 1992, ONCOGENE, V7, P1027; LONDON SJ, 1992, JAMA-J AM MED ASSOC, V267, P941, DOI 10.1001/jama.267.7.941; MARIANICOSTANTINI R, 1988, CANCER RES, V48, P199; PAGE DL, 1985, CANCER, V55, P2698, DOI 10.1002/1097-0142(19850601)55:11<2698::AID-CNCR2820551127>3.0.CO;2-A; PAGE DL, 1992, BREAST, V1, P3; PARKER CL, 1988, AM J EPIDEMIOL, V128, P467; PAVELIC SP, 1992, CANCER RES, V52, P2597; PETERSEN OW, 1987, CANCER RES, V47, P5748; PIKE MC, 1981, 8 BANB REP; SANTOS GF, 1988, J BIOL CHEM, V263, P9565; SIERRA F, 1982, P NATL ACAD SCI-BIOL, V79, P1795, DOI 10.1073/pnas.79.6.1795; TAUCHI K, 1989, VIRCHOWS ARCH A, V416, P65, DOI 10.1007/BF01606471; THEILLET C, 1989, ONCOGENE, V4, P915; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; WALKER KJ, 1992, EUR J CANCER, V28A, P34, DOI 10.1016/0959-8049(92)90379-G; WELLINGS SR, 1975, J NATL CANCER I, V55, P231; WHITTAKER JL, 1986, INT J CANCER, V38, P651, DOI 10.1002/ijc.2910380506	35	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					969	974						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455947				2022-12-28	WOS:A1993KT22000019
J	ROSSLER, U; ANDRES, AC; REICHMANN, E; SCHMAHL, W; WERENSKIOLD, AK				ROSSLER, U; ANDRES, AC; REICHMANN, E; SCHMAHL, W; WERENSKIOLD, AK			T1, AN IMMUNOGLOBULIN SUPERFAMILY MEMBER, IS EXPRESSED IN H-RAS-DEPENDENT EPITHELIAL TUMORS OF MAMMARY CELLS	ONCOGENE			English	Article							ANTIGEN GENE FAMILY; CARCINOEMBRYONIC ANTIGEN; ONCOGENE EXPRESSION; TRANSGENIC MICE; INDUCTION; GLAND; TRANSCRIPTION; TRANSFORMATION; EMBRYOGENESIS; INVASION	T1 is a glycosylated protein in the carcinoembryonic antigen (CEA) family of tumour marker molecules. It was originally identified by virtue of its transient induction after the expression of p21H-ras in NIH3T3 fibroblasts. Here we show that the T1 gene is activated in mammary adenocarcinomas of transgenic mice harbouring an H-ras transgene under the control of the mammary-specific whey acidic protein (WAP) promoter. By contrast, T1 mRNA was not, or only faintly, detectable in mammary carcinomas of transgenic mice bearing a WAP-myc transgene. Thus, T1 overexpression does not appear to be a general tumour-specific phenomenon. A dependence of T1 gene expression on the action of p21H-ras is suggested by the observation of T1 mRNA in nude mouse tumours generated from H-ras-transformed cultured mammary epithelial cells. Interestingly, activation of the T1 gene is also found during the maturation of the mammary gland (3-4 weeks after birth), whereas it is absent during its terminal differentiation in pregnancy and lactation. This expression pattern suggests a role for the secreted T1 glycoprotein in the phase of epithelial proliferation of the mammary gland. It appears that p21H-ras-induced transformation of mammary epithelial cells mimicks the situation occurring in puberty. In both developmental stages the T1 glycoprotein might affect celt interactions of the proliferating epithelial cells with the surrounding stroma. It might thus promote ductal outgrowth in gland maturation as well as invasive growth of p21H-ras-transformed mammary epithelial cells.	GSF FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,DEPT CELL CHEM,INGOLST LANDSTR 1,W-8042 NEUHERBERG,GERMANY; GSF FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,INST PATHOL,W-8042 NEUHERBERG,GERMANY; UNIV BERN,INST CLIN CANC RES,CH-3004 BERN,SWITZERLAND; INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Bern; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)								ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; ANDRES AC, 1991, ONCOGENE, V6, P771; BEAUCHEMIN N, 1989, CANCER RES, V49, P2017; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; COURNOYER D, 1988, CANCER RES, V48, P3153; GO VLW, 1982, CANCER PHILA S, V30, P2618; GOLD P, 1965, J EXP MED, V121, P439, DOI 10.1084/jem.121.3.439; GOLD P, 1965, J EXP MED, V122, P467, DOI 10.1084/jem.122.3.467; HASLAM SZ, 1989, ENDOCRINOLOGY, V125, P2766, DOI 10.1210/endo-125-5-2766; HUANG JQ, 1990, DEVELOPMENT, V110, P573; INAGUMA Y, 1988, DEV BIOL, V128, P245, DOI 10.1016/0012-1606(88)90288-6; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; KLEMENZ R, 1989, P NATL ACAD SCI USA, V86, P5708, DOI 10.1073/pnas.86.15.5708; KNIGHT CH, 1982, J REPROD FERTIL, V65, P521, DOI 10.1530/jrf.0.0650521; KODELJA V, 1989, J BIOL CHEM, V264, P6906; KRATOCHWIL K, 1969, DEV BIOL, V20, P46, DOI 10.1016/0012-1606(69)90004-9; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; REDMOND SMS, 1988, ONCOGENE, V2, P259; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; ROBINSON SD, 1991, DEVELOPMENT, V113, P867; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; THOMPSON J, 1988, TUMOR BIOL, V9, P63, DOI 10.1159/000217547; THOMPSON JA, 1989, BIOCHEM BIOPH RES CO, V158, P996, DOI 10.1016/0006-291X(89)92821-0; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; WERENSKIOLD AK, 1992, EUR J BIOCHEM, V204, P1041, DOI 10.1111/j.1432-1033.1992.tb16726.x; WERENSKIOLD AK, 1989, MOL CELL BIOL, V9, P5207, DOI 10.1128/MCB.9.11.5207; ZIMMERMANN W, 1988, CANCER RES, V48, P2500	28	22	23	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					609	617						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437844				2022-12-28	WOS:A1993KN00800011
J	MARSHALL, MS; HETTICH, LA				MARSHALL, MS; HETTICH, LA			CHARACTERIZATION OF RAS EFFECTOR MUTANT INTERACTIONS WITH THE NF1-GAP RELATED DOMAIN	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; GENE-PRODUCT; ADENYLATE-CYCLASE; SACCHAROMYCES-CEREVISIAE; NEUROFIBROMATOSIS GENE; CATALYTIC DOMAIN; GAP; P21; MUTATIONS; TRANSFORMATION	The GTPase activating proteins Ras GAP and the neurofibromatosis-type 1 (NF1) gene product have been implicated as both potential mediators and regulators of the mitogenic effects of the ras proteins. In this study, the interactions of selected Ras effector mutants with the NF1-GAP related domain (NF1-GRD) were investigated. The NF1-GRD was unable to stimulate the GTPase of Ras[Asn33], Ras[Ser35] or Ras[Asn38], all transformation defective mutants. Each of these mutants had reduced but detectable binding to the NF1-GRD (apparent K(D) of 9 muM, 4 muM and 2 muM respectively, vs 0.5 muM for normal Ha-ras). The NF1-GRD was able to fully stimulate the intrinsic GTPase of the transformation-defective Ras[Gly26Ile27] and Ras[Glu45] mutants, each of which bound the NF1-GRD with wild type affinity or better (K(D)=0.13 muM and 0.4 muM respectively). The transforming Ras[Glu30Lys31] protein showed no GTPase stimulation and bound most poorly to the NF1-GRD (apparent K(D) of 16 muM). The interaction of the NF1-GRD with these specific Ras effector mutations is similar to that observed for Ras GAP. When the relative transforming activity of the valine 12 form of each Ras mutant was plotted against the apparent K(D) for NF1-GRD binding, little correlation was observed. These results support the hypothesis that the NF1 gene product does not function as a downstream effector of Ras in the mitogenic pathway.	WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA	Walther Cancer Institute	MARSHALL, MS (corresponding author), INDIANA UNIV, SCH MED, DEPT MED, DIV HEMATOL ONCOL, INDIANAPOLIS, IN 46202 USA.							BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOS JL, 1989, CANCER RES, V49, P4682; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DECLUE JE, 1991, MOL CELL BIOL, V11, P3132, DOI 10.1128/MCB.11.6.3132; DOMINGUEZ I, 1991, EMBO J, V10, P3215, DOI 10.1002/j.1460-2075.1991.tb04884.x; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GOLDBERG NS, 1991, ARCH DERMATOL, V127, P1705, DOI 10.1001/archderm.127.11.1705; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; MARSHALL MS, 1988, MOL CELL BIOL, V8, P52, DOI 10.1128/MCB.8.1.52; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, 1990, ONCOGENE, V5, P1281; MITTS MR, 1991, MOL CELL BIOL, V11, P4591, DOI 10.1128/MCB.11.9.4591; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SIGAL IS, 1988, COLD SPRING HARB SYM, V53, P863, DOI 10.1101/SQB.1988.053.01.099; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STONE JC, 1991, MOL CELL BIOL, V11, P6158, DOI 10.1128/MCB.11.12.6158; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; WILLUMSEN BM, 1989, NATO ADV SCI I A-LIF, V165, P165; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	33	27	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					425	431						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426748				2022-12-28	WOS:A1993KN00600022
J	RUTHER, U; WOODROOFE, C; FATTORI, E; CILIBERTO, G				RUTHER, U; WOODROOFE, C; FATTORI, E; CILIBERTO, G			INDUCIBLE FORMATION OF LIVER-TUMORS IN TRANSGENIC MICE	ONCOGENE			English	Article							C-REACTIVE PROTEIN; EXPRESSION; TUMORIGENESIS; GENES	Transgenic mice have been generated with an inducible SV40 t/T antigen construct with the aim of analysing the early changes that take place in the course of liver tumorigenesis. The strictly liver-specific human C-reactive protein (CRP) gene promoter was chosen for the control of the transgene expression because this promoter can be turned on transiently by injection of bacterial lipopolysaccharide. Among 10 independently derived CRP-Tag mouse lines five showed inducible expression of the CRP-Tag transgene in liver. However, only one had a tight control of the transgene with virtually no expression under physiological conditions and high levels of Tag expression after stimulation. Females of this line were used to analyse the progression of liver alterations upon repeated induction of the t/T antigen for different lengths of time. The first signs of transgene-induced liver alterations could be monitored by the activation of the marker enzyme gamma-glutamyltranspeptidase 30 days after the start of the induction program. After 90 days hepatocellular carcinomas were already detectable. Thus, CRP-Tag mice constitute an excellent system to analyse the sequential events that take place during liver carcinogenesis.	IST RIC BIOL MOLEC,DEPT GENET,I-00040 POMEZIA,ITALY; EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Ciliberto, Gennaro/J-4131-2017	Ciliberto, Gennaro/0000-0003-2851-8605				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ARCONE R, 1988, NUCLEIC ACIDS RES, V16, P3195, DOI 10.1093/nar/16.8.3195; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; CILIBERTO G, 1987, EMBO J, V6, P4017, DOI 10.1002/j.1460-2075.1987.tb02745.x; CILIBERTO G, 1987, NUCLEIC ACIDS RES, V15, P5859; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; GANTER U, 1989, EMBO J, V8, P3733; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HELD WA, 1989, EMBO J, V8, P183, DOI 10.1002/j.1460-2075.1989.tb03363.x; HOGAN B, 1986, MANIPULATION MOUSE E; KLEIN G, 1983, CELL, V32, P311, DOI 10.1016/0092-8674(83)90449-X; MAJELLO B, 1990, EMBO J, V9, P457, DOI 10.1002/j.1460-2075.1990.tb08131.x; MESSING A, 1985, NATURE, V316, P461, DOI 10.1038/316461a0; NOWELL PC, 1986, CANCER RES, V46, P2203; OGAWA K, 1980, CANCER RES, V40, P725; RUTENBURG AM, 1969, J HISTOCHEM CYTOCHEM, V17, P517, DOI 10.1177/17.8.517; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SANDGREN EP, 1989, ONCOGENE, V4, P715; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; TONIATTI C, 1990, MOL BIOL MED, V7, P199; TOOZE J, 1990, DNA TUMOR VIRUSES; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	22	19	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					87	93						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423999				2022-12-28	WOS:A1993KN00500010
J	Tornell, J; Farzad, S; EspanderJansson, A; Matejka, G; Isaksson, O; Rymo, L				Tornell, J; Farzad, S; EspanderJansson, A; Matejka, G; Isaksson, O; Rymo, L			Expression of Epstein-Barr nuclear antigen 2 in kidney tubule cells induces tumors in transgenic mice	ONCOGENE			English	Article						Epstein-Barr virus; EBNA(2); transgenic mice; renal cancer	LYMPHOEPITHELIOMA-LIKE CARCINOMA; FACTOR-II GENE; HODGKINS-DISEASE; LYMPHOMA-CELLS; VIRAL GENOME; WILMS-TUMOR; VIRUS; DNA; PROTEIN; RNA	The effect of EBNA2 in normal cells in vivo has not as yet been explored. The experiments described here were initiated to follow the consequences of the expression of EBNA2 in different tissues in transgenic mice. EBNA2 transgenic strains were generated using a vector containing EBNA2 encoding sequences under the control of the simian virus 40 (SV40) early enhancer/promoter fused to the endogenous EBNA2 Wp promoter. Control mice carrying a transgene with the same sequence but lacking the EBV DNA part remained healthy during observation periods of up to 15 months. The SV-EBNA2 transgenic animals, however, over time developed abdominal masses that on necropsy showed to be due to kidney tumors. Histological examination revealed the presence of tumors with the morphology of kidney adenocarcinoma with a solid growth pattern. At the age of 20 weeks the kidneys of all animals investigated showed disseminated islands of tubular hyperplasia but no true malignant neoplasms. At about 50 weeks of age multiple foci of microscopic tubular adenocarcinomas were found in both kidneys. Eventually, tumors could be diagnosed in about 90% of the SV-EBNA2 transgenic mice. EBNA2-encoding RNA was expressed in both non-malignant kidney tissue and in tumors as shown by cDNA/PCR analysis. Immunoprecipitation and immunoblot analysis showed that the tumor cells contained a polypeptide of the same size as EBNA2 in B95-8 cells that reacted with a monoclonal anti-EBNA2 antibody. Immunohistochemistry demonstrated nuclear expression of EBNA2 in hyperplastic tubules and in tumor tissue.	GOTHENBURG UNIV,DEPT PHYSIOL & PHARMACOL,S-41345 GOTHENBURG,SWEDEN; GOTHENBURG UNIV,DEPT CLIN CHEM & TRANSFUS MED,S-41345 GOTHENBURG,SWEDEN; GOTHENBURG UNIV,DEPT CELL BIOL,S-41345 GOTHENBURG,SWEDEN; GOTHENBURG UNIV,DEPT INTERNAL MED,S-41345 GOTHENBURG,SWEDEN	University of Gothenburg; University of Gothenburg; University of Gothenburg; University of Gothenburg					NCI NIH HHS [CA 28380-08] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028380] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBOT SD, 1990, J VIROL, V64, P2126, DOI 10.1128/JVI.64.5.2126-2134.1990; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BEGIN LR, 1987, J SURG ONCOL, V36, P280, DOI 10.1002/jso.2930360413; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; CALENDER A, 1987, P NATL ACAD SCI USA, V84, P8060, DOI 10.1073/pnas.84.22.8060; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; CORDIER M, 1990, J VIROL, V64, P1002, DOI 10.1128/JVI.64.3.1002-1013.1990; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FINKE J, 1987, J VIROL, V61, P3870, DOI 10.1128/JVI.61.12.3870-3878.1987; GOSH D, 1990, J VIROL, V64, P1855; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; HIRSHFELD H, 1995, P 5 INT C HORM CANC, P140; HOGAN B, 1986, MANIPULATING MOUSE E; HUEN DS, 1993, J GEN VIROL, V74, P1381, DOI 10.1099/0022-1317-74-7-1381; HUFF JE, 1991, IARC SCI PUBL, V115, P229; KING W, 1980, J VIROL, V36, P506, DOI 10.1128/JVI.36.2.506-518.1980; KNUTSON JC, 1990, J VIROL, V64, P2530, DOI 10.1128/JVI.64.6.2530-2536.1990; Koike K, 1993, Nihon Rinsho, V51, P536; LABRECQUE LG, 1995, CANCER RES, V55, P39; LEE ES, 1995, NEW ENGL J MED, V332, P19, DOI 10.1056/NEJM199501053320104; Liebowitz David, 1993, P107; MCCLAIN KL, 1995, NEW ENGL J MED, V332, P12, DOI 10.1056/NEJM199501053320103; OFVERSTEDT LG, 1984, BIOCHIM BIOPHYS ACTA, V782, P120, DOI 10.1016/0167-4781(84)90014-9; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PITTALUGA S, 1992, MODERN PATHOL, V5, P661; RAABTRAUB N, 1991, J VIROL, V65, P7032, DOI 10.1128/JVI.65.12.7032-7036.1991; RICKSTEN A, 1987, J GEN VIROL, V68, P2407, DOI 10.1099/0022-1317-68-9-2407; RING CJA, 1994, J GEN VIROL, V75, P1, DOI 10.1099/0022-1317-75-1-1; RYMO L, 1985, P NATL ACAD SCI USA, V82, P3435, DOI 10.1073/pnas.82.10.3435; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAEFER BC, 1995, P NATL ACAD SCI USA, V92, P10565, DOI 10.1073/pnas.92.23.10565; SEARLE PF, 1994, J GEN VIROL, V75, P1125, DOI 10.1099/0022-1317-75-5-1125; SHIBATA D, 1992, AM J PATHOL, V140, P769; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; STADLER W, 1993, ANN ONCOL, V4, P451, DOI 10.1093/oxfordjournals.annonc.a058550; SU IJ, 1991, BLOOD, V77, P799; WANG F, 1987, P NATL ACAD SCI USA, V84, P3452, DOI 10.1073/pnas.84.10.3452; WEISS LM, 1987, AM J PATHOL, V129, P86; Wilson J B, 1992, Curr Top Microbiol Immunol, V182, P375; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; Yamamura K, 1990, Gastroenterol Jpn, V25 Suppl 2, P49; ZIMBERSTROBL U, 1991, J VIROL, V65, P415, DOI 10.1128/JVI.65.1.415-423.1991	47	15	16	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1521	1528						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622868				2022-12-28	WOS:A1996UF07600016
J	Thick, J; Metcalfe, JA; Mak, YF; Beatty, D; Minegishi, M; Dyer, MJS; Lucas, G; Taylor, AMR				Thick, J; Metcalfe, JA; Mak, YF; Beatty, D; Minegishi, M; Dyer, MJS; Lucas, G; Taylor, AMR			Expression of either the TCL1 oncogene, or transcripts from its homologue MTCP1/c6.1B, in leukaemic and non-leukaemic T cells from ataxia telangiectasia patients	ONCOGENE			English	Article						ataxia telangiectasia; MTCP1; TCL1; leukaemia	CHRONIC LYMPHOCYTIC-LEUKEMIA; MOLECULAR ANALYSIS; CHAIN LOCUS; TRANSLOCATION; BREAKPOINT; GENE	Patients with the recessively inherited disorder ataxia telangiectasia (A-T) have a high level of specific chromosome translocations which can be easily observed in peripheral T cells and show a greatly increased predisposition to leukaemia/lymphoma, mainly of T cell origin, Some translocation cells proliferate into a large clone and may develop into T cell prolymphocytic leukaemia (T-PLL), By the time of diagnosis of T-PLL, the clone contains many more genetic changes in the form of additional translocations, T-PLL is also seen in non-A-T individuals where expression of either TCL1 (at 14q32) or the c6.1B/MTCP1 A1 transcript (at-Xq28) has been demonstrated in just a few instances, We show here, that expression of TCL1 occurs in leukaemic T cells from A-T patients with chromosome 14 rearrangements, Expression of TCL1 also occurs in the preleukaemic clone cells of A-T patients containing the primary translocation alone, Some expression of TCL1 could also be detected in randomly selected A-T patients without large cytogenetic clones and without any evidence of leukaemic change, We also show that expression of the B1 transcript from a second gene, MTCP1, occurred at a relatively high level only in two T-PLL tumours from A-T patients with t(X;14) translocations whereas the MTCP1/A1 transcript is much more widely expressed in both tumour and non tumour cells of A-T and non-A-T individuals.	UNIV BIRMINGHAM,SCH MED,INST CANC STUDIES,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND; UNIV CAPE TOWN,RED CROSS WAR MEM CHILDRENS HOSP,DEPT PAEDIAT & CHILD HLTH,RONDEBOSCH 7700,SOUTH AFRICA; TOHOKU UNIV,TB & CANC RES INST,DEPT PAEDIAT,SENDAI,MIYAGI 980,JAPAN; ROYAL CANC HOSP,CANC RES INST,SUTTON SM2 5NG,SURREY,ENGLAND; UNIV WALES COLL CARDIFF,DEPT HAEMATOL,CARDIFF CF4 4XN,S GLAM,WALES	University of Birmingham; University of Cape Town; Tohoku University; University of London; Institute of Cancer Research - UK; Cardiff University			Dyer, Martin/F-2691-2014	Dyer, Martin/0000-0002-5033-2236				BAER R, 1987, P NATL ACAD SCI USA, V84, P9069, DOI 10.1073/pnas.84.24.9069; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVEY MP, 1988, P NATL ACAD SCI USA, V85, P9287, DOI 10.1073/pnas.85.23.9287; FISCH P, 1993, ONCOGENE, V8, P3271; FU TB, 1994, CANCER RES, V54, P6297; GAW LM, 1987, EMBO J, V6, P2273; MADANI A, 1995, ONCOGENE, V10, P2259; MENGLEGAW L, 1988, P NATL ACAD SCI USA, V85, P9171, DOI 10.1073/pnas.85.23.9171; MINEGISHI M, 1991, LEUKEMIA, V5, P88; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RUSSO G, 1988, CELL, V53, P137, DOI 10.1016/0092-8674(88)90495-3; RUSSO G, 1989, P NATL ACAD SCI USA, V86, P602, DOI 10.1073/pnas.86.2.602; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SHERRINGTON PD, 1994, ONCOGENE, V9, P2377; SOULIER J, 1994, ONCOGENE, V9, P3565; Sparkes R.S., 1980, CANCER GENET CYTOGEN, V1, P329; STERN MH, 1993, ONCOGENE, V8, P2475; TAYLOR AMR, 1992, BRIT J CANCER, V66, P5, DOI 10.1038/bjc.1992.208; TAYLOR AMR, 1986, INT J CANCER, V37, P511, DOI 10.1002/ijc.2910370407; TAYLOR AMR, 1992, LEUKEMIA, V6, P961; TAYLOR AMR, 1982, ATAXIA TELANGIECTASI, P53; THICK J, 1994, LEUKEMIA, V8, P564; THICK J, 1992, GENE CHROMOSOME CANC, V5, P321, DOI 10.1002/gcc.2870050407; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; VIRGILIO L, 1993, P NATL ACAD SCI USA, V90, P9275, DOI 10.1073/pnas.90.20.9275	25	32	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					379	386						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570215				2022-12-28	WOS:A1996TR53800017
J	Zwerschke, W; Joswig, S; JansenDurr, P				Zwerschke, W; Joswig, S; JansenDurr, P			Identification of domains required for transcriptional activation and protein dimerization in the human papillomavirus type-16 E7 protein	ONCOGENE			English	Article						papillomavirus; transformation; E7; transcriptional activation; dimerization	ADENOVIRUS E1A; RETINOBLASTOMA PROTEIN; HUMAN KERATINOCYTES; DNA-SYNTHESIS; TRANSFORMATION; SEQUENCES; GENE; ONCOPROTEIN; BINDING; TRANSACTIVATION	To analyse the potential of the E7 oncogene of HPV-16 to activate transcription, we constructed hybrid proteins containing various portions of the HPV-16 E7 protein fused to the DNA binding region of the bacterial LexA repressor. We found that full length HPV-16 E7 is capable to mediate activation of two different reporter genes, which carry LexA binding sites in their promoters. In contrast, E7 from HPV-11, a low-risk type papillomavirus, was unable to activate transcription, when analysed in the same assay. Mutations in the transforming domains of HPV-16 E7 did not affect the ability of the protein to activate transcription, indicating that it represents a novel function of the oncoprotein, which is not sensitive to any known inactivating mutations. Analysis of E7 subdomains revealed that the N-terminal part of HPV-16 E7 retains the capacity to activate transcription. A second trans-activation domain is located in the C-terminal part of E7; however, in the context of the full length E7 protein this activity is blocked by an adjacent domain. These results reveal a second pathway for transcriptional activation by HPV-16 E7, independent of its interaction with pRB-E2F complexes. Using the E7-LexA hybrid proteins, it is shown that E7 can form homodimers and this property involves a zinc finger structure in the C-terminal part of the protein, partially overlapping with the domain that negatively regulates transcriptional activation by E7.	DEUTSCH KREBSFORSCHUNGSZENTRUM, FORSCH SCHWERPUNKT ANGEW TUMORVIROL, ABT 620, D-69120 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)			Jansen-Dürr, Pidder/ABG-2466-2020	Jansen-Dürr, Pidder/0000-0001-7771-3429; Zwerschke, Werner/0000-0003-1137-2953				ARROYO M, 1993, MOL CELL BIOL, V13, P6537, DOI 10.1128/MCB.13.10.6537; BANKS L, 1990, ONCOGENE, V5, P1383; BRENT R, 1984, NATURE, V312, P612, DOI 10.1038/312612a0; CICCOLINI F, 1994, ONCOGENE, V9, P2633; DEFEOJONES D, 1993, J VIROL, V67, P716, DOI 10.1128/JVI.67.2.716-725.1993; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIORE F, 1995, CELL CYCLE MATERIALS, P211; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; KAMENS J, 1991, NEW BIOL, V3, P1005; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MUNGER K, 1991, J VIROL, V65, P3943; MUNGER K, 1989, J VIROL, V63, P4417; PATRICK DR, 1994, J BIOL CHEM, V269, P6842; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; RAWLS JA, 1990, J VIROL, V64, P6121, DOI 10.1128/JVI.64.12.6121-6129.1990; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; SCHMITT A, 1994, J VIROL, V68, P7051, DOI 10.1128/JVI.68.11.7051-7059.1994; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; TOMMASINO M, 1993, ONCOGENE, V8, P195; WATANABE S, 1990, J VIROL, V64, P207, DOI 10.1128/JVI.64.1.207-214.1990; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245; ZURHAUSEN H, 1985, VIRUSES CANCER, P82	37	37	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	1996	12	1					213	220						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552395				2022-12-28	WOS:A1996TQ01400027
J	West, MJ; Sullivan, NF; Willis, AE				West, MJ; Sullivan, NF; Willis, AE			Translational upregulation of the c-myc oncogene in Bloom's syndrome cell lines	ONCOGENE			English	Article						c-myc; Bloom's syndrome; translation; eIF-4E; eIF-2 alpha	DNA LIGASE-I; 5' UNTRANSLATED REGION; HEAVY-CHAIN LOCUS; MESSENGER-RNA; MALIGNANT TRANSFORMATION; ERYTHROLEUKEMIA-CELLS; SYNDROME LYMPHOCYTES; SYNDROME FIBROBLASTS; INCREASED EXPRESSION; BURKITTS-LYMPHOMA	Previous studies have shown a constitutive increase in the levels of c-myc protein in cell lines derived from patients with the cancer-prone disorder Bloom's Syndrome (BS), We report here that this overexpression results from a specific increase in the translation of the c-myc mRNA and is not the result of either a chromosomal translocation involving the c-myc locus or an amplification of this gene, We also did not detect any increase in the stability of the c-myc protein or any significant increases in the levels of c-myc mRNA expressed in BS cells compared to control cell Lines, Overall, there is a 39-80% increase in the association of the c-myc mRNA with polysomes in BS cell lines, Since, in some cases, overexpression of the c-myc protein has been shown to increase levels of the translation initiation factors eIF-4E and eIF-2 alpha, which may themselves play a role in malignant conversion, we have also examined the levels of these proteins in BS cells and found them to be either comparable or lower than those in control cell lines, These data suggest that if c-myc does contribute to the cancer predisposition phenotype in BS then it does not appear to act via an eIF-4E and eIF-2 alpha mediated pathway.	UNIV LEICESTER, DEPT BIOCHEM, LEICESTER LE1 7RH, LEICS, ENGLAND; NUVENTURES LTD, NEWCASTLE UPON TYNE NE2 4HE, TYNE & WEAR, ENGLAND	University of Leicester				Willis, Anne/0000-0002-1470-8531; West, Michelle/0000-0002-9497-9365				BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERNHEIM A, 1981, CANCER GENET CYTOGEN, V3, P307, DOI 10.1016/0165-4608(81)90039-X; CHAGANTI RS, 1974, P NATL ACAD SCI USA, V71, P4508, DOI 10.1073/pnas.71.11.4508; CHAN JYH, 1988, J BIOL CHEM, V263, P18231; CHAN JYH, 1987, NATURE, V325, P357, DOI 10.1038/325357a0; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; DALLAFAVERA R, 1982, NATURE, V299, P61; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; GERMAN J, 1989, CLIN GENET, V35, P57; GERMAN J, 1994, P NATL ACAD SCI USA, V91, P6669, DOI 10.1073/pnas.91.14.6669; GERMAN J, 1977, AM J HUM GENET, V29, P553; GERMAN J, 1983, CHROMOSOME MUTATION; HANN SR, 1992, GENE DEV, V6, P1229, DOI 10.1101/gad.6.7.1229; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; ISHIZAKI K, 1981, MUTAT RES, V80, P213, DOI 10.1016/0027-5107(81)90189-5; KEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KREPINSKY AB, 1979, HUM GENET, V50, P151, DOI 10.1007/BF00390236; KURIHARA T, 1987, MUTAT RES, V184, P147, DOI 10.1016/0167-8817(87)90071-X; LANDERS JE, 1994, ONCOGENE, V9, P2745; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LAZARUS P, 1992, ONCOGENE, V7, P1037; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MCDANIEL LD, 1992, P NATL ACAD SCI USA, V89, P7968, DOI 10.1073/pnas.89.17.7968; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MIYAGI Y, 1995, CANCER LETT, V91, P247, DOI 10.1016/0304-3835(95)03737-H; MOORE JP, 1987, ONCOGENE RES, V2, P65; NERI A, 1988, P NATL ACAD SCI USA, V85, P2748, DOI 10.1073/pnas.85.8.2748; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROWE M, 1989, J VIROL, V63, P1031, DOI 10.1128/JVI.63.3.1031-1039.1989; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; SCHWAB M, 1986, MOL CELL BIOL, V6, P2752, DOI 10.1128/MCB.6.7.2752; SEABRIGH.M, 1971, LANCET, V2, P971; SHINDO H, 1993, ACTA NEUROPATHOL, V86, P345, DOI 10.1007/BF00369446; SHIRAMIZU B, 1991, BLOOD, V77, P1516; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; SULLIVAN NF, 1988, CURR TOP MICROBIOL, V141, P208; SULLIVAN NF, 1989, ONCOGENE, V4, P1509; SULLIVAN NF, 1989, ONCOGENE, V4, P1497; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; THEODORAKIS NG, 1988, J BIOL CHEM, V263, P14579; WARREN ST, 1981, P NATL ACAD SCI-BIOL, V78, P3133, DOI 10.1073/pnas.78.5.3133; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WATT R, 1983, P NATL ACAD SCI-BIOL, V80, P6307, DOI 10.1073/pnas.80.20.6307; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448; WEI YF, 1995, MOL CELL BIOL, V15, P3206; WILLIS AE, 1987, NATURE, V325, P355, DOI 10.1038/325355a0; WILLIS AE, 1987, P NATL ACAD SCI USA, V84, P8016, DOI 10.1073/pnas.84.22.8016; YANG SW, 1992, P NATL ACAD SCI USA, V89, P2227, DOI 10.1073/pnas.89.6.2227; ZECH L, 1976, INT J CANCER, V17, P47, DOI 10.1002/ijc.2910170108	61	31	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2515	2524						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545108				2022-12-28	WOS:A1995TP18800007
J	REID, RL; LINDHOLM, PF; MIRESKANDARI, A; DITTMER, J; BRADY, JN				REID, RL; LINDHOLM, PF; MIRESKANDARI, A; DITTMER, J; BRADY, JN			STABILIZATION OF WILD-TYPE P53 IN HUMAN T-LYMPHOCYTES TRANSFORMED BY HTLV-I	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; VIRUS TYPE-I; HUMAN PAPILLOMAVIRUS TYPE-16; CORD BLOOD-LYMPHOCYTES; MONOCLONAL-ANTIBODIES; LEUKEMIA LYMPHOMA; SV40-TRANSFORMED CELLS; ACTIVATING MUTATIONS; INCREASED EXPRESSION; MOLECULAR-CLONING	Adult T-cell leukemia/lymphoma is an aggressive malignancy associated with infection by the human T-lymphotropic virus type-I (HTLV-1). We now demonstrate that p53 expression is elevated in the HTLV-1-transformed T-lymphocyte lines C81, MT-2, MT-4 and HUT 102. In pulse-chase experiments, the p53 protein demonstrated a prolonged half-life of 2 to 8 h in HTLV-1-transformed cells compared with 0.5 to 1.0 h for wild-type p53 in primary human and murine fibroblasts, or human peripheral blood lymphocytes. In cell lines C81 and HUT 102, which exhibited the longest p53 protein half-life, the wild-type-related PAb1620 epitope was detected at reduced levels. The PAb240 mutant-related p53 epitope was not detected in any of the transformed cell lines. By direct sequence analysis of RT-PCR products, the entire p53 cDNA coding sequence was determined to be wild-type in all four cell lines. Stabilization of wild-type p53 may represent its functional inactivation and contribute to lymphocyte transformation by HTLV-I.	NCI,MOLEC VIROL LAB,BLDG 41,ROOM B602,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Dittmer, Juergen/G-1160-2011					BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHIECOBIANCHI L, 1988, LEUKEMIA, V2, pS223; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KOEFFLER HP, 1986, P NATL ACAD SCI USA, V83, P4035, DOI 10.1073/pnas.83.11.4035; KONDO T, 1987, LANCET, V2, P159; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LUBBERT M, 1989, ONCOGENE, V4, P643; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MARUYAMA K, 1990, CANCER RES, V50, pS5697; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOSNER J, 1992, ONCOGENE, V7, P661; NAGAI H, 1991, JPN J CANCER RES, V82, P1421, DOI 10.1111/j.1349-7006.1991.tb01815.x; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; ROWLEY JD, 1984, HUMAN T CELL LEUKEMI, P85; SAKASHITA A, 1992, BLOOD, V79, P477; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SANADA I, 1985, BLOOD, V65, P649; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEIKI M, 1982, P NATL ACAD SCI-BIOL, V79, P6899, DOI 10.1073/pnas.79.22.6899; SEIKI M, 1984, NATURE, V309, P640, DOI 10.1038/309640a0; SOUSSI T, 1990, ONCOGENE, V5, P945; SQUIRES J, 1988, P AM ASSOC CANC RES, V29, P454; SUGITO S, 1991, INT J CANCER, V49, P880, DOI 10.1002/ijc.2910490614; TOKUDOME S, 1989, CANCER RES, V49, P226; UESHIMA Y, 1981, BLOOD, V58, P420; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; YEARGIN J, 1992, LEUKEMIA, V6, pS85; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	73	97	98	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3029	3036						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414503				2022-12-28	WOS:A1993MC09300017
J	MIN, SY; MASCARENHAS, NT; TAPAROWSKY, EJ				MIN, SY; MASCARENHAS, NT; TAPAROWSKY, EJ			FUNCTIONAL-ANALYSIS OF THE CARBOXY-TERMINAL TRANSFORMING REGION OF V-MYC - BINDING TO MAX IS NECESSARY, BUT NOT SUFFICIENT, FOR CELLULAR-TRANSFORMATION	ONCOGENE			English	Article							AVIAN MYELOCYTOMATOSIS VIRUS; HUMAN C-MYC; LARGE-T-ANTIGEN; DNA-BINDING; LEUCINE ZIPPER; N-MYC; TRANSCRIPTIONAL ACTIVATION; MULTISTEP TRANSFORMATION; ERYTHROLEUKEMIA-CELLS; DIMERIZATION DOMAINS	To understand the mechanism by which the Myc protein contributes to cell growth and development, our laboratory is studying functions of the avian myelocytomatosis virus 29 (MC29) Gag-Myc protein (v-Myc) in the mouse fibroblast cell line C3H10T1/2. Previously, we identified two specific regions in v-Myc which are required for co-transformation with activated H-ras. One maps to the amino-terminal portion of v-Myc (amino acids 1-137) and has the potential to activate transcription of a basal promoter. The second region spans the carboxy-terminal region of v-Myc (amino acids 244-410), contains a basic/helix-loop-helix/leucine zipper motif and specifies the nuclear location of the protein. In this study, we have generated a series of deletion mutations within the MC29 gag-myc gene to define precisely the carboxy-terminal transforming region using the co-transformation of C3H10T1/2 celts as an assay. v-Myc proteins encoded by selected deletion mutations were also examined for their intracellular location, the ability to interact with the Max protein and the potential to bind specifically to DNA. Our results demonstrate that integrity of both the basic/helix-loop-helix and the leucine zipper motifs of v-Myc is required for co-transforming activity, but that the major nuclear localization signal sequence of v-Myc can be deleted without compromising the ability of v-Myc to cooperate with activated H-Ras p21 to transform C3H10T1/2 celts. In addition, while the binding of v-Myc to Max is necessary for ras/myc co-transformation, it is not sufficient, and also requires the integrity of Myc sequences specifying site-specific DNA binding.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Min, Soyoung/0000-0001-7511-1520	NATIONAL CANCER INSTITUTE [R01CA042835, R23CA042835] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42835] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMS HD, 1982, CELL, V29, P427, DOI 10.1016/0092-8674(82)90159-3; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLACKWOOD EM, 1992, GENE DEV, V6, P166; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DANG CV, 1989, J BIOL CHEM, V264, P18019; DAVENPORT EA, 1992, EXP CELL RES, V202, P532, DOI 10.1016/0014-4827(92)90108-K; DAVENPORT EA, 1988, ANTICANCER RES, V8, P959; DAVIS LJ, 1993, ONCOGENE, V8, P125; DEAN M, 1986, J BIOL CHEM, V261, P9161; DEPINHO R, 1987, J CELL BIOCHEM, V33, P257, DOI 10.1002/jcb.240330404; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FARINA SF, 1992, J VIROL, V66, P2698, DOI 10.1128/JVI.66.5.2698-2708.1992; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HANN SR, 1985, NATURE, V310, P592; HEANEY ML, 1986, J VIROL, V60, P167, DOI 10.1128/JVI.60.1.167-176.1986; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERKHOFF E, 1991, ONCOGENE, V6, P93; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KITCHENER G, 1980, P NATL ACAD SCI-BIOL, V77, P1637, DOI 10.1073/pnas.77.3.1637; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MIN SY, 1992, ONCOGENE, V7, P1531; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; REDDY CD, 1992, ONCOGENE, V7, P2085; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; Sambrook J, 1989, MOL CLONING LABORATO; SHEINESS D, 1978, J VIROL, V28, P600, DOI 10.1128/JVI.28.2.600-610.1978; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TAPAROWSKY EJ, 1987, CANCER RES, V47, P4125; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; VENNSTROM B, 1982, J VIROL, V42, P773, DOI 10.1128/JVI.42.3.773-779.1982; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P2146, DOI 10.1073/pnas.80.8.2146; WEINBERG RA, 1989, ONCOGENES MOL ORIGIN, P307; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028	57	12	12	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2691	2701						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378081				2022-12-28	WOS:A1993LX34300010
J	LEVY, LS; LOBELLERICH, PA; OVERBAUGH, J				LEVY, LS; LOBELLERICH, PA; OVERBAUGH, J			FLVI-2, A TARGET OF RETROVIRAL INSERTIONAL MUTAGENESIS IN FELINE THYMIC LYMPHOSARCOMAS, ENCODES BMI-1	ONCOGENE			English	Article							MYC TRANSGENIC MICE; LEUKEMIA-VIRUS; GENE; TRANSDUCTION; SEQUENCES; PROTEINS; ONCOGENE; LYMPHOMA; PROVIRUS; TUMORS	LC-FeLV is a myc-containing strain of feline leukemia virus which induces thymic lymphosarcoma in the domestic cat with short latency. A locus in feline DNA, termed flvi-2, is commonly interrupted in naturally occurring and experimentally induced thymic lymphosarcomas containing LC-FeLV; thus, interruption of a gene encoded by flvi-2 may cooperate with the myc oncogene in the induction of T-cell tumors by LC-FeLV. Clones homologous to flvi-2 have been isolated from a normal human thymus cDNA library. Nucleotide sequence analysis of the cDNA clones demonstrates that flvi-2 encodes bmi-1, a gene previously identified as a target for MoMuLV integration and as a myc-collaborator in retrovirally-induced B-cell lymphomas in Emu-myc transgenic mice. In feline thymic lymphomas, retroviral integrations occur downstream of the gene, and result in enhanced expression of a bmi-1 transcript of normal size. These findings demonstrate the interruption of bmi-1 in natural as well as experimentally induced tumors, implicate the activation of bmi-1 in the induction of T-cell as well as B-cell lymphoma, and support the premise that bmi-1 functions as a myc collaborator.	UNIV WASHINGTON,DEPT MICROBIOL SC-42,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	LEVY, LS (corresponding author), TULANE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,1430 TULANE AVE,NEW ORLEANS,LA 70112, USA.				NATIONAL CANCER INSTITUTE [R01CA048801, R01CA051080] Funding Source: NIH RePORTER; NCI NIH HHS [CA-48801, CA-51080] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BONHAM L, 1987, J VIROL, V61, P3072, DOI 10.1128/JVI.61.10.3072-3081.1987; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; HARDY WD, 1990, RETROVIRUS BIOL HUMA, P33; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; LEVY LS, 1988, J VIROL, V62, P4770, DOI 10.1128/JVI.62.12.4770-4773.1988; LEVY LS, 1992, J VIROL, V66, P2885, DOI 10.1128/JVI.66.5.2885-2892.1992; LEVY LS, 1984, NATURE, V308, P853, DOI 10.1038/308853a0; MATTHEWS EA, 1989, INT J CANCER, V43, P1120, DOI 10.1002/ijc.2910430627; MULLINS JI, 1984, NATURE, V308, P856, DOI 10.1038/308856a0; NEIL JC, 1984, NATURE, V308, P814, DOI 10.1038/308814a0; ONIONS D, 1987, INT J CANCER, V40, P40, DOI 10.1002/ijc.2910400108; OVERBAUGH J, 1992, VIROLOGY, V188, P558, DOI 10.1016/0042-6822(92)90510-V; PATANJALI SR, 1991, P NATL ACAD SCI USA, V88, P1943, DOI 10.1073/pnas.88.5.1943; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0	25	39	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1833	1838						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8390036				2022-12-28	WOS:A1993LG68200015
J	MADDEN, SL; COOK, DM; RAUSCHER, FJ				MADDEN, SL; COOK, DM; RAUSCHER, FJ			A STRUCTURE-FUNCTION ANALYSIS OF TRANSCRIPTIONAL REPRESSION MEDIATED BY THE WT1, WILMS-TUMOR SUPPRESSOR PROTEIN	ONCOGENE			English	Article							RETINOBLASTOMA-SUSCEPTIBILITY GENE; ADENOVIRUS E1A PROTEIN; ZINC FINGER PROTEIN; MAMMALIAN-CELLS; EXPRESSION; ACTIVATION; PRODUCT; BINDING; DOMAINS; GROWTH	The chromosome 11p13 Wilms' tumor locus (wt1) encodes a zinc finger-containing transcription factor (WT1). WT1 binds to the consensus sequence (5'-GCGGGGGCG3') and represses transcription when bound to this site in vivo. The mechanism of repression is not yet defined. To investigate the mechanisms of transcriptional repression and map the domains of WT1 responsible, we constructed hybrid proteins between the yeast GAL4 1-147 DNA binding domain and WT1. Fusion of a 298 amino acid glutamine-proline-rich N-terminal segment of WT1 to the GAL4 DNA binding domain created a potent transcriptional repressor. The use of N- and C-terminal truncations of this segment demonstrated that as few as 96 amino acids were required for active repression by GAL4-WT1 hybrid proteins in NIH3T3 fibroblasts. However, the truncated GAL4-WT1 fusion proteins functioned poorly as repressors in embryonic kidney-derived 293 cells, suggesting cell type-specific requirements for transcriptional repression. Site-directed mutagenesis of the WT1 repression domain revealed that deletion of homopolymeric proline and glycine regions, as well as single amino acid changes, partially inactivated the repression function. Single repressor binding sites placed upstream of the transcription start site conferred WT1-mediated repression to a heterologous promoter, whereas multiple sites resulted in additive (non-synergistic) increases in transcriptional repression. Significant repression of transcription was observed when binding sites were placed 760 base pairs upstream or 1000 base pairs downstream relative to the site of transcription initiation. We conclude that the transcriptional repression function of WT1 is contained in the N-terminal, non-DNA binding domain of the protein and that repression can be functionally transferred to a heterologous DNA binding domain.	WISTAR INST ANAT & BIOL,3601 SPRUCE ST,PHILADELPHIA,PA 19104	The Wistar Institute					NATIONAL CANCER INSTITUTE [P01CA047983, P01CA052009, P30CA010815] Funding Source: NIH RePORTER; NCI NIH HHS [CA10815, CA47983, CA52009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABER DA, 1992, ADV CANCER RES, V59, P41, DOI 10.1016/S0065-230X(08)60302-4; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; JAYNES JB, 1988, NATURE, V336, P744, DOI 10.1038/336744a0; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAHESWARAN S, 1993, IN PRESS P NATL ACAD; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MONTENARH M, 1992, ONCOGENE, V7, P1673; MORRIS JF, 1991, ONCOGENE, V6, P2339; NEVINS JR, 1992, SCIENCE, V258, P424; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SHARMA PM, 1992, CANCER RES, V52, P6407; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SPAETE RR, 1985, J VIROL, V56, P136; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	46	118	122	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1713	1720						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510918				2022-12-28	WOS:A1993LG68200001
J	MICHELIN, S; DAYAGROSJEAN, L; SUREAU, F; SAID, S; SARASIN, A; SUAREZ, HG				MICHELIN, S; DAYAGROSJEAN, L; SUREAU, F; SAID, S; SARASIN, A; SUAREZ, HG			CHARACTERIZATION OF A C-MET PROTOONCOGENE ACTIVATED IN HUMAN XERODERMA-PIGMENTOSUM CELLS AFTER TREATMENT WITH N-METHYL-N'-NITRO-N-NITROSOGUANIDINE (MNNG)	ONCOGENE			English	Article							TYROSINE KINASE FAMILY; DNA; GENE; LINE; TRANSFORMATION; REARRANGEMENTS; ABNORMALITIES; RECEPTOR; PRODUCT; REPEATS	Human xeroderma pigmentosum (XP) fibroblasts were transformed with N-methyl-N'-nitro-N-nitrosoguanidine (MNNG). The transformed cells, called ASKMN, were immortalized, grew in agar and were tumorigenic in nude mice. A trp-met oncogene was identified in ASKMN cells, after transfection of high molecular weight DNA on 3T3 mouse cells. The ASKMN cells and the 3T3 transformants expressed the 5-kb mRNA transcribed by the tpr-met oncogene and its p65tpr-met phosphorylated protein. Using the polymerase chain reaction (PCR) technique followed by hybridization with synthetic probes or direct sequencing, we showed that the sequence encompassing the 'rearranged breakpoint' was the same as that previously described in the tpr-met oncogene present in the MNNG-HOS cells. However, G to A transitions found in the tpr or met sequences of the ASKMN oncogene, probably the result of the specific mutagenic activity of MNNG, were absent in the MNNG-HOS gene. Apparently normal chromosomes 1 and 7 were identified in the ASKMN cell metaphases using several cytogenetic techniques.	INST RECH SCI CANC,GENET MOLEC LAB,CNRS,UPR 42,BOITE POSTALE 8,F-94801 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS)								ALLARD MW, 1991, BIOTECHNIQUES, V10, P24; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BERNHEIM A, 1981, HUM GENET, V57, P432, DOI 10.1007/BF00281699; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BROOKES P, 1964, NATURE, V202, P781, DOI 10.1038/202781a0; CARIELLO NF, 1990, MUTAT RES, V231, P165, DOI 10.1016/0027-5107(90)90023-W; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; Deininger PL, 1989, MOBILE DNA, P619; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRECO A, 1992, ONCOGENE, V7, P237; HANAWALT PC, 1986, TRENDS GENET, V2, P124, DOI 10.1016/0168-9525(86)90201-5; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HYRIEN O, 1987, EMBO J, V6, P2401, DOI 10.1002/j.1460-2075.1987.tb02518.x; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; KRAEMER KH, 1987, ARCH DERMATOL, V123, P241, DOI 10.1001/archderm.123.2.241; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MICHELIN S, 1991, EXP CELL RES, V196, P314, DOI 10.1016/0014-4827(91)90266-W; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; NALDINI L, 1991, ONCOGENE, V6, P501; NARDEUX PC, 1987, BIOCHEM BIOPH RES CO, V146, P395, DOI 10.1016/0006-291X(87)90542-0; PARK M, 1986, COLD SPRING HARB SYM, V51, P967, DOI 10.1101/SQB.1986.051.01.110; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; RHIM JS, 1975, NATURE, V256, P751, DOI 10.1038/256751a0; STARY A, 1992, NUCLEIC ACIDS RES, V20, P4269, DOI 10.1093/nar/20.16.4269; STOPPALYONNET D, 1990, P NATL ACAD SCI USA, V87, P1551, DOI 10.1073/pnas.87.4.1551; SUAREZ H, 1988, BIOCHIMIE, V70, P969, DOI 10.1016/0300-9084(88)90239-8; SUAREZ HG, 1989, ANTICANCER RES, V9, P1331; SUAREZ HG, 1991, ONCOGENE, V6, P677; TESTA JR, 1990, ONCOGENE, V5, P1565; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1973; YOSIDA TH, 1983, CANCER GENET CYTOGEN, V8, P153, DOI 10.1016/0165-4608(83)90047-X; YUNIS JJ, 1978, CYTOGENET CELL GENET, V22, P679, DOI 10.1159/000131052	36	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1983	1991						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510940				2022-12-28	WOS:A1993LG68200031
J	SHACKLEFORD, GM; SHIVAKUMAR, S; SHIUE, L; MASON, J; KENYON, C; VARMUS, HE				SHACKLEFORD, GM; SHIVAKUMAR, S; SHIUE, L; MASON, J; KENYON, C; VARMUS, HE			2 WNT GENES IN CAENORHABDITIS-ELEGANS	ONCOGENE			English	Article							PROTO-ONCOGENE INT-1; SEGMENT-POLARITY GENE; XENOPUS EMBRYOS; C-ELEGANS; DROSOPHILA HOMOLOG; MESSENGER-RNA; SEQUENCE; EXPRESSION; PROTOONCOGENE; WINGLESS	wnt genes encode secretory glycoproteins that have been implicated in growth control and development in mice, frogs and insects. In this report we examine properties of two wnt genes recently identified in the nematode Caenorhabditis elegans. The first gene, Ce-wnt-1, was previously identified by a polymerase chain reaction-based screen of genomic DNA, and the second, Ce-wnt-2, was fortuitously encountered in a survey of clones in a cDNA library by the Caenorhabditis Genome Project. Full-length or nearly full-length cDNAs representing both mRNAs encode proteins that are similar in length, sequence and functional domains to other Wnt proteins. Primary products of 372 and 362 amino acids begin with a hydrophobic signal peptide, include two potential N-linked glycosylation sites and contain the 22 cysteine residues conserved throughout the wnt family. In contrast to mammalian and insect wnt genes with four or five exons and conserved intron-exon boundaries, Ce-wnt-1 has nine coding exons; only one of the eight identified introns interrupts the coding sequence at a position homologous to an intron position in other wnt genes. The major transcript derived from Ce-wnt-1 is 1.4 kb in length, and the 22 nucleotides at its 5' end are added by a trans-splicing mechanism. Ce-wnt-2 is also expressed via a single major transcript, 1.5 kb in length. Both RNAs are detectable in all larval forms and adults, but they are most abundant at the embryonic stage. Ce-wnt-1 is localized to the left arm of chromosome II and Ce-wnt-2 maps to a cluster of genes on chromosome IV.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Mason, John O/A-1926-2010	Mason, John O/0000-0002-0489-2400				BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BLUMENTHAL T, 1988, TRENDS GENET, V4, P305, DOI 10.1016/0168-9525(88)90107-2; BRENNER S, 1974, GENETICS, V77, P71; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DIBB NJ, 1989, J MOL BIOL, V205, P603, DOI 10.1016/0022-2836(89)90229-5; EISENBERG LM, 1992, IN PRESS DEV BIOL; EMMONS SW, 1979, P NATL ACAD SCI USA, V76, P1333, DOI 10.1073/pnas.76.3.1333; FIELDS C, 1990, NUCLEIC ACIDS RES, V18, P1509, DOI 10.1093/nar/18.6.1509; FROHMAN M, 1992, IN PRESS METHODS ENZ; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; KAMB A, 1989, P NATL ACAD SCI USA, V86, P4372, DOI 10.1073/pnas.86.12.4372; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KRAUSE M, 1984, MOL BIOL CYTOSKELETO; Maniatis T., 1982, MOL CLONING; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; ROSENQUIST TA, 1988, GENE DEV, V2, P606, DOI 10.1101/gad.2.5.606; RUSSELL J, 1992, UNPUB DEVELOPMENT; SCHALLER D, 1990, NUCLEIC ACIDS RES, V18, P2033, DOI 10.1093/nar/18.8.2033; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; UZVOLGYI E, 1988, P NATL ACAD SCI USA, V85, P3034, DOI 10.1073/pnas.85.9.3034; VANOOYEN A, 1984, CELL, V39, P233, DOI 10.1016/0092-8674(84)90209-5; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WTERSTON R, 1992, NAT GENET, V1, P114	35	26	51	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1857	1864						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510930				2022-12-28	WOS:A1993LG68200018
J	OTTERSON, GA; KRATZKE, RA; LIN, AY; JOHNSTON, PG; KAYE, FJ				OTTERSON, GA; KRATZKE, RA; LIN, AY; JOHNSTON, PG; KAYE, FJ			ALTERNATIVE SPLICING OF THE RBP1 GENE CLUSTERS IN AN INTERNAL EXON THAT ENCODES POTENTIAL PHOSPHORYLATION SITES	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; CELL-CYCLE; TRANSCRIPTION FACTOR; PRODUCT; PROTEINS; BINDING; EXPRESSION; CARCINOMA; COMPLEX; IDENTIFICATION	We have isolated cDNA and genomic clones for the human retinoblastoma binding protein 1 (RBP1) gene, and have identified alternative splicing of RBP1 clustered within a 207-nucleotide internal exon. Three of the predicted RPB1 peptides share amino-terminal and carboxy-terminal domains, while a fourth species encodes a distinct carboxy-terminal domain. Functional analysis of these peptides demonstrated that they are capable of precipitating retinoblastoma (RB) protein in vitro from K562 cell lysates, but cannot bind to mutant RB protein. However, each of the RBP1 peptides differed within an internal exon that contains potential casein kinase II and p34cdc2 phosphorylation sites. Immunoblot analysis using polyclonal alpha-RBP1 antiserum revealed that the RBP1 protein is expressed in a wide range of cell lines of differing histologic type and migrates on sodium dodecyl sulfate-polyacrylamide gel electrophoresis predominantly as a 200-kDa protein. Immunohistochemical analysis using the alpha-RBP1 antiserum demonstrated a distinct nuclear staining pattern that was eliminated when the antiserum was preabsorbed with RBP1 peptide. The RBP1 gene encodes a widely expressed 200-kDa nuclear protein and undergoes alternative splicing that predicts a family of RB-binding peptides.	USN HOSP,NCI,NAVY ONCOL BRANCH,BLDG 8,RM 5101,BETHESDA,MD 20889; UNIV HLTH SCI,UNIFORMED SERV,BETHESDA,MD 20889	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy			kaye, frederic/E-2437-2011					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; Battey, 1986, BASIC METHODS MOL BI; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; CARNEY DN, 1985, CANCER RES, V45, P2913; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KRATZKE RA, 1992, J BIOL CHEM, V267, P25998; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; NEVINS JR, 1991, TRENDS BIOCHEM SCI, V16, P435, DOI 10.1016/0968-0004(91)90171-Q; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YOKOTA J, 1988, ONCOGENE, V3, P471	38	21	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					949	957						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455946				2022-12-28	WOS:A1993KT22000017
J	BOYER, PL; COLMENARES, C; STAVNEZER, E; HUGHES, SH				BOYER, PL; COLMENARES, C; STAVNEZER, E; HUGHES, SH			SEQUENCE AND BIOLOGICAL-ACTIVITY OF CHICKEN SNON CDNA CLONES	ONCOGENE			English	Article							V-SKI ONCOGENE; RETROVIRUS VECTORS; CELLS; GENE; VIRUSES; MUSCLE	cDNA clones of the ski-related gene, sno, were isolated from a chicken cDNA library and sequenced. In contrast to the human system, from which two forms of sno cDNAs have been isolated, we obtained only one type of chicken sno cDNA, that encoding snoN. The coding region for chicken snoN was inserted into the retroviral vectors RCAS(A) and RCASBP(A) and introduced into chicken embryo fibroblasts (CEFs) or quail embryo cells (QECs). Like the various forms of ski, snoN appears to be localized in the nucleus, and high levels of snoN expression cause transformation of CEFs and muscle differentiation of QECs. In contrast to ski however, low-level expression of snoN cannot induce transformation, and is only weakly myogenic.	NCI,FREDERICK CANC RES & DEV CTR,ABL,BASIC RES PROGRAM,POB B,FREDERICK,MD 21702; UNIV CINCINNATI,MED CTR,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University System of Ohio; University of Cincinnati					NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARKAS AE, 1986, VIROLOGY, V151, P131, DOI 10.1016/0042-6822(86)90111-X; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; Maniatis T., 1982, MOL CLONING; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; SUTRAVE P, 1989, MOL CELL BIOL, V9, P4046, DOI 10.1128/MCB.9.9.4046; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462	13	88	93	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					457	466						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426750				2022-12-28	WOS:A1993KN00600025
J	SeppLorenzino, L; Eberhard, I; Ma, ZP; Cho, C; Serve, H; Liu, F; Rosen, N; Lupu, R				SeppLorenzino, L; Eberhard, I; Ma, ZP; Cho, C; Serve, H; Liu, F; Rosen, N; Lupu, R			Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells	ONCOGENE			English	Article						signaling; erbB receptors; heregulin	GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE-C-GAMMA; TYROSINE KINASE; CARCINOMA-CELLS; EGF RECEPTOR; TUMOR-CELLS; ACTIVATING FACTOR; ONCOGENE PRODUCT; NEU RECEPTOR; PROTEIN	Heregulins (HRGs) induce tyrosine phosphorylation of several members of the erb-B family of receptors. Although originally isolated as the ligands for p185(c-erbB-2), recent evidence suggests that other receptors of the erb B family, including p180(erbB-3) and p180(erbB-4), are their true cognate receptors. Stimulation of MDA MB-453 cells with HRG beta 2 resulted in the tyrosine phosphorylation of p185(c-erbB-2) and p180(erbB-4) in a time- and dose-dependent fashion, This event was accompanied by the formation of multimeric complexes between the activated receptors and SH2-containing proteins. Ligand caused p120-rasGTPase activating protein (GAP), SHC and the p85 subunit of phosphatidylinositol-3'-kinase (PI3K) to be associated with both p185(c-erbB-2) and p180(erbB-4). In addition, tyrosine phosphorylation of p85-PI3K and SHC, but not of GAP or of its associated p62 and p190 proteins, was also detected, HRG also induced the association of GRB2 with tyrosine phosphorylated p185(c-erbB-2)) p180(crbB-4) and SHC. Activation of mitogen-activated protein kinase (MAPK) (> 30-fold over untreated controls) was observed upon receptor(s) activation, as it was the induction of the immediate early gene c-fos (> 200-fold). These observations suggest that p21(ras) activation plays a role in the HRG pathway. Furthermore, comparative anlaysis of the binding of p85-PI3K to 185(c-crbB-2) and p180(crbB-4), revealed a preferential association with activated p180(erbB-4). These findings might suggest a model of HRG action in which the relative expression of the various erb-B family members and the partitioning of signal transduction molecules between each type of receptor might determine the nature of the signal elicited by the ligand and the biological response attained.	MEM SLOAN KETTERING CANC CTR, PROGRAM MOLEC BIOL, PROGRAM CELL BIOLOG & GENET, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, PROGRAM MOLEC BIOL, DEPT MED, NEW YORK, NY 10021 USA; GEORGETOWN UNIV, VINCENT T LOMBARDI CANC RES CTR, WASHINGTON, DC 20007 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Georgetown University			Rosen, Neal/ABF-2677-2020		NCI NIH HHS [R01 CA 55406-01, R01 CA 58706-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058706, R01CA055406] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1988, MOL REPROD DEV; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; DAVIS JG, 1991, BIOCHEM BIOPH RES CO, V179, P1536, DOI 10.1016/0006-291X(91)91747-Z; DECORTE V, 1994, J CELL SCI, V107, P405; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; DOUGALL WC, 1994, ONCOGENE, V9, P2109; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUANG SS, 1992, J BIOL CHEM, V267, P11508; JALLAL B, 1992, J BIOL CHEM, V267, P4357; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KITA YA, 1994, FEBS LETT, V349, P139, DOI 10.1016/0014-5793(94)00644-X; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Lehtola L, 1989, GROWTH FACTORS, V1, DOI 10.3109/08977198909000256; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LIN YZJ, 1991, ONCOGENE, V6, P639; LUPU R, 1995, SEMIN CANCER BIOL, V6, P135, DOI 10.1006/scbi.1995.0016; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; LUPU R, 1993, BREAST CANCER RES TR, V27, P83, DOI 10.1007/BF00683195; LUPU R, 1991, INT S PRINC TAK CANC, V22, P49; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; NISHIBE S, 1990, P NATL ACAD SCI USA, V87, P424, DOI 10.1073/pnas.87.1.424; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NORMANNO N, 1994, BREAST CANCER RES TR, V29, P11, DOI 10.1007/BF00666178; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; PANDIELLA A, 1989, ONCOGENE, V4, P1299; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1992, J BIOL CHEM, V267, P12266; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; RAJKUMAR T, 1994, BREAST CANCER RES TR, V29, P3, DOI 10.1007/BF00666177; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SANGHERA JS, 1990, FEBS LETT, V273, P223, DOI 10.1016/0014-5793(90)81090-B; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SCOTT GK, 1993, MOL CELL BIOL, V13, P2247, DOI 10.1128/MCB.13.4.2247; SEGATTO O, 1993, ONCOGENE, V8, P2105; SEGATTO O, 1992, ONCOGENE, V7, P1339; SEPPLORENZINO L, 1994, CELL GROWTH DIFFER, V5, P1077; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; STAEBLER A, 1994, BREAST CANCER RES TR, V31, P175, DOI 10.1007/BF00666151; TANG C, 1994, P AM ASSOC CANC RES, V35, pA214; TAVERNA D, 1991, CELL GROWTH DIFFER, V2, P145; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANDEVIJVER MJ, 1991, BIOCHIM BIOPHYS ACTA, V1072, P33, DOI 10.1016/0304-419X(91)90005-6; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	74	66	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	1996	12	8					1679	1687						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622888				2022-12-28	WOS:A1996UG45800010
J	Kiefer, P; Mathieu, M; Mason, I; Dickson, C				Kiefer, P; Mathieu, M; Mason, I; Dickson, C			Secretion and mitogenic activity of zebrafish FGF3 reveal intermediate properties relative to mouse and Xenopus homologues	ONCOGENE			English	Article						zebrafish FGF3; fibroblast growth factor; mitogenesis; protein chimeras	FIBROBLAST GROWTH-FACTOR; LIGAND-BINDING SPECIFICITY; PROTO-ONCOGENE INT-2; FACTOR RECEPTORS; FACTOR FAMILY; DEVELOPMENTAL EXPRESSION; CLONING; CELLS; PRODUCT; LAEVIS	Zebrafish (Brachyodanio rerio) Fgf-3 cDNAs expressed in COS-1 cells give rise to a heterogeneous set of secreted proteins with relative molecular masses in the range of 29-30.5 kDa. These proteins associate strongly with the extracellular matrix but are quantitatively released into the culture medium in the presence of heparin (5 mu g/ml). Extracellular zebrafish FGF3 (ZFGF3) also contains a smaller sized component that appears to result from an amino-terminal proteolytic cleavage. These properties are similar to those described for Xenopus FGF3 (XFGF3). Receptor binding experiments indicate that ZFGF3 has a higher affinity for the IIIb rather than the IIIc isoform of FGFR2; properties that are more reminiscent of the mouse than the Xenopus homologue. Consistent with the FGF receptor binding properties, ZFGF3 shows a restricted mitogenic potential and a reduced transforming activity on NIH3T3 cells compared to XFGF3. Hybrid proteins made between Xenopus and zebrafish FGF3 implicate the C-terminal region in determining the differences in receptor binding affinities, mitogenic potency and transforming activity. Thus, ZFGF3 shows the structural and secretory properties of XFGF3, but has biological properties more akin to those of the mouse homologue.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; UNITED MED & DENT SCH,GUYS & ST THOMAS HOSP,DEPT DEV NEUROBIOL,LONDON SE1 9RT,ENGLAND	Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London			Mason, Ivor/B-1859-2008	Mason, Ivor/0000-0001-8390-3050				BAIRD A, 1991, CANCER CELL-MON REV, V3, P239; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BATES B, 1991, MOL CELL BIOL, V11, P1840, DOI 10.1128/MCB.11.4.1840; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; DELL KR, 1992, J BIOL CHEM, V267, P21225; Dickson C, 1989, Prog Growth Factor Res, V1, P123, DOI 10.1016/0955-2235(89)90006-9; DIXON M, 1989, MOL CELL BIOL, V9, P4896, DOI 10.1128/MCB.9.11.4896; EMORI Y, 1992, FEBS LETT, V314, P176, DOI 10.1016/0014-5793(92)80968-M; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRIESEL R, 1991, MOL CELL BIOL, V11, P2481, DOI 10.1128/MCB.11.5.2481; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KIEFER P, 1993, EMBO J, V12, P4159, DOI 10.1002/j.1460-2075.1993.tb06100.x; KIEFER P, 1991, MOL CELL BIOL, V11, P5929, DOI 10.1128/MCB.11.12.5929; KIEFER P, 1993, MOL CELL BIOL, V13, P5781, DOI 10.1128/MCB.13.9.5781; KIEFER P, 1994, EMBO J, V13, P4126, DOI 10.1002/j.1460-2075.1994.tb06730.x; KIEFER P, 1996, CURR TOP DEV BIOL, V25, P77; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; MAHMOOD R, 1995, DEVELOPMENT, V121, P1399; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MATHIEU M, 1995, J BIOL CHEM, V270, P6779, DOI 10.1074/jbc.270.12.6779; MATHIEU M, 1995, IN PRESS J BIOL CHEM; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; PETERS G, 1991, SEMIN VIROL, V2, P319; POULIN ML, 1994, BBA-MOL CELL RES, V1220, P209, DOI 10.1016/0167-4889(94)90137-6; SEDDON AP, 1995, BIOCHEMISTRY-US, V34, P731, DOI 10.1021/bi00003a004; SHI DL, 1992, DEVELOPMENT, V116, P261; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; STRAHLE U, 1992, Current Biology, V2, P135, DOI 10.1016/0960-9822(92)90256-A; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; TANNAHILL D, 1992, DEVELOPMENT, V115, P695; WILKIE AOM, 1995, CURR BIOL, V5, P500; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZIMMER Y, 1993, J BIOL CHEM, V268, P7899	42	25	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1503	1511						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622866				2022-12-28	WOS:A1996UF07600014
J	Walkenhorst, J; Goga, A; Witte, ON; SupertiFurga, G				Walkenhorst, J; Goga, A; Witte, ON; SupertiFurga, G			Analysis of human c-Abl tyrosine kinase activity and regulation in S-pombe	ONCOGENE			English	Article						protein tyrosine kinase; SH3 domain; SH2 domain; autophosphorylation; Abl	FISSION YEAST; BCR-ABL; TRANSFORMING ACTIVITY; SIGNAL-TRANSDUCTION; SH2 DOMAIN; PROTEIN; SRC; GENE; AUTOPHOSPHORYLATION; MUTATIONS	c-Abl protein tyrosine kinase activity is tightly regulated in vertebrate cells. Several mutations, including deletions of the SH3 domain, can activate abl and convert it into an oncogene. To study c-Abl activity in a cellular environment likely to lack specific regulators, we have expressed human c-Abl in Schizosaccharomyces pombe in an inducible fashion. c-Abl, but not a kinase inactive form of the molecule, causes growth arrest followed by death of the cells. Concomitant to Abl expression we observed extensive phosphorylation of endogenous proteins on tyrosine. Mutations in the SH2 domain or in the autophosphorylation site dramatically reduce the ability of Abl to confer the growth arrest phenotype and to phosphorylate endogenous proteins, suggesting a fundamental role of these structures in the activity of the enzyme. An SH3 domain deletion mutant of Abl is equally active as wild type c-Abl in yeast, even under conditions allowing detection of subtle differences. These results demonstrate that there is no intrinsic regulation of c-Abl kinase activity via the SH3 domain and suggest that the inhibitory effect of the SH3 domain observed in mammalian cells is mediated by a factor that is absent in fission yeast. Expression of Abl in S.pombe provides a novel quantitative assay for Abl activity and regulation.	EUROPEAN MOLEC BIOL LAB, D-69012 HEIDELBERG, GERMANY; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA	European Molecular Biology Laboratory (EMBL); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles			Superti-Furga, Giulio/AAE-5681-2019; Superti-Furga, Giulio/F-4755-2015	Superti-Furga, Giulio/0000-0002-0570-1768				AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; BEACH D, 1985, CURR GENET, V10, P297, DOI 10.1007/BF00365626; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; HJERMSTAD SJ, 1993, ONCOGENE, V8, P2283; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON PK, 1993, ONCOGENE, V8, P1943; Koegl M, 1995, ONCOGENE, V11, P2317; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; MATTIONI T, 1995, ONCOGENE, V10, P1325; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORGAN DO, 1994, CURR OPIN CELL BIOL, V6, P239, DOI 10.1016/0955-0674(94)90142-2; MULLER AJ, 1993, P NATL ACAD SCI USA, V90, P3457, DOI 10.1073/pnas.90.8.3457; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PAWSON T, 1988, ONCOGENE, V3, P491; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PONTICELLI AS, 1982, CELL, V29, P953, DOI 10.1016/0092-8674(82)90458-5; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAWYERS CL, 1994, CELL, V77, P1; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SUPERTIFURGA G, 1995, FEBS LETT, V369, P62, DOI 10.1016/0014-5793(95)00636-N; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	40	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	1996	12	7					1513	1520						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622867				2022-12-28	WOS:A1996UF07600015
J	Sacchi, N; Schiaffonati, L; Magnani, I; Pappalardo, C; Hughes, AJ; Darfler, M; Hoogeveen, AT				Sacchi, N; Schiaffonati, L; Magnani, I; Pappalardo, C; Hughes, AJ; Darfler, M; Hoogeveen, AT			Detection and subcellular localization of an AML1 chimeric protein in the t(8;21) positive acute myeloid leukemia	ONCOGENE			English	Article						acute myeloid leukemia; translocation (8;21); AML1 gene; chimeric protein	FUSION TRANSCRIPT; NUCLEAR FACTOR; VIRUS ENHANCERS; DNA-BINDING; GENE; RUNT; TRANSLOCATION; IDENTIFICATION; DOMAIN; CORE	AML1, a gene encoding a protein of the PEBP2/CBF family of transcription factors is disrupted by translocations associated with human leukemia. In the t(8;21) acute myelogenous leukemia (AML), AML1 was found fused to a gene on chromosome 8 that we designated CDR (also known as ETO and MTG8). Immunoprecipitation experiments followed by immunoblotting using a combination of antibodies against different epitopes of one of the predicted chimeric proteins encoded by a fully characterized fusion transcript enabled us to visualize a chimeric protein in the t(8;21) Kasumi-1 cell line. The estimated size of this protein is 64 kDa, Immunoblotting of leukemic blasts containing the t(8;21) detected a protein of the same size, Immunofluorescence experiments indicate that the chimeric protein is localized in the nucleus. A normal AML1 protein of 27 kDa was also detected in t(8;21) Kasumi-1 cells, It remains to be established by which mechanism the mutant AML1 isoform may contribute to the leukemogenesis process of t(8;21)-positive acute myeloid leukemia.	UNIV MILAN, SCH MED, DEPT PATHOL, I-20133 MILAN, ITALY; LIFE TECHNOL INC, GAITHERSBURG, MD USA; ERASMUS UNIV ROTTERDAM, SCH MED, DEPT CLIN GENET, ROTTERDAM, NETHERLANDS	University of Milan; Thermo Fisher Scientific; Erasmus University Rotterdam	Sacchi, N (corresponding author), UNIV MILAN, SCH MED, DEPT BIOL & GENET, VIA VIOTTI 3-5, I-20133 MILAN, ITALY.							ASOU H, 1991, BLOOD, V77, P2031; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; BORAL AL, 1989, J VIROL, V63, P76, DOI 10.1128/JVI.63.1.76-84.1989; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; DEGREEF GE, 1995, LEUKEMIA, V9, P282; ERICKSON P, 1992, BLOOD, V80, P1825; HARLOW E, 1988, ANTIBODIES LABORATOR; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1993, BLOOD, V81, P2728; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; OHKI M, 1993, SEMIN CANCER BIOL, V4, P369; PIETTE J, 1987, EMBO J, V6, P1331, DOI 10.1002/j.1460-2075.1987.tb02372.x; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; SACCHI N, 1994, GENE CHROMOSOME CANC, V11, P226, DOI 10.1002/gcc.2870110405; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; THORNELL A, 1988, MOL CELL BIOL, V8, P1625, DOI 10.1128/MCB.8.4.1625; TIGHE JE, 1994, BLOOD, V84, P2115, DOI 10.1182/blood.V84.7.2115.bloodjournal8472115; VANDELOCHT LTF, 1994, LEUKEMIA, V8, P1780; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89	35	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	1996	12	2					437	444						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570222				2022-12-28	WOS:A1996TR53800024
J	Savatier, P; Lapillonne, H; vanGrunsven, LA; Rudkin, B; Samarut, J				Savatier, P; Lapillonne, H; vanGrunsven, LA; Rudkin, B; Samarut, J			Withdrawal of differentiation inhibitory activity leukemia inhibitory factor up-regulates D-type cyclins and cyclin-dependent kinase inhibitors in mouse embryonic stem cells	ONCOGENE			English	Article						mouse embryonic stem cells; mouse embryo; cell cycle; G1-cyclins; cyclin-dependent kinase inhibitors; gastrulation; DIA/LIF	AUTORADIOGRAPHIC ANALYSIS; MESODERM FORMATION; DIFFERENT REGIONS; GENE-EXPRESSION; CARCINOMA-CELLS; RETINOIC ACID; T-GENE; FIBROBLASTS; PROTEIN; G(1)	The expression of E and D-type cyclins, Cyclin-Dependent Kinase (CDK) 2 and 4, as web as CDK inhibitors p21(Cip1) and p27(Kip1) were examined during in vitro differentiation of mouse embryonic stem (ES) cells. ES cells cultured in presence of Differentiation Inhibitory Activity/Leukemia Inhibitory Factor (DIA/LIF) express very low levels of cylin E/CDK2 complexes, p21(Cip1) and p27(Kip1) CDK inhibitors, while cylin D/CDK4-associated kinase activity is undetectable. Withdrawal of DIA/LIF, which induces differentiation, results in the progressive up-regulation of all. Up-regulation of D cyclins occurs through an increase in the steady-state levels of mRNA, concomitantly with the activation of Brachyury and Goosecoid, two early markers of mesoderm differentiation. Similarly, cells from the epiblast of the early postimplantation mouse embryo do not express any cyclin D/CDK4 complexes, These are progressively up-regulated at gastrulation and early organogenesis, DIA/LIF-stimulated ES cells are not growth-arrested by overexpression of p16(Ink4a), a specific inhibitor of CDK4 and CDK6. We propose that the G1/S transition may be regulated by a minimal mechanism in mouse embryonic stem cells. Induction of differentiation triggers the establishment of a more sophisticated mechanism involving both cyclin D/CDK4- and CDK inhibitor-associated control of G1-phase progression.			Savatier, P (corresponding author), ECOLE NORMALE SUPER LYON,LA INRA,UMR 49 CNRS,LAB BIOL MOLEC & CELLULAIRE,46 ALLEE ITALIE,F-69364 LYON 07,FRANCE.		Samarut, Jacques/AAD-2587-2019; van Grunsven, Leo/E-5839-2010; SAVATIER, Pierre/J-4663-2014	van Grunsven, Leo/0000-0002-0990-7034; RUDKIN, Brian B./0000-0003-3700-1982				AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; ANDO K, 1995, ONCOGENE, V10, P751; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BEDDINGTON RSP, 1981, J EMBRYOL EXP MORPH, V64, P87; BEDDINGTON RSP, 1982, J EMBRYOL EXP MORPH, V69, P265; BEDDINGTON RSP, 1983, J EMBRYOL EXP MORPH, V75, P189; BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAMJANOV I, 1971, ROUX ARCH DEV BIOL, V167, P288; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DIWAN SB, 1976, J NATL CANCER I, V57, P937, DOI 10.1093/jnci/57.4.937; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVANS M, 1981, J REPROD FERTIL, V62, P625; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; ILES SA, 1977, J EMBRYOL EXP MORPH, V38, P63; JIANG W, 1993, ONCOGENE, V8, P3447; JOHANSSON BM, 1995, MOL CELL BIOL, V15, P141, DOI 10.1128/MCB.15.1.141; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KIYOKAWA H, 1992, P NATL ACAD SCI USA, V89, P2444, DOI 10.1073/pnas.89.6.2444; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; KLEINSMITH LJ, 1964, CANCER RES, V24, P1544; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KRANENBURG O, 1995, ONCOGENE, V10, P87; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LI Y, 1994, CANCER RES, V54, P6078; LUKAS J, 1994, ONCOGENE, V9, P2159; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; LUKAS J, 1995, MOL CELL BIOL, V15, P2660; MARTIN GR, 1980, SCIENCE, V209, P676; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCAULEY A, 1993, DEVELOPMENT, V117, P873; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MUMMERY CL, 1987, DEV BIOL, V121, P10, DOI 10.1016/0012-1606(87)90133-3; NICHOLS J, 1990, DEVELOPMENT, V110, P1341; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PALMERO I, 1993, ONCOGENE, V8, P1049; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3462; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROBERTSON EJ, 1986, EXPT APPROACHES MAMM, P475; ROGERS MB, 1991, DEVELOPMENT, V113, P815; ROSS ME, 1994, J NEUROSCI, V14, P6384; SAVATIER P, 1994, ONCOGENE, V9, P809; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; Smith AG., 1991, J TISSUE CULT METHOD, V13, P89, DOI [10.1007/BF01666137, DOI 10.1007/BF01666137, 10.1007/bf01666137]; SOLTER D, 1980, INT J CANCER, V25, P341, DOI 10.1002/ijc.2910250306; SOLTER D, 1973, EXPERIENTIA, V29, P701, DOI 10.1007/BF01944785; TAM SW, 1994, ONCOGENE, V9, P2663; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	81	221	232	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					309	322						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570208				2022-12-28	WOS:A1996TR53800010
J	Kushner, DB; Pereira, DS; Liu, XH; Graham, FL; Ricciardi, RP				Kushner, DB; Pereira, DS; Liu, XH; Graham, FL; Ricciardi, RP			The first exon of Ad12 E1A excluding the transactivation domain mediates differential binding of COUP-TF and NF-kappa B to the MHC class I enhancer in transformed cells	ONCOGENE			English	Article						adenovirus; E1A; COUP-TF; NF-kappa B	DNA-BINDING; RAT-CELLS; GENE-EXPRESSION; P65 SUBUNIT; TRANSCRIPTION FACTORS; REL ONCOGENE; ADENOVIRUS-TYPE-12; PROTEINS; P50; REPRESSION	The major histocompatibility complex class I enhancer is the target for adenovirus-12 E1A-mediated down-regulation of class I transcription. In Ad12 transformed rodent cells, the class I enhancer is down-regulated through increased binding of the repressor COUP-TF to the R2 element and decreased binding of the activator NF-kappa B (p50/p65) to the R1 element. The reduced surface levels of class I antigens contribute to the tumorigenic potential of Ad12 transformed cells by favoring their immunoescape from cytotoxic T-lymphocytes. Previous studies using transformed containing hybrid Ad5/Ad12 E1A (plus Ad12 E1B) genes have indicated that sequences within the first exon of the 266R Ad12 E1A gene are required for class I down-regulation and tumorigenesis. In this study we demonstrate that these same sequences, which exclude the Ad12 CR3 transactivation domain, are also required for increased COUP-TF binding to the R2 element and decreased NF-kappa B binding to the R1 element of the class I enhancer. We further show that diminished NF-kappa B binding is not due to a lack of NF-kappa B1-p50 in the nuclei of Ad12 transformed rat cells.	UNIV PENN,SCH DENT MED,DEPT MICROBIOL,PHILADELPHIA,PA 19104; UNIV PENN,GRAD GRP MOLEC BIOL,PHILADELPHIA,PA 19104; MCMASTER UNIV,DEPT BIOL,HAMILTON,ON L8S 4K1,CANADA; MCMASTER UNIV,DEPT PATHOL,HAMILTON,ON L8S 4K1,CANADA	University of Pennsylvania; University of Pennsylvania; McMaster University; McMaster University				Kushner, David B/0000-0002-6260-5094	NCI NIH HHS [CA-29797] Funding Source: Medline; NIAID NIH HHS [5-T32-AI0735] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029797] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKRILL AM, 1988, ONCOGENE, V3, P483; ACKRILL AM, 1989, VIROLOGY, V172, P643, DOI 10.1016/0042-6822(89)90207-9; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EAGER KB, 1985, P NATL ACAD SCI USA, V82, P5525, DOI 10.1073/pnas.82.16.5525; FRIEDMAN DJ, 1988, VIROLOGY, V165, P303, DOI 10.1016/0042-6822(88)90689-7; GALLIMORE PH, 1974, J MOL BIOL, V89, P49, DOI 10.1016/0022-2836(74)90162-4; GE RW, 1992, J VIROL, V66, P6969, DOI 10.1128/JVI.66.12.6969-6978.1992; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRAHAM FL, 1974, NATURE, V251, P687, DOI 10.1038/251687a0; ISRAEL A, 1989, NUCLEIC ACIDS RES, V17, P5245, DOI 10.1093/nar/17.13.5245; JELINEK T, 1994, J VIROL, V68, P888, DOI 10.1128/JVI.68.2.888-896.1994; JELINEK T, 1992, J VIROL, V66, P4117, DOI 10.1128/JVI.66.7.4117-4125.1992; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRALLI A, 1992, J VIROL, V66, P6979, DOI 10.1128/JVI.66.12.6979-6988.1992; LIU X, 1996, IN PRESS MOL CELL BI, V16; LIU XH, 1994, ONCOGENE, V9, P2183; MEIJER I, 1992, CELL IMMUNOL, V145, P56, DOI 10.1016/0008-8749(92)90312-D; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; NIELSCH U, 1991, EMBO J, V10, P4169, DOI 10.1002/j.1460-2075.1991.tb04995.x; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PEREIRA DS, 1995, VIROLOGY, V211, P268, DOI 10.1006/viro.1995.1400; PEREIRA DS, 1994, INT J ONCOL, V5, P1197; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PERRICAUDET M, 1980, NATURE, V288, P174, DOI 10.1038/288174a0; PLAKSIN D, 1993, J EXP MED, V177, P1651, DOI 10.1084/jem.177.6.1651; QIU YH, 1994, TRENDS ENDOCRIN MET, V5, P234, DOI 10.1016/1043-2760(94)P3081-H; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; RAZIUDDIN J A M, 1991, Proceedings of the National Academy of Sciences of the United States of America, V88, P9426; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHOUTEN GJ, 1995, EMBO J, V14, P1498, DOI 10.1002/j.1460-2075.1995.tb07136.x; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SEGARS JH, 1993, MOL CELL BIOL, V13, P6157, DOI 10.1128/MCB.13.10.6157; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; TANAKA K, 1985, SCIENCE, V228, P26, DOI 10.1126/science.3975631; TELLING GC, 1994, J VIROL, V68, P877, DOI 10.1128/JVI.68.2.877-887.1994; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VASAVADA R, 1986, P NATL ACAD SCI USA, V83, P5257, DOI 10.1073/pnas.83.14.5257; YEWDELL JW, 1988, VIROLOGY, V162, P236, DOI 10.1016/0042-6822(88)90413-8	53	22	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					143	151						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552385				2022-12-28	WOS:A1996TQ01400018
J	Judware, R; Culp, LA				Judware, R; Culp, LA			Over-expression of transfected N-myc oncogene in human SKNSH neuroblastoma cells down-regulates expression of beta 1 integrin subunit	ONCOGENE			English	Article						neuroblastoma; N-myc; integrin; NCAM; transfection	NEURO-BLASTOMA; SIGNAL TRANSDUCTION; GENE-EXPRESSION; ADHESION; MODULATION; ANTIGENS; CULTURE; MAX; HLA	Amplification of the N-myc oncogene is associated with progression of neuroblastoma in humans, Previous studies indicated that neuroblastoma cell lines which are amplified for the N-myc gene and over-express N-myc exhibit enhanced tumorigenic properties when injected into athymic nude mice, In addition, neuroblastoma cells which over-express N-myc (IMR32 cells) expressed little or no beta 1, alpha 2, or alpha 3 integrin subunits, as compared with cells which do not express N-myc (SKNSH cells), In order to probe the possible relationship between N-myc and beta 1 integrin gene expressions more directly, transfection experiments were performed in which an N-myc cDNA (on the episomal expression vector pREP4; high-level constitutive expression is driven by an RSV-LTR promoter) was introduced into SKNSH cells, Expression of N-myc produced significant morphological alterations in transfected cells; one subpopulation of cells remained spread on tissue culture substrata, while a second subpopulation became rounded and grew as multi-cellular aggregates, Spread (attached) cells expressed low levels of N-myc and high levels of beta 1 integrin, while rounded (loose) cells expressed relatively high levels of N-myc and low levels of beta 1 integrin, Maintenance of transfected cells in higher concentrations of selective agent produced a higher proportion of loose cells, which expressed even greater amounts of N-myc and even less beta 1 integrin; a similar effect was observed in attached cells, Interestingly, loose cell populations expressed elevated levels of the neural cell adhesion molecule [NCAM]. The results presented here infer that N-myc regulates the expression of the beta 1 integrin and NCAM cell-surface receptors responsible for cell:extracellular matrix interaction and possibly cell:cell adhesion.			Judware, R (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,10900 EUCLID AVE,CLEVELAND,OH 44106, USA.				NATIONAL CANCER INSTITUTE [F32CA065068, T32CA059366] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017139] Funding Source: NIH RePORTER; NCI NIH HHS [1F32CA65068, CA59366] Funding Source: Medline; NINDS NIH HHS [NS17139] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKESON R, 1990, MOL CELL BIOL, V10, P2012, DOI 10.1128/MCB.10.5.2012; ALBELDA SM, 1993, LAB INVEST, V68, P4; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BERNARDS R, 1991, EMBO J, V10, P1119, DOI 10.1002/j.1460-2075.1991.tb08052.x; BIEDLER JL, 1973, CANCER RES, V33, P2643; BRADYKALNAY SM, 1993, CLIN EXP METASTAS, V11, P313, DOI 10.1007/BF00058051; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; BRODEUR GM, 1991, BIOCH MOL ASPECTS SE, P251; CERVELLA P, 1993, J BIOL CHEM, V268, P5148; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; COOPER MJ, 1990, CANCER RES, V50, P3694; FELTNER DE, 1989, J IMMUNOL, V143, P4292; FLICKINGER KS, 1994, EXP CELL RES, V213, P156, DOI 10.1006/excr.1994.1185; Goridis C, 1992, Semin Cell Biol, V3, P189; GROSS N, 1994, INT J CANCER, V59, P141, DOI 10.1002/ijc.2910590124; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JUDWARE R, 1995, CLIN EXP METASTAS, V13, P123, DOI 10.1007/BF00133617; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KLEINMAN NR, 1994, BRIT J CANCER, V69, P670, DOI 10.1038/bjc.1994.129; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPSON LA, 1983, J IMMUNOL, V130, P2471; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; MOENS CB, 1993, DEVELOPMENT, V119, P485; RASCHELLA G, 1994, CANCER RES, V54, P2251; RETTIG WJ, 1987, CANCER RES, V47, P1383; Sambrook J, 1989, MOL CLONING LABORATO; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; VANTVEER LJ, 1993, EMBO J, V12, P195, DOI 10.1002/j.1460-2075.1993.tb05645.x; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x	33	40	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2599	2607						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545117				2022-12-28	WOS:A1995TP18800016
J	Cooper, HM; Armes, P; Britto, J; Gad, J; Wilks, AF				Cooper, HM; Armes, P; Britto, J; Gad, J; Wilks, AF			Cloning of the mouse homologue of the deleted in colorectal cancer gene (mDCC) and its expression in the developing mouse embryo	ONCOGENE			English	Article						DCC; tumorigenesis; sequence; embryogenesis; neural tube	TUMOR-SUPPRESSOR GENE; ADHESION MOLECULE NCAM; MESSENGER-RNA; FREQUENT LOSS; DCC; HETEROZYGOSITY; CARCINOMAS; GROWTH	Loss of DCC gene expression has now been demonstrated in a wide variety of metastatic cancers. Here we present the nucleotide sequence and predicted amino acid sequence of mouse DCC, Mouse and human DCC share 96% identity at the amino acid level, Analysis of DCC mRNA expression throughout the mid to late stages of gestation in the mouse, demonstrated that DCC mRNA is expressed at significantly higher levels in the developing mouse embryo than in any adult tissue, In addition, we show that an embryo-specific, alternatively spliced, form of DCC is expressed in day 9.5 through day 18.5 embryos. The expression of both alternatively spliced forms of DCC is developmentally regulated such that the embryonic form of DCC predominates in day 9.5 and 10.5 embryos. In the later stage embryos the expression of this alternatively spliced form of DCC is down-regulated with respect to that of the adult form, Whole-mount in situ hybridization of day 11.5 mouse embryos revealed that DCC mRNA is expressed at high levels in the developing brain and the neural tube, However, no DCC mRNA could be detected in any other embryonic tissue at this stage of development, These observations suggest that during embryogenesis DCC may play a pivotal role in the development of the central nervous system.	ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,MELBOURNE,VIC 3050,AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Cooper, HM (corresponding author), LUDWIG INST CANC RES,MELBOURNE TUMOUR BIOL BRANCH,MELBOURNE,VIC 3050,AUSTRALIA.		Wilks, Andrew F/R-5542-2019; Cooper, Helen/G-3505-2010; COOPER, HOWARD/M-7304-2014; Cooper, Helen M/AAA-2182-2019	Cooper, Helen M/0000-0001-9838-5743; Wilks, Andrew F/0000-0002-8554-2399				Ausubel F.M., 1994, CURRENT PROTOCOLS MO, V1; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BIXBY JL, 1991, ANNU REV CELL BIOL, V7, P117, DOI 10.1146/annurev.cellbio.7.1.117; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; CHOWCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; CHUONG CM, 1994, DEV BIOL, V164, P383, DOI 10.1006/dbio.1994.1208; CONLON RA, 1992, DEVELOPMENT, V116, P357; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DEVILEE P, 1991, ONCOGENE, V6, P311; DOHERTY P, 1992, NATURE, V356, P791, DOI 10.1038/356791a0; ENOMOTO T, 1995, BRIT J CANCER, V71, P462, DOI 10.1038/bjc.1995.94; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GAO X, 1993, CANCER RES, V53, P2723; GIMA T, 1994, INT J CANCER, V57, P480, DOI 10.1002/ijc.2910570407; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HOHNE MW, 1992, CANCER RES, V52, P2616; HUANG Y, 1992, CANCER RES, V52, P6525; IONO H, 1994, CANCER, V73, P1324; ITOH F, 1993, INT J CANCER, V53, P260, DOI 10.1002/ijc.2910530215; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWLOR KG, 1992, CELL GROWTH DIFFER, V3, P609; MIRAGALL F, 1988, DEV BIOL, V129, P516, DOI 10.1016/0012-1606(88)90397-1; MIYAKE K, 1993, BLOOD, V82, P927; MIYAKE S, 1994, CANCER RES, V54, P3007; OELERICHS RB, 1993, ONCOGENE, V8, P11; ONEAL KD, 1993, LYMPHOKINE CYTOK RES, V12, P309; PIERCEALL WE, 1994, DEV BIOL, V166, P654, DOI 10.1006/dbio.1994.1345; PIERCEALL WE, 1994, J CELL BIOL, V124, P1017, DOI 10.1083/jcb.124.6.1017; PORFIRI E, 1993, BLOOD, V81, P2696; REALE MA, 1994, CANCER RES, V54, P4493; RUGH R, 1991, MOUSE ITS REPRODUCTI; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHECK AC, 1993, CANCER RES, V53, P5605; UCHINO S, 1992, CANCER RES, V52, P3099; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; ZORN AM, 1992, DEV BIOL, V149, P197, DOI 10.1016/0012-1606(92)90276-M	42	53	55	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2243	2254						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570174				2022-12-28	WOS:A1995TK70200007
J	ELWOOD, NJ; COOK, WD; METCALF, D; BEGLEY, CG				ELWOOD, NJ; COOK, WD; METCALF, D; BEGLEY, CG			SCL, THE GENE IMPLICATED IN HUMAN T-CELL LEUKEMIA, IS ONCOGENIC IN A MURINE T-LYMPHOCYTE CELL-LINE	ONCOGENE			English	Article							ABELSON LEUKEMIA-VIRUS; DNA-BINDING MOTIF; LOOP-HELIX GENES; C-MYC; ERYTHROID-DIFFERENTIATION; CHROMOSOMAL TRANSLOCATION; TRANSGENIC MICE; BALB/C MICE; TAL-1 GENE; EXPRESSION	SCL (TAL-1) is implicated in the generation of human T-cell acute lymphoblastic leukaemia. To directly examine the role of this putative oncogene, an SCL retrovirus was constructed and used to infect a v-ABL transformed T-lymphocyte cell line. Thirteen independent SCL-infected and four control cell lines were established and injected subcutaneously into syngeneic mice. Mice injected with SCL-infected clonal cell lines died significantly more rapidly than control animals. By day 200 46% (40/87) of animals injected with SCL-infected cell lines had died due to disseminated transplantable lymphoid tumours. In contrast only 22% of control mice were dead by day 200 (P < 0.0015). Of possible relevance to the enhanced tumourigenesis, some SCL-infected cell lines displayed increased clonogenicity in agar. Increased cell growth was even more striking when ex-vivo tumour-derived cell lines were studied. Thus, SCL can co-operate with v-ABL to hasten T-cell tumourigenesis. This is the first direct evidence demonstrating that SCL can behave as an oncogene.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,DEPT SURG,PARKVILLE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,DEPT DIAGNOST HAEMATOL,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital; Royal Melbourne Hospital				Elwood, Ngaire/0000-0002-4740-2416				ABELSON HT, 1970, CANCER RES, V30, P2208; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1992, BLOOD, V79, P1327; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BERNARD O, 1991, ONCOGENE, V6, P1477; BOWTELL DDL, 1987, ANAL BIOCHEM, V162, P463, DOI 10.1016/0003-2697(87)90421-0; BOWTELL DDL, 1987, MOL BIOL MED, V4, P229; BOYD AW, 1989, BLOOD, V73, P1896; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHUNG SW, 1991, P NATL ACAD SCI USA, V88, P1858; COOK WD, 1987, MOL CELL BIOL, V7, P2631, DOI 10.1128/MCB.7.7.2631; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COOK WD, 1982, P NATL ACAD SCI-BIOL, V79, P2917, DOI 10.1073/pnas.79.9.2917; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; ELWOOD NJ, 1991, TODAYS LIFE SCI, V3, P16; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; GARRELL J, 1991, BIOESSAYS, V13, P493, DOI 10.1002/bies.950131002; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1992, ONCOGENE, V7, P653; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; Hariharan I K, 1988, Oncogene Res, V3, P387; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HAUPT Y, 1992, ONCOGENE, V7, P981; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MENDOZA GR, 1976, J IMMUNOL, V117, P1573; MOUTHON MA, 1993, BLOOD, V81, P647; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; NAUMOVSKI L, 1992, BLOOD S1, V80, pA301; POTTER M, 1973, SCIENCE, V182, P592, DOI 10.1126/science.182.4112.592; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; ROWE WP, 1970, VIROLOGY, V42, P1136, DOI 10.1016/0042-6822(70)90362-4; SCHER CD, 1975, NATURE, V253, P729, DOI 10.1038/253729a0; TANIGAWA T, 1993, IN PRESS P NATL ACAD; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VISVADER J, 1991, ONCOGENE, V6, P187; VISVADER J, 1991, TRENDS BIOCHEM SCI, V16, P330, DOI 10.1016/0968-0004(91)90137-K; WANECK GL, 1981, CELL, V26, P79, DOI 10.1016/0092-8674(81)90035-0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862	56	36	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3093	3101						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414511				2022-12-28	WOS:A1993MC09300026
J	TARUNINA, M; JENKINS, JR				TARUNINA, M; JENKINS, JR			HUMAN P53 BINDS DNA AS A PROTEIN HOMODIMER BUT MONOMERIC VARIANTS RETAIN FULL TRANSCRIPTION TRANSACTIVATION ACTIVITY	ONCOGENE			English	Article							WILD-TYPE P53; CELLULAR TUMOR-ANTIGEN; MONOCLONAL-ANTIBODIES; T-ANTIGEN; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS; ONCOGENE PRODUCT; GENE; SEQUENCE; AMPLIFICATION	Wild-type human p53 protein is able to self-associate and consists predominantly of homotetramers in solution. In earlier work we identified the protein sequence motifs involved in p53 quaternary structure and showed that while monomeric p53 protein retains tumour suppressor function, monomeric tumour mutant p53 lacks dominant transforming activity. In this report we use point mutated and truncated cDNA genes encoding self-association defective human p53 proteins to investigate the relationship between p53 protein quaternary structure and the associated activities of transcription transactivation and target specific DNA binding. We show that p53 binds to a target oligonucleotide as a protein homodimer and that p53 dimerisation is required for detectable DNA binding. We found no evidence for p53 tetramer:DNA complexes and we suggest that the quaternary structure status of p53 may regulate a DNA binding associated activity. Monomeric p53 proteins failed to bind DNA in these assays but exhibited increased transactivating activity. Thus, both transcription transactivation and tumour suppressor functions act independently of p53 protein self-association and DNA binding. We propose that our results validate the p53 dimerisation motif as a target for rational anticancer drug design. We predict that compounds able to block p53 dimer assembly would inhibit the dominant transforming activities of mutant p53 in tumours retaining expression of a mutant allele, while leaving intact the wild-type p53 associated activities of transcription transactivation and transformation suppression in unaffected tissue.	MARIE CURIE RES INST, CELL PROLIFERAT LAB, OXTED RH8 0TL, SURREY, ENGLAND									ADDISON C, 1990, ONCOGENE, V5, P423; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BRAIN R, 1993, UNPUB; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CARDER P, 1993, ONCOGENE, V8, P1397; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHUMAKOV P, 1990, J CELL BIOCH S14C, V106, P269; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DAVID YB, 1988, ONCOGENE, V3, P179; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JENKINS JR, 1988, ONCOGENE HDB, P403; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KUBERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MURTHY SCS, 1985, P NATL ACAD SCI USA, V82, P2230, DOI 10.1073/pnas.82.8.2230; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; ROVINSKI B, 1988, ONCOGENE, V2, P445; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHMEIG F, 1988, VIROLOGY, V194, P132; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	59	101	102	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1993	8	11					3165	3173						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414520				2022-12-28	WOS:A1993MC09300035
J	HOWARD, JC; YOUSEFI, S; CHEONG, G; BERNSTEIN, A; BENDAVID, Y				HOWARD, JC; YOUSEFI, S; CHEONG, G; BERNSTEIN, A; BENDAVID, Y			TEMPORAL-ORDER AND FUNCTIONAL-ANALYSIS OF MUTATIONS WITHIN THE FLI-1 AND P53 GENES DURING THE ERYTHROLEUKEMIAS INDUCED BY F-MULV	ONCOGENE			English	Article								The erythroleukemias induced by Friend murine leukemia virus (F-MuLV) result from the accumulation of a number of genetic changes, including activation of the Fli-1 proto-oncogene and inactivation of the p53 tumor suppressor gene. We have determined the temporal order of mutation of the genes involved in this multistage malignancy, by serial in vivo transplantation of F-MuLV induced primary erythroleukemias into syngenic Balb/c mice. These primary tumors are capable of growing when transplanted into syngenic mice, but die after several days of in vitro culture. From the transplanted tumors grown in syngenic mice, erythropoietin-dependent cell lines were established in culture that are clonally related to cells in the primary tumors. We show that retroviral insertional activation of the Fli-1 ets family member is the first detectable genetic event in F-MuLV induced primary erythroleukemias. Mutations in the p53 gene were observed in the Epo-dependent celt lines but not in the transplanted erythroleukemias used to establish these cell lines in culture. These data suggest that activation of Fli-1 plays an important role in the early stages of F-MuLV-induced leukemia, perhaps by altering the self-renewal probabilities of erythroid progenitor cells and that p53 mutations immortalize these cells, enabling them to grow in vitro in the presence of Epo.	SUNNYBROOK HLTH SCI CTR S218, DIV CANC RES, REICHMANN RES BLDG, 2075 BAYVIEW AVE, TORONTO M4N 3M5, ONTARIO, CANADA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO M5G 1X5, ONTARIO, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A1, ONTARIO, CANADA; UNIV TORONTO, DEPT MED BIOPHYS, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto			Yousefi, Shida/AAU-7986-2020; Yousefi, Shida/L-9689-2016	Yousefi, Shida/0000-0002-9855-4305; Yousefi, Shida/0000-0002-9855-4305				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BEN-DAVID Y, 1990, New Biologist, V2, P1015; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; DAVID YB, 1988, ONCOGENE, V3, P179; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HANKINS WD, 1989, ANN NY ACAD SCI, V554, P21, DOI 10.1111/j.1749-6632.1989.tb22405.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINO M, 1991, MOL CELL BIOL, V11, P5527, DOI 10.1128/MCB.11.11.5527; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JENKINS JR, 1984, NUCLEIC ACIDS RES, V12, P5609, DOI 10.1093/nar/12.14.5609; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LACOMBE C, 1991, J BIOL CHEM, V266, P6952; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LAVIGUEUR A, 1991, ONCOGENE, V6, P2197; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; MAGER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1703, DOI 10.1073/pnas.78.3.1703; MCDONALD J, 1987, MOL CELL BIOL, V7, P365, DOI 10.1128/MCB.7.1.365; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1990, LEUKEMIA, V4, P20; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; ROVINSKI B, 1988, ONCOGENE, V2, P445; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SHIBUYA T, 1983, P NATL ACAD SCI-BIOL, V80, P3721, DOI 10.1073/pnas.80.12.3721; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; SLINGERLAND JM, 1991, BLOOD, V77, P1500; TSUNEFUMI S, 1982, J CELL PHYSL, V1, P185; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZHANG LQ, 1993, ONCOGENE, V8, P1621	40	49	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2721	2729						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378083				2022-12-28	WOS:A1993LX34300013
J	LEONE, A; FLATOW, U; VANHOUTTE, K; STEEG, PS				LEONE, A; FLATOW, U; VANHOUTTE, K; STEEG, PS			TRANSFECTION OF HUMAN NM23-H1 INTO THE HUMAN MDA-MB-435 BREAST-CARCINOMA CELL-LINE - EFFECTS ON TUMOR METASTATIC POTENTIAL, COLONIZATION AND ENZYMATIC-ACTIVITY	ONCOGENE			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; YEAST SCHIZOSACCHAROMYCES-POMBE; GTP-BINDING PROTEINS; COLORECTAL-CARCINOMA; DISEASE PROGRESSION; GOOD PROGNOSIS; EXPRESSION; GENE; CANCER; DROSOPHILA	We report the phenotypic effects of transfection of human nm23-H1 cDNA into the human MDA-MB-435 breast carcinoma cell line. Upon mammary fat pad or subcutaneous injection into nude mice, both the nm23-H1 and control transfected lines produced primary tumors; however, the nm23-H1-transfected lines produced metastases in significantly fewer mice than did control transfected lines. Reductions in tumor metastatic potential in vivo were accompanied by decreased colonization in soft agar and an altered colonization response to transforming growth factor beta in vitro. Total nucleoside diphosphate kinase activity, an enzymatic activity possessed by the Nm23 family, was not directly correlated with Nm23-H1 expression levels or suppression of metastatic potential in all cases examined. The data establish that nm23-H1 has functional suppressive effects on the tumor metastatic potential of a human breast carcinoma cell line, and suggest that it may regulate signal responsiveness in the colonization response.	NIH,PATHOL LAB,BLDG 10,ROOM 2A33,BETHESDA,MD 20892; FREDERICK CANC RES & DEV FACIL,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA			leone, alvaro/AAQ-7051-2020; Leone, Alvaro/K-6410-2016	Leone, Alvaro/0000-0003-3815-9052				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARNES R, 1991, AM J PATHOL, V139, P245; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; COHN KH, 1991, LANCET, V338, P722, DOI 10.1016/0140-6736(91)91444-Y; CREANOR J, 1989, J CELL SCI, V93, P185; DEAROLF CR, 1988, DEV BIOL, V129, P169, DOI 10.1016/0012-1606(88)90171-6; DEAROLF CR, 1988, DEV BIOL, V129, P159, DOI 10.1016/0012-1606(88)90170-4; DICKINSON JR, 1983, J CELL SCI, V60, P355; FLORENES VA, 1992, CANCER RES, V52, P6088; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GOLDEN A, 1993, ONCOGENES TUMOR SUPP, P345; GORSCH SM, 1992, CANCER RES, V52, P6949; HAILAT N, 1991, J CLIN INVEST, V88, P341, DOI 10.1172/JCI115299; Hart I R, 1991, Semin Cancer Biol, V2, P87; HAUT M, 1991, J NATL CANCER I, V83, P712, DOI 10.1093/jnci/83.10.712; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; HIGASHIYAMA M, 1992, BRIT J CANCER, V66, P533, DOI 10.1038/bjc.1992.308; HIRAYAMA R, 1991, J NATL CANCER I, V83, P1249, DOI 10.1093/jnci/83.17.1249; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KANTOR JD, 1993, CANCER RES, V53, P1971; KEIM D, 1992, J CLIN INVEST, V89, P919, DOI 10.1172/JCI115672; KIKKAWA S, 1990, J BIOL CHEM, V265, P21536; KIKKAWA S, 1991, J BIOL CHEM, V266, P12795; KOBAYASHI S, 1992, JPN J CANCER RES, V83, P859, DOI 10.1111/j.1349-7006.1992.tb01991.x; LAKSO M, 1992, CELL GROWTH DIFFER, V3, P873; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1993, ONCOGENE, V8, P855; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MELKI R, 1992, BIOCHEM BIOPH RES CO, V187, P65, DOI 10.1016/S0006-291X(05)81459-7; NAKAYAMA T, 1992, J NATL CANCER I, V84, P1349, DOI 10.1093/jnci/84.17.1349; NICKERSON JA, 1984, J BIOL CHEM, V259, P1297; NICOLSON GL, 1987, CANCER RES, V47, P1473; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; PRICE JE, 1990, CANCER RES, V50, P717; RANDAZZO PA, 1991, SCIENCE, V254, P850, DOI 10.1126/science.1658935; RANDAZZO PA, 1992, J BIOL CHEM, V267, P18182; RIES AB, 1990, CANCER STATISTICS RE; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; ROYDS JA, 1993, J NATL CANCER I, V85, P727, DOI 10.1093/jnci/85.9.727; SASTREGARAU X, 1992, INT J CANCER, V50, P533, DOI 10.1002/ijc.2910500406; SCHWARZ LC, 1988, CANCER RES, V48, P6999; SIMPSON JF, 1993, LAB INVEST, V68, pA20; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1993, BREAST CANCER RES TR, V25, P175, DOI 10.1007/BF00662142; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; TENG DHF, 1991, NATURE, V353, P437, DOI 10.1038/353437a0; THEODORESCU D, 1991, J CELL PHYSIOL, V148, P380, DOI 10.1002/jcp.1041480308; THOMAS DG, 1975, COMPUT BIOMED RES, V8, P423, DOI 10.1016/0010-4809(75)90048-8; TUBIANA M, 1991, BREAST CANCER RES TR, V18, P125, DOI 10.1007/BF01990028; VANDEVIJVER MJ, 1991, BIOCHIM BIOPHYS ACTA, V1072, P33, DOI 10.1016/0304-419X(91)90005-6; WANG LM, 1993, CANCER RES, V53, P717	52	297	309	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2325	2333						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8395676				2022-12-28	WOS:A1993LT36800002
J	ROSELL, R; LI, SR; SKACEL, Z; MATE, JL; MAESTRE, J; CANELA, M; TOLOSA, E; ARMENGOL, P; BARNADAS, A; ARIZA, A				ROSELL, R; LI, SR; SKACEL, Z; MATE, JL; MAESTRE, J; CANELA, M; TOLOSA, E; ARMENGOL, P; BARNADAS, A; ARIZA, A			PROGNOSTIC IMPACT OF MUTATED K-RAS GENE IN SURGICALLY RESECTED NONSMALL CELL LUNG-CANCER PATIENTS	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; ONCOGENE ACTIVATION; ENZYMATIC AMPLIFICATION; POINT MUTATION; ADENOCARCINOMA; MARKER; DNA	Mutated K-ras oncogenes have been detected in a third of lung adenocarcinomas, located usually in codon 12, its presence correlating negatively with survival. To further define the role of K-ras point mutations in non-small cell lung cancer, we studied the presence of mutated K-ras genes in surgical specimens from 66 patients. Polymerase chain reaction was performed from sections of formalin-fixed paraffin-embedded tissue. We screened for point mutations in codons 12, 13 and 61 of the K-ras gene by dot blot hybridization analysis with mutation-specific oligonucleotide probes. Ras gene mutations were present in 13 of 66 carcinomas (20%), nine in codon 12 and four in codon 61. Three squamous cell carcinomas harbored two different point mutations in K-ras codon 12. Mutated K-ras genes were found more frequently in squamous cell carcinomas (eight of 38) than in adenocarcinoma (three of 22). Analysis of nucleotide sequence disclosed a multifarious mutation pattern of K-ras codon 12, where the most common conversion was from glycine (GGT) to valine (GTT). K-ras point mutation positive subset had poorer survival, nine of the 13 patients died during the follow-up period as compared with 22 of 53 patients with no mutation in the K-ras gene (P=0.01). The difference was also strikingly significant when stratified according to node status.	UNIV BADALONA, HOSP GERMANS & PUJOL, DEPT IMMUNOL, E-08916 BADALONA, SPAIN; UNIV BADALONA, HOSP GERMANS TRIAS & PUJA, DEPT THORAC SURG, E-08916 BADALONA, SPAIN		ROSELL, R (corresponding author), UNIV BADALONA, HOSP GERMAN TRIAS & PUJOL, DEPT MED ONCOL, E-08916 BADALONA, SPAIN.			MATE SANZ, JOSE LUIS/0000-0002-4829-3426				[Anonymous], 1982, Am J Clin Pathol, V77, P123; ANWAR K, 1992, CANCER RES, V52, P5991; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; DIXON WJ, 1983, BMDP STATISTICAL SOF, P555; ENOMOTO T, 1991, CANCER RES, V51, P5308; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; KOBAYASHI T, 1990, CANCER, V66, P289, DOI 10.1002/1097-0142(19900715)66:2<289::AID-CNCR2820660216>3.0.CO;2-6; KRAEGEL SA, 1992, CANCER RES, V52, P4724; LEVI S, 1991, CANCER RES, V51, P3497; MARIYAMA M, 1989, JPN J CANCER RES, V80, P622, DOI 10.1111/j.1349-7006.1989.tb01687.x; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; MITSUDOMI T, 1991, CANCER RES, V51, P4999; MOUNTAIN CF, 1986, CHEST, V89, pS225, DOI 10.1378/chest.89.4.225S; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; RODENHUIS S, 1992, CANCER RES, V52, pS2665; RODENHUIS S, 1988, CANCER RES, V48, P5738; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Slebos R J, 1992, Diagn Mol Pathol, V1, P136, DOI 10.1097/00019606-199206000-00007; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; SLEBOS RJC, 1991, J NATL CANCER I, V83, P1024, DOI 10.1093/jnci/83.14.1024; SLEBOS RJC, 1992, J NATL CANCER I MONO, V13, P23; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; SUGIO K, 1992, CANCER RES, V52, P2903; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TADA M, 1990, CANCER-AM CANCER SOC, V66, P930, DOI 10.1002/1097-0142(19900901)66:5<930::AID-CNCR2820660519>3.0.CO;2-W; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VRIES MV, 1986, GENE, V50, P313	31	149	151	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1993	8	9					2407	2412						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8395679				2022-12-28	WOS:A1993LT36800011
J	CROUCH, DH; FISHER, F; CLARK, W; JAYARAMAN, PS; GODING, CR; GILLESPIE, DAF				CROUCH, DH; FISHER, F; CLARK, W; JAYARAMAN, PS; GODING, CR; GILLESPIE, DAF			GENE-REGULATORY PROPERTIES OF MYC HELIX-LOOP-HELIX LEUCINE-ZIPPER MUTANTS - MAX-DEPENDENT DNA-BINDING AND TRANSCRIPTIONAL ACTIVATION IN YEAST CORRELATES WITH TRANSFORMING CAPACITY	ONCOGENE			English	Article							HUMAN C-MYC; SACCHAROMYCES-CEREVISIAE; PROTEIN EXPRESSION; ESCHERICHIA-COLI; CELL-CYCLE; MOTIF; DIFFERENTIATION; OLIGOMERIZATION; SPECIFICITY; RECOGNITION	Max is a basic helix-loop-helix/leucine zipper (bHLH/LZ) protein that forms sequence-specific DNA-binding complexes with the c-Myc oncoprotein (Myc). Using Saccharomyces cerevisiae, we have shown that the Max bHLH/LZ domain enables Myc to activate transcription through CACGTG and CACATG sequences in vivo, and that the number and context of such sites determines the level of activation. In addition, we have used yeast to investigate the role of the Myc helix-loop-helix (HLH) and leucine zipper (LZ) motifs in mediating Max-dependent DNA-binding and transcriptional activation in vivo using HLH/LZ mutants generated by site-directed mutagenesis. The results show that, while both motifs are essential for Myc to activate transcription, helix 2 of the HLH together with the contiguous LZ suffice to mediate complex formation with Max, whilst helix 1 is essential for sequence-specific DNA binding of Myc-Max complexes. Furthermore, the ability of Myc HLH/LZ mutants to hind DNA and activate transcription in collaboration with Max correlates closely with their neoplastic transforming activity in higher eukaryotic cells.	BEATSON INST CANC RES, CANC RES CAMPAIGN,BEATSON LABS,GARSCUBE ESTATE, SWITCHBACK RD, GLASGOW G61 1BD, SCOTLAND; MARIE CURIE RES INST, EUKARYOT TRANSCRIPT LAB, OXTED RH8 0TL, SURREY, ENGLAND	Beatson Institute			Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544; /0000-0002-6500-9095; Goding, Colin/0000-0002-1614-3909				Abate C, 1990, Semin Cancer Biol, V1, P19; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BERBERICH S, 1992, ONCOGENE, V7, P775; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; CROUCH DH, 1990, ONCOGENE, V5, P683; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FISHER F, 1991, ONCOGENE, V6, P1099; FISHER F, 1992, EMBO J, V11, P4103, DOI 10.1002/j.1460-2075.1992.tb05503.x; GIBOSN TJ, 1993, IN PRESS PROTEIN ENG; GILLESPIE DAF, 1991, SEMINARS VIROLOGY, V2, P329; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MIN SY, 1992, ONCOGENE, V7, P1531; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; Penn L J, 1990, Semin Cancer Biol, V1, P69; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; REDDY CD, 1992, ONCOGENE, V7, P2085; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; STAROVASNIK MA, 1992, BIOCHEMISTRY-US, V31, P9891, DOI 10.1021/bi00156a006; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; VINSON CR, 1992, NEW BIOL, V4, P396; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WATERS CM, 1991, ONCOGENE, V6, P797; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448	51	37	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1993	8	7					1849	1855						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510929				2022-12-28	WOS:A1993LG68200017
J	SAKAMOTO, K; HOWARD, T; OGRYZKO, V; XU, NZ; CORSICO, CC; JONES, DH; HOWARD, B				SAKAMOTO, K; HOWARD, T; OGRYZKO, V; XU, NZ; CORSICO, CC; JONES, DH; HOWARD, B			RELATIVE MITOGENIC ACTIVITIES OF WILD-TYPE AND RETINOBLASTOMA BINDING-DEFECTIVE SV40 T-ANTIGENS IN SERUM-DEPRIVED AND SENESCENT HUMAN-DIPLOID FIBROBLASTS	ONCOGENE			English	Article							EMBRYONAL CARCINOMA-CELLS; SUPPRESSOR GENE-PRODUCT; LARGE TUMOR-ANTIGEN; SUSCEPTIBILITY GENE; TRANSCRIPTION FACTOR; SV40-TRANSFORMED CELLS; INTERLEUKIN-2 RECEPTOR; CELLULAR PROTEINS; SODIUM-BUTYRATE; RB PROTEIN	A novel gene transfer approach was used to investigate whether the retinoblastoma (Rb)-binding domain of simian virus 40 (SV40) T antigen is required for efficient T antigen-mediated stimulation of DNA synthesis is quiescent or senescent human embryo fibroblasts. In senescent cells, comparison between wild-type T antigen and a mutant defective in Rb binding (Glu-107-->Lys) revealed the latter to have almost-equal-to 15-fold lower activity. In contrast, comparison of wild-type and Rb- T antigens in serum-deprived quiescent cells revealed a much smaller (1.8-fold) difference. Surprisingly, an 18-fold differential could be induced by treating quiescent cells with the differentiating agent sodium butyrate. These results suggest that the role of Rb in control of the cell cycle is strongly dependent on the physiological state of the cell and the mechanism of growth arrest.	NICHHD,MOLEC GROWTH REGULAT LAB,BLDG 6,ROOM 416,BETHESDA,MD 20892; NIH,HOWARD HUGHES MED INST,RES SCHOLARS PROGRAM,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA			Ogryzko, Vasily/M-6665-2015	Ogryzko, Vasily/0000-0002-8548-1389				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUCHMAN AR, 1980, DNA TUMOR VIRUSES, P799; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DUKOVICH M, 1987, NATURE, V327, P518, DOI 10.1038/327518a0; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FORDIS CM, 1990, P NATL ACAD SCI USA, V87, P1169, DOI 10.1073/pnas.87.3.1169; FOSS FM, 1989, ONCOGENE RES, V5, P13; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GIORDANO T, 1990, EXP CELL RES, V192, P193; GOLDSTEIN S, 1989, NUCLEIC ACIDS RES, V17, P3959, DOI 10.1093/nar/17.10.3959; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN SD, 1985, J CELL PHYSIOL, V125, P122, DOI 10.1002/jcp.1041250116; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; ISAACS WB, 1991, CANCER RES, V51, P4716; JONES DH, 1990, BIOTECHNIQUES, V8, P17; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KOSAKA M, 1991, EXP CELL RES, V192, P46, DOI 10.1016/0014-4827(91)90155-N; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NARANJO JR, 1990, NUCLEIC ACIDS RES, V18, P3605, DOI 10.1093/nar/18.12.3605; PADMANABHAN R, 1988, ANAL BIOCHEM, V170, P341, DOI 10.1016/0003-2697(88)90640-9; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SAKAMOTO K, 1991, J BIOL CHEM, V266, P3031; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TANG SJ, 1990, BIOCHIM BIOPHYS ACTA, V1048, P59, DOI 10.1016/0167-4781(90)90022-T; THOMAS NSB, 1991, ONCOGENE, V6, P317; TSUDO M, 1987, P NATL ACAD SCI USA, V84, P4215, DOI 10.1073/pnas.84.12.4215; UCHIYAMA T, 1981, J IMMUNOL, V126, P1393; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116	55	28	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1887	1893						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8390037				2022-12-28	WOS:A1993LG68200021
J	MURAKAMI, K; MAVROTHALASSITIS, G; BHAT, NK; FISHER, RJ; PAPAS, TS				MURAKAMI, K; MAVROTHALASSITIS, G; BHAT, NK; FISHER, RJ; PAPAS, TS			HUMAN ERG-2 PROTEIN IS A PHOSPHORYLATED DNA-BINDING PROTEIN - A DISTINCT MEMBER OF THE ETS FAMILY	ONCOGENE			English	Article							LONG TERMINAL REPEAT; LEUKEMIA-VIRUS; C-FOS; ONCOGENE; GENE; SEQUENCE; ONCOPROTEIN; ACTIVATION; ERYTHROBLASTOSIS; RETROVIRUS-E26	We describe the identification of the ERG-2 gene products using an antibody raised against recombinant human ERG-2 protein. ERG-2 is a nuclear phosphoprotein and binds to purine-rich sequences (C/G)(C/a)GG-AA(G/a)T. ERG-2 protein, with a half-life of 21 h, is considerably more stable than the short-lived ETS-1 or ETS-2 proteins. Its phosphorylation is stimulated by phorbal myristate acetate (PMA), but not by Ca2+ ion-phore treatment. ETS-1 protein is phosphorylated by Ca2+-dependent events, whereas ERG-2 protein is phosphorylated by activation of protein kinase C, suggesting their involvement in distinct signal transduction mechanisms. The expression of ERG-2 protein is restricted to few cell types and is high in early myeloid cells, indicating that it may function at an early stage of hematopoietic lineage determination. The DNA-binding sequence for ERG-2 protein is identified by using a random oligonucleotide selection procedure. The selected sequence is very similar to the binding sequence determined for human ETS-1 using the same method. Like other ets proteins, ERG-2 is a sequence-specific DNA-binding protein and is expressed at higher levels in early myeloid cells than in mature lymphoid cells. These results suggest that it may act as a regulator of genes required for maintenance and/or differentiation of early hematopoietic cells.	NCI,MOLEC ONCOL LAB,FREDERICK,MD 21702; INC DYNCORP,PROGRAM RESOURCES,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Fisher, Robert/B-1431-2009					BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FISHER RJ, 1991, ONCOGENE, V6, P1001; FUJIWARA S, 1988, ONCOGENE, V2, P99; FUJIWARA S, 1990, HYBRIDOMA, V9, P559, DOI 10.1089/hyb.1990.9.559; FUJIWARA S, 1990, MOL CELL BIOL, V10, P1249, DOI 10.1128/MCB.10.3.1249; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOIZUMI S, 1990, ONCOGENE, V5, P675; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; MAVROTHALASSITIS G, 1990, DNA CELL BIOL, V9, P783, DOI 10.1089/dna.1990.9.783; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDKE K, 1982, CELL, V31, P643; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SISK WP, 1986, GENE, V48, P183, DOI 10.1016/0378-1119(86)90076-4; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699	40	42	43	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1559	1566						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502479				2022-12-28	WOS:A1993LE06400019
J	OZAKI, T; SAKIYAMA, S				OZAKI, T; SAKIYAMA, S			MOLECULAR-CLONING OF RAT CALPACTIN-I HEAVY-CHAIN CDNA WHOSE EXPRESSION IS INDUCED IN V-SRC-TRANSFORMED RAT CULTURE CELL-LINES	ONCOGENE			English	Note							TYROSINE KINASE SUBSTRATE; EPIDERMAL GROWTH-FACTOR; AVIAN-SARCOMA VIRUS; MESSENGER-RNA; GENE-PRODUCT; PROTEIN; FIBROBLASTS; BINDING; P36; HOMOLOGY	A cDNA clone, termed NO2, was isolated from a rat 3Y1 cDNA library using a differential screening procedure. The amount of NO2 mRNA was increased in 3Y1 cells transformed with the Schmidt-Ruppin strain of Rous sarcoma virus (SR-3Y1) compared with that in 3Y1 cells. Sequence analysis revealed that NO2 cDNA encodes a p36 calpactin I heavy chain. In addition, the amount of a p11 calpactin I light-chain mRNA was also increased in v-src-transformed rat culture cells. The expression of both p36 and p11 genes was also induced in several sets of transformed cells, including v-H-ras-, v-mos- or SV40-transformed 3Y1 cells. As the expression of p36 and p11 genes was increased in transformed cells irrespective of the nature of oncogene products, overexpression of p36 and p11 genes might be involved in the key step of cellular transformation.	CHIBA CANC CTR,RES INST,DIV BIOCHEM,666-2 NITONA,CHUOH KU,CHIBA 260,JAPAN	Chiba Cancer Center								BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; BRYAN WR, 1955, JNCI-J NATL CANCER I, V16, P317; CALABRETTA B, 1986, P NATL ACAD SCI USA, V83, P1495, DOI 10.1073/pnas.83.5.1495; CALABRETTA B, 1986, J BIOL CHEM, V261, P2628; COOPER JA, 1983, CURR TOP MICROBIOL, V107, P125; DAVIDSON FF, 1987, J BIOL CHEM, V262, P1698; ERIKSON E, 1980, CELL, V21, P829, DOI 10.1016/0092-8674(80)90446-8; FROHLICH M, 1990, MOL CELL BIOL, V10, P3216, DOI 10.1128/MCB.10.6.3216; GAL S, 1986, J BIOL CHEM, V261, P1760; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GLENNEY J, 1986, J BIOL CHEM, V261, P7247; GLENNEY J, 1986, P NATL ACAD SCI USA, V83, P4258, DOI 10.1073/pnas.83.12.4258; GLENNEY JR, 1985, P NATL ACAD SCI USA, V82, P7884, DOI 10.1073/pnas.82.23.7884; GOULD KL, 1986, MOL CELL BIOL, V6, P2738, DOI 10.1128/MCB.6.7.2738; GROUDINE M, 1975, P NATL ACAD SCI USA, V72, P4464, DOI 10.1073/pnas.72.11.4464; HUANG KS, 1986, CELL, V46, P191, DOI 10.1016/0092-8674(86)90736-1; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JINDAL HK, 1991, J BIOL CHEM, V266, P5169; KEUTZER JC, 1990, EXP CELL RES, V188, P153, DOI 10.1016/0014-4827(90)90291-H; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; KRISTENSEN T, 1986, BIOCHEMISTRY-US, V25, P4497, DOI 10.1021/bi00364a007; Maniatis T, 1989, DECONTAMINATION DILU; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIS CJM, 1987, J BIOL CHEM, V262, P10663; SARIS CJM, 1986, CELL, V46, P201, DOI 10.1016/0092-8674(86)90737-3; SCHMIDTRUPPIN KH, 1964, ONCOLOGIA-BASEL, V17, P247, DOI 10.1159/000224235; SHIU RPC, 1977, P NATL ACAD SCI USA, V74, P3840, DOI 10.1073/pnas.74.9.3840; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; UNKELESS J, 1974, J BIOL CHEM, V249, P4295	31	30	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1707	1710						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8389036				2022-12-28	WOS:A1993LE06400038
J	OHTANIFUJITA, N; FUJITA, T; AOIKE, A; OSIFCHIN, NE; ROBBINS, PD; SAKAI, T				OHTANIFUJITA, N; FUJITA, T; AOIKE, A; OSIFCHIN, NE; ROBBINS, PD; SAKAI, T			CPG METHYLATION INACTIVATES THE PROMOTER ACTIVITY OF THE HUMAN RETINOBLASTOMA TUMOR-SUPPRESSOR GENE	ONCOGENE			English	Article							DNA METHYLATION; TRANSCRIPTIONAL ACTIVATION; TUMORIGENIC EXPRESSION; CYTOSINE METHYLATION; HUMAN CHROMOSOME-11; HUMAN NEOPLASIA; FACTOR BINDING; HUMAN CANCERS; SP1; HYPOMETHYLATION	Cytosine methylation of CpG sites in the promoter region of eucaryotic genes is involved in the inactivation of expression of certain genes. Given that methylation can lead to reduced transcription, it is possible that expression of tumor-suppressor genes is also inactivated by hypermethylation, thereby contributing to the etiology of cancer. Recently we found five sporadic retinoblastoma tumors (16% of all unilateral cases) with hypermethylation of the 5' end of the retinoblastoma gene without detecting any structural abnormalities. However, it is unclear whether the promoter of the retinoblastoma gene is actually inactivated by its hypermethylation. Here we show that specific hypermethylation in the promoter region of the retinoblastoma gene reduces its expression to only 8% of the unmethylated control. Furthermore, we have found that two transcription factors important for the promoter activity, an activating transcription factor (ATF)-like factor and the retinoblastoma binding factor 1, do not bind when their recognition sequences are CpG methylated. These results in vitro strongly support the hypothesis that CpG methylation of the human tumor-suppressor gene can result in the inactivation of the gene and thus lead to oncogenesis.	KYOTO PREFECTURAL UNIV MED,DEPT PREVENT MED,KAMIKYO KU,KYOTO 602,JAPAN; UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261	Kyoto Prefectural University of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								ADAMS RLP, 1990, BIOCHEM J, V265, P309, DOI 10.1042/bj2650309; BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383; BENHATTAR J, 1989, NUCLEIC ACIDS RES, V17, P10179, DOI 10.1093/nar/17.24.10179; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHEAH MSC, 1984, JNCI-J NATL CANCER I, V73, P1057; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; DEBUSTROS A, 1988, P NATL ACAD SCI USA, V85, P5693; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709; HARRINGTON MA, 1988, P NATL ACAD SCI USA, V85, P2066, DOI 10.1073/pnas.85.7.2066; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jones P A, 1990, Adv Cancer Res, V54, P1, DOI 10.1016/S0065-230X(08)60806-4; JONES PA, 1986, CANCER RES, V46, P461; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; MAKOS M, 1992, P NATL ACAD SCI USA, V89, P1929, DOI 10.1073/pnas.89.5.1929; SAKAI T, 1991, AM J HUM GENET, V48, P880; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816	27	288	298	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1063	1067						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455933				2022-12-28	WOS:A1993KT22000031
J	MANAK, JR; PRYWES, R				MANAK, JR; PRYWES, R			PHOSPHORYLATION OF SERUM RESPONSE FACTOR BY CASEIN KINASE .2. EVIDENCE AGAINST A ROLE IN GROWTH-FACTOR REGULATION OF FOS-EXPRESSION	ONCOGENE			English	Article							TERNARY COMPLEX-FORMATION; DNA-BINDING ACTIVITY; C-FOS; TRANSCRIPTIONAL ACTIVATION; GENE-TRANSFER; ELEMENT; PROTEIN; SEQUENCES; P67SRF; CELLS	Serum response factor (SRF) is a transcription factor involved in the serum and growth factor regulation of the c-fos gene. SRF is phosphorylated by casein kinase II (CKII), which causes a large increase in its DNA-binding activity. CKII activity has been shown to be stimulated by growth factors and serum. Since c-fos transcription is induced by a number of the same agents that stimulate CKII activity, and sincefos activation and CKII stimulation demonstrate similar rapid kinetics, a role was proposed for CKII in regulating fos expression via its phosphorylation of SRF. In this report, we provide evidence against this hypothesis by using several different strategies. First, by immunoprecipitation of SRF from cells, we show that the phosphorylation state of SRF does not change upon growth factor treatment. Second, by two-dimensional electrophoresis of lysates from a cell line that overexpresses SRF, we show that, although SRF exists in the cell in several different isoforms, there is no change in their relative amounts upon serum stimulation. Third, we tested the activity of an SRF mutant that binds DNA at constitutively high levels irrespective of CKII phosphorylation. If phosphorylation is regulatory, this mutant would be expected to consitutitively activate (or repress) fos expression. However, when overexpressed stably in cetls this mutant had no effect on endogenous c-fos expression, suggesting that CKII phosphorylation of SRF is not the limiting event for fos activation.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University				Manak, John/0000-0002-6562-7694	NATIONAL CANCER INSTITUTE [R01CA050329] Funding Source: NIH RePORTER; NCI NIH HHS [CA 50329-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; CARROLL D, 1989, J BIOL CHEM, V264, P7345; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FILHOL O, 1990, BIOCHEMISTRY-US, V29, P9928, DOI 10.1021/bi00494a025; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; GAUTHIERROUVIERE C, 1991, CELL REGUL, V2, P575, DOI 10.1091/mbc.2.7.575; GAUTHIERROUVIERE C, 1991, EMBO J, V10, P2921, DOI 10.1002/j.1460-2075.1991.tb07842.x; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HARLOW E, 1988, ANTIBODIES LABORATOR, P641; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; KLARLUND JK, 1988, J BIOL CHEM, V263, P15873; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LEUNG S, 1989, NUCLEIC ACIDS RES, V17, P1177, DOI 10.1093/nar/17.3.1177; LUO K, 1990, ONCOGENE, V5, P921; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; MOHUN TJ, 1991, EMBO J, V10, P933, DOI 10.1002/j.1460-2075.1991.tb08027.x; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; PRYWES R, 1988, COLD SPRING HARB SYM, V53, P739, DOI 10.1101/SQB.1988.053.01.084; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; PRYWES R, 1992, NUCLEIC ACIDS RES, V20, P513, DOI 10.1093/nar/20.3.513; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SUBRAMANIAM M, 1989, NATURE, V340, P64, DOI 10.1038/340064a0; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217	54	40	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					703	711						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437853				2022-12-28	WOS:A1993KN00800022
J	CROWE, AJ; HAYMAN, MJ				CROWE, AJ; HAYMAN, MJ			POSTTRANSLATIONAL MODIFICATIONS OF THE ENV-SEA ONCOGENE PRODUCT - THE ROLE OF PROTEOLYTIC PROCESSING IN TRANSFORMATION	ONCOGENE			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; GROWTH-FACTOR RECEPTOR; HUMAN-IMMUNODEFICIENCY-VIRUS; TYROSINE KINASE-ACTIVITY; CELL-SURFACE EXPRESSION; MET PROTO-ONCOGENE; C-MET; INSULIN-RECEPTOR; MAMMALIAN-CELLS; RETROVIRUS S13	The transforming gene product of the S13 avian erythroblastosis virus, env-sea, is a member of the growth factor receptor class of tyrosine kinases. The env-sea precursor protein gp155env-sea is proteolytically processed into the mature cleavage products gp85env-sea and gp70env-sea which are subsequently terminally glycosylated. Previous studies have shown that the abnormal glycosylation of gp155env-sea which takes place in the presence of the inhibitor castanospermine inhibits the proteolytic cleavage of gp155env-sea and blocks its transforming ability. To define a role for proteolytic processing of env-sea in transformation, we have introduced mutations at the protease recognition site which efficiently block cleavage without affecting the biosynthesis or transport of the resulting uncleaved protein. We show here that an uncleaved but fully glycosylated sea-encoded protein retains the ability to transform chicken embryo fibroblasts, indicating that proteolytic processing is not essential for transformation by the env-sea tyrosine kinase.	SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NCI NIH HHS [CA42573, CA28146, 5T32 CA09176] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009176, P01CA028146, R01CA042573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BENEDICT SH, 1985, VIROLOGY, V145, P154, DOI 10.1016/0042-6822(85)90210-7; BEUG H, 1985, VIROLOGY, V145, P141, DOI 10.1016/0042-6822(85)90209-0; BEUG H, 1984, CELL, V36, P963, DOI 10.1016/0092-8674(84)90046-1; BEUG H, 1982, J CELL PHYSL S, V1, P195; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRADAC J, 1986, VIROLOGY, V150, P491, DOI 10.1016/0042-6822(86)90313-2; CHAN AML, 1988, ONCOGENE, V2, P593; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; CROWE AJ, 1991, J VIROL, V65, P2533, DOI 10.1128/JVI.65.5.2533-2538.1991; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; EINFELD D, 1988, P NATL ACAD SCI USA, V85, P8688, DOI 10.1073/pnas.85.22.8688; GEYER H, 1988, J BIOL CHEM, V263, P11760; GIORDANO S, 1989, ONCOGENE, V4, P1383; HARDWICK JM, 1986, J CELL BIOL, V103, P829, DOI 10.1083/jcb.103.3.829; HAYMAN M, 1978, VIROLOGY, V85, P475, DOI 10.1016/0042-6822(78)90454-3; HAYMAN MJ, 1986, VIROLOGY, V150, P270, DOI 10.1016/0042-6822(86)90287-4; HAYMAN MJ, 1985, P NATL ACAD SCI USA, V82, P8237, DOI 10.1073/pnas.82.23.8237; HEDO JA, 1983, J BIOL CHEM, V258, P20; HUNTER E, 1989, CURR TOP MICROBIOL, V157, P188; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KNIGHT J, 1988, ONCOGENE, V2, P317; KNIGHT J, 1990, VIROLOGY, V178, P232, DOI 10.1016/0042-6822(90)90398-B; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIPSICK JS, 1986, J VIROL, V59, P267, DOI 10.1128/JVI.59.2.267-275.1986; MONDINO A, 1991, MOL CELL BIOL, V11, P6084, DOI 10.1128/MCB.11.12.6084; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, IN PRESS EMBO J; NICHOLS EJ, 1985, MOL CELL BIOL, V5, P3467, DOI 10.1128/MCB.5.12.3467; PEREZ LG, 1987, J VIROL, V61, P1609, DOI 10.1128/JVI.61.5.1609-1614.1987; PINTER A, 1984, J VIROL, V49, P452, DOI 10.1128/JVI.49.2.452-458.1984; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; SCHMIDT JA, 1985, EMBO J, V4, P105, DOI 10.1002/j.1460-2075.1985.tb02323.x; SCHWALLER M, 1989, VIROLOGY, V172, P367; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; STOKER AW, 1988, J VIROL, V62, P1008, DOI 10.1128/JVI.62.3.1008-1015.1988; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198; WEISS CD, 1990, J VIROL, V64, P5674, DOI 10.1128/JVI.64.11.5674-5677.1990; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YOSHIMASA Y, 1988, SCIENCE, V240, P784, DOI 10.1126/science.3283938; YOSHIMASA Y, 1990, J BIOL CHEM, V265, P17230	45	12	12	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					181	189						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423995				2022-12-28	WOS:A1993KN00500022
J	SMITH, KT; COGGINS, LW; DOHERTY, I; PENNIE, WD; CAIRNEY, M; CAMPO, MS				SMITH, KT; COGGINS, LW; DOHERTY, I; PENNIE, WD; CAIRNEY, M; CAMPO, MS			BPV-4 INDUCES AMPLIFICATION AND ACTIVATION OF SILENT BPV-1 IN A SUBLINE OF C127 CELLS	ONCOGENE			English	Article							BOVINE PAPILLOMAVIRUS TYPE-4; MOUSE CELLS; MORPHOLOGICAL TRANSFORMATION; TERMINAL DOMAIN; DNA-SEQUENCES; CATTLE; GENE; MAINTENANCE; REPLICATION; VIRUS	BPV4-induced malignant transformation of C127 mouse fibroblasts in vitro is the result of a 'hit and run' mechanism. Viral DNA is lost on continued subculture of transformed cell lines without loss of any malignant characteristics. The DNA from these cells harbours specific amplified sequences. Two such amplified fragments of approximately 10kb and 12kb were molecularly cloned and designated HL-10 and HL-12 respectively. HL-10 transformed C127 celts efficiently and therefore encodes a transforming function, whereas the 12 kb clone did not. Heteroduplexes showed that HL-12 was homologous to HL-10 except for two additional tandem copies of an approximately 1.7 kb sequence. Sequence analysis of HL-10 revealed that the clone contained a 5.2 kb region from BPV-1 including the transforming ORFs. Transformation studies have shown differences between HL-10 and BPV-1, indicating that the host flanking sequences may contribute to the transforming potential of the BPV-1 ORFs. The BPV-1 DNA was associated with sequences homologous to murine autonomously replicating sequences (ARS) implicated in the establishment of multiple tandem DNA repeats. As the parental cells contain the set of sequences amplified in transformed cells in single copy and show none of the characteristics of transformed cells, we conclude that BPV-4 has activated these sequences by amplification and rearrangement. These phenomena may be mediated through an interaction between BPV-4 proteins and the BPV-1 origin of DNA replication or via the ARS region.	BEATSON INST CANC RES, CRC BEATSON LABS, GLASGOW G61 1BD, SCOTLAND	Beatson Institute								AGRAWAL R, 1992, J GEN VIROL, V73, P201, DOI 10.1099/0022-1317-73-1-201; CAMPO MS, 1978, CELL, V15, P1411, DOI 10.1016/0092-8674(78)90065-X; CAMPO MS, 1985, EMBO J, V4, P1819, DOI 10.1002/j.1460-2075.1985.tb03856.x; CAMPO MS, 1990, ONCOGENE, V5, P303; CAMPO MS, 1982, J GEN VIROL, V63, P255, DOI 10.1099/0022-1317-63-2-255; CAMPO MS, 1986, CIBA F SYMP, V120, P117; CHEN EY, 1982, NATURE, V299, P529, DOI 10.1038/299529a0; Coggins LW, 1987, ELECTRON MICROS, P1; FERGUSON J, 1978, ADV TECHNIQUES BIOL, V2, P123; GAUKROGER J, 1991, J GEN VIROL, V72, P1165, DOI 10.1099/0022-1317-72-5-1165; GILBERT D, 1989, CELL, V56, P143, DOI 10.1016/0092-8674(89)90885-4; GREEN M, 1987, CELL, V51, P795, DOI 10.1016/0092-8674(87)90102-4; GRUMMT F, 1989, CELL, V56, P143, DOI 10.1016/0092-8674(89)90886-6; HOLST A, 1988, CELL, V52, P355; JACKSON ME, 1991, MOL CARCINOGEN, V4, P382, DOI 10.1002/mc.2940040510; JAGGAR RT, 1990, J GEN VIROL, V71, P3041, DOI 10.1099/0022-1317-71-12-3041; JARRETT WFH, 1978, NATURE, V274, P215, DOI 10.1038/274215a0; KLEINBERGER T, 1986, MOL CELL BIOL, V6, P1958, DOI 10.1128/MCB.6.6.1958; LAMBERT PF, 1987, CELL, V50, P69, DOI 10.1016/0092-8674(87)90663-5; LIU Y, 1990, J VIROL, V64, P5903, DOI 10.1128/JVI.64.12.5903-5911.1990; LUSKY M, 1986, P NATL ACAD SCI USA, V83, P3609, DOI 10.1073/pnas.83.11.3609; MACNAB JCM, 1987, J GEN VIROL, V68, P2525, DOI 10.1099/0022-1317-68-10-2525; MARSH JL, 1984, GENE, V32, P481, DOI 10.1016/0378-1119(84)90022-2; MORGAN D, 1990, J VIROL, V64, P969, DOI 10.1128/JVI.64.3.969-976.1990; POPESCU NC, 1990, CANCER RES, V50, P1316; SATO H, 1989, VIROLOGY, V168, P195, DOI 10.1016/0042-6822(89)90423-6; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; SMITH KT, 1989, ONCOGENE, V4, P409; SMITH KT, 1988, VIROLOGY, V164, P39, DOI 10.1016/0042-6822(88)90617-4; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; STENLUND A, 1987, SCIENCE, V236, P1666, DOI 10.1126/science.3037693; TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0	32	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1993	8	1					151	156						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380914				2022-12-28	WOS:A1993KN00500018
J	Chen, RH; Juo, PCH; Curran, T; Blenis, J				Chen, RH; Juo, PCH; Curran, T; Blenis, J			Phosphorylation of c-Fos at the C-terminus enhances its transforming activity	ONCOGENE			English	Article						c-Fos; MAP kinase; pp90(RSK)	SERUM RESPONSE ELEMENT; ACTIVATED PROTEIN-KINASE; IMMEDIATE-EARLY GENE; DNA-BINDING ACTIVITY; GROWTH-FACTOR; MAP KINASES; TRANSCRIPTIONAL ACTIVATION; NUCLEAR-LOCALIZATION; CELL-PROLIFERATION; COMPLEX-FORMATION	c-Fos is phosphorylated by MAP kinase and the 90 kDa-ribosomal S6 kinase (RSK) in vitro at serines 362 and 374 (rat) which we demonstrate are major in vivo phosphorylation sites in early G1. We have constructed c-Fos mutants with these serines changed to aspartic acid residues (FosD) to mimic phosphorylation or to alanine residues (FosA) to prevent phosphorylation. Cells expressing FosD exhibited a more extensive transformed phenotype than those expressing either FosA or wild type c-Fos (FosWT). We also observed that FosA has a reduced half-life in comparison with FosD in G1. Furthermore, we observed enhanced AP-1 transactivation activity in cells expressing FosD. These results indicate that phosphorylation of c-Fos at its extreme carboxy-terminus, possibly by MAP kinase and RSK, supports the proliferative response by increasing c-Fos stability and/or by increasing its transactivation activity. Under conditions in which the MAP kinase pathway is constitutively activated, c-Fos phosphorylation probably contributes to cellular transformation. The highly conserved nature of these phosphorylation sites in other c-fos family members suggest that these may also be targets of MAP kinase and RSK.	HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; ST JUDE CHILDRENS RES HOSP, DEPT DEV NEUROBIOL, MEMPHIS, TN 38105 USA	Harvard University; Harvard Medical School; St Jude Children's Research Hospital			Curran, Thomas/AAE-7631-2019; Curran, Tom/C-1164-2008; Curran, Tom/D-7515-2011; Curran, Tom/F-5234-2018	Curran, Thomas/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551	NATIONAL CANCER INSTITUTE [R01CA046595, R37CA046595] Funding Source: NIH RePORTER; NCI NIH HHS [CA46595] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1984, CELL, V36, P259; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GRUDA MC, 1994, ONCOGENE, V9, P2537; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KONIG H, 1991, MOL CELL BIOL, V11, P2451; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MALIK RK, 1991, J BIOL CHEM, V266, P8576; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUI M, 1990, ONCOGENE, V5, P249; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MILLER AD, 1984, CELL, V36, P51; NEUBERG M, 1991, ONCOGENE, V6, P1325; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; Sambrook J, 1989, MOL CLONING; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	48	142	143	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	1996	12	7					1493	1502						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622865				2022-12-28	WOS:A1996UF07600013
J	Wu, XP; Rubin, M; Fan, Z; DeBlasio, T; Soos, T; Koff, A; Mendelsohn, J				Wu, XP; Rubin, M; Fan, Z; DeBlasio, T; Soos, T; Koff, A; Mendelsohn, J			Involvement of p27(KIP1) in G(1) arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody	ONCOGENE			English	Article						EGF receptor; mAb; p27(KIP1); cyclins; CDKs; cell cycle arrest	PROTEIN-KINASE; BREAST-CANCER; FACTOR-ALPHA; CELLS; CARCINOMA; CYCLIN	Activation of the cyclin dependent kinases (CDK4/CDK6 and CDK2) is required for G(1) phase progression and entry into S-phase. The activation of these kinases is regulated by checkpoints that monitor environmental and intracellular conditions. Progression into S-phase is controlled, in part, by the availability of growth factors, and we have investigated the relationship between growth factor availability and the activation of the CDK kinases. Blocking activation of epidermal growth factor (EGF) receptor tyrosine kinase with anti-EGF receptor monoclonal antibody (mAb) 225 induces G(1) phase cell cycle arrest in DiFi human colon adenocarcinoma cells. When DiFi cells are treated with mAb 225 for 24 h, eve observe marked decreases in the activities of CDK2 kinase and cyclin E-associated CDK kinase which are not accompanied by reduced levels of cyclin E and CDK2 proteins. However, the amount of cyclin/CDK kinase inhibitor p27(KIP1) increases in the mAb-treated cells and p27(KIP1) is bound to CDK2 in increasing amounts. Immunodepletion of p27(KIP1) removes an inhibitory activity from lysates of mAb-treated cells: the immuno-depleted and heated lysates lose the capacity to inhibit cyclin E/CDK2 activity in an in vitro assay. The results suggest that G(1) arrest in the cell cycle induced by EGF receptor blockade involves p27(KIP1).	MEM SLOAN KETTERING CANC CTR,LAB RECEPTOR BIOL,PROGRAM MOL PHARMACOL & THERAPEUT,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT PHARMACOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University				Rubin, Mark/0000-0002-8321-9950	NCI NIH HHS [CA42060, CA 37641] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042060, U01CA037641, U19CA037641, R37CA042060] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ARTEAGA CL, 1988, MOL ENDOCRINOL, V2, P1064, DOI 10.1210/mend-2-11-1064; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DIVGI CR, 1991, J NATL CANCER I, V83, P97, DOI 10.1093/jnci/83.2.97; FAN Z, 1995, FJ CELL BIOL, V131, P235; GILL GN, 1984, J BIOL CHEM, V259, P7755; GRANA X, 1995, ONCOGENE, V11, P211; GROSS ME, 1991, CANCER RES, V51, P1452; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HALL M, 1995, ONCOGENE, V11, P1581; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARRIS AL, 1989, CANCER CEL, V7, P353; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KARNES WE, 1992, GASTROENTEROLOGY, V102, P474, DOI 10.1016/0016-5085(92)90093-E; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1995, PROGR CELL CYCLE RES, P141; MASUI H, 1984, CANCER RES, V44, P1002; MASUI H, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P394; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mendelsohn J, 1990, Semin Cancer Biol, V1, P339; NEAL DE, 1985, LANCET, V1, P366; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SAINSBURY JRC, 1985, J CLIN PATHOL, V38, P1225, DOI 10.1136/jcp.38.11.1225; Sato J D, 1983, Mol Biol Med, V1, P511; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VEALE D, 1987, BRIT J CANCER, V55, P513, DOI 10.1038/bjc.1987.104; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871	37	212	225	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1397	1403						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622855				2022-12-28	WOS:A1996UF07600003
J	Albini, A; Benelli, R; Presta, M; Rusnati, M; Ziche, M; Rubartelli, A; Paglialunga, G; Bussolino, F; Noonan, D				Albini, A; Benelli, R; Presta, M; Rusnati, M; Ziche, M; Rubartelli, A; Paglialunga, G; Bussolino, F; Noonan, D			HIV-tat protein is a heparin-binding angiogenic growth factor	ONCOGENE			English	Article						HIV; tat; heparin; growth factor; angiogenesis	HUMAN-IMMUNODEFICIENCY-VIRUS; FIBROBLAST GROWTH; KAPOSIS-SARCOMA; 3-DIMENSIONAL STRUCTURE; FUNCTIONAL DOMAINS; BASEMENT-MEMBRANE; ENDOTHELIAL-CELLS; BASIC DOMAIN; RECEPTOR; GENE	Transgenic animal studies have linked the expression of the HIV-1 tat gene to the appearance of Kaposi's sarcoma (KS)-like lesions. We have recently shown that recombinant tat is angiogenic in vivo, and that tat angiogenic response is enhanced by heparin. Also in the rabbit cornea model, recombinant HIV-1 tat alone is poorly angiogenic, but gives a good response when combined with heparin. Like many angiogenic growth factors, tat has a basic domain similar to that of several heparin binding angiogenic factors, including FGF, VEGF and HGF, suggesting that this region is important in endothelial cell activation. We show that tat binds heparin sepharose with a high affinity, similar to bFGF. Binding of tat to the cell surface is also modulated by heparin. Biological activities of tat, such as induction of endothelial cell growth, migration and invasion in vitro are all enhanced by low concentrations and inhibited by high concentrations of heparin, as has been shown for other heparin-binding angiogenic factors. Heparan sulfate is also effective, whereas the unsulfated polysaccharide K5 does not enhance tat activity. Furthermore, a peptide encompassing the tat basic domain is able to induce growth and migration of endothelial cells, while an adjacent peptide is not. Our data indicate that the tat basic domain plays a key role in its vascular cell activation properties, and strongly suggest that extracellular HIV-tat is essentially a 'new' heparin-binding angiogenic factor.	UNIV BRESCIA, DEPT BIOMED SCI & BIOTECHNOL, BRESCIA, ITALY; UNIV FLORENCE, DEPT PHARMACOL, FLORENCE, ITALY; UNIV TURIN, DEPT GENET BIOL & MED CHEM, TURIN, ITALY	University of Brescia; University of Florence; University of Turin	Albini, A (corresponding author), IST NAZL RIC CANC, I-16132 GENOA, ITALY.		Noonan, Douglas M/A-8620-2010; Bussolino, Federico/AES-3951-2022; Presta, Marco/B-4345-2010; Rubartelli, Anna/AAA-1259-2021; Benelli, Roberto/AAF-3143-2019; Rusnati, Marco/F-1168-2010; Bussolino, Federico/K-2500-2016	Noonan, Douglas M/0000-0001-8058-0719; Benelli, Roberto/0000-0002-9769-0954; Rusnati, Marco/0000-0001-9968-5908; PRESTA, Marco/0000-0002-4398-8376; Bussolino, Federico/0000-0002-5348-1341; Albini, Adriana/0000-0002-9624-5103				ALBINI A, 1987, J CELL BIOL, V105, P1867, DOI 10.1083/jcb.105.4.1867; ALBINI A, 1994, AIDS, V8, P1237, DOI 10.1097/00002030-199409000-00004; ALBINI A, 1995, P NATL ACAD SCI USA, V92, P4838, DOI 10.1073/pnas.92.11.4838; ALBINI A, 1987, CANCER RES, V47, P3239; ARMES J, 1989, ADV CANCER RES, V53, P73; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; BARILLARI G, 1992, J IMMUNOL, V149, P3727; BARNETT SW, 1994, SCIENCE, V266, P642, DOI 10.1126/science.7939718; BONIFACI N, 1995, AIDS, V9, P995, DOI 10.1097/00002030-199509000-00003; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BUONAGURO L, 1994, J VIROL, V68, P2677, DOI 10.1128/JVI.68.4.2677-2682.1994; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CARMICHAEL J, 1987, CANCER RES, V47, P936; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CORALLINI A, 1993, CANCER RES, V53, P5569; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; FOLKMAN J, 1988, AM J PATHOL, V130, P393; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FRIEDMANKIEN AE, 1982, ANN INTERN MED, V96, P693, DOI 10.7326/0003-4819-96-6-693; GARCIA JA, 1988, EMBO J, V7, P3143, DOI 10.1002/j.1460-2075.1988.tb03181.x; GEIER SA, 1993, AIDS, V7, P746, DOI 10.1097/00002030-199305000-00027; GEIER SA, 1993, J AQUIR IMMUNE DEFIC, V6, P262; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; HAUBER J, 1989, J VIROL, V63, P1181, DOI 10.1128/JVI.63.3.1181-1187.1989; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOFMAN FM, 1993, BLOOD, V82, P2774; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISHIHARA M, 1986, J BIOL CHEM, V261, P3575; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LOTZ M, 1994, J CELL BIOL, V124, P365, DOI 10.1083/jcb.124.3.365; MAGLIONE D, 1993, ONCOGENE, V8, P925; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MORTARINI R, 1992, CANCER RES, V52, P4499; NEWSOME DA, 1984, AM J OPHTHALMOL, V98, P590, DOI 10.1016/0002-9394(84)90245-9; PASSANITI A, 1992, LAB INVEST, V67, P519; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROBBINS KC, 1983, NATURE, V305, P605, DOI 10.1038/305605a0; ROTH WK, 1992, AIDS, V6, P895, DOI 10.1097/00002030-199209000-00001; RUSNATI M, 1993, J CELL PHYSIOL, V154, P152, DOI 10.1002/jcp.1041540119; SAFAI B, 1985, ANN INTERN MED, V103, P744, DOI 10.7326/0003-4819-103-5-744; SCALA G, 1994, J EXP MED, V179, P961, DOI 10.1084/jem.179.3.961; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; TESSLER S, 1994, J BIOL CHEM, V269, P12456; THOMPSON EW, 1991, CANCER RES, V51, P2670; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZICHE M, 1989, LAB INVEST, V61, P629; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557	60	134	141	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	1996	12	2					289	297						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570206				2022-12-28	WOS:A1996TR53800008
J	Kyritsis, AP; Zhang, BH; Zhang, W; Xiao, M; Takeshima, H; Bondy, ML; Cunningham, JE; Levin, VA; Bruner, J				Kyritsis, AP; Zhang, BH; Zhang, W; Xiao, M; Takeshima, H; Bondy, ML; Cunningham, JE; Levin, VA; Bruner, J			Mutations of the p16 gene in gliomas	ONCOGENE			English	Article						astrocytoma; brain tumor; MTS1; glioblastoma	SSCP ANALYSIS; CELLS	In the present study we investigated the frequency of p16 gene exon 2 mutations in 35 malignant gliomas, using either direct sequencing of the PCR products or cloning into the pCRII vector and sequencing of the cloned PCR products. No mutations were detected during direct sequencing of the PCR products. However, after sequencing ofindividual clones, we found multiple mutations in 5 tumors involving codons 73(GCC to ACC, Ala to Thr), 76 (GCC to GTC, Ala to Va), 85(GCT to ACT, Ala to Thr), 98(CAC to TAC, His to Tyr), 102 (GCG to GTG, Ala to Val), 106 (GTG to ATG, Val to Met), 107 (CGC to TGC, Arg to Cys), 127 (GCA to GTA, Ala to Val), 128 (CGG to TGG, Arg to Trp) and 136 (GGC to GAG, Gly to Asp). Mutations were found only in glioblastomas and were either C to T or G to A transitions. Each mutation was detected in a small percentage of tumor cells (1.3-22%) using individual colony sequencing and southern hybridization with mutant oligonucleotides, consistent with the heterogenous cell population of glioblastomas. The presence of p16 gene mutations only in glioblastomas suggests that they are late events in glioma development.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT EPIDEMIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kyritsis, AP (corresponding author), UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT NEUROONCOL,1515 HOLCOMBE BLVD,BOX 100,HOUSTON,TX 77030, USA.		Cunningham, John/GWB-9698-2022	Cunningham, John/0000-0002-1805-9743	NCI NIH HHS [CCSG-CA16672, P01-CA55261] Funding Source: Medline; NINDS NIH HHS [R29 NS32269-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055261, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS032269] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; FAN E, 1993, MUTAT RES, V288, P85, DOI 10.1016/0027-5107(93)90210-7; GIANI C, 1994, CANCER RES, V54, P6338; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; HE J, 1994, CANCER RES, V54, P5804; IGAKI H, 1994, BIOCHEM BIOPH RES CO, V203, P1090, DOI 10.1006/bbrc.1994.2294; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KYRITSIS AP, 1992, INT J ONCOL, V1, P149; KYRITSIS AP, 1994, JNCI-J NATL CANCER I, V86, P344, DOI 10.1093/jnci/86.5.344; LI Y, 1994, CANCER RES, V54, P6078; MOULTON T, 1995, AM J PATHOL, V146, P613; NELSON JS, 1983, CANCER, V52, P550, DOI 10.1002/1097-0142(19830801)52:3<550::AID-CNCR2820520327>3.0.CO;2-C; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1994, ONCOGENE, V9, P3375; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; WU JK, 1993, AM J HUM GENET, V52, P1273; ZHOU XL, 1994, ONCOGENE, V9, P3737	22	58	62	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					63	67						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552400				2022-12-28	WOS:A1996TQ01400008
J	Miyaki, M; Tanaka, K; KikuchiYanoshita, R; Muraoka, M; Konishi, M; Takeichi, M				Miyaki, M; Tanaka, K; KikuchiYanoshita, R; Muraoka, M; Konishi, M; Takeichi, M			Increased cell-substratum adhesion, and decreased gelatinase secretion and cell growth, induced by E-cadherin transfection of human colon carcinoma cells	ONCOGENE			English	Article						E-cadherin; colon carcinoma; cell adhesion; gelatinase; cell growth	FAMILIAL ADENOMATOUS POLYPOSIS; TUMOR-CELLS; EXPRESSION; CANCER; PROGRESSION; MOLECULES; TUMORIGENICITY; SUPPRESSION; INVASION	Metastasis of colon carcinomas is assumed to be caused by multiple steps, which include a loss of cell adhesion that results in the release of carcinoma cells from the original tumor tissue, A human colon carcinoma cell line COKFu was established from a poorly differentiated metastatic adenocarcinoma without cell-cell adhesion and without expression of E-cadherin mRNA and protein, This cell line was co-transfected with mouse E-cadherin cDNA in an expression vector and a neomycin-resistant gene, The parental carcinoma cells had a spindle shape and were scattered, whereas the transfected cells, which expressed exogenous E-cadherin gene, showed a more compact shape with strong cell-cell adhesion and with increased adhesiveness to collagen gel, These cells showed a significantly low anchorage independency (2-7%) and decreased invasiveness (30%) compared to the parental cells, Growth rate of transfectants was decreased both in vitro and in the subcutis of nude mice, with decreased lymphnode metastasis in the case of intravenous injection, It was additionally found that activity of 62 kd gelatinase, secreted from parental cells, was lost or decreased in E-cadherin-transfected cells. These results suggest that E-cadherin is not only involved in the cell-cell adhesion of colon carcinomas, it also has a wider effect, including cell-substratum adhesion and the regulation of proteinase secretion from the cells resulting in partial suppression of invasiveness and tumorigenic growth.	KYOTO UNIV,FAC SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN	Kyoto University	Miyaki, M (corresponding author), TOKYO METROPOLITAN INST MED SCI,DEPT BIOCHEM,BUNKYO KU,3-18-22 HONKOMAGOME,TOKYO 113,JAPAN.		Takeichi, Masatoshi/G-5903-2012	Takeichi, Masatoshi/0000-0002-9931-3378				ALBINI A, 1987, CANCER RES, V47, P3239; AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BUSSEMAKERS MJG, 1992, CANCER RES, V52, P2916; CHEN WC, 1991, J CELL BIOL, V114, P319, DOI 10.1083/jcb.114.2.319; DIMANCHEBOITREL MT, 1994, INT J CANCER, V56, P512, DOI 10.1002/ijc.2910560410; DOKI M, 1992, CANCER RES, V53, P3421; DORUDI S, 1993, AM J PATHOL, V142, P981; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; HASHIMOTO M, 1989, JPN J CANCER RES, V80, P459, DOI 10.1111/j.1349-7006.1989.tb02336.x; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KATOH K, 1987, CELL STRUCT FUNCT, V12, P575, DOI 10.1247/csf.12.575; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3801; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MIYAKI M, 1994, CANCER RES, V54, P3011; MIYAKI M, 1990, CANCER RES, V50, P7166; MIYAKI M, 1995, CRIT REV ONCOL HEMAT, V19, P1, DOI 10.1016/1040-8428(94)00129-H; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCIPPER JH, 1991, CANCER RES, V51, P6328; SHIMOYAMA Y, 1991, CANCER LETT, V57, P131, DOI 10.1016/0304-3835(91)90206-W; SHIOZAKI H, 1991, AM J PATHOL, V139, P17; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; TANAKA K, 1993, ONCOGENE, V8, P2253; UMBAS R, 1992, CANCER RES, V52, P5104; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M	32	57	61	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2547	2552						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545111				2022-12-28	WOS:A1995TP18800010
J	TAKAHASHI, M; ASAI, N; IWASHITA, T; ISOMURA, T; MIYAZAKI, K; MATSUYAMA, M				TAKAHASHI, M; ASAI, N; IWASHITA, T; ISOMURA, T; MIYAZAKI, K; MATSUYAMA, M			CHARACTERIZATION OF THE RET PROTOONCOGENE PRODUCTS EXPRESSED IN MOUSE L-CELLS	ONCOGENE			English	Article							PROTOONCOGENE RET; CADHERIN; TYROSINE; NEUROBLASTOMA	The ret proto-oncogene (proto-ret) encodes a receptor type tyrosine kinase with a cadherin-related sequence in the extracellular domain. To investigate whether the proto-Ret protein functions as a cell adhesion molecule like cadherins, we transfected the human proto-ret gene fused to the SV40 promoter or cytomegalovirus (CMV) promoter into mouse L cells in which cadherins are not expressed. Three transfectants with high levels of expression of the proto-Ret proteins were obtained. The proto-Ret proteins were expressed as 150 kDa and 170 kDa glycoproteins in transfectants as observed in human neuroblastoma cells. Cell fractionation experiments revealed that the 170 kDa protein but not the 150 kDa protein was detected predominantly in the plasma membrane fraction, indicating that the 170 kDa protein represents the mature glycosylated form of the proto-Ret protein present on the cell surface. Both 150 kDa and 170 kDa proto-Ret proteins showed tyrosine kinase activity in immunocomplex kinase assay. It is known that cadherins have Ca2+-dependent homophilic binding activity and are resistant to trypsinization in the presence of Ca2+. When L cells expressing the proto-Ret proteins were treated with trypsin in the presence of Ca2+, the 170 kDa protein was resistant to its digestion. On the other hand, it was completely digested in the presence of EGTA, suggesting the possibility that the proto-Ret protein interacts with Ca2+ like cadherins. However, the transfectants did not show clear adhesive properties in cell aggregation assays.	NAGOYA UNIV,SCH MED,DEPT SURG,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NAGOYA UNIV,SCH MED,DEPT RADIOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN	Nagoya University; Nagoya University	TAKAHASHI, M (corresponding author), NAGOYA UNIV,SCH MED,DEPT PATHOL,65 TSURUMAI CHO,SHOWA KU,NAGOYA,AICHI 466,JAPAN.		Takahashi, Masahide/AAN-4770-2020; ASAI, Naoya/I-7377-2014; TAKAHASHI, Masahide/I-7244-2014	Takahashi, Masahide/0000-0002-2803-2683; 				HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IKEDA I, 1990, ONCOGENE, V5, P1291; IWAMOTO T, 1993, ONCOGENE, V8, P1087; KUMA K, 1992, P JPN ACAD B-PHYS, V68, P106, DOI 10.2183/pjab.68.106; MIYAZAKI K, 1993, BIOCHEM BIOPH RES CO, V193, P565, DOI 10.1006/bbrc.1993.1661; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; SANTORO M, 1990, ONCOGENE, V5, P1595; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; THOM D, 1977, BIOCHEM J, V168, P187, DOI 10.1042/bj1680187	15	89	91	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2925	2929						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414495				2022-12-28	WOS:A1993MC09300005
J	MICHIELS, L; VANDERRAUWELAERT, E; VANHASSELT, F; KAS, K; MERREGAERT, J				MICHIELS, L; VANDERRAUWELAERT, E; VANHASSELT, F; KAS, K; MERREGAERT, J			FAU CDNA ENCODES A UBIQUITIN-LIKE-S30 FUSION PROTEIN AND IS EXPRESSED AS AN ANTISENSE SEQUENCE IN THE FINKEL-BISKIS-REILLY MURINE SARCOMA-VIRUS	ONCOGENE			English	Article							V-FOS; C-FOS; NUCLEOTIDE-SEQUENCE; CELLULAR GENES; FBR-MUSV; CELLS; IDENTIFICATION; TRANSFORMATION; INTERFERON; ONCOGENE	The Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) is capable of inducing osteosarcomas in susceptible mice. This retrovirus transduced sequences derived from the transcription factor c-fos and from an unrelated mouse sequence called fox. Here, we describe the cloning and sequence analysis of human and mouse cellular cDNAs hybridizing to the fox sequence. The cloned cDNAs encode for a single ubiquitin-like (Fubi) protein fused in frame to S30, a protein of the small ribosomal subunit. Fubi conserved amino acid residues known to be involved in the ATP-dependent proteolytic activity of ubiquitin. Moreover, the fau gene is conserved in several species, while its mRNA is ubiquitously expressed in different mouse tissues. Surprisingly, FBR-MuSV transduced the complete but mutated open reading frame (ORF) in its reversed transcriptional orientation. This is the first report about a retrovirus in which an antisense sequence to a cellular gene, which we called fau (FBR-MuSV-associated ubiquitously expressed gene), is discovered. Rat-2 cells transfected with plasmids containing v-fau/fox recombinants of FBR-MuSV revealed a twofold increase of the transformation capacity of FBR-MuSV 'in vitro' because of the fau antisense sequence. Newly formed retropseudogenes were identified in three out of eight primary radiation-induced osteosarcomas. This high incidence of creating retropseudogenes in these Sr-90-induced bone tumours may contribute to the mechanism by which FBR-MuSV, originally isolated from such tumours, acquired the fau gene in its reverse orientation.	UNIV INSTELLING ANTWERP,DEPT BIOCHEM,MOLEC BIOTECHNOL LAB,UNIVERSITEITSPLEIN 1,B-2610 WILRIJK,BELGIUM	University of Antwerp			Michiels, Luc/AGH-3847-2022	Michiels, Luc/0000-0001-5065-2048				AHRENS PB, 1990, J GEN VIROL, V71, P1675, DOI 10.1099/0022-1317-71-8-1675; BANERJI J, 1990, P NATL ACAD SCI USA, V87, P2374, DOI 10.1073/pnas.87.6.2374; BENTVELZEN P, 1978, J NATL CANCER I, V60, P401, DOI 10.1093/jnci/60.2.401; BUTT TR, 1988, J BIOL CHEM, V263, P16364; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; DAVIE JR, 1990, BIOCHEMISTRY-US, V29, P4752, DOI 10.1021/bi00472a002; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FINKEL MP, 1973, BONE CERTAIN ASPECTS, P353; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; GOMEZMARQUEZ J, 1988, FEBS LETT, V226, P217, DOI 10.1016/0014-5793(88)81425-X; GUARINO LA, 1990, P NATL ACAD SCI USA, V87, P409, DOI 10.1073/pnas.87.1.409; GUIS D, 1990, MOL CELL BIOL, V10, P4243; HAAS AL, 1987, J BIOL CHEM, V262, P11315; JANOWSKI M, 1990, INT J RADIAT BIOL, V57, P677, DOI 10.1080/09553009014550851; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; JENUWEIN T, 1985, CELL, V41, P629, DOI 10.1016/S0092-8674(85)80035-0; JIANCHILL JL, 1969, J VIROL, V4, P549; KAS K, 1992, BIOCHEM BIOPH RES CO, V187, P927, DOI 10.1016/0006-291X(92)91286-Y; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; LOEB KR, 1992, J BIOL CHEM, V267, P7806; LUND PK, 1985, J BIOL CHEM, V260, P7609; MATTHIAS PD, 1983, EMBO J, V2, P1487, DOI 10.1002/j.1460-2075.1983.tb01612.x; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MERREGAERT J, 1984, CR SOC BIOL, V178, P171; MEYERS G, 1991, VIROLOGY, V180, P602, DOI 10.1016/0042-6822(91)90074-L; MEYERS G, 1989, NATURE, V341, P491, DOI 10.1038/341491a0; MICHIELS L, 1986, VIRUS RES, V5, P11, DOI 10.1016/0168-1702(86)90062-6; MICHIELS L, 1984, INT J CANCER, V33, P511, DOI 10.1002/ijc.2910330415; MICHIELS L, 1992, THESIS U ANTWERP; MILLER AD, 1984, CELL, V36, P51; MONIA BP, 1990, BIO-TECHNOL, V8, P209, DOI 10.1038/nbt0390-209; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; REDMAN KL, 1989, NATURE, V338, P438, DOI 10.1038/338438a0; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SWAIN A, 1992, SCIENCE, V255, P841, DOI 10.1126/science.1371365; TONOLIO D, 1988, P NATL ACAD SCI USA, V85, P851; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; VANBEVEREN C, 1984, VIROLOGY, V135, P229, DOI 10.1016/0042-6822(84)90133-8; VANDERRAUWELAERT E, 1988, ONCOGENE, V2, P215; WISDOM R, 1990, MOL CELL BIOL, V10, P5626, DOI 10.1128/MCB.10.11.5626; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	49	47	57	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2537	2546						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8395683				2022-12-28	WOS:A1993LT36800026
J	CATLING, AD; WYKE, JA; FRAME, MC				CATLING, AD; WYKE, JA; FRAME, MC			MITOGENESIS OF QUIESCENT CHICK FIBROBLASTS BY V-SRC - DEPENDENCE ON EVENTS AT THE MEMBRANE LEADING TO EARLY CHANGES IN AP-1	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; DNA-BINDING ACTIVITY; C-JUN; TRANSFORMING PROTEIN; PHOSPHORYLATION; FOS; PP60V-SRC; SEQUENCE; PROMOTER; INVITRO	Activation of rapidly reversible temperature-sensitive (ts) v-Src in quiescent chicken embryo fibroblasts (CEFs) results in both morphological transformation and exit from G0 to G1, resulting in mitosis. This phenomenon permits examination of cellular responses very soon after activating the oncoprotein, and we have used this to study changes in endogenous AP-1, and the regulation of its major components, in the first few hours after activating v-Src. This approach contrasts with a number of studies that have demonstrated enhanced activity of exogenously added AP-1 components in cells transformed by v-Src. Reactivation of a membrane-associated tyrosine kinase (tsRCAN-29) results in a several-fold increase in AP-1 DNA binding and a similar increase in the activity of an AP-1-responsive reporter soon after temperature shift. c-Jun and c-Fos are regulated at a number of levels in response to both stimuli. In quiescent RCAN-29-infected CEFs stimulated into cycle by shift to permissive temperature, c-fos transcripts are elevated by 15 min and remain above basal level for at least 4 h. Serum induces much greater elevation of c-fos transcripts, although this response is transient. Despite the difference in magnitude of the transcript responses, the stimulation of nuclear c-Fos protein is similar in both serum and v-Src-stimulated cultures. No elevation in c-jun transcripts or nuclear c-Jun protein level is evident in v-Src-stimulated quiescent CEFs. However, there is an early change in the tryptic phosphopeptide map of p39 c-Jun in response to both v-Src and serum. Upon stimulation we observed a novel redistribution of phosphate in the carboxy-terminal tryptic phosphopeptide that may be responsible in part for the increase in AP-1 DNA binding. Phosphorylation of amino-terminal serines 63 and 73 on peptides Y and X, believed to be responsible for regulation of the transactivation function of c-Jun, is constitutively high in resting CEF cultures; stimulation with serum or v-Src results in only a modest increase in phosphorylation at these sites. Significantly, reactivation of a non-myristylated, transformation-defective version of the tsRCAN-29 v-Src protein (RCAN-29A2) is unable to induce resting CEFs to reenter cycle. In addition, this mutant fails to induce early increases in AP-1 activity, implying that these nuclear changes require crucial signalling events at the cell periphery, and that these events correlate with the biological consequences of expression of v-Src.	BEATSON INST CANC RES,CANC RES CAMPAIGN,BEATSON LABS,WOLFSON LAB MOLEC PATHOL,GLASGOW G61 1BD,SCOTLAND	Beatson Institute								ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BELL JG, 1975, J GEN VIROL, V27, P127, DOI 10.1099/0022-1317-27-2-127; BEUG H, 1978, CELL, V14, P843, DOI 10.1016/0092-8674(78)90340-9; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACK EJ, 1991, ONCOGENE, V6, P1949; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CALOTHY G, 1987, J VIROL, V61, P1678, DOI 10.1128/JVI.61.5.1678-1681.1987; COLLETT MS, 1979, J VIROL, V29, P770, DOI 10.1128/JVI.29.2.770-781.1979; COOPER JA, 1988, PEPTIDES PROTEIN PHO, P85; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; CROUCH DH, 1990, ONCOGENE, V5, P683; CURRAN T, 1984, CELL, V36, P259; DURKIN JP, 1984, J CELL PHYSIOL, V120, P135, DOI 10.1002/jcp.1041200205; Fourney R.M., 1988, FOCUS, V10, P5; FRAME MC, 1991, ONCOGENE, V6, P205; GILLESPIE DAF, 1991, SEMINARS VIROLOGY, V2, P329; GILMER TM, 1983, J VIROL, V45, P462, DOI 10.1128/JVI.45.1.462-465.1983; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HARLOW E, 1988, ANTIBODIES LABORATOR, P641; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JACKSON JA, 1992, J BIOL CHEM, V267, P17444; JAHNER D, 1991, ONCOGENE, V6, P1259; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; LUO K, 1990, ONCOGENE, V5, P921; Maniatis T., 1982, MOL CLONING; MULLER R, 1987, ONCOGENE RES, V2, P19; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STOKER AW, 1984, MOL CELL BIOL, V4, P1508, DOI 10.1128/MCB.4.8.1508; STOKER AW, 1986, J VIROL, V58, P876, DOI 10.1128/JVI.58.3.876-883.1986; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; VOSATKA RJ, 1989, J CELL PHYSIOL, V138, P493, DOI 10.1002/jcp.1041380308; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WELHAM MJ, 1988, J VIROL, V62, P1898, DOI 10.1128/JVI.62.6.1898-1906.1988; WELHAM MJ, 1990, ONCOGENE, V5, P161; WHITE MK, 1988, MOL CELL BIOL, V8, P135; WYKE JA, 1973, VIROLOGY, V53, P152, DOI 10.1016/0042-6822(73)90474-1	52	37	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1875	1886						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510932				2022-12-28	WOS:A1993LG68200020
J	FISCELLA, M; ULLRICH, SJ; ZAMBRANO, N; SHIELDS, MT; LIN, D; LEESMILLER, SP; ANDERSON, CW; MERCER, WE; APPELLA, E				FISCELLA, M; ULLRICH, SJ; ZAMBRANO, N; SHIELDS, MT; LIN, D; LEESMILLER, SP; ANDERSON, CW; MERCER, WE; APPELLA, E			MUTATION OF THE SERINE 15 PHOSPHORYLATION SITE OF HUMAN P53 REDUCES THE ABILITY OF P53 TO INHIBIT CELL-CYCLE PROGRESSION	ONCOGENE			English	Article							CASEIN KINASE-II; WILD-TYPE; TRANSCRIPTIONAL ACTIVATION; PROTEIN-KINASE; GROWTH; GENE; SUPPRESSOR; INVITRO; P53-PROTEIN; EXPRESSION	Overexpression of wild-type p53 prevents cells from entering the S phase of the cell cycle. The amino-terminal transactivation region of p53 is phosphorylated by several protein kinases, including DNA-PK, a nuclear serine/threonine protein kinase that in vitro requires DNA for activity. DNA-PK was recently shown to phosphorylate serines 15 and 37 of human p53 (Lees-Miller et al, 1992. Mol. Cell. Biol., 12, 5041-5049). To prevent phosphorylation at these sites, mutants were constructed that changed the codons for serine 15 or serine 37 to alanine codons. Expression of p53-Ala-37 in stably transformed T98G cells blocked progression of the cells into S phase as well as did the expression of wild-type p53. In contrast, p53-Ala-15 was partially defective in blocking cell cycle progression. Several cell clones transformed with the mutant p53-Ala-15 gene expressed normal levels of p53 mRNA but accumulated little or no detectable p53 protein. However, by using a transient expression system driven by a strong cytomegalovirus promoter, we showed that the inability of p53-Ala-15 to fully block cell cycle progression was not due to inadequate levels of expression or to a failure of the mutant protein to accumulate in the nucleus. These results suggest that phosphorylation of Ser-15 may affect p53 function.	NIH,CELL BIOL LAB,BETHESDA,MD 20892; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	National Institutes of Health (NIH) - USA; Jefferson University; United States Department of Energy (DOE); Brookhaven National Laboratory			Zambrano, Nicola/B-9352-2014	Zambrano, Nicola/0000-0001-9395-3481; Lees-Miller, Susan/0000-0001-5809-2516	NCI NIH HHS [CA 42866] Funding Source: Medline; NCRR NIH HHS [BRSG S07 RR05417] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042866] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005417] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BASSIRI RM, 1972, ENDOCRINOLOGY, V90, P722, DOI 10.1210/endo-90-3-722; CHEN YR, 1991, J VIROL, V65, P5131, DOI 10.1128/JVI.65.10.5131-5140.1991; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JDONEHOWER LA, 1992, NATURE, V356, P215; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KLESSIG DF, 1975, J VIROL, V16, P1650, DOI 10.1128/JVI.16.6.1650-1668.1975; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MEEK DW, 1990, J VIROL, V64, P1734, DOI 10.1128/JVI.64.4.1734-1744.1990; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER W E, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P251; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MERCER WE, 1985, EXP CELL RES, V160, P31, DOI 10.1016/0014-4827(85)90233-2; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MONTENARH M, 1992, ONCOGENE, V7, P1673; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; OROURKE RW, 1990, ONCOGENE, V5, P1829; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RICHARDSON WD, 1984, J VIROL, V51, P559, DOI 10.1128/JVI.51.2.559-562.1984; RIGAUDY P, 1989, NUCLEIC ACIDS RES, V20, P8375; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SHEN YM, 1982, MOL CELL BIOL, V2, P1145, DOI 10.1128/MCB.2.9.1145; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SILVERMAN L, 1989, J VIROL, V63, P4376, DOI 10.1128/JVI.63.10.4376-4385.1989; SOUSSI T, 1990, ONCOGENE, V5, P945; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TACK LC, 1992, J VIROL, V66, P1312, DOI 10.1128/JVI.66.3.1312-1320.1992; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; UMPHRESS JL, 1992, EUR J BIOCHEM, V203, P239, DOI 10.1111/j.1432-1033.1992.tb19852.x; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	59	172	174	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1519	1528						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502477				2022-12-28	WOS:A1993LE06400015
J	LAZAR, V; HAZARD, F; BERTIN, F; JANIN, N; BELLET, D; BRESSAC, B				LAZAR, V; HAZARD, F; BERTIN, F; JANIN, N; BELLET, D; BRESSAC, B			SIMPLE SEQUENCE REPEAT POLYMORPHISM WITHIN THE P53 GENE	ONCOGENE			English	Note							PROTEIN	This report describes a new polymorphism, in intron 3 of the p53 gene, which consists of a single repeat of 16 nucleotides, absent in the published wild-type p53 gene sequence. In the Caucasian population tested (n = 82), 28% of individuals were heterozygotes for this polymorphism. Using PCR-based analysis, we were able to demonstrate p53 allelic losses in three of six breast tumors from heterozygote patients tested.	INST GUSTAVE ROUSSY,IMMUNOL MOLEC LAB,39 RUE CAMILLE DESMOULINS,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,ANAT PATHOL LAB C,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,DEPT MED,F-94805 VILLEJUIF,FRANCE; FAC SCI PHARMACEUT & BIOL PARIS,IMMUNOL LAB,CNRS,URA 1484,F-75006 PARIS,FRANCE	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS)			Lazar, Vladimir/AAQ-2086-2020; Lazar, Vladimir/AAV-2087-2020; Paillerets, Brigitte Bressac-de/D-8954-2018	Paillerets, Brigitte Bressac-de/0000-0003-0245-8608				AHUJA HG, 1990, ONCOGENE, V5, P1409; ARA S, 1990, NUCLEIC ACIDS RES, V18, P4961, DOI 10.1093/nar/18.16.4961; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CARBONE D, 1991, ONCOGENE, V6, P1691; CHUMAKOV PM, 1991, NUCLEIC ACIDS RES, V19, P6969, DOI 10.1093/nar/19.24.6969-a; CHUMAKOV PM, 1991, NUCLEIC ACIDS RES, V19, P4804; COOPER DN, 1991, HUM GENET, V87, P409; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FUTREAL PA, 1991, NUCLEIC ACIDS RES, V19, P6977, DOI 10.1093/nar/19.24.6977; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; SOUSSI T, 1990, ONCOGENE, V5, P945	13	89	92	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1703	1705						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502490				2022-12-28	WOS:A1993LE06400037
J	FILMUS, J; SHI, W; SPENCER, T				FILMUS, J; SHI, W; SPENCER, T			ROLE OF TRANSFORMING GROWTH FACTOR-ALPHA (TGF-ALPHA) IN THE TRANSFORMATION OF RAS-TRANSFECTED RAT INTESTINAL EPITHELIAL-CELLS	ONCOGENE			English	Article							HUMAN-COLON; FACTOR-RECEPTOR; AUTOCRINE GROWTH; HA-RAS; CARCINOMA-CELLS; TRANSGENIC MICE; EXPRESSION; CANCER; GENE; INDUCTION	Most intestinal tumors express transforming growth factor alpha (TGF-alpha) while normal immature crypt cells, the targets for tumor initiation, do not. We have used a rat intestinal cell line derived from immature epithelial crypt cells (IEC-18) to investigate the role of this growth factor in intestinal tumorigenesis. ras transformation of IEC-18 cells induces expression and secretion of TGF-alpha. By studying several independently derived IEC-ras clones, we have established that the amount of TGF-alpha secreted is proportional to the level of activated ras expressed by each clone. The growth of all ras-transformed IEC clones is significantly inhibited by neutralizing antibodies against TGF-alpha and by an antisense TGF-alpha expression vector, indicating a mitogenic role for this growth factor through an autocrine loop. To determine whether TGF-alpha itself can transform intestinal cells, IEC-18 clones transfected with TGF-alpha expression vectors were isolated and characterized. None of the TGF-alpha-expressing clones show any signs of tumorigenic transformation even when they secrete as much TGF-alpha as the IEC-ras clones. It seems, therefore, that TGF-alpha per se does not have the capacity to transform rat epithelial intestinal cells and that its role is mostly related to autocrine growth stimulation.	UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto	FILMUS, J (corresponding author), SUNNYBROOK HLTH SCI CTR,DIV CANC RES,REICHMANN RES BLDG,2075 BAYVIEW AVE,TORONTO M4N 3M5,ON,CANADA.							ANZANO MA, 1989, CANCER RES, V49, P2898; BARNARD JA, 1991, AM J PHYSIOL, V261, pC994, DOI 10.1152/ajpcell.1991.261.6.C994; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BUICK RN, 1987, EXP CELL RES, V170, P300, DOI 10.1016/0014-4827(87)90308-9; CIARDIELLO F, 1990, J CELL BIOCHEM, V42, P45, DOI 10.1002/jcb.240420105; CIARDIELLO F, 1991, P NATL ACAD SCI USA, V88, P7792, DOI 10.1073/pnas.88.17.7792; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; CIARDIELLO F, 1989, FEBS LETT, V250, P474, DOI 10.1016/0014-5793(89)80779-3; CIARDIELLO F, 1988, MOL ENDOCRINOL, V2, P1202, DOI 10.1210/mend-2-12-1202; COLLETTA G, 1991, ONCOGENE, V6, P583; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DERNYCK R, 1992, ADV CANCER RES, V58, P27; DIMARCO E, 1989, ONCOGENE, V4, P831; FILMUS J, 1992, ONCOGENE, V7, P521; FILMUS J, 1987, MOL CELL BIOL, V7, P251, DOI 10.1128/MCB.7.1.251; FINZI E, 1988, MOL CARCINOGEN, V1, P7, DOI 10.1002/mc.2940010105; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GOUSTIN AS, 1986, CANCER RES, V46, P1015; HAUFT SM, 1992, J CELL BIOL, V117, P825, DOI 10.1083/jcb.117.4.825; HELDIN CH, 1989, EUR J BIOCHEM, V184, P487, DOI 10.1111/j.1432-1033.1989.tb15041.x; HOFER DR, 1991, CANCER RES, V51, P2780; IMANISHI K, 1989, J NATL CANCER I, V81, P220, DOI 10.1093/jnci/81.3.220; KARNES WE, 1992, GASTROENTEROLOGY, V102, P474, DOI 10.1016/0016-5085(92)90093-E; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LIU C, 1990, BRIT J CANCER, V62, P425, DOI 10.1038/bjc.1990.311; MARKOWITZ SD, 1990, J CLIN INVEST, V86, P356, DOI 10.1172/JCI114709; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MCGEADY ML, 1989, ONCOGENE, V4, P1375; MORISHIGE K, 1991, CANCER RES, V51, P5951; MURTHY U, 1989, INT J CANCER, V44, P110, DOI 10.1002/ijc.2910440120; QUARONI A, 1981, J NATL CANCER I, V67, P1353; REISS M, 1991, CANCER RES, V51, P6254; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SALOMON DS, 1990, CANCER CELL-MON REV, V2, P389; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SHANKAR V, 1989, MOL CARCINOGEN, V2, P1, DOI 10.1002/mc.2940020102; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STROMBERG K, 1992, CANCER RES, V52, P341; TANAKA S, 1991, AM J PATHOL, V139, P123; THOMAS DM, 1992, GUT, V33, P628, DOI 10.1136/gut.33.5.628; TRICOLI JV, 1986, CANCER RES, V46, P6169; WATANABE S, 1987, P NATL ACAD SCI USA, V84, P1258, DOI 10.1073/pnas.84.5.1258; YASUI W, 1988, CANCER RES, V48, P137; YOSHIDA K, 1990, JPN J CANCER RES, V81, P43, DOI 10.1111/j.1349-7006.1990.tb02505.x	48	45	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1017	1022						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455929				2022-12-28	WOS:A1993KT22000025
J	MAROC, N; ROTTAPEL, R; ROSNET, O; MARCHETTO, S; LAVEZZI, C; MANNONI, P; BIRNBAUM, D; DUBREUIL, P				MAROC, N; ROTTAPEL, R; ROSNET, O; MARCHETTO, S; LAVEZZI, C; MANNONI, P; BIRNBAUM, D; DUBREUIL, P			BIOCHEMICAL-CHARACTERIZATION AND ANALYSIS OF THE TRANSFORMING POTENTIAL OF THE FLT3/FLK2 RECEPTOR TYROSINE KINASE	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; C-KIT RECEPTOR; GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTOR; FMS PROTO-ONCOGENE; W-MUTANT MICE; SIGNAL TRANSDUCTION; MOUSE DEVELOPMENT; PROGENITOR CELLS; BONE-MARROW	We recently cloned an additional member of the receptor type tyrosine kinase class III. This new gene, called Flt3 by our group [Rosnet, O., Mattei, M.G., Marchetto, S. & Birnbaum, D. (1991). Genomics, 9, 380-385; Rosnet, O., Marchetto, S., deLapeyriere, 0. & Birnbaum, D. (1991). Oncogene, 6, 1641-16501 and Flk2 by others [Matthews, W., Jordan, C.T., Wieg, G.W., Pardoll, D. & Lemischka, I.R. (1991). Cell, 65, 1143-11521 is strongly related to the important developmental genes Kit, Fms and Pdgfr. The murine 3.2-kb full-length cDNA, when introduced into COS-1 cells, shows the expression of two polypeptides with apparent molecular weights of 155 kDa and 132 kDa. Treatment of cells with N-linked glycosylation inhibitors results in the expression of a 110-kDa protein. We have shown that FLT3 contains an intrinsic tyrosine kinase activity. A point mutation in a highly conserved residue within the phosphoryltransferase domain inactivates the catalytic function of this receptor, whereas activation by way of a chimeric molecule between the ligand-binding domain of colony-stimulating factor type 1 (CSF-1) receptor (CSF-1R) and the kinase domain of FLT3 results, in the presence of CSF-1, in the development of the transforming activity of this receptor as shown by anchorage-independent cell growth. Finally, expression analysis of the FLT3 protein shows that, in addition to the hematopoietic system, FLT3 is strongly expressed in neural, gonadal, hepatic and placental tissues in the mouse.	INSERM, UNITE 119, MOLEC ONCOL LAB, 27 BD ROURE, F-13009 MARSEILLE, FRANCE; INSERM, UNITE 119, MOLEC HEMATOL LAB, F-13009 MARSEILLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)			Dubreuil, Patrice/V-4816-2019; Rosnet, Olivier/G-3536-2013; dubreuil, patrice/F-5346-2011	Dubreuil, Patrice/0000-0003-1155-1150; dubreuil, patrice/0000-0003-1155-1150; Maroc, Nicolas/0000-0001-7285-509X; Rottapel, Robert/0000-0002-6024-5558; Rosnet, Olivier/0000-0002-3020-910X				ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BIRG F, 1903, IN PRESS BLOOD; BROXMEYER HE, 1991, CANCER CELL-MON REV, V3, P480; CAO Y, 1990, Technique (Philadelphia), V2, P109; CAROW CE, 1991, BLOOD, V78, P2216, DOI 10.1182/blood.V78.9.2216.bloodjournal7892216; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; DANIEL TO, 1987, J BIOL CHEM, V262, P9778; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GODIN I, 1991, NATURE, V352, P807, DOI 10.1038/352807a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LEV S, 1990, MOL CELL BIOL, V10, P6064, DOI 10.1128/MCB.10.11.6064; LINNEKIN D, 1990, BIOCHEM J, V271, P317, DOI 10.1042/bj2710317; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; METCALF D, 1991, P NATL ACAD SCI USA, V88, P6239, DOI 10.1073/pnas.88.14.6239; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MORAN MF, 1988, ONCOGENE, V3, P665; MOTRO B, 1991, DEVELOPMENT, V113, P1207; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; OHTSUKA M, 1990, MOL CELL BIOL, V10, P1664, DOI 10.1128/MCB.10.4.1664; PAPAYANNOPOULOU T, 1991, BLOOD, V78, P1403; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; QUELLE FW, 1991, J BIOL CHEM, V266, P609; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1993, IN PRESS ONCOGENE; RIEDEL H, 1986, NATURE, V324, P68, DOI 10.1038/324068a0; ROHRSCHNEIDER LR, 1989, ONCOGENE, V4, P1015; ROSNET O, 1991, ONCOGENE, V6, P1641; ROSNET O, 1991, GENOMICS, V9, P380, DOI 10.1016/0888-7543(91)90270-O; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; ROUSSEL MF, 1990, MOL CELL BIOL, V10, P2407, DOI 10.1128/MCB.10.5.2407; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SHERR CJ, 1990, BLOOD, V75, P1; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SORRENTINO V, 1991, ONCOGENE, V6, P149; STANLEY ER, 1980, MONONUCLEAR PHAGOC 1, P415; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; TSUJI K, 1991, BLOOD, V78, P1223; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VU TH, 1989, MOL CELL BIOL, V9, P4563, DOI 10.1128/MCB.9.10.4563; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	59	91	98	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1993	8	4					909	918						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8384358				2022-12-28	WOS:A1993KT22000012
J	JACKSON, P; BOS, E; BRAITHWAITE, AW				JACKSON, P; BOS, E; BRAITHWAITE, AW			WILD-TYPE MOUSE-P53 DOWN-REGULATES TRANSCRIPTION FROM DIFFERENT VIRUS ENHANCER PROMOTERS	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; CELL NUCLEAR ANTIGEN; P53 GENE-MUTATIONS; LARGE T-ANTIGEN; TUMOR-ANTIGEN; CHLORAMPHENICOL ACETYLTRANSFERASE; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS; EUKARYOTIC CELLS; DNA-REPLICATION	The protein encoded by the tumour-suppressor gene p53 can complex with SV40 virus large T antigen, the adenovirus E1B 58-kDa protein and the E6 protein of human papillomavirus type 16. The functions of these complexes are unclear, but there is some evidence to suggest that binding of p53 to these viral proteins may inactivate p53 function. Recent reports have shown that p53 is involved in regulation of transcription. We have considered the possibility that p53 may regulate transcription of viral genes important for virus replication and/or transformation. Inactivation of p53 function by formation of such complexes might then permit correct expression of these viral genes. Since p53 can bind to the SV40 virus enhancer/promoter, we have investigated the effect of p53 on transcription from this promoter and report here that mouse p53 is a potent repressor of the SV40 enhancer/promoter. Mutations within p53 severely inhibited this activity and provided some evidence to show that the N-terminus of p53 contains residues essential for this function. We also show that mouse p53 represses transcription from the promoters of viruses that do not express proteins that complex with p53: the human cytomegalovirus early promoter and the Rous sarcoma virus long terminal repeat. By studying the effect of p53 on transcription in different cell lines, we show that the effects of p53 on promoters may be cell type specific.			JACKSON, P (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV CELL BIOL,CELL TRANSFORMAT GRP,GPO BOX 334,CANBERRA,ACT 2601,AUSTRALIA.							BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BENCHIMOL S, 1982, EMBO J, V1, P1055, DOI 10.1002/j.1460-2075.1982.tb01296.x; BRAITHWAITE AW, 1991, ONCOGENE, V6, P781; BRAITHWAITE AW, 1991, NEW BIOL, V3, P18; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN YM, 1991, ONCOGENE, V6, P1799; CHENG J, 1992, CANCER RES, V52, P222; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; ISAACS WB, 1991, CANCER RES, V51, P4716; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1988, ONCOGENE HDB, P403; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MERCER WF, 1990, J CELL BIOCHEM, V14, P285; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OHASHI Y, 1992, BIOCHIM BIOPHYS ACTA, V1130, P175, DOI 10.1016/0167-4781(92)90525-5; OROURKE RW, 1990, ONCOGENE, V5, P1829; PRIDMORE RD, 1987, GENE, V56, P309, DOI 10.1016/0378-1119(87)90149-1; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Sambrook J, 1989, MOL CLONING LABORATO; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; STURZBECHER HW, 1988, ONCOGENE, V3, P405; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TKAHASHI T, 1991, ONCOGENE, V6, P1775; TRAVALI S, 1989, J BIOL CHEM, V264, P7466; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084; ZHANG XL, 1990, VIROLOGY, V180, P199	58	56	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					589	597						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8382357				2022-12-28	WOS:A1993KN00800009
J	YOUNG, J; LEGGETT, B; WARD, M; THOMAS, L; BUTTENSHAW, R; SEARLE, J; CHENEVIXTRENCH, G				YOUNG, J; LEGGETT, B; WARD, M; THOMAS, L; BUTTENSHAW, R; SEARLE, J; CHENEVIXTRENCH, G			FREQUENT LOSS OF HETEROZYGOSITY ON CHROMOSOME-14 OCCURS IN ADVANCED COLORECTAL CARCINOMAS	ONCOGENE			English	Article							NEURO-BLASTOMA; DNA; GENE; IDENTIFICATION; DEFICIENCY; PATHOLOGY; LOCATION; CLONING	The current model for colorectal tumorigenesis defines four specific mutations (activation of a ras proto-oncogene and inactivation of the APC, p53 and DCC tumor-suppressor genes) that accumulate in a colonic epithelial cell as it progresses towards a carcinoma. However, further mutations must be needed for progression to malignancy because advanced adenomas have been observed with all four of these mutations. Loss of heterozygosity (LOH) for 11 loci spanning the distal portion of the long arm of chromosome 14 was studied in 89 sporadic colorectal adenocarcinomas and 25 adenomas. The overall rate of LOH in carcinomas was 53% (46/86 informative carcinomas). The smatlest region of overlap (SRO) of deletions includes the markers D14SI9 to D14S20. No LOH was seen in the 18 informative adenomas examined. There was a significant trend towards higher levels of LOH within the SRO in advanced Dukes' stages (P = 0.016). Since frequent loss of heterozygosity in a specific region of a chromosome may reflect the inactivation of a tumor-suppressor gene located there, these data suggest that a gene involved in the progression of colonic neoplasia may reside on the distal portion of the long arm of chromosome 14, and that its inactivation may be a critical event in this process.	UNIV QUEENSLAND,QUEENSLAND INST MED RES,BRISBANE,QLD 4000,AUSTRALIA; ROYAL BRISBANE HOSP FDN,BANCROFT CTR,GLAXO GASTROENTEROL RES LAB,BRISBANE,QLD,AUSTRALIA	QIMR Berghofer Medical Research Institute; University of Queensland	YOUNG, J (corresponding author), UNIV QUEENSLAND,SCH MED,DEPT PATHOL,JOINT ONCOL PROGRAM,QUEENSLAND CANC FUND RES UNIT,HERSTON RD,BRISBANE,QLD 4006,AUSTRALIA.		Leggett, Barbara A/D-3579-2011; Young, Joanne P/H-7774-2014	Chenevix-Trench, Georgia/0000-0002-1878-2587; Leggett, Barbara/0000-0003-2062-7380				BAIRD M, 1986, AM J HUM GENET, V39, P489; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BAKHSHI A, 1983, NEW ENGL J MED, V309, P826, DOI 10.1056/NEJM198310063091404; BRODEUR GM, 1989, CANCER GENET CYTOGEN, V41, P153, DOI 10.1016/0165-4608(89)90243-4; BUFILL JA, 1990, ANN INTERN MED, V113, P779, DOI 10.7326/0003-4819-113-10-779; COX DW, 1985, NATURE, V316, P79, DOI 10.1038/316079a0; COX DW, 1989, HUMAN GENOME MAPPING, V10; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FRIEDMAN EA, 1985, CANCER INVEST, V3, P453, DOI 10.3109/07357908509039806; FUJIMOTO E, 1988, NUCLEIC ACIDS RES, V16, P380, DOI 10.1093/nar/16.1.380; HOFF M, 1988, NUCLEIC ACIDS RES, V16, P10400, DOI 10.1093/nar/16.21.10400; HOFKER MH, 1990, GENOMICS, V6, P33, DOI 10.1016/0888-7543(90)90445-Z; KELSEY GD, 1988, J MED GENET, V25, P361, DOI 10.1136/jmg.25.6.361; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KONSTANTINOVA LN, 1991, HUM GENET, V86, P491; MARTIN C, 1988, NUCLEIC ACIDS RES, V16, P5220, DOI 10.1093/nar/16.11.5220; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MITELMAN F, 1991, CATALOG CHROMOSOME A; NAKAMURA Y, 1988, AM J HUM GENET, V43, P854; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P6257, DOI 10.1093/nar/16.13.6257; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P3593, DOI 10.1093/nar/16.8.3593; NEWLAND RC, 1987, CANCER, V60, P852, DOI 10.1002/1097-0142(19870815)60:4<852::AID-CNCR2820600422>3.0.CO;2-5; RABIN M, 1986, SOMAT CELL MOLEC GEN, V12, P209, DOI 10.1007/BF01560668; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; SASAKI M, 1989, CANCER RES, V49, P4402; SNEDECOR GW, 1980, STATISTICAL METHODS, P206; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; SUZUKI T, 1989, CANCER RES, V49, P1095; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; YOUNG J, 1992, CANCER RES, V52, P285; ZHANG WD, 1990, JPN J CANCER RES, V81, P108, DOI 10.1111/j.1349-7006.1990.tb02534.x	33	76	77	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					671	675						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437850				2022-12-28	WOS:A1993KN00800018
J	STRASSER, A; HARRIS, AW; CORY, S				STRASSER, A; HARRIS, AW; CORY, S			E-MU-BCL-2 TRANSGENE FACILITATES SPONTANEOUS TRANSFORMATION OF EARLY PRE-B AND IMMUNOGLOBULIN-SECRETING CELLS BUT NOT T-CELLS	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; LIGHT CHAIN GENE; HUMAN FOLLICULAR LYMPHOMA; C-MYC ONCOGENE; BCL-2 GENE; CHROMOSOME-TRANSLOCATION; VARIANT TRANSLOCATION; MEMBRANE PROTEIN; ACTIVATION; EXPRESSION	To assess the lymphoid tumorigenic potential of bcl-2, mice of five independent strains expressing a bcl-2 transgene in B and/or T cells were monitored for disease up to 12 months of age. Lymphoma prevalence was minimal in the T lineage but significant, although low (3-15%), in the B lineage. The principal types of tumors were plasmacytomas secreting immunoglobulin and novel lymphomas that expressed markers such as Sca-1, CD4, Thy-1, CD34 and CD45(B220), consistent with an origin very early in B-lymphoid development. Rearrangement of the c-myc gene was common in the plasmacytomas, implying a synergistic role for myc and bcl-2 in their etiology, but was not detected in the lymphomas.	ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute			Cory, Suzanne/E-1642-2013; Strasser, Andreas/C-7581-2013	Cory, Suzanne/0000-0002-6818-3451; Strasser, Andreas/0000-0002-5020-4891	NATIONAL CANCER INSTITUTE [R01CA043540] Funding Source: NIH RePORTER; NCI NIH HHS [CA43540] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI M, 1990, J EXP MED, V171, P559, DOI 10.1084/jem.171.2.559; ADACHI M, 1989, P NATL ACAD SCI USA, V86, P2771, DOI 10.1073/pnas.86.8.2771; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; AISENBERG AC, 1988, BLOOD, V71, P969; ALLEN JD, 1991, GENE DEV, V5, P509, DOI 10.1101/gad.5.4.509; ARMITAGE JO, 1988, J NATL CANCER I, V80, P576, DOI 10.1093/jnci/80.8.576; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BROWN J, 1991, INT IMMUNOL, V3, P175, DOI 10.1093/intimm/3.2.175; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DEJONG D, 1988, NEW ENGL J MED, V318, P1373, DOI 10.1056/NEJM198805263182106; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; FREDRICKSON GG, 1989, J EXP MED, V169, P1473, DOI 10.1084/jem.169.4.1473; GAUWERKY CE, 1988, P NATL ACAD SCI USA, V85, P8548, DOI 10.1073/pnas.85.22.8548; GAUWERKY CE, 1989, P NATL ACAD SCI USA, V86, P8867, DOI 10.1073/pnas.86.22.8867; HARIHARAN IK, 1989, MOL CELL BIOL, V9, P2798, DOI 10.1128/MCB.9.7.2798; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; HILLION J, 1991, ONCOGENE, V6, P169; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HORNING SJ, 1984, NEW ENGL J MED, V311, P1471, DOI 10.1056/NEJM198412063112303; HUA C, 1990, ONCOGENE, V5, P233; KIEM HP, 1990, ONCOGENE, V5, P1815; KUDO A, 1987, EMBO J, V6, P103, DOI 10.1002/j.1460-2075.1987.tb04725.x; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; LANDAU NR, 1984, P NATL ACAD SCI-BIOL, V81, P5836, DOI 10.1073/pnas.81.18.5836; LEE JT, 1989, J CLIN INVEST, V84, P1454, DOI 10.1172/JCI114320; LEE MS, 1987, BLOOD, V70, P90; LIMPENS J, 1991, ONCOGENE, V6, P2271; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MCDONNELL TJ, 1990, MOL CELL BIOL, V10, P1901, DOI 10.1128/MCB.10.5.1901; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MUFTI GJ, 1983, BLOOD, V62, P1142; NUNEZ G, 1991, NATURE, V353, P71, DOI 10.1038/353071a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PEGORARO L, 1984, P NATL ACAD SCI-BIOL, V81, P7166, DOI 10.1073/pnas.81.22.7166; PORTLOCK CS, 1979, ANN INTERN MED, V90, P10, DOI 10.7326/0003-4819-90-1-10; RAGHOEBIER S, 1991, BLOOD, V77, P1560; RECHAVI G, 1989, LEUKEMIA, V3, P57; RICHARDSON ME, 1987, BLOOD, V70, P444; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; STETLERSTEVENSON M, 1990, J NATL CANCER I, V82, P855, DOI 10.1093/jnci/82.10.855; STRASSER A, 1990, CURR TOP MICROBIOL, V166, P175; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TSUJIMOTO Y, 1987, ONCOGENE, V2, P3; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904; WU L, 1991, NATURE, V349, P71, DOI 10.1038/349071a0; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929; ZELENETZ AD, 1991, J EXP MED, V173, P197, DOI 10.1084/jem.173.1.197; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0; ZUTTER M, 1991, BLOOD, V78, P1062	64	127	134	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1993	8	1					1	9						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423986				2022-12-28	WOS:A1993KN00500001
J	Arrowsmith, CH; Morin, P				Arrowsmith, CH; Morin, P			New insights into p53 function from structural studies	ONCOGENE			English	Review						tumor suppressor; protein-DNA interaction, oligomerization	TUMOR SUPPRESSOR GENE; WILD-TYPE; DNA-BINDING; MUTANT P53; MONOCLONAL-ANTIBODY; PROTEIN; MUTATIONS; ANTIGEN; CELLS; OLIGOMERIZATION		UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5G 2M9,CANADA	University of Toronto	Arrowsmith, CH (corresponding author), UNIV TORONTO,ONTARIO CANC INST,DIV MOL & STRUCT BIOL,610 UNIV AVE,TORONTO,ON M5G 2M9,CANADA.			Arrowsmith, Cheryl/0000-0002-4971-3250				BAI YW, 1995, SCIENCE, V269, P192, DOI 10.1126/science.7618079; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; CARIELLO NF, 1994, CANCER RES, V54, P4454; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1995, SCIENCE, V267, P1515, DOI 10.1126/science.7878474; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; CREIGHTON TE, 1984, PROTEINS STRUCTURES, pCH7; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HAN KA, 1992, NUCLEIC ACIDS RES, V20, P1979, DOI 10.1093/nar/20.8.1979; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; JOHNSON CR, 1995, BIOCHEMISTRY-US, V34, P5309, DOI 10.1021/bi00016a002; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MILNER J, 1993, ONCOGENE, V8, P2001; MONOD J, 1963, J MOL BIOL, V6, P306, DOI 10.1016/S0022-2836(63)80091-1; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SINGERLAND JM, 1993, EMBO J, V12, P1029; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; STURZBECHER HW, 1987, ONCOGENE, V1, P210; TARUNINA M, 1993, ONCOGENE, V8, P3165; ULRICH SJ, 1992, ONCOGENE, V7, P1635; VOJTESEK B, 1995, ONCOGENE, V10, P389; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; WOLKOWICZ R, 1995, P NATL ACAD SCI USA, V92, P6842, DOI 10.1073/pnas.92.15.6842; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	59	92	93	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1379	1385						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622853				2022-12-28	WOS:A1996UF07600001
J	Chackalaparampil, I; Peri, A; Nemir, M; Mckee, MD; Lin, PH; Mukherjee, BB; Mukherjee, AB				Chackalaparampil, I; Peri, A; Nemir, M; Mckee, MD; Lin, PH; Mukherjee, BB; Mukherjee, AB			Cells in vivo and in vitro from osteopetrotic mice homozygous for c-src disruption show suppression of synthesis of osteopontin, a multifunctional extracellular matrix protein	ONCOGENE			English	Article						osteopontin; src-deficient; epidermal growth factor (EGF); homozygous; osteopetrosis	TYROSINE KINASE; GROWTH-FACTOR; PHOSPHOPROTEIN; BONE; OSTEOCLASTS; EXPRESSION; ACTIVATION; INDUCTION; PATHWAYS	Mice carrying homozygous disruption of the c-src protooncogene (Src-/-) develop osteopetrosis due to an impaired ability of osteoclasts to adhere to the bone surface and/or to form bone-resorbing ruffled border. It has also been reported that osteopontin (OPN), a secreted phosphoprotein, mediates osteoclast adherence to the bone matrix. We report here that cells from Src-/- mice, both in vitro and in vivo, express OPN mRNA and protein at a significantly reduced level as compared to cells from Src+/- and +/+ animals, suggesting a potential role for the proto-oncogene c-src in the regulation of OPN gene expression. Our data also show that OPN gene expression can be induced by treatment of Src -/- cells with epidermal growth factor (EGF) and 12-O-tetradecanoyl phorbol-13-acetate (TPA). Results obtained from studies using inhibitors of receptor tyrosine kinases (RTKs) and protein kinase C (PKC) suggest that PKC and RTK are positioned in a pathway with PKC as the downstream effector for the EGF-induced OPN gene expression in Src-/- cells, and that pp60(c-src) and EGF may regulate OPN gene expression through a common signalling pathway. Furthermore, contrary to published reports, our study shows that EGF-mediated cell signalling does not require functional interaction between the EGF-receptor and pp60(c-src).	MCGILL UNIV, DEPT BIOL, MONTREAL, PQ H3A 1B1, CANADA; NICHHD, SECT DEV GENET, HERITABLE DISORDERS BRANCH, NIH, BETHESDA, MD 20892 USA; UNIV MONTREAL, FAC DENT, DEPT STOMATOL, MONTREAL, PQ H3C 3J7, CANADA; RUTGERS STATE UNIV, WAKSMAN INST, DEPT MICROBIOL, PISCATAWAY, NJ 08855 USA	McGill University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Universite de Montreal; Rutgers State University New Brunswick			McKee, Marc D/E-2187-2011; Lin, Pei-Hui/I-3011-2015	McKee, Marc D/0000-0001-8349-965X; Lin, Pei-Hui/0000-0002-3894-5099				BARON R, 1989, ANAT RECORD, V224, P317, DOI 10.1002/ar.1092240220; BENDAYAN M, 1989, COLLOIDAL GOLD PRINC, V1, P33; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAIG AM, 1991, GENE, V100, P163, DOI 10.1016/0378-1119(91)90362-F; CRAIG AM, 1989, J BIOL CHEM, V264, P9682; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DENHARDT DT, 1995, ANN NY ACAD SCI, V760, P127, DOI 10.1111/j.1749-6632.1995.tb44625.x; Dveksler G S, 1992, PCR Methods Appl, V1, P283; GADEAU AP, 1993, ARTERIOSCLER THROMB, V13, P120, DOI 10.1161/01.ATV.13.1.120; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; LAVERDURE GR, 1987, FEBS LETT, V222, P261, DOI 10.1016/0014-5793(87)80382-4; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOPEZ CA, 1995, ANN NY ACAD SCI, V760, P324, DOI 10.1111/j.1749-6632.1995.tb44648.x; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MARKS S C JR, 1987, Applied Pathology, V5, P172; MCKEE MD, 1990, ANAT REC, V228, P77, DOI 10.1002/ar.1092280112; MCKEE MD, 1992, ANAT REC, V234, P479, DOI 10.1002/ar.1092340404; MCKEE MD, 1995, ANN NY ACAD SCI, V760, P177, DOI 10.1111/j.1749-6632.1995.tb44629.x; MCKEE MD, 1993, ANAT REC, V3, P219; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; Nanci A, 1996, MICROSC RES TECHNIQ, V33, P214; QURESHI SA, 1991, ONCOGENE, V6, P995; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; SINGH K, 1990, J BIOL CHEM, V265, P18696; SINGH K, 1993, J BIOCHEM-TOKYO, V114, P702, DOI 10.1093/oxfordjournals.jbchem.a124240; SINGH K, 1992, J BIOL CHEM, V267, P23847; SMITH JH, 1989, J CELL PHYSIOL, V139, P189, DOI 10.1002/jcp.1041390126; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	38	42	44	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	1996	12	7					1457	1467						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622862				2022-12-28	WOS:A1996UF07600010
J	Jones, J; Sugiyama, M; Speight, PM; Watt, FM				Jones, J; Sugiyama, M; Speight, PM; Watt, FM			Restoration of alpha(v)beta(5) integrin expression in neoplastic keratinocytes results in increased capacity for terminal differentiation and suppression of anchorage-independent growth	ONCOGENE			English	Article						squamous cell carcinoma; adhesion; extracellular matrix; vitronectin	SQUAMOUS-CELL CARCINOMAS; MONOCLONAL-ANTIBODIES; HUMAN-SKIN; FIBRONECTIN; ADHESION; VITRONECTIN; INVOLUCRIN; RECEPTOR; LOCALIZATION; ALPHA-5-BETA-1-INTEGRIN	Loss of expression of specific integrins is a feature of poorly differentiated oral squamous cell carcinomas (SCCs) and cell lines derived from them. In order to test whether there is a direct link between loss of integrins and abnormal keratinocyte growth and differentiation, we 'repaired' an SCC line, H357, by transfection of its missing integrin subunit, alpha(v). We analysed seven independent alpha(v)-expressing clones and compared them with four empty vector controls and with the parental cell line. alpha(v) was expressed on the cell surface as a functional alpha(v) beta(5) heterodimer. The parental cells expressed beta(5) mRNA and introduction of alpha(v) had no effect on beta(5) mRNA levels nor on cell surface levels of any other integrins examined. Introduction of alpha(v) had no consistent effect on the growth rate of cells on tissue culture plastic. However, anchorage-independent growth was strongly suppressed and the alpha(v)-transfectants showed an increased capacity for terminal differentiation, as assayed by expression of involucrin. These results are consistent with the known role of integrins in regulating keratinocyte terminal differentiation and suggest that integrin loss may be directly responsible for the abnormal behaviour of keratinocytes in a subset of oral SCCs.	IMPERIAL CANC RES FUND, KERATINOCYTE LAB, LONDON WC2A 3PX, ENGLAND; UCL EASTMAN DENT HOSP, INST DENT SURG, DEPT ORAL PATHOL, LONDON WC1X 8LD, ENGLAND	Cancer Research UK; University College London Hospitals NHS Foundation Trust; University of London; University College London			Watt, Fiona/AHB-0226-2022	Watt, Fiona/0000-0001-9151-5154				ADAMS JC, 1991, J CELL BIOL, V115, P829, DOI 10.1083/jcb.115.3.829; ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALBELDA SM, 1993, LAB INVEST, V68, P4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; DITTEL BN, 1993, BLOOD, V81, P2272; DOWNER CS, 1993, J PATHOL, V171, P183, DOI 10.1002/path.1711710306; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; EISENBERG E, 1987, ORAL SURG ORAL MED O, V64, P313, DOI 10.1016/0030-4220(87)90011-9; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GLADSON CL, 1994, INTEGRINS BIOL PROBL, P83; GRINNELL F, 1992, J INVEST DERMATOL, V98, P410, DOI 10.1111/1523-1747.ep12499839; HOTCHIN NA, 1992, J BIOL CHEM, V267, P14852; HOTCHIN NA, 1995, J CELL BIOL, V128, P1209, DOI 10.1083/jcb.128.6.1209; HOTCHIN NA, 1993, J CELL SCI, V106, P1131; HUDSON DL, 1992, HYBRIDOMA, V11, P367, DOI 10.1089/hyb.1992.11.367; HUGHES DE, 1994, J PATHOL, V173, P97, DOI 10.1002/path.1711730205; JONES J, 1993, J PATHOL, V169, P235, DOI 10.1002/path.1711690210; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; KAUFMANN R, 1989, J CELL BIOL, V109, P1807, DOI 10.1083/jcb.109.4.1807; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NICHOLSON LJ, 1991, J CELL SCI, V98, P225; PELTONEN J, 1989, J CLIN INVEST, V84, P1916, DOI 10.1172/JCI114379; PRIME SS, 1990, J PATHOL, V160, P259, DOI 10.1002/path.1711600313; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; REILLY JT, 1988, J CLIN PATHOL, V41, P1269, DOI 10.1136/jcp.41.12.1269; Rheinwald JG., 1989, CELL GROWTH DIVISION, P81; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; RYYNANEN J, 1991, J INVEST DERMATOL, V97, P562, DOI 10.1111/1523-1747.ep12481896; SCHREINER C, 1991, CANCER RES, V51, P1738; SONNENBERG A, 1986, J HISTOCHEM CYTOCHEM, V34, P1037, DOI 10.1177/34.8.2426332; SUGIYAMA M, 1993, CARCINOGENESIS, V14, P2171, DOI 10.1093/carcin/14.10.2171; SUMITOMO S, 1986, ORAL SURG ORAL MED O, V62, P155, DOI 10.1016/0030-4220(86)90038-1; TENCHINI ML, 1993, CELL ADHES COMMUN, V1, P55, DOI 10.3109/15419069309095681; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONDEMBORNE AEG, 1989, LEUCOCYTE TYPING, V4, P951; WATT FM, 1993, J CELL SCI, V106, P175; WATT FM, 1993, DEVELOPMENT, P185; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; Wolf G T, 1992, J Natl Cancer Inst Monogr, P67; WOLF GT, 1990, JNCI-J NATL CANCER I, V82, P1566, DOI 10.1093/jnci/82.19.1566; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; ZAMBRUNO G, 1995, J CELL BIOL, V129, P853, DOI 10.1083/jcb.129.3.853	47	37	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					119	126						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552382				2022-12-28	WOS:A1996TQ01400015
J	Kamps, MP; Wright, DD; Lu, Q				Kamps, MP; Wright, DD; Lu, Q			DNA-binding by oncoprotein E2A-Pbx1 is important for blocking differentiation but dispensable for fibroblast transformation	ONCOGENE			English	Article						E2A-Pbx1; oncoprotein; differentiation; leukemia	PRE-B; MAMMALIAN-CELLS; TRANSLOCATION PROTEIN; CRYSTAL-STRUCTURE; HOMEOBOX GENES; LEUKEMIA; MICE; COMPLEX; DOMAIN; PBX1	The t(1;19) chromosomal translocation of pediatric pre-B cell lymphoblastic leukemia produces the E2A-PBX1 oncogene, which can transform fibroblasts, induce acute myeloid leukemia and T cell lymphomas in mice, and immortalize factor-dependent myeloid progenitors in cultured marrow. The homeodomain of Pbx1 binds ATCAATCAA, and while Pbx1 does not activate transcription through this motif, E2A-Pbx1 induces constitutive transactivation. Here, we investigate whether DNA-binding by Pbx1 or transcriptional activation by E2A are essential for the transforming abilities off E2A-Pbx1. Elimination of DNA-binding in E2A-Pbx1 by point mutations in the Pbx1 homeodomain or by large deletions that removed the Pbx1 homeodomain and carboxyl terminus did not alter ability of E2A-Pbx1 to induce focus-formation in fibroblast, even though these mutations completely eliminated its ability to activate transcription through the PRS. These same DNA-binding mutations, however, severely impaired or eliminated the ability of E2A-Pbx1 to immortalize factor-dependent myeloid progenitors in marrow cultures. Elimination of the first transcriptional activation domain of E2A abolished both fibroblast and myeloid transforming activities while elimination of the second altered neither of these activities. We conclude that DNA-binding is important for the ability of E2A-Pbx1 to disrupt differentiation, as evidenced in myeloblast immortalization, but dispensable for its ability to induce focus-formation, and that the aminoterminal domain of E2A, which strongly activates transcription, is essential for both transforming activities.	UNIV CALIF SAN DIEGO,SCH MED,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093	University of California System; University of California San Diego	Kamps, MP (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DEPT PATHOL,9500 GILMAN DR,LA JOLLA,CA 92093, USA.				NATIONAL CANCER INSTITUTE [R01CA056876] Funding Source: NIH RePORTER; NCI NIH HHS [5 RO1 CA56876] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER S, 1988, CELL, V52, P685, DOI 10.1016/0092-8674(88)90406-0; ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; Ausubel FM, 1988, MOL REPROD DEV; CARROLL A, 1984, BLOOD, V63, P716; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; FITZPATRICK VD, 1992, NATURE, V356, P610, DOI 10.1038/356610a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KAMPS MP, 1994, ONCOGENE, V9, P3159; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEBRUN DP, 1994, ONCOGENE, V9, P1641; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; LU Q, 1996, IN PRESS P NATL ACAD; LU QA, 1995, MOL CELL BIOL, V15, P3786; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PEERS B, 1995, UNPUB; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; VERSHON AK, 1995, GENE DEV, V9, P182, DOI 10.1101/gad.9.2.182; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WILLIAMS DL, 1984, CELL, V36, P101, DOI 10.1016/0092-8674(84)90078-3; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5	32	39	39	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					19	30						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552391				2022-12-28	WOS:A1996TQ01400003
J	Dhordain, P; Albagli, O; Ansieau, S; Koken, MHM; Deweindt, C; Quief, S; Lantoine, D; Leutz, A; Kerckaert, JP; Leprince, D				Dhordain, P; Albagli, O; Ansieau, S; Koken, MHM; Deweindt, C; Quief, S; Lantoine, D; Leutz, A; Kerckaert, JP; Leprince, D			The BTB/POZ domain targets the LAZ3/BCL6 oncoprotein to nuclear dots and mediates homomerisation in vivo	ONCOGENE			English	Article						LAZ3/BCL6; lymphoma; BTB/POZ domain; Kruppel-like Zinc finger; nuclear dots; two-hybrid system	POSITION-EFFECT VARIEGATION; FINGER ENCODING GENE; CONSERVED DOMAIN; PROTEIN; EXPRESSION; DROSOPHILA; TRANSLOCATIONS; SEGMENTATION; LOCALIZATION; ENHANCER	The LAZ3/BCL6 gene was identified by its disruption in 3q27 translocations associated with diffuse large cell lymphomas, It is predicted to be a transcription factor as it contains six Kruppel-like Zinc finger motifs and a N-terminal BTB/POZ domain, a protein/protein interaction interface that is widely conserved in Metazoans, Using two antisera raised against non overlapping regions of the predicted ORF, we demonstrate that the LAZ3/BCL6 protein appears as a close ca, 79 kDa doublet in B lymphoid cell lines with either a rearranged or a non rearranged LAZ3/BCL6 locus, By immunofluorescence experiments on transiently transfected COS-1 or NTH3T3 cells, we show that the LAZ3/BCL6 protein displays a punctuated nuclear localisation. This appears to rely on LAZ3/BCL6 proper folding and/or activities as it is impaired in a hormone reversible-fashion through fusion of LAZ3/BCL6 to the ligand-binding domain of the oestrogen receptor, Moreover, deletion of its BTB/POZ domain leads to the disappearance of the nuclear dots although the protein remains nuclear, In addition, by using the yeast two-hybrid system, we show that the LAZ3/BCL6 BTB/POZ domain homomerises in vivo, Thus, the LAZ3/BCL6 BTB/POZ domain has the capability to self-interact and target the protein to discrete nuclear substructures.	IRCL,U124 INSERM,F-59045 LILLE,FRANCE; MAX DELBRUCK CENTRUM MOLEK MED,D-13122 BERLIN,GERMANY; HOP ST LOUIS,CTR HAYEM,U43 CNRS,F-75475 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Helmholtz Association; Max Delbruck Center for Molecular Medicine; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite			Ansieau, Stephane/I-6195-2016; Leutz, Achim/K-9643-2013; koken, marcel/N-1349-2019; koken, marcel/J-8154-2012	Leutz, Achim/0000-0001-8259-927X; koken, marcel/0000-0002-0839-0125; Leprince, Dominique/0000-0002-1999-0775; ANSIEAU, Stephane/0000-0003-0989-2108				ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BARON BW, 1995, GENE CHROMOSOME CANC, V13, P221, DOI 10.1002/gcc.2870130314; BASTARD C, 1994, BLOOD, V83, P2423; BROWN JL, 1993, DEVELOPMENT, V117, P45; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHEN W, 1995, MOL CELL BIOL, V15, P3424; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; COOLEY L, 1994, SCIENCE, V266, P590, DOI 10.1126/science.7939713; DANIEL MT, 1993, BLOOD, V82, P1858; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GODT D, 1993, DEVELOPMENT, V119, P799; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; HWANG JJ, 1993, EMBO J, V12, P2337, DOI 10.1002/j.1460-2075.1993.tb05888.x; JONGENS TA, 1994, GENE DEV, V8, P2123, DOI 10.1101/gad.8.18.2123; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KAWAMATA N, 1994, BIOCHEM BIOPH RES CO, V204, P366, DOI 10.1006/bbrc.1994.2468; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KOBAYASHI H, 1993, BLOOD, V81, P3027; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; MIKI T, 1994, BLOOD, V83, P26; Miller J.H., 1972, EXPT MOL GENETICS; NACHEVA E, 1993, BLOOD, V82, P231, DOI 10.1182/blood.V82.1.231.bloodjournal821231; NUMOTO M, 1993, NUCLEIC ACIDS RES, V21, P3767, DOI 10.1093/nar/21.16.3767; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; OTSUKI T, 1995, BLOOD, V85, P2877, DOI 10.1182/blood.V85.10.2877.bloodjournal85102877; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; Picard Didier, 1994, Current Opinion in Biotechnology, V5, P511, DOI 10.1016/0958-1669(94)90066-3; RAFF JW, 1994, EMBO J, V13, P5977, DOI 10.1002/j.1460-2075.1994.tb06943.x; SCHMID MF, 1994, J CELL BIOL, V124, P341, DOI 10.1083/jcb.124.3.341; SUGAWARA M, 1994, MOL CELL BIOL, V14, P8438, DOI 10.1128/MCB.14.12.8438; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; VONKALM L, 1994, EMBO J, V13, P3505, DOI 10.1002/j.1460-2075.1994.tb06657.x; WAY M, 1995, J CELL BIOL, V128, P51, DOI 10.1083/jcb.128.1.51; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	44	115	119	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2689	2697						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545127				2022-12-28	WOS:A1995TP18800026
J	Kevil, C; Carter, P; Hu, B; DeBenedetti, A				Kevil, C; Carter, P; Hu, B; DeBenedetti, A			Translational enhancement of FGF-2 by eIF-4 factors, and alternate utilization of CUG and AUG codons for translation initiation	ONCOGENE			English	Article						FGF-2; eIF-4E/F; breast cancer; translation/secretion	FIBROBLAST GROWTH-FACTOR; 5' NONTRANSLATED REGION; MOUTH-DISEASE-VIRUS; MESSENGER-RNA; PROTEIN-SYNTHESIS; INTERNAL INITIATION; MALIGNANT TRANSFORMATION; CELLS; EXPRESSION; SITE	The FGF-2 mRNA of most mammals contains a long and inhibitory 5' UTR in addition to at least two CUG codons upstream and in frame with the AUG start codon. These CUGs are used for translation initiation to generate several polypeptides, Cells overexpressing the translation initiation factor 4E produce and secrete large amounts of FGF-2, and particularly the largest, CUG1-initiated form. Overexpression of FGF-2 ia due to a translational enhancement of its mRNA, as indicated by its association with large polyribosomes in contrast to control cells, where it partitions mostly in fractions lighter than 80 S or small polyribosomes. Breast carcinomas expressing elevated eIF-4E also exhibit the large FGF-2 isoforms, which could play an important role in tumor angiogenesis. Translation of in vitro transcribed rat FGF-2 in reticulocyte lysates resulted in synthesis of four polypeptides, of similar size to those observed in vivo. Addition of purified eIF-4E preferentially increased translation of CUG1- and AUG-initiated isoforms. Since the different isoforms of FGF-2 may have different roles and intracellular distribution, the effects of the eIF-4 factors on FGF-2 expression could be important for the control of cell proliferation and differentiation.	LOUISIANA STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, SHREVEPORT, LA 71105 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport				Kevil, Christopher/0000-0003-0863-7260				ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ANANDAPPA SY, 1994, BRIT J CANCER, V69, P772, DOI 10.1038/bjc.1994.146; ANTHONY DD, 1991, J BIOL CHEM, V266, P10218; BARVE SS, 1994, J IMMUNOL, V152, P1171; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; CHAMPEME MH, 1994, MODERN PATHOL, V7, P900; CLEMENS MJ, 1987, TRANSCRIPTION TRANSL, P263; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; DASSO MC, 1990, EUR J BIOCHEM, V187, P361, DOI 10.1111/j.1432-1033.1990.tb15313.x; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; DOSAKAAKITA H, 1991, ONCOGENE, V6, P371; DUNCAN R, 1987, J BIOL CHEM, V262, P380; Florkiewicz RZ, 1991, GROWTH FACTORS, V4, P265, DOI 10.3109/08977199109043912; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOSPODAROWICZ D, 1987, J CELL PHYSIOL, P15; HALABAN R, 1988, ONCOGENE RES, V3, P177; HANN SR, 1992, GENE DEV, V6, P1229, DOI 10.1101/gad.6.7.1229; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; JOSHIBARVE S, 1992, J BIOL CHEM, V267, P21038; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; KEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107; KLAGSBRUN M, 1986, P NATL ACAD SCI USA, V83, P2448, DOI 10.1073/pnas.83.8.2448; KLEIN PS, 1994, SCIENCE, V265, P803, DOI 10.1126/science.8047887; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUHN R, 1990, J VIROL, V64, P4625; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LE SY, 1993, NUCLEIC ACIDS RES, V21, P2445, DOI 10.1093/nar/21.10.2445; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MORLEY SJ, 1994, MOL BIOL REP, V19, P221, DOI 10.1007/BF00986964; MORRISON RS, 1990, CANCER RES, V50, P2524; PAUSE A, 1993, CURR OPIN STRUC BIOL, V3, P953, DOI 10.1016/0959-440X(93)90161-D; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; Rhoads RE, 1991, CURR OPIN CELL BIOL, V3, P1019, DOI 10.1016/0955-0674(91)90123-G; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SCHEPER GC, 1992, J BIOL CHEM, V267, P7269; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; SHANTZ LM, 1994, CANCER RES, V54, P2313; SHIMASAKI S, 1988, BIOCHEM BIOPH RES CO, V157, P256, DOI 10.1016/S0006-291X(88)80041-X; SHIURBA RA, 1991, DEVELOPMENT, V113, P487; SLACK J, 1994, MOL REPROD DEV, V39, P118, DOI 10.1002/mrd.1080390118; Sonenberg Nahum, 1993, Gene Expression, V3, P317; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; TAHARA SM, 1991, J BIOL CHEM, V266, P3594; THEILLET C, 1989, ONCOGENE, V4, P915; THOMAS AAM, 1992, NEW BIOL, V4, P404; THOMAS AAM, 1992, EUR J BIOCHEM, V207, P471, DOI 10.1111/j.1432-1033.1992.tb17073.x; THOMAS AAM, 1991, J VIROL, V65, P2953, DOI 10.1128/JVI.65.6.2953-2959.1991; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; WELLSTEIN A, 1991, MOL F ONCOLOGY; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330	65	132	134	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2339	2348						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570185				2022-12-28	WOS:A1995TK70200018
J	CHUMAKOV, AM; MILLER, CW; CHEN, DL; KOEFFLER, HP				CHUMAKOV, AM; MILLER, CW; CHEN, DL; KOEFFLER, HP			ANALYSIS OF P53 TRANSACTIVATION THROUGH HIGH-AFFINITY BINDING-SITES	ONCOGENE			English	Article							LARGE T-ANTIGEN; WILD-TYPE P53; E1B-58KD TUMOR-ANTIGEN; CELL-CYCLE CONTROL; A MOUSE CELLS; SIMIAN VIRUS-40; TRANSFORMED-CELLS; TRANSCRIPTIONAL ACTIVATION; ALTERED PHOSPHORYLATION; SV40-TRANSFORMED CELLS	Alterations or elimination of the p53 protein is frequently occurring during human carcinogenesis. Overexpression of wild-type p53 has a profound growth-inhibitory effect on many cell lines, including strong and apparently non-sequence specific repression of a number of promoters. Consistent with the hypothesis that it acts as transcriptional regulator, wild-type p53 protein binds DNA and activates transcription of several promoters. We have studied DNA binding and transactivation (TA) properties of human wild-type and mutant p53 proteins representing four major mutational hotspots. DNA-gel retardation was used to detect specific p53-DNA complexes in nuclear extracts, with radiolabelled oligonucleotides representing high affinity p53-binding sites (HBS) as a probe. p53-specific complexes were identified by competition with unlabelled 'self' oligos and by double band-shifts in the presence of anti-p53 antibodies. To show transactivation by p53, TK promoter-driven CAT reporter gene was placed 3' of the p53-binding site. CAT activity was assayed after co-transfection of reporters with either wild-type (WT) or mutant p53 expression constructs into human cells that do not express p53 (SKOV3). We found that wild-type p53 has strong transactivating effect on the reporter. All mutants, with the exception of His273, were inactive in TA-assay. p53 is a target of several oncogenes found in DNA tumor viruses. We examined the effect of either SV40 T-ag or 55 kDa EIB protein of Ad5 on DNA binding and transactivation by p53 in transformed COS-1 and 293 cell lines, respectively. COS-1 extracts produced strong p53-dependent band-shift of the HBS oligos, that was doubleshifted by anti-p53 but not anti-T-ag antibodies, indicating that T-ag is not part of the complex. COS-1 cells had a high level of WT p53-dependent expression of transfected CAT reporter, indicating the presence of transactivation-competent p53, acting through the HBS element. In human Ad-transformed 293 cells, endogenous p53 was also transactivation competent and capable of DNA binding. In summary, we found efficient transactivation of HBS motif by WT and His273-p53. Studies of COS-1 and 293 cells suggest that a proportion of p53 in transformed cells display wild-type DNA binding and TA properties and that expression of transcriptionally inactive mutant p53 proteins in these cells does not interfere with WT-dependent transactivation.			CHUMAKOV, AM (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, CEDARS SINAI MED CTR, 8700 BEVERLY BLVD, LOS ANGELES, CA 90048 USA.		Chumakov, Alexey/N-1541-2014	Chumakov, Alexey/0000-0003-2733-3166				AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; CHEN JD, 1992, ONCOGENE, V7, P1167; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEPPERT W, 1989, ONCOGENE, V4, P1103; DEPPERT W, 1990, ONCOGENE, V5, P1701; DEPPERT W, 1989, CURR TOP MICROBIOL I, V144, P37; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1988, ONCOGENE HDB, P403; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KOEFFLER HP, 1990, MOL CELL ENDOCRINOL, V70, P1, DOI 10.1016/0303-7207(90)90053-B; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LIN JY, 1991, J VIROL, V65, P2066, DOI 10.1128/JVI.65.4.2066-2072.1991; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUBBERT M, 1989, ONCOGENE, V4, P643; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILLER CW, 1993, ONCOGENE, V8, P1815; MOBERG KH, 1992, J CELL BIOCHEM, V49, P208, DOI 10.1002/jcb.240490213; OROURKE RW, 1990, ONCOGENE, V5, P1829; PRASOLOV V S, 1988, Molekulyarnaya Biologiya (Moscow), V22, P1371; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REISHAUS E, 1990, ONCOGENE, V5, P137; SAMBROOK J, 1989, MOL CLONING LABORATO, V1, P636; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; STEINMEYER K, 1990, ONCOGENE, V5, P1691; STEINMEYER K, 1988, ONCOGENE, V3, P501; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TACK LC, 1989, J VIROL, V63, P1310, DOI 10.1128/JVI.63.3.1310-1317.1989; TACK LC, 1989, J VIROL, V63, P3362, DOI 10.1128/JVI.63.8.3362-3367.1989; TACK LC, 1992, J VIROL, V66, P1312, DOI 10.1128/JVI.66.3.1312-1320.1992; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991	53	50	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3005	3011						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414502				2022-12-28	WOS:A1993MC09300014
J	HOFMANN, W; ROYER, HD; DRECHSLER, M; SCHNEIDER, S; ROYERPOKORA, B				HOFMANN, W; ROYER, HD; DRECHSLER, M; SCHNEIDER, S; ROYERPOKORA, B			CHARACTERIZATION OF THE TRANSCRIPTIONAL REGULATORY REGION OF THE HUMAN WT1 GENE	ONCOGENE			English	Article							WILMS-TUMOR GENE; ZINC-FINGER PROTEIN; FACTOR-A-CHAIN; PROMOTER REGION; GENITOURINARY DEVELOPMENT; ADENOSINE-DEAMINASE; HOMOZYGOUS DELETION; BINDING PROTEINS; SUPPRESSOR WT1; RECEPTOR GENE	Specific control of the expression of the Wilms tumor gene WT1 is important for normal development of the kidney. In order to characterise the transcriptional control region of the WT1 gene we have isolated genomic clones spanning the upstream region, the first WT1 exon and the 5' end of the Wit1 gene. DNA sequencing revealed that the WT1 promoter lacks a TATA box or CCAAT motif and has a GC content of 71%. Four transcriptional start sites are clustered within a 32 bp region. GC-boxes are present at nucleotide positions - 413, - 160, + 84 and + 158. DNAaseI protection assays with purified Sp1 protein revealed the existence of 11 different binding sites in the WT1 promoter. WT1 and Wit1 promoter activities were tested in COS-7 cells with luciferase reporter gene constructs either containing or lacking an SV40 enhancer. WT1 promoter activity was found in a fragment extending from 449 bp upstream to 201 bp downstream of the WT1 start site. It was 26 fold lower in the absence of the SV40 enhancer than in the presence. Cotransfection with a Sp1 expression vector stimulated both constructs 3-4 fold. Wit1 promoter activity was identified in a DNA fragment extending from 200 bp upstream of the putative Wit1 TATA box to 130 bp downstream. Several potential recognition sites for WT1/EGR, Pax-8, and GAGA-like transcription factors are present in the WT1 promoter.	UNIV HEIDELBERG, INST HUMAN GENET, IMNEVENHEIMER FELD 328, W-6900 HEIDELBERG, GERMANY; MAX DELBRUCK CTR MOLEC MED, BERLIN, GERMANY	Ruprecht Karls University Heidelberg; Helmholtz Association; Max Delbruck Center for Molecular Medicine			Royer, Hans-dieter/AAH-6293-2019					ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; AVIVI A, 1992, ONCOGENE, V7, P1957; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BRENNER B, 1992, ONCOGENE, V7, P1431; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; COMPTON DA, 1990, GENOMICS, V6, P309, DOI 10.1016/0888-7543(90)90571-B; COWELL JK, 1991, ONCOGENE, V6, P595; DESCHEEMAEKER KA, 1992, J BIOL CHEM, V267, P15086; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GLOSS B, 1990, J VIROL, V64, P5577, DOI 10.1128/JVI.64.11.5577-5584.1990; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; Hastie Nicholas D., 1992, Human Molecular Genetics, V1, P293; HOFFMAN EK, 1987, MOL CELL BIOL, V7, P2592, DOI 10.1128/MCB.7.7.2592; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1991, AM J HUM GENET, V48, P997; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; KERRIGAN LA, 1991, J BIOL CHEM, V266, P574; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KRIWACKI RW, 1992, P NATL ACAD SCI USA, V89, P9759, DOI 10.1073/pnas.89.20.9759; KUSHNER L, 1992, J UROLOGY, V148, P555, DOI 10.1016/S0022-5347(17)36652-1; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Maniatis T., 1982, MOL CLONING COLD SPR; MATSUNAGA E, 1981, HUM GENET, V57, P231; MATSUZAWA Y, 1991, ONCOGENE, V6, P1561; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; MERCHANT JL, 1991, MOL CELL BIOL, V11, P2686, DOI 10.1128/MCB.11.5.2686; MIWA H, 1992, LEUKEMIA, V6, P405; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; POLEEV A, 1992, DEVELOPMENT, V116, P611; PRITCHARDJONES K, 1991, ONCOGENE, V6, P2211; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RICCARDI VM, 1978, PEDIATRICS, V61, P604; ROYERPOKORA B, 1991, GENE CHROMOSOME CANC, V3, P89, DOI 10.1002/gcc.2870030203; ROYERPOKORA B, 1992, GENE CHROMOSOME CANC, V5, P132, DOI 10.1002/gcc.2870050207; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER S, 1993, IN PRESS HUM GENET; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TADOKORO K, 1992, ONCOGENE, V7, P1215; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597; TON CCT, 1991, GENOMICS, V10, P293, DOI 10.1016/0888-7543(91)90516-H; VALERIO D, 1985, EMBO J, V4, P437, DOI 10.1002/j.1460-2075.1985.tb03648.x; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WINOTO A, 1989, EMBO J, V8, P729, DOI 10.1002/j.1460-2075.1989.tb03432.x; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	68	54	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1993	8	11					3123	3132						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414514				2022-12-28	WOS:A1993MC09300029
J	PRICE, BD; CALDERWOOD, SK				PRICE, BD; CALDERWOOD, SK			INCREASED SEQUENCE-SPECIFIC P53 DNA-BINDING ACTIVITY AFTER DNA-DAMAGE IS ATTENUATED BY PHORBOL ESTERS	ONCOGENE			English	Article							PROTEIN KINASE-C; WILD-TYPE P53; TUMOR SUPPRESSOR PROTEIN; CELL-CYCLE; GROWTH-REGULATION; MUTANT P53; MONOCLONAL-ANTIBODY; IONIZING-RADIATION; GENE-PRODUCT; 3T3 CELLS	Damage to cellular DNA greatly increases the levels of the tumor-suppressor gene p53 and induces cell cycle arrest in G1. A critical function of wild-type p53 is its ability to bind to specific DNA sequences. The effect of DNA damage on the sequence-specific DNA-binding properties of cellular p53 was investigated using DNA gel mobility-shift assays with nuclear extracts from NIH-3T3 cells. DNA damage (initiated by radiation) induced a rapid, cycloheximide-sensitive increase in the levels of nuclear p53-DNA binding activity and an increase in the half-life of the p53 protein. Increased p53-DNA binding activity could be detected at low (0.2 Gy), non-lethal doses of radiation. The tumor promoter 12-O-tetradecanoyl phorbol 13-acetate (TPA) attenuated the DNA damage-induced increase in p53-DNA binding activity by decreasing the half-life of the p53 protein. The tumor promoter properties of TPA may therefore be mediated by interfering with the cellular p53 response to DNA damage. The increased levels of p53 bound to specific DNA sequences following DNA damage may induce cell cycle arrest. p53-mediated growth arrest could occur by inhibition of DNA replication and/or alterations in transcription of cell cycle genes.			PRICE, BD (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,STRESS PROT GRP RM JF209,44 BINNEY ST,BOSTON,MA 02115, USA.				NATIONAL CANCER INSTITUTE [R29CA044940] Funding Source: NIH RePORTER; NCI NIH HHS [R29CA44940] Funding Source: Medline; PHS HHS [R01 47407] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRUCE JL, 1993, CANCER RES, V53, P1; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JFOORD OS, 1993, MOL CELL BIOL, V13, P1378; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATLZMAN W, 1984, MOL CELL BIOL, V4, P1689; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MORA PT, 1982, MOL CELL BIOL, V2, P763, DOI 10.1128/MCB.2.7.763; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; PRICE BD, 1989, J BIOL CHEM, V264, P16638; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHOHAT O, 1987, ONCOGENE, V1, P277; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; STEINMEYER K, 1988, ONCOGENE, V3, P501; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; TOLMACH LJ, 1977, RADIAT RES, V71, P653, DOI 10.2307/3574633; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; WEICHSELBAUM RR, 1991, J NATL CANCER I, V83, P480, DOI 10.1093/jnci/83.7.480; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	54	67	68	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3055	3062						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414506				2022-12-28	WOS:A1993MC09300021
J	SEITE, P; HILLION, J; DAGAY, MF; BERGER, R; LARSEN, CJ				SEITE, P; HILLION, J; DAGAY, MF; BERGER, R; LARSEN, CJ			BCL2 COMPLEX REARRANGEMENT IN FOLLICULAR LYMPHOMA - TRANSLOCATION MBR J(H) AND DELETION IN THE VCR REGION OF THE SAME BCL2 ALLELE	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; VARIANT T(2-18) TRANSLOCATION; BREAKPOINT-CLUSTER REGION; LIGHT CHAIN GENE; B-CELL LYMPHOMA; CHROMOSOMAL TRANSLOCATION; T(14-18) TRANSLOCATION; MALIGNANT-LYMPHOMAS; EXPRESSION; TRANSCRIPTS	Two rearrangements affecting the same allele of the BCL2 gene were characterized by molecular analysis of an untreated follicular lymphoma. The first rearrangement interested the major breakpoint region (mbr) on chromosome 18 and a J(H) segment on chromosome 14. The other one was located at the 5' end of the BCL2 gene, in the so called variant cluster region (vcr), and consisted of a series of deletions that removed part of a DNA region where initiation of transcription normally occurs. Interestingly, both rearrangements involved the same BCL2 allele. The simultaneous presence of mbr (or mcr) translocations and of minor rearrangements in vcr has been previously suggested by restriction map analysis in a significant number of follicular lymphomas. The significance of these abnormalities on the oncogenic process is discussed.	INST GENET MOLEC,INSERM,U301,27 RUE J DODU,F-75010 PARIS,FRANCE; HOP ST LOUIS,ANAT PATHOL LAB,F-75010 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite				Seite, Paule/0000-0002-7809-7610				ADACHI M, 1990, J EXP MED, V171, P559, DOI 10.1084/jem.171.2.559; ADACHI M, 1990, ONCOGENE, V5, P1653; AMAKAWA R, 1991, BLOOD, V77, P1970; AVENTIN A, 1990, BRIT J HAEMATOL, V74, P367, DOI 10.1111/j.1365-2141.1990.tb02599.x; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1986, J EXP MED, V164, P315, DOI 10.1084/jem.164.1.315; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COTTER F, 1990, BLOOD, V76, P131; DEJONG D, 1989, J EXP MED, V169, P613, DOI 10.1084/jem.169.3.613; FREUND AM, 1989, P NATL ACAD SCI USA, V86, P7465, DOI 10.1073/pnas.86.19.7465; GAULARD P, 1992, AM J PATHOL, V140, P1089; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; HILLION J, 1991, ONCOGENE, V6, P169; JONVEAUX P, 1992, BRIT J HAEMATOL, V81, P620, DOI 10.1111/j.1365-2141.1992.tb03006.x; KIEM HP, 1990, ONCOGENE, V5, P1815; KONISHI H, 1990, CANCER RES, V50, P2698; LARSEN CJ, 1990, NOUV REV FR HEMATOL, V32, P401; LARSEN CJ, 1993, NOUV REV FR HEMATOL, V35, P37; LEROUX D, 1991, GENE CHROMOSOME CANC, V3, P205, DOI 10.1002/gcc.2870030306; LEROUX D, 1990, BRIT J HAEMATOL, V75, P290, DOI 10.1111/j.1365-2141.1990.tb02669.x; LIMPENS J, 1991, ONCOGENE, V6, P2271; MIKRAKI V, 1991, GENE CHROMOSOME CANC, V3, P117, DOI 10.1002/gcc.2870030206; OSADA H, 1989, JPN J CANCER RES, V80, P711, DOI 10.1111/j.1349-7006.1989.tb01702.x; PEZZELLA F, 1990, AM J PATHOL, V137, P225; PRICE CGA, 1991, LEUKEMIA, V5, P548; RIMOKH R, 1993, BLOOD, V81, P136; Sambrook J., 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEITE P, 1993, GENE CHROMOSOME CANC, V6, P39, DOI 10.1002/gcc.2870060108; SEITE P, 1993, LEUKEMIA, V7, P410; SETO M, 1991, JPN J CANCER RES, V82, P65, DOI 10.1111/j.1349-7006.1991.tb01747.x; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; TASHIRO S, 1992, ONCOGENE, V7, P573; TSUJIMOTO Y, 1987, P NATL ACAD SCI USA, V84, P1329, DOI 10.1073/pnas.84.5.1329; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904; ZELENETZ AD, 1991, BLOOD, V78, P1552; 1991, GUIDELINES CANCER CY	41	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3073	3080						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414508				2022-12-28	WOS:A1993MC09300023
J	KOVAR, H; AUINGER, A; JUG, G; ARYEE, D; ZOUBEK, A; SALZERKUNTSCHIK, M; GADNER, H				KOVAR, H; AUINGER, A; JUG, G; ARYEE, D; ZOUBEK, A; SALZERKUNTSCHIK, M; GADNER, H			NARROW SPECTRUM OF INFREQUENT P53 MUTATIONS AND ABSENCE OF MDM2 AMPLIFICATION IN EWING TUMORS	ONCOGENE			English	Article							CONFORMATION POLYMORPHISM ANALYSIS; POLYMERASE CHAIN-REACTION; MURINE LEUKEMIA-VIRUS; RAS GENE-MUTATIONS; HUMAN BRAIN-TUMORS; MONOCLONAL-ANTIBODIES; REACTION PRODUCTS; MULTIPLE-MYELOMA; POINT MUTATIONS; HUMAN SARCOMAS	The p53 and MDM2 genes are part of a physiological pathway frequently impaired in human cancer. With the exception of tumours occasionally associated with hereditary predisposition, childhood malignancies have not been studied in detail vet. This is the first report on the analysis of p53 and MDM2 in a group of non-hereditary paediatric neoplasms referred to as the Ewing tumours (ETs). Thirty-seven primary tumours and cell lines from 19 patients were screened for the presence of p53 mutations. Only 5% of the primary tumour specimens were found to carry an alteration within this gene. However, p53 mutations were 10-fold enriched in ET cell lines, thus indicating a selective growth advantage in vitro. Strikingly, five out of nine alterations detected were missense mutations within codon 273, which were previously reported to impair only partially the normal p53 function. Two single-base substitutions occurred at codons 277 and 176, and two alterations were loss-of-function mutations. Investigation of the MDM2 gene revealed neither gene amplification in the primary tumours and cell lines nor significant overexpression in any of the cell lines. Our data therefore suggest that impairment of cellular mechanisms involving p53 is rare in a distinct group of childhood malignancies.	ST ANNA CHILDRENS HOSP,CHILDRENS CANC RES INST,VIENNA,AUSTRIA; UNIV VIENNA,INST PATHOL ANAT,VIENNA BONE TUMOR REGISTRY,A-1090 VIENNA,AUSTRIA	Saint Anna Children's Hospital; University of Vienna				Kovar, Heinrich/0000-0001-6873-9109				AMBROS IM, 1991, CANCER, V67, P1886, DOI 10.1002/1097-0142(19910401)67:7<1886::AID-CNCR2820670712>3.0.CO;2-U; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BUDOWLE B, 1991, AM J HUM GENET, V48, P137; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN YM, 1991, ONCOGENE, V6, P1799; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DELACALLEMARTIN O, 1990, NUCLEIC ACIDS RES, V18, P4963, DOI 10.1093/nar/18.16.4963; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; FELIX CA, 1992, J CLIN INVEST, V89, P640, DOI 10.1172/JCI115630; FELIX CA, 1992, CANCER RES, V52, P2243; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FREBOURG T, 1992, CANCER RES, V52, P1; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JURGENS H, 1988, CANCER, V61, P23, DOI 10.1002/1097-0142(19880101)61:1<23::AID-CNCR2820610106>3.0.CO;2-M; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KOVAR H, 1990, ONCOGENE, V5, P1067; KOVAR H, 1991, NUCLEIC ACIDS RES, V19, P3507, DOI 10.1093/nar/19.13.3507; KOVAR H, 1992, ONCOGENE, V7, P2169; KOVAR H, 1993, IN PRESS CLIN CHEM E; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVY R, 1979, P NATL ACAD SCI USA, V76, P6552, DOI 10.1073/pnas.76.12.6552; LIPINSKI M, 1987, CANCER RES, V47, P183; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MEDCALF EA, 1992, ONCOGENE, V7, P71; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILLER CW, 1990, CANCER RES, V50, P7950; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MUJOO K, 1987, CANCER RES, V47, P1098; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; NERI A, 1991, HAEMATOLOGICA S4, V76, P31; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OHGAKI H, 1991, CANCER RES, V51, P6202; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PORTIER M, 1992, ONCOGENE, V7, P2539; PREUDHOMME C, 1992, BRIT J HAEMATOL, V81, P440, DOI 10.1111/j.1365-2141.1992.tb08253.x; SAYLORS RL, 1991, CANCER RES, V51, P4721; SELS FT, 1992, ONCOGENE, V7, P643; SPINARDI L, 1991, NUCLEIC ACIDS RES, V19, P4009, DOI 10.1093/nar/19.14.4009; SPRUCK CH, 1992, CANCER RES, V52, P4787; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THIELE CJ, 1987, J CLIN INVEST, V80, P804, DOI 10.1172/JCI113137; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; TOGUCHIDA J, 1992, CANCER RES, V52, P6194; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A	61	111	114	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2683	2690						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378080				2022-12-28	WOS:A1993LX34300009
J	ZHANG, J; TRENT, JM; MELTZER, PS				ZHANG, J; TRENT, JM; MELTZER, PS			RAPID ISOLATION AND CHARACTERIZATION OF AMPLIFIED DNA BY CHROMOSOME MICRODISSECTION - IDENTIFICATION OF IGF1R AMPLIFICATION IN MALIGNANT-MELANOMA	ONCOGENE			English	Article							HOMOGENEOUSLY STAINING REGIONS; GENE AMPLIFICATION; CELL-LINES; N-MYC; INSULIN; RECEPTOR; ONCOGENE; CLONES	We describe a novel strategy characterizing gene amplification in human neoplasia based on targeting double minutes (dmin) and homogeneously staining regions (hsr) for chromosome microdissection. This strategy allows the rapid generation of an amplification unit microclone library and permits the rapid identification of the chromosomal origin of the amplified sequences following fluorescence in situ hybridization (FISH). This strategy has been applied to an hsr-bearing malignant melanoma cell line, HA-A, which was then demonstrated to encode multiple overexpressed copies of the IGF1R gene. This strategy combines all steps for detection, cloning, mapping and isolation of amplified gene(s) into a single process that is readily applicable to any specimen carrying cytologic evidence of gene amplification.	UNIV MICHIGAN,DEPT RADIAT ONCOL,MED SCI RES BLDG 2,ROOM C560,1150 W MED CTR DR,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PEDIAT,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [R01CA029476, R37CA029476] Funding Source: NIH RePORTER; NCI NIH HHS [CA-29476] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERNS EMJJ, 1992, CANCER RES, V52, P1036; COWELL JK, 1982, ANNU REV GENET, V16, P21, DOI 10.1146/annurev.ge.16.120182.000321; DJABALI M, 1991, GENOMICS, V10, P1053, DOI 10.1016/0888-7543(91)90198-N; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUKUMOTO M, 1988, P NATL ACAD SCI USA, V85, P6846, DOI 10.1073/pnas.85.18.6846; GUAN XY, 1992, GENOMICS, V14, P680, DOI 10.1016/S0888-7543(05)80168-5; HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KINZLER KW, 1986, P NATL ACAD SCI USA, V83, P1031, DOI 10.1073/pnas.83.4.1031; KULL FC, 1983, J BIOL CHEM, V258, P6561; LEBON TR, 1986, J BIOL CHEM, V261, P7685; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; MELTZER PS, 1992, NAT GENET, V1, P24, DOI 10.1038/ng0492-24; RODECK U, 1987, INT J CANCER, V40, P687, DOI 10.1002/ijc.2910400520; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STARK GR, 1984, ANN REV BIOCH, V53, P448; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; TELENIUS H, 1992, GENOMICS, V13, P718, DOI 10.1016/0888-7543(92)90147-K; Trent J M, 1987, Methods Enzymol, V151, P267, DOI 10.1016/S0076-6879(87)51023-0; TRENT JM, 1984, CANCER RES, V44, P233; ZHANG J, 1993, BLOOD, V81, P3365	22	46	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2827	2831						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378091				2022-12-28	WOS:A1993LX34300025
J	MULLAUER, L; FUJITA, H; ISHIZAKI, A; KUZUMAKI, N				MULLAUER, L; FUJITA, H; ISHIZAKI, A; KUZUMAKI, N			TUMOR-SUPPRESSIVE FUNCTION OF MUTATED GELSOLIN IN RAS-TRANSFORMED CELLS	ONCOGENE			English	Article							PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PHOSPHOLIPASE-C; HUMAN PLATELET; IDENTIFICATION; EXPRESSION; CARCINOMA; ONCOGENE; PROFILIN; SEQUENCE; PROTEINS	The flat revertant R1, isolated from human activated Ha-ras oncogene-transformed NIH3T3 fibroblasts (EJ-NIH3T3), expresses a variant form of the actin-regulatory protein gelsolin (p92-5.7). We have cloned cDNAs encoding p92-5.7 and identified as the cause of the expression of p92-5.7 a point mutation in codon 321, which results in an amino acid change from proline to histidine. In order to understand the role of p92-5.7 in reversion of ras-transformed cells, cDNAs encoding p92-5.7 or human authentic gelsolin as a control were transfected into EJ-NIH3T3 cells. All the transfectants that produced p92-5.7 and one of three transfectants that produced human authentic gelsolin either lost or reduced tumorigenicity in syngeneic mice. These results demonstrate that mutated gelsolin can suppress a ras tumor and suggest that authentic gelsolin, if expressed at increased levels, may have a similar suppressive potential. Our data propose an important role for gelsolin in celllar signal transduction pathways that involve the mammalian ras proto-oncogene.	HOKKAIDO UNIV,SCH MED,INST CANC,MOLEC GENET LAB,KITA 15 NISHI 7,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University			Müllauer, Leonhard/GSN-9884-2022	Müllauer, Leonhard/0000-0002-3399-078X				BANNO Y, 1992, J BIOL CHEM, V267, P6488; BANYARD MRC, 1990, EXP CELL RES, V187, P180, DOI 10.1016/0014-4827(90)90135-W; CHAPONNIER C, 1989, AM J PATHOL, V134, P597; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DADABAY CY, 1991, J CELL BIOL, V112, P1151, DOI 10.1083/jcb.112.6.1151; DIEFFENBACH CW, 1989, J BIOL CHEM, V264, P13281; FUJITA H, 1990, EXP CELL RES, V186, P115, DOI 10.1016/0014-4827(90)90217-X; FUKAMI K, 1988, P NATL ACAD SCI USA, V85, P9057, DOI 10.1073/pnas.85.23.9057; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KUZUMAKI N, 1989, MOL CELL BIOL, V9, P2258, DOI 10.1128/MCB.9.5.2258; KWIATKOWSKI DJ, 1988, AM J HUM GENET, V42, P565; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; MACHESKY LM, 1990, CELL REGUL, V1, P937, DOI 10.1091/mbc.1.12.937; MULLAUER L, 1991, CANCER LETT, V59, P37, DOI 10.1016/0304-3835(91)90133-3; OIKAWA T, 1988, INT J CANCER, V42, P435, DOI 10.1002/ijc.2910420321; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; VANDEKERCKHOVE J, 1990, J CELL BIOL, V111, P95, DOI 10.1083/jcb.111.1.95; VOJTEK A, 1991, CELL, V66, P497, DOI 10.1016/0092-8674(81)90013-1; WANG E, 1984, J CELL BIOL, V98, P761, DOI 10.1083/jcb.98.2.761; WAY M, 1988, J MOL BIOL, V203, P1127, DOI 10.1016/0022-2836(88)90132-5; YIN HL, 1988, J CELL BIOL, V106, P805, DOI 10.1083/jcb.106.3.805; YIN HL, 1984, J BIOL CHEM, V259, P5271; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912; YU FX, 1991, J BIOL CHEM, V266, P19269	32	71	72	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2531	2536						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8395682				2022-12-28	WOS:A1993LT36800025
J	SETH, A; ROBINSON, L; THOMPSON, DM; WATSON, DK; PAPAS, TS				SETH, A; ROBINSON, L; THOMPSON, DM; WATSON, DK; PAPAS, TS			TRANSACTIVATION OF GATA-1 PROMOTER WITH ETS1, ETS2 AND ERGB/HU-FLI-1 PROTEINS - STABILIZATION OF THE ETS1 PROTEIN-BINDING ON GATA-1 PROMOTER SEQUENCES BY MONOCLONAL-ANTIBODY	ONCOGENE			English	Article							ERYTHROID TRANSCRIPTION FACTOR; LONG TERMINAL REPEAT; C-ETS-1 PROTOONCOGENE; GENE; EXPRESSION; INDUCTION; COOPERATE; ONCOGENE; LINEAGES; VIRUS	Ets family proteins activate transcription via binding to the GGAA core sequence located in the promoter/ enhancer elements of many cellular and viral genes. GATA-1 is an erythroid-specific transcription factor. The promoter of the chicken GATA-1 gene contains multiple ets binding sites (EBS), two of them are present in palindromic form. The GATA-1 promoter has been shown to be activated by the E26 virus. In this study, we have analysed whether the palidromic EBS of the chicken GATA-1 promoter is a target for binding and activation by members of the cellular ets gene family products. The results herein indicate that both EBS in the palindrome are required for DNA-binding because mutations in either site reduces the activity by at least 95%. Moreover, DNA binding of ETS1 to the EBS palindrome is dramatically stabilized in the presence of a specific monoclonal antibody whose epitope maps between amino acid positions 240-260. Although each of the single sites bind, the efficiency of binding is extremely low. Furthermore, for efficient binding the two sites must be in an inverted configuration because of the fact that the oligonucleotide containing the left and right EBS in the same orientation binds 10-fold less than the oligonucleotide containing the EBS palindrome. Additionally, we show that the transcription of a reporter gene (CAT) either linked to the GATA-1 EBS palindrome or GATA-1 promoter can be activated by cotransfection with ETS1, alternatively-spliced ETS1, ETS2 or ERGB/Hu-FLI-1 expression vectors.	PROGRAM RESOURCES INC,DYNCORP,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	SETH, A (corresponding author), NCI,MOLEC ONCOL LAB,FREDERICK,MD 21702, USA.							ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ASCIONE R, 1992, INT J ONCOL, V1, P631; AURIGEMMA RE, 1992, J VIROL, V66, P3056, DOI 10.1128/JVI.66.5.3056-3061.1992; Ausubel FM, 1988, MOL REPROD DEV; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HANNON R, 1991, P NATL ACAD SCI USA, V88, P3004, DOI 10.1073/pnas.88.8.3004; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HODGE DR, IN PRESS ADV GENE TE; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOIZUMI S, 1990, ONCOGENE, V5, P675; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; NERLOV C, 1991, ONCOGENE, V6, P1583; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OKA T, 1991, ONCOGENE, V6, P2077; PANAYIOTAKIS A, IN PRESS J VIRAL DIS; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; RUSCETTI S, 1992, J VIROL, V66, P20, DOI 10.1128/JVI.66.1.20-26.1992; SETH A, 1989, ONCOGENE RES, V5, P61; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1990, ONCOGENE, V5, P1761; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WERNERT N, 1992, AM J PATHOL, V140, P119; YUAN CC, 1989, J VIROL, V61, P205	38	95	96	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1783	1790						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510925				2022-12-28	WOS:A1993LG68200009
J	CASTELLAZZI, M; LOISEAU, L; PIU, F; SERGEANT, A				CASTELLAZZI, M; LOISEAU, L; PIU, F; SERGEANT, A			CHIMERIC C-JUN CONTAINING AN HETEROLOGOUS HOMODIMERIZATION DOMAIN TRANSFORMS PRIMARY CHICK-EMBRYO FIBROBLASTS	ONCOGENE			English	Article							DNA-BINDING PROTEIN; LEUCINE ZIPPER; TRANSCRIPTIONAL ACTIVATOR; DIMERIZATION SPECIFICITY; NEGATIVE REGULATION; GENE FAMILY; V-JUN; FOS; ONCOGENE; EXPRESSION	To investigate a possible role for c-Jun homodimers in c-Jun-mediated transformation, we designed two chimeric c-Jun derivatives, called c-Jun(eb1) and c-Jun(gcn4). In these chimeric derivatives the natural dimerization domain of c-Jun was replaced by the heterologous homodimerization domain of the Epstein-Barr virus EB1 or the yeast GCN4 transcription factor. Chick embryo fibroblasts chronically infected with retroviruses expressing c-Jun, c-Jun(eb1) or c-Jun(gcn4) are transformed. Infection with each construction results in sustained growth in low serum and development of colonies from single cells in agar with similar efficiencies. In contrast to c-Jun, c-Jun(eb1) and c-Jun(gcn4) confer additional phenotypic alterations related to in vitro transformation including a condensed cell morphology and ability to develop highly invasive, fast growing colonies in agar. These data suggest that c-Jun homodimers can transform chick embryo fibroblasts and activate cellular functions which influence cell morphology and invasive potential in agar. These findings are consistent with the notion that cellular transformation by c-jun is mediated by c-Jun homodimers.			CASTELLAZZI, M (corresponding author), ECOLE NORMALE SUPER, BIOL MOLEC & CELLULAIRE LAB, CNRS, UMR 49, 46 ALLEE ITALIE, F-69364 LYON, FRANCE.							ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BLACK EJ, 1991, ONCOGENE, V6, P1949; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BRUN G, 1989, NUCLEIC ACIDS RES, V17, P6393, DOI 10.1093/nar/17.15.6393; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; CHANG YN, 1990, J VIROL, V64, P3358, DOI 10.1128/JVI.64.7.3358-3369.1990; CHEVALLIERGRECO A, 1986, EMBO J, V5, P3243, DOI 10.1002/j.1460-2075.1986.tb04635.x; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1990, ONCOGENE, V5, P929; DENG TL, 1992, P NATL ACAD SCI USA, V89, P8572, DOI 10.1073/pnas.89.18.8572; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FLEMINGTON E, 1990, P NATL ACAD SCI USA, V87, P9459, DOI 10.1073/pnas.87.23.9459; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GIOT JF, 1991, NUCLEIC ACIDS RES, V19, P1251, DOI 10.1093/nar/19.6.1251; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAI SI, 1990, ONCOGENE, V5, P39; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MATSUI M, 1990, ONCOGENE, V5, P249; MOLDERS H, 1987, ONCOGENE, V1, P377; MORGAN IM, 1992, ONCOGENE, V7, P1119; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NEUBERG M, 1991, ONCOGENE, V6, P1325; NGUYEN VT, 1988, ANAL BIOCHEM, V171, P404, DOI 10.1016/0003-2697(88)90505-2; NISHIMURA T, 1988, ONCOGENE, V3, P659; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OKUNO H, 1991, ONCOGENE, V6, P1491; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PU WT, 1991, P NATL ACAD SCI USA, V88, P6901, DOI 10.1073/pnas.88.16.6901; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SCHUERMANN M, 1991, ONCOGENE, V6, P567; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SELLERS JW, 1989, NATURE, V341, P74, DOI 10.1038/341074a0; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	64	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1149	1160						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479740				2022-12-28	WOS:A1993KY32800006
J	FRITSCHE, M; HAESSLER, C; BRANDNER, G				FRITSCHE, M; HAESSLER, C; BRANDNER, G			INDUCTION OF NUCLEAR ACCUMULATION OF THE TUMOR-SUPPRESSOR PROTEIN P53 BY DNA-DAMAGING AGENTS	ONCOGENE			English	Article							CELL-CYCLE PROGRESSION; WILD-TYPE P53; TRANSFORMED-CELLS; MOUSE CELLS; MONOCLONAL-ANTIBODIES; SIMIAN VIRUS-40; SV40-TRANSFORMED CELLS; ACTIVATING MUTATIONS; ANTICANCER AGENTS; TOPOISOMERASE-II	Cancer therapy drugs, such as diamminedichloroplatinum (cisplatin), mitomycin C, etoposide and a number of other compounds, as well as energy-rich radiation, are known to act on cellular DNA. These agents are shown to induce nuclear accumulation of the so-called tumor-suppressor protein p53 in fibroblastoid cells, as well as in epithelioid normal and immortalized cells of murine, simian, and human origin. p53 accumulation starts a few hours after treatment and can remain detectable in surviving cells for at least 20 days. Accumulation occurs because of increased p53 protein stability and depends on ongoing translation. It is not the result of enhanced gene expression. A number of cell cycle inhibitors do not affect p53 protein accumulation, suggesting that the process may start from several points in the cell cycle. Since the increase in the nuclear p53 protein levels occurs within a few hours in most of the treated normal diploid cells, it is unlikely that the accumulated p53 protein is derived from a mutated p53 gene. The results obtained are in accordance with the view that the DNA damage-induced p53 accumulation may either inhibit cell growth, allowing DNA repair processes, or, in the case of severe damage, initiate apoptosis.	UNIV FREIBURG,INST MED MIKROBIOL & HYG,VIROL ABT,POB 820,W-7800 FREIBURG,GERMANY	University of Freiburg								ABDELLA BR, 1984, ENV HLTH PERSPECT, V64, P3; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BARKET J, 1990, ONCOGENE, V5, P893; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BAYREUTHER K, 1988, P NATL ACAD SCI USA, V85, P5112, DOI 10.1073/pnas.85.14.5112; BENNETT WP, 1991, ONCOGENE, V6, P1779; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; COLVIN M, 1981, CANCER TREAT REP, V65, P89; COOK PR, 1976, NATURE, V263, P679, DOI 10.1038/263679a0; DEPPERT W, 1990, ONCOGENE, V5, P1701; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dustin P., 1984, MICROTUBULES; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FRITSCHE M, 1991, J CANCER RES CLIN, V117, P30; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GLAZER RI, 1980, MOL PHARMACOL, V17, P111; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HEBEL M, 1986, Z NATURFORSCH C, V41, P94; HINDS P, 1987, MOL CELL BIOL, V63, P739; HOFFMAN BD, 1991, CYTOMETRY, V12, P26, DOI 10.1002/cyto.990120105; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUBERMAN JA, 1981, CELL, V23, P647, DOI 10.1016/0092-8674(81)90426-8; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; ISAACS WB, 1991, CANCER RES, V51, P4716; JENKINS JR, 1988, ONCOGENE HDB, P403; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KAKUNAGA T, 1978, P NATL ACAD SCI USA, V75, P1334, DOI 10.1073/pnas.75.3.1334; KASTAN MB, 1991, CANCER RES, V51, P6304; Kato H., 1977, International Rev Cytol, V49, P55; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KEPPLER BK, 1990, NEW J CHEM, V14, P389; KINZEL V, 1990, PROG CLIN BIOL RES, V340, P133; KNOWLES BB, 1979, J IMMUNOL, V122, P1798; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KRAISS S, 1991, EXP CELL RES, V192, P157, DOI 10.1016/0014-4827(91)90170-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEHMANN AR, 1981, J CANCER RES CLIN, V100, P117, DOI 10.1007/BF00403361; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI JC, 1984, P NATL ACAD SCI USA, V81, P5964; LIN JY, 1990, VIROLOGY, V176, P302, DOI 10.1016/0042-6822(90)90258-S; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOUIS JM, 1988, BIOCHIM BIOPHYS ACTA, V950, P395, DOI 10.1016/0167-4781(88)90136-4; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Maniatis T., 1982, MOL CLONING; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1990, ONCOGENE, V5, P973; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MICHALOVITZ D, 1986, MOL CELL BIOL, V6, P3531, DOI 10.1128/MCB.6.10.3531; MILLER CW, 1990, CANCER RES, V50, P7950; MONDAL S, 1976, NATURE, V260, P710, DOI 10.1038/260710a0; MORA PT, 1982, MOL CELL BIOL, V2, P763, DOI 10.1128/MCB.2.7.763; MORA PT, 1980, NATURE, V288, P722, DOI 10.1038/288722a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; PARKER WB, 1987, CANCER RES, V47, P979; PERO RW, 1990, CANCER RES, V50, P4619; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; POTMESIL M, 1983, CANCER RES, V43, P3528; REDDY MV, 1987, MUTAT RES, V179, P75; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REIHSAUS E, 1990, ONCOGENE, V5, P137; ROBB JA, 1973, EXP CELL RES, V81, P120, DOI 10.1016/0014-4827(73)90118-3; Roberts J J, 1979, Prog Nucleic Acid Res Mol Biol, V22, P71, DOI 10.1016/S0079-6603(08)60799-0; ROBERTS JJ, 1957, NATURE, V179, P1181, DOI 10.1038/1791181a0; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; ROTER V, 1991, ADV CANCER RES, V57, P257; SANFORD KK, 1948, J NATL CANCER I, V9, P229; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SELBY CP, 1990, P NATL ACAD SCI USA, V87, P3522, DOI 10.1073/pnas.87.9.3522; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHERLEY JL, 1991, J BIOL CHEM, V266, P24815; SHOHAT O, 1987, ONCOGENE, V1, P277; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; SOUSSI T, 1987, ONCOGENE, V1, P71; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TERADA N, 1991, J IMMUNOL, V147, P698; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TOLMACH LJ, 1977, RADIAT RES, V71, P653, DOI 10.2307/3574633; TOSCANI A, 1988, ONCOGENE RES, V3, P223; TRASK DK, 1988, P NATL ACAD SCI USA, V85, P1417, DOI 10.1073/pnas.85.5.1417; WALKER PR, 1991, CANCER RES, V51, P1078; WALTERS RA, 1974, BIOPHYS J, V14, P99, DOI 10.1016/S0006-3495(74)70002-9; WASSERMANN K, 1990, MOL PHARMACOL, V38, P38; WATSON PA, 1991, CYTOMETRY, V12, P242, DOI 10.1002/cyto.990120306; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WINTERSBERGER E, 1984, FEBS LETT, V166, P326, DOI 10.1016/0014-5793(84)80105-2; WOOD RD, 1991, BIOESSAYS, V13, P447, DOI 10.1002/bies.950130904; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YOST HJ, 1990, TRENDS GENET, V6, P223, DOI 10.1016/0168-9525(90)90183-7; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	115	875	888	0	24	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					307	318						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426740				2022-12-28	WOS:A1993KN00600009
J	KASTELEIN, RA; SHANAFELT, AB				KASTELEIN, RA; SHANAFELT, AB			GM-CSF RECEPTOR - INTERACTIONS AND ACTIVATION	ONCOGENE			English	Review							COLONY-STIMULATING FACTOR; EXPRESSION CLONING; GROWTH-HORMONE; GENE FAMILY; GRANULOCYTE; INTERLEUKIN-3; BINDING; SUBUNIT; RECONSTITUTION; MOLECULE				KASTELEIN, RA (corresponding author), DNAX RES INST MOLEC & CELLULAR BIOL INC, MOLEC & CELLULAR BIOL RES INST, DEPT MOLEC BIOL, PALO ALTO, CA 94304 USA.							ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; ELLIOTT MJ, 1989, BLOOD, V74, P2349; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Heyworth CM, 1990, GROWTH FACTORS, V2, P197, DOI 10.3109/08977199009071506; IMLER JL, 1992, EMBO J, V11, P2047, DOI 10.1002/j.1460-2075.1992.tb05262.x; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KAUSHANSKY K, 1989, P NATL ACAD SCI USA, V86, P1213, DOI 10.1073/pnas.86.4.1213; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; MEROPOL NJ, 1992, J BIOL CHEM, V267, P14266; METCALF D, 1986, BLOOD, V67, P257; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; PARK LS, 1992, P NATL ACAD SCI USA, V89, P4295, DOI 10.1073/pnas.89.10.4295; Parry D A, 1991, J Mol Recognit, V4, P63, DOI 10.1002/jmr.300040205; SCHEFFLER JE, 1991, IN PRESS BIOCHEMISTR; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SHANAFELT AB, 1992, IN PRESS J BIOL CHEM; SMITH LJ, 1992, J MOL BIOL, V224, P899, DOI 10.1016/0022-2836(92)90457-U; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; WANG HM, 1992, J BIOL CHEM, V267, P979; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; ZURAWSKI SM, 1989, EMBO J, V8, P2583, DOI 10.1002/j.1460-2075.1989.tb08397.x	34	31	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					231	236						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426734				2022-12-28	WOS:A1993KN00600001
J	Zariwala, M; Liu, E; Xiong, Y				Zariwala, M; Liu, E; Xiong, Y			Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15(INK4b) and p18(INK4c) in tumor-derived cell lines and primary tumors	ONCOGENE			English	Article						p18(Ink4c); INK CDK inhibitors; mutation		The growth suppressing activity of the retinoblastoma susceptibility gene product, pRb, is down regulated by cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) whose kinase activity is negatively regulated by CDK inhibitors of the pld family. We have examined the genomic status of two recently isolated p16-related CDK inhibitors, p15 and p18, in 15 normal and 73 tumor-derived cell lines established from 23 different tissues, as well as 26 invasive primary breast cancers and 20 acute myelogenous leukemias. p15 was found to be homozygously deleted in 22% of the tumor derived cell Lines, but no point mutations were found in either the cultured cells or the two types of primary tumors. With the exception of one breast cancer cell line, no deletions or mutations were found in the p18 gene in either cultured cell lines or primary tumors. These results indicate that mutation of the p18 gene occurs rarely in human tumors. Thus, while they share a very similar biochemical mechanism of inhibiting the kinase activity of CDK4 and CDK6, members of the p16 gene family play different roles in controlling cell proliferation and suppressing tumor growth.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill			Liu, Edison/C-4141-2008		NCI NIH HHS [CA 65572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065572] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIECHE I, 1994, CANCER RES, V54, P4274; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; GUAN KL, IN PRESS MOL BIOL CE; HAINSWORTH PJ, 1991, CANCER GENET CYTOGEN, V52, P205; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; HE J, 1994, CANCER RES, V54, P5804; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KNAPEK DF, 1995, CANCER RES, V55, P1607; KODURU PRK, IN PRESS BLOOD; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LI Y, 1994, CANCER RES, V54, P6078; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OKUDA T, 1995, BLOOD, V85, P2321, DOI 10.1182/blood.V85.9.2321.bloodjournal8592321; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OTSUKI T, 1995, CANCER RES, V55, P1436; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; WASHIMI O, 1995, CANCER RES, V55, P514; XU L, 1994, CANCER RES, V54, P5262; YOSHIDA S, 1995, CANCER RES, V55, P2756; ZHANG SY, 1994, CANCER RES, V54, P5050	32	41	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					451	455						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570224				2022-12-28	WOS:A1996TR53800026
J	Allemand, I; Grimber, G; Kornprobst, M; Bennoun, M; Molina, T; Briand, P; Joulin, V				Allemand, I; Grimber, G; Kornprobst, M; Bennoun, M; Molina, T; Briand, P; Joulin, V			Compensatory apoptosis in response to SV40 large T antigen expression in the liver	ONCOGENE			English	Article						transgenic mice; SV40 T antigen; hepatocarcinogenesis; apoptosis	TRANSGENIC MICE; CELL-DEATH; RAT-LIVER; P53 GENE; DNA; PROTEIN; GROWTH; TUMORIGENESIS; FRAGMENTATION; DISEASE	Transgenesis allows the in vivo determination of the effects of oncogene expression in normal tissues, In an attempt to understand the mechanism underlying liver transformation, we had previously created transgenic mice carrying the SV40 early gene sequences, which developed hepatocarcinoma in a reproducible way, In the present study, we show that constant expression of the transgene was directly correlated to an abnormally increased hepatocyte proliferation, even at the adult stage, We further demonstrate in this model that the preneoplastic stage of hepatocarcinoma is characterized by marked ploidy alterations as early as 1 month, including the emergence of aneuploid and hyperpolyploid cells, and the persistence of an important diploid cell population, We show that this elevated proliferation is early and transiently counterbalanced by a mechanism of apoptosis, which maintains liver homeostasis. The disappearance of this programmed cell death response effective during preneoplasia might signal the commitment of the liver to neoplasia.	INST COCHIN GENET MOLEC, INSERM U380, F-75014 PARIS, FRANCE; UNIV PARIS 06, FAC MED ST ANTOINE, INSERM U402, F-75571 PARIS 12, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite			Molina, Thierry/ABA-5214-2020	Molina, Thierry/0000-0002-3929-9754; allemand, isabelle/0000-0002-8861-7632; JOULIN, Virginie/0000-0003-1091-7819				BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BURSCH W, 1984, CARCINOGENESIS, V5, P453, DOI 10.1093/carcin/5.4.453; BURSCH W, 1990, CARCINOGENESIS, V11, P847, DOI 10.1093/carcin/11.5.847; BURSCH W, 1992, TRENDS PHARMACOL SCI, V13, P245, DOI 10.1016/0165-6147(92)90077-J; CHEN JD, 1992, ONCOGENE, V7, P1167; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLUMBANO A, 1985, LAB INVEST, V52, P670; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUBOIS N, 1991, J HEPATOL, V13, P227, DOI 10.1016/0168-8278(91)90819-W; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FAUSTO N, 1989, LAB INVEST, V60, P4; Fausto Nelson, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P117; FROMM L, 1994, MOL CELL BIOL, V14, P6743, DOI 10.1128/MCB.14.10.6743; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HIRAMATSU N, 1994, HEPATOLOGY, V19, P1354, DOI 10.1002/hep.1840190606; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; LEDDACOLUMBANO GM, 1991, AM J PATHOL, V139, P1099; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MAGAUD JP, 1989, J HISTOCHEM CYTOCHEM, V37, P1517, DOI 10.1177/37.10.2476478; MITA E, 1994, BIOCHEM BIOPH RES CO, V204, P468, DOI 10.1006/bbrc.1994.2483; MOORE M, 1992, J VIROL, V66, P641, DOI 10.1128/JVI.66.2.641-649.1992; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MOSSIN L, 1994, EXP CELL RES, V214, P551, DOI 10.1006/excr.1994.1293; NEVINS JR, 1992, SCIENCE, V258, P424; OBERHAMMER F, 1993, J CELL SCI, V104, P317; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; ROUQUET N, 1995, ONCOGENE, V11, P1061; SANDGREN EP, 1989, ONCOGENE, V4, P715; SCHULTEHERMANN R, 1990, CANCER RES, V50, P5127; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SYMONDS HS, 1993, MOL CELL BIOL, V13, P3255, DOI 10.1128/MCB.13.6.3255; WEBBER EM, 1994, AM J PATHOL, V145, P398; WESSEL R, 1992, VIROLOGY, V189, P293, DOI 10.1016/0042-6822(92)90705-T; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	50	20	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2583	2590						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545115				2022-12-28	WOS:A1995TP18800014
J	Bannister, AJ; Oehler, T; Wilhelm, D; Angel, P; Kouzarides, T				Bannister, AJ; Oehler, T; Wilhelm, D; Angel, P; Kouzarides, T			Stimulation of c-Jun activity by CBP: c-Jun residues Ser63/73 are required for CBP induced stimulation in vivo and CBP binding in vitro	ONCOGENE			English	Article						c-Jun; c-Fos; AP-1; CBP; transcription; activation	DNA-BINDING; ACTIVATION DOMAIN; TRANSCRIPTIONAL ACTIVATION; PROTO-ONCOGENE; LEUCINE ZIPPER; V-JUN; FOS; PHOSPHORYLATION; INVITRO; KINASE	The CBP protein mediates PKA induced transcription by binding to the PKA phosphorylated activation domain of CREB. Here we show that CBP also stimulates the activity of both c-Jun and v-Jun in vivo. The CREB binding domain of CBP is sufficient to contact to c-Jun in vitro. When this domain of CBP is linked to the activation domain of VP16 and expressed in vivo it stimulates c-Jun dependent transcription. Deletion analysis of c-Jun indicate that the CBP binding site is within the N-terminal activation domain. Loss of binding to CBP in vitro correlates with severely reduced transactivation capacity in vivo. Mutation of Ser63/73 in c-Jun, or the corresponding position in v-Jun (Ser36/46) leads to reduced binding to CBP in vitro and abolishes augmentation of transcription in vivo. These data are consistent with a mechanism by which CBP acts as a co-activator protein for Jun dependent transcription by interacting with the Jun IV-terminal activation domain.	UNIV CAMBRIDGE, WELLCOME CRC INST, CAMBRIDGE CB2 1QR, ENGLAND; UNIV CAMBRIDGE, DEPT PATHOL, CAMBRIDGE CB2 1QR, ENGLAND; FORSCHUNGSZENTRUM KARLSRUHE, INST GENET, D-76021 KARLSRUHE, GERMANY	University of Cambridge; University of Cambridge; Helmholtz Association; Karlsruhe Institute of Technology			Wilhelm, Dagmar/B-6915-2009; Piris, Miguel A/AAP-1445-2020	Wilhelm, Dagmar/0000-0002-7757-4075; Piris, Miguel A/0000-0001-5839-3634; Bannister, Andrew/0000-0002-6312-4436; Kouzarides, Tony/0000-0002-8918-4162	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANNWEILER A, 1991, NUCLEIC ACIDS RES, V19, P3750, DOI 10.1093/nar/19.13.3750; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BANNISTER AJ, 1994, NUCLEIC ACIDS RES, V22, P5173, DOI 10.1093/nar/22.24.5173; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BLACK EJ, 1994, ONCOGENE, V9, P2363; BROWN HJ, 1995, EMBO J, V14, P124, DOI 10.1002/j.1460-2075.1995.tb06982.x; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DAI TN, 1995, ONCOGENE, V10, P849; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DIXIT VM, 1989, J BIOL CHEM, V264, P16905; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; OEHLER T, 1993, ONCOGENE, V8, P1141; OEHLER T, 1992, MOL CELL BIOL, V12, P5508, DOI 10.1128/MCB.12.12.5508; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1994, EMBO J, V13, P6006, DOI 10.1002/j.1460-2075.1994.tb06946.x; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810	36	298	300	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2509	2514						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545107				2022-12-28	WOS:A1995TP18800006
J	Esteve, P; delPeso, L; Lacal, JC				Esteve, P; delPeso, L; Lacal, JC			Induction of apoptosis by rho in NIH 3T3 cells requires two complementary signals. Ceramides function as a progression factor for apoptosis	ONCOGENE			English	Article						rho; apoptosis; ceramides	GTP-BINDING PROTEIN; ADP-RIBOSYLTRANSFERASE; GROWTH-FACTORS; GENE-PRODUCT; VERO CELLS; DEATH; PROLIFERATION; FIBROBLASTS; INVOLVEMENT; EXPRESSION	We have previously reported that Pho genes, members of the ras superfamily, are tumorigenic when overexpressed in NIH 3T3 cells. As other known oncogenes, they also induce apoptosis after serum deprivation but not in the presence of growth factors. In the present study, we provide evidence that overexpression of the Aplysia Rho protein in NIH 3T3 cells induces the generation of phosphatidylcholine (PC)-derived second messengers as a result of activation of a PC-specific phospholipase D (PC-PLD) as previously reported for ras-transformed cells. In contrast, removal of serum in the Rho transfectants, but not in normal NTH 3T3 cells or cells transformed by the was oncogene, induced the production of ceramides as a result of activation of an sphingomyelinase (SMase). Furthermore, the rho-expressing cells underwent apoptosis in the presence of serum when exogenous ceramides were added, and this process was accelerated if cells were treated with exogenous SMase. Thus, Rho proteins act as an initiation signal that is necessary but not sufficient for the induction of apoptosis in NIH 3T3 cells. We propose here that induction of apoptosis in NM 3T3 cells requires two complementary signals: an initiation signal generated even in the presence of serum which 'primes' the cells, making them sensitive to a progression signal, triggered by serum removal, which we have identified as generation of ceramides.	CSIC, INST INVEST BIOMED, MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			del Peso, Luis/K-9391-2014; Lacal, Juan Carlos/AAL-2235-2020; Lacal, Juan Carlos/N-9064-2015	del Peso, Luis/0000-0003-4014-5688; Lacal, Juan Carlos/0000-0002-1908-2777				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AEPFELBACHER M, 1994, P NATL ACAD SCI USA, V91, P4263, DOI 10.1073/pnas.91.10.4263; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; ARENDS MJ, 1994, MOL BIOL HISTOPATHOL, P151; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; AVRAHAM H, 1990, BIOCHEM BIOPH RES CO, V168, P114, DOI 10.1016/0006-291X(90)91682-I; BALLESTERO RP, 1991, SUPERFAMILY RAS RELA, P237; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; CARNERO A, 1994, ONCOGENE, V9, P1387; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HAUSER JML, 1994, J BIOL CHEM, V269, P6803; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HOFFMAN B, 1994, ONCOGENE, V9, P1807; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JI L, 1995, FEBS LETT, V358, P211, DOI 10.1016/0014-5793(94)01428-4; JIMENEZ B, 1995, ONCOGENE, V10, P811; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOLESNICK R, 1994, MOL CHEM NEUROPATHOL, V21, P287, DOI 10.1007/BF02815356; LACAL JC, 1994, ONCOL REP, V1, P677; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LANG P, 1992, J BIOL CHEM, V267, P11677; LINETTE GP, 1994, CURR OPIN CELL BIOL, V6, P809, DOI 10.1016/0955-0674(94)90049-3; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MORII N, 1992, J BIOL CHEM, V267, P20921; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; PERONA R, 1993, ONCOGENE, V8, P1285; RIBEIRO JM, 1993, BIOCHEMISTRY-US, V32, P9129, DOI 10.1021/bi00086a018; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SELF AJ, 1993, ONCOGENE, V8, P655; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SUGAI M, 1992, P NATL ACAD SCI USA, V89, P8903, DOI 10.1073/pnas.89.19.8903; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8	58	40	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2657	2665						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545123				2022-12-28	WOS:A1995TP18800022
J	JIANG, D; SRINIVASAN, A; LOZANO, G; ROBBINS, PD				JIANG, D; SRINIVASAN, A; LOZANO, G; ROBBINS, PD			SV40 T-ANTIGEN ABROGATES P53-MEDIATED TRANSCRIPTIONAL ACTIVITY	ONCOGENE			English	Article							LARGE TUMOR-ANTIGEN; WILD-TYPE P53; RETINOBLASTOMA SUSCEPTIBILITY GENE; HUMAN PAPILLOMAVIRUS TYPE-16; TRANSFORMED-CELLS; SV40-TRANSFORMED CELLS; CELLULAR PROTEIN; SUPPRESSOR GENE; BINDING-SITE; MUTANT P53	Recent evidence suggests that the tumor-suppressor protein p53 functions as a transcriptional regulator to control cell proliferation. An interaction with p53 is required for SV40 T antigen to transform primary cells; however, the effect of T antigen binding on p53 function is not known. In order to determine if an interaction with T antigen results in loss of p53-mediated transcriptional activity, we have used vectors expressing either a p53-GAL4 fusion protein or a wild-type p53 protein in transient co-transfection assays with T-antigen expression vectors. We have demonstrated that coexpression of T antigen significantly reduces both p53-GAL4-mediated transcription from a GAL4-dependent CAT reporter and p53-mediated transcription from a consensus p53 binding site in vivo. Moreover, T antigen was able to reduce binding of p53-GAL4 to its GAL4 binding sequence in gel shift experiments in vitro. These observed activities of T antigen were all dependent upon a functional p53-binding domain. In addition, coexpression of human papillomavirus type 18 E6 protein, able to bind to p53, was able to significantly reduce p53-mediated transcription. These results suggest that an interaction of certain viral oncoproteins with p53 results in loss of transcriptional activity of p53, a function that is important for maintaining normal cell growth.	UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261; UNIV TEXAS,MD ANDERSEN CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030; UNIV PITTSBURGH,DEPT BIOL SCI,PITTSBURGH,PA 15260	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL CANCER INSTITUTE [R01CA055227] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55227] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARTEK J, 1990, ONCOGENE, V5, P893; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CLARK R, 1983, MOL CELL BIOL, V3, P220, DOI 10.1128/MCB.3.2.220; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LANFORD RE, 1988, VIROLOGY, V167, P72, DOI 10.1016/0042-6822(88)90055-4; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MORA PT, 1982, MOL CELL BIOL, V2, P763, DOI 10.1128/MCB.2.7.763; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OROURKE RW, 1990, ONCOGENE, V5, P1829; OSIFCHIN N, 1993, UNPUB J BIOL CHEM; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; PRIVES C, 1991, COLD SH Q B, V56, P227; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J, 1989, MOL CLONING LABORATO; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; STEPHENS T, 1991, J NIH RES, V3, P34; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	63	104	107	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2805	2812						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378089				2022-12-28	WOS:A1993LX34300022
J	LI, PM; FUKAZAWA, H; YAMAMOTO, C; MIZUNO, S; TANAKA, K; HORI, M; YAGINUMA, S; SAITO, T; UEHARA, Y				LI, PM; FUKAZAWA, H; YAMAMOTO, C; MIZUNO, S; TANAKA, K; HORI, M; YAGINUMA, S; SAITO, T; UEHARA, Y			METHOD OF IDENTIFYING INHIBITORS OF ONCOGENIC TRANSFORMATION - SELECTIVE-INHIBITION OF CELL-GROWTH IN SERUM-FREE MEDIUM	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; PROTEIN-TYROSINE KINASES; RAT-KIDNEY CELLS; HERBIMYCIN-A; TYRPHOSTINS; ERBSTATIN; INVITRO	We developed a new method for evaluating inhibitors of onocogenic signal transduction pathways based on different growth abilities between normal and transformed cells in a defined serum-free medium. The growth rates of src, abl or ras oncogene-transformed cells, activated raf proto-oncogene transformed cells, and normal NIH3T3 cells were 60-90%, 20-30% and 10% in a serum-free medium, respectively, compared to the growth rates in a serum-containing medium. An addition of a growth factor (PDGF, FGF or TGF-beta) stimulated the growth of normal NIH3T3 cells by 40-80% in a serum-free medium. Herbimycin A, a specific cytoplasmic protein tyrosine kinase inhibitor, selectively inhibited the growth of src or abl transformed cells in the serum-free medium resulting in about 10-fold or fivefold lower IC50 than those in the serum-containing medium. The antibiotic did not show such an effect on ras transformed cells, and the treatment of src transformed cells with other protein kinase inhibitors or cytotoxic drugs showed tittle IC50 shifts between the two media. Thus, this method of comparing growth inhibition in the serum-free and the serum-containing media may be useful in evaluating specific inhibitors of signaling pathways mediated by growth factors and certain oncogene products.	NATL INST HLTH, DEPT BIOACT MOLEC, 1-23-1 TOYAMA, SHINJUKU KU, TOKYO 162, JAPAN; SHOWA COLL PHARMACEUT SCI, TOKYO 194, JAPAN; ASAHI CHEM IND CO LTD, SHIZUOKA 41023, JAPAN	Showa Pharmaceutical University								AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ARMAND JP, 1990, EUR J CANCER, V26, P417, DOI 10.1016/0277-5379(90)90005-E; BROWDER TM, 1989, CANCER CELL-MON REV, V1, P9; CUADRADO A, 1990, BIOCHEM BIOPH RES CO, V170, P526, DOI 10.1016/0006-291X(90)92123-H; FUKAZAWA H, 1990, BIOCHEM BIOPH RES CO, V173, P276, DOI 10.1016/S0006-291X(05)81053-8; FUKAZAWA H, 1991, BIOCHEM PHARMACOL, V42, P1661; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; HONMA Y, 1992, ANTICANCER RES, V12, P189; HONMA Y, 1989, CANCER RES, V49, P331; IMOTO M, 1990, BIOCHEM BIOPH RES CO, V173, P208, DOI 10.1016/S0006-291X(05)81042-3; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; LEVITZKI A, 1991, TRENDS PHARMACOL SCI, V12, P171, DOI 10.1016/0165-6147(91)90538-4; LYALL RM, 1989, J BIOL CHEM, V264, P14503; OKABE M, 1992, BLOOD, V80, P1330; PIRONIN M, 1992, INT J CANCER, V51, P980, DOI 10.1002/ijc.2910510624; SHINDOOKADA N, 1989, MOL CARCINOGEN, V2, P159, DOI 10.1002/mc.2940020309; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; TRITTON TR, 1990, CANCER CELL-MON REV, V2, P95; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; UEHARA Y, 1985, JPN J CANCER RES, V76, P672; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; UMEZAWA H, 1986, J ANTIBIOT, V39, P170, DOI 10.7164/antibiotics.39.170; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541	26	26	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1993	8	7					1731	1735						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510919				2022-12-28	WOS:A1993LG68200003
J	SAJJADI, FG; PASQUALE, EB				SAJJADI, FG; PASQUALE, EB			5 NOVEL AVIAN EPH-RELATED TYROSINE KINASES ARE DIFFERENTIALLY EXPRESSED	ONCOGENE			English	Article							GROWTH-FACTOR; PROTEIN-KINASES; RECEPTOR; GENE; FAMILY; IDENTIFICATION; ENCODES; OVEREXPRESSION; PP60C-SRC; ONCOGENE	We have identified cDNA clones that encode five new avian receptor-like tyrosine kinases of the Eph subclass, by screening two chicken embryonic cDNA libraries with DNA probes. We have designated them Cek6 to Cek10. The identification of these kinases indicates that the Eph subclass comprises at least 10 members and, therefore, represents a very large family of receptor-like tyrosine kinases. Variants of Cek10 and of Cek5 (a previously identified Eph-related kinase) containing amino acid insertion sequences in the juxtamembrane domain were also isolated. The Cek5 variant is expressed in the brain, but not in other tissues of the 10-day chick embryo. Analysis of 10-day chick embryo mRNAs shows the newly identified tyrosine kinases to be all expressed in both the embryonic brain and body tissues. In adult tissues, they display distinct patterns of expression. Cek6, Cek7, Cek8, Cek9 and Cek10 are likely to play significant roles in embryonic signal transduction pathways, including those involved in neural development. Their distinct tissue distributions in the adult suggest that the different members of the Eph family may each serve specific functions.	LA JOLLA CANC RES FDN,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					NCI NIH HHS [CA56721] Funding Source: Medline; NICHD NIH HHS [HD26351] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026351, R29HD026351] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA056721] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHAN J, 1991, ONCOGENE, V6, P1057; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MARU Y, 1990, ONCOGENE, V5, P445; MERCOLA M, 1988, DEVELOPMENT, V102, P451; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; SAJJADI FG, 1991, NEW BIOL, V3, P769; Sambrook J, 1989, MOL CLONING LABORATO; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	35	133	153	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1807	1813						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510926				2022-12-28	WOS:A1993LG68200012
J	HU, LF; CHEN, F; ZHENG, X; ERNBERG, I; CAO, SL; CHRISTENSSON, B; KLEIN, G; WINBERG, G				HU, LF; CHEN, F; ZHENG, X; ERNBERG, I; CAO, SL; CHRISTENSSON, B; KLEIN, G; WINBERG, G			CLONABILITY AND TUMORIGENICITY OF HUMAN EPITHELIAL-CELLS EXPRESSING THE EBV ENCODED MEMBRANE-PROTEIN LMP1	ONCOGENE			English	Article							EPSTEIN-BARR-VIRUS; NASOPHARYNGEAL CARCINOMA; HUMAN KERATINOCYTES; NEOPLASTIC TRANSFORMATION; NUCLEAR ANTIGEN; BNLF-1 GENE; B-CELLS; ONCOGENE; GENOME; DEATH	Two isolates of the EBV-LMP1 gene were compared for their ability to induce phenotypic changes in a non-tumorigenic human keratinocyte line, Rhek-1, immortalized with an adenovirus 12-SV40 hybrid virus. One isolate, designated B-LMP1, was derived from B95-8, a B-cell line of marmoset origin, that carries a viral strain from a mononucleosis patient. The other, designated C-LMP1, originated from a nude mouse passaged Chinese NPC tumor, CAO. Both types of transfectants were less serum dependent than the non-transfected and the vector-transfected controls. The ability to grow on low serum increased with increasing LMP1 expression. All transfectants were more highly clonable than the non-transfected or vector-transfected controls. Clonability in soft agarose increased with increasing LMP1 expression. Nine of 24 C-LMP1 transfectants produced tumors in SCID mice. Seven of them grew invasively into the surrounding tissue. Only one of 12 B-LMP1 transfected Rhek-1 clones was tumorigenic. It did not grow invasively. All tumorigenic transfectants expressed LMP1 at high or moderate levels. All tumors were found to express LMP1. Transfectants with low LMP1 expression did not produce tumors. The untransfected Rhek-1 cells and six vector control clones failed to produce tumors.	KAROLINSKA INST,DEPT TUMOR BIOL,BOX 60400,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT PATHOL,S-14186 HUDDINGE,SWEDEN; SHANGHAI MED UNIV,TUMOR HOSP,SHANGHAI,PEOPLES R CHINA; FRED HUTCHINSON CANC RES CTR,PROGRAMME CANC BIOL,SEATTLE,WA 98104	Karolinska Institutet; Karolinska Institutet; Fudan University; Fred Hutchinson Cancer Center			Winberg, Gosta/I-5686-2013	Winberg, Gosta/0000-0002-3371-4056	NATIONAL CANCER INSTITUTE [R01CA030264] Funding Source: NIH RePORTER; NCI NIH HHS [2RQI CA30264-10] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSONANVRET M, 1977, INT J CANCER, V20, P486, DOI 10.1002/ijc.2910200403; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BAICHWAL VR, 1989, ONCOGENE, V4, P67; CHEN ML, 1992, ONCOGENE, V7, P2131; CUOMO L, 1993, IN PRESS INT J CANCE; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FIDLER IJ, 1991, ANTICANCER RES, V11, P17; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; Hausen H., 1970, NATURE, V228, P1056; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENLE G, 1968, P NATL ACAD SCI USA, V59, P94, DOI 10.1073/pnas.59.1.94; HENLE W, 1970, J NATL CANCER I, V44, P225; HU LF, 1991, J GEN VIROL, V72, P2399, DOI 10.1099/0022-1317-72-10-2399; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KLEIN G, 1974, P NATL ACAD SCI USA, V71, P4737, DOI 10.1073/pnas.71.12.4737; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBOWITZ D, 1992, J VIROL, V66, P4612, DOI 10.1128/JVI.66.7.4612-4616.1992; MANN KP, 1987, J VIROL, V61, P2100, DOI 10.1128/JVI.61.7.2100-2108.1987; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; RHIM JS, 1989, ANTICANCER RES, V9, P1345; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; RYMO L, 1985, P NATL ACAD SCI USA, V82, P3435, DOI 10.1073/pnas.82.10.3435; SALCEDO R, 1991, J VIROL, V65, P5558, DOI 10.1128/JVI.65.10.5558-5563.1991; Sambrook J, 1989, MOL CLONING LABORATO; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WOLF H, 1973, NATURE-NEW BIOL, V244, P245, DOI 10.1038/newbio244245a0; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051; ZHANG RD, 1991, CANCER RES, V51, P2029	34	178	205	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1575	1583						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8389032				2022-12-28	WOS:A1993LE06400021
J	RIDGWAY, PJ; HALE, TK; BRAITHWAITE, AW				RIDGWAY, PJ; HALE, TK; BRAITHWAITE, AW			P53 CONFERS A SELECTIVE ADVANTAGE ON TRANSFECTED HELA-CELLS	ONCOGENE			English	Article							WILD-TYPE P53; TRANSCRIPTIONAL ACTIVATION; MONOCLONAL-ANTIBODIES; CDNA CLONE; TRANSFORMATION; GROWTH; GENE; EXPRESSION; ANTIGEN; MOUSE	The p53 gene, which is frequently mutated in various tumors, encodes a phosphoprotein thought to have a key role in the regulation of cell proliferation. To explore their biological effects, the HeLa carcinoma line, which does not express p53, was co-transfected with plasmid constructs expressing wild-type or mutant p53 proteins, or unrelated proteins, along with a plasmid conferring resistance to a neomycin-kanamycin antibiotic analog (G418). Both wild-type and mutant forms of p53 stimulated the number of G418-resistant colonies between 5- and 36-fold. Further investigation of colony development revealed that p53 enhanced cell survival, leading to increased colony numbers, but did not stimulate cell growth. Nonetheless, we suggest that an initial slowing of cell growth caused by expression of the unintegrated p53 plasmids renders the transfectants resistant to selection with G418, thus causing a higher frequency of G418-resistant colonies. p53 constructs were found to be expressed transiently in HeLa cells as expected, but the G418-resistant colonies frequently failed to express p53. This loss of p53 expression may be due to negative regulatory effects of p53 on the cytomegalovirus promoter that drives the selection marker.	AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV CELL BIOL,GPO BOX 334,CANBERRA,ACT 2601,AUSTRALIA	Australian National University; John Curtin School of Medical Research								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BENCHIMOL S, 1982, EMBO J, V1, P1055, DOI 10.1002/j.1460-2075.1982.tb01296.x; BRAITHWAITE AW, 1991, ONCOGENE, V6, P781; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEPPERT W, 1990, ONCOGENE, V5, P1701; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1984, NUCLEIC ACIDS RES, V12, P5609, DOI 10.1093/nar/12.14.5609; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; OROURKE RW, 1990, ONCOGENE, V5, P1829; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SHOHAT O, 1987, ONCOGENE, V1, P277; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SOUSSI T, 1990, ONCOGENE, V5, P945; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	29	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1069	1074						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455934				2022-12-28	WOS:A1993KT22000032
J	SEGAWA, K; MINOWA, A; SUGASAWA, K; TAKANO, T; HANAOKA, F				SEGAWA, K; MINOWA, A; SUGASAWA, K; TAKANO, T; HANAOKA, F			ABROGATION OF P53-MEDIATED TRANSACTIVATION BY SV40 LARGE T-ANTIGEN	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; TUMOR-ANTIGEN; P53 PROTEIN; DNA-REPLICATION; WILD-TYPE; TRANSFORMATION; CELLS; PROMOTERS; SEQUENCE; PRODUCT	p53 is known to bind specifically to the 44-bp human DNA sequence in an immunoprecipitation assay. We show here that the transcription of the reporter CAT gene linked with the herpesvirus thymidine kinase (tk) promoter containing the 44-base sequence is enhanced by mouse wild-type but not mutant-type p53 in F9 and p53-null Saos-2 cells. The p53-mediated transactivation was dramatically abrogated by introduction of SV40 large T antigen (SVLT) in Saos-2 cells in which p53 was clearly associated with SVLT. Furthermore, the p53-SVLT complex did not bind to the 44-base sequence at all. Thus, SVLT sequesters the transactivation function of the wild-type p53 by inhibiting the binding of p53 to the 44-base sequence. This is good evidence to show 'loss of functions' in the product of a tumor-suppressor oncogene by a dominant oncogene product at a molecular level.	INST PHYS & CHEM RES RIKEN,PHYSIOL LAB,WAKO,SAITAMA 35101,JAPAN	RIKEN	SEGAWA, K (corresponding author), KEIO UNIV,SCH MED,DEPT MICROBIOL,35 SHINANOMACHI,SHINJUKU KU,TOKYO 160,JAPAN.							AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BUCHKOVITCH K, 1989, CELL, V58, P1099; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1988, ONCOGENE, V3, P313; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOEKEN M, 1988, CELL, V55, P1171, DOI 10.1016/0092-8674(88)90261-9; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MURAKAMI Y, 1991, P NATL ACAD SCI USA, V88, P3947, DOI 10.1073/pnas.88.9.3947; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEGAWA K, 1986, VIROLOGY, V155, P334, DOI 10.1016/0042-6822(86)90197-2; SEGAWA K, 1987, MOL CELL BIOL, V7, P556, DOI 10.1128/MCB.7.1.556; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUGANO S, 1984, J VIROL, V52, P884, DOI 10.1128/JVI.52.3.884-891.1984; SUGASAWA K, 1992, P NATL ACAD SCI USA, V89, P1055, DOI 10.1073/pnas.89.3.1055; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	38	60	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					543	548						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8382354				2022-12-28	WOS:A1993KN00800003
J	HAO, MM; FINLAY, CA; LOZANO, G				HAO, MM; FINLAY, CA; LOZANO, G			A FUNCTIONALLY INACTIVE P53 LI-FRAUMENI SYNDROME MUTANT	ONCOGENE			English	Article							WILD-TYPE P53; TRANSCRIPTIONAL ACTIVATION; NUCLEAR-LOCALIZATION; PROTEINS BIND; GENE-PRODUCT; T-ANTIGEN; DNA; MUTATIONS; CANCER; CELLS	Germline mutations in the tumor-suppressor p53 have been recently identified in Li-Fraumeni syndrome patients. We analysed the function of one of these mutations, an arg-to-trp substitution at amino acid 245 in the murine p53 gene. This p53LFS mutant could not, unlike wild-type p53, suppress foci formation of rat embryo-fibroblasts. Like other p53 mutants it cooperated with activated ras to transform rat embryo fibroblasts. Overexpression of p53LFS thus resulted in a phenotype similar to other mutant p53s. The p53LFS protein was also transcriptionally inactive in contrast to previous studies using a p53LFS/GAL4 fusion protein. To better understand the functional domain disrupted in p53LFS, we developed a dimerization assay and showed that p53LFS still dimerized. In addition, p53LFS retained its ability to bind SV40 large T antigen and not hsc70, both characteristics of wild-type p53. Using immunofluorescence, we localized p53LFS to the nucleus. From these results we conclude that p53LFS represents an unusual p53 mutant in that it retains many characteristics of wild-type p53, however activities critical for growth suppression are lost.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030; PRINCETON UNIV,DEPT BIOL,PRINCETON,NJ 08544	University of Texas System; UTMD Anderson Cancer Center; Princeton University					NCI NIH HHS [CA47296] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA047296, R01CA047296] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LI FP, 1982, JAMA-J AM MED ASSOC, V247, P2692, DOI 10.1001/jama.247.19.2692; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; OROURKE RW, 1990, ONCOGENE, V5, P1829; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SILVER PA, 1984, P NATL ACAD SCI-BIOL, V81, P5951, DOI 10.1073/pnas.81.19.5951; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	40	12	12	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					299	306						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426739				2022-12-28	WOS:A1993KN00600008
J	LUDLOW, JW; HOWELL, RL; SMITH, HC				LUDLOW, JW; HOWELL, RL; SMITH, HC			HYPOXIC STRESS INDUCES REVERSIBLE HYPOPHOSPHORYLATION OF PRB AND REDUCTION IN CYCLIN A ABUNDANCE INDEPENDENT OF CELL-CYCLE PROGRESSION	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; GLUCOSE-REGULATED PROTEINS; HAMSTER OVARY CELLS; SEA-URCHIN EGGS; SV40 LARGE-T; TRANSCRIPTION FACTOR; MESSENGER-RNA; CDC2 KINASE; PRODUCT; INDUCTION	The effect of hypoxic stress on the phosphorylation state of the product of retinoblastoma susceptibility gene (pRB) and cyclin A abundance was examined in CV-1P monkey kidney cells. Flow cytometric DNA histogram analysis and [H-3]-thymidine incorporation assays demonstrated that hypoxia inhibited cell cycle progression and cell division. Within 6-12 h of hypoxia, pRB became hypophosphorylated and cyclin A abundance fell below detection limits. Hypophosphorylation of pRB and loss of cyclin A detection occurred without progression of cells through S-phase. These effects were found to be reversible by reoxygenation of the hypoxic cultures. Cells were shown to resume DNA synthesis within 12 - 16 h of reoxygenation concomitant with pRB hyperphosphorylation and an increase in cyclin A detection. These data demonstrate that hypoxic stress blocks the progression of these cells through the phases of the cell cycle and suggests that the effect might arise from the down regulation of key cell cycle controlling elements. The data also raise the possibility that maintaining pRB in a hyperphosphorylated state may be crucial for S-phase progression as well as S-phase entry.	UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT PATHOL, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester	LUDLOW, JW (corresponding author), UNIV ROCHESTER, CTR CANC, DIV TUMOR BIOL, BOX 704, 601 ELMWOOD AVE, ROCHESTER, NY 14642 USA.			Smith, Harold/0000-0001-6257-6791	NCI NIH HHS [CA56940, CA11198] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198, R29CA056940] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUTLER AJ, 1991, J BIOL CHEM, V266, P18250; CHANG SC, 1989, MOL CELL BIOL, V9, P2153, DOI 10.1128/MCB.9.5.2153; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; COLEMAN CN, 1988, J NATL CANCER I, V80, P310, DOI 10.1093/jnci/80.5.310; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEWEY WC, 1976, RADIAT RES, V65, P511, DOI 10.2307/3574383; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HEACOCK CS, 1990, BRIT J CANCER, V62, P217, DOI 10.1038/bjc.1990.264; HEACOCK CS, 1986, INT J RADIAT ONCOL, V12, P1287, DOI 10.1016/0360-3016(86)90155-0; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; KOCH CJ, 1971, RADIAT RES, V48, P74, DOI 10.2307/3573396; KOWK TT, 1989, RADIAT RES, V119, P261; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; KWOK TT, 1989, INT J RADIAT ONCOL, V16, P1301; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE AS, 1983, J BIOL CHEM, V258, P597; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LOCK RB, 1990, CANCER RES, V50, P3761; LUCA FC, 1989, J CELL BIOL, V109, P1895, DOI 10.1083/jcb.109.5.1895; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; PELMAN HRB, 1986, CELL, V46, P959; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; RICE GC, 1985, INT J RADIAT ONCOL, V11, P1817, DOI 10.1016/0360-3016(85)90038-0; ROLL DE, 1991, MOL CELL BIOCHEM, V103, P141; SCIANDRA JJ, 1984, P NATL ACAD SCI-BIOL, V81, P4843, DOI 10.1073/pnas.81.15.4843; SHEN JW, 1989, MOL CELL BIOL, V9, P3284, DOI 10.1128/MCB.9.8.3284; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; Shew J.-Y., 1989, ONCOGENE RES, V1, P205; SORGER PK, 1987, J MOL BIOL, V194, P341, DOI 10.1016/0022-2836(87)90380-9; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SUTHERLAND RM, 1982, INT J RADIAT ONCOL, V8, P745, DOI 10.1016/0360-3016(82)90726-X; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAUPEL P, 1987, RADIAT RES, V2, P707; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WEBSTER KA, 1988, CAN J ZOOL, V66, P1046, DOI 10.1139/z88-155; WILSON RE, 1989, J NATL CANCER I, V81, P1235, DOI 10.1093/jnci/81.16.1235; XU HJ, 1989, ONCOGENE, V4, P807; YOUNG SD, 1988, P NATL ACAD SCI USA, V85, P9533, DOI 10.1073/pnas.85.24.9533	57	43	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					331	339						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426741				2022-12-28	WOS:A1993KN00600012
J	Kubota, S; Siomi, H; Hatanaka, M; Pomerantz, RJ				Kubota, S; Siomi, H; Hatanaka, M; Pomerantz, RJ			Cis trans-activation of the interleukin-9 receptor gene in an HTLV-I-transformed human lymphocytic cell	ONCOGENE			English	Article						interleukin-9; receptor; T-lymphocyte; long terminal repeat; HTLV-I; HIV-1	VIRUS TYPE-I; NF-KAPPA-B; LEUKEMIA-ASSOCIATED ANTIGEN; STIMULATING FACTOR GENE; TRANSCRIPTIONAL ACTIVATOR; TRANSACTIVATOR TAX; MOLECULAR-CLONING; T-CELLS; EXPRESSION; PROTEIN	The MT-2 cell-line, which had been established through in vitro cell to cell transmission of human T-cell leukemia virus type T (HTLV-I) among human primary lymphocytes, was shown to possess multiple copies of integrated proviruses, including defective proviral genomes. By analysing a genomic clone, we identified the integration site of a single HTLV-I long terminal repeat (LTR) in the interleukin-9 (IL-9) receptor (IL-9R) gene. The integrated HTLV-I-LTR was shown to be functional as a promoter and the integration site was located in an intron upstream of the first coding exon of the IL-9R gene. Upon analysis of total cellular RNA, specific expression of HTLV-I-LTR IL-9R chimeric mRNAs in MT-2 cells was demonstrated. Cloning and characterization of these cDNAs have identified HTLV-I-IL-9R chimeric splicing, using either intact or alternative splice sites within the IL-9R gene. The potential roles of multiple interactions between IL-9, IL-9R and HTLV-I in the monoclonal expansion and transformation of MT-2 cells are explored.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,DIV INFECT DIS,SECT MOL RETROVIROL,PHILADELPHIA,PA 19107; KYOTO UNIV,INST VIRUS RES,SAKYO KU,KYOTO 60601,JAPAN	Jefferson University; Kyoto University			Siomi, Haruhiko/A-7020-2015	Siomi, Haruhiko/0000-0001-8690-3822	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036552] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36552] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHMED YF, 1991, CELL, V64, P727, DOI 10.1016/0092-8674(91)90502-P; CHANG MS, 1994, BLOOD, V83, P3199; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coffin J. M., 1990, VIROLOGY, P1437; DEROSSI A, 1985, VIROLOGY, V143, P640, DOI 10.1016/0042-6822(85)90405-2; Derse David, 1994, AIDS Research and Human Retroviruses, V10, pS120; DITTMER J, 1993, J VIROL, V67, P6087, DOI 10.1128/JVI.67.10.6087-6095.1993; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; FAN N, 1992, J CLIN MICROBIOL, V30, P905, DOI 10.1128/JCM.30.4.905-910.1992; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; HAERTLE T, 1985, J BIOL CHEM, V229, P563; HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HIRAI H, 1992, ONCOGENE, V7, P1737; HOUSSIAU FA, 1992, J IMMUNOL, V148, P3147; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; IINO T, 1986, J GEN VIROL, V67, P1373, DOI 10.1099/0022-1317-67-7-1373; KELLEHER K, 1991, BLOOD, V77, P1436; KOBAYASHI N, 1984, EMBO J, V3, P1399; Krainer AR, 1988, TRANSCRIPTION SPLICI, P131; LI M, 1993, MOL CELL BIOL, V13, P6490, DOI 10.1128/MCB.13.10.6490; MERZ H, 1991, BLOOD, V78, P1311; MIURA S, 1991, MOL CELL BIOL, V11, P1313, DOI 10.1128/MCB.11.3.1313; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MORI K, 1987, J GEN VIROL, V68, P499, DOI 10.1099/0022-1317-68-2-499; MORI N, 1994, BLOOD, V84, P1688; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; OSAME M, 1986, LANCET, V1, P1031; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RENAULD JC, 1993, ADV IMMUNOL, V54, P79, DOI 10.1016/S0065-2776(08)60533-7; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SABE H, 1988, INT J CANCER, V41, P880, DOI 10.1002/ijc.2910410619; SCHRECK R, 1990, MOL CELL BIOL, V10, P1281, DOI 10.1128/MCB.10.3.1281; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; SUZUKI T, 1993, ONCOGENE, V8, P2391; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TAKEUCHI K, 1985, J GEN VIROL, V66, P1825, DOI 10.1099/0022-1317-66-8-1825; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; UYTTENHOVE C, 1991, J EXP MED, V173, P519, DOI 10.1084/jem.173.2.519; YAMAOKA S, 1992, ONCOGENE, V7, P433; YAMASHITA I, 1994, BLOOD, V84, P1573	47	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1441	1447						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622860				2022-12-28	WOS:A1996UF07600008
J	Rodewald, HR; Sato, TN				Rodewald, HR; Sato, TN			Tie1, a receptor tyrosine kinase essential for vascular endothelial cell integrity, is not critical for the development of hematopoietic cells	ONCOGENE			English	Article						Tie1; receptor tyrosine kinase; hematopoietic stem cells; lymphocyte development; recombination-activating-gene (RAG)-2-deficient mice; colony-forming cells	MOLECULAR-CLONING; PROGENITOR CELLS; STEM-CELLS; C-KIT; EXPRESSION; MOUSE; FAMILY; GENES; MEMBER; DIFFERENTIATION	The receptor tyrosine kinase Tiel is expressed in both vascular endothelial cells and immature hematopoietic cells. Expression of a common signaling molecule in distinct cellular Lineages may suggest common ancestry of these lineages in ontogeny and/or utilization of shared signaling pathways, Tie l-deficient mice carrying a targeted insertional mutation in germ line show defects in endothelial cell integrity resulting in edema and hemorrhage. To analyse the potential role of this kinase in hematopoietic cells, we have now compared hematopoietic compartments in wildtype and Tiel-deficient mice, The results show: (1) Total cellularity is mildly reduced comparing Tie1(-/-) and wildtype fetal liver from day 15.5 of gestation, (2) In vitro colony assays and cell transfer experiments of fetal liver cells into lymphocyte-deficient recombination-activating-gene-2(-/-) mice reveal that Tie1(-/-) hematopoietic progenitor cells can generate myeloid lineages as well as T and B lymphocytes, (3) Tie1(-/-) fetal liver cells contain long-term (at least 4 months) bone marrow-reconstituting hematopoietic stem cells suggesting that this kinase is not critical for stem cell-engraftment nor self-renewal.	BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND; ROCHE INST MOLEC BIOL,ROCHE RES CTR,NUTLEY,NJ 07110	Roche Holding								ARMSTRONG E, 1993, LEUKEMIA, V7, P1585; AUGUSTIN HG, 1994, BIOESSAYS, V16, P901, DOI 10.1002/bies.950161208; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; DUMONT DJ, 1993, ONCOGENE, V8, P1293; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; ERA T, 1994, IMMUNOL REV, V137, P35, DOI 10.1111/j.1600-065X.1994.tb00658.x; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GULLEY ML, 1988, J IMMUNOL, V140, P3751; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; IKUTA K, 1992, P NATL ACAD SCI USA, V89, P1502, DOI 10.1073/pnas.89.4.1502; IWAMA A, 1993, BIOCHEM BIOPH RES CO, V195, P301, DOI 10.1006/bbrc.1993.2045; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NICOLA NA, 1981, BLOOD, V58, P376; NIENHUIS AW, 1985, CELL, V42, P421, DOI 10.1016/0092-8674(85)90099-6; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; OGAWA M, 1993, DEVELOPMENT, V117, P1089; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PAUL WE, 1989, CELL, V57, P521, DOI 10.1016/0092-8674(89)90121-9; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; RAJEWSKY K, 1992, SCIENCE, V256, P483, DOI 10.1126/science.1570513; RISAU W, 1988, DEVELOPMENT, V102, P471; RODEWALD HR, 1994, EMBO J, V13, P4229, DOI 10.1002/j.1460-2075.1994.tb06743.x; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROSNET O, 1991, ONCOGENE, V6, P1641; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; Shortman K, 1990, Semin Immunol, V2, P3; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; UCHIDA N, 1993, CURR OPIN IMMUNOL, V5, P177, DOI 10.1016/0952-7915(93)90002-A; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ZIEGLER SF, 1993, ONCOGENE, V8, P663	41	45	46	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					397	404						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570217				2022-12-28	WOS:A1996TR53800019
J	Dorin, D; Cohen, L; DelVillar, K; Poullet, P; Mohr, R; Whiteway, M; Witte, O; Tamanoi, F				Dorin, D; Cohen, L; DelVillar, K; Poullet, P; Mohr, R; Whiteway, M; Witte, O; Tamanoi, F			Kir, a novel ras-family G-protein, induces invasive pseudohyphal growth in Saccharomyces cerevisiae	ONCOGENE			English	Article						Ras-family G-protein; Saccharomyces cerevisiae; pseudohyphae; MAP kinase cascade	PHEROMONE RESPONSE PATHWAY; FILAMENTOUS GROWTH; YEAST; SUBUNITS; ELEMENTS; HOMOLOG; DOMAIN; GENE; IRA2	Kir belongs to a novel class of Ras-family G-proteins which includes Gem and Rad, These proteins are unique among Ras super-family G-proteins since their expression is under transcriptional regulation in mammalian cells, To gain insight into the function of Kir, we took advantage of the well-defined signal transduction pathways of yeast, When kir is expressed in Saccharomyces cerevisiae, the transformants form pseudohyphae and exhibit invasive properties characteristic of yeast cells are undergoing a developmental transition induced by GTPase nitrogen starvation, Analysis of pseudohyphal signaling pathway mutants suggests that the Kir-induced pseudohyphae formation requires a MAP kinase cascade involving ste20, ste11, ste7 but not ste5 gene products, Furthermore, our results are consistent with the idea that Kir functions upstream of the STE20 kinase which plays a critical role in two distinct MAP kinase cascades.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90095 USA; NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, MONTREAL, PQ H4P 2R2, CANADA	University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; National Research Council Canada					NATIONAL CANCER INSTITUTE [R35CA053867, R01CA041996] Funding Source: NIH RePORTER; NCI NIH HHS [CA53867, CA41996] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; COHEN L, 1994, P NATL ACAD SCI USA, V91, P12448, DOI 10.1073/pnas.91.26.12448; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; NOMOTO S, 1990, EMBO J, V9, P691, DOI 10.1002/j.1460-2075.1990.tb08161.x; QADOTA H, 1994, P NATL ACAD SCI USA, V91, P9317, DOI 10.1073/pnas.91.20.9317; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; SHERMAN F, 1986, FMETHODS YEAST GENET, P153; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; TANAKA K, 1992, MOL CELL BIOL, V12, P631, DOI 10.1128/MCB.12.2.631; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WRIGHT RM, 1993, CURR GENET, V23, P388, DOI 10.1007/BF00312623; ZHU JH, 1995, J BIOL CHEM, V270, P4805, DOI 10.1074/jbc.270.9.4805	24	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2267	2271						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570176				2022-12-28	WOS:A1995TK70200009
J	Subramanian, T; Boyd, JM; Chinnadurai, G				Subramanian, T; Boyd, JM; Chinnadurai, G			Functional substitution identifies a cell survival promoting domain common to adenovirus E1B 19 kDa and Bcl-2 proteins	ONCOGENE			English	Article						apoptosis; Bcl-2 family; E1B 19 kDa protein; p53; NH1 domain	TUMOR-NECROSIS-FACTOR; EARLY REGION E1B; LP+ LOCUS; DEATH; GENE; TRANSFORMATION; APOPTOSIS; ANTIGEN; DNA; ONCOGENE	The adenovirus E1B 19 kDa protein provides a cell survival function during adenovirus infection and facilitates efficient virus replication by preventing premature cell death. These functions resemble those performed by the protein coded by the proto-oncogene Bcl-2. The Bcl-2 protein, which provides a survival function in cells exposed to a number of cell death-inducing stimuli, can substitute for the 19 kDa protein during adenovirus infection, Although these two survival-promoting proteins are not overtly related by primary amino acid sequence, they appear to share short homologous sequences. In order to determine if these sequence motifs constitute common functional domains, we carried out domain exchanges between the 19 kDa and Bcl-2 proteins, Our results indicate that a seven amino acid region of the Bcl-2 protein (108-YRRDFAE-114) can efficiently substitute for the corresponding 19 kDa domain (47-YKWEFEE-53). Mutagenizing this domain in Bcl-2 abolishes the survival promoting activity of Bcl-2, Substitution of the 19 kDa sequences into Bcl-2 restores the survival promoting activity, albeit at reduced levels, Our results suggest that this domain (designated NH1) may constitute a common functional domain for the 19 kDa protein and survival promoting members of the Bcl-2 family of proteins.	ST LOUIS UNIV,MED CTR,INST MOLEC VIROL,ST LOUIS,MO 63110	Saint Louis University					NATIONAL CANCER INSTITUTE [R01CA031719, R01CA033616] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA033616, CA-31719, CA-33616] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1992, CURRENT PROTOCOLS MO; BABISS LE, 1984, J VIROL, V52, P389, DOI 10.1128/JVI.52.2.389-395.1984; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1995, IN PRESS ONCOGENE; CHINNADURAI G, 1983, CELL, V33, P759, DOI 10.1016/0092-8674(83)90018-1; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GOODING LR, 1991, J VIROL, V65, P3083, DOI 10.1128/JVI.65.6.3083-3094.1991; GREEN M, 1983, J VIROL, V48, P604, DOI 10.1128/JVI.48.3.604-615.1983; HASHIMOTO S, 1991, INT IMMUNOL, V3, P343, DOI 10.1093/intimm/3.4.343; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; MCLORIE W, 1991, J GEN VIROL, V72, P1467, DOI 10.1099/0022-1317-72-6-1467; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PILDER S, 1984, J VIROL, V52, P664, DOI 10.1128/JVI.52.2.664-671.1984; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SUBRAMANIAN T, 1984, J BIOL CHEM, V259, P1777; SUBRAMANIAN T, 1993, GENE, V124, P173, DOI 10.1016/0378-1119(93)90391-F; SUBRAMANIAN T, 1984, J VIROL, V52, P336, DOI 10.1128/JVI.52.2.336-343.1984; SUBRAMANIAN T, 1995, CELL GROWTH DIFFER, V6, P131; TAKEMORI N, 1984, J VIROL, V52, P793, DOI 10.1128/JVI.52.3.793-805.1984; TARODI B, 1993, INT J ONCOL, V3, P467; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	38	42	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2403	2409						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570192				2022-12-28	WOS:A1995TK70200025
J	LANGGUT, W; REISSER, T; KERSTEN, H; NISHIMURA, S				LANGGUT, W; REISSER, T; KERSTEN, H; NISHIMURA, S			MODULATION OF EPIDERMAL GROWTH-FACTOR RECEPTOR ACTIVITY AND RELATED RESPONSES BY THE 7-DEAZAGUANINE DERIVATIVE, QUEUINE	ONCOGENE			English	Article							TRANSFER-RNA; PROTO-ONCOGENES; TYROSINE KINASE; C-FOS; PHOSPHORYLATION; ACTIVATION; PROTEINS; ENZYME; CELLS; BASE	Epidermal growth factor (EGF) induces autophosphorylation of its cognate receptor at tyrosine residues. Here we show that queuine (q), a widely distributed modified guanine analogue occurring free or as a tRNA wobble base, modulates this EGF receptor activity in vitro and in intact cells. Autophosphorylation of the immunopurified receptor from human A431 epidermoid carcinoma cells was enhanced three to fourfold in the presence of physiological concentrations of q. Using a membrane fraction of A431 cells, a twofold increase in autophosphorylation activity in the presence of q was observed, however, only when the receptor was activated by the ligand. In intact A431 cells, q enhanced the initial ligand-induced autophosphorylation of the EGF receptor three to fourfold. However, upon longer treatment of the cells with EGF in the presence of q, significantly less autophosphorylated receptor was detectable compared with stimulation of cells in the absence of q. A similar q-dependent modulation of EGF receptor autophosphorylation was observed also in human cervical carcinoma cells HeLa-S3. Treatment of q-deficient HeLa cells with EGF induced the c-fos gene expression, transiently increased the activity of the anoxic stress protein LDH k, and stimulated proliferation. Treatment of HeLa cells with EGF in the presence of q resulted in a delayed c-fos gene expression and an accelerated increase and decrease of LDH k activity. The stimulatory effect of low doses of EGF on HeLa cell proliferation was completely antagonized in the presence of q. The results suggest that the mitogenic signalling initiated by the EGF receptor is modulated by q.	NATL CANC CTR,RES INST,DIV BIOL,TOKYO 104,JAPAN	National Cancer Center - Japan	LANGGUT, W (corresponding author), UNIV ERLANGEN NURNBERG,FAK MED,INST BIOCHEM,FAHRSTR 17,W-8520 ERLANGEN,GERMANY.							ANDERSON GR, 1981, J BIOL CHEM, V256, P583; BERTICS PJ, 1988, J BIOL CHEM, V263, P3610; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; DIETZ AA, 1967, ANAL BIOCHEM, V20, P246, DOI 10.1016/0003-2697(67)90030-9; EMMERICH B, 1985, CANCER RES, V45, P4308; FRENCH BT, 1991, P NATL ACAD SCI USA, V88, P370, DOI 10.1073/pnas.88.2.370; FUJITAYAMAGUCHI Y, 1989, BIOCHEM J, V263, P813, DOI 10.1042/bj2630813; GOGH NM, 1988, ANAL BIOCHEM, V173, P93; HELIN K, 1991, J BIOL CHEM, V266, P8363; HUBLER L, 1992, BIOCHEM J, V281, P107, DOI 10.1042/bj2810107; KASAI H, 1975, BIOCHEMISTRY-US, V14, P4198, DOI 10.1021/bi00690a008; KATZE JR, 1982, SCIENCE, V216, P55; KATZE JR, 1979, P NATL ACAD SCI USA, V76, P3271, DOI 10.1073/pnas.76.7.3271; KERSTEN H, 1988, Biofactors, V1, P27; Kersten H., 1990, CHROMATOGRAPHY MODIF, V45, pB69; LANGGUT W, 1990, FEBS LETT, V265, P33, DOI 10.1016/0014-5793(90)80877-L; LANGGUT W, 1993, BIOFACTORS, V4, P117; LANGGUT W, 1990, Biofactors, V2, P245; LANGGUT W, 1989, CHEM BIOL PTERIDINES, P356; MAHR U, 1990, Biofactors, V2, P185; NISHIMURA S, 1983, PROG NUCLEIC ACID RE, V28, P49, DOI 10.1016/S0079-6603(08)60082-3; OKADA N, 1978, P NATL ACAD SCI USA, V75, P4247, DOI 10.1073/pnas.75.9.4247; OKADA N, 1979, EUR J BIOCHEM, V254, P3062; SZABO L, 1988, BIOFACTORS, V1, P242; TODDERUD G, 1989, Biofactors, V2, P11; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; WHITAKER JR, 1980, ANAL BIOCHEM, V109, P156, DOI 10.1016/0003-2697(80)90024-X; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	29	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3141	3147						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414516				2022-12-28	WOS:A1993MC09300031
J	WILLIAMS, AC; BROWNE, SJ; YEUDAL, WA; PATERSON, IC; MARSHALL, CJ; LANE, DP; PARASKEVA, C				WILLIAMS, AC; BROWNE, SJ; YEUDAL, WA; PATERSON, IC; MARSHALL, CJ; LANE, DP; PARASKEVA, C			MOLECULAR EVENTS INCLUDING P53 AND K-RAS ALTERATIONS IN THE IN-VITRO PROGRESSION OF A HUMAN COLORECTAL ADENOMA CELL-LINE TO AN ADENOCARCINOMA	ONCOGENE			English	Article							POLYPOSIS COLI PATIENTS; HUMAN COLONIC ADENOMA; GENE-MUTATIONS; CYTOGENETIC ABNORMALITIES; POSSIBLE INVOLVEMENT; HUMAN CHROMOSOME-1; TUMOR PROGRESSION; LUNG-CANCER; HUMAN DNA; CARCINOMA	The aim of the current study was to identify genetic abnormalities in human colorectal adenoma and carcinoma derived cell lines, and to determine whether the genetic changes which occur in vitro are relevant to the in vivo situation. Loss of 1p(33-35) region was shown to be the most common chromosome 1 abnormality and loss of heterozygosity (LOH) of the DCC gene and/or adjacent sequences was detected in all adenoma derived cells as well as the carcinoma cell lines. The level of p53 protein was also investigated as increased cellular p53 protein had previously been associated with mutation of the p53 gene. A further aim was to investigate genetic changes in our in vitro model of tumour progression, where the adenoma derived PC/AA cell line has previously been converted in vitro to two distinct tumorigenic phenotypes, producing either an adenocarcinoma or a mucinous carcinoma in athymic nude mice. Progression to the adenocarcinoma phenotype was shown to involve a specific chromosome 1 rearrangement, loss of both normal copies of chromosome 18 (although DCC gene sequences were retained), loss of the remaining wild type allele of k-ras resulting in homozygosity for the k-ras codon 12 mutation and increased cellular p53 protein as detected by SDS-PAGE Western blotting. The increase in p53 protein was shown not to be due to the acquisition of a mutation in the p53 gene. Interestingly, progression of the adenoma derived PC/AA cell line to the mucinous malignant phenotype did not involve any of these molecular rearrangements, suggesting that different genetically distinct pathways are involved in colorectal carcinogenesis. These studies show that the genetic changes in our in vitro model of human colorectal tumour progression are similar to those observed in in vivo studies.	UNIV BRISTOL,DEPT ORAL MED PATHOL & MICROBIOL,BRISTOL BS2 8HW,AVON,ENGLAND; INST CANC RES,CHESTER BEATTY LABS,CELL & MOLEC BIOL SECT,LONDON SW3 6JB,ENGLAND; UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,CRC,CELL TRANSFORMAT RES GRP,DUNDEE DD1 4HN,SCOTLAND	University of Bristol; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Dundee	WILLIAMS, AC (corresponding author), UNIV BRISTOL,SCH MED SCI,DEPT PATHOL & MICROBIOL,UNIV WALK,BRISTOL BS8 1TD,AVON,ENGLAND.		Lane, David P/C-4920-2008; Paterson, Ian/G-8688-2011	Paterson, Ian/0000-0001-9156-401X; Williams, Ann/0000-0002-6009-7137; Lane, David/0000-0003-0551-3545				BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; DELATTRE O, 1987, NUCLEIC ACIDS RES, V15, P1343, DOI 10.1093/nar/15.3.1343; EHRHART JC, 1988, ONCOGENE, V3, P595; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FARR CJ, 1988, ONCOGENE, V3, P673; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1992, FASEB J, V6, P2783, DOI 10.1096/fasebj.6.10.1321771; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FRITSCHE M, 1993, ONCOGENE, V8, P307; GENDLER SJ, 1987, P NATL ACAD SCI USA, V84, P6060, DOI 10.1073/pnas.84.17.6060; HAGUE A, 1992, INT J ONCOL, V1, P201; HALVORSEN TB, 1988, J CLIN PATHOL, V41, P1068, DOI 10.1136/jcp.41.10.1068; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; KASTAN MB, 1991, CANCER RES, V51, P6304; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3965; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEISTER I, 1990, CANCER RES, V50, P7232; LEVI S, 1991, CANCER RES, V51, P3497; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MANNING AM, 1991, ONCOGENE, V6, P1471; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MULERIS M, 1990, CANCER GENET CYTOGEN, V44, P107, DOI 10.1016/0165-4608(90)90203-M; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5707, DOI 10.1093/nar/16.12.5707; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P4747, DOI 10.1093/nar/16.10.4747; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLAH E, 1989, CANCER GENET CYTOGEN, V43, P179, DOI 10.1016/0165-4608(89)90029-0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PARASKEVA C, 1990, INT J CANCER, V46, P753, DOI 10.1002/ijc.2910460434; PARASKEVA C, 1992, INT J CANCER, V51, P661, DOI 10.1002/ijc.2910510426; PARASKEVA C, 1988, INT J CANCER, V41, P908; PARASKEVA C, 1984, INT J CANCER, V34, P49, DOI 10.1002/ijc.2910340109; PARASKEVA C, 1989, INT J CANCER, V43, P743, DOI 10.1002/ijc.2910430434; PARASKEVA C, 1989, CANCER RES, V49, P1282; QUNITILLA M, 1986, NATURE, V322, P78; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SAKAI E, 1992, ONCOGENE, V7, P927; SEABRIGH.M, 1971, LANCET, V2, P971; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; SUNDBLAD AS, 1982, CANCER, V50, P2504, DOI 10.1002/1097-0142(19821201)50:11<2504::AID-CNCR2820501141>3.0.CO;2-A; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WILLIAMS AC, 1990, CANCER RES, V50, P4724; WILLIAMS AC, 1992, INT J CANCER, V52, P785, DOI 10.1002/ijc.2910520519; WONG Z, 1987, ANN HUM GENET, V51, P269, DOI 10.1111/j.1469-1809.1987.tb01062.x; YOUNG J, 1992, CANCER RES, V52, P285	58	42	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3063	3072						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414507				2022-12-28	WOS:A1993MC09300022
J	FRACCHIOLLA, NS; LOMBARDI, L; SALINA, M; MIGLIAZZA, A; BALDINI, L; BERTI, E; CRO, L; POLLI, E; MAIOLO, AT; NERI, A				FRACCHIOLLA, NS; LOMBARDI, L; SALINA, M; MIGLIAZZA, A; BALDINI, L; BERTI, E; CRO, L; POLLI, E; MAIOLO, AT; NERI, A			STRUCTURAL ALTERATIONS OF THE NF-KAPPA-B TRANSCRIPTION FACTOR LYT-10 IN LYMPHOID MALIGNANCIES	ONCOGENE			English	Note							NON-HODGKINS-LYMPHOMA; DNA-BINDING SUBUNIT; CELL-CYCLE CONTROL; V-REL; P65 SUBUNIT; C-REL; CHROMOSOMAL TRANSLOCATION; ONCOGENIC CONVERSION; PROTOONCOGENE BCL-3; PROTO-ONCOGENE	We have previously reported the identification of a novel putative proto-oncogene involved in the breakpoint of a t(10;14)(q24;q32) chromosomal translocation in a case of B-cell lymphoma. This gene, called lyt-10 (NFKB2/p52), is a member of the NF-KB family of transcription factors and displays a high degree of homology with the NFKB1/p50. Here we describe the genomic organization of the lyt-10 gene based on the restriction analysis of genomic phage clones and the sequence determination of exon-intron boundaries. The lyt-10 gene spans a genomic region of about 8 kb on 10q24, and contains 24 exons, ranging in size between 41 and 258 base pairs. To improve the understanding of the role of lyt-10 in lymphomagenesis, we performed Southern blot analysis to detect alterations of the lyt-10 gene in a large panel of cases representative of different types of lymphoid malignancies. We found rearrangements in 5 of 228 (approximately 2%) cases analysed: two cases of B-cell lymphoma, one case of multiple myeloma and two cases of T-cell lymphoma. The use of various probes specific for different regions of the lyt-10 locus revealed that rearrangements in positive cases lead to the partial or total deletion of the carboxy-terminal region containing the ankyrin domain. Taken together, our results indicate that lyt-10 gene rearrangements represent a recurrent lesion that may be involved in the pathogenesis of both B- and T-cell malignancies, and suggest that truncation of the ankyrin domain may be a common mechanism of lesion leading to abnormal lyt-10 activation in lymphoid neoplasia.	UNIV MILAN,OSPED MAGGIORE,IRCCS,IST SCI MED,SERV EMATOL,I-20122 MILAN,ITALY; UNIV MILAN,OSPED MAGGIORE,IRCCS,DERMATOL CLIN 1,I-20122 MILAN,ITALY	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan			Fracchiolla, Nicola Stefano/K-1915-2015; Berti, Emilio/F-5256-2012; neri, antonino/I-9690-2014	Fracchiolla, Nicola Stefano/0000-0002-5356-8690; Berti, Emilio/0000-0001-6753-4910; Baldini, Luca/0000-0003-2964-9981; Cro, Lilla Marcella/0000-0002-6007-5667; neri, antonino/0000-0001-9047-5912; Critelli, Salvatore/0000-0001-7325-0228; Fracchiolla, Nicola/0000-0002-8982-8079				BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROTHMAN AR, 1990, CANCER RES, V50, P3795; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DELIA D, 1989, CANCER RES, V49, P4901; FAINBERG AP, 1983, ANAL BIOCHEM, V132, P6; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GRUMONT RJ, 1988, ONCOGENE RES, V4, P1; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LU D, 1991, ONCOGENE, V6, P1235; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; Maniatis T., 1982, MOL CLONING; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OFFIT K, 1991, BLOOD, V77, P1508; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; VANKRIEKEN JHJM, 1990, LEUKEMIA, V4, P811; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	45	118	120	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2839	2845						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378093				2022-12-28	WOS:A1993LX34300027
J	KIVINEN, L; PITKANEN, K; LAIHO, M				KIVINEN, L; PITKANEN, K; LAIHO, M			HUMAN RETINOBLASTOMA GENE-PRODUCT PREVENTS C-HA-RAS ONCOGENE-MEDIATED CELLULAR-TRANSFORMATION OF MOUSE FIBROBLASTS	ONCOGENE			English	Article								Suppression of tumor formation and restoration of normal growth of cells has been an insignia that the retinoblastoma gene (RB1) functions as a tumor suppressor gene. The tumor suppressive functions of RB are suggested to associate with regulation of cell cycle events or gene transcription. We have analysed here the interactions of RB and c-Ha-ras oncogene by gene transfection studies. Mouse fibroblasts stably expressing high levels human wild type (wt) pRB or mutant pRB were transfected with genomic or LTR promoter driven c-Ha-ras(Val-12) expression vectors. We find that expression of normal, but not mutant RB protein in the cells prevents c-Ha-ras oncogene mediated cellular transformation and colony formation in soft agar. Analysis of stable RB and genomic c-Ha-ras cell transfectants for expression of pRB and p21ras by immunoblotting indicates a strong correlation with the presence of high levels of RB protein and inhibition of ras-transformation. Moreover, during culturing the RB and genomic c-Ha-ras expressing clones a progressive transformation of phenotypically normal clones was observed which paralleled loss or decrease of RB expression and concomitant increase in p21ras production. These findings suggest a functional cross-talk between RB protein and p21ras, which balances the cell phenotype between normal and transformed states.	UNIV HELSINKI, DEPT VIROL, SF-00014 HELSINKI, FINLAND	University of Helsinki								BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOWTELL DDL, 1987, ANAL BIOCHEM, V162, P463, DOI 10.1016/0003-2697(87)90421-0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHEN PL, 1992, CELL GROWTH DIFFER, V3, P119; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; FURUKAWA Y, 1992, J BIOL CHEM, V267, P17121; GOODRICH DW, 1992, CANCER RES, V52, P1968; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KRATZKE RA, 1992, J BIOL CHEM, V267, P25998; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MUNCASTER MM, 1992, CANCER RES, V52, P654; NEVINS JR, 1992, SCIENCE, V258, P424; PITKANEN K, 1993, EXP CELL RES, V207, P99, DOI 10.1006/excr.1993.1167; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; SISTONEN L, 1990, ONCOGENE, V5, P815; STIRDIVANT SM, 1992, J BIOL CHEM, V267, P14846; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	55	9	9	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2703	2711						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378082				2022-12-28	WOS:A1993LX34300011
J	CHAN, AML; CHEDID, M; MCGOVERN, ES; POPESCU, NC; MIKI, T; AARONSON, SA				CHAN, AML; CHEDID, M; MCGOVERN, ES; POPESCU, NC; MIKI, T; AARONSON, SA			EXPRESSION CDNA CLONING OF A SERINE KINASE TRANSFORMING GENE	ONCOGENE			English	Article							ENDOCRINE NEOPLASIA TYPE-2A; DEPENDENT PROTEIN-KINASE; OKADAIC ACID; TUMOR PROMOTER; ONCOGENE; CELLS; CHROMOSOME-10; PHOSPHORYLATION; INTERLEUKIN-1; HYBRIDIZATION	By ectopic expression of cDNAs derived from a Ewing sarcoma cell line in NIH3T3 celts, we isolated a transforming gene (est). Sequence analysis revealed homology to the cot oncogene, which encodes a novel serine kinase. Whereas the cot product was truncated at its carboxy-terminal end as a result of gene rearrangement during transfection, est encodes the normal cot product. Thus, this gene can be activated as an oncogene by overexpression as well as by gene rearrangement. NIH3T3 cells transfected with est formed progressively growing colonies in soft agar and were tumorigenic in nude mice. The 3.2-kb est transcript was expressed at low level in both human fibroblasts and epithelial cells. Addition of the tumor promoter, okadaic acid (OA), or cytokine, interleukin 1 (IL-1), but not serum or platelet-derived growth factor (PDGF), induced increased expression of the est transcript. Using fluorescence in situ hybridization, we localized the est gene to the short arm of human chromosome 10 at band p11.2.	NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,1E24,BETHESDA,MD 20892; NCI,BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Chan, Andrew/AAC-1145-2020; Chan, Andrew Man-Lok/J-9497-2013	Chan, Andrew/0000-0001-9923-5464; Chan, Andrew Man-Lok/0000-0001-9923-5464				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DINARELLO CA, 1991, BLOOD, V77, P1627; FERRARI S, 1985, FEBS LETT, V184, P72, DOI 10.1016/0014-5793(85)80656-6; GUY GR, 1991, J BIOL CHEM, V266, P14343; GUY GR, 1992, J BIOL CHEM, V267, P1846; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HEIDARAN MA, 1990, ONCOGENE, V5, P1265; HESCHELER J, 1988, PFLUG ARCH EUR J PHY, V412, P248, DOI 10.1007/BF00582504; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; LAIRMORE TC, 1991, GENOMICS, V9, P181, DOI 10.1016/0888-7543(91)90237-9; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; Maniatis T., 1982, MOL CLONING; MATHEW CGP, 1987, NATURE, V328, P527, DOI 10.1038/328527a0; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; NADINDAVIS SA, 1988, EMBO J, V7, P985, DOI 10.1002/j.1460-2075.1988.tb02905.x; NAROD SA, 1992, AM J HUM GENET, V51, P469; NORUM RA, 1990, GENOMICS, V8, P313, DOI 10.1016/0888-7543(90)90287-5; ONEILL LAJ, 1990, IMMUNOL TODAY, V11, P292; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; QWARNSTROM EE, 1991, P NATL ACAD SCI USA, V88, P1232, DOI 10.1073/pnas.88.4.1232; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SELTEN G, 1986, CELL, V46, P606; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SIMPSON NE, 1987, NATURE, V328, P528, DOI 10.1038/328528a0; SIMPSON NE, 1991, CYTOGENET CELL GENET, V58, P428, DOI 10.1159/000133170; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; VANBEVEREN C, 1981, NATURE, V289, P258, DOI 10.1038/289258a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	41	33	35	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1329	1333						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479752				2022-12-28	WOS:A1993KY32800026
J	SHARMA, SV				SHARMA, SV			MELITTIN-INDUCED HYPERACTIVATION OF PHOSPHOLIPASE-A2 ACTIVITY AND CALCIUM INFLUX IN RAS-TRANSFORMED CELLS	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; A431 CELLS; MEMBRANE; PROTEINS; VENOM; DIACYLGLYCEROL; FACILITATION; FLUORESCENCE; LIPOXYGENASE; FIBROBLASTS	The activated ras oncogene is a key mediator of cellular transformation and is present in a wide variety of primary human neoplasms. The biochemical role of the ras oncogene in cellular transformation is at present unclear, and hence approaches to control its activities in transformed cells have met with limited success. Previous studies have demonstrated the ability of melittin, a 26 amino acid amphipathic peptide from bee venom, to specifically counterselect for cells in culture that express high levels of the ras oncogene product. The biochemical basis for this counterselection is currently unknown. This study demonstrates the ability of melittin to hyperactivate phospholipase A2 (PLA2) in ras-transformed cells by the mediation of enhanced influx of calcium ions (Ca2+). This hyperactivation of PLA2 and Ca2+ mobilization in ras-transformed cells by melittin is mimicked by the calcium ionophore, A23187. Both melittin- and A23187-mediated PLA2 hyperactivation require Ca2+. However, the action of melittin is strongly dependent on extracellular Ca2+, whereas that of A23187 is not. Melittin-induced Ca2+ influx and PLA2 hyperactivation is inhibited by manganese ions (Mn2+). These studies reveal a close correlation between the extent of PLA2 hyperactivation and Ca2+ mobilization, suggesting a causal relationship.			SHARMA, SV (corresponding author), UNIV TENNESSEE CTR HLTH SCI, DEPT MICROBIOL & IMMUNOL, MEMPHIS, TN 38163 USA.				NATIONAL CANCER INSTITUTE [R01CA055983] Funding Source: NIH RePORTER; NCI NIH HHS [CA 55983] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARGIOLAS A, 1983, J BIOL CHEM, V258, P3697; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1989, ANTICANCER RES, V9, P1427; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BARSAGI D, 1988, J CELL BIOL, V106, P1649, DOI 10.1083/jcb.106.5.1649; BATENBURG AM, 1987, BIOCHIM BIOPHYS ACTA, V903, P155, DOI 10.1016/0005-2736(87)90165-9; BOS JL, 1989, CANCER RES, V49, P4682; CHANG JP, 1988, J BIOL CHEM, V263, P18614; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DUFOURCQ J, 1977, BIOCHIM BIOPHYS ACTA, V467, P1, DOI 10.1016/0005-2736(77)90236-X; FLETCHER JE, 1991, BIOCHEM CELL BIOL, V69, P274, DOI 10.1139/o91-042; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; GONZALEZ FA, 1988, J CELL PHYSIOL, V135, P269, DOI 10.1002/jcp.1041350214; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALL A, 1989, G PROTEINS MEDIATORS; KUNOS G, 1984, P NATL ACAD SCI-BIOL, V81, P6178, DOI 10.1073/pnas.81.19.6178; LACHOWIEZ RM, 1988, FEBS LETT, V234, P195, DOI 10.1016/0014-5793(88)81332-2; LOMBARDO D, 1985, J BIOL CHEM, V260, P7234; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MACARA IG, 1986, J BIOL CHEM, V261, P9321; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; METZ SA, 1986, BIOCHEM PHARMACOL, V35, P3371, DOI 10.1016/0006-2952(86)90438-7; MIX LL, 1984, BIOCHEM BIOPH RES CO, V119, P69, DOI 10.1016/0006-291X(84)91619-X; MOLLAY C, 1976, BIOCHIM BIOPHYS ACTA, V426, P317, DOI 10.1016/0005-2736(76)90340-0; MOOLENAAR WH, 1986, J BIOL CHEM, V261, P279; MUFSON RA, 1979, NATURE, V280, P73; PANDIELLA A, 1989, J BIOL CHEM, V264, P12914; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; Rasmussen H, 1990, Curr Top Cell Regul, V31, P1; ROZENGURT E, 1981, CELL, V23, P781, DOI 10.1016/0092-8674(81)90442-6; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SESSA G, 1969, J BIOL CHEM, V244, P3575; SHAH GV, 1990, ENDOCRINOLOGY, V127, P613, DOI 10.1210/endo-127-2-613; SHARMA SV, 1992, ONCOGENE, V7, P193; SHIER WT, 1979, P NATL ACAD SCI USA, V76, P195, DOI 10.1073/pnas.76.1.195; SHIER WT, 1980, P NATL ACAD SCI-BIOL, V77, P137, DOI 10.1073/pnas.77.1.137; SNIDER RM, 1984, P NATL ACAD SCI-BIOL, V81, P3905, DOI 10.1073/pnas.81.12.3905; VINCENTINI LM, 1984, J BIOL CHEM, V259, P6912; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WHEELER LA, 1987, J BIOL CHEM, V262, P6531; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4; YUNES R, 1977, ARCH BIOCHEM BIOPHYS, V183, P105, DOI 10.1016/0003-9861(77)90424-6	46	54	56	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1993	8	4					939	947						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455945				2022-12-28	WOS:A1993KT22000016
J	QUINLAN, MP				QUINLAN, MP			EXPRESSION OF ANTISENSE E1A IN 293 CELLS RESULTS IN ALTERED CELL MORPHOLOGIES AND CESSATION OF PROLIFERATION	ONCOGENE			English	Article							ADENOVIRUS-INDUCED ALTERATIONS; PRIMARY EPITHELIAL-CELLS; LONG TERMINAL REPEAT; MAMMARY-TUMOR VIRUS; CHROMOSOME-ABERRATIONS; GENE-EXPRESSION; MAMMALIAN-CELLS; E1A-12S PROTEIN; DNA FRAGMENTS; FRAGILE SITES	To determine whether continued E1A expression is required to maintain immortalization, 293 cells, a cell line that has been immortalized and transformed by adenovirus E1A and E1B, respectively, were transfected by an antisense E1A expression vector. In the presence of low serum, 293 cells underwent a transient, viable, nonproliferative phase wherein cells with altered morphologies were detected. However, only those clones which did not integrate the antisense sequences and exhibited a morphology similar to the original 293 cells were able to survive. High serum concentrations resulted in fewer clones, which rapidly discarded the antisense DNA. Similar experiments with an antisense CAT vector did not give rise to cells with either altered morphologies or growth rates. Furthermore, CAT antisense DNA was integrated into the 293 cell DNA. Hela cells, which were not immortalized or transformed by E1, were unaffected by the expression of antisense E1A and integrated the antisense DNA into genomic DNA. Consistently, the addition of synthetic antisense, but not sense oligonucleotides resulted in a transient inhibition of 293 cell DNA synthesis. These data demonstrate that even after extended periods of time in culture, cells immortalized by E1A still require E1A expression to activate the cell cycle and prevent them from senescing.			QUINLAN, MP (corresponding author), UNIV TENNESSEE CTR HLTH SCI,DEPT MICROBIOL & IMMUNOL,MEMPHIS,TN 38163, USA.				NATIONAL CANCER INSTITUTE [R01CA050540] Funding Source: NIH RePORTER; NCI NIH HHS [CA50540] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI GR, 1990, J VIROL, V64, P3427, DOI 10.1128/JVI.64.7.3427-3436.1990; BELLETT AJD, 1982, CHROMOSOMA, V84, P571, DOI 10.1007/BF00292856; BELLETT AJD, 1985, MOL CELL BIOL, V5, P1933, DOI 10.1128/MCB.5.8.1933; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; CAPOROSSI D, 1990, J GEN VIROL, V71, P801, DOI 10.1099/0022-1317-71-4-801; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CHANG S E, 1986, Biochimica et Biophysica Acta, V823, P161, DOI 10.1016/0304-419X(86)90001-6; DEGOLS G, 1991, NUCLEIC ACIDS RES, V19, P945, DOI 10.1093/nar/19.4.945; DIPAOLO JA, 1983, JNCI, V70, P114; DURNAM D, 1986, CANCER CELL, V4, P349; GALLIMORE PH, 1974, J MOL BIOL, V89, P49, DOI 10.1016/0022-2836(74)90162-4; GORBUNOVA LV, 1982, MOL GEN GENET, V187, P473, DOI 10.1007/BF00332631; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1974, COLD SPRING HARB SYM, V39, P637, DOI 10.1101/SQB.1974.039.01.077; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; INOUYE M, 1988, GENE, V72, P25, DOI 10.1016/0378-1119(88)90124-2; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; LEBEAU MM, 1986, BLOOD, V67, P849; LUKASH LL, 1985, J CELL SCI, V78, P97; MCDOUGALL JK, 1971, J GEN VIROL, V12, P43, DOI 10.1099/0022-1317-12-1-43; MIROSHNICHENKO OI, 1989, GENE, V84, P83, DOI 10.1016/0378-1119(89)90142-X; MURRAY JD, 1982, J VIROL, V44, P1072, DOI 10.1128/JVI.44.3.1072-1075.1982; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; QUINLAN MP, 1987, P NATL ACAD SCI USA, V84, P3283, DOI 10.1073/pnas.84.10.3283; QUINLAN MP, 1986, CANCER CELL, V4, P327; RINGOLD GM, 1977, P NATL ACAD SCI USA, V74, P2879, DOI 10.1073/pnas.74.7.2879; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Sambrook J, 1989, MOL CLONING LABORATO; SIMON R, 1990, MOL CELL BIOL, V10, P5609, DOI 10.1128/MCB.10.11.5609; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPINDLER KR, 1984, J VIROL, V52, P706, DOI 10.1128/JVI.52.2.706-710.1984; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; Stout J T, 1987, Methods Enzymol, V151, P519; VANDERKROL AR, 1988, BIOTECHNIQUES, V6, P958; WEBER JM, 1990, J GEN VIROL, V71, P585, DOI 10.1099/0022-1317-71-3-585; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WIGLER M, 1981, CELL, V24, P33, DOI 10.1016/0092-8674(81)90498-0; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; YOUNG HA, 1977, J VIROL, V21, P139, DOI 10.1128/JVI.21.1.139-146.1977; YUNIS JJ, 1987, SOMAT CELL MOLEC GEN, V13, P397, DOI 10.1007/BF01534938	51	14	14	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					257	265						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426736				2022-12-28	WOS:A1993KN00600004
J	SAVOYSKY, E; SUZUKI, M; SIMBULAN, C; TAMAI, K; OHUCHI, T; AKIYAMA, T; YOSHIDA, S				SAVOYSKY, E; SUZUKI, M; SIMBULAN, C; TAMAI, K; OHUCHI, T; AKIYAMA, T; YOSHIDA, S			IMMUNOPURIFIED RB PROTEIN INHIBITS SV40-T ANTIGEN-DEPENDENT STIMULATION OF DNA-POLYMERASE ALPHA	ONCOGENE			English	Article							LARGE T-ANTIGEN; SIMIAN VIRUS-40 ORIGIN; REPLICATION INVITRO; CALF THYMUS; RETINOBLASTOMA GENE; PURIFIED PROTEINS; STRAND SYNTHESIS; INITIATION; PRIMASE; COMPLEX	It has been shown that purified SV40 large T antigen (Tag) forms a complex with both human and calf thymus DNA polymerase alpha and stimulates its activity. Furthermore, Tag has also been found to complex with purified human Rb protein. Here, we show the effect of Rb protein on the stimulation of DNA polymerase alpha by Tag, in an in vitro system using either purified human or calf thymus DNA polymerase alpha and either primed single-stranded M13 DNA or calf thymus-activated DNA. Both human and calf thymus enzymes were dose-dependently stimulated several fold by Tag. The stimulation was also observed in the coupled reaction of primase and polymerase alpha, using unprimed single-stranded M13 DNA. These stimulatory effects were, however, completely abolished by preincubating Tag with an equimolar amount of Rb protein. primase activity of DNA polymerase alpha-primase complex was also stimulated by Tag, and this stimulation was abolished by the presence of Rb protein. In contrast, free primase was not affected by either Tag or Rb protein. Kinetic analysis revealed that in the presence of Tag the apparent K(m) for the template of either human or calf DNA polymerase alpha was decreased by approximately 2.5-fold and the V(max) was increased twofold, whereas Tag complexed with Rb protein did not affect the K(m) or the V(max). These results suggest a competition between Rb protein and DNA polymerase alpha for binding to Tag, which may be a key step for the initiation of SV40 DNA replication.	NAGOYA UNIV,SCH MED,DIS MECH & CONTROL RES INST,CANC CELL BIOL LAB,SHOWA KU,NAGOYA,AICHI 466,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,DEPT ONCOGENE RES,OSAKA,JAPAN	Nagoya University; Osaka University			Suzuki, Motoshi/I-7246-2014; Tamai, Katsuyuki/F-4743-2013	Suzuki, Motoshi/0000-0003-0682-5006; Tamai, Katsuyuki/0000-0003-4094-3911; Simbulan-Rosenthal, Ph.D, Cynthia M./0000-0002-5070-0342				BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DODSON M, 1987, SCIENCE, V238, P964, DOI 10.1126/science.2823389; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KELLY TJ, 1988, J BIOL CHEM, V263, P17889; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MURAKAMI Y, 1992, P NATL ACAD SCI USA, V89, P952, DOI 10.1073/pnas.89.3.952; MURPHY CI, 1988, J VIROL, V62, P2951, DOI 10.1128/JVI.62.8.2951-2959.1988; SAVOYSKY E, 1992, BIOCHEM BIOPH RES CO, V187, P697, DOI 10.1016/0006-291X(92)91251-K; SHIODA M, 1991, BIOCHEMISTRY-US, V30, P11403, DOI 10.1021/bi00112a006; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; SOPRANO KJ, 1983, VIROLOGY, V109, P127; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; TAMAI K, 1988, BIOCHIM BIOPHYS ACTA, V950, P263, DOI 10.1016/0167-4781(88)90122-4; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; UZVOLGYI E, 1991, CELL GROWTH DIFFER, V2, P297; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1989, J BIOL CHEM, V264, P2801; YOSHIDA S, 1981, BIOCHIM BIOPHYS ACTA, V654, P194, DOI 10.1016/0005-2787(81)90172-6; YOSHIDA S, 1983, BIOCHIM BIOPHYS ACTA, V741, P348, DOI 10.1016/0167-4781(83)90155-0	32	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					319	325						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8381219				2022-12-28	WOS:A1993KN00600010
J	Ferracini, R; Olivero, M; DiRenzo, MF; Martano, M; DeGiovanni, C; Nanni, P; Basso, G; Scotlandi, K; Lollini, PL; Comoglio, PM				Ferracini, R; Olivero, M; DiRenzo, MF; Martano, M; DeGiovanni, C; Nanni, P; Basso, G; Scotlandi, K; Lollini, PL; Comoglio, PM			Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas	ONCOGENE			English	Article						rhabdomyosarcoma; hepatocyte growth factor; proto-oncogenes; tyrosine kinase receptors	HEPATOCYTE GROWTH-FACTOR; TUMOR ALVEOLAR RHABDOMYOSARCOMA; RECEPTOR TYROSINE KINASE; FACTOR SCATTER FACTOR; N-MYC ONCOGENE; C-MET; EPITHELIAL-CELLS; MOLECULAR-CLONING; METASTATIC ABILITY; SEQUENCE-ANALYSIS	The MET oncogene encodes the receptor for HGF/Scatter Factor, known to control cell motility and invasion in epithelial cells, We report that the Met/HGF receptor, absent in differentiated adult skeletal muscles, is aberrantly expressed in clinical samples and in established cell lines of human rhabdomyosarcomas. In both the embryonal and alveolar histotypes the oncogene is overexpressed and, in some cases, amplified, The Met receptor is exposed at the cell surface and is functionally active in response to HGF/Scatter Factor, Accordingly, rhabdomyosarcoma cells exhibit an invasive phenotype in vitro in response to exogenous HGF/Scatter factor, As the factor is known to be produced by connective tissues, a paracrine stimulation of rhabdomyosarcoma invasiveness in vivo is hypothesized, Two alveolar rhabdomyosarcomas were found to co-express the 'two-kringle' alternatively-spliced HGF/Scatter Factor variant, which has been previously shown to stimulate cell motility and matrix invasion in vitro, These cells displayed the invasive phenotype in the absence of exogenous HGF/Scatter Factor, suggesting an autocrine mechanism in vivo, These data indicate that aberrant expression of the MET proto-oncogene provides rhabdomyosarcoma cells with the same property as embryonal myoblasts to migrate into the surrounding connective tissues.	UNIV TURIN,SCH MED,INST CANC RES,TURIN,ITALY; UNIV BOLOGNA,RIZZOLI ORTHOPAED INST,INST CANC RES,BOLOGNA,ITALY; UNIV BOLOGNA,RIZZOLI ORTHOPAED INST,ONCOL LAB,BOLOGNA,ITALY	University of Turin; IRCCS Istituto Ortopedico Rizzoli; University of Bologna; IRCCS Istituto Ortopedico Rizzoli; University of Bologna	Ferracini, R (corresponding author), SAVIGLIANO GEN HOSP,ORTHOPAED DIV,VIA OSPEDALI 14,I-121028 SAVIGLIANO,ITALY.		DI RENZO, Maria Flavia/B-6091-2012; Ferracini, Riccardo/AAL-4622-2020; De Giovanni, Carla/B-1312-2009; olivero, martina/J-4811-2018; Scotlandi, Katia/J-9009-2016; Lollini, Pier Luigi/A-7644-2008	DI RENZO, Maria Flavia/0000-0002-5093-3373; olivero, martina/0000-0002-6815-3498; Scotlandi, Katia/0000-0001-6114-9499; Lollini, Pier Luigi/0000-0003-1702-4108; Comoglio, Paolo/0000-0002-7056-5328; BASSO, GIUSEPPE/0000-0002-2634-9302; Nanni, Patrizia/0000-0001-5319-0803				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ASMAR L, 1994, CANCER, V74, P2579, DOI 10.1002/1097-0142(19941101)74:9<2579::AID-CNCR2820740928>3.0.CO;2-A; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOTTARO DP, 1991, SCIENCE, V254, P1382; Braun AC, 1975, CANCER COMPREHENSIVE, V3, P3; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHAM AML, 1991, SCIENCE, V254, P1382; CHARDIN P, 1985, INT J CANCER, V35, P647, DOI 10.1002/ijc.2910350513; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFER A, 1991, BIOCHEM J, V278, P35, DOI 10.1042/bj2780035; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DEFRANCES MC, 1992, DEVELOPMENT, V116, P387; DEGIOVANNI C, 1989, ANTICANCER RES, V9, P1943; DIAS P, 1994, SEMIN DIAGN PATHOL, V11, P3; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1995, CANCER RES, V55, P1129; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1992, ONCOGENE, V7, P2549; EBERT M, 1994, CANCER RES, V54, P5775; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FERRACINI R, 1995, ONCOGENE, V10, P739; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GALIMI F, 1994, J CELL BIOL, V127, P1743, DOI 10.1083/jcb.127.6.1743; GARSON JA, 1986, LANCET, V1, P1496; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HAYASHI Y, 1990, INT J CANCER, V45, P705, DOI 10.1002/ijc.2910450423; HOULDSWORTH J, 1990, CANCER RES, V50, P6417; ITAKURA Y, 1994, CANCER LETT, V83, P235, DOI 10.1016/0304-3835(94)90325-5; JOSEPHSILVERSTEIN J, 1989, J CELL BIOL, V108, P2459, DOI 10.1083/jcb.108.6.2459; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KOBAYASHI H, 1992, CANCER RES, V52, P3610; KOSCIELNIAK E, 1992, MED PEDIATR ONCOL, V20, P209, DOI 10.1002/mpo.2950200305; KUNIYASU H, 1992, BIOCHEM BIOPH RES CO, V189, P227, DOI 10.1016/0006-291X(92)91548-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU YH, 1994, MOL CELL BIOL, V14, P7046, DOI 10.1128/MCB.14.11.7046; LOLLINI PL, 1991, INVAS METAST, V11, P116; LONGATI P, 1994, ONCOGENE, V9, P49; MCCUSKER RH, 1989, J BIOL CHEM, V264, P7795; MEDICO E, 1996, MOL BIOL CELL, V7; MICHALOPOULOS G, 1984, CANCER RES, V44, P4414; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MIYAZAWA K, 1991, EUR J BIOCHEM, V197, P15, DOI 10.1111/j.1432-1033.1991.tb15876.x; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1985, CELL, V42, P460; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NANNI P, 1989, INVAS METAST, P231; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; PARHAM DM, 1994, SEMIN DIAGN PATHOL, V11, P39; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROSEN EM, 1990, INVAS METAST, V10, P49; SACCONE S, 1992, GENOMICS, V13, P912, DOI 10.1016/0888-7543(92)90191-T; SCHWEIGERER L, 1987, P NATL ACAD SCI USA, V84, P842, DOI 10.1073/pnas.84.3.842; SEKI T, 1990, BIOCHEM BIOPH RES CO, V172, P321, DOI 10.1016/S0006-291X(05)80212-8; SHAPIRO DN, 1993, CANCER RES, V53, P5108; SHIMOMURA T, 1992, CYTOTECHNOLOGY, V8, P219, DOI 10.1007/BF02522039; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1989, J CELL PHYSIOL, V139, P565, DOI 10.1002/jcp.1041390316; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STRATTON MR, 1990, ONCOGENE, V5, P1297; STRATTON MR, 1989, BRIT J CANCER, V60, P202, DOI 10.1038/bjc.1989.251; SUBLETT JE, 1995, ONCOGENE, V11, P545; TOLLEFSEN SE, 1989, P NATL ACAD SCI USA, V86, P1543, DOI 10.1073/pnas.86.5.1543; TOLLEFSEN SE, 1989, J BIOL CHEM, V264, P13810; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAO MS, 1993, CELL GROWTH DIFFER, V4, P571; TSOKOS M, 1994, SEMIN DIAGN PATHOL, V11, P26; Uriel J., 1975, CANCER COMPREHENSIVE, V3, P21; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WEIDNER KM, 1990, J CELL BIOL, V111, P2907	88	112	114	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1697	1705						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622890				2022-12-28	WOS:A1996UG45800012
J	Kretschmer, C; Murphy, C; Biesinger, B; Beckers, J; Fickenscher, H; Kirchner, T; Fleckenstein, B; Ruther, U				Kretschmer, C; Murphy, C; Biesinger, B; Beckers, J; Fickenscher, H; Kirchner, T; Fleckenstein, B; Ruther, U			A Herpes saimiri oncogene causing peripheral T-cell lymphoma in transgenic mice	ONCOGENE			English	Article						herpes virus; transgenic mice; T-cell lymphoma; tumor induction; oncogene	DELETION MUTANTS; U RNAS; REGION; VIRUS; GENE; TRANSFORMATION; CLASSIFICATION; MARMOSETS; SEQUENCES; STRAINS	Herpesvirus saimiri is an oncogenic virus causing rapid T-cell lymphomas in New World primates and rabbits, Deletion analysis of one strain of H saimiri has indicated an open reading frame, StpA, necessary for oncogenicity in monkeys, We have investigated the function of StpA in tumor induction by the generation of transgenic mice, Expression of two different constructs caused the development of peripheral lymphomas, The infiltrating cells were of T-cell origin, expressing mainly the CD4 phenotype and restricted sets of V beta chains, Thus, StpA is not only necessary for the oncogenicity of Herpesvirus saimiri, but is also sufficient for the induction of peripheral pleomorphic T-cell lymphomas.	HANNOVER MED SCH,INST MOL BIOL,D-30623 HANNOVER,GERMANY; UNIV ERLANGEN NURNBERG,INST PATHOL,D-91054 ERLANGEN,GERMANY; EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY; UNIV ERLANGEN NURNBERG,INST KLIN & MOLEK VIROL,D-91054 ERLANGEN,GERMANY	Hannover Medical School; University of Erlangen Nuremberg; European Molecular Biology Laboratory (EMBL); University of Erlangen Nuremberg			Beckers, Johannes/K-7237-2012; Murphy, Carol/ABE-4282-2021; Fickenscher, Helmut/A-3004-2010; Fickenscher, Helmut/J-9655-2019	Beckers, Johannes/0000-0001-7874-3822; Murphy, Carol/0000-0003-1353-8558; Fickenscher, Helmut/0000-0003-0043-1153				AHUJA SK, 1993, J BIOL CHEM, V268, P20691; ALBRECHT JC, 1992, J VIROL, V66, P3937, DOI 10.1128/JVI.66.6.3937-3940.1992; ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; BIEINGER B, 1995, J BIOL CHEM, V270, P4729; BIESINGER B, 1990, VIROLOGY, V176, P505, DOI 10.1016/0042-6822(90)90020-R; BIESINGER B, 1992, P NATL ACAD SCI USA, V89, P3116, DOI 10.1073/pnas.89.7.3116; BODEMER W, 1986, J VIROL, V60, P114, DOI 10.1128/JVI.60.1.114-123.1986; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; COLE GA, 1994, INT IMMUNOL, V6, P1767, DOI 10.1093/intimm/6.11.1767; DESROSIERS RC, 1984, J VIROL, V49, P343, DOI 10.1128/JVI.49.2.343-348.1984; DESROSIERS RC, 1982, J VIROL, V43, P352, DOI 10.1128/JVI.43.1.352-356.1982; DESROSIERS RC, 1985, SCIENCE, V228, P184, DOI 10.1126/science.2983431; FALINI B, 1990, BLOOD, V75, P434; FLECKENSTEIN B, 1979, BIOCHIM BIOPHYS ACTA, V560, P301, DOI 10.1016/0304-419X(79)90007-6; FLECKENSTEIN B, 1982, HERPESVIRUSES, V1, P253; FODOR WL, 1995, J VIROL, V69, P3889, DOI 10.1128/JVI.69.6.3889-3892.1995; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; HARRIS NL, 1994, BLOOD, V84, P1361; HODGES E, 1994, LEUKEMIA, V8, P295; HOGAN B, 1986, MANIPULATING MOUSE E, P230; HUEGIN AW, 1991, SCIENCE, V252, P424; HUNT RD, 1970, J NATL CANCER I, V44, P447; JUNG JU, 1994, MOL CELL BIOL, V14, P7235, DOI 10.1128/MCB.14.11.7235; JUNG JU, 1991, P NATL ACAD SCI USA, V88, P7051, DOI 10.1073/pnas.88.16.7051; KOOMEY JM, 1984, J VIROL, V50, P662, DOI 10.1128/JVI.50.2.662-665.1984; KORBJUHN P, 1993, BLOOD, V82, P217, DOI 10.1182/blood.V82.1.217.bloodjournal821217; LEE SI, 1988, CELL, V54, P599, DOI 10.1016/S0092-8674(88)80004-7; LEE SI, 1990, J VIROL, V64, P3905, DOI 10.1128/JVI.64.8.3905-3915.1990; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MEDVECZKY P, 1984, J VIROL, V52, P938, DOI 10.1128/JVI.52.3.938-944.1984; MURPHY C, 1994, ONCOGENE, V9, P221; MURTHY S, 1986, EMBO J, V5, P1625, DOI 10.1002/j.1460-2075.1986.tb04405.x; MURTHY SCS, 1989, J VIROL, V63, P3307, DOI 10.1128/JVI.63.8.3307-3314.1989; MYER VE, 1992, P NATL ACAD SCI USA, V89, P1296, DOI 10.1073/pnas.89.4.1296; NICHOLAS J, 1992, NATURE, V355, P362, DOI 10.1038/355362a0; PALLESEN G, 1993, ADV CANCER RES, V62, P179, DOI 10.1016/S0065-230X(08)60319-X; ROTHER RP, 1994, J VIROL, V68, P730, DOI 10.1128/JVI.68.2.730-737.1994; ROUVIER E, 1993, J IMMUNOL, V150, P5445; SCHAFFER PA, 1975, J NATL CANCER I, V55, P1243, DOI 10.1093/jnci/55.5.1243; STANSFELD AG, 1988, LANCET, V1, P292; STANSFELD AG, 1988, LANCET, V1, P603; SZOMOLANYI E, 1987, J VIROL, V61, P3485, DOI 10.1128/JVI.61.11.3485-3490.1987; THOMSON BJ, 1991, NATURE, V351, P530, DOI 10.1038/351530a0; TRIMBLE JJ, 1988, SCIENCE, V239, P1145, DOI 10.1126/science.2830673; WOODROOFE C, 1992, DNA CELL BIOL, V11, P587, DOI 10.1089/dna.1992.11.587; YAO M, 1994, BRIT J HAEMATOL, V87, P535, DOI 10.1111/j.1365-2141.1994.tb08309.x; ZHOU XG, 1994, HISTOPATHOLOGY, V24, P115, DOI 10.1111/j.1365-2559.1994.tb01289.x	47	33	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1609	1616						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622880				2022-12-28	WOS:A1996UG45800002
J	Theodorakis, P; DSaEipper, C; Subramanian, T; Chinnadurai, G				Theodorakis, P; DSaEipper, C; Subramanian, T; Chinnadurai, G			Unmasking of a proliferation-restraining activity of the anti-apoptosis protein EBV BHRF1	ONCOGENE			English	Article						Bcl-2 family; EBV-BHRF1; apoptosis; oncogenesis; p53; E1A; R-ras	PROGRAMMED CELL-DEATH; B-CELLS; BCL-2 GENE; C-MYC; VIRUS; P53; EXPRESSION; E1A; ONCOGENES; HOMOLOG	The BHRF1 protein of Epstein-Barr virus (EBV) is a structural and functional homolog of the Bcl-2 protein, Both BHRF1 and Bcl-2 proteins promote the survival of cells exposed to various apoptotic stimuli. This promotion of cell survival is associated with a block in proliferation, It is believed that the Bcl-2 family of anti-apoptosis proteins contribute to oncogenesis merely by promoting cell survival. We have discovered that mutations within a regulatory domain of the BHRF1 protein not only suppress apoptosis induced by the tumor suppressor protein p53, but also permit efficient proliferation of cells that would otherwise undergo total apoptosis, These gain-of-function mutants of BHRF1 cooperate more efficiently with the E1a oncogene in transformation of primary rat kidney cells where E1A expression results in apoptosis. Our results suggest that such mutational inactivation of a proliferation-restraining activity in the BHRF1 gene may play a direct role in oncogenesis.	ST LOUIS UNIV,MED CTR,INST MOLEC VIROL,ST LOUIS,MO 63110	Saint Louis University					NCI NIH HHS [CA-33616, R01 CA033616, CA-31719] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033616, R01CA031719] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAKHSHI A, 1985, CELL, V41, P889; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1995, ONCOGENE, V11, P1921; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; COX AD, 1994, ONCOGENE, V9, P3281; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HELLER M, 1981, J VIROL, V38, P632, DOI 10.1128/JVI.38.2.632-648.1981; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; KORSMEYER SJ, 1992, BLOOD, V80, P879; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; PEARSON GR, 1987, VIROLOGY, V160, P151, DOI 10.1016/0042-6822(87)90055-9; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SAEZ R, 1994, ONCOGENE, V9, P2877; Subramanian T, 1995, ONCOGENE, V11, P2403; SUBRAMANIAN T, 1993, GENE, V124, P173, DOI 10.1016/0378-1119(93)90391-F; TAKAYAMA S, 1994, DNA CELL BIOL, V13, P679, DOI 10.1089/dna.1994.13.679; TARODI B, 1994, VIROLOGY, V201, P404, DOI 10.1006/viro.1994.1309; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WANG HG, 1994, ONCOGENE, V9, P2751; WHITE E, 1993, GENE DEV, V7, P2277, DOI 10.1101/gad.7.12a.2277; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	44	56	60	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1707	1713						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622891				2022-12-28	WOS:A1996UG45800013
J	Torres, M; Bogenmann, E				Torres, M; Bogenmann, E			Nerve growth factor induces a multimeric TrkA receptor complex in neuronal cells that includes Crk, SHC and PLC-gamma 1 but excludes P130(CAS)	ONCOGENE			English	Article						c-Crk; TrkA; NGF; signal transduction	GUANINE-NUCLEOTIDE EXCHANGE; PHOSPHOTYROSINE-CONTAINING PROTEINS; TYROSINE PHOSPHORYLATION; KINASE-ACTIVITY; TRANSFORMING PROTEIN; RAS; PROTOONCOGENE; BINDING; PRODUCT; ASSOCIATION	Binding of nerve growth factor (NGF) to the TrkA receptor results in homodimerization, and activation of the intrinsic tyrosine kinase activity of the receptor, leading to multiple phosphorylations. We investigated the in vivo formation and composition of the receptor complex induced by NGF in a central nervous system-derived cell line (B104-neo), transfected with the human cDNA for TrkA. Using receptor-activated immunoprecipitation followed by analysis of the immune complexes by SDS-PAGE and immunoblotting, we show that NGF induces the association of TrkA with c-Crk-II in a multimeric complex that also includes SHC and PLC-gamma 1. While the tyrosine phosphorylation of TrkA, SHC and PLC-gamma gamma 1 increased with time in the presence of NGF and was inhibited by the tyrosine kinase inhibitor K252a, the state of tyrosine phosphorylation of c-Crk-II did not appear to change with NGF treatment. Immunodepletion studies demonstrated that the interaction of c-Crk-II with TrkA not only occurs indirectly through the SHC proteins, but may also involve another mode of binding. Furthermore, we show that c-Crk-II is associated with tyrosine phosphorylated p130(CAS) is unstimulated cells and that NGF treatment results in the de-association of p130(CAS)/c-Crk-II complex in the absence of an apparent change in the tyrosine phosphorylation of p130(CAS). These results clearly implicate c-Crk-II in the NGF signaling pathway and support the concept that more than one signaling molecule known to participate in the activation of Ras associates with TrkA upon NGF treatment.	UNIV SO CALIF, SCH MED, DEPT PEDIAT, PASADENA, CA 91125 USA; UNIV SO CALIF, SCH PHARM, DEPT MOLEC PHARMACOL & TOXICOL, PASADENA, CA 91125 USA; CALTECH, DIV BIOL, PASADENA, CA 91125 USA	University of Southern California; University of Southern California; California Institute of Technology	Torres, M (corresponding author), CHILDRENS HOSP LOS ANGELES, RES INST, 4650 SUNSET BLVD MS57, LOS ANGELES, CA 90027 USA.				NINDS NIH HHS [NS25795] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025795] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altin JG, 1991, GROWTH FACTORS, V4, P145, DOI 10.3109/08977199109000265; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BASU T, 1994, ONCOGENE, V9, P3483; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BERG MM, 1992, J BIOL CHEM, V267, P13; BOGENMANN E, 1995, ONCOGENE, V10, P1915; BORRELLO MG, 1994, ONCOGENE, V9, P1661; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; FAJARDO JE, 1993, MOL CELL BIOL, V13, P7295, DOI 10.1128/MCB.13.12.7295; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HASHIMOTO Y, 1994, ONCOGENE, V9, P869; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MARONEY AC, 1995, J NEUROCHEM, V64, P540; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MUROYA K, 1992, BIOCHIM BIOPHYS ACTA, V1135, P353, DOI 10.1016/0167-4889(92)90243-5; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OGAWA S, 1994, ONCOGENE, V9, P1669; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; OHMICHI M, 1991, BIOCHEM BIOPH RES CO, V179, P217, DOI 10.1016/0006-291X(91)91357-I; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RAFFIONI S, 1993, ANNU REV BIOCHEM, V62, P823; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TORRES M, 1993, J IMMUNOL, V150, P1563; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WIESMULLER L, 1994, CELL SIGNAL, V6, P247, DOI 10.1016/0898-6568(94)90030-2; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	57	29	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	1996	12	1					77	86						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552402				2022-12-28	WOS:A1996TQ01400010
J	Sudo, T; Nishikawa, S; Ogawa, M; Kataoka, H; Ohno, N; Izawa, A; Hayashi, SI; Nishikawa, SI				Sudo, T; Nishikawa, S; Ogawa, M; Kataoka, H; Ohno, N; Izawa, A; Hayashi, SI; Nishikawa, SI			Functional hierarchy of c-kit and c-fms in intramarrow production of CFU-M	ONCOGENE			English	Article						c-kit; c-fms; hematopoiesis M-CSF; mAb	COLONY-STIMULATING FACTOR; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; PROGENITOR CELLS; FACTOR CSF-1; EXPRESSION; RECEPTOR; DIFFERENTIATION; MOUSE; HEMATOPOIESIS	Whereas the molecular natures of M-CSF/CSF-1 and its receptor c-fms are well characterized, its actual role in the intramarrow hematopoiesis remains obscure, This is because disruption of this signaling pathway results in the osteopetrosis mouse that lacks the bone cavity for hematopoiesis. To elucidate the role of c-fms in intramarrow hematopoiesis, we produced an antagonistic monoclonal antibody to murine c-fms and investigated its expression and function in the normal bone marrow, c-fms(+) cells were detected both in mature and immature hematopoietic cells, Morphologically, c-kit(+)c-fms(-), c-kit(+)c-fms(+) and c-kit(-)c-fms(+) cells were medium sized blasts, large promyelocytes with azurophilic granules and mature monocytes respectively, CFU-M was 10-fold more enriched in the c-kit(+)c-fms(-) than c-kit(+)c-fms(+) fraction, Moreover, injection of the anti c-fms antibody had no effect on the production of CFU-M in the bone marrow, while anti-c-kit mAb could deplete them, hs ckit(+)c-fms(+) cells were readily generated in the culture of c-kit(+)c-fms(-) cells, most of the CFU-M in the bone marrow are, in fact, c-fms(-) cells that differentiate into c-fms(+) upon culture, These observations indicate a clear functional hierarchy of c-kit and c-fms in the bone marrow, Namely, c-kit plays the primary role in the production and maintenance of CFU-M, while c-fms, though it co-expressed with c-kit and functions as the growth receptor for M-CSF in the culture, has only a minimum role in the proliferation of c-fms(+) cells in the bone marrow.	KYOTO UNIV,FAC MED,DEPT MOLEC GENET,SAKYO KU,KYOTO 60601,JAPAN; TORAY INDUSTRIES LTD,BASIC RES LABS,KAMAKURA,KANAGAWA 248,JAPAN	Kyoto University; Toray Industries, Inc.								ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BERNSTEIN A, 1991, SEMIN HEMATOL, V28, P138; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BICKNELL DC, 1988, EXP HEMATOL, V16, P88; BOEGEL F, 1985, EXP HEMATOL, V13, P912; BYRNE PV, 1981, J CELL BIOL, V91, P848, DOI 10.1083/jcb.91.3.848; COFFMAN RL, 1986, IMMUNOL REV, V69, P5; ERA T, 1994, IMMUNOL REV, V137, P35, DOI 10.1111/j.1600-065X.1994.tb00658.x; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GREENBERGER J, 1992, EXP HEMATOL, V20, P92; GUILBERT LJ, 1980, J CELL BIOL, V85, P153, DOI 10.1083/jcb.85.1.153; HAYASHI SI, 1990, J EXP MED, V171, P1683, DOI 10.1084/jem.171.5.1683; HOLMES KL, 1985, P NATL ACAD SCI USA, V82, P6687, DOI 10.1073/pnas.82.19.6687; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; KAWASAKI ES, 1985, SCIENCE, V230, P291, DOI 10.1126/science.2996129; LANIER LL, 1982, HYBRIDOMA, V1, P125, DOI 10.1089/hyb.1.1982.1.125; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; NAITO M, 1991, AM J PATHOL, V139, P657; NESS SA, 1994, CURR OPIN GENET DEV, V4, P718, DOI 10.1016/0959-437X(94)90139-T; NISHIKAWA S, 1994, IMMUNOL LETT, V40, P163, DOI 10.1016/0165-2478(94)90188-0; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; PANTERNE B, 1993, J CELL PHYSIOL, V155, P282, DOI 10.1002/jcp.1041550209; RALPH P, 1977, CANCER RES, V37, P546; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; SHADDUCK RK, 1993, EXP HEMATOL, V21, P515; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SPANGRUDE GJ, 1991, CURR OPIN IMMUNOL, V3, P171, DOI 10.1016/0952-7915(91)90046-4; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; WONG GG, 1987, SCIENCE, V235, P1504, DOI 10.1126/science.3493529; YASUNAGA Y, 1995, J EXP MED, V182, P315; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	37	151	159	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2469	2476						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545103				2022-12-28	WOS:A1995TP18800002
J	Ahn, MJ; Langenfeld, J; Moasser, MM; Rusch, V; Dmitrovsky, E				Ahn, MJ; Langenfeld, J; Moasser, MM; Rusch, V; Dmitrovsky, E			Growth suppression of transformed human bronchial epithelial cells by all-trans-retinoic acid occurs through specific retinoid receptors	ONCOGENE			English	Article						all-trans-retinoic acid; bronchial epithelial cells; retinoid receptors	ACUTE PROMYELOCYTIC LEUKEMIA; HUMAN LUNG-CANCER; X-RECEPTOR; THYROID-HORMONE; DIFFERENTIATION THERAPY; NUCLEAR RECEPTORS; RIBONUCLEIC-ACID; VITAMIN-A; ALPHA; BETA	The retinoids are reported to chemoprevent second aerodigestive tract cancers in patients with prior lung or head and neck cancers, Since those retinoids already examined in clinical trials do not induce major clinical responses in lung cancers, it is hypothesized that the beneficial chemoprevention activity in lung neoplasias occurs within 'fields' of carcinogen-transformed epithelial cells, To begin to investigate this retinoid action during lung carcinogenesis, the BZR-T33 ras transformed human bronchial epithelial cell line that grows in an anchorage independent manner was examined, This study reports, as compared to controls, that all-trans-retinoic acid (RA)-treatment suppresses BZR-T33 proliferation in monolayer cultures and in anchorage independent and cloning efficiency growth assays, RA induces RAR-gamma 2 > RAR gamma 1 in BZR-T33 cells but expression at the total cellular RNA level of RAR alpha and RXR alpha is not augmented by RA-treatment, RAR beta mRNA expression is repressed before and after RA-treatment and is only detected using a reverse transcription polymerase chain reaction (RT-PCR) assay, To determine directly which of these expressed retinoid receptors signals growth suppression, each receptor was individually transfected into BZR-T33 cells using episomal expression vectors, Growth inhibitory effects of these transfectants were compared to a control; episomal vector in colony efficiency assays, RAR gamma over-expression in the presence or absence of RA-treatment did not suppress BZR-T33 growth more than controls, In contrast, over-expression of the other examined retinoid receptors inhibited BZR-T33 cellular cloning efficiency prior to RA-treatment and in this decreasing order after RA-treatment: RAR alpha > RAR beta > RXR alpha, The findings reported here reveal that RA suppresses proliferation and cloning efficiency in this transformed human bronchial epithelial cell through specific retinoid receptors, Further work is needed to evaluate the role of RA or its nuclear receptors in inhibiting even earlier steps in lung carcinogenesis.	MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,DEPT MED,MOLEC MED LAB,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,DEPT SURG,THORAC SERV,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,MOLEC PHARMACOL & THERAPEUT PROGRAM,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [T32CA009512, R01CA054494] Funding Source: NIH RePORTER; NCI NIH HHS [2R01-CA54494-04, T32-CA-09512] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN MJ, 1995, ONCOGENE, V10, P2307; AMSTAD P, 1988, MOL CARCINOGEN, V1, P151, DOI 10.1002/mc.2940010303; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; BRAND N, 1988, NATURE, V332, P851; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GEBERT JF, 1991, ONCOGENE, V6, P1859; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; Gudas Lorraine J., 1994, P443; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HOULE B, 1991, GENE CHROMOSOME CANC, V3, P358, DOI 10.1002/gcc.2870030506; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LECHNER JF, 1982, IN VITRO CELL DEV B, V18, P633; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MOASSER MM, 1994, ONCOGENE, V9, P833; MOASSER MM, 1995, ONCOGENE, V10, P1537; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NERVI C, 1991, EXP CELL RES, V195, P163, DOI 10.1016/0014-4827(91)90512-S; PASTORINO U, 1993, J CLIN ONCOL, V11, P1216, DOI 10.1200/JCO.1993.11.7.1216; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; REDDEL RR, 1988, CANCER RES, V48, P1904; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	46	30	31	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2357	2364						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570187				2022-12-28	WOS:A1995TK70200020
J	KANDA, H; TAJIMA, H; LEE, GH; NOMURA, K; OHTAKE, K; MATSUMOTO, K; NAKAMURA, T; KITAGAWA, T				KANDA, H; TAJIMA, H; LEE, GH; NOMURA, K; OHTAKE, K; MATSUMOTO, K; NAKAMURA, T; KITAGAWA, T			HEPATOCYTE GROWTH-FACTOR TRANSFORMS IMMORTALIZED MOUSE-LIVER EPITHELIAL-CELLS	ONCOGENE			English	Article							ANCHORAGE-INDEPENDENT GROWTH; SCATTER FACTOR; HEPATOCELLULAR-CARCINOMA; MET PROTOONCOGENE; MOLECULAR-CLONING; HEPATIC-FAILURE; HEPATOPOIETIN-A; KINASE-ACTIVITY; MELANOMA-CELLS; C-MET	Transforming activity of hepatocyte growth factor (HGF) was demonstrated utilizing immortalized but not fully transformed mouse hepatocytes (MLE-10). Rat HGF cDNA, expressed under the control of a cytomegalovirus promoter, was transfected together with the neomycin resistance gene (PSV2neo) into MLE-10 cells by the calcium phosphate method, and propagated G418-resistant colonies were harvested colony by colony. After checking for integration and expression of exogenous HGF, five cell lines (MLE-10-HGF-1 approximately 5) were established. Three cell lines transfected with the vector only (MLE-10-CMV-1 approximately 3) were also established in the same manner. All MLE-10-HGF cell lines grew much faster than the MLE-10-CMV and original MLE-10 cells in culture and produced large colonies in soft agar, which colony production was blocked by the addition of anti-HGF antibody to the agar. After addition of HGF, original and MLE-10-CMV lines produced colonies in soft agar. The high-HGF-production lines (MLE-10-HGF-4 and -5) also gave rise to tumors within 2 weeks when implanted into the nude mice subcutis. In contrast, all MLE-10-CMV and original MLE-10 cells were negative in these growth assays. A rough parallelism between the level of HGF expression and the growth rate in both soft agar and nude mice subcutis was evident among MLE-10-HGF cell lines. Those with higher HGF production tended to grow in a scattered fashion in culture. High-affinity HGF receptor, HGFR/met, was expressed in MLE-10 and all the derived cell lines. Since HGF and/or HGFR/met gene expression is seen in various tumors and the serum HGF level is elevated in patients with hepatic disease, the present results indicate a possible significance of HGF and its receptor system in carcinogenesis, most probably via autocrine and/or paracrine mechanisms.	OSAKA UNIV,SCH MED,BIOMED RES CTR,DIV BIOCHEM,SUITA,OSAKA 565,JAPAN	Osaka University	KANDA, H (corresponding author), JAPANESE FDN CANC RES,INST CANC,DEPT PATHOL,KAMI IKEBUKURO 1-37-1,TOSHIMA KU,TOKYO 170,JAPAN.							BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHAN AML, 1988, ONCOGENE, V2, P593; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER CS, 1986, EMBO J, V5, P2623, DOI 10.1002/j.1460-2075.1986.tb04543.x; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FURLONG RA, 1991, J CELL SCI, V100, P173; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; HALABAN R, 1992, ONCOGENE, V7, P2195; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; HIGUCHI O, 1991, BIOCHEM BIOPH RES CO, V176, P599, DOI 10.1016/S0006-291X(05)80226-8; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KANDA H, 1983, CARCINOGENESIS, V14, P1061; KONISHI T, 1991, BIOCHEM BIOPH RES CO, V180, P765, DOI 10.1016/S0006-291X(05)81131-3; KURIBAYASHI K, 1988, NUCLEIC ACIDS RES S, V19, P61; LEE GH, 1989, CANCER RES, V49, P403; LEE GH, 1987, HEPATOLOGY, V7, P937, DOI 10.1002/hep.1840070524; LEE GH, 1991, INT J CANCER, V47, P60, DOI 10.1002/ijc.2910470112; LINDROOS P, 1992, CARCINOGENESIS, V13, P139, DOI 10.1093/carcin/13.1.139; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; MICHALOPOULOS GK, 1992, HEPATOLOGY, V15, P149, DOI 10.1002/hep.1840150125; MIYAZAKI M, 1992, CELL BIOL INT REP, V16, P145, DOI 10.1016/S0309-1651(06)80108-6; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NAKAMURA T, 1991, Progress in Growth Factor Research, V3, P67, DOI 10.1016/0955-2235(91)90014-U; NALDINI L, 1991, ONCOGENE, V6, P501; NISHINO T, 1991, BIOCHEM BIOPH RES CO, V181, P323, DOI 10.1016/S0006-291X(05)81421-4; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SHIMODA A, 1992, ACTA HEPATOL JPN, V33, P766; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAHARA E, 1990, J CANCER RES CLIN, V116, P121, DOI 10.1007/BF01612665; TAJIMA H, 1992, EXP CELL RES, V202, P423, DOI 10.1016/0014-4827(92)90095-P; TAJIMA H, 1991, FEBS LETT, V291, P229, DOI 10.1016/0014-5793(91)81291-F; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; TEMPEST PR, 1988, BRIT J CANCER, V58, P3, DOI 10.1038/bjc.1988.150; TOMIYA T, 1992, HEPATOLOGY, V15, P1, DOI 10.1002/hep.1840150102; UEHARA Y, 1992, J CELL BIOL, V117, P889, DOI 10.1083/jcb.117.4.889; WATANABE T, 1990, J EXP MED, V172, P759, DOI 10.1084/jem.172.3.759; YOSHINAGA Y, 1992, JPN J CANCER RES, V83, P1257, DOI 10.1111/j.1349-7006.1992.tb02755.x; ZARNEGAR R, 1989, CANCER RES, V49, P3314	51	47	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3047	3053						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414505				2022-12-28	WOS:A1993MC09300020
J	ICHII, S; TAKEDA, S; HORII, A; NAKATSURU, S; MIYOSHI, Y; EMI, M; FUJIWARA, Y; KOYAMA, K; FURUYAMA, J; UTSUNOMIYA, J; NAKAMURA, Y				ICHII, S; TAKEDA, S; HORII, A; NAKATSURU, S; MIYOSHI, Y; EMI, M; FUJIWARA, Y; KOYAMA, K; FURUYAMA, J; UTSUNOMIYA, J; NAKAMURA, Y			DETAILED ANALYSIS OF GENETIC ALTERATIONS IN COLORECTAL TUMORS FROM PATIENTS WITH AND WITHOUT FAMILIAL ADENOMATOUS POLYPOSIS (FAP)	ONCOGENE			English	Article							GERM-LINE MUTATIONS; APC GENE; P53 GENE; SOMATIC MUTATIONS; CANCER; IDENTIFICATION; TUMORIGENESIS; CARCINOMA; OCCUR; LOCUS	To examine early genetic events during colorectal carcinogenesis, we searched for genetic alterations in 75 adenomas from seven patients with familial polyposis coli (FAP) and in 64 sporadic colorectal tumors (63 carcinomas and one adenoma). We investigated germ-line and somatic mutations in the APC gene, somatic mutations in the K-ras and p53 genes, and loss of heterozygosity (LOH) on chromosome 8p21-22. Thirty-two FAP adenomas carried detectable somatic mutations in the APC gene. The frequency of somatic APC mutations among adenomas was the same regardless of differences in size or histopathological classification. On the other hand, K-ras mutation was very rare in small adenomas where dysplasia was mild or moderate but frequent in large adenomas with severe dysplasia. Mutation of the p53 gene was observed in only two adenomas and LOH on 8p22 was detected in none. These results imply that a second 'hit' in the APC gene, but not necessarily mutation in K-ras or p53, is an important and critical event for formation of a colorectal adenoma.	JAPANESE FDN CANC RES,INST CANC,DEPT BIOCHEM,1-37-1 KAMI IKEBUKURO,TOSHIMA KU,TOKYO 170,JAPAN; HYOGO MED UNIV,DEPT GENET,NISHINOMIYA,HYOGO 663,JAPAN; HYOGO MED UNIV,DEPT PHARMACEUT,NISHINOMIYA,HYOGO 663,JAPAN	Japanese Foundation for Cancer Research; Hyogo College of Medicine; University of Hyogo; Hyogo College of Medicine; University of Hyogo			Horii, Akira/AAW-2839-2021	Horii, Akira/0000-0002-3967-3291				AMICO DD, 1992, CANCER RES, V52, P1996; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOYNTON RF, 1992, P NATL ACAD SCI USA, V89, P3385, DOI 10.1073/pnas.89.8.3385; EMI M, 1992, CANCER RES, V52, P5368; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUJIWARA Y, 1993, CANCER RES, V53, P1172; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORII A, 1992, CANCER RES, V52, P6696; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Ichii Shigetoshi, 1992, Human Molecular Genetics, V1, P387, DOI 10.1093/hmg/1.6.387; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KANEKO K, 1991, NUCLEIC ACIDS RES, V19, P6059, DOI 10.1093/nar/19.21.6059-a; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNUDSON AG, 1985, CANCER RES, V45, P1437; LOPEZGALINDEZ C, 1988, P NATL ACAD SCI USA, V85, P3522, DOI 10.1073/pnas.85.10.3522; MIKI Y, 1992, GENE CHROMOSOME CANC, V4, P81, DOI 10.1002/gcc.2870040112; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; NAGASE H, 1992, CANCER RES, V52, P4055; Nagase Hiroki, 1992, Human Mutation, V1, P467, DOI 10.1002/humu.1380010603; NAKATSURU S, 1992, HUM MOL GENET, V1, P559, DOI 10.1093/hmg/1.8.559; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; SATO T, 1990, CANCER RES, V50, P7184; TAKEDA S, 1993, IN PRESS HUM MUT, V2; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901	33	142	143	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2399	2405						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8395678				2022-12-28	WOS:A1993LT36800010
J	MARSHALL, H; POPOWICZ, P; ENGEL, G; MARTENS, I; LINDER, S				MARSHALL, H; POPOWICZ, P; ENGEL, G; MARTENS, I; LINDER, S			LACK OF C-JUN EXPRESSION IN A TRANSFORMED-CELL LINE ISOLATED BY GLUCOCORTICOID PROMOTION OF RAS-TRANSFECTED RAT EMBRYO FIBROBLASTS	ONCOGENE			English	Article							GROWTH ARREST; DNA-BINDING; ONCOGENE; DOMAIN; COOPERATION; ACTIVATION; REQUIRES; PROTEINS; RECEPTOR; HORMONE	Rat embryo fibroblasts (REFs) are inefficiently transformed by the T24-ras oncogene. A contributing factor to cellular resistance to transformation is the limited tolerance to p21-ras oncoprotein expression. Here we present data suggesting that long-term glucocorticoid treatment of ras oncogene-transfected REFs results in increased tolerance to p21-ras oncoproteins, leading to expression of the transformed phenotype. Stably transformed cell lines that expressed high levels of H-ras and could be maintained in the absence of hormone were isolated. In three out of four tines studied, the AP-1-dependent collagenase gene was expressed at a low level. In one of these lines, low collagenase expression was paralleled by lack of c-jun mRNA. Immunochemical analysis revealed that progression to hormone independence was not paralleled by mutations in the p53 gene. We propose that a decreased expression of AP-1-driven genes may result in increased tolerance to p21-ras oncoprotein.	KAROLINSKA INST & HOSP, RADIUMHEMMET, DEPT ONCOL, DIV EXPTL ONCOL, S-10401 STOCKHOLM, SWEDEN	Karolinska Institutet; Karolinska University Hospital								ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; CUZIN F, 1984, CANCER CELL, V2, P109; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DOTTO GP, 1985, NATURE, V318, P472; EDMONDS M, 1969, J BIOL CHEM, V244, P1314; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; FURTH ME, 1987, ONCOGENE, V1, P47; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, ONCOGENE, V6, P669; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINDER S, 1990, VIROLOGY, V179, P78, DOI 10.1016/0042-6822(90)90276-W; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MARSHALL H, 1991, EXP CELL RES, V194, P35, DOI 10.1016/0014-4827(91)90126-F; MARTENS I, 1988, P NATL ACAD SCI USA, V85, P5571, DOI 10.1073/pnas.85.15.5571; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; QUINN CO, 1990, J BIOL CHEM, V265, P22342; REIHSAUS E, 1990, ONCOGENE, V5, P137; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; RUBIN E, 1992, CANCER RES, V52, P878; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; RUSCONI S, 1990, GENE, V89, P211, DOI 10.1016/0378-1119(90)90008-F; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; WEINBERG RA, 1989, CANCER RES, V49, P3713; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YAMASHITA T, 1988, INT J CANCER, V42, P930, DOI 10.1002/ijc.2910420624; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	53	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1303	1309						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479751				2022-12-28	WOS:A1993KY32800023
J	WANG, SM; NISHIGORI, C; MIYAKOSHI, J; TSUKADA, T; SHUNG, BS; YAGI, T; TAKEBE, H				WANG, SM; NISHIGORI, C; MIYAKOSHI, J; TSUKADA, T; SHUNG, BS; YAGI, T; TAKEBE, H			ACTIVATION OF C-MOS ONCOGENE BY INTEGRATION OF AN ENDOGENOUS LONG TERMINAL REPEAT ELEMENT DURING TRANSFECTION OF GENOMIC DNA FROM MOUSE SKIN TUMOR-CELLS	ONCOGENE			English	Article							MURINE SARCOMA-VIRUS; NUCLEOTIDE-SEQUENCE; TRANSFORMING GENE; PROTO-ONCOGENE; CELLULAR ONCOGENE; EXPRESSION; LTR; REARRANGEMENT; TRANSCRIPTS; JUNCTIONS	An activated c-mos oncogene was identified in a transformed clone of golden hamster embryo cells transfected with DNA extracted from cells cultured from a UV-induced mouse skin tumor. Southern blot hybridization with a v-mos oncogene probe showed that the mos oncogene was amplified in the primary and secondary transformed cells but not in the original tumor cells. Expression of the mos oncogene was very high in the primary and secondary transformants, but mos mRNA was undetectable in the original tumor cells. A genomic DNA fragment containing the activated mos oncogene was cloned and sequenced. The upstream mouse sequence of the mos oncogene, which functions as the transcription terminator, was lost and replaced by a mouse endogenous long terminal repeat (LTR) element that provides the promoter sequence, resulting in high expression of the gene. The rearrangement apparently occurred during transfection, since the polymerase chain reaction (PCR) product encompassing the junction region was present in the primary and secondary transformants but not in the original tumor cells. The LTR element is likely to have been amplified during the skin tumor development caused by UV irradiation. Southern blot hybridization showed that the copy number of LTR in the tumor cells was significantly higher than that in normal skin cells. The amplification of the LTR in the cells may have increased the chance of recombination between the LTR and c-mos gene during the DNA transfection.	KYOTO UNIV,FAC MED,DEPT DERMATOL,SAKYO KU,KYOTO 606,JAPAN	Kyoto University	WANG, SM (corresponding author), KYOTO UNIV,FAC MED,DEPT EXPTL RADIOL,SAKYO KU,KYOTO 606,JAPAN.							BARDWELL L, 1989, MUTAGENESIS, V4, P245, DOI 10.1093/mutage/4.4.245; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; CANAANI E, 1983, P NATL ACAD SCI-BIOL, V80, P7118, DOI 10.1073/pnas.80.23.7118; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Coffin J.M., 1984, RNA TUMOR VIRUSES, P1109; COHEN JB, 1983, NATURE, V306, P797, DOI 10.1038/306797a0; DHAR R, 1980, P NATL ACAD SCI-BIOL, V77, P3937, DOI 10.1073/pnas.77.7.3937; DONOGHUE DJ, 1983, J VIROL, V45, P607, DOI 10.1128/JVI.45.2.607-617.1983; FITZGERALD M, 1981, CELL, V24, P251, DOI 10.1016/0092-8674(81)90521-3; FUJIMOTO S, 1985, P NATL ACAD SCI USA, V82, P2072, DOI 10.1073/pnas.82.7.2072; GAO CL, 1988, ONCOGENE, V3, P267; HEARD JM, 1987, MOL CELL BIOL, V7, P2425, DOI 10.1128/MCB.7.7.2425; HOROWITZ M, 1984, EMBO J, V3, P2937, DOI 10.1002/j.1460-2075.1984.tb02235.x; HOUSEY GM, 1985, BIOCHEM BIOPH RES CO, V127, P391, DOI 10.1016/S0006-291X(85)80172-8; KIRSCHMEIER P, 1982, P NATL ACAD SCI-BIOL, V79, P2773, DOI 10.1073/pnas.79.9.2773; KUFF EL, 1983, NATURE, V302, P547, DOI 10.1038/302547a0; MCGEADY ML, 1986, DNA-J MOLEC CELL BIO, V5, P289, DOI 10.1089/dna.1986.5.289; MITRA G, 1989, P NATL ACAD SCI USA, V86, P8650, DOI 10.1073/pnas.86.22.8650; MIYAKOSHI J, 1990, CANCER RES, V50, P278; MOLONEY JOHN B., 1966, NAT CANCER INST MONOGR, V22, P139; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; OHUCHI T, 1992, ONCOGENE, V7, P331; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PERUCHO M, 1980, CELL, V22, P309, DOI 10.1016/0092-8674(80)90178-6; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; RECHAVI G, 1982, NATURE, V300, P607, DOI 10.1038/300607a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; TATSUKA M, 1988, EXP CELL RES, V178, P154, DOI 10.1016/0014-4827(88)90386-2; VANBEVEREN C, 1981, NATURE, V289, P258, DOI 10.1038/289258a0; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; VANDERHOORN FA, 1982, EMBO J, V1, P1313, DOI 10.1002/j.1460-2075.1982.tb01316.x; VANDERHOORN FA, 1984, NUCLEIC ACIDS RES, V12, P2147, DOI 10.1093/nar/12.4.2147; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078; WILSON JH, 1982, MOL CELL BIOL, V2, P1258, DOI 10.1128/MCB.2.10.1258; WOOD TG, 1984, P NATL ACAD SCI-BIOL, V81, P7817, DOI 10.1073/pnas.81.24.7817	37	2	2	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1009	1016						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455928				2022-12-28	WOS:A1993KT22000024
J	JEGO, N; THOMAS, G; HAMELIN, R				JEGO, N; THOMAS, G; HAMELIN, R			SHORT DIRECT REPEATS FLANKING DELETIONS, AND DUPLICATING INSERTIONS IN P53 GENE IN HUMAN CANCERS	ONCOGENE			English	Note							HUMAN BREAST-CANCER; CELL-LINES; GASTRIC-CANCER; LUNG-CANCER; MUTATIONS; CARCINOMA; FREQUENT; LEUKEMIA; TUMORS; ABNORMALITIES	Compilation of 740 independent p53 mutations from a wide variety of human cancers was performed between 1989 and April 1992. Deletions or insertions were observed in 10% of the cases. Insertions ranged from 1 to 14 nucleotides. In 14 out of 16 cases, the inserted nucleotide(s) duplicated the sequence where it was inserted. The deletions ranged from one to 37 nucleotides. Twenty six cases were single nucleotide deletions and 19 of them were localized at iterated nucleotides. In all 26 deletions of two nucleotides or more, a direct repeat of 2-8 base pairs was present on the unaltered sequence in the close vicinity of the deletion. In 15 of these cases, the deletion removed a complete repeat and the entire region in between repeats. In the remaining cases, the deletion imperfectly removed one or both repeats and/or the intercalating sequence. Both p53 insertions and deletions can be explained by a slipped-mispairing mechanism as proposed for germinal mutations of a small number of eukaryotic genes. Less frequent than the deamination of 5-methyl cytosine in CpG dinucleotides, mutations resulting in loss or gain of nucleotide base pairs may represent the second highest endogenous mutagenic event for p53 gene in human cancers.	INST CURIE,GENET TUMEURS LAB,26 RUE ULM,F-75231 PARIS 05,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie								BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; BRACHMAN DG, 1991, CANCER RES, V51, P6393; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CHIBA I, 1990, ONCOGENE, V5, P1603; CHUNG R, 1991, GENE CHROMOSOME CANC, V3, P323, DOI 10.1002/gcc.2870030502; CUNNINGHAM J, 1992, CANCER RES, V52, P1974; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FENAUX P, 1991, BLOOD, V78, P1652; FRANKEL RH, 1992, CANCER RES, V52, P1427; FUJIMOTO K, 1992, CANCER RES, V52, P1393; FULTS D, 1992, CANCER RES, V52, P674; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HAN ES, 1992, GENE CHROMOSOME CANC, V4, P1; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; ISAACS WB, 1991, CANCER RES, V51, P4716; JONVEAUX P, 1991, ONCOGENE, V6, P2243; KIM JH, 1991, J NATL CANCER I, V83, P938, DOI 10.1093/jnci/83.13.938; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; KRAWCZAK M, 1991, HUM GENET, V86, P425; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MAZARS R, 1991, ONCOGENE, V6, P1685; MILLER CW, 1992, CANCER RES, V52, P1695; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MURAKAMI Y, 1991, CANCER RES, V51, P5520; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OHGAKI H, 1991, CANCER RES, V51, P6202; OKAMOTO A, 1991, CANCER RES, V51, P5171; OSBORNE RJ, 1991, CANCER RES, V51, P6194; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; SATO T, 1992, CANCER RES, V52, P1643; SHIRASAWA S, 1991, CANCER RES, V51, P2874; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SOMMER SS, 1992, J NATL CANCER I, V84, P246, DOI 10.1093/jnci/84.4.246; SUGIMOTO K, 1991, BLOOD, V77, P1153; SUGITO S, 1991, INT J CANCER, V49, P880, DOI 10.1002/ijc.2910490614; SUZUKI H, 1992, CANCER RES, V52, P734; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAMURA G, 1991, CANCER RES, V51, P3056; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; THOMPSON AM, 1992, INT J CANCER, V50, P528, DOI 10.1002/ijc.2910500405; TOMINAGA O, 1992, IN PRESS CRIT REV ON; VAHAKANGAS KH, 1992, LANCET, V339, P576, DOI 10.1016/0140-6736(92)90866-2; VARLEY JM, 1991, ONCOGENE, V6, P413; YAGINUMA Y, 1991, CANCER RES, V51, P6506; YAMADA Y, 1991, CANCER RES, V51, P5800	56	98	98	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					209	213						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380918				2022-12-28	WOS:A1993KN00500026
J	Chiba, I; Shindoh, M; Yasuda, M; Yamazaki, Y; Amemiya, A; Sato, Y; Fujinaga, K; Notani, K; Fukuda, H				Chiba, I; Shindoh, M; Yasuda, M; Yamazaki, Y; Amemiya, A; Sato, Y; Fujinaga, K; Notani, K; Fukuda, H			Mutations in the p53 gene and human papillomavirus infection as significant prognostic factors in squamous cell carcinomas of the oral cavity	ONCOGENE			English	Article						p53; human papillomavirus; oral squamous cell carcinoma; prognosis	TUMOR-SUPPRESSOR GENE; POLYMERASE CHAIN-REACTION; CERVICAL CARCINOMAS; NECK-CANCER; LUNG-CANCER; FREQUENT; HEAD; DNA; ASSOCIATION; EXPRESSION	The p53 gene has been indicated to be a tumor is found in mutated form in common human cancers, Human papillomavirus (HPV) has oncogenic activity in cervical and oral squamous cell carcinomas (SCCs), The E6 protein of HPV is known to bind with p53 protein and inactivate the tumor suppressor activity by promoting p53 degradation, Because of this background, we examined 38 primary, resected specimens of oral SCCs for detection of p53 mutations and HPV DNAs, Exons 5 through 8 of the p53 gene were examined using the PCR-SSCP method, p53 Mutations were observed in nine cases (24%), HPV-DNA detection and typing were performed using PCR with 'high risk group' HPV-specific primers, HPV DNA sequences were detected in eight cases (21%), The AvaII digestion pattern of PCR-amplified HPV DNA showed that HPV-16 was present in all eight cases, Seven cases were p53 mutation-positive/HPV-negative, six cases were p53 mutation-negative/HPV-positive, and two intraosseus SCC cases were p53 mutation-positive/HPV-positive. Thus, 15/38 (40%) cases had inactivation of the p53 protein. Interestingly, p53 mutation-negative/HPV-negative cases had a poorer prognosis than p53 mutation positive or HPV-positive cases (P<0.01), We conclude that (1) mutation in the p53 gene and/or HPV infection are frequent (40%) in oral SCC; (2) inactivation of p53 function by mutation and HPV infection are important genetic events in the development of 40% similar to of oral SCCs; (3) p53 mutation and HPV infection are not mutually exclusive events and (4) other oncogenes or tumor suppresor genes may be crucial in the development of oral SCC if the prognosis is poor.	HOKKAIDO UNIV, SCH DENT, DEPT ORAL PATHOL, KITA KU, SAPPORO, HOKKAIDO 060, JAPAN; HOKKAIDO UNIV, SCH DENT, DEPT DENT RADIOL, KITA KU, SAPPORO, HOKKAIDO 060, JAPAN; HOKKAIDO UNIV, SCH ENGN, DEPT INFORMAT SCI, SAPPORO, HOKKAIDO 060, JAPAN; SAPPORO MED UNIV, CANC RES INST, DEPT MOLEC BIOL, CHUO KU, SAPPORO, HOKKAIDO 060, JAPAN	Hokkaido University; Hokkaido University; Hokkaido University; Sapporo Medical University	Chiba, I (corresponding author), HOKKAIDO UNIV, SCH DENT,DEPT ORAL SURG 1,KITA KU,KITA-13, NISHI 7, SAPPORO, HOKKAIDO 060, JAPAN.		Shindoh, Masanobu/A-4799-2012	Shindoh, Masanobu/0000-0002-7782-5823				BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALARAM P, 1995, INT J CANCER, V61, P450, DOI 10.1002/ijc.2910610403; BOYLE JO, 1993, CANCER RES, V53, P4477; BRACHMAN DG, 1992, CANCER RES, V52, P4832; BRANDWEIN M, 1994, MODERN PATHOL, V7, P720; BUSBYEARLE RMC, 1994, BRIT J CANCER, V69, P732, DOI 10.1038/bjc.1994.138; CAAMANO J, 1993, AM J PATHOL, V142, P1131; CARBONE DP, 1994, CHEST, V106, pS377, DOI 10.1378/chest.106.6.377S; CHANG F, 1994, BRIT J CANCER, V70, P346, DOI 10.1038/bjc.1994.305; CHIBA I, 1990, ONCOGENE, V5, P1603; FIELD JK, 1987, J ORAL PATHOL MED, V16, P97, DOI 10.1111/j.1600-0714.1987.tb01474.x; FRANK JL, 1994, CANCER-AM CANCER SOC, V73, P181, DOI 10.1002/1097-0142(19940101)73:1<181::AID-CNCR2820730131>3.0.CO;2-3; FUJINAGA Y, 1991, J GEN VIROL, V72, P1039, DOI 10.1099/0022-1317-72-5-1039; FUJITA M, 1992, CANCER RES, V52, P5323; Gonzalez-Moles M A, 1994, Bull Group Int Rech Sci Stomatol Odontol, V37, P79; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HELLAND A, 1993, J PATHOL, V171, P105, DOI 10.1002/path.1711710207; HERMANEK P, 1987, TNM CLASSIFICATION M, P1; HIGGINS GD, 1991, LANCET, V338, P910, DOI 10.1016/0140-6736(91)91773-N; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; LAZARUS P, 1995, INT J CANCER, V60, P458, DOI 10.1002/ijc.2910600406; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MIWA K, 1995, BRIT J CANCER, V71, P219, DOI 10.1038/bjc.1995.47; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PARK DJ, 1994, ONCOGENE, V9, P205; RIOU G, 1990, LANCET, V335, P1171; SAKAI E, 1992, ONCOGENE, V7, P927; SAKAI E, 1992, INT J CANCER, V52, P867, DOI 10.1002/ijc.2910520606; SARANATH D, 1989, JPN J CANCER RES, V80, P430, DOI 10.1111/j.1349-7006.1989.tb02332.x; SAUTER ER, 1992, AM J SURG, V164, P651, DOI 10.1016/S0002-9610(05)80727-5; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHIN DM, 1994, CANCER RES, V54, P321; SOMERS KD, 1992, CANCER RES, V52, P5997; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TASE T, 1988, CANCER RES, V48, P993; VOGELSTEIN B, 1989, RECESSIVE ONCOGENES; WAHI PN, 1971, INT HISTOLOGICAL CLA, P15; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	43	81	81	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	1996	12	8					1663	1668						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622886				2022-12-28	WOS:A1996UG45800008
J	Petrocelli, T; Poon, R; Drucker, DJ; Slingerland, JM; Rosen, CF				Petrocelli, T; Poon, R; Drucker, DJ; Slingerland, JM; Rosen, CF			UVB radiation induces p21(Cip1/WAF1) and mediates G1 and S phase checkpoints	ONCOGENE			English	Review						cell cycle; checkpoint; p21(Cip1/WAF1); cyclin G; UVB irradiation	CELL-CYCLE CHECKPOINT; NORMAL HUMAN-SKIN; WILD-TYPE P53; PYRIMIDINE DIMERS; MAMMALIAN-CELLS; RETINOBLASTOMA PROTEIN; RAT KERATINOCYTES; DEPENDENT KINASE; DNA-REPLICATION; CDK2 ACTIVITY	In a search for effecters and targets of UVB signaling in mammalian cells, we screened a keratinocyte cDNA library with differentially subtracted UVB-enriched cDNA probes. One of the UVB induced cDNA clones proved to be the rat p21(Cip1/WAF1) homologue. UVB irradiation caused a rise in p53 protein levels, in association with induction of p21(Cip1/WAF1) and cyclin G expression. The effects of UVB irradiation induced p21(Cip1/WAF1) on the cell cycle were examined. In contrast to gamma irradiation, which caused G2 arrest, UVB treatment of asynchronous neonatal rat keratinocytes (NK) led to a marked inhibition of replicative DNA synthesis and prolonged G1 and S phase arrests, persisting to 18-24 h, with recovery of cycling by 36 h post-UVB. G1 arrest was accompanied by inhibition of cyclin D-, E- and A-associated kinases. Kinase inhibition was not due to reduction in cyclin or cdk proteins. While the association of cyclin E with Cdk2 was moderately reduced, cyclin D1/Cdk4 and cyclin A/Cdk2 complexes were not disrupted. The activating threonine 160 phosphorylation of Cdk2 in cyclin complexes was not inhibited. An incremental binding of p21 with Cdk4 paralleled the inhibition of cyclin D1/Cdk4 kinase and a similar rise in Cdk2 binding to p21 was associated with inhibition of cyclin E and cyclin A dependent kinases. Furthermore, a rise in measurable p21(Cip1/WAF1)-Cdk2 inhibitory activity paralleled the loss of G1 cyclin-dependent kinase activity, supporting a role for p21(Cip1/WAF1) in the UVB-induced checkpoints.	UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, DIV CANC BIOL, DEPT MED BIOPHYS, TORONTO, ON M4N 3M5, CANADA; UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, DIV CANC BIOL, DEPT MED, TORONTO, ON M4N 3M5, CANADA; UNIV TORONTO, DEPT MED & CLIN BIOCHEM, TORONTO, ON M5S 1B2, CANADA; UNIV TORONTO, DEPT MED GENET, TORONTO, ON M5S 1B2, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto			Drucker, Daniel J/A-4092-2010					BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BRASH DE, 1982, NATURE, V298, P189, DOI 10.1038/298189a0; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAMPBELL C, 1993, CANCER RES, V53, P2697; CANMAN CE, 1994, CANCER RES, V54, P5054; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DOMON M, 1968, RADIAT RES, V35, P350, DOI 10.2307/3572382; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLISON MJ, 1981, PHOTOCHEM PHOTOBIOL, V34, P465, DOI 10.1111/j.1751-1097.1981.tb09026.x; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FREEMAN SE, 1988, J INVEST DERMATOL, V90, P814, DOI 10.1111/1523-1747.ep12462039; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HALL PA, 1993, ONCOGENE, V8, P203; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HONIGSMANN H, 1987, J PHOTOCH PHOTOBIO B, V1, P33, DOI 10.1016/1011-1344(87)80004-0; ISHIZAKI K, 1994, INT J CANCER, V58, P254, DOI 10.1002/ijc.2910580218; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KAUFMANN WK, 1991, MOL CELL BIOL, V11, P3711, DOI 10.1128/MCB.11.7.3711; KAUFMANN WK, 1994, MUTAT RES, V314, P67, DOI 10.1016/0921-8777(94)90062-0; KEYSE SM, 1988, MOL CELL BIOL, V8, P5425, DOI 10.1128/MCB.8.12.5425; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAU CC, 1994, P NATL ACAD SCI USA, V79, P7491; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LI JJ, 1993, CELL, V74, P223, DOI 10.1016/0092-8674(93)90413-K; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI Y, 1994, ONCOGENE, V9, P2261; LITTLE JB, 1995, J BIOL CHEM, V270, P11033, DOI 10.1074/jbc.270.19.11033; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; LIU M, 1995, ONCOGENE, V10, P1955; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURNANE JP, 1995, CANCER METAST REV, V14, P17, DOI 10.1007/BF00690208; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PEACOCK JW, 1995, MOL CELL BIOL, V15, P1446; PEAK MJ, 1987, PHOTOCHEM PHOTOBIOL, V45, P381, DOI 10.1111/j.1751-1097.1987.tb05390.x; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Romerdahl C A, 1989, Cancer Commun, V1, P209; ROSEN CF, 1990, CANCER RES, V50, P2631; ROSEN CF, 1992, AM J PHYSIOL, V263, pC1103, DOI 10.1152/ajpcell.1992.263.5.C1103; ROSEN CF, 1995, AM J PHYSIOL-CELL PH, V268, pC846, DOI 10.1152/ajpcell.1995.268.4.C846; ROSENSTEIN BS, 1987, PHOTOCHEM PHOTOBIOL, V45, P775, DOI 10.1111/j.1751-1097.1987.tb07881.x; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SLINGERLAND JM, 1991, BLOOD, V77, P1500; SMITH ML, 1995, ONCOGENE, V10, P1053; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; TAMURA K, 1993, ONCOGENE, V8, P2113; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAI LH, 1993, ONCOGENE, V8, P1593; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAMASHITA M, 1992, DEV BIOL, V149, P8, DOI 10.1016/0012-1606(92)90259-J; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZOLZER F, 1984, PHOTOCHEM PHOTOBIOL, V40, P49, DOI 10.1111/j.1751-1097.1984.tb04552.x	112	82	83	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	1996	12	7					1387	1396						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622854				2022-12-28	WOS:A1996UF07600002
J	Baker, SJ; Reddy, EP				Baker, SJ; Reddy, EP			Transducers of life and death: TNF receptor superfamily and associated proteins	ONCOGENE			English	Review						TNF receptor superfamily; Fas; CD40; apoptosis; death domain; TRADD; FADD/MORT-1; RIP; TRAF domain	ACTIVATION; DOMAIN	Signal transduction pathways which are initiated by members of the TNF superfamily utilize receptors which are devoid of intrinsic catalytic activity, Isolation and characterization of death domain (TNF-RI, Fas, TRADD, FADD/MORT-1, RIP) and TRAF domain-containing proteins (TRAF-1 TRAF-2, TRAF-3) have partially bridged a large molecular gap within one of several signaling pathways which originate at the plasma membrane and terminate in the nucleus. The ability of these two protein families to selectively dimerize and bind to related receptors allows them to govern diverse cellular responses which culminate in cellular proliferation, differentiation, effector functions, and apoptosis.			Baker, SJ (corresponding author), TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,3307 N BROAD ST,PHILADELPHIA,PA 19140, USA.		Reddy, E. Premkumar/F-6233-2011					ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; BAKER SJ, 1995, ONCOGENE, V11, P413; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BIGDA J, 1994, J EXP MED, V180, P445, DOI 10.1084/jem.180.2.445; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BOLDIN MP, 1995, FEBS LETT, V367, P39, DOI 10.1016/0014-5793(95)00534-G; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; CONLEY ME, 1994, CURR OPIN GENET DEV, V4, P401, DOI 10.1016/0959-437X(94)90028-0; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GRELL M, 1994, EUR J IMMUNOL, V24, P2563, DOI 10.1002/eji.1830241045; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HU HM, 1994, J BIOL CHEM, V269, P30069; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; ITOH N, 1993, J BIOL CHEM, V268, P10932; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STRASSER A, 1995, NATURE, V373, P385, DOI 10.1038/373385a0; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WONG GHW, 1994, J IMMUNOL, V152, P1751; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	48	398	436	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					1	9						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552378				2022-12-28	WOS:A1996TQ01400001
J	PRONK, GJ; DEVRIESSMITS, AMM; ELLIS, C; BOS, JL				PRONK, GJ; DEVRIESSMITS, AMM; ELLIS, C; BOS, JL			COMPLEX-FORMATION BETWEEN THE P21(RAS) GTPASE-ACTIVATING PROTEIN AND PHOSPHOPROTEINS P62 AND P190 IS INDEPENDENT OF P21(RAS) SIGNALING	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; RAS P21 GTPASE; NIH 3T3 CELLS; GENE-EXPRESSION; MOLECULAR-CLONING; MAP KINASE; GAP; PHOSPHORYLATION; TRANSFORMATION	We have investigated whether complex formation between the p21ras GTPase-activating protein (GAP) and the phosphotyrosine-containing proteins p62 and p190 is dependent on functional p21ras, to test the hypothesis that binding of p21(ras)GTP to GAP enables GAP to associate with these phosphoproteins. The formation of p21(ras)GTP was inhibited by a dominant interfering mutant of p21ras, p21ras(Asn-17), which was introduced with a vaccinia virus expression system. We used NIH3T3 cells in which complex formation between GAP and tyrosine-phosphorylated p62 and p190 can be induced either by v-src transformation, by incubating the cells with the phosphotyrosine phosphatase inhibitor pervanadate or by activation of a growth factor receptor tyrosine kinase. In all cases, expression of p21ras(Asn-17) did not affect the presence or the formation of the GAP-phosphoprotein complexes. To monitor the effectiveness of p21ras inhibition, we measured p21ras-mediated phosphorylation of extracellular signal-regulated kinase 2 (ERK2). In all cases, expression of p21ras(Asn-17) completely blocked signalling to ERK2. From these data we conclude that p21(ras)GTP formation is not essential for complex formation between GAP and tyrosine-phosphorylated p62 and p190, and thus complex formation does not depend on interaction of GAP with p21(ras)GTP.	UNIV UTRECHT,PHYSIOL CHEM LAB,VONDELLAAN 24A,3521 GG UTRECHT,NETHERLANDS; CHESTER BEATTY LABS,LONDON,ENGLAND	Utrecht University; University of London; Institute of Cancer Research - UK								ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; BULLER RML, 1988, J VIROL, V62, P866, DOI 10.1128/JVI.62.3.866-874.1988; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1993, UNPUB; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHANG JH, 1993, ONCOGENE, V8, P959; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DUBYAK GR, 1980, J BIOL CHEM, V255, P306; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LIU XQ, 1991, MOL CELL BIOL, V11, P2511, DOI 10.1128/MCB.11.5.2511; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MOLLOY CJ, 1992, MOL CELL BIOL, V12, P3903, DOI 10.1128/MCB.12.9.3903; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PRONK GJ, 1992, ONCOGENE, V7, P389; PRONK GJ, 1992, J BIOL CHEM, V267, P24508; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHECHTER Y, 1980, NATURE, V284, P556; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; TAMURA S, 1983, BIOCHEM BIOPH RES CO, V113, P80, DOI 10.1016/0006-291X(83)90434-5; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	55	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2773	2780						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378086				2022-12-28	WOS:A1993LX34300019
J	ZERLIN, M; JULIUS, MA; GOLDFARB, M				ZERLIN, M; JULIUS, MA; GOLDFARB, M			NEP - A NOVEL RECEPTOR-LIKE TYROSINE KINASE EXPRESSED IN PROLIFERATING NEUROEPITHELIA	ONCOGENE			English	Article							CYTOPLASMIC SIGNALING PROTEINS; NERVE GROWTH-FACTOR; NEUROTROPHIC FACTOR; OLIGODENDROCYTE DEVELOPMENT; PHOSPHOTYROSINE ANTIBODY; BINDING-SITE; FAMILY; DIFFERENTIATION; DOMAINS; CELLS	We have isolated a murine cDNA, nep, which encodes a novel receptor-like protein tyrosine kinase. The kinase region of NEP protein bears 50% amino acid sequence identity to the neurotrophin receptors (TRKs). While the intracytoplasmic portion of NEP also contains a short kinase insert region and C-terminal tail reminiscent of the TRK proteins, the putative extracellular domain of NEP is unrelated to any known proteins. The nep gene is strongly expressed within proliferating neuroepithelia of mouse embryos, commencing at the early somite stage (embryonic day 8.0) and persisting in the proliferative ventricular zones of the brain and spinal cord, suggesting that one function of NEP kinase is to signal proliferation of neuroepithelial cells in response to an as yet unknown ligand. The nep gene is also expressed in embryonic sensory ganglia, striated muscle and epidermis, as well as in several adult tissues, including the ventricle linings and glia subpopulations tn the brain.	CTR MOLEC MED & IMMUNOL,NEWARK,NJ 07103; COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032	Columbia University								BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAUB O, 1991, DEVELOPMENT, V112, P397; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOLBOOK F, 1991, NEURON, V6, P845; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LETWIN K, 1988, ONCOGENE, V3, P621; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARTIN GR, 1975, CELL, V6, P467, DOI 10.1016/0092-8674(75)90035-5; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; MCKINNON RD, 1990, NEURON, V5, P603, DOI 10.1016/0896-6273(90)90215-2; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; RUTA M, 1988, ONCOGENE, V3, P9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBUYA M, 1990, ONCOGENE, V5, P519; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603	39	60	63	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2731	2739						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8397369				2022-12-28	WOS:A1993LX34300014
J	SIF, S; CAPOBIANCO, AJ; GILMORE, TD				SIF, S; CAPOBIANCO, AJ; GILMORE, TD			THE V-REL ONCOPROTEIN INCREASES EXPRESSION FROM SP1 SITE-CONTAINING PROMOTERS IN CHICKEN-EMBRYO FIBROBLASTS	ONCOGENE			English	Article							NF-KAPPA-B; HUMAN-IMMUNODEFICIENCY-VIRUS; GTPASE-ACTIVATING PROTEIN; TRANSCRIPTION FACTOR SP1; RETICULOENDOTHELIOSIS VIRUS; C-REL; SPLEEN-CELLS; ONCOGENIC TRANSFORMATION; SYNERGISTIC ACTIVATION; CELLULAR PROTEINS	The v-Rel oncoprotein of the avian Rev-T retrovirus is a member of a family of related transcription factors, which also includes the subunits of NF-kappaB and several other interacting cellular proteins. We show here that v-Rel specifically increased expression from a reporter plasmid containing multiple Spl binding sites approximately sixfold in chicken embryo fibroblasts (CEFs), even though v-Rel did not bind directly to these sites. v-Rel also increased expression from a reporter plasmid containing a human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR) in which the kappaB binding sites were mutated but which still contained intact Sp1 binding sites. The increase in Sp1-site transactivation does not precisely correlate with transformation by v-Rel since one non-transforming v-Rel mutant still induced expression from the Sp1 site-containing promoter. v-Rel appears to increase expression from Sp1 site-containing promoters by affecting the transactivation domain of Sp1, since v-Rel increased the activity of a Gal4-Sp1 fusion protein, which contains the Spl transactivation domain but lacks the Sp1 DNA-binding domain. As compared with v-Rel, c-Rel induced only a slight increase in expression from the reporter plasmid containing Sp1 sites. However, v-Ras and v-Src (but not v-Myb) induced increases in transcription from the reporter plasmid containing Sp1 sites to the same extent as v-Rel, but through pathways that appear to be independent from v-Rel. These results suggest that certain oncoproteins might increase transcription from many genes that contain Sp1 binding sites, and that this might be important for certain aspects of transformation by these proteins.	BOSTON UNIV,DEPT BIOL,5 CUMMINGTON ST,BOSTON,MA 02215	Boston University			Sif, Said/AAE-5554-2019	Capobianco, Anthony/0000-0002-3706-6797; Sif, Said/0000-0001-6268-1145	NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER; NCI NIH HHS [CA47763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BORELLINI F, 1991, J BIOL CHEM, V266, P15850; BORELLINI F, 1990, MOL CELL BIOL, V10, P5541, DOI 10.1128/MCB.10.10.5541; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; DAVIS JN, 1990, ONCOGENE, V5, P1109; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FRANKLIN RB, 1977, VIROLOGY, V83, P313, DOI 10.1016/0042-6822(77)90176-3; GELINAS C, 1988, ONCOGENE, V3, P349; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1992, CANCER SURV, V15, P69; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KAMENS J, 1991, NEW BIOL, V3, P1005; KAMINE J, 1991, P NATL ACAD SCI USA, V88, P8510, DOI 10.1073/pnas.88.19.8510; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOCHEL T, 1991, ONCOGENE, V6, P615; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LI YC, 1991, MOL CELL BIOL, V11, P1883, DOI 10.1128/MCB.11.4.1883; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; MORIN PJ, 1992, NUCLEIC ACIDS RES, V20, P2453, DOI 10.1093/nar/20.10.2453; MORIN PJ, 1993, NUCLEIC ACIDS RES, V21, P2157, DOI 10.1093/nar/21.9.2157; MORRISON LE, 1991, ONCOGENE, V6, P1657; MORRISON LE, 1989, ONCOGENE, V4, P677; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; MOSIALOS G, 1993, ONCOGENE, V8, P721; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; SARKAR S, 1993, IN PRESS ONCOGENE; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1991, ONCOGENE, V6, P2297; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	60	43	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2501	2509						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361761				2022-12-28	WOS:A1993LT36800022
J	ALI, IU; SAXENA, A; MEISSNER, S; BARRICK, J; LIDEREAU, R				ALI, IU; SAXENA, A; MEISSNER, S; BARRICK, J; LIDEREAU, R			CLOSE PROXIMITY OF C-ERBA2 AND C-ERBA-BETA GENES ON THE SHORT ARM OF CHROMOSOME-3	ONCOGENE			English	Note							THYROID-HORMONE RECEPTOR; RENAL-CELL CARCINOMA; HUMAN LUNG-CANCER; DELETION; LOCALIZATION; REGION; HETEROZYGOSITY; SEQUENCE; HOMOLOGS; PROTEIN	The common loss region on the short arm of chromosome 3 (3p) in human breast tumors harbors two members of the c-erbA receptor gene family, c-erbA2 and c-erbA-beta, both of which recognize a BamHI polymorphism in human genomic DNA. Analysis of lymphocyte DNAs from 50 normal individuals and lymphocyte and tumor DNAs from 116 breast cancer patients revealed identical genotypes (a/a, b/b or a/b) for both probes. Furthermore, deletion of the same allele (a/- or -/b) of c-erbA2 and c-erbA-beta was detected in 25% of the 66 breast tumors from patients with constitutionally heterozygous genotypes for both genes. No sequence homology was detected between the c-erbA2 and c-erbA-beta genes, suggesting a physical linkage between these two genes. Digestion of the genomic DNA with combinations of restriction enzymes and hybridization with c-erbA2, which is a genomic fragment, and c-erbA-beta, which is a cDNA clone, provide evidence that c-erbA2 and a region of the c-erbA-beta gene are physically contiguous on the short arm of chromosome 3 and are separated by no more than 1.8 kb of DNA sequences.	NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892; CTR RENE HUGUENIN,F-92211 ST CLOUD,FRANCE	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Rene Huguenin Hospital	ALI, IU (corresponding author), NINCDS,SURG NEUROL BRANCH,BETHESDA,MD 20892, USA.							ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DOBROVIC A, 1988, CANCER RES, V48, P682; DOUGLAS JB, 1991, GENOMICS, V9, P398, DOI 10.1016/0888-7543(91)90274-I; DRABKIN H, 1988, P NATL ACAD SCI USA, V85, P9258, DOI 10.1073/pnas.85.23.9258; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GOSDEN JR, 1986, CYTOGENET CELL GENET, V43, P150, DOI 10.1159/000132313; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HIBI K, 1992, ONCOGENE, V7, P445; JANSSON M, 1983, EMBO J, V2, P561, DOI 10.1002/j.1460-2075.1983.tb01463.x; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; LAUDET V, 1991, NUCLEIC ACIDS RES, V19, P1105, DOI 10.1093/nar/19.5.1105; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; LEDUC F, 1989, AM J HUM GENET, V44, P282; MIYAJIMA N, 1989, CELL, V57, P31, DOI 10.1016/0092-8674(89)90169-4; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; RIDER SH, 1987, ANN HUM GENET, V51, P153, DOI 10.1111/j.1469-1809.1987.tb01057.x; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SPURR NK, 1984, EMBO J, V3, P159, DOI 10.1002/j.1460-2075.1984.tb01777.x; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YAMAKAWA K, 1991, CANCER RES, V51, P4707; YOKOTA J, 1989, CANCER RES, V49, P3958; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	25	3	3	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2299	2301						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8393165				2022-12-28	WOS:A1993LP17100033
J	ALESSI, DR; SMYTHE, C; KEYSE, SM				ALESSI, DR; SMYTHE, C; KEYSE, SM			THE HUMAN CL100 GENE ENCODES A TYR/THR-PROTEIN PHOSPHATASE WHICH POTENTLY AND SPECIFICALLY INACTIVATES MAP KINASE AND SUPPRESSES ITS ACTIVATION BY ONCOGENIC RAS IN XENOPUS-OOCYTE EXTRACTS	ONCOGENE			English	Note							EPIDERMAL GROWTH-FACTOR; RABBIT SKELETAL-MUSCLE; P34CDC2; PURIFICATION; REQUIREMENT; CELLS	The expression of the human CL100 gene and its mouse homologue 3CH134 is increased up to 40-fold in fibroblasts exposed to oxidative/heat stress and growth factors. CL100 is a member of an expanding family of protein tyrosine phosphatases with amino acid sequence similarity to a Tyr/Ser-protein phosphatase encoded by the late H1 gene of vaccinia virus. Here we show that the CL100 phosphatase, expressed and purified in bacteria, rapidly and potently inactivates recombinant MAP kinase in vitro by the concomitant dephosphorylation of both its phosphothreonine and phosphotyrosine residues. Furthermore, CL100 suppresses the [val12] ras-induced activation of MAP kinase in a cell-free system from Xenopus oocytes. Both activities are abolished by mutagenesis of the highly conserved cysteine (Cys-258) within the phosphatase active site. In contrast to the vaccinia H1 phosphatase, CL100 shows no measurable catalytic activity towards a remember of other substrate proteins modified on serine, threonine or tyrosine residues. Our results demonstrate that CL100 is a dual specificity phosphatase and indicate that MAP kinase is one of its physiological targets. CL100 may be the first example of a new class of protein phosphatases responsible for modulating the activation of MAP kinase following exposure of quiescent cells to growth factors and further implicates MAP kinase activation/deactivation in the cellular response to stress.	UNIV DUNDEE, INST MED SCI,DEPT BIOCHEM,MRC, PROT PHOSPHORYLAT UNIT, DUNDEE DD1 4HN, SCOTLAND; UNIV DUNDEE, NINEWELLS HOSP & MED SCH,BIOMED RES CTR,ICRF, MOLEC PHARMACOL UNIT, DUNDEE DD1 9SY, SCOTLAND	University of Dundee; University of Dundee			Keyse, Stephen M./B-9575-2009	Keyse, Stephen M./0000-0002-5150-8221; Alessi, Dario/0000-0002-2140-9185				ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CHAMBERS TC, 1990, J BIOL CHEM, V265, P16940; CHARLES CH, 1992, ONCOGENE, V7, P187; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COHEN P, 1988, METHOD ENZYMOL, V159, P427; DEANA AD, 1990, BIOCHIM BIOPHYS ACTA, V1051, P199, DOI 10.1016/0167-4889(90)90194-I; DENT P, 1992, EUR J BIOCHEM, V210, P1037, DOI 10.1111/j.1432-1033.1992.tb17509.x; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GUAN K, 1993, TRENDS BIOCHEM SCI, V18, P6, DOI 10.1016/0968-0004(93)90079-3; GUAN K, 1992, P NATL ACAD SCI USA, V89, P12175, DOI 10.1073/pnas.89.24.12175; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HENDRIX P, 1993, J BIOL CHEM, V268, P7330; HSUAN J, 1991, METHOD ENZYMOL, V200, P378; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; MCGOWAN CH, 1987, EUR J BIOCHEM, V166, P713, DOI 10.1111/j.1432-1033.1987.tb13570.x; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NAKIELNY S, 1991, EUR J BIOCHEM, V199, P713, DOI 10.1111/j.1432-1033.1991.tb16175.x; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SATO HT, 1992, SEMIN CANCER BIOL, V3, P169; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STEWART AA, 1981, EUR J BIOCHEM, V115, P197; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; THOAMS G, 1992, CELL, V68, P3; THOM D, 1977, BIOCHEM J, V168, P187, DOI 10.1042/bj1680187; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351	45	318	330	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1993	8	7					2015	2020						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8390041				2022-12-28	WOS:A1993LG68200035
J	NICKLIN, MJH; ZECHNER, D; KISLYAKOVA, T				NICKLIN, MJH; ZECHNER, D; KISLYAKOVA, T			ACCUMULATED HELIX-DESTABILIZING MUTATIONS IN THE LEUCINE-ZIPPER OF C-FOS LEADS TO ATTENUATION AND TEMPERATURE SENSITIVITY OF FUNCTION	ONCOGENE			English	Article							DNA-BINDING DOMAIN; CELLULAR-TRANSFORMATION; GROWTH-FACTOR; JUN; PROTEIN; GENE; EXPRESSION; THERMOSTABILITY; TRANSCRIPTION; FIBROBLASTS	Fos protein heterodimerizes through one surface of an alpha-helical domain called the leucine zipper. We have investigated the effect of destabilizing this domain by multiply substituting small residues of its non-interacting surface with glycine. Ternary complex formation between mutated Fos, Jun and DNA was determined in vitro in the presence of denaturant. We also tested the ability of constitutively expressed, mutated Fos proteins to support anchorage independent growth of the cell line Rat1A. Combinations of two substitutions are tolerated in both assays of Fos function, while four substitutions resulted in attenuation in both functions. Rat1A expressing one of the quadruple mutants also showed temperature sensitivity in anchorage independent growth. In dense monolayers of these cells, stromelysin (a Fos-responsive gene product) decreased in abundance as a function of temperature and was less abundant even at 34-degrees-C than in cells that overexpressed the wild-type c-fos mRNA. However the mutant transgene itself appeared to show temperature sensitive expression. We suggest that creating a range of glycine substitutions for small residues in the non-interacting face of a leucine zipper might be of general use as a strategy to produce attenuated mutants of other transcription factors.	FORSCH INST MOLEK PATHOL,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)				Nicklin, Martin/0000-0002-0127-1131				ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BOHMANN D, 1989, SCIENCE, V246, P911; BUSSLINGER M, 1981, CELL, V27, P289, DOI 10.1016/0092-8674(81)90412-8; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HARAI SI, 1989, NEW BIOL, V1, P181; HECHT M H, 1986, Proteins Structure Function and Genetics, V1, P43, DOI 10.1002/prot.340010108; IMANAKA T, 1986, NATURE, V324, P695, DOI 10.1038/324695a0; JOOSS K, 1992, ONCOGENE, V7, P1933; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LOVELLBADGE RH, 1987, TERATOCARCINOMAS EMB, P132; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; MILLER AD, 1984, CELL, V36, P51; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; NEMETHY G, 1966, J PHYS CHEM-US, V70, P998, DOI 10.1021/j100876a008; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; NICKLIN MJH, 1991, ONCOGENE, V6, P173; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PARKS GD, 1986, J VIROL, V60, P376, DOI 10.1128/JVI.60.2.376-384.1986; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; PREVELIGE P, 1988, PREDICTION PROTEIN S, P391; SCHUERMANN M, 1991, NUCLEIC ACIDS RES, V19, P739, DOI 10.1093/nar/19.4.739; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SERRANO L, 1992, NATURE, V356, P453, DOI 10.1038/356453a0; SHORTLE D, 1985, GENETICS, V110, P539; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	47	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1737	1749						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510920				2022-12-28	WOS:A1993LG68200004
J	SLEEMAN, JP				SLEEMAN, JP			XENOPUS A-MYB IS EXPRESSED DURING EARLY SPERMATOGENESIS	ONCOGENE			English	Article							HUMAN LYMPHOCYTES-T; C-MYB; V-MYB; ERYTHROID-DIFFERENTIATION; NUCLEOTIDE-SEQUENCE; MYELOID-LEUKEMIA; CDNA CLONES; CELL-LINES; GENE; ONCOGENE	c-myb has been studied intensely, but other members of the myb gene family have been largely overlooked. This paper describes the isolation and characterization of a Xenopus cDNA sequence, XAMyb, closely related to human A-myb. Xenopus provides a valuable experimental model for investigating the involvement of genes in cell proliferation, differentiation and development. Although no expression of XAMyb was detected in oocytes or eggs or during early embryogenesis, there is a low level of expression within ovarian tissue, which is down-regulated in response to hormones that stimulate oocyte maturation. However, in adult male Xenopus, virtually all A-myb expression is in the testis, particularly within the nuclei of spermatogonial cells, the mitotically proliferating early progenitors of spermatozoa. Expression falls dramatically during meiosis and is virtually undetectable during subsequent spermiogenesis. This pattern of expression of Xenopus A-myb during the preterminal differentiation/ proliferation phase of germ cell development resembles the expression of c-myb in similar phases during haematopoiesis. These results suggest related roles for myb variants during the development of different stem cell-derived populations.	WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND				Sleeman, Jonathan P/H-2515-2013	Sleeman, Jonathan P/0000-0003-1718-7687				ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERGER SL, 1987, METHODS ENZYMOL, V152; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CLURMAN B, 1988, IMMUNOL SER, V41, P55; CRAIG RW, 1984, CANCER RES, V44, P442; DESBIENS X, 1991, DEVELOPMENT, V111, P699; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRIFFIN CA, 1985, CANCER RES, V45, P272; Gurdon J.B., 1977, Methods Cell Biol, V16, P125; HARLOW E, 1988, ANTIBODIES LABORATOR; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JACKSON D, 1991, PLANT CELL, V3, P115, DOI 10.1105/tpc.3.2.115; JACKSON R, 1987, METHOD ENZYMOL, V96, P50; KALT MR, 1976, J EXP ZOOL, V195, P393, DOI 10.1002/jez.1401950306; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KREIG PA, 1989, DEV BIOL, V133, P93; KREIG PA, 1987, METHOD ENZYMOL, V155, P397; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOFTS B, 1974, PHYSL AMPHIBIA; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEINESS D, 1984, MOL CELL BIOL, V9, P5456; SHENONG G, 1991, BIOCHIM BIOPHYS ACTA, V1032, P39; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P431; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TORELLI G, 1985, MOL CELL BIOL, V5, P2874, DOI 10.1128/MCB.5.10.2874; TORELLI G, 1987, CANCER RES, V47, P5266; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WESTON K, 1989, CELL, V58, P83	53	91	94	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1931	1941						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510936				2022-12-28	WOS:A1993LG68200026
J	RAMQVIST, T; MAGNUSSON, KP; WANG, YS; SZEKELY, L; KLEIN, G; WIMAN, KG				RAMQVIST, T; MAGNUSSON, KP; WANG, YS; SZEKELY, L; KLEIN, G; WIMAN, KG			WILD-TYPE P53 INDUCED APOPTOSIS IN A BURKITT-LYMPHOMA (BL) LINE THAT CARRIES MUTANT P53	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; PROGRAMMED CELL-DEATH; TUMOR-ANTIGEN; PROTEIN; GROWTH; TRANSLOCATION; LOCALIZATION; ASSOCIATION; MUTATIONS; INDUCTION	All Burkitt lymphoma (BL) biopsies and cell lines carry a c-myc/Ig translocation. The resulting constitutive activation of c-myc is regarded as an essential factor for the progressive growth of the tumor cells. At least 60% of BL cell lines carry a mutated p53 gene as well. It has been shown that the growth of mutant p53 carrying tumor cells could be inhibited by the introduction of wild-type p53. In order to examine whether this also applies to the presumably 'myc-driven' BL cell, we have transfected the Epstein-Barr virus (EBV) negative BL41 cell line with a temperature sensitive p53 mutant (p53-Val135) that expresses p53 with a largely mutant conformation at 37.5-degrees-C and mostly wild-type conformation at 32-degrees-C. At 37.5-degrees-C, the p53-Val135 transfected cells behaved like the parental or neo transfected control cells. However, expression of exogenous wild-type p53 at 32-degrees-C resulted in a rapid reduction of the number of viable cells white the parental and neo control cells remained unaffected. Cell death was due to apoptosis as shown by chromatin and nuclear condensation and specific DNA fragmentation. The first signs of apoptosis were evident after 10 h at 32-degrees-C and after 3 days 90-100% of the cells had undergone apoptosis. These findings indicate an incompatibility between expression of wild-type p53 and progressive growth of BL cells if their neoplastic development has included a p53 mutation. The question whether apoptosis was induced in by the wild-type protein per se or by the contradictory signals of a constitutively activated c-myc and wild-type p53 needs further investigation.	KAROLINSKA INST,DEPT TUMOR BIOL,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet			Wiman, Klas/AAB-8399-2021; Magnusson, Kristinn P Pétur/X-4907-2019; Magnusson, Kristinn/A-6479-2011; Szekely, Laszlo/B-1268-2009	Wiman, Klas/0000-0002-7113-524X; Magnusson, Kristinn P Pétur/0000-0003-4528-6826; Magnusson, Kristinn/0000-0003-4528-6826; 	NCI NIH HHS [5R01 CA14054] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA014054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P553; ASKEW DS, 1991, ONCOGENE, V6, P1915; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CASEY G, 1991, ONCOGENE, V6, P1791; CHENG J, 1992, CANCER RES, V52, P222; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; ISAACS WB, 1991, CANCER RES, V51, P4716; LANE DP, 1979, NATURE, V351, P453; LENIOR GM, 1985, IARC SCI PUBL, V60, P309; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; POTTER M, 1987, SCIENCE, V235, P787, DOI 10.1126/science.3810165; ROWE M, 1985, INT J CANCER, V35, P435, DOI 10.1002/ijc.2910350404; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHALUSKY G, 1991, P NATL ACAD SCI USA, V88, P8982; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; TORSTEINSDOTTIR S, 1989, INT J CANCER, V43, P273, DOI 10.1002/ijc.2910430219; VOSS H, 1992, Methods in Molecular and Cellular Biology, V3, P30; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WIMAN KG, 1991, ONCOGENE, V6, P1633; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	33	144	146	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1495	1500						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502475				2022-12-28	WOS:A1993LE06400012
J	ALGATE, PA; MCCUBREY, JA				ALGATE, PA; MCCUBREY, JA			AUTOCRINE TRANSFORMATION OF HEMATOPOIETIC-CELLS RESULTING FROM CYTOKINE MESSAGE STABILIZATION AFTER INTRACISTERNAL-A PARTICLE TRANSPOSITION	ONCOGENE			English	Article							DEPENDENT HEMATOPOIETIC-CELLS; C-MOS ONCOGENE; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; INTERLEUKIN-3 GENE; MURINE INTERLEUKIN-3; GROWTH-FACTORS; HOMEOBOX GENE; MALIGNANT TRANSFORMATION; TYROSINE PHOSPHORYLATION	Cell lines that no longer require exogenous interleukin 3 (IL-3) for growth were isolated from an IL-3-dependent cell tine that possesses characteristics of early lymphoid cells. Unlike the parental cells (FL5.12), these autocrine transformed lines (FL-IL3-R) constitutively secreted IL-3, were rearranged at the IL-3 locus and formed tumors upon injection into syngeneic mice. The rearrangement and IL-3 expression resulted from the transposition of an intracisternal A particle (IAP) provirus into the 3' untranslated region of the IL-3 gene. This region contained ATTTA sequence motifs that have been associated with cytokine and oncogene mRNA instability. IL-3 transcripts from the autocrine transformed cell lines had a longer half-life than similar transcripts isolated from either phorbol ester-stimulated T cells or the WEHI-3B myelomonocytic cell line. IAP proviral transposition did not alter the transcription rate of the IL-3 gene in FL-IL3-R cells. Therefore, IAP proviral transposition can activate IL-3 gene expression by prolonging mRNA stability, and this mechanism can contribute to the autocrine transformation of the hemopoietic cells.	E CAROLINA UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,GREENVILLE,NC 27858	University of North Carolina; East Carolina University				McCubrey, James/0000-0001-6027-3156	NCI NIH HHS [R01 CA51025] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051025] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BARLOW DP, 1987, EMBO J, V6, P617, DOI 10.1002/j.1460-2075.1987.tb04799.x; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLANKENSTEIN T, 1990, J EXP MED, V171, P965, DOI 10.1084/jem.171.3.965; BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; BROWDER TM, 1989, MOL CELL BIOL, V9, P204, DOI 10.1128/MCB.9.1.204; BROWN MA, 1987, CELL, V50, P809, DOI 10.1016/0092-8674(87)90339-4; CAMPBELL HD, 1985, EUR J BIOCHEM, V150, P297, DOI 10.1111/j.1432-1033.1985.tb09020.x; CANAANI E, 1983, P NATL ACAD SCI-BIOL, V80, P7118, DOI 10.1073/pnas.80.23.7118; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY RJ, 1985, NUCLEIC ACIDS RES, V13, P289, DOI 10.1093/nar/13.1.289; CHRISTY RJ, 1988, MOL CELL BIOL, V8, P1093, DOI 10.1128/MCB.8.3.1093; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DUHRSEN U, 1990, EMBO J, V9, P1087, DOI 10.1002/j.1460-2075.1990.tb08214.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERRIS DK, 1988, BIOCHEM BIOPH RES CO, V154, P991, DOI 10.1016/0006-291X(88)90237-9; FUNG MC, 1984, NATURE, V307, P233, DOI 10.1038/307233a0; GOUGH NM, 1985, EMBO J, V4, P645, DOI 10.1002/j.1460-2075.1985.tb03678.x; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HAPEL AJ, 1986, LYMPHOKINE RES, V5, P249; HAWLEY RG, 1984, MOL CELL BIOL, V4, P2565, DOI 10.1128/MCB.4.12.2565; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; HOROWITZ M, 1984, EMBO J, V3, P2937, DOI 10.1002/j.1460-2075.1984.tb02235.x; Ihle J N, 1989, Year Immunol, V5, P59; IHLE JN, 1987, J IMMUNOL, V138, P3051; ISFORT R, 1988, J BIOL CHEM, V263, P19203; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; KONGSUWAN K, 1989, NUCLEIC ACIDS RES, V17, P1881, DOI 10.1093/nar/17.5.1881; KONO T, 1990, P NATL ACAD SCI USA, V87, P1806, DOI 10.1073/pnas.87.5.1806; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; LESLIE KB, 1991, MOL CELL BIOL, V11, P5562, DOI 10.1128/MCB.11.11.5562; Maniatis T., 1982, MOL CLONING; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; MCCUBREY J, 1989, ONCOGENE RES, V4, P97; MCCUBREY J, 1983, J VIROL, V45, P950, DOI 10.1128/JVI.45.3.950-955.1983; MCCUBREY JA, 1990, BLOOD, V76, P63; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; MIETZ JA, 1992, MOL CELL BIOL, V12, P220, DOI 10.1128/MCB.12.1.220; MIETZ JA, 1987, J VIROL, V61, P3020, DOI 10.1128/JVI.61.10.3020-3029.1987; MIYATAKE S, 1985, P NATL ACAD SCI USA, V82, P316, DOI 10.1073/pnas.82.2.316; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MURATANI K, 1991, P NATL ACAD SCI USA, V88, P11315, DOI 10.1073/pnas.88.24.11315; OVERELL RW, 1987, MOL CELL BIOL, V7, P3394, DOI 10.1128/MCB.7.10.3394; PALACIOS R, 1984, NATURE, V309, P126, DOI 10.1038/309126a0; PARNES JR, 1982, CELL, V29, P661, DOI 10.1016/0092-8674(82)90182-9; PAYNE GS, 1982, NATURE, V295, P209, DOI 10.1038/295209a0; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRADER JW, 1986, ANNU REV IMMUNOL, V4, P205, DOI 10.1146/annurev.iy.04.040186.001225; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; SUGITA T, 1990, J EXP MED, V171, P2001, DOI 10.1084/jem.171.6.2001; TOHYAMA K, 1990, EMBO J, V9, P1823, DOI 10.1002/j.1460-2075.1990.tb08307.x; VANBEVEREN C, 1980, P NATL ACAD SCI-BIOL, V77, P3307; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; WHEELER EF, 1987, MOL CELL BIOL, V7, P1673, DOI 10.1128/MCB.7.5.1673; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0; YMER S, 1986, NUCLEIC ACIDS RES, V14, P5901, DOI 10.1093/nar/14.14.5901; 1991, PROMEGA PROTOCOLS AP, P90	73	43	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1221	1232						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479745				2022-12-28	WOS:A1993KY32800013
J	STACKER, SA; HOVENS, CM; VITALI, A; PRITCHARD, MA; BAKER, E; SUTHERLAND, GR; WILKS, AF				STACKER, SA; HOVENS, CM; VITALI, A; PRITCHARD, MA; BAKER, E; SUTHERLAND, GR; WILKS, AF			MOLECULAR-CLONING AND CHROMOSOMAL LOCALIZATION OF THE HUMAN HOMOLOG OF A RECEPTOR RELATED TO TYROSINE KINASES (RYK)	ONCOGENE			English	Article							DEPENDENT PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; MILLER-DIEKER SYNDROME; CATALYTIC SUBUNIT; CONSERVED FEATURES; CDNA CLONES; CELL-LINE; LOCALIZATION; SEQUENCE; GENE	A cDNA encoding the human homologue of mouse RYK (related to receptor tyrosine kinases) has been cloned from an interleukin 1 (IL-1)-stimulated human hepatoma cDNA library by cross-species hybridization using the mouse RYK cDNA as a probe. The sequence of the 3067-bp cDNA clone encoding human RYK predicts a transmembrane protein with a cytoplasmic domain that contains the consensus sequences (subdomains I-XI) of the protein tyrosine kinase (PTK) family. The highly conserved motif -D-F-G- (subdomain VII) of the catalytic domain of other receptor-type tyrosine kinases is altered to -D-N-A- in human RYK. In addition, a number of other changes were found in the ATP binding site (subdomains I and II) and the motif [-I-H-R-D-L-A-A-R-N-] found in subdomain VI. Comparison of the human and mouse RYK sequences shows a 92% conservation at the nucleotide level and 97% at the amino acid level. There was no significant homology between the extracellular domain of RYK and the other families of receptor tyrosine kinases described to date. RYK therefore appears to define a new subclass of receptor-type tyrosine kinases whose structure has remained highly conserved across species.	LUDWIG INST CANC RES, MELBOURNE TUMOUR BIOL BRANCH, PO ROYAL MELBOURNE HOSP, PARKVILLE, VIC 3050, AUSTRALIA; WOMENS & CHILDRENS HOSP, DEPT CYTOGENET & MOLEC GENET, ADELAIDE, SA 5006, AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Womens & Childrens Hospital Australia			Wilks, Andrew F/R-5542-2019; Sutherland, Grant Robert/D-2606-2012	Hovens, Christopher/0000-0002-0610-1289; Wilks, Andrew F/0000-0002-8554-2399; Stacker, Steven/0000-0003-4096-9273				ADAMS RA, 1968, CANCER RES, V28, P1121; BUECHLER JA, 1989, BIOCHEMISTRY-US, V28, P3018, DOI 10.1021/bi00433a042; CALLEN DF, 1992, GENOMICS, V13, P1178, DOI 10.1016/0888-7543(92)90035-Q; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; CHOU YH, 1991, P NATL ACAD SCI USA, V88, P4897, DOI 10.1073/pnas.88.11.4897; DEMMER LA, 1987, J BIOL CHEM, V262, P2458; DOBYNS WB, 1991, AM J HUM GENET, V48, P584; EIPERS PG, 1991, GENOMICS, V11, P621, DOI 10.1016/0888-7543(91)90069-Q; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HOVENS CH, 1962, P NATL ACAD SCI USA, V89, P11818; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOSIK KS, 1988, NEURON, V1, P127, DOI 10.1016/0896-6273(88)90196-1; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KWIATKOWSKI DJ, 1990, AM J HUM GENET, V46, P559; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMHONWAH AM, 1986, P NATL ACAD SCI USA, V83, P4864, DOI 10.1073/pnas.83.13.4864; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MORAN MF, 1988, ONCOGENE, V3, P665; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; SAMBROK J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; STARK KL, 1991, DEVELOPMENT, V113, P641; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WHITEHEAD RH, 1987, CANCER RES, V47, P2683; WILKS AF, 1988, ONCOGENE, V3, P289; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLKS AF, 1992, ADV CANCER RES, V60, P43; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZABEL BU, 1983, P NATL ACAD SCI-BIOL, V80, P6932, DOI 10.1073/pnas.80.22.6932	40	40	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1347	1356						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8386829				2022-12-28	WOS:A1993KY32800028
J	MOLES, JP; MOYRET, C; GUILLOT, B; JEANTEUR, P; GUILHOU, JJ; THEILLET, C; BASSETSEGUIN, N				MOLES, JP; MOYRET, C; GUILLOT, B; JEANTEUR, P; GUILHOU, JJ; THEILLET, C; BASSETSEGUIN, N			P53-GENE MUTATIONS IN HUMAN EPITHELIAL SKIN CANCERS	ONCOGENE			English	Article							RAS GENE; ONCOGENE; HETEROZYGOSITY; AMPLIFICATION; PROGRESSION; SPECIFICITY; CARCINOMAS; CELLS	In the present study we analysed 38 epithelial skin cancers, 19 basal cell carcinomas (BCCs), 13 squamous cell carcinomas (SCCs) and six Bowen diseases (BwDs), using a combination of polymerase chain reaction (PCR) and single-stranded conformation polymorphism (SSCP) techniques for the presence of p53 and RAS gene mutations. Whereas 48% (9/19) of the BCCs tested presented a mutated p53 gene, the frequency was lower (15%, 2/13) in our series of SCCs and negatve in the BwDs. Nine of the 11 characterized mutations were single-nucleotide substitutions and, interestingly, seven of these involved CC dimers, where a C was changed into a T or a G (three C-->T transitions and four C-->G transversions). This mutational pattern, added to the fact that all the mutated tumors occurred at sun-exposed body sites, implicates UV light in their genesis. Furthermore, we observed two internal deletions of 6 and 24 bp whose flanking sequences contained two or three Cs on either strand. In addition to molecular detection, we searched for p53 protein accumulation, by immunocytochemical staining, in a subset of 23 epithelial skin tumors (nine bearing a mutation, 14 which scored negative in our assay). Three commercially available anti-p53 antibodies (PAb CM1, mAbs DO7 and 1801) were used, and 3/23 (all showing a mutated p53 gene) presented specific nuclear staining. In contrast to other reported data we could not detect any activating RAS gene mutation in our series of human skin cancers.	CNRS,CRBM,DERMATOL MOLEC LAB,BP 5051,ROUTE DE MENDE,F-34033 MONTPELLIER,FRANCE; UNIV MONTPELLIER 2,CNRS,URA 1191,F-34095 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier			Theillet, Charles/O-7634-2018; Molès, Jean-Pierre/M-2286-2017	Molès, Jean-Pierre/0000-0002-6863-6350; Theillet, Charles/0000-0001-5555-2759				ADNANE J, 1989, ONCOGENE, V4, P1389; BENNETT WP, 1991, ONCOGENE, V6, P1779; BIANCHI AB, 1991, P NATL ACAD SCI USA, V88, P7590, DOI 10.1073/pnas.88.17.7590; Brash D., 1991, P NATL ACAD SCI USA, V88, P1012; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BURNS PA, 1991, ONCOGENE, V6, P2363; CARBONE D, 1991, NUCLEIC ACIDS RES, V6, P1691; CHEN LC, 1992, J NATL CANCER I, V84, P506, DOI 10.1093/jnci/84.7.506; COTSARELIS G, 1989, CELL, V57, P201, DOI 10.1016/0092-8674(89)90958-6; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DROBETSKY EA, 1987, P NATL ACAD SCI USA, V84, P9103, DOI 10.1073/pnas.84.24.9103; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GLASS AG, 1989, JAMA-J AM MED ASSOC, V262, P2097, DOI 10.1001/jama.262.15.2097; GREENHALGH DA, 1989, MOL CARCINOGEN, V2, P199, DOI 10.1002/mc.2940020406; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUSAIN Z, 1990, ARCH DERMATOL, V126, P324, DOI 10.1001/archderm.126.3.324; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; MAZARS GR, 1992, ONCOGENE, V7, P781; MAZARS R, 1991, ONCOGENE, V6, P1685; MCGREGOR WG, 1991, MOL CELL BIOL, V11, P1927, DOI 10.1128/MCB.11.4.1927; MILLER JH, 1985, J MOL BIOL, V182, P45, DOI 10.1016/0022-2836(85)90026-9; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P445, DOI 10.1002/mc.2940040606; PORTIER M, 1992, IN PRESS ONCOGENE; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SOUSSI T, 1990, ONCOGENE, V5, P945; SPINARDI L, 1991, NUCLEIC ACIDS RES, V19, P4009, DOI 10.1093/nar/19.14.4009; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; VANDERSCHROEFF JG, 1990, J INVEST DERMATOL, V94, P423, DOI 10.1111/1523-1747.ep12874504	29	194	195	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					583	588						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437842				2022-12-28	WOS:A1993KN00800008
J	LEE, MS; YANG, JH; SALEHI, Z; ARNSTEIN, P; CHEN, LS; JAY, G; RHIM, JS				LEE, MS; YANG, JH; SALEHI, Z; ARNSTEIN, P; CHEN, LS; JAY, G; RHIM, JS			NEOPLASTIC TRANSFORMATION OF A HUMAN KERATINOCYTE CELL-LINE BY THE V-FOS ONCOGENE	ONCOGENE			English	Article							OSTEO-SARCOMA VIRUS; HUMAN EPIDERMAL-KERATINOCYTES; PROTO-ONCOGENE; TRANSCRIPTION; EXPRESSION; PRODUCT; ACID; DNA; CARCINOMA; LEUKEMIAS	To analyze the role of the fos oncogene in the growth of human epithelial cells, we have transfected a nontumorigenic human epidermal keratinocyte line (RHEK1) immortalized by the Ad12-SV40 hybrid virus with a plasmid carrying the v-fos gene together with plasmid pSV2-neo which confers resistance to neomycin. Individual neomycin-resistant clones were isolated and characterized with respect to morphological alteration. Of 16 independent clones analyzed, two appeared morphologically transformed and formed foci in culture. Only the two clones with a transformed phenotype were found by Southern blot hybridization analysis to contain the transfected v-fos gene. These clones formed colonies in soft agar and induced tumors when transplanted into nude mice. Analysis of fos specific mRNA and protein demonstrated that the transfected v-fos gene was expressed in these two clonal lines. These findings suggest that expression of the v-fos gene might facilitate the process of neoplastic transformation of human epithelial cells in culture. This appears to represent the first demonstration of the transforming potential of the v-fos gene in human cells.	NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; JEROME H HOLLAND LAB, VIROL LAB, ROCKVILLE, MD 20855 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Jay, Gregory/C-6346-2013					BANKSSCHLEGEL SP, 1983, J CELL BIOL, V96, P330, DOI 10.1083/jcb.96.2.330; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; CURRAN T, 1984, CELL, V36, P259; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FINKEL MP, 1966, SCIENCE, V151, P698, DOI 10.1126/science.151.3711.698; FINKEL MP, 1973, 24TH P S COLST RES S, V24, P353; FINKEL MP, 1975, FRONTIERS RADIATION, V10, P28; GANTT R, 1987, CANCER RES, V47, P1390; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENHALGH DA, 1988, MOL CARCINOGEN, V1, P134, DOI 10.1002/mc.2940010209; GREENHALGH DA, 1990, P NATL ACAD SCI USA, V87, P643, DOI 10.1073/pnas.87.2.643; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; JENUWEIN T, 1985, CELL, V41, P629, DOI 10.1016/S0092-8674(85)80035-0; KHARBANDA S, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P23; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; LEE CK, 1979, P SOC EXP BIOL MED, V162, P214, DOI 10.3181/00379727-162-40650; LEVY JA, 1978, J VIROL, V26, P11, DOI 10.1128/JVI.26.1.11-15.1978; LEVY JA, 1973, J NATL CANCER I, V51, P525; MAVILIO F, 1987, BLOOD, V69, P160; MILLER AD, 1985, J VIROL, V55, P521, DOI 10.1128/JVI.55.3.521-526.1985; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MULLER R, 1985, BIOCHIM BIOPHYS ACTA, V823, P207; PINTO A, 1987, BLOOD, V70, P1450; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; RHIM JS, 1989, ONCOGENE, V4, P1403; RHIM JS, 1981, P NATL ACAD SCI-BIOL, V78, P313, DOI 10.1073/pnas.78.1.313; RHIM JS, 1969, P SOC EXP BIOL MED, V132, P1091; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; SKOUV J, 1986, CARCINOGENESIS, V7, P331, DOI 10.1093/carcin/7.2.331; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TERRIER P, 1988, BRIT J CANCER, V57, P43, DOI 10.1038/bjc.1988.6; VERMA IM, 1986, TRENDS GENET, V2, P93, DOI 10.1016/0168-9525(86)90191-5; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; VERMA IM, 1987, ADV CANCER RES, V49, P29, DOI 10.1016/S0065-230X(08)60793-9	40	14	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					387	393						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426745				2022-12-28	WOS:A1993KN00600018
J	Mai, S; HanleyHyde, J; Fluri, M				Mai, S; HanleyHyde, J; Fluri, M			c-Myc overexpression associated DHFR gene amplification in hamster, rat, mouse and human cell lines	ONCOGENE			English	Article						c-Myc deregulation; DHFR; genomic instability	DIHYDROFOLATE-REDUCTASE GENE; WILD-TYPE P53; DNA AMPLIFICATION; METHOTREXATE RESISTANCE; SV40 REPLICATION; CANCER; CYCLE; TRANSCRIPTION; EXPRESSION; ONCOGENES	We have analysed relative DHFR gene copy numbers in nine cell fines of various cell type and species origins. The cells studied expressed either low, low and inducible or constitutively elevated levels of c-Myc protein. DHFR gene amplification was observed only when c-Myc protein levels were upregulated. The amplification of the DHFR gene was transient in inducible cell Lines. Cell lines exhibiting constitutively deregulated c-Myc protein levels, however, showed both DHFR gene amplification and ongoing rearrangements of the DHFR locus. In contrast, the relative gene copy numbers of ribonucleotide reductase R1 subunit, ornithine decarboxylase, syndecan 2, glyceraldehyde-3-phosphate-dehydrogenase and cyclin C remained unaffected irrespective of c-Myc protein levels, suggesting a locus-specific genomic instability of the DHFR gene in cells with deregulated c-Myc protein levels. Overall, the results of the present study support the notion that DHFR gene amplification as a consequence of c-Myc deregulation may occur in a variety of cell lines irrespective of their cell type and species origins.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92837 USA	Scripps Research Institute	Mai, S (corresponding author), BASEL INST IMMUNOL, GRENZACHERSTR 487, CH-4005 BASEL, SWITZERLAND.		Mai, Sabine/E-5667-2017	Mai, Sabine/0000-0002-5797-2201				AHNEN DJ, 1992, CELL BIOCH S G, V16, P143; ALITALO K, 1985, TRENDS BIOCHEM SCI, V10, P194, DOI 10.1016/0968-0004(85)90190-2; ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENEVISTY N, 1992, GENE DEV, V6, P2513; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOURHIS J, 1991, CANCER RES, V51, P33; CHANG ACY, 1978, NATURE, V275, P617, DOI 10.1038/275617a0; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; CLASSON M, 1993, GENE, V133, P153, DOI 10.1016/0378-1119(93)90633-E; CLASSON M, 1990, ONCOGENE, V5, P1371; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DELIDAKIS C, 1989, EMBO J, V8, P891, DOI 10.1002/j.1460-2075.1989.tb03450.x; DENIS N, 1991, ONCOGENE, V6, P1453; DIJKWEL PA, 1994, NUCLEIC ACIDS RES, V22, P4989, DOI 10.1093/nar/22.23.4989; ECKHARDT SG, 1994, P NATL ACAD SCI USA, V91, P6674, DOI 10.1073/pnas.91.14.6674; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FEO S, 1994, ONCOGENE, V9, P955; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HUANG AP, 1994, EXP CELL RES, V213, P335, DOI 10.1006/excr.1994.1207; HUANG AP, 1995, CANCER RES, V55, P1758; HUANG AP, 1994, ONCOGENE, V9, P491; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KAHANA C, 1985, P NATL ACAD SCI USA, V82, P1673, DOI 10.1073/pnas.82.6.1673; KARN J, 1989, ONCOGENE, V4, P773; LAVI S, 1981, P NATL ACAD SCI-BIOL, V78, P6144, DOI 10.1073/pnas.78.10.6144; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Luecke-Huhle Christine, 1994, Carcinogenesis (Oxford), V15, P695; LUECKEHUHLE C, 1990, INT J RADIAT BIOL, V58, P577; LUECKEHUHLE C, 1989, MOL TOXICOL, V2, P237; MA C, 1990, MOL CELL BIOL, V10, P1338, DOI 10.1128/MCB.10.4.1338; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; MAI S, 1990, UCLA SYM BI, V136, P319; MAI S, 1995, GENOME, V38, P780, DOI 10.1139/g95-099; MAI S, 1994, GENE, V148, P253, DOI 10.1016/0378-1119(94)90696-3; MAI S, 1994, NUCLEIC ACIDS RES, V22, P2264, DOI 10.1093/nar/22.12.2264; MAI S, 1995, NUCLEIC ACIDS RES, V23, P1, DOI 10.1093/nar/23.1.1; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARIANI BD, 1984, J BIOL CHEM, V259, P1901; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; OTTO E, 1989, J BIOL CHEM, V264, P3390; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PIERCE A, 1992, J BIOL CHEM, V267, P3894; POTTER M, 1992, CARCINOGENESIS, V13, P1681, DOI 10.1093/carcin/13.10.1681; PRODY CA, 1989, P NATL ACAD SCI USA, V86, P690, DOI 10.1073/pnas.86.2.690; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Sambrook J, 1989, MOL CLONING LABORATO; SANTELLI RV, 1991, MECH DEVELOP, V36, P59, DOI 10.1016/0925-4773(91)90072-E; SCHIMKE RT, 1978, SCIENCE, V202, P1051, DOI 10.1126/science.715457; SHAH DM, 1986, SCIENCE, V233, P478, DOI 10.1126/science.233.4762.478; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STARK GR, 1993, ADV CANCER RES, V61, P87, DOI 10.1016/S0065-230X(08)60956-2; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; TEMIN HM, 1988, CANCER RES, V48, P1697; THELANDER L, 1986, MOL CELL BIOL, V6, P3433, DOI 10.1128/MCB.6.10.3433; TLSTY TD, 1990, P NATL ACAD SCI USA, V87, P3132, DOI 10.1073/pnas.87.8.3132; TLSTY TD, 1989, P NATL ACAD SCI USA, V86, P9441, DOI 10.1073/pnas.86.23.9441; TLSTY TD, 1984, MOL CELL BIOL, V4, P1050, DOI 10.1128/MCB.4.6.1050; VAUGHN JP, 1990, CELL, V61, P1075, DOI 10.1016/0092-8674(90)90071-L; WAHL GM, 1989, CANCER RES, V49, P1333; WEINBERG RA, 1989, CANCER RES, V49, P3713; WOLFFE AP, 1991, J CELL SCI, V99, P210; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; YALKINOGLU AO, 1991, J VIROL, V65, P3175, DOI 10.1128/JVI.65.6.3175-3184.1991; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	75	82	85	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					277	288						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570205				2022-12-28	WOS:A1996TR53800007
J	Waber, PG; Lee, NK; Nisen, PD				Waber, PG; Lee, NK; Nisen, PD			Frequent allelic loss at chromosome arm 3p is distinct from genetic alterations of the Von-Hippel Lindau tumor suppressor gene in head and neck cancer	ONCOGENE			English	Article						Von-Hippel Lindau Syndrome; chromosome 3; loss of heterozygosity; head and neck cancer	SQUAMOUS-CELL CARCINOMAS; UPPER AERODIGESTIVE TRACT; P53 MUTATIONS; DISEASE GENE; IDENTIFICATION; POLYMORPHISMS; LINES	Previous molecular genetic studies revealed that allelic loss of chromosome arm 3p is a frequent event in upper aerodigestive tract squamous cell carcinoma (UADT SCC), Recently, the Von-Hippel Lindau (VHL) tumor suppressor gene was identified at chromosome band 3p25-26. To determine if the VHL locus is altered in these tumors, a paired series of 26 tumors and blood from patients with UADT SCC that were previously shown to exhibit allelic loss of 3p were tested for LOH surrounding the VHL locus using four different polymorphic markers, All of the samples (100%) exhibited LOH for at least 1 marker, However, no LOH was detected using a polymorphism within exon 1 of the VHL gene which was informative for 18 of the 26 cases, Furthermore, mutations of the VHL gene could not be identified by single-strand conformation polymorphism, dideoxyfingerprint or direct DNA sequence analysis, In addition, the VHL gene was not inactivated by hypermethylation in any of the 26 tumor samples studied, These findings demonstrate that allelic loss of chromosome arm 3p in UADT SCC involves regions surrounding the VHL locus but does not include the VHL gene, The VHL gene, therefore, does not appear to be involved in the pathogenesis of UADT SCC.	UNIV TEXAS, SW MED CTR, DEPT PEDIAT, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT OTOLARYNGOL HEAD & NECK SURG, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								BARDENHEUER W, 1994, GENOMICS, V19, P291, DOI 10.1006/geno.1994.1060; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; BURNS JE, 1993, BRIT J CANCER, V67, P1274, DOI 10.1038/bjc.1993.238; CHUNG KY, 1993, CANCER RES, V53, P1676; CROSSEY PA, 1994, HUM GENET, V93, P53; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GLAVAC D, 1993, HUM MUTAT, V2, P404, DOI 10.1002/humu.1380020513; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HOSOE S, 1990, GENOMICS, V8, P634, DOI 10.1016/0888-7543(90)90249-T; Jones Michael H., 1992, Human Molecular Genetics, V1, P131, DOI 10.1093/hmg/1.2.131; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEE NK, 1994, INT J ONCOL, V5, P205; LEE NK, 1994, ONCOL REP, V1, P637; LEE NK, 1993, ARCH OTOLARYNGOL, V119, P1125; LI H, 1993, HUM MOL GENET, V2, P1326, DOI 10.1093/hmg/2.8.1326; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; MAESTRO R, 1993, CANCER RES, V53, P5775; NAWROZ H, 1994, CANCER RES, V54, P1152; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; RICHARDS FM, 1993, HUM MOL GENET, V2, P879, DOI 10.1093/hmg/2.7.879; Sambrook J, 1989, MOL CLONING LABORATO; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; SEKIDO Y, 1994, ONCOGENE, V9, P1599; SHUIN T, 1994, CANCER RES, V54, P2852; SOMERS KD, 1992, CANCER RES, V52, P5997; VANDERRIET P, 1994, CANCER RES, V54, P1156; WABER PG, 1993, CANCER RES, V53, P6028; WEBER JL, 1989, AM J HUM GENET, V44, P388; WU CL, 1994, CANCER RES, V54, P6484; YIN XY, 1993, INT J CANCER, V54, P322, DOI 10.1002/ijc.2910540226	32	36	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	1996	12	2					365	369						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570213				2022-12-28	WOS:A1996TR53800015
J	Patel, AM; Incognito, LS; Schechter, GL; Wasilenko, WJ; Somers, KD				Patel, AM; Incognito, LS; Schechter, GL; Wasilenko, WJ; Somers, KD			Amplification and expression of EMS-1 (cortactin) in head and neck squamous cell carcinoma cell lines	ONCOGENE			English	Article						cortactin; amplification; head and neck cancer	BREAST-CANCER; CYCLIN D1; GENES; SUBSTRATE; ONCOGENE; IDENTIFICATION; INT-2; ABNORMALITIES; CLONING; REGION	Amplification of chromosome 11q13 DNA sequences is detected in approximately 30% of primary head and neck squamous cell carcinomas (HNSCC). The amplified region includes genes for cyclin D1, hst-1, int-2, and more recently, ems-1, Ems-1 encodes an 80/85kd cytoskeletal associated protein termed cortactin, which has been shown to bind F-actin and is a pp60src substrate. We investigated 16 HNSCC cell Lines for ems-1 DNA amplification and gene expression by western blotting and immunofluorescence using mAb 4F11. Amplification of ems-1 DNA was detected in 8/16 (50%) cell lines and was related directly to overexpression of cortactin by western blotting and immunofluorescence, Western blotting detected both forms of cortactin, p80 and p85, at equal intensity. Immunofluorescent staining revealed low levels of cortactin localized to the cytoplasm and surface membrane in normal bronchial epithelial cells and tumor cell cultures with single copy ems-1 DNA. In contrast, tumor cell cultures with ems-1 DNA amplification demonstrated intense, homogeneous cortactin cytoplasmic staining. These results suggest that overexpression of p80/85 may be a useful marker to identify 11q13 amplification, a molecular alteration correlated with the presence of lymph node metastasis in head and neck cancer.	EASTERN VIRGINIA MED SCH,DEPT MICROBIOL & IMMUNOL,NORFOLK,VA 23501; EASTERN VIRGINIA MED SCH,DEPT OTOLARYNGOL HEAD & NECK SURG,NORFOLK,VA 23501; EASTERN VIRGINIA MED SCH,HEAD & NECK TUMOR BIOL PROGRAM,NORFOLK,VA 23501	Eastern Virginia Medical School; Eastern Virginia Medical School; Eastern Virginia Medical School								ADELAIDE J, 1988, ONCOGENE, V2, P413; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; Field J K, 1992, Eur J Cancer B Oral Oncol, V28B, P67, DOI 10.1016/0964-1955(92)90016-T; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P430; LOVEC H, 1994, ONCOGENE, V9, P323; MAA MC, 1992, ONCOGENE, V7, P2429; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER D, 1994, ORAL ONCOL, V30B, P113; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11576, DOI 10.1073/pnas.91.24.11576; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1992, CANCER RES, V52, P5229; SCHUURING E, 1992, ONCOGENE, V7, P355; SOMERS KD, 1992, CANCER RES, V52, P5997; SOOD AK, 1981, P NATL ACAD SCI-BIOL, V78, P616, DOI 10.1073/pnas.78.1.616; TSUDA T, 1989, CANCER RES, V49, P5505; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; XU L, 1994, INT J CANCER, V59, P383, DOI 10.1002/ijc.2910590316; ZHAN X, 1993, J BIOL CHEM, V268, P24427	33	53	56	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					31	35						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552396				2022-12-28	WOS:A1996TQ01400004
J	Wieland, I; Bohm, M; Arden, KC; Ammermuller, T; Bogatz, S; Viars, CS; Rajewsky, MF				Wieland, I; Bohm, M; Arden, KC; Ammermuller, T; Bogatz, S; Viars, CS; Rajewsky, MF			Allelic deletion mapping on chromosome 5 in human lung carcinomas	ONCOGENE			English	Article						microdissection; PCR-SSCP; microsatellite markers; APC; del-27; tumor suppressor gene	POLYMERASE CHAIN-REACTION; SQUAMOUS-CELL CARCINOMA; TUMOR-SUPPRESSOR GENE; DIFFERENCE CLONING; HUMAN DNA; CANCER; HYBRIDIZATION; P53; HETEROZYGOSITY; ADENOCARCINOMA	We analysed allelic deletions on chromosome 5 in microdissected human non-small cell lung cancers. Thirty-four primary squamous cell carcinomas, 15 primary adenocarcinomas and five regional lymph node metastases were investigated for loss of heterozygosity (LOH) in chromosomal region 5p15-q21. The sites analysed included the APC tumor suppressor gene at 5q21, five polymorphic microsatellite markers and the putative tumor suppressor locus del-27, that was assigned to chromosomal region 5p13-12 by fluorescence in situ hybridization (FISH) analysis. Allelic deletions encompassed larger genomic regions more often in squamous cell carcinomas than in adenocarcinomas. The del-27 amd APC regions were identified as two distinct regions with the highest LOH frequencies within 5p15-q21. In squamous cell carcinomas LOH frequencies were 73% at the del-27 and 70% at the APC locus. In adenocarcinomas LOH at the del-27 and APC loci occurred in 38% of the informative cases. Allelic deletion of the APC gene and at the del-27 locus was also detected in the metastases. The results suggest involvement of at least two tumor suppressor genes on chromosome 5 in lung tumorigenesis.	UNIV ESSEN GESAMTHSCH,SCH MED,INST CELL BIOL CANC RES,D-45122 ESSEN,GERMANY; UNIV CALIF SAN DIEGO,DEPT MED,LUDWIG INST CANC RES,LA JOLLA,CA 92093	University of Duisburg Essen; Ludwig Institute for Cancer Research; University of California System; University of California San Diego	Wieland, I (corresponding author), UNIV ESSEN GESAMTHSCH,SCH MED,INST CELL BIOL CANC RES,VIRCHOWSTR 173,D-45122 ESSEN,GERMANY.			Wieland, Ilse/0000-0002-8017-3029				AHSEE KW, 1994, CANCER RES, V54, P1617; ALLAN GJ, 1994, HUM MUTAT, V3, P283, DOI 10.1002/humu.1380030317; ASHTONRICKARDT PG, 1991, ONCOGENE, V6, P1881; BOHM M, 1994, CLIN EXP METASTAS, V12, P55, DOI 10.1007/BF01784334; BOHM M, 1993, CANCER GENET CYTOGEN, V65, P83, DOI 10.1016/0165-4608(93)90211-4; BOS JL, 1989, CANCER RES, V49, P4682; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; DALY MC, 1993, ONCOGENE, V8, P1721; DAMICO D, 1992, CANCER RES, V52, P1996; FONG KM, 1995, CANCER RES, V55, P220; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HENSEL CH, 1990, CANCER RES, V50, P3067; HORII A, 1992, CANCER RES, V52, P6696; HOSOE S, 1994, CANCER RES, V54, P1787; JACKY PB, 1991, ACT CYTOGENETICS LAB, P89; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; KOK K, 1994, CANCER RES, V54, P4183; LEMIEUX N, 1992, CYTOGENET CELL GENET, V59, P311, DOI 10.1159/000133277; LOEB LA, 1994, CANCER RES, V54, P5059; MERLO A, 1994, CANCER RES, V54, P640; MIURA I, 1992, CANCER RES, V52, P1322; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PELTOMAKI P, 1993, CANCER RES, V53, P5853; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; POWELL SM, 1994, GASTROENTEROLOGY, V107, P1759, DOI 10.1016/0016-5085(94)90818-4; RIED T, 1994, CANCER RES, V54, P1801; RODRIGUEZ E, 1994, CANCER RES, V54, P3398; Sambrook J, 1989, MOL CLONING LABORATO; SATO S, 1994, CANCER RES, V54, P5652; SHAPIRO GI, 1995, CANCER RES, V55, P505; SHISEKI M, 1994, CANCER RES, V54, P5643; SPEICHER MR, 1995, CANCER RES, V55, P1010; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TESTA JR, 1993, CANCER DETECT PREV, V17, P267; TSUCHIYA E, 1992, CANCER RES, V52, P2478; WASHIMI O, 1995, CANCER RES, V55, P514; WEBER JL, 1989, AM J HUM GENET, V44, P388; WHANGPENG J, 1991, GENE CHROMOSOME CANC, V3, P168, DOI 10.1002/gcc.2870030303; White B. A., 1993, PCR PROTOCOLS CURREN; WIELAND I, 1990, P NATL ACAD SCI USA, V87, P2720, DOI 10.1073/pnas.87.7.2720; WIELAND I, 1994, CANCER RES, V54, P1772; WIELAND I, 1992, P NATL ACAD SCI USA, V89, P9705, DOI 10.1073/pnas.89.20.9705; WLODARSKA I, 1994, CYTOGENET CELL GENET, V65, P179, DOI 10.1159/000133627; YOKOYAMA S, 1992, CANCER RES, V52, P873	47	47	52	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					97	102						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552404				2022-12-28	WOS:A1996TQ01400012
J	FORSTER, A; RABBITTS, TH				FORSTER, A; RABBITTS, TH			A METHOD FOR IDENTIFYING GENES WITHIN YEAST ARTIFICIAL CHROMOSOMES - APPLICATION TO ISOLATION OF MLL FUSION CDNAS FROM ACUTE-LEUKEMIA TRANSLOCATIONS	ONCOGENE			English	Article							HUMAN ACUTE-LEUKEMIA; DROSOPHILA-TRITHORAX; SELECTION; 11Q23; REARRANGEMENT; REGIONS; PROBES	The majority of chromosomal translocations breakpoints are within regions of the genome where few DNA probes are available. The use of yeast artificial chromosomes (YACs) containing long stretches of human DNA allows dispersed DNA markers to be used to identify the position of breakpoints but does not readily allow subcloning of the precise breakpoint within the YAC DNA nor the cDNAs containing the affected genes. We describe a procedure allowing rapid isolation of cDNAs corresponding to genes within a YAC clone. Random cDNA is hybridised to PCR-generated biotinylated fragments of total DNA from a yeast strain harbouring a YAC clone. The hybrids can be recovered to facilitate subsequent cloning of the cDNA molecules. The application of this method to the cloning of cDNA molecules carrying sequences involved in the translocation t(4;11)(q21;q23) is illustrated.	MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology			Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; BARR FG, 1993, NAT GENET, V3, P133; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CORRAL J, 1993, P NATL ACAD SCI USA, V90, P8538, DOI 10.1073/pnas.90.18.8538; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; ELVIN P, 1990, NUCLEIC ACIDS RES, V18, P3913, DOI 10.1093/nar/18.13.3913; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Korn Bernhard, 1992, Human Molecular Genetics, V1, P235, DOI 10.1093/hmg/1.4.235; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MORGAN JG, 1992, NUCLEIC ACIDS RES, V20, P5173, DOI 10.1093/nar/20.19.5173; MORRISSEY J, 1993, BLOOD, V81, P1124; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RABBITTS TH, 1993, IN PRESS NATURE; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; STONG RC, 1985, BLOOD, V65, P21, DOI 10.1182/blood.V65.1.21.21; TAGLE DA, 1993, NATURE, V361, P751, DOI 10.1038/361751a0; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9	22	2	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3157	3160						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414518				2022-12-28	WOS:A1993MC09300033
J	WATANABE, M; MURAMATSU, MA; HIRAI, H; SUZUKI, T; FUJISAWA, J; YOSHIDA, M; ARAI, KI; ARAI, N				WATANABE, M; MURAMATSU, MA; HIRAI, H; SUZUKI, T; FUJISAWA, J; YOSHIDA, M; ARAI, KI; ARAI, N			HTLV-I ENCODED TAX IN ASSOCIATION WITH NF-KAPPA-B PRECURSOR P105 ENHANCES NUCLEAR-LOCALIZATION OF NF-KAPPA-B P50 AND P65 IN TRANSFECTED CELLS	ONCOGENE			English	Article							VIRUS TYPE-I; LONG TERMINAL REPEAT; TRANSCRIPTIONAL ACTIVATOR; BINDING-PROTEINS; TRANS-ACTIVATION; CDNA CLONES; LEUKEMIA; EXPRESSION; GENES; INDUCTION	NF-kappaB is a heterodimeric protein composed of two subunits, p50 and p65, and is sequestered in the cytoplasm as an inactive form through the association with an inhibitory protein, IkappaB. In the present study, the effect of HTLV-1 encoded Tax on the exogenously expressed NF-kappaB p105, which encodes a precursor of p50, was investigated using a COS-7 expression system. When p105 was expressed in COS-7 cells, the precursor p105 and the processed p50 were retained in the cytosolic fraction by associating each other, and p50 was not detected in the nuclear fraction. In the cells co-expressing p105 and Tax, the p50/p105 ratio in the cytosolic fraction reduced with an induction of p50 in the nuclear fraction, which gave rise to a significant increase in NF-kappaB binding activity. Enhancement of NF-kappaB binding activity was not observed by adenovirus encoded EIA and bovine papilloma virus encoded E2, and correlated well with the ability of Tax to associate with p105. When p105DELTAX which lacks the repeats of the ankyrin motif was expressed in this system, p105DELTAX and processed p50 were detected in the nuclear fraction and p50/p105DELTAX ratio was not affected by co-expression with Tax. In the same expression system, exogenously expressed NF-kappaB p65 was retained in the cytoplasm by p105 and further expression of Tax allowed entry of p65 in the nucleus. These results suggest that, in this model system, p105 acts as an IkappaB to sequester p50 and p65 in the cytoplasm and that Tax by inhibiting IkappaB activity of p105, enhances nuclear localization of p50 and p65. These findings raise a possibility for a novel mechanism for the induction of NF-kappaB in the nucleus by Tax.	UNIV TOKYO,INST MED SCI,DEPT MOLEC & DEV BIOL,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN; UNIV TOKYO,DEPT CELLULAR & MOLEC BIOL,TOKYO 108,JAPAN; DNAX INC,MOLEC & CELLULAR BIOL INST,DEPT MOLEC BIOL,PALO ALTO,CA 94304	University of Tokyo; University of Tokyo; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.								ARAI N, 1992, PHARMACOL THERAPEUT, V55, P303, DOI 10.1016/0163-7258(92)90054-4; ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; CRENON I, 1993, ONCOGENE, V8, P867; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA JI, 1991, J VIROL, V65, P4525, DOI 10.1128/JVI.65.8.4525-4528.1991; HEIKE T, 1989, EMBO J, V8, P1411, DOI 10.1002/j.1460-2075.1989.tb03522.x; HIRAI H, 1992, ONCOGENE, V7, P1737; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LINDHOLM P F, 1990, New Biologist, V2, P1034; LINDHOLM PF, 1992, J VIROL, V66, P1294, DOI 10.1128/JVI.66.3.1294-1302.1992; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OSAME M, 1986, LANCET, V1, P1031; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; Sambrook J, 1989, MOL CLONING LABORATO; SAWADA M, 1990, J VIROL, V64, P4002, DOI 10.1128/JVI.64.8.4002-4006.1990; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHURMAN L, 1989, J IMMUNOL, V143, P3806; SODROSKI JG, 1984, SCIENCE, V226, P177; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TSUBOI A, 1991, INT IMMUNOL, V3, P807, DOI 10.1093/intimm/3.8.807; WATANABE T, 1990, J EXP MED, V172, P759, DOI 10.1084/jem.172.3.759; YOKOTA T, 1985, P NATL ACAD SCI USA, V82, P68, DOI 10.1073/pnas.82.1.68; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIDA M, 1987, ANNU REV IMMUNOL, V5, P541, DOI 10.1146/annurev.iy.05.040187.002545; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	38	64	64	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2949	2958						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414497				2022-12-28	WOS:A1993MC09300008
J	FIORETOS, T; HEISTERKAMP, N; GROFFEN, J; BENJES, S; MORRIS, C				FIORETOS, T; HEISTERKAMP, N; GROFFEN, J; BENJES, S; MORRIS, C			CRK PROTOONCOGENE MAPS TO HUMAN-CHROMOSOME BAND 17P13	ONCOGENE			English	Note							BREAST-CANCER; GENE; P53; INVOLVEMENT; ALLELOTYPE; SH2	A genomic DNA fragment, isolated from a human phage library using a chicken crk cDNA probe, was shown to derive from the human CRK locus. We have used fluorescent in situ hybridization (FISH) to map CRK distal in chromosome band 17p13, a region which demonstrates frequent deletion or loss of heterozygosity in a wide range of human cancers.	CHRISTCHURCH HOSP,CHRISTCHURCH SCH MED,DEPT PATHOL,CYTOGENET & MOLEC ONCOL UNIT,CHRISTCHURCH,NEW ZEALAND; CHILDRENS HOSP LOS ANGELES,DEPT PATHOL,MOLEC DIAGN SECT,LOS ANGELES,CA 90027	Christchurch Hospital New Zealand; University of Otago; Children's Hospital Los Angeles			Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273; Fioretos, Thoas/0000-0002-3235-6154	NCI NIH HHS [CA47456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA047456, R01CA047456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COGEN PH, 1992, AM J HUM GENET, V50, P584; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DISILVESTRE D, 1990, NUCLEIC ACIDS RES, V18, P5924, DOI 10.1093/nar/18.19.5924; FUJIMORI M, 1991, CANCER RES, V51, P89; HEISTERKAMP N, 1983, Journal of Molecular and Applied Genetics, V2, P57; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; MATSUDA M, 1992, MOL CELL BIOL, V12, P3842; MATSUMURA K, 1992, CANCER RES, V52, P3474; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MORRIS C, 1993, HUM GENET, V91, P31, DOI 10.1007/BF00230218; NISHIDA N, 1993, CANCER RES, V53, P368; PRESTI JC, 1991, CANCER RES, V51, P5405; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO T, 1990, CANCER RES, V50, P7184; SAXENA A, 1992, CANCER RES, V52, P6716; TENHOEVE J, 1993, IN PRESS ONCOGENE; TSAO SW, 1991, ANTICANCER RES, V11, P1975; Williams Lewis T., 1992, Current Biology, V2, P601, DOI 10.1016/0960-9822(92)90169-B	21	13	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2853	2855						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378094				2022-12-28	WOS:A1993LX34300029
J	GRIMES, HL; AMBROSE, MR; GOODENOW, MM				GRIMES, HL; AMBROSE, MR; GOODENOW, MM			C-SKI TRANSCRIPTS WITH AND WITHOUT EXON-2 ARE EXPRESSED IN SKELETAL-MUSCLE AND THROUGHOUT CHICK EMBRYOGENESIS	ONCOGENE			English	Note							ONCOGENE; TRANSFORMATION; GENE; DIFFERENTIATION; ACTIVATION; VIRUSES; QUAIL; CDNAS	Overexpression of v-ski or c-ski cDNAs has a pronounced effect on proliferation, morphological transformation and myogenic differentiation in cells in culture and in transgenic animals. Yet, little is known about expression of the c-ski locus or the relationship between c-ski cDNAs and alternatively spliced c-ski transcripts in chicken tissues, particularly in skeletal muscle or during embryogenesis. We developed a series of probes and oligonucleotide primers specific for the eight coding exons and the long 3' noncoding region found in chicken c-ski mRNAs. The most abundant chicken c-ski mRNAs in a vast array of tissues are 8.5 kb, with additional, but less abundant, mRNAs of 7.5, 6.5 and 4.4 kb. Steady-state levels of c-ski mRNAs, indistinguishable from transcripts in other tissues, accumulate in skeletal muscle from embryonic, newly hatched, and adult chicks. Only exon 2, a small exon of 111 bp, was found to be alternatively spliced in c-ski mRNAs. Transcripts with and without exon 2 appear in all tissues, in somites, and from the earliest stages of chick embryogenesis. Thus, c-ski cDNA sequences, which extend about 4.3 kb, represent either the least abundant form of c-ski mRNAs in tissues or a severely truncated form of the major 8.5 kb transcripts.	UNIV FLORIDA,COLL MED,GRAD PROGRAM IMMUNOL & MOLEC PATHOL,BOX 100275,GAINESVILLE,FL 32610; UNIV FLORIDA,COLL MED,DEPT PATHOL,GAINESVILLE,FL 32610; UNIV FLORIDA,COLL MED,DEPT PEDIAT,DIV IMMUNOL,GAINESVILLE,FL 32610; UNIV FLORIDA,COLL MED,CTR MAMMALIAN GENET,GAINESVILLE,FL 32610	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida				Grimes, H. Leighton/0000-0001-8162-6758	NCI NIH HHS [T32 CA09126] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009126] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEESON D, 1990, EMBO J, V9, P2101, DOI 10.1002/j.1460-2075.1990.tb07378.x; BOTTAZZI ME, 1993, ONCOGENE, V8, P731; BOYER PL, 1993, ONCOGENE, V8, P457; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLAYCOMB WC, 1987, BIOCHEM J, V247, P701, DOI 10.1042/bj2470701; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; COLMENARES C, 1991, MOL CELL BIOL, V11, P1167, DOI 10.1128/MCB.11.2.1167; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GOODENOW MM, 1987, J VIROL, V87, P2489; GRIMES HL, 1992, NUCLEIC ACIDS RES, V20, P1511, DOI 10.1093/nar/20.7.1511; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; LARSEN J, 1992, ONCOGENE, V7, P1903; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MOSCOVICI C, 1982, EXPRESSION DIFFERENT, P435; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAGASE T, 1990, NUCLEIC ACIDS RES, V18, P337, DOI 10.1093/nar/18.2.337; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; SLEEMAN JP, 1993, ONCOGENE, V8, P67; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; Stavnezer E., 1988, ONCOGENE HDB, P393; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4046; STRATTON MR, 1989, CARCINOGENESIS, V10, P899, DOI 10.1093/carcin/10.5.899; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; SUTRAVE P, 1989, MOL CELL BIOL, V9, P4046, DOI 10.1128/MCB.9.9.4046; SUTRAVE P, 1991, ONCOGENE, V6, P353; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; WISDOM R, 1992, GENE DEV, V6, P667, DOI 10.1101/gad.6.4.667	32	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2863	2868						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378095				2022-12-28	WOS:A1993LX34300031
J	XU, L; WALLEN, R; PATEL, V; DEPINHO, RA				XU, L; WALLEN, R; PATEL, V; DEPINHO, RA			ROLE OF 1ST EXON-INTRON SEQUENCES IN THE REGULATION OF MYC FAMILY ONCOGENIC POTENCY	ONCOGENE			English	Article							BURKITT-LYMPHOMA CELLS; C-MYC; N-MYC; MESSENGER-RNA; EMBRYO FIBROBLASTS; GENE FAMILY; LUNG-CANCER; EXPRESSION; TRANSCRIPTION; ELONGATION	cis-Acting sequence elements that participate in the regulation of myc family gene expression in normal tissues and that serve as potential targets for the deregulation of expression in tumors have been localized to the first exon/intron region of all three myc family genes. To test directly the importance of these cis elements in the tumor-associated deregulation of myc family gene expression, we have compared the oncogenic activities of complete (exons 1, 2 and 3) and truncated (exons 2 and 3 only) c-, N- and L-myc expression constructs in the rat embryo fibroblast (REF) cooperation assay. Removal of the first exon/intron region from each construct was associated with a dramatic increase in oncogenic potency by several criteria. Analysis of N-myc/ras-transformed cell lines demonstrated (i) fewer transfected N-myc gene copies and an overall higher level of steady-state N-myc mRNA with the truncated N-myc expression construct and (ii) the presence of a significant block to transcriptional elongation in the first exon of the complete N-myc expression construct. These results indicate that the first exon of N-myc plays an important role in governing oncogenic potency, possibly through transcriptional control mechanisms.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, 1300 MORRIS PK AVE, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine				DePinho, Ronald/0000-0002-5625-577X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028317] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY009300] Funding Source: NIH RePORTER; NCI NIH HHS [2P30CA13330-20] Funding Source: Medline; NEI NIH HHS [R01 EY09300-01] Funding Source: Medline; NICHD NIH HHS [R01 HD28317-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AUSUBEL FM, 1991, CURR PROTOCOLS MOL B, V1; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BONNIEU A, 1990, ONCOGENE, V5, P1585; Cleveland J L, 1988, Oncogene Res, V3, P357; DEPINHO R, 1984, MOL CELL BIOL, V4, P2905, DOI 10.1128/MCB.4.12.2905; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; EICK D, 1987, ONCOGENE, V2, P61; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; FASANO O, 1983, Journal of Molecular and Applied Genetics, V2, P173; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEGOUY E, 1987, EMBO J, V6, P3359, DOI 10.1002/j.1460-2075.1987.tb02657.x; LIN X, 1991, MOL CELL BIOL, V11, P6007, DOI 10.1128/MCB.11.12.6007; Maniatis T, 1989, MOL CLONING; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MORROW MA, 1992, GENE DEV, V6, P61, DOI 10.1101/gad.6.1.61; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; NAU MM, 1984, CURR TOP MICROBIOL, V113, P172; NILSEN TW, 1984, MOL CELL BIOL, V4, P2235, DOI 10.1128/MCB.4.10.2235; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SEJERSEN T, 1987, EXP CELL RES, V172, P304, DOI 10.1016/0014-4827(87)90389-2; SHOWE LC, 1987, ANNU REV IMMUNOL, V5, P253, DOI 10.1146/annurev.iy.05.040187.001345; SPENCER CA, 1990, ONCOGENE, V5, P777; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; TORRES R, 1992, Current Opinion in Cell Biology, V4, P468, DOI 10.1016/0955-0674(92)90013-3; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WISDOM R, 1990, J BIOL CHEM, V265, P19015; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455	39	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1993	8	9					2547	2553						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361763				2022-12-28	WOS:A1993LT36800027
J	PAQUISFLUCKLINGER, V; MICHIELS, JF; VIDAL, F; ALQUIER, C; POINTIS, G; BOURDON, V; CUZIN, F; RASSOULZADEGAN, M				PAQUISFLUCKLINGER, V; MICHIELS, JF; VIDAL, F; ALQUIER, C; POINTIS, G; BOURDON, V; CUZIN, F; RASSOULZADEGAN, M			EXPRESSION IN TRANSGENIC MICE OF THE LARGE T-ANTIGEN OF POLYOMAVIRUS INDUCES SERTOLI-CELL TUMORS AND ALLOWS THE ESTABLISHMENT OF DIFFERENTIATED CELL-LINES	ONCOGENE			English	Article							C-MYC GENE; EARLY REGION; VIRUS; MOUSE; ONCOGENE; PROTEIN; INVITRO; TUMORS; TRANSFORMATION; FIBROBLASTS	The large T antigen of polyomavirus (PyLT) efficiently immortalizes rodent fibroblasts, but, unlike SV40 T antigen, it is not sufficient to achieve complete oncogenic transformation. We analysed a series of transgenic mouse families that express the PyLT protein under control of the viral enhancer-promoter region. In all of them, the transgene was expressed in the seminiferous epithelium of the testis (Sertoli and germ cells), with no pathological consequences during most of the animals' lives. However, every old male developed large bilateral tumours of the testes, generated by the proliferation of Sertoli cell derivatives. Cell lines could be readily established both from the tumours and from the still apparently normal testis before the onset of tumoral growth. They retained in vitro morphological and ultrastructural features characteristic of Sertoli cells. But, in addition to this major Sertoli component, the maintenance of a cellular contingent of germinal origin was suggested by the expression of genes that are normally transcribed during the premeiotic and early meiotic stages of spermatogenesis (LDH-X, Hox1.4 and c-kit). The two cell types remained tightly associated, even at tate passages in culture, and could not be separated by conventional cloning procedures. This association in culture of the two cell types whose interaction is critical for spermatogenesis may provide a useful toot for its molecular analysis.	FAC SCI NICE,INSERM,UNITE 273,F-06108 NICE 2,FRANCE; UNIV NICE,FAC MED,F-06100 NICE,FRANCE; FAC MED NORD,INSERM,UNITE 270,F-91007 MARSEILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite			Rassoulzadegan, Minoo/O-7939-2016					ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; BAUTCH VL, 1989, MOL BIOL MED, V6, P309; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; DAWE CJ, 1987, AM J PATHOL, V127, P243; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; Finch CE, 1990, LONGEVITY SENESCENCE; FRIEDMANN T, 1979, CELL, V17, P715, DOI 10.1016/0092-8674(79)90278-2; GALIANA E, 1990, J NEUROSCI RES, V26, P269, DOI 10.1002/jnr.490260302; GALLIOT B, 1989, DEVELOPMENT, V107, P343; HADLEY MA, 1985, J CELL BIOL, V101, P1511, DOI 10.1083/jcb.101.4.1511; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HINTZ M, 1977, DEV BIOL, V57, P375, DOI 10.1016/0012-1606(77)90222-6; HOFFMAN MC, 1992, EXP CELL RES, V201, P417; HOGAN B, 1986, MANIPULATING MOUSE E; HOLLAND PWH, 1987, J CELL BIOL, V105, P473, DOI 10.1083/jcb.105.1.473; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5086; JENSEN NA, 1989, MOL BIOL MED, V6, P493; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KRIPPL B, 1988, NUCLEIC ACIDS RES, V16, P8963, DOI 10.1093/nar/16.18.8963; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Leonard Davis G., 1986, BASIC METHODS MOL BI; Maniatis T., 1982, MOL CLONING; MANOVA K, 1990, DEVELOPMENT, V110, P1057; MATHER JP, 1980, BIOL REPROD, V23, P243, DOI 10.1095/biolreprod23.1.243; MOUGNEAU E, 1988, ONCOGENE RES, V2, P177; NEVINS JR, 1992, NATURE, V358, P375, DOI 10.1038/358375a0; PAUL D, 1988, EXP CELL RES, V175, P354, DOI 10.1016/0014-4827(88)90199-1; PESCHON JJ, 1987, P NATL ACAD SCI USA, V84, P5316, DOI 10.1073/pnas.84.15.5316; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; Russell L. D., 1990, HISTOLOGICAL HISTOPA; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; SILVER J, 1978, CELL, V15, P485, DOI 10.1016/0092-8674(78)90018-1; SOEDA E, 1979, CELL, V17, P357, DOI 10.1016/0092-8674(79)90162-4; STEINBERGER A, 1975, METHOD ENZYMOL, P283; TAHRIJOUTEI A, 1989, ENDOCRINOLOGY, V125, P605, DOI 10.1210/endo-125-2-605; TAKASE M, 1988, ENDOCRINOL JAPON, V35, P285; VANDENELSEN P, 1982, GENE, V18, P175, DOI 10.1016/0378-1119(82)90115-9; WANG R, 1991, J VIROL, V65, P5174, DOI 10.1128/JVI.65.10.5174-5183.1991; WINOCOUR E, 1963, VIROLOGY, V19, P158, DOI 10.1016/0042-6822(63)90005-9; WOLGEMUTH DJ, 1987, P NATL ACAD SCI USA, V84, P5813, DOI 10.1073/pnas.84.16.5813; ZERLIN M, 1987, ONCOGENE, V1, P19; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	44	48	50	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2087	2094						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8393161				2022-12-28	WOS:A1993LP17100008
J	SCHMIEG, FI; SIMMONS, DT				SCHMIEG, FI; SIMMONS, DT			P53 MUTANTS WITH CHANGES IN CONSERVED REGION-II - 3 CLASSES WITH DIFFERING ANTIBODY REACTIVITY, SV40-T ANTIGEN-BINDING AND ABILITY TO INHIBIT TRANSFORMATION OF RAT-CELLS	ONCOGENE			English	Article							LARGE T-ANTIGEN; WILD-TYPE P53; TUMOR SUPPRESSOR GENE; NONSPECIFIC DNA-BINDING; SIMIAN VIRUS-40; MONOCLONAL-ANTIBODY; ACTIVATING MUTATIONS; RESPONSIVE ELEMENT; PROTEINS BIND; ONCOGENE	The wild-type p53 gene is able to inhibit the ability of a number of oncogenes to induce transformation, but this inhibition is frequently lost when the p53 gene undergoes mutation. In this study, we generated mutated mouse p53 proteins containing conservative amino acid substitutions at residues 127 to 138 and at 140. The mutant proteins fell into three distinct classes. Class I proteins reacted well with PAb246 (246+), poorly with PAb240 (240-), bound to SV40 T antigen (T+), and inhibited the transformation of rat embryo fibroblasts by adenovirus E1a and activated ras. Class II proteins were 246-, 240+, T-, and failed to inhibit transformation. Class III proteins were 246+, 240-, but T-, and varied in their ability to inhibit transformation. The existence and properties of the Class III proteins suggest that the residues mutated in this class are important for binding to T antigen. They also lead us to conclude that the maintenance of an apparent wild-type structure is not sufficient for p53 to inhibit transformation and that the loss of T antigen binding does not necessarily result in loss of transformation inhibition. We propose the existence of a third activity important for the ability of p53 to inhibit transformation.			SCHMIEG, FI (corresponding author), UNIV DELAWARE,SCH LIFE & HLTH SCI,NEWARK,DE 19716, USA.				NATIONAL CANCER INSTITUTE [R55CA055234] Funding Source: NIH RePORTER; NCI NIH HHS [CA55234] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; CASEY G, 1991, ONCOGENE, V6, P1791; DEPPERT W, 1990, ONCOGENE, V5, P1701; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN HJL, 1992, J VIROL, V66, P5443, DOI 10.1128/JVI.66.9.5443-5452.1992; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; MEDCALF EA, 1992, ONCOGENE, V7, P71; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1987, ONCOGENE, V1, P453; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PROSSER J, 1990, ONCOGENE, V5, P1573; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RISSER R, 1974, VIROLOGY, V59, P477, DOI 10.1016/0042-6822(74)90457-7; RITTLING SR, 1992, ONCOGENE, V7, P935; RUGGERI B, 1991, CANCER RES, V51, P6615; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHIO Y, 1992, P NATL ACAD SCI USA, V89, P5206; SIMMONS DT, 1990, J VIROL, V64, P4858, DOI 10.1128/JVI.64.10.4858-4865.1990; SIMMONS DT, 1990, J VIROL, V64, P1973, DOI 10.1128/JVI.64.5.1973-1983.1990; SOUSSI T, 1987, ONCOGENE, V1, P71; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	52	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2043	2050						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8393158				2022-12-28	WOS:A1993LP17100003
J	COOK, JL; WILSON, BA; WOLF, LA; WALKER, TA				COOK, JL; WILSON, BA; WOLF, LA; WALKER, TA			E1A-ONCOGENE EXPRESSION LEVEL IN SARCOMA-CELLS - AN INDEPENDENT DETERMINANT OF CYTOLYTIC SUSCEPTIBILITY AND TUMOR REJECTION	ONCOGENE			English	Article							NATURAL-KILLER CELLS; ADENOVIRUS-TRANSFORMED CELLS; CELLULAR GENE-EXPRESSION; E1A ONCOGENE; ACTIVATED MACROPHAGES; MONOCLONAL-ANTIBODIES; SIMIAN VIRUS-40; NK SENSITIVITY; H-RAS; C-MYC	Ad2/5 E1A oncogene expression induces cytolytic susceptibility of rodent cells to natural killer lymphocytes. To determine whether the requisite thresholds of E1A oncoprotein expression differ for induction of cytolytic susceptibility as compared with other. E1A-related activities, sarcoma cells expressing low or normal levels of E1A oncoproteins were compared for differences in morphological transformation, transactivation of viral genes, cytolytic susceptibility and tumorigenicity. Low-level E1A expression transformed sarcoma cells and transactivated the Ad5 E2A gene but did not induce the increased cytolytic susceptibility observed with normal levels of E1A expression. Furthermore, low-level E1A expressers retained the tumorigenicity of parental cells, whereas normal-level expressers were non-tumorigenic in hosts with intact natural killer (NK)-cell responses. In contrast to E1A, E1B oncogene expression caused no changes in morphological, cytolytic or tumorigenic phenotypes in these sarcoma cells. These data define an expression threshold for E1A-induced cytolytic susceptibility and associated NK-cell-dependent tumor rejection. The results suggest that the cellular mechanisms involved in E1A induction of cytolytic susceptibility differ from those involved in E1A-mediated cellular transformation and viral gene transactivation.	UNIV COLORADO, HLTH SCI CTR, DEPT MED, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DEPT MICROBIOL IMMUNOL, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	COOK, JL (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED, DEPT MED, ROBERT W LISLE RES LAB IMMUNOL & TUMOR CELL BIOL, DENVER, CO 80206 USA.				NCI NIH HHS [CA 41387] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA041387, R01CA041387] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON SK, 1989, MOL IMMUNOL, V26, P985, DOI 10.1016/0161-5890(89)90117-X; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BRANTON PE, 1984, BIOCHIM BIOPHYS ACTA, V780, P67, DOI 10.1016/0304-419X(84)90007-6; BRUNET LJ, 1988, MOL CELL BIOL, V8, P4799, DOI 10.1128/MCB.8.11.4799; CHAMBERS WH, 1989, J EXP MED, V169, P1373, DOI 10.1084/jem.169.4.1373; COOK JL, 1984, SCIENCE, V224, P612, DOI 10.1126/science.6710160; COOK JL, 1982, INT J CANCER, V30, P795, DOI 10.1002/ijc.2910300619; COOK JL, 1986, P NATL ACAD SCI USA, V83, P6965, DOI 10.1073/pnas.83.18.6965; COOK JL, 1983, P NATL ACAD SCI-BIOL, V80, P5995, DOI 10.1073/pnas.80.19.5995; COOK JL, 1979, CANCER RES, V39, P1455; COOK JL, 1989, J VIROL, V63, P3408, DOI 10.1128/JVI.63.8.3408-3415.1989; COOK JL, 1989, J IMMUNOL, V142, P4527; COOK JL, 1987, J VIROL, V61, P2155, DOI 10.1128/JVI.61.7.2155-2161.1987; COOK JL, 1987, J VIROL, V61, P3510, DOI 10.1128/JVI.61.11.3510-3520.1987; EDDY BE, 1964, PROG EXP TUMOR RES, V4, P1; FRESA KL, 1987, J IMMUNOL, V138, P1215; GOTLIEBSTEMATSK.T, 1964, VIROLOGY, V22, P314, DOI 10.1016/0042-6822(64)90022-4; GREENBERG AH, 1987, CELL IMMUNOL, V109, P444, DOI 10.1016/0008-8749(87)90327-3; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HERBST RS, 1988, J VIROL, V62, P4634, DOI 10.1128/JVI.62.12.4634-4643.1988; HERRMANN CH, 1989, MOL CELL BIOL, V9, P5412, DOI 10.1128/MCB.9.12.5412; HITT MM, 1990, VIROLOGY, V179, P667, DOI 10.1016/0042-6822(90)90134-D; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JOHNSON PW, 1987, J IMMUNOL, V138, P3996; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; Karber G., 1931, ARCH EXP PATHOL PH, V162, P480, DOI DOI 10.1007/BF01863914; KELEKAR A, 1987, MOL CELL BIOL, V7, P3899, DOI 10.1128/MCB.7.11.3899; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; LABOW MA, 1990, MOL CELL BIOL, V10, P3343, DOI 10.1128/MCB.10.7.3343; LANZA LA, 1986, J IMMUNOL, V137, P2716; LEWIS AM, 1985, SCIENCE, V227, P15, DOI 10.1126/science.3843807; LEWIS AM, 1984, CURR TOP MICROBIOL, V110, P1; LEWIS ED, 1985, NATURE, V317, P172, DOI 10.1038/317172a0; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; ORTALDO JR, 1986, PATHOL IMMUNOPATH R, V5, P203, DOI 10.1159/000157014; PHILLIPS B, 1991, J VIROL, V65, P5680, DOI 10.1128/JVI.65.11.5680-5692.1991; PILDER S, 1984, J VIROL, V52, P664, DOI 10.1128/JVI.52.2.664-671.1984; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; POPE JH, 1964, J EXP MED, V120, P121, DOI 10.1084/jem.120.2.121; REICH NC, 1983, VIROLOGY, V128, P480, DOI 10.1016/0042-6822(83)90274-X; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RULEY HE, 1985, CANCER CELLS 3 GROWT, P257; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; SATYABHAMA S, 1988, DNA-J MOLEC CELL BIO, V7, P203, DOI 10.1089/dna.1988.7.203; SHALLOWAY D, 1987, MOL CELL BIOL, V7, P3582, DOI 10.1128/MCB.7.10.3582; SHEIL JM, 1984, J IMMUNOL, V132, P1578; SHENK T, 1991, ADV CANCER RES, V57, P47; STEIN R, 1984, MOL CELL BIOL, V4, P2792, DOI 10.1128/MCB.4.12.2792; TRIMBLE WS, 1986, NATURE, V321, P782, DOI 10.1038/321782a0; VANDENELSEN P, 1983, VIROLOGY, V131, P242, DOI 10.1016/0042-6822(83)90549-4; VANDENELSEN P, 1983, VIROLOGY, V128, P377; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; VERSTEEG R, 1989, J IMMUNOL, V143, P4331; WALKER TA, 1991, P NATL ACAD SCI USA, V88, P6491, DOI 10.1073/pnas.88.15.6491; ZAJCHOWSKI DA, 1988, J VIROL, V62, P1762, DOI 10.1128/JVI.62.5.1762-1767.1988; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	61	20	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1993	8	3					625	635						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437846				2022-12-28	WOS:A1993KN00800013
J	SATO, H; SEIKI, M				SATO, H; SEIKI, M			REGULATORY MECHANISM OF 92-KDA TYPE-IV COLLAGENASE GENE-EXPRESSION WHICH IS ASSOCIATED WITH INVASIVENESS OF TUMOR-CELLS	ONCOGENE			English	Article							NF-KAPPA-B; NECROSIS FACTOR-ALPHA; RHEUMATOID SYNOVIAL FIBROBLASTS; HUMAN IMMUNODEFICIENCY VIRUS; BASEMENT-MEMBRANE COLLAGEN; DNA-BINDING PROTEIN; GROWTH-FACTOR-BETA; NUCLEAR FACTOR; STROMELYSIN PROMOTER; TRANSCRIPTION FACTOR	92-kDa Type IV collagenase, a member of matrix metalloproteinases, is believed to play a critical role in physiological tissue-remodeling processes and also in many pathological conditions such as tumor invasion. We analyzed the 5'-flanking sequence of the 92 kDa type IV collagenase gene that controls the expression of the gene by ligating it to the chloramphenicol acetyltransferase gene. Deletion and mutation analysis revealed that three motifs, homologous to the binding sites for AP-1, NF-kappaB, and Sp-1 proteins, contributed positively to induction by 12-O-tetradecanoyl-phorbol-13-acetate (TPA) and tumor necrosis factor alpha (TNFalpha). The AP-1 site was indispensable but not sufficient for the induction and required synergistic cooperation with either the kappaB or the Sp-1 site. In OST cells, a nuclear factor which bound to Sp-1 was constitutively expressed, and those bound to AP-1 and kappaB elements were rapidly induced by TNFalpha treatment. Comparison of the findings with those for the promoters of other TPA-inducible matrix metalloproteinases, interstitial collagenase and stromelysin 1, revealed that the signal to the AP-1 sites is common for the TPA-inducibility of the genes but that the signals to the KB or Sp-1 sites, which are not present in interstitial collagenase and stromelysin 1 promoters, are the unique determinant for the inducibility of the 92 kDa type IV collagenase gene.			SATO, H (corresponding author), KANAZAWA UNIV, CANC RES INST, DEPT MOLEC VIROL & ONCOL, KANAZAWA, ISHIKAWA 920, JAPAN.		SATO, Hiroshi/D-8454-2015; Seiki, Motoharu/K-9443-2015					ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHIN JR, 1985, J BIOL CHEM, V260, P2367; CHUA CC, 1985, J BIOL CHEM, V260, P5213; COLLIER IE, 1988, J BIOL CHEM, V263, P10711; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; FRISCH SM, 1987, P NATL ACAD SCI USA, V84, P2600, DOI 10.1073/pnas.84.9.2600; FRISCH SM, 1990, ONCOGENE, V5, P75; FUJITA T, 1989, NUCLEIC ACIDS RES, V17, P3335, DOI 10.1093/nar/17.9.3335; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; Liotta L A, 1982, Cancer Metastasis Rev, V1, P277, DOI 10.1007/BF00124213; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MIZEL SB, 1981, P NATL ACAD SCI-BIOL, V78, P2474, DOI 10.1073/pnas.78.4.2474; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1989, BIOCHEM J, V258, P463, DOI 10.1042/bj2580463; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAKAJIMA M, 1987, CANCER RES, V47, P4869; NAKAJIMA M, 1990, J NATL CANCER I, V82, P1890, DOI 10.1093/jnci/82.24.1890; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NONAKA M, 1990, MOL CELL BIOL, V10, P6283, DOI 10.1128/MCB.10.12.6283; OKADA Y, 1990, BIOCHEM BIOPH RES CO, V171, P610, DOI 10.1016/0006-291X(90)91190-4; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OKADA Y, 1986, J BIOL CHEM, V261, P14245; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; PYKE C, 1992, CANCER RES, V52, P1336; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO H, 1992, ONCOGENE, V7, P77; SAUS J, 1988, J BIOL CHEM, V263, P6742; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P959, DOI 10.1128/MCB.9.3.959; SIRUMCONNOLLY K, 1991, NUCLEIC ACIDS RES, V19, P335, DOI 10.1093/nar/19.2.335; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213	60	711	725	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					395	405						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426746				2022-12-28	WOS:A1993KN00600019
J	KLEMPNAUER, KH				KLEMPNAUER, KH			METHYLATION-SENSITIVE DNA-BINDING BY V-MYB AND C-MYB PROTEINS	ONCOGENE			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; CELLULAR HOMOLOG; PROTO-ONCOGENE; TRANSCRIPTIONAL ACTIVATION; NUCLEOTIDE-SEQUENCE; TRANS-ACTIVATION; GENE; DIFFERENTIATION; EXPRESSION; PRODUCT	The retroviral oncogene v-myb and its cellular homolog c-myb encode nuclear DNA-binding phosphoproteins (v-MYB and c-MYB) that function as transcriptional regulators. v-MYB and c-MYB recognize a nucleotide sequence motif, PyAAC(G)/(T)G, that is present in the promoter region of the myb-inducible mim-1 gene and is required for regulation of mim-1 expression by v-MYB and c-MYB. Since the myb-binding motif contains a CpG dinucleotide that constitutes a potential target for methylation, we have investigated whether recognition of the binding site by myb proteins is sensitive to CpG methylation of the binding motif. The results presented here demonstrate that bacterially expressed v-MYB as well as authentic v-MYB and c-MYB bind to the myb binding site in a methylation-sensitive manner. Our observations raise the interesting possibility that myb function can be regulated by methylation of myb binding sites.			KLEMPNAUER, KH (corresponding author), MAX PLANCK INST IMMUNBIOL,HANS SPEMANN LAB,STUBEWEG 51,W-7800 FREIBURG,GERMANY.							BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYLE WJ, 1983, P NATL ACAD SCI-BIOL, V80, P2834, DOI 10.1073/pnas.80.10.2834; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CRAIG RW, 1984, CANCER RES, V44, P442; EVAN GI, 1984, MOL CELL BIOL, V4, P591; GARCIA A, 1991, ONCOGENE, V6, P265; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1983, J VIROL, V46, P212, DOI 10.1128/JVI.46.1.212-220.1983; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JACKSON D, 1991, PLANT CELL, V3, P115, DOI 10.1105/tpc.3.2.115; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; Moscovici C., 1982, ADV VIRAL ONCOL, V1, P83; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; OEHLER T, 1990, NUCLEIC ACIDS RES, V18, P1703, DOI 10.1093/nar/18.7.1703; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; PAZARES J, 1987, EMBO J, V6, P3552; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; STOBERGRASSER U, 1992, ONCOGENE, V7, P589; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	41	33	34	2	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					111	115						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423989				2022-12-28	WOS:A1993KN00500013
J	KLINGELHUTZ, AJ; SMITH, PP; GARRETT, LR; MCDOUGALL, JK				KLINGELHUTZ, AJ; SMITH, PP; GARRETT, LR; MCDOUGALL, JK			ALTERATION OF THE DCC TUMOR-SUPPRESSOR GENE IN TUMORIGENIC HPV-18 IMMORTALIZED HUMAN KERATINOCYTES TRANSFORMED BY NITROSOMETHYLUREA	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; SQUAMOUS-CELL CARCINOMA; HUMAN FORESKIN KERATINOCYTES; OPEN READING FRAMES; NEOPLASTIC TRANSFORMATION; CERVICAL-CARCINOMA; CHROMOSOME CHANGES; EPITHELIAL-CELLS; DNA; IDENTIFICATION	A human papillomavirus type 18 (HPV-18)-immortalized human keratinocyte cell line (1811) has been transformed to tumorigenicity in nude mice by treatment with the carcinogen nitrosomethylurea (NMU). The NMU transformants (1811-NMU-T) showed additional chromosome alterations as compared with parental 1811 cells, including 18q deletion in two of two 1811-NMU-T lines analysed. Restriction fragment length polymorphism (RFLP) analysis indicated that both 1811-NMU-T lines had lost one allele of the 18q deleted in colon cancer (DCC) tumor-suppressor gene. Reverse transcriptase polymerase chain reaction (RT-PCR) showed that DCC expression was absent or barely detectable in the 1811-NMU-T cells as compared with 1811 or normal keratinocytes, suggesting that the remaining DCC allele in the 1811-NMU-T cells was also altered. These studies indicate that reduction or loss of DCC expression may be an important step in NMU transformation of HPV-immortalized cells to tumorigenicity.	UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	KLINGELHUTZ, AJ (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV CANC BIOL,M616,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.		Klingelhutz, Aloysius/L-9081-2018	Klingelhutz, Aloysius/0000-0003-4258-5046				ATKIN NB, 1991, CANCER GENET CYTOGEN, V55, P153, DOI 10.1016/0165-4608(91)90071-2; ATKIN NB, 1990, CANCER GENET CYTOGEN, V44, P229, DOI 10.1016/0165-4608(90)90052-C; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BOYNTON RF, 1992, P NATL ACAD SCI USA, V89, P3385, DOI 10.1073/pnas.89.8.3385; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEVILEE P, 1991, ONCOGENE, V6, P311; DIPAOLO JA, 1989, ONCOGENE, V4, P395; DURST M, 1989, VIROLOGY, V173, P767, DOI 10.1016/0042-6822(89)90595-3; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GARRETT LR, 1993, IN PRESS CARCINOGENE; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HORIKOSHI T, 1992, CANCER RES, V52, P108; HOWLEY PM, 1991, CANCER RES, V51, pS5019; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KAUR P, 1989, VIROLOGY, V173, P302, DOI 10.1016/0042-6822(89)90247-X; KAUR P, 1989, J GEN VIROL, V70, P1261, DOI 10.1099/0022-1317-70-5-1261; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LAWLOR KG, 1992, CELL GROWTH DIFFER, V3, P609; LORINCZ AT, 1987, J NATL CANCER I, V79, P671; MARLHENS F, 1987, NUCLEIC ACIDS RES, V15, P1348, DOI 10.1093/nar/15.3.1348; MUNGER K, 1989, J VIROL, V63, P4417; NARAYANAN R, 1992, ONCOGENE, V7, P553; NG SY, 1985, MOL CELL BIOL, V5, P2720, DOI 10.1128/MCB.5.10.2720; PECORARO G, 1991, AM J PATHOL, V138, P1; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SMITH PP, 1989, INT J CANCER, V44, P1124, DOI 10.1002/ijc.2910440631; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; UCHINO S, 1992, CANCER RES, V52, P3099; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WINKELSTEIN W, 1990, AM J EPIDEMIOL, V131, P945, DOI 10.1093/oxfordjournals.aje.a115614; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; WORSHAM MJ, 1991, GENE CHROMOSOME CANC, V3, P420, DOI 10.1002/gcc.2870030604; WU SQ, 1991, CANCER RES, V51, P3323	42	54	56	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					95	99						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380923				2022-12-28	WOS:A1993KN00500011
J	Gotoh, N; Muroya, K; Hattori, S; Nakamura, S; Chida, K; Shibuya, M				Gotoh, N; Muroya, K; Hattori, S; Nakamura, S; Chida, K; Shibuya, M			The SH2 domain of Shc suppresses EGF-induced mitogenesis in a dominant negative manner	ONCOGENE			English	Article						EGF receptor; Shc; SH2 domain; mitogenesis; Ras	EPIDERMAL GROWTH-FACTOR; GUANINE-NUCLEOTIDE EXCHANGE; TYROSINE KINASE-ACTIVITY; TRANSFORMING ACTIVITY; SIGNAL TRANSDUCTION; FACTOR RECEPTOR; RAS; GRB2; PROTEIN; BINDING	Recently, we have shown that an EGF-R-mutant lacking the autophosphorylation sites phosphorylates She and retains mitogenic activity, In this report, we have shown that in these cells, in response to EGF, Ras is fully activated with formation of the tyrosine-phosphorylated Shc-Grb2-mSOS complex without the receptor. This pointed out the importance of She in EGF-induced Ras activation, To investigate the mechanism of tyrosine phosphorylation of She by EGF-R, we carried out in vitro kinase assays using immunoprecipitated EGF-R and bacterially-expressed She proteins as substrates, The EGF-R phosphorylated She, but not the She SH2 mutant, lacking binding ability for phosphotyrosine, This suggests that intact She SH2 is essential for the full-length She to become phosphorylated, probably by inducing a conformational change in She. Thus a She SH2 peptide may inhibit competitively She phosphorylation. We microinjected the She SH2 domain into NIH3T3 cells overexpressing the EGF-R. Microinjected She SH2 greatly suppressed EGF-induced DNA synthesis. But microinjection of neither the She SH2 mutant nor PLC-gamma 1 SH2 had any effect, This suppressing effect was rescued by comicroinjection of the full-length She, suggesting She SH2 specifically suppressed the She pathway. Thus we concluded She phosphorylation is crucial, whereas receptor autophosphorylation is dispensable, in EGF-induced mitogenesis.	UNIV TOKYO, INST MED SCI, DEPT GENET, MINATO KU, TOKYO 108, JAPAN; UNIV TOKYO, INST MED SCI, DEPT CANC CELL RES, MINATO KU, TOKYO 108, JAPAN; NATL INST NEUROSCI, DIV BIOCHEM & CELLULAR BIOL, KODAIRA, TOKYO 187, JAPAN	University of Tokyo; University of Tokyo; National Center for Neurology & Psychiatry - Japan								BASU T, 1994, ONCOGENE, V9, P3483; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; HASHIMOTO Y, 1994, ONCOGENE, V9, P869; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI NX, 1994, ONCOGENE, V9, P3457; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	40	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2525	2533						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545109				2022-12-28	WOS:A1995TP18800008
J	Besser, D; Urich, M; Sakaue, M; Messerschmitt, A; BallmerHofer, K; Nagamine, Y				Besser, D; Urich, M; Sakaue, M; Messerschmitt, A; BallmerHofer, K; Nagamine, Y			Urokinase-type plasminogen activator gene regulation by polyomavirus middle-T antigen	ONCOGENE			English	Article						AP1; middle-T; plasminogen activator; polyomavirus; signal transduction	SIZED TUMOR-ANTIGEN; PHOSPHATIDYLINOSITOL KINASE; ONCOGENIC TRANSFORMATION; CELL-TRANSFORMATION; TYROSINE KINASES; GROWTH-FACTORS; RAT-CELLS; PROTEIN; EXPRESSION; VIRUS	Expression of polyomavirus middle-T antigen (middle-T) is involved in the formation of various tumors in vivo, e,g, hemangiomas and mammary gland tumors, Several genes have been shown to be activated in middle-T-expressing cells, but the underlying mechanisms have only been partially elucidated, Among the genes regulated by middle-T, the urokinase-type plasminogen activator (uPA) gene seems to be of primary importance for the development of the transformed phenotype, We have found that the uPA gene is highly expressed in eEnd2 cells derived from a hemangioma expressing middle-T, NIH3T3 cells show negligible levels of uPA mRNA but its expression was highly induced by infecting with a middle-T-expressing retrovirus, Middle-T did not affect uPA mRNA stability, Transient cotransfection experiments using a uPA-reporter gene construct and a middle-T expression vector showed that high uPA mRNA levels are due to increased uPA promoter activity, Analyses of various signaling molecules by transient cotransfection assays and in vitro kinase assays established that a signaling pathway involving c-Src, SOS, Ras, Raf-l and ERK is activated by middle-T in NIH3T3 cells, resulting in the activation of the uPA gene promoter via PEA3/AP1 elements, In contrast, in eEnd2 cells uPA gene induction is only partially dependent on this pathway, suggesting the involvement of additional signaling molecules in endothelial cells.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND; KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,CHUO KU,KOBE 650,JAPAN	Friedrich Miescher Institute for Biomedical Research; Kobe University			Besser, Daniel/A-8304-2012	Besser, Daniel/0000-0002-4958-9624; Ballmer-Hofer, Kurt/0000-0002-3800-9129				ANDRUS L, 1988, J BIOL CHEM, V263, P6183; BELIN D, 1985, EUR J BIOCHEM, V148, P225, DOI 10.1111/j.1432-1033.1985.tb08829.x; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; Blasi F, 1990, Semin Cancer Biol, V1, P117; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CASSADY AI, 1991, NUCLEIC ACIDS RES, V19, P6839, DOI 10.1093/nar/19.24.6839; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DECLUE JE, 1993, MOL CELL BIOL, V13, P6799, DOI 10.1128/MCB.13.11.6799; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DILWORTH SM, 1993, J VIROL, V67, P2235, DOI 10.1128/JVI.67.4.2235-2244.1993; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLOTTRAHMEL B, 1992, NEUROREPORT, V3, P1077, DOI 10.1097/00001756-199212000-00011; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; ITO Y, 1979, VIROLOGY, V98, P261, DOI 10.1016/0042-6822(79)90545-2; ITO Y, 1980, J VIROL, V35, P219, DOI 10.1128/JVI.35.1.219-232.1980; JELINEK MA, 1992, ONCOGENE, V7, P1687; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KAPLAN D R, 1988, Biochimica et Biophysica Acta, V948, P345; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KWAAN HC, 1992, CANCER METAST REV, V11, P291, DOI 10.1007/BF01307184; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEE JS, 1994, J BIOL CHEM, V269, P2887; LEE JS, 1993, NUCLEIC ACIDS RES, V21, P3365, DOI 10.1093/nar/21.15.3365; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; MARKLAND W, 1987, BIOCHIM BIOPHYS ACTA, V907, P299, DOI 10.1016/0304-419X(87)90011-4; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTE BM, 1995, ONCOGENE, V10, P167; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; MUSER J, 1989, ONCOGENE, V4, P1433; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAMEH LE, 1991, ONCOGENE, V6, P1049; RAPTIS L, 1991, J VIROL, V65, P5203, DOI 10.1128/JVI.65.10.5203-5210.1991; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SCHONTHAL A, 1992, P NATL ACAD SCI USA, V89, P4972, DOI 10.1073/pnas.89.11.4972; SEGAWA K, 1982, P NATL ACAD SCI-BIOL, V79, P6812, DOI 10.1073/pnas.79.22.6812; SEILERTUYNS A, 1981, J MOL BIOL, V151, P607, DOI 10.1016/0022-2836(81)90426-5; SRINIVAS S, 1994, P NATL ACAD SCI USA, V91, P10064, DOI 10.1073/pnas.91.21.10064; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TIENARI J, 1991, CELL REGUL, V2, P285, DOI 10.1091/mbc.2.4.285; Tooze J, 1980, DNA TUMOR VIRUSES; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; URICH M, IN PRESS J BIOL CHEM; VASSALLI JD, 1994, FIBRINOLYSIS, V8, P172, DOI 10.1016/0268-9499(94)90715-3; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WILLIAMS RL, 1988, CELL, V52, P121; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7; ZHENG CF, 1994, J BIOL CHEM, V269, P19947; ZIEGLER A, 1990, J BIOL CHEM, V265, P21194	72	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2383	2391						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570190				2022-12-28	WOS:A1995TK70200023
J	ISHIKAWA, H; ASANO, M; KANDA, T; KUMAR, S; GELINAS, C; ITO, Y				ISHIKAWA, H; ASANO, M; KANDA, T; KUMAR, S; GELINAS, C; ITO, Y			2 NOVEL FUNCTIONS ASSOCIATED WITH THE REL ONCOPROTEINS - DNA-REPLICATION AND CELL-SPECIFIC TRANSCRIPTIONAL ACTIVATION	ONCOGENE			English	Article							NF-KAPPA-B; V-REL; C-REL; BINDING-PROTEIN; ONCOGENIC TRANSFORMATION; GENE-EXPRESSION; SUBUNIT; FAMILY; HOMOLOGY; ELEMENTS	The v-Rel oncoprotein and its cellular homolog c-Rel belong to the Rel/kappaB family of transcription factors. Members of this family share extensive sequence similarity in their N-terminal halves, a region referred to as the Rel Homology Region (RHR), bind to NF-kappaB DNA motifs and form heterodimers with one another. Whereas c-Rel activates transcription of kappaB-linked genes, v-Rel behaves as a dominant-interfering mutant of c-Rel- and kappaB-mediated transcription activation. Here we describe two novel activities of the Rel oncoproteins. One induces kappaB-site dependent stimulation of polyomavirus (Py) DNA replication and maps to the N-terminus of the RHR, a region where no transcription activation function was detected. This activity is common to v-Rel, c-Rel, p52 (p49/lyt10), RelA (p65) and the p50 subunit of NF-kappaB. The second promotes transcriptional activation in undifferentiated F9 cells and maps 3' to the RHR, a region essential for the transforming activity of v-Rel.	KYOTO UNIV,INST VIRUS RES,DEPT VIRAL ONCOL,SAKYO KU,KYOTO 606,JAPAN; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854	Kyoto University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center			Kanda, Teru/J-7313-2019	Kanda, Teru/0000-0002-1391-3349				BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BARU M, 1991, J VIROL, V65, P3496, DOI 10.1128/JVI.65.7.3496-3503.1991; BENNETTCOOK ER, 1991, EMBO J, V10, P959, DOI 10.1002/j.1460-2075.1991.tb08030.x; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; CHENG LZ, 1992, P NATL ACAD SCI USA, V89, P589, DOI 10.1073/pnas.89.2.589; CHRIST C, 1991, GENE DEV, V5, P751, DOI 10.1101/gad.5.5.751; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DIFFLEY JFX, 1990, TRENDS GENET, V6, P427, DOI 10.1016/0168-9525(90)90305-P; DOUGHERTY JP, 1989, J VIROL, V63, P3209, DOI 10.1128/JVI.63.7.3209-3212.1989; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; GARSON K, 1990, VIROLOGY, V177, P106, DOI 10.1016/0042-6822(90)90464-3; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GUO ZS, 1992, MOL CELL BIOL, V12, P2514, DOI 10.1128/MCB.12.6.2514; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIM KJ, 1979, J IMMUNOL, V122, P549; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LEE JH, 1991, ONCOGENE, V6, P665; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MEYUHAS O, 1990, J BIOL CHEM, V265, P11465; MORGAN IM, 1993, ONCOGENE, V8, P1135; MORRISON LE, 1992, ONCOGENE, V7, P1137; MURAKAMI Y, 1991, P NATL ACAD SCI USA, V88, P3947, DOI 10.1073/pnas.88.9.3947; MURAKAMI Y, 1990, ONCOGENE, V5, P5; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WASYLYK C, 1990, ONCOGENE, V5, P1055	58	28	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2889	2896						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414493				2022-12-28	WOS:A1993MC09300001
J	FUNG, YKT; TANG, A; MURPHREE, AL; ZHANG, FH; QIU, WR; WANG, SW; SHI, XH; LEE, L; DRISCOLL, B; WU, KJ				FUNG, YKT; TANG, A; MURPHREE, AL; ZHANG, FH; QIU, WR; WANG, SW; SHI, XH; LEE, L; DRISCOLL, B; WU, KJ			THE RB GENE SUPPRESSES THE GROWTH OF NORMAL-CELLS	ONCOGENE			English	Article							HUMAN RETINOBLASTOMA GENE; WILMS-TUMOR-ASSOCIATION; LARGE T-ANTIGEN; SV40 LARGE-T; SUSCEPTIBILITY GENE; HUMAN CHROMOSOME-11; TUMORIGENIC EXPRESSION; CARCINOMA-CELLS; DNA-BINDING; PRODUCT	The suppression of tumor formation, first demonstrated by somatic cell hybrid and microcell fusion experiments, suggests the existence of a class of genes that selectively suppress the growth of tumor cells but not normal cells. The reintroduction of these genes into tumor cells presumably renders the cells responsive to in vivo growth inhibitory environment. As the inheritance of a defective retinoblastoma gene (Rb-1) allele results in a predisposition to the development of various cancers, and since inactivation of both alleles are observed in tumor cells, the Rb gene has been suspected to have the ability to suppress tumor growth. Data presented here demonstrated that different types of normal cells, which have a limited life span, were also growth arrested by a transfected Rb gene. Cell lines which are resistant to the growth suppression effect of the Rb gene in vitro, retain the ability to form tumors in nude mice even in the presence of a stable and highly expressed wild type Rb protein. We conclude that while the Rb gene can suppress the growth of many tumor cell lines, its growth suppression effect is not tumor specific.	CHILDRENS HOSP,DIV PATHOL & OPHTHALMOL,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT OPHTHALMOL,LOS ANGELES,CA 90027	Children's Hospital Los Angeles; University of Southern California; University of Southern California; University of Southern California; University of Southern California	FUNG, YKT (corresponding author), CHILDRENS HOSP,DIV HEMATOL ONCOL,LOS ANGELES,CA 90027, USA.				NATIONAL EYE INSTITUTE [R01EY007846] Funding Source: NIH RePORTER; NEI NIH HHS [EY07846] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DOWDY SF, 1991, SCIENCE, V254, P293, DOI 10.1126/science.1656527; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARRIS H, 1969, NATURE, V223, P363, DOI 10.1038/223363a0; HARRIS H, 1969, NATURE, V224, P1314; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOUFOS A, 1984, NATURE, V309, P171; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MUNCASTER MM, 1992, CANCER RES, V52, P654; OREILLY DR, 1988, J VIROL, V62, P3109, DOI 10.1128/JVI.62.9.3109-3119.1988; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; REEVE AE, 1984, NATURE, V309, P174, DOI 10.1038/309174a0; RICCARDI VM, 1980, CANCER GENET CYTOGEN, V2, P131, DOI 10.1016/0165-4608(80)90056-4; RULEY HE, 1985, CANCER CELL, V3, P257; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; STANBRIDGE EJ, 1976, NATURE, V260, P17, DOI 10.1038/260017a0; STIRDIVANT SM, 1992, MOL CELL BIOL, V12, P1905, DOI 10.1128/MCB.12.5.1905; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TANG A, 1989, ONCOGENE, V4, P401; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; VARLEY JM, 1989, ONCOGENE, V4, P725; WEINBERG RA, 1990, TRENDS BIOCHEM SCI, V15, P199, DOI 10.1016/0968-0004(90)90162-5; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1991, CANCER RES, V51, P4481; YOKOTA J, 1988, ONCOGENE, V3, P471	47	50	53	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2659	2672						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378078				2022-12-28	WOS:A1993LX34300007
J	RAO, GN; LASSEGUE, B; GRIENDLING, KK; ALEXANDER, RW				RAO, GN; LASSEGUE, B; GRIENDLING, KK; ALEXANDER, RW			HYDROGEN-PEROXIDE STIMULATES TRANSCRIPTION OF C-JUN IN VASCULAR SMOOTH-MUSCLE CELLS - ROLE OF ARACHIDONIC-ACID	ONCOGENE			English	Article								We reported previously that hydrogen peroxide induces DNA synthesis in rat aortic smooth muscle (RASM) cells. In the present paper we studied the mechanism by which hydrogen peroxide induces c-jun mRNA, an early response gene whose activation is required for mitogen-stimulated cell growth. Hydrogen peroxide induced c-jun mRNA in growth-arrested RASM cells in a time dependent manner. This stimulation was significantly inhibited by mepacrine, a phospholipase A2 (PLA2) inhibitor. Arachidonic acid, a PLA2 product, also increased c-jun mRNA with a time course similar to that of hydrogen peroxide. The increases in c-jun mRNA induced by hydrogen peroxide and arachidonic acid were significantly reduced (55%) by down-regulation of protein kinase C with a phorbol ester. Furthermore, the effect of hydrogen peroxide on c-jun mRNA was also reduced by NDGA, an inhibitor of the lipoxygenase-cytochrome P450 monooxygenase system, suggesting that metabolism of arachidonic acid through this pathway is required for the induction of c-jun mRNA by oxidants. Both hydrogen peroxide and arachidonic acid significantly increased c-jun transcription as demonstrated by nuclear run-on assays. Together these observations suggest that: (1) the induction of c-jun mRNA by hydrogen peroxide is mediated by PLA2-dependent arachidonic acid release and metabolism through the lipoxygenase-cytochrome P450 mono-oxygenase system; (2) PKC appears to be involved in this signaling pathway and (3) the induction of c-jun mRNA by hydrogen peroxide in RASM cells is due to increased transcription.			RAO, GN (corresponding author), EMORY UNIV, SCH MED, DIV CARDIOL, ATLANTA, GA 30322 USA.			Griendling, Kathy/0000-0002-9456-8582; Lassegue, Bernard/0000-0003-4924-6506				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AUWERX J, 1992, ONCOGENE, V7, P2271; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BRIGHTMAN AO, 1992, BIOCHIM BIOPHYS ACTA, V1105, P109, DOI 10.1016/0005-2736(92)90168-L; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COOPER DR, 1989, BIOCHEM BIOPH RES CO, V161, P327, DOI 10.1016/0006-291X(89)91600-8; CRANE FL, 1985, BIOCHIM BIOPHYS ACTA, V811, P233, DOI 10.1016/0304-4173(85)90013-8; CRAWFORD D, 1988, ONCOGENE, V3, P27; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; ELLEM KAO, 1983, BIOCHEM BIOPH RES CO, V112, P183, DOI 10.1016/0006-291X(83)91814-4; ERIKSON E, 1985, P NATL ACAD SCI USA, V82, P742, DOI 10.1073/pnas.82.3.742; FAFEUR V, 1991, J CELL PHYSIOL, V149, P277, DOI 10.1002/jcp.1041490214; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; FORCE T, 1991, J BIOL CHEM, V266, P6650; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GLASGOW WC, 1992, J BIOL CHEM, V267, P10771; GOPALAKRISHNA R, 1989, P NATL ACAD SCI USA, V86, P6758, DOI 10.1073/pnas.86.17.6758; GRANGER DN, 1986, ACTA PHYSIOL SCAND, V126, P47; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GUY GR, 1993, J BIOL CHEM, V268, P2141; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; HORIGUCHI J, 1989, MOL CELL BIOL, V9, P252, DOI 10.1128/MCB.9.1.252; KARIN M, 1991, HORMONAL CONTROL REG, P235; KONTOS HA, 1984, CIRC RES, V55, P295, DOI 10.1161/01.RES.55.3.295; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LARSSON R, 1988, J BIOL CHEM, V263, P17452; LARSSON R, 1989, CANCER RES, V49, P5627; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MAKI A, 1992, FASEB J, V6, P919, DOI 10.1096/fasebj.6.3.1740241; MESSINA JL, 1992, J BIOL CHEM, V267, P9223; MILLER AM, 1989, J LAB CLIN MED, V113, P355; MURAKAMI Y, 1991, P NATL ACAD SCI USA, V88, P3947, DOI 10.1073/pnas.88.9.3947; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; PALUMBO EJ, 1992, BIOCHEM BIOPH RES CO, V187, P1439, DOI 10.1016/0006-291X(92)90463-U; RALPH RK, 1990, CANCER LETT, V49, P181, DOI 10.1016/0304-3835(90)90156-R; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; RUDLAND PS, 1977, BIOCHEM BIOPH RES CO, V75, P556, DOI 10.1016/0006-291X(77)91508-X; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; SHIBANUMA M, 1988, J CELL PHYSIOL, V136, P379, DOI 10.1002/jcp.1041360224; SHIBANUMA M, 1990, ONCOGENE, V5, P1025; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; TRAVO P, 1980, BLOOD VESSELS, V17, P110; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; TSUNAWAKI S, 1986, J BIOL CHEM, V261, P1563	61	125	129	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2759	2764						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378085				2022-12-28	WOS:A1993LX34300017
J	MILNER, J; CHAN, YS; MEDCALF, EA; WANG, Y; ECKHART, W				MILNER, J; CHAN, YS; MEDCALF, EA; WANG, Y; ECKHART, W			PARTIALLY TRANSFORMED T3T3 CELLS EXPRESS HIGH-LEVELS OF MUTANT-P53 IN THE WILD-TYPE IMMUNOREACTIVE FORM WITH DEFECTIVE OLIGOMERIZATION	ONCOGENE			English	Article							TUMOR SUPPRESSOR PROTEIN; LARGE T-ANTIGEN; SIMIAN VIRUS-40; MONOCLONAL-ANTIBODIES; P53 PROTEIN; CONFORMATION; GENE; PHOSPHORYLATION; LOCALIZATION; REPLICATION	High levels of wild-type p53 suppress transformed growth of many cell lines and yet murine T3T3 cells shown partially transformed growth despite high endogenous levels of phenotypically 'wild-type' p53. On sequencing T3T3 p53 was found to encode missense mutations at codons 230 and 287 and, although endogenous T3T3 p53 is 'wild type', the protein adopted the mutant phenotype when expressed in vitro. Size fractionation of T3T3 cell lysate indicated monomeric p53 possibly in complex with a low molecular weight protein. When expressed in vitro T3T3 p53 formed dimers and higher order structures. Thus T3T3 cells appear (i) to drive endogenous mutant p53 to adopt conformational epitopes characteristic of the 'wild-type' protein, and (ii) to interfer with normal assembly of p53 quaternary structure. Phosphopeptide mapping of p53 from 3T3x cells, T3T3 cells and SV3T3 cells indicated reduced amino terminal phosphorylation of the mutant p53 phenotype. Alternative splicing of p53 was also detected in 3T3x cells; similar splicing occurs in wild-type p53 (Han & Kulesz-Martin, 1992; Nucl. Acids Res., 20, 1979-1981) and a possible regulatory function is discussed.	UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1QP,ENGLAND; SALK INST BIOL STUDIES,SAN DIEGO,CA 92138	University of Cambridge; Salk Institute					NATIONAL CANCER INSTITUTE [R01CA013884, P30CA014195, R37CA013884] Funding Source: NIH RePORTER; NCI NIH HHS [CA 14195, CA 13884] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADDISON C, 1990, ONCOGENE, V5, P423; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CATHALA G, 1983, DNA CELL BIOL, V2, P339; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; GANNON JV, 1990, EMBO J, V9, P1591; GOGOS JA, 1992, SCIENCE, V257, P1951, DOI 10.1126/science.1290524; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HAN KA, 1992, NUCLEIC ACIDS RES, V20, P1979, DOI 10.1093/nar/20.8.1979; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU T, 1992, SCIENCE, V257, P1946, DOI 10.1126/science.1411512; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEDCALF EA, 1992, ONCOGENE, V7, P71; MEEK DW, 1990, J VIROL, V64, P1734, DOI 10.1128/JVI.64.4.1734-1744.1990; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1990, ONCOGENE, V5, P1683; MILNER J, 1986, VIROLOGY, V153, P21; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; SHOHATFOORD O, 1991, NUCLEIC ACIDS RES, V19, P5191; SOUSSI T, 1990, ONCOGENE, V5, P945; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZERRAHN J, 1992, ONCOGENE, V7, P1371	46	22	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					2001	2008						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510941				2022-12-28	WOS:A1993LG68200033
J	FEITELSON, MA; ZHU, M; DUAN, LX; LONDON, WT				FEITELSON, MA; ZHU, M; DUAN, LX; LONDON, WT			HEPATITIS-B X-ANTIGEN AND P53 ARE ASSOCIATED INVITRO AND IN LIVER-TISSUES FROM PATIENTS WITH PRIMARY HEPATOCELLULAR-CARCINOMA	ONCOGENE			English	Article							VIRUS-DNA; HEPATOMA-CELL; GENE PRODUCT; C-MYC; PROTEIN; REARRANGEMENT; INTEGRATION; TRANSACTIVATION; TRANSFORMATION; CHROMOSOME-17P	To test the hypothesis that hepatitis B x antigen (HBxAg) binds to the tumor-suppressor protein p53, immunoprecipitation was carried out with monoclonal anti-x or monoclonal anti-p53 using radiolabeled HBxAg and p53 made by in vitro translation. The results showed that anti-p53 specifically immunoprecipitates HBxAg only in the presence of p53 and that anti-x specifically immunoprecipitates p53 only in the presence of HBxAg. to determine whether HBxAg binds p53 in vivo, immunoprecipitation and Western blot analysis of liver samples from 10 hepatitis B virus (HBV)-infected patients with primary hepatocellular carcinoma (PHC) were carried out. A protein band at 53 000 daltons that specifically immunoprecipitated with a monoclonal anti-x was identified as p53 by Western blotting with a monoclonal anti-p53. Anti-p53 specifically immunoprecipitated bands of 28 000, 17 000 and 13 000 daltons, which were identified as HBxAg polypeptides by Western blotting with anti-HBx. These findings suggest that HBxAg binds to p53 and that this association is important to the development of PHC.	MIL MED UNIV 4, XIAN, SHAANXI, PEOPLES R CHINA; FOX CHASE CANC CTR, PHILADELPHIA, PA 19111 USA; THOMAS JEFFERSON UNIV, DIV INFECT DIS, PHILADELPHIA, PA 19107 USA	Air Force Military Medical University; Fox Chase Cancer Center; Jefferson University	FEITELSON, MA (corresponding author), THOMAS JEFFERSON UNIV, DEPT PATHOL & CELL BIOL, ROOM 219, JALUMNI HALL, PHILADELPHIA, PA 19107 USA.				NCI NIH HHS [CA-40737, CA-06927] Funding Source: Medline; NCRR NIH HHS [RR-05895] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005895] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AOKI N, 1989, MOL BIOL MED, V6, P395; AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; Beasley R.P., 1984, VIRAL HEPATITIS LIVE, P209; BEUTOW KH, 1989, P NATL ACAD SCI USA, V86, P8852; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; DEJEAN A, 1984, P NATL ACAD SCI-BIOL, V81, P5350, DOI 10.1073/pnas.81.17.5350; DEJEAN A, 1990, MOL BIOL MED, V7, P213; FEITELSON MA, 1990, VIROLOGY, V177, P357, DOI 10.1016/0042-6822(90)90491-9; FEITELSON MA, 1990, VIROLOGY, V177, P367, DOI 10.1016/0042-6822(90)90492-A; FUJIMORI M, 1991, CANCER RES, V51, P89; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GU JR, 1988, CARCINOGENESIS, V9, P697, DOI 10.1093/carcin/9.5.697; HATADA I, 1988, ONCOGENE, V3, P537; HINO O, 1991, P NATL ACAD SCI USA, V88, P9248, DOI 10.1073/pnas.88.20.9248; HINO O, 1989, CANCER GENET CYTOGEN, V37, P273, DOI 10.1016/0165-4608(89)90059-9; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOSONO S, 1991, ONCOGENE, V6, P237; HOWLEY PM, 1991, ADV AP BIOT, V13, P139; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HU KQ, 1990, P NATL ACAD SCI USA, V87, P7140, DOI 10.1073/pnas.87.18.7140; ISHIKAWA F, 1986, P NATL ACAD SCI USA, V83, P3209, DOI 10.1073/pnas.83.10.3209; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KOCH S, 1984, EMBO J, V3, P2185, DOI 10.1002/j.1460-2075.1984.tb02111.x; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LONDON WT, 1981, HUM PATHOL, V12, P1085, DOI 10.1016/S0046-8177(81)80329-2; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATSUBARA K, 1990, MOL BIOL MED, V7, P243; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MORIARTY AM, 1985, SCIENCE, V227, P429, DOI 10.1126/science.2981434; MOROY T, 1986, NATURE, V324, P276, DOI 10.1038/324276a0; MOROY T, 1989, ONCOGENE, V4, P59; MURAKAMI Y, 1991, CANCER RES, V51, P3356; OKUDA K, 1992, HEPATOLOGY, V15, P948, DOI 10.1002/hep.1840150532; OU J, 1985, P NATL ACAD SCI USA, V82, P83, DOI 10.1073/pnas.82.1.83; PASQUINELLI C, 1988, J VIROL, V62, P629, DOI 10.1128/JVI.62.2.629-632.1988; RITTER SE, 1991, VIROLOGY, V182, P841, DOI 10.1016/0042-6822(91)90626-M; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEFFNER M, 1990, CELL, V63, P1129; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SHAFRITZ DA, 1981, NEW ENGL J MED, V305, P1067, DOI 10.1056/NEJM198110293051807; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SIMON D, 1990, CANCER GENET CYTOGEN, V45, P255, DOI 10.1016/0165-4608(90)90091-N; SLAGLE BL, 1991, CANCER RES, V51, P49; Szmuness W, 1978, Prog Med Virol, V24, P40; TAKADA S, 1990, J VIROL, V64, P822, DOI 10.1128/JVI.64.2.822-828.1990; TAKADA S, 1989, ONCOGENE, V4, P189; TOKINO T, 1987, J VIROL, V61, P3848, DOI 10.1128/JVI.61.12.3848-3854.1987; TROWBRIDGE R, 1988, VIRAL HEPATITIS LIVE, P764; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; WALKER GJ, 1991, CANCER RES, V51, P4367; WANG J, 1992, ONCOGENE, V7, P1653; WANG WL, 1991, CANCER RES, V51, P4971; WANG WL, 1991, HEPATOLOGY, V14, P29, DOI 10.1002/hep.1840140106; WILL H, 1985, P NATL ACAD SCI USA, V82, P891, DOI 10.1073/pnas.82.3.891; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; ZHOU YZ, 1988, J VIROL, V62, P4224, DOI 10.1128/JVI.62.11.4224-4231.1988	60	320	337	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1109	1117						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8386823				2022-12-28	WOS:A1993KY32800001
J	CARUSO, M; MARTELLI, F; GIORDANO, A; FELSANI, A				CARUSO, M; MARTELLI, F; GIORDANO, A; FELSANI, A			REGULATION OF MYOD GENE-TRANSCRIPTION AND PROTEIN FUNCTION BY THE TRANSFORMING DOMAINS OF THE ADENOVIRUS E1A ONCOPROTEIN	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; DNA-BINDING PROTEIN; LARGE T-ANTIGENS; HUMAN CYCLIN-A; CELL-CYCLE; MYOGENIC DIFFERENTIATION; RETINOBLASTOMA PROTEIN; REPRESS TRANSCRIPTION; G1 PHASE; PRODUCT	It has been demonstrated that the adenovirus E1A gene products inhibit myogenic differentiation in the mouse C2 muscle cell line. During myogenic differentiation, cell growth and tissue-specific gene expression are mutually exclusive. Since E1A exerts multiple effects on different cellular pathways through alteration of cell growth control and transcriptional regulation, we investigated in more detail the molecular mechanisms underlying the inhibitory effect of E1A on myogenic differentiation. To this end, we used mutant derivatives of E1A that lack the 'conserved domain' sequences to which the functional domains of E1A have been mapped, and we observed the effect of constitutive expression of these E1A mutants on myogenesis in the murine C2 muscle cell line. Our results demonstrate that E1A interferes with myogenesis through at least two mechanisms: (i) the inhibition of MyoD expression; (ii) the repression of MyoD-dependent transcriptional activation. In addition, we demonstrate also that the repression of MyoD transcription depends upon sequences located in the N-terminus of E1A and correlates well with the site of E1A/p300 association. Further, the inhibition of transcriptional activation by MyoD depends both on conserved region 1 and on conserved region 2, the two transforming domains of E1A. We demonstrate also that a similar inhibitory effect on the MyoD transactivating function is provided by the polyomavirus and SV40 large T oncoproteins.	CRS,IST REGINA ELENA STUDIO & CURA TUMORI,VIA DELLE MESSI DORO 156,I-00158 ROME,ITALY; CNR,IST BIOL CELLULARE,I-00137 ROME,ITALY; TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT PATHOL & BIOCHEM,PHILADELPHIA,PA 19140; CNR,IST TECNOL BIOMED,I-00161 ROME,ITALY	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Consiglio Nazionale delle Ricerche (CNR); Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR)			Caruso, Maurizia/G-8895-2013; Martelli, Fabio/AAL-3788-2020; Giordano, Antonio/F-1927-2010; Felsani, Armando/D-1784-2010	Caruso, Maurizia/0000-0001-5445-6343; Martelli, Fabio/0000-0002-8624-7738; Giordano, Antonio/0000-0002-5959-016X; Felsani, Armando/0000-0001-8851-6295				BADER D, 1992, J CELL BIOL, V5, P763; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; COPPOLA JA, 1990, ONCOGENE, V5, P1731; DAUBAS P, 1985, NUCLEIC ACIDS RES, V13, P4623, DOI 10.1093/nar/13.13.4623; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; ENKEMANN SA, 1990, CELL GROWTH DIFFER, V1, P375; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMEL PA, 1992, TRENDS GENET, V8, P180, DOI 10.1016/0168-9525(92)90221-O; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KALVAKOLANU DVR, 1991, P NATL ACAD SCI USA, V88, P7459, DOI 10.1073/pnas.88.17.7459; KHANDJIAN EW, 1992, ONCOGENE, V7, P909; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KONIECZNY SF, 1989, ONCOGENE, V4, P473; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MAIONE R, 1992, ONCOGENE, V7, P85; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; OFFRINGA R, 1988, NUCLEIC ACIDS RES, V16, P10973, DOI 10.1093/nar/16.23.10973; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; ROCHETTEEGLY C, 1990, GENE DEV, V4, P137, DOI 10.1101/gad.4.1.137; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SLEIGH MJ, 1978, CELL, V14, P79, DOI 10.1016/0092-8674(78)90303-3; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STEIN RW, 1987, MOL CELL BIOL, V7, P1164, DOI 10.1128/MCB.7.3.1164; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TIMMERS HTM, 1989, J VIROL, V63, P1470, DOI 10.1128/JVI.63.3.1470-1473.1989; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VANDENELSEN P, 1983, VIROLOGY, V128, P377; VANORMONDT H, 1978, GENE, V4, P309, DOI 10.1016/0378-1119(78)90048-3; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEYDERT A, 1985, P NATL ACAD SCI USA, V82, P7183, DOI 10.1073/pnas.82.21.7183; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984; ZINGG JM, 1991, NUCLEIC ACIDS RES, V19, P6433, DOI 10.1093/nar/19.23.6433	91	91	93	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					267	278						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8381218				2022-12-28	WOS:A1993KN00600005
J	Gao, C; Arlinghaus, RB; Singh, B				Gao, C; Arlinghaus, RB; Singh, B			Further characterization of the c-mos transcript and its cell cycle specific expression in NIH3T3 cells	ONCOGENE			English	Article						c-mos expression; transcriptional regulation; cell cycle control	PROTO-ONCOGENE; SARCOMA-VIRUS; MEIOTIC MATURATION; MOUSE-TISSUES; IDENTIFICATION; SEQUENCES; RNA; UPSTREAM; PRODUCT; CLONING	The mouse c-mos proto-oncogene is primarily expressed in germ cells. Our previous studies demonstrated c-mos RNA expression in mouse somatic cells, with the highest level present in the G(2) phase of the cell cycle (Tsui et al., 1993). We have identified the transcription start site of this G(2) specific c-mos transcript to be located about 1580 bp upstream from the open reading frame based on RT-PCR and RNase protection experiments. Upstream sequences containing this transcription start site directed highest expression of the luciferase reporter gene in M phase of the cell cycle. These results suggest that c-mos transcripts are produced in G, phase and that c-Mos protein albeit at extremely low levels would accumulate in M phase.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [P30CA016672, R01CA045125] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA45125] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; HERZOG NK, 1989, ONCOGENE, V4, P1307; HERZOG NK, 1988, ONCOGENE, V3, P225; JANG SK, 1990, GENE DEV, V4, P1560, DOI 10.1101/gad.4.9.1560; JONES M, 1980, P NATL ACAD SCI-BIOL, V77, P2651, DOI 10.1073/pnas.77.5.2651; LEIBOVITCH SA, 1990, ONCOGENE, V5, P1149; LEIBOVITCH SA, 1991, ONCOGENE, V6, P1617; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MCGEADY ML, 1986, DNA-J MOLEC CELL BIO, V5, P289, DOI 10.1089/dna.1986.5.289; NASH M, 1984, J VIROL, V50, P478, DOI 10.1128/JVI.50.2.478-488.1984; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PROPST F, 1984, NUCLEIC ACIDS RES, V12, P8381, DOI 10.1093/nar/12.22.8381; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; TOBEY RA, 1990, P NATL ACAD SCI USA, V87, P5104, DOI 10.1073/pnas.87.13.5104; TSUI L, 1993, THESIS U TEXAS GRADU; TSUI LV, 1993, INT J ONCOL, V2, P493; WOOD TG, 1984, P NATL ACAD SCI-BIOL, V81, P7817, DOI 10.1073/pnas.81.24.7817; ZHAO X, 1990, ONCOGENE, V5, P1727; ZHAO X, 1991, ONCOGENE, V6, P43; ZINKEL SS, 1992, MOL CELL BIOL, V12, P2029, DOI 10.1128/MCB.12.5.2029	23	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1571	1576						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622874				2022-12-28	WOS:A1996UF07600022
J	Hobert, O; Schilling, JW; Beckerle, MC; Ullrich, A; Jallal, B				Hobert, O; Schilling, JW; Beckerle, MC; Ullrich, A; Jallal, B			SH3 domain-dependent interaction of the proto-oncogene product Vav with the focal contact protein zyxin	ONCOGENE			English	Article						vav; SH3; zyxin; focal adhesions	C-SRC ACTIVITY; TYROSINE; BINDING; KINASE; RAS; GTPASE; CELLS	Scr homology 3 (SH3) domain-mediated protein-protein interactions have been implicated in the localization of proteins to specific sites within the cell. We present evidence that the product of the vav proto-oncogene, p95(vav), interacts specifically with the focal adhesion protein zyxin both in vitro and in yeast two hybrid system. Solution binding and two-hybrid system experiments demonstrate that association of Vav with the LIM domain protein zyxin is mediated by the C-terminal SH3 domain of Vav and involves the proline-rich N-terminus of zyxin. The interaction appears to be selective, since no binding of the proline-rich N-terminus of zyxin with other SH3 domain-containing proteins such as GRB-2, phospholipase C gamma, GTPase-activating protein, or p85 was detected.	MAX PLANCK INST BIOCHEM,DEPT BIOL MOLEC,D-82152 MARTINSRIED,GERMANY; SUGEN INC,REDWOOD CITY,CA 94063; UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112	Max Planck Society; Utah System of Higher Education; University of Utah				Hobert, Oliver/0000-0002-7634-2854				ADAMS JM, 1992, ONCOGENE, V7, P611; BAGSAGI D, 1993, CELL, V79, P83; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; EVANS GA, 1993, BIOCHEM J, V294, P399; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HALL A, 1993, PHILOS T ROY SOC B, V340, P267, DOI 10.1098/rstb.1993.0067; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HOBERT O, 1994, J BIOL CHEM, V269, P20225; HOFFMAN R, 1989, BLOOD, V74, P1196; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MERILAINEN J, 1993, J CELL SCI, V105, P647; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; MUSSACCHIO A, 1992, FEBS LETT, V307, P55; OKADA M, 1993, J BIOL CHEM, V268, P18070; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PODACK ER, 1991, ANNU REV CELL BIOL, V7, P479, DOI 10.1146/annurev.cellbio.7.1.479; POO WJ, 1988, NATURE, V332, P378, DOI 10.1038/332378a0; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WENG ZG, 1993, J BIOL CHEM, V268, P14956; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZMUIDZINAS A, 1995, EMBO J, V14, P1	50	76	76	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1577	1581						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622875				2022-12-28	WOS:A1996UF07600023
J	LeCouter, JE; Whyte, PFM; Rudnicki, MA				LeCouter, JE; Whyte, PFM; Rudnicki, MA			Cloning and expression of the Rb-related mouse p130 mRNA	ONCOGENE			English	Article						p130; cDNA; mouse	RETINOBLASTOMA GENE FAMILY; EMBRYONAL CARCINOMA-CELLS; TRANSCRIPTION FACTOR E2F; PROTEIN; DIFFERENTIATION; INTERACTS; CONTAINS; MUTATION; PRODUCT; MEMBER	The mouse p130 cDNA was cloned from a thymus-derived library using the human p130 cDNA as a probe. The 4515-bp mouse cDNA encodes a putative 1092 aa protein with predicted molecular mass of 123kD. Comparison of mouse and human sequences reveals the mouse protein lacks 43 aa in a conserved domain, relative to the human sequence, located amino-terminal to the pocket region. Northern analysis of P19 embryonal carcinoma (EC) and RA-induced P19 cultures indicates p130 mRNA is not expressed at detectable levels in undifferentiated stem cells and is strongly upregulated after post-mitotic neurons begin to accumulate. Northern analysis of adult mouse tissues indicated that the 4.8 kb p130 mRNA is expressed ubiquitously, however, a putative 9-truncated 1.7 kb isoform is detected solely in testis. Forced expression of mouse p130 induced growth suppression of P19 EC cells and Western analysis of transfected P19 cells suggested the cloned cDNA encodes the full-length p130 protein.	MCMASTER UNIV,INST MOLEC BIOL & BIOTECHNOL,CANC RES GRP,HAMILTON,ON L8S 4K1,CANADA	McMaster University								ADRA CN, 1988, SOMAT CELL MOLEC GEN, V14, P69, DOI 10.1007/BF01535050; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CORBEIL HB, 1995, ONCOGENE, V11, P909; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HANNON GJ, 1993, GENE DEV, V7, P2366; HARLOW E, 1988, ANTIBODIES LAB MANUA, P483; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; KAWASAKI E, 1990, PCR PROTOCOLS GUIDE, P22; KIM KK, 1995, GENOMICS, V28, P520, DOI 10.1006/geno.1995.1184; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; Maniatis T., 1982, MOL CLONING; MAYOL X, 1993, ONCOGENE, V8, P2561; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; RUDNICKI MA, 1987, TERATOCARCINOMAS EMB, P32; SAVATIER P, 1994, ONCOGENE, V9, P809; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLACK RS, 1993, ONCOGENE, V8, P1585; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WHYTE P, 1995, SEMIN CANCER BIOL, V6, P83, DOI 10.1006/scbi.1995.0011; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x	42	28	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1433	1440						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622859				2022-12-28	WOS:A1996UF07600007
J	Lee, JM; Fournel, M; Veillette, A; Branton, PE				Lee, JM; Fournel, M; Veillette, A; Branton, PE			Association of CD45 with Lck and components of the Ras signalling pathway in pervanadate-treated mouse T-cell lines	ONCOGENE			English	Article						CD45; protein tyrosine phosphatase; T-cell activation; Lck; pervanadate	TYROSINE PROTEIN-KINASE; GUANINE-NUCLEOTIDE EXCHANGE; VAV PROTOONCOGENE PRODUCT; LEUKOCYTE-COMMON ANTIGEN; HUMAN LYMPHOCYTES-T; PHOSPHATASE CD45; ADAPTER PROTEIN; SH2 DOMAIN; B-CELLS; ACTIVATION	Pervanadate treatment of a mouse T-cell hybridoma cell line overexpressing an activated form of p56(lck) was shown to result in tyrosine phosphorylation of CD45. Immunoprecipitates prepared under mild lysis conditions using antibodies against CD45 contained a number of other proteins, including p56(lck), that were not evident in the absence of pervanadate treatment or in T cells lacking activated Lck, implying that under these conditions, CD45 is present within complexes containing Lck and other proteins. Analyses involving deletion mutants of p56(lck) indicated that interactions with CD45 did not absolutely require the SH2 and SH3 regions of Lck. Three proteins of the Ras signalling pathway were also shown to associated with CD45: the GTPase-activating protein for Ras (rasGAP), the signalling protein Grb2, and, possibly via complex formation with Grb2, the guanine nucleotide exchange factor mammalian son of sevenless (mSOS). In addition, CD45 was also found in immunoprecipitates prepared from these cells using an antiserum which recognizes Vav, It is possible that rasGAP, Grb2 and Vav bind to phosphotyrosine residues on CD45 via SH2 domains, and such interactions may be specific as other SH2-containing proteins, including phospholipase C alpha (PLC gamma), the p85 subunit of phosphatidylinositol 3-kinase (PI 3-kinase), She and Syp/PTP1D were not detectably associated with CD45 under the same conditions. These data suggested that in addition to its role as a protein tyrosine phosphatase, CD45 may participate in T-cell activation by serving as a membrane docking site for components of the Pas signalling pathway.	MCGILL UNIV, MCGILL CANC CTR, DEPT BIOCHEM, MONTREAL, PQ H3G 1Y6, CANADA; MCGILL UNIV, MCGILL CANC CTR, DEPT MED, MONTREAL, PQ H3G 1Y6, CANADA; MCGILL UNIV, MCGILL CANC CTR, DEPT ONCOL, MONTREAL, PQ H3G 1Y6, CANADA	McGill University; McGill University; McGill University								ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BARBEAU D, 1994, ONCOGENE, V9, P359; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BROOKSWILSON AR, 1989, MOL CELL BIOL, V9, P2214, DOI 10.1128/MCB.9.5.2214; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURNS CM, 1994, J BIOL CHEM, V269, P13594; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; FURUKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928, DOI 10.1073/pnas.91.23.10928; GERVAIS FG, 1993, MOL CELL BIOL, V13, P7112, DOI 10.1128/MCB.13.11.7112; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; Hunter T, 1989, CURR OPIN CELL BIOL, V1, P1168, DOI 10.1016/S0955-0674(89)80068-7; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; IIDA N, 1994, J BIOL CHEM, V269, P28576; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KORETZKY GA, 1993, J BIOL CHEM, V268, P8958; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P8628, DOI 10.1073/pnas.85.22.8628; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P21551; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1990, ONCOGENE, V5, P809; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RESKEKUNZ AB, 1985, EUR J IMMUNOL, V15, P1048, DOI 10.1002/eji.1830151017; ROWLEY RB, 1993, CELL MOL BIOL RES, V39, P209; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SCHNEIDER H, 1995, EUR J IMMUNOL, V25, P1044, DOI 10.1002/eji.1830250428; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; SCHRAVEN B, 1994, J BIOL CHEM, V269, P29102; SCHRAVEN B, 1990, NATURE, V345, P71, DOI 10.1038/345071a0; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; STOVER DR, 1994, MOL CELL BIOL, V14, P5523, DOI 10.1128/MCB.14.8.5523; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; SU J, 1994, J BIOL CHEM, V269, P18731; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; TAKEDA A, 1994, P NATL ACAD SCI USA, V88, P7734; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; VEILLETTE A, 1992, TRENDS GENET, V8, P61, DOI 10.1016/0168-9525(92)90045-6; VOLAREVIC S, 1993, SCIENCE, V260, P541, DOI 10.1126/science.8475386; VOLAREVIC S, 1990, P NATL ACAD SCI USA, V87, P7085, DOI 10.1073/pnas.87.18.7085; VOLAREVIC S, 1992, J EXP MED, V176, P835, DOI 10.1084/jem.176.3.835; WEIL R, 1994, J BIOL CHEM, V269, P22830; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS MJ, 1984, P NATL ACAD SCI-BIOL, V81, P6836, DOI 10.1073/pnas.81.21.6836; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	72	27	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	1996	12	2					253	263						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570203				2022-12-28	WOS:A1996TR53800005
J	McKenna, WG; Bernhard, EJ; Markiewicz, DA; Rudoltz, MS; Maity, A; Muschel, RJ				McKenna, WG; Bernhard, EJ; Markiewicz, DA; Rudoltz, MS; Maity, A; Muschel, RJ			Regulation of radiation-induced apoptosis in oncogene-transfected fibroblasts: Influence of H-ras on the G2 delay	ONCOGENE			English	Article						apoptosis; G2 delay; X-rays; cyclin B1	IRRADIATED MURINE TUMORS; INDUCED MITOTIC DELAY; HAMSTER OVARY CELLS; DNA STRAND BREAKS; IONIZING-RADIATION; EMBRYO CELLS; HELA-CELLS; V-MYC; SACCHAROMYCES-CEREVISIAE; P34CDC2 KINASE	Primary fibroblasts, after serum withdrawal or after irradiation, do not undergo apoptosis. Myc-transfected fibroblasts, in contrast, undergo apoptosis upon serum withdrawal and after irradiation. We have studied the relationship of apoptosis induction to effects on the G2 phase cell cycle in a series of rat embryo cells transformed by ras(H) plus myc or immortalized by myc alone. In this system, while the presence of ras(H) had little effect on the extent of apoptosis induction by serum withdrawal, ras(H) greatly suppressed the apoptotic response of myc-transfected cells to X-rays. The cells into which ras(H) had been introduced showed a profound G2 arrest associated with suppression of cyclin B1 mRNA expression. In contrast, cells with myc alone had a minimal G2 delay after irradiation and no suppression of cyclin B1 mRNA expression, We hypothesize that ras(H), by influencing the G2 response of cells to X-rays, exerts an anti-apoptotic effect. In support of this hypothesis; we found that treatment of cells with caffeine, an agent that relieves the G2 delay after irradiation resulted in increased apoptosis in the irradiated cells, but not in control cells.	UNIV PENN,DEPT RADIAT ONCOL,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania			BERNHARD, ERIC/HIU-0025-2022	Maity, Amit/0000-0001-7151-2845	NCI NIH HHS [CA64227] Funding Source: Medline; NIGMS NIH HHS [GM47439] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047439] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; BERNHARD EJ, 1994, RADIAT RES, V140, P393, DOI 10.2307/3579118; BRACEY TS, 1995, ONCOGENE, V10, P2391; CARR AM, 1995, SEMIN CELL BIOL, V6, P65, DOI 10.1016/1043-4682(95)90002-0; CHANG EH, 1987, SCIENCE, V237, P1036, DOI 10.1126/science.3616624; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; ELDIERY WS, 1994, CANCER RES, V54, P1169; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVANS DL, 1993, CANCER RES, V53, P2133; FAN SJ, 1995, CANCER RES, V55, P1649; GORCZYCA W, 1993, CANCER RES, V53, P1945; GORCZYCA W, 1993, LEUKEMIA, V7, P659; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; HURWITZ C, 1969, BIOPHYS J, V9, P607, DOI 10.1016/S0006-3495(69)86407-6; ILIAKIS G, 1990, CANCER RES, V50, P6575; KARBANDA S, 1994, ONCOGENE, V9, P3005; KASID U, 1987, SCIENCE, V237, P1039, DOI 10.1126/science.3616625; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LING CC, 1994, RADIOTHER ONCOL, V32, P129; LING CC, 1994, RADIOTHER ONCOL, V33, P17; LING CC, 1989, RADIAT RES, V120, P267, DOI 10.2307/3577713; LOCK RB, 1990, CANCER RES, V50, P3767; LOCK RB, 1994, CANCER RES, V54, P4933; LOCK RB, 1992, CANCER RES, V52, P1817; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MAITY A, 1994, BIOCHEM BIOPH RES CO, V202, P908, DOI 10.1006/bbrc.1994.2016; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; MARKIEWICZ DA, 1994, INT J RADIAT ONCOL, V28, P135, DOI 10.1016/0360-3016(94)90151-1; MCKENNA WG, 1990, CANCER RES, V50, P97; MCKENNA WG, 1991, RADIAT RES, V125, P283, DOI 10.2307/3578111; MCKENNA WG, 1990, INT J RADIAT ONCOL, V18, P849, DOI 10.1016/0360-3016(90)90407-B; MCKENNA WG, 1981, J BIOL CHEM, V265, P6435; MEYN RE, 1993, INT J RADIAT BIOL, V64, P583, DOI 10.1080/09553009314551801; Milas Luka, 1994, In Vivo (Attiki), V8, P665; MUSCHEL RJ, 1992, RADIAT RES, V132, P153, DOI 10.2307/3578520; MUSCHEL RJ, 1986, CANCER RES, V46, P4104; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; MUSCHEL RJ, 1993, CANCER RES, V53, P1128; MUSHCEL R, 1985, AM J PATHOL, V121, P1; OCONNOR PM, 1993, J BIOL CHEM, V268, P8298; OCONNOR PM, 1994, P NATL ACAD SCI USA, V91, P9480, DOI 10.1073/pnas.91.20.9480; PALAYOOR ST, 1995, RADIAT RES, V141, P235, DOI 10.2307/3579000; POWELL SN, 1995, CANCER RES, V55, P1643; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; RADFORD IR, 1994, INT J RADIAT BIOL, V65, P229, DOI 10.1080/09553009414550261; RADFORD IR, 1994, INT J RADIAT BIOL, V65, P217, DOI 10.1080/09553009414550251; RODEMANN HP, 1991, SCANNING MICROSCOPY, V5, P1135; ROWLEY R, 1992, RADIAT RES, V132, P144, DOI 10.2307/3578519; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; RUSSELL KJ, 1995, CANCER RES, V55, P1639; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; STEPHENS LC, 1991, RADIAT RES, V127, P308, DOI 10.2307/3577946; TOLMACH LJ, 1977, RADIAT RES, V71, P653, DOI 10.2307/3574633; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1992, RADIAT RES, V132, P141, DOI 10.2307/3578518; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; ZHEN WN, 1995, RADIAT RES, V141, P170, DOI 10.2307/3579044	65	77	80	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					237	245						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570201				2022-12-28	WOS:A1996TR53800003
J	RiveroLezcano, OM; Marcilla, A; Robbins, KC				RiveroLezcano, OM; Marcilla, A; Robbins, KC			Mutations in the non-catalytic domains of Fyn and Fgr tyrosine kinases reveal differences in mechanisms of their regulation	ONCOGENE			English	Article						Fyn; Fgr; tyrosine kinase; mutation; SH2 and SH3 domains	PROTEIN-KINASES; SH2 DOMAIN; C-SRC; GENE; PROTOONCOGENE; ACTIVATION; P60C-SRC; BINDING	Non-catalytic domains of tyrosine kinases from the Src family are believed to be regulated intra- and intermolecularly through protein-protein interactions. We have deleted the SH2 and SH3 domains from Fyn and Fgr and have generated two point mutations in residues completely conserved in all members of the Src family. The dramatically different biological effects of these mutations suggest that non-catalytic domains regulate Src family kinase activities through distinctly different mechanisms.	NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			marcilla, antonio/F-9996-2010; Rivero-Lezcano, Octavio Miguel/J-9089-2015	marcilla, antonio/0000-0003-0004-0531; Rivero-Lezcano, Octavio Miguel/0000-0002-8793-0731				ABRAMS CS, 1995, J BIOL CHEM, V270, P333, DOI 10.1074/jbc.270.1.333; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BOEUF H, 1995, ONCOGENE, V10, P433; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHANG CM, 1995, P NATL ACAD SCI USA, V92, P3928, DOI 10.1073/pnas.92.9.3928; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER JA, 1984, J BIOL CHEM, V259, P7835; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; RIVEROLEZCANO OM, 1994, FEBS LETT, V338, P183, DOI 10.1016/0014-5793(94)80361-7; ROBBINS KC, 1985, EMBO J, V4, P1783, DOI 10.1002/j.1460-2075.1985.tb03851.x; SARTOR O, 1992, J BIOL CHEM, V267, P3460; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; VEILLETTE A, 1992, ONCOGENE, V7, P971; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417	20	5	5	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2675	2679						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545125				2022-12-28	WOS:A1995TP18800024
J	Stadler, M; ChelbiAlix, MK; Koken, MHM; Venturini, L; Lee, C; Saib, A; Quignon, F; Pelicano, L; Guillemin, MC; Schindler, C; deThe, H				Stadler, M; ChelbiAlix, MK; Koken, MHM; Venturini, L; Lee, C; Saib, A; Quignon, F; Pelicano, L; Guillemin, MC; Schindler, C; deThe, H			Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element	ONCOGENE			English	Article						leukaemia; growth suppressor; promoter; STAT; cytokines	ACUTE PROMYELOCYTIC LEUKEMIA; PRIMARY BILIARY-CIRRHOSIS; DEPENDENT PROTEIN-KINASE; ZINC-FINGER; RAR-ALPHA; T(15-17) TRANSLOCATION; STIMULATED GENES; NUCLEAR-BODIES; EXPRESSION; CELLS	PML is a nuclear matrix protein with growth suppressing properties, whose expression is deregulated during oncogenesis. Moreover, in the t(15;17) translocation of acute promyelocytic leukaemia (APL), PML fusion to the retinoic acid receptor alpha (RAR alpha) is the likely molecular basis of leukaemogenesis. Here we show that interferons (IFNs) alpha, beta, and gamma upregulate PML mRNA expression. Analysis of 5' genomic sequences of the PML gene revealed an IFN-alpha/-beta stimulated response element (ISRE) and an IFN-gamma activation site (GAS) in the untranslated first exon. Binding of TFN signal transducers and activators of transcription (STATs) was demonstrated to be weak for the PML GAS, but strong for the PML ISRE which also seemed to contribute substantially to the IFN-gamma response. Thus, PML is a primary target gene of IFNs and would appear as a suitable candidate for mediating some of their antiproliferative effects. Abnormalities of PML structure, localisation or expression in human malignancy, constitute examples of how an IFN target gene may be altered in oncogenesis.	HOP ST LOUIS, CNRS, UPR A0043, F-75010 PARIS, FRANCE; COLUMBIA UNIV COLL PHYS & SURG, DIV MOLEC MED, NEW YORK, NY 10032 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Columbia University			koken, marcel/J-8154-2012; Quignon, Frédérique/P-4249-2017; koken, marcel/N-1349-2019	koken, marcel/0000-0002-0839-0125; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL21006-19] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; BRASCH K, 1992, EXP CELL RES, V202, P211, DOI 10.1016/0014-4827(92)90068-J; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; CHELBIALIX MK, 1995, IN PRESS LEUKEMIA; DANIEL MT, 1993, BLOOD, V82, P1858; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; FAGIOLI M, 1992, ONCOGENE, V7, P1083; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; GULDNER HH, 1992, J IMMUNOL, V149, P4067; HANASH SM, 1993, GENE CHROMOSOME CANC, V8, P34, DOI 10.1002/gcc.2870080107; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KORIOTH F, 1995, J CELL BIOL, V130, P1, DOI 10.1083/jcb.130.1.1; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MAUL GG, 1993, J GEN VIROL, V74, P2679, DOI 10.1099/0022-1317-74-12-2679; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; NIKOVITS W, 1990, MOL CELL BIOL, V10, P3468, DOI 10.1128/MCB.10.7.3468; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PINE R, 1988, NUCLEIC ACIDS RES, V16, P1371, DOI 10.1093/nar/16.4.1371; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; ROUSSELOT P, 1994, ONCOGENE, V9, P545; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; STREHLOW I, 1993, J BIOL CHEM, V268, P16590; STUURMAN N, 1992, J CELL SCI, V101, P773; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TERRIS B, 1995, CANCER RES, V55, P1590; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WERNERT N, 1992, AM J PATHOL, V140, P119; WILLIAMS BRG, 1991, EUR J BIOCHEM, V200, P1, DOI 10.1111/j.1432-1033.1991.tb21041.x; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WONDISFORD FE, 1989, J BIOL CHEM, V264, P14601	63	271	277	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2565	2573						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545113				2022-12-28	WOS:A1995TP18800012
J	Casares, S; Ionov, Y; Ge, HY; Stanbridge, E; Perucho, M				Casares, S; Ionov, Y; Ge, HY; Stanbridge, E; Perucho, M			The microsatellite mutator phenotype of colon cancer cells is often recessive	ONCOGENE			English	Article						mutator mutations; genomic instability; microsatellites; somatic cell hybrids	COLORECTAL-CANCER; MISMATCH REPAIR; GENETIC INSTABILITY; CHAIN-REACTION; DNA; MUTATIONS; CARCINOMA; CARCINOGENESIS; SEQUENCES; HISTORY	A new mutator mechanism for tumorigenesis, characterized by somatic genomic instability (SGI) at simple repeated sequences (SRS) or microsatellites, underlies hereditary nonpolyposis colorectal cancer (HNPCC) and some sporadic tumors of the colon and other types, To determine whether the microsatellite mutator phenotype (MMP) is dominant or recessive, we generated somatic cell hybrids between a tumor cell line without SGI at SRS (D98OR) and colon carcinoma cell lines with relative low (HCT-15) and high (LS174-T) SGI at SRS, The normal fidelity of replication of these unstable sequences was observed in each of these cell hybrids, Fusion of HCT-1S/DLD-1 low instability cells, with LS174-T, HCT116 and LoVo cell Lines, all exhibiting relative high instability, also restored the replication fidelity of SRS in all of the hybrids, Hybrids between the high instability cell lines did not grow possibly because of senescence or apoptosis, These results indicate that, in the cell lines analysed, the characterized mutator phenotype of the mismatch repair system resulting in high SGI at SRS, and the uncharacterized mutator phenotype underlying low SGI at SRS, are both recessive, The results also suggest that different tumor cells of the MMP harbor distinct altered growth-related genes.	CALIF INST BIOL RES,LA JOLLA,CA 92037; UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	University of California System; University of California Irvine				Perucho, Manuel/0000-0002-2169-2662				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRANCH P, 1995, NAT GENET, V9, P232; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BURKS RT, 1994, ONCOGENE, V9, P1163; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; HAN HJ, 1993, CANCER RES, V53, P5087; HEARNE CM, 1992, TRENDS GENET, V8, P288, DOI 10.1016/0168-9525(92)90256-4; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KAHN SM, 1995, CARCINOGENESIS, V16, P1223, DOI 10.1093/carcin/16.5.1223; KNUDSON AG, 1985, CANCER RES, V45, P1437; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOI M, 1994, CANCER RES, V54, P4308; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LOEB LA, 1991, CANCER RES, V51, P3075; LOEB LA, 1974, CANCER RES, V34, P2311; LOTHE RA, 1993, CANCER RES, V53, P5849; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PEINADO MA, 1992, P NATL ACAD SCI USA, V89, P10065, DOI 10.1073/pnas.89.21.10065; PEINADO MA, 1993, INT J ONCOL, V2, P123; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PELTOMAKI P, 1993, CANCER RES, V53, P5853; REENAN RAG, 1992, GENETICS, V132, P963; RHYU MG, 1994, ONCOGENE, V9, P29; RISINGER JI, 1993, CANCER RES, V53, P5100; Saxon P J, 1987, Methods Enzymol, V151, P313, DOI 10.1016/S0076-6879(87)51026-6; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, J BIOL CHEM, V269, P14367; WEBER JL, 1993, HUM MOL GENET, V2, P1123, DOI 10.1093/hmg/2.8.1123; WEISSMAN B, 1980, CYTOGENET CELL GENET, V28, P227, DOI 10.1159/000131536; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YEE CJ, 1994, CANCER RES, V54, P1641	51	39	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2303	2310						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570181				2022-12-28	WOS:A1995TK70200014
J	Park, SH; Weinberg, RA				Park, SH; Weinberg, RA			A putative effector of Ral has homology to Rho/Rac GTPase activating proteins	ONCOGENE			English	Article						Ral; Rho GTPase activating protein; protein interactions	PLATELET GN-PROTEINS; BINDING PROTEINS; GENE-PRODUCTS; IDENTIFICATION; EXPRESSION; RHO	We report here the cloning of a gene encoding a novel Pal interacting protein (RIP1) from a cDNA expression library using radiolabeled Pal as probe, RIP1 binds to Pal in a GTP-dependent manner, The 4.1 kb transcript of the RIP1 gene is present in all tissues analysed and encodes for a protein product of 648 residues, RIP1 shares sequence similarity with GAP proteins that are capable of activating the GTPase activity of members of the Rho/Rac family of GTPases, When tested, RIP1 could activate the GTPase activity of CDC42 and, to a lesser extent, Rad but not RhoA, Pas, or Pal. Activated Pal had no direct effect on the GTPase-activating ability of RIP1, in vitro.	MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)					NCI NIH HHS [CA39826-11] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039826] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BHULLAR RP, 1990, FEBS LETT, V260, P48, DOI 10.1016/0014-5793(90)80063-O; BHULLAR RP, 1992, FEBS LETT, V298, P61, DOI 10.1016/0014-5793(92)80022-9; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; EMKEY R, 1991, J BIOL CHEM, V266, P9703; HATEBOER G, 1995, EMBO J, V14, P3159, DOI 10.1002/j.1460-2075.1995.tb07318.x; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLOFSSON B, 1988, ONCOGENE, V3, P231; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; WILDEY GM, 1993, BIOCHEM BIOPH RES CO, V194, P552, DOI 10.1006/bbrc.1993.1855	24	165	168	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2349	2355						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570186				2022-12-28	WOS:A1995TK70200019
J	YANO, T; SANDER, CA; CLARK, HM; DOLEZAL, MV; JAFFE, ES; RAFFELD, M				YANO, T; SANDER, CA; CLARK, HM; DOLEZAL, MV; JAFFE, ES; RAFFELD, M			CLUSTERED MUTATIONS IN THE 2ND EXON OF THE MYC GENE IN SPORADIC BURKITT-LYMPHOMA	ONCOGENE			English	Article							HUMAN C-MYC; CASEIN KINASE-II; PHOSPHORYLATION SITE; NUCLEOTIDE-SEQUENCE; SOMATIC MUTATION; PROTEIN-KINASE; 1ST EXON; ONCOGENE; TRANSCRIPTION; REGION	The primary tumors from 15 untreated patients with Burkitt's lymphoma were analysed for abnormalities in the coding region of the MYC gene by single stranded conformational polymorphism (SSCP) analysis followed by DNA sequencing. Fourteen of the 15 tumors had one or more clonal mutations. Forty one mutations were found in the second exon; only one occurred in the third exon. Seven tumors had mutations that clustered in a region spanning amino acids 38-63. Four of these possessed mutations that altered prolines at positions 57 (3), 60 (1), and 63 (1). Seven tumors were mutated in the central portions of the second exon. These occurred at position 95 (2), position 115 (2), position 137 (1), and position 138 (3). Analysis of the published sequences from five lymphoma cell lines and one primary tumor showed a similar clustering of mutations, with all six having mutations in codons between positions 38-63. The regions where mutations occurred have been associated with a variety of properties, including transcriptional activation and cellular transformation. The number and location of mutations showed no correlation with either chromosome 8 or chromosome 14 breakpoints or with the Epstein-Bar virus positivity of the tumors. This unexpected, frequent occurrence of clustered mutations in the second exon of the MYC gene suggests a rote for the mutated MYC proteins in the pathogenesis of Burkitt's lymphoma, possibly through altered interactions of this domain with other cellular factors.	NCI,PATHOL LAB,HEMATOPATHOL SECT,BLDG 10,ROOM 2N110,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Jaffe, Elaine/G-8981-2014					ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAMPBELL MJ, 1992, MOL IMMUNOL, V29, P193, DOI 10.1016/0161-5890(92)90100-C; CARE A, 1986, EMBO J, V5, P905, DOI 10.1002/j.1460-2075.1986.tb04302.x; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; FRYKBERG L, 1987, ONCOGENE, V1, P415; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GILLESPIE DAF, 1989, MOL CELL BIOL, V9, P865, DOI 10.1128/MCB.9.2.865; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; JOHNSTON JM, 1991, BLOOD, V78, P2419; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KEOHAVONG P, 1989, P NATL ACAD SCI USA, V86, P9253, DOI 10.1073/pnas.86.23.9253; LEE WMF, 1985, MOL CELL BIOL, V5, P3345, DOI 10.1128/MCB.5.12.3345; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MURPHY W, 1986, P NATL ACAD SCI USA, V83, P2939, DOI 10.1073/pnas.83.9.2939; Nisson P E, 1991, PCR Methods Appl, V1, P120; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PAABO S, 1990, J BIOL CHEM, V265, P4718; PAPAS TS, 1985, NATURE, V318, P237, DOI 10.1038/318237a0; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; RABBITTS TH, 1983, NATURE, V306, P806, DOI 10.1038/306806a0; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RUSTGI AK, 1991, COLD SH Q B, V56, P163; SAKSELA K, 1992, ONCOGENE, V7, P347; SETH A, 1991, J BIOL CHEM, V266, P23521; SHOWE LC, 1985, MOL CELL BIOL, V5, P501, DOI 10.1128/MCB.5.3.501; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; STREET AJ, 1990, CURR TOP MICROBIOL, V166, P251; SUN LK, 1986, NUCLEIC ACIDS RES, V14, P4037, DOI 10.1093/nar/14.10.4037; SZAJNERT MF, 1987, NUCLEIC ACIDS RES, V15, P4553, DOI 10.1093/nar/15.11.4553; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; WATT R, 1983, NATURE, V303, P725, DOI 10.1038/303725a0; YANO T, 1992, BLOOD, V79, P1282, DOI 10.1182/blood.V79.5.1282.bloodjournal7951282; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510	41	93	95	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2741	2748						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8397370				2022-12-28	WOS:A1993LX34300015
J	KITAGAWA, M; OKABE, T; OGINO, H; MATSUMOTO, H; SUZUKITAKAHASHI, I; KOKUBO, T; HIGASHI, H; SAITOH, S; TAYA, Y; YASUDA, H; OHBA, Y; NISHIMURA, S; TANAKA, N; OKUYAMA, A				KITAGAWA, M; OKABE, T; OGINO, H; MATSUMOTO, H; SUZUKITAKAHASHI, I; KOKUBO, T; HIGASHI, H; SAITOH, S; TAYA, Y; YASUDA, H; OHBA, Y; NISHIMURA, S; TANAKA, N; OKUYAMA, A			BUTYROLACTONE-I, A SELECTIVE INHIBITOR OF CDK2 AND CDC2 KINASE	ONCOGENE			English	Article							TRANSCRIPTION FACTOR E2F; RETINOBLASTOMA-SUSCEPTIBILITY GENE; MATURATION-PROMOTING FACTOR; CELL-CYCLE CONTROL; PROTEIN-KINASE; POTENT INHIBITOR; RB PROTEIN; SACCHAROMYCES-CEREVISIAE; S-PHASE; PHOSPHORYLATION	We screened cdc2 kinase inhibitors from cultured mediums of micro organisms using purified mouse cyclin B-cdc2 kinase and a specific substrate peptide for cdc2 kinase. A selective inhibitor of cdc2 kinase was isolated from the cultured medium of Aspergillus species F-25799, and identified as butyrolactone I. Butyrolactone I inhibited cdc2 and cdk2 kinases but it had little effect on mitogen-activated protein kinase, protein kinase C, cyclic-AMP dependent kinase, casein kinase II, casein kinase I or epidermal growth factor-receptor tyrosine kinase. Its inhibitory effect was found to be due to competition with ATP. Butyrolactone I selectively inhibited the H1 histone phosphorylation in nuclear extracts. It also inhibited the phosphorylation of the product of retinoblastoma susceptibility gene in nuclear extracts and intact cells. Thus butyrolactone I should be very useful for elucidating the function of cdc2 and cdk2 kinases in cell cycle regulation.	MERCK RES LABS, BANYU TSUKUBA RES INST COLLABORAT, OKUBO 3, TSUKUBA 30033, JAPAN; NATL CANC CTR, RES INST, DIV BIOL, CHUO KU, TOKYO 104, JAPAN; KANAZAWA UNIV, FAC PHARMACEUT SCI, DIV BIOL, KANAZAWA, ISHIKAWA 920, JAPAN	National Cancer Center - Japan; Kanazawa University			Higashi, Hideaki/F-6872-2012					ABE K, 1991, EXP CELL RES, V192, P122, DOI 10.1016/0014-4827(91)90166-R; AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; AKIYAMA T, 1990, ONCOGENE, V5, P179; Beavo J A, 1974, Methods Enzymol, V38, P299; BRAUN S, 1984, J BIOL CHEM, V259, P2051; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KIRIYAMA N, 1977, CHEM PHARM BULL, V25, P2593; KITAGAWA M, 1992, ONCOGENE, V7, P1067; KITAGAWA M, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P431; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MINEO C, 1986, EXP CELL RES, V167, P53, DOI 10.1016/0014-4827(86)90203-X; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NAKAJO S, 1986, BIOCHEM INT, V13, P701; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PARKER PJ, 1985, EUR J BIOCHEM, V148, P579, DOI 10.1111/j.1432-1033.1985.tb08879.x; PINES J, 1990, New Biologist, V2, P389; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAY LB, 1988, J BIOL CHEM, V263, P12721; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SETO M, 1992, ONCOGENE, V7, P1401; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SZEPETOWSKI P, 1992, ONCOGENE, V7, P751; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TAYA Y, 1990, GENETIC BASIS FOR CARCINOGENESIS, P171; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; YASUDA H, 1981, BIOCHEMISTRY-US, V20, P4414, DOI 10.1021/bi00518a028; YASUDA H, 1991, CELL STRUCT FUNCT, V16, P105, DOI 10.1247/csf.16.105; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	73	247	256	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1993	8	9					2425	2432						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8395680				2022-12-28	WOS:A1993LT36800013
J	FINNERTY, H; KELLEHER, K; MORRIS, GE; BEAN, K; MERBERG, DM; KRIZ, R; MORRIS, JC; SOOKDEO, H; TURNER, KJ; WOOD, CR				FINNERTY, H; KELLEHER, K; MORRIS, GE; BEAN, K; MERBERG, DM; KRIZ, R; MORRIS, JC; SOOKDEO, H; TURNER, KJ; WOOD, CR			MOLECULAR-CLONING OF MURINE FLT AND FLT4	ONCOGENE			English	Note							RECEPTOR TYROSINE KINASE; CHROMOSOMAL LOCALIZATION; SEQUENCE-ANALYSIS; GROWTH-FACTOR; FAMILY; GENE; IDENTIFICATION	A wide range of growth and differentiation processes are regulated by the signalling of receptor tyrosine kinases (RTKs). We have developed a nested polymerase chain reaction (PCR) procedure with degenerate primers, and used it to identify RTKs expressed in murine fetal thymus. A novel RTK, called FLT4, and the murine homologue of FLT were found, and their PCR fragment sequences were used to isolate larger cDNA clones spanning the complete coding regions of these receptors. FLT4 was found to contain an extracellular region similar to the corresponding sequences of FLT and Flk-1, containing seven immunoglobulin domains.			FINNERTY, H (corresponding author), GENET INST INC, 87 CAMBRIDGE PK DR, CAMBRIDGE, MA 02140 USA.							APRELIKOVA O, 1992, CANCER RES, V52, P746; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; GALLAND F, 1992, GENOMICS, V13, P475, DOI 10.1016/0888-7543(92)90277-Y; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HUNTER T, 1991, METHOD ENZYMOL, P3; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PAUL SR, 1992, INT J CELL CLONING, V10, P309, DOI 10.1002/stem.5530100509; PONCZ M, 1982, P NATL ACAD SCI-BIOL, V79, P4298, DOI 10.1073/pnas.79.14.4298; RAZ V, 1991, ONCOGENE, V6, P753; ROSNET O, 1991, GENOMICS, V9, P380, DOI 10.1016/0888-7543(91)90270-O; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBUYA M, 1990, ONCOGENE, V5, P519; TERMAN BI, 1991, ONCOGENE, V6, P1677; VONHEIJNE G, 1987, SEQUENCE ANAL MOL BI, P113; WILKS AF, 1989, GENE, V85, P67, DOI 10.1016/0378-1119(89)90465-4; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YOSHIDA MC, 1987, CYTOGENET CELL GENET, V46, P724	22	86	100	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2293	2298						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8393164				2022-12-28	WOS:A1993LP17100032
J	FOOS, G; NATOUR, S; KLEMPNAUER, KH				FOOS, G; NATOUR, S; KLEMPNAUER, KH			TATA-BOX DEPENDENT TRANSACTIVATION OF THE HUMAN HSP70 PROMOTER BY MYB PROTEINS	ONCOGENE			English	Article							ONCOGENE C-MYB; GENE V-MYB; NUCLEOTIDE-SEQUENCE; CELLULAR PROGENITOR; PROTO-ONCOGENE; EXPRESSION; DIFFERENTIATION; DNA; CELLS; CDNA	The oncogene v-myb and its cellular progenitor c-myb encode nuclear, DNA-binding phosphoproteins that function as transcriptional regulators. Previous studies have demonstrated the existence of two distinct transactivation mechanisms for Myb-inducible promoters. One of these mechanisms, exemplified by the chicken mim-1 promoter, involves specific binding of Myb protein to Myb binding sites located upstream of the transcriptional start site. A second mechanism, exemplified by the human HSP70 promoter, does not require the presence of specific Myb binding sites. Here, we have more closely investigated transactivation of the human HSP70 promoter by Myb proteins. Mutational analysis of the human HSP70 promoter failed to show a correlation between Myb-inducibility and the presence of a particular upstream transcription factor binding site, but instead showed that Myb-inducibility was dependent on the presence of a particular type of TATA-box. This suggests that the TATA-box is involved in transactivation by v-Myb and that only a subset of TATA-boxes confers Myb-inducibility. Activation of the HSP70 promoter is dependent on the presence of most of the carboxy terminal amino acid sequences of v-Myb, including the previously identified acidic transactivation domain and a putative leucine-zipper region. Finally, we show that the HSP70 promoter is activated in a Myb binding site independent fashion not only by v-Myb, but also by chicken c-Myb and chicken B-Myb. These observations raise the possibility that the ability to transactivate in a Myb binding-site independent manner is a common property among Myb proteins. Since chicken B-Myb has been shown previously to be unable to transactivate a Myb binding-site containing promoter, such as the mim-1 promoter (Foos et al., 1992), our results also show that both modes of transactivation are independent of each other.	MAX PLANCK INST IMMUNBIOL,HANS SPEMANN LAB,STUBEWEG 51,W-7800 FREIBURG,GERMANY	Max Planck Society								AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; BOYLE WJ, 1983, P NATL ACAD SCI-BIOL, V80, P2834, DOI 10.1073/pnas.80.10.2834; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CRAIG RW, 1984, CANCER RES, V44, P442; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENE JM, 1987, MOL CELL BIOL, V7, P3646, DOI 10.1128/MCB.7.10.3646; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; LAM EWF, 1992, ONCOGENE, V7, P1185; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LUM LSY, 1992, MOL CELL BIOL, V12, P2599, DOI 10.1128/MCB.12.6.2599; MCMAHON J, 1988, ONCOGENE, V3, P717; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; Moscovici C., 1982, ADV VIRAL ONCOL, V1, P83; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKANO T, 1992, ONCOGENE, V7, P527; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; TAYLOR ICA, 1990, MOL CELL BIOL, V10, P165, DOI 10.1128/MCB.10.1.165; THEISEN M, 1986, EMBO J, V5, P719, DOI 10.1002/j.1460-2075.1986.tb04273.x; TOKODORO K, 1988, P NATL ACAD SCI USA, V85, P8900; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; WEINTRAUB SJ, 1992, MOL CELL BIOL, V12, P512, DOI 10.1128/MCB.12.2.512; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	47	48	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1775	1782						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510924				2022-12-28	WOS:A1993LG68200008
J	IWABUCHI, K; LI, B; BARTEL, P; FIELDS, S				IWABUCHI, K; LI, B; BARTEL, P; FIELDS, S			USE OF THE 2-HYBRID SYSTEM TO IDENTIFY THE DOMAIN OF P53 INVOLVED IN OLIGOMERIZATION	ONCOGENE			English	Note							WILD-TYPE P53; T-ANTIGEN; MUTANT P53; SV40-TRANSFORMED CELLS; PROTEINS BIND; SEQUENCE; TRANSFORMATION; IDENTIFICATION; MUTATIONS; ONCOGENE	We used a yeast-based genetic assay, the two-hybrid system, to characterize the domain of the tumor-suppressor p53 involved in oligomerization. This assay relies on the reconstitution of the function of a transcriptional activator, the yeast GAL4 protein, via the interaction of a protein fused to the DNA-binding domain of GAL4 with a protein fused to the transcriptional activation domain of GAL4. We show by a reconstruction experiment that this approach could detect the interaction of p53 deleted for its N-terminal activation domain with SV40 large T antigen. We then searched a library of human proteins present as activation domain hybrids for proteins that can interact with the hybrid of p53 with the DNA-binding domain. This search identified 36 plasmids containing the p53 gene, representing 10 different classes. These results provide an additional in viro demonstration of p53 oligomerization. The smallest p53 fragment identified from screening the library contained only amino acids 331-393, indicating that this small C-terminal fragment is sufficient to mediate oligomerization. In addition, a mutant p53 protein could bind to the wild-type protein in this assay, providing support for the idea that mutant forms of p53 act in a dominant-negative manner through C-terminal oligomerization with the wild type.	SUNY,DEPT MICROBIOL,STONY BROOK,NY 11794; SUNY,GRAD PROGRAM MOLEC & CELL BIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College					NCI NIH HHS [CA54699] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054699] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Miller J.H., 1972, EXPT MOL GENETICS; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8	32	171	200	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1693	1696						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502489				2022-12-28	WOS:A1993LE06400035
J	HALL, FL; WILLIAMS, RT; WU, LT; WU, F; CARBONAROHALL, DA; HARPER, JW; WARBURTON, D				HALL, FL; WILLIAMS, RT; WU, LT; WU, F; CARBONAROHALL, DA; HARPER, JW; WARBURTON, D			2 POTENTIALLY ONCOGENIC CYCLINS, CYCLIN-A AND CYCLIN-D1, SHARE COMMON PROPERTIES OF SUBUNIT CONFIGURATION, TYROSINE PHOSPHORYLATION AND PHYSICAL ASSOCIATION WITH THE RB PROTEIN	ONCOGENE			English	Note							RETINOBLASTOMA GENE-PRODUCT; HISTONE-H1 KINASE-ACTIVITY; E2F TRANSCRIPTION FACTOR; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; CANDIDATE ONCOGENE; CDC2; MITOSIS; P34CDC2; TRANSFORMATION	Originally identified as a 'mitotic cyclin', cyclin A exhibits properties of growth factor sensitivity, susceptibility to viral subversion and association with a tumor-suppressor protein, properties which are indicative of an S-phase-promoting factor (SPF) as well as a candidate proto-oncogene. Other recent studies have identified human cyclin D1 (PRAD1) as a putative G1 cyclin and candidate proto-oncogene. However, the specific enzymatic activities and, hence, the precise biochemical mechanisms through which cyclins function to govern cell cycle progression remain unresolved. In the present study we have investigated the coordinate interactions between these two potentially oncogenic cyclins, cyclin-dependent protein kinase subunits (cdks) and the Rb tumor-suppressor protein. The distribution of cyctin D isoforms was modulated by serum factors in primary fetal rat lung epithelial cells. Moreover, cyclin D1 was found to be phosphorylated on tyrosine residues in vivo and, like cyclin A, was readily phosphorylated by pp60c-src in vitro. In synchronized human osteosarcoma cells, cyclin D1 is induced in early G1 and becomes associated with p9Ckshs1, a Cdk-binding subunit. Immunoprecipitation experiments with human osteosarcoma cells and Ewing's sarcoma cells demonstrated that cyclin D1 is associated with both p34cdc2 and p33cdk2, and that cyclin D1 immune complexes exhibit appreciable histone H1 kinase activity. Immobilized, recombinant cyclins A and D1 were found to associate with cellular proteins in complexes that contain the p105Rb protein. This study identifies several common aspects of cyclin biochemistry, including tyrosine phosphorylation and the potential to interact directly or indirectly with the Rb protein, that may ultimately relate membrane-mediated signaling events to the regulation of gene expression.	UNIV SO CALIF, SCH MED, CHILDRENS HOSP, DIV NEONATAL & PEDIAT PULMUNOL, LOS ANGELES, CA 90054 USA; BAYLOR COLL MED, DEPT BIOCHEM, HOUSTON, TX 77030 USA; UNIV SO CALIF, SCH PHARM, LOS ANGELES, CA 90054 USA	Children's Hospital Los Angeles; University of Southern California; Baylor College of Medicine; University of Southern California	HALL, FL (corresponding author), UNIV SO CALIF, SCH MED, CHILDRENS HOSP LOS ANGELES, DIV ORTHOPAED SURG, 4650 SUNSET BLVD, LOS ANGELES, CA 90054 USA.			Harper, Jeffrey/0000-0002-6944-7236	NHLBI NIH HHS [HL-44977, HL-44060] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044977, R01HL044060] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BLANQUET V, 1990, GENOMICS, V8, P595, DOI 10.1016/0888-7543(90)90052-V; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CARBONAROHALL D, 1993, IN PRESS ONCOGENE; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DOBBS LG, 1986, AM REV RESPIR DIS, V134, P141; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HALL FL, 1991, J BIOL CHEM, V266, P17430; Hall FL, 1991, CURR OPIN CELL BIOL, V3, P176, DOI 10.1016/0955-0674(91)90136-M; HARADA S, 1991, ONCOGENE, V6, P461; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; Hunt T, 1991, Semin Cell Biol, V2, P213; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MINSHULL J, 1989, J CELL SCI, P77; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MORGAN DO, 1991, METHOD ENZYMOL, V200, P645; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MURRAY AW, 1991, NATURE, V349, P367, DOI 10.1038/349367a0; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PINES J, 1990, New Biologist, V2, P389; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POST M, 1988, AM REV RESPIR DIS, V137, P525, DOI 10.1164/ajrccm/137.3.525; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SAMIEI M, 1991, J BIOL CHEM, V266, P14889; SANGHERA JS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P335, DOI 10.1016/0167-4889(92)90240-C; TAMURA T, 1990, ONCOGENE, V5, P1259; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WARBURTON D, 1989, J APPL PHYSIOL, V66, P901, DOI 10.1152/jappl.1989.66.2.901; WILLIAMS RT, 1992, ONCOGENE, V7, P423; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	60	73	73	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1377	1384						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479754				2022-12-28	WOS:A1993KY32800032
J	OEHLER, T; PINTZAS, A; STUMM, S; DARLING, A; GILLESPIE, D; ANGEL, P				OEHLER, T; PINTZAS, A; STUMM, S; DARLING, A; GILLESPIE, D; ANGEL, P			MUTATION OF A PHOSPHORYLATION SITE IN THE DNA-BINDING DOMAIN IS REQUIRED FOR REDOX-INDEPENDENT TRANSACTIVATION OF AP1-DEPENDENT GENES BY V-JUN	ONCOGENE			English	Article							C-JUN; FOS; ONCOGENE; INVITRO; REGION; AP-1	The ability of the nuclear onocprotein Jun to activate transcription is controlled both by level of DNA binding and by the activity of its transactivation domain. Control of DNA binding is achieved by two mechanisms: phosphorylation and redox regulation. Mutation of Ser-226 inhibits phosphorylation of the DNA binding, resulting in enhanced DNA-binding and transactivation activity of Jun. In contrast, mutation of Cys-252, which is the target for repression of DNA-binding activity under oxidative conditions, results in a strong decrease of Jun-specific activation of transcription. However, transactivation by c-Jun-Cys-252 is fully restored upon mutation of Ser-226. Both mutations are also found in the oncogenic counterpart of c-Jun, v-Jun, and are the only differences between these proteins in the DNA-binding domain, suggesting that v-Jun escapes down-modulation of DNA binding by both mechanisms. However, inhibition of phosphorylation of Ser-226 is absolutely required for the ability of v-Jun to activate transcription of AP-1-dependent genes in a redox-independent manner.	KERNFORSCHUNGSZENTRUM KARLSRUHE GMBH, INST GENET, POSTFACH 3640, W-7500 KARLSRUHE 1, GERMANY; BEATSON INST CANC RES, CANC RES CAMPAIGN BEATSON LABS, WOLFSON LAB MOLEC PATHOL, GLASGOW G61 1BD, SCOTLAND	Helmholtz Association; Karlsruhe Institute of Technology; Beatson Institute			Piris, Miguel A/AAP-1445-2020	Piris, Miguel A/0000-0001-5839-3634; Gillespie, David/0000-0002-6338-0544				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; COHEN DR, 1990, ONCOGENE, V5, P929; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; FRAME MC, 1991, ONCOGENE, V6, P205; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MORGAN IM, 1992, ONCOGENE, V7, P1119; OEHLER T, 1992, MOL CELL BIOL, V12, P5508, DOI 10.1128/MCB.12.12.5508; PONTA H, 1992, BIOCHIM BIOPHYS ACTA, V1129, P255, DOI 10.1016/0167-4781(92)90501-P; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	25	40	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1141	1147						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479739				2022-12-28	WOS:A1993KY32800005
J	VANHAESEBROECK, B; REED, JC; DEVALCK, D; GROOTEN, J; MIYASHITA, T; TANAKA, S; BEYAERT, R; VANROY, F; FIERS, W				VANHAESEBROECK, B; REED, JC; DEVALCK, D; GROOTEN, J; MIYASHITA, T; TANAKA, S; BEYAERT, R; VANROY, F; FIERS, W			EFFECT OF BCL-2 PROTOONCOGENE EXPRESSION ON CELLULAR-SENSITIVITY TO TUMOR NECROSIS FACTOR-MEDIATED CYTOTOXICITY	ONCOGENE			English	Article							DNA FRAGMENTATION; FOLLICULAR LYMPHOMA; CHROMOSOMAL BREAKPOINT; THYMOCYTE APOPTOSIS; TRANSGENIC MICE; GENE-EXPRESSION; RESISTANT CELLS; CYTO-TOXICITY; B-CELLS; DEATH	Introduction and expression of the proto-oncogene bcl-2 (B-cell lymphoma/leukemia 2) has been shown to extend the survival of certain hematopoietic cell lines after growth factor deprivation, by blocking apoptosis or programmed cell death. We investigated the effect of bcl-2 expression on cellular sensitivity to lysis by tumor necrosis factor (TNF), a cytokine capable of inducing apoptosis in several tumor cell lines. Introduction of the human bcl-2 gene in the highly TNF-sensitive L929 mouse fibrosarcoma cell fine did not result in altered TNF sensitivity. Likewise, NIH3T3 and REF cells, which are resistant to TNF cytotoxicity but become TNF sensitive upon cotreatment with actinomycin D or upon expression of the adenovirus EIA gene, did not show altered TNF sensitivity upon bcl-2 transfection. Despite constitutive expression of the endogenous bcl-2 gene, human MCF7 breast carcinoma cells, as well as HL60 promyelocytic leukemia and U937 histiocytic lymphoma cell lines were found to be TNF sensitive. bcl-2-overexpressing derivatives of these cell lines did not acquire reduced TNF sensitivity and still exhibited the characteristic pattern of internucleosomal DNA fragmentation of TNF-induced apoptosis. Moreover, bcl-2 expression in the interleukin 3 (IL-3)-dependent myeloid cell line 32D protected these cells from apoptosis resulting from growth factor deprivation, but not from apoptosis induced by TNF. These data clearly establish the absence of a correlation between bcl-2 gene expression and cellular sensitivity to TNF-induced cell lysis. These findings are discussed in the context of the hypothesis of different pathways for induction of apoptosis, only some of which are affected by bcl-2 expression.	STATE UNIV GHENT,MOLEC BIOL LAB,K L LEDEGANCKSTR 35,B-9000 GHENT,BELGIUM; UNIV PENN,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19104	Ghent University; University of Pennsylvania			van Roy, Frans M/C-6123-2009; Beyaert, Rudi/B-2589-2009	van Roy, Frans M/0000-0003-4358-1039; Beyaert, Rudi/0000-0002-5704-582X	NATIONAL CANCER INSTITUTE [R01CA047956] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47956] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALNEMRI ES, 1990, J BIOL CHEM, V265, P17323; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COHEN JJ, 1984, J IMMUNOL, V132, P38; DEALTRY GB, 1987, EUR J IMMUNOL, V17, P689, DOI 10.1002/eji.1830170517; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; HALDAR S, 1989, NATURE, V342, P195, DOI 10.1038/342195a0; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; IMAMURA K, 1988, J BIOL CHEM, V263, P10247; KYPRIANOU N, 1991, J NATL CANCER I, V83, P346, DOI 10.1093/jnci/83.5.346; LANCASTER JR, 1989, FEBS LETT, V248, P169, DOI 10.1016/0014-5793(89)80454-5; LASTER SM, 1988, J IMMUNOL, V141, P2629; MACDONALD HR, 1990, NATURE, V343, P642, DOI 10.1038/343642a0; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MIYASHITA T, 1992, IN PRESS CANCER RES, V52; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NEALE ML, 1988, IMMUNOLOGY, V64, P81; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PEZZELLA F, 1990, AM J PATHOL, V137, P225; REED JC, 1990, P NATL ACAD SCI USA, V87, P3660, DOI 10.1073/pnas.87.10.3660; REED JC, 1990, MOL CELL BIOL, V10, P4370, DOI 10.1128/MCB.10.8.4370; REED JC, 1991, CANCER RES, V51, P6529; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; RUBIN BY, 1988, CANCER RES, V48, P6006; RUFF MR, 1981, LYMPHOKINES, V2, P235; SCHMID DS, 1986, P NATL ACAD SCI USA, V83, P1881, DOI 10.1073/pnas.83.6.1881; SCHMID DS, 1987, LYMPHOKINE RES, V6, P195; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; SUFFYS P, 1991, EUR J BIOCHEM, V195, P465, DOI 10.1111/j.1432-1033.1991.tb15727.x; TADA H, 1986, J IMMUNOL METHODS, V93, P157, DOI 10.1016/0022-1759(86)90183-3; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VANHAESEBROECK B, 1991, CANCER RES, V51, P2469; VANHAESEBROECK B, 1990, VIROLOGY, V176, P362, DOI 10.1016/0042-6822(90)90006-D; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Walker N I, 1988, Methods Achiev Exp Pathol, V13, P18; WARING P, 1990, J BIOL CHEM, V265, P14476; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAMAUCHI N, 1989, CANCER RES, V49, P1671; ZIMMERMAN RJ, 1989, CANCER RES, V49, P1644	55	121	123	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1075	1081						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455935				2022-12-28	WOS:A1993KT22000033
J	WOJTASZEK, PA; STUMPO, DJ; BLACKSHEAR, PJ; MACARA, IG				WOJTASZEK, PA; STUMPO, DJ; BLACKSHEAR, PJ; MACARA, IG			SEVERELY DECREASED MARCK EXPRESSION CORRELATES WITH RAS-REVERSION BUT NOT WITH MITOGENIC RESPONSIVENESS	ONCOGENE			English	Article							PROTEIN-KINASE-C; MAJOR SPECIFIC SUBSTRATE; TRANSFORMED-CELLS; BACTERIAL LIPOPOLYSACCHARIDE; PHOSPHOINOSITIDE HYDROLYSIS; CELLULAR SUBSTRATE; FLAT REVERTANTS; GROWTH-FACTOR; BOVINE BRAIN; GENE-PRODUCT	Phorbol ester-inducible phosphorylation of MARCKS, the '80-kDa' substrate of protein kinase C, was undetectable in several phenotypically dominant, non-transformed revertants independently derived from the ras-transformed cell line NIH3T3 DT-ras. Extremely low expression of MARCKS protein accounted for this apparent lack of phosphorylation. MARCKS-encoding mRNA levels were correspondingly decreased relative to normal and ras-transformed cells in all four ras revertant cell lines studied: C-11 and F-2, derived by 5-azacytidine treatment and selection with ouabain; CHP 9CJ, derived by ethytmethane sulfonate mutagenesis and selection with cis-hydroxy-L-proline; and 12-V3, derived by transfection with the human Krev-1 gene. However, re-expression of MARCKS after transfection of a cloned MARCKS cDNA into the C-11 ras revertant cells was not sufficient to induce retransformation. In fact, no significant difference in sensitivity to mitogenic stimulation by phorbol esters was observed among several cell lines expressing widely varying levels of MARCKS. This evidence argues against a direct role for MARCKS in mitogenic signaling. However, the strong correlation between attentuation of MARCKS expression and phenotypically dominant ras reversion suggests that a common negative regulatory mechanism might be responsible for both effects, presenting a potentially useful strategy for identifying factors involved in transducing the ras signal.	UNIV VERMONT,COLL MED,DEPT PATHOL,BURLINGTON,VT 05405; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED,DURHAM,NC 27710	University of Vermont; Duke University; Howard Hughes Medical Institute			Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529	NCI NIH HHS [CA-43551] Funding Source: Medline; NIEHS NIH HHS [ES 01247] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001247] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; ALBERT KA, 1986, P NATL ACAD SCI USA, V83, P2822, DOI 10.1073/pnas.83.9.2822; ALONSO T, 1988, P NATL ACAD SCI USA, V85, P4271, DOI 10.1073/pnas.85.12.4271; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HARTWIG JH, 1992, NATURE, V356, P61; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; JOSEPH CK, 1992, J BIOL CHEM, V267, P1327; KAMATA T, 1987, ONCOGENE, V1, P37; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLIGMAN D, 1986, J NEUROCHEM, V47, P298; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKALL J, 1979, ANAL BIOCHEM, V95, P270, DOI 10.1016/0003-2697(79)90216-1; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MILLAR JBA, 1989, P NATL ACAD SCI USA, V86, P3204, DOI 10.1073/pnas.86.9.3204; MORRIS JDH, 1989, ONCOGENE, V4, P27; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; PARRIES G, 1987, P NATL ACAD SCI USA, V84, P2648, DOI 10.1073/pnas.84.9.2648; PIZON V, 1988, ONCOGENE, V3, P201; ROSEN A, 1989, J BIOL CHEM, V264, P9118; Sambrook J, 1989, MOL CLONING LABORATO; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; SIMEK SL, 1989, P NATL ACAD SCI USA, V86, P7410, DOI 10.1073/pnas.86.19.7410; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; WU WCS, 1982, P NATL ACAD SCI-BIOL, V79, P5249, DOI 10.1073/pnas.79.17.5249; YANAGIHARA K, 1990, ONCOGENE, V5, P1179	38	19	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					755	760						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437859				2022-12-28	WOS:A1993KN00800028
J	KOLCH, W; HEIDECKER, G; TROPPMAIR, J; YANAGIHARA, K; BASSIN, RH; RAPP, UR				KOLCH, W; HEIDECKER, G; TROPPMAIR, J; YANAGIHARA, K; BASSIN, RH; RAPP, UR			RAF REVERTANT CELLS RESIST TRANSFORMATION BY NONNUCLEAR ONCOGENES AND ARE DEFICIENT IN THE INDUCTION OF EARLY RESPONSE GENES BY TPA AND SERUM	ONCOGENE			English	Article							PROTEIN KINASE-C; NIH 3T3 CELLS; SIGNAL TRANSDUCTION; V-RAF; TYROSINE PHOSPHORYLATION; NEGATIVE AUTOREGULATION; EXTRACELLULAR SIGNALS; NUCLEOTIDE-SEQUENCE; FLAT REVERTANTS; AUTO-REGULATION	A revertant cell line was generated from v-raf transformed NIH/3T3 fibroblasts. These cells, termed CHP25, express a functional v-raf oncogene. However, they are non-tumorigenic, do not form colonies in soft agar and possess a flat morphology. CHP25 cell are resistant to re-transformation by sis, ras, tyrosine kinase as well as serine/threonine kinase-encoding oncogenes suggesting that Raf functions downstream of most membrane associated signal transducers. In contrast to v-raf transformed cells, in which the endogenous Raf-1 protein kinase is constitutively activated, v-Raf in CHP25 cells does not activate endogenous Raf-1 kinase. Since mitogen regulation of Raf-1 kinase in CHP25 cells is intact, we conclude that CHP25 cells are blocked at the level of Raf-1 substrate phosphorylation. Consistent with this interpretation CHP25 cells show specific alterations of early gene induction. The serum induction of c-fos and junD as well as the serum and TPA (12-O-tetradecanoylphorbol-13-acetate) induction of junB and egr-1 are almost completely abolished. Only v-fos can transform CHP25, whereas c-fos, v-myc, c-jun and junB are ineffective. These data suggest that the lesion responsible for the revertant phenotype of CHP25 cells is the inability to activate the AP-1 complex. We conclude that Raf-1 signaling is essential for transformation of NIH/3T3 cells by peripheral oncogenes and for regulation of a subset of early response genes by TPA and serum growth factors.	NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702; NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20855	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Kolch, Walter/ABF-2102-2021	Troppmair, Jakob/0000-0002-0611-3837; Kolch, Walter/0000-0001-5777-5016				APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CIARDIELLO F, 1988, CANCER RES, V48, P2483; Cleveland J L, 1988, Oncogene Res, V3, P357; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DESSUREAULT J, 1990, J CELL BIOCHEM, V43, P293, DOI 10.1002/jcb.240430309; GERFAUX J, 1990, MOL CARCINOGEN, V3, P103, DOI 10.1002/mc.2940030208; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HAYNES JR, 1988, MOL CELL BIOL, V8, P2419, DOI 10.1128/MCB.8.6.2419; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HEIDECKER G, 1992, IN PRESS ADV CANCER; HEIDECKER G, 1989, GENES SIGNAL TRANSDU, P339; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KOLCH W, 1990, ONCOGENE, V5, P713; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KUZUMAKI N, 1989, MOL CELL BIOL, V9, P2258, DOI 10.1128/MCB.9.5.2258; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MCMAHON AP, 1990, DEVELOPMENT, V108, P281; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NOSE K, 1989, MOL CARCINOGEN, V2, P208, DOI 10.1002/mc.2940020407; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; ROEBROEK AJM, 1986, VIRUS RES, V6, P15, DOI 10.1016/0168-1702(86)90053-5; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SCHONTHAL A, 1989, ONCOGENE, V4, P629; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; TROPPMAIR J, 1989, P NATL ACAD SCI USA, V86, P9941, DOI 10.1073/pnas.86.24.9941; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; VANBEVEREN C, 1984, VIROLOGY, V135, P229, DOI 10.1016/0042-6822(84)90133-8; VARNUM BC, 1989, ONCOGENE, V4, P119; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WILSON T, 1988, EMBO J, V7, P4193, DOI 10.1002/j.1460-2075.1988.tb03316.x; WISDOM R, 1990, MOL CELL BIOL, V10, P5626, DOI 10.1128/MCB.10.11.5626; YAMADA H, 1990, MOL CELL BIOL, V10, P1822, DOI 10.1128/MCB.10.4.1822; YANAGIHARA K, 1990, ONCOGENE, V5, P1179; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	71	28	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					361	370						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426742				2022-12-28	WOS:A1993KN00600015
J	Ellis, C; Kasmi, F; Ganju, P; Walls, E; Panayotou, G; Reith, AD				Ellis, C; Kasmi, F; Ganju, P; Walls, E; Panayotou, G; Reith, AD			A juxtamembrane autophosphorylation site in the Eph family receptor tyrosine kinase, Sek, mediates high affinity interaction with p59fyn	ONCOGENE			English	Article						Sek; Eph-like receptors; p59fyn; SH2-binding motif; autophosphorylation sites	GROWTH-FACTOR RECEPTOR; GLUTATHIONE-S-TRANSFERASE; SH2 DOMAINS; SRC FAMILY; PHOSPHORYLATION SITES; ESCHERICHIA-COLI; PDGF RECEPTOR; BETA-RECEPTOR; PROTEINS; BINDING	The large subfamily of receptor tyrosine kinases (RTKs) for which Eph is the prototype have likely roles in intercellular communication during normal mammalian development, but the biochemical signalling pathways utilised by this family are poorly characterised, We have now identified two in vitro autophosphorylation sites within the juxtamembrane domain of the Eph family member Sek, and a candidate binding protein for the activated Sek kinase, Specific antibodies defined Sek as a 130 kDa glycoprotein with protein kinase activity expressed in keratinocytes, whilst a bacterially expressed gst-Sek kinase domain fusion protein autophosphorylated exclusively on tyrosine residues, confirming that Sek encodes an authentic protein tyrosine kinase, Two dimensional phosphopeptide mapping and site-directed mutagenesis defined juxtamembrane residue Y602 as a major site of in vitro autophosphorylation in Sek, whilst Y596 was phosphorylated to a lower stoichiometry. Complementary approaches of in vitro binding assays and BIAcore analysis revealed a high affinity association between the Y602 Sek autophosphorylation site and the cytoplasmic tyrosine kinase p59fyn, an interaction mediated through the SH2 domain of this intracellular signalling molecule, Moreover, these data identify the novel phosphotyrosyl motif pYEDP as mediating high affinity association with fyn-SH2, extending the previously defined consensus motif for this interaction, The extensive conservation of this fyn-binding motif within the juxtamembrane domain of Eph family RTKs suggests that signalling through fyn, or fyn-related, tyrosine kinases may be utilised by many members of this large subclass of transmembrane receptors.	INST CANC RES, CHESTER BEATTY LABS, LONDON SW3 6JB, ENGLAND; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND; UNIV LONDON UNIV COLL, DEPT BIOCHEM & MOLEC BIOL, LONDON WC1E 6BT, ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Ludwig Institute for Cancer Research; University of London; University College London								ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ANDRES AC, 1994, ONCOGENE, V9, P1461; BARE DJ, 1993, ONCOGENE, V8, P1429; CHAN J, 1991, ONCOGENE, V6, P1057; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; GANJU P, 1994, ONCOGENE, V9, P1613; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; INGRAHAM CA, 1992, ONCOGENE, V7, P95; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KIYOKAWA E, 1994, CANCER RES, V54, P3645; KURIYAN J, 1993, CURR OPIN STRUC BIOL, V3, P828, DOI 10.1016/0959-440X(93)90145-B; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LUO K, 1990, ONCOGENE, V5, P921; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MARU Y, 1990, ONCOGENE, V5, P445; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NIETO MA, 1992, DEVELOPMENT, V116, P1137; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; REITH AD, 1991, GENOME ANAL, V3, P105; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; YAGI T, 1993, NATURE, V366, P742, DOI 10.1038/366742a0; YAGI T, 1993, ONCOGENE, V8, P3343; YAGI T, 1994, ONCOGENE, V9, P2433; ZHOU R, 1994, J NEUROSCI RES, V37, P129, DOI 10.1002/jnr.490370117; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	56	99	107	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	1996	12	8					1727	1736						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622893				2022-12-28	WOS:A1996UG45800015
J	Greulich, H; Reichman, C; Hanafusa, H				Greulich, H; Reichman, C; Hanafusa, H			Delay in serum stimulation of Erk activity caused by oncogenic transformation	ONCOGENE			English	Article						Erk; Crk; signal transduction; mitogenesis	EPIDERMAL GROWTH-FACTOR; GTPASE-ACTIVATING PROTEIN; MAP KINASE; NUCLEOTIDE EXCHANGE; GUANINE-NUCLEOTIDES; GENE-PRODUCT; V-CRK; TYROSINE; PHOSPHORYLATION; FIBROBLASTS	Mitogenic growth factor stimulation activates several signal transduction pathways, including the well-characterized Ras-Erk pathway, resulting in transient activation of Erk1 and Erk2. Oncogenic transformation, however, causes constitutive activation of growth signalling pathways, resulting in an accelerated rate of cell division. We investigated the effects of transformation on serum and growth factor stimulation of Erk1 and Erk2, and show that stimulation of these MAP kinases, as well as the Erk activator Mek, is delayed in oncogene transformed cells. Possible mechanisms of this delay are explored. In addition, our data indicate that prolonged mitogenic stimulation does not necessarily result in constitutive activation of Erk1 and Erk2.	ROCKEFELLER UNIV,MOLEC ONCOL LAB,NEW YORK,NY 10021	Rockefeller University					NCI NIH HHS [CA09673-19, CA44356] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; HANAFUSA H, 1969, P NATL ACAD SCI USA, V63, P318, DOI 10.1073/pnas.63.2.318; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WELHAM MJ, 1990, ONCOGENE, V5, P161; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011	38	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1689	1695						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622889				2022-12-28	WOS:A1996UG45800011
J	Perez, JL; Jing, SQ; Wong, TW				Perez, JL; Jing, SQ; Wong, TW			Identification of two isoforms of the Cak receptor kinase that are coexpressed in breast tumor cell lines	ONCOGENE			English	Article						receptor kinases; cell adhesion; receptor isoforms	GROWTH-FACTOR; FACTOR-VIII; TYROSINE; SURFACE; DNA	The Cak receptor kinase is a member of a novel family of receptors that are characterized by the unique structure of the ectodomains. We have identified a new isoform of Cak that differs from the original isolate by the deletion of 37 amino acids in the cytoplasmic juxtamembrane sequence. Analysis of the genomic sequence suggests that the two isoforms arise by exon skipping. The isoform-specific insert contains the motif NPXY, which was previously shown to be involved in diverse signaling function in a number of receptors. By RNase protection analyses, we found that the long isoform, Cak I is expressed at three- to sevenfold the abundance of the short isoform (Cak II). By Western blotting, Cak I receptor was found to be expressed in mouse embryos and in adult brain. Cak II protein was not detected in mouse embryos or adult tissues, but is abundantly expressed in some breast tumor cell lines. The expression profile of Cak suggests that its primary function is likely to be in developmental regulation. The coexpression of the Cak isoforms in some epithelial cell lines suggests that heterodimer formation may be a key feature in the function of the rectpror	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854; AMGEN INC,THOUSAND OAKS,CA 91320	Rutgers State University New Brunswick; Rutgers State University Medical Center; Amgen					NIGMS NIH HHS [1 F31 GM16363-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM016363] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVES R, 1995, ONCOGENE, V10, P610; BARBACID M, 1993, ONCOGENE, V8, P2033; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CREPARO A, 1995, J BIOL CHEM, V270, P15639; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; KANE WH, 1988, BLOOD, V71, P539; KARN T, 1993, ONCOGENE, V8, P3277; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; LAI C, 1994, ONCOGENE, V8, P877; PEREZ JL, 1994, ONCOGENE, V9, P211; POOLE S, 1981, J MOL BIOL, V153, P273, DOI 10.1016/0022-2836(81)90278-3; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SANCHEZ MP, 1994, P NATL ACAD SCI USA, V91, P1819, DOI 10.1073/pnas.91.5.1819; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TRACY PB, 1983, P NATL ACAD SCI-BIOL, V80, P2380, DOI 10.1073/pnas.80.8.2380; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; ZHOU S, 1995, J BIOL CHEM, V270, P14863	28	40	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1469	1477						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622863				2022-12-28	WOS:A1996UF07600011
J	Givol, I; Givol, D; Rulong, S; Resau, J; Tsarfaty, I; Hughes, SH				Givol, I; Givol, D; Rulong, S; Resau, J; Tsarfaty, I; Hughes, SH			Overexpression of human p21(waf1/cip1) arrests the growth of chicken embryo fibroblasts transformed by individual oncogenes	ONCOGENE			English	Article						retrovirus; growth suppressor; cell cycle; waf1/cip1; p53	CYCLIN-DEPENDENT KINASES; SARCOMA VIRUS; P53; DNA; VECTORS; CELLS; EXPRESSION; INHIBITOR; PROTEIN; P21	In normal cells, cell growth and division is controlled by the interplay between proto-oncogenes and tumor genes, Cancer cells usually have both suppressor activated an suppressor gene, High level expression of a tumor suppressor, p53, can block the growth of cancer cells, waf1/cip1 is transactivated by the tumor suppressor p53 and the p21(waf1/cip1)protein is itself a suppressor of cell growth, To test the effect of growth suppression genes on the growth of cells transformed by individual oncogenes, we have used replication-competent retroviral vectors to induce high level expression of p53 and p21(waf1/cip1). Overexpression of p21(waf1/cip1) arrests chicken embryo fibroblasts (CEF) transformed by v-Src, tf-Ras, c-Mos and c-Myc. These data suggest that p21(waf1/cip1) might be a useful tool in gene therapy for human cancer.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702; WEIZMANN INST SCI,DEPT MOLEC CELL BIOL,IL-76100 REHOVOT,ISRAEL; TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN MICROBIOL,IL-69978 TEL AVIV,ISRAEL	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine				Tsarfaty, Ilan/0000-0002-5230-7093				CHEDID M, 1994, ONCOGENE, V9, P3021; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GIVOL I, 1992, ONCOGENE, V7, P141; GIVOL I, 1994, CELL GROWTH DIFFER, V5, P419; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUGHES S, 1984, VIROLOGY, V136, P89, DOI 10.1016/0042-6822(84)90250-2; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; JIANG HP, 1994, ONCOGENE, V9, P3397; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4923; LI R, 1994, NATURE, V371, P535; LI Y, 1994, ONCOGENE, V9, P2261; LOWE SW, 1993, CELL, V74, P954; LOWE SW, 1994, SCIENCE, V266, P804; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MICHIELI P, 1994, CANCER RES, V54, P3391; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; THORNTHWAITE JT, 1980, CYTOMETRY, V1, P229, DOI 10.1002/cyto.990010309; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAKUT R, 1995, ONCOGENE, V11, P393; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	41	30	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2609	2618						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545118				2022-12-28	WOS:A1995TP18800017
J	Borrello, MG; Smith, DP; Pasini, B; Bongarzone, I; Greco, A; Lorenzo, MJ; Arighi, E; Miranda, C; Eng, C; Alberti, L; Bocciardi, R; Mondellini, P; Scopsi, L; Romeo, G; Ponder, BAJ; Pierotti, MA				Borrello, MG; Smith, DP; Pasini, B; Bongarzone, I; Greco, A; Lorenzo, MJ; Arighi, E; Miranda, C; Eng, C; Alberti, L; Bocciardi, R; Mondellini, P; Scopsi, L; Romeo, G; Ponder, BAJ; Pierotti, MA			RET activation by germline MEN2A and MEN2B mutations	ONCOGENE			English	Article						RET; receptor tyrosine kinase; multiple endocrine neoplasia type 2; inherited cancer syndrome; oncogene	MULTIPLE ENDOCRINE NEOPLASIA; NEUROBLASTOMA CELL-LINES; PROTO-ONCOGENE; TYROSINE KINASE; PROTOONCOGENE; EXPRESSION; DIFFERENTIATION; CARCINOMAS; SEQUENCE; GENE	The RET proto-oncogene encodes a receptor tyrosine kinase (TK), It has been shown that distinct germline mutations in the RET proto-oncogene are associated with the dominantly inherited cancer syndromes multiple endocrine neoplasia type 2A and 2B (MEN 2A and MEN 2B) and familial medullary thyroid carcinoma (FMTC) as well as Hirschsprung disease (HSCR), a congenital disorder characterised by absent enteric innervation, In this study, we have transfected NIH3T3 and PC12 phaeochromocytoma cells with MEN2A (Cys634-->Arg) and MEN2B (Met918-->Thr) RET constructs, Both caused transformation of the NIH3T3 cells and differentiation of PC12 cells, The Bet (MEN2A) and Bet (MEN2B) proteins were constitutively phosphorylated on tyrosine, and their in vitro kinase activity was significantly higher than that of the wild type protein, The MTC cell line TT carries a Cys634-->Trp MEN2A mutation, and we have shown by immunoelectronmicroscopy that Ret is clustered on the cell surface in a manner reminiscent of ligand-induced aggregation of cell surface receptors, RET is activated, as RET/PTC oncogene, by somatic rearrangements which link the TK domain to a constitutive dimerization interface in papillary thyroid carcinomas, We have compared the biological and biochemical activity of the TK domains of the wild type and MEN 2B Ret in the context of the RET/PTC, The results show that the MEN2B mutation significantly increases the TK domain enzymatic activity suggesting that dimerization may be still necessary for MEN 2B Bet to express its full activity.	IST NAZL TUMORI,DIV EXPTL ONCOL A,I-20133 MILAN,ITALY; UNIV CAMBRIDGE,ADDENBROOKES HOSP,CRC,HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 2QQ,ENGLAND; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,BOSTON,MA 02115; IST GIANNINA GASLINI,GENET MOLEC LAB,I-16147 GENOA,ITALY; IST NAZL TUMORI,DIV ANAT PATHOL & CYTOL,I-20133 MILAN,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Genoa; IRCCS Istituto Giannina Gaslini; Fondazione IRCCS Istituto Nazionale Tumori Milan			Bocciardi, Renata/J-8577-2016; Pasini, Barbara/AHI-2004-2022; Pierotti, Marco Alessandro/AAC-4728-2022; Borrello, Maria Grazia/C-3161-2017; Bongarzone, Italia/B-9544-2017; Greco, Angela/C-1953-2017	Bocciardi, Renata/0000-0001-8415-3802; Pasini, Barbara/0000-0002-4373-1212; Pierotti, Marco Alessandro/0000-0002-7431-8332; Borrello, Maria Grazia/0000-0002-6854-2848; Bongarzone, Italia/0000-0003-2530-9170; Greco, Angela/0000-0003-2994-0349; Eng, Charis/0000-0002-3693-5145; Lorenzo, Maria Jesus/0000-0003-4416-0615				ASAI N, 1995, MOL CELL BIOL, V15, P1613; BIEDLER JL, 1978, CANCER RES, V38, P3751; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; BORRELLO MG, 1994, ONCOGENE, V9, P1661; BUNONE G, 1995, CELL RES, V217, P92; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; ENG C, 1995, GENE CHROMOSOME CANC, V12, P209, DOI 10.1002/gcc.2870120308; FABIEN N, 1994, INT J ONCOL, V4, P623; FARNDON JR, 1986, BRIT J SURG, V73, P278, DOI 10.1002/bjs.1800730411; GRECO A, 1993, CELL GROWTH DIFFER, V4, P539; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Leong S, 1981, ADV THYROID NEOPLASI, P95; LORENZO MJ, 1995, ONCOGENE, V10, P1377; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAUE F, 1994, ENDOCRINOLOGY METABO, pR12; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SANTORO M, 1994, ONCOGENE, V9, P509; SCHIMKE RN, 1984, ANNU REV MED, V35, P25, DOI 10.1146/annurev.me.35.020184.000325; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SCOPSI L, 1992, ULTRASTRUCT PATHOL, V16, P351, DOI 10.3109/01913129209061363; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAHIRA T, 1991, ONCOGENE, V6, P2333; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	44	129	129	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2419	2427						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570194				2022-12-28	WOS:A1995TK70200027
J	Dorsey, MJ; Tae, HJ; Sollenberger, KG; Mascarenhas, NT; Johansen, LM; Taparowsky, EJ				Dorsey, MJ; Tae, HJ; Sollenberger, KG; Mascarenhas, NT; Johansen, LM; Taparowsky, EJ			B-ATF: A novel human bZIP protein that associates with members of the AP-1 transcription factor family	ONCOGENE			English	Article						leucine zipper; transcription factor; AP-1; two hybrid assays	GLUTATHIONE-S-TRANSFERASE; AMP RESPONSE ELEMENT; CYCLIC-AMP; DNA-BINDING; ESCHERICHIA-COLI; SIGNAL TRANSDUCTION; SOMATOSTATIN GENE; NUCLEAR-PROTEIN; TAX PROTEIN; FOS PROTEIN	A new member of the ATF/CREB family of transcription factors, called B-ATF, has been isolated from a cDNA library prepared from Epstein-Barr virus stimulated human B cells, B-ATF is a 125 amino acid nuclear protein possessing a basic leucine zipper domain that is most similar to the basic leucine zipper of ATF3. Northern blot analysis of polyadenylated mRNA isolated from a variety of human tissues and established cell lines indicates that the 1.0 kilobase B-ATF mRNA is expressed differentially, with the strongest hybridization detected in lung and in Raji Burkitt's lymphoma, Efficient homodimerization of the B-ATF protein cannot be detected using the yeast two hybrid system or using in vitro binding assays with glutathione-s-transferase-B-ATF and maltose binding protein-B-ATF fusion proteins produced in E. coli. However, a yeast two hybrid library screen has identified the human oncoprotein JunB as a specific binding partner for B-ATF, Glutathione-s-transferase-B-ATF heterodimerizes efficiently with in vitro translated JunB, c-Jun, and JunD, but only weakly associates with c-Fos, In addition, electrophoretic mobility shift assays demonstrate that a B-ATF/c-Jun protein complex can interact with DNA containing a consensus binding site for AP-1, suggesting that B-ATF functions as a tissue-specific modulator of the AP-1 transcription complex in human cells.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NCI NIH HHS [R01-CA42835, F32-CA61635] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042835, F32CA061635] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARTANDI S, 1993, METHODS MOL GENET, V1, P267; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COLLINSHICOK J, 1994, MOL CELL BIOL, V14, P2837, DOI 10.1128/MCB.14.5.2837; DAVENPORT EA, 1992, EXP CELL RES, V202, P532, DOI 10.1016/0014-4827(92)90108-K; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P12; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LASSAR AB, 1986, CELL, V47, P649, DOI 10.1016/0092-8674(86)90507-6; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; Miller J. H, 1972, EXPT MOL GENETICS; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NOMURA N, 1993, J BIOL CHEM, V268, P4259; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PESCINI R, 1994, J BIOL CHEM, V269, P1159; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; Sambrook J, 1989, MOL CLONING LABORATO; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; VAIDYA TB, 1992, GENE, V119, P223; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; YUTZEY KE, 1989, MOL CELL BIOL, V9, P1397, DOI 10.1128/MCB.9.4.1397; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	52	93	96	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2255	2265						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570175				2022-12-28	WOS:A1995TK70200008
J	vanWeering, DHJ; Medema, JP; vanPuijenbroek, A; Burgering, BMT; Baas, PD; Bos, JL				vanWeering, DHJ; Medema, JP; vanPuijenbroek, A; Burgering, BMT; Baas, PD; Bos, JL			Ret receptor tyrosine kinase activates extracellular signal-regulated kinase 2 in SK-N-MC cells	ONCOGENE			English	Article						Ret; Pas; Raf; signal transduction; MAP kinase; cAMP	PHOSPHORYLATION; PROTOONCOGENE; INHIBITION; MUTATIONS; COMPLEX; PROTEIN; CAMP; SHC	Ret is a receptor tyrosine kinase predominantly expressed in tissue derived from the neuroectoderm and is involved in multiple endocrine neoplasia type 2A and 2B, familiar medullary thyroid carcinoma, and Hirschsprung's disease, The ligand for the receptor is still unknown, Previously, using a human epidermal growth factor receptor - Ret chimaeric receptor (HERRet) stably transfected into fibroblasts, it was shown that Pet activation induces the activation of p21ras, but, surprisingly, activation of extracellular signal-regulated kinase 2 (ERK2) was not observed (Santoro et al, (1994), Mol. Cell, Biol., 14, 663), In this report we describe early signaling events induced by the activated HERRet fusion receptor in a cell line derived from neuroectodermal tissue, SK-N-MC, In these cells, activated HERRet induces tyrosine phosphorylation of She, complex formation of She with Grb2 and Sos and activation of p21ras, Importantly, also ERK2 is activated, This activation was strong and sustained for at least 2 h, Activation was abolished by the dominant negative p21ras(asn17) mutant, showing that activation of ERK2 is mediated by p21ras, These results suggest that Pet can induce ERK2 activation in a p21ras dependent manner in cells derived from tissue where Pet is endogenously expressed.	UNIV UTRECHT,PHYSIOL CHEM LAB,GRAD SCH DEV BIOL,3508 TA UTRECHT,NETHERLANDS; HUBRECHT LAB,GRAD SCH DEV BIOL,3584 CT UTRECHT,NETHERLANDS	Utrecht University; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)				Medema, Jan Paul/0000-0003-3045-2924				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ASAI N, 1995, MOL CELL BIOL, V15, P1613; ATTIE T, 1994, HUM MOL GENET, V3, P1439; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; BASU T, 1994, ONCOGENE, V9, P3483; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BORRELLO MG, 1994, ONCOGENE, V9, P1661; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DEVRIESSMITS AMM, 1995, ONCOGENE, V10, P919; DEVRIESSMITS AMM, 1995, METHOD ENZYMOL, V255, P221; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; JHIANG SM, 1994, J LAB CLIN MED, V123, P331; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LIPS CJM, 1994, NEW ENGL J MED, V331, P828, DOI 10.1056/NEJM199409293311302; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, ONCOGENE, V8, P2773; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TSUZUKI T, 1995, ONCOGENE, V10, P191; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	40	62	64	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2207	2214						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570170				2022-12-28	WOS:A1995TK70200003
J	NAKAMURA, K; HORI, T; SATO, N; SUGIE, K; KAWAKAMI, T; YODOI, J				NAKAMURA, K; HORI, T; SATO, N; SUGIE, K; KAWAKAMI, T; YODOI, J			REDOX REGULATION OF A SRC FAMILY PROTEIN-TYROSINE KINASE P56(LCK) IN T-CELLS	ONCOGENE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIGEN RECEPTOR; IL-2 RECEPTOR; KAPPA-B; TRANSCRIPTION FACTOR; CYTOPLASMIC DOMAINS; BINDING-ACTIVITY; CD4 RECEPTOR; HTLV-I; ACTIVATION	Protein tyrosine phosphorylation was examined after T cells were exposed to oxidative stress in vitro to investigate the possible involvement of redox regulation in T-cell signaling. Oxidative reagents such as hydrogen peroxide (H2O2) and diamide, which oxidize the free sulfhydryl groups in the cells, markedly induced tyrosine phosphorylation of multiple cellular proteins, especially a 55-kDa protein, of cultured peripheral blood T lymphocytes (PBL blasts). The 55-kDa molecule phosphorylated by diamide turned out to be a src family protein tyrosine kinase, p56lck. The immune complex kinase assay showed that the kinase activity of p56lck of diamide-treated PBL blasts was enhanced. The tryptic peptide mapping of p56lck demonstrated that diamide induced the phosphorylation both at Tyr-394 (autophosphorylation site) and at Tyr-505 (negative regulatory site). Taken together, the tyrosine phosphorylation and presumably kinase activity of p56lck were swiftly enhanced by oxidative stress, indicating that T cells have a redox-sensitive signaling mechanism, which is partly mediated by the lymphocyte-specific protein tyrosine kinase p56lck.	KYOTO UNIV, INST VIRUS RES, DEPT BIOL RESPONSES, KYOTO 60601, JAPAN; KYOTO UNIV, CTR RADIAT BIOL, DEPT LATE EFFECT STUDIES, KYOTO 60601, JAPAN; LA JOLLA INST ALLERGY & IMMUNOL, LA JOLLA, CA 92037 USA	Kyoto University; Kyoto University; La Jolla Institute for Immunology			Kawakami, Toshiaki/O-1616-2015					ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DROGE W, 1992, IMMUNOL TODAY, V13, P211, DOI 10.1016/0167-5699(92)90156-2; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HSI ED, 1989, J BIOL CHEM, V264, P10836; HURLEY TR, 1989, ONCOGENE, V4, P265; JUNE CH, 1990, J IMMUNOL, V144, P1591; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; LUO K, 1990, ONCOGENE, V5, P921; LUO K, 1990, ONCOGENE, V5, P803; MARTH JD, 1989, J IMMUNOL, V142, P2430; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; OKADA M, 1991, J BIOL CHEM, V266, P24249; OKAMOTO T, 1992, INT IMMUNOL, V4, P811, DOI 10.1093/intimm/4.7.811; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEFTON BM, 1991, ONCOGENE, V6, P683; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; YODOI J, 1992, IMMUNOL TODAY, V13, P405, DOI 10.1016/0167-5699(92)90091-K; YODOI J, 1985, J IMMUNOL, V134, P1623; YODOI J, 1991, ADV CANCER RES, V57, P381	43	195	198	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1993	8	11					3133	3139						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414515				2022-12-28	WOS:A1993MC09300030
J	ZU, YL; MAEKAWA, T; NOMURA, N; NAKATA, T; ISHII, S				ZU, YL; MAEKAWA, T; NOMURA, N; NAKATA, T; ISHII, S			REGULATION OF TRANSACTIVATING CAPACITY OF CRE-BPA BY PHORBOL ESTER TUMOR PROMOTER TPA	ONCOGENE			English	Article							PROTEIN-KINASE-C; LEUCINE ZIPPER PROTEINS; ELEMENT-BINDING PROTEIN; AMP RESPONSE ELEMENT; ATF CDNA CLONES; CYCLIC-AMP; SOMATOSTATIN GENE; JUN ENCODES; TRANSCRIPTION; CRE-BP1	CRE-BPa, here designated as CRE-BPaalpha, is a novel member of the CRE (cAMP response element)-binding protein CRE-BP1 family. CRE-BPaalpha has four regions highly homologous to CRE-BP1, including a putative metal finger structure and a DNA-binding domain consisting of a basic amino acid cluster and a leucine zipper. CRE-BPa specifically binds to CRE as a homodimer or heterodimer with c-Jun or CRE-BP1. Here we report three alternative splicing forms of CRE-BPaalpha: two of them, CRE-BPabeta and CRE-BPagamma, lack the N-terminal 7 and 33 amino acids of CRE-BPaalpha, and the third one CRE-BPadelta, has 16 additional amino acids in the N-terminus and amino acids 156-508 of CRE-BPaalpha. In CAT cotransfection experiments using CV-1 cells, transient expression of each of four CRE-BPa proteins caused a 1.6- to 3.4-fold increase of CRE-dependent transcription, respectively. Interestingly, these weak trans-activating capacities of CRE-BPa proteins were enhanced 2.7- to 3.6-fold by treatment of cells with 12-0-tetradecanoyl-phorbol 13-acetate (TPA). However, CRE-BPa did not affect the TPA-induced and TRE (TPA response element)-dependent transcription. These results indicate that CRE-BPa is a CRE-dependent trans-activator, and that CRE-BPa can confer TPA inducibility on CRE. Thus, CRE-BPa has an unique characteristic of cross-talk between cAMP pathway and TPA pathway.	TSUKUBA LIFE SCI CTR,INST PHYS & CHEM RES,MOLEC GENET LAB,TSUKUBA,IBARAKI 305,JAPAN; NIPPON MED COLL,INST GERONTOL,MOLEC BIOL LAB,NAKAHARA KU,KANAGAWA 211,JAPAN	RIKEN; Nippon Medical School			Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHUNG B, 1986, P NATL ACAD SCI USA, V83, P8962, DOI 10.1073/pnas.83.23.8962; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KANEHISA M, 1984, NUCLEIC ACIDS RES, V12, P203, DOI 10.1093/nar/12.1Part1.203; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAEKAWA T, 1991, ONCOGENE, V6, P627; MATSUDA S, 1991, J BIOL CHEM, V266, P18188; METZ R, 1991, GENE DEV, V5, P174; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOMURA N, 1993, J BIOL CHEM, V268, P4259; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; SAKURAI A, 1991, BIOCHEM BIOPH RES CO, V181, P629, DOI 10.1016/0006-291X(91)91237-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; YOSHIMURA T, 1990, EMBO J, V9, P2535; YU Y, 1991, J BIOL CHEM, V266, P24134	44	18	22	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2749	2758						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378084				2022-12-28	WOS:A1993LX34300016
J	BONHAM, K; FUJITA, DJ				BONHAM, K; FUJITA, DJ			ORGANIZATION AND ANALYSIS OF THE PROMOTER REGION AND 5' NONCODING EXONS OF THE HUMAN C-SRC PROTOONCOGENE	ONCOGENE			English	Article							EXPRESS HIGH-LEVELS; GENE-PRODUCT; MAMMALIAN-CELLS; KINASE-ACTIVITY; NEURONAL CELLS; PLASMID DNA; V-SRC; PP60C-SRC; SEQUENCE; FORM	In order to help clarify the cellular mechanisms that regulate expression of the human c-src proto-oncogene, we have isolated a series of overlapping genomic clones that contain the c-src promoter region, as well as three previously uncharacterized exons. These exons encode the 350-bp 5' untranslated region of the c-src mRNA and span 35 kb of genomic DNA, extending the human c-src locus to approximately 60 kb. Subcloning and sequence analysis of the 5' flanking region of the gene revealed a high GC content and several consensus Sp1 and AP2 binding sites. However, TATA or CAAT boxes were not present, a characteristic shared by other GC-rich promoters. Promoter-CAT constructs demonstrated that the promoter was functional in transfection assays and that its activity was dependent on correct orientation. CAT-promoter deletion constructs were used to define the 5' boundary for maximal promoter activity and to reveal the presence of both positive and negative regulatory elements. S1 analyses of human c-src mRNA from cell lines indicated that multiple transcription start sites were utilized.	UNIV CALGARY,MED CTR,CELL REGULAT GRP,CALGARY T2N 4N1,AB,CANADA; UNIV CALGARY,DEPT MED BIOCHEM,MRC,SIGNAL TRANSDUCT GRP,CALGARY T2N 4N1,AB,CANADA	University of Calgary; University of Calgary								ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOLEN JB, 1985, P NATL ACAD SCI USA, V82, P7275, DOI 10.1073/pnas.82.21.7275; BRUGGE J, 1987, GENE DEV, V1, P287, DOI 10.1101/gad.1.3.287; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; DORAI T, 1991, MOL CELL BIOL, V11, P4165, DOI 10.1128/MCB.11.8.4165; DORAI T, 1990, MOL CELL BIOL, V10, P4068, DOI 10.1128/MCB.10.8.4068; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; EVANS T, 1988, J MOL BIOL, V199, P61, DOI 10.1016/0022-2836(88)90379-8; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FULTS DW, 1985, MOL CELL BIOL, V5, P327; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GHOSN CR, 1992, ONCOGENE, V7, P2345; GIBBS CP, 1985, J VIROL, V53, P19, DOI 10.1128/JVI.53.1.19-24.1985; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUTKIND JS, 1991, MOL CELL BIOL, V11, P1500, DOI 10.1128/MCB.11.3.1500; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; HOFFMANFALK H, 1983, CELL, V32, P589, DOI 10.1016/0092-8674(83)90478-6; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JORCYK CL, 1990, ONCOGENE, V6, P323; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15505; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KREIG P, 1983, ANAL BIOCHEM, V134, P288; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LICHTENBERG U, 1992, ONCOGENE, V7, P849; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MAVROTHALASSITIS GJ, 1990, ONCOGENE, V5, P1337; OCONNOR TJ, 1992, CELL GROWTH DIFFER, V3, P435; PARKER RC, 1985, MOL CELL BIOL, V5, P831, DOI 10.1128/MCB.5.4.831; PARSONS SJ, 1986, BIOCHEM BIOPH RES CO, V134, P736, DOI 10.1016/S0006-291X(86)80482-X; PATEL M, 1990, ONCOGENE, V5, P201; PESTOV DG, 1991, NUCLEIC ACIDS RES, V19, P6527, DOI 10.1093/nar/19.23.6527; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; ROSEN N, 1986, J BIOL CHEM, V261, P13745; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; SUDOL M, 1988, ONCOGENE RES, V2, P345; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TANAKA A, 1990, ONCOGENE RES, V5, P305; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; TANAKA A, 1986, MOL CELL BIOL, V6, P3900, DOI 10.1128/MCB.6.11.3900; ZAFARULLAH M, 1988, MOL CELL BIOL, V8, P4469, DOI 10.1128/MCB.8.10.4469; ZIEGLER SF, 1991, ONCOGENE, V6, P283	53	41	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1973	1981						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510939				2022-12-28	WOS:A1993LG68200030
J	MILLER, CW; CHUMAKOV, A; SAID, J; CHEN, DL; ASLO, A; KOEFFLER, HP				MILLER, CW; CHUMAKOV, A; SAID, J; CHEN, DL; ASLO, A; KOEFFLER, HP			MUTANT-P53 PROTEINS HAVE DIVERSE INTRACELLULAR ABILITIES TO OLIGOMERIZE AND ACTIVATE TRANSCRIPTION	ONCOGENE			English	Article							WILD-TYPE P53; MAMMALIAN-CELLS; GENE; EXPRESSION; MUTATIONS; SEQUENCE; DOMAIN; TRANSFORMATION; ELEMENT; JUN	Accumulating evidence supports the hypothesis that tumor-suppressor p53 can act as a transcriptional activator. Insertion of high-affinity p53 DNA binding sites up-stream of a promoter yields a p53-responsive vector. Chimeric proteins fusing p53 and the GAL4 DNA-binding domain demonstrate the presence of a transcriptional activating domain in the N-terminus of p53. GAL4-p53 chimeras constructed using naturally occurring p53 mutations at either codon 141 (Tyr-141) or 175 (His-175) of p53 had little ability to activate the reporter gene; in contrast, mutations at either codon 248 (Trp-248) or 273 (His-273) produced greater transcriptional activities than did wild-type p53. GAL4 chimeras can be used to analyse interactions between different domains of p53 and between different p53 alleles; a DNA binding site is defined, and a simple measurement can be made of function. We had expected that coexpression of GAL4 chimeras and p53 alleles would squelch transcriptional activation downstream of GAL binding sites. Surprisingly, coexpression of either p53 (Trp-248) or (His-273) with the GALA-p53 (wild-type, His-273, Trp-248, His-175, Tyr-141) effectors conferred an increase in transcriptional activation as compared with the effector alone. Oligomerization of p53 alleles with GAL4-p53 chimeras could underlie this effect, leading to an increase in transcription-activating motifs near the promoter. To test this possibility, we constructed a GAL4- p53 C-terminal chimera with p53 residues 160-393, lacking the transcriptional activating domain but retaining regions believed to be important in p53 oligomerization. Neither GAL4-p53 (C-terminus) nor p53 expression vectors were able to transactivate G5E1B-CAT alone. Both p53 (His-273) and (Trp-248) co-expressed with GAL4-p53 (C-terminus) were able to transactivate the G5E1B-CAT reporter gene; in contrast, p53 (Tyr-141) was not able to activate transcription. p53 (Tyr-141/His-273) behaved as a dominant negative mutant and inhibited the ability of the combination of p53 (His-273) and GAL4-p53 (C-terminus) to stimulate the reporter gene. Double immunoprecipitation by sequentially using GAL4 and p53 antibodies showed that p53 (His-273) and (Tyr-141/ His-273), but not p53 (Tyr-141), can efficiently oligomerize in vivo to the C-terminal region of p53. Transcriptional activating function of p53 may be modulated by oligomerization; some mutations, such as His-273 and Trp-248, participate in these functions. The p53 proteins with mutations at Tyr-141 and His-175 have lost their abilities to transactivate and oligomerize efficiently in vivo, perhaps resulting in loss of their tumor-suppressor activities. In contrast, mutations in the region of codons 248 and 273 result in p53 proteins with potent abilities to transactivate and oligomerize in vivo, suggesting that these proteins in conjunction with loss of the normal allele of p53 may be able to behave in a similar way to recessive oncogenes.	UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,DEPT PATHOL,LOS ANGELES,CA 90048	Cedars Sinai Medical Center; University of California System; University of California Los Angeles	MILLER, CW (corresponding author), UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,SCH MED,DEPT MED,DIV HEMATOL ONCOL,5019 DAVIS BLDG,LOS ANGELES,CA 90048, USA.		Chumakov, Alexey/N-1541-2014	Chumakov, Alexey/0000-0003-2733-3166	NATIONAL CANCER INSTITUTE [P30CA042710, P01CA042710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042792] Funding Source: NIH RePORTER; NCI NIH HHS [CA42710] Funding Source: Medline; NIDDK NIH HHS [DK42792] Funding Source: Medline; PHS HHS [IRT370] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BUSCH SJ, 1990, ONCOGENE, V63, P729; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FIELDS S, 1989, NATURE, V340, P240; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GLASS CK, 1990, CELL, V5, P1549; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1988, ONCOGENE HDB; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRAISS S, 1992, BIOCHIM BIOPHYS ACTA, V1119, P11, DOI 10.1016/0167-4838(92)90227-5; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KRAISS S, 1991, EXP CELL RES, V192, P157, DOI 10.1016/0014-4827(91)90170-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MALKIN D, 1990, SCIENCE, V250, P1236; MEDCALF EA, 1992, ONCOGENE, V7, P71; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OROURKE RW, 1990, ONCOGENE, V5, P1829; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SADOWSKI I, 1988, NATURE, V335, P653; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SOUSSI T, 1990, ONCOGENE, V5, P945; STEINMEYER K, 1988, ONCOGENE, V3, P501; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570	47	48	50	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1815	1824						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510927				2022-12-28	WOS:A1993LG68200013
J	REISSMANN, PT; KOGA, H; TAKAHASHI, R; FIGLIN, RA; HOLMES, EC; PIANTADOSI, S; CORDONCARDO, C; SLAMON, DJ				REISSMANN, PT; KOGA, H; TAKAHASHI, R; FIGLIN, RA; HOLMES, EC; PIANTADOSI, S; CORDONCARDO, C; SLAMON, DJ			INACTIVATION OF THE RETINOBLASTOMA SUSCEPTIBILITY GENE IN NON-SMALL-CELL LUNG-CANCER	ONCOGENE			English	Article							RAS ONCOGENE ACTIVATION; GROWTH-FACTOR RECEPTORS; OSTEO-SARCOMA; RB GENE; ALTERED EXPRESSION; DNA-SEQUENCE; HUMAN-BREAST; SHORT ARM; EGF-R; CARCINOMA	Mutations that prevent the normal expression of the retinoblastoma susceptibility gene (RB) have been linked to the pathogenesis of several human malignancies. Mutational inactivation of this tumor-suppressor gene appears to initiate the development of retinoblastoma, and may also contribute to the pathogenesis of osteosarcomas, soft-tissue sarcomas, small-cell lung cancer and other malignancies. In cooperation with the Lung Cancer Study Group, we studied the structure and expression of the RB gene in a cohort of 219 primary non-small-cell lung cancers (NSCLCs). RB gene structure was studied at the DNA level by Southern blot and chromosome 13 restriction fragment length polymorphism analyses. Expression of the RB gene was evaluated by Northern analysis of the transcript and immunohistochemical analysis of the protein (p105RB). Immunohistochemistry of the RB protein proved to be the most sensitive method for the detection of Rb gene inactivation. Absent or abnormal RB protein staining was detected in 53/163 (32%) evaluable cases studied, while Northern analysis showed 22/219 cases to have an altered or absent RB transcript. Southern analysis revealed only two cases of structural alteration of the gene, but loss of heterozygosity from chromosome 13 was common in tumors that failed to express the protein. Analysis of the clinical outcomes of the patients whose tumors were studied did not show any correlation of RB inactivation with time to relapse or death. The data from this study indicate that the RB gene is inactivated in a significant number of NSCLCs. The role that these mutations may play in the development of NSCLC remains to be defined.	UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90024 USA; BAYLOR UNIV, CTR BIOTECHNOL, THE WOODLANDS, TX 77381 USA; JOHNS HOPKINS UNIV, JOHNS HOPKINS ONCOL CTR, BALTIMORE, MD 21205 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT SURG, LOS ANGELES, CA 90024 USA; MEM SLOAN KETTERING CANC CTR, DEPT PATHOL, NEW YORK, NY 10021 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Baylor College of Medicine; Baylor University; Johns Hopkins University; Johns Hopkins Medicine; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [CA 55827] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMSON DH, 1984, OPHTHALMOLOGY, V91, P1351; ABRAMSON DH, 1976, T AM ACAD OPHTHALMOL, V81, pP454; BALABAN G, 1982, CANCER GENET CYTOGEN, V6, P213, DOI 10.1016/0165-4608(82)90058-9; BENEDICT WF, 1983, CANCER GENET CYTOGEN, V10, P311, DOI 10.1016/0165-4608(83)90090-0; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CANCE WG, 1990, NEW ENGL J MED, V323, P1457, DOI 10.1056/NEJM199011223232105; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CERNY T, 1986, BRIT J CANCER, V54, P265, DOI 10.1038/bjc.1986.172; CHAUM E, 1984, CYTOGENET CELL GENET, V38, P82, DOI 10.1159/000132037; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHENG J, 1990, BLOOD, V75, P730; CHIBA I, 1990, ONCOGENE, V5, P1603; COX DR, 1972, J R STAT SOC B, V34, P187; DAZZI H, 1989, BRIT J CANCER, V59, P746, DOI 10.1038/bjc.1989.156; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HENDLER FJ, 1984, J CLIN INVEST, V74, P647, DOI 10.1172/JCI111463; HENSEL CH, 1990, CANCER RES, V50, P3067; HOVIG E, 1987, CANCER GENET CYTOGEN, V24, P327, DOI 10.1016/0165-4608(87)90115-4; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KAGIMOTO M, 1985, INT J CANCER, V35, P809, DOI 10.1002/ijc.2910350618; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KITCHIN FD, 1974, J MED GENET, V11, P244, DOI 10.1136/jmg.11.3.244; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOGA H, UNPUB; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MANIATIS T, 1982, MOL CLONING LABORATO, P282; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; MIYAKI M, 1985, JPN J CANCER RES, V76, P260; MORI N, 1990, ONCOGENE, V5, P1713; MURAKAMI Y, 1991, ONCOGENE, V6, P37; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; REISSMANN PT, 1989, ONCOGENE, V4, P839; RODENHUIS S, 1988, CANCER RES, V48, P5738; RYGAARD K, 1990, CANCER RES, V50, P5312; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASANO H, 1990, CANCER, V66, P2150, DOI 10.1002/1097-0142(19901115)66:10<2150::AID-CNCR2820661018>3.0.CO;2-7; SHERWIN SA, 1981, CANCER RES, V41, P3538; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; STRATTON MR, 1989, BRIT J CANCER, V60, P202, DOI 10.1038/bjc.1989.251; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; VARLEY JM, 1989, ONCOGENE, V4, P725; VEALE D, 1987, BRIT J CANCER, V55, P513, DOI 10.1038/bjc.1987.104; VOGEL F, 1979, HUM GENET, V52, P1; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; XU HJ, 1991, CANCER RES, V51, P2735; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1988, ONCOGENE, V3, P471; YOKOTA J, 1988, ONCOGENE, V2, P607	67	153	157	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1993	8	7					1913	1919						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8390038				2022-12-28	WOS:A1993LG68200024
J	TZENG, YJ; GUHL, E; GRAESSMANN, M; GRAESSMANN, A				TZENG, YJ; GUHL, E; GRAESSMANN, M; GRAESSMANN, A			BREAST-CANCER FORMATION IN TRANSGENIC ANIMALS INDUCED BY THE WHEY ACIDIC PROTEIN SV40 T-ANTIGEN (WAP-SV-T) HYBRID GENE	ONCOGENE			English	Article							HA-RAS; MICE; EXPRESSION; ONCOGENES; CELLS; TRANSCRIPTION; INFORMATION; MECHANISMS; CARCINOMA; RECEPTORS	After injection of the whey acidic protein (WAP)-SV-T hybrid gene into fertilized mouse eggs, eight independent transgenic mouse lines were obtained. Females from three lines developed mammary carcinomas with high frequency, coinciding mostly with lactation. In contrast to the endogenous WAP gene, expression of the hybrid gene continued after lactation. The tumor cells had a very invasive growth characteristic. Tumor regression in vivo was not observed. However, after transfer into tissue culture 25% of the cells ceased to express the hybrid gene and acquired the growth characteristic of normal cells. It was possible to retransform these cells by injection of wild-type SV40 DNA, but not after transfer of the hybrid WAP-SV-T gene. Inactivation of the endogenous WAP and of the WAP-SV-T transgene did not correlate with DNA methylation.	FREE UNIV BERLIN,INST MOLEK BIOL & BIOCHEM,ARNIMALLEE 22,W-1000 BERLIN 33,GERMANY	Free University of Berlin								ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; BERGER MS, 1988, CANCER RES, V48, P1238; BURDON T, 1991, J BIOL CHEM, V266, P6909; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; CAMPBELL SM, 1984, NUCLEIC ACIDS RES, V12, P8685, DOI 10.1093/nar/12.22.8685; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GRAESSMANN A, 1973, DEV BIOL, V35, P180, DOI 10.1016/0012-1606(73)90016-X; GRAESSMANN A, 1993, DNA METHYLATION MOL, P404; GRAESSMANN M, 1976, P NATL ACAD SCI USA, V73, P366, DOI 10.1073/pnas.73.2.366; GRAESSMANN M, 1983, METHOD ENZYMOL, V101, P482; GRAESSMANN M, 1984, J MOL BIOL, V180, P111, DOI 10.1016/0022-2836(84)90433-9; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HENDERSON BE, 1988, CANCER RES, V48, P246; HOGAN B, 1986, MANPULATING MOUSE EM; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MESSING A, 1985, NATURE, V316, P461, DOI 10.1038/316461a0; PARKIN DM, 1984, B WORLD HEALTH ORGAN, V62, P163, DOI 10.1139/b84-027; PITTIUS CW, 1988, MOL ENDOCRINOL, V2, P1027, DOI 10.1210/mend-2-11-1027; Sambrook J, 1989, MOL CLONING LABORATO; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; SCHWABE JWR, 1991, TRENDS BIOCHEM SCI, V16, P291, DOI 10.1016/0968-0004(91)90121-B; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TOOZE J, 1981, MOL BIOL TUMOR VIR 2; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049	30	67	70	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1965	1971						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8390039				2022-12-28	WOS:A1993LG68200029
J	CHEN, TM; CHEN, CA; HSIEH, CY; CHANG, DY; CHEN, YH; DEFENDI, V				CHEN, TM; CHEN, CA; HSIEH, CY; CHANG, DY; CHEN, YH; DEFENDI, V			THE STATE OF P53 IN PRIMARY HUMAN CERVICAL CARCINOMAS AND ITS EFFECTS IN HUMAN PAPILLOMAVIRUS-IMMORTALIZED HUMAN CERVICAL CELLS	ONCOGENE			English	Article							WILD-TYPE P53; CELLULAR TUMOR-ANTIGEN; ACTIVATING MUTATIONS; GEL-ELECTROPHORESIS; EPITHELIAL-CELLS; MUTANT P53; PROTEIN; DNA; LINES; TRANSFORMATION	Wild-type (wt) p53 acts as a tumor suppressor, while certain mutant type (mt) p53 may exhibit 'oncogenic' function. We have recently demonstrated that human papillomavirus type 18 (HPV-18) E6 can partially overcome the growth-suppressive effects of wt p53, but it remains unclear what role p53 plays in cervical carcinogenesis. In this report, we have examined nine HPV-immortalized human cervical epithelial cell lines and 13 HPV-positive and two HPV-negative primary cervical cancers for p53 mutations by polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP). None of them contained p53 mutations in exons 5-9 where most p53 mutations in human tumors have been found. The entire p53-coding region of the two HPV-negative cervical cancers was sequenced and no mutations were noted. In order to examine the effects of wt p53 and mt p53 on HPV-immortalized human cells, we transfected HPV-immortalized cell lines with wt p53 and a mt p53 (mtp43Val-135). The results indicate that HPV-immortalized cells cannot tolerate large amounts of exogenous wt p53, while mt p53Val-135 can enhance transformation of these cells. The results support the notion that inactivation of wt p53 by E6 may be important for HPV-associated transformation and also suggests that mt p53 can act as an oncogene in HPV-immoralized human cells.	NYU MED CTR,DEPT PATHOL,550 1ST AVE,NEW YORK,NY 10016; NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016; NATL TAIWAN UNIV,COLL MED,DEPT OBSTET & GYNECOL,TAIPEI,TAIWAN; NATL TAIWAN UNIV,COLL MED,DEPT PHARM,TAIPEI,TAIWAN	New York University; New York University; National Taiwan University; National Taiwan University				CHEN, CHI-AN/0000-0001-6670-7939; defendi, vittorio/0000-0002-0707-6900				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1990, ONCOGENE, V5, P893; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN TM, 1992, ONCOGENE, V7, P1541; CROOK T, 1991, ONCOGENE, V6, P873; DEAN SW, 1989, EXP CELL RES, V183, P473, DOI 10.1016/0014-4827(89)90406-0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUJITA M, 1992, CANCER RES, V52, P5323; Gai X X, 1988, Oncogene Res, V3, P377; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOSONO S, 1991, ONCOGENE, V6, P237; HOWLEY PM, 1991, CANCER RES, V51, pS5019; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; INOUE H, 1992, VIROLOGY, V187, P343, DOI 10.1016/0042-6822(92)90325-J; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; LEE YY, 1992, P AM ASSOC CANC RES, V33, P339; LEHMAN TA, 1991, CANCER RES, V51, P4090; Manos M. M., 1990, PCR PROTOCOLS GUIDE, P356; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; OKAMOTO A, 1991, CANCER RES, V51, P5632; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PECORARO G, 1989, P NATL ACAD SCI USA, V86, P563, DOI 10.1073/pnas.86.2.563; PECORARO G, 1991, AM J PATHOL, V138, P1; POHL J, 1988, MOL CELL BIOL, V8, P2078, DOI 10.1128/MCB.8.5.2078; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; RIOU G, 1990, LANCET, V335, P1171; ROVINSKI B, 1988, ONCOGENE, V2, P445; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; WRIGHT PA, 1991, ONCOGENE, V6, P1693; YAGINUMA Y, 1991, CANCER RES, V51, P6506; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	56	40	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1511	1518						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8389030				2022-12-28	WOS:A1993LE06400014
J	LI, CCH; CHEN, E; OCONNELL, CD; LONGO, DL				LI, CCH; CHEN, E; OCONNELL, CD; LONGO, DL			DETECTION OF C-MOS PROTOONCOGENE EXPRESSION IN HUMAN-CELLS	ONCOGENE			English	Note							MURINE SARCOMA-VIRUS; MATURATION-PROMOTING FACTOR; KINASE-ACTIVITY; MEIOTIC MATURATION; TRANSFORMING GENE; XENOPUS OOCYTES; CDC2 PROTEIN; DEVELOPMENTAL REGULATION; PROTOONCOGENE PRODUCT; HUMAN NEUROBLASTOMAS	Although the human c-mos proto-oncogene has been characterized for more than a decade, very little is known about its protein product and its expression in somatic cells. We generated three human c-mos-specific antisera and report here the detection of c-mos protein in a human neuroblastoma cell line, SK-N-BE2 (BE2). Both Western (immuno-) blot and immunoprecipitation analyses detected a p37 as the major form and p40 and p35 as minor forms of the c-mos protein. Using Northern blot analysis, 3.5- and 1.7-kb c-mos messages were detected. Using a highly sensitive method that combines reverse transcription and the polymerase chain reaction (RT-PCR), c-mos RNA was detected in all the human samples examined. With Western blot analysis, we further showed that c-mos proteins are expressed in cervical carcinoma-derived cell lines. This ubiquitous expression of low levels of c-mos suggests a fundamental role for the c-mos proto-oncogene.	NCI,FREDERICK CANC RES & DEV CTR,DIV CANC TREATMENT,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	LI, CCH (corresponding author), INC DYNCORP,PROGRAM RESOURCES,BIOL CARCINOGENESIS & DEV PROGRAM,POB B,BLDG 567,ROOM 202,FREDERICK,MD 21702, USA.		Longo, Dan L./F-6022-2011		NCI NIH HHS [N01-CO-74102] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BIEDLER JL, 1988, ADV NEUROBLASTOMA RE, V2, P265; BLAIR DG, 1986, CELL, V46, P785, DOI 10.1016/0092-8674(86)90354-5; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CHIN MT, 1989, J VIROL, V63, P2967, DOI 10.1128/JVI.63.7.2967-2976.1989; COFFIN JM, 1981, J VIROL, V40, P953, DOI 10.1128/JVI.40.3.953-957.1981; COHEN JB, 1983, NATURE, V306, P797, DOI 10.1038/306797a0; DANOS O, 1984, CANCER CELLS ONCOGEN, V2, P291; DIAMOND SL, 1990, J CELL PHYSL, V143, P3641; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; FREEMAN RS, 1991, MOL CELL BIOL, V11, P1713, DOI 10.1128/MCB.11.3.1713; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; HERZOG NK, 1989, ONCOGENE, V4, P1307; HERZOG NK, 1990, J VIROL, V64, P3093, DOI 10.1128/JVI.64.6.3093-3096.1990; KESHET E, 1988, ONCOGENE, V2, P235; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; LEIBOVITCH SA, 1990, ONCOGENE, V5, P1149; LEIBOVITCH SA, 1991, ONCOGENE, V6, P1617; LI CCH, 1987, J VIROL, V61, P2684, DOI 10.1128/JVI.61.9.2684-2690.1987; LI CCH, 1990, PAPILLOMAVIRUSES, P119; LIU JX, 1990, ONCOGENE, V5, P171; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; OGISO Y, 1986, BIOCHEM BIOPH RES CO, V140, P477, DOI 10.1016/0006-291X(86)90757-6; OKAZAKI K, 1991, JPN J CANCER RES, V82, P250, DOI 10.1111/j.1349-7006.1991.tb01837.x; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; PAPKOFF J, 1981, CELL, V27, P109, DOI 10.1016/0092-8674(81)90365-2; PARKAR MH, 1988, CANCER LETT, V43, P185, DOI 10.1016/0304-3835(88)90169-3; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PAULES RS, 1988, ONCOGENE, V3, P59; PROPST F, 1990, P NATL ACAD SCI USA, V87, P9703, DOI 10.1073/pnas.87.24.9703; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SETH A, 1987, P NATL ACAD SCI USA, V84, P3560, DOI 10.1073/pnas.84.11.3560; SETH A, 1988, ONCOGENE HDB, P195; SINGH B, 1988, ONCOGENE, V3, P79; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SMITH LD, 1971, DEV BIOL, V25, P232, DOI 10.1016/0012-1606(71)90029-7; SUNKARA PS, 1979, P NATL ACAD SCI USA, V76, P2799, DOI 10.1073/pnas.76.6.2799; VANBEVEREN C, 1981, NATURE, V289, P258, DOI 10.1038/289258a0; VANDERHOORN FA, 1991, ONCOGENE, V6, P929; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078; YEE C, 1985, AM J PATHOL, V119, P361; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604; ZHAO X, 1990, ONCOGENE, V5, P1727; ZHAO X, 1991, ONCOGENE, V6, P43; ZHOU R, 1991, CELL GROWTH DIFFER, V2, P257; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	65	33	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1685	1691						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502488				2022-12-28	WOS:A1993LE06400034
J	TSAI, LH; LEES, E; FAHA, B; HARLOW, E; RIABOWOL, K				TSAI, LH; LEES, E; FAHA, B; HARLOW, E; RIABOWOL, K			THE CDK2 KINASE IS REQUIRED FOR THE G1-TO-S TRANSITION IN MAMMALIAN-CELLS	ONCOGENE			English	Article							P34CDC2 PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; CYCLIN-A; SCHIZOSACCHAROMYCES-POMBE; PHOSPHORYLATION SITES; CDC28 MUTATION; G1 PHASE; GENE; MITOSIS	In the cell cycle of fission and budding yeast, the p34cdc2/cDC28 kinase is required for both the G1-to-S and G2-to-M phase transitions. In vertebrates, the homologous p34cdc2 kinase is required for G2-to-M phase transitions but appears to be dispensible for DNA synthesis. We have investigated the function of a related kinase, p33cdk2, using serum-stimulated quiescent human fibroblasts. While the p33cdk2 protein was expressed at constant levels throughout the cell cycle, p33cdk2 kinase activity was first detected a few hours prior to the onset of DNA synthesis. Microinjection of anti-p33cdk2 antibodies blocked cells from entering S phase. Pre-adsorbtion of these antibodies with cdk2 protein abrogated their blocking effect suggesting that the G1 arrest caused by these antibodies is cdk2-specific. These results indicate that p33cdk2 is required for the G1-to-S phase transition in mammalian cells. We also show evidence to suggest that the cyclin E/p33cdk2 complex is likely to be required for entry into S phase since the timing of the cyclin E-associated kinase activity was coincident with that of p33cdk2 and preclearing of either component abolished the majority of the histone H1 kinase activity present in the lysates harvested from the late G1.	UNIV CALGARY, SO ALBERTA CANC RES CTR, DEPT MED BIOCHEM, CALGARY T2N 1N4, ALBERTA, CANADA	University of Calgary	TSAI, LH (corresponding author), MASSACHUSETTS GEN HOSP, CTR CANC, BLDG 149, 13TH ST, BOSTON, MA 02129 USA.				NCI NIH HHS [CA55339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BOOHER R, 1986, MOL CELL BIOL, V6, P3523, DOI 10.1128/MCB.6.10.3523; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FAHA B, 1992, PEZCOLLER F S, V3, P107; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FERNANDEZ A, 1991, EXP CELL RES, V195, P468, DOI 10.1016/0014-4827(91)90398-E; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HAMAGUCHI JR, 1992, J CELL BIOL, V117, P1041, DOI 10.1083/jcb.117.5.1041; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARTWELL LH, 1973, J BACTERIOL, V115, P966, DOI 10.1128/JB.115.3.966-974.1973; HARTWELL LH, 1974, BACTERIOL REV, V38, P164, DOI 10.1128/MMBR.38.2.164-198.1974; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; REED SI, 1980, GENETICS, V95, P561; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STARK H, 1989, PEPTIDES, V10, P717, DOI 10.1016/0196-9781(89)90102-2; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	64	327	340	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1993	8	6					1593	1602						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502482				2022-12-28	WOS:A1993LE06400023
J	BIANCHI, AB; FISCHER, SM; ROBLES, AI; RINCHIK, EM; CONTI, CJ				BIANCHI, AB; FISCHER, SM; ROBLES, AI; RINCHIK, EM; CONTI, CJ			OVEREXPRESSION OF CYCLIN-D1 IN MOUSE SKIN CARCINOGENESIS	ONCOGENE			English	Article							CELL NUCLEAR ANTIGEN; HARVEY-RAS ONCOGENE; MESSENGER-RNA; CANDIDATE ONCOGENE; PAPILLOMAS; TUMORS; GENE; CARCINOMAS; MICE; HETEROZYGOSITY	Recent studies have provided evidence suggesting that disruption of cyclin function may play a critical role in tumorigenesis. Cyclin D1, a putative G1 cyclin previously isolated in human parathyroid adenomas (designated PRAD1) and mouse macrophages (designated Cyl1), has been implicated in various neoplasias including breast and squamous cell carcinomas (SCC). The role of cyclin altered regulation in the different stages of tumor progression has not been studied in a well defined animal model system. In the study presented here, Cyl1 was mapped to the distal end of mouse chromosome 7 and found to be dramatically overexpressed in skin SCC. In premalignant stages of tumor development, early papillomas showed basal Cyl1 transcript levels, whereas overexpression was observed in most advanced papillomas. These findings suggest that altered expression of cyclin D1 plays a critical role in mouse skin carcinogenesis and may be related to the acquisition of autonomous growth by papillomas. Further studies on the role of cyclin D1 in the mouse model system should prove valuable for understanding the multistep basis of tumor progression.	UNIV TEXAS, MD ANDERSON CANC CTR,DEPT CARCINOGENESIS,DIV RES, SCI PK,POB 389, SMITHVILLE, TX 78957 USA; OAK RIDGE NATL LAB, DIV BIOL, OAK RIDGE, TN 37831 USA	University of Texas System; UTMD Anderson Cancer Center; United States Department of Energy (DOE); Oak Ridge National Laboratory				Robles, Ana/0000-0001-5019-4374	NCI NIH HHS [CA42157, CA53123] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053123, R01CA042157] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDAZ CM, 1989, MOL CARCINOGEN, V2, P22, DOI 10.1002/mc.2940020104; ALDAZ CM, 1991, CANCER RES, V51, P1045; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BIANCHI AB, 1991, P NATL ACAD SCI USA, V88, P7590, DOI 10.1073/pnas.88.17.7590; BIANCHI AB, 1990, P NATL ACAD SCI USA, V87, P6902, DOI 10.1073/pnas.87.17.6902; BIANCHI AB, 1993, IN PRESS MAMMALIAN G, V4; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BURNS F, 1983, ENVIRON HEALTH PERSP, V50, P309, DOI 10.2307/3429562; BURNS FJ, 1976, CANCER RES, V36, P1422; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONTI CJ, 1986, CARCINOGENESIS, V7, P1845, DOI 10.1093/carcin/7.11.1845; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FISCHER SM, 1988, CANCER RES, V48, P658; GREENWELL A, 1991, CANCER LETT, V59, P251, DOI 10.1016/0304-3835(91)90149-C; HENNINGS H, 1985, J NATL CANCER I, V74, P735; HENNINGS H, 1985, CARCINOGENESIS, V6, P1607, DOI 10.1093/carcin/6.11.1607; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; JOHNSON DK, 1989, P NATL ACAD SCI USA, V86, P8862, DOI 10.1073/pnas.86.22.8862; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KIDD VJ, 1992, MOL CARCINOGEN, V5, P95, DOI 10.1002/mc.2940050203; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; Lew D J, 1992, Trends Cell Biol, V2, P77, DOI 10.1016/0962-8924(92)90076-Y; MARKS F, 1990, CARCINOGENESIS, V11, P2085, DOI 10.1093/carcin/11.12.2085; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REDDY AL, 1987, INT J CANCER, V39, P261, DOI 10.1002/ijc.2910390223; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENTHAL ET, 1980, CELL, V20, P487, DOI 10.1016/0092-8674(80)90635-2; RUGGERI B, 1991, CANCER RES, V51, P6615; SLAGA T J, 1989, P1; STEINERT PM, 1984, P NATL ACAD SCI-BIOL, V81, P5709, DOI 10.1073/pnas.81.18.5709; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; VANDIERENDONCK JH, 1991, AM J PATHOL, V138, P1165; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; Xiong Y, 1991, Curr Biol, V1, P362, DOI 10.1016/0960-9822(91)90193-Z; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; YUSPA SH, 1988, ADV CANCER RES, V50, P25, DOI 10.1016/S0065-230X(08)60434-0	47	116	116	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1127	1133						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479737				2022-12-28	WOS:A1993KY32800003
J	OGRIS, E; MUDRAK, I; WINTERSBERGER, E				OGRIS, E; MUDRAK, I; WINTERSBERGER, E			DISTINCT AMOUNTS OF POLYOMAVIRUS LARGE T-ANTIGEN ARE REQUIRED FOR DIFFERENT FUNCTIONS OF THE PROTEIN	ONCOGENE			English	Article							SIMIAN VIRUS-40; BINDING-SITES; TUMOR-ANTIGEN; DNA HELICASE; REPLICATION; FIBROBLASTS; INFECTION; PHOSPHORYLATION; IMMORTALIZATION; TRANSFORMATION	Many cellular and some virally coded proteins regulating key events in higher cells have been found to be multifunctional. One example of such a protein is the polyomavirus large T antigen, which is involved not only in viral DNA replication and gene expression but also in the induction of the S phase in host cells, in the immortalization of various cell types and in the transactivation of some cellular genes. We recently constructed cell lines in which T antigen was synthesized under the control of a hormone-inducible promoter. This allowed us to induce different concentrations of the protein in the cell and to investigate the levels of large T antigen required for replication, S-phase induction and transactivation of a growth-regulated promoter. We found that significantly higher concentrations of large T antigen are required for the replication function of the protein than for either S phase induction or transactivation. These observations for the first time provide clear evidence for a potential regulation of different functions of a pleiotropic protein by the amount of that protein produced in the cell.	UNIV VIENNA,INST MOLEK BIOL,DR BOHR GASSE 9,A-1030 VIENNA,AUSTRIA	University of Vienna; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)				Ogris, Egon/0000-0001-5950-9264				BERGER H, 1986, J VIROL, V60, P768, DOI 10.1128/JVI.60.2.768-770.1986; BOCKUS BJ, 1987, J VIROL, V61, P1147, DOI 10.1128/JVI.61.4.1147-1154.1987; CHENG SH, 1990, MOL CELL BIOL, V10, P5569, DOI 10.1128/MCB.10.10.5569; COWIE A, 1984, J VIROL, V52, P750, DOI 10.1128/JVI.52.3.750-760.1984; COWIE A, 1986, MOL CELL BIOL, V6, P4344, DOI 10.1128/MCB.6.12.4344; DILWORTH SM, 1982, P NATL ACAD SCI-BIOL, V79, P1059, DOI 10.1073/pnas.79.4.1059; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; FRIEDMAN M, 1986, CONTEMP POLICY ISSUE, V4, P1, DOI 10.1111/j.1465-7287.1986.tb00827.x; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JAT PS, 1986, J VIROL, V59, P746, DOI 10.1128/JVI.59.3.746-750.1986; KINGSTON RE, 1986, MOL CELL BIOL, V10, P3343; LORIMER HE, 1991, J VIROL, V65, P687, DOI 10.1128/JVI.65.2.687-699.1991; MARTENS I, 1989, J VIROL, V63, P2126, DOI 10.1128/JVI.63.5.2126-2133.1989; OGRIS E, 1992, J VIROL, V66, P53, DOI 10.1128/JVI.66.1.53-61.1992; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PARSONS RE, 1991, J VIROL, V65, P2798, DOI 10.1128/JVI.65.6.2798-2806.1991; POMERANTZ BJ, 1984, J VIROL, V49, P925, DOI 10.1128/JVI.49.3.925-937.1984; PRIVES C, 1990, CELL, V61, P735, DOI 10.1016/0092-8674(90)90179-I; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; ROTHENEDER H, 1991, NUCLEIC ACIDS RES, V19, P6805, DOI 10.1093/nar/19.24.6805; Sambrook J, 1989, MOL CLONING LABORATO; SEKI M, 1990, BIOCHEMISTRY-US, V29, P1003, DOI 10.1021/bi00456a024; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STRAUSS M, 1990, ONCOGENE, V5, P1223; TEMPLETON D, 1986, J VIROL, V57, P367, DOI 10.1128/JVI.57.1.367-370.1986; TOOZE J, 1980, DNA TUMOURS VIRUSES; TURLER H, 1985, J VIROL, V53, P579; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WANG EH, 1991, J BIOL CHEM, V266, P12668; WEICHSELBRAUN I, 1989, J VIROL, V63, P961, DOI 10.1128/JVI.63.2.961-964.1989; WEINBERG RA, 1990, TRENDS BIOCHEM SCI, V15, P199, DOI 10.1016/0968-0004(90)90162-5; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; ZHU JY, 1989, J VIROL, V63, P4777, DOI 10.1128/JVI.63.11.4777-4786.1989	34	10	10	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1277	1283						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8386826				2022-12-28	WOS:A1993KY32800020
J	IWAMOTO, T; TANIGUCHI, M; ASAI, N; OHKUSU, K; NAKASHIMA, I; TAKAHASHI, M				IWAMOTO, T; TANIGUCHI, M; ASAI, N; OHKUSU, K; NAKASHIMA, I; TAKAHASHI, M			CDNA CLONING OF MOUSE RET PROTOONCOGENE AND ITS SEQUENCE SIMILARITY TO THE CADHERIN SUPERFAMILY	ONCOGENE			English	Note							CELL-ADHESION MOLECULE; GENE FAMILY; EXPRESSION; PROTOONCOGENE; NEUROBLASTOMA; IDENTIFICATION; UVOMORULIN; DISEASE	We report the nucleotide sequence of the mouse ret proto-oncogene (proto-ret) and the deduced amino acid sequence. It encodes a transmembrane tyrosine kinase of 1115 amino acids that shows 83% homology with the human proto-Ret protein. The amino acid sequence revealed that the structures of the extracellular domain as well as the tyrosine kinase domain are similar in human and mouse proto-Ret proteins. Interestingly, the extracellular domains of both human and mouse proto-Ret proteins contain a cadherin-related sequence that is known to be important for Ca2+-dependent homophilic binding of the cadherins. When we examined transcription of the proto-ret gene in a variety of mouse tissues, it was detected in lymph nodes of C3H/HeJ-gld/gld mice and in normal mouse spinal cord. Furthermore, its transcription was found in the Neuro-2a mouse neuroblastoma cell line but not in 13 other rodent cell lines surveyed. Western blot analysis showed that proto-Ret proteins are expressed as 140-kDa and 160-kDa glycoproteins in Neuro-2a cells.	NAGOYA UNIV,SCH MED,DEPT IMMUNOL,65 TSURUMAI CHO,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NAGOYA UNIV,SCH MED,DEPT PATHOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN	Nagoya University; Nagoya University			TAKAHASHI, Masahide/I-7244-2014; ASAI, Naoya/I-7377-2014; Takahashi, Masahide/AAN-4770-2020	Takahashi, Masahide/0000-0002-2803-2683				AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; DONALIES M, 1991, P NATL ACAD SCI USA, V88, P8024, DOI 10.1073/pnas.88.18.8024; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; IKEDA I, 1990, ONCOGENE, V5, P1291; KUMA K, 1992, IN PRESS P JPN ACAD; KUMA K, 1992, IN PRESS MOL BIOL EV; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAGAO M, 1990, JPN J CANCER RES, V81, P309, DOI 10.1111/j.1349-7006.1990.tb02566.x; NOSE A, 1987, EMBO J, V6, P3655, DOI 10.1002/j.1460-2075.1987.tb02698.x; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896-6273(91)90291-7; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO M, 1990, ONCOGENE, V5, P1595; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TANIGUCHI M, 1992, ONCOGENE, V7, P1491	23	154	162	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1087	1091						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455936				2022-12-28	WOS:A1993KT22000035
J	GUTMANN, DH; BOGUSKI, M; MARCHUK, D; WIGLER, M; COLLINS, FS; BALLESTER, R				GUTMANN, DH; BOGUSKI, M; MARCHUK, D; WIGLER, M; COLLINS, FS; BALLESTER, R			ANALYSIS OF THE NEUROFIBROMATOSIS TYPE-1 (NF1) GAP-RELATED DOMAIN BY SITE-DIRECTED MUTAGENESIS	ONCOGENE			English	Article							AFFINITY CAMP PHOSPHODIESTERASE; GTPASE-ACTIVATING PROTEIN; SACCHAROMYCES-CEREVISIAE; GENE-PRODUCT; RAS GTPASE; MAMMALIAN GAP; YEAST; IDENTIFICATION; SEQUENCE; ENCODES	The gene for von Recklinghausen neurofibromatosis type 1 (NF1) was recently identified by positional cloning and found to encode a protein with sequence similarity to a family of eucaryotic GTPase-activating proteins (GAPs). Expression of the NF1-GAP-related domain (NF1GRD) has been shown to complement yeast strains deficient in the yeast GAP homologs, IRA1 and IRA2, to interact with human RAS proteins and to accelerate the conversion of ras-GTP to ras-GDP. Further analysis of this region has revealed a number of residues that are highly conserved between members of the GAP family. Mutational analysis of a representative number of these residues produced one of three effects: (1) no change in NF1GRD function. (2) complete disruption of NF1GRD function and (3) intermediate retention of NF1GRD function. One of these mutations at residue 1423 was shown to have reduced ability to negatively regulate ras in yeast, which is interesting in tight of a recent report demonstrating a similar naturally occurring mutation in human malignancies.	UNIV MICHIGAN,DEPT NEUROL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT RADIAT ONCOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109; NIH,NATL CTR BIOTECHNOL INFORMAT,BETHESDA,MD 20894; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; Cold Spring Harbor Laboratory				Gutmann, David/0000-0002-3127-5045; Marchuk, Douglas/0000-0002-3110-6671; Wigler, Michael/0000-0003-4396-1971	NINDS NIH HHS [NS23410] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023410] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSEN LB, 1993, IN PRESS MOL CELL BI; BALDARI C, 1985, GENE, V35, P27, DOI 10.1016/0378-1119(85)90154-4; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BANROQUES J, 1986, CELL, V46, P837, DOI 10.1016/0092-8674(86)90065-6; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOGUSKI MS, 1992, NEW BIOL, V4, P247; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GIBBS JB, 1987, P NATL ACAD SCI USA, V262, P10426; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LI Y, 1992, CELL, V69, P1; Maniatis T., 1982, MOL CLONING; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; NISHI T, 1991, ONCOGENE, V6, P1555; Riccardi VM., 1993, PLASTIC RECONST SURG, V91, P561, DOI [10.1097/00006534-199303000-00029, DOI 10.1097/00006534-199303000-00029]; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SASS P, 1986, P NATL ACAD SCI USA, V83, P9303, DOI 10.1073/pnas.83.24.9303; SHERMAN F, 1986, LABORATORY COURSE MA; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSCHUMPER G, 1980, GENE, V10, P157, DOI 10.1016/0378-1119(80)90133-X; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WANG Y, 1991, CELL REGUL, V2, P453, DOI 10.1091/mbc.2.6.453; WIESMULLER L, 1992, J BIOL CHEM, V267, P10207; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	39	57	57	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					761	769						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437860				2022-12-28	WOS:A1993KN00800029
J	SUN, Y; HEGAMYER, G; COLBURN, NH				SUN, Y; HEGAMYER, G; COLBURN, NH			NASOPHARYNGEAL CARCINOMA SHOWS NO DETECTABLE RETINOBLASTOMA SUSCEPTIBILITY GENE ALTERATIONS	ONCOGENE			English	Note							EPSTEIN-BARR VIRUS; HUMAN PROSTATE CARCINOMA; CELL LINES HNE-1; LARGE T-ANTIGEN; HUMAN BLADDER; RB GENE; INACTIVATION; EXPRESSION; PROTEIN; MUTATIONS	Since multistage carcinogenesis is frequently associated with the loss of suppressor gene activity, and since in over 90% of cases of nasopharyngeal carcinoma (NPC) p53 alterations are not involved [Sun, Y., Hegamyer, G.H., Cheng, Y.-J., Hildesheim, A., Chen, J.-Y., Chen, I.-H., Cao, Y., Yao, K.-T. & Colburn, N.H. (1992). Proc. Natl. Acad. Sci. USA, 89, 6516-6520] we investigated the possible involvement of the inactivation of the retinoblastoma susceptibility gene (RB) in nasopharyngeal carcinogenesis. We analysed the expression, gross structure and possible point mutation of the RB gene in an NPC cell line as well as seven NPC biopsies obtained from seven patients. The NPC cell line expresses the RB gene with a normal size and abundance, as assayed by reverse transcriptase polymerase chain reaction (RT-PCR) and Northern hybridization. No point mutation was detected in two independent E1A/large T-binding regions, which are the common sites for mutations in the RB gene. NPC biopsies also showed no point mutations at four exon-intron boundaries at which point mutations have been reported in other human carcinomas. The biopsies and cell tine had no deletions in the promoter region of the gene and showed no gross deletions or rearrangements. Taken together, we conclude that, in contrast to multistage carcinogenesis leading to human retinoblastoma, osteogenic sarcomas and carcinomas of lung, breast, bladder and prostate, nasopharyngeal carcinogenesis appears unlikely to involve RB gene alterations.	NCI, CELL BIOL SECT, VIRAL CARCINOGENESIS LAB, FREDERICK, MD 21702 USA; NCI, FCRDC, DYNCORP, PROGRAM RESOURCES INC, BCDP, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74102] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOYNTON RF, 1991, CANCER RES, V51, P5766; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHENG J, 1990, BLOOD, V75, P730; DETHE G, 1982, VIRAL INFECTIONS HUM, P126; Dryja T P, 1986, Symp Fundam Cancer Res, V39, P115; Evans Alfred S., 1990, Annals of Epidemiology, V1, P71; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GLASER R, 1989, P NATL ACAD SCI USA, V86, P9524, DOI 10.1073/pnas.86.23.9524; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG DP, 1991, CANCER GENET CYTOGEN, V54, P91, DOI 10.1016/0165-4608(91)90035-S; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; ISHIKAWA J, 1991, CANCER RES, V51, P5736; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KLEIN G, 1974, P NATL ACAD SCI USA, V71, P4737, DOI 10.1073/pnas.71.12.4737; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LERMAN MI, 1991, HUM GENET, V86, P567; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHEW JY, 1990, CELL GROWTH DIFFER, V1, P17; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SUN Y, 1992, P NATL ACAD SCI USA, V89, P6516, DOI 10.1073/pnas.89.14.6516; SUN Y, 1992, BIOTECHNIQUES, V12, P639; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; YA C, 1991, MOL CARCINOGEN, V4, P297, DOI 10.1002/mc.2940040408; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; YAO K, 1990, INT J CANCER, V45, P83, DOI 10.1002/ijc.2910450116; ZENG Y, 1985, ADV CANCER RES, V44, P121, DOI 10.1016/S0065-230X(08)60027-5; ZHANG SH, 1983, INT J CANCER, V31, P587, DOI 10.1002/ijc.2910310509; 1978, SCI SINICA, V21, P127	42	61	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1993	8	3					791	795						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437863				2022-12-28	WOS:A1993KN00800033
J	DUFORT, D; DROLET, M; NEPVEU, A				DUFORT, D; DROLET, M; NEPVEU, A			A PROTEIN-BINDING SITE FROM THE MURINE C-MYC PROMOTER CONTRIBUTES TO TRANSCRIPTIONAL BLOCK	ONCOGENE			English	Article							MOUSE ERYTHROLEUKEMIA-CELLS; RNA POLYMERASE-II; 3' END FORMATION; GENE-EXPRESSION; ANTITERMINATION PROTEIN; SNRNA PROMOTER; LAC PROMOTER; 1ST EXON; ELONGATION; TERMINATION	Recent studies have revealed that expression of several eukaryotic genes can be regulated at the level of transcription elongation. As a first step to elucidate the mechanism by which transcription elongation is modulated, several groups have identified sequences necessary for transcriptional block within the c-myc gene. These studies indicated that transcriptional block depends not only on sequences surrounding the sites of block, but also on sequences within the promoter: some deletions within the c-myc promoter eliminated transcriptional block and, with chimeric constructs, transcriptional block was observed when some heterologous promoters but not others were fused to the c-myc termination region. Using a chimeric construct containing the H-2K(b) major histocompatibility class gene promoter linked to the c-myc first exon, we show that transcriptional block is increased by the addition of a 25 bp DNA sequence from the c-myc promoter. Similar results are obtained whether this sequence is inserted upstream or downstream of the transcription initiation site. We further show that nuclear factors interact with this sequence in vitro. Interestingly, when a mutated version of this sequence was tested, we observed decreased nuclear factor binding in vitro as well as reduced transcriptional block in nuclear run-on transcription assays. These results suggest that interactions of protein factors with specific nucleotide sequences near the transcription initiation site can affect elongation of transcription at sites located further down stream.	MCGILL UNIV,DEPT ONCOL,687 PINE AVE W,MONTREAL H3A 1A1,QUEBEC,CANADA	McGill University			/AAB-8315-2020	Dufort, Daniel/0000-0002-6477-596X				ASSELIN C, 1989, ONCOGENE, V4, P549; BARIK S, 1987, CELL, V50, P885, DOI 10.1016/0092-8674(87)90515-0; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BESSE M, 1986, EMBO J, V5, P1377, DOI 10.1002/j.1460-2075.1986.tb04370.x; DEVEGVAR HEN, 1986, CELL, V47, P259; EICK D, 1987, ONCOGENE, V2, P61; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; FERAMISCO JR, 1982, J BIOL CHEM, V257, P1024; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; HERNANDEZ N, 1986, CELL, V47, P249, DOI 10.1016/0092-8674(86)90447-2; HERNANDEZ N, 1988, EMBO J, V7, P3125, DOI 10.1002/j.1460-2075.1988.tb03179.x; Hochschild A., 1990, DNA TOPOLOGY ITS BIO, P107; HORWITZ RJ, 1987, CELL, V51, P631, DOI 10.1016/0092-8674(87)90132-2; KERPPOLA TK, 1988, MOL CELL BIOL, V8, P4389, DOI 10.1128/MCB.8.10.4389; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; Maxam A M, 1980, Methods Enzymol, V65, P499; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; MOSSING MC, 1986, SCIENCE, V233, P889, DOI 10.1126/science.3090685; MULLER HP, 1989, CELL, V58, P767, DOI 10.1016/0092-8674(89)90110-4; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; ROBERT J, 1987, CELL, V51, P483, DOI 10.1016/0092-8674(87)90644-1; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SPENCER CA, 1990, ONCOGENE, V5, P777; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WRIGHT S, 1989, P NATL ACAD SCI USA, V86, P505, DOI 10.1073/pnas.86.2.505; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x	35	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					165	171						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423994				2022-12-28	WOS:A1993KN00500020
J	SHIN, S; STEFFEN, DL				SHIN, S; STEFFEN, DL			FREQUENT ACTIVATION OF THE LCK GENE BY PROMOTER INSERTION AND ABERRANT SPLICING IN MURINE LEUKEMIA VIRUS-INDUCED RAT LYMPHOMAS	ONCOGENE			English	Article							TYROSINE-PROTEIN-KINASE; INBRED MOUSE STRAINS; SIGNAL TRANSDUCTION; CD4 RECEPTOR; P56LCK; SITES; MICE; RNA	We have analysed DNA and RNA from 36 T-cell lymphomas induced in Fischer rats by Moloney murine leukemia virus for alterations affecting the structure or expression of the lck gene. At least five primary tumors (14%) have a proviral insertion upstream of lck. In at least four of the tumors, proviral insertion increases lck mRNA levels an average of eight-fold. Overexpression of lck results from transcription initiating in the viral promoter and extending into lck sequences. Three different structures of hybrid transcript were detected. In all three, the hybrid RNAs are spliced to a normal lck splice acceptor in the first exon of lck, resulting in removal of three out of frame ATG codons which would be expected to increase the translation efficiency of the hybrid message. In one tumor, the viral splice donor is used, in one tumor, proviral insertion generates a splice donor sequence one base pair downstream of the long terminal repeat boundary, and in two tumors, a cryptic splice donor in the upstream lck sequences is used. The significance of these unusual splicing patterns and of the higher frequency of proviral insertions adjacent to lck in rats relative to mice is discussed.	BAYLOR COLL MED,DIV MOLEC VIROL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine					NCI NIH HHS [CA30674] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA030674] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ADLER HT, 1988, J VIROL, V62, P4113, DOI 10.1128/JVI.62.11.4113-4122.1988; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BERGER SL, 1987, METHOD ENZYMOL, V152, P215; BILOFSKY HS, 1986, NUCLEIC ACIDS RES, V14, P1, DOI 10.1093/nar/14.1.1; CHANG KS, 1984, MOL CELL BIOL, V4, P2498, DOI 10.1128/MCB.4.11.2498; CLOYD MW, 1980, J EXP MED, V151, P542, DOI 10.1084/jem.151.3.542; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GISSELBRECHT S, 1981, INT J CANCER, V27, P531, DOI 10.1002/ijc.2910270417; GREEN N, 1980, J EXP MED, V152, P2498; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; KRETZ KA, 1989, NUCLEIC ACIDS RES, V17, P5864, DOI 10.1093/nar/17.14.5864; LAWRENCE CB, 1989, EUGENE SOFTWARE PACK; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LI JP, 1991, J VIROL, V65, P2408, DOI 10.1128/JVI.65.5.2408-2414.1991; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MUCENSKI ML, 1987, J VIROL, V61, P2929, DOI 10.1128/JVI.61.9.2929-2933.1987; MUCENSKI ML, 1988, J VIROL, V62, P839, DOI 10.1128/JVI.62.3.839-846.1988; MUCENSKI ML, 1987, ONCOGENE RES, V2, P33; MUCENSKI ML, 1986, MOL CELL BIOL, V6, P4236, DOI 10.1128/MCB.6.12.4236; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SELDEN RF, 1987, CURRENT PROTOCOLS MO; SITBON M, 1985, VIROLOGY, V140, P144, DOI 10.1016/0042-6822(85)90453-2; STEFFEN D, 1984, P NATL ACAD SCI-BIOL, V81, P2097, DOI 10.1073/pnas.81.7.2097; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VIJAYA S, 1987, J VIROL, V61, P1164, DOI 10.1128/JVI.61.4.1164-1170.1987; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	32	12	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					141	149						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423992				2022-12-28	WOS:A1993KN00500017
J	Froeschle, A; Carnac, G; Alric, S; Montarras, D; Pinset, C; RochetteEgly, C; Bonnieu, A				Froeschle, A; Carnac, G; Alric, S; Montarras, D; Pinset, C; RochetteEgly, C; Bonnieu, A			RXR alpha is essential for mediating the all-trans retinoic acid-induced growth arrest of C2 myogenic cells	ONCOGENE			English	Article						retinoic acid; RXR alpha; growth arrest; muscle cell	ACUTE PROMYELOCYTIC LEUKEMIA; X-RECEPTOR; THYROID-HORMONE; TERMINAL DIFFERENTIATION; LINE BA-HAN-1C; MUSCLE-CELLS; EXPRESSION; CLONING; MYOD1; GENE	In C2 muscle cells, retinoic acid (RA) induces growth arrest associated with terminal differentiation. These RA actions are presumed to be mediated through nuclear receptors (RARs and RXRs) that belong to the superfamily of ligand-dependent transcription factors, In this study, we have characterized a myogenic C2 subclone, that unlike parental cells, is resistant to growth inhibition and differentiation by RA, Examination of these RA-sensitive and resistant C2 cells for the expression of retinoid acid receptors revealed a lack of RXR alpha expression at the myoblast stage in resistant C2 cells, To determine the functions of RXR alpha, we introduced an RXR alpha expression vector into RA-resistant C2 cells by transient or stable transfections, Our results show that RXR alpha restores the response to RA in this subclone with respect to AP1 inhibition and growth arrest, These observations indicate that RXR alpha plays a crucial role in mediating RA induced growth arrest of C2 myogenic cells.	INRA,LAB DIFFERENCIAT CELLULAIRE & CROISSANCE,F-34060 MONTPELLIER 01,FRANCE; INST PASTEUR,DEPT BIOL MOLEC,URA 1148 CNRS,F-75724 PARIS 15,FRANCE; INST GENET & BIOL MOLEC & CELLULAIRE,CNRS,INSERM,ULP,F-67404 ILLKIRCH GRAFFENS,FRANCE	INRAE; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			Bonnieu, Anne/ABA-7182-2020; Carnac, Gilles/N-6744-2018	Carnac, Gilles/0000-0002-3518-8774				ALBAGLICURIEL O, 1993, DIFFERENTIATION, V52, P201, DOI 10.1111/j.1432-0436.1993.tb00632.x; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; ARNOLD HH, 1992, J CELL BIOL, V118, P877, DOI 10.1083/jcb.118.4.877; CARNAC G, 1993, ENDOCRINOLOGY, V133, P2171, DOI 10.1210/en.133.5.2171; CARNAC G, 1993, ONCOGENE, V8, P3103; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHAWLA A, 1994, P NATL ACAD SCI USA, V91, P1786, DOI 10.1073/pnas.91.5.1786; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DE LUCA LM, 1991, FASEB J, V5, P2924; DEFACQUE H, 1994, BIOCHEM BIOPH RES CO, V203, P272, DOI 10.1006/bbrc.1994.2178; DOWNES M, 1994, ENDOCRINOLOGY, V134, P2658, DOI 10.1210/en.134.6.2658; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GABBERT HE, 1988, CANCER RES, V48, P5264; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Gudas Lorraine J., 1994, P443; HALEVY O, 1993, J CELL PHYSIOL, V154, P566, DOI 10.1002/jcp.1041540315; HEERY DM, 1993, P NATL ACAD SCI USA, V90, P4281, DOI 10.1073/pnas.90.9.4281; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Hofmann Clementine, 1994, P387; Hong Waun Ki, 1994, P597; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; KIZAKI M, 1993, BLOOD, V82, P3592; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOVE JM, 1994, CURR OPIN CELL BIOL, V6, P825, DOI 10.1016/0955-0674(94)90051-5; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; MOASSER MM, 1994, ONCOGENE, V9, P833; MOMOI T, 1992, BIOCHEM BIOPH RES CO, V187, P245, DOI 10.1016/S0006-291X(05)81484-6; MONTARRAS D, 1989, EMBO J, V8, P2203, DOI 10.1002/j.1460-2075.1989.tb08343.x; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NAGY L, 1995, MOL CELL BIOL, V15, P3540; NILSEN DA, 1983, P NATL ACAD SCI USA, V80, P5198; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; PINSET C, 1988, DIFFERENTIATION, V38, P28, DOI 10.1111/j.1432-0436.1988.tb00588.x; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; VINCENT S, 1993, NUCLEIC ACIDS RES, V21, P1498, DOI 10.1093/nar/21.6.1498; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YANGYEN HF, 1991, NEW BIOL, V3, P1206; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	53	14	14	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					411	421						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570219				2022-12-28	WOS:A1996TR53800021
J	Takahashi, K; Stamenkovic, I; Cutler, M; Saya, H; Tanabe, KK				Takahashi, K; Stamenkovic, I; Cutler, M; Saya, H; Tanabe, KK			CD44 hyaluronate binding influences growth kinetics and tumorigenicity of human colon carcinomas	ONCOGENE			English	Article						CD44; hyaluronate; colon carcinoma; adhesion molecule; metastases	LYMPHOCYTE-HOMING RECEPTOR; CELL-SURFACE GLYCOPROTEIN; NON-HODGKINS-LYMPHOMA; MONOCLONAL-ANTIBODIES; TUMOR-GROWTH; FIBRONECTIN RECEPTOR; ACID BINDING; EXPRESSION; ADHESION; VARIANT	CD44 is a cell surface receptor for hyaluronate that is implicated in the regulation of tumor growth and metastatic potential. Transformation of colon mucosa to carcinoma is associated with overexpression of several CD44 alternative splice variants. The functional roles of CD44 isoforms in colon carcinoma tumor progression remain unclear. CD44H expression is downregulated in colon carcinomas compared to paired normal mucosa. In the present study we demonstrate that reintroduction of CD44H back into colon carcinoma cells by stable transfection reduces their in vitro growth rate and tumorigenicity. Examination of several colon carcinoma cell lines and use of mutant CD44H reveal that this in vitro and irt vivo growth reduction requires the ability of CD44H to bind hyaluronate. These observations indicate that the CD44H downregulation associated with transformation of mucosa to colon carcinoma may provide the carcinoma cells with a growth advantage. Furthermore, the reduction in tumor growth rate mediated by reintroduction of CD44H into colon carcinoma cells is dependent on its ability to bind hyaluronate.	MASSACHUSETTS GEN HOSP, DEPT SURG, DIV SURG ONCOL, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT PATHOL, BOSTON, MA 02114 USA; KUMAMOTO UNIV, SCH MED, DEPT ONCOL, KUMAMOTO 860, JAPAN	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Kumamoto University			Saya, Hideyuki/J-4325-2013		NCI NIH HHS [CA64454, CA55735] Funding Source: Medline; NIDDK NIH HHS [DK433351] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064454, R01CA055735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; BIRCH M, 1991, CANCER RES, V51, P6660; BROWN PJ, 1985, SCIENCE, V228, P1448, DOI 10.1126/science.4012302; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; CANNISTRA SA, 1993, CANCER RES, V53, P3830; COOPER DL, 1992, BIOCHEM BIOPH RES CO, V182, P569, DOI 10.1016/0006-291X(92)91770-Q; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; FOX SB, 1994, CANCER RES, V54, P4539; GALLATIN WM, 1989, P NATL ACAD SCI USA, V86, P4654, DOI 10.1073/pnas.86.12.4654; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; GUO YJ, 1994, CANCER RES, V54, P422; GUO YJ, 1994, CANCER RES, V54, P1561; HEIDER KH, 1993, J CELL BIOL, V120, P227, DOI 10.1083/jcb.120.1.227; HOFMANN M, 1991, CANCER RES, V51, P5292; HORST E, 1990, LEUKEMIA, V4, P595; JALKANEN S, 1986, SCIENCE, V233, P556, DOI 10.1126/science.3726548; JALKANEN S, 1991, J CLIN INVEST, V87, P1835, DOI 10.1172/JCI115205; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; JALKANEN ST, 1986, EUR J IMMUNOL, V16, P1195, DOI 10.1002/eji.1830161003; JOENSUU H, 1993, AM J PATHOL, V143, P867; JOENSUU H, 1993, BRIT J CANCER, V68, P428, DOI 10.1038/bjc.1993.354; KNUDSON W, 1993, P NATL ACAD SCI USA, V90, P4003, DOI 10.1073/pnas.90.9.4003; LESLEY J, 1992, J EXP MED, V175, P257, DOI 10.1084/jem.175.1.257; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; MORIKAWA K, 1988, CANCER RES, V48, P1943; MULDER JWR, 1994, LANCET, V344, P1470, DOI 10.1016/S0140-6736(94)90290-9; NAGASAKA S, 1995, J NEUROSURG, V82, P858, DOI 10.3171/jns.1995.82.5.0858; PALS ST, 1989, BLOOD, V73, P885; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; REBER S, 1990, INT J CANCER, V46, P919, DOI 10.1002/ijc.2910460528; SCHREINER C, 1991, CANCER RES, V51, P1738; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SEITER S, 1993, J EXP MED, V177, P443, DOI 10.1084/jem.177.2.443; SHIMIZU Y, 1989, J IMMUNOL, V143, P2457; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; SY MS, 1992, J EXP MED, V176, P623, DOI 10.1084/jem.176.2.623; TAKESHIMA H, 1994, ONCOGENE, V9, P2135; TANABE KK, 1995, ANN SURG, V222, P493; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; TANABE KK, 1993, MOL CARCINOGEN, V7, P212, DOI 10.1002/mc.2940070403; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; TOLG C, 1993, NUCLEIC ACIDS RES, V21, P1225, DOI 10.1093/nar/21.5.1225; TOOLE BP, 1979, P NATL ACAD SCI USA, V76, P6299, DOI 10.1073/pnas.76.12.6299; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; WIELENGA VJM, 1993, CANCER RES, V53, P4754; ZHANG LR, 1995, CANCER RES, V55, P428	56	53	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2223	2232						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570172				2022-12-28	WOS:A1995TK70200005
J	LIU, BX; WEI, W; BROEK, D				LIU, BX; WEI, W; BROEK, D			THE CATALYTIC DOMAIN OF THE MOUSE SOS1 GENE-PRODUCT ACTIVATES RAS PROTEINS IN-VIVO AND IN-VITRO	ONCOGENE			English	Article							SACCHAROMYCES-CEREVISIAE; ADENYLATE-CYCLASE; CDC25 GENE; IDENTIFICATION; PATHWAY; CLONING; CDNAS	Nucleotide exchange factors (NEFs) which are structurally related to the yeast Saccharomyces cerevisiae CDC25 gene product have recently been identified in mammals. One of these NEFs, cdc25, has been shown to activate RAS in yeast and to promote nucleotide exchange on RAS proteins in vitro. The cdc25 from mammals is expressed at high levels in brain tissue but not in a variety of other tissues examined. The vertebrate sos1 and sos2 gene products have a domain structurally related to the catalytic domain of the yeast CDC25NEF. The expression pattern of sos1 and sos2 is widespread, showing detectable levels of expression in all tissues examined, although the levels vary dramatically in various tissues. In this report we demonstrate that the catalytic domain of SOS1NEF can complement the loss of CDC25 function in yeast, can bind tightly to the nucleotide-free form of H-ras in vitro and can promote nucleotide exchange on the H-ras protein in vitro.	UNIV SO CALIF,SCH MED,KENNETH NORRIS JR COMPREHENS CANC CTR,DEPT BIOCHEM & MOLEC BIOL,LOS ANGELES,CA 90033	University of Southern California					NATIONAL CANCER INSTITUTE [R01CA050261] Funding Source: NIH RePORTER; NCI NIH HHS [NCI CA50261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACQUET E, 1993, IN PRESS J BIOL CHEM; KIM JH, 1991, MOL CELL BIOL, V11, P3894, DOI 10.1128/MCB.11.8.3894; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; Sambrook J, 1989, MOL CLONING LABORATO; Sherman F., 1986, METHODS YEAST GENETI; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; YOUNG D, 1989, P NATL ACAD SCI USA, V86, P7989, DOI 10.1073/pnas.86.20.7989	18	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3081	3084						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414509				2022-12-28	WOS:A1993MC09300024
J	SCHUERMANN, M; HENNIG, G; MULLER, R				SCHUERMANN, M; HENNIG, G; MULLER, R			TRANSCRIPTIONAL ACTIVATION AND TRANSFORMATION BY CHIMERIC FOS-ESTROGEN RECEPTOR PROTEINS - ALTERED PROPERTIES AS A CONSEQUENCE OF GENE FUSION	ONCOGENE			English	Article							C-FOS; V-FOS; CELLULAR-TRANSFORMATION; GLUCOCORTICOID RECEPTOR; NEGATIVE REGULATOR; BINDING DOMAINS; AUTO-REGULATION; PROTO-ONCOGENE; JUN; TRANSACTIVATION	We have generated a series of conditionally active Fos and FosB proteins by fusion with a C-terminal fragment of the human estrogen receptor (ER) which harbours the ligand binding site and the overlapping hormone-inducible transactivation domain TAF-2. The chimaeric Fos-ER proteins showed estrogen-inducible activation of TRE (TPA-responsive element)-directed trapscription and hormone-dependent transformation of fibroblasts. These properties of the fusion proteins were independent of the transregulatory and transforming properties of their normal non-fused counterparts c-Fos, v-Fos, FosB-L and FosB-S. Thus c-Fos-ER and FosB-S-ER were strong transforming proteins in the presence of hormone, although c-Fos and FosB-S possess only marginal oncogenic properties. In addition, all fusion proteins showed increased transactivation in the presence of estrogen, again most noticeable in the case of c-Fos-ER and FosB-S-ER. The ER-fusion thus basically eliminated the differences in the transactivating potential seen among the various native Fos proteins. Our data therefore provide evidence: (i) that the hormone binding domain of the human estrogen receptor, apart from delivering hormonal control to a heterologous protein, can have profound effects on the activity of certain transcription factors, particularly on proteins with weak oncogenic and/or transregulatory potential, and (ii) that the transforming potential of c-Fos and FosB-S can be dramatically elevated by increasing their transactivating properties.	PHILIPPS UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,EMIL MANNKOPFF STR 2,D-35037 MARBURG,GERMANY	Philipps University Marburg			Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				ADAMKIEWICZ J, 1990, ONCOGENE, V5, P525; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; JOOSS K, 1992, ONCOGENE, V7, P1933; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LUCIBELLO F, 1989, CELL, V59, P9989; LUCIBELLO F C, 1991, Critical Reviews in Oncogenesis, V2, P259; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; LUCIBELLO FC, 1991, NEW BIOL, V3, P671; MILLER AD, 1984, CELL, V36, P51; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NEUBERG M, 1991, ONCOGENE, V6, P1325; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUERMANN M, 1991, ONCOGENE, V6, P567; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3213, DOI 10.1073/pnas.83.10.3213; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TORA L, 1989, CELL, V59, P447; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WISDOM R, 1992, GENE DEV, V6, P667, DOI 10.1101/gad.6.4.667; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	43	31	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2781	2790						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378087				2022-12-28	WOS:A1993LX34300020
J	JACKSON, PK; PASKIND, M; BALTIMORE, D				JACKSON, PK; PASKIND, M; BALTIMORE, D			MUTATION OF A PHENYLALANINE CONSERVED IN SH3-CONTAINING TYROSINE KINASES ACTIVATES THE TRANSFORMING ABILITY OF C-ABL	ONCOGENE			English	Article							MURINE LEUKEMIA-VIRUS; NORMAL CELLULAR HOMOLOG; FUJINAMI SARCOMA-VIRUS; STRUCTURAL SIMILARITY; SIGNAL TRANSDUCTION; NUCLEOTIDE-SEQUENCE; CATALYTIC DOMAINS; PHOSPHOLIPASE-C; LYMPHOID-CELLS; GENE-PRODUCTS	c-abl is the normal cellular homolog of the v-abl transforming gene of Abelson murine leukemia virus. By constructing recombinants between c- and v-abl retroviruses, we show that a point mutation in c-Abl is sufficient to change the myristoylated form of c-Abl into a protein able to transform fibroblasts, but not capable of transforming bone marrow or inducing Abelson disease. This activating mutation, which changes the phenylalanine at amino acid 420 to valine (F420V) found in the homologous position of v-Abl, is positioned outside of the SH3 domain, a region typically modified in transforming alleles of abl. Phenylalanine 420 is perfectly conserved among tyrosine kinases with N-terminal SH3 domains (the Src and Abl families). The equivalent position in other protein tyrosine kinases is a conserved hydrophobic residue that predicts the specific family to which that kinase belongs. Mutation of phenylalanine 420 to other hydrophobic residues activates c-Abl. Unlike other transforming variants of Abl, the F420V mutant protein is not highly phosphorylated on tyrosine. Mutation of the nearby proposed autophosphorylation site, tyrosine 412, shows that this tyrosine is not strictly required for fibroblast transformation in either F420V or SH3-deleted variants of c-Abl (IV).	WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; ROCKEFELLER UNIV,NEW YORK,NY 10021	Massachusetts Institute of Technology (MIT); Whitehead Institute; Rockefeller University				Jackson, Peter/0000-0002-1742-2539	NATIONAL CANCER INSTITUTE [R01CA051462] Funding Source: NIH RePORTER; NCI NIH HHS [NCI CA51462-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELSON HT, 1970, CANCER RES, V30, P2213; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BERNARDS A, 1988, ONCOGENE, V2, P297; BERNARDS A, 1987, MOL CELL BIOL, V7, P3231, DOI 10.1128/MCB.7.9.3231; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KAMPS MP, 1988, ONCOGENE, V2, P305; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KONOPKA JB, 1984, J VIROL, V51, P223, DOI 10.1128/JVI.51.1.223-232.1984; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LATT SA, 1983, J VIROL, V45, P1195, DOI 10.1128/JVI.45.3.1195-1199.1983; LEE R, 1985, RNA TUMOR VIRUSES, P861; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MELO JV, 1992, LEUKEMIA, V6, P786; MURTAGH K, 1986, J VIROL, V60, P599, DOI 10.1128/JVI.60.2.599-606.1986; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; PAWSON T, 1988, ONCOGENE, V3, P491; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PIWINICAWORMS H, 1987, CELL, V49, P75; PONTICELLI AS, 1982, CELL, V29, P953, DOI 10.1016/0092-8674(82)90458-5; PROBER JM, 1987, SCIENCE, V238, P336, DOI 10.1126/science.2443975; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; REYNOLDS FH, 1980, J VIROL, V36, P374, DOI 10.1128/JVI.36.2.374-386.1980; ROSENBERG N, 1975, P NATL ACAD SCI USA, V72, P1932, DOI 10.1073/pnas.72.5.1932; ROSENBERG NE, 1980, J VIROL, V36, P563; SCHER CD, 1975, NATURE, V253, P729, DOI 10.1038/253729a0; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TAKEMORI T, 1987, EMBO J, V6, P951, DOI 10.1002/j.1460-2075.1987.tb04844.x; WANG JYJ, 1988, ONCOGENE RES, V3, P293; WANG JYJ, 1984, CELL, V36, P349; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WEINMASTER GA, 1988, J VIROL, V62, P2016, DOI 10.1128/JVI.62.6.2016-2025.1988; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0; WITTE ON, 1979, NATURE, V5730, P396; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	57	34	37	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1943	1956						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510937				2022-12-28	WOS:A1993LG68200027
J	SHAY, JW; WRIGHT, WE; BRASISKYTE, D; VANDERHAEGEN, BA				SHAY, JW; WRIGHT, WE; BRASISKYTE, D; VANDERHAEGEN, BA			E6 OF HUMAN PAPILLOMAVIRUS TYPE-16 CAN OVERCOME THE M1 STAGE OF IMMORTALIZATION IN HUMAN MAMMARY EPITHELIAL-CELLS BUT NOT IN HUMAN FIBROBLASTS	ONCOGENE			English	Article							HUMAN BREAST-CANCER; RETINOBLASTOMA SUSCEPTIBILITY GENE; HUMAN-DIPLOID FIBROBLASTS; LARGE TUMOR-ANTIGEN; LARGE T-ANTIGEN; P53 MUTATIONS; SV40-TRANSFORMED CELLS; CELLULAR SENESCENCE; TRANSFORMED-CELLS; GROWTH	Immortalization is the consequence of the inactivation or bypass of two mortality stage mechanisms, M1 and M2, which are controlled by several genes including Rb and p53 in human fibroblasts. Abrogation of the M1 controls can be obtained through the activity of DNA tumor virus genes such as E6 and E7 of human papillomavirus 16 (HPV16). Fibroblasts expressing both E6 (which binds p53) and E7 (which binds Rb) bypass MI and continue replicating (exhibit an extended lifespan) until an independent mechanism, M2, is activated. The inactivation of the M2 mechanism finally results in celt immortalization. The present study establishes a difference in the tissue-specific mechanisms for the control of the M1 stage of cellular senescence. The expression of HPV16 E6 was sufficient to bypass the MI stage of cellular senescence and confer an extended lifespan in human mammary epithelial cells but not in fibroblasts. This implies that the M1 mechanism in human mammary epithelial cells does not involve the constitutive activation of Rb function as it does in fibroblasts. In addition, the results confirmed that the expression of HPV16 E6 (or both E6 and E7) did not directly immortalize the human mammary epithelial cells, since the inactivation of a second event, M2, was required to achieve immortalization. These observations are considered in the context of the telomere shortening model of cellular senescence.			SHAY, JW (corresponding author), UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.		Shay, Jerry W/F-7878-2011		NCI NIH HHS [CA50195] Funding Source: Medline; NIA NIH HHS [AG07992] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007992] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLSOP RC, 1992, IN PRESS P NATL ACAD; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BARTEK J, 1990, ONCOGENE, V5, P893; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BRONSTEIN I, 1990, BIOTECHNIQUES, V8, P310; COLES C, 1992, CANCER RES, V52, P5291; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DAVIDOFF AM, 1991, CANCER RES, V51, P2605; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DUNBAR BS, 1987, 2 DIMENSIONAL ELECTR, P335; GILLESPIE PG, 1991, P NATL ACAD SCI USA, V88, P2563, DOI 10.1073/pnas.88.6.2563; GIRARDI AJ, 1965, J CELL COMPAR PHYSL, V65, P69, DOI 10.1002/jcp.1030650110; GRIEDER CW, 1990, BIOESSAYS, V12, P363; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P538; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HAYFLICK L, 1980, AGING ITS CHEM, P227; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; KIPLING D, 1992, HUM MOL GENET, V1, P3, DOI 10.1093/hmg/1.1.3-a; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LINDER S, 1990, EXP CELL RES, V191, P1, DOI 10.1016/0014-4827(90)90027-8; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTIN GM, 1977, AM J PATHOL, V89, P484; MAZARS R, 1992, CANCER RES, V52, P3918; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MUNGER K, 1989, J VIROL, V63, P4417; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OSBORNE RJ, 1991, CANCER RES, V51, P6194; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; PIRISI L, 1992, J VIROL, V44, P268; Pollock Raphael E., 1992, Cancer Bulletin (Houston), V44, P268; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SCHEFFNER M, 1990, CELL, V63, P11291; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAY JW, 1992, EXP GERONTOL, V27, P477, DOI 10.1016/0531-5565(92)90003-I; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1992, MUTAT RES, V277, P163, DOI 10.1016/0165-1110(92)90003-R; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; SIDRANSKY D, 1992, CANCER RES, V52, P2984; STAMPFER M, 1980, IN VITRO CELL DEV B, V16, P415; STAMPS AC, 1992, EUR J CANCER, V28A, P1495, DOI 10.1016/0959-8049(92)90552-D; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STEIN GH, 1985, J CELL PHYSIOL, V125, P36, DOI 10.1002/jcp.1041250106; VANDERHAEGEN BA, 1993, IN PRESS IN VIGRO CE; VARLEY JM, 1991, ONCOGENE, V6, P413; WATANABE S, 1989, J VIROL, V63, P965, DOI 10.1128/JVI.63.2.965-969.1989; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088	79	230	239	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1407	1413						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8389027				2022-12-28	WOS:A1993LE06400002
J	ZHANG, LQ; LEMARCHANDEL, V; ROMEO, PH; BENDAVID, Y; GREER, P; BERNSTEIN, A				ZHANG, LQ; LEMARCHANDEL, V; ROMEO, PH; BENDAVID, Y; GREER, P; BERNSTEIN, A			THE FLI-1 PROTOONCOGENE, INVOLVED IN ERYTHROLEUKEMIA AND EWINGS-SARCOMA, ENCODES A TRANSCRIPTIONAL ACTIVATOR WITH DNA-BINDING SPECIFICITIES DISTINCT FROM OTHER ETS FAMILY MEMBERS	ONCOGENE			English	Article							MURINE LEUKEMIA-VIRUS; PUTATIVE ONCOGENE; GENE FAMILY; C-ETS; CELLS; EXPRESSION; IDENTIFICATION; ENHANCER; CONTAINS; PROTEINS	The late stages of the erythroleukemias induced by either the replication-defective Friend spleen focus-forming virus (SFFV) or the Friend murine leukemia virus (FMuLV) are associated with the insertional activation of one of two members (Spi-1 or Fli-1) of the Ets protooncogene family of transcriptional factors. Fli-1 is not rearranged or activated in the erythroleukemias induced by SFFV, and similarly Spi-1 is not rearranged or activated in the leukemic cell clones induced by F-MuLV. This strict specificity of integration sites suggests that Fli-1 and Spi-1 may be functionally distinct and transactivate different downstream genes during the progression of multistage Friend erythroleukemia. In this study, we show that the Fli-1 protein, like other Ets proteins, has DNA-binding activity and can act as a sequence-specific transcriptional activator. We also show that the Fli-1 and Spi-1 proteins are functionally distinct in that they recognize and transactivate through distinct DNA binding sites. Furthermore, we have identified an octanucleotide core sequence that is required in vitro for optimal binding of Fli-1 to the Drosophila E74 target and the promoter sequence of the human GPIIb gene.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV TORONTO,INST MED SCI,TORONTO M5S 1A1,ONTARIO,CANADA; HOP HENRI MONDOR,INSERM,U91,F-94010 CRETEIL,FRANCE; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M5S 1A1,ONTARIO,CANADA; SUNNYBROOK HLTH SCI CTR,DIV CANC RES,TORONTO M4N 3M5,ON,CANADA; QUEENS UNIV,DEPT PATHOL,KINGSTON K7L 3N6,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Queens University - Canada; University of Toronto			Romeo, Paul-Henri/L-5989-2017	Romeo, Paul-Henri/0000-0002-8294-0367				ATCHISON ML, 1988, EMBO J, V7, P4213, DOI 10.1002/j.1460-2075.1988.tb03318.x; AURIGEMMA RE, 1992, J VIROL, V66, P3056, DOI 10.1128/JVI.66.5.3056-3061.1992; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BHAT NK, 1987, P NATL ACAD SCI USA, V86, P7495; BOULOUKOS KE, 1988, MOL CELL BIOL, V9, P5718; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOERNER TJ, 1990, IN PRESS METHODS ENZ; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PRIBYL LJ, 1991, ONCOGENE, V6, P1175; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	41	85	87	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1621	1630						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502483				2022-12-28	WOS:A1993LE06400026
J	ABDELHAFIZ, HAM; CHEN, CY; MARCELL, T; KROLL, DJ; HOEFFLER, JP				ABDELHAFIZ, HAM; CHEN, CY; MARCELL, T; KROLL, DJ; HOEFFLER, JP			STRUCTURAL DETERMINANTS OUTSIDE OF THE LEUCINE ZIPPER INFLUENCE THE INTERACTIONS OF CREB AND ATF-2 - INTERACTION OF CREB WITH ATF-2 BLOCKS E1A ATF-2 COMPLEX-FORMATION	ONCOGENE			English	Article							ELEMENT-BINDING PROTEIN; T7 RNA-POLYMERASE; DNA-BINDING; RESPONSE ELEMENT; ENHANCER BINDING; TRANSCRIPTION; EXPRESSION; DOMAINS; ZINC; ADENOSINE-3',5'-MONOPHOSPHATE	Dimerization of leucine zipper-containing proteins has been associated characteristically with the formation of a coiled-coil structure between two compatible leucine zipper motifs. In the present study we demonstrate the association of the leucine zipper of cAMP response element-binding protein (CREB) with a zinc finger motif of ATF-2. The association of the CREB leucine zipper with the ATF-2 zinc finger is stabilized if the ATF-2 leucine zipper is intact, implying that the preferred interactive structure of ATF-2 juxtaposes the amino-terminal zinc finger motif of this protein with the carboxy-terminal leucine zipper of this same protein. Furthermore, we demonstrate that the association of the CREB leucine zipper with the ATF-2 zinc finger in vitro blocks the association of the adenoviral E1a protein with ATF-2. Similarly, overexpression of full-length CREB, or a truncated version of this protein corresponding to the carboxy-terminal 74 amino acids that make up the DNA-binding and dimerization domains, can block the ATF-2-mediated transcriptional stimulation by E1a in vivo. Mutation of the ATF-2 zinc finger motif stimulates DNA binding of this protein, and abolishes interactions with E1a and CREB proteins. These results demonstrate that the structural conformation of ATF-2 is critical for DNA binding and protein-protein interactions and, further, that leucine zippers can mediate protein-protein interactions with structural motifs other than leucine zippers.	UNIV COLORADO,SCH MED,CTR CANC,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262; UNIV COLORADO,SCH PHARM,DENVER,CO 80262; UNIV COLORADO,DEPT MED,DIV MED ONCOL,DENVER,CO 80262; UNIV COLORADO,DEPT MED,DIV ENDOCRINOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045872] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45872] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; BENBROOK DM, 1990, ONCOGENE, V5, P295; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; Chen C Y, 1991, Protein Expr Purif, V2, P402, DOI 10.1016/1046-5928(91)90101-N; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; FLINT KJ, 1991, ONCOGENE, V6, P2019; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MACKETT M, 1990, NUCLEIC ACIDS RES, V18, P1082, DOI 10.1093/nar/18.4.1082; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHIFF LA, 1988, P NATL ACAD SCI USA, V85, P4195, DOI 10.1073/pnas.85.12.4195; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418; YUN Y, 1990, MOL ENDOCRINOL, V4, P931, DOI 10.1210/mend-4-6-931; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G; ZU YL, 1991, J BIOL CHEM, V266, P24134	33	60	60	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1161	1174						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479741				2022-12-28	WOS:A1993KY32800007
J	HAURY, M; FREITAS, A; HERMITTE, V; COUTINHO, A; HIBNER, U				HAURY, M; FREITAS, A; HERMITTE, V; COUTINHO, A; HIBNER, U			THE PHYSIOLOGY OF BCL-2 EXPRESSION IN MURINE B-LYMPHOCYTES	ONCOGENE			English	Article							MONOCLONAL-ANTIBODY; POPULATION-DYNAMICS; GENE-EXPRESSION; TRANSGENIC MICE; CELL SURVIVAL; MOUSE; RECEPTORS; SELECTION; APOPTOSIS; PROTEIN	Quantitation of bcl-2 gene expression in B-lineage lymphocytes from normal adult mice allows the identification of four cell populations, characterized by successive three- to fivefold increases in average mRNA levels: bone marrow pre-B cells, bone marrow B cells, splenic B cells and long-lived splenic B cells. Thus, in line with previous experiments using overexpression systems, a correlation between longevity and levels of bcl-2 mRNA exists also in the physiology of B-lineage cells. The data are compatible with a quantitative regulation of expression, possibly determined at selective differentiation steps. No difference in bcl-2 expression was detected by comparing splenic IgD+ with IgD- B cells, while distinctly low levels of bcl-2 mRNA were scored in peritoneal CD5+ and CD5- B cells. These observations indicate that the reported persistence of peritoneal B cells may be controlled by mechanisms other than bcl-2 gene expression.	INST PASTEUR,CNRS,URA 359,UNITE IMMUNOBIOL,25 RUE DOCTEUR ROUX,F-75724 PARIS 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			freitas, antonio/A-2482-2013	Hibner, Urszula/0000-0002-5520-7311; Haury, Matthias/0000-0002-1796-1479; Coutinho, Antonio/0000-0002-0857-9227; freitas, antonio/0000-0001-6392-7178				ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; ANDRADE L, 1989, EUR J IMMUNOL, V19, P1117, DOI 10.1002/eji.1830190623; BRUCE J, 1981, J IMMUNOL, V127, P2496; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; COFFMAN RL, 1981, J EXP MED, V153, P269, DOI 10.1084/jem.153.2.269; Coutinho A, 1992, Int Rev Immunol, V8, P173, DOI 10.3109/08830189209055572; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; Freitas A A, 1989, Int Immunol, V1, P342, DOI 10.1093/intimm/1.4.342; FREITAS AA, 1990, INT IMMUNOL, V2, P15, DOI 10.1093/intimm/2.1.15; FREITAS AA, 1986, IMMUNOL REV, V91, P5, DOI 10.1111/j.1600-065X.1986.tb01482.x; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; GURFINKEL N, 1987, EUR J IMMUNOL, V17, P567, DOI 10.1002/eji.1830170421; HAYAKAWA K, 1985, J EXP MED, V161, P1554, DOI 10.1084/jem.161.6.1554; HERZENBERG LA, 1986, IMMUNOL REV, V93, P81, DOI 10.1111/j.1600-065X.1986.tb01503.x; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; KINCADE PW, 1981, J IMMUNOL METHODS, V42, P17, DOI 10.1016/0022-1759(81)90220-9; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LEVY M, 1987, EUR J IMMUNOL, V17, P295, DOI 10.1002/eji.1830170223; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; MARCOS MAR, 1989, EUR J IMMUNOL, V19, P2031, DOI 10.1002/eji.1830191110; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NATHANSON SD, 1977, J IMMUNOL METHODS, V18, P225, DOI 10.1016/0022-1759(77)90176-4; NERGRINI G, 1987, CELL, V49, P455; NUNEZ G, 1991, NATURE, V353, P71, DOI 10.1038/353071a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OSMOND DG, 1986, IMMUNOL REV, V93, P103, DOI 10.1111/j.1600-065X.1986.tb01504.x; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; ROCHA B, 1983, J IMMUNOL, V131, P2158; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SPRENT J, 1973, CELL IMMUNOL, V7, P40, DOI 10.1016/0008-8749(73)90181-0; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Thomas-Vaslin V, 1989, Int Immunol, V1, P237, DOI 10.1093/intimm/1.3.237; THOMASVASLIN V, 1990, INT IMMUNOL, V2, P74; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; YEH TM, 1991, INT IMMUNOL, V3, P1329, DOI 10.1093/intimm/3.12.1329	40	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1257	1262						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479747				2022-12-28	WOS:A1993KY32800017
J	HARA, E; OKAMOTO, S; NAKADA, S; TAYA, Y; SEKIYA, S; ODA, K				HARA, E; OKAMOTO, S; NAKADA, S; TAYA, Y; SEKIYA, S; ODA, K			PROTEIN-PHOSPHORYLATION REQUIRED FOR THE FORMATION OF E2F COMPLEXES REGULATES N-MYC TRANSCRIPTION DURING DIFFERENTIATION OF HUMAN EMBRYONAL CARCINOMA-CELLS	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; DNA-BINDING PROTEINS; CYCLIN-A; TRANSIENT DECREASE; STEM-CELLS; RB GENE; EXPRESSION; REGION; TRANSACTIVATION; ADENOVIRUS-E1A	The human embryonal carcinoma (EC) cell line NEC14 can be induced to differentiate morphologically by the addition of 10(-2) M N,N'-hexamethylene-bis-acetamide (HMBA). The N-myc gene is expressed at a high level in the undifferentiated cells, but the level decreased steeply after 12-24 h HMBA treatment, returning to its original level after 48 h. The alteration in the N-myc level was well correlated with the formation of complexes with the E2F motif in the N-myc promoter region, and no complex was formed with cell extracts prepared from cells treated with HMBA for 12-24 h. The absence of E2F complexes during this period was caused by an inhibitor generated by a phosphatase reaction. Treatment of the 12-h extract with a cyclic AMP-dependent protein kinase resulted in the formation of E2F complexes, and treatment of the undifferentiated (0 h) and 48-h extracts with a calf intestinal phosphatase abolished complex formation completely. An inhibitor generated by the 0-h extract after treatment with a phosphatase inhibited E2F complex formation by the untreated 0-h extract in the presence of phosphatase inhibitors, okadaic acid and sodium vanadate. One of the two E2F complexes in the undifferentiated cells contained cyclin A, but the complex with similar mobility, formed after the transient decrease in the N-myc level, did not.	SCI UNIV TOKYO,DEPT BIOL SCI & TECHNOL,NODA,CHIBA 278,JAPAN; SCI UNIV TOKYO,DEPT APPL BIOL SCI,NODA,CHIBA 278,JAPAN; CHIBA UNIV,SCH MED,DEPT OBSTET & GYNECOL,CHIBA 280,JAPAN; NATL CANC CTR,RES INST,DIV BIOL,CHUO KU,TOKYO 104,JAPAN	Tokyo University of Science; Tokyo University of Science; Chiba University; National Cancer Center - Japan								ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FRIEND M, 1981, NUCLEIC ACIDS RES, V9, P6509; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GORMAN CM, 1985, CELL, V42, P519, DOI 10.1016/0092-8674(85)90109-6; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARA E, 1991, NUCLEIC ACIDS RES, V19, P7097, DOI 10.1093/nar/19.25.7097; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HASEGAWA T, 1990, DIFFERENTIATION, V42, P191, DOI 10.1111/j.1432-0436.1990.tb00761.x; HASEGAWA T, 1991, DIFFERENTIATION, V47, P107, DOI 10.1111/j.1432-0436.1991.tb00228.x; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JACOBOVITS A, 1985, NATURE, V318, P188; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KATO K, 1990, MOL CELL BIOL, V10, P486, DOI 10.1128/MCB.10.2.486; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MATSUNO K, 1989, J BIOL CHEM, V264, P18707; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PINES J, 1990, New Biologist, V2, P389; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; REICHEL R, 1987, CELL, V48, P501, DOI 10.1016/0092-8674(87)90200-5; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Sambrook J, 1989, MOL CLONING LABORATO; SEJERSEN T, 1986, J CELL PHYSIOL, V127, P274, DOI 10.1002/jcp.1041270213; SEKIYA S, 1990, GYNECOL ONCOL, V36, P69, DOI 10.1016/0090-8258(90)90111-W; SEKIYA S, 1985, DIFFERENTIATION, V29, P259, DOI 10.1111/j.1432-0436.1985.tb00325.x; SEKIYA S, 1988, INT J GYNECOL PATHOL, V7, P373, DOI 10.1097/00004347-198812000-00008; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Silver L.M., 1983, TERATOCARCINOMA STEM; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TAKEHANA K, 1991, GENE, V103, P219, DOI 10.1016/0378-1119(91)90276-H; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VELCICH A, 1985, NATURE, V318, P595; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	59	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1023	1032						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8384353				2022-12-28	WOS:A1993KT22000026
J	NIKOLAKAKI, E; COFFER, PJ; HEMELSOET, R; WOODGETT, JR; DEFIZE, LHK				NIKOLAKAKI, E; COFFER, PJ; HEMELSOET, R; WOODGETT, JR; DEFIZE, LHK			GLYCOGEN-SYNTHASE KINASE-3 PHOSPHORYLATES JUN FAMILY MEMBERS INVITRO AND NEGATIVELY REGULATES THEIR TRANSACTIVATING POTENTIAL IN INTACT-CELLS	ONCOGENE			English	Article							DNA-BINDING ACTIVITY; PROTEIN-KINASE; C-JUN; FOS PROTEINS; METALLOTHIONEIN GENE; TRANSCRIPTION; ACTIVATION; PRODUCT; EXPRESSION; AP-1	Expression of immediate-early genes involving the 12-O-tetradecanoyl phorbol 13-acetate (TPA)-responsive element (TRE) is modulated by post-translational modification of pre-existing activator protein 1 (AP-1) constituents. One of the components of AP-1, c-Jun, has been shown to be phosphorylated by glycogen synthase kinase 3 (GSK-3) in vitro in a region proximal to the DNA-binding domain, resulting in decreased DNA binding. Here, we have used transient transfection to show that AP-1 activity is inhibitable by coexpression of GSK-3 in intact cells. Furthermore, we show that the c-Jun-related proteins JunD and JunB are subject to similar regulation by GSK-3 in intact cells. Comparison of tryptic phosphopeptide maps of the three Jun proteins incubated with GSK-3 in vitro with maps of the same proteins immunoprecipitated from P-32-labelled cells indicates similar sites of phosphorylation. Together, these data support the hypothesis that GSK-3 is an important regulator of AP-1 activity in vivo.	HUBRECHT LAB DEV BIOL,UPPSALALAAN 8,3584 CT UTRECHT,NETHERLANDS; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Ludwig Institute for Cancer Research			Coffer, Paul/AAF-7970-2020; Woodgett, Jim/F-1087-2010; Coffer, Paul J/A-5769-2009	Woodgett, Jim/0000-0003-3731-5797; 				ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BENBROOK DM, 1990, ONCOGENE, V5, P295; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DWARKI VJ, 1990, EMBO J, V9003, P2253; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODE N, 1992, J BIOL CHEM, V267, P16878; HUGHES K, 1992, EUR J BIOCHEM, V203, P305, DOI 10.1111/j.1432-1033.1992.tb19860.x; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MULLER R, 1987, ONCOGENE RES, V2, P19; PULVERER B, 1992, IN PRESS ONCOGENE; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAYLOR WE, 1990, P NATL ACAD SCI USA, V87, P4098, DOI 10.1073/pnas.87.11.4098; Woodgett J R, 1990, Semin Cancer Biol, V1, P389; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3	40	190	194	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					833	840						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8384354				2022-12-28	WOS:A1993KT22000003
J	ALEXANDROPOULOS, K; QURESHI, SA; FOSTER, DA				ALEXANDROPOULOS, K; QURESHI, SA; FOSTER, DA			HA-RAS FUNCTIONS DOWNSTREAM FROM PROTEIN-KINASE-C IN V-FPS-INDUCED GENE-EXPRESSION MEDIATED BY TPA RESPONSE ELEMENTS	ONCOGENE			English	Note							PHOSPHOLIPASE-D; TYROSINE KINASES; BINDING-PROTEIN; ONCOGENIC RAS; 3T3 CELLS; ACTIVATION; SRC; HYDROLYSIS; PHOSPHATIDYLCHOLINE; TRANSFORMATION	v-Fps activates promoters under the control of the 12-O-tetradecanoyl phorbol 13-acetate (TPA) response element (TRE). The induction of TRE-mediated transcription by v-Fps was sensitive to a dominant-negative mutant of Ha-Ras. An activated derivative of Ha-Ras, v-Ha-Ras, also activated TRE-mediated transcription. v-Fps-induced TRE-mediated gene expression was sensitive to depleting cells of protein kinase C (PKC), whereas v-Ha-Ras-induced TRE-mediated transcription was insensitive to PKC depletion, suggesting that Ha-Ras functions downstream from PKC in v-Fps-induced TRE-mediated gene expression. Consistent with this hypothesis, the induction of TRE-mediated gene expression by phorbol esters that activate PKC directly was blocked by the dominant-negative Ha-Ras mutant. Thus, v-Fps-induced activation of TRE-mediated gene expression is via an intracellular signaling mechanism that is dependent upon both PKC and Ha-Ras and Ha-Ras functions downstream from PKC.	CUNY HUNTER COLL, INST BIOMOLEC STRUCT & FUNCT, 695 PK AVE, NEW YORK, NY 10021 USA; CUNY HUNTER COLL, DEPT BIOL SCI, NEW YORK, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; Hunter College (CUNY)					NATIONAL CANCER INSTITUTE [R01CA046677, R29CA046677] Funding Source: NIH RePORTER; NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RRO-3037-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALEXANDROPOULOS K, 1992, NUCLEIC ACIDS RES, V20, P2355, DOI 10.1093/nar/20.9.2355; ALEXANDROPOULOS K, 1992, CELL GROWTH DIFFER, V3, P731; ALEXANDROPOULOS K, 1991, J BIOL CHEM, V266, P15583; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BOCCKINO SB, 1985, J BIOL CHEM, V260, P4201; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; COCKCROFT S, 1985, NATURE, V314, P534, DOI 10.1038/314534a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FOSTER DA, 1985, CELL, V42, P105, DOI 10.1016/S0092-8674(85)80106-9; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HURST KM, 1990, BIOCHEM J, V272, P749, DOI 10.1042/bj2720749; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JOSEPH CK, 1992, J BIOL CHEM, V267, P1327; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; MORRIS JDH, 1989, ONCOGENE, V4, P27; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PRICE BD, 1989, J BIOL CHEM, V264, P16638; QURESHI SA, 1991, MOL CELL BIOL, V11, P102, DOI 10.1128/MCB.11.1.102; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; QURESHI SA, 1992, J BIOL CHEM, V267, P17635; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; QURESHI SA, 1991, ONCOGENE, V6, P995; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPANGLER R, 1989, P NATL ACAD SCI USA, V86, P7017, DOI 10.1073/pnas.86.18.7017; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VALLAR L, 1987, NATURE, V330, P566, DOI 10.1038/330566a0; XIE MS, 1991, BIOCHEM J, V278, P81, DOI 10.1042/bj2780081; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	46	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1993	8	3					803	807						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437865				2022-12-28	WOS:A1993KN00800035
J	BENIT, L; CHARON, M; COCAULT, L; WENDLING, F; GISSELBRECHT, S				BENIT, L; CHARON, M; COCAULT, L; WENDLING, F; GISSELBRECHT, S			THE WS-MOTIF COMMON TO V-MPL AND MEMBERS OF THE CYTOKINE RECEPTOR SUPERFAMILY IS DISPENSABLE FOR MYELOPROLIFERATIVE LEUKEMIA-VIRUS PATHOGENICITY	ONCOGENE			English	Note							MURINE SARCOMA-VIRUS; MOLECULAR-CLONING; PROGENITOR CELLS; ONCOGENICITY; EXPRESSION; RETROVIRUS; SEQUENCES; INVITRO	Several motifs are conserved in the extracellular domain of the cloned chains of the recently described cytokine receptor superfamily. One of them, usually close to the transmembrane region, is the 'WS motif'. Its function remains unknown, but it has been recently shown that the integrity of this motif is essential for interleukin 2 receptor beta-chain and erythropoietin receptor activity [Miyazaki, T., Maruyama, M., Yamada, G., Hatakeyama, M. & Taniguchi, T. (1991). EMBO J., 10, 3191-3197; Watowich, S.S., Yoshimura, A., Longmore, G.D., Hilton, D.J., Hoshimura, Y. & Lodish, H.R. (1992). Proc. Natl. Acad. Sci. USA, 89, 2140-21441. This WS motif is present in the v-mpl oncogene, which has been transduced in the myeloproliferative leukemia virus (MPLV). v-mpl encodes a truncated transmembrane protein that belongs to this growth factor receptor family. We demonstrate that determinants of MPLV pathogenesis are encoded by the env-mpl fusion gene and that the complete deletion of the WS motif does not abolish MPLV oncogenic properties.	HOP COCHIN,ICGM,INSERM,U363,27 RUE FAUBOURG ST JACQUES,F-75674 PARIS 14,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier				PETIT, Laurence/0000-0002-2475-9367				BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CHIBA T, 1992, BIOCHEM BIOPH RES CO, V184, P485, DOI 10.1016/0006-291X(92)91220-K; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HANAFUSA H, 1977, J EXP MED, V146, P1735, DOI 10.1084/jem.146.6.1735; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; OLIFF AI, 1980, J VIROL, V33, P475, DOI 10.1128/JVI.33.1.475-486.1980; PENCIOLELLI JF, 1987, J VIROL, V61, P579, DOI 10.1128/JVI.61.2.579-583.1987; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; SOUYRI M, 1989, J VIROL, V63, P3944, DOI 10.1128/JVI.63.9.3944-3953.1989; VELU TJ, 1989, J VIROL, V63, P1384, DOI 10.1128/JVI.63.3.1384-1392.1989; VIGON I, 1992, IN PRESS P NATL ACAD; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WENDLING F, 1989, LEUKEMIA, V3, P475; WENDLING F, 1986, VIROLOGY, V149, P242, DOI 10.1016/0042-6822(86)90125-X; WENDLING F, 1989, BLOOD, V73, P1161	25	9	13	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					787	790						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8382360				2022-12-28	WOS:A1993KN00800032
J	CHENG, JT; HSU, HL; HWANG, LY; BAER, R				CHENG, JT; HSU, HL; HWANG, LY; BAER, R			PRODUCTS OF THE TAL1-ONCOGENE - BASIC HELIX LOOP HELIX PROTEINS PHOSPHORYLATED AT SERINE RESIDUES	ONCOGENE			English	Article							T-CELL LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING MOTIF; CHROMOSOMAL TRANSLOCATION; ENHANCER-BINDING; TAL-1 GENE; SCL GENE; C-MYC; EXPRESSION; LOCUS	TAL1 gene rearrangement is observed in nearly 30% of patients with T-cell acute lymphoblastic leukemia (T-ALL), and thus it represents the most common genetic lesion associated with this disease. Nevertheless, the presence of TAL1 gene products in normal or leukemic cells has not been reported. Therefore, immunoprecipitation with anti-TAL1 antisera was used to demonstrate the presence of TAL1 phosphoproteins, pp42TAL1 and pp22TAL1, in both T-ALL and erythroleukemia cell lines. The pp42TAL1 and pp22TAL1 proteins appear to be phosphorylated forms of full-length and truncated TAL1 gene products respectively. Phosphoamino acid analysis revealed that pp42TAL1 contains phosphoserine residues. The TAL1 phosphoproteins were detected in all of the T-ALL cell lines that harbor obvious TAL1 gene rearrangements. Interestingly, pp42TAL1 and pp22TAL1 were also present in some, but not all, of the T-ALL lines without detectable TAL1 gene alterations. Therefore, TAL1 activation may promote leukemogenesis in a far greater proportion of T-ALL patients than the 30% that bear gross TAL1 gene rearrangements.	UNIV TEXAS, SW MED CTR, DEPT MICROBIOL, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL CANCER INSTITUTE [R01CA046593] Funding Source: NIH RePORTER; NCI NIH HHS [CA46593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; APLAN PD, 1992, BLOOD, V79, P1327; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BERNARD O, 1991, ONCOGENE, V6, P1477; BOHMANN D, 1990, CANCER CELL-MON REV, V2, P337; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CABRERA CV, 1991, EMBO J, V10, P2965, DOI 10.1002/j.1460-2075.1991.tb07847.x; CARROLL AJ, 1990, BLOOD, V76, P1220; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHEN Q, 1990, J EXP MED, V172, P1403, DOI 10.1084/jem.172.5.1403; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; FITZGERALD TJ, 1991, BLOOD, V78, P2686; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; GREEN AR, 1991, ONCOGENE, V6, P475; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HARLOW E, 1988, ANTIBODIES LABORATOR; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JONSSON OG, 1991, J CLIN INVEST, V87, P2029, DOI 10.1172/JCI115232; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MINOWADA J, 1988, Cancer Reviews, V10, P1; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH RG, 1981, J IMMUNOL, V126, P596; TYCKO B, 1989, J EXP MED, V169, P369, DOI 10.1084/jem.169.2.369; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416; XIA Y, 1992, GENE CHROMOSOME CANC, V4, P211, DOI 10.1002/gcc.2870040304	35	59	61	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1993	8	3					677	683						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437851				2022-12-28	WOS:A1993KN00800019
J	TEDESCO, D; FISCHERFANTUZZI, L; VESCO, C				TEDESCO, D; FISCHERFANTUZZI, L; VESCO, C			LIMITS OF TRANSFORMING COMPETENCE OF SV40 NUCLEAR AND CYTOPLASMIC LARGE T-MUTANTS WITH ALTERED RB-BINDING SEQUENCES	ONCOGENE			English	Article							LARGE TUMOR-ANTIGEN; RETINOBLASTOMA SUSCEPTIBILITY GENE; SIMIAN VIRUS-40; DNA-REPLICATION; EMBRYO FIBROBLASTS; TRANSGENIC MICE; ORIGIN-BINDING; HUMAN-CELLS; PROTEIN; PHOSPHORYLATION	Multiple amino acid substitutions were introduced into the SV40 large T region that harbors the retinoblastoma protein (Rb) binding site and the nuclear transport signal, changing either one or both of these determinants. Mutant activities were examined in a set of assays allowing different levels of transforming potential to be, distinguished; phenotypic changes in established and pre-crisis rat embryo fibroblasts (REFs) were detected under isogenic cell conditions, and comparisons made with other established rodent cells. The limit of the transforming ability of mutants with important substitutions in the Rb binding site fell between two transformation levels of the same established rat cells. Such cells could be induced to form dense foci but not agar colonies (their parental pre-crises REFs, as expected, were untransformed either way). Nonetheless, agar colony induction was possible in other cell lines, such as mouse NIH3T3 and (for one of the mutants) rat F2408. All these mutants efficiently immortalized pre-crisis REFs. The transforming ability of cytoplasmic mutants appeared to depend on the integrity of the Rb-binding sequence to approximately the same extent as that of the wild-type large T, although evidence of in vivo Rb-cytoplasmic large T complexes was not found. The presence or absence of small t was critical when the transforming task of mutants was near the limit of their abilities.	CNR,INST BIOL CELLULARE,VIALE MARX 43,I-00137 ROME,ITALY	Consiglio Nazionale delle Ricerche (CNR)								ASSELIN C, 1985, J VIROL, V56, P958, DOI 10.1128/JVI.56.3.958-968.1985; BIKEL I, 1987, CELL, V48, P321, DOI 10.1016/0092-8674(87)90435-1; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; CHEN S, 1987, J VIROL, V61, P3521, DOI 10.1128/JVI.61.11.3521-3527.1987; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEPPERT W, 1990, J VIROL, V64, P838, DOI 10.1128/JVI.64.2.838-846.1990; DOBBELSTEIN M, 1992, ONCOGENE, V7, P837; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FANTUZZI LF, 1988, MOL CELL BIOL, V8, P5495; FANTUZZI LF, 1987, ONCOGENE RES, V1, P229; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; FRIEDMAN M, 1986, CONTEMP POLICY ISSUE, V4, P1, DOI 10.1111/j.1465-7287.1986.tb00827.x; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GRAND RJA, 1989, ONCOGENE, V4, P1291; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; LANFORD RE, 1985, MOL CELL BIOL, V5, P1043, DOI 10.1128/MCB.5.5.1043; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MANFREDI JJ, 1990, J VIROL, V64, P5250, DOI 10.1128/JVI.64.11.5250-5259.1990; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MONTANO X, 1990, P NATL ACAD SCI USA, V87, P7448, DOI 10.1073/pnas.87.19.7448; PANNUTI A, 1987, J VIROL, V61, P1296, DOI 10.1128/JVI.61.4.1296-1299.1987; PEDEN KWC, 1990, J VIROL, V64, P2912, DOI 10.1128/JVI.64.6.2912-2921.1990; PINKERT CA, 1987, VIROLOGY, V160, P169, DOI 10.1016/0042-6822(87)90057-2; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; RUTILA JE, 1989, ONCOGENE RES, V4, P303; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SCHEIDTMANN KH, 1991, J VIROL, V65, P1479, DOI 10.1128/JVI.65.3.1479-1490.1991; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; SLEIGH MJ, 1978, CELL, V14, P79, DOI 10.1016/0092-8674(78)90303-3; SOMPAYRAC L, 1988, VIROLOGY, V163, P391, DOI 10.1016/0042-6822(88)90279-6; SOMPAYRAC L, 1985, MOL CELL BIOL, V5, P1191, DOI 10.1128/MCB.5.5.1191; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; THIMMAPPAYA B, 1979, J VIROL, V30, P668, DOI 10.1128/JVI.30.3.668-673.1979; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; VANDYKE TA, 1987, J VIROL, V61, P2029, DOI 10.1128/JVI.61.6.2029-2032.1987; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WILDEMAN AG, 1989, P NATL ACAD SCI USA, V86, P2123, DOI 10.1073/pnas.86.7.2123; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116; ZHU JY, 1991, J VIROL, V65, P2778, DOI 10.1128/JVI.65.6.2778-2790.1991; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	54	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					549	557						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8382355				2022-12-28	WOS:A1993KN00800004
J	BAKER, AH; RIDGE, SA; HOY, T; CACHIA, PG; CULLIGAN, D; BAINES, P; WHITTAKER, JA; JACOBS, A; PADUA, RA				BAKER, AH; RIDGE, SA; HOY, T; CACHIA, PG; CULLIGAN, D; BAINES, P; WHITTAKER, JA; JACOBS, A; PADUA, RA			EXPRESSION OF THE COLONY-STIMULATING FACTOR-I RECEPTOR IN B-LYMPHOCYTES	ONCOGENE			English	Article							FMS PROTO-ONCOGENE; FACTOR-I RECEPTOR; C-FMS; CSF-1 RECEPTOR; CELL-LINES; HUMAN-MONOCYTES; PRODUCT; ACTIVATION; TRANSCRIPTION; KINASE	The FMS proto-oncogene encodes for the colony-stimulating factor 1 receptor (CSF-1R), whose expression within the haematopoietic system has previously been thought to be restricted to cells of the mononuclear phagocyte lineage. We have studied the expression of the CSF-1R in peripheral blood mononuclear cells by indirect immunofluorescence and flow cytometry. FMS expression was detected on both monocytes and B lymphocytes from all samples analysed, including 14 haematologically normal individuals and 31 patients (23 in remission following cytotoxic therapy for lymphoma, six with B-cell chronic lymphocytic leukaemia and two with chronic myelomonocytic leukaemia). The level of FMS expression on B lymphocytes was lower than the level of expression detected on monocytes isolated from the same sample. FMS mRNA expression in B lymphocytes has been confirmed by a reverse transcription-polymerase chain reaction (RT-PCR)-based technique and Northern blot analysis. Thus, FMS may play a role in the normal function of B lymphocytes and, because of its potential oncogenic activity, may contribute to the pathogenesis of malignancies of this cell type.	UNIV WALES COLL MED, DEPT HAEMATOL, LEUKAEMIA RES FUND PRELEUKAEMIA UNIT, HEATH PK, CARDIFF CF4 4XN, S GLAM, WALES	Cardiff University			PADUA, Rose Ann/E-8621-2019; Baker, Andy/AAO-5250-2021; Padua, Rose Ann/GVT-5961-2022	PADUA, Rose Ann/0000-0001-9964-7864; Baker, Andy/0000-0003-1441-5576; 				ASHMUN RA, 1989, BLOOD, V73, P827; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BORZILLO GV, 1989, MOL CELL BIOL, V9, P3973, DOI 10.1128/MCB.9.9.3973; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOUDHURY GG, 1991, FEBS LETT, V282, P351, DOI 10.1016/0014-5793(91)80511-Z; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DAS SK, 1982, J BIOL CHEM, V257, P13679; DECINO P, 1988, ONCOGENE RES, V3, P33; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; DOWNING JR, 1991, ONCOGENE, V6, P607; GUILBERT LJ, 1986, J BIOL CHEM, V261, P4024; HEARD JM, 1987, CELL, V51, P663, DOI 10.1016/0092-8674(87)90135-8; HEIDARAN MA, 1992, ONCOGENE, V7, P147; HORIGUCHI J, 1986, BIOCHEM BIOPH RES CO, V141, P924, DOI 10.1016/S0006-291X(86)80131-0; HORIGUCHI J, 1987, BLOOD, V69, P1259; JANOWSKAWIECZOREK A, 1991, BLOOD, V77, P1796; KHALILI K, 1984, J MOL BIOL, V175, P453, DOI 10.1016/0022-2836(84)90179-7; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; MELCHERS F, 1984, CELL, V37, P715, DOI 10.1016/0092-8674(84)90407-0; MULLER R, 1983, MOL CELL BIOL, V3, P1062; OSTER W, 1987, BLOOD, V70, P1700; REGENSTREIF LJ, 1989, DEV BIOL, V133, P284, DOI 10.1016/0012-1606(89)90319-9; REISBACH G, 1989, BLOOD, V74, P959; REISBACH G, 1987, CELL IMMUNOL, V109, P246, DOI 10.1016/0008-8749(87)90308-X; RETTENMIER CW, 1986, J CLIN INVEST, V77, P1740, DOI 10.1172/JCI112496; RIDGE SA, 1990, P NATL ACAD SCI USA, V87, P1377, DOI 10.1073/pnas.87.4.1377; RIDGE SA, 1990, BLOOD S, V1, pA244; ROBERTS WM, 1992, BLOOD, V79, P586; ROBERTS WM, 1991, BLOOD S, V1, pA340; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; Sambrook J, 1989, MOL CLONING LABORATO; SENGUPTA A, 1988, P NATL ACAD SCI USA, V85, P8062, DOI 10.1073/pnas.85.21.8062; SHERR CJ, 1990, BLOOD, V75, P1; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SORG R, 1991, EXP HEMATOL, V19, P882; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; TOBAL K, 1990, LEUKEMIA, V4, P486; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VISVADER J, 1989, MOL CELL BIOL, V9, P1336, DOI 10.1128/MCB.9.3.1336; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; [No title captured]	46	25	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					371	378						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426743				2022-12-28	WOS:A1993KN00600016
J	BASTYR, EJ; LU, J; STOWE, R; GREEN, A; VINIK, AI				BASTYR, EJ; LU, J; STOWE, R; GREEN, A; VINIK, AI			LOW-MOLECULAR-WEIGHT GTP-BINDING PROTEINS ARE ALTERED IN PLATELET HYPERAGGREGATION IN IDDM	ONCOGENE			English	Note							PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE HYDROLYSIS; KINASE-C; PHOSPHOLIPASE-C; GENE-PRODUCT; ACTIVATION; PHOSPHORYLATION; PURIFICATION; THROMBIN; MEMBRANES; CYTOSOL	We examined the hypothesis that hyperaggregating platelets from patients with insulin dependent diabetes mellitus (IDDM) have an alteration in location and function of the guanine nucleotide (GTP)-binding proteins. Platelets from 10 IDDM and 12 age-matched healthy control subjects were collected and washed. Thrombin-induced platelet aggregation (0.025 and 0.05 units for 60 seconds) was increased in IDDM (8.3 +/- 1.8% vs 22.3 +/- 4.4%, P < .05 and 49.9 +/- 7.3% vs 70.9 +/- 7.0%, P < .05). Four small molecular weight GTP-binding proteins were identified by binding of [P-32]-GTP on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in the cytosol and membranes of these platelets. Each showed specificity for binding [P-32]-GTP by competitive inhibition with unlabeled GTP. The total of the 27/28 kDa proteins was decreased in the membrane fraction (414 +/- 30 vs 252 +/- 40 dpm mug-1 protein x min, P < .05) and increased in the cytosolic fraction (62 +/- 8 vs 129 +/- 21 dpm unit-1 LDH x min, P < .05) in IDDM. The 21 kDa protein (60.3 +/- 3.5 vs 45.4 +/- 2.9 dpm mug-1 protein x min, P < .05) was decreased in platelet membrane in persons with IDDM. In conclusion, increased platelet aggregation in IDDM is accompanied by an altered cellular distribution of a 27/28 kDa GTP-binding protein. These data suggest that the low molecular weight GTP-binding proteins of the 27/28 kDa range may play an important regulatory role in the hyperaggregatory platelets in diabetes.	UNIV TEXAS,MED BRANCH,DEPT PHARMACOL,GALVESTON,TX 77550; EASTERN VIRGINIA MED SCH,DIABET RES INST,DEPT INTERNAL MED,NORFOLK,VA 23501	University of Texas System; University of Texas Medical Branch Galveston; Eastern Virginia Medical School	BASTYR, EJ (corresponding author), UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,DIV ENDOCRINOL,3152 MED RES BLDG,GALVESTON,TX 77555, USA.		Bastyr, Edward/AFP-2625-2022					BALDASSARE JJ, 1986, BIOCHEM BIOPH RES CO, V137, P801, DOI 10.1016/0006-291X(86)91150-2; BALDASSARE JJ, 1989, BIOCHEMISTRY-US, V28, P56, DOI 10.1021/bi00427a009; BALLESTER R, 1987, J BIOL CHEM, V262, P2688; BASTYR EJ, 1989, DIABETES, V38, P1097, DOI 10.2337/diabetes.38.9.1097; BASTYR EJ, 1992, THROMB RES, V65, P241, DOI 10.1016/0049-3848(92)90244-5; BASTYR EJ, 1987, DIABETES S1, V236, pA208; BHULLAR RP, 1987, BIOCHEM J, V245, P617, DOI 10.1042/bj2450617; BURGOYNE RD, 1989, TRENDS BIOCHEM SCI, V14, P394, DOI 10.1016/0968-0004(89)90281-8; COLWELL JA, 1976, DIABETES, V25, P826; CRAVEN PA, 1989, J CLIN INVEST, V83, P1667, DOI 10.1172/JCI114066; DARBON JM, 1990, BIOCHEM BIOPH RES CO, V168, P527, DOI 10.1016/0006-291X(90)92353-2; DIDSBURY JR, 1990, BIOCHEM BIOPH RES CO, V171, P840; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KLAFF LJ, 1981, AM J MED, V70, P627, DOI 10.1016/0002-9343(81)90585-4; Kobbah M, 1985, Acta Paediatr Scand Suppl, V320, P50; LAPETINA EG, 1987, P NATL ACAD SCI USA, V84, P2261, DOI 10.1073/pnas.84.8.2261; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; LAPETINA EG, 1990, FEBS LETT, V268, P400, DOI 10.1016/0014-5793(90)81293-W; LEE TS, 1989, P NATL ACAD SCI USA, V86, P5141, DOI 10.1073/pnas.86.13.5141; MACINTYRE DE, 1985, FEBS LETT, V180, P160, DOI 10.1016/0014-5793(85)81063-2; NAGATA K, 1989, J BIOL CHEM, V264, P17000; OHMORI T, 1989, J BIOL CHEM, V264, P1877; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; RESNICK RJ, 1988, P NATL ACAD SCI USA, V85, P2474, DOI 10.1073/pnas.85.8.2474; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SIESS W, 1990, BIOCHEM J, V271, P815, DOI 10.1042/bj2710815; STASIA MJ, 1989, BIOCHEMISTRY-US, V28, P9659, DOI 10.1021/bi00451a018; WATSON SP, 1985, P NATL ACAD SCI USA, V82, P2623, DOI 10.1073/pnas.82.9.2623; WHITE TE, 1990, P NATL ACAD SCI USA, V87, P759; ZAVOICO GB, 1985, P NATL ACAD SCI USA, V82, P3859, DOI 10.1073/pnas.82.11.3859; 1979, DIABETES, V28, P1039	31	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					515	518						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426753				2022-12-28	WOS:A1993KN00600033
J	COHEN, DR; VANDERMARK, SE; MCGOVERN, JD; BRADLEY, MP				COHEN, DR; VANDERMARK, SE; MCGOVERN, JD; BRADLEY, MP			TRANSCRIPTIONAL REGULATION IN THE TESTIS - A ROLE FOR TRANSCRIPTION FACTOR AP-1 COMPLEXES AT VARIOUS STAGES OF SPERMATOGENESIS	ONCOGENE			English	Article							MALE GERM LINE; C-FOS PROTEIN; IMMEDIATE-EARLY GENE; LEUCINE ZIPPER; JUN-B; DIFFERENTIAL EXPRESSION; BINDING AFFINITIES; MESSENGER-RNA; ONC GENES; CELLS	The products of two proto-oncogenes, c-fos and c-jun, have been implicated in signal transduction pathways as regulators of gene expression. Both proto-oncogenes are members of gene families encoding closely related proteins that together make up transcription factor AP-1. The expression of members of this transcription factor has been associated with cellular pathways that result in both mitosis and differentiation. We have been studying the process of spermatogenesis, which is a complex, continual cycle of cell renewal, proliferation and differentiation. Using a seasonal breeder, the European red fox (Vulpes vulpes), as our model, we have examined the expression of five AP-1 family members (c-fos, fra-1, fra-2, c-jun and junB) with a view to elucidating their role in the regulation of spermatogenesis. Unique patterns of expression, falling into three broad categories, were observed for the five genes: (i) continuous expression throughout the spermatogenic cycle (c-fos); (ii) expression only at times corresponding to the onset and shutdown of spermatogenesis (fra-1, fra-2 and c-jun); and (iii) expression only at the onset of the cycle (junB). Furthermore, the proteins were expressed in both premeiotic and post-meiotic cell types, suggesting a role in haploid, as well as diploid, gene expression in this tissue. The data suggest distinct, although not necessarily unrelated, roles for the different components of transcription factor AP-1 in the regulation of spermatogenesis.	CSIRO,DIV WILDLIFE & ECOL,COOPERAT RES CTR BIO CONTROL VERTEBRATE PESTS,LYNEHAM,ACT 2602,AUSTRALIA	Commonwealth Scientific & Industrial Research Organisation (CSIRO)	COHEN, DR (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV CELL BIOL,CANBERRA,ACT 2601,AUSTRALIA.			Cohen, Donna/0000-0002-0419-9542				ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ALCIVAR AA, 1990, J BIOL CHEM, V265, P20160; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COHEN DR, 1990, ONCOGENE, V5, P929; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; Curran T, 1988, ONCOGENE HDB, P307; Englund J., 1970, Viltrevy, V8, P1; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; Hecht NB., 1986, EXPT APPROACHES MAMM, P151; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MASON I, 1985, DIFFERENTIATION, V30, P76, DOI 10.1111/j.1432-0436.1985.tb00516.x; MATSUI M, 1990, ONCOGENE, V5, P249; MELLSTROM B, 1991, ONCOGENE, V6, P1959; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; MULLER R, 1983, NATURE, V304, P454, DOI 10.1038/304454a0; MULLER R, 1983, EMBO J, V2, P679, DOI 10.1002/j.1460-2075.1983.tb01484.x; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PELTOHUIKKO M, 1991, ACTA PHYSIOL SCAND, V141, P283, DOI 10.1111/j.1748-1716.1991.tb09080.x; PONZETTO C, 1985, MOL CELL BIOL, V5, P1791, DOI 10.1128/MCB.5.7.1791; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RUBIN MR, 1986, SCIENCE, V233, P663, DOI 10.1126/science.3726554; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SHIN C, 1990, J NEUROCHEM, V55, P1050, DOI 10.1111/j.1471-4159.1990.tb04595.x; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; SORRENTINO V, 1988, P NATL ACAD SCI USA, V85, P2191, DOI 10.1073/pnas.85.7.2191; STEWART TA, 1984, SCIENCE, V226, P707, DOI 10.1126/science.6494906; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907; ZAKERI ZF, 1987, MOL CELL BIOL, V7, P1791, DOI 10.1128/MCB.7.5.1791; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	52	42	45	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					443	455						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426749				2022-12-28	WOS:A1993KN00600024
J	PULVERER, BJ; HUGHES, K; FRANKLIN, CC; KRAFT, AS; LEEVERS, SJ; WOODGETT, JR				PULVERER, BJ; HUGHES, K; FRANKLIN, CC; KRAFT, AS; LEEVERS, SJ; WOODGETT, JR			COPURIFICATION OF MITOGEN-ACTIVATED PROTEIN-KINASES WITH PHORBOL ESTER-INDUCED C-JUN KINASE-ACTIVITY IN U937 LEUKEMIC-CELLS	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; ENHANCER ACTIVITY; MAP KINASES; PHOSPHORYLATION; INSULIN; GENES; DIFFERENTIATION; EXPRESSION; TYROSINE; TPA	Phorbol esters, such as phorbol myristate acetate (PMA), cause differentiation of U937 human mono-myelocytic cells along the macrophage pathway. Within 15 min of PMA treatment DNA binding of the c-jun transcription factor is increased and is accompanied by rapid changes in the phosphate content of the c-jun protein. Phorbol esters stimulate phosphorylation of serines 63 and 73 located within the Al transactivation domain of c-Jun that have previously been shown to positively regulate activity. A protein kinase activity is detectable in extracts of phorbol ester-treated U937 cells that specifically targets these two serines. Using novel assays, the protein kinase activity has been purified over 1000-fold. The major portion of protein kinase activity co-chromatographs over three columns with pp42/44 mitogen-activated protein kinases as judged by immunological methods. The significance of these results with respect to mitogen-induced transcription of AP-1-responsive genes is discussed.	PRINCESS MARGARET HOSP, ONTARIO CANC INST, 500 SHERBOURNE ST, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV ALABAMA, DEPT HAEMATOL ONCOL, BIRMINGHAM, AL 35294 USA; CHESTER BEATTY LABS, INST CANC RES, LONDON SW3 6JB, ENGLAND	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Alabama System; University of Alabama Birmingham; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK			Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797	NATIONAL CANCER INSTITUTE [R01CA042533] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42533] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ADUNYAH SE, 1991, J BIOL CHEM, V266, P5670; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACK EJ, 1991, ONCOGENE, V6, P1949; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODE N, 1992, J BIOL CHEM, V267, P16878; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KRAFT AS, 1989, CANCER RES, V49, P1287; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; PAPAVASSILIOU AG, 1992, ANAL BIOCHEM, V203, P302, DOI 10.1016/0003-2697(92)90317-Z; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SHERMAN ML, 1990, J BIOL CHEM, V265, P3320; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WILLIAM F, 1990, J BIOL CHEM, V265, P18166; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Woodgett J R, 1990, Semin Cancer Biol, V1, P389	45	78	84	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					407	415						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426747				2022-12-28	WOS:A1993KN00600020
J	SCHONTHAL, A; FERAMISCO, JR				SCHONTHAL, A; FERAMISCO, JR			INHIBITION OF HISTONE H1 KINASE EXPRESSION, RETINOBLASTOMA PROTEIN-PHOSPHORYLATION, AND CELL-PROLIFERATION BY THE PHOSPHATASE INHIBITOR OKADAIC ACID	ONCOGENE			English	Article							SV40 LARGE-T; GENE-PRODUCT; TUMOR PROMOTER; CYCLIN-A; M-PHASE; SUSCEPTIBILITY GENE; MAMMALIAN-CELLS; FISSION YEAST; MESSENGER-RNA; CDC2 KINASE	Phosphorylation events are major regulatory mechanisms of signal transduction pathways that regulate gene expression and cell growth. To study the potential involvement of serine-threonine specific phosphatases in these processes we used okadaic acid (OA), an inhibitor of type 1 and type 2A protein phosphatases. Here we present evidence that OA arrests cells at defined points in the cell cycle. Concomitantly, expression and associated histone H1 kinase activity of cdc2 and cyclin A, two cell cycle regulatory proteins, are repressed by this agent. Furthermore, phosphorylation of the tumor suppressor protein retinoblastoma, an event thought to be necessary in order to permit cells to proliferate, is inhibited when OA is present. These effects are fully reversible since removal of OA restores cdc2 and cyclin A expression as well as histone H1 kinase activity, and the cells resume growth. Since cdc2 and cyclin A have previously been shown to be absolutely required for cell cycle progression it is likely that blockage of synthesis of these components contributes to the cytostatic effects of OA. Furthermore, our results suggest a positive role for OA sensitive protein phosphatases in the regulation of expression of these cell cycle regulatory proteins.	UNIV CALIF SAN DIEGO,CTR CANC,DEPT PHARMACOL,LA JOLLA,CA 92093	University of California System; University of California San Diego	SCHONTHAL, A (corresponding author), UNIV CALIF SAN DIEGO,CTR CANC,DEPT CHEM,LA JOLLA,CA 92093, USA.		Schonthal, Axel/ABH-3846-2020	Schonthal, Axel/0000-0003-0662-5653				ALBERTS AS, 1992, IN PRESS P NATL ACAD; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Bravo R., 1990, GROWTH FACTORS DIFFE, P324; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DEAN NM, 1991, CARCINOGENESIS, V12, P665, DOI 10.1093/carcin/12.4.665; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DOU QP, 1992, P NATL ACAD SCI USA, V89, P3256, DOI 10.1073/pnas.89.8.3256; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; HERSCHMAN HR, 1989, CARCINOGENESIS, V10, P1495, DOI 10.1093/carcin/10.8.1495; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; ISHIDA Y, 1992, J CELL PHYSIOL, V150, P484, DOI 10.1002/jcp.1041500308; KIM SJ, 1990, CELL REGUL, V1, P269, DOI 10.1091/mbc.1.3.269; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LAU LF, 1991, HORMONAL CONTROL REG, P165; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUSCHER B, 1991, EMBO J, V10, P865, DOI 10.1002/j.1460-2075.1991.tb08019.x; MCGOWAN CH, 1990, MOL CELL BIOL, V10, P3847, DOI 10.1128/MCB.10.7.3847; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORDAN LJ, 1990, CANCER COMMUN, V2, P237, DOI 10.3727/095535490820874290; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RIME H, 1990, CELL DIFFER DEV, V29, P47, DOI 10.1016/0922-3371(90)90023-P; RIVEDAL E, 1990, BIOCHEM BIOPH RES CO, V167, P1302, DOI 10.1016/0006-291X(90)90665-A; SAGER R, 1992, Current Opinion in Cell Biology, V4, P155, DOI 10.1016/0955-0674(92)90026-9; SAKAI R, 1989, P NATL ACAD SCI USA, V86, P9946, DOI 10.1073/pnas.86.24.9946; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SCHONTHAL A, 1991, NEW BIOL, V3, P977; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; SUGANUMA M, 1990, CANCER RES, V50, P3521; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; THEVENIN C, 1991, J BIOL CHEM, V266, P9363; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDRE DD, 1992, J CELL SCI, V101, P79; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; WILLIAMS RT, 1992, ONCOGENE, V7, P423; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x	79	64	65	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					433	441						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8381221				2022-12-28	WOS:A1993KN00600023
J	Zeng, YX; ElDeiry, WS				Zeng, YX; ElDeiry, WS			Regulation of p21(WAF1/CIP1) expression by p53-independent pathways	ONCOGENE			English	Article						p21(WAF1/CIP1); transcription; p53; differentiation; TPA; cell cycle	CELL-CYCLE; P53; SUPPRESSION; GROWTH; GADD45	The CDK-inhibitor p21(WAF1/CIP1) has been implicated as a growth arrest mediator in p53-tumour suppression, cellular senescence and terminal differentiation. Cell type specific differences in p53-independent p21 expression and cell cycle arrest were found following treatment of human tumour cell lines with serum, 12-O-tetra-decanoyl-phorbol-13-acetate (TPA) or okadaic (OA). TPA induced p21 in ML1, K562 and HL60 leukemia cells, whereas OA induced p21 in SW480 and GM4723 carcinoma cells as well as in leukemic cells. In addition, TPA- and serum- but not OA-induced cell cycle arrest was reversed upon return of p21 to basal levels. To further investigate the mechanisms underlying p53-independent regulation of p21, the transcription inhibitor, Actinomycin D (AMD), was used to block p21 expression. The results showed a complete inhibition of p21 mRNA and protein induction by TPA or adriamycin but little effect on p21 mRNA induced by OA in the presence of AMD. These results suggested that TPA-induced p21 expression requires transcription initiation, while a post-transcriptional mechanism may be involved in OA-induction as well. Transient transfection assays with p21 promoter-luciferase reporters and TPA or OA treatment further confirmed that TPA, and to a lesser extent, OA, initiated transcription of p21. Finally, the protein kinase C inhibitor, staurosporine, was found to interfere with p21 induction and prevent cell cycle arrest following treatment with TPA but not OA, suggesting a requirement for PKC in TPA activation of p21 expression.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,DEPT MED,LAB MOLEC ONCOL & CELL CYCLE REGULAT,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,CTR CANC,PHILADELPHIA,PA 19104	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania			El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266				ATKINS KB, 1995, CELL GROWTH DIFFER, V6, P713; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BI SC, 1992, LEUKEMIA, V6, P839; CLARKE PR, 1993, MOL BIOL CELL, V4, P397, DOI 10.1091/mbc.4.4.397; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FAN SJ, 1994, CANCER RES, V54, P5824; GRANA X, 1995, ONCOGENE, V11, P211; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HIRAMA T, 1995, BLOOD, V86, P841; JIANG HP, 1994, ONCOGENE, V9, P3397; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATIRA A, 1993, CLIN EXP IMMUNOL, V92, P347; LI Y, 1994, ONCOGENE, V9, P2261; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHIELI P, 1994, CANCER RES, V54, P3391; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; SCHWALLER J, 1995, J CLIN INVEST, V95, P973, DOI 10.1172/JCI117806; SHAO ZM, 1995, ONCOGENE, V11, P493; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TERADA T, 1995, NATURE, V376, P358; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, NATURE, V366, P704; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG W, 1995, CANCER RES, V55, P668	36	273	284	1	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1557	1564						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622872				2022-12-28	WOS:A1996UF07600020
J	Licht, JD; Shaknovich, R; English, MA; Melnick, A; Li, JY; Reddy, JC; Dong, S; Chen, SJ; Zelent, A; Waxman, S				Licht, JD; Shaknovich, R; English, MA; Melnick, A; Li, JY; Reddy, JC; Dong, S; Chen, SJ; Zelent, A; Waxman, S			Reduced and altered DNA-binding and transcriptional properties of the PLZF-retinoic acid receptor-alpha chimera generated in t(11;17)-associated acute promyelocytic leukemia	ONCOGENE			English	Article						retinoid; transcription; leukemia; zinc finger	ZINC-FINGER; RAR-ALPHA; RESPONSE ELEMENT; CELL-LINE; BETA-GENE; PROTEIN; FUSION; PML; IDENTIFICATION; TRANSLOCATION	Acute promyelocytic leukemia (APL) associated with chromosomal rearrangement t(11;17) is a distinct syndrome which, unlike typical t(15;17) APL, fails to respond to all-trans retinoic acid (ATRA) therapy. In t(11;17) the PLZF gene, encoding a Kruppel-like zinc finger protein, is fused to the retinoic acid receptor-alpha (RAR alpha) gene, yielding two classes of chimeric proteins, PLZF protein was found in the nucleus in a punctate speckled pattern that differed from the nuclear body expression pattern of the PML protein affected in t(15;17) APL. The reciprocal PLZF-RAR alpha and RAR alpha-PLZF fusion proteins were localized to the nucleus both in the presence and absence of ATRA, PLZF-RAR alpha, in combination with the retinoid X receptor (RXR) bound to a retinoic acid-responsive element (RARE) less efficiently than RAR alpha and formed multimeric DNA-protein complexes. PLZF-RAR alpha stimulated ATRA-dependent transcription of RARE-containing reporter genes with diminished activity compared to wild-type RAR alpha, In addition, PLZF-RAR alpha antagonized the function of coexpressed wild-type RAR alpha, an effect relieved by over-expression of RXR. Leukemogenesis in t(11;17) APL may be related to interference with ATRA-mediated differentiation due to sequestration of RXR by the PLZF-RAR alpha chimera. However, disruption of the function of the myeloid-specific PLZF protein may also play an important role.	MT SINAI MED CTR,DEPT MED,NEW YORK,NY 10029; SHANGHAI MED UNIV 2,RUI JIN HOSP,SHANGHAI INST HEMATOL,SHANGHAI,PEOPLES R CHINA; CANC RES INST,LEUKEMIA RES FUND,LONDON SW3 6JB,ENGLAND; MT SINAI SCH MED,DIV NEOPLAST DIS,NEW YORK,NY 10029	Icahn School of Medicine at Mount Sinai; Shanghai Jiao Tong University; University of London; Institute of Cancer Research - UK; Icahn School of Medicine at Mount Sinai	Licht, JD (corresponding author), MT SINAI MED CTR,BROOKDALE CTR MOLEC BIOL,BOX 1126,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029, USA.		Zelent, Arthur/B-3532-2009; Melnick, Ari/AAA-5763-2020; Licht, Jonathan/L-4239-2019	Zelent, Arthur/0000-0002-7968-9888; Licht, Jonathan/0000-0002-3942-1369	NCI NIH HHS [CA 59936] Funding Source: Medline; NIGMS NIH HHS [T32GM07280-17] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059936] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007280] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Ausubel FM, 1988, MOL REPROD DEV; BANERJEE R, 1992, P NATL ACAD SCI USA, V89, P9996, DOI 10.1073/pnas.89.21.9996; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CHOMIENNE C, 1991, J CLIN INVEST, V88, P2150, DOI 10.1172/JCI115547; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; COREY SJ, 1994, LEUKEMIA, V8, P1350; DANIEL MT, 1993, BLOOD, V82, P1858; DEFRANCO C, 1993, BIOCHEM BIOPH RES CO, V194, P425, DOI 10.1006/bbrc.1993.1837; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; ELBARADI T, 1991, MECH DEVELOP, V35, P155, DOI 10.1016/0925-4773(91)90015-X; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRIGNANI F, 1995, CANCER RES, V55, P440; GRIGNANI F, 1994, BLOOD, V83, P10; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; GUIDEZ F, 1994, LEUKEMIA, V8, P312; HABER DA, 1992, P NATL ACAD SCI USA, V89, P6010, DOI 10.1073/pnas.89.13.6010; HARLOW E, 1988, ANTIBODIES LABORATOR; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KLIEWER SA, 1992, NATURE, V355, P441; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LANOTTE M, 1991, BLOOD, V77, P1080; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LI JY, 1994, BLOOD, V84, pA41; LICHT JD, 1994, MOL CELL BIOL, V14, P4057, DOI 10.1128/MCB.14.6.4057; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; PUVION DF, 1995, EXP CELL RES, V218, P9; REDNER RL, 1994, BLOOD, V84, pA375; REID A, 1995, IN PRESS BLOOD; ROUSSELOT P, 1994, ONCOGENE, V9, P545; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TERRIS B, 1995, CANCER RES, V55, P1590; TESTA U, 1994, CANCER RES, V54, P4508; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZELENT A, 1994, BRIT J HAEMATOL, V86, P451, DOI 10.1111/j.1365-2141.1994.tb04773.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	57	87	87	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					323	336						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570209				2022-12-28	WOS:A1996TR53800011
J	Weih, F; Lira, SA; Bravo, R				Weih, F; Lira, SA; Bravo, R			Overexpression of RelB in transgenic mice does not affect I kappa B alpha levels: Differential regulation of RelA and RelB by the inhibitor protein	ONCOGENE			English	Article						RelB; I kappa B alpha; transgenic mice	TRANSCRIPTION FACTORS; ACTIVATION; INTERACTS; ENCODES; FAMILY	In mouse lymphoid tissues, RelB heterodimers represent the constitutive kappa B-binding activity, whereas RelA and c-Rel complexes most likely are involved in inducible kappa B-binding and gene activation. Our laboratory has previously shown that the potential excess of NF-kappa B activity in transgenic mice overexpressing RelA is counteracted by a dramatic increase in I kappa B alpha, mainly due to its increased stability through association with RelA. As an attempt to elucidate the in vivo mechanisms that lead to the constitutive DNA-binding activity of RelB heterodimers, we have generated mouse lines overexpressing a relB transgene in a position-independent and copy number-dependent manner, Expression of RelB in these transgenic animals is very high in immature thymocytes and restricted to T cell areas in secondary lymphoid tissues, In contrast to the results obtained with RelA-transgenic thymocytes, we demonstrate here that overexpression of RelB results in a dramatic increase in overall kappa B-binding activity, Interestingly, I kappa B alpha protein levels are not altered in the RelB-transgenic animals, indicating that within the same cell type RelA and RelB complexes are differentially regulated by I kappa B alpha.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC ONCOL,PRINCETON,NJ 08543	Bristol-Myers Squibb								ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; ALLEN JM, 1992, MOL CELL BIOL, V12, P2758, DOI 10.1128/MCB.12.6.2758; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; CARRASCO D, 1994, DEVELOPMENT, V120, P2991; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DIDONATO JA, 1993, MOL CELL BIOL, V13, P1572; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P1184; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GRILLI M, 1993, INT REV CYTOL, V143, P1; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; LANG G, 1991, NUCLEIC ACIDS RES, V19, P5851, DOI 10.1093/nar/19.21.5851; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LERNBECHER T, 1994, EMBO J, V13, P4069; LEWIS DB, 1991, J EXP MED, V173, P89, DOI 10.1084/jem.173.1.89; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; PEREZ P, 1995, MOL CELL BIOL, V15, P3523; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; WEIH F, 1994, ONCOGENE, V9, P3289; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0	40	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					445	449						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570223				2022-12-28	WOS:A1996TR53800025
J	Yamashiro, DJ; Nakagawara, A; Ikegaki, N; Liu, XG; Brodeur, GM				Yamashiro, DJ; Nakagawara, A; Ikegaki, N; Liu, XG; Brodeur, GM			Expression of TrkC in favorable human neuroblastomas	ONCOGENE			English	Article						neuroblastoma; TrkA; TrkB; TrkC; NT-3	NERVE GROWTH-FACTOR; N-MYC AMPLIFICATION; RAT TRKC; FACTOR RECEPTOR; CELL LINES; PROTOONCOGENE; ENCODES; NEUROTROPHIN-3; CULTURE; FAMILY	Human neuroblastomas have been found to express the neurotrophin receptors TrkA and TrkB. Expression of TrkA correlates with favorable outcome, while expression of full-length TrkB is associated with unfavorable, more aggressive, N-myc amplified tumors. In this study we have determined the expression of TrkC in neuroblastoma primary tumors and cell lines. Using probes for the extracellular domain and the tyrosine kinase domain of human TrkC, we found by Northern analysis that TrkC mRNA is expressed in 14 of 55 (25%) tumors from a representative panel of neuroblastomas, A 14 kb transcript was detected by both probes, indicating that it would encode the full-length TrkC protein. A significant association was found between TrkC mRNA expression detected by Northern analysis and lower stage tumors [stage 1, 2, 4S, 11 of 30 (37%); vs stage 3, 4, 3 of 25 (12%), chi(2) = 4.4, P< 0.04]. Only one of eight primary tumors with N-myc amplification had detectable TrkC mRNA expression and none of the eight neuroblastoma cell lines expressed TrkC by Northern analysis. Our results suggest that TrkC is involved in the biology of favorable neuroblastomas.	CHILDRENS HOSP,DIV ONCOL,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia					NCI NIH HHS [CA 09615] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009615] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AZAR CG, 1990, CELL GROWTH DIFFER, V1, P421; BIEDLER JL, 1976, J NATL CANCER I, V57, P683, DOI 10.1093/jnci/57.3.683; BIEDLER JL, 1978, CANCER RES, V38, P3751; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BORRELLO MG, 1993, INT J CANCER, V54, P540, DOI 10.1002/ijc.2910540404; BRODEUR GM, 1994, SEMIN DIAGN PATHOL, V11, P118; BRODEUR GM, 1993, J NATL CANCER I, V85, P344, DOI 10.1093/jnci/85.5.344; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1455; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHN SL, 1990, ONCOGENE, V5, P1821; EBENDAL T, 1992, J NEUROSCI RES, V32, P461, DOI 10.1002/jnr.490320402; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; KAPLAN DR, 1991, SCIENCE, V252, P158; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1994, FASEB J, V8, P738, DOI 10.1096/fasebj.8.10.8050673; KOGNER P, 1993, CANCER RES, V53, P2044; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; MANESS LM, 1994, NEUROSCI BIOBEHAV R, V18, P143, DOI 10.1016/0149-7634(94)90043-4; MCGREGOR LM, 1994, GENOMICS, V22, P267, DOI 10.1006/geno.1994.1383; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; NAKAGAWARA A, 1995, GENOMICS, V25, P538, DOI 10.1016/0888-7543(95)80055-Q; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; SAMBROOK J, 1990, MOL CLONING LABORATO; SEGAL RA, 1994, P NATL ACAD SCI USA, V91, P12867, DOI 10.1073/pnas.91.26.12867; SHELTON DL, 1995, J NEUROSCI, V15, P477, DOI 10.1523/jneurosci.15-01-00477.1995; SUZUKI T, 1993, J NATL CANCER I, V85, P377, DOI 10.1093/jnci/85.5.377; TISCHLER AS, 1984, CANCER, V54, P1344, DOI 10.1002/1097-0142(19841001)54:7<1344::AID-CNCR2820540718>3.0.CO;2-J; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; WARIS T, 1973, EXPERIENTIA, V29, P1128, DOI 10.1007/BF01946760; [No title captured]	35	73	77	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					37	41						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552397				2022-12-28	WOS:A1996TQ01400005
J	Hurlin, PJ; Foley, KP; Ayer, DE; Eisenman, RN; Hanahan, D; Arbeit, JM				Hurlin, PJ; Foley, KP; Ayer, DE; Eisenman, RN; Hanahan, D; Arbeit, JM			Regulation of Myc and Mad during epidermal differentiation and HPV-associated tumorigenesis	ONCOGENE			English	Article						Myc-Mad network; epithelial differentiation; HPV; neoplastic progression; keratinocytes	C-MYC; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; CELL-DIFFERENTIATION; HUMAN KERATINOCYTES; NEOPLASTIC-CELLS; GENE-EXPRESSION; PROTEIN; PROLIFERATION; DISTINCT	c-Myc and Mad each form heterodimers with Max that bind the same E-box related DNA sequences, Whereas Myc:Max complexes activate transcription and promote cell proliferation and transformation, Mad:Max complexes repress transcription and block c-Myc-mediated cell transformation. Here we examine these antagonistic transcription factors during epithelial differentiation and neoplastic progression, During differentiation of primary human keratinocytes, Mad is rapidly induced and c-Myc is downregulated, resulting in a switch from c-Myc:Max to Mad:Max heterodimers, In normal epidermis and colonic mucosa c-myc expression is proliferating cell layers, while mad restricted to differentiating cell layers, Using HPV18 transformed keratinocytes that vary in their ability to differentiate in organotypic cultures, we find that Mad induction occurs only in those cells that retain a differentiation response, In the epidermis of transgenic mice in which expression of the HPV16 E6 and E7 oncogenes are targeted to basal keratinocytes, neoplastic progression occurs and is marked by an expansion of c-myc expressing basal-like cells. Expression of mad is found only in growth-arrested differentiating cells on the outer edges of preneoplastic lesions, The squamous cell carcinomas that arise evidence a variable number of sites within the tumor masses where mad expression and morphological differentiation coincide; increasing malignancy correlates with loss of both mad and capability to differentiate, These results indicate that c-Myc and Mad expression are tightly coupled to the transition from proliferation to differentiation of epithelial cells and that restriction of Mad expression may be associated with loss of normal differentiation capability and with tumorigenesis.	FRED HUTCHINSON CANC RES CTR, DIV BASIC SCI, SEATTLE, WA 98104 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT SURG, SAN FRANCISCO, CA 94143 USA	Fred Hutchinson Cancer Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Arbeit, Jeffrey/K-6920-2019; Foley, Kevin/ABC-1041-2020	Ayer, Donald/0000-0002-5595-3269	NATIONAL CANCER INSTITUTE [R01CA057138, R01CA047632] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA47632-07A1, R01CA57138] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; Angerer L.M., 1992, IN SITU HYBRIDIZATIO, P15; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; ASSELINEAU D, 1986, J INVEST DERMATOL, V86, P181, DOI 10.1111/1523-1747.ep12284237; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; AYER DE, 1995, GENE DEV, V80, P767; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Broders AC, 1932, NYJ MED, V32, P667; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; DOTTO GP, 1986, EMBO J, V5, P2853, DOI 10.1002/j.1460-2075.1986.tb04579.x; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; Farthing Alan J., 1994, Trends in Microbiology, V2, P170, DOI 10.1016/0966-842X(94)90667-X; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; FUCHS E, 1993, J CELL SCI, P197; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; HURLING PJ, 1995, IN PRESS EMBO J; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KOPAN R, 1987, J CELL BIOL, V105, P427, DOI 10.1083/jcb.105.1.427; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LARSSON LG, 1994, ONCOGENE, V9, P1247; Maniatis T., 1982, MOL CLONING; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MERRICK DT, 1992, AM J PATHOL, V140, P167; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; OKUN MR, 1988, GROSS MICROSCOPIC PA, V2, P806; PIENTENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POTTEN CS, 1992, GUT, V33, P71, DOI 10.1136/gut.33.1.71; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SCHWEIZER J, 1984, CELL, V37, P159, DOI 10.1016/0092-8674(84)90311-8; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SPENCER CA, 1991, ADV CANCER RES, V56, P1; TAKASAKI Y, 1981, J EXP MED, V154, P1899, DOI 10.1084/jem.154.6.1899; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; WILLE JJ, 1985, CARCINOGENESIS, V6, P1181, DOI 10.1093/carcin/6.8.1181; YAAR M, 1993, CLIN RES, V41, pA486, DOI 10.1006/excr.1993.1143; YOUNUS J, 1992, J CELL PHYSIOL, V152, P232, DOI 10.1002/jcp.1041520203; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZURHAUSEN H, 1990, VIROLOGY, V184, P9	63	149	150	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2487	2501						15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545105				2022-12-28	WOS:A1995TP18800004
J	CALLAGHAN, T; ANTCZAK, M; FLICKINGER, T; RAINES, M; MYERS, M; KUNG, HJ				CALLAGHAN, T; ANTCZAK, M; FLICKINGER, T; RAINES, M; MYERS, M; KUNG, HJ			A COMPLETE DESCRIPTION OF THE EGF-RECEPTOR EXON STRUCTURE - IMPLICATIONS IN ONCOGENIC ACTIVATION AND DOMAIN EVOLUTION	ONCOGENE			English	Article							GROWTH-FACTOR-RECEPTOR; AVIAN-LEUKOSIS VIRUS; TYROSINE KINASE-ACTIVITY; HUMAN-BRAIN TUMORS; C-ERBB ACTIVATION; INDUCED ERYTHROBLASTOSIS; SIGNAL TRANSDUCTION; SELF-PHOSPHORYLATION; CATALYTIC DOMAINS; PHOSPHOLIPASE-C	In this paper, we report that the chicken Epidermal Growth Factor Receptor (EGF-R), encoded by the proto-oncogene c-erbB, is comprised of 28 exons and spans over 75 Kb. The four previously identified domains which make up the extracellular ligand binding region of the receptor are coded for by two copies of a 300 amino acid repeat. We have demonstrated that the 3' end of each repeat coincides with the 3' end of the last exon making up the repeat. This alignment suggests that an exon-duplication may have occurred in the ligand-binding region of the gene. The transmembrane domain is encoded within a single exon and the exon boundaries of the catalytic domain closely match those defined by structural homology with other kinases. Along with the 54 chicken splice sites, the region 5' to the first exon was also sequenced. The proposed promoter region is greater than 70% GC, contains five repeats of the consensus Spl binding sequence and does not have a CCATT or TATA box. In addition to the presence of these characteristic housekeeping features, expression analysis confirms the promoter activity of this region and four sets of TCC repeats similar to those found in the human EGF-R promoter have been identified. To our knowledge this represents the first complete description of the exon-intron structure of the EGF-receptor family. The elucidation of the EGF-R exon structure provides insight into the domain evolution of the receptor-kinases and the mechanisms for the oncogenic conversion of EGF-R in erythroleukemias and glioblastomas.			CALLAGHAN, T (corresponding author), CASE WESTERN RESERVE UNIV, SCH MED, DEPT MOLEC BIOL & MICROBIOL, CLEVELAND, OH 44106 USA.		Kung, Hsing-Jien/C-7651-2013		NCI NIH HHS [P-30 CA43703, NCI CA 39207] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039207, R37CA039207, P30CA043703] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ANDRE C, 1992, ONCOGENE, V7, P685; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; BEUG H, 1982, J CELL PHYSIOL, P195; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; FLICKINGER TW, 1992, MOL CELL BIOL, V12, P883, DOI 10.1128/MCB.12.2.883; FUNG YKT, 1983, CELL, V33, P357, DOI 10.1016/0092-8674(83)90417-8; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOKKEL E, 1992, ONCOGENE, V7, P1423; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GOODWIN RG, 1986, MOL CELL BIOL, V6, P3128, DOI 10.1128/MCB.6.9.3128; HALEY J, 1987, ONCOGENE RES, V1, P375; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNON R, 1991, P NATL ACAD SCI USA, V88, P3004, DOI 10.1073/pnas.88.8.3004; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MAIHLE NJ, 1989, BIOCHIM BIOPHYS ACTA, V948, P287, DOI 10.1016/0304-419X(89)90003-6; MAIHLE NJ, 1991, P NATL ACAD SCI USA, V88, P1825, DOI 10.1073/pnas.88.5.1825; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MEINSENHELDER J, 1989, CELL, V57, P1109; NILSEN TW, 1985, CELL, V41, P719, DOI 10.1016/S0092-8674(85)80052-0; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; Partanen A M, 1990, Curr Top Dev Biol, V24, P31, DOI 10.1016/S0070-2153(08)60083-6; PAWSON T, 1988, ONCOGENE, V3, P491; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; RAINES MA, 1985, P NATL ACAD SCI USA, V82, P2287, DOI 10.1073/pnas.82.8.2287; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SALIER JP, 1989, BIOTECHNIQUES, V7, P30; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEJTER ED, 1986, CELL, V46, P1091, DOI 10.1016/0092-8674(86)90709-9; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SERGEANT A, 1982, EMBO J, V1, P237, DOI 10.1002/j.1460-2075.1982.tb01153.x; STECK PA, 1988, CANCER RES, V48, P5433; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; TOH H, 1985, NATURE, V314, P199, DOI 10.1038/314199a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; VISVADER J, 1989, MOL CELL BIOL, V9, P1336, DOI 10.1128/MCB.9.3.1336; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WHITE MRA, 1992, ONCOGENE, V7, P677; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAMAZAKI H, 1988, MOL CELL BIOL, V8, P1816, DOI 10.1128/MCB.8.4.1816	70	45	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1993	8	11					2939	2948						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414496				2022-12-28	WOS:A1993MC09300007
J	STERN, MH; SOULIER, J; ROSENZWAJG, M; NAKAHARA, K; CANKIKLAIN, N; AURIAS, A; SIGAUX, F; KIRSCH, IR				STERN, MH; SOULIER, J; ROSENZWAJG, M; NAKAHARA, K; CANKIKLAIN, N; AURIAS, A; SIGAUX, F; KIRSCH, IR			MTCP-1 - A NOVEL GENE ON THE HUMAN-CHROMOSOME XQ28 TRANSLOCATED TO THE T-CELL RECEPTOR ALPHA/DELTA LOCUS IN MATURE T-CELL PROLIFERATIONS	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; VARIABLE REGION GENES; ATAXIA-TELANGIECTASIA; MOLECULAR ANALYSIS; CHAIN LOCUS; BREAKPOINT; PATIENT; INVERSION; SEQUENCES; RECOMBINATION	T-cell lymphoproliferative diseases are often associated with recurrent chromosomal translocations involving T cell receptor genes (TCR) and genes that are thought to play a role in the pathogenesis of these diseases. Whereas numerous such genes have already been identified in acute T cell leukemias, no candidate gene has vet been identified to play a role in the heterogeneous group of T cell proliferations with a mature phenotype. We here report the molecular cloning of two examples of the rare but recurrent t(X;14) translocation. The first translocation was associated with a benign clonal proliferation in an ataxia telangiectasia patient and the second with a T cell prolymphocytic leukemia. Both translocations implicated the TCR alpha/delta locus and a common breakpoint region on chromosome Xq28. A previously unidentified gene, abnormally transcribed in both T cell proliferations, was characterized in the immediate proximity of the breakpoints. This Xq28 gene has no homology with known sequences, uses a complex alternative splicing pattern and demonstrates two short open reading frames. This gene, named MTCP-1 (Mature T Cell Proliferation-1) is the first candidate gene potentially involved in the leukemogenic process of mature T cell proliferations.	NATL CANC INST,NAVY MED ONCOL BRANCH,BETHESDA,MD 20889; SLUZBA ZA MED GENET,LJUBLJANA,SLOVENIA; INST CURIE,CNRS,URA620,F-75005 PARIS,FRANCE	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	STERN, MH (corresponding author), HOP ST LOUIS,HEMATOL MOLEC LAB,F-75475 PARIS,FRANCE.		Rosenzwajg, Michelle/AAF-6276-2019; Stern, Marc-Henri/A-2728-2011	Rosenzwajg, Michelle/0000-0001-5312-6203; Stern, Marc-Henri/0000-0002-8100-2272				AURIAS A, 1980, MUTAT RES, V69, P369, DOI 10.1016/0027-5107(80)90101-3; BAER R, 1987, P NATL ACAD SCI USA, V84, P9069, DOI 10.1073/pnas.84.24.9069; Battey, 1986, BASIC METHODS MOL BI; BEATTY DW, 1986, S AFR MED J, V69, P115; BERTNESS VL, 1990, CANCER GENET CYTOGEN, V44, P47, DOI 10.1016/0165-4608(90)90196-H; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; CANKI N, 1983, ZDRAV VESTN, V52, P567; DALLAPICCOLA B, 1984, INT J CANCER, V34, P171, DOI 10.1002/ijc.2910340206; DAVEY MP, 1988, P NATL ACAD SCI USA, V85, P9287, DOI 10.1073/pnas.85.23.9287; HECHT F, 1984, SCIENCE, V226, P1445, DOI 10.1126/science.6438800; ISOBE M, 1988, P NATL ACAD SCI USA, V85, P3933, DOI 10.1073/pnas.85.11.3933; KASAI M, 1992, MOL CELL BIOL, V12, P4751, DOI 10.1128/MCB.12.10.4751; KLEIN MH, 1987, P NATL ACAD SCI USA, V84, P6884, DOI 10.1073/pnas.84.19.6884; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAWRENCE JB, 1988, CELL, V52, P51; LIEBER MR, 1991, FASEB J, V5, P2934, DOI 10.1096/fasebj.5.14.1752360; LIPKOWITZ S, 1990, J EXP MED, V172, P409, DOI 10.1084/jem.172.2.409; MCCAW BK, 1975, P NATL ACAD SCI USA, V72, P2071, DOI 10.1073/pnas.72.6.2071; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; MENGLEGAW L, 1988, P NATL ACAD SCI USA, V85, P9171, DOI 10.1073/pnas.85.23.9171; MENGLEGAW L, 1987, EMBO J, V6, P2273, DOI 10.1002/j.1460-2075.1987.tb02501.x; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; ROMANROMAN S, 1991, EUR J IMMUNOL, V21, P927, DOI 10.1002/eji.1830210411; RUSSO G, 1988, CELL, V53, P137, DOI 10.1016/0092-8674(88)90495-3; RUSSO G, 1989, P NATL ACAD SCI USA, V86, P602, DOI 10.1073/pnas.86.2.602; STERN MH, 1988, HUM GENET, V78, P33, DOI 10.1007/BF00291230; STERN MH, 1989, BLOOD, V74, P2076; STERN MH, 1989, BLOOD, V73, P1285; STERN MH, 1993, CAUSES CONSEQUENCES, P165; TAKIHARA Y, 1988, P NATL ACAD SCI USA, V85, P6097, DOI 10.1073/pnas.85.16.6097; TAYLOR AMR, 1982, ATAXIA TELANGIECTASI, P53; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; THICK J, 1992, GENE CHROMOSOME CANC, V5, P321, DOI 10.1002/gcc.2870050407; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TYCKO B, 1990, CANCER CELL-MON REV, V2, P1; WITZIG TE, 1986, AM J HEMATOL, V21, P139, DOI 10.1002/ajh.2830210204; WYATT RT, 1992, J EXP MED, V175, P1575, DOI 10.1084/jem.175.6.1575	41	143	147	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2475	2483						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361760				2022-12-28	WOS:A1993LT36800019
J	HADMAN, M; LOO, M; BOS, TJ				HADMAN, M; LOO, M; BOS, TJ			INVIVO VIRAL AND CELLULAR JUN COMPLEXES EXHIBIT DIFFERENTIAL INTERACTION WITH A NUMBER OF INVITRO GENERATED AP-1-LIKE AND CREB-LIKE TARGET SEQUENCES	ONCOGENE			English	Article							C-JUN; LEUCINE ZIPPER; FOS PROTEIN; EMBRYO FIBROBLASTS; V-JUN; DNA; AP-1; TRANSCRIPTION; DOMAIN; ONCOGENE	A direct comparison of the relative DNA-binding capabilities of in vivo Jun-containing complexes derived from overexpression of the highly transforming viral Jun (VJ-1 CEF), the weakly transforming chicken cellular Jun (CJ-3 CEF) or background endogenous Jun (RCAS CEF) was assessed by gel mobility-shift assays using a synthetic oligonucleotide containing the consensus sequence TGACTCA (consensus AP-1). Chicken embryo fibroblasts (CEFs) expressing background c-Jun levels (RCAS CEF) contain almost undetectable levels of c-Jun but retain significant DNA-binding activity with two distinct complexes capable of binding specifically to the consensus AP-1 site. CEFs overexpressing either v-Jun or c-Jun contain these same two complexes and, while showing marked increases in Jun protein levels, do not exhibit any increase in DNA binding or transcriptional activation activity, suggesting that much of the overexpressed protein is inactive. Gel-shift assays performed in the presence of a Jun-specific antibody revealed a reduction in binding by both complexes, suggesting that each contains Jun or a Jun cross-reactive protein. Antibodies specific for Jun B, c-Fos, Fos B and CREB failed to interact with either complex. However, antibody specific for Fra-2 caused a slight supershift, suggesting that one or both complexes may contain Fra-2. Gel-shift competition assays with 16 'AP-1- and CREB-like' target sequences revealed that, within each cell type, the two protein complexes varied in their ability to recognize the mutant target sequences. These results clearly indicate differences in potential target recognition by each specific in vivo complex, and suggest that each may preferentially bind its own subset of target DNAs. In addition, a comparison of binding by individual complexes derived from CEFs overexpressing v-Jun and c-Jun also revealed differences in target recognition. Thus, in vivo complexes formed by overexpression of v-Jun and c-Jun vary in their ability to recognize and bind to a number of 'AP-1- and CREB-like' target sequences. This has important implications with regard to the mechanisms involved in cell transformation by v-Jun.	EASTERN VIRGINIA MED SCH, DEPT MICROBIOL & IMMUNOL, POB 1980, NORFOLK, VA 23501 USA	Eastern Virginia Medical School					NCI NIH HHS [NCI R29 CA 51982] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA051982] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1989, ONCOGENE, V4, P123; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1990, ONCOGENE, V5, P929; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GROSSI M, 1991, ONCOGENE, V6, P1767; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HUGHES M, 1992, CELL GROWTH DIFFER, V3, P889; HUGHES S, 1984, VIROLOGY, V136, P89, DOI 10.1016/0042-6822(84)90250-2; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; RANSONE LJ, 1990, MOL CELL BIOL, V10, P4565, DOI 10.1128/MCB.10.9.4565; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; RYSECK RP, 1991, ONCOGENE, V6, P533; RYSECK RP, 1990, ONCOGENE, V5, P1091; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SHARMA A, 1989, P NATL ACAD SCI USA, V86, P491, DOI 10.1073/pnas.86.2.491; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SU HY, 1991, ONCOGENE, V6, P1759; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; VOGT PK, 1990, CANCER BIOL, V1, P27	37	41	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1993	8	7					1895	1903						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510933				2022-12-28	WOS:A1993LG68200022
J	DUMONT, DJ; GRADWOHL, GJ; FONG, GH; AUERBACH, R; BREITMAN, ML				DUMONT, DJ; GRADWOHL, GJ; FONG, GH; AUERBACH, R; BREITMAN, ML			THE ENDOTHELIAL-SPECIFIC RECEPTOR TYROSINE KINASE, TEK, IS A MEMBER OF A NEW SUBFAMILY OF RECEPTORS	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTORS; IMMUNOGLOBULIN SUPERFAMILY; BINDING-SITE; CELL-LINE; HETEROGENEITY; SEQUENCE; DOMAINS; GAP; DNA	We have cloned a 4.2-kb murine cDNA encoding the Tek receptor tyrosine kinase (RTK), which is expressed in endothelial cells and their progenitors. The 1122-residue protein contains an extracellular domain comprising three fibronectin type III repeats fused to two immunoglobulin-like loops that are in turn separated by three epidermal growth factor-like repeats. The association of these different structural motifs and their characteristic arrangement in the Tek extracellular domain has been reported for only one other RTK, Tie, an endothelial-specific RTK of human origin. We show here that Tek and Tie are encoded by distinct genes and that, together, these receptors define a new subfamily of RTKs. In addition, we demonstrate that the tek cDNA, when introduced into COS cells, encodes a product of 140 kDa and that this protein and/or tek transcripts are detectable in highly vascularized embryonic tissues and in some, but not all, cell lines of endothelial origin.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV WISCONSIN,CTR DEV BIOL,MADISON,WI 53706	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Wisconsin System; University of Wisconsin Madison			Gradwohl, Gérard/AFM-9024-2022; Gradwohl, Gérard/H-8543-2014	Gradwohl, Gérard/0000-0002-6730-2615; Gradwohl, Gérard/0000-0002-6730-2615				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUBOIS NA, 1991, EXP CELL RES, V196, P302, DOI 10.1016/0014-4827(91)90265-V; DUMONT JD, 1992, ONCOGENE, V7, P1471; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GERRITSEN ME, 1987, BIOCHEM PHARMACOL, V36, P2701, DOI 10.1016/0006-2952(87)90252-8; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; GUMKOWSKI F, 1987, BLOOD VESSELS, V24, P11; HARLOW E, 1988, ANTIBODIES LABORATOR; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; NODEN DM, 1989, AM REV RESPIR DIS, V140, P1097, DOI 10.1164/ajrccm/140.4.1097; NODEN DM, 1988, DEVELOPMENT, V103, P121; OBESO J, 1990, LAB INVEST, V63, P259; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PENDL J, 1992, IN PRESS DEV BIOL; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Sambrook J, 1989, MOL CLONING LABORATO; SCWARZBAUER JE, 1987, EMBO J, V6, P2573; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TERMAN BI, 1991, ONCOGENE, V6, P1677; WAGNER RC, 1980, ADV MICROCIRCULAT, V9, P45; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YAMAGUCHI TP, 1993, IN PRESS DEVELOPMENT	32	158	180	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1293	1301						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8386827				2022-12-28	WOS:A1993KY32800022
J	PROUTY, SM; HANSON, KD; BOYLE, AL; BROWN, JR; SHICHIRI, M; FOLLANSBEE, MR; KANG, W; SEDIVY, JM				PROUTY, SM; HANSON, KD; BOYLE, AL; BROWN, JR; SHICHIRI, M; FOLLANSBEE, MR; KANG, W; SEDIVY, JM			A CELL-CULTURE MODEL SYSTEM FOR GENETIC ANALYSES OF THE CELL-CYCLE BY TARGETED HOMOLOGOUS RECOMBINATION	ONCOGENE			English	Article							EMBRYONIC STEM-CELLS; MAMMALIAN-CELLS; POLYOMA-VIRUS; 3T3 CELLS; C-MYC; GROWTH; PROTEIN; TRANSFORMATION; ONCOGENE; EXPRESSION	Analysis of how external proliferation signals impinge on the regulation of the cell cycle is ideally performed in cells that are capable of normal physiological withdrawal into the quiescent (G0) phase of the cell cycle as well as resumption of growth following appropriate stimuli. Targeted homologous recombination (gene targeting) provides an important new approach to determine the function of specific genes in these cellular processes. Current gene targeting methodology necessitates the use of immortal and stably diploid cell lines. This report investigates several rodent cell lines, by both genetic and physiological criteria, for use in gene targeting studies of the G0 to G1 transition. All murine cell lines examined were aneuploid. Some rat cell lines were euploid by chromosome number, but three specific genes, c-myc, c-raf-1 and Rb, were not always diploid. Only one cell line, an early-passage subclone of the Rat-I cell line, was diploid for c-myc, c-raf-I and Rb. An hprt- derivative of this cell line was isolated (designated TGR-1) and its karyotype was established by G-banding. TGR-1 cells were shown to withdraw into G0 upon serum starvation and to uniformly enter S phase after refeeding. Expression patterns of the c-myc, c-raf-1 and Rb genes and several properties of the gene products were found to be normal. The frequency of targeted homologous recombination of the c-myc and c-raf-1 loci was found to be within values observed with other cell lines. Thus, by both genetic and physiological criteria the TGR-1 cell line is a good model system for the analysis of the roles of c-myc, c-raf-1 and Rb in signal transduction, and will probably prove useful in studies involving other genes.	YALE UNIV, SCH MED, DEPT MOLEC BIOPHYS & BIOCHEM, 333 CEDAR ST, NEW HAVEN, CT 06510 USA	Yale University				Shichiri, Masayoshi/0000-0002-5704-1378	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041690] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM41690] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BERINSTEIN N, 1992, MOL CELL BIOL, V12, P360, DOI 10.1128/MCB.12.1.360; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOLLAG RJ, 1989, ANNU REV GENET, V23, P199, DOI 10.1146/annurev.ge.23.120189.001215; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; CAMERINI-OTERO R D, 1990, New Biologist, V2, P337; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; DAVIS AC, 1992, MOL CELL BIOL, V12, P2769, DOI 10.1128/MCB.12.6.2769; DELARCO JE, 1978, J CELL PHYSIOL, V94, P335, DOI 10.1002/jcp.1040940311; FLUCK MM, 1979, VIROLOGY, V96, P205, DOI 10.1016/0042-6822(79)90185-5; FREEMAN AE, 1973, P NATL ACAD SCI USA, V70, P2415, DOI 10.1073/pnas.70.8.2415; HARLOW E, 1988, ANTOBODIES; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8047, DOI 10.1073/pnas.85.21.8047; HARTZELL S, 1989, MOL CELL BIOL, V9, P2567, DOI 10.1128/MCB.9.6.2567; HASTY P, 1991, MOL CELL BIOL, V11, P5586, DOI 10.1128/MCB.11.11.5586; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JANSEN HW, 1984, NATURE, V307, P281, DOI 10.1038/307281a0; JASIN M, 1988, GENE DEV, V2, P1353, DOI 10.1101/gad.2.11.1353; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KOLCH W, 1990, ONCOGENE, V5, P713; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LITTLEFIELD JW, 1963, P NATL ACAD SCI USA, V50, P568, DOI 10.1073/pnas.50.3.568; LOWY DR, 1978, J VIROL, V26, P291, DOI 10.1128/JVI.26.2.291-298.1978; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MORTENSEN RM, 1991, P NATL ACAD SCI USA, V88, P7036, DOI 10.1073/pnas.88.16.7036; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; PARKER BA, 1979, J VIROL, V52, P456; PRASAD I, 1976, J VIROL, V18, P436, DOI 10.1128/JVI.18.2.436-444.1976; REID LH, 1991, MOL CELL BIOL, V11, P2769, DOI 10.1128/MCB.11.5.2769; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Sambrook J, 1989, MOL CLONING; SEDIVY JM, 1989, P NATL ACAD SCI USA, V86, P227, DOI 10.1073/pnas.86.1.227; SEDIVY JM, 1987, CELL, V50, P379, DOI 10.1016/0092-8674(87)90492-2; SEDIVY JM, 1992, GENE TARGETING; SEIF R, 1977, J VIROL, V24, P721, DOI 10.1128/JVI.24.3.721-728.1977; SIMINOVITCH L, 1976, CELL, V7, P1, DOI 10.1016/0092-8674(76)90249-X; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINBERG RA, 1989, BLOOD, V74, P529	50	46	47	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1993	8	4					899	907						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455944				2022-12-28	WOS:A1993KT22000011
J	CHARLES, CH; YOON, JK; SIMSKE, JS; LAU, LF				CHARLES, CH; YOON, JK; SIMSKE, JS; LAU, LF			GENOMIC STRUCTURE, CDNA-SEQUENCE, AND EXPRESSION OF GLY96, A GROWTH FACTOR-INDUCIBLE IMMEDIATE-EARLY GENE ENCODING A SHORT-LIVED GLYCOSYLATED PROTEIN	ONCOGENE			English	Note							NF-KAPPA-B; C-FOS; CELLS; FIBROBLASTS; TRANSITION; MYC; SET	We report the cDNA sequence and genomic structure of gly96, an immediate early gene inducible by serum growth factors in mouse fibroblasts. It encodes a 153-amino acid protein that does not share significant sequence similarity with any known protein. In the adult mouse, gly96 is expressed predominantly in the lung, testes and the uterus. We have identified the Gly96 protein in Balb/c 3T3 cells using affinity-purified antibodies recognizing the Gly96 polypeptide. We show that Gly96 is glycosylated and has a short half-life in serum stimulated fibroblasts.	UNIV ILLINOIS,COLL MED,DEPT GENET,808 S WOOD ST,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital				Lau, Lester/0000-0002-4364-2914	NATIONAL CANCER INSTITUTE [R01CA046565, R01CA052220] Funding Source: NIH RePORTER; NCI NIH HHS [CA52220, CA46565] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRAVO R, 1990, CELL GROWTH DIFFER, V1, P305; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CROZE E, 1989, J CELL BIOL, V108, P1597, DOI 10.1083/jcb.108.5.1597; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; HARLOW E, 1988, ANTIBODIES LABORATOR; HAZEL TG, 1991, MOL CELL BIOL, V11, P3239, DOI 10.1128/MCB.11.6.3239; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; WILLIAMS GT, 1992, MOL CELLULAR APPROAC, P1151	22	55	64	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					797	801						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437864				2022-12-28	WOS:A1993KN00800034
J	OKUNO, H; AKAHORI, A; SATO, H; XANTHOUDAKIS, S; CURRAN, T; IBA, H				OKUNO, H; AKAHORI, A; SATO, H; XANTHOUDAKIS, S; CURRAN, T; IBA, H			ESCAPE FROM REDOX REGULATION ENHANCES THE TRANSFORMING ACTIVITY OF FOS	ONCOGENE			English	Article							DNA-BINDING ACTIVITY; GROWTH-STIMULATING ACTIVITY; CHICKEN-EMBRYO FIBROBLASTS; JUN PROTO-ONCOGENE; C-JUN; LEUCINE ZIPPER; V-FOS; GENE FAMILY; PROTEINS; PHOSPHORYLATION	Fos and Jun form dimeric complexes that bind to DNA sequences containing activator protein 1 (AP-1) sites and regulate gene expression. The in vitro DNA-binding activity of these proteins is sensitive to reduction-oxidation (redox). Reduction of a single conserved cysteine residue, located in the DNA-binding domain, either by reducing agents or by a nuclear redox factor (Ref-1), is required for AP-1 DNA-binding activity. Replacing the critical cysteine with serine results in a protein that can bind to DNA in vitro even under oxidizing conditions. To determine whether redox control affects the function of Fos in vivo, we have constructed, and compared the properties of, retroviral vectors expressing either a truncated Fos protein (F118-211) or a truncated Fos protein in which the critical cysteine was replaced by serine (FC154S). In infected chicken embryo fibroblasts (CEFs), both vectors expressed similar levels of Fos protein, which formed heterodimers with Jun at equivalent efficiencies. However, extracts from cells expressing FC154S exhibited a threefold increase in AP-1 DNA-binding activity compared with cells expressing F118-211. Furthermore, this enhanced binding activity was resistant to treatment with the oxidizing agent diamide. Infection of CEFs by virus expressing FC154S resulted in increased numbers of transformed colonies and an increase in colony size compared with those obtained following infection by virus expressing Fos 118-211. These results suggest that redox regulation may limit the total level of functional Fos-Jun complexes in vivo and that escape from this control enhances transforming activity.	UNIV TOKYO,INST MED SCI,DEPT TUMOR VIRUS RES,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN; ROCHE INST MOLEC BIOL,DEPT MOLEC ONCOL & VIROL,NUTLEY,NJ 07110	University of Tokyo			Curran, Tom/F-5234-2018; Curran, Tom/C-1164-2008; Curran, Thomas/AAE-7631-2019; Curran, Tom/D-7515-2011	Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; OKUNO, HIROYUKI/0000-0001-6237-6503				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1991, ONCOGENE, V6, P2179; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; CURRAN T, 1984, CELL, V36, P259; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GENTZ R, 1988, SCIENCE, V239, P1150; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; IBA H, 1988, ONCOGENE RES, V2, P121; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; KENUWEIN T, 1987, CELL, V48, P647; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATSUI M, 1990, ONCOGENE, V5, P249; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OKUNO H, 1991, ONCOGENE, V6, P1491; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; YOSHIDA T, 1991, BIOCHEM BIOPH RES CO, V174, P934, DOI 10.1016/0006-291X(91)91508-A; YOSHIDA T, 1989, ONCOGENE RES, V5, P79; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	43	106	108	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					695	701						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437852				2022-12-28	WOS:A1993KN00800021
J	BERLINGIERI, MT; SANTORO, M; BATTAGLIA, C; GRIECO, M; FUSCO, A				BERLINGIERI, MT; SANTORO, M; BATTAGLIA, C; GRIECO, M; FUSCO, A			THE ADENOVIRUS E1A GENE BLOCKS THE DIFFERENTIATION OF A THYROID EPITHELIAL-CELL LINE, HOWEVER THE NEOPLASTIC PHENOTYPE IS ACHIEVED ONLY AFTER COOPERATION WITH OTHER ONCOGENES	ONCOGENE			English	Article							MURINE SARCOMA-VIRUS; TRANSFORMATION; TRANSCRIPTION; RETROVIRUS; SEQUENCES; DNA; THYROGLOBULIN; INFECTIVITY; ACTIVATION; EXPRESSION	The PC Cl 3 cell line is a well characterized epithelial thyroid cell fine of Fischer rat origin. This cell line has the peculiarity of retaining in vitro the typical markers of thyroid differentiation (i.e. thyroglobulin synthesis and secretion, iodide uptake and dependence on TSH for growth). The PC Cl 3 cells have been transfected with the E1A gene of Adenovirus 5. The E1A transfected cells, PC E1A, partially lost the dependency on TSH for growth and completely lost the ability to trap iodide and synthesize thyroglobulin; however they did not acquire the typical markers of the neoplastic phenotype. A highly malignant phenotype was achieved after infection of the PC E1A cells with retroviruses carrying the v-raf, v-abl and polyoma virus middle T oncogenes. In contrast, the PC E1A cells transfected with the E1B gene of Adenovirus were not tumorigenic at all, and those infected with retroviruses carrying oncogenes of the ras family displayed a very weak tumorigenic phenotype.	UNIV NAPOLI,FAC MED & CHIRURG 2,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,CNR,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria				Grieco, Michele/0000-0002-4212-7814; Fusco, Alfredo/0000-0003-3332-5197				AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; BELLETT AJD, 1989, J VIROL, V63, P303, DOI 10.1128/JVI.63.1.303-310.1989; BERLINGIERI MT, 1988, MOL CELL BIOL, V8, P226; BRAITHWAITE AW, 1981, NEW BIOL, V3, P18; COLLETTA G, 1983, MOL CELL BIOL, V3, P2099, DOI 10.1128/MCB.3.11.2099; CONE RD, 1988, MOL CELL BIOL, V8, P1036, DOI 10.1128/MCB.8.3.1036; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DILAURO R, 1982, GENE, V19, P117, DOI 10.1016/0378-1119(82)90196-2; FUSCO A, 1985, J VIROL, V56, P284, DOI 10.1128/JVI.56.1.284-292.1985; FUSCO A, 1982, CANCER RES, V42, P618; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; IKEKUBO K, 1980, METABOLISM, V29, P673, DOI 10.1016/0026-0495(80)90113-4; ITO T, 1992, CANCER RES, V52, P1369; JACKSON P, 1985, J VIROL, V55, P644, DOI 10.1128/JVI.55.3.644-650.1985; KELAKAR A, 1986, MOL CELL BIOL, V6, P7; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LYNCH MJ, 1989, CANCER RES, V49, P5429; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; Maniatis T., 1982, MOL CLONING; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; PARASKEVA C, 1980, INT J CANCER, V25, P631, DOI 10.1002/ijc.2910250513; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; STOW ND, 1982, NUCLEIC ACIDS RES, V10, P5105, DOI 10.1093/nar/10.17.5105; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WHITE P, 1988, NATURE, V334, P124; YAN DH, 1991, ONCOGENE, V6, P343; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	34	43	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					249	255						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426735				2022-12-28	WOS:A1993KN00600003
J	DoucRasy, S; Barrois, M; Fogel, S; Ahomadegbe, JC; Stehelin, D; Coll, J; Riou, G				DoucRasy, S; Barrois, M; Fogel, S; Ahomadegbe, JC; Stehelin, D; Coll, J; Riou, G			High incidence of loss of heterozygosity and abnormal imprinting of H19 and IGF2 genes in invasive cervical carcinomas. Uncoupling of H19 and IGF2 expression and biallelic hypomethylation of H19	ONCOGENE			English	Article						cervical cancer; H19; IGF2; loss of imprinting; allele switch; methylation	GROWTH FACTOR-II; BECKWITH-WIEDEMANN SYNDROME; WILMS-TUMOR; HUMAN CANCER; METHYLATION; RELAXATION; ALLELES; RNA	The few imprinted genes characterized so far include the insulin-like growth factor-2 gene (IGF2) coding for a foetal growth factor and the H19 gene whose normal function is unknown but which is likely to act as an RNA with an antitumour effect, IGF2 is expressed by the paternal allele and H19 by the maternal allele. This reciprocal expression is quite interesting because both H19 and IGF2 genes are located close to each other on chromosome 11p15.5 in a region subject to loss of heterozygosity (LOH), Moreover, loss of imprinting (LOI) or biallelic expression has been proposed as an epigenetic mechanism for tumorigenesis in a variety of human cancers including Wilms' tumour, In this study we report the LOH, LOI and methylation status of H19 and IGF2 genes in 29 invasive cervical carcinomas of different clinical stages, Fourteen (48%) and 13 (45%) tumours were heterozygous for H19 and IGF2 respectively, LOH for H19 and IGF2 genes were found in 2 of 14 (14%) and 3 of 13 (23%) informative tumours, respectively, LOI of H19 and IGF2 was detected in 2 of 12 (17%) and 5 of 10 (50%) tumours with no LOH, respectively, More interestingly, monoallelic expression of the otherwise silent H19 allele (allele switch) was observed in 2 of 12 (17%) tumours and biallelic expression of IGF2 was detected in one specimen of normal cervix adjacent to the tumour, The expressing H19 allele, and to a lower degree also the silent allele, were hypomethylated in tumours suggesting that demethylation of both H19 alleles may be associated with an early step of imprinting alteration. In cervical cancer H19 and IGF2 expressions could be independently regulated, In conclusion, our data suggest that H19 and IGF2 genes, via deletions and/or abnormal imprinting, could play a crucial role in a large proportion (58%) of cervical cancers where they may be associated with disease progression.	INST GUSTAVE ROUSSY,LAB PHARMACOL CLIN & MOLEC,F-94800 VILLEJUIF,FRANCE; INST PASTEUR,CNRS,URA 1160,F-59019 LILLE,FRANCE	UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; COUTURIER J, 1991, J VIROL, V65, P4534, DOI 10.1128/JVI.65.8.4534-4538.1991; DOUCRASY S, 1993, INT J ONCOL, V2, P753; EKSTROM TJ, 1995, DEVELOPMENT, V121, P309; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HASHIMOTO K, 1995, NAT GENET, V9, P109, DOI 10.1038/ng0295-109; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HOWLEY PM, 1991, CANCER RES, V51, pS5019; HU JF, 1995, MOL ENDOCRINOL, V9, P628, DOI 10.1210/me.9.5.628; JINNO Y, 1995, NAT GENET, V10, P318, DOI 10.1038/ng0795-318; KONDO M, 1995, ONCOGENE, V10, P1193; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LI XR, 1995, ONCOGENE, V11, P221; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; PFEIFER K, 1994, GENE DEV, V8, P1867, DOI 10.1101/gad.8.16.1867; POIRIER F, 1991, DEVELOPMENT, V113, P1105; RACHMILEWITZ J, 1992, FEBS LETT, V309, P25, DOI 10.1016/0014-5793(92)80731-U; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RANIER S, 1995, CANCER RES, V55, P1836; REIK W, 1994, HUM MOL GENET, V3, P1297, DOI 10.1093/hmg/3.8.1297; RIOU G, 1988, ONCOGENE, V3, P329; RIOU G, 1985, PAPILLOMAVIRUSES MOL, V32, P47; SCHNEID H, 1993, J MED GENET, V30, P353, DOI 10.1136/jmg.30.5.353; SCHOFIELD PN, 1992, INSULIN LIKE GROWTH; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SURANI MA, 1994, CURR OPIN CELL BIOL, V6, P390, DOI 10.1016/0955-0674(94)90031-0; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P6967, DOI 10.1093/nar/19.24.6967; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; TREMBLAY KD, 1995, NAT GENET, V9, P407, DOI 10.1038/ng0495-407; TYCKO B, 1994, AM J PATHOL, V144, P431; VANGURP RJHLM, 1994, JNCI-J NATL CANCER I, V86, P1070, DOI 10.1093/jnci/86.14.1070; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61; ZHANG YH, 1993, AM J HUM GENET, V53, P113; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	41	111	119	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					423	430						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570220				2022-12-28	WOS:A1996TR53800022
J	Peverali, FA; Orioli, D; Tonon, L; Ciana, P; Bunone, G; Negri, M; DellaValle, G				Peverali, FA; Orioli, D; Tonon, L; Ciana, P; Bunone, G; Negri, M; DellaValle, G			Retinoic acid-induced growth arrest and differentiation of neuroblastoma cells are counteracted by N-myc and enhanced by max overexpressions	ONCOGENE			English	Article						differentiation; N-Myc; Max; neuroblastoma; proliferation; retinoic acid	HUMAN NEURO-BLASTOMA; C-MYC; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; EMBRYONIC LETHALITY; EXPRESSION; PROTEIN; LINES; GENE; PROGRESSION	N-myc expression is negatively regulated by retinoic acid (RA) which induces the growth arrest and differentiation of neuroblastoma (NB) cells. However, it has not been completely defined whether N-Myc promotes growth and/or antagonises neuronal differentiation of NE cells or whether the down regulation of N-myc occurs as a consequence of the onset of differentiation. By transfecting an N-myc gene construct into these cells, we found that the constitutive overexpression of N-myc stimulated proliferation in RA containing medium and, although these cells were still responsive to RA, they were no longer able to differentiate. Since N-Myc functions appear to be mediated by heterodimerization with Max, the ectopic overexpression of max in NE cells was also investigated, In contrast to N-Myc, Max strongly induced the differentiation by enhancing the effects of RA. Max-transfected cells rapidly arrested growth and differentiated fully within a few days of RA treatment. These findings suggest that the relative levels of N-Myc compared to Max appears to be crucial in stimulating neuroblastoma growth or differentiation, and may contribute to explain the remarkable clinical behaviour of neuroblastomas.	UNIV PAVIA,DIPARTIMENTO GENET & MICROBIOL A BUZZATI TRAV,I-27100 PAVIA,ITALY	University of Pavia			Ciana, Paolo/F-9224-2012; Peverali, Fiorenzo/J-2660-2012	Peverali, Fiorenzo/0000-0001-6717-6586; CIANA, PAOLO/0000-0001-5771-5638; ORIOLI, DONATA/0000-0002-3830-3408				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BIEDLER JL, 1978, CANCER RES, V38, P3751; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRODEUR GM, 1981, CANCER RES, V41, P4678; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; BUNONE G, 1995, EXP CELL RES, V217, P92, DOI 10.1006/excr.1995.1067; BURSCH W, 1990, CARCINOGENESIS, V11, P847, DOI 10.1093/carcin/11.5.847; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; GHAZAL P, 1992, P NATL ACAD SCI USA, V89, P7630, DOI 10.1073/pnas.89.16.7630; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PEVERALI FA, 1990, DIFFERENTIATION, V45, P61, DOI 10.1111/j.1432-0436.1990.tb00458.x; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; PIACENTINI M, 1992, INT J CANCER, V52, P271, DOI 10.1002/ijc.2910520220; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; THIELE CJ, 1988, EXP CELL BIOL, V56, P321; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; YOUNG J L JR, 1986, Cancer, V58, P598, DOI 10.1002/1097-0142(19860715)58:2+<598::AID-CNCR2820581332>3.0.CO;2-C; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	40	54	54	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					457	462						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570225				2022-12-28	WOS:A1996TR53800027
J	Rochefort, P; Caillou, B; Michiels, FM; Ledent, C; Talbot, M; Schlumberger, M; Lavelle, F; Monier, R; Feunteun, J				Rochefort, P; Caillou, B; Michiels, FM; Ledent, C; Talbot, M; Schlumberger, M; Lavelle, F; Monier, R; Feunteun, J			Thyroid pathologies in transgenic mice expressing a human activated Ras gene driven by a thyroglobulin promoter	ONCOGENE			English	Article						transgenic mice; activated ras; papillary thyroid carcinoma; thyroid dysgenesis	TISSUE-SPECIFIC EXPRESSION; ONCOGENE ACTIVATION; INTESTINAL NEOPLASIA; HIGH-FREQUENCY; TRANSFORMATION; MUTATIONS; TUMORS; CARCINOMA; CELLS; INHIBITION	Four transgenic mice carrying the human activated c-Ha-Ras gene, the expression of which was driven into the thyroid gland by a bovine thyroglobulin promoter, have been produced. The M1 and M2 mice developed papillary thyroid carcinomas and the M2 mouse also developed a lung carcinoma, however none of them transmitted the transgene. Both the M3 and the M4 mice gave rise to transgenic lines. M3 progeny mice develop a goitre with morphological aspects of hyperplasia as well as a thymus hyperplasia, M4 developed a papillary thyroid carcinoma and a lung carcinoma. Lung tumors but not thyroid tumors were observed in M4 adult transgenic progeny. In this M4 line, thyroid dysgenesis leading to growth retardation and premature death was observed upon serial backcross that enhanced the DBA/2J genetic background. The development of thyroid tumors in M1, M2, M4 transgenic mice demonstrates the oncogenic potential of activated Ras gene in the thyroid gland. The M4 line raises interesting questions relative to the interference between the Ras-mediated signal transduction pathway and thyroid morphogenesis.	INST GUSTAVE ROUSSY,CNRS,URA 1967,LAB GENET ONCOL,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,SERV HISTOPATHOL A,VILLEJUIF,FRANCE; FREE UNIV BRUSSELS,INST RECH INTERDISCIPLINAIRE,BRUSSELS,BELGIUM; INST GUSTAVE ROUSSY,NUCL MED SERV,VILLEJUIF,FRANCE; RHONE POULENC RORER,VITRY,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Universite Libre de Bruxelles; Vrije Universiteit Brussel; UNICANCER; Gustave Roussy; Sanofi-Aventis			Feunteun, Jean/AAZ-1267-2020	Feunteun, Jean/0000-0003-1212-9189				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ANDRES AC, 1991, ONCOGENE, V6, P771; AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; BIANCIFIORI C, 1979, PATHOLOGY TUMORS ANI, P451; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BONGARZONE I, 1989, ONCOGENE, V4, P1457; BOS JL, 1989, CANCER RES, V49, P4682; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CHRISTOPHE D, 1994, MOL CELL ENDOCRINOL, V64, P5; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; FOWLIS DJ, 1993, EUR J CANCER, V29A, P638, DOI 10.1016/S0959-8049(05)80170-4; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; GUAZZI S, 1994, EMBO J, V13, P3339, DOI 10.1002/j.1460-2075.1994.tb06636.x; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; HOGAN B, 1986, MANIPULATING MOUSE E; KARGA H, 1991, J CLIN ENDOCR METAB, V73, P832, DOI 10.1210/jcem-73-4-832; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; LEDENT C, 1991, ENDOCRINOLOGY, V129, P1391, DOI 10.1210/endo-129-3-1391; LEDENT C, 1990, P NATL ACAD SCI USA, V87, P6176, DOI 10.1073/pnas.87.16.6176; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1990, ONCOGENE, V5, P1833; LEMOINE NR, 1988, ONCOGENE, V3, P541; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; NAMBA H, 1990, J CLIN ENDOCR METAB, V71, P223, DOI 10.1210/jcem-71-1-223; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; SAID S, 1994, J ENDOCRINOL INVEST, V17, P371, DOI 10.1007/BF03349004; SANTELLI G, 1993, CANCER RES, V53, P5523; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SCHLUMBERGER M, 1986, J CLIN ENDOCR METAB, V63, P960; SHI YF, 1991, CANCER RES, V51, P2690; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SUAREZ HG, 1991, ONCOGENE, V6, P677; SUAREZ HG, 1990, ONCOGENE, V5, P565; TREMBLAY PJ, 1989, MOL CELL BIOL, V9, P854, DOI 10.1128/MCB.9.2.854; Whitten WK, 1971, ADV BIOSCI, V6, P129, DOI DOI 10.1016/B978-0-08-017571-3.50013-9; WRIGHT PA, 1991, ONCOGENE, V6, P471; YUKAWA K, 1989, J EXP MED, V170, P711, DOI 10.1084/jem.170.3.711	40	58	59	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					111	118						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552381				2022-12-28	WOS:A1996TQ01400014
J	SHAUGHNESSY, JD; OWENS, JD; WIENER, F; HILBERT, DM; HUPPI, K; POTTER, M; MUSHINSKI, JF				SHAUGHNESSY, JD; OWENS, JD; WIENER, F; HILBERT, DM; HUPPI, K; POTTER, M; MUSHINSKI, JF			RETROVIRAL ENHANCER INSERTION 5' OF C-MYC IN 2 TRANSLOCATION-NEGATIVE MOUSE PLASMACYTOMAS UP-REGULATES C-MYC EXPRESSION TO DIFFERENT EXTENTS	ONCOGENE			English	Article							MURINE LEUKEMIA-VIRUS; MESSENGER-RNA; DNA FRAGMENTS; TRANSCRIPTIONAL ACTIVATION; CHROMOSOME TRANSLOCATIONS; NUCLEOTIDE-SEQUENCE; AGAROSE GELS; T-LYMPHOMAS; ONC GENE; V-ABL	Essentially all murine plasmacytomas have deregulated c-myc expression that is typically brought about by chromosomal translocations between the c-myc/Pvt-1 locus and one of the immunoglobulin loci. ABPC 22 and RFPC 2782 are BALB/c plasmacytomas that lack chromosomal translocations yet have Southern blot evidence of c-myc gene rearrangements. In this report we show that proviral integrations 5' of the c-myc gene can deregulate c-myc expression in mouse plasmacytomas. Analysis of DNA sequences 5' of the c-myc genes from both tumors demonstrated that rearrangements were caused by retroviral integrations 5' of c-myc exon 1. The proviral insertion in RFPC 2782 was associated with a high steady-state c-myc mRNA level comparable to that seen in plasmacytomas with typical translocations. An analogous proviral insertion in ABPC 22 was associated with a c-myc RNA level that was only 38% of that of RFPC 2782. Nuclear run-on studies of c-myc transcription showed that ABPC 22 has both a lower rate of transcription and a greater degree of transcriptional attenuation than RFPC 2782. DNA sequencing of the long terminal repeat of each tumor provirus showed that the ABPC 22 provirus harbors a deletion of one of the two direct repeats in the viral enhancer, whereas both repeats are present in the RFPC 2782 provirus. These data indicate that maximum LTR enhancer effectiveness in plasmacytomas in vivo requires the presence of both LTR direct repeats. The documentation of the low level of steady-state c-myc mRNA in ABPC 22 supports the notion that deregulated c-myc expression, even at low steady state levels, is effective in supporting the development of plasmacytomas.	NCI,GENET LAB,BETHESDA,MD 20892; UNIV MARYLAND,DEPT ZOOL,COLL PK,MD 20742; KAROLINSKA INST,DEPT TUMOR BIOL,S-10401 STOCKHOLM 60,SWEDEN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland College Park; Karolinska Institutet								AXELSON H, 1991, ONCOGENE, V6, P2263; BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BAUER SR, 1989, ONCOGENE, V4, P615; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CLURMAN BE, 1988, CELLULAR ONCOGENE AC, P55; CORCORAN LM, 1984, CELL, V37, P113, DOI 10.1016/0092-8674(84)90306-4; CORY S, 1985, EMBO J, V4, P675, DOI 10.1002/j.1460-2075.1985.tb03682.x; CROUSE GF, 1982, J BIOL CHEM, V257, P7887; CUYPERS HT, 1984, CELL, V37, P141; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; FAHRLANDER PD, 1985, P NATL ACAD SCI USA, V82, P3746, DOI 10.1073/pnas.82.11.3746; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GRAHAM M, 1985, NATURE, V314, P740, DOI 10.1038/314740a0; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; KAKKIS E, 1988, NUCLEIC ACIDS RES, V16, P77, DOI 10.1093/nar/16.1.77; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KEATH EJ, 1984, CELL, V37, P521, DOI 10.1016/0092-8674(84)90382-9; KRAFT R, 1988, BIOTECHNIQUES, V6, P554; LAIMINS LA, 1984, J VIROL, V49, P183, DOI 10.1128/JVI.49.1.183-189.1984; MARCU KB, 1983, P NATL ACAD SCI-BIOL, V80, P519, DOI 10.1073/pnas.80.2.519; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; MUSHINSKI JF, 1988, CELLULAR ONCOGENE AC, P181; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; OHNO S, 1991, INT J CANCER, V49, P102, DOI 10.1002/ijc.2910490119; OHNO S, 1984, J EXP MED, V159, P1762, DOI 10.1084/jem.159.6.1762; PAYNE GS, 1982, NATURE, V295, P209, DOI 10.1038/295209a0; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; POTTER M, 1990, CARCINOGENESIS, V11, P1, DOI 10.1093/carcin/11.1.1; POTTER M, 1987, SCIENCE, V235, P787, DOI 10.1126/science.3810165; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; REICIN A, 1986, MOL CELL BIOL, V6, P4088, DOI 10.1128/MCB.6.11.4088; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SKALKA AM, 1988, GENETIC RECOMBINATIO, P701; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; SRINIVASAN A, 1984, SCIENCE, V233, P286; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WEISSINGER EM, 1991, P NATL ACAD SCI USA, V88, P8735, DOI 10.1073/pnas.88.19.8735; WIENER F, 1984, P NATL ACAD SCI-BIOL, V81, P1159, DOI 10.1073/pnas.81.4.1159; WIENER F, 1984, J EXP MED, V159, P276, DOI 10.1084/jem.159.1.276; WIESLANDER L, 1979, ANAL BIOCHEM, V98, P305, DOI 10.1016/0003-2697(79)90145-3; YANG JQ, 1985, EMBO J, V4, P1441, DOI 10.1002/j.1460-2075.1985.tb03800.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; 1972, J HERED, V63, P69	53	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3111	3121						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414513				2022-12-28	WOS:A1993MC09300028
J	TOMINAGA, O; HAMELIN, R; TROUVAT, V; SALMON, RJ; LESEC, G; THOMAS, G; REMVIKOS, Y				TOMINAGA, O; HAMELIN, R; TROUVAT, V; SALMON, RJ; LESEC, G; THOMAS, G; REMVIKOS, Y			FREQUENTLY ELEVATED CONTENT OF IMMUNOCHEMICALLY DEFINED WILD-TYPE P53 PROTEIN IN COLORECTAL ADENOMAS	ONCOGENE			English	Article								Mutations of the p53 tumour-suppressor gene are considered to be rare in human colorectal adenomas, a premalignant state of the digestive tract. We have analysed a series of 32 exophytic tumours of the colon and rectum for the presence of p53 protein. In 26 of the 28 pure adenomas, the presence of significant levels of p53 proteins was established by a sensitive two-point enzyme-linked immunosorbent assay. The detectability of p53 protein was frequently limited to PAb 1801, recognizing an N-terminal epitope. Immunoblotting of the fractions captured by the monoclonal antibodies revealed that PAb 421 reacted exclusively with a 53-kDa species, whereas an additional 48-kDa band was detected after incubation with PAb 1801. In the adenomas, the mutant conformation-specific PAb 240 was always negative and no mutations were detected on exons 5-8 in three large and highly dysplastic lesions, selected for their high p53 protein content. The remaining four of the 32 tumours presented foci of cancer. Three of these were shown to contain 'mutant' PAb 240-reactive p53, and gene mutations were identified in two by denaturing gradient gel electrophoresis and sequencing of the amplified products. Intense p53 nuclear immunohistochemical staining was associated with the malignant areas. We conclude that a novel mechanism affecting the regulation of p53 protein could occur in colorectal adenomas	INST CURIE, RADIOPATHOL LAB, 26 RUE ULM, F-75231 PARIS, FRANCE; LAB ANALYSE CELLULAIRE & PATHOL, F-03200 VICHY, FRANCE; INST CURIE, GENET TUMEURS LAB, F-75231 PARIS, FRANCE; INST CURIE, DEPT CHIRURG, F-75231 PARIS, FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BARTEK J, 1990, ONCOGENE, V5, P893; BAUNOCH DA, 1992, ONCOGENE, V7, P2351; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CROOK T, 1991, ONCOGENE, V6, P873; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DEPPERT W, 1990, ONCOGENE, V5, P1701; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAMELIN R, 1993, ONCOGENE, V8, P2213; HAMMEL PR, 1991, GASTROEN CLIN BIOL, V15, P529; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LAURENTPUIG P, 1992, GASTROENTEROLOGY, V102, P1136; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LUBBERT M, 1988, J EXP MED, V167, P873, DOI 10.1084/jem.167.3.873; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PIGNATELLI M, 1992, INT J CANCER, V50, P683, DOI 10.1002/ijc.2910500503; REMVIKOS Y, 1992, BRIT J CANCER, V66, P758, DOI 10.1038/bjc.1992.352; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHIRASAWA S, 1991, CANCER RES, V51, P2874; SHOHAT O, 1987, ONCOGENE, V1, P277; STEINMEYER K, 1990, ONCOGENE, V5, P1691; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; TOMINAGA O, 1992, Critical Reviews in Oncogenesis, V3, P257; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; VANDENBERG FM, 1989, J PATHOL, V157, P193, DOI 10.1002/path.1711570304; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302	42	56	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2653	2658						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378077				2022-12-28	WOS:A1993LX34300006
J	OTTO, A; DEPPERT, W				OTTO, A; DEPPERT, W			UP-REGULATION OF MDM-2 EXPRESSION IN METH A TUMOR-CELLS TOLERATING WILD-TYPE P53	ONCOGENE			English	Article							A MOUSE CELLS; MUTANT P53; BREAST-CANCER; CYCLE CONTROL; MONOCLONAL-ANTIBODIES; ACTIVATING MUTATIONS; SUPPRESSOR GENE; GROWTH ARREST; SARCOMA-CELLS; NORMAL 3T3	Overexpression of mouse wild-type p53 (wt p53) in mouse Meth A tumor cells after transfection of wt p53 encoding vectors induced a strong growth-inhibitory response. Cells of only few of randomly selected surviving colonies contained and expressed the transfected wt p53 specific DNA. Despite expressing authentic wt p53, such cells (MethAp53wt) exhibited a similar phenotype as the parental Meth A cells. These cells overexpressed the mdm-2 (mouse double minute-2) gene, both at the RNA and at the protein level. Recently, the MDM-2 protein has been identified as a cellular target of p53, which can abolish its tumor suppressor activity. We, therefore, suggest that MDM-2 has mitigated the growth-inhibitory effect of wt p53 in MethAp53wt cells. Upregulation of mdm-2 expression in MethAp53wt cells was mediated by wt p53, as analysis of Meth A cells carrying a tsp53 (p53Val135) revealed a strict dependence of mdm-2 upregulation upon wt p53 expression. Our results propose that a balanced ratio of MDM-2 and p53 will allow cells to tolerate a limited expression of wt p53. This tolerance is not mediated by a direct inactivation of wt p53 via complex formation with MDM-2, as the majority of both MDM-2 and wt p53 in MethAp53wt cells was not complexed to each other.	UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY	Heinrich Pette Institute; University of Hamburg								AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BARTEK J, 1990, ONCOGENE, V5, P893; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN YM, 1991, ONCOGENE, V6, P1799; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DEPPERT W, 1990, ONCOGENE, V5, P1701; DEPPERT W, 1989, NATO ASI SER, P399; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEINBERG AP, 1983, ANAL BIOCHEM, V136, P6; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUKASAWA K, 1991, MOL CELL BIOL, V11, P3472, DOI 10.1128/MCB.11.7.3472; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1992, CELL, V69, P1237; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PATSCHINSKY T, 1990, ONCOGENE, V5, P1071; PATSCHINSKY T, 1992, J VIROL, V66, P3846, DOI 10.1128/JVI.66.6.3846-3859.1992; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Sambrook J, 1989, J SAMBROOK MOL CLONI; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHOHAT O, 1987, ONCOGENE, V1, P277; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; STEINMEYER K, 1990, ONCOGENE, V5, P1691; STEINMEYER K, 1988, ONCOGENE, V3, P501; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAKAHASHI T, 1992, CANCER RES, V52, P2340; WEISSKER SN, 1992, ONCOGENE, V7, P1921; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZERRAHN J, 1992, ONCOGENE, V7, P1371	65	58	58	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2591	2603						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361769				2022-12-28	WOS:A1993LT36800033
J	AVANTAGGIATI, ML; NATOLI, G; BALSANO, C; CHIRILLO, P; ARTINI, M; DEMARZIO, E; COLLEPARDO, D; LEVRERO, M				AVANTAGGIATI, ML; NATOLI, G; BALSANO, C; CHIRILLO, P; ARTINI, M; DEMARZIO, E; COLLEPARDO, D; LEVRERO, M			THE HEPATITIS-B VIRUS (HBV) PX TRANSACTIVATES THE C-FOS PROMOTER THROUGH MULTIPLE CIS-ACTING ELEMENTS	ONCOGENE			English	Article							SERUM RESPONSE ELEMENT; PROTO-ONCOGENE FOS; X-GENE PRODUCT; EPIDERMAL GROWTH-FACTOR; SIGNAL TRANSDUCTION; ENHANCER ELEMENT; 12-O-TETRADECANOYL PHORBOL-13-ACETATE; TRANSCRIPTIONAL ACTIVATION; MEDIATE INDUCTION; TRANSGENIC MICE	The hepatitis B virus (HBV) X protein (pX) stimulates transcription regulated by cis-acting elements that control many viral and cellular genes, including the c-myc and the c-fos proto-oncogenes. Using several c-fos promoter deletion mutants, we found the serum-responsive element (SRE) located at -315, the modified TPA-responsive element located at -296 (fos-AP-1 binding site, FAP) and the region spanning from nucleotide -220 to -120, which contains an NF1-like site and several stretches of sequence homologous to the AP-2 consensus binding sites, to be responsive to pX. pX does not modify the pattern of the retarded complexes bound to the SRE/FAP region which, in our system, appears to be occupied by SRE-binding factors. The activation of the SRE does not involve complex formation between SRE-binding factors and pX, it is not associated with an increase in serum response factor binding to the SRE and it does not determine changes in SRE mobility-shift pattern.	POLICLIN UMBERTO L,MED CLIN 1,I-00161 ROME,ITALY; POLICLIN UMBERTO 1,FDN ANDREA CESALPINO,I-00161 ROME,ITALY	Sapienza University Rome; University Hospital Sapienza Rome; Sapienza University Rome; University Hospital Sapienza Rome			Natoli, gioacchino/J-2100-2018; Balsano, Clara/AAK-9870-2020; Natoli, gioacchino/ABB-8679-2020; Levrero, Massimo/G-5680-2016	Balsano, Clara/0000-0002-9615-7031; Levrero, Massimo/0000-0002-4978-0875; Natoli, Gioacchino/0000-0003-0711-2411				ALEXANDRE C, 1991, ONCOGENE, V6, P543; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; BALSANO C, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P572; BALSANO C, 1991, BIOCHEM BIOPH RES CO, V176, P985, DOI 10.1016/0006-291X(91)90379-L; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BUSCHER M, 1988, ONCOGENE, V3, P301; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; Curran T, 1988, ONCOGENE HDB, P307; DEJAN A, 1986, NATURE, V322, P70; DESCHAMPS J, 1985, SCIENCE, V230, P1174, DOI 10.1126/science.3865371; FAKTOR O, 1990, ONCOGENE, V5, P867; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FISCH TM, 1989, MOL CELL BIOL, V9, P1327, DOI 10.1128/MCB.9.3.1327; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GAUTHIERROUVIERE C, 1992, ONCOGENE, V7, P363; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENE WC, 1989, IMMUNOL TODAY, V10, P272, DOI 10.1016/0167-5699(89)90141-2; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HAYES TE, 1988, GENE DEV, V2, P1713, DOI 10.1101/gad.2.12b.1713; HERRERA RE, 1989, NATURE, V340, P2083; HU KQ, 1990, P NATL ACAD SCI USA, V87, P7140, DOI 10.1073/pnas.87.18.7140; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KOIKE K, 1989, MOL BIOL MED, V6, P151; KONIG H, 1989, EMBO J, V8, P2259; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; LEVRERO M, 1990, J VIROL, V64, P3082, DOI 10.1128/JVI.64.6.3082-3086.1990; LEVRERO M, 1990, VIROLOGY, V174, P299, DOI 10.1016/0042-6822(90)90079-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RUNKEL L, 1991, MOL CELL BIOL, V11, P1270, DOI 10.1128/MCB.11.3.1270; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHALASTA G, 1990, MOL CELL BIOL, V10, P5558, DOI 10.1128/MCB.10.10.5558; SCHONTHAL A, 1989, ONCOGENE, V4, P629; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SETO E, 1988, P NATL ACAD SCI USA, V85, P8286, DOI 10.1073/pnas.85.21.8286; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TROUCHE D, 1991, J IMMUNOL, V147, P2398; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; UNGER T, 1990, EMBO J, V9, P1889, DOI 10.1002/j.1460-2075.1990.tb08315.x; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WILSTON T, NATURE, V336, P396; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; ZAHM P, 1988, ONCOGENE, V3, P169; ZHOU DX, 1990, J VIROL, V64, P4025, DOI 10.1128/JVI.64.8.4025-4028.1990	69	69	72	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1567	1574						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502480				2022-12-28	WOS:A1993LE06400020
J	HANNA, Z; JANKOWSKI, M; TREMBLAY, P; JIANG, XY; MILATOVICH, A; FRANCKE, U; JOLICOEUR, P				HANNA, Z; JANKOWSKI, M; TREMBLAY, P; JIANG, XY; MILATOVICH, A; FRANCKE, U; JOLICOEUR, P			THE VIN-1 GENE, IDENTIFIED BY PROVIRUS INSERTIONAL MUTAGENESIS, IS THE CYCLIN D2	ONCOGENE			English	Article							T(11-14) CHROMOSOME-TRANSLOCATION; INTEGRATION SITE; CELL; DNA; ONCOGENE; BREAKPOINT; LYMPHOMA; BCL-1; PHASE	The Vin-1 gene was initially identified as a gene whose expression is altered by the integration of proviruses in the Vin-1 common site of integration in retrovirus-induced rodent T-cell leukemias. We have now isolated the Vin-1 cDNA. Sequencing of the Vin-1 cDNA and Vin-1 exons revealed that the proviruses are integrated at the 5' end of the Vin-1 gene in an inverse transcriptional orientation. The sequence of the Vin-1 gene is identical to that of the recently identified G1-phase cyclin D2 gene. The human homolog of the Vin-1/cyclin D2 gene (CCND2) was mapped to chromosome 12, band p13.3, by in situ hybridization, confirming previous mapping data. Our results strongly support a role of the cyclin D2 gene in oncogenesis and thereby implicate altered cell cycle regulation in transformation.	CLIN RES INST MONTREAL, MOLEC BIOL LAB, 110 PINE AVE W, MONTREAL H2W 1R7, QUEBEC, CANADA; STANFORD UNIV, MED CTR, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, DEPT GENET, STANFORD, CA 94305 USA; UNIV MONTREAL, DEPT MICROBIOL & IMMUNOL, MONTREAL H3C 3J7, QUEBEC, CANADA; MCGILL UNIV, DEPT EXPTL MED, MONTREAL H3G 1A4, PQ, CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Howard Hughes Medical Institute; Stanford University; Stanford University; Universite de Montreal; McGill University				Jiang, Xiaoyan/0000-0002-8974-7340	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000298] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00298] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ERIKSON J, 1984, P NATL ACAD SCI-BIOL, V81, P4144, DOI 10.1073/pnas.81.13.4144; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KIYOKAWA H, 1992, P NATL ACAD SCI USA, V89, P2444, DOI 10.1073/pnas.89.6.2444; Kung H J, 1991, Curr Top Microbiol Immunol, V171, P1; LAMMIE GA, 1991, ONCOGENE, V6, P439; Maniatis T., 1982, MOL CLONING; MATSUSHIME H, 1991, COLD SPRING HARB SYM, V56, P69; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MILATOVICH A, 1991, GENOMICS, V11, P1040, DOI 10.1016/0888-7543(91)90030-I; MITELMAN F, 1988, CATALOG CHROMOSOME A, P515; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POIRIER Y, 1988, J VIROL, V62, P3985, DOI 10.1128/JVI.62.11.3985-3992.1988; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBUYA H, 1992, JCELL, V70, P57; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TREMBLAY PJ, 1992, J VIROL, V66, P1344, DOI 10.1128/JVI.66.3.1344-1353.1992; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; VILLEMUR R, 1987, MOL CELL BIOL, V7, P512, DOI 10.1128/MCB.7.1.512; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; YUNIS JJ, 1976, SCIENCE, V191, P1268, DOI 10.1126/science.1257746	34	78	80	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1993	8	6					1661	1666						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502486				2022-12-28	WOS:A1993LE06400030
J	HAWTHORN, LA; CHAPMAN, R; OSCIER, D; COWELL, JK				HAWTHORN, LA; CHAPMAN, R; OSCIER, D; COWELL, JK			THE CONSISTENT 13Q14 TRANSLOCATION BREAKPOINT SEEN IN CHRONIC B-CELL LEUKEMIA (BCLL) INVOLVES DELETION OF THE D13S25 LOCUS WHICH LIES DISTAL TO THE RETINOBLASTOMA PREDISPOSITION GENE	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; MOLECULAR DEFINITION; CHROMOSOME-13; ABNORMALITIES; HYBRID	Structural rearrangements involving chromosome 13 are frequently seen in B-cell chronic lymphocytic leukaemia. The presence of reciprocal translocations involving 13q14 in 10-15% of cases pinpoints the location of a gene important in leukaemogenesis. In order to characterise the exact location of the 13q14 breakpoint, somatic cell hybrids were constructed between mouse 3T3 cells and leukaemic cells from 5 patients with translocations involving chromosome 13. Hybrid pairs were isolated which carried either of the two derivative chromosomes carrying subsections of 13 and the position of the breakpoint investigated using a series of probes along the length of the chromosome. In all cases the translocation breakpoint lay distal to the 13q14.1 breakpoint region associated with rhabdomyosarcoma tumours and proximal to the D13S31 locus which lies in 13q14.3. In three translocations the RB1 gene was deleted as a result of the translocation but in at least one other case the BCLL breakpoint did not involve the RB1 gene, which consistently cosegregated in hybrids carrying other proximal markers. The D13S25 probe, which lies between RB1 and D13S31, however, was deleted in the translocation retaining RB1. It appears therefore that deletion of a gene(s) in this 2Mbp region is a critical event in some cases of BCLL tumorigenesis.	INST CHILD HLTH,ONCOL GRP,ICRF,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND; ROYAL BOURNEMOUTH HOSP,DEPT HAEMATOL,BOURNEMOUTH BH7 7DW,ENGLAND	University of London; University College London				Hawthorn, Lesleyann/0000-0001-8179-0937; Cowell, John/0000-0002-2079-5950				ABBOTT C, 1991, GENOMICS, V9, P73, DOI 10.1016/0888-7543(91)90222-Z; BOWCOCK AM, 1991, GENOMICS, V11, P517, DOI 10.1016/0888-7543(91)90058-M; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; COWELL JK, 1987, BRIT J CANCER, V55, P661, DOI 10.1038/bjc.1987.135; COWELL JK, 1989, CYTOGENET CELL GENET, V52, P1, DOI 10.1159/000132827; COWELL JK, 1992, ANN ONCOL, V3, P693, DOI 10.1093/oxfordjournals.annonc.a058319; COWELL JK, 1992, HUMAN CYTOGENETICS P, P202; FITCHETT M, 1987, CANCER GENET CYTOGEN, V24, P143, DOI 10.1016/0165-4608(87)90091-4; HOGG A, 1992, ONCOGENE, V7, P1444; JULIUSSON G, 1991, LEUKEMIA LYMPHOMA, V5, P21, DOI 10.3109/10428199109103374; JULIUSSON G, 1990, CANCER GENET CYTOGEN, V45, P143, DOI 10.1016/0165-4608(90)90079-P; JULIUSSON G, 1990, NEW ENGL J MED, V323, P720, DOI 10.1056/NEJM199009133231105; LUI Y, 1992, GENES CHROMS CANCER, V45, P250; MICHALSKI AJ, 1992, ONCOGENE, V7, P1595; MITCHELL CD, 1991, ONCOGENE, V6, P89; MITCHELL CD, 1989, ONCOGENE, V4, P253; MORRIS CM, 1991, GENE CHROMOSOME CANC, V3, P455, DOI 10.1002/gcc.2870030607; NICHOLS J, 1992, BLOOD, V80, P2953; OSCIER D, 1990, BLOOD, V76, P241; PETERSON LC, 1992, GENE CHROMOSOME CANC, V4, P273, DOI 10.1002/gcc.2870040402; Sambrook J, 1989, COLD SPRING HARBOR L, V3	21	78	79	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1415	1419						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502470				2022-12-28	WOS:A1993LE06400003
J	STROBL, LJ; KOHLHUBER, F; MAUTNER, J; POLACK, A; EICK, D				STROBL, LJ; KOHLHUBER, F; MAUTNER, J; POLACK, A; EICK, D			ABSENCE OF A PAUSED TRANSCRIPTION COMPLEX FROM THE C-MYC P2-PROMOTER OF THE TRANSLOCATION CHROMOSOME IN BURKITTS-LYMPHOMA CELLS - IMPLICATION FOR THE C-MYC P1/P2 PROMOTER SHIFT	ONCOGENE			English	Article							RNA-POLYMERASE-II; EPSTEIN-BARR-VIRUS; 1ST EXON; B-CELL; STRUCTURAL ALTERATIONS; VARIANT TRANSLOCATION; CHROMATIN STRUCTURE; SOMATIC MUTATION; HL60 CELLS; GENE	We have shown recently that pausing of RNA polymerase II (pol II) at the transcription start site regulates expression from the P2 promoter of the proto-oncogene c-myc. RNAs initiated at the P2 promoter usually contribute > 80% to steady-state c-myc RNA levels in normal cells. In Burkitt's lymphoma (BL) cells c-myc is chromosomally translocated to an immunoglobulin (1g) gene and preferentially transcribed from the upstream P1 promoter. We have studied the activity of c-myc promoters in two BL cell lines with high expression of P1 RNA. Kinetic nuclear run-on experiments show that the initiation rate at the c-myc P1 promoter in BL2 and BL60 cells is not increased compared with control BJAB cells, whereas the number of paused polymerases at the P2 promoter is greatly diminished. The translocation c-myc gene of BL60 cells was cloned and stably transfected into the BL cell line Raji. The transfected c-myc gene regained the ability to form a paused transcription complex at the c-myc P2 promoter. The data suggest that a paused polymerase at the c-myc P2 promoter impedes transcription from the upstream P1 promoter on a normal c-myc gene. The c-myc gene on the translocation chromosome in BL cells has lost the ability to retain pol II at the P2 promoter, probably by interaction with elements of the adjacent Ig gene locus.	FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT, INST KLIN MOLEK BIOL & TUMORGENET, MARCHIONINISTR 25, D-81377 MUNICH, GERMANY				Strobl, Lothar J/M-7357-2014	Strobl, Lothar J/0000-0001-8389-1862				ALLEN RW, 1987, J BIOL CHEM, V262, P649; APEL TW, 1992, ONCOGENE, V7, P1267; ASSELIN C, 1989, ONCOGENE, V4, P549; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENGAL E, 1989, J BIOL CHEM, V264, P18926; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CHUNG J, 1987, CELL, V51, P1001, DOI 10.1016/0092-8674(87)90586-1; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DENNY CT, 1985, MOL CELL BIOL, V5, P3199, DOI 10.1128/MCB.5.11.3199; DEUSCHLE U, 1990, SCIENCE, V248, P480, DOI 10.1126/science.2158670; DYSON PJ, 1985, EMBO J, V4, P2885, DOI 10.1002/j.1460-2075.1985.tb04018.x; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; EICK D, 1988, ONCOGENE, V3, P397; EICK D, 1990, ONCOGENE, V5, P1397; FLORES O, 1989, J BIOL CHEM, V264, P8913; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALUSKA FG, 1986, NATURE, V324, P158, DOI 10.1038/324158a0; HARTL P, 1987, MOL CELL BIOL, V7, P2037, DOI 10.1128/MCB.7.6.2037; HAYDAY AC, 1984, NATURE, V307, P334, DOI 10.1038/307334a0; HENGLEIN B, 1989, MOL CELL BIOL, V9, P2105, DOI 10.1128/MCB.9.5.2105; HOROWITZ H, 1982, NUCLEIC ACIDS RES, V10, P5447, DOI 10.1093/nar/10.18.5447; JOOS S, 1992, HUM MOL GENET, V1, P625, DOI 10.1093/hmg/1.8.625; KEPHART DD, 1992, MOL CELL BIOL, V12, P2067, DOI 10.1128/MCB.12.5.2067; KLEIN G, 1974, P NATL ACAD SCI USA, V71, P3283, DOI 10.1073/pnas.71.8.3283; KOHLHUBER F, 1993, IN PRESS ONCOGENE; KRUGER W, 1987, J MOL BIOL, V195, P31, DOI 10.1016/0022-2836(87)90325-1; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; LACY J, 1987, P NATL ACAD SCI USA, V84, P5838, DOI 10.1073/pnas.84.16.5838; LEE HS, 1992, GENE DEV, V6, P284, DOI 10.1101/gad.6.2.284; Lenoir G M, 1985, IARC Sci Publ, P309; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MENGLEGAW L, 1987, EMBO J, V6, P1959, DOI 10.1002/j.1460-2075.1987.tb02458.x; MEULIA T, 1992, MOL CELL BIOL, V12, P4590, DOI 10.1128/MCB.12.10.4590; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; NISHIKURA K, 1985, P NATL ACAD SCI USA, V82, P2900, DOI 10.1073/pnas.82.9.2900; PARKER CS, 1984, CELL, V37, P273, DOI 10.1016/0092-8674(84)90323-4; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; PLET A, 1992, ONCOGENE, V7, P1847; POLACK A, 1991, ONCOGENE, V6, P2033; POLACK A, 1987, EMBO J, V6, P2959, DOI 10.1002/j.1460-2075.1987.tb02601.x; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RAY R, 1991, MOL CELL BIOL, V11, P2154, DOI 10.1128/MCB.11.4.2154; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1989, J BIOL CHEM, V264, P10799; RICHMAN A, 1989, MOL CELL BIOL, V9, P4962, DOI 10.1128/MCB.9.11.4962; RICHMAN A, 1989, SCIENCE, V246, P494, DOI 10.1126/science.2683072; ROBERTS S, 1992, GENE DEV, V6, P1562, DOI 10.1101/gad.6.8.1562; ROBERTS S, 1992, EMBO J, V11, P1085, DOI 10.1002/j.1460-2075.1992.tb05147.x; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHOWE LC, 1987, P NATL ACAD SCI USA, V84, P2824, DOI 10.1073/pnas.84.9.2824; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STEVENS A, 1989, BIOCHEM BIOPH RES CO, V159, P508, DOI 10.1016/0006-291X(89)90022-3; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; SUN LK, 1986, NUCLEIC ACIDS RES, V14, P4037, DOI 10.1093/nar/14.10.4037; SUSSMAN DJ, 1991, NUCLEIC ACIDS RES, V19, P5045, DOI 10.1093/nar/19.18.5045; SZAJNERT MF, 1987, NUCLEIC ACIDS RES, V15, P4553, DOI 10.1093/nar/15.11.4553; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WANG AM, 1985, SCIENCE, V228, P149, DOI 10.1126/science.3856324; WIMAN KG, 1984, P NATL ACAD SCI-BIOL, V81, P6798, DOI 10.1073/pnas.81.21.6798; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510; ZEIDLER R, 1992, THESIS L MAXIMILIANS; ZIMBERSTROBL U, 1991, J VIROL, V65, P415, DOI 10.1128/JVI.65.1.415-423.1991	82	35	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1993	8	6					1437	1447						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502472				2022-12-28	WOS:A1993LE06400006
J	PALMERO, I; HOLDER, A; SINCLAIR, AJ; DICKSON, C; PETERS, G				PALMERO, I; HOLDER, A; SINCLAIR, AJ; DICKSON, C; PETERS, G			CYCLIN-D1 AND CYCLIN-D2 ARE DIFFERENTIALLY EXPRESSED IN HUMAN B-LYMPHOID CELL-LINES	ONCOGENE			English	Article							EPSTEIN-BARR VIRUS; T(11-14) CHROMOSOME-TRANSLOCATION; BURKITTS-LYMPHOMA; LYMPHOCYTIC LYMPHOMA; CENTROCYTIC LYMPHOMA; CANDIDATE ONCOGENE; MOLECULAR-CLONING; BCL-1 LOCUS; GENE; DNA	The cyclin D1 gene can be transcriptionally activated in lymphoid tumours as a result of chromosomal rearrangements but is normally silent in B and T lymphocytes. By isolating cyclin D1-related cDNAs from a B-lymphoid cell tine, we identified clones that contain the coding sequences of human cyclin D2. The predicted 289 amino acid protein shares 63% identity with human cyclin D1. Although cyclin D2 transcripts were detected in many lymphoid cell lines, it was not ubiquitously expressed and there was no apparent correlation with cyclin D1 levels. For example, two B-cell leukaemia lines, JVM-2 and Karpas 620, both of which have 11q13 translocations and express cyclin D1, contained markedly different amounts of cyclin D2. An obvious distinction between these cells is that the JVM-2 line, which expresses high levels of cyclin D2, was immortalized by Epstein-Barr virus (EBV). We subsequently found that cyclin D2 is consistently expressed in group III Burkitt's lymphoma (BL) and in lymphoblastoid cell lines immortalized by EBV, but not in group I BLs, in which expression of the EBV genome is more restricted. The data imply that the D-type cyclins may have non-overlapping functions at specific stages of lymphocyte differentiation and that the expression of cyclin D2 may be influenced, directly or indirectly, by EBV.	IMPERIAL CANC RES FUND, 44 LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND; ST MARYS HOSP, SCH MED, LUDWIG INST CANC RES, LONDON W2 1PG, ENGLAND	Cancer Research UK; Imperial College London; Ludwig Institute for Cancer Research			Palmero, Ignacio/B-4346-2013	Sinclair, Alison/0000-0001-8510-8691				ALTIOK E, 1992, P NATL ACAD SCI USA, V89, P905, DOI 10.1073/pnas.89.3.905; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; BODESCOT M, 1987, J VIROL, V61, P3424, DOI 10.1128/JVI.61.11.3424-3430.1987; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMENTS GB, 1975, INT J CANCER, V16, P125, DOI 10.1002/ijc.2910160114; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; GREGORY CD, 1988, J EXP MED, V167, P1811, DOI 10.1084/jem.167.6.1811; HINUMA Y, 1967, P SOC EXP BIOL MED, V124, P107; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KIYOKAWA H, 1992, P NATL ACAD SCI USA, V89, P2444, DOI 10.1073/pnas.89.6.2444; KLEIN G, 1975, INTERVIROLOGY, V5, P319, DOI 10.1159/000149930; KLEIN G, 1989, CELL, V58, P5, DOI 10.1016/0092-8674(89)90394-2; KODURU PRK, 1989, ONCOGENE, V4, P929; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAMMIE GA, 1992, ONCOGENE, V7, P2381; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; Lenoir G M, 1985, IARC Sci Publ, P309; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEDEIROS LJ, 1990, BLOOD, V76, P2086; MEEKER TC, 1989, BLOOD, V74, P1801; MELO JV, 1986, INT J CANCER, V38, P531, DOI 10.1002/ijc.2910380413; MENEZES J, 1975, BIOMEDICINE, V22, P276; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NACHEVA E, 1990, BRIT J HAEMATOL, V74, P70, DOI 10.1111/j.1365-2141.1990.tb02540.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; RABBITTS PH, 1988, ONCOGENE, V3, P99; RIMOKH R, 1990, GENE CHROMOSOME CANC, V2, P223, DOI 10.1002/gcc.2870020310; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUURING E, 1992, ONCOGENE, V7, P355; SETO M, 1992, ONCOGENE, V7, P1401; SHOWE LC, 1987, ANNU REV IMMUNOL, V5, P253, DOI 10.1146/annurev.iy.05.040187.001345; TAKADA K, 1989, J VIROL, V63, P445, DOI 10.1128/JVI.63.1.445-449.1989; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; WILLIAMS ME, 1991, BLOOD, V78, P493; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; Xiong Y, 1991, Curr Biol, V1, P362, DOI 10.1016/0960-9822(91)90193-Z; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	55	107	111	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1993	8	4					1049	1054						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455931				2022-12-28	WOS:A1993KT22000029
J	GILLET, G; MICHEL, D; CRISANTI, P; GUERIN, M; HERAULT, Y; PESSAC, B; CALOTHY, G; BRUN, G; VOLOVITCH, M				GILLET, G; MICHEL, D; CRISANTI, P; GUERIN, M; HERAULT, Y; PESSAC, B; CALOTHY, G; BRUN, G; VOLOVITCH, M			SERUM FACTORS AND V-SRC CONTROL 2 COMPLEMENTARY MITOGENIC PATHWAYS IN QUAIL NEURORETINAL CELLS IN CULTURE	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; EPIDERMAL GROWTH-FACTOR; AMINO-ACID-SEQUENCES; PROTEIN GENES RPS12; TYROSINE KINASES; C-JUN; PLATELET PROTEIN; RAT FIBROBLASTS; INDUCIBLE GENE; TRANSFORMATION	Quail neuroretinal cells (QNR cells) from 7-day-old embryos do not proliferate even in the presence of 8% fetal calf serum. After infection by the Rous sarcoma virus (RSV) they proliferate actively and exhibit a transformed phenotype; this effect is mediated by the oncoprotein pp60v-src. Secondary cultures infected by the thermosensitive strain tsNY68 of RSV are blocked in G0 either by thermal inactivation of pp60v-src at 41.5-degrees-C or by serum deprivation at the permissive temperature (36.5-degrees-C). Cell division is reinduced either by pp60v-src thermal renaturation or by subsequent serum addition. Our results indicate that v-src and serum control two synergic pathways leading to G0/G1 transition in QNR cells. In order to characterize genes related to the mitogenic and transforming effects of v-src in nerve cells, we have constructed a cDNA library from QNR cells transformed by tsNY68. We report the properties of five molecular clones isolated by differential screening of this library. Unlike immediate-early genes like c-fos, they are induced in mid and late G1. Four of them correspond to unknown mRNAs and the last one codes for nucleolin. This set of v-src-regulated genes is likely to code for functions deficient in terminally differentiated QNR cells and necessary for the progression in G1.	CNRS,CTR BIOL CELLULAIRE,F-94205 IVRY,FRANCE; INST CURIE,F-91405 ORSAY,FRANCE; INST CURIE,BIOCHIM LAB,F-75231 PARIS 05,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	GILLET, G (corresponding author), ENS LYON,BIOL MOLEC & CELLULAIRE LAB,CNRS,UMR 49,46 ALLEE ITALIE,F-69364 LYON,FRANCE.		gillet, germain/A-9095-2013; Herault, Yann/B-5500-2012	Herault, Yann/0000-0001-7049-6900; Volovitch, Michel/0000-0002-7488-764X; GILLET, Germain/0000-0002-1514-327X				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BELL SM, 1990, J BIOL CHEM, V265, P1333; BRUN G, 1989, NUCLEIC ACIDS RES, V17, P6393, DOI 10.1093/nar/17.15.6393; CALOTHY G, 1980, COLD SPRING HARB SYM, V44, P983, DOI 10.1101/SQB.1980.044.01.106; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; GLAICHENHAUS N, 1986, EMBO J, V5, P1261, DOI 10.1002/j.1460-2075.1986.tb04355.x; GOLDEN A, 1988, ONCOGENE HDB, P149; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAMAGUCHI M, 1990, MOL CELL BIOL, V10, P830, DOI 10.1128/MCB.10.2.830; HERAULT Y, 1992, NUCLEIC ACIDS RES, V20, P6377, DOI 10.1093/nar/20.23.6377; HERAULT Y, 1991, NUCLEIC ACIDS RES, V19, P4001, DOI 10.1093/nar/19.14.4001; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JAHNER D, 1991, ONCOGENE, V6, P1259; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; Karin M, 1991, CURR OPIN CELL BIOL, V3, P467, DOI 10.1016/0955-0674(91)90075-A; KAWAI S, 1971, VIROLOGY, V46, P470, DOI 10.1016/0042-6822(71)90047-X; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MICHEL D, 1989, ONCOGENE RES, V4, P127; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; PESSAC B, 1983, NATURE, V302, P616, DOI 10.1038/302616a0; PESSAC B, 1983, BRAIN RES, V275, P53, DOI 10.1016/0006-8993(83)90416-X; PESSAC B, 1974, SCIENCE, V185, P709, DOI 10.1126/science.185.4152.709; PINES J, 1990, New Biologist, V2, P389; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; REED JC, 1991, CELL GROWTH DIFFER, V2, P231; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; RYAZANOV A G, 1990, New Biologist, V2, P843; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; Sambrook J, 1989, MOL CLONING LABORATO; SEFTON BM, 1980, J VIROL, V33, P220, DOI 10.1128/JVI.33.1.220-229.1980; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SRIVASTAVA M, 1990, J BIOL CHEM, V265, P14922; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; VIK TA, 1990, P NATL ACAD SCI USA, V87, P2685, DOI 10.1073/pnas.87.7.2685; WEHLAM MJ, 1990, ONCOGENE, V5, P161; WHITE MK, 1990, MOL CELL BIOL, V10, P1301, DOI 10.1128/MCB.10.4.1301; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	48	34	34	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					565	574						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437841				2022-12-28	WOS:A1993KN00800006
J	ZIEGLER, SF; BIRD, TA; SCHNERINGER, JA; SCHOOLEY, KA; BAUM, PR				ZIEGLER, SF; BIRD, TA; SCHNERINGER, JA; SCHOOLEY, KA; BAUM, PR			MOLECULAR-CLONING AND CHARACTERIZATION OF A NOVEL RECEPTOR PROTEIN TYROSINE KINASE FROM HUMAN PLACENTA	ONCOGENE			English	Article							EGF-LIKE REPEATS; LEUKEMIA-CELLS; GENE-PRODUCT; DOMAINS; ENCODES; FAMILY; NOTCH; IMMUNOGLOBULIN; FIBRONECTIN; HOMOLOGY	Using a polymerase chain reaction-based approach we have isolated and characterized a cDNA (HPK-6) from human placental RNA encoding a novel receptor protein tvrosine kinase. This receptor tyrosine kinase has a unique extracellular domain, with an immunoglobulin-like domain at the amino terminus followed by three EGF-like cysteine repeats and three fibronectin type III repeats, giving the HPK-6 gene extracellular domain a novel combination of structural motifs. A comparison of the HPK-6 sequence with other receptor tyrosine kinases shows that the HPK-6 gene is the human homolog of the murine tek gene and very closely related to the recently described receptor tyrosine kinase tie. The HPK-6 gene is expressed predominantly in placenta and lung, with a lower level in umbilical vein endothelial cells, brain and kidney. The HPK-6 cDNA, when transfected into COS-7 cells, encodes a 140-kDa protein with in vitro kinase activity.			ZIEGLER, SF (corresponding author), IMMUNEX CORP,51 UNIV ST,SEATTLE,WA 98101, USA.							APRELIKOVA O, 1992, CANCER RES, V52, P746; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; CHAN J, 1991, ONCOGENE, V6, P1057; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIS C G, 1990, New Biologist, V2, P410; DUMONT DJ, 1992, ONCOGENE, V7, P1471; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; KITAGAWA T, 1976, J BIOCHEM-TOKYO, V79, P233, DOI 10.1093/oxfordjournals.jbchem.a131053; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; RESCIGNO J, 1991, ONCOGENE, V6, P1909; SASAKI M, 1988, J BIOL CHEM, V263, P1653; SCHROEDER HW, 1987, SCIENCE, V238, P791, DOI 10.1126/science.3118465; SIEGELMAN MH, 1990, CELL, V61, P611, DOI 10.1016/0092-8674(90)90473-R; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TERMAN BI, 1991, ONCOGENE, V6, P1677; ULLRICH A, 1990, CELL, V61, P243; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	35	95	108	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					663	670						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8382358				2022-12-28	WOS:A1993KN00800017
J	PUISIEUX, A; PONCHEL, F; OZTURK, M				PUISIEUX, A; PONCHEL, F; OZTURK, M			P53 AS A GROWTH SUPPRESSOR GENE IN HBV-RELATED HEPATOCELLULAR-CARCINOMA CELLS	ONCOGENE			English	Note							ANTIGEN; MUTATION; PROTEIN; ALLELES; LIVER	Mutations of the p53 detected in human hepatocellular carcinomas suggest that its inactivation is a critical step in hepatocellular carcinogenesis. In order to test whether the expression of p53 is compatible with the transformed phenotype of hepatoma cells, we transfected Hep 3B cell line with p53 expression vectors. This cell line, which contains integrated hepatitis B virus sequences, is a good model to study whether the wild-type p53 can function as a tumour suppressor gene in virus-related hepatocellular carcinoma. Wild-type and mutant p53 (Ala143)-expression vectors containing a neo(R) gene were used. The number of antibiotic-resistant colonies was six times lower after transfection with wild-type p53 vector as compared to the mutant vector. As measured by a specific radioimmunoassay, six of eight (75%) colonies randomly selected after mutant p53 transfections expressed the transfected mutant p53 protein. In contrast, out of eight colonies from wild-type p53-transfections, none expressed detectable p53 protein. The absence of p53 protein was due to the selective deletion of transfected wild-type p53 cDNA sequences. These studies demonstrate that the growth of hepatocellular carcinoma cells is not compatible with the expression of wild-type p53. Therefore, p53 should be considered as a tumour suppressor gene in hepatocytes.	CTR LEON BERARD,ONCOL MOLEC LAB,F-69373 LYON,FRANCE; MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA	UNICANCER; Centre Leon Berard; Harvard University; Massachusetts General Hospital			OZTURK, MEHMET/AAS-7241-2021; ozturk, mehmet/G-3330-2014	OZTURK, MEHMET/0000-0002-6092-9706; PUISIEUX, Alain/0000-0002-9938-3798	NATIONAL CANCER INSTITUTE [R01CA054567, R29CA049832] Funding Source: NIH RePORTER; NCI NIH HHS [CA-49832, CA-54567] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ASUBEL FM, 1991, CURRENT PROTOCOLS MO; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CASEY G, 1991, ONCOGENE, V6, P1791; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HOSONO S, 1991, ONCOGENE, V6, P237; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; ISAACS WB, 1991, CANCER RES, V51, P4716; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; MORGAN RA, 1990, HUM GENE THER, V1, P135, DOI 10.1089/hum.1990.1.2-135; MURAKAMI Y, 1991, CANCER RES, V51, P5520; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; PUISIEUX A, 1991, CANCER RES, V51, P6185; ROBINSON WS, 1990, J MED VIROL, V31, P18, DOI 10.1002/jmv.1890310106; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	21	38	38	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					487	490						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8381223				2022-12-28	WOS:A1993KN00600028
J	KELMAN, Z; SIMONCHAZOTTES, D; GUENET, JL; YARDEN, Y				KELMAN, Z; SIMONCHAZOTTES, D; GUENET, JL; YARDEN, Y			THE MURINE VIK GENE (CHROMOSOME-9) ENCODES A PUTATIVE RECEPTOR WITH UNIQUE PROTEIN-KINASE MOTIFS	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; NUCLEOSIDE DIPHOSPHATE KINASE; TYROSINE KINASE; DICTYOSTELIUM-DISCOIDEUM; CONSERVED FEATURES; SEQUENCE HOMOLOGY; CATALYTIC DOMAIN; MESSENGER-RNAS; SERINE KINASE; FAMILY	Receptor tyrosine kinases are involved in the regulation of cell growth and may play a central role in embryonic development. We recently developed a polymerase chain reaction (PCR)-based gene cloning procedure that allows selective isolation of genes that encode novel transmembrane tyrosine kinases in tissues of embryonic origin. By employing this protocol on mRNA from a 12.5 day post-coitum mouse placenta, we identified a gene for a putative receptor protein kinase. The deduced amino acid sequence predicts the existence of an approximately 200 amino acid long extracellular domain that shows no similarity to known proteins. The cytoplasmic portion contains a core sequence that is structurally homologous to the tyrosine kinase family. However, a few highly conserved short blocks of sequences, shared by all protein kinases, display variations in the isolated gene. These include the glycine-rich block at the nucleotide-binding cleft and the Asp-Phe-Gly triplet at the substrate recognition site. On the basis of these variations, we named the gene vik for variant in the kinase. Northern analysis revealed two widely expressed transcripts of vik with molecular weights of 3 and 2.5 kb. Chromosomal mapping using restriction fragment length polymorphism localized the gene to murine chromosome 9. The unique structural landmarks of vik at both the extracellular and the cytoplasmic domains suggest novel ligand as well as substrate specificity of the presumed receptor.	WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL; INST PASTEUR, UNITE GENET MAMMIFERES, F-75724 PARIS 15, FRANCE	Weizmann Institute of Science; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			YARDEN, YOSEF/K-1467-2012					AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; AVNER P, 1988, TRENDS GENET, V4, P18, DOI 10.1016/0168-9525(88)90123-0; BONHOMME F, 1979, CR ACAD SCI D NAT, V289, P545; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; BUECHLER JA, 1989, BIOCHEMISTRY-US, V28, P2065, DOI 10.1021/bi00431a015; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; CHAN J, 1991, ONCOGENE, V6, P1057; CHOU YH, 1991, P NATL ACAD SCI USA, V88, P4897, DOI 10.1073/pnas.88.11.4897; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GUENET JL, 1986, CURR TOP MICROBIOL, V127, P109; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HOGAN B, 1986, MANIPULATING MOUSE E; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Kuchler K, 1990, CURR OPIN CELL BIOL, V2, P617, DOI 10.1016/0955-0674(90)90102-K; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; Maniatis T., 1982, MOL CLONING; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MONTAGUTELLI X, 1990, J HERED, V81, P490, DOI 10.1093/oxfordjournals.jhered.a111033; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2707; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; RAZ V, 1991, ONCOGENE, V6, P753; REID HH, 1990, P NATL ACAD SCI USA, V86, P8722; ROSNET O, 1991, ONCOGENE, V6, P1641; SAFRAN A, 1990, ONCOGENE, V5, P635; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHOWS TB, 1968, SCIENCE, V160, P1356, DOI 10.1126/science.160.3834.1356; STARK KL, 1991, DEVELOPMENT, V113, P641; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; TAN JL, 1990, MOL CELL BIOL, V10, P3578, DOI 10.1128/MCB.10.7.3578; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALKER JC, 1990, NATURE, V345, P743, DOI 10.1038/345743a0; WILKS A F, 1990, Progress in Growth Factor Research, V2, P97, DOI 10.1016/0955-2235(90)90026-G; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; Yarden Y, 1991, CURR OPIN STRUC BIOL, V1, P582, DOI 10.1016/S0959-440X(05)80081-8	56	22	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1993	8	1					37	44						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380921				2022-12-28	WOS:A1993KN00500005
J	SNIJDERS, AJ; HAASE, VH; BERNARDS, A				SNIJDERS, AJ; HAASE, VH; BERNARDS, A			4 TISSUE-SPECIFIC MOUSE LTK MESSENGER-RNAS PREDICT TYROSINE KINASES THAT DIFFER UPSTREAM OF THEIR TRANSMEMBRANE SEGMENT	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM; PROTEIN; RETENTION; GENE; GLYCOPROTEIN; SIGNAL; ER; IDENTIFICATION; EXPRESSION; TRANSPORT	Two alternatively spliced mouse lymphocyte and brain ltk cDNAs predict small transmembrane tyrosine kinases that use CUG translational start codons and that differ upstream of their transmembrane segment. A recently isolated human neuroblastoma ltk cDNA, in contrast, includes a regular AUG start codon and predicts a more conventional receptor kinase with a larger N-terminal segment. This raised the suggestion that previous mouse cDNAs may have been aberrantly spliced or incomplete and questioned the significance of a recent study that localized the lymphoid ltk protein to the endoplasmic reticulum. Here we show that mice tissue-specifically express four ltk mRNAs. In addition to the two previously described lymphoid and brain mRNAs, we now describe two mRNAs from C1300 neuroblastoma cells that start with five exons which are absent from lymphoid or brain transcripts. The pair of C1300 mRNAs differ by the same alternatively spliced exon that distinguishes brain from lymphoid mRNAs and predict much larger receptor-type kinases that use regular AUG start codons. Our results also show that at least one of the larger, more conventional C1300 ltk receptors shares the endoplasmic reticulum localization of the shorter lymphoid protein.	MASSACHUSETTS GEN HOSP,CTR CANC,MOLEC GENET LAB,BLDG 149,13TH ST,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Haase, Volker Hans/AAJ-5061-2021; Haase, Volker Hans/A-6758-2013	Haase, Volker Hans/0000-0002-7051-8994				BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GABATHULER R, 1990, J CELL BIOL, V111, P1803, DOI 10.1083/jcb.111.5.1803; GREEN SA, 1992, J CELL BIOL, V117, P47, DOI 10.1083/jcb.117.1.47; HAASE VH, 1991, ONCOGENE, V6, P2319; HURTLEY SM, 1989, ANN REV CELL BIOL, V5, P227; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KROLEWSKI JJ, 1991, EMBO J, V10, P2911, DOI 10.1002/j.1460-2075.1991.tb07841.x; KROLEWSKI JJ, 1990, ONCOGENE, V5, P277; KUROKI K, 1989, MOL CELL BIOL, V9, P4459, DOI 10.1128/MCB.9.10.4459; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MARU Y, 1990, ONCOGENE RES, V5, P199; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; PAABO S, 1987, CELL, V50, P311, DOI 10.1016/0092-8674(87)90226-1; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; ROTHMAN JE, 1987, CELL, V50, P521, DOI 10.1016/0092-8674(87)90024-9; STIRZAKER SC, 1989, CELL, V56, P741, DOI 10.1016/0092-8674(89)90677-6; TORENTINO AL, 1974, J BIOL CHEM, V249, P811; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	29	15	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					27	35						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380920				2022-12-28	WOS:A1993KN00500004
J	TULCHINSKY, E; KRAMEROV, D; FORD, HL; RESHETNYAK, E; LUKANIDIN, E; ZAIN, S				TULCHINSKY, E; KRAMEROV, D; FORD, HL; RESHETNYAK, E; LUKANIDIN, E; ZAIN, S			CHARACTERIZATION OF A POSITIVE REGULATORY ELEMENT IN THE MTS1 GENE	ONCOGENE			English	Article							CALCIUM-BINDING PROTEIN; LIGATION-MEDIATED PCR; CULTURED MOUSE CELLS; 1ST INTRON; DNA METHYLATION; MESSENGER-RNAS; CD3-DELTA GENE; COLLAGEN GENE; PROMOTER; TRANSCRIPTION	The first intron of the mts1 gene, a gene that is selectively expressed in metastatic cells and in normal cells that are motile, was found to be highly homologous to the CD3delta enhancer element. Because of the homology between the CD3delta enhancer and the first intron of mts1, we analysed the first intron of the mts1 gene to determine whether it functions as a transcriptional regulatory element. Highly metastatic CSML-100 cells transfected with chloramphenicol acetyl transferase-containing plasmids demonstrated the ability of the mts1 first intron to function as a positive regulatory element. In vitro foot-printing analysis using extracts from CSML-0 cells (which express mts1 at low levels) or CSML-100 cells (which express mts1 at high levels) identified a protected 16-nucleotide element in the first intron of mts1, regardless of the extract used. However, in vivo footprinting analysis of the same region identified the protected 16-nucleotide fragment only in the mts1 intron from CSML-100 cells, not from CSML-0 cells. Differences in the methylation pattern of the mts1 gene in CSML-100 cells and CSML-0 cells are known to exist, and may in part be responsible for the mts1 footprinting differences observed in vivo from the different cell tines.	UNIV ROCHESTER,601 ELMWOOD AVE,ROCHESTER,NY 14642; MOSCOW GENE BIOL INST,MOSCOW,RUSSIA	University of Rochester; Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences			Tulchinsky, Eugene/ABD-7070-2021		NCI NIH HHS [R01 CA46635, R01-CA36432, 2-P30-CA11198] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198, R01CA036432] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, V2; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BARRACLOUGH R, 1984, NUCLEIC ACIDS RES, V12, P8097, DOI 10.1093/nar/12.21.8097; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BORNSTEIN P, 1987, P NATL ACAD SCI USA, V84, P8869, DOI 10.1073/pnas.84.24.8869; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; CALABRETTA B, 1986, J BIOL CHEM, V261, P2628; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CEDAR H, 1984, DNA METHYLATION BIOC, P147; CELANDER D, 1987, J VIROL, V61, P269, DOI 10.1128/JVI.61.2.269-275.1987; DELEON M, 1991, J NEUROSCI RES, V29, P155; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; DONATO R, 1986, CELL CALCIUM, V7, P123, DOI 10.1016/0143-4160(86)90017-5; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; FREDERICKSON RM, 1989, NUCLEIC ACIDS RES, V17, P253, DOI 10.1093/nar/17.1.253; GEORGOPOULOS K, 1990, EMBO J, V9, P109, DOI 10.1002/j.1460-2075.1990.tb08086.x; GEORGOPOULOS K, 1988, EMBO J, V7, P2401, DOI 10.1002/j.1460-2075.1988.tb03085.x; GERKE V, 1985, EMBO J, V4, P2917, DOI 10.1002/j.1460-2075.1985.tb04023.x; GLENNEY JR, 1989, J CELL BIOL, V108, P569, DOI 10.1083/jcb.108.2.569; GOTO K, 1988, J BIOCHEM-TOKYO, V103, P48, DOI 10.1093/oxfordjournals.jbchem.a122237; HORTON W, 1987, P NATL ACAD SCI USA, V84, P8864, DOI 10.1073/pnas.84.24.8864; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; KILLEN PD, 1988, J BIOL CHEM, V263, P12310; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; LAHERTY CD, 1989, J BIOL CHEM, V264, P11222; LINZER DIH, 1983, P NATL ACAD SCI-BIOL, V80, P4271, DOI 10.1073/pnas.80.14.4271; Maniatis T, 1989, DECONTAMINATION DILU; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURAKAMI T, 1990, MOL CELL BIOL, V10, P1180, DOI 10.1128/MCB.10.3.1180; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; RASSART E, 1986, J VIROL, V58, P96, DOI 10.1128/JVI.58.1.96-106.1986; REID LH, 1990, P NATL ACAD SCI USA, V87, P4299, DOI 10.1073/pnas.87.11.4299; SELIG S, 1988, EMBO J, V7, P419, DOI 10.1002/j.1460-2075.1988.tb02829.x; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; TULCHINSKY EM, 1990, GENE, V87, P219, DOI 10.1016/0378-1119(90)90305-B; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; YUTZEY KE, 1989, MOL CELL BIOL, V9, P1397, DOI 10.1128/MCB.9.4.1397	46	34	35	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					79	86						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423998				2022-12-28	WOS:A1993KN00500009
J	Sandhu, AK; Kaur, GP; Reddy, DE; Rane, NS; Athwal, RS				Sandhu, AK; Kaur, GP; Reddy, DE; Rane, NS; Athwal, RS			A gene on 6q 14-21 restores senescence to immortal ovarian tumor cells	ONCOGENE			English	Article						cellular senescence; ovarian tumor; chromosome transfer; immortal cell growth	INDEFINITE DIVISION; SUPPRESSOR GENES; FREQUENT LOSS; HETEROZYGOSITY; CHROMOSOME-6; IDENTIFICATION; EXPRESSION; CARCINOMAS; INVITRO; CANCER	We have identified a gene on 6q14-21 which restores senescence to immortal ovarian tumor cells. Single gpt tagged human chromosomes, present in mouse/human monochromosomal hybrids, were introduced into immortal human and rat ovarian tumor cells via microcell fusion. Analysis of chromosome transfer clones for cell morphology and growth properties revealed that chromosome 6 or 6q restored senescence to both human and rat ovarian tumor cells while chromosomes 10 or 14 did not affect the proliferative potential of these cells. Reversion to immortal growth concordant with loss of the donor chromosome confirmed the presence of a senescence gene on 6q. During continuous maintenance of microcell hybrids in MX medium, rare immortal revertant clones grew out of the human and rat senescent cell populations. Analysis of independent revertant clones of rat cells, for chromosome 6 markers, revealed a common deletion of chromosomal region 6q14-21 in all revertants. Restoration of senescence following introduction of a gpt tagged chromosome segment 6q13-21 into human and rat ovarian tumor cells confirmed the location of a senescence gene in this region. In contrast, introduction of a chromosome 6 lacking the region 6q14-21 did not impart senescence in these cells. Based on these results we assigned the senescence gene (SEN 6A) to region 6q14-21.	TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University								ADAMS AT, 1985, EXP CELL BIOL, V53, P181; ATHWAL RS, 1985, SOMAT CELL MOLEC GEN, V11, P177, DOI 10.1007/BF01534706; BRAVARD A, 1992, INT J CANCER, V51, P476, DOI 10.1002/ijc.2910510323; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; CLIBY W, 1993, CANCER RES, V53, P2393; Del Senno L., 1992, Human Molecular Genetics, V1, P354; EHLEN T, 1990, ONCOGENE, V5, P219; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; GODWIN AK, 1992, J NATL CANCER I, V84, P592, DOI 10.1093/jnci/84.8.592; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GUALANDI F, 1994, GENE CHROMOSOME CANC, V10, P77, DOI 10.1002/gcc.2870100202; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARPER JW, 1993, CELL, V75, P805; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; KLEIN CB, 1991, SCIENCE, V251, P796, DOI 10.1126/science.1990442; LEE JH, 1990, CANCER RES, V50, P2724; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; NEGRINI M, 1994, CANCER RES, V54, P1331; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; OSBORNE RJ, 1994, BRIT J CANCER, V69, P429, DOI 10.1038/bjc.1994.79; PARASKEVA C, 1989, INT J CANCER, V43, P743, DOI 10.1002/ijc.2910430434; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; RIMESSI P, 1994, ONCOGENE, V9, P3467; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SAITO S, 1992, CANCER RES, V52, P5815; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCHNEIDER EL, 1976, P NATL ACAD SCI USA, V73, P3584, DOI 10.1073/pnas.73.10.3584; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; TESTA JR, 1994, CANCER RES, V54, P2778; TEYSSIER JR, 1992, ANTICANCER RES, V12, P997; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; WELCH DR, 1994, ONCOGENE, V9, P255; [No title captured]	42	57	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					247	252						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570202				2022-12-28	WOS:A1996TR53800004
J	Brezden, CB; Rauth, AM				Brezden, CB; Rauth, AM			Differential cell death in immortalized and non-immortalized cells at confluency	ONCOGENE			English	Article						apoptosis; necrosis; confluency; immortalized; non-immortalized; p53-independence	P53; APOPTOSIS	Rat embryo fibroblast cells that have been immortalized by viral transfection have an altered cell cycle control. These cells have been observed to die via an apoptotic death when grown to confluency which, in at least one of the cell line pairs studied, was independent of the presence of wildtype or mutant p53. This confluency-dependent apoptotic cell death was observed in thirteen of fourteen rodent and human cell lines tested. In contrast, primary rodent and human cell strains (fibroblasts) entered a quiescent G(1)/G(0) state at confluency. Two weeks later, these non-immortalized cells underwent necrosis, not apoptosis. As the medium was not replenished during this two week period, cell necrosis was probably due to deprivation of nutrients and growth factors. These results indicate that mechanisms of cell death may differ between transformed and non-transformed cells under physiological stressed situations, such as high cell density. It may be possible to exploit these differences to increase the efficacy of chemotherapeutic compounds towards neoplastic cells.	UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON,CANADA; ONTARIO CANC INST,DIV EXPTL THERAPEUT,TORONTO,ON M4X 1K9,CANADA	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto								BOWEN ID, 1993, CELL BIOL INT, V17, P365, DOI 10.1006/cbir.1993.1075; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GANNOUNZAKI L, 1994, EXP CELL RES, V213, P375, DOI 10.1006/excr.1994.1212; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KARNOVSKY MJ, 1964, J CELL BIOL, V23, P217, DOI 10.1083/jcb.23.2.217; KASTAN MB, 1991, CANCER RES, V51, P6304; LING V, 1974, J CELL PHYSIOL, V83, P103, DOI 10.1002/jcp.1040830114; LOCK RB, 1994, CANCER RES, V54, P4933; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MIRZAYANS R, 1994, BRIT J CANCER, V68, P838; MYMRYK JS, 1994, ONCOGENE, V9, P1187; PEACOCK JW, 1994, EMBO J, V13, P1084, DOI 10.1002/j.1460-2075.1994.tb06357.x; PRICE TNC, 1994, ONCOGENE, V9, P2897; SMETS LA, 1994, ANTI-CANCER DRUG, V5, P3, DOI 10.1097/00001813-199402000-00001; TOMEI LD, 1993, P NATL ACAD SCI USA, V90, P853, DOI 10.1073/pnas.90.3.853; WYLLIE AH, 1973, J PATHOL, V111, P2552; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	24	23	23	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					201	206						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552393				2022-12-28	WOS:A1996TQ01400025
J	Connor, RJ; Pasquale, EB				Connor, RJ; Pasquale, EB			Genomic organization and alternatively processed forms of Cek5, a receptor protein-tyrosine kinase of the Eph subfamily	ONCOGENE			English	Article						exon-intron structure; alternative splicing; alternative polyadenylation; domain structure; gene family	GROWTH-FACTOR-RECEPTOR; FACTOR-I RECEPTOR; INSULIN-RECEPTOR; MESSENGER-RNA; GENE; IDENTIFICATION; EXPRESSION; EVOLUTION; ENCODES; LIGAND	The genomic organization of Cek5, a receptor tyrosine kinase of the Eph subfamily, was elucidated utilizing a strategy involving PCR amplification of Cek5 genomic DNA, Cek5 is the first Eph-related kinase for which the exon-intron structure of the entire coding region has been determined, The Cek5 gene spans over 35 kb and comprises at least 16 exons, The exon-intron structure of Cek5 can be correlated with the proposed domain structure of the Eph subfamily, with the exception of an Ig motif in the extracellular domain, Intron positions in the Cek5 gene coincide with the locations of the deletions, substitutions, or insertions that have been described in a number of Eph-related kinases. This suggests that alternative processing plays a major role in generating the structural variability observed in the Eph subfamily. Consistent with this hypothesis, analysis of the Cek5 gene indicated that: (i) a variant form of Cek5 containing an insertion in the juxtamembrane region (Cek5+) arises through the use of alternative 5' splice sites, and (ii) a soluble form of Cek5 comprising only the extracellular domain (Cek5s) may exist, which originates by alternative polyadenylation. RT-PCR analysis and RNase protection assays revealed the expression of both Cek5+ and Cek5s at various stages of chicken development.	LA JOLLA CANC RES FDN, LA JOLLA, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute					NCI NIH HHS [CA56721] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056721] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBOTT AM, 1992, J BIOL CHEM, V267, P10759; AGNES F, 1994, GENE, V145, P283, DOI 10.1016/0378-1119(94)90021-3; ANDRE C, 1992, ONCOGENE, V7, P685; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BLAKE CCF, 1985, INT REV CYTOL, V93, P149, DOI 10.1016/S0074-7696(08)61374-1; Bork P, 1992, CURR OPIN STRUC BIOL, V2, P413; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; CECCHERINI I, 1993, BIOCHEM BIOPH RES CO, V196, P1288, DOI 10.1006/bbrc.1993.2392; CHAN J, 1991, ONCOGENE, V6, P1057; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CIOSSEK T, 1995, ONCOGENE, V10, P97; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DAVIS C G, 1990, New Biologist, V2, P410; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DOOLITTLE RF, 1992, PROTEIN SCI, V1, P191; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; FEENER EP, 1993, J BIOL CHEM, V268, P11256; FLICKINGER TW, 1992, MOL CELL BIOL, V12, P883, DOI 10.1128/MCB.12.2.883; GANDINO L, 1994, J BIOL CHEM, V269, P1815; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; KIYOKAWA E, 1994, CANCER RES, V54, P3645; KORHONEN J, 1994, ONCOGENE, V9, P395; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; LEE CC, 1994, J BIOL CHEM, V269, P19457; LI Y, 1994, MOL CELL BIOL, V14, P7660, DOI 10.1128/MCB.14.11.7660; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; Moore DD, 1995, GLOB MOB SURV; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NIETO MA, 1992, DEVELOPMENT, V116, P1137; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OGRADY P, 1994, J BIOL CHEM, V269, P25193; PAJUSOLA K, 1993, ONCOGENE, V8, P2931; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1994, DEV BIOL, V163, P491, DOI 10.1006/dbio.1994.1165; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; Patthy L, 1991, CURR OPIN STRUC BIOL, V1, P351, DOI 10.1016/0959-440X(91)90033-P; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; ROGERS JH, 1989, TRENDS GENET, V5, P213, DOI 10.1016/0168-9525(89)90084-X; ROUER E, 1989, GENE, V84, P105, DOI 10.1016/0378-1119(89)90144-3; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ AS, 1993, ONCOGENE, V8, P509; SCHWARZBAUER JE, 1987, EMBO J, V6, P2573, DOI 10.1002/j.1460-2075.1987.tb02547.x; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SIEVER DA, 1994, GENE, V148, P219, DOI 10.1016/0378-1119(94)90692-0; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOANS C, 1994, ONCOGENE, V9, P3353; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; SUDHOF TC, 1985, SCIENCE, V228, P893, DOI 10.1126/science.3873704; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; VALENZUELA DM, 1995, ONCOGENE, V10, P1573; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	68	32	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2429	2438						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570195				2022-12-28	WOS:A1995TK70200028
J	Ekstrand, BC; Mansfield, TA; Bigner, SH; Fearon, ER				Ekstrand, BC; Mansfield, TA; Bigner, SH; Fearon, ER			DCC expression is altered by multiple mechanisms in brain tumors	ONCOGENE			English	Article						DCC (deleted in colorectal cancer) gene; brain tumor; tumor suppressor genes; chromosome 18q; glioblastoma; cancer genetics	MALIGNANT HUMAN GLIOMAS; CHROMOSOMAL-ABNORMALITIES; HUMAN MEDULLOBLASTOMA; COLORECTAL CANCERS; SUPPRESSOR GENES; HETEROZYGOSITY; AMPLIFICATION; ASTROCYTOMA; XENOGRAFTS; RNA	The DCC (deleted in colorectal cancer) candidate tumor suppressor gene spans greater than 1350 kilobases at chromosome 18q21.1 and encodes a transmembrane protein of unknown function. Although DCC is expressed in a number of adult tissues, its expression is highest in the brain and we have, therefore, undertaken studies to determine if DCC inactivation might contribute to tumors arising there, Decreased or absent DCC protein expression was noted in more than 50% of the thirty brain tumors studied. Although specific mutations in the DCC gene were not identified, a variety of mechanisms appeared to contribute to the altered DCC expression, including allelic loss, aberrant splicing of transcripts and allele-specific loss of transcripts. In total, the data suggest that DCC inactivation may be important in brain tumor pathogenesis.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; DUKE UNIV,SCH MED,DEPT PATHOL,DURHAM,NC 27706	Yale University; Yale University; Yale University; Duke University					NICHD NIH HHS [HD07149] Funding Source: Medline; NIGMS NIH HHS [GM07205] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIGNER SH, 1988, CANCER RES, V48, P405; BIGNER SH, 1989, CANCER GENET CYTOGEN, V40, P111, DOI 10.1016/0165-4608(89)90152-0; BIGNER SH, 1988, CANCER GENET CYTOGEN, V30, P91, DOI 10.1016/0165-4608(88)90096-9; BIGNER SH, 1990, CANCER RES, V50, P2347; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CHO KR, 1995, CURR OPIN GENET DEV, V5, P72, DOI 10.1016/S0959-437X(95)90056-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEAVER JE, 1994, CELL, V76, P1, DOI 10.1016/0092-8674(94)90165-1; COLLINS VP, 1993, FASEB J, V7, P926, DOI 10.1096/fasebj.7.10.8344489; FAULKNER KW, 1983, J PEDIATR-US, V103, P600, DOI 10.1016/S0022-3476(83)80598-8; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FUJIMOTO M, 1989, GENOMICS, V4, P210, DOI 10.1016/0888-7543(89)90302-9; FULTS D, 1990, CANCER RES, V50, P5784; GIANI C, 1994, CANCER RES, V54, P6338; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HUMPHREY PA, 1988, CANCER RES, V48, P2231; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; ILINO H, 1994, CANCER, V73, P1324; ITOH F, 1993, INT J CANCER, V53, P260, DOI 10.1002/ijc.2910530215; JAMES CD, 1988, CANCER RES, V48, P5546; JEN J, 1994, CANCER RES, V54, P6353; JOSYLN G, 1991, CELL, V66, P601; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KARLBOM AE, 1993, HUM GENET, V92, P169; KLEIHUES P, 1991, HISTOLOGICAL TYPING; KLINGELHUTZ AJ, 1995, ONCOGENE, V10, P1581; KNUDSON AG, 1993, NAT GENET, V5, P103, DOI 10.1038/ng1093-103; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KORNBLITH PL, 1987, NEUROLOGIC ONCOLOGY, P35; KRAFT R, 1988, BIOTECHNIQUES, V6, P554; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; LEON SP, 1994, NEUROSURGERY, V34, P708, DOI 10.1227/00006123-199404000-00021; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MIYAKE S, 1994, CANCER RES, V54, P3007; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; PIERCEALL WE, 1994, DEV BIOL, V166, P654, DOI 10.1006/dbio.1994.1345; PIERCEALL WE, 1994, J CELL BIOL, V124, P1017, DOI 10.1083/jcb.124.6.1017; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; RASHEED BKA, 1994, CANCER RES, V54, P1324; REALE MA, 1994, CANCER RES, V54, P4493; ROYDS JA, 1986, ACTA NEUROPATHOL, V70, P320, DOI 10.1007/BF00686091; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHECK AC, 1993, CANCER RES, V53, P5605; SCHERER JH, 1940, AM J CANCER, V40, P159; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Schold S C Jr, 1983, J Neurooncol, V1, P5; SHATKIN AJ, 1969, FUNDAMENTAL TECHNIQU, P231; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; WAINWRIGHT B, 1994, NAT GENET, V8, P3, DOI 10.1038/ng0994-3; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WIKSTRAND CJ, 1983, CANCER RES, V43, P3327	54	44	45	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2393	2402						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570191				2022-12-28	WOS:A1995TK70200024
J	BOCCO, JL; REIMUND, B; CHATTON, B; KEDINGER, C				BOCCO, JL; REIMUND, B; CHATTON, B; KEDINGER, C			RB MAY ACT AS A TRANSCRIPTIONAL COACTIVATOR IN UNDIFFERENTIATED F9 CELLS	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; EIIA EARLY PROMOTER; HUMAN MYC PROMOTER; SV40 LARGE-T; SUSCEPTIBILITY GENE; FACTOR E2F; DNA-BINDING; TRANS-ACTIVATION; ADENOVIRUS-E1A PREVENTS; MOLECULAR-CLONING	The reversible interaction of the retinoblastoma susceptibility gene product (Rb) with the cellular transcription factor E2F has recently been demonstrated. Activation of the adenovirus E2a promoter by the products of the viral E1a gene correlates with the ability of both early E1a proteins to sequester Rb, thereby releasing E2F from inactive complexes with this protein. The E2a promoter is also efficiently stimulated by a product (17.5 kDa) of the viral E4 gene. The specific interaction of this E4 protein with E2F results in the formation of complexes that bind cooperatively to the two neighboring E2F binding sites in the E2a promoter. We have previously shown that in undifferentiated F9 cells (F9EC) the E2a promoter is refractory to E2F-mediated activation by E1a, but not by E4. Using both band-shift and transfection experiments, we now demonstrate (i) that in F9EC cells the E4 product, in combination with E2F, recruits Rb into a stable multiprotein complex and (ii) that in these undifferentiated cells, as opposed to their differentiated counterpart, Rb is actively involved in the transcriptional stimulation of the E2a promoter by E4. Our results suggest that, depending on the cell state, Rb may behave either as a transcriptional activator (F9EC cells) or as a transcriptional inhibitor (differentiated F9 cells).	INST CHIM BIOL,GENET MOLEC EUCARYOTES LAB,CNRS,INSERM,U184,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			CHATTON, Bruno/R-3813-2019	Bocco, Jose Luis/0000-0002-9682-1270; CHATTON, Bruno/0000-0003-4515-7119				ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOEUF H, 1990, ONCOGENE, V5, P691; BOEUF H, 1990, P NATL ACAD SCI USA, V87, P1782, DOI 10.1073/pnas.87.5.1782; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GODING C, 1985, EMBO J, V4, P1523, DOI 10.1002/j.1460-2075.1985.tb03812.x; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HARDY S, 1989, GENE DEV, V3, P1062, DOI 10.1101/gad.3.7.1062; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; HUANG S, 1992, DNA CELL BIOL, V11, P539, DOI 10.1089/dna.1992.11.539; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P875, DOI 10.1128/MCB.4.5.875; JACKS T, 1992, NATURE, V359, P395; JALINOT P, 1987, MOL CELL BIOL, V7, P3806, DOI 10.1128/MCB.7.10.3806; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEFF T, 1984, P NATL ACAD SCI-BIOL, V81, P4381, DOI 10.1073/pnas.81.14.4381; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; MORAN E, 1991, Current Biology, V1, P281, DOI 10.1016/0960-9822(91)90084-A; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; NEILL SD, 1991, J VIROL, V65, P5364, DOI 10.1128/JVI.65.10.5364-5373.1991; NEVINS JR, 1991, TRENDS BIOCHEM SCI, V16, P435, DOI 10.1016/0968-0004(91)90171-Q; NEVINS JR, 1992, SCIENCE, V258, P424; OCONNOR RJ, 1991, NUCLEIC ACIDS RES, V19, P6579, DOI 10.1093/nar/19.23.6579; PARTRIDGE JF, 1991, EMBO J, V10, P3819, DOI 10.1002/j.1460-2075.1991.tb04951.x; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SCHONTHAL A, 1993, ONCOGENE, V8, P433; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHEW JY, 1990, CELL GROWTH DIFFER, V1, P17; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZAJCHOWSKI DA, 1987, GENE, V58, P243, DOI 10.1016/0378-1119(87)90379-9; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	83	15	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2977	2986						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414500				2022-12-28	WOS:A1993MC09300011
J	CARNAC, G; ALBAGLICURIEL, O; DESCLOZEAUX, M; VANDROMME, M; GLINEUR, C; BEGUE, A; LAUDET, V; BONNIEU, A				CARNAC, G; ALBAGLICURIEL, O; DESCLOZEAUX, M; VANDROMME, M; GLINEUR, C; BEGUE, A; LAUDET, V; BONNIEU, A			OVEREXPRESSION OF C-ERBA PROTOONCOGENE ENHANCES MYOGENIC DIFFERENTIATION	ONCOGENE			English	Article							RETINOIC ACID RECEPTORS; THYROID-HORMONE RECEPTORS; MUSCLE-SPECIFIC GENES; V-ERBA; TRANSCRIPTIONAL ACTIVATION; NUCLEAR RECEPTOR; MESSENGER-RNA; SKI ONCOGENE; MYOD1 GENE; EXPRESSION	Triiodothyronine (T3) positively regulates both the expression of the MyoD gene, a key myogenic regulator, and C2 muscle cell differentiation. To directly examine the role of its nuclear receptors in the control of myogenesis, we introduced a c-erbA expression vector into C2 muscle cells by transient or stable transfection. Our results show that c-erbA can play a potent role in the triggering of muscle terminal differentiation since its overexpression leads to: (1) a complete abrogation of the activity of the myogenesis inhibitor Ap-1 (fos/jun) transcription factor; (2) an enhanced induction of MyoD expression upon T3 treatment; (3) the acquisition by T3 of the ability to trigger both growth arrest and terminal differentiation in the presence of large amounts of serum mitogens, a property that is otherwise specific to retinoic acid (RA). Thus, c-erbA is one of the two proto-oncogenes (with c-ski) that acts as positive regulator of muscle differentiation. Furthermore, the fact that c-erbA overexpression allows T3 to largely mimic the RA effects indicates that their biological differences in the modulation of myogenic program primarily rely on the differential expression of their receptors in C2 muscle cells rather than on an intrinsic specificity of their target genes.	INRA,DIFFERENCIAT CELLULAIRE & CROISSANCE LAB,F-34060 MONTPELLIER,FRANCE; CTR RECH BIOCHIM MACROMOLEC,DEPT CELL BIOL,CNRS,INSERM,F-34033 MONTPELLIER,FRANCE; INST PASTEUR,CNRS,URA 1160,ONCOL MOLEC U186,F-59019 LILLE,FRANCE	INRAE; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			Vandromme, Marie M/N-6615-2018; Bonnieu, Anne/ABA-7182-2020; Vandromme, Marie/ABC-3003-2021; Carnac, Gilles/N-6744-2018	Carnac, Gilles/0000-0002-3518-8774; vandromme, Marie/0000-0002-5675-7999				ALBAGLICURIEL O, 1993, DIFFERENTIATION, V52, P201, DOI 10.1111/j.1432-0436.1993.tb00632.x; BEDO G, 1989, NATURE, V339, P231, DOI 10.1038/339231a0; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; CARNAC G, 1992, MOL ENDOCRINOL, V6, P1185, DOI 10.1210/me.6.8.1185; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; COLMENARES C, 1991, MOL CELL BIOL, V11, P1167, DOI 10.1128/MCB.11.2.1167; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DESBOIS C, 1991, ONCOGENE, V6, P2129; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; HERMANN T, 1991, CELL REGUL, V2, P565, DOI 10.1091/mbc.2.7.565; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KONIECZNY SF, 1989, ONCOGENE, V4, P473; KUWANO Y, 1985, J BIOCHEM-TOKYO, V97, P983, DOI 10.1093/oxfordjournals.jbchem.a135175; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LAUDET V, 1991, NUCLEIC ACIDS RES, V19, P1105, DOI 10.1093/nar/19.5.1105; LAZAR MA, 1989, P NATL ACAD SCI USA, V86, P7771, DOI 10.1073/pnas.86.20.7771; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MOORE D D, 1990, New Biologist, V2, P100; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NILSEN DA, 1983, P NATL ACAD SCI USA, V80, P5198; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLSON EN, 1991, MOL CELL BIOCHEM, V104, P7; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PAIN B, 1990, New Biologist, V2, P284; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; PINSET C, 1988, DIFFERENTIATION, V38, P28, DOI 10.1111/j.1432-0436.1988.tb00588.x; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SCHROEDER C, 1990, ONCOGENE, V5, P1445; SCHROEDER C, 1992, ONCOGENE, V7, P217; STRAHLE U, 1989, NATURE, V339, P629, DOI 10.1038/339629a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YANGYEN HF, 1991, NEW BIOL, V3, P1206; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	56	19	19	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3103	3110						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414512				2022-12-28	WOS:A1993MC09300027
J	HWANG, LY; SIEGELMAN, M; DAVIS, L; OPPENHEIMERMARKS, N; BAER, R				HWANG, LY; SIEGELMAN, M; DAVIS, L; OPPENHEIMERMARKS, N; BAER, R			EXPRESSION OF THE TAL1 PROTOONCOGENE IN CULTURED ENDOTHELIAL-CELLS AND BLOOD-VESSELS OF THE SPLEEN	ONCOGENE			English	Article							LOOP-HELIX PROTEINS; DNA-BINDING MOTIF; T-CELL; CHROMOSOME-TRANSLOCATION; ENHANCER-BINDING; GENE-EXPRESSION; LEUKEMIA; SCL; ACTIVATION; MYOD	The TALI proto-oncogene encodes a basic helix-loop-helix (bHLH) protein that has been implicated in the pathogenesis of T-cell acute lymphoblastic leukemia. Normal expression of TALI is observed in erythrocytic, megakaryocytic and mastocytic cells of the hematopoietic lineage. We now report that both RNA transcripts and polypeptide products of TALI are present in human umbilical vein endothelial cells cultured in vitro. Moreover, in situ hybridization revealed a restricted pattern of TALI expression in endothelial cells in vivo, including vessels within the white pulp and follicles of the spleen. In view of its presumptive role as a transcriptional factor, the TAL1 gene product may serve during normal development as a regulator of endothelial cell growth or differentiation.	UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,SIMMONS ARTHRIT RES CTR,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PATHOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL CANCER INSTITUTE [R01CA046593] Funding Source: NIH RePORTER; NCI NIH HHS [CA46593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; BASH RO, 1993, IN PRESS BLOOD; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BERNARD O, 1991, ONCOGENE, V6, P1477; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHEN Q, 1990, J EXP MED, V172, P1403, DOI 10.1084/jem.172.5.1403; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; CHENG JT, 1993, ONCOGENE, V8, P677; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; FUJITA T, 1983, SURV IMMUNOL RES, V2, P375; FUNK WD, 1991, MOL BIOL MED, V8, P185; GOLDFARB AN, 1992, BLOOD, V80, P2858; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; LEE ME, 1991, J BIOL CHEM, V266, P16188; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MOUTHON MA, 1993, BLOOD, V81, P647; MUELLER C, 1988, IMMUNOL REV, V103, P73, DOI 10.1111/j.1600-065X.1988.tb00750.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAMIKAWA R, 1988, SCIENCE, V242, P1684, DOI 10.1126/science.3201256; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OPPENHEIMERMARKS N, 1990, J IMMUNOL, V145, P140; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; VISVADER J, 1991, ONCOGENE, V6, P187; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416	32	68	68	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3043	3046						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414504				2022-12-28	WOS:A1993MC09300019
J	GHOSH, PK; ANDERSON, J; COHEN, N; TAKESHITA, K; ATWEH, GF; LEBOWITZ, P				GHOSH, PK; ANDERSON, J; COHEN, N; TAKESHITA, K; ATWEH, GF; LEBOWITZ, P			EXPRESSION OF THE LEUKEMIA-ASSOCIATED GENE, P18, IN NORMAL AND MALIGNANT-TISSUES - INACTIVATION OF EXPRESSION IN A PATIENT WITH CLEAVED B-CELL LYMPHOMA LEUKEMIA	ONCOGENE			English	Note							GROWTH ARREST; PHORBOL ESTER; PHOSPHOPROTEIN; DIFFERENTIATION; PHOSPHORYLATION; IDENTIFICATION; CHROMOSOME-1; CONSERVATION; STATHMIN; LIGHT	p18 is a well conserved gene coding for an 18 kDa cytosolic phosphoprotein. Although the function of p18 is unknown, it is suspected of playing a role in regulation of cell proliferation or the proliferation-differentiation switch. Here we have found p18 mRNA expression highest in testis, brain, thymus and a multipotent hematopoietic stem cell line and lowest in liver. p18 was also expressed vigorously in all but one of 85 diverse tumor cell lines and primary human malignant specimens examined. In five primary tumors, expression was substantially elevated with respect to expression in contiguous normal tissue. Expression in chronic phase chronic myelogenous leukemia cells was far greater than in normal blood cells and increased with progression of disease. In liver material, the highest level of p18 was found in a primary hepatoblastoma, a stem cell tumor, whereas a benign adenoma demonstrated very low level expression. Cells from a cleaved B cell lymphoma/leukemia failed to express p18 whereas 18 specimens from other B lymphoid malignancies, including a second cleaved cell malignancy, expressed p18 at substantial levels. These data are consistent with p18 playing a role in control of cell proliferation in at least certain tissues. The questions arise if high level p18 expression in certain malignancies may play a primary role in driving cell proliferation or, based on chromosomal localization and inactivation of p18 expression in one lymphoma, if p18 may act as a tumor suppressor.	YALE UNIV,SCH MED,HEMATOL SECT,333 CEDAR ST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,GASTROENTEROL SECT,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,CTR COMPREHENS CANC,NEW HAVEN,CT 06510; CUNY MT SINAI SCH MED,DEPT MED,HEMATOL SECT,NEW YORK,NY 10029	Yale University; Yale University; Yale University; Yale University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; BRAVERMAN R, 1986, J BIOL CHEM, V261, P14342; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COOPER HL, 1989, J IMMUNOL, V143, P956; DOYE V, 1989, J BIOL CHEM, V264, P12134; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; FERRUCCI JT, 1990, BILIARY LITHOTRIPSY, V2, P1; FEUERSTEIN N, 1984, J BIOL CHEM, V259, P2782; FONG C, 1989, P NATL ACAD SCI USA, V86, P3756; HANASH S, 1989, BLOOD S1, V74, pA347; HANASH SM, 1988, J BIOL CHEM, V263, P12813; KOPPEL J, 1990, J BIOL CHEM, V265, P3703; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MATHEW CGP, 1987, NATURE, V328, P524, DOI 10.1038/328524a0; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHUBART UK, 1989, DNA-J MOLEC CELL BIO, V8, P389, DOI 10.1089/dna.1.1989.8.389; ZHU XX, 1989, J BIOL CHEM, V264, P14556	19	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2869	2872						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8397372				2022-12-28	WOS:A1993LX34300032
J	ZHANG, W; FUNK, WD; WRIGHT, WE; SHAY, JW; DEISSEROTH, AB				ZHANG, W; FUNK, WD; WRIGHT, WE; SHAY, JW; DEISSEROTH, AB			NOVEL DNA-BINDING OF P53 MUTANTS AND THEIR ROLE IN TRANSCRIPTIONAL ACTIVATION	ONCOGENE			English	Note							WILD-TYPE P53; ACUTE MYELOGENOUS LEUKEMIA; MONOCLONAL-ANTIBODIES; GENE AMPLIFICATION; PROTEIN; EXPRESSION; CELLS; SITE; WILD-TYPE-P53; ELEMENT	The protein product of the normal p53 gene binds to the DNA p53CON element (GGACATGCCCGGGCATGTCC, Funk et al., 1992), thereby activating transcription from adjacent promoters. Two mutants, 248 (Arg-->Trp) and 281 (Asp-->Gly), failed to bind p53CON and to activate transcription. However, in contrast to previous reports that all p53 mutants fail to bind to the other p53 binding elements, two p53 mutants, 143 (Val-->Ala) and 273 (Arg-->His), retained both p53CON binding and transcriptional activation functions. A third mutant 175 (Arg-->His) bound to the p53CON but did not activate transcription. These data suggest that the DNA binding and transcriptional activation functions of p53 mutants in tumor cells are dependent on the specific missense mutations acquired in the p53 gene and the target sequences of p53 in the genome.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,BOX 24,1515 HOLCOMBE BLVD,HOUSTON,TX 77030; UNIV TEXAS,SW MED CTR DALLAS,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Shay, Jerry W/F-7878-2011		NATIONAL CANCER INSTITUTE [P01CA055164, R01CA050195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007992] Funding Source: NIH RePORTER; NCI NIH HHS [CA50195, P01 CA55164] Funding Source: Medline; NIA NIH HHS [AG07992] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARTWELL L, 1992, CELL, V71, P542; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HU GY, 1992, BRIT J HAEMATOL, V81, P489, DOI 10.1111/j.1365-2141.1992.tb02979.x; HUPP TP, 1992, CELL, V27, P875; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KOEFFLER HP, 1986, P NATL ACAD SCI USA, V83, P4035, DOI 10.1073/pnas.83.11.4035; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SOUSSI T, 1990, ONCOGENE, V5, P945; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1992, P NATL ACAD SCI USA, V89, P3952, DOI 10.1073/pnas.89.9.3952; ZHANG W, 1992, ONCOGENE, V7, P1645; ZHANG W, 1992, GENE, V117, P271, DOI 10.1016/0378-1119(92)90738-B; ZHANG W, 1993, IN PRESS CANCER RES	34	97	97	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2555	2559						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361764				2022-12-28	WOS:A1993LT36800028
J	DUTERQUECOQUILLAUD, M; NIEL, C; PLAZA, S; STEHELIN, D				DUTERQUECOQUILLAUD, M; NIEL, C; PLAZA, S; STEHELIN, D			NEW HUMAN ERG ISOFORMS GENERATED BY ALTERNATIVE SPLICING ARE TRANSCRIPTIONAL ACTIVATORS	ONCOGENE			English	Article							PUTATIVE ONCOGENE SPI-1; MURINE LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; ETS PROTO-ONCOGENE; DNA-BINDING; C-ETS; V-ETS; CHROMOSOMAL LOCALIZATION; GENE FAMILY; PROTEINS	The erg gene is a member of the ets gene family. ETS proteins have been shown to bind specifically the (GGAA/T) motif and to transactivate via this consensus sequence. The human erg products exhibit almost-equal-to 70% homology with ETS proteins in their DNA-binding domain. We have isolated three erg cDNAs from a human fetal liver library. Two of them are different from the previously described erg-1 and erg-2 cDNAs (Rao et al., Science, 1987, 237, 635-639), in the middle of their coding sequence and in their 5' part where a novel initiation codon is introduced. These isoforms are generated by alternative RNA splicing from a single gene that leads to the inclusion or exclusion of different exon sequences. The three cDNAs expressed by an in vitro transcription-translation system direct the synthesis of proteins of almost-equal-to 38, 49 and 55 kDa. These in vitro erg products were tested for their DNA-binding activity by gel mobility-shift assays with different probes containing the ETS-specific binding site. The results indicated that all these erg isoforms are able to bind the ETS binding site in a specific manner. Our data using transient transfection assays indicate that erg protein isoforms function as transcriptional activators.			DUTERQUECOQUILLAUD, M (corresponding author), INST PASTEUR,CNRS,URA 1160,1 RUE CALMETTE,F-59019 LILLE,FRANCE.		plaza, serge/F-5290-2015; Niel, Christian/G-3712-2013	Duterque-Coquillaud, Martine/0000-0003-3943-5629				ANTON IA, 1988, NATURE, V336, P719, DOI 10.1038/336719a0; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1988, ONCOGENE RES, V2, P371; CHEN T, 1992, DEV BIOL, V151, P176, DOI 10.1016/0012-1606(92)90225-6; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; JORCYK CL, 1991, ONCOGENE, V6, P523; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; MESSING J, 1983, METHOD ENZYMOL, V101, P20; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRIBYL LJ, 1991, ONCOGENE, V6, P1175; PRIBYL LJ, 1988, DEV BIOL, V127, P45, DOI 10.1016/0012-1606(88)90187-X; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; SACCHI N, 1988, Genomics, V3, P110, DOI 10.1016/0888-7543(88)90140-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SPEGELAERE P, 1991, J VIROL, V65, P4919, DOI 10.1128/JVI.65.9.4919-4928.1991; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	62	45	51	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1865	1873						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510931				2022-12-28	WOS:A1993LG68200019
J	DELEEUW, B; SUIJKERBUIJK, RF; BALEMANS, M; SINKE, RJ; DEJONG, B; MOLENAAR, WM; MELONI, AM; SANDBERG, AA; GERAGHTY, M; HOFKER, M; ROPERS, HH; VANKESSEL, AG				DELEEUW, B; SUIJKERBUIJK, RF; BALEMANS, M; SINKE, RJ; DEJONG, B; MOLENAAR, WM; MELONI, AM; SANDBERG, AA; GERAGHTY, M; HOFKER, M; ROPERS, HH; VANKESSEL, AG			SUBLOCALIZATION OF THE SYNOVIAL SARCOMA-ASSOCIATED T(X-18) CHROMOSOMAL BREAKPOINT IN XP11.2 USING COSMID CLONING AND FLUORESCENCE INSITU HYBRIDIZATION	ONCOGENE			English	Article							EPITHELIAL DIFFERENTIATION; TUMORS; TRANSLOCATION; ABERRATIONS; SEQUENCES; FEATURES	In a previous study we localized the synovial sarcoma-associated t(X;18)(p11;q11) breakpoint within the ornithine aminotransferase-like 1 (OATL1) cluster on the X chromosome. This localization was delineated from both somatic cell hybrid and fluorescence in situ hybridization (FISH) analysis of patient material, using OAT-specific cDNA and YAC probes. Simultaneously, Knight et al. (1992, MoL Hum. Genet, in press) mapped this same breakpoint in their patient material adjacent to the more proximal OATL2 region on the X chromosome. Here we report the analysis of two additional tumors and demonstrate that again in these cases the chromosomal break occurs within the OATL1 cluster. In order to further specify the breakpoint, we subcloned the OATL1 YAC (no. 2) into cosmids. At least one of these cosmids (0.38) hybridizes to sequences that bracket the translocation breakpoint, as demonstrated by both Southern blot and FISH analysis. These observations confirm and substantiate our previous findings. In addition, cosmid 0.38 should be a valuable instrument for the ultimate isolation and identification of the gene(s) involved in the development of synovial sarcoma.	UNIV GRONINGEN,DEPT HUMAN GENET,9700 AB GRONINGEN,NETHERLANDS; UNIV GRONINGEN,DEPT PATHOL,9700 AB GRONINGEN,NETHERLANDS; GENET CTR,SCOTTSDALE,AZ; CANC CTR,SCOTTSDALE,AZ; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; LEIDEN UNIV,DEPT HUMAN GENET,2300 RA LEIDEN,NETHERLANDS	University of Groningen; University of Groningen; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Leiden University; Leiden University - Excl LUMC	DELEEUW, B (corresponding author), CATHOLIC UNIV NIJMEGEN,DEPT HUMAN GENET,POB 9101,6500 HB NIJMEGEN,NETHERLANDS.		Sinke, Richard J/A-1462-2009; van Kessel, Ad Geurts/A-2810-2010					ARNOLDUS EPJ, 1989, HUM GENET, V83, P231, DOI 10.1007/BF00285162; BATES PF, 1983, GENE, V26, P137, DOI 10.1016/0378-1119(83)90183-X; BERGER W, 1992, NAT GENET, V1, P199, DOI 10.1038/ng0692-199; DRIESEN MS, 1991, GENOMICS, V11, P1079, DOI 10.1016/0888-7543(91)90035-D; ENZINGER FM, 1988, SOFT TISSUE TUMORS, P658; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FISHER C, 1986, HUM PATHOL, V17, P996, DOI 10.1016/S0046-8177(86)80083-1; FLETCHER JA, 1991, NEW ENGL J MED, V324, P436, DOI 10.1056/NEJM199102143240702; GILGENKRANTZ S, 1990, ONCOGENE, V5, P1063; KNIGHT JC, 1992, IN PRESS MOL HUM GEN; LANDEGENT JE, 1987, HUM GENET, V77, P366, DOI 10.1007/BF00291428; LEEUW BD, 1993, GENE CHROMOSOME CANC, V6, P182; LIMON J, 1991, GENE CHROMOSOME CANC, V3, P338, DOI 10.1002/gcc.2870030504; MIETTINEN M, 1983, VIRCHOWS ARCH B, V44, P187, DOI 10.1007/BF02890169; MITCHELL GA, 1988, J BIOL CHEM, V263, P1488; MITELMAN F, 1990, CATALOG CHROMOSOME A; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA; SUIJKERBUIJK RF, 1992, CANCER GENET CYTOGEN, V63, P8, DOI 10.1016/0165-4608(92)90056-E; SUIJKERBUIJK RF, 1991, AM J HUM GENET, V48, P269; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; WIEACKER P, 1984, AM J HUM GENET, V36, P265	22	37	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1457	1463						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8389029				2022-12-28	WOS:A1993LE06400008
J	ZASTAWNY, RL; SALVINO, R; CHEN, JM; BENCHIMOL, S; LING, V				ZASTAWNY, RL; SALVINO, R; CHEN, JM; BENCHIMOL, S; LING, V			THE CORE PROMOTER REGION OF THE P-GLYCOPROTEIN GENE IS SUFFICIENT TO CONFER DIFFERENTIAL RESPONSIVENESS TO WILD-TYPE AND MUTANT P53	ONCOGENE			English	Article							MULTIDRUG-RESISTANCE GENE; MONOCLONAL-ANTIBODY; SIMIAN VIRUS-40; EXPRESSION; CELLS; DNA; TISSUES; SUPPRESSOR; SEQUENCE; PRODUCT	The overexpression of P-glycoprotein is thought to be responsible for resistance to chemotherapy in some non-responsive cancers. The mechanism by which P-glycoprotein is overexpressed in human tumors is poorly understood. However, several lines of evidence suggest that the major regulatory mechanism of P-glycoprotein overexpression in human tumors is at the transcriptional level. During tumor progression one of the most commonly observed alterations is mutation of the p53 tumor-suppressor gene. It has been shown that the p53 protein plays a role in transcriptional regulation. To gain insight into the effect p53 protein may have on P-glycoprotein promoter activity, we transiently co-transfected plasmids containing the hamster pgp1 or human mdr1 promoter linked to the chloramphenicol acetyltransferase (CAT) reporter gene with plasmids encoding either wild-type or mutant p53 protein into Chinese hamster ovary (CHO) cells. In this report, we show that wild-type p53 protein represses P-glycoprotein promoter activity, while mutant forms of p53 protein enhance P-glycoprotein promoter activity. Furthermore, we present data which indicate that the transcriptional regulatory effects of p53 are mediated through interactions with pgp1/mdr1 core promoter sequences. These findings have implications for our understanding of the molecular mechanism(s) by which p53 protein functions as a transcriptional regulator of gene expression. In addition, our results suggest a mechanism by which P-glycoprotein may be overexpressed in human cancers that also express mutant forms of p53 protein.	UNIV TORONTO,ONTARIO CANC INST,500 SHERBOURNE ST,TORONTO M4X 1K9,ONTARIO,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M4X 1K9,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto				Benchimol, Samuel/0000-0003-3433-890X	NCI NIH HHS [CA37130] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037130] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELL DR, 1985, J CLIN ONCOL, V3, P311, DOI 10.1200/JCO.1985.3.3.311; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; DEUCHARS KL, 1987, MOL CELL BIOL, V7, P718, DOI 10.1128/MCB.7.2.718; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HAMADA H, 1988, CANCER RES, V48, P4926; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HIRT B, 1967, J MOL BIOL, V26, P363; JARRELL KA, 1991, P NATL ACAD SCI USA, V88, P102, DOI 10.1073/pnas.88.1.102; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MA DDF, 1987, LANCET, V1, P135; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MILNER J, 1987, ONCOGENE, V1, P453; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; SAFA AR, 1988, P NATL ACAD SCI USA, V85, P7187, DOI 10.1073/pnas.85.19.7187; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TEETER LD, 1991, CELL GROWTH DIFFER, V2, P429; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	40	144	147	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1529	1535						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502478				2022-12-28	WOS:A1993LE06400016
J	KOHLHUBER, F; STROBL, LJ; EICK, D				KOHLHUBER, F; STROBL, LJ; EICK, D			EARLY DOWN-REGULATION OF C-MYC IN DIMETHYLSULFOXIDE-INDUCED MOUSE ERYTHROLEUKEMIA (MEL) CELLS IN MEDIATED AT THE P1/P2 PROMOTERS	ONCOGENE			English	Note							RNA POLYMERASE-II; PREMATURE TERMINATION; 5' END; GENE; TRANSCRIPTION; EXPRESSION; DIFFERENTIATION; REQUIREMENTS; ARREST; BLOCK	A block of RNA elongation in exon 1 of the murine c-myc gene has been described for normal mouse fibroblasts, lymphoid and myeloid cell lines and mouse erythroleukemia (MEL) cells. MEL cells differentiate after induction with the chemical agent dimethylsulfoxide (DMSO). The rapid initial down-regulation of c-myc that occurs after treatment with DMSO has been explained by an increase in the block of RNA elongation within the 3' part of c-myc exon 1. In contrast to these reports, we find that down-regulation of c-myc in DMSO-induced MEL cells occurs at the c-myc P1 and P2 promoters. The P1 promoter is repressed by inhibition of initiation, whereas transcription of P2 RNA is blocked by retention of RNA polymerase II at or close to the P2 promoter. The earlier described block of RNA elongation at a run of five thymidines in the 3' part of c-myc exon 1 was not observed.	GSF MUNICH,FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,INST KLIN MOLEK BIOL & TUMORGENET,W-8000 MUNICH 70,GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health			Strobl, Lothar J/M-7357-2014	Strobl, Lothar J/0000-0001-8389-1862				ASSELIN C, 1989, ONCOGENE, V4, P549; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; CHUNG J, 1987, CELL, V51, P1001, DOI 10.1016/0092-8674(87)90586-1; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; LEE HS, 1992, GENE DEV, V6, P284, DOI 10.1101/gad.6.2.284; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; OBRIEN T, 1991, MOL CELL BIOL, V11, P5285, DOI 10.1128/MCB.11.10.5285; PLET A, 1992, ONCOGENE, V7, P1847; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SPENCER CA, 1991, ADV CANCER RES, P1; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WRIGHT S, 1989, P NATL ACAD SCI USA, V86, P505, DOI 10.1073/pnas.86.2.505; WRIGHT S, 1991, P NATL ACAD SCI USA, V88, P11383, DOI 10.1073/pnas.88.24.11383	21	19	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1099	1102						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455938				2022-12-28	WOS:A1993KT22000037
J	MORRIS, JDH; CROOK, T; BANDARA, LR; DAVIES, R; LATHANGUE, NB; VOUSDEN, KH				MORRIS, JDH; CROOK, T; BANDARA, LR; DAVIES, R; LATHANGUE, NB; VOUSDEN, KH			HUMAN PAPILLOMAVIRUS TYPE-16 E7 REGULATES E2F AND CONTRIBUTES TO MITOGENIC SIGNALING	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; KINASE-II PHOSPHORYLATION; TRANSCRIPTION FACTOR; DNA-SYNTHESIS; MUTATIONAL ANALYSIS; HUMAN KERATINOCYTES; ADENOVIRUS E1A; RB PROTEIN; 3T3 CELLS; TRANSFORMATION	We have produced human papillomavirus type 16 E7 protein in a bacterial expression system and examined the mitogenic activity of this protein in Swiss 3T3 cells after scrape loading. The ability of E7 to induce cellular DNA synthesis in quiescent mouse fibroblasts is strongly enhanced by the presence of a single growth factor such as insulin. Although only weakly mitogenic, introduction of E7 alone resulted in the rapid induction of the transcriptionally active form of E2F, which was not enhanced further by the addition of insulin. Mutant E7 proteins defective for RB binding failed to induce the active form of E2F or act synergistically with insulin to stimulate DNA synthesis. The ability of E7 to regulate E2F may therefore be necessary, but is not sufficient, for full induction of DNA synthesis.	ST MARYS HOSP, SCH MED, LUDWIG INST CANC RES, NORFOLK PL, LONDON W2 1PG, ENGLAND; NATL INST MED RES, LONDON NW7 1AA, ENGLAND	Imperial College London; Ludwig Institute for Cancer Research; MRC National Institute for Medical Research				Davies, Rachel/0000-0002-2162-6219				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BANKS L, 1990, ONCOGENE, V5, P1383; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DURST M, 1987, ONCOGENE, V1, P251; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; IMAI Y, 1991, J VIROL, V65, P4966, DOI 10.1128/JVI.65.9.4966-4972.1991; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KANDA T, 1988, VIROLOGY, V165, P321, DOI 10.1016/0042-6822(88)90694-0; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MCNEIL PL, 1984, J CELL BIOL, V98, P1556, DOI 10.1083/jcb.98.4.1556; METCALFE JC, 1985, J CELL SCI, P199; MORRIS JDH, 1989, ONCOGENE, V4, P27; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; PAGANO M, 1992, ONCOGENE, V7, P1681; PATRIDGE JF, 1991, EMBO J, V10, P3819; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; ROZENGURT E, 1985, J CELL SCI, P229; SATO H, 1989, VIROLOGY, V168, P195, DOI 10.1016/0042-6822(89)90423-6; SHIVJI MKK, 1991, MOL CELL BIOL, V11, P1686, DOI 10.1128/MCB.11.3.1686; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; WATANABE S, 1990, J VIROL, V64, P207, DOI 10.1128/JVI.64.1.207-214.1990; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7	45	48	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1993	8	4					893	898						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455943				2022-12-28	WOS:A1993KT22000010
J	SUDOL, M; GREULICH, H; NEWMAN, L; SARKAR, A; SUKEGAWA, J; YAMAMOTO, T				SUDOL, M; GREULICH, H; NEWMAN, L; SARKAR, A; SUKEGAWA, J; YAMAMOTO, T			A NOVEL YES-RELATED KINASE, YRK, IS EXPRESSED AT ELEVATED LEVELS IN NEURAL AND HEMATOPOIETIC TISSUES	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; CELL ANTIGEN RECEPTOR; AVIAN-SARCOMA VIRUS; SIGNAL TRANSDUCTION; CATALYTIC DOMAINS; FIBRONECTIN GENE; SRC FAMILY; TRANSFORMATION; FYN; ASSOCIATION	While screening a chicken kidney cDNA library for the normal homolog of the yes oncogene, we isolated a clone that encodes a novel non-receptor type protein tyrosine kinase of the Src family. We named this gene product Yrk (York), as an acronym for Yes-related kinase. As predicted from the cDNA sequence, the Yrk protein consists of 536 amino acids and has all the canonical features of a Src kinase. At the amino terminus it contains a myristylation signal, followed by a unique domain, SH3 and SH2 motifs, an ATP binding site, a kinase region and a carboxy-terminal sequence with a potential regulatory tyrosine at position 530. The sequence of the Yrk protein showed 79% identity with human Fyn and 72% identity with chicken Yes. To eliminate the possibility that the Yrk protein is an avian homolog of mammalian Fyn, we isolated and sequenced the chicken fyn cDNA. The sequence data together with Southern and Northern blot analyses showed that the chicken yrk gene is distinct from the chicken fyn gene. Antibodies generated against the unique domain of the yrk protein expressed in bacteria precipitated a 60-kDa protein that was active in an immune complex kinase assay and was phosphorylated on tyrosine. Expression of the Yrk protein in adult chicken tissues was elevated in cerebellum and spleen. Relatively high levels of Yrk were also found in lung and skin.	ROCKEFELLER UNIV, CELL BIOL LAB, NEW YORK, NY 10021 USA; UNIV TOKYO, INST MED SCI, MINATO KU, TOKYO 108, JAPAN	Rockefeller University; University of Tokyo	SUDOL, M (corresponding author), ROCKEFELLER UNIV, MOLEC ONCOL LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.				NCI NIH HHS [CA01605, CA45757] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA045757] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BRADFORD M, 1988, ANAL BIOCHEM, V58, P705; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOKE M P, 1989, New Biologist, V1, P66; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; FAGAN JB, 1981, J BIOL CHEM, V256, P520; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; KITAMURA N, 1982, NATURE, V297, P205, DOI 10.1038/297205a0; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Maniatis T., 1982, MOL CLONING; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; NAHARRO G, 1983, J VIROL, V47, P611, DOI 10.1128/JVI.47.3.611-619.1983; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; PAWSON T, 1988, ONCOGENE, V3, P491; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEMBA K, 1990, MOL CELL BIOL, V10, P3095, DOI 10.1128/MCB.10.6.3095; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUDOL M, 1989, J NEUROSCI RES, V24, P1, DOI 10.1002/jnr.490240103; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; SUDOL M, 1993, IN PRESS MOL BASIS H; SUDOL M, 1992, IN PRESS NEUROCHEM I; TOYOSHIMA K, 1990, ADV SEC MESS PHOSPH, V24, P284; TYAGI JS, 1983, J BIOL CHEM, V258, P5787; Veillette A, 1991, Semin Immunol, V3, P143; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YOSHIDA M, 1980, NATURE, V287, P653, DOI 10.1038/287653a0; ZHAO YH, 1990, ONCOGENE, V5, P1629	39	62	67	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1993	8	4					823	831						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455940				2022-12-28	WOS:A1993KT22000002
J	KALTHOFF, H; SCHMIEGEL, W; ROEDER, C; KASCHE, D; SCHMIDT, A; LAUER, G; THIELE, HG; HONOLD, G; PANTEL, K; RIETHMULLER, G; SCHERER, E; MAURER, J; MAACKE, H; DEPPERT, W				KALTHOFF, H; SCHMIEGEL, W; ROEDER, C; KASCHE, D; SCHMIDT, A; LAUER, G; THIELE, HG; HONOLD, G; PANTEL, K; RIETHMULLER, G; SCHERER, E; MAURER, J; MAACKE, H; DEPPERT, W			P53 AND K-RAS ALTERATIONS IN PANCREATIC EPITHELIAL-CELL LESIONS	ONCOGENE			English	Article							GROWTH FACTOR-ALPHA; LARGE T-ANTIGEN; MONOCLONAL-ANTIBODIES; COLORECTAL TUMORIGENESIS; ADENOCARCINOMA CELLS; EXOCRINE PANCREAS; SIMIAN VIRUS-40; TUMOR-ANTIGEN; GENE; MUTATIONS	We have analysed the expression of p53 at the mRNA level, and extensively at the protein level by immunostaining, Western blotting, and ELISA measurements revealing a p53 increase in 8 out of 14 cell lines established from human pancreatic carcinomas. The mRNA levels closely paralleled the protein levels in most of the cell lines. Overexpression of p53 in tumor cells correlated with mutations in the p53 gene. Immunocytochemistry was also performed with tissue cryosections showing a nuclear p53 staining in 8 out of 12 exocrine, and 2 out of 2 endocrine tumors. In addition, nonmalignant peri-tumoral tissue specimens and cells derived from pancreatic juice of acute pancreatic patients were also positively stained. These findings may suggest functions of p53 in stress situations induced by acute inflammation or tissue regeneration. Genomic mutations in the tumor suppressor gene were associated with point mutations in either codon 12, 13 or 61 in the c-K-RAS oncogene in about two-thirds of cell lines. The frequent activations of a RAS oncogene in combination with mutations of a tumor suppressor gene are likely to contribute to the malignant phenotype of pancreatic adenocarcinomas.	UNIV MUNICH,INST IMMUNOL,W-8000 MUNICH 2,GERMANY; NETHERLANDS CANC INST,1066 CX AMSTERDAM,NETHERLANDS; FU BERLIN,KLINIKUM STEGLITZ,INNERE MED ABT,W-1000 BERLIN 45,GERMANY; HEINRICH PETTE INST,TUMORVIROL ABT,HAMBURG,GERMANY	University of Munich; Netherlands Cancer Institute; Free University of Berlin; Heinrich Pette Institute	KALTHOFF, H (corresponding author), UNIV HAMBURG,MED KLIN,IMMUNOL ABT,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY.		Kalthoff, Holger/B-1618-2010; Lauer, Georg/J-1467-2018	Lauer, Georg/0000-0002-9792-4271				ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BAKER SJ, 1990, CANCER RES, V50, P7717; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1992, IN PRESS J CELL SCI; BARTON CM, 1991, BRIT J CANCER, V64, P1076, DOI 10.1038/bjc.1991.467; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOS JL, 1989, CANCER RES, V49, P4682; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHANG K, 1991, J HISTOCHEM CYTOCHEM, V39, P1281, DOI 10.1177/39.9.1680897; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1989, NATO ASI SERIES H, V34, P399; EISENSTADT E, 1982, P NATL ACAD SCI-BIOL, V79, P1945, DOI 10.1073/pnas.79.6.1945; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FERNANDEZPOL JA, 1989, J CELL BIOCHEM, V41, P159, DOI 10.1002/jcb.240410306; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GISH WR, 1987, J VIROL, V61, P2864, DOI 10.1128/JVI.61.9.2864-2876.1987; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HALL PA, 1991, LANCET, V338, P513, DOI 10.1016/0140-6736(91)90586-E; HAN KA, 1992, NUCLEIC ACIDS RES, V20, P1979, DOI 10.1093/nar/20.8.1979; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; KAKU M, 1980, GANN, V71, P596; KALTHOFF H, 1991, ONCOGENE, V6, P1015; KALTHOFF H, 1992, IN PRESS INT S CLIN; KLOPPEL G, 1988, PANCREAS CONNECTION, P122; LEMOINE NR, 1992, GASTROENTEROLOGY, V102, P230, DOI 10.1016/0016-5085(92)91805-E; LEMOINE NR, 1991, J PATHOL, V165, P7; LEMOINE NR, 1991, GASTROENTEROLOGY, V101, P1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; METZGAR RS, 1982, CANCER RES, V42, P601; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILNER J, 1987, ONCOGENE, V1, P453; MORGAN RT, 1980, INT J CANCER, V25, P591, DOI 10.1002/ijc.2910250507; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OHMURA E, 1990, CANCER RES, V50, P103; OKABE T, 1983, CANCER, V51, P662, DOI 10.1002/1097-0142(19830215)51:4<662::AID-CNCR2820510419>3.0.CO;2-X; OZANNE B, 1980, J CELL PHYSIOL, V105, P163, DOI 10.1002/jcp.1041050118; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; SHIBATA D, 1990, BAILLIERE CLIN GASTR, V4, P151, DOI 10.1016/0950-3528(90)90044-H; SMITH JJ, 1987, P NATL ACAD SCI USA, V84, P7567, DOI 10.1073/pnas.84.21.7567; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; VANKRANEN HJ, 1991, CARCINOGENESIS, V12, P1477, DOI 10.1093/carcin/12.8.1477; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; WEBER K, 1975, EXP CELL RES, V95, P111, DOI 10.1016/0014-4827(75)90615-1; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZERRAHN J, 1992, ONCOGENE, V7, P1371	54	211	213	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					289	298						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426738				2022-12-28	WOS:A1993KN00600007
